PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	DUYAO, MP; KESSLER, DJ; SPICER, DB; BARTHOLOMEW, C; CLEVELAND, JL; SIEKEVITZ, M; SONENSHEIN, GE				DUYAO, MP; KESSLER, DJ; SPICER, DB; BARTHOLOMEW, C; CLEVELAND, JL; SIEKEVITZ, M; SONENSHEIN, GE			TRANSACTIVATION OF THE C-MYC PROMOTER BY HUMAN T-CELL LEUKEMIA-VIRUS TYPE-1 TAX IS MEDIATED BY NF-KAPPA-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR NECROSIS FACTOR; LONG TERMINAL REPEAT; HTLV-I; GENE-EXPRESSION; NUCLEAR FACTOR; LYMPHOCYTES-T; ACTIVATION; PROTEIN; BINDING; REGION	Human T cell leukemia virus type 1 is the causative agent of adult T cell leukemia. The virus encodes a 40-kDa protein, tax, that is important for the immortalization of T cells. Expression of tax activates several cellular transcription factors, including NF-kappa-B. We have previously identified two functional NF-kappa-B binding sites within the murine c-myc gene: upstream regulatory element (URE) and internal regulatory element (IRE). Using transient cotransfection analysis of Jurkat or HeLa cells, we report that tax can transactivate chimeric TK-CAT constructs containing multiple copies of wild-type URE or IRE, but not constructs with mutated versions of these elements. Furthermore, tax induced transcriptional activity of murine and human c-myc promoter-CAT hybrid genes in Jurkat and HeLa cells. A mutated tax expression vector, which fails to activate NF-kappa-B, was unable to induce either murine or human c-myc-CAT or URE/IRE-TK-CAT constructs. Mutant c-myc gene-CAT constructs, in which the URE and IRE were mutated either singly or in combination by site directed mutagenesis, displayed significantly reduced CAT activation upon cotransfection with a tax expression vector. These results suggest that tax can transactivate the c-myc gene through NF-kappa-B. The tax-induced stimulation of this oncogene may play a role in T cell immortalization.	BOSTON UNIV, SCH MED, DEPT BIOCHEM, BOSTON, MA 02118 USA; ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38101 USA; CUNY MT SINAI SCH MED, DEPT MICROBIOL, NEW YORK, NY 10029 USA	Boston University; St Jude Children's Research Hospital; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007429] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07429] Funding Source: Medline; NIAID NIH HHS [AI07309] Funding Source: Medline; NIA NIH HHS [AG00115] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; AVIGAN MI, 1990, J BIOL CHEM, V265, P18538; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; GAZZOLO L, 1987, NATURE, V326, P714, DOI 10.1038/326714a0; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; JACOBSON S, 1988, NATURE, V331, P540, DOI 10.1038/331540a0; KEATH EJ, 1984, CELL, V39, P339, DOI 10.1016/0092-8674(84)90012-6; KESSLER DJ, 1990, CURR TOP MICROBIOL I, V166, P211; LEE TH, 1984, SCIENCE, V226, P57, DOI 10.1126/science.6089350; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LIN JX, 1987, J BIOL CHEM, V262, P11908; MANN DL, 1987, SCIENCE, V236, P1103, DOI 10.1126/science.2883731; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PAUL NL, 1990, J VIROL, V64, P5412, DOI 10.1128/JVI.64.11.5412-5419.1990; PIERCE JW, 1991, MOL CELL BIOL, V11, P1431, DOI 10.1128/MCB.11.3.1431; PLUMB M, 1989, NUCLEIC ACIDS RES, V17, P73, DOI 10.1093/nar/17.1.73; POTEAT HT, 1989, J VIROL, V63, P1604, DOI 10.1128/JVI.63.4.1604-1611.1989; ROSEN CA, 1987, P NATL ACAD SCI USA, V84, P4919, DOI 10.1073/pnas.84.14.4919; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; [No title captured]	28	141	142	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16288	16291						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1644814				2022-12-25	WOS:A1992JJ45800047
J	WAKAO, H; SCHMITT-NEY, M; GRONER, B				WAKAO, H; SCHMITT-NEY, M; GRONER, B			MAMMARY GLAND-SPECIFIC NUCLEAR FACTOR IS PRESENT IN LACTATING RODENT AND BOVINE MAMMARY TISSUE AND COMPOSED OF A SINGLE POLYPEPTIDE OF 89 KDA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CASEIN GENE; GROWTH-FACTOR RECEPTOR; EPITHELIAL-CELL LINE; EXPRESSION; PROLACTIN; ACTIVATION; INDUCTION; C-ERBB-2; PROTEIN	Mammary epithelial cells, under the regulation of the lactogenic hormones, produce high amounts of milk proteins during the lactation period. The caseins are the most abundant milk proteins. We have studied the regulation of beta-casein gene expression and found that the lactogenic hormones induce transcription of the beta-casein gene promoter. The hormonal regulation is mediated in part by a mammary gland-specific transcription factor (MGF). MGF is a specific DNA-binding protein which recognizes the sequence 5'-ACTTCTTGGAATT3'. This sequence is conserved with slight variations in the alpha- and beta-casein gene promoters of the cow and rodents at position -87 to -99. Bovine MGF and rodent MGF behaved identically when their DNA binding properties and migration in polyacrylamide gels as protein-DNA complexes were compared. MGF was purified to near homogeneity from nuclear extracts of mammary epithelial cells derived from lactating rats. The combination of Bio-Rex 70-, DNA-Sepharose-, and sequence-specific DNA affinity column chromatography yielded a highly purified preparation of MGF. The purification from nuclear extract was more than 2400-fold, and the yield of MGF activity was 11%. A protein of 89 kDa was visualized by silver staining after sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The apparent molecular weight was confirmed by UV cross-linking of the factor to its cognate DNA binding sequence and subsequent gel electrophoresis. Excision of the 89-kDa band from the gel and renaturation of the protein restored its specific DNA binding ability. This indicates that MGF is composed of a single polypeptide.	FRIEDRICH MIESCHER INST, SCHWARZWALDALLEE 215, POB 2543, CH-4002 BASEL, SWITZERLAND	Friedrich Miescher Institute for Biomedical Research			WAKAO, Hiroshi/A-4242-2012					BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; BOUTIN JM, 1989, MOL ENDOCRINOL, V3, P1455, DOI 10.1210/mend-3-9-1455; BUCK K, 1992, ENDOCRINOLOGY, V130, P1108, DOI 10.1210/en.130.3.1108; Danielson M, 1991, NUCLEAR HORMONE RECE, P39; Dembinski T. C., 1987, The mammary gland. Development, regulation, and function., P355; DOPPLER W, 1990, MOL ENDOCRINOL, V4, P912, DOI 10.1210/mend-4-6-912; DOPPLER W, 1989, P NATL ACAD SCI USA, V86, P104, DOI 10.1073/pnas.86.1.104; GOODMAN HS, 1990, MOL ENDOCRINOL, V4, P1661, DOI 10.1210/mend-4-11-1661; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HENNIGHAUSEN L, 1991, TRANSGENIC ANIMALS, P65; HYNES NE, 1990, MOL CELL BIOL, V10, P4027, DOI 10.1128/MCB.10.8.4027; SCHMIDHAUSER C, 1990, P NATL ACAD SCI USA, V87, P9118, DOI 10.1073/pnas.87.23.9118; SCHMITT-NEY M, 1992, P NATL ACAD SCI USA, V89, P3130, DOI 10.1073/pnas.89.7.3130; TAVERNA D, 1991, CELL GROWTH DIFFER, V2, P145; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; Vonderhaar B K, 1988, Cancer Treat Res, V40, P251; VONDERHAAR BK, 1989, ANNU REV PHYSIOL, V51, P641, DOI 10.1146/annurev.ph.51.030189.003233; YOSHIMURA M, 1990, P NATL ACAD SCI USA, V87, P3670, DOI 10.1073/pnas.87.10.3670	18	130	135	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16365	16370						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1644820				2022-12-25	WOS:A1992JJ45800060
J	WU, CB; PELECH, SL; VEIS, A				WU, CB; PELECH, SL; VEIS, A			THE INVITRO PHOSPHORYLATION OF THE NATIVE RAT INCISOR DENTIN PHOSPHOPHORYNS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-II; CALCIUM-ION BINDING; LIVER CYTOSOL; PROTEIN-KINASES; SUBSTRATE DETERMINANTS; MOLECULAR-WEIGHT; SITE SPECIFICITY; PURIFICATION; BONE; TS	Phosphophoryns are the major non-collagenous proteins of the mineralized matrix of rat incisor dentin. Nearly half the phosphophoryn residues are serines, and 85-90% of these are phosphorylated. Since phosphorylation may be important for phosphophoryn function, it was of interest to identify the kinase(s) responsible for catalyzing their phosphophorylation. Rat osteosarcoma (ROS) 17/2.8 osteoblast-like cells were selected as the enzyme source. Native rat incisor phosphophoryns (RIPP-I, II, III) were not substrates for any of the ROS 17/2.8 messenger-dependent kinases but were phosphorylated by membrane-associated endogenous messenger-independent kinases. These were resolved chromatographically and identified as casein kinase (CK) I and II by elution properties and immunoblotting with a CKII antibody. The CKI preferentially used RIPP-III as substrate, while CKII preferred RIPP-I and II. Heparin at 100 and 500 ng/assay and NaCl at 0.25-0.4 M inhibited phosphorylation of the RIPP by CKI and CKII in parallel. At 10 mm spermine, phosphorylation of RIPP-I and II by CKII, and of RIPP-III by CKI were inhibited, but phosphorylation of RIPP-III by CKII was enhanced. Purified sea star oocyte CKII demonstrated the same substrate specificity and spermine concentration shift as the ROS 17/2.8 CKII. These data show that osteoblast-like cells are a rich source of membrane-bound CKI and CKII activity. The different patterns of phosphorylation of RIPP-I, II, and III further show that they are distinct synthetic products of the odontoblast.	NORTHWESTERN UNIV, DIV ORAL BIOL, CONNECT TISSUE RES LAB, CHICAGO, IL 60611 USA	Northwestern University					NIDCR NIH HHS [DE-01374] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE001374] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE001374] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ACKERMAN P, 1990, P NATL ACAD SCI USA, V87, P821, DOI 10.1073/pnas.87.2.821; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTLER WT, 1981, COLLAGEN REL RES, V1, P187; FLOTOW H, 1991, J BIOL CHEM, V266, P3724; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; GLOVER CVC, 1986, J BIOL CHEM, V261, P14349; HATHAWAY GM, 1979, J BIOL CHEM, V254, P762; HATHAWAY GM, 1982, CURR TOP CELL REGUL, V21, P101; KITAS EA, 1990, BIOCHEM BIOPH RES CO, V170, P635, DOI 10.1016/0006-291X(90)92139-Q; KUBOKI Y, 1979, J DENT RES, V58, P1926, DOI 10.1177/00220345790580092001; KUENZEL EA, 1985, P NATL ACAD SCI USA, V82, P737, DOI 10.1073/pnas.82.3.737; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; KUO JF, 1971, J BIOL CHEM, V246, P7159; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SL, 1977, BIOCHEMISTRY-US, V16, P2971, DOI 10.1021/bi00632a026; LEE SL, 1980, INT J PEPT PROT RES, V16, P231; LITCHFIELD DW, 1990, FEBS LETT, V261, P117, DOI 10.1016/0014-5793(90)80650-8; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAJESKA RJ, 1984, CHEM BIOL MINERALIZE, P279; MARIN O, 1986, EUR J BIOCHEM, V160, P239, DOI 10.1111/j.1432-1033.1986.tb09962.x; MEGGIO F, 1982, FEBS LETT, V141, P257, DOI 10.1016/0014-5793(82)80061-6; MEGGIO F, 1984, EUR J BIOCHEM, V145, P593, DOI 10.1111/j.1432-1033.1984.tb08598.x; MEGGIO F, 1988, FEBS LETT, V237, P225, DOI 10.1016/0014-5793(88)80206-0; MEGGIO F, 1989, EUR J BIOCHEM, V186, P459, DOI 10.1111/j.1432-1033.1989.tb15229.x; MIKUNITAKAGAKI Y, 1990, BIOCHEM J, V268, P593, DOI 10.1042/bj2680593; PELECH SL, 1990, BIOCHIM BIOPHYS ACTA, V1051, P100, DOI 10.1016/0167-4889(90)90179-H; PINNA LA, 1990, PEPT PROT PHOSPH, P145; RABIE A M, 1991, Journal of Dental Research, V70, P380; RABIE AM, 1991, THESIS NW U EVANSTON; RAHIMA M, 1988, CALCIFIED TISSUE INT, V42, P104, DOI 10.1007/BF02556342; RAO MC, 1987, ENDOCRINOLOGY, V120, P1010, DOI 10.1210/endo-120-3-1010; RODAN GA, 1983, BONE MINERAL RES, P244; SABSAY B, 1991, BIOCHEM J, V276, P699, DOI 10.1042/bj2760699; SANGHERA JS, 1992, BIOCHEM J, V283, P829, DOI 10.1042/bj2830829; SOMMERCORN J, 1987, J BIOL CHEM, V262, P3839; STETLERSTEVENSON WG, 1987, CALCIFIED TISSUE INT, V40, P97, DOI 10.1007/BF02555712; STETLERSTEVENSON WG, 1983, BIOCHEMISTRY-US, V22, P4326, DOI 10.1021/bi00287a025; VEIS A, 1988, CIBA F SYMP, V136, P161; Veis A., 1989, P189; Veis A, 1983, BIOMINERALIZATION BI, V240, p[273, 35]; WU CB, 1990, BIOMATERIALS, V11, P16	41	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16588	16594						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1644838				2022-12-25	WOS:A1992JJ45800092
J	BALDASSARE, JJ; HENDERSON, PA; BURNS, D; LOOMIS, C; FISHER, GJ				BALDASSARE, JJ; HENDERSON, PA; BURNS, D; LOOMIS, C; FISHER, GJ			TRANSLOCATION OF PROTEIN-KINASE-C ISOZYMES IN THROMBIN-STIMULATED HUMAN PLATELETS - CORRELATION WITH 1,2-DIACYLGLYCEROL LEVELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; GLYCOPROTEIN-IIB-IIIA; PHOSPHOLIPASE-C; CALCIUM-CHANNEL; ALPHA-THROMBIN; PHORBOL ESTER; PHOSPHORYLATION; ACTIVATION; CELLS; FIBROBLASTS	Human platelets were found by immunoblot analysis to express protein kinase C (PKC) isozymes-alpha, beta, delta, and zeta, but not gamma, epsilon, or eta. Exposure of platelets to thrombin, in the presence of 1 mM calcium, induced increased membrane association of PKC-alpha, -beta, and -zeta, while the subcellular distribution of PKC-delta remained unaltered. Maximal membrane association (2-fold) of PKC-alpha, -beta, and -zeta occurred within 1 min and was sustained for at least 10 min after the addition of thrombin. Similar results were obtained in the presence of the RGDS peptide, which blocks thrombin-induced binding of fibrinogen to its receptor, which indicates that PKC translocation was independent of fibrinogen binding. In the absence of added extracellular calcium, thrombin-induced translocation of PKC-alpha, -beta, and -zeta was transient, reaching a maximum at 1 min and returning to base line by 10 min. In the presence of calcium, thrombin induced a rapid (within 15 s) 8-fold rise in inositol 1,4,5-trisphosphate, which returned to baseline levels within 1 min, and a biphasic increase in sn-1,2-diacylglycerol (DAG), with peaks at 15 s and 2 min, which remained elevated for at least 5 min. Chelation of external calcium abolished the second phase of DAG formation but had no effect on the kinetics or magnitude of the increase in inositol 1,4,5-trisphosphate or the first phase of DAG formation. Two early PKC-dependent functions, serotonin release and 40-kDa protein phosphorylation, were independent of extracellular calcium and sustained DAG. These data demonstrate that in thrombin-stimulated human platelets the duration of the increased PKC membrane association closely parallels that of increased DAG content, and sustained elevations in DAG content and PKC translocation are dependent on extracellular calcium.	SPHINX PHARMACEUT CORP,DURHAM,NC 27710; UNIV MICHIGAN,DEPT DERMATOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan	BALDASSARE, JJ (corresponding author), ST LOUIS UNIV,DEPT INTERNAL MED,DIV NEPHROL,ST LOUIS,MO 63110, USA.		Henderson, Peter Alan/Q-5145-2019	Henderson, Peter Alan/0000-0002-7461-1758	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040901] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR039691] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 40901-01A1] Funding Source: Medline; NIAMS NIH HHS [AR39691] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AGRANOFF BW, 1983, J BIOL CHEM, V258, P2076; BALDASSARE JJ, 1986, J BIOL CHEM, V261, P1942; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BURNS DJ, 1990, J BIOL CHEM, V265, P12044; COOK SJ, 1990, J BIOL CHEM, V265, P620; CRABOS M, 1991, BIOCHEM BIOPH RES CO, V178, P878, DOI 10.1016/0006-291X(91)90973-B; DIXON JF, 1985, J BIOL CHEM, V260, P16088; DOOLITTLE RF, 1986, URFS ORFS, P87; DOWNES CP, 1986, BIOCHEM J, V238, P501, DOI 10.1042/bj2380501; FERRELL JE, 1989, P NATL ACAD SCI USA, V86, P2234, DOI 10.1073/pnas.86.7.2234; FISHER GJ, 1991, J CELL PHYSIOL, V146, P309, DOI 10.1002/jcp.1041460216; FOURNIER A, 1989, BIOCHEM BIOPH RES CO, V161, P556, DOI 10.1016/0006-291X(89)92635-1; FUKAMI K, 1989, J BIOL CHEM, V264, P14985; GARTNER TK, 1985, J BIOL CHEM, V260, P1891; GINSBERG M, 1985, J BIOL CHEM, V260, P3931; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; GRIENDLING KK, 1986, J BIOL CHEM, V261, P5901; HAGIWARA M, 1990, ARCH BIOCHEM BIOPHYS, V280, P201, DOI 10.1016/0003-9861(90)90536-8; HASLAM RJ, 1977, BIOCHEM BIOPH RES CO, V77, P714, DOI 10.1016/S0006-291X(77)80037-5; HONEYCUTT PJ, 1986, J BIOL CHEM, V261, P5900; JAMES G, 1992, J CELL BIOL, V116, P863, DOI 10.1083/jcb.116.4.863; KAIBUCHI K, 1983, J BIOL CHEM, V258, P6701; KARBUCHI K, 1983, J BIOL CHEM, V258, P6701; KILEY SC, 1991, J BIOL CHEM, V266, P23761; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEACH KL, 1988, J BIOL CHEM, V263, P13223; MARAIS RM, 1989, EUR J BIOCHEM, V182, P129, DOI 10.1111/j.1432-1033.1989.tb14809.x; MATAZAKI T, 1989, J BIOL CHEM, V264, P14729; NAKASHIMA S, 1991, BIOCHEM J, V275, P355, DOI 10.1042/bj2750355; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; PESSIN MS, 1990, J BIOL CHEM, V265, P7959; PITTNER RA, 1991, BIOCHEM J, V277, P371, DOI 10.1042/bj2770371; PREISS J, 1986, J BIOL CHEM, V261, P8597; RAND ML, 1988, BIOCHEM J, V251, P279, DOI 10.1042/bj2510279; RYBAK ME, 1988, BLOOD, V72, P714; RYBAK MEM, 1989, J BIOL CHEM, V264, P14617; SANNO K, 1983, J BIOL CHEM, V258, P2010; SHARPS ES, 1982, ANAL BIOCHEM, V124, P421, DOI 10.1016/0003-2697(82)90059-8; SIESS W, 1989, PHYSIOL REV, V69, P58, DOI 10.1152/physrev.1989.69.1.58; SINGAGLIA F, 1988, BIOCHEM BIOPH RES CO, V154, P258; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UHING RJ, 1989, J BIOL CHEM, V264, P9224; VANBLITTERSWIJK WJ, 1991, J BIOL CHEM, V266, P10337; WALKER G, 1990, FASEB J, V4, P2924, DOI 10.1096/fasebj.4.11.2116341; WAYS DK, 1992, J BIOL CHEM, V267, P4799; WILLIAMS JA, 1990, BIOCHEM J, V270, P149, DOI 10.1042/bj2700149; WRIGHT TM, 1988, J BIOL CHEM, V263, P9374; YAMAGUCHI A, 1987, FEBS LETT, V225, P228, DOI 10.1016/0014-5793(87)81163-8	49	133	133	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15585	15590						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1639799				2022-12-25	WOS:A1992JG11300053
J	CORNEJO, J; BEALE, SI; TERRY, MJ; LAGARIAS, JC				CORNEJO, J; BEALE, SI; TERRY, MJ; LAGARIAS, JC			PHYTOCHROME ASSEMBLY - THE STRUCTURE AND BIOLOGICAL-ACTIVITY OF 2(R),3(E)-PHYTOCHROMOBILIN DERIVED FROM PHYCOBILIPROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BILIVERDIN-IX-ALPHA; FREMYELLA-DIPLOSIPHON; CYANIDIUM-CALDARIUM; DIMETHYL ESTER; C-PHYCOCYANIN; BILE-PIGMENTS; BIOSYNTHESIS; PHYCOBILINS; INVITRO; CHROMOPHORE	The unicellular rhodophyte, Porphyridium cruentum, and the filamentous cyanobacterium, Calothrix sp. PCC 7601, contain phycobiliproteins that have covalently bound phycobilin chromophores. Overnight incubation of solvent-extracted cells at 40-degrees-C with methanol liberates free phycobilins that are derived from the protein-bound bilins by methanolytic cleavage of the thioether linkages between bilin and apoprotein. Two of the free bilins were identified as 3(E)-phycocyanobilin and 3(E)-phycoerythrobilin by comparative spectrophotometry and high pressure liquid chromatography. Methanolysis also yields a third bilin free acid whose absorption and H-1 NMR spectra support the assignment of the 3(E)-phytochromobilin structure. This novel bilin is the major pigment isolated from cells that are pre-extracted with acetone-containing solvents. Since phytochrome- or phytochromobilin-containing proteins are not present in either organism, the 3(E)-phytochromobilin must arise by oxidation of phycobilin chromophores. This pigment is not obtained by similar treatment of a cyanobacterium and a rhodophyte that lack phycoerythrin. Therefore, 3(E)-phytochromobilin appears to be derived from phycoerythrobilin-containing proteins. Comparative CD spectroscopy of 3(E)-phytochromobilin and 3(E)-phycocyanobilin suggests that the two bilins share the R stereochemistry at the 2-position in the reduced pyrrole ring. Incubation of 2(R),3(E)-phytochromobilin with recombinant oat apophytochrome yields a covalent bilin adduct that is photoactive and spectrally indistinguishable from native oat phytochrome isolated from etiolated seedlings. These results establish that the phycobiliprotein-derived 2(R),3(E)-phytochromobilin is a biologically active phytochrome chromophore precursor.	BROWN UNIV, DEPT BIOL & MED, PROVIDENCE, RI 02912 USA; UNIV CALIF DAVIS, DEPT BIOCHEM & BIOPHYS, DAVIS, CA 95616 USA	Brown University; University of California System; University of California Davis			Lagarias, John Clark/L-3139-2013; Terry, Matthew/B-3000-2012; Terry, Matthew/ABE-6419-2020	Lagarias, John Clark/0000-0002-2093-0403; Terry, Matthew/0000-0001-5002-2708; Terry, Matthew/0000-0001-5002-2708				[Anonymous], [No title captured]; ARCIERO DM, 1988, J BIOL CHEM, V263, P18343; ARCIERO DM, 1988, J BIOL CHEM, V263, P18350; BEALE SI, 1983, PLANT PHYSIOL, V71, P263, DOI 10.1104/pp.71.2.263; BEALE SI, 1991, J BIOL CHEM, V266, P22328; BEALE SI, 1991, J BIOL CHEM, V266, P22333; BEALE SI, 1991, J BIOL CHEM, V266, P22341; BEALE SI, 1991, NEW COMPREHENSIVE BI, V19, P155; BEGUIN S, 1985, BIOCHIMIE, V67, P109, DOI 10.1016/S0300-9084(85)80236-4; BERKELMAN TR, 1986, ANAL BIOCHEM, V156, P194, DOI 10.1016/0003-2697(86)90173-9; BROCKMANN H, 1973, CHEM BER-RECL, V106, P803, DOI 10.1002/cber.19731060309; CHAPMAN DJ, 1967, J AM CHEM SOC, V89, P5976, DOI 10.1021/ja00999a058; COLE WJ, 1967, J AM CHEM SOC, V89, P3643, DOI 10.1021/ja00990a055; CRESPI HL, 1967, J AM CHEM SOC, V89, P3642, DOI 10.1021/ja00990a054; CRESPI HL, 1969, PHYTOCHEMISTRY, V8, P759, DOI 10.1016/S0031-9422(00)85848-3; DEFORCE L, 1991, P NATL ACAD SCI USA, V88, P10392, DOI 10.1073/pnas.88.23.10392; DUERRING M, 1991, J MOL BIOL, V217, P577, DOI 10.1016/0022-2836(91)90759-Y; ELICH TD, 1989, J BIOL CHEM, V264, P12902; ELICH TD, 1989, J BIOL CHEM, V264, P183; GLAZER AN, 1977, J BIOL CHEM, V252, P32; GOSSAUER A, 1978, J AM CHEM SOC, V100, P5928, DOI 10.1021/ja00486a053; GOSSAUER A, 1974, LIEBIGS ANN CHEM, P1496; JACKMAN LM, 1969, APPLICATIONS NMR SPE; KILLILEA SD, 1980, BIOCHEM J, V187, P311, DOI 10.1042/bj1870311; KLEIN G, 1977, H-S Z PHYSIOL CHEM, V358, P1077; KLEIN G, 1978, LIEBIGS ANN CHEM, P267; KROES HH, 1970, MEDED LANDBOUWHOGESC, V7018, P1; LAGARIAS JC, 1979, J AM CHEM SOC, V101, P5030, DOI 10.1021/ja00511a038; LAGARIAS JC, 1980, J AM CHEM SOC, V102, P4821, DOI 10.1021/ja00534a042; LAGARIAS JC, 1989, P NATL ACAD SCI USA, V86, P5778, DOI 10.1073/pnas.86.15.5778; LAGARIAS JC, 1987, PHOTOCHEM PHOTOBIOL, V46, P5, DOI 10.1111/j.1751-1097.1987.tb04729.x; LITTS JC, 1983, J BIOL CHEM, V258, P1025; MANITTO P, 1979, EXPERIENTIA, V35, P1418, DOI 10.1007/BF01962757; McDonagh A. F., 1979, PORPHYRINS, VVI; MCDONAGH AF, 1980, BIOCHEM J, V189, P193, DOI 10.1042/bj1890193; MURAO S, 1982, AGR BIOL CHEM TOKYO, V46, P2031, DOI 10.1080/00021369.1982.10865379; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; RUDIGER W, 1967, H-S Z PHYSIOL CHEM, V348, P129, DOI 10.1515/bchm2.1967.348.1.129; RUDIGER W, 1967, H-S Z PHYSIOL CHEM, V348, P1554; RUDIGER W, 1980, Z NATURFORSCH C, V35, P763; SCHIRMER T, 1987, J MOL BIOL, V196, P677, DOI 10.1016/0022-2836(87)90040-4; SCHRAM BL, 1971, EUR J BIOCHEM, V19, P581, DOI 10.1111/j.1432-1033.1971.tb01352.x; SIEGELMAN HW, 1966, PLANT PHYSIOL, V41, P1289, DOI 10.1104/pp.41.8.1289; TERRY MJ, 1991, J BIOL CHEM, V266, P22215; WAHLEITHNER JA, 1991, P NATL ACAD SCI USA, V88, P10387, DOI 10.1073/pnas.88.23.10387; WELLER JP, 1980, CHEM BER-RECL, V113, P1603, DOI 10.1002/cber.19801130439	46	70	72	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14790	14798						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634523				2022-12-25	WOS:A1992JF08800045
J	TAKEUCHI, Y; YANAGISHITA, M; HASCALL, VC				TAKEUCHI, Y; YANAGISHITA, M; HASCALL, VC			RECYCLING OF TRANSFERRIN RECEPTORS AND HEPARAN-SULFATE PROTEOGLYCANS IN A RAT PARATHYROID CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED ENDOCYTOSIS; CALCIUM; SECRETION; TRANSPORT; PROTEINS; SURFACE; COMPARTMENTS; MICROTUBULES; MEMBRANE; PATHWAYS	We examined recycling of heparan sulfate (HS) proteoglycans and transferrin receptor (Tf-R) in a rat parathyroid cell line. While extracellular Ca2+ concentration ([Ca2+]e) regulates the recycling of HS proteoglycans in parathyroid cells, such that HS proteoglycans only recycle when [Ca2+]e is lowered below physiological levels, recycling of Tf-R occurs equally well both in 0.05 mM (low) and 2 mM (high) [Ca2+]e. Inhibiting endocytosis chemically with phenylarsine oxide or at low temperature (4-degrees-C) did not abolish the effects of changing [Ca2+], on HS proteoglycans in the recycling compartment even though transport of HS proteoglycans from the Golgi complex to the cell surface was inhibited in low [Ca2+]e. Microtubules are not involved in the recycling of HS proteoglycans or of Tf-R since nocodazole did not affect these processes. Inhibiting the increase of intracellular Ca2+ by an intracellular Ca2+ chelator sustained recycling of HS proteoglycans even in the presence of high [Ca2+]e. These observations show that the exocytosis pathway of HS proteoglycans in the recycling compartment is specifically regulated by [Ca2+]e, whereas that for constitutive secretion is not. Therefore, the recycling of HS proteoglycans may be directly related to some functions of parathyroid cells regulated by [Ca2+]e. Although the mechanism by which [Ca2+], regulates the exocytosis and recycling of HS proteoglycans is uncertain, it is suggested that an increase of intracellular Ca2+ is necessary, but not necessarily sufficient, for inhibiting their exocytosis.	NIDR,BONE RES BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)								BALCH WE, 1989, J BIOL CHEM, V264, P16965; BROWN EM, 1982, MINER ELECTROL METAB, V8, P130; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; FITZPATRICK LA, 1988, P NATL ACAD SCI USA, V859, P2115; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GOMEZCAMBRONERO J, 1989, J BIOL CHEM, V264, P21699; HUEBERS HA, 1987, PHYSIOL REV, V67, P520, DOI 10.1152/physrev.1987.67.2.520; KAPLAN J, 1985, J CELL BIOL, V101, P121, DOI 10.1083/jcb.101.1.121; KELLY RB, 1990, CELL, V61, P5, DOI 10.1016/0092-8674(90)90206-T; KOVAL M, 1989, J CELL BIOL, V108, P2169, DOI 10.1083/jcb.108.6.2169; NEMETH EF, 1987, J BIOL CHEM, V262, P5188; PARCZYK K, 1989, J BIOL CHEM, V264, P16837; SALZMAN NH, 1989, J CELL BIOL, V109, P2097, DOI 10.1083/jcb.109.5.2097; SHERWOOD LM, 1966, NATURE, V209, P52, DOI 10.1038/209052a0; SHOBACK DM, 1984, P NATL ACAD SCI-BIOL, V81, P3113, DOI 10.1073/pnas.81.10.3113; STEIN BS, 1986, J BIOL CHEM, V261, P319; TAKEUCHI Y, 1992, J BIOL CHEM, V267, P14677; TAKEUCHI Y, 1990, J BIOL CHEM, V265, P13661; WILEMAN T, 1985, BIOCHEM J, V232, P1	19	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14685	14690						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634514				2022-12-25	WOS:A1992JF08800031
J	TANG, PM; BONDOR, JA; SWIDEREK, KM; DEPAOLIROACH, AA				TANG, PM; BONDOR, JA; SWIDEREK, KM; DEPAOLIROACH, AA			MOLECULAR-CLONING AND EXPRESSION OF THE REGULATORY (RG1) SUBUNIT OF THE GLYCOGEN-ASSOCIATED PROTEIN PHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; AMINO-ACID-SEQUENCE; RAT-LIVER NUCLEI; BINDING SUBUNIT; CATALYTIC SUBUNIT; CELLULAR-REGULATION; PHOSPHORYLASE-PHOSPHATASE; SYNTHASE KINASE-3; MESSENGER-RNA; BOUND FORM	DNA clones encoding the glycogen-binding (R(Gl)) subunit of glycogen-associated protein phosphatase were isolated from rabbit skeletal muscle lambda-gt11 cDNA libraries. Overlapping clones provided an open reading frame of 3327 nucleotides that predicts a polypeptide of 1109 amino acids with a molecular weight of 124,257. Northern hybridization of rabbit RNA identified a major mRNA transcript of 7.5 kilobases present in skeletal, diaphragm, and cardiac muscle, but not in brain, kidney, liver, and lung. Southern analysis of rabbit genomic DNA digested with various restriction endonucleases gave rise to a single hybridizing fragment, suggesting that a single gene is present. Expression of the complete R(Gl) subunit coding sequence in Escherichia coli generated a protein of apparent molecular weight on sodium dodecyl sulfate-polyacrylamide gel electrophoresis of approximately 160,000, similar to the size of the polypeptide detected by Western immunoblot in rabbit skeletal muscle extracts. The R(Gl) subunit shares significant homology with the Saccharomyces cerevisiae GAC1 gene product which is involved in activation of glycogen synthase and glycogen accumulation. The homology with GAC1 substantiates the role of this enzyme in control of glycogen metabolism. Hydropathy analysis of the R(Gl) subunit amino acid sequence revealed the presence of a hydrophobic region in the COOH terminus, suggesting a potential association with membrane. This result suggests that the same phosphatase regulatory component may be involved in targeting the enzyme both to membranes and to glycogen.	INDIANA UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOL, 635 BARNHILL DR, INDIANAPOLIS, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis					NHLBI NIH HHS [P01 HL06308:PROJ.7] Funding Source: Medline; NIDDK NIH HHS [DK20542, DK36569] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL006308] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036569, P60DK020542] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AITKEN A, 1982, EUR J BIOCHEM, V126, P235, DOI 10.1111/j.1432-1033.1982.tb06771.x; ARINO J, 1988, P NATL ACAD SCI USA, V85, P4252, DOI 10.1073/pnas.85.12.4252; BAI GE, 1988, FASEB J, V2, P3010, DOI 10.1096/fasebj.2.14.2846396; BALLOU LM, 1983, BIOCHEMISTRY-US, V22, P3393, DOI 10.1021/bi00283a014; BERNDT N, 1987, FEBS LETT, V223, P340, DOI 10.1016/0014-5793(87)80316-2; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CAUDWELL FB, 1986, FEBS LETT, V194, P85, DOI 10.1016/0014-5793(86)80056-4; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHISHOLM AAK, 1988, BIOCHIM BIOPHYS ACTA, V968, P392, DOI 10.1016/0167-4889(88)90032-8; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1989, J BIOL CHEM, V264, P21435; DENT P, 1990, FEBS LETT, V259, P281, DOI 10.1016/0014-5793(90)80027-G; DENT P, 1989, FEBS LETT, V248, P67, DOI 10.1016/0014-5793(89)80433-8; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DEPAOLIROACH AA, 1985, ADV PROT PHOSPHATASE, V1, P59; DEPAOLIROACH AA, 1989, ADV PROTEIN PHOSPHAT, V5, P479; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIOL CJ, 1988, ARCH BIOCHEM BIOPHYS, V267, P797, DOI 10.1016/0003-9861(88)90089-6; FOULKES JG, 1980, EUR J BIOCHEM, V105, P195, DOI 10.1111/j.1432-1033.1980.tb04489.x; GOEDDEL DV, 1990, METHOD ENZYMOL, V185, P3; GOEDDEL DV, 1979, NATURE, V281, P544, DOI 10.1038/281544a0; GREEN DD, 1987, P NATL ACAD SCI USA, V84, P4880, DOI 10.1073/pnas.84.14.4880; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HIRAGA A, 1986, EUR J BIOCHEM, V161, P763, DOI 10.1111/j.1432-1033.1986.tb10505.x; HIRAGA A, 1987, EUR J BIOCHEM, V163, P253, DOI 10.1111/j.1432-1033.1987.tb10795.x; HOLMES CFB, 1986, EUR J BIOCHEM, V155, P173, DOI 10.1111/j.1432-1033.1986.tb09473.x; HUBBARD MJ, 1990, EUR J BIOCHEM, V189, P243, DOI 10.1111/j.1432-1033.1990.tb15483.x; HUBBARD MJ, 1989, EUR J BIOCHEM, V180, P457, DOI 10.1111/j.1432-1033.1989.tb14668.x; HUBBARD MJ, 1989, EUR J BIOCHEM, V186, P701, DOI 10.1111/j.1432-1033.1989.tb15263.x; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; INGEBRITSEN TS, 1983, SCIENCE, V221, P331, DOI 10.1126/science.6306765; JAKES S, 1986, BIOCHIM BIOPHYS ACTA, V888, P135, DOI 10.1016/0167-4889(86)90079-0; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KINCAID RL, 1988, P NATL ACAD SCI USA, V85, P8983, DOI 10.1073/pnas.85.23.8983; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KURET J, 1986, FEBS LETT, V203, P197, DOI 10.1016/0014-5793(86)80741-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MANIATIS T, 1978, CELL, V15, P687, DOI 10.1016/0092-8674(78)90036-3; MARUYAMA T, 1986, NUCLEIC ACIDS RES, V14, pR151, DOI 10.1093/nar/14.suppl.r151; MESSING J, 1983, METHOD ENZYMOL, V101, P20; NEVINS JR, 1983, ANNU REV BIOCHEM, V52, P441, DOI 10.1146/annurev.bi.52.070183.002301; NIMMO GA, 1978, EUR J BIOCHEM, V87, P341, DOI 10.1111/j.1432-1033.1978.tb12383.x; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLENDER KK, 1989, BIOCHEM BIOPH RES CO, V159, P72, DOI 10.1016/0006-291X(89)92406-6; SILVA OBD, 1987, FEBS LETT, V221, P415, DOI 10.1016/0014-5793(87)80966-3; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STRALFORS P, 1985, EUR J BIOCHEM, V149, P295, DOI 10.1111/j.1432-1033.1985.tb08926.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; STULL JT, 1986, ENZYMES, V17, P114; TAMURA S, 1989, P NATL ACAD SCI USA, V86, P1796, DOI 10.1073/pnas.86.6.1796; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VILLAMORUZZI E, 1987, EUR J BIOCHEM, V169, P659, DOI 10.1111/j.1432-1033.1987.tb13658.x; WERA S, 1991, J BIOL CHEM, V266, P339; YANG SD, 1980, J BIOL CHEM, V255, P1759; ZHANG WM, 1989, FASEB J, V3, P2532, DOI 10.1096/fasebj.3.13.2509275	63	160	165	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					15782	15789						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1651919				2022-12-25	WOS:A1991GB97700042
J	HUBERT, C; HOUOT, AM; CORVOL, P; SOUBRIER, F				HUBERT, C; HOUOT, AM; CORVOL, P; SOUBRIER, F			STRUCTURE OF THE ANGIOTENSIN I-CONVERTING ENZYME GENE - 2 ALTERNATE PROMOTERS CORRESPOND TO EVOLUTIONARY STEPS OF A DUPLICATED GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUCRASE-ISOMALTASE; MOLECULAR-CLONING; SMALL-INTESTINE; MESSENGER-RNA; DNA; MEMBRANE; PROTEIN; TRANSCRIPTION; EXPRESSION; REGIONS	Overlapping genomic clones containing the entire sequence of the human angiotensin I-converting enzyme (ACE) gene were isolated from a lambda-phage human DNA library. This gene spans 21 kilobases (kb) and comprises 26 exons, ranging in size from 88 to 481 base pairs. Intron-exon boundaries were sequenced and the relative positions of the exons were mapped. The two different mRNAs transcribed from the ACE gene were assigned to their respective exons. The large endothelial type ACE mRNA (4.3 kb long) is transcribed from exon 1 to exon 26, excluding exon 13. The 3-kb long testicular ACE mRNA is transcribed from exon 13 to exon 26. Exon 13 encodes for the 67 amino acids of the NH2-terminal region of the testicular ACE, whereas downstream exons encode a sequence common to both isozymes. The gene duplication suggested by the internal homology of the endothelial ACE mRNA is now confirmed by the presence of two homologous clusters of eight exons (exons 4-11 and exons 17-24) having similar sizes and codon phases at exon-intron boundaries. The presence of two alternate promoters was investigated by ribonuclease protection assays. The different 5' ends of the two ACE transcripts revealed a promoter for the endothelial ACE mRNA in the 5'-flanking region of the first exon and a promoter for the testicular ACE mRNA situated in intron 12.			HUBERT, C (corresponding author), COLL FRANCE,INSERM,U36,3 RUE ULM,F-75231 PARIS 05,FRANCE.							BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BERNSTEIN KE, 1989, J BIOL CHEM, V264, P11945; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLIER IE, 1988, J BIOL CHEM, V263, P10711; DADAMIO L, 1989, P NATL ACAD SCI USA, V86, P7103, DOI 10.1073/pnas.86.18.7103; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; EHLERS MRW, 1989, P NATL ACAD SCI USA, V86, P7741, DOI 10.1073/pnas.86.20.7741; ELDORRY HA, 1982, P NATL ACAD SCI-BIOL, V79, P4295, DOI 10.1073/pnas.79.14.4295; ERDOS EG, 1987, LAB INVEST, V56, P365; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERGLY MJ, 1981, P SOC EXP BIOL MED, V166, P35; GERVITZ RK, 1987, COMP BIOCHEM PHYS A, V86, P503, DOI 10.1016/0300-9629(87)90533-0; HOOPER NM, 1987, BIOCHEM J, V247, P85, DOI 10.1042/bj2470085; HOWARD TE, 1990, MOL CELL BIOL, V10, P4294, DOI 10.1128/MCB.10.8.4294; HUNZIKER W, 1986, CELL, V46, P227, DOI 10.1016/0092-8674(86)90739-7; KARIN M, 1984, NATURE, V308, P513, DOI 10.1038/308513a0; KRULEWITZ AH, 1984, AM J PHYSIOL, V247, pC163, DOI 10.1152/ajpcell.1984.247.3.C163; KUMAR RS, 1989, J BIOL CHEM, V264, P16754; LATTION AL, 1989, FEBS LETT, V252, P99, DOI 10.1016/0014-5793(89)80897-X; LAWN RM, 1978, CELL, V15, P1157, DOI 10.1016/0092-8674(78)90043-0; Maniatis T., 1982, MOL CLONING; MANTEI N, 1988, EMBO J, V7, P2705, DOI 10.1002/j.1460-2075.1988.tb03124.x; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIBLER U, 1987, ANNU REV GENET, V21, P237, DOI 10.1146/annurev.ge.21.120187.001321; SCHLEGEL.S, 1972, BIOCHIM BIOPHYS ACTA, V258, P506, DOI 10.1016/0005-2744(72)90242-2; SHAI SY, 1990, BIOCHEM BIOPH RES CO, V167, P1128, DOI 10.1016/0006-291X(90)90640-9; SJOSTROM H, 1980, J BIOL CHEM, V255, P1332; SOUBRIER F, 1988, P NATL ACAD SCI USA, V85, P9386, DOI 10.1073/pnas.85.24.9386; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STRITTMATTER SM, 1985, ENDOCRINOLOGY, V117, P1374, DOI 10.1210/endo-117-4-1374; TERUYA JH, 1990, MOL CELL BIOL, V10, P2315, DOI 10.1128/MCB.10.5.2315; VELLETRI PA, 1985, ENDOCRINOLOGY, V116, P2516, DOI 10.1210/endo-116-6-2516; WEI L, 1991, J BIOL CHEM, V266, P9002; WILBUR WJ, 1983, P NATL ACAD SCI-BIOL, V80, P726, DOI 10.1073/pnas.80.3.726; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	37	367	405	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15377	15383						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1651327				2022-12-25	WOS:A1991GB09700082
J	VERWEIJ, CL; GEERTS, M; AARDEN, LA				VERWEIJ, CL; GEERTS, M; AARDEN, LA			ACTIVATION OF INTERLEUKIN-2 GENE-TRANSCRIPTION VIA THE T-CELL SURFACE-MOLECULE CD28 IS MEDIATED THROUGH AN NF-KB-LIKE RESPONSE ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ANTIGEN RECEPTOR; LYMPHOCYTES-T; KAPPA-B; CHLORAMPHENICOL ACETYLTRANSFERASE; MONOCLONAL-ANTIBODIES; NUCLEAR FACTORS; EXPRESSION; ENHANCER; PROLIFERATION; CALCIUM	Production of interleukin-2 (IL-2) by human T-lymphocytes can be augmented by costimulation via CD28. It has been reported that signaling via CD28 acts by stabilization of lymphokine mRNAs (Lindsten, T., June, C. H., Ledbetter, J. A., Stella, G., and Thompson, C. B. (1989) Science 244, 339-343). Here we demonstrate that costimulation via CD28 also provides a signal which activates transcription of the IL-2 gene. A CD28-responsive element (CD28RE) in the IL-2 enhancer at position -162 to -152 was identified. This so far unidentified element shows sequence similarity to the kB enhancer motif. In vitro binding studies have demonstrated that the via CD28-induced signal synergizes with either phorbol myristate acetate or anti-CD3 for the induction of a nuclear factor that binds CD28RE and the human immunodeficiency virus (HIV-1) NF-kB motif. The significance of the sequence similarity of CD28RE with the kB enhancer motif was demonstrated by cross-competition studies using unlabeled CD28RE, HIV-1 NF-kB binding site, and a mutated version of the NF-kB motif. In addition, we found that NF-kB-dependent reporter gene expression was induced by costimulation via CD28. These results indicate that besides an effect on lymphokine mRNA stabilization, stimulation via CD28 acts at the level of transcription via coinduction of an NF-kB-like activity.	UNIV AMSTERDAM,EXPTL & CLIN IMMUNOL LAB,AMSTERDAM,NETHERLANDS	University of Amsterdam	VERWEIJ, CL (corresponding author), NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,AMSTERDAM,NETHERLANDS.							BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BRUNVAND MW, 1988, J BIOL CHEM, V263, P18904; DAMLE NK, 1983, J IMMUNOL, V131, P2296; DURAND DB, 1987, J EXP MED, V165, P395, DOI 10.1084/jem.165.2.395; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; FRASER JD, 1991, SCIENCE, V251, P313, DOI 10.1126/science.1846244; FUJITA T, 1986, CELL, V46, P401, DOI 10.1016/0092-8674(86)90660-4; GILLIS S, 1978, J IMMUNOL, V120, P2027; GMUNDER H, 1984, EUR J BIOCHEM, V142, P153, DOI 10.1111/j.1432-1033.1984.tb08263.x; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRUTERS RA, 1991, EUR J IMMUNOL, V21, P167, DOI 10.1002/eji.1830210125; HANSEN JA, 1980, IMMUNOGENETICS, V10, P247, DOI 10.1007/BF01561573; IMBODEN JB, 1985, J IMMUNOL, V134, P663; JUNE CH, 1990, IMMUNOL TODAY, V11, P211, DOI 10.1016/0167-5699(90)90085-N; JUNE CH, 1987, MOL CELL BIOL, V7, P4472, DOI 10.1128/MCB.7.12.4472; KOULOVA L, 1991, J EXP MED, V173, P759, DOI 10.1084/jem.173.3.759; KRONKE M, 1985, J EXP MED, V161, P1593, DOI 10.1084/jem.161.6.1593; LEDBETTER JA, 1987, P NATL ACAD SCI USA, V84, P1384, DOI 10.1073/pnas.84.5.1384; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; LINSLEY PS, 1990, P NATL ACAD SCI USA, V87, P5031, DOI 10.1073/pnas.87.13.5031; MARTIN PJ, 1986, J IMMUNOL, V136, P3282; NIELSEN DA, 1989, ANAL BIOCHEM, V179, P19, DOI 10.1016/0003-2697(89)90193-0; OHLSSON H, 1986, CELL, V45, P35, DOI 10.1016/0092-8674(86)90535-0; PANTALEO G, 1987, EUR J IMMUNOL, V17, P55, DOI 10.1002/eji.1830170110; PIERCE JW, 1988, P NATL ACAD SCI USA, V85, P1482, DOI 10.1073/pnas.85.5.1482; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; TONGSTARKSEN SE, 1989, J IMMUNOL, V142, P702; TRUNEH A, 1985, NATURE, V313, P318, DOI 10.1038/313318a0; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421; VANLIER RAW, 1988, EUR J IMMUNOL, V18, P167; VANLIER RAW, 1989, LEUKOCYTE TYPING, V4, P353; VERWEIJ CL, 1990, J BIOL CHEM, V265, P15788; WEISS A, 1986, J IMMUNOL, V137, P819; WEISS A, 1984, J IMMUNOL, V133, P123	36	187	190	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14179	14182						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1650350				2022-12-25	WOS:A1991FZ35100011
J	CHEN, ZD; COAN, C; FIELDING, L; CASSAFER, G				CHEN, ZD; COAN, C; FIELDING, L; CASSAFER, G			INTERACTION OF CRATP WITH THE PHOSPHORYLATION SITE OF THE SARCOPLASMIC-RETICULUM ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM ADENOSINE-TRIPHOSPHATASE; LIMITING CONFORMATIONAL CHANGE; REACTION-MECHANISM; DIVALENT-CATION; ENERGY-TRANSFER; CA-2+ ATPASE; BINDING-SITE; CA-2+-ATPASE; SUBSTRATE; FLUORESCENCE	The chromium moiety of gamma,beta-bidentate CrATP slowly accepts a ligand from the sarcoplasmic reticulum CaATPase to form an exchange inert coordination complex (k + 1 = 0.083 min-1; k - 2 = 0.003 min-1, 37-degrees-C, 100-mu-M CaCl2). The stability of the Cr3+ coordinate bonds allowed the complex to be isolated by filtration techniques at neutral pH without acid precipitation. We found 4-5 nmol of [gamma-P-32]CrATP to bind to 1 mg of sarcoplasmic reticulum protein with the subsequent occlusion of 7-8 nmol of Ca-45(2+). At 37-degrees-C, the CrATP.ATPase complex could be formed in the absence of Ca2+, although the reaction was 2-3 times slower than in the presence of Ca2+. Inhibition by P(i), by orthovanadate, and by fluorescein 5'-isothiocyanate verified that the bound CrATP was at the catalytic site. The site of CrATP attachment was found to be on the A tryptic fragment, possibly on the A2 subfragment. It was determined that Ca2+ binding to high affinity sites on the enzyme controls the rate by which the Cr3+ moiety accepts the ligand from the enzyme. The rate of change in the EPR spectrum of iodoacetamide spin-labeled ATPase was shown to follow the rate of ligand acceptance, rather than the binding of Ca2+ and substrate per se. This particular change has been attributed to the formation of an activated complex that is immediately precursory to phosphorylation and indicates here that this complex cannot be properly formed until the metal has been chelated by the enzyme. It is concluded that control over metal chelation (Cr3+ here, Mg2+ in the normal mechanism) is one means by which Ca2+ activates the enzyme.	UNIV PACIFIC, SCH DENT, DEPT PHYSIOL, SAN FRANCISCO, CA 94115 USA	University of the Pacific					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038073] Funding Source: NIH RePORTER; NCRR NIH HHS [RR05301] Funding Source: Medline; NIGMS NIH HHS [GM38073] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON KW, 1983, J BIOL CHEM, V258, P4276; Bevington PR, 1969, DATA REDUCTION ERROR; BIRMACHU W, 1989, BIOCHEMISTRY-US, V28, P3940, DOI 10.1021/bi00435a047; BISHOP JE, 1988, BIOCHEMISTRY-US, V27, P5233, DOI 10.1021/bi00414a043; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CHAMPEIL P, 1978, J BIOL CHEM, V253, P1179; CHIPMAN DM, 1988, BIOCHEMISTRY-US, V27, P5707, DOI 10.1021/bi00415a047; CLELAND WW, 1982, METHOD ENZYMOL, V87, P159; CLELAND WW, 1979, ADV INORG BIOCHEM, V1, P163; COAN C, 1983, BIOCHEMISTRY-US, V22, P5826, DOI 10.1021/bi00294a022; COAN C, 1986, J BIOL CHEM, V261, P394; COAN C, 1979, J BIOL CHEM, V254, P2968; COAN CR, 1977, J BIOL CHEM, V252, P3044; COLL RJ, 1984, J BIOL CHEM, V259, P4249; COLL RJ, 1986, BIOCHEM BIOPH RES CO, V138, P652, DOI 10.1016/S0006-291X(86)80546-0; DEMEIS L, 1981, SARCOPLASMIC RETICUL; DUPONT Y, 1976, BIOCHEM BIOPH RES CO, V71, P544, DOI 10.1016/0006-291X(76)90821-4; DUPONT Y, 1980, EUR J BIOCHEM, V109, P231, DOI 10.1111/j.1432-1033.1980.tb04788.x; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; FERNANDEZBELDA F, 1984, J BIOL CHEM, V259, P9687; GANTZER ML, 1982, BIOCHEMISTRY-US, V21, P4083, DOI 10.1021/bi00260a026; HANEL AM, 1990, BIOCHEMISTRY-US, V29, P5210, DOI 10.1021/bi00473a030; HIGHSMITH S, 1984, J BIOL CHEM, V259, P4651; INESI G, 1984, J BIOL CHEM, V259, P996; INESI G, 1985, ANNU REV PHYSIOL, V47, P573, DOI 10.1146/annurev.ph.47.030185.003041; INESI G, 1980, J BIOL CHEM, V255, P3025; JENCKS WP, 1989, J BIOL CHEM, V264, P18855; KURZMACK M, 1977, BIOCHEM BIOPH RES CO, V78, P772, DOI 10.1016/0006-291X(77)90246-7; LACAPERE JJ, 1990, J BIOL CHEM, V265, P348; LACAPERE JJ, 1990, J BIOL CHEM, V265, P8583; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MITCHINSON C, 1982, FEBS LETT, V146, P87, DOI 10.1016/0014-5793(82)80710-2; MOOS M, 1988, J BIOL CHEM, V263, P6005; MURPHY AJ, 1977, ARCH BIOCHEM BIOPHYS, V180, P114, DOI 10.1016/0003-9861(77)90014-5; MURPHY AJ, 1976, BIOCHEMISTRY-US, V15, P4492, DOI 10.1021/bi00665a025; NAKAMOTO RK, 1986, FEBS LETT, V194, P258, DOI 10.1016/0014-5793(86)80096-5; ORLOWSKI S, 1988, J BIOL CHEM, V263, P17576; PAULS H, 1980, EUR J BIOCHEM, V109, P523, DOI 10.1111/j.1432-1033.1980.tb04824.x; PETITHORY JR, 1986, BIOCHEMISTRY-US, V25, P4493, DOI 10.1021/bi00364a006; PICK U, 1980, BIOCHIM BIOPHYS ACTA, V626, P255, DOI 10.1016/0005-2795(80)90216-0; SERPERSU EH, 1982, EUR J BIOCHEM, V122, P347, DOI 10.1111/j.1432-1033.1982.tb05887.x; SHIGEKAWA M, 1983, J BIOL CHEM, V258, P8698; SHIGEKAWA M, 1983, J BIOL CHEM, V258, P4157; SMITH PK, 1985, ANAL BIOCHEM, V122, P347; SQUIER TC, 1987, J BIOL CHEM, V262, P4748; STAHL N, 1987, BIOCHEMISTRY-US, V26, P7654, DOI 10.1021/bi00398a019; TAKISAWA H, 1981, NATURE, V290, P271, DOI 10.1038/290271a0; THORLEYL.DA, 1973, EUR J BIOCHEM, V40, P403, DOI 10.1111/j.1432-1033.1973.tb03209.x; VILLAFRANCA JJ, 1982, METHOD ENZYMOL, V87, P180; VILSEN B, 1987, BIOCHIM BIOPHYS ACTA, V898, P313, DOI 10.1016/0005-2736(87)90072-1; VILSEN B, 1986, BIOCHIM BIOPHYS ACTA, V855, P429, DOI 10.1016/0005-2736(86)90089-1; WAKABAYASHI S, 1987, J BIOL CHEM, V262, P11524; YAMADA S, 1980, J BIOL CHEM, V255, P3108	53	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1991	266	19					12386	12394						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FV180	1648096				2022-12-25	WOS:A1991FV18000046
J	GRAPENGIESSER, E; GYLFE, E; HELLMAN, B				GRAPENGIESSER, E; GYLFE, E; HELLMAN, B			CYCLIC-AMP AS A DETERMINANT FOR GLUCOSE INDUCTION OF FAST CA2+ OSCILLATIONS IN ISOLATED PANCREATIC BETA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUAL-WAVELENGTH FLUOROMETRY; INDUCED ELECTRICAL-ACTIVITY; SINGLE-MOUSE ISLETS; CYTOPLASMIC CA-2+; B-CELLS; INTRACELLULAR CA-2+; CALCIUM; LANGERHANS; POTASSIUM; SECRETAGOGUES	The effect of glucose on the cytoplasmic Ca2+ concentration ([Ca2+]i) of pancreatic beta-cells from ob/ob-mice was examined by dual wavelength recordings of the 340/380 nm fluorescence excitation ratio of fura-2. Single beta-cells responded to 11-20 mm glucose with an initial lowering of [Ca2+]i, followed by an increase usually manifested as large amplitude oscillations (300-500 nm) with a frequency of 0.2-0.5/min (a-type). Particularly in freshly isolated beta-cells, there were also superimposed fast oscillations with frequencies of 2-8/min and amplitudes in the 70-250 nM range (b-type) and sometimes pronounced [Ca2+]i transients exceeding 250 nM with durations below 10 s (c-type). After addition of 1-100 nM glucagon or 1 mM of the dibutyryl or 8-bromo derivatives of cyclic AMP, glucose generated numerous b-type oscillations superimposed on those of the a-type or on an elevated steady-state level. The duration of the b-type oscillations increased slightly when glucose was raised from 11 to 16 mM. The c-type transients probably represent a separate reaction predominantly seen when raising cyclic AMP much above its normal concentration. It is concluded that glucose can induce fast oscillations of [Ca2+]i also in isolated beta-cells, especially when measures are taken to increase their cyclic AMP content.	UNIV UPPSALA,BIOMED,DEPT MED CELL BIOL,BOX 571,S-75123 UPPSALA,SWEDEN	Uppsala University				Gylfe, Erik/0000-0002-8414-2107				ASHCROFT FM, 1984, NATURE, V312, P446, DOI 10.1038/312446a0; Atwater I., 1986, BIOPHYSICS PANCREATI, P31; ATWATER I, 1989, MOL CELLULAR BIOL DI, P49; CHANCE B, 1975, ANAL BIOCHEM, V66, P498, DOI 10.1016/0003-2697(75)90617-X; CHAY TR, 1985, BIOPHYS J, V48, P815, DOI 10.1016/S0006-3495(85)83840-6; CHAY TR, 1983, BIOPHYS J, V42, P181, DOI 10.1016/S0006-3495(83)84384-7; COOK DL, 1983, METABOLISM, V32, P681, DOI 10.1016/0026-0495(83)90124-5; DEAN PM, 1970, J PHYSIOL-LONDON, V210, P255, DOI 10.1113/jphysiol.1970.sp009207; GRAPENGIESSER E, 1988, BIOCHEM BIOPH RES CO, V150, P419, DOI 10.1016/0006-291X(88)90537-2; GRAPENGIESSER E, 1988, BIOCHEM BIOPH RES CO, V151, P1299, DOI 10.1016/S0006-291X(88)80503-5; GRAPENGIESSER E, 1989, EXP CLIN ENDOCRINOL, V93, P321, DOI 10.1055/s-0029-1210875; GRAPENGIESSER E, 1989, ACTA PHYSIOL SCAND, V136, P113, DOI 10.1111/j.1748-1716.1989.tb08636.x; GRAPENGIESSER E, 1989, ARCH BIOCHEM BIOPHYS, V268, P404, DOI 10.1016/0003-9861(89)90602-4; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GYLFE E, 1991, CELL CALCIUM, V12, P229, DOI 10.1016/0143-4160(91)90023-8; GYLFE E, 1988, J BIOL CHEM, V263, P5044; HAHN HJ, 1974, J BIOL CHEM, V249, P5275; HELLMAN B, 1990, CELL CALCIUM, V11, P413, DOI 10.1016/0143-4160(90)90053-W; HELLMAN B, 1965, ANN NY ACAD SCI, V131, P541, DOI 10.1111/j.1749-6632.1965.tb34819.x; HELLMAN B, 1975, ENDOCRINOLOGY, V97, P392, DOI 10.1210/endo-97-2-392; Hellman B., 1986, CALCIUM CELL FUNCTIO, P253; HENQUIN JC, 1983, ENDOCRINOLOGY, V112, P2218, DOI 10.1210/endo-112-6-2218; HENQUIN JC, 1982, PFLUG ARCH EUR J PHY, V393, P322, DOI 10.1007/BF00581418; HENQUIN JC, 1983, BIOCHEM BIOPH RES CO, V112, P614, DOI 10.1016/0006-291X(83)91508-5; JOHANSSON H, 1989, CELL CALCIUM, V10, P205, DOI 10.1016/0143-4160(89)90003-1; LERNMARK A, 1974, DIABETOLOGIA, V10, P431, DOI 10.1007/BF01221634; PIPELEERS D, 1984, EXPERIENTIA, V40, P1114, DOI 10.1007/BF01971459; RORSMAN P, 1986, J PHYSIOL-LONDON, V374, P531, DOI 10.1113/jphysiol.1986.sp016096; ROSARIO LM, 1990, BIOPHYS J, V57, pA306; SCHUIT FC, 1985, ENDOCRINOLOGY, V117, P834, DOI 10.1210/endo-117-3-834; SHERMAN A, 1988, BIOPHYS J, V54, P411, DOI 10.1016/S0006-3495(88)82975-8; SMITH PA, 1990, FEBS LETT, V261, P187, DOI 10.1016/0014-5793(90)80667-8; SUSSMAN KE, 1987, DIABETES, V36, P571, DOI 10.2337/diabetes.36.5.571; SYKES JA, 1959, P SOC EXP BIOL MED, V100, P125, DOI 10.3181/00379727-100-24546; VALDEOLMILLOS M, 1989, FEBS LETT, V259, P19, DOI 10.1016/0014-5793(89)81484-X	35	71	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1991	266	19					12207	12210						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FV180	1648087				2022-12-25	WOS:A1991FV18000019
J	ZANGER, UM; LUND, J; SIMPSON, ER; WATERMAN, MR				ZANGER, UM; LUND, J; SIMPSON, ER; WATERMAN, MR			ACTIVATION OF TRANSCRIPTION IN CELL-FREE-EXTRACTS BY A NOVEL CAMP-RESPONSIVE SEQUENCE FROM THE BOVINE CYP17 GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DEPENDENT TRANSCRIPTION; REGULATORY ELEMENTS; P-450(11-BETA) GENE; TUMOR-CELLS; EXPRESSION; REGION; SYSTEM	An in vitro transcription system has been developed to study the transcriptional control of steroid hydroxylase gene expression in steroidogenic tissues using upstream sequences of these genes in rabbit beta-globin promoter/reporter constructs. Analysis of deletion mutants of the upstream region of the bovine CYPI7 (p45017-alpha) gene in whole cell extracts prepared from mouse Y1 adrenocortical cells revealed that sequences activating transcription in vitro are identical to those previously identified in vivo, namely the novel cAMP-responsive sequences crsI (-243 to -225 base pairs) and crsII (-80 to -40 base pairs). These sequences do not contain the known cAMP response elements, CRE or AP-2. In similar extracts from nonsteroidogenic mouse SVT2 cells, crsI was unable to activate transcription. Partially purified protein factor(s) binding to crsI were prepared from Y1 extracts by crsI-specific DNA affinity chromatography. This fraction activated transcription in vitro in SVT2 extracts only when crsI was present in the template. This in vitro transcription system will permit further investigation of crsI and its cognate factors and of the transcriptional regulation of the other steroid hydroxylase genes.	UNIV TEXAS,SW MED CTR,DEPT OBSTET & GYNECOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,CECIL H & IDA GREEN CTR REPROD BIOL SCI,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	ZANGER, UM (corresponding author), UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235, USA.		Zanger, Ulrich M./A-9364-2012	Zanger, Ulrich M./0000-0002-5276-2002	NICHD NIH HHS [HD 13234] Funding Source: Medline; NIDDK NIH HHS [DK 28350] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD013234] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028350] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHLGREN R, 1990, J BIOL CHEM, V265, P3313; HONDA SI, 1990, J BIOCHEM-TOKYO, V108, P1042, DOI 10.1093/oxfordjournals.jbchem.a123303; INOUE H, 1988, EUR J BIOCHEM, V171, P435, DOI 10.1111/j.1432-1033.1988.tb13808.x; JOHN ME, 1986, P NATL ACAD SCI USA, V83, P4715, DOI 10.1073/pnas.83.13.4715; KAGAWA N, 1990, J BIOL CHEM, V265, P11299; LUND J, 1990, J BIOL CHEM, V265, P3304; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; MONTMINY MR, 1990, TRENDS NEUROSCI, V13, P184, DOI 10.1016/0166-2236(90)90045-C; MOROHASHI KI, 1990, J BIOCHEM-TOKYO, V108, P1050, DOI 10.1093/oxfordjournals.jbchem.a123304; RICE DA, 1990, J BIOL CHEM, V265, P8052; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; ROSENFELD PJ, 1986, J BIOL CHEM, V261, P1398; SIMPSON ER, 1988, ANNU REV PHYSIOL, V50, P427, DOI 10.1146/annurev.ph.50.030188.002235; WATERMAN MR, 1989, TRENDS ENDOCRIN MET, V1, P99, DOI 10.1016/1043-2760(89)90011-8; WESTIN G, 1987, NUCLEIC ACIDS RES, V15, P6787, DOI 10.1093/nar/15.17.6787; WONG M, 1989, J BIOL CHEM, V264, P12867	16	31	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1991	266	18					11417	11420						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FT762	1646805				2022-12-25	WOS:A1991FT76200004
J	INAMOTO, S; YOSHIOKA, Y; OHTSUBO, E				INAMOTO, S; YOSHIOKA, Y; OHTSUBO, E			SITE-SPECIFIC AND STRAND-SPECIFIC NICKING INVITRO AT ORIT BY THE TRAY-TRAI ENDONUCLEASE OF PLASMID R100	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRATION HOST FACTOR; DNA HELICASE-I; ESCHERICHIA-COLI; SEX FACTOR; GENE-PRODUCT; F-PLASMID; PROTEIN; IDENTIFICATION; NUCLEOTIDE; SEQUENCE	We developed an in vitro system to reproduce a site- and strand-specific nicking at the oriT region of plasmid R100. The nicking reaction was dependent on the purified TraY protein and on the lysate, which was prepared from cells overproducing the TraI protein. This supports the idea that the protein products of two genes, traY and traI, constitute an endonuclease that introduces a specific nick in vivo in the oriT region of the conjugative plasmids related to R100. The products were the "complex" DNA molecules with a protein covalently linked with the 5'-end of the nick. The nick was introduced in the strand, which is supposed to be transferred to recipient cells during conjugation, and was located at the site 59 base pairs upstream of the TraY protein binding site, sbyA.	UNIV TOKYO,INST APPL MICROBIOL,YAYOI 1-1-1,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo								ABDELMONEM M, 1977, J MOL BIOL, V110, P667, DOI 10.1016/S0022-2836(77)80083-1; ABDELMONEM M, 1983, P NATL ACAD SCI-BIOL, V80, P4659, DOI 10.1073/pnas.80.15.4659; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; COHEN A, 1968, COLD SPRING HARB SYM, V33, P635, DOI 10.1101/SQB.1968.033.01.071; DEMPSEY WB, 1987, J BACTERIOL, V169, P4391, DOI 10.1128/jb.169.9.4391-4392.1987; DEMPSEY WB, 1989, MOL MICROBIOL, V3, P561, DOI 10.1111/j.1365-2958.1989.tb00202.x; DEMPSEY WB, 1990, MOL MICROBIOL, V4, P1019, DOI 10.1111/j.1365-2958.1990.tb00674.x; DEPEW RE, 1978, J BIOL CHEM, V253, P511; EVERETT R, 1980, J MOL BIOL, V136, P129, DOI 10.1016/0022-2836(80)90309-5; GAMAS P, 1987, MOL GEN GENET, V207, P302, DOI 10.1007/BF00331593; HARRISON B, 1986, ANAL BIOCHEM, V158, P307, DOI 10.1016/0003-2697(86)90555-5; IHLER G, 1969, P NATL ACAD SCI USA, V63, P138, DOI 10.1073/pnas.63.1.138; INAMOTO S, 1990, J GEN APPL MICROBIOL, V36, P287, DOI 10.2323/jgam.36.287; INAMOTO S, 1990, J BIOL CHEM, V265, P6461; INAMOTO S, 1988, J BACTERIOL, V170, P2749, DOI 10.1128/jb.170.6.2749-2757.1988; KLINE BC, 1971, BIOCHEMISTRY-US, V10, P4975, DOI 10.1021/bi00802a022; MACHIDA Y, 1982, CELL, V30, P29, DOI 10.1016/0092-8674(82)90008-3; MANIATIS T, 1982, MOL CLONING LABORATO, P90; Maxam A M, 1980, Methods Enzymol, V65, P499; MCDONELL MW, 1977, J MOL BIOL, V110, P119, DOI 10.1016/S0022-2836(77)80102-2; MCINTIRE SA, 1987, J BACTERIOL, V169, P3829, DOI 10.1128/jb.169.8.3829-3832.1987; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MORRISON A, 1979, CELL, V17, P175, DOI 10.1016/0092-8674(79)90305-2; OHKI M, 1968, COLD SPRING HARB SYM, V33, P651, DOI 10.1101/SQB.1968.033.01.074; OHTSUBO E, 1978, MOL GEN GENET, V159, P131, DOI 10.1007/BF00270886; PANSEGRAU W, 1990, J BIOL CHEM, V265, P10637; RUPP WD, 1968, COLD SPRING HARB SYM, V33, P647, DOI 10.1101/SQB.1968.033.01.073; SANCAR A, 1979, J BACTERIOL, V137, P692, DOI 10.1128/JB.137.1.692-693.1979; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; THOMPSON R, 1984, EMBO J, V3, P1175, DOI 10.1002/j.1460-2075.1984.tb01947.x; THOMPSON TL, 1989, J MOL BIOL, V207, P505, DOI 10.1016/0022-2836(89)90460-9; TRAXLER BA, 1988, J MOL BIOL, V204, P205, DOI 10.1016/0022-2836(88)90609-2; WILLETTS N, 1986, GENET RES, V47, P1, DOI 10.1017/S0016672300024447; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YOSHIOKA Y, 1987, J BACTERIOL, V169, P619, DOI 10.1128/jb.169.2.619-623.1987; YOSHIOKA Y, 1990, J MOL BIOL, V214, P39, DOI 10.1016/0022-2836(90)90145-C	37	39	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10086	10092						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	1645338				2022-12-25	WOS:A1991FP08600017
J	STOJILKOVIC, SS; IIDA, T; MERELLI, F; TORSELLO, A; KRSMANOVIC, LZ; CATT, KJ				STOJILKOVIC, SS; IIDA, T; MERELLI, F; TORSELLO, A; KRSMANOVIC, LZ; CATT, KJ			INTERACTIONS BETWEEN CALCIUM AND PROTEIN-KINASE-C IN THE CONTROL OF SIGNALING AND SECRETION IN PITUITARY GONADOTROPHS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-SECRETION; PHORBOL ESTERS; INOSITOL TRISPHOSPHATE; CYTOSOLIC CALCIUM; CHROMAFFIN CELLS; CA-2+ CHANNELS; RELEASE; ACTIVATION; RESPONSES; OSCILLATIONS	Single pituitary gonadotrophs exhibit episodes of spontaneous fluctuations in cytoplasmic calcium concentration ([Ca2+]i) due to entry through voltage-sensitive calcium channels (VSCC) and show prominent agonist-induced oscillations in [Ca2+]i that are generated by periodic release of intracellular Ca2+. Gonadotropin releasing hormone (GnRH) elicited three types of Ca2+ responses: at low doses, subthreshold, with an increase in basal [Ca2+]i; at intermediate doses, oscillatory, with dose-dependent modulation of spiking frequency; and at high doses, biphasic, without oscillations. Elevation of [Ca2+]i or activation of protein kinase C (PKC) did not influence the frequency of agonist-induced [Ca2+]i spikes but caused dose-dependent reductions in amplitude for all types of Ca2+ response. Stimulation of transient Ca2+ spikes by GnRH was followed by inhibition of the spontaneous fluctuations. GnRH also reduced the ability of high extracellular K+ to promote Ca2+ influx through VSCC. Activation of PKC by phorbol esters stimulated Ca2+ influx in quiescent cells but inhibited influx when VSCC were already activated, either spontaneously or by high K+. In contrast to their biphasic actions on [Ca2+]i, phorbol esters exerted only stimulatory actions on gonadotropin release, even when Ca2+ influx was concomitantly reduced. However, pituitary cells had to be primed with an appropriate [Ca2+]i level before exocytosis could be amplified by PKC. In PKC-depleted cells, all actions of phorbol esters on Ca2+ entry and amplitude modulation, and on LH release, were abolished. GnRH-induced LH secretion was also significantly reduced, especially the plateau phase of the response. These data indicate that Ca2+ and PKC serve as interacting signals during the cascade of cellular events triggered by agonist stimulation, in which Ca2+ turns cell responses on or off, and PKC amplifies the positive and negative effects of Ca2+.			STOJILKOVIC, SS (corresponding author), NICHHD,ENDOCRINOL & REPROD RES BRANCH,BLDG 10,RM B1-L400,BETHESDA,MD 20892, USA.							ABOUSAMRA AB, 1987, ENDOCRINOLOGY, V121, P965, DOI 10.1210/endo-121-3-965; ALBERT PR, 1987, J BIOL CHEM, V262, P6577; ALBERT PR, 1984, J BIOL CHEM, V259, P5350; ANDERSON JM, 1987, LIFE SCI, V41, P519, DOI 10.1016/0024-3205(87)90230-X; ANDREWS WV, 1988, J BIOL CHEM, V263, P13755; ARMSTRONG D, 1988, J GEN PHYSIOL, V92, pA10; ARTALEJO CR, 1990, NATURE, V348, P239, DOI 10.1038/348239a0; BALLA T, 1989, ARCH BIOCHEM BIOPHYS, V270, P398, DOI 10.1016/0003-9861(89)90043-X; BARRETT PQ, 1989, ENDOCR REV, V10, P496, DOI 10.1210/edrv-10-4-496; BEGGS MJ, 1989, ENDOCRINOLOGY, V124, P667, DOI 10.1210/endo-124-2-667; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BITTNER MA, 1990, J NEUROCHEM, V54, P205, DOI 10.1111/j.1471-4159.1990.tb13302.x; CHANG JP, 1988, ENDOCRINOLOGY, V123, P87, DOI 10.1210/endo-123-1-87; CHANG JP, 1986, J BIOL CHEM, V261, P9105; CHANG JP, 1988, J BIOL CHEM, V263, P18614; CONNOLLY TM, 1986, CELL, V46, P951, DOI 10.1016/0092-8674(86)90077-2; CROXTON TL, 1988, ENDOCRINOLOGY, V123, P1783, DOI 10.1210/endo-123-4-1783; DERIEMER SA, 1985, NATURE, V313, P316; FRENCH MB, 1989, ENDOCRINOLOGY, V124, P2235, DOI 10.1210/endo-124-5-2235; GOLDBETER A, 1990, P NATL ACAD SCI USA, V87, P1461, DOI 10.1073/pnas.87.4.1461; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARRIS KM, 1986, BIOCHEM BIOPH RES CO, V134, P1298, DOI 10.1016/0006-291X(86)90391-8; HIROTA K, 1985, J BIOL CHEM, V260, P3243; HOCKBERGER P, 1989, NATURE, V338, P340, DOI 10.1038/338340a0; HOLL RW, 1988, J BIOL CHEM, V263, P9682; HUANG KP, 1989, TRENDS NEUROSCI, V12, P425, DOI 10.1016/0166-2236(89)90091-X; IZUMI S, 1990, BIOCHEM BIOPH RES CO, V170, P359, DOI 10.1016/0006-291X(90)91282-W; IZUMI SI, 1989, ARCH BIOCHEM BIOPHYS, V275, P410, DOI 10.1016/0003-9861(89)90388-3; JOHNSON MS, 1988, J ENDOCRINOL, V116, P231, DOI 10.1677/joe.0.1160231; JUDD AM, 1987, MOL CELL ENDOCRINOL, V54, P107, DOI 10.1016/0303-7207(87)90147-X; JUDD AM, 1989, ENDOCRINOLOGY, V125, P1134, DOI 10.1210/endo-125-3-1134; LACERDA AE, 1988, NATURE, V335, P249, DOI 10.1038/335249a0; LEONG D, 1990, 72ND END SOC ANN M A, P955; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MCARDLE CA, 1987, J BIOL CHEM, V262, P5028; MERWE PA, 1990, BIOCHEM J, V268, P493; MESSING RO, 1986, BIOCHEM BIOPH RES CO, V136, P1049, DOI 10.1016/0006-291X(86)90439-0; MORGAN RO, 1987, J BIOL CHEM, V262, P1166; NAOR Z, 1988, MOL ENDOCRINOL, V2, P512, DOI 10.1210/mend-2-6-512; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PIETROBON D, 1990, NATURE, V346, P651, DOI 10.1038/346651a0; RANE SG, 1986, P NATL ACAD SCI USA, V83, P184, DOI 10.1073/pnas.83.1.184; RINK TJ, 1989, TRENDS NEUROSCI, V12, P43, DOI 10.1016/0166-2236(89)90133-1; SHANGOLD GA, 1988, P NATL ACAD SCI USA, V85, P6566, DOI 10.1073/pnas.85.17.6566; SHEARMAN MS, 1989, PHARMACOL REV, V41, P211; STOJILKOVIC S S, 1990, New Biologist, V2, P272; STOJILKOVIC SS, 1990, SCIENCE, V248, P1663, DOI 10.1126/science.2163546; STOJILKOVIC SS, 1988, J BIOL CHEM, V263, P17307; STOJILKOVIC SS, 1988, J BIOL CHEM, V263, P13054; STOJILKOVIC SS, 1990, P NATL ACAD SCI USA, V87, P8855, DOI 10.1073/pnas.87.22.8855; STOJILKOVIC SS, 1989, J BIOL CHEM, V264, P10939; STUTZIN A, 1989, AM J PHYSIOL, V257, pC865, DOI 10.1152/ajpcell.1989.257.5.C865; VIRGILIO FD, 1986, J BIOL CHEM, V261, P32; VIRMANI MA, 1989, CLIN RES, V37, pA849; WOODS NM, 1987, BIOCHEM J, V246, P619, DOI 10.1042/bj2460619	58	90	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10377	10384						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	1645348				2022-12-25	WOS:A1991FP08600060
J	HENSEL, CH; XIANG, RH; SAKAGUCHI, AY; NAYLOR, SL				HENSEL, CH; XIANG, RH; SAKAGUCHI, AY; NAYLOR, SL			USE OF THE SINGLE-STRAND CONFORMATION POLYMORPHISM TECHNIQUE AND PCR TO DETECT P53 GENE-MUTATIONS IN SMALL-CELL LUNG-CANCER	ONCOGENE			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; THERMOSTABLE DNA-POLYMERASE; TUMOR-ANTIGEN; SV40-TRANSFORMED CELLS; POINT MUTATIONS; OSTEO-SARCOMA; T-ANTIGEN; EXPRESSION; CARCINOMA; TRANSFORMATION	Recent studies have suggested that the p53 oncoprotein might function normally as a tumor suppressor. Mutations in highly conserved regions of the p53 gene have been observed in numerous types of tumors and tumor cell lines. To detect in a more sensitive manner p53 gene mutations in small cell lung cancer (SCLC) we utilized the single strand conformation polymorphism (SSCP) technique of Orita et al., (1989). Using PCR primers for the most highly conserved regions of the p53 gene, including exons 4-9, we have identified p53 mutations in 5 of 9 small cell lung cancer (SCLC) tumor DNA samples and in 1 SCLC cell line. None of the mutations seen in tumor DNA samples were present in normal DNA from the same patients, indicating that mutation of the p53 gene in these tumors was a somatic event. Of the six mutations observed, two were found in exon 7, three were found in the region encompassing exons 8 and 9, and one was found in the region encompassing exons 5 and 6. Nucleotide sequencing of one of the exon 7 mutations and one of the exon 8-9 mutations indicated that each was a C to T transition. In SCLC-6 the mutation resulted in substitution of serine for proline at amino acid 278 and in SCLC-4 substitution of tryptophan for arginine at amino acid 248, both nonconservative amino acid substitutions. Both of these changes are in regions of the p53 gene where mutations have been observed in other tumors. Two additional mutations were observed in SCLC cell lines using conventional PCR techniques. One of these is a mutation which results in altered splicing of the p53 pre-mRNA.			HENSEL, CH (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT CELLULAR & STRUCT BIOL,SAN ANTONIO,TX 78284, USA.				NATIONAL CANCER INSTITUTE [R29CA044764, F32CA008711] Funding Source: NIH RePORTER; NCI NIH HHS [CA44764, CA08711] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BIRD AP, 1980, NUCLEIC ACIDS RES, V8, P1499, DOI 10.1093/nar/8.7.1499; CHENG J, 1990, BLOOD, V75, P730; DUNCAN BK, 1980, NATURE, V287, P560, DOI 10.1038/287560a0; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRIEND SH, 1988, NEW ENGL J MED, V318, P618; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GIBBS RA, 1989, P NATL ACAD SCI USA, V86, P1919, DOI 10.1073/pnas.86.6.1919; GRIPPO P, 1968, J MOL BIOL, V36, P195, DOI 10.1016/0022-2836(68)90375-6; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HENSEL CH, 1990, CANCER RES, V50, P3067; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JENKINS JR, 1984, NATURE, V312, P641; JOHNSON BE, 1988, J CLIN INVEST, V82, P502, DOI 10.1172/JCI113624; KNUDSON AG, 1985, CANCER RES, V45, P1437; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; KRICKER MC, 1989, GENE, V85, P199, DOI 10.1016/0378-1119(89)90481-2; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEDUC F, 1989, AM J HUM GENET, V44, P282; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MCBRIDE OW, 1986, P NATL ACAD SCI USA, V83, P130, DOI 10.1073/pnas.83.1.130; MORI N, 1989, CANCER RES, V49, P5130; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SOUSSI T, 1987, ONCOGENE, V1, P71; SOUSSI T, 1989, J VIROL, V63, P3894, DOI 10.1128/JVI.63.9.3894-3901.1989; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAKAHASHI T, 1990, J CLIN INVEST, V86, P363, DOI 10.1172/JCI114710; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TOGUCHIDA J, 1988, CANCER RES, V48, P3939; VARLEY JM, 1989, ONCOGENE, V4, P725; WANG LM, 1988, BIOTECHNIQUES, V6, P839; WEICHSELBAUM RR, 1988, P NATL ACAD SCI USA, V85, P2106, DOI 10.1073/pnas.85.7.2106; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHANGPENG J, 1982, SCIENCE, V215, P181, DOI 10.1126/science.6274023; WHANGPENG J, 1982, CANCER GENET CYTOGEN, V6, P119, DOI 10.1016/0165-4608(82)90077-2; XU HJ, 1989, ONCOGENE, V4, P807; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YOKOTA J, 1988, ONCOGENE, V3, P471	54	83	83	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1991	6	6					1067	1071						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1648702				2022-12-25	WOS:A1991GU62200025
J	CHIAO, PJ; KANNAN, P; YIM, SO; KRIZMAN, DB; WU, TA; GALLICK, GE; TAINSKY, MA				CHIAO, PJ; KANNAN, P; YIM, SO; KRIZMAN, DB; WU, TA; GALLICK, GE; TAINSKY, MA			SUSCEPTIBILITY TO RAS ONCOGENE TRANSFORMATION IS COREGULATED WITH SIGNAL TRANSDUCTION THROUGH GROWTH-FACTOR RECEPTORS	ONCOGENE			English	Article							PROTEIN-TYROSINE KINASE; SARCOMA-VIRUS; MOLECULAR-CLONING; CELL-LINE; ORNITHINE DECARBOXYLASE; NUCLEOTIDE-SEQUENCE; RIBONUCLEIC-ACID; CHINESE-HAMSTER; EGF RECEPTOR; GENE	The human teratocarcinoma cell line PA-1 was derived from culturing ascites fluid cells from a patient with an ovarian germ line tumor. We previously described a nonneoplastic variant cloned from the PA-1 human teratocarcinoma cell line, clone 6, which at passage 40 was resistant to transformation by activated ras oncogenes. However, these cells could be transformed by a plasmid containing both myc and ras. Another PA-1 cell variant, clone 1, isolated at passage 63 and used 50 passages later becomes tumorigenic in nude mice after transfection with an activated ras oncogene (Tainsky et al, Anticancer Res., 8, 899-914, 1988). We report here that the progression from ras resistance to ras susceptibility occurs in both clone 1 and clone 6 cells during 25 passages in culture. In the presence of epidermal growth factor, transforming growth factor-alpha, and basic fibroblast growth factor, the ras-transformable cells exhibit anchorage independent growth, whereas the ras-resistant cells can not be growth stimulated by these growth factors. Similarly, ornithine decarboxylase (ODC) activity was inducible in ras susceptible and ras transformed cells by these growth factors, but not in the ras resistant cells. These differences are not due to the level and activity of epidermal growth factor receptor or to the level of expression of 25 proto-oncogenes.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,1515 HOLCOMBE BLVD,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center	TAINSKY, MA (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.			Tainsky, Michael/0000-0002-0261-831X	NATIONAL CANCER INSTITUTE [R01CA042810] Funding Source: NIH RePORTER; NCI NIH HHS [CA-42810] Funding Source: Medline; PHS HHS [09299] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANISOWICZ A, 1987, P NATL ACAD SCI USA, V84, P7188, DOI 10.1073/pnas.84.20.7188; BLAIR DG, 1980, P NATL ACAD SCI-BIOL, V77, P3504, DOI 10.1073/pnas.77.6.3504; BOS JL, 1989, CANCER RES, V49, P4682; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLBURN NH, 1985, MOL CELL BIOL, V5, P890, DOI 10.1128/MCB.5.4.890; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; DEVARE SG, 1983, P NATL ACAD SCI-BIOL, V80, P731, DOI 10.1073/pnas.80.3.731; DIPAOLO JA, 1983, J NATL CANCER I, V70, P3; DONNER L, 1982, J VIROL, V41, P489, DOI 10.1128/JVI.41.2.489-500.1982; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; ELLIS RW, 1981, NATURE, V292, P506, DOI 10.1038/292506a0; FEDELE LA, 1982, J VIROL, V41, P489; FRANCHINI G, 1983, P NATL ACAD SCI-BIOL, V80, P7385, DOI 10.1073/pnas.80.24.7385; FRIEND SH, 1986, NATURE, V323, P5643; GUMERLOCK PH, 1989, ANAL BIOCHEM, V180, P158, DOI 10.1016/0003-2697(89)90105-X; HARLOW E, 1985, MOL CELL BIOL, V5, P1601, DOI 10.1128/MCB.5.7.1601; HIGHFIELD PE, 1980, J VIROL, V36, P271, DOI 10.1128/JVI.36.1.271-279.1980; HONEGGER AM, 1987, MOL CELL BIOL, V7, P4568, DOI 10.1128/MCB.7.12.4568; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; KAPLAN PL, 1983, CELL, V33, P931, DOI 10.1016/0092-8674(83)90036-3; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; KOI M, 1989, P NATL ACAD SCI USA, V86, P8773, DOI 10.1073/pnas.86.22.8773; KRIZMAN DB, 1990, SOMAT CELL MOLEC GEN, V16, P115; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; Maniatis T., 1982, MOL CLONING; MARK GE, 1984, SCIENCE, V224, P285, DOI 10.1126/science.6324342; MILLER AD, 1984, CELL, V36, P51; MORIARITY DM, 1981, P NATL ACAD SCI-BIOL, V78, P2752, DOI 10.1073/pnas.78.5.2752; MORLA AO, 1986, P NATL ACAD SCI USA, V83, P8191, DOI 10.1073/pnas.83.21.8191; NUNN M, 1984, VIROLOGY, V139, P330, DOI 10.1016/0042-6822(84)90378-7; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SAGER R, 1983, P NATL ACAD SCI-BIOL, V80, P7601, DOI 10.1073/pnas.80.24.7601; SAGER R, 1984, CANCER CELL, V2, P487; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; SCHREIBER AB, 1986, SCIENCE, V232, P1250, DOI 10.1126/science.2422759; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SRINIVASAN A, 1981, P NATL ACAD SCI-BIOL, V78, P2077, DOI 10.1073/pnas.78.4.2077; STERN DF, 1986, MOL CELL BIOL, V6, P870, DOI 10.1128/MCB.6.3.870; TABOR CW, 1976, ANNU REV BIOCHEM, V45, P285, DOI 10.1146/annurev.bi.45.070176.001441; TAINSKY MA, 1984, SCIENCE, V225, P643, DOI 10.1126/science.6740333; TAINSKY MA, 1988, ANTICANCER RES, V8, P899; TAINSKY MA, 1987, MOL CELL BIOL, V7, P1280, DOI 10.1128/MCB.7.3.1280; TREVILLYAN JM, 1983, BIOCHIM BIOPHYS ACTA, V762, P187, DOI 10.1016/0167-4889(83)90070-8; WATSON DK, 1983, P NATL ACAD SCI USA, V80, P4036; Williams-Ashman H G, 1972, Adv Enzyme Regul, V10, P225, DOI 10.1016/0065-2571(72)90016-7; ZEUTHEN J, 1980, INT J CANCER, V25, P19, DOI 10.1002/ijc.2910250104	55	14	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1991	6	5					713	720						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT825	1646984				2022-12-25	WOS:A1991GT82500005
J	STORK, P; LODA, M; BOSARI, S; WILEY, B; POPPENHUSEN, K; WOLFE, H				STORK, P; LODA, M; BOSARI, S; WILEY, B; POPPENHUSEN, K; WOLFE, H			DETECTION OF K-RAS MUTATIONS IN PANCREATIC AND HEPATIC NEOPLASMS BY NONISOTOPIC MISMATCHED POLYMERASE CHAIN-REACTION	ONCOGENE			English	Article							HUMAN-COLON; ENZYMATIC AMPLIFICATION; POINT MUTATIONS; TRANSGENIC MICE; GENE-MUTATIONS; ONCOGENES; DNA; ACTIVATION; TUMORIGENESIS; CARCINOMAS	Mutations within codon 12 leading to activation of Kirsten-ras (K-ras) genes occur in a wide variety of human tumors, but have been reported most frequently in pancreatic carcinomas. We studied twenty-four paraffin-embedded pancreatic and hepatic tumors and two colon carcinoma cell lines with a rapid and simple approach that exploits allele-specific amplification of genomic DNA in a polymerase chain reaction (PCR). We extend the utility of this technique, which is dependent on an exact match at the 3' nucleotide between synthetic oligonucleotides and template DNA, to analyse paraffin-embedded tumor samples for the presence of point mutations at the first and second base of codon 12 of the K-ras gene. The PCR mismatch amplification technique demonstrated a 66% incidence of K-ras mutations at codon 12 in the group of pancreatic neoplasms as a whole. The percentage of mutations varied only slightly in the pancreatic cancer subcategories: 75% in ampullary, 66% in bile duct and 57% in the ductal adenocarcinomas. One islet cell carcinoma and normal tissues adjacent to the tumors revealed wild-type alleles only. One hepatoblastoma and one of six hepatocellular carcinomas also had codon 12 mutations. The PCR mismatch is a sensitive and rapid method that may be useful in screening neoplasms for K-ras point mutation and can be applied to archival material. This application allows a retrospective analyses of a wide range of pathological specimens to determine the role of K-ras mutations in human tumorigenesis.	NEW ENGLAND MED CTR HOSP, DEPT PATHOL, 171 HARRISON AVE, BOSTON, MA 02111 USA	Tufts Medical Center	WOLFE, H (corresponding author), NEW ENGLAND MED CTR HOSP, DEPT PATHOL, 171 HARRISON AVE, BOSTON, MA 02111 USA.		Bosari, Silvano/K-7744-2016	Bosari, Silvano/0000-0002-9744-6951				ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BOS JL, 1989, CANCER RES, V49, P4682; BURMER GC, 1989, P NATL ACAD SCI USA, V86, P2403, DOI 10.1073/pnas.86.7.2403; CAPON DJ, 1983, NATURE, V304, P507, DOI 10.1038/304507a0; CHEHAB FF, 1989, P NATL ACAD SCI USA, V86, P9178, DOI 10.1073/pnas.86.23.9178; COWAN NJ, 1983, MOL CELL BIOL, V3, P1738, DOI 10.1128/MCB.3.10.1738; EHLEN T, 1989, BIOCHEM BIOPH RES CO, V160, P441, DOI 10.1016/0006-291X(89)92452-2; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; GRUNEWALD K, 1989, INT J CANCER, V43, P1037, DOI 10.1002/ijc.2910430614; GU JR, 1986, J CELL PHYSIOL, P13; JIANG W, 1989, ONCOGENE, V4, P923; KWOK S, 1990, NUCLEIC ACIDS RES, V18, P999, DOI 10.1093/nar/18.4.999; NEWTON CR, 1989, NUCLEIC ACIDS RES, V17, P2503, DOI 10.1093/nar/17.7.2503; OKAYAMA H, 1989, J LAB CLIN MED, V114, P105; QUAIFE CJ, 1987, CELL, V48, P1023, DOI 10.1016/0092-8674(87)90710-0; RODENHUIS S, 1988, CANCER RES, V48, P5738; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANTOS E, 1989, FASEB J, V3, P2151, DOI 10.1096/fasebj.3.10.2666231; SHIBATA DK, 1988, J EXP MED, V167, P225, DOI 10.1084/jem.167.1.225; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SMIT VTHBM, 1988, NUCLEIC ACIDS RES, V16, P7773, DOI 10.1093/nar/16.16.7773; TADA M, 1990, CANCER RES, V50, P1121; WATATANI M, 1989, CANCER RES, V49, P1103; WU DY, 1989, P NATL ACAD SCI USA, V86, P2757, DOI 10.1073/pnas.86.8.2757	28	96	103	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1991	6	5					857	862						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT825	1646989				2022-12-25	WOS:A1991GT82500023
J	MANSER, E; LEUNG, T; MONFRIES, C; TEO, M; HALL, C; LIM, L				MANSER, E; LEUNG, T; MONFRIES, C; TEO, M; HALL, C; LIM, L			DIVERSITY AND VERSATILITY OF GTPASE ACTIVATING PROTEINS FOR THE P21RHO SUBFAMILY OF RAS-G PROTEINS DETECTED BY A NOVEL OVERLAY ASSAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BCR GENE-PRODUCTS; NEUROFIBROMATOSIS TYPE-1; MOLECULAR-CLONING; N-CHIMAERIN; KINASE-C; GAP; ENCODES; DOMAIN; IDENTIFICATION; SEQUENCE	The p21ras superfamily, involved in diverse processes including cell growth and intracellular trafficking, possesses intrinsic GTPase activity and cycles between GTP-bound active and GDP-bound quiescent states. This intrinsic activity, which results in down-regulation, is accelerated by GTPase activating proteins (GAPs). Other proteins regulating the GDP/GTP cycle include exchange proteins and dissociation inhibitors. The p21s rho, rac, and cdc42Hs constitute a subfamily implicated in cytoskeletal organization. BCR and n-chimaerin are prototypes of a new GAP family for these p21s. To investigate proteins modulating GTP hydrolysis of the three p21s, we developed a novel overlay assay applicable to tissue extracts. Diverse GAPs with different specificities were identified in all rat tissues. Brain contained rac1 GAPs of 45, 50, 85, 100, and 150 kDa. The p50 and p150 GAPs also act on rhoA and cdc42Hs and are ubiquitous, while the p45-GAP, n-chimaerin, is brain- and testis-specific and acts preferentially on rac1; the p100 GAP acts on both rac1 and cdc42Hs and is brain-specific. A new class of p21-interacting proteins was also identified. This diversity, versatility, and tissue specificity of GAPs may be required for fine control of the down-regulation of GTP-bound p21s and the suggested specific downstream effects of individual GAPs, which could involve "cross-talk" between GAPs and p21s.	INST NEUROL, LONDON WC1N 1PJ, ENGLAND	University of London; University College London	MANSER, E (corresponding author), NATL UNIV SINGAPORE, INST MOLEC & CELL BIOL, SINGAPORE 0511, SINGAPORE.		Hall, Christine/C-8390-2009; Manser, Edward/ABD-2301-2020					AHMED S, 1990, BIOCHEM J, V272, P767, DOI 10.1042/bj2720767; AHMED S, 1991, BIOCHEM J, V280, P233, DOI 10.1042/bj2800233; ARAKI S, 1991, MOL CELL BIOL, V11, P1438, DOI 10.1128/MCB.11.3.1438; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BURSTEIN ES, 1992, P NATL ACAD SCI USA, V89, P1154, DOI 10.1073/pnas.89.4.1154; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; DHUT S, 1988, ONCOGENE, V3, P561; DIDSBURY J, 1989, J BIOL CHEM, V264, P16387; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GARRETT MD, 1991, BIOCHEM J, V276, P833, DOI 10.1042/bj2760833; GOLUBIC M, 1991, EMBO J, V10, P2897, DOI 10.1002/j.1460-2075.1991.tb07839.x; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; HART MJ, 1991, J BIOL CHEM, V266, P20840; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LI WJ, 1989, ONCOGENE, V4, P127; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MCCORMICK F, 1990, ONCOGENE, V5, P1281; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; RON D, 1991, NEW BIOL, V3, P372; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; YATANI A, 1991, J BIOL CHEM, V266, P22222; YERAMIAN P, 1987, NUCLEIC ACIDS RES, V15, P1869, DOI 10.1093/nar/15.4.1869	33	63	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16025	16028						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1644791				2022-12-25	WOS:A1992JJ45800006
J	ARORA, N; KLIMPEL, KR; SINGH, Y; LEPPLA, SH				ARORA, N; KLIMPEL, KR; SINGH, Y; LEPPLA, SH			FUSIONS OF ANTHRAX TOXIN LETHAL FACTOR TO THE ADP-RIBOSYLATION DOMAIN OF PSEUDOMONAS EXOTOXIN-A ARE POTENT CYTOTOXINS WHICH ARE TRANSLOCATED TO THE CYTOSOL OF MAMMALIAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE-CYCLASE TOXIN; BACILLUS-ANTHRACIS; PROTECTIVE ANTIGEN; DIPHTHERIA-TOXIN; ESCHERICHIA-COLI; BORDETELLA-PERTUSSIS; EUKARYOTIC CELLS; RECEPTOR-BINDING; TERMINAL END; LOW-PH	The lethal factor (LF) and edema factor (EF) components of anthrax toxin are toxic to animal cells only if internalized by interaction with the protective antigen (PA) component. PA binds to a cell surface receptor and is proteolytically cleaved to expose a binding site for LF and EF. To study how LF and EF are internalized and trafficked within cells, LF was fused to the translocation and ADP-ribosylation domains (domains II and III, respectively) of Pseudomonas exotoxin A. LF fusion proteins containing Pseudomonas exotoxin A domains II and III were less toxic than those containing only domain III. Fusion proteins with a functional endoplasmic reticulum retention sequence, REDLK, at the carboxyl terminus of domain III were less toxic than those with a nonfunctional sequence, LDER. The most potent fusion protein, FP33, had an EC50 = 2 pM on Chinese hamster ovary cells, exceeding that of native Pseudomonas exotoxin A (EC50 = 420 pm). Toxicity of all the fusion proteins required the presence of PA and was blocked by monensin. These data suggest that LF and LF fusion proteins are efficiently translocated from acidified endosomes directly to the cytosol without trafficking through other organelles, as is required for Pseudomonas exotoxin A. This system provides a potential vehicle for importing diverse proteins into the cytosol of mammalian cells.	NIDR, MICROBIOL ECOL LAB, BLDG 30, RM 309, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)								ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; BHATNAGAR R, 1989, INFECT IMMUN, V57, P2107, DOI 10.1128/IAI.57.7.2107-2114.1989; BLAUSTEIN RO, 1989, P NATL ACAD SCI USA, V86, P2209, DOI 10.1073/pnas.86.7.2209; CHAUDHARY VK, 1988, P NATL ACAD SCI USA, V85, P2939, DOI 10.1073/pnas.85.9.2939; CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P308, DOI 10.1073/pnas.87.1.308; COLLIER RJ, 1971, J BIOL CHEM, V246, P1496; ESCUYER V, 1991, INFECT IMMUN, V59, P3381, DOI 10.1128/IAI.59.10.3381-3386.1991; FRIEDLANDER AM, 1986, J BIOL CHEM, V261, P7123; FRYLING C, 1992, INFECT IMMUN, V60, P497, DOI 10.1128/IAI.60.2.497-502.1992; GORDON VM, 1988, INFECT IMMUN, V56, P1066, DOI 10.1128/IAI.56.5.1066-1069.1988; GORDON VM, 1989, J BIOL CHEM, V264, P14792; HAMBLETON P, 1984, Vaccine, V2, P125, DOI 10.1016/0264-410X(84)90003-3; HANSKI E, 1989, TRENDS BIOCHEM SCI, V14, P459, DOI 10.1016/0968-0004(89)90106-0; HARRISSMITH PW, 1958, J GEN MICROBIOL, V19, P91, DOI 10.1099/00221287-19-1-91; HWANG J, 1987, CELL, V48, P129, DOI 10.1016/0092-8674(87)90363-1; JINNO Y, 1989, J BIOL CHEM, V264, P15953; JINNO Y, 1988, J BIOL CHEM, V263, P13203; KOEHLER TM, 1991, MOL MICROBIOL, V5, P1501, DOI 10.1111/j.1365-2958.1991.tb00796.x; Leppla S.H., 1991, SOURCEBOOK BACTERIAL, P277; LEPPLA SH, 1988, METHOD ENZYMOL, V165, P103; LEPPLA SH, 1991, METHOD ENZYMOL, V195, P153; LEPPLA SH, 1984, ADV CYCLIC NUCL PROT, V17, P189; LEPPLA SH, 1982, P NATL ACAD SCI-BIOL, V79, P3162, DOI 10.1073/pnas.79.10.3162; LEPPLA SH, 1976, INFECT IMMUN, V14, P1077, DOI 10.1128/IAI.14.4.1077-1086.1976; LEPPLA SH, 1990, SALISBURY MED B S, V68, P41; Leppla SH, 1988, BACTERIAL PROTEIN TO, P111; LITTLE SF, 1991, BIOCHEM BIOPH RES CO, V180, P531, DOI 10.1016/S0006-291X(05)81097-6; MADSHUS IH, 1989, INFECT IMMUN, V57, P1873, DOI 10.1128/IAI.57.7.1873-1878.1989; MIDDLEBROOK JL, 1977, CAN J MICROBIOL, V23, P183, DOI 10.1139/m77-026; MOEHRING TJ, 1977, CELL, V11, P447, DOI 10.1016/0092-8674(77)90063-0; MOSKAUG JO, 1989, J BIOL CHEM, V264, P15709; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; OELTMANN TN, 1991, FASEB J, V5, P2334, DOI 10.1096/fasebj.5.10.1676688; OGATA M, 1990, J BIOL CHEM, V265, P20678; PASTAN I, 1991, SCIENCE, V254, P1173, DOI 10.1126/science.1683495; PEZARD C, 1991, INFECT IMMUN, V59, P3472, DOI 10.1128/IAI.59.10.3472-3477.1991; QUINN CP, 1991, J BIOL CHEM, V266, P20124; ROBERTSON DL, 1986, GENE, V44, P71, DOI 10.1016/0378-1119(86)90044-2; SANDVIG K, 1981, J BIOL CHEM, V256, P9068; SEETHARAM S, 1991, J BIOL CHEM, V266, P17376; SIEGALL CB, 1989, J BIOL CHEM, V264, P14256; SINGH Y, 1989, J BIOL CHEM, V264, P11099; SINGH Y, 1991, J BIOL CHEM, V266, P15493; SINGH Y, 1989, J BIOL CHEM, V264, P19103; SMITH H, 1962, J GEN MICROBIOL, V29, P517, DOI 10.1099/00221287-29-3-517; SMITH H, 1954, NATURE, V173, P869, DOI 10.1038/173869a0; STENMARK H, 1991, J CELL BIOL, V113, P1025, DOI 10.1083/jcb.113.5.1025; Stephen J., 1986, Pharmacology of bacterial toxins, P381; STRAUCH KL, 1989, J BACTERIOL, V171, P2689, DOI 10.1128/jb.171.5.2689-2696.1989; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; WICK MJ, 1990, ANNU REV MICROBIOL, V44, P335, DOI 10.1146/annurev.mi.44.100190.002003; YOSHIDA T, 1991, EXP CELL RES, V192, P389, DOI 10.1016/0014-4827(91)90056-Z	52	106	112	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15542	15548						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1639793				2022-12-25	WOS:A1992JG11300046
J	LUNARDI, J; HURKO, O; ENGEL, WK; ATTARDI, G				LUNARDI, J; HURKO, O; ENGEL, WK; ATTARDI, G			THE MULTIPLE ADP/ATP TRANSLOCASE GENES ARE DIFFERENTIALLY EXPRESSED DURING HUMAN MUSCLE DEVELOPMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ADENINE-NUCLEOTIDE TRANSLOCATOR; ADP ATP TRANSLOCASE; MOLECULAR-CLONING; MITOCHONDRIAL-DNA; SEQUENCE; CARRIER; MYOGENESIS; PATTERNS; ENCODE; CELLS	The expression of the genes encoding the three isoforms of the human ADP/ATP translocase (T1, T2, and T3) has been analyzed at different stages of myogenic differentiation in an in vitro muscle cell system and compared with that in mature muscle. The results indicate that the three stages of muscle differentiation corresponding to myoblast proliferation, myotube formation, and mature muscle fibers are characterized by a different pattern of expression of the ADP/ATP translocase genes. In particular, the two T2-specific mRNAs are present at high, similar levels in myoblasts and myotubes and markedly decrease in amount in mature adult muscle. By contrast, the T3-specific mRNA is present in high amount in growing myoblasts, decreases markedly in myotubes, and is barely detectable in adult muscle. Finally, the T1-specific mRNA is present at a high level in adult muscle and is not detectable in either myoblasts or myotubes. Therefore, T1 gene expression appears to be a marker of a late stage in myogenesis. A parallel investigation of expression of the myosin heavy chain mRNA revealed absence of hybridization with the specific probe in RNA from proliferating myoblasts, a significant hybridization in myotube RNA, and a strong signal in adult muscle RNA.	CALTECH,DIV BIOL,PASADENA,CA 91125; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205; UNIV SO CALIF,SCH MED,CTR NEUROMUSCULAR,LOS ANGELES,CA 90033	California Institute of Technology; Johns Hopkins University; University of Southern California					NIAMS NIH HHS [AR38231] Funding Source: Medline; NIGMS NIH HHS [GM-11726] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038231] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AFFARA NA, 1980, J MOL BIOL, V140, P449; AMALDI F, 1968, J MOL BIOL, V33, P737, DOI 10.1016/0022-2836(68)90317-3; BATHGATE B, 1989, EUR J BIOCHEM, V183, P303, DOI 10.1111/j.1432-1033.1989.tb14929.x; BATTINI R, 1987, J BIOL CHEM, V262, P4355; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COBIANCHI F, 1987, METHOD ENZYMOL, V152, P94; COZENS AL, 1989, J MOL BIOL, V206, P261, DOI 10.1016/0022-2836(89)90477-4; DAVIS LG, 1986, BASIC METHODS MOL BI, P143; DUBIN DT, 1982, J MOL BIOL, V157, P1, DOI 10.1016/0022-2836(82)90510-1; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GAINES G, 1984, MOL CELL BIOL, V4, P1605, DOI 10.1128/MCB.4.8.1605; GEKAKIS N, 1989, J BIOL CHEM, V264, P3658; GUNNING P, 1987, MOL CELL BIOL, V7, P4100, DOI 10.1128/MCB.7.11.4100; HOULDSWORTH J, 1988, P NATL ACAD SCI USA, V85, P377, DOI 10.1073/pnas.85.2.377; HURKO O, 1986, ANN NEUROL, V20, P573, DOI 10.1002/ana.410200504; KLINGENBERG M, 1989, ARCH BIOCHEM BIOPHYS, V270, P1, DOI 10.1016/0003-9861(89)90001-5; KLINGENBERG M, 1985, ENZYMES BIOL MEMBR, V4, P511; KOLAROV J, 1990, J BIOL CHEM, V265, P12711; KU DH, 1990, J BIOL CHEM, V265, P16060; LAWSON JE, 1988, J BIOL CHEM, V263, P14812; LI K, 1989, J BIOL CHEM, V264, P13998; LI K, 1990, J BIOL CHEM, V265, P20585; LUNARDI J, 1991, J BIOL CHEM, V266, P16534; MEDFORD RM, 1983, J BIOL CHEM, V258, P1063; MILLER JB, 1986, P NATL ACAD SCI USA, V83, P3860, DOI 10.1073/pnas.83.11.3860; NECKELMANN N, 1987, P NATL ACAD SCI USA, V84, P7580, DOI 10.1073/pnas.84.21.7580; OJALA D, 1980, CELL, V22, P393, DOI 10.1016/0092-8674(80)90350-5; POWELL SJ, 1989, BIOCHEMISTRY-US, V28, P866, DOI 10.1021/bi00428a069; SABINA RL, 1989, MOL CELL BIOL, V9, P2244, DOI 10.1128/MCB.9.5.2244; SCHULTHEISS HP, 1984, EUR J BIOCHEM, V143, P599, DOI 10.1111/j.1432-1033.1984.tb08412.x; Vignais P. V., 1985, STRUCTURE PROPERTIES, V2, P139; WEBSTER KA, 1990, J CELL PHYSIOL, V142, P566, DOI 10.1002/jcp.1041420316	32	44	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15267	15270						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1639771				2022-12-25	WOS:A1992JG11300003
J	LUVISETTO, S; SCHMEHL, I; INTRAVAIA, E; CONTI, E; AZZONE, GF				LUVISETTO, S; SCHMEHL, I; INTRAVAIA, E; CONTI, E; AZZONE, GF			MECHANISM OF LOSS OF THERMODYNAMIC CONTROL IN MITOCHONDRIA DUE TO HYPERTHYROIDISM AND TEMPERATURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; CHARGE TRANSLOCATION STOICHIOMETRY; BROWN ADIPOSE-TISSUE; DELTA-MU-H; OXIDATIVE-PHOSPHORYLATION; INNER MEMBRANE; PROTON PUMPS; LOWER LIMITS; RESPIRATION; CONDUCTANCE	Incubation of normal mitochondria at 45-degrees-C results in increases of respiration and of total apparent proton conductance (TAPC, respiration/proton motive force) and in an upward shift of the flow-force relationships. Similar effects are observed during operation of the redox proton pumps at different sites of the respiratory chain. These effects are accompanied by an almost equivalent increase of the passive proton conductance (PPC, proton leakage/proton motive force). In mitochondria from 3,3,5-triiodo-L-thyronine (T3)-treated rats there are also increases of respiration and of TAPC and an upward shift of flow-force relationships, more pronounced at the level of the cytochrome oxidase proton pump. However, at variance from the incubation at 45-degrees-C, in mitochondria from T3-treated rats there is only a slight increase of PPC. Addition of bovine serum albumin to normal mitochondria incubated at 45-degrees-C results in a marked depression of TAPC in the nonlinear range of the flow-force relationships. An equivalent effect is not observed in mitochondria from T3-treated rats. The experimental results have been compared with computer simulations obtained on the basis of a chemiosmotic model of energy transduction. The increase of TAPC following incubation at high temperature is apparently due to changes of the proton conductance mainly at the level of PPC, while the increase of TAPC following T3 administration is rather due to changes presumably at the level of the redox or ATPase proton pumps.	CNR,STUDY PHYSIOL MITOCHONDRIA UNIT,I-35121 PADUA,ITALY	Consiglio Nazionale delle Ricerche (CNR)	LUVISETTO, S (corresponding author), UNIV PADUA,INST GEN PATHOL,CTR NATL RICH MITOCHONDRIAL PHYSIOL,VIA TRIESTE 75,I-35131 PADUA,ITALY.		Luvisetto, Siro/K-1844-2019; Luvisetto, Siro/AAJ-6985-2021; Luvisetto, Siro/M-9557-2015	Luvisetto, Siro/0000-0003-1399-2152; Luvisetto, Siro/0000-0003-1399-2152				AZZONE GF, 1966, REGULATION METABOLIC, V7, P332; BEAVIS AD, 1987, J BIOL CHEM, V262, P6174; BEAVIS AD, 1987, J BIOL CHEM, V262, P6165; BRAND MD, 1991, BIOCHEM J, V275, P81, DOI 10.1042/bj2750081; BRAND MD, 1990, J THEOR BIOL, V145, P267, DOI 10.1016/S0022-5193(05)80131-6; CARR FE, 1984, P NATL ACAD SCI-BIOL, V81, P974, DOI 10.1073/pnas.81.3.974; CHAPPELL JB, 1964, BIOCHEM J, V90, P225, DOI 10.1042/bj0900225; DUSZYNSKI J, 1985, FEBS LETT, V182, P243, DOI 10.1016/0014-5793(85)80307-0; Eyring H., 1963, MODERN CHEM KINETICS; GARLID KD, 1989, BIOCHIM BIOPHYS ACTA, V976, P109, DOI 10.1016/S0005-2728(89)80219-1; Guernsey DL, 1983, MOL BASIS THYROID HO, P293; HAFNER RP, 1988, EUR J BIOCHEM, V178, P511, DOI 10.1111/j.1432-1033.1988.tb14477.x; HAFNER RP, 1989, FEBS LETT, V248, P175, DOI 10.1016/0014-5793(89)80455-7; HAFNER RP, 1991, BIOCHEM J, V275, P75, DOI 10.1042/bj2750075; KLINGENBERG M, 1990, TRENDS BIOCHEM SCI, V15, P108, DOI 10.1016/0968-0004(90)90194-G; KRISHNAMOORTHY G, 1984, BIOCHEMISTRY-US, V23, P1640, DOI 10.1021/bi00303a009; LUVISETTO S, 1987, BIOCHEMISTRY-US, V26, P7332, DOI 10.1021/bi00397a021; LUVISETTO S, 1991, FEBS LETT, V291, P17, DOI 10.1016/0014-5793(91)81093-N; LUVISETTO S, 1989, BIOCHEMISTRY-US, V28, P1100, DOI 10.1021/bi00429a026; LUVISETTO S, 1990, J BIOL CHEM, V266, P1034; MASSARI S, 1972, J MEMBRANE BIOL, V9, P57, DOI 10.1007/BF01868043; MITCHELL P, 1967, BIOCHEM J, V104, P588, DOI 10.1042/bj1040588; NICHOLLS DG, 1977, EUR J BIOCHEM, V77, P349, DOI 10.1111/j.1432-1033.1977.tb11674.x; OUHABI R, 1991, BIOCHIM BIOPHYS ACTA, V1060, P293, DOI 10.1016/S0005-2728(05)80319-6; PIETROBON D, 1981, EUR J BIOCHEM, V117, P389, DOI 10.1111/j.1432-1033.1981.tb06350.x; PIETROBON D, 1986, BIOCHEMISTRY-US, V25, P767, DOI 10.1021/bi00352a005; PIETROBON D, 1985, BIOCHEMISTRY-US, V24, P5764, DOI 10.1021/bi00342a012; PIETROBON D, 1987, BIOCHEMISTRY-US, V26, P7339, DOI 10.1021/bi00397a022; ROSSI E, 1970, EUR J BIOCHEM, V12, P319, DOI 10.1111/j.1432-1033.1970.tb00853.x; ROTTENBERG H, 1986, BIOCHEMISTRY-US, V25, P1747, DOI 10.1021/bi00355a045; SHEARS SB, 1979, BIOCHEM J, V178, P505, DOI 10.1042/bj1780505; TONINELLO A, 1988, J BIOL CHEM, V263, P19407; WALZ D, 1990, BIOCHIM BIOPHYS ACTA, V1019, P171, DOI 10.1016/0005-2728(90)90196-B; WESTERHOFF HV, 1984, BIOCHIM BIOPHYS ACTA, V768, P257, DOI 10.1016/0304-4173(84)90019-3; WIKSTROM M, 1981, ANNU REV BIOCHEM, V50, P623, DOI 10.1146/annurev.bi.50.070181.003203; ZOLKIEWSKA A, 1989, ARCH BIOCHEM BIOPHYS, V275, P580; ZORATTI M, 1986, BIOCHEMISTRY-US, V25, P760, DOI 10.1021/bi00352a004; ZORATTI M, 1986, BIOCHIM BIOPHYS ACTA, V851, P123, DOI 10.1016/0005-2728(86)90255-0	38	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15348	15355						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1639781				2022-12-25	WOS:A1992JG11300017
J	SMYTH, SS; HILLERY, CA; PARISE, LV				SMYTH, SS; HILLERY, CA; PARISE, LV			FIBRINOGEN BINDING TO PURIFIED PLATELET GLYCOPROTEIN-IIB-IIIA (INTEGRIN-ALPHA-IIB-BETA-3) IS MODULATED BY LIPIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDIC-ACID; GPIIB-IIIA; MONOCLONAL-ANTIBODY; MEMBRANE; RECEPTOR; COMPLEX; ACTIVATION; INTEGRIN; POLYPHOSPHOINOSITIDE; ERYTHROCYTES	Soluble fibrinogen binding to the glycoprotein IIb-IIIa complex (integrin alpha(IIb)beta-3) requires platelet activation. The intracellular mediator(s) that convert glycoprotein IIb-IIIa into an active fibrinogen receptor have not been identified. Because the lipid composition of the platelet plasma membrane undergoes changes during activation, we investigated the effects of lipids on the fibrinogen binding properties of purified glycoprotein IIb-IIIa. Anion exchange chromatography of lipids extracted from platelets exposed to thrombin or other platelet agonists resolved an activity that increased fibrinogen binding to glycoprotein IIb-IIIa. A monoester phosphate was important for activity, and phosphatidic acid coeluted with the peak of activity. Purified phosphatidic acid dose-dependently promoted a specific interaction between glycoprotein IIb-IIIa and fibrinogen which possessed many but not all of the properties of fibrinogen binding to activated platelets. Phosphatidic acid appeared to increase the proportion of fibrinogen binding-competent glycoprotein IIb-IIIa complexes without altering their affinity for fibrinogen. The effects of phosphatidic acid were a result of specific structural properties of the lipid and were not mimicked by other phospholipids. Lysophosphatidic acid, however, was a potent inducer of fibrinogen binding to glycoprotein IIb-IIIa. These results demonstrate that specific lipids can affect fibrinogen binding to purified glycoprotein IIb-IIIa and suggest that the lipid environment has the potential to influence fibrinogen binding to its receptor.	UNIV N CAROLINA, CTR THROMBOSIS & HEMOSTASIS, DEPT PHARMACOL, CB 7365, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT PEDIAT, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT MED, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL038405] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007040] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07149-15, R29HL38405] Funding Source: Medline; NIGMS NIH HHS [GM07040] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAN D, 1978, BIOCHIM BIOPHYS ACTA, V508, P277, DOI 10.1016/0005-2736(78)90330-9; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; BENTON AM, 1982, BLOOD, V60, P642; BILLAH MM, 1981, J BIOL CHEM, V256, P5399; BODARY SC, 1989, J BIOL CHEM, V264, P18859; BRASS LF, 1985, J BIOL CHEM, V260, P7875; CHERESH DA, 1987, J CELL BIOL, V105, P1163, DOI 10.1083/jcb.105.3.1163; COLLER BS, 1983, J CLIN INVEST, V72, P325, DOI 10.1172/JCI110973; CONFORTI G, 1990, J BIOL CHEM, V265, P4011; CULLIS PR, 1983, MEMBRANE FLUIDITY BI, P39; DAWSON RMC, 1967, BIOCHEM J, V102, P205, DOI 10.1042/bj1020205; DECOURCELLES DD, 1989, J BIOL CHEM, V264, P3274; DITTMER JC, 1964, J LIPID RES, V5, P126; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; EXTON JH, 1990, J BIOL CHEM, V265, P1; FERRELL JE, 1984, J CELL BIOL, V98, P1992, DOI 10.1083/jcb.98.6.1992; FITZGERALD LA, 1985, J BIOL CHEM, V260, P1366; FITZGERALD LA, 1985, ANAL BIOCHEM, V151, P169, DOI 10.1016/0003-2697(85)90067-3; FITZGERALD LA, 1987, J BIOL CHEM, V262, P3936; HERMANOWSKIVOSATKA A, 1992, CELL, V68, P341, DOI 10.1016/0092-8674(92)90475-R; HILLERY CA, 1991, J BIOL CHEM, V266, P14663; HOLMSEN H, 1990, HEMATOLOGY, P1182; HUANG R, 1991, J BIOL CHEM, V266, P1652; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; ITAYA K, 1966, CLIN CHIM ACTA, V14, P361, DOI 10.1016/0009-8981(66)90114-8; JALINK K, 1990, J BIOL CHEM, V265, P12232; KAZAL LA, 1963, P SOC EXP BIOL MED, V113, P989; KROLL MH, 1989, J CELL PHYSIOL, V139, P558, DOI 10.1002/jcp.1041390315; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; LEUNG NL, 1983, BIOCHEM BIOPH RES CO, V113, P483, DOI 10.1016/0006-291X(83)91751-5; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; Low M. G, 1990, METHODS INOSITIDE RE, P145; MARGUERIE GA, 1979, J BIOL CHEM, V254, P5357; MCEVER RP, 1980, J CLIN INVEST, V66, P1311, DOI 10.1172/JCI109983; MEULEN JVD, 1990, BIOCHEM J, V271, P693; MORRIS AJ, 1990, J BIOL CHEM, V265, P13501; MUSTARD JF, 1989, METHOD ENZYMOL, V169, P3; NEUFELD EJ, 1983, J BIOL CHEM, V258, P2461; NEWMAN PJ, 1985, BLOOD, V65, P227; NOLAN RD, 1990, J BIOL CHEM, V265, P2441; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; PARISE LV, 1985, J BIOL CHEM, V260, P1750; PARISE LV, 1985, J BIOL CHEM, V260, P698; PHILLIPS DR, 1983, J BIOL CHEM, V258, P240; PHILLIPS DR, 1988, BLOOD, V71, P831; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; PLOW EF, 1984, J BIOL CHEM, V259, P5388; PLOW EF, 1985, P NATL ACAD SCI USA, V82, P8057, DOI 10.1073/pnas.82.23.8057; PONCZ M, 1987, J BIOL CHEM, V262, P8476; PREISS J, 1986, J BIOL CHEM, V261, P8597; RITTENHOUSESIMMONS S, 1979, J CLIN INVEST, V63, P580, DOI 10.1172/JCI109339; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHATTIL SJ, 1987, J BIOL CHEM, V262, P992; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; SIESS W, 1985, BLOOD, V65, P1141; SMYTH SS, 1992, J CELL BIOCH F, V16, P162; STEINER B, 1991, BLOOD, V78, P363; WATSON SP, 1988, BIOCHEM J, V249, P345, DOI 10.1042/bj2490345; WRIGHT SD, 1986, J IMMUNOL, V136, P1759	62	58	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15568	15577						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1639797				2022-12-25	WOS:A1992JG11300051
J	ALMOUSTAFA, AE; QUATANNENS, B; DIETERLENLIEVRE, F; SAULE, S				ALMOUSTAFA, AE; QUATANNENS, B; DIETERLENLIEVRE, F; SAULE, S			TUMORIGENIC EFFECTS MEDIATED IN THE AVIAN EMBRYO BY ONE OR MORE ONCOGENES ASSOCIATED WITH V-MYC	ONCOGENE			English	Note							C-MYC; CELLS; TRANSFORMATION; E26; EXPRESSION; RETROVIRUS; DOMAINS; INVIVO; QUAIL; ERBA	We have previously shown that introduction of the v-myc oncogene in chick or quail embryos at E3 induces rapidly growing heart rhabdomyomas. We now report that a retrovirus containing one or two other oncogenes induces additional pathologies specified by the v-myc-associated oncogene. The v-mil/myc combination introduced at E3 induces, in addition to heart rhabdomyomas, tumors of proliferating celts aggregated onto the luminal aspect of vessels in both chick and quail embryos. In the quail these cells react positively with the quail-specific mAb QH1, which recognizes endothelial and most hemopoietic cells, while chick intravascular cells do not react with the chick-specific mAb VIA2 that recognizes hemopoietic cells. Thus the v-mil/myc tumors appear to be of endothelial origin. The v-myb-ets/myc combination injected at E3 induces cardiorhabdomyomas and aggressive VIA2-positive hemopoietic tumors in chick embryos, but only the v-myc-induced cardiorhabdomyomas in quail embryos. When injected into hatched animals, v-myc alone transforms hemopoietic and perhaps endothelial cells, but not cardiac cells. Thus the developmental stage at which a cell type can be transformed by v-myc and another associated oncogene depends on as yet undefined species-specific factors. More importantly, several examples of oncogene cooperation in vivo are adduced by these experiments. The type of cell transformed is specified by the viral oncogene combination.	CNRS,INST EMBRYOL CELLULAIRE & MOLEC,49BIS AV BELLE GABRIELLE,F-94130 NOGENT SUR MARNE,FRANCE; COLL FRANCE,F-75231 PARIS 05,FRANCE; INST PASTEUR,CNRS,URA 1160,F-59019 LILLE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; College de France; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris								ALEXANDER RW, 1979, J NATL CANCER I, V62, P359; ALMOUSTAFA AE, 1988, CELL DIFFER DEV, V25, P119, DOI 10.1016/0922-3371(88)90005-6; AMOUYEL P, 1989, J VIROL, V63, P3382, DOI 10.1128/JVI.63.8.3382-3388.1989; BACHNOU N, 1991, ONCOGENE, V6, P1041; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BECHADE C, 1988, J VIROL, V62, P1211; Begg AM, 1927, LANCET, V1, P912; BIEGALKE BJ, 1987, J VIROL, V61, P2139; COLL J, 1983, EXP CELL RES, V149, P151, DOI 10.1016/0014-4827(83)90388-9; FERRE F, 1986, CR ACAD SCI III-VIE, V303, P633; GEGONNE A, 1987, MOL CELL BIOL, V7, P806, DOI 10.1128/MCB.7.2.806; GRAF T, 1979, VIROLOGY, V99, P431, DOI 10.1016/0042-6822(79)90024-2; GRAF T, 1986, CELL, V45, P357, DOI 10.1016/0092-8674(86)90321-1; JAFFREDO T, 1989, DEVELOPMENT, V105, P679; KAHN P, 1986, CELL, V45, P349, DOI 10.1016/0092-8674(86)90320-X; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; MARTIN P, 1986, J VIROL, V57, P1191, DOI 10.1128/JVI.57.3.1191-1194.1986; MARTIN P, 1986, VIROLOGY, V153, P272, DOI 10.1016/0042-6822(86)90030-9; Moscovici C, 1975, Curr Top Microbiol Immunol, V71, P79; MURRAY JA, 1930, SCI REP CANCER RES F, V9, P1; PARDANAUD L, 1987, DEVELOPMENT, V100, P339; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RONG PM, 1987, DEV BIOL, V122, P338, DOI 10.1016/0012-1606(87)90299-5; SAULE S, 1987, P NATL ACAD SCI USA, V84, P7982, DOI 10.1073/pnas.84.22.7982; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917	27	16	16	2	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1992	7	8					1667	1670						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1630827				2022-12-25	WOS:A1992JE81300027
J	ULLRICH, SJ; MERCER, WE; APPELLA, E				ULLRICH, SJ; MERCER, WE; APPELLA, E			HUMAN WILD-TYPE P53 ADOPTS A UNIQUE CONFORMATIONAL AND PHOSPHORYLATION STATE INVIVO DURING GROWTH ARREST OF GLIOBLASTOMA CELLS	ONCOGENE			English	Article							CELLULAR TUMOR-ANTIGEN; LARGE-T-ANTIGEN; MUTANT P53; SV40-TRANSFORMED CELLS; MONOCLONAL-ANTIBODIES; SUPPRESSOR PROTEIN; TRANSFORMED-CELLS; CYCLE CONTROL; EXPRESSION; GENE	The wild-type (wt) human tumor-suppressor gene product, p53, and its mutant form have been analysed in an in vivo system in which the inducible expression of wt p53 results in growth arrest in the G1 phase of the cell cycle. Two major pools of p53 are detected after wt p53 expression by their differential reactivity with the p53 monoclonal antibodies PAb 421 and 1801 as well as the mutant and wt-specific monoclonal antibodies PAb 240 and 1620; one pool contains wt and mutant p53 and is characterized as having a mutant conformation, whereas the other pool contains only wt p53 with a wt conformation. As G1 arrest is entered, the amount of wt p53 associated with the mutant pool decreases, such that by 12 h free wt and mutant p53 are the - major pools. Two-dimensional gel analysis of the p53 pools revealed that free wt p53 is phosphorylated to a greater degree than mutant p53, which correlated with the loss of the PAb 421 epitope on wt p53. In summary, the ability of wt p53 to exert an antiproliferative effect correlates with the presence of a unique conformational state of wt p53 characterized by increased phosphorylation and the loss of both the PAb 421 epitope and association with mutant p53 pool, whereas mutant p53 is unable to assume this conformational state.	THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,PHILADELPHIA,PA 19107	Jefferson University	ULLRICH, SJ (corresponding author), NCI,CELL BIOL LAB,BLDG 37,RM 1B03,BETHESDA,MD 20892, USA.							BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; DAVIDOFF AM, 1991, P NATL ACAD SCI USA, V88, P5006, DOI 10.1073/pnas.88.11.5006; DELEO AB, 1979, P NATL ACAD SCI USA, V76, P2420, DOI 10.1073/pnas.76.5.2420; DEPPERT W, 1990, ONCOGENE, V5, P1701; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINDLAY CA, 1989, CELL, V57, P1083; GANNON JV, 1990, EMBO J, V9, P1591; GARRELS JI, 1979, J BIOL CHEM, V254, P7961; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KASTAN MB, 1991, CANCER RES, V51, P4279; KERN SE, 1991, ONCOGENE, V6, P131; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; KRAISS S, 1991, EXP CELL RES, V192, P157, DOI 10.1016/0014-4827(91)90170-Y; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEHMAN TA, 1991, CANCER RES, V51, P4090; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LUBBERT M, 1989, ONCOGENE, V4, P643; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MERCER WE, 1990, ONCOGENE, V5, P973; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MERCER WE, 1985, EXP CELL RES, V160, P31, DOI 10.1016/0014-4827(85)90233-2; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MILNER J, 1991, P ROY SOC B-BIOL SCI, V245, P139, DOI 10.1098/rspb.1991.0100; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1990, ONCOGENE, V5, P1683; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PRASOLOV V S, 1988, Molekulyarnaya Biologiya (Moscow), V22, P1371; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; REIHSAUS E, 1990, ONCOGENE, V5, P137; ROVINSKI B, 1988, ONCOGENE, V2, P445; SCHEIDTMANN KH, 1990, J VIROL, V64, P672, DOI 10.1128/JVI.64.2.672-679.1990; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHOHAT O, 1987, ONCOGENE, V1, P277; VANROY F, 1990, ONCOGENE, V5, P207; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x	52	148	153	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1992	7	8					1635	1643						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1630823				2022-12-25	WOS:A1992JE81300021
J	DARNAY, BG; WANG, YL; RODWELL, VW				DARNAY, BG; WANG, YL; RODWELL, VW			IDENTIFICATION OF THE CATALYTICALLY IMPORTANT HISTIDINE OF 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; PSEUDOMONAS-MEVALONII; NUCLEOTIDE-SEQUENCE; DIRECTED MUTAGENESIS; ARABIDOPSIS-THALIANA; CDNA; BIOSYNTHESIS; INHIBITORS; PATHWAY; ENZYMES	We identify His381 of Pseudomonas mevalonii 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase as the basic residue functional in catalysis. The catalytic domain of 20 HMG-CoA reductases contains a single conserved histidine (His381 of the P. mevalonii enzyme). Diethyl pyrocarbonate inactivated the P. mevalonii enzyme, and hydroxylamine partially restored activity. We changed His381 to alanine, lysine, asparagine, and glutamine. The mutant proteins were overexpressed, purified to homogeneity, and characterized. His381 mutant enzymes were not inactivated by diethyl pyrocarbonate. All four mutant enzymes exhibited wild-type crystal morphology and chromatographed on substrate affinity supports like wild-type enzyme. The mutant enzymes had low catalytic activity (V(max) 0.06-0.5% that of wild-type enzyme), but K(m) values approximated those for wild-type enzyme. For wild-type enzyme and mutant enzymes H381A, H381N, and H381Q, K(m) values at pH 8.1 were 0.45, 0.27, 3.7, and 0.71 mM [(R,S)-mevalonate]; 0.05, 0.03, 0.20, and 0.11 mM [coenzyme A]; 0.22,0.14, 0.81, and 0.62 mM [NAD+]. K(m) values at pH 11 for wild-type enzyme and mutant enzyme H381K were 0.32 and 0.75 mM [(R,S)-mevalonate]; 0.24 and 0.50 mM [coenzyme A]; 0.15 and 1.23 mM [NAD+]. Both pK values for the enzyme-substrate complex increased relative to wild-type enzyme (by 1-2.5 pH units for pK1 and by 0.5-1.3 pH units for pK2). For mutant enzyme H381K, the pK1 of 10.2 is consistent with lysine acting as a general base at high pH. His381 of P. mevalonii HMG-CoA reductase, and consequently the histidine of the consensus Leu-Val-Lys-Ser-His-Met-Xaa-Xaa-Asn-Arg-Ser motif of the catalytic domain of eukaryotic HMG-CoA reductases, thus is the general base functional in catalysis.	PURDUE UNIV,DEPT BIOCHEM,1153 BIOCHEM BLDG,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047113] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 47113] Funding Source: Medline; NIAID NIH HHS [AI 127713] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BACH TJ, 1991, LIPIDS, V26, P637, DOI 10.1007/BF02536429; BASSON ME, 1988, MOL CELL BIOL, V8, P3797, DOI 10.1128/MCB.8.9.3797; BASSON ME, 1986, P NATL ACAD SCI USA, V83, P5563, DOI 10.1073/pnas.83.15.5563; BEACH MJ, 1989, J BACTERIOL, V171, P2994, DOI 10.1128/jb.171.6.2994-3001.1989; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CAELLES C, 1989, PLANT MOL BIOL, V13, P627, DOI 10.1007/BF00016018; CHEN HJ, 1990, J BIOL CHEM, V265, P4622; CHIN DJ, 1984, NATURE, V308, P613, DOI 10.1038/308613a0; CHYE ML, 1991, PLANT MOL BIOL, V16, P567, DOI 10.1007/BF00023422; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ENDO A, 1988, KLIN WOCHENSCHR, V66, P421, DOI 10.1007/BF01745510; GERTLER FB, 1988, MOL CELL BIOL, V8, P2713, DOI 10.1128/MCB.8.7.2713; GILL JF, 1985, J BIOL CHEM, V260, P9393; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HSIAO KC, 1991, NUCLEIC ACIDS RES, V19, P2787, DOI 10.1093/nar/19.10.2787; JORDANSTARCK TC, 1989, J BIOL CHEM, V264, P17919; JORDANSTARCK TC, 1989, J BIOL CHEM, V264, P17913; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAM WL, 1992, J BIOL CHEM, V267, P5829; LAWRENCE CM, 1990, 40TH ANN M AM CRYST, P68; LEARNED RM, 1989, P NATL ACAD SCI USA, V86, P2779, DOI 10.1073/pnas.86.8.2779; LUNDBLAD RL, 1984, CHEM REAGENTS PROTEI, V1, P105; LUSKEY KL, 1985, J BIOL CHEM, V260, P271; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; RAJKOVIC A, 1989, P NATL ACAD SCI USA, V86, P8217, DOI 10.1073/pnas.86.21.8217; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SKALNIK DG, 1985, DNA-J MOLEC CELL BIO, V4, P439, DOI 10.1089/dna.1985.4.439; STERMER BA, 1991, PHYSIOL MOL PLANT P, V39, P1935; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Tipton K F, 1979, Methods Enzymol, V63, P183; VELOSO D, 1981, BIOCHEMISTRY-US, V20, P887, DOI 10.1021/bi00507a036; WANG Y, 1989, J BACTERIOL, V171, P5567, DOI 10.1128/jb.171.10.5567-5571.1989; WANG YL, 1990, J BIOL CHEM, V265, P21634; WOODWARD HD, 1988, J BIOL CHEM, V263, P18411; 1983, OLIGONUCLEOTIDE DIRE, P1	37	54	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15064	15070						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634543				2022-12-25	WOS:A1992JF08800082
J	SENGELOV, H; NIELSEN, MH; BORREGAARD, N				SENGELOV, H; NIELSEN, MH; BORREGAARD, N			SEPARATION OF HUMAN NEUTROPHIL PLASMA-MEMBRANE FROM INTRACELLULAR VESICLES CONTAINING ALKALINE-PHOSPHATASE AND NADPH OXIDASE ACTIVITY BY FREE-FLOW ELECTROPHORESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBCELLULAR-LOCALIZATION; CYTOCHROME-B; MICROBICIDAL OXIDASE; COMPARTMENT; PROTEINS; SYSTEM; TRANSLOCATION; MOBILIZATION; ACTIVATION; COMPONENT	A putative reservoir of functional plasma membrane proteins, the secretory vesicle identified by latent alkaline phosphatase and tetranectin, has previously been demonstrated based on indirect evidence (Borregaard, N., Miller, L. J., and Springer, T. A. (1987) Science 237, 1204-1206; Borregaard, N., Christensen, L., Bjerrum, 0. W., Birgens, H. S., and Clemmesen, I. (1990) J. Clin. Invest. 85, 408-416). Difficulties in separating plasma membranes from this entity by density gradient centrifugation has prohibited discriminative dynamic and quantitative studies of secretory vesicles and plasma membranes. By combining density centrifugation with free flow electrophoresis we overcame this obstacle. Freshly prepared unperturbed human neutrophils were subjected to nitrogen cavitation followed by density centrifugation on Percoll gradients. Light membrane fractions containing plasma membranes and secretory vesicles were applied to high voltage free flow electrophoresis on an Elphor VaP 22. Plasma membrane vesicles, identified by HLA class I antigen mixed enzyme-linked immunosorbent assay (Bjerrum, O. W., and Borregaard, N. (1990) Scand. J. Immunol. 31, 305-313) and I-125 applied to cells before cavitation, were clearly separated from secretory vesicles. Electron microscopy revealed a morphology typical of plasma membranes in the former fraction and a population of vesicles with markedly different appearance in the latter. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis profiles demonstrated distinct differences in protein patterns between the two fractions. Superoxide generating capacity induced by sodium dodecyl sulfate and cytosol, an entity traditionally ascribed to the plasma membrane, was largely confined to fractions containing secretory vesicles. Thus, the majority of membrane-bound NADPH oxidase components of light membranes of human neutrophils colocalize with secretory vesicles.	UNIV COPENHAGEN,RIGSHOSP,INST PATHOL ANAT,DK-2100 COPENHAGEN,DENMARK	Rigshospitalet; University of Copenhagen	SENGELOV, H (corresponding author), RIGSHOSP,DEPT INTERNAL MED & HAEMATOL L,BLEGDAMSVEJ 9,DK-2100 COPENHAGEN,DENMARK.			Sengelov, Henrik/0000-0002-5991-2958				BJERRUM OW, 1990, SCAND J IMMUNOL, V31, P305, DOI 10.1111/j.1365-3083.1990.tb02773.x; BJERRUM OW, 1989, EUR J HAEMATOL, V43, P67; BJERRUM OW, 1987, J IMMUNOL, V138, P3913; BORREGAARD N, 1987, SCIENCE, V237, P1204, DOI 10.1126/science.3629236; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; BORREGAARD N, 1990, J CLIN INVEST, V85, P408, DOI 10.1172/JCI114453; BOS A, 1978, BIOCHIM BIOPHYS ACTA, V525, P37, DOI 10.1016/0005-2744(78)90197-3; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROMBERG Y, 1985, J BIOL CHEM, V260, P3539; CLARK RA, 1987, J BIOL CHEM, V262, P4065; DEBANNE MT, 1982, NATURE, V298, P398, DOI 10.1038/298398a0; DECHATELET LR, 1970, BIOCHEM MED METAB B, V4, P61, DOI 10.1016/0006-2944(70)90103-1; DELBUONO BJ, 1989, J CELL PHYSIOL, V141, P636, DOI 10.1002/jcp.1041410323; DEWALD B, 1982, J CLIN INVEST, V70, P518, DOI 10.1172/JCI110643; FLETCHER MP, 1983, BLOOD, V62, P792; FRANCIS JW, 1990, BIOCHIM BIOPHYS ACTA, V1025, P1, DOI 10.1016/0005-2736(90)90183-O; GOTTLIEB C, 1965, BLOOD-J HEMATOL, V25, P875, DOI 10.1182/blood.V25.6.875.875; HANIG K, 1974, METHOD ENZYMOL, V31, P746; HARMS E, 1980, P NATL ACAD SCI-BIOL, V77, P6139, DOI 10.1073/pnas.77.10.6139; JESAITIS AJ, 1988, J CELL BIOL, V107, P921, DOI 10.1083/jcb.107.3.921; KLEMPNER MS, 1980, J CELL BIOL, V86, P21, DOI 10.1083/jcb.86.1.21; KOBAYASHI T, 1991, J CELL BIOL, V113, P743, DOI 10.1083/jcb.113.4.743; KRAUSE KH, 1987, J CLIN INVEST, V80, P107, DOI 10.1172/JCI113035; LACAL P, 1988, J BIOL CHEM, V263, P9946; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARSH M, 1987, J CELL BIOL, V104, P875, DOI 10.1083/jcb.104.4.875; MENASHI S, 1981, J BIOL CHEM, V256, P4095; MILLER LJ, 1987, J CLIN INVEST, V80, P535, DOI 10.1172/JCI113102; MOLLINEDO F, 1984, J BIOL CHEM, V259, P7143; MORRE DJ, 1983, EUR J CELL BIOL, V31, P263; OHNO Y, 1985, J BIOL CHEM, V260, P2409; ROTROSEN D, 1988, J BIOL CHEM, V263, P10958; SEGAL AW, 1979, BIOCHEM J, V182, P181, DOI 10.1042/bj1820181	34	93	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14912	14917						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634531				2022-12-25	WOS:A1992JF08800063
J	MORRICAL, SW; WONG, ML; ALBERTS, BM				MORRICAL, SW; WONG, ML; ALBERTS, BM			AMPLIFICATION OF SNAP-BACK DNA-SYNTHESIS REACTIONS BY THE UVSX RECOMBINASE OF BACTERIOPHAGE-T4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED DNA; GENE-41 PROTEIN; GENETIC-RECOMBINATION; REPLICATION APPARATUS; PURIFICATION; POLYMERASE; EXCHANGE; HELICASE; FILAMENTS; PRODUCTS	The uvsX protein of bacteriophage T4 is a recA-type recombinase. This protein has previously been shown to help initiate DNA replication on a double-stranded DNA template by catalyzing synapsis between the template and a homologous DNA single strand that serves as primer. Here, we demonstrate that this replication-initiating activity of the uvsX protein greatly amplifies the snap-back (hairpin-primed) DNA synthesis that is catalyzed by the T4 DNA polymerase holoenzyme on linear, single-stranded DNA templates. Amplification requires the presence of uvsX protein, the DNA polymerase holoenzyme, T4 gene 32 protein, and a T4 DNA helicase, in a reaction that is modulated by the T4 uvsY protein (an accessory protein to the uvsX recombinase). The reaction products consist primarily of large networks of double-stranded and single-stranded DNA. With alkali or heat treatment, these networks resolve into dimer-length single-stranded DNA chains that renature instantaneously to reform a monomer-length double helix. A simple model can explain this uvsX protein-dependent amplification of snap-back DNA synthesis; the mechanism proposed makes several predictions that are confirmed by our experiments.	UNIV CALIF SAN FRANCISCO, SCH MED, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco					NIGMS NIH HHS [GM 24020, GM 11869] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024020, R01GM024020, F32GM011869] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERNSTEIN C, 1983, BACTERIOPHAGE T, V4, P138; BITTNER M, 1979, J BIOL CHEM, V254, P9565; DANNENBERG R, 1983, J VIROL, V45, P813, DOI 10.1128/JVI.45.2.813-831.1983; ENGLUND PT, 1971, J BIOL CHEM, V246, P5684; FORMOSA T, 1986, CELL, V47, P793, DOI 10.1016/0092-8674(86)90522-2; FORMOSA T, 1984, COLD SPRING HARB SYM, V49, P363, DOI 10.1101/SQB.1984.049.01.043; FORMOSA T, 1986, J BIOL CHEM, V261, P6107; GOULIAN M, 1968, J BIOL CHEM, V243, P627; GRIFFITH J, 1985, J BIOL CHEM, V260, P4484; HARRIS LD, 1989, J MOL BIOL, V206, P19, DOI 10.1016/0022-2836(89)90520-2; HINTON DM, 1986, J BIOL CHEM, V261, P5663; HUBERMAN JA, 1968, COLD SPRING HARB SYM, V33, P509, DOI 10.1101/SQB.1968.033.01.059; JONGENEEL CV, 1984, J BIOL CHEM, V259, P2925; KODADEK T, 1989, J BIOL CHEM, V264, P16451; KODADEK T, 1988, BIOCHEMISTRY-US, V27, P3210, DOI 10.1021/bi00409a013; KODADEK T, 1987, NATURE, V326, P312, DOI 10.1038/326312a0; KODADEK T, 1988, J BIOL CHEM, V263, P9427; KOLLER B, 1984, CELL, V36, P613, DOI 10.1016/0092-8674(84)90341-6; Kornberg A., 1980, DNA REPLICATION; KOZINSKI AW, 1983, BACTERIOPHAGE T, V4, P111; LIU CC, 1981, J BIOL CHEM, V256, P2813; LUDER A, 1982, P NATL ACAD SCI-BIOL, V79, P1101, DOI 10.1073/pnas.79.4.1101; Maniatis T., 1982, MOL CLONING; MILLER H, 1987, METHOD ENZYMOL, V152, P145; MORRICAL SW, 1990, J BIOL CHEM, V265, P15096; MORRIS CF, 1979, J BIOL CHEM, V254, P6797; MORRIS CF, 1979, J BIOL CHEM, V254, P6787; Mosig G, 1983, BACTERIOPHAGE, V4, P120; NOSSAL NG, 1974, J BIOL CHEM, V249, P5668; VENKATESAN M, 1982, J BIOL CHEM, V257, P2426; YAMAMOTO KR, 1970, VIROLOGY, V40, P734, DOI 10.1016/0042-6822(70)90218-7; YONESAKI T, 1985, EUR J BIOCHEM, V148, P127, DOI 10.1111/j.1432-1033.1985.tb08816.x; YONESAKI T, 1989, J BIOL CHEM, V264, P7814; YONESAKI T, 1985, EMBO J, V4, P3321, DOI 10.1002/j.1460-2075.1985.tb04083.x	34	20	47	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					14031	14038						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1649833				2022-12-25	WOS:A1991FY02700090
J	ROBERTS, VA; FREEMAN, HC; OLSON, AJ; TAINER, JA; GETZOFF, ED				ROBERTS, VA; FREEMAN, HC; OLSON, AJ; TAINER, JA; GETZOFF, ED			ELECTROSTATIC ORIENTATION OF THE ELECTRON-TRANSFER COMPLEX BETWEEN PLASTOCYANIN AND CYTOCHROME-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLUE COPPER PROTEINS; SPINACH PLASTOCYANIN; POPLAR PLASTOCYANIN; CONFORMATION CHANGE; PREFERRED SITES; POTENTIAL-FIELD; IONIC-STRENGTH; NUCLEIC-ACIDS; ACTIVE-SITE; FERRICYANIDE	To understand the specificity and efficiency of protein-protein interactions promoting electron transfer, we evaluated the role of electrostatic forces in precollision orientation by the development of two new methods, computer graphics alignment of protein electrostatic fields and a systematic orientational search of intermolecular electrostatic energies for two proteins at preset separation distances. We applied these methods to the plastocyanin/cytochrome c interaction, which is faster than random collision, but too slow for study by molecular dynamics techniques. Significant electrostatic potentials were concentrated on one-fourth (969 angstrom-2) of the plastocyanin surface, with the greatest negative potential centered on the Tyr-83 hydroxyl within the acidic patch, and on one-eighth (632 angstrom-2) of the cytochrome c surface, with the greatest positive potential centered near the exposed heme edge. Coherent electrostatic fields occurred only over these regions, suggesting that local, rather than global, charge complementarity controls productive recognition. The three energetically favored families of precollision orientations all directed the positive region surrounding the heme edge of cytochrome c toward the acidic patch of plastocyanin but differed in heme plane orientation. Analysis of electrostatic fields, electrostatic energies of precollision orientations with 12 and 6 angstrom separation distances, and surface topographies suggested that the favored orientations should converge to productive complexes promoting a single electron-transfer pathway from the cytochrome c heme edge to Tyr-83 of plastocyanin. Direct interactions of the exposed Cu ligand in plastocyanin with the cytochrome c heme edge are not unfavorable sterically or electrostatically but should occur no faster than randomly, indicating that this is not the primary pathway for electron transfer.	Scripps Res Inst, RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; UNIV SYDNEY, DEPT INORGAN CHEM, SYDNEY, NSW 2006, AUSTRALIA	Scripps Research Institute; University of Sydney			Tainer, John/GWQ-4878-2022	Tainer, John/0000-0003-1659-2429				ADAMS DJ, 1979, CHEM PHYS LETT, V62, P329, DOI 10.1016/0009-2614(79)80190-6; AHMED AJ, 1981, J BIOL CHEM, V256, P1611; ALLISON SA, 1988, BIOPOLYMERS, V27, P251, DOI 10.1002/bip.360270207; ANDERSON GP, 1987, BIOCHIM BIOPHYS ACTA, V894, P386, DOI 10.1016/0005-2728(87)90117-4; ARMSTRONG GD, 1986, BIOCHEMISTRY-US, V25, P6947, DOI 10.1021/bi00370a031; AUGUSTIN MA, 1983, J BIOL CHEM, V258, P6405; BEOKUBETTS D, 1983, J CHEM SOC CHEM COMM, P1150, DOI 10.1039/c39830001150; BEOKUBETTS D, 1985, INORG CHEM, V24, P1677, DOI 10.1021/ic00205a017; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BRUNSCHWIG BS, 1985, INORG CHEM, V24, P3743, DOI 10.1021/ic00217a010; BURCH AM, 1990, SCIENCE, V247, P831, DOI 10.1126/science.2154849; BUTLER J, 1983, J BIOL CHEM, V258, P6400; COLMAN PM, 1978, NATURE, V272, P319, DOI 10.1038/272319a0; CONNOLLY ML, 1985, COMPUT CHEM, V9, P1, DOI 10.1016/0097-8485(85)80011-5; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; COOKSON DJ, 1980, BIOCHIM BIOPHYS ACTA, V591, P162, DOI 10.1016/0005-2728(80)90230-3; DURELL SR, 1990, ARCH BIOCHEM BIOPHYS, V277, P241, DOI 10.1016/0003-9861(90)90575-J; FISH LE, 1985, MOL BIOL PHOTOSYNTHE, P111; FISHER CL, 1990, J MOL GRAPHICS, V8, P125, DOI 10.1016/0263-7855(90)80052-H; FREEMAN HC, 1981, COORD CHEM, V21, P29; GETZOFF ED, 1983, NATURE, V306, P287, DOI 10.1038/306287a0; GETZOFF ED, 1986, BIOPHYS J, V49, P191, DOI 10.1016/S0006-3495(86)83634-7; GEYSEN HM, 1987, SCIENCE, V235, P1184, DOI 10.1126/science.3823878; GUSS JM, 1983, J MOL BIOL, V169, P521; GUSS JM, 1986, J MOL BIOL, V192, P361, DOI 10.1016/0022-2836(86)90371-2; KING GC, 1985, BIOCHIM BIOPHYS ACTA, V806, P262, DOI 10.1016/0005-2728(85)90104-5; KOPPENOL WH, 1982, J BIOL CHEM, V257, P4426; KOPPENOL WH, 1978, BIOCHIM BIOPHYS ACTA, V503, P499, DOI 10.1016/0005-2728(78)90149-4; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MATTHEW JB, 1983, NATURE, V301, P169, DOI 10.1038/301169a0; MAUK MR, 1986, BIOCHEMISTRY-US, V25, P7085, DOI 10.1021/bi00370a049; MAYO SL, 1986, SCIENCE, V233, P948, DOI 10.1126/science.3016897; MORAND LZ, 1989, BIOCHEMISTRY-US, V28, P8039, DOI 10.1021/bi00446a011; NORTHRUP SH, 1988, SCIENCE, V241, P67, DOI 10.1126/science.2838904; O'Donnell T. J., 1981, Computer Graphics, V15, P133, DOI 10.1145/965161.806799; POULOS TL, 1980, J BIOL CHEM, V255, P322; POULOS TL, 1987, J BIOL CHEM, V262, P13881; RUSH JD, 1988, BIOCHEMISTRY-US, V27, P5876, DOI 10.1021/bi00416a009; SALEMME FR, 1976, J MOL BIOL, V102, P563, DOI 10.1016/0022-2836(76)90334-X; SEGAL MG, 1978, J AM CHEM SOC, V100, P4585, DOI 10.1021/ja00482a044; SHARP K, 1987, SCIENCE, V236, P1460, DOI 10.1126/science.3589666; SIMONDSEN RP, 1982, BIOCHEMISTRY-US, V21, P6366, DOI 10.1021/bi00268a008; SINCLAIRDAY JD, 1985, J CHEM SOC CHEM COMM, P505, DOI 10.1039/c39850000505; SYKES AG, 1985, CHEM SOC REV, V14, P283, DOI 10.1039/cs9851400283; TAKABE T, 1989, J BIOCHEM-TOKYO, V105, P98, DOI 10.1093/oxfordjournals.jbchem.a122627; TAKABE T, 1984, J BIOCHEM-TOKYO, V96, P385, DOI 10.1093/oxfordjournals.jbchem.a134849; TAKANO T, 1981, J MOL BIOL, V153, P95, DOI 10.1016/0022-2836(81)90529-5; TAKANO T, 1981, J MOL BIOL, V153, P79, DOI 10.1016/0022-2836(81)90528-3; TAKENAKA K, 1984, J BIOCHEM-TOKYO, V96, P1813, DOI 10.1093/oxfordjournals.jbchem.a135015; TOLLIN G, 1986, P NATL ACAD SCI USA, V83, P3693, DOI 10.1073/pnas.83.11.3693; WARWICKER J, 1989, J MOL BIOL, V206, P381, DOI 10.1016/0022-2836(89)90487-7; WARWICKER J, 1982, J MOL BIOL, V157, P671, DOI 10.1016/0022-2836(82)90505-8; WEBER PC, 1985, J BIOL CHEM, V260, P5568; WEINER PK, 1981, J COMPUT CHEM, V2, P287, DOI 10.1002/jcc.540020311; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; WENDOLOSKI JJ, 1987, SCIENCE, V238, P794, DOI 10.1126/science.2823387; WOOD PM, 1974, BIOCHIM BIOPHYS ACTA, V357, P370, DOI 10.1016/0005-2728(74)90027-9	57	111	112	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1991	266	20					13431	13441						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FX132	1649191				2022-12-25	WOS:A1991FX13200098
J	CROOK, T; WREDE, D; TIDY, J; SCHOLEFIELD, J; CRAWFORD, L; VOUSDEN, KH				CROOK, T; WREDE, D; TIDY, J; SCHOLEFIELD, J; CRAWFORD, L; VOUSDEN, KH			STATUS OF C-MYC, P53 AND RETINOBLASTOMA GENES IN HUMAN PAPILLOMAVIRUS POSITIVE AND NEGATIVE SQUAMOUS-CELL CARCINOMAS OF THE ANUS	ONCOGENE			English	Article								We have examined a series of squamous cell carcinomas (SCC) of the anus, anal intraepithelial neoplasia grade III (AINIII) lesions and haemorrhoids for the presence of sequences from transforming human papillomavirus (HPV) types by polymerase chain reaction (PCR)/Southern blotting. In addition, the same DNAs have been analysed for abnormalities in the c-myc, p53 and retinoblastoma (Rb-1) gene loci by Southern blotting. HPV16 sequences were detected in a total of 38 of 50 (76%) and HPV18 sequences in 4 of the 50 cancers (8%). Of 12 haemorrhoids examined, none contained HPV16 or HPV18 sequences. Amplification of c-myc was demonstrated in 15 of the 50 cancers (30%), of which 13 were HPV16 positive, and one also positive for HPV18. Amplification of c-myc was not observed in the 5 AINIII or any of the 41 haemorrhoid DNAs analysed. Rearrangement of c-myc was not seen in any of the DNAs. Gross rearrangement, or loss of p53 or Rb-1 loci was not observed in any normal or tumour tissue. However, in preliminary analysis of p53 sequence, three tumours negative for HPV were heterozygous for p53 point mutation whereas six HPV positive tumours and two haemorrhoids were wild-type sequence throughout exons four to ten.	ST MARYS HOSP, SCH MED, LUDWIG INST CANC RES, NORFOLK PL, LONDON WC2, ENGLAND; SAMARITAN HOSP WOMEN, DEPT GYNAECOL, LONDON NW1, ENGLAND; UNIV CAMBRIDGE, DEPT PATHOL, IMPERIAL CANCER RES FUND, TUMOUR VIRUS GRP, CAMBRIDGE CB2 1QP, ENGLAND; UNIV SHEFFIELD, NO GEN HOSP, CTR CLIN SCI, SURG UNIT, SHEFFIELD S5 7AU, ENGLAND	Ludwig Institute for Cancer Research; University of Cambridge; Northern General Hospital; University of Sheffield	VOUSDEN, KH (corresponding author), ST MARYS HOSP, SCH MED, LUDWIG INST CANC RES, NORFOLK PL, LONDON WC2, ENGLAND.							Austin D F, 1982, Natl Cancer Inst Monogr, V62, P89; BARTEK J, 1990, ONCOGENE, V5, P893; BECKMANN AM, 1989, INT J CANCER, V43, P1042, DOI 10.1002/ijc.2910430615; CHIBA I, 1990, ONCOGENE, V5, P1603; CROOK T, 1990, ONCOGENE, V5, P619; CROOK T, 1989, MOL CARCINOGEN, V2, P308, DOI 10.1002/mc.2940020605; CROOK T, 1991, IN PRESS J VIROL; CROOK T, 1991, IN PRESS ONCOGENE; DALING JR, 1987, NEW ENGL J MED, V317, P973, DOI 10.1056/NEJM198710153171601; DARLING SM, 1986, P NATL ACAD SCI USA, V83, P135, DOI 10.1073/pnas.83.1.135; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; HAUSEN HZ, 1988, MOL CARCINOGEN, V1, P147, DOI 10.1002/mc.2940010302; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; KONDOLEON S, 1987, NUCLEIC ACIDS RES, V15, P10605, DOI 10.1093/nar/15.24.10605; MORI N, 1990, ONCOGENE, V5, P1713; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P5707, DOI 10.1093/nar/16.12.5707; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OCADIZ R, 1987, CANCER RES, V47, P4173; PALMER JG, 1987, LANCET, V2, P42; PALMER JG, 1989, DIS COLON RECTUM, V32, P1016, DOI 10.1007/BF02553872; PECORARO G, 1989, P NATL ACAD SCI USA, V86, P563, DOI 10.1073/pnas.86.2.563; RABBITTS TH, 1984, NATURE, V309, P592, DOI 10.1038/309592a0; REISSMANN PT, 1989, ONCOGENE, V4, P839; RIOU G, 1987, LANCET, V1, P761; RIOU G, 1990, LANCET, V335, P1171; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SCHEURLEN W, 1986, INT J CANCER, V38, P671, DOI 10.1002/ijc.2910380509; SCHOLEFIELD JH, 1989, LANCET, V2, P765; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TUCK SP, 1989, ONCOGENE RES, V4, P81; VOUSDEN KH, 1989, CANCER CELL-MON REV, V1, P43; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YOUNG LS, 1989, BRIT MED J, V298, P14, DOI 10.1136/bmj.298.6665.14	37	97	98	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1991	6	7					1251	1257						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1650445				2022-12-25	WOS:A1991GV26000022
J	BACCARINI, M; GILL, GN; STANLEY, ER				BACCARINI, M; GILL, GN; STANLEY, ER			EPIDERMAL GROWTH-FACTOR STIMULATES PHOSPHORYLATION OF RAF-1 INDEPENDENTLY OF RECEPTOR AUTOPHOSPHORYLATION AND INTERNALIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; SERINE-THREONINE KINASE; PDGF BETA-RECEPTOR; TYROSINE PHOSPHORYLATION; PHOSPHOLIPASE-C; EGF RECEPTOR; FACTOR-I; SIGNALING COMPLEX; CARCINOMA-CELLS; SWISS 3T3-CELLS	Phosphorylation of the RAF-1 protooncogene product and activation of its associated serine/threonine kinase are common features of the response of cells to peptide growth factors. We have used wild-type and mutant epidermal growth factor (EGF) receptors to investigate mechanisms of RAF-1 phosphorylation. In vivo EGF treatment rapidly stimulated phosphorylation of RAF-1 exclusively on serine residues. Stimulation of RAF-1 phosphorylation occurred at 37-degrees-C but not at 4-degrees-C and persisted after dissociation of EGF from its receptor. EGF-induced RAF-1 serine phosphorylation required the intrinsic tyrosine kinase activity of the EGF receptor but was independent of EGF receptor self-phosphorylation and of ligand-induced receptor internalization. Down-regulation of protein kinase C did not affect the EGF-induced increase in RAF-1 phosphorylation. These data suggest that the activated tyrosine kinase activity of the EGF receptor enhances serine phosphorylation of RAF-1 via an intermediary molecule(s).	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT DEV BIOL & CANC,1300 MORRIS PK AVE,BRONX,NY 10461; UNIV CALIF SAN DIEGO,SCH MED,DEPT MED,DIV ENDOCRINOL & METAB,LA JOLLA,CA 92093	Yeshiva University; Albert Einstein College of Medicine; University of California System; University of California San Diego			Baccarini, Manuela/B-6481-2014; Stanley, Evan R/J-9154-2013	Baccarini, Manuela/0000-0002-3033-391X; Stanley, Evan R/0000-0002-2910-2065	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM013149] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA032551, R01CA026504, R37CA026504] Funding Source: NIH RePORTER; NCI NIH HHS [CA 32551, CA 26504] Funding Source: Medline; NIADDK NIH HHS [AM13149] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; AHN NG, 1990, J BIOL CHEM, V265, P11487; AHN NG, 1990, J BIOL CHEM, V265, P11495; APP H, 1991, IN PRESS MOL CELL BI; BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; BERRY N, 1990, P NATL ACAD SCI USA, V87, P2294, DOI 10.1073/pnas.87.6.2294; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COUGHLIN SR, 1989, SCIENCE, V243, P1991; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; GILL GN, 1984, J BIOL CHEM, V259, P7755; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; GUILBERT LJ, 1986, J BIOL CHEM, V261, P4024; HAIGLER HT, 1980, J BIOL CHEM, V255, P1239; HSUAN JJ, 1989, BIOCHEM J, V262, P659, DOI 10.1042/bj2620659; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KOLCH W, 1988, BIOCHIM BIOPHYS ACTA, V949, P233, DOI 10.1016/0167-4781(88)90087-5; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN CR, 1986, CELL, V44, P839, DOI 10.1016/0092-8674(86)90006-1; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MCCUNE BK, 1989, J BIOL CHEM, V264, P15501; MIYASAKA T, 1990, J BIOL CHEM, V265, P4730; MIYATA Y, 1989, J BIOL CHEM, V264, P15565; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; RAPP UR, 1988, HDB ONCOGENES, P213; RAPP UR, 1987, ONCOGENES CANCER, P55; RAY LB, 1988, J BIOL CHEM, V263, P12721; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SCHULTZ AM, 1985, VIROLOGY, V146, P78, DOI 10.1016/0042-6822(85)90054-6; SENGUPTA A, 1988, P NATL ACAD SCI USA, V85, P8062, DOI 10.1073/pnas.85.21.8062; SMITH MR, 1990, MOL CELL BIOL, V10, P3828, DOI 10.1128/MCB.10.7.3828; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUSA M, 1989, CELL, V57, P817, DOI 10.1016/0092-8674(89)90796-4; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WALTON GM, 1990, J BIOL CHEM, V265, P1750; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WHITELEY B, 1986, J CELL BIOL, V103, P1355, DOI 10.1083/jcb.103.4.1355; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; YOUNG S, 1987, BIOCHEM J, V244, P775, DOI 10.1042/bj2440775	50	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					10941	10945						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	1645717				2022-12-25	WOS:A1991FQ77400039
J	DALMAN, HM; NEUBIG, RR				DALMAN, HM; NEUBIG, RR			2 PEPTIDES FROM THE ALPHA-2A-ADRENERGIC RECEPTOR ALTER RECEPTOR-G PROTEIN COUPLING BY DISTINCT MECHANISMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET ALPHA-2-ADRENERGIC RECEPTOR; GUANINE-NUCLEOTIDE; BETA-2-ADRENERGIC RECEPTOR; ADRENERGIC-RECEPTORS; ANTAGONIST BINDING; SYNTHETIC PEPTIDES; ALPHA-SUBUNIT; AGONIST; DOMAINS; SITE	Peptides derived from various regions of the alpha-2A-adrenergic receptor (alpha-2A-AR) were used to study receptor-G protein interactions. Binding of the partial agonist [I-125]-p-iodoclonidine and the full agonist [H-3]bromoxidine (UK14,304) to membrane preparations from human platelet was potently reduced by peptides (12-14 amino acids) from the second cytoplasmic loop (A) and the C-terminal side of the third cytoplasmic loop (Q). Binding of the antagonist [H-3]yohimbine was significantly less affected. Five other peptides had no significant effects on ligand binding at concentrations less than 100-mu-M. The IC50 values for peptides A and Q were 7 and 27-mu-M for [I-125]-p-iodoclonidine binding at the platelet alpha-2A receptor, 15 and 71-mu-M for the neuroblastoma-glioma (NG108-15) alpha-2B receptor, and greater than 300-mu-M for yohimbine binding at both alpha-2A and alpha-2B receptors. Competition studies demonstrate that at concentrations of 100-mu-M, peptides A and Q reduce the affinity of bromoxidine for the platelet alpha-2A-AR and this effect was abolished in the presence of guanine nucleotide. Alpha-2A-AR-stimulated GTPase activity in platelet membranes was inhibited by peptide Q with an IC50 of 16-mu-M but A was inactive. These data suggest that both the second cytoplasmic loop and the C-terminal part of the third cytoplasmic loop of the alpha-2A-AR are important in the interaction between the alpha-2-AR and G(i) protein. Peptide Q appears to destabilize the high affinity state of the alpha-2-AR by binding directly to G(i) thus preventing it from coupling to the receptor under both binding and GTPase assay conditions. The peptide from the second cytoplasmic loop (A) also reduces high affinity agonist binding in a G protein-dependent manner but its interaction with receptor and G protein is distinct in that it does not prevent activation of the G protein. These results provide new information about regions of the alpha-2-adrenergic receptor involved in G protein coupling and high affinity agonist binding.	UNIV MICHIGAN,SCH MED,DEPT PHARMACOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT INTERNAL MED,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DIV HYPERTENS,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan				Neubig, Richard/0000-0003-0501-0008	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020557] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL37551] Funding Source: Medline; NIAMS NIH HHS [AR20557] Funding Source: Medline; NIGMS NIH HHS [GM39561] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BYLUND DB, 1988, TRENDS PHARMACOL SCI, V9, P356, DOI 10.1016/0165-6147(88)90254-4; BYLUND DB, 1988, J PHARMACOL EXP THER, V245, P600; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; DOHLMAN HG, 1987, J BIOL CHEM, V262, P14282; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; GERHARDT MA, 1990, MOL PHARMACOL, V38, P214; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUYER CA, 1990, J BIOL CHEM, V265, P17307; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; KIM MH, 1985, FEBS LETT, V192, P321, DOI 10.1016/0014-5793(85)80134-4; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KUROSE H, 1983, J BIOL CHEM, V258, P4870; LANG JC, 1989, J RECEPTOR RES, V9, P313, DOI 10.3109/10799898909066061; LIMBIRD LE, 1983, J CYCLIC NUCL PROT, V9, P191; NEUBIG RR, 1986, BIOCHIM BIOPHYS ACTA, V854, P67, DOI 10.1016/0005-2736(86)90065-9; NEUBIG RR, 1988, BIOCHEMISTRY-US, V27, P2374, DOI 10.1021/bi00407a019; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; PALM D, 1989, FEBS LETT, V254, P89, DOI 10.1016/0014-5793(89)81015-4; REGAN JW, 1988, P NATL ACAD SCI USA, V85, P6301, DOI 10.1073/pnas.85.17.6301; STRADER CD, 1987, J BIOL CHEM, V262, P16439; THOMSEN WJ, 1988, MOL PHARMACOL, V34, P814; WONG SKF, 1990, J BIOL CHEM, V265, P6219; YARDEN Y, 1986, P NATL ACAD SCI USA, V83, P6785; ZENG DW, 1990, P NATL ACAD SCI USA, V87, P3102, DOI 10.1073/pnas.87.8.3102	26	104	106	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					11025	11029						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	1645720				2022-12-25	WOS:A1991FQ77400051
J	JOSLIN, G; FALLON, RJ; BULLOCK, J; ADAMS, SP; PERLMUTTER, DH				JOSLIN, G; FALLON, RJ; BULLOCK, J; ADAMS, SP; PERLMUTTER, DH			THE SEC RECEPTOR RECOGNIZES A PENTAPEPTIDE NEODOMAIN OF ALPHA-ANTITRYPSIN-PROTEASE COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-1-PROTEINASE INHIBITOR; NEUTROPHIL CHEMOATTRACTANT; PROTEINASE-INHIBITORS; PLASMINOGEN-ACTIVATOR; HUMAN-MONOCYTES; ELASTASE; EXPRESSION; BINDING; SUBSTRATE	Formation of the covalently stabilized alpha-1-antitrypsin (alpha-1-AT)-neutrophil elastase complex, the archetype of serpin-enzyme complexes, results in a structurally rearranged alpha-1-AT molecule that possesses chemo-attractant activities, mediates an increase in synthesis of alpha-1-AT by mononuclear phagocytes and hepatocytes, and is more rapidly cleared from the circulation than is the native alpha-1-AT molecule. We have recently identified an abundant, high affinity cell surface receptor on human hepatoma HepG2 cells and human monocytes that binds alpha-1-AT-elastase complexes, mediates endocytosis and lysosomal degradation of alpha-1-AT-elastase complexes, and induces an increase in synthesis of alpha-1-AT. We have referred to this receptor as the serpin-enzyme complex, or SEC, receptor because it also recognizes complexes of serpins antithrombin III, alpha-1-antichymotrypsin, and C1 inhibitor with their cognate enzymes. In the current study, we show that a pentapeptide domain in the carboxyl terminal fragment of alpha-1-AT (amino acids 370-374, FVFLM) is sufficient for binding to the SEC receptor. A synthetic analog of this pentapeptide (peptide 105C, FVYLI) blocks binding and internalization of alpha-1-AT-I-125-trypsin complexes by HepG2 cells. I-125-Peptide 105C binds specifically and saturably to HepG2 cells, and its binding is blocked by alpha-1-AT-trypsin or alpha-1-AT-elastase complexes. Alterations of this sequence introduced into synthetic peptides (mutations, deletions, or scrambling) demonstrate that binding of the pentapeptide domain is sequence-specific. Comparisons with the sequences of other serpins in the corresponding region indicate that this pentapeptide neodomain is highly conserved.	WASHINGTON UNIV,SCH MED,DEPT PEDIAT,400 S KINGSHIGHWAY BLVD,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PHYSIOL,ST LOUIS,MO 63110; MONSANTO CO,DEPT BIOL SCI,ST LOUIS,MO 63167	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Monsanto					NHLBI NIH HHS [HL-37784] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037784] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANDA MJ, 1988, J EXP MED, V167, P1608, DOI 10.1084/jem.167.5.1608; BANDA MJ, 1988, J BIOL CHEM, V263, P4481; BARBEYMOREL C, 1987, J EXP MED, V166, P1041, DOI 10.1084/jem.166.4.1041; BARBEYMOREL C, 1991, PEDIATR RES, V29, P133, DOI 10.1203/00006450-199102000-00005; BLASI F, 1987, J CELL BIOL, V104, P801, DOI 10.1083/jcb.104.4.801; CARRELL RW, 1986, J CLIN INVEST, V78, P1427, DOI 10.1172/JCI112731; CRYSTAL RG, 1990, J CLIN INVEST, V85, P1343, DOI 10.1172/JCI114578; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; ESPRAMER V, 1981, TRENDS NEUROSCI, V4, P267; HERSHEY AD, 1990, SCIENCE, V247, P958, DOI 10.1126/science.2154852; HRYB DJ, 1986, P NATL ACAD SCI USA, V83, P3253, DOI 10.1073/pnas.83.10.3253; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI H, 1990, J BIOL CHEM, V265, P14732; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; MORTON PA, 1989, J BIOL CHEM, V264, P7228; OLSON ST, 1985, J BIOL CHEM, V260, P153; PEMBERTON PA, 1988, NATURE, V336, P257, DOI 10.1038/336257a0; PERLMUTTER DH, 1988, J BIOL CHEM, V263, P16499; PERLMUTTER DH, 1989, AM J PHYSIOL, V257, pL147, DOI 10.1152/ajplung.1989.257.4.L147; PERLMUTTER DH, 1990, J BIOL CHEM, V265, P16713; PERLMUTTER DH, 1990, P NATL ACAD SCI USA, V87, P3753, DOI 10.1073/pnas.87.10.3753; PERLMUTTER DH, 1991, HEPATOLOGY, V13, P172, DOI 10.1002/hep.1840130125; PERLMUTTER DH, 1988, J CLIN INVEST, V81, P17744; RIVIER JE, 1978, BIOCHEMISTRY-US, V17, P1976; ROBERTS BE, 1973, P NATL ACAD SCI USA, V70, P2330, DOI 10.1073/pnas.70.8.2330; RUBIN H, 1990, J BIOL CHEM, V265, P1199; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; WAGNER SL, 1989, J BIOL CHEM, V264, P611; WRIGHT HT, 1984, J BIOL CHEM, V259, P4335; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531	31	109	115	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					11282	11288						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	1645729				2022-12-25	WOS:A1991FQ77400089
J	BLUM, H; BALSCHI, JA; JOHNSON, RG				BLUM, H; BALSCHI, JA; JOHNSON, RG			COUPLED INVIVO ACTIVITY OF CREATINE-PHOSPHOKINASE AND THE MEMBRANE-BOUND (NA+,K+)-ATPASE IN THE RESTING AND STIMULATED ELECTRIC ORGAN OF THE ELECTRIC FISH NARCINE-BRASILIENSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFUSED RAT-HEART; NUCLEAR MAGNETIC-RESONANCE; HIGH-ENERGY PHOSPHATE; SKELETAL-MUSCLE; KINASE REACTION; PHOSPHORYLCREATINE SHUTTLE; SATURATION TRANSFER; ALPHA-SUBUNIT; CDNA SEQUENCE; SURFACE COIL	Physiological control of the plasma membrane sodium pump, (Na+, K+)-ATPase, is essential for proper function of eukaryotic cells. In the electric organ of the elasmobranch Narcine brasiliensis, the normal demands placed upon the pump during the process of generation of electrical currents call for large and rapid changes in activity of this enzyme, making this a good model for the study of its cellular regulation. P-31 NMR spectroscopic techniques were used to study metabolic regulation of membrane pump function in resting and stimulated electric organ and in skeletal muscle of the live, intact N. brasiliensis. Because the ATP synthetic abilities of the electric organ by glycolysis or oxidative phosphoylation are extremely limited, depletion of phosphocreatinine (PCr) could be used to determine the activity of the (Na+, K+)-ATPase after the electric organ was stimulated to discharge, and to measure the net flux from PCr to ATP through the creatine phosphokinase (CPK) reaction in the electric organ. Saturation transfer, an NMR technique which measures exchange rates, was applied to determine the unidirectional flux in the forward direction through the same reaction in the electric organ and in skeletal muscle as a control. The pseudo first-order rate constant k(f) for the CPK reaction at 24-degrees-C in resting electric organ was 0.000 +/- 0.002 s-1 (n = 10) and in skeletal muscle was 0.08 +/- 0.03 s-1 (n = 3). The results demonstrate that in resting electric organ, which is well supplied with CPK, there was no measurable flux through this reaction, although CPK when extracted is highly active. Measured and calculated levels of all substrates for the creatine kinase reaction in the electric organ are similar to those in unstimulated skeletal muscle, where the creatine phosphokinase reaction rates are high in vivo. In contrast to the resting electric organ, during stimulation of the electric organ the measured net rate constant was > 0.08 s-1. In addition, as shown by lack of PCr depletion, there was virtually no net turnover of ATP in the resting organ compared to the stimulated organ. The marked difference in the (Na+, K+)-ATPase activity in the resting and activated electric organ confirmed earlier results (Blum, H., Nioka, S., and Johnson, R. G., Jr. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 1247-1251). Together, these results suggest that there is a novel method of coordinate regulation of cellular enzymes of great sensitivity and rapidity.	UNIV PENN, MED CTR, DEPT PHYSIOL, PHILADELPHIA, PA 19104 USA; UNIV ALABAMA, CARDIOVASC NUCL MED RESONANCE LAB, BIRMINGHAM, AL 35294 USA	University of Pennsylvania; University of Alabama System; University of Alabama Birmingham	BLUM, H (corresponding author), UNIV PENN, MED CTR, DEPT MED BIOCHEM & BIOPHYS, PHILADELPHIA, PA 19104 USA.							ALGER JR, 1984, Q REV BIOPHYS, V17, P83, DOI 10.1017/S0033583500005266; ARONSTAM RS, 1982, PROGR CHOLINERGIC BI, P45; ARRIODUPONT M, 1988, FEBS LETT, V240, P181, DOI 10.1016/0014-5793(88)80364-8; BARRANTES FJ, 1985, J BIOL CHEM, V260, P3024; BESSMAN SP, 1981, SCIENCE, V211, P448, DOI 10.1126/science.6450446; BITTL JA, 1987, BIOCHEMISTRY-US, V26, P6083, DOI 10.1021/bi00393a021; BITTL JA, 1987, CIRC RES, V60, P871, DOI 10.1161/01.RES.60.6.871; BLUM H, 1990, P NATL ACAD SCI USA, V87, P1247, DOI 10.1073/pnas.87.3.1247; BLUM H, 1990, ABSTR SOC MAGN RES M, P897; BOLINGER L, 1988, BIOPHYS J, V53, pA214; CANTLEY LC, 1981, CURR TOP BIOENERG, V11, P201; CHAPMAN RA, 1986, AM J PHYSIOL, V251, pC920, DOI 10.1152/ajpcell.1986.251.6.C920; CLAUSEN T, 1989, KIDNEY INT, V35, P1, DOI 10.1038/ki.1989.1; CLAUSEN T, 1986, PHYSIOL REV, V66, P542, DOI 10.1152/physrev.1986.66.3.542; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P104, DOI 10.1016/0926-6569(63)90211-6; COHN M, 1962, J BIOL CHEM, V237, P176; CONNETT RJ, 1988, AM J PHYSIOL, V254, pR949, DOI 10.1152/ajpregu.1988.254.6.R949; ELDAR H, 1989, MAGNET RESON MED, V11, P121, DOI 10.1002/mrm.1910110111; FORSEN S, 1963, J CHEM PHYS, V39, P2892, DOI 10.1063/1.1734121; HASELGROVE JC, 1987, REV MAGN RESON MED, V2, P167; HSIEH PS, 1988, MAGNET RESON MED, V7, P56, DOI 10.1002/mrm.1910070107; IGNARRO LJ, 1989, FASEB J, V3, P31, DOI 10.1096/fasebj.3.1.2642868; JACOBUS WE, 1973, J BIOL CHEM, V248, P4803; KAWAKAMI K, 1986, J BIOCHEM-TOKYO, V100, P389, DOI 10.1093/oxfordjournals.jbchem.a121726; KAWAKAMI K, 1985, NATURE, V316, P733, DOI 10.1038/316733a0; KUPRIYANOV VV, 1984, BIOCHIM BIOPHYS ACTA, V805, P319, DOI 10.1016/0167-4889(84)90014-4; KUSHMERICK MJ, 1986, J BIOL CHEM, V261, P4420; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; MCGILVERY RW, 1974, J BIOL CHEM, V249, P5845; MEYER RA, 1984, AM J PHYSIOL, V246, pC365, DOI 10.1152/ajpcell.1984.246.5.C365; MILNERWH.EJ, 1971, BIOCHEM J, V122, P727, DOI 10.1042/bj1220727; MISAWA K, 1982, BIOCHIM BIOPHYS ACTA, V718, P227, DOI 10.1016/0304-4165(82)90224-0; MORRISON JF, 1965, BIOCHEM J, V97, P37, DOI 10.1042/bj0970037; MURPHY E, 1986, AM J PHYSIOL, V251, pC496, DOI 10.1152/ajpcell.1986.251.4.C496; NEUBAUER S, 1988, CIRC RES, V63, P1; OGAWA S, 1978, P NATL ACAD SCI USA, V75, P1796, DOI 10.1073/pnas.75.4.1796; OTSU N, 1989, J HISTOCHEM CYTOCHEM, V37, P1465, DOI 10.1177/37.10.2778305; REED GH, 1972, J BIOL CHEM, V247, P3073; REES D, 1989, MAGNET RESON MED, V9, P39, DOI 10.1002/mrm.1910090107; ROSSIER BC, 1987, TRENDS BIOCHEM SCI, V12, P483, DOI 10.1016/0968-0004(87)90235-0; SCHIMERLIK MI, 1973, J BIOL CHEM, V248, P8418; SMITH GA, 1983, P NATL ACAD SCI-BIOL, V80, P7178, DOI 10.1073/pnas.80.23.7178; SPENCER RGS, 1988, BIOPHYS J, V54, P921, DOI 10.1016/S0006-3495(88)83028-5; STEENBERGEN C, 1987, CIRC RES, V60, P700, DOI 10.1161/01.RES.60.5.700; SWEADNER KJ, 1980, NEW ENGL J MED, V302, P777, DOI 10.1056/NEJM198004033021404; TAYLOR DJ, 1986, MAGN RESON MED, V2, P502; TURNER DC, 1973, P NATL ACAD SCI USA, V70, P702, DOI 10.1073/pnas.70.3.702; UGURBIL K, 1987, ANN NY ACAD SCI, V508, P265; URAYAMA O, 1989, J BIOL CHEM, V264, P8271; VEECH RL, 1979, J BIOL CHEM, V254, P6538; WALLIMANN T, 1985, J CELL BIOL, V100, P1063, DOI 10.1083/jcb.100.4.1063; Watts D. C., 1973, ENZYMES, V8, P384; WEST BL, 1984, P NATL ACAD SCI-BIOL, V81, P7007, DOI 10.1073/pnas.81.22.7007	53	46	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10254	10259						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	1645345				2022-12-25	WOS:A1991FP08600042
J	MINNICH, A; COLLET, X; ROGHANI, A; CLADARAS, C; HAMILTON, RL; FIELDING, CJ; ZANNIS, VI				MINNICH, A; COLLET, X; ROGHANI, A; CLADARAS, C; HAMILTON, RL; FIELDING, CJ; ZANNIS, VI			SITE-DIRECTED MUTAGENESIS AND STRUCTURE-FUNCTION ANALYSIS OF THE HUMAN APOLIPOPROTEIN-A-I - RELATION BETWEEN LECITHIN-CHOLESTEROL ACYLTRANSFERASE ACTIVATION AND LIPID-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY LIPOPROTEINS; SYNTHETIC PEPTIDE ANALOGS; AMINO-ACID-SEQUENCE; CELL-DERIVED CHOLESTEROL; AMPHIPATHIC HELIX; APOA-I; UNILAMELLAR LIPOSOMES; PLASMA-LIPOPROTEINS; M13 VECTORS; GENE	We have mutagenized the human apoA-I gene and have generated cell lines which express normal and mutant apoA-I forms. Point mutations were introduced which changed Gln-1, Gln-2 to Arg,Arg, Pro99 to His, and Pro121 to His. In addition, the following amino acid deletions (DELTA) were generated: DELTA-113-124, DELTA-148-186, DELTA-212-233, and DELTA-213-243. The apoA-I form isolated from the culture medium of C127 cells was analyzed for its ability to activate lecithin-cholesterol acyltransferase (LCAT) and to bind to phospholipid vesicles and high density lipoprotein (HDL). Compared with the wild type (WT) apoA-I, the relative activation of LCAT achieved by the point mutations Gln-1, Gln-2 --> Arg,Arg, Pro99 --> His, and Pro121 --> His were 106 +/- 7, 92 +/- 6, and 77 +/- 9%, respectively. Kinetic analysis of one mutant apoA-I form showed similar V(max) but a 15-fold increase in the K(m) of the mutant apoA-I form. Furthermore, the activation achieved by the internal deletion mutants DELTA-113-124, DELTA-148-186, DELTA-212-233, and DELTA-213-243 was 47 +/- 3, 0.5 +/- 0.4, 28 +/- 4 and 13 +/-5%, respectively. Mutants deficient in their ability to activate LCAT displayed alterations in liposome and HDL binding, compared with WT as determined by density gradient ultracentrifugation analysis of the culture medium. Thus, the peak recovery (approximately 50%) of apoA-I bound to HDL was at density 1.14 g/ml for the WT apoA-I, at 1.18 g/ml for the mutants DELTA-113-124 and DELTA-148-186, and at d > 1.21 g/ml for the DELTA-212-233 and DELTA-213-243. Electron microscopy of the proteoliposome LCAT substrate generated by WT and mutant apoA-I forms showed that the carboxyl-terminal deletion mutants which displayed aberrant binding to HDL also displayed reduced ability to convert the spherical lecithin-cholesterol vesicles into discs compared with WT. The findings suggest that (a) the importance of the carboxyl terminus of apoA-I for LCAT activation is related to its ability to bind to lipid and/or to form discoidal substrate for LCAT, and (b) the interaction of several domains of apoA-I are required for the activation of LCAT.	BOSTON UNIV, SCH MED,DEPT MED,INST CARDIOVASC,MOLEC GENET SECT, BOSTON, MA 02118 USA; BOSTON UNIV, SCH MED, DEPT BIOCHEM, BOSTON, MA 02118 USA; UNIV CALIF SAN FRANCISCO, MED CTR, CARDIOVASC RES CTR, SAN FRANCISCO, CA 94143 USA	Boston University; Boston University; University of California System; University of California San Francisco			Collet, Xavier/M-6938-2017		NHLBI NIH HHS [HL14237, HL33952, HL26335] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033952, P50HL014237, P01HL026335] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANANTHARAMAIAH GM, 1990, ARTERIOSCLEROSIS, V10, P95, DOI 10.1161/01.ATV.10.1.95; ASSMANN G, 1974, P NATL ACAD SCI USA, V80, P6147; BANKA CL, 1991, J BIOL CHEM, V266, P23886; BARKIA A, 1988, J LIPID RES, V29, P77; BOGUSKI MS, 1986, J LIPID RES, V27, P1011; BRASSEUR R, 1991, J BIOL CHEM, V266, P16120; BREWER HB, 1978, BIOCHEM BIOPH RES CO, V80, P623, DOI 10.1016/0006-291X(78)91614-5; CARTER P, 1987, METHOD ENZYMOL, V154, P382; CARUTHERS MH, 1985, SCIENCE, V230, P281, DOI 10.1126/science.3863253; CASTRO GR, 1988, BIOCHEMISTRY-US, V27, P25, DOI 10.1021/bi00401a005; CHEUNG MC, 1987, J LIPID RES, V28, P913; CHEUNG MC, 1988, BIOCHIM BIOPHYS ACTA, V960, P73, DOI 10.1016/0005-2760(88)90011-2; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DORY L, 1983, P NATL ACAD SCI-BIOL, V80, P3489, DOI 10.1073/pnas.80.11.3489; FIELDING CJ, 1972, BIOCHEM BIOPH RES CO, V46, P1943; FIELDING CJ, 1990, ADV CHOLESTEROL RES, P271; FRANCONE OL, 1989, J BIOL CHEM, V264, P7066; FUKUSHIMA D, 1980, J BIOL CHEM, V255, P651; FUNKE H, 1991, J CLIN INVEST, V87, P371, DOI 10.1172/JCI114997; GUO LSS, 1980, J LIPID RES, V21, P993; HAMILTON RL, 1980, J LIPID RES, V21, P981; HAMILTON RL, 1976, J CLIN INVEST, V58, P667, DOI 10.1172/JCI108513; HARA H, 1991, J BIOL CHEM, V266, P3080; HUSSAIN MM, 1991, ELECTROPHORESIS, V12, P273, DOI 10.1002/elps.1150120408; INNERARITY TL, 1983, J BIOL CHEM, V258, P2341; JONAS A, 1991, J LIPID RES, V32, P97; JONAS A, 1985, BIOCHEMISTRY-US, V24, P3508, DOI 10.1021/bi00335a018; JONAS A, 1986, J LIPID RES, V27, P689; JONAS A, 1987, PLASMA LIPOPROTEINS, P299; KANELLIS P, 1980, J BIOL CHEM, V255, P1464; KARATHANASIS SK, 1983, P NATL ACAD SCI-BIOL, V80, P6147, DOI 10.1073/pnas.80.20.6147; KRYSTAL M, 1986, P NATL ACAD SCI USA, V83, P2709, DOI 10.1073/pnas.83.8.2709; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LI WH, 1988, J LIPID RES, V29, P245; LOWY DR, 1978, J VIROL, V26, P291, DOI 10.1128/JVI.26.2.291-298.1978; MAHLEY RW, 1984, J LIPID RES, V25, P1277; MAKRIDES SC, 1988, EUR J BIOCHEM, V173, P465, DOI 10.1111/j.1432-1033.1988.tb14022.x; MARCEL YL, 1991, J BIOL CHEM, V266, P3644; MCLEAN J, 1986, P NATL ACAD SCI USA, V83, P2335, DOI 10.1073/pnas.83.8.2335; MENZEL HJ, 1984, J BIOL CHEM, V259, P3070; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NICHOLS A, 1990, ADV CHOLESTEROL RES, P315; PATSCH W, 1980, J BIOL CHEM, V255, P3178; POWNALL HJ, 1980, P NATL ACAD SCI-BIOL, V77, P3154, DOI 10.1073/pnas.77.6.3154; RALL SC, 1986, J LIPID RES, V27, P436; RALL SC, 1984, J BIOL CHEM, V259, P63; REDGRAVE TG, 1975, ANAL BIOCHEM, V65, P42, DOI 10.1016/0003-2697(75)90488-1; RHOGANI A, 1988, BIOCHEMISTRY-US, V27, P7428; SCHMITZ G, 1984, P NATL ACAD SCI USA, V80, P6081; SCHONFELD G, 1990, ATHEROSCLEROSIS, V81, P81, DOI 10.1016/0021-9150(90)90014-A; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SEGREST JP, 1983, J BIOL CHEM, V258, P2290; SHEPHERD J, 1977, BIOCHIM BIOPHYS ACTA, V489, P486, DOI 10.1016/0005-2760(77)90169-2; SHOULDERS CC, 1983, NUCLEIC ACIDS RES, V11, P2827, DOI 10.1093/nar/11.9.2827; SOUTAR AK, 1975, BIOCHEMISTRY-US, V14, P3057, DOI 10.1021/bi00685a003; Sparrow J T, 1980, Ann N Y Acad Sci, V348, P187, DOI 10.1111/j.1749-6632.1980.tb21300.x; SPARROW JT, 1982, CRC CR REV BIOCH MOL, V13, P87, DOI 10.3109/10409238209108710; SUBBARAO NK, 1988, PROTEINS, V3, P187, DOI 10.1002/prot.340030307; TAKADA Y, 1990, BIOCHIM BIOPHYS ACTA, V104, P169; UTERMANN G, 1984, EUR J BIOCHEM, V144, P326; VANLOO B, 1991, J LIPID RES, V32, P1253; VONECKARDSTEIN A, 1990, J BIOL CHEM, V265, P8610; WOLF H, 1988, COMPUT APPL BIOSCI, V4, P187; YOKAYAMA S, 1980, J BIOL CHEM, V255, P7333; ZANNIS VI, 1982, J BIOL CHEM, V257, P536; ZANNIS VI, 1983, P NATL ACAD SCI-BIOL, V80, P2574, DOI 10.1073/pnas.80.9.2574; ZANNIS VI, 1986, METHOD ENZYMOL, V128, P823; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	68	110	114	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16553	16560						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1644835				2022-12-25	WOS:A1992JJ45800087
J	PILZ, RB; EIGENTHALER, M; BOSS, GR				PILZ, RB; EIGENTHALER, M; BOSS, GR			CHEMICALLY-INDUCED MURINE ERYTHROLEUKEMIA CELL-DIFFERENTIATION IS SEVERELY IMPAIRED WHEN CAMP-DEPENDENT PROTEIN-KINASE ACTIVITY IS REPRESSED BY TRANSFECTED GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLIOMA HYBRID-CELLS; REGULATORY SUBUNIT; CYCLIC-AMP; MOUSE ERYTHROLEUKEMIA; ERYTHROID-DIFFERENTIATION; SELECTIVE INCREASE; RECEPTOR PROTEIN; HL-60 CELLS; EXPRESSION; INHIBITION	During chemically induced differentiation of murine erythroleukemia (MEL) cells, cAMP-dependent protein kinase activity increases, and the enzyme's isozyme pattern changes. To examine the enzyme's role during MEL cell differentiation, we stably transfected MEL cells with recombinant plasmids in which the mouse metallothionein I promoter controlled expression of either a mutant form of the type I regulatory subunit of cAMP-dependent protein kinase (R(I)) or the enzyme's specific peptide inhibitor (PKI); expressing either sequence rendered cells cAMP-dependent protein kinase-deficient. Chemically induced differentiation of MEL cells as assessed by beta-globin mRNA and hemoglobin accumulation was inhibited in R, mutant and PKI transfectants; adding zinc further inhibited differentiation in the transfectants but had no effect on parental MEL cells. The inhibition of differentiation correlated with the amount of R(I) mutant mRNA and protein in the R(I) mutant transfectants and with the cells' degree of cAMP-dependent protein kinase deficiency in both the R(I) mutant and PKI transfectants. Overexpression of wild type R(I) did not interfere with differentiation or enzyme activity. We conclude that cAMP-dependent protein kinase activity is important for chemically induced differentiation of MEL cells and that the down-regulation of R(I) protein which occurs during MEL cell differentiation is not essential for differentiation to proceed.			PILZ, RB (corresponding author), UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA.			Boss, Gerry/0000-0002-9758-8714	NATIONAL CANCER INSTITUTE [K08CA001548] Funding Source: NIH RePORTER; NCI NIH HHS [K08 CA01548] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEEBE SJ, 1986, ENZYMES, V17, P73; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL PL, 1990, GENE DEV, V4, P1252, DOI 10.1101/gad.4.7.1252; CHOCHUNG YS, 1990, CANCER RES, V50, P7093; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; DAY RN, 1989, J BIOL CHEM, V264, P431; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; DOSKELAND SO, 1988, METHOD ENZYMOL, V159, P147; EMLER CA, 1982, FEBS LETT, V142, P210, DOI 10.1016/0014-5793(82)80136-1; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; GANGULY S, 1988, J BIOL CHEM, V263, P3216; GAZITT Y, 1978, CANCER RES, V38, P3779; GINTY DD, 1991, J BIOL CHEM, V266, P15325; GLASS DB, 1978, ANAL BIOCHEM, V87, P566, DOI 10.1016/0003-2697(78)90707-8; GROSS RE, 1990, J BIOL CHEM, V265, P8152; GROVE JR, 1989, J BIOL CHEM, V264, P19506; LOHMANN SM, 1983, EMBO J, V2, P153, DOI 10.1002/j.1460-2075.1983.tb01398.x; LOHMANN SM, 1984, ADV CYCLIC NUCL PROT, V18, P63; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; MATSUI T, 1986, CANCER RES, V46, P583; MERRILL AH, 1986, J BIOL CHEM, V261, P2610; OLSEN SR, 1991, J BIOL CHEM, V266, P11158; OTTEN AD, 1989, J BIOL CHEM, V264, P20255; PALMITER RD, 1982, NATURE, V300, P611, DOI 10.1038/300611a0; PILZ RB, 1990, J BIOL CHEM, V265, P8880; PROFOUSJUCHELKA HR, 1983, MOL CELL BIOL, V3, P229, DOI 10.1128/MCB.3.2.229; REUBEN RC, 1976, P NATL ACAD SCI USA, V73, P862, DOI 10.1073/pnas.73.3.862; RIFKIND RA, 1987, BLOOD CELLS, V13, P277; ROUGEON F, 1977, GENE, V1, P229, DOI 10.1016/0378-1119(77)90047-6; SANDBERG M, 1990, BIOCHEM BIOPH RES CO, V167, P323, DOI 10.1016/0006-291X(90)91768-N; SCHWARTZ DA, 1983, J BIOL CHEM, V258, P777; SCHWARTZ DA, 1985, J BIOL CHEM, V260, P6296; SIMON MN, 1989, EMBO J, V8, P2039, DOI 10.1002/j.1460-2075.1989.tb03612.x; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STEINBERG RA, 1981, J BIOL CHEM, V256, P731; TSIFTSOGLOU AS, 1979, CANCER RES, V39, P3849; WALTER U, 1979, P NATL ACAD SCI USA, V76, P3251, DOI 10.1073/pnas.76.7.3251; WOODFORD TA, 1989, J BIOL CHEM, V264, P13321	40	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16161	16167						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1644803				2022-12-25	WOS:A1992JJ45800030
J	PARK, CW; WALKER, MD				PARK, CW; WALKER, MD			SUBUNIT STRUCTURE OF CELL-SPECIFIC-E BOX-BINDING PROTEINS ANALYZED BY QUANTITATION OF ELECTROPHORETIC MOBILITY SHIFT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN GENE ENHANCER; PANCREATIC BETA-CELLS; DNA-BINDING; TRANSCRIPTION FACTOR; IMMUNOGLOBULIN ENHANCER; 5'-FLANKING REGION; II GENE; EXPRESSION; DIMERIZATION; SEQUENCE	Expression of insulin and immunoglobulin genes is dependent on the presence of E boxes (consensus sequence CAXXTG) within the enhancer regions. These sequences are recognized by cell-specific nuclear factors IEF1 (insulin enhancer factor 1) and LEF1 (lymphoid enhancer factor 1). Although IEF1 and LEF1 are distinct by several parameters, they are both recognized by antisera to the mouse helix-loop-helix (HLH) protein Al (a homolog of the human protein E47, product of the E2A gene). This suggests that A1/E47 or a close relative is a component of both complexes. In order to further characterize the complexes, we have used in vitro translated DNA-binding proteins of known size to verify that electrophoretic mobility shift analysis can be used to estimate the molecular weight of DNA-binding proteins from both the HLH family and the leucine zipper family. Under the conditions used, migration is relatively insensitive to changes in protein charge. This analysis, in combination with mixing experiments between nuclear extracts and in vitro translated HLH proteins, indicates that IEF1 and LEF1 are dimeric complexes. IEF1 behaves as a complex of two proteins, one of which is 67 kDa and is recognized by antibodies to A1, and the second of which is 25 kDa. LEF1 on the other hand, appears to be a complex of two proteins of 67 kDa. The size of the 67-kDa subunits is consistent with that reported for the full-length E2A gene products. The 25-kDa subunit of IEF1 forms DNA-binding heterodimers with A1 but not MyoD and is present in a limited range of cell types, features characteristic of class B HLH proteins such as MyoD and achaete-scute. Taken together, the data support the idea that the E2A gene products are involved directly in regulation of insulin and immunoglobulin gene expression; regulation of the insulin gene apparently requires, in addition, the 25-kDa HLH protein (designated IESF1 for insulin enhancer-specific factor 1).	WEIZMANN INST SCI,DEPT BIOCHEM,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								ALPERT S, 1988, CELL, V53, P295, DOI 10.1016/0092-8674(88)90391-1; ARONHEIM A, 1991, NUCLEIC ACIDS RES, V19, P3893, DOI 10.1093/nar/19.14.3893; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BADING H, 1988, NUCLEIC ACIDS RES, V16, P5241, DOI 10.1093/nar/16.12.5241; BECKMANN H, 1991, GENE DEV, V5, P1057, DOI 10.1101/gad.5.6.1057; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BOAM DSW, 1990, J BIOL CHEM, V265, P8285; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; CORDLE SR, 1991, MOL CELL BIOL, V11, P1734, DOI 10.1128/MCB.11.3.1734; CROWE DT, 1989, MOL CELL BIOL, V9, P1784, DOI 10.1128/MCB.9.4.1784; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GERMAN MS, 1991, MOL ENDOCRINOL, V5, P292, DOI 10.1210/mend-5-2-292; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KARLSSON O, 1987, P NATL ACAD SCI USA, V84, P8819, DOI 10.1073/pnas.84.24.8819; KARLSSON O, 1989, MOL CELL BIOL, V9, P823, DOI 10.1128/MCB.9.2.823; KERPPOLA TK, 1991, SCIENCE, V254, P1210, DOI 10.1126/science.1957173; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LEDOUARIN NM, 1988, CELL, V53, P169, DOI 10.1016/0092-8674(88)90375-3; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; MERMOD N, 1988, NATURE, V332, P557, DOI 10.1038/332557a0; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NELSON C, 1990, GENE DEV, V4, P1035, DOI 10.1101/gad.4.6.1035; OHLSSON H, 1988, P NATL ACAD SCI USA, V85, P4228, DOI 10.1073/pnas.85.12.4228; OHLSSON H, 1991, MOL ENDOCRINOL, V5, P897, DOI 10.1210/mend-5-7-897; Sambrook J, 1989, MOL CLONING LABORATO; SANTERRE RF, 1981, P NATL ACAD SCI-BIOL, V78, P4339, DOI 10.1073/pnas.78.7.4339; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; SHIBASAKI Y, 1990, BIOCHEM BIOPH RES CO, V170, P314, DOI 10.1016/0006-291X(90)91276-X; SHIEH SY, 1991, J BIOL CHEM, V266, P16708; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; VISVADER J, 1991, ONCOGENE, V6, P187; WALKER MD, 1990, NUCLEIC ACIDS RES, V18, P1159, DOI 10.1093/nar/18.5.1159; WALKER MD, 1983, NATURE, V306, P557, DOI 10.1038/306557a0; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WHELAN J, 1989, MOL CELL BIOL, V9, P3253, DOI 10.1128/MCB.9.8.3253; WHELAN J, 1990, MOL CELL BIOL, V10, P1564, DOI 10.1128/MCB.10.4.1564; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; ZINKEL SS, 1987, NATURE, V328, P178, DOI 10.1038/328178a0	49	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15642	15649						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1639803				2022-12-25	WOS:A1992JG11300061
J	ARZATE, H; OLSON, SW; PAGE, RC; GOWN, AM; NARAYANAN, AS				ARZATE, H; OLSON, SW; PAGE, RC; GOWN, AM; NARAYANAN, AS			PRODUCTION OF A MONOCLONAL-ANTIBODY TO AN ATTACHMENT PROTEIN DERIVED FROM HUMAN CEMENTUM	FASEB JOURNAL			English	Article						CEMENTUM; ATTACHMENT PROTEIN; ANTIBODY TO ATTACHMENT PROTEIN; FIBROBLASTS	HUMAN GINGIVAL FIBROBLASTS; PERIODONTAL-LIGAMENT; BONE SIALOPROTEIN; MINERALIZED TISSUES; INVITRO; CELLS; OSTEOPONTIN; EXTRACTS; DENTIN	Cementum is the mineralized structure that covers the surface of the roots of teeth; it serves as the attachment site for collagen fibers of adjacent soft connective tissues. Very little is known about how cementum formation is regulated or how it affects other periodontal structures. We have raised a monoclonal antibody that may aid in studies to determine the biology and function of cementum. Mice were immunized with a 55-kDa attachment protein partially purified from human cementum and a monoclonal antibody, H166, was produced. Incubation of tissue sections with this antibody and fluorescein isothiocyanate-conjugated secondary antibody revealed that it immunostains cementum but not dentin, gingiva, or periodontal ligament. Alveolar bone did not bind the antibody, although a few paravascular cells were positive. Long bones, kidney, liver, skin, and several other tissues were negative. Protein fractions separated from cementum extracts by binding to immobilized H166 column contained 55-, 49-, 39-, 29- to-31-, and 23- to 26-kDa components that cross-reacted with the antibody in Western blots; these components were previously shown to be derived from a common precursor. We conclude that the antibody recognizes a group of proteins related to 55-kDa attachment protein in cementum. Our data show that the antibody could serve as a marker for cementum.	UNIV WASHINGTON,SCH MED,DEPT PATHOL,SM-30,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,ORAL BIOL RES CTR,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle			Arzate, Higinio/K-1934-2019		NCI NIH HHS [CA-36250] Funding Source: Medline; NIDCR NIH HHS [DE-08229] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE008229] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ARZATE H, 1991, IN PRESS BONE MINER; BARTOLD PM, 1990, MATRIX, V10, P10, DOI 10.1016/S0934-8832(11)80132-0; BARTOLD PM, 1988, J PERIODONTAL RES, V23, P13, DOI 10.1111/j.1600-0765.1988.tb01020.x; BIRKEDALHANSEN H, 1977, CALC TISS RES, V23, P39, DOI 10.1007/BF02012764; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTLER WT, 1989, CONNECT TISSUE RES, V23, P123, DOI 10.3109/03008208909002412; CHO MI, 1989, ANAT REC, V223, P209, DOI 10.1002/ar.1092230214; CHRISTNER P, 1977, CALC TISS RES, V23, P147, DOI 10.1007/BF02012780; FISHER LW, 1987, J BIOL CHEM, V262, P9702; GLIMCHER MJ, 1989, CALCIFIED TISSUE INT, V45, P165, DOI 10.1007/BF02556060; KAZUGAI S, 1991, BONE MINER, V13, P235; MCALLISTER B, 1990, J PERIODONTAL RES, V25, P99, DOI 10.1111/j.1600-0765.1990.tb00899.x; MCCULLOCH CAG, 1987, ANAT RECORD, V219, P233, DOI 10.1002/ar.1092190304; MCCURDY SP, 1990, ARCH ORAL BIOL, V35, P347, DOI 10.1016/0003-9969(90)90181-9; MELCHER AH, 1986, J PERIODONTAL RES, V21, P592, DOI 10.1111/j.1600-0765.1986.tb01497.x; Melcher AH, 1988, PERIODONTOLOGY TODAY, P6; MIKI Y, 1987, J DENT RES, V66, P1399, DOI 10.1177/00220345870660082301; NAGATA T, 1991, BIOCHEM J, V274, P513, DOI 10.1042/bj2740513; NARAYANAN AS, 1985, J DENT RES, V64, P1111, DOI 10.1177/00220345850640090201; NISHIMURA K, 1989, J PERIODONTAL RES, V24, P146, DOI 10.1111/j.1600-0765.1989.tb00869.x; OLSON S, 1991, J DENT RES, V70, P1272, DOI 10.1177/00220345910700090801; POLSON AM, 1986, J CLIN PERIODONTOL, V13, P995; Slavkin HC, 1988, J PERIODONTAL RES, V23, P28; SOMERMAN MJ, 1987, ARCH ORAL BIOL, V32, P879, DOI 10.1016/0003-9969(87)90101-4; SOMERMAN MJ, 1991, J PERIODONTAL RES, V26, P10, DOI 10.1111/j.1600-0765.1991.tb01620.x; SOMERMAN MJ, 1987, J PERIODONTOL, V58, P349, DOI 10.1902/jop.1987.58.5.349; TSUKADA T, 1987, AM J PATHOL, V126, P51	27	68	75	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1992	6	11					2990	2995		10.1096/fasebj.6.11.1644261	http://dx.doi.org/10.1096/fasebj.6.11.1644261			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JJ665	1644261				2022-12-25	WOS:A1992JJ66500013
J	CLARKE, EP; CATES, GA; BALL, EH; SANWAL, BD				CLARKE, EP; CATES, GA; BALL, EH; SANWAL, BD			A COLLAGEN-BINDING PROTEIN IN THE ENDOPLASMIC-RETICULUM OF MYOBLASTS EXHIBITS RELATIONSHIP WITH SERINE PROTEASE INHIBITORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARG-GLY-ASP; RETINOIC ACID; SKELETAL MYOBLASTS; SARCOPLASMIC-RETICULUM; TERATOCARCINOMA CELLS; DISULFIDE ISOMERASE; MOLECULAR-CLONING; DIFFERENTIATION; SEQUENCE; GLYCOPROTEIN	Several cDNA clones encoding a 46-kDa collagen-binding glycoprotein (gp46) from rat skeletal myoblasts were isolated and sequenced. The cDNA encoded a 17-amino acid signal peptide and a 400-amino acid mature protein, containing three potential N-linked oligosaccharide attachment sites. The cDNA sequence of gp46 shows 93% identity in the coding region with J6, a retinoic acid-inducible gene coding for a protein of unknown function described from embryonal carcinoma F9 cells. The first 41 NH2-terminal amino acids of the predicted J6 sequence are, however, different from the gp46 sequence as a result of a 7-base pair insertion in the gp46 cDNA. In addition, the NH2-terminal amino acid sequence of hsp47, a collagen-binding protein found in chick embryo fibroblasts, shows 64% identity to gp46 over 36 residues. Interestingly, this alignment begins 10 residues inward from the first amino acid in the mature form of gp46. A significant sequence similarity was observed between gp46 and members of the serine protease inhibitor (serpin) family. Unlike other serpins, however, gp46 is both a heat shock and a collagen-binding protein and is localized to the lumen of the endoplasmic reticulum, as suggested by the presence of the RDEL sequence at the COOH terminus. This sequence is similar to other proposed endoplasmic reticulum retention signals.	QUEENS UNIV,DEPT BIOCHEM,KINGSTON K7L 3N6,ONTARIO,CANADA	Queens University - Canada	CLARKE, EP (corresponding author), UNIV WESTERN ONTARIO,DEPT BIOCHEM,LONDON N6A 5C1,ONTARIO,CANADA.			Ball, Eric/0000-0003-2542-9156				ANDRES DA, 1990, J BIOL CHEM, V265, P5952; BRINKER JM, 1985, P NATL ACAD SCI USA, V82, P3649, DOI 10.1073/pnas.82.11.3649; Carrell R.W, 1986, PROTEINASE INHIBITOR, P403; CARRELL RW, 1987, COLD SPRING HARB SYM, V52, P527, DOI 10.1101/SQB.1987.052.01.060; CATES GA, 1984, J BIOL CHEM, V259, P2646; CATES GA, 1987, FEBS LETT, V218, P195, DOI 10.1016/0014-5793(87)81045-1; CATES GA, 1987, BIOCHEM CELL BIOL, V65, P767, DOI 10.1139/o87-100; CHANDRA T, 1983, BIOCHEMISTRY-US, V22, P5055, DOI 10.1021/bi00291a001; CHENG SY, 1987, J BIOL CHEM, V262, P11221; EHRLICH HJ, 1990, J BIOL CHEM, V265, P13029; FLIEGEL L, 1990, J BIOL CHEM, V265, P15496; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; GEETHAHABIB M, 1988, CELL, V54, P1053, DOI 10.1016/0092-8674(88)90120-1; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; GUDAS LJ, 1990, ANN NY ACAD SCI, V580, P245, DOI 10.1111/j.1749-6632.1990.tb17933.x; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; HUGHES RC, 1987, EUR J BIOCHEM, V163, P57, DOI 10.1111/j.1432-1033.1987.tb10736.x; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KURACHI K, 1981, P NATL ACAD SCI-BIOL, V78, P6826, DOI 10.1073/pnas.78.11.6826; KURKINEN M, 1984, J BIOL CHEM, V259, P5915; LAWRENCE DA, 1990, J BIOL CHEM, V265, P20293; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; Maniatis T., 1982, MOL CLONING; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NAGATA K, 1986, J BIOL CHEM, V261, P7531; NAGATA K, 1988, BIOCHEM BIOPH RES CO, V153, P428, DOI 10.1016/S0006-291X(88)81242-7; NANDAN D, 1990, J CELL BIOL, V110, P1673, DOI 10.1083/jcb.110.5.1673; NANDAN D, 1988, EXP CELL RES, V179, P289, DOI 10.1016/0014-4827(88)90368-0; NANDAN D, 1990, ARCH BIOCHEM BIOPHYS, V278, P291, DOI 10.1016/0003-9861(90)90263-X; OSTWALD TJ, 1974, J BIOL CHEM, V249, P974; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; PIEZ KA, 1984, EXTRACELLULAR MATRIX, P1; PIHLAJANIEMI T, 1987, EMBO J, V6, P643, DOI 10.1002/j.1460-2075.1987.tb04803.x; POTEMPA J, 1988, J BIOL CHEM, V263, P7364; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIEH BH, 1987, J BIOL CHEM, V262, P6055; SORGER PK, 1987, J MOL BIOL, V194, P341, DOI 10.1016/0022-2836(87)90380-9; STEIN PE, 1989, BIOCHEM J, V262, P103, DOI 10.1042/bj2620103; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; SUZUKI K, 1987, J BIOL CHEM, V262, P611; TAYLOR A, 1985, EXP CELL RES, V159, P47, DOI 10.1016/S0014-4827(85)80036-7; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; VUOLTEENAHO R, 1990, J BIOL CHEM, V265, P15611; WANG SY, 1990, J BIOL CHEM, V265, P15818; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477; YANNARIELLOBROWN J, 1990, BIOCHEM J, V265, P383, DOI 10.1042/bj2650383; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	52	59	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17230	17235						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1654327				2022-12-25	WOS:A1991GF44500041
J	USUI, S; YU, L				USUI, S; YU, L			SUBUNIT-IV (MR = 14,384) OF THE CYTOCHROME-B-C1 COMPLEX FROM RHODOBACTER-SPHAEROIDES - CLONING, DNA SEQUENCING, AND UBIQUINONE BINDING DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BC1 COMPLEX; C REDUCTASE; PROTEIN; DERIVATIZATION; PURIFICATION; PROBES; R-26	The Rhodobacter sphaeroides gene encoding subunit IV of the cytochrome b-c1 complex (fbcQ) was cloned and sequenced. The fbcQ cistron is 372 base pairs long and encodes 124 amino acid residues. The molecular mass of subunit IV, deduced from the nucleotide sequence, is 14,384 Da. A hydropathy plot of the predicted amino acid sequence revealed only one transmembrane helix; it is near the C-terminal end. The 3-azido-2-methyl-5-methoxy-6-(3,7-dimethyl[H-3]octyl)-1,4-benzoquinone ([H-3]azido-Q)-labeled subunit IV was isolated from the [H-3]-azido-Q-treated cytochrome b-c1 complex. A ubiquinone-binding peptide was obtained by digesting the labeled subunit IV with V8 protease followed by high performance liquid chromatography separation. Amino acid analysis and partial N-terminal sequencing of this ubiquinone-binding peptide revealed that it corresponded to residues 77-124 of subunit IV. Based on the hydropathy profile and predicted tendency to form alpha-helices and beta-sheets, we propose a structural model for subunit IV. In this model the ubiquinone-binding domain is located near the surface of the membrane.			USUI, S (corresponding author), OKLAHOMA STATE UNIV,DEPT BIOCHEM,STILLWATER,OK 74078, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030721, R37GM030721] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 30721] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS KM, 1990, BIOCHEMISTRY-US, V29, P2645, DOI 10.1021/bi00463a004; BARR PJ, 1986, BIOTECHNIQUES, V4, P428; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; COHENBAZIRE G, 1957, J CELL COMPAR PHYSL, V49, P25, DOI 10.1002/jcp.1030490104; DAVIS RW, 1980, ADV BACTERIAL GENET, P120; DEISENHOFER J, 1989, SCIENCE, V245, P1463, DOI 10.1126/science.245.4925.1463; DONOHUE TJ, 1986, J BACTERIOL, V168, P962, DOI 10.1128/jb.168.2.962-972.1986; GABELLINI N, 1982, EUR J BIOCHEM, V126, P106; HEINRIKSON RL, 1984, ANAL BIOCHEM, V136, P65, DOI 10.1016/0003-2697(84)90307-5; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; KRIAUCIUNAS A, 1989, BIOCHIM BIOPHYS ACTA, V976, P70, DOI 10.1016/S0005-2728(89)80190-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANGER PR, 1981, P NATL ACAD SCI-BIOL, V78, P6633, DOI 10.1073/pnas.78.11.6633; LEARY JJ, 1983, P NATL ACAD SCI-BIOL, V80, P4045, DOI 10.1073/pnas.80.13.4045; LJUNGDAHL O, 1987, BIOCHIM BIOPHYS ACTA, V891, P227; MCCURLEY JP, 1990, BIOCHIM BIOPHYS ACTA, V1020, P176, DOI 10.1016/0005-2728(90)90049-A; Pfennig N, 1974, BERGEYS MANUAL SYSTE, V8th, P24; PURVIS DJ, 1990, J BIOL CHEM, V265, P1208; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; USUI S, 1990, BIOCHEMISTRY-US, V29, P4618, DOI 10.1021/bi00471a017; USUI S, 1990, BIOCHEM BIOPH RES CO, V167, P575, DOI 10.1016/0006-291X(90)92063-6; YANG XH, 1986, J BIOL CHEM, V261, P2282; YU L, 1984, J BIOL CHEM, V259, P5752; YU L, 1991, BIOCHEMISTRY-US, V30, P4934, DOI 10.1021/bi00234a014; YU L, 1987, BIOCHEMISTRY-US, V26, P3658, DOI 10.1021/bi00386a060; YUN CH, 1990, EUR J BIOCHEM, V194, P399, DOI 10.1111/j.1432-1033.1990.tb15633.x; 1989, PROMEGA PROTOCOLS AP, P144	28	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					15644	15649						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1651916				2022-12-25	WOS:A1991GB97700020
J	GRIENDLING, KK; TAUBMAN, MB; AKERS, M; MENDLOWITZ, M; ALEXANDER, RW				GRIENDLING, KK; TAUBMAN, MB; AKERS, M; MENDLOWITZ, M; ALEXANDER, RW			CHARACTERIZATION OF PHOSPHATIDYLINOSITOL-SPECIFIC PHOSPHOLIPASE-C FROM CULTURED VASCULAR SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOTENSIN-II; DIACYLGLYCEROL ACCUMULATION; INOSITOL TRISPHOSPHATE; PARTIAL-PURIFICATION; NA+/H+ EXCHANGE; MULTIPLE FORMS; BOVINE BRAIN; RAT-BRAIN; PROTEINS; SEQUENCE	Phosphoinositide-specific phospholipase C (PLC) activities have been partially purified from cultured vascular smooth muscle cells and analyzed for substrate specificity, calcium and pH requirements, and molecular weight. The purification procedure involved DEAE-cellulose and heparin-Sepharose chromatographies followed by Mono Q and size exclusion high performance liquid chromatography. This technique resolves multiple peaks of activity using phosphatidylinositol (PI) and PI 4,5-bisphosphate (PIP2) as substrates. The major peak was purified to near homogeneity as analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. PLC activity in vascular smooth muscle cells can be divided into two types based on their calcium and pH requirements, substrate preferences, and molecular weights. The low molecular weight PLC hydrolyzes both PI and PIP2, has a molecular mass of 58 kDa, requires the most calcium for full activation, and has a PI-pH profile that shifts slightly with calcium concentration. Screening a cDNA library with oligonucleotides directed against several of the known PLCs identified a highly expressed PLC cDNA that is 99% homologous to PLC-alpha, suggesting that this low molecular weight peak in fact corresponds to PLC-alpha. The high molecular mass peak (157 kDa) shows much greater activity against PI than PIP2, is active at lower calcium concentrations, and has a PI-pH optimum of 5.0 regardless of calcium concentration. Each of the PIP2 PLC activities is strongly dependent on the relative levels of calcium and pH in the assay buffer. These observations suggest that vascular smooth muscle contains both a high and low molecular weight PLC whose activities are affected markedly by the changes in calcium and pH accompanying hormonal stimulation of the cell.	CUNY MT SINAI SCH MED, BROOKDALE CTR MOLEC BIOL, NEW YORK, NY 10029 USA; CUNY MT SINAI SCH MED, DEPT MED, MOLEC MED UNIT, NEW YORK, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	GRIENDLING, KK (corresponding author), EMORY UNIV, DEPT MED, DIV CARDIOL, POB DRAWER LL, ATLANTA, GA 30322 USA.			Griendling, Kathy/0000-0002-9456-8582	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038206, R29HL038206, R01HL043302, R37HL038206, R01HL035013] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL43302, HL38206, HL35013] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AIYAR J, 1989, FASEB J, V3, P1298; ALEXANDER RW, 1985, HYPERTENSION, V7, P447, DOI 10.1161/01.HYP.7.3.447; BANNO Y, 1986, BIOCHEM BIOPH RES CO, V136, P713, DOI 10.1016/0006-291X(86)90498-5; BENNETT CF, 1988, NATURE, V334, P268, DOI 10.1038/334268a0; BENNETT CF, 1987, J BIOL CHEM, V262, P13789; BERK BC, 1987, J BIOL CHEM, V262, P5057; BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; BROCK TA, 1985, J BIOL CHEM, V260, P4158; BROCK TA, 1985, HYPERTENSION, V7, pI105, DOI 10.1161/01.HYP.7.3_Pt_2.I105; CARTER HR, 1987, BIOCHEM J, V244, P639, DOI 10.1042/bj2440639; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CROOKE ST, 1989, CELL CALCIUM, V10, P309, DOI 10.1016/0143-4160(89)90057-2; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FUKUI T, 1988, J BIOL CHEM, V263, P17730; GRIENDLING KK, 1988, J BIOL CHEM, V263, P10620; GRIENDLING KK, 1986, J BIOL CHEM, V261, P5901; GRIENDLING KK, 1987, J BIOL CHEM, V262, P14555; HARNIKORT V, 1987, J CELL BIOL, V104, P855, DOI 10.1083/jcb.104.4.855; HIRASAWA K, 1982, BIOCHEM J, V205, P437, DOI 10.1042/bj2050437; HOFMANN SL, 1982, J BIOL CHEM, V257, P6461; HOMMA Y, 1988, J BIOL CHEM, V263, P6592; KATADA T, 1987, J BIOL CHEM, V262, P11897; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOW MG, 1984, BIOCHEM J, V221, P813, DOI 10.1042/bj2210813; MANNE V, 1987, BIOCHEM J, V243, P763, DOI 10.1042/bj2430763; NABIKA T, 1985, J BIOL CHEM, V260, P4661; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; REBECCHI MJ, 1987, J BIOL CHEM, V262, P12526; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RYU SH, 1987, J BIOL CHEM, V262, P12511; Sambrook J, 1989, MOL CLONING LABORATO; SIESS W, 1983, BIOCHIM BIOPHYS ACTA, V752, P329, DOI 10.1016/0005-2760(83)90131-5; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; SUH PG, 1988, J BIOL CHEM, V263, P14497; TAKENAWA T, 1981, J BIOL CHEM, V256, P6769; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; TRAVO P, 1980, BLOOD VESSELS, V17, P110; WILSON DB, 1984, J BIOL CHEM, V259, P1718	38	94	94	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15498	15504						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1651335				2022-12-25	WOS:A1991GB09700100
J	KUMAR, KN; EGGEMAN, KT; ADAMS, JL; MICHAELIS, EK				KUMAR, KN; EGGEMAN, KT; ADAMS, JL; MICHAELIS, EK			HYDRODYNAMIC PROPERTIES OF THE PURIFIED GLUTAMATE-BINDING PROTEIN SUBUNIT OF THE N-METHYL-D-ASPARTATE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID; FUNCTIONAL EXPRESSION; MEMBRANE PROTEINS; BRAIN; PURIFICATION; NEURONS; CLONING	The hydrodynamic properties of the previously purified glutamate-binding protein from rat synaptic membranes were determined in order to estimate the molecular size of the protein in its native state. This protein is apparently a subunit of a multisubunit complex that forms the N-methyl-D-aspartate subtype of glutamate receptor and has a molecular size of approximately 70 kDa based on electrophoretic migration under denaturing conditions. On the basis of results obtained from H2O/D2O sucrose density gradient sedimentation and gel filtration chromatography of the purified glutamate-binding protein we calculated the partial specific volume of the protein-detergent complex to be 0.766 cc3/g, the Stokes radius of the complex as 4.9 nm, the M(c) of the complex as 203,000 +/- 22,000 and the M(r) of the protein as 182,000 +/- 19,000. These results are indicative of stable self-association of the glutamate-binding protein and are in agreement with recent studies indicating that more than one molecule of glutamate may be required to activate the N-methyl-D-aspartate receptor-associated ion channel.	UNIV KANSAS,DEPT BIOCHEM,LAWRENCE,KS 66045; UNIV KANSAS,CTR BIOMED RES,LAWRENCE,KS 66045	University of Kansas; University of Kansas	KUMAR, KN (corresponding author), UNIV KANSAS,DEPT PHARMACOL & TOXICOL,5056 MALOTT HALL,LAWRENCE,KS 66045, USA.				NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R37AA004732, R01AA004732] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA04732] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; CHEN JW, 1988, J BIOL CHEM, V263, P417; CLARKE S, 1975, J BIOL CHEM, V250, P5459; COTMAN CW, 1987, TRENDS NEUROSCI, V10, P273, DOI 10.1016/0166-2236(87)90172-X; COTMAN CW, 1987, TRENDS NEUROSCI, V10, P263, DOI 10.1016/0166-2236(87)90170-6; CURTIS DR, 1974, ERG PHYSIOL BIOL CH, V69, P97; EATON MJ, 1990, J BIOL CHEM, V265, P16195; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; IKIN AF, 1990, BIOCHEMISTRY-US, V29, P2290, DOI 10.1021/bi00461a012; JAHR CE, 1987, NATURE, V325, P522, DOI 10.1038/325522a0; JAVITT DC, 1990, MOL PHARMACOL, V37, P603; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; LY AM, 1991, BIOCHEMISTRY-US, V30, P4307, DOI 10.1021/bi00231a029; MACDERMOTT AB, 1986, NATURE, V321, P515; NEUHOFF V, 1979, HOPPESEYLERS Z PHYSL, V360, P1675; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; PATNEAU DK, 1990, J NEUROSCI, V10, P2385; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TANFORD C, 1976, BIOCHIM BIOPHYS ACTA, V457, P133, DOI 10.1016/0304-4157(76)90009-5; WANG H, 1991, IN PRESS NEUROSCIENC; WATKINS JC, 1990, TRENDS PHARMACOL SCI, V11, P25, DOI 10.1016/0165-6147(90)90038-A; ZAMYATNIN AA, 1984, ANNU REV BIOPHYS BIO, V13, P145, DOI 10.1146/annurev.bb.13.060184.001045	22	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					14947	14952						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1651315				2022-12-25	WOS:A1991GB09700025
J	SINGH, Y; KLIMPEL, KR; QUINN, CP; CHAUDHARY, VK; LEPPLA, SH				SINGH, Y; KLIMPEL, KR; QUINN, CP; CHAUDHARY, VK; LEPPLA, SH			THE CARBOXYL-TERMINAL END OF PROTECTIVE ANTIGEN IS REQUIRED FOR RECEPTOR-BINDING AND ANTHRAX TOXIN ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT ADENYLATE-CYCLASE; BACILLUS-ANTHRACIS; MOLECULAR-CLONING; LETHAL TOXIN; EDEMA FACTOR; ESCHERICHIA-COLI; FACTOR GENE; EXPRESSION; SEQUENCE; CELLS	Anthrax toxin consists of three separate proteins produced by Bacillus anthracis: protective antigen (PA), lethal factor (LF), and edema factor (EF). Previous work showed that the process by which these proteins damage eukaryotic cells begins with binding of PA (83 kDa) to cell surface receptors. PA is then cleaved by a cell surface protease so as to expose a high-affinity binding site for LF or EF on the COOH-terminal, receptor-bound, 63-kilodalton fragment. In this report we more closely define a region of PA involved in receptor binding. The gene encoding PA was mutagenized so as to delete 3, 5, 7, 12, or 14 amino acids from the carboxyl terminus of the protein, and the truncated PA variants were purified from Bacillus subtilis or Escherichia coli. Deletion of 3, 5, or 7 amino acids reduced the binding of PA to cells and the subsequent toxicity of the PA.LF complex to J774A.1 cells and also the ability to cause EF binding to cells. Deletion of 12 or 14 amino acids completely eliminated all these activities. These results show that the carboxy terminus comprises or is part of the receptor-binding domain of PA.	NIDR, MICROBIAL ECOL LAB, BLDG 30, RM 309, BETHESDA, MD 20892 USA; NCI, MOLEC BIOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								BEALL FA, 1962, J BACTERIOL, V83, P1274, DOI 10.1128/JB.83.6.1274-1280.1962; BHATNAGAR R, 1989, INFECT IMMUN, V57, P2107, DOI 10.1128/IAI.57.7.2107-2114.1989; BLAUSTEIN RO, 1989, P NATL ACAD SCI USA, V86, P2209, DOI 10.1073/pnas.86.7.2209; CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P308, DOI 10.1073/pnas.87.1.308; FRIEDLANDER AM, 1986, J BIOL CHEM, V261, P7123; GORDON VM, 1988, INFECT IMMUN, V56, P1066, DOI 10.1128/IAI.56.5.1066-1069.1988; HANNA PC, 1989, J BACTERIOL, V171, P6815, DOI 10.1128/jb.171.12.6815-6820.1989; HANNA PC, 1990, 90TH ANN M AM SOC MI; KAWAMURA F, 1984, J BACTERIOL, V160, P442, DOI 10.1128/JB.160.1.442-444.1984; LEPPLA SH, 1982, P NATL ACAD SCI-BIOL, V79, P3162, DOI 10.1073/pnas.79.10.3162; LEPPLA SH, 1988, METHOD ENZYMOL, V165, P103; LEPPLA SH, 1990, SALISBURY MED B S, V68, P41; Leppla SH, 1988, BACTERIAL PROTEIN TO, P111; LITTLE SF, 1988, INFECT IMMUN, V56, P1807, DOI 10.1128/IAI.56.7.1807-1813.1988; MOCK M, 1988, GENE, V64, P277, DOI 10.1016/0378-1119(88)90342-3; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; OBRIEN J, 1985, INFECT IMMUN, V47, P306, DOI 10.1128/IAI.47.1.306-310.1985; PROIA RL, 1980, J BIOL CHEM, V255, P2025; ROBERTSON DL, 1988, GENE, V73, P363, DOI 10.1016/0378-1119(88)90501-X; ROBERTSON DL, 1986, GENE, V44, P71, DOI 10.1016/0378-1119(86)90044-2; ROLF JM, 1990, J BIOL CHEM, V265, P7331; SHIRHATTI V, 1985, ANAL BIOCHEM, V147, P410, DOI 10.1016/0003-2697(85)90290-8; SINGH Y, 1989, J BIOL CHEM, V264, P11099; SINGH Y, 1989, J BIOL CHEM, V264, P19103; SMITH H, 1955, BRIT J EXP PATHOL, V36, P460; STANLEY JL, 1961, J GEN MICROBIOL, V26, P49, DOI 10.1099/00221287-26-1-49; Stephen J., 1986, Pharmacology of bacterial toxins, P381; TIPPETTS MT, 1988, J BACTERIOL, V170, P2263, DOI 10.1128/jb.170.5.2263-2266.1988; TURNBULL P, 1990, BACTERIAL DISEASES T, V3, P364; VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0; VODKIN MH, 1983, CELL, V34, P693, DOI 10.1016/0092-8674(83)90402-6; WELKOS SL, 1988, GENE, V69, P287, DOI 10.1016/0378-1119(88)90439-8	32	72	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15493	15497						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1651334				2022-12-25	WOS:A1991GB09700099
J	MCELDOON, JP; DORDICK, JS				MCELDOON, JP; DORDICK, JS			THIOL AND MN2+-MEDIATED OXIDATION OF VERATRYL ALCOHOL BY HORSERADISH-PEROXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGNIN MODEL DIMER; PHANEROCHAETE-CHRYSOSPORIUM; MANGANESE PEROXIDASE; SUPEROXIDE; RADICALS; METHOXYBENZENES; GENERATION; MECHANISM; CLEAVAGE; SYSTEMS	Horseradish peroxidase has been shown to catalyze the oxidation of veratryl alcohol (3,4-dimethoxybenzyl alcohol) and benzyl alcohol to the respective aldehydes in the presence of reduced glutathione, MnCl2, and an organic acid metal chelator such as lactate. The oxidation is most likely the result of hydrogen abstraction from the benzylic carbon of the substrate alcohol leading to eventual disproportionation to the aldehyde product. An aromatic cation radical intermediate, as would be formed during the oxidation of veratryl alcohol in the lignin peroxidase-H2O2 system, is not formed during the horseradish peroxidase-catalyzed reaction. In addition to glutathione, dithiothreitol, L-cysteine, and beta-mercaptoethanol are capable of promoting veratryl alcohol oxidation. Non-thiol reductants, such as ascorbate or dihydroxyfumarate (known substrates of horseradish peroxidase), do not support oxidation of veratryl alcohol. Spectral evidence indicates that horseradish peroxidase compound II is formed during the oxidation reaction. Furthermore, electron spin resonance studies indicate that glutathione is oxidized to the thiyl radical. However, in the absence of Mn2+ the thiyl radical is unable to promote the oxidation of veratryl alcohol. In addition, Mn3+ is unable to promote the oxidation of veratryl alcohol in the absence of glutathione. These results suggest that the ultimate oxidant of veratryl alcohol is a Mn3+-GSH or Mn2+-GS. complex (where GS. is the glutathiyl radical).	UNIV IOWA,DEPT CHEM & BIOCHEM ENGN,IOWA CITY,IA 52242; UNIV IOWA,CTR BIOCATALYSIS & BIOPROC,IOWA CITY,IA 52242	University of Iowa; University of Iowa								AKAZAWA T, 1958, J BIOL CHEM, V232, P403; BUETTNER GR, 1978, BIOCHEM BIOPH RES CO, V83, P69, DOI 10.1016/0006-291X(78)90398-4; BUETTNER GR, 1987, FREE RADICAL BIO MED, V3, P259, DOI 10.1016/S0891-5849(87)80033-3; BUHLER DR, 1961, ARCH BIOCHEM BIOPHYS, V92, P424, DOI 10.1016/0003-9861(61)90381-2; Dixon M., 1979, ENZYMES, Vthird; DORDICK JS, 1986, BIOCHEMISTRY-US, V25, P2946, DOI 10.1021/bi00358a032; DUNFORD HB, 1976, COORDIN CHEM REV, V19, P187, DOI 10.1016/S0010-8545(00)80316-1; GLENN JK, 1985, ARCH BIOCHEM BIOPHYS, V242, P329, DOI 10.1016/0003-9861(85)90217-6; HALLIWELL B, 1976, BIOCHEM J, V153, P513, DOI 10.1042/bj1530513a; HALLIWELL B, 1978, PHOTOCHEM PHOTOBIOL, V28, P757, DOI 10.1111/j.1751-1097.1978.tb07013.x; HAMMEL KE, 1985, J BIOL CHEM, V260, P8348; HARMAN LS, 1984, J BIOL CHEM, V259, P5606; KERSTEN PJ, 1990, BIOCHEM J, V268, P475, DOI 10.1042/bj2680475; KERSTEN PJ, 1985, J BIOL CHEM, V260, P2609; LEISOLA M, 1985, J BIOTECHNOL, V2, P379, DOI 10.1016/0168-1656(85)90024-0; MISRA HP, 1974, J BIOL CHEM, V249, P2151; PASCZYNSKI A, 1986, ARCH BIOCHEM BIOPHYS, V244, P750; PEREZ U, 1990, BIOCHIM BIOPHYS ACTA, V1038, P98, DOI 10.1016/0167-4838(90)90016-9; ROSS D, 1985, J BIOL CHEM, V260, P5028; RYU K, 1989, J AM CHEM SOC, V111, P8026, DOI 10.1021/ja00202a060; SAUNDERS BC, 1964, PEROXIDASE; SCHMIDT HWH, 1989, BIOCHEMISTRY-US, V28, P1776, DOI 10.1021/bi00430a053; WARIISHI H, 1989, J BIOL CHEM, V264, P14185; WARIISHI H, 1989, BIOCHEMISTRY-US, V28, P6017, DOI 10.1021/bi00440a044; WATERS WA, 1965, OXIDATION ORGANIC A, V5, P185; WHITAKER JR, 1972, PRINCIPLES ENZYMOLOG, P591; YAMAZAKI I, 1963, BIOCHIM BIOPHYS ACTA, V77, P47, DOI 10.1016/0006-3002(63)90468-2	27	24	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14288	14293						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1650355				2022-12-25	WOS:A1991FZ35100029
J	DENNING, GM; WELSH, MJ				DENNING, GM; WELSH, MJ			POLARIZED DISTRIBUTION OF BRADYKININ RECEPTORS ON AIRWAY EPITHELIAL-CELLS AND INDEPENDENT COUPLING TO 2ND MESSENGER PATHWAYS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANINE TRACHEAL EPITHELIUM; ARACHIDONIC-ACID; G-PROTEIN; ALPHA-TOXIN; ACTIVATION; PHOSPHOLIPASE-A2; ACCUMULATION; INVOLVEMENT; TRANSPORT; SECRETION	Bradykinin stimulates Cl- secretion by airway epithelia, but different patterns of secretion result from addition to the mucosal and submucosal surfaces. Earlier work suggested that bradykinin activates two second messenger pathways: increasing inositol phosphates (InsP) via phosphatidylinositol bisphosphate hydrolysis and increasing cAMP via arachidonic acid metabolism. In this study, we measured arachidonic acid release and InsP production in cultured canine tracheal epithelial cells. Bradykinin increased the two second messengers via independent mechanisms: (a) dose-response curves with different incubation media demonstrated that each second messenger could be generated independently of the other; (b) phorbol ester inhibited InsP production but stimulated arachidonic acid release; (c) for polarized cultures, submucosal bradykinin stimulated production of both second messengers but mucosal bradykinin stimulated only arachidonic acid release. To determine if differences in second messenger formation at the two membranes resulted from differences in hormone-receptor interactions, we compared bradykinin binding to the apical and basolateral membranes. Both the binding capacities and affinity constants (K(D)) were different (basolateral K(D), 257 +/- 53 pm; apical K(D) 39 +/- 3 pM). These data demonstrate polarized coupling of bradykinin receptors to second messenger pathways in airway epithelial cells and suggest that this polarized coupling is due to different bradykinin receptors at the two membranes.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT INTERNAL MED,IOWA CITY,IA 52242	Howard Hughes Medical Institute; University of Iowa				Welsh, Michael/0000-0002-1646-6206	NHLBI NIH HHS [HL 42385] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042385] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHNERTHILGER G, 1985, J BIOL CHEM, V260, P2730; AXELROD J, 1988, TRENDS NEUROSCI, V11, P117, DOI 10.1016/0166-2236(88)90157-9; BURCH RM, 1987, P NATL ACAD SCI USA, V84, P6374, DOI 10.1073/pnas.84.18.6374; CARSON MR, 1989, AM J PHYSIOL, V257, pL259, DOI 10.1152/ajplung.1989.257.4.L259; CASEY PJ, 1988, J BIOL CHEM, V263, P2577; COLEMAN DL, 1984, AM J PHYSIOL, V246, pC355, DOI 10.1152/ajpcell.1984.246.3.C355; FAIN JN, 1988, FASEB J, V2, P2569, DOI 10.1096/fasebj.2.10.2838362; FUSSLE R, 1981, J CELL BIOL, V91, P83, DOI 10.1083/jcb.91.1.83; IRVINE R F, 1986, P89; LEIKAUF GD, 1986, AM J PHYSIOL, V250, pF47, DOI 10.1152/ajprenal.1986.250.1.F47; LO WWY, 1987, FEBS LETT, V224, P1, DOI 10.1016/0014-5793(87)80410-6; MANNING DC, 1986, J PHARMACOL EXP THER, V237, P504; MCCANN JD, 1989, AM J PHYSIOL, V257, pL116, DOI 10.1152/ajplung.1989.257.2.L116; MUNSON PJ, 1983, METHOD ENZYMOL, V92, P543; PALMER S, 1986, BIOCHEM J, V238, P491, DOI 10.1042/bj2380491; RANGACHARI PK, 1988, REGUL PEPTIDES, V21, P237, DOI 10.1016/0167-0115(88)90006-7; REGOLI D, 1980, PHARMACOL REV, V32, P1; SLIVKA SR, 1988, J BIOL CHEM, V263, P14640; SMITH JJ, 1990, AM J PHYSIOL, V258, pL369, DOI 10.1152/ajplung.1990.258.6.L369; STERANKA LR, 1989, FASEB J, V3, P2019, DOI 10.1096/fasebj.3.9.2545496; WELSH MJ, 1987, PHYSIOL REV, V67, P1143, DOI 10.1152/physrev.1987.67.4.1143; WELSH MJ, 1985, J MEMBRANE BIOL, V88, P149, DOI 10.1007/BF01868429	22	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1991	266	20					12932	12938						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FX132	1649170				2022-12-25	WOS:A1991FX13200024
J	GARDELLA, TJ; AXELROD, D; RUBIN, D; KEUTMANN, HT; POTTS, JT; KRONENBERG, HM; NUSSBAUM, SR				GARDELLA, TJ; AXELROD, D; RUBIN, D; KEUTMANN, HT; POTTS, JT; KRONENBERG, HM; NUSSBAUM, SR			MUTATIONAL ANALYSIS OF THE RECEPTOR-ACTIVATING REGION OF HUMAN PARATHYROID-HORMONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT OSTEO-SARCOMA; ESCHERICHIA-COLI; BINDING DOMAINS; DOWN-REGULATION; CELL LINE; PROTEIN; MUTAGENESIS; MEMBRANES; CLONING; CD2	The first 4 residues of parathyroid hormone (PTH) are highly conserved in evolution and are important for biological activity. We randomly mutated codons 1-4 of human PTH (hPTH) with degenerate oligonucleotides and, after expression in COS cells, screened the mutants for receptor binding and cAMP-stimulating activity using ROS 17/2.8 cells. This survey identified Glu4 and Val2 as important determinants of receptor binding and activation, respectively. Positions 1 and 3 were more tolerant of substitutions indicating that these sites are less vital to hormone function. Activities of synthetic hPTH(1-34) analogs further demonstrated the importance of positions 2 and 4. The binding affinity of [Ala4, Tyr34] hPTH(1-34)NH2 was 100-fold reduced relative to [Tyr34]hPTH(1-34)NH2 (K(d) values = 653 +/- 270 and 4 +/- 1 nM, respectively), and [Arg2, Tyr34]hPTH(1-34)NH2 was a weak partial agonist which bound well to the ROS cell receptor (K(d) = 31 +/- 10 nm). The Arg2 analog was nearly as potent as PTH(3-34) as an in vitro PTH antagonist in osteoblast derived cells. However, unlike PTH(3-34), [Arg2]PTH was a full agonist in opossum kidney (OK) cells. These observations suggest that the activation domains of the OK and ROS cell PTH receptors are different. Thus, amino-terminal PTH analogs may be useful as probes for distinguishing properties of PTH receptors.	HARVARD UNIV, SCH MED, BOSTON, MA 02114 USA	Harvard University; Harvard Medical School	GARDELLA, TJ (corresponding author), MASSACHUSETTS GEN HOSP, ENDOCRINE UNIT, BOSTON, MA 02114 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK011794, F32DK008316] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK08316, DK11794] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABOUSAMRA AB, 1989, ENDOCRINOLOGY, V125, P2594; ABOUSAMRA AB, 1987, J BIOL CHEM, V262, P1129; Barany G, 1979, PEPTIDES           A, V2, P1; BARDEN JA, 1989, EUR J BIOCHEM, V184, P379, DOI 10.1111/j.1432-1033.1989.tb15030.x; BORN W, 1987, MOL ENDOCRINOL, V1, P5, DOI 10.1210/mend-1-1-5; BOWIE JU, 1989, P NATL ACAD SCI USA, V86, P2152, DOI 10.1073/pnas.86.7.2152; CAULFIELD MP, 1990, ENDOCRINOLOGY, V127, P83, DOI 10.1210/endo-127-1-83; CAULFIELD MP, 1988, ENDOCRINOLOGY, V123, P2949, DOI 10.1210/endo-123-6-2949; COHEN FE, 1991, J BIOL CHEM, V266, P1997; COLE JA, 1989, J BONE MINER RES, V4, P723; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; GARDELLA TJ, 1990, J BIOL CHEM, V265, P15854; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GOLTZMANN D, 1975, J BIOL CHEM, V250, P3199; LOEB DD, 1989, NATURE, V340, P397, DOI 10.1038/340397a0; MAJESKA RJ, 1980, ENDOCRINOLOGY, V107, P1494, DOI 10.1210/endo-107-5-1494; NUSSBAUM SR, 1980, J BIOL CHEM, V255, P183; NUTT RF, 1988, ENDOCRINOLOGY, V122, P3008; OLIPHANT AR, 1986, GENE, V44, P177, DOI 10.1016/0378-1119(86)90180-0; POTTS JT, 1971, P NATL ACAD SCI USA, V68, P63, DOI 10.1073/pnas.68.1.63; Rosenblatt M, 1981, Pathobiol Annu, V11, P53; ROSENBLATT M, 1980, ENDOCRINOLOGY, V107, P545, DOI 10.1210/endo-107-2-545; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SEGRE GV, 1979, J BIOL CHEM, V254, P6980; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8749, DOI 10.1093/nar/13.24.8749; TEITELBAUM AP, 1984, ENDOCRINOLOGY, V114, P980, DOI 10.1210/endo-114-3-980; TREGEAR GW, 1973, ENDOCRINOLOGY, V93, P1349, DOI 10.1210/endo-93-6-1349; YAMAMOTO I, 1988, ENDOCRINOLOGY, V122, P1208, DOI 10.1210/endo-122-4-1208; ZULL JE, 1990, J BIOL CHEM, V265, P5671	30	63	72	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1991	266	20					13141	13146						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FX132	1649179				2022-12-25	WOS:A1991FX13200056
J	LIANG, M; GARRISON, JC				LIANG, M; GARRISON, JC			THE EPIDERMAL GROWTH-FACTOR RECEPTOR IS COUPLED TO A PERTUSSIS TOXIN-SENSITIVE GUANINE-NUCLEOTIDE REGULATORY PROTEIN IN RAT HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISLET-ACTIVATING PROTEIN; PHOSPHOLIPASE-C-GAMMA; STIMULATE PHOSPHOINOSITIDE HYDROLYSIS; PHORBOL 12-MYRISTATE 13-ACETATE; LYSOSOMAL-ENZYME SECRETION; ANGIOTENSIN-II RECEPTOR; GTP-BINDING PROTEIN; TYROSINE PHOSPHORYLATION; EGF RECEPTOR; KINASE-C	Activation of epidermal growth factor (EGF) receptors stimulates inositol phosphate production in rat hepatocytes via a pertussis toxin-sensitive mechanism, suggesting the involvement of a G protein in the process. Since the first event after receptor-G protein interaction is exchange of GTP for GDP on the G protein, the effect of EGF was measured on the initial rates of guanosine 5'-O-(3-[S-35]thiotriphosphate) ([S-35] GTP-gamma-S) association and [alpha-P-32]GDP dissociation in rat hepatocyte membranes. The initial rate of [S-35]GTP-gamma-S binding was stimulated by EGF, with a maximal effect observed at 8 nM EGF. EGF also increased the initial rate of [alpha-P-32]GDP dissociation. The effect of EGF on [S-35]GTP-gamma-S association was blocked by boiling the peptide for 5 min in 5 mM dithiothreitol or by incubation of the membranes with guanosine 5'-O-(2-thiodiphosphate) (GDP-beta-S). EGF-stimulated [S-35]GTP-gamma-S binding was completely abolished in hepatocyte membranes prepared from pertussis toxin-treated rats and was inhibited in hepatocyte membranes that were treated directly with the resolved A-subunit of pertussis toxin. The amount of guanine nucleotide binding affected by occupation of the EGF receptor was approximately 6 pmol/mg of membrane protein. Occupation of angiotensin II receptors, which are known to couple to G proteins in hepatic membranes, also stimulated [S-35]GTP-gamma-S association with and [alpha-P-32]GDP dissociation from the membranes. The effect of angiotensin II on [alpha-P-32]GDP dissociation was blocked by the angiotensin II receptor antagonist [Sar1, Ile8]angiotensin II, demonstrating that the guanine nucleotide binding was receptor-mediated. In A431 human epidermoid carcinoma cells, EGF stimulates inositol lipid breakdown, but the effect is not blocked by treatment of the cells with pertussis toxin. In these cells, EGF had no effect on [S-35]GTP-gamma-S binding. Occupation of the beta-adrenergic receptor in A431 cell membranes with isoproterenol did stimulate [S-35]GTP-gamma-S binding, and the effect could be completely blocked by l-propranolol. These results support the concept that in hepatocyte membranes, EGF receptors interact with a pertussis toxin-sensitive G protein via a mechanism similar to other hormone receptor-G protein interactions, but that in A431 human epidermoid carcinoma cells, EGF may activate phospholipase C via different mechanisms.	UNIV VIRGINIA,SCH MED,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908	University of Virginia					NCI NIH HHS [CA-40042] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA040042] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BESTERMAN JM, 1986, J BIOL CHEM, V261, P723; BRADFORD PG, 1985, FEBS LETT, V183, P317, DOI 10.1016/0014-5793(85)80801-2; BRANDT DR, 1986, J BIOL CHEM, V261, P1656; BRANDT SJ, 1985, P NATL ACAD SCI USA, V82, P3277, DOI 10.1073/pnas.82.10.3277; BRASS LF, 1986, J BIOL CHEM, V261, P6838; BROOKER G, 1976, SCIENCE, V194, P270, DOI 10.1126/science.184530; BURNS DL, 1987, INFECT IMMUN, V55, P24, DOI 10.1128/IAI.55.1.24-28.1987; CAMPANILE CP, 1982, J BIOL CHEM, V257, P4951; CHURCH JG, 1988, J BIOL CHEM, V263, P4242; CRANE JK, 1982, J BIOL CHEM, V257, P4959; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; EARP HS, 1988, J BIOL CHEM, V263, P13868; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HART MJ, 1990, J BIOL CHEM, V265, P5990; HEPLER JR, 1988, J BIOL CHEM, V263, P7610; HEPLER JR, 1990, BIOCHEM J, V270, P337, DOI 10.1042/bj2700337; HEPLER JR, 1987, J BIOL CHEM, V262, P2951; HEPLER JR, 1986, BIOCHEM J, V239, P141, DOI 10.1042/bj2390141; HESKETH TR, 1985, NATURE, V313, P481, DOI 10.1038/313481a0; HOWE PH, 1989, BIOCHEM J, V261, P879, DOI 10.1042/bj2610879; HUANG CL, 1989, J BIOL CHEM, V264, P4391; HUGHES BP, 1987, BIOCHEM J, V248, P911, DOI 10.1042/bj2480911; IMAMURA K, 1988, J BIOL CHEM, V263, P14093; JOHNSON RM, 1986, P NATL ACAD SCI USA, V83, P2032, DOI 10.1073/pnas.83.7.2032; JOHNSON RM, 1987, J BIOL CHEM, V262, P17285; JOHNSON RM, 1989, SCIENCE, V246, P121, DOI 10.1126/science.2506643; KOJIMA I, 1986, FEBS LETT, V204, P347, DOI 10.1016/0014-5793(86)80841-9; KRUPINSKI J, 1988, J BIOL CHEM, V263, P12333; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUTTRELL L, 1990, J BIOL CHEM, V265, P16873; LYALL RM, 1989, J BIOL CHEM, V264, P14503; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARTIN TFJ, 1986, J BIOL CHEM, V261, P2918; MASTERS SB, 1985, BIOCHEM J, V227, P933, DOI 10.1042/bj2270933; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOLSKI TFP, 1984, BIOCHEM BIOPH RES CO, V124, P644, DOI 10.1016/0006-291X(84)91603-6; MULDOON LL, 1988, J BIOL CHEM, V263, P18834; MURTHY US, 1988, BIOCHEM BIOPH RES CO, V152, P1228, DOI 10.1016/S0006-291X(88)80416-9; NAIR BG, 1989, BIOCHEM J, V264, P563, DOI 10.1042/bj2640563; NAKAMURA T, 1985, J BIOL CHEM, V260, P3584; NISHIBE S, 1989, J BIOL CHEM, V264, P10335; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; OKAJIMA F, 1984, J BIOL CHEM, V259, P3863; PFEILSCHIFTER J, 1986, BIOCHEM J, V236, P289, DOI 10.1042/bj2360289; PIKE LJ, 1987, J BIOL CHEM, V262, P1644; POBINER BF, 1985, J BIOL CHEM, V260, P6200; POHL SL, 1976, METHODS RECEPTOR R 1, P160; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; ROSOFF PM, 1987, J IMMUNOL, V139, P2419; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; SCHIMMEL RJ, 1986, BIOCHEM BIOPH RES CO, V135, P823, DOI 10.1016/0006-291X(86)91002-8; TAMURA M, 1983, J BIOL CHEM, V258, P6756; TEITELBAUM I, 1990, J BIOL CHEM, V265, P4218; THOM RE, 1989, FEBS LETT, V244, P181, DOI 10.1016/0014-5793(89)81188-3; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUDA T, 1986, J BIOCHEM-TOKYO, V100, P1631, DOI 10.1093/oxfordjournals.jbchem.a121871; VERGHESE MW, 1985, BIOCHEM BIOPH RES CO, V127, P450, DOI 10.1016/S0006-291X(85)80181-9; VOLPI M, 1985, P NATL ACAD SCI USA, V82, P2708, DOI 10.1073/pnas.82.9.2708; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WAHL MI, 1987, BIOCHEM BIOPH RES CO, V142, P688, DOI 10.1016/0006-291X(87)91469-0; WALKER F, 1988, BIOCHEM J, V256, P109, DOI 10.1042/bj2560109; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	68	89	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1991	266	20					13342	13349						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FX132	1649188				2022-12-25	WOS:A1991FX13200085
J	SCHWANINGER, R; BECKERS, CJM; BALCH, WE				SCHWANINGER, R; BECKERS, CJM; BALCH, WE			SEQUENTIAL TRANSPORT OF PROTEIN BETWEEN THE ENDOPLASMIC-RETICULUM AND SUCCESSIVE GOLGI COMPARTMENTS IN SEMI-INTACT CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR STOMATITIS-VIRUS; YEAST SECRETORY PATHWAY; ASPARAGINE-LINKED OLIGOSACCHARIDES; SENSITIVE FUSION PROTEIN; ATP-COUPLED TRANSPORT; BINDING YPT1 PROTEIN; GENE-PRODUCT; BREFELDIN-A; FREE SYSTEM; BHK CELLS	The vectorial transport of vesicular stomatitis virus (VSV) G protein between the ER and the cis and medial Golgi compartments has been reconstituted using semi-intact (perforated) cells. The transport of VSV-G protein between successive compartments is measured by the sequential processing of the two N-linked oligosaccharide chains present on VSV-G protein to the endoglycosidase (endo) H-resistant structures which have unique electrophoretic mobilities during sodium dodecyl sulfate-gel electrophoresis. The appearance of a form of VSV-G which contains only one endo H-resistant oligosaccharide chain (G(H1)) is kinetically and biochemically indistinguishable from the appearance of the Man5, endo D-sensitive form (G(D)), the latter being a processing reaction diagnostic of transport from the ER to the cis Golgi compartment. These results provide evidence that the cis Golgi compartment may contain in addition to alpha-1,2-mannosidase I, both N-acetylglucosamine transferase I and alpha-1,2-mannosidase II. VSV-G protein is subsequently processed to the form which contains two endo H-resistant oligosaccharides (G(H2)) contains a second wave of vesicular transport. Processing of G(H1) to G(H2) in vitro occurs only after a lag period following the appearance of G(H1); processing is sensitive to N-ethylmaleimide, guanosine-5'-O-(3-thiotriphosphate), and a synthetic peptide homologous to the rab1 protein effector domain, and processing is inhibited in the absence of free Ca2+ (in the presence of EGTA), reagents which potently inhibit ER to cis Golgi transport. These results suggest that VSV-G protein proceeds through at least two rounds of vesicular transport from the ER to the medial Golgi compartment for processing to the G(H2) form, providing a model system to study the regulation of the vectorial membrane fission and fusion events involved in vesicular trafficking and organelle dynamics in the early stages of the secretory pathway.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute	SCHWANINGER, R (corresponding author), SCRIPPS RES INST, DEPT CELL BIOL, LA JOLLA, CA 92037 USA.				NATIONAL CANCER INSTITUTE [P01CA027489] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042336, R01GM033301] Funding Source: NIH RePORTER; NCI NIH HHS [CA27489] Funding Source: Medline; NIGMS NIH HHS [GM42336, GM 33301] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACON RA, 1989, J CELL BIOL, V109, P1015, DOI 10.1083/jcb.109.3.1015; BAKER D, 1990, P NATL ACAD SCI USA, V87, P355, DOI 10.1073/pnas.87.1.355; BAKER D, 1988, CELL, V54, P335, DOI 10.1016/0092-8674(88)90196-1; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BALCH WE, 1986, J BIOL CHEM, V261, P4690; BALCH WE, 1984, CELL, V39, P525, DOI 10.1016/0092-8674(84)90459-8; BALCH WE, 1986, J BIOL CHEM, V261, P4681; BALCH WE, 1989, J BIOL CHEM, V264, P16965; BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BECKERS CJM, 1990, J BIOL CHEM, V265, P18298; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; COOPER MS, 1990, CELL, V61, P135, DOI 10.1016/0092-8674(90)90221-Y; DECURTIS I, 1988, P NATL ACAD SCI USA, V85, P8052, DOI 10.1073/pnas.85.21.8052; DECURTIS I, 1989, CELL, V58, P719, DOI 10.1016/0092-8674(89)90106-2; DUNPHY WG, 1985, CELL, V42, P13, DOI 10.1016/S0092-8674(85)80097-0; FARQUHAR MG, 1985, ANNU REV CELL BIOL, V1, P447, DOI 10.1146/annurev.cb.01.110185.002311; FRIES E, 1980, P NATL ACAD SCI-BIOL, V77, P3870, DOI 10.1073/pnas.77.7.3870; GLASGOW LR, 1977, J BIOL CHEM, V252, P8615; HAUBRUCK H, 1989, EMBO J, V8, P1427, DOI 10.1002/j.1460-2075.1989.tb03524.x; HAUBRUCK H, 1990, EMBO J, V9, P1957, DOI 10.1002/j.1460-2075.1990.tb08323.x; HAUBRUCK H, 1987, EMBO J, V6, P4049, DOI 10.1002/j.1460-2075.1987.tb02750.x; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFAY F, 1974, J VIROL, V14, P1220, DOI 10.1128/JVI.14.5.1220-1228.1974; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MACHAMER CE, 1990, P NATL ACAD SCI USA, V87, P6944, DOI 10.1073/pnas.87.18.6944; MACHAMER CE, 1988, J BIOL CHEM, V263, P5948; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NAKANO A, 1988, J CELL BIOL, V107, P851, DOI 10.1083/jcb.107.3.851; NAKANO A, 1989, J CELL BIOL, V109, P2677, DOI 10.1083/jcb.109.6.2677; NEWMAN AP, 1987, J CELL BIOL, V105, P1587, DOI 10.1083/jcb.105.4.1587; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PAQUET MR, 1986, J BIOL CHEM, V261, P4367; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PLUTNER H, 1990, EMBO J, V9, P2375, DOI 10.1002/j.1460-2075.1990.tb07412.x; ROTHMAN JE, 1987, J BIOL CHEM, V262, P12502; RUOHOLA H, 1988, J CELL BIOL, V107, P1465, DOI 10.1083/jcb.107.4.1465; SCHMITT HD, 1988, CELL, V53, P635, DOI 10.1016/0092-8674(88)90579-X; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; STERNS T, 1990, P NATL ACAD SCI USA, V87, P1238; TABAS I, 1979, J BIOL CHEM, V254, P1655; VIDA TA, 1990, J CELL BIOL, V111, P2871, DOI 10.1083/jcb.111.6.2871; WEIDMAN PJ, 1989, J CELL BIOL, V108, P1589, DOI 10.1083/jcb.108.5.1589; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0	56	64	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1991	266	20					13055	13063						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FX132	1649174				2022-12-25	WOS:A1991FX13200042
J	MARCELLUS, R; WHITFIELD, JF; RAPTIS, L				MARCELLUS, R; WHITFIELD, JF; RAPTIS, L			POLYOMA-VIRUS MIDDLE TUMOR-ANTIGEN STIMULATES MEMBRANE-ASSOCIATED PROTEIN-KINASE-C AT LOWER LEVELS THAN REQUIRED FOR PHOSPHATIDYLINOSITOL KINASE ACTIVATION AND NEOPLASTIC TRANSFORMATION	ONCOGENE			English	Article							T-ANTIGEN; TYROSINE KINASE; RAT-CELLS; PP60C-SRC; GENE; SRC; PRODUCT; DEPHOSPHORYLATION; PHOSPHORYLATION; FIBROBLASTS	Twelve independent rat F111 cell lines expressing the polyoma virus middle tumor antigen (mT) under control of the dexamethasone-regulatable MMTV-LTR promoter were assayed for levels of membrane-associated protein kinase C (PKC) activity. Low background levels of mT antigen expression (approximately 2%), although insufficient for transformation, triggered a dramatic increase in PKC activity. Under the same conditions, levels of the mT-associated phosphatidylinositol kinase activity were low, indicating that this kinase might be a factor limiting transformation in this cell system.	QUEENS UNIV, DEPT MICROBIOL & IMMUNOL, KINGSTON K7L 3N6, ONTARIO, CANADA; NATL RES COUNCIL CANADA, INST BIOL SCI, CELL SYST SECT, OTTAWA K1A 0R6, ONTARIO, CANADA	Queens University - Canada; National Research Council Canada	RAPTIS, L (corresponding author), QUEENS UNIV, DEPT MICROBIOL & IMMUNOL, KINGSTON K7L 3N6, ONTARIO, CANADA.							BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; CHAKRAVARTHY BR, 1990, BIOCHEM BIOPH RES CO, V171, P1105, DOI 10.1016/0006-291X(90)90798-R; CHAKRAVARTHY BR, 1989, BIOCHEM BIOPH RES CO, V160, P340, DOI 10.1016/0006-291X(89)91661-6; CHENG SH, 1988, EMBO J, V7, P3845, DOI 10.1002/j.1460-2075.1988.tb03270.x; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; DOBROVOLNY MA, 1990, 6TH ANN M ONC FRED, P80; DOTTO GP, 1985, NATURE, V318, P472; DRUKER BJ, 1990, J VIROL, V64, P4454, DOI 10.1128/JVI.64.9.4454-4461.1990; DURKIN JP, 1990, CELL SIGNAL, V2, P285, DOI 10.1016/0898-6568(90)90056-G; DURKIN JP, 1990, IN PRESS CELLULAR SI; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; GELINAS C, 1985, VIROLOGY, V146, P233, DOI 10.1016/0042-6822(85)90007-8; GORGA FR, 1990, J VIROL, V64, P105, DOI 10.1128/JVI.64.1.105-112.1990; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; KAPLAN DR, 1989, BIOCHIM BIOPHYS ACTA, V948, P345, DOI 10.1016/0304-419X(89)90006-1; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P3624, DOI 10.1073/pnas.83.11.3624; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LOUIE RR, 1988, J VIROL, V62, P4673, DOI 10.1128/JVI.62.12.4673-4679.1988; MACARA IG, 1984, P NATL ACAD SCI-BIOL, V81, P2728, DOI 10.1073/pnas.81.9.2728; MARSHALL CJ, 1989, INT J CANCER, P29; MATTHEWS JT, 1986, J VIROL, V58, P239, DOI 10.1128/JVI.58.2.239-246.1986; NORI M, 1990, MOL CELL BIOL, V10, P4155, DOI 10.1128/MCB.10.8.4155; RAPTIS L, 1986, BIOCHEM BIOPH RES CO, V136, P995, DOI 10.1016/0006-291X(86)90431-6; RAPTIS L, 1986, BIOCHEM BIOPH RES CO, V140, P1106, DOI 10.1016/0006-291X(86)90749-7; RAPTIS L, 1988, BIOCHEM BIOPH RES CO, V154, P306, DOI 10.1016/0006-291X(88)90685-7; RAPTIS L, 1985, MOL CELL BIOL, V5, P2476, DOI 10.1128/MCB.5.9.2476; RAPTIS L, 1989, J VIROL, V63, P753, DOI 10.1128/JVI.63.2.753-758.1989; TREISMAN R, 1981, NATURE, V292, P595, DOI 10.1038/292595a0; ULUG ET, 1990, J VIROL, V64, P3895, DOI 10.1128/JVI.64.8.3895-3904.1990; WHITFIELD JF, 1990, CALCIUM CELL CYCLES; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0	37	14	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1991	6	6					1037	1040						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1648699				2022-12-25	WOS:A1991GU62200020
J	LINDNER, R; UNGEWICKELL, E				LINDNER, R; UNGEWICKELL, E			CLATHRIN-ASSOCIATED PROTEINS OF BOVINE BRAIN COATED VESICLES - AN ANALYSIS OF THEIR NUMBER AND ASSEMBLY-PROMOTING ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; SODIUM DODECYL-SULFATE; GEL-ELECTROPHORESIS; PLASMA-MEMBRANE; MONOCLONAL-ANTIBODIES; PURIFICATION; POLYPEPTIDES; BINDING; PITS; RECONSTITUTION	In search of hitherto undiscovered coat proteins, clathrin-associated proteins (APs) from coated vesicles of bovine brain were affinity-purified by one cycle of coat assembly and fractionated by gel filtration on Superose 6. Immunochemical and gel electrophoretic analysis of the fractions revealed, besides AP180, auxilin, HA1, and HA2, a component with M(r) approximately 140,000. This protein (p140) is present in coated vesicles in about equimolar proportion to auxilin. The contribution of HA1, HA2, AP180, and auxilin to the total assembly activity in the Tris-soluble coat protein fraction were quantitatively analyzed by measuring the reduction in activity when each protein was removed from the mixture by immunoaffinity chromatography. It was found that AP180 accounts for 61% and HA2 for 33% of the activity, whereas auxilin, HA1, and p140 made a negligible contribution. Based on the relative molar concentration of APs in the coat protein fraction, AP180 is about 4 times more active in promoting clathrin assembly than are HA2 or the other APs.	MAX PLANCK INST BIOCHEM, W-8033 MARTINSRIED, GERMANY	Max Planck Society				Lindner, Robert/0000-0002-6421-5778				AHLE S, 1990, J CELL BIOL, V111, P19, DOI 10.1083/jcb.111.1.19; AHLE S, 1986, EMBO J, V5, P3143, DOI 10.1002/j.1460-2075.1986.tb04621.x; AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; BECK KA, 1991, J BIOL CHEM, V266, P4437; BRETSCHER A, 1978, FEBS LETT, V85, P145, DOI 10.1016/0014-5793(78)81267-8; CAMPBELL C, 1984, BIOCHEMISTRY-US, V23, P4420, DOI 10.1021/bi00314a028; CHIN DJ, 1989, P NATL ACAD SCI USA, V86, P9289, DOI 10.1073/pnas.86.23.9289; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GOUD B, 1985, J CELL BIOL, V100, P521, DOI 10.1083/jcb.100.2.521; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; HAWKES R, 1986, METHOD ENZYMOL, V121, P484; HEUSER J, 1980, J CELL BIOL, V84, P560, DOI 10.1083/jcb.84.3.560; KEEN JH, 1986, J CELL BIOL, V102, P1325, DOI 10.1083/jcb.102.4.1325; KEEN JH, 1987, J CELL BIOL, V105, P1989, DOI 10.1083/jcb.105.5.1989; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; KOHTZ DS, 1988, J BIOL CHEM, V263, P7418; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANFREDI JJ, 1987, J BIOL CHEM, V262, P12182; MATSUI W, 1990, BIOCHEMISTRY-US, V29, P10791, DOI 10.1021/bi00500a011; MOORE MS, 1987, SCIENCE, V236, P558, DOI 10.1126/science.2883727; Morris SA, 1989, CURR OPIN CELL BIOL, V1, P684, DOI 10.1016/0955-0674(89)90034-3; MURPHY JE, 1991, J BIOL CHEM, V266, P4401; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; ORCI L, 1985, P NATL ACAD SCI USA, V82, P5385, DOI 10.1073/pnas.82.16.5385; PEARSE BMF, 1984, EMBO J, V3, P1951, DOI 10.1002/j.1460-2075.1984.tb02075.x; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PRASAD K, 1988, BIOCHEMISTRY-US, V27, P6098, DOI 10.1021/bi00416a040; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SMYTHE E, 1989, J CELL BIOL, V108, P843, DOI 10.1083/jcb.108.3.843; UNANUE ER, 1981, CELL, V26, P439, DOI 10.1016/0092-8674(81)90213-0; UNGEWICKELL E, 1989, ANAL BIOCHEM, V179, P352, DOI 10.1016/0003-2697(89)90143-7; VIRSHUP DM, 1988, J CELL BIOL, V106, P39, DOI 10.1083/jcb.106.1.39; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	36	83	83	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16567	16573						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1644836				2022-12-25	WOS:A1992JJ45800089
J	MAITY, SN; SINHA, S; RUTESHOUSER, EC; DECROMBRUGGHE, B				MAITY, SN; SINHA, S; RUTESHOUSER, EC; DECROMBRUGGHE, B			3 DIFFERENT POLYPEPTIDES ARE NECESSARY FOR DNA-BINDING OF THE MAMMALIAN HETEROMERIC CCAAT BINDING-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; SEQUENCE IDENTITY; YEAST HAP2; PROTEIN; PURIFICATION; ACTIVATION; PROMOTER; SUBUNITS; CLONING	Full-length cDNA clones for the CBF-A and CBF-B subunits of the CCAAT binding mammalian heteromeric transcription factor (CBF) have previously been isolated from both rat and mouse. Whereas recombinant CBF-B binds to DNA after complementation with a highly purified CBF-A fraction, recombinant CBF-A was unable to bind to DNA after complementation with either purified CBF-B or recombinant CBF-B. However, when recombinant CBF-A, synthesized as a fusion protein with glutathione S-transferase was denatured together with a highly purified fraction containing CBF-A in the presence of 5.5 M guanidine hydrochloride and subsequently renatured, the recombinant CBF-A bound to DNA after complementation with CBF-B. This binding of recombinant CBF-A could not be detected if recombinant CBF-A was not mixed during the denaturation-renaturation process together with the purified fraction containing the 32-kDa CBF-A. Using a Southwestern blot we demonstrated that a polypeptide of approximately 40 kDa, present in the purified CBF-A fraction, bound to DNA after complementation with both recombinant CBF-A and CBF-B. After fractionation of the purified CBF-A preparation by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, a species of approximately 40 kDa was eluted from the gel and shown to have DNA binding activity after complementation with both recombinant CBF-A and CBF-B. Our results indicate that a third polypeptide, designated CBF-C, forms a tight complex with CBF-A. Together with CBF-A and CBF-B, CBF-C is required for the DNA binding activity of CBF.			MAITY, SN (corresponding author), UNIV TEXAS, MD ANDERSON CANC CTR, DEPT MOLEC GENET, HOUSTON, TX 77030 USA.			Maity, Sankar/0000-0002-2387-6545	NATIONAL CANCER INSTITUTE [R01CA049515] Funding Source: NIH RePORTER; NCI NIH HHS [CA49515] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BECKER DM, 1991, P NATL ACAD SCI USA, V88, P1968, DOI 10.1073/pnas.88.5.1968; CHODOSH LA, 1988, CELL, V53, P25, DOI 10.1016/0092-8674(88)90484-9; DORN A, 1987, CELL, V50; FORSBURG SL, 1989, GENE DEV, V3, P1166, DOI 10.1101/gad.3.8.1166; HAHN S, 1988, MOL CELL BIOL, V8, P655, DOI 10.1128/MCB.8.2.655; HATAMOCHI A, 1988, J BIOL CHEM, V263, P5940; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; MAITY SN, 1990, P NATL ACAD SCI USA, V87, P5378, DOI 10.1073/pnas.87.14.5378; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; MAITY SN, 1992, J BIOL CHEM, V267, P8286; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; OLESEN J, 1987, CELL, V51, P953, DOI 10.1016/0092-8674(87)90582-4; OLESEN JT, 1990, GENE DEV, V4, P1714, DOI 10.1101/gad.4.10.1714; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; PINKHAM JL, 1987, MOL CELL BIOL, V7, P575; QUITSCHKE WW, 1989, J BIOL CHEM, V264, P9539; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; VUORIO T, 1990, J BIOL CHEM, V265, P22480	21	123	125	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16574	16580						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1644837				2022-12-25	WOS:A1992JJ45800090
J	HUTSON, SM; WALLIN, R; HALL, TR				HUTSON, SM; WALLIN, R; HALL, TR			IDENTIFICATION OF MITOCHONDRIAL BRANCHED-CHAIN AMINOTRANSFERASE AND ITS ISOFORMS IN RAT-TISSUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT CARBOXYLASE ACTIVITY; AMINO-ACIDS; LIVER; TRANSAMINASE; PURIFICATION; HEPATOCYTES; PROTEINS; CELLS	The tissue distribution and subcellular location of branched chain aminotransferase was analyzed using polyclonal antibodies against the enzyme purified from rat heart mitochondria (BCAT(m)). Immunoreactive proteins were visualized by immunoblotting. The antiserum recognized a 41-kDa protein in the 100,000 x g supernatant from a rat heart mitochondrial sonicate. The 41-kDa protein was always present in mitochondria which contained branched chain aminotransferase activity, skeletal muscle, kidney, stomach, and brain, but not in cytosolic fractions. In liver mitochondria, which have very low levels of branched chain aminotransferase activity, the 41-kDa protein was not present. However, two immunoreactive proteins of slightly higher molecular masses were identified. These proteins were located in hepatocytes. The 41-kDa protein was present in fetal liver mitochondria but not in liver mitochondria from 5-day neonates. Thus disappearance of the 41-kDa protein coincided with the developmental decline in liver branched chain aminotransferase activity. Two-dimensional immunoblots of isolated BCAT(m) immunocomplexes showed that the liver immunoreactive proteins were clearly different from the heart and kidney proteins which exhibited identical immunoblots. Investigation of BCAT(m) in subcellular fractions prepared from different skeletal muscle fiber types revealed that branched chain aminotransferase is exclusively a mitochondrial enzyme in skeletal muscles. Although total detergent-extractable branched chain aminotransferase activity was largely independent of fiber type, branched chain aminotransferase activity and BCAT(m) protein concentration were highest in mitochondria prepared from white gastrocnemius followed by mixed skeletal muscles with lowest activity and protein concentration found in soleus mitochondria. These quantitative differences in mitochondrial branched chain aminotransferase activity and enzyme protein content suggest there may be differential expression of BCAT(m) in different muscle fiber types.	WAKE FOREST UNIV, BOWMAN GRAY SCH MED, RHEUMATOL SECT, WINSTON SALEM, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center	HUTSON, SM (corresponding author), WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT BIOCHEM, MED CTR BLVD, WINSTON SALEM, NC 27157 USA.				NIDDK NIH HHS [DK 34738] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034738] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARMSTRONG RB, 1984, AM J ANAT, V171, P259, DOI 10.1002/aja.1001710303; BLOCK KP, 1985, J NUTR, V115, P1550, DOI 10.1093/jn/115.12.1550; BOOTH RFG, 1978, BIOCHEM J, V176, P365, DOI 10.1042/bj1760365; HARRIS RA, 1991, A BENZON S, V30, P374; HUTSON SM, 1988, J BIOL CHEM, V263, P3618; HUTSON SM, 1988, J NUTR, V118, P1475, DOI 10.1093/jn/118.12.1475; ICHIHARA A, 1975, BIOCHEM BIOPH RES CO, V67, P1313, DOI 10.1016/0006-291X(75)90170-9; ICHIHARA A, 1975, ANN NY ACAD SCI, V259, P347, DOI 10.1111/j.1749-6632.1975.tb25431.x; Ichihara A, 1985, TRANSAMINASES, P430; IKEDA T, 1976, BIOCHIM BIOPHYS ACTA, V445, P622, DOI 10.1016/0005-2744(76)90115-7; IKEDA Y, 1989, PROG CLIN BIOL RES, V321, P37; KADOWAKI H, 1982, BIOCHEM J, V202, P777, DOI 10.1042/bj2020777; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai J.C.K., 1989, NEUROMETHODS, P43; LANOUE KF, 1986, BIOCHEMISTRY-US, V25, P7667, DOI 10.1021/bi00371a058; LINDROS KO, 1985, BIOCHEM J, V228, P757, DOI 10.1042/bj2280757; NAYLOR SL, 1980, SOMAT CELL GENET, V6, P641, DOI 10.1007/BF01538643; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; RIEDERER BM, 1987, J NEUROSCI, V7, P864; RUDIGER HW, 1972, BIOCHEM J, V126, P445, DOI 10.1042/bj1260445; SABOURIN PJ, 1988, METHOD ENZYMOL, V166, P288; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SHINNICK FL, 1976, BIOCHIM BIOPHYS ACTA, V437, P477, DOI 10.1016/0304-4165(76)90016-7; SPACH PI, 1991, BIOCHIM BIOPHYS ACTA, V1056, P40, DOI 10.1016/S0005-2728(05)80070-2; WALLIN R, 1990, J BIOL CHEM, V265, P6019; WALLIN R, 1984, P NATL ACAD SCI-BIOL, V81, P4095, DOI 10.1073/pnas.81.13.4095; WALLIN R, 1991, PEDIATR RES, V30, P281, DOI 10.1203/00006450-199109000-00017; WALLIN R, 1988, BIOCHEM J, V250, P557, DOI 10.1042/bj2500557	28	97	97	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15681	15686						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1639805				2022-12-25	WOS:A1992JG11300066
J	KIKUCHI, A; KURODA, S; SASAKI, T; KOTANI, K; HIRATA, K; KATAYAMA, M; TAKAI, Y				KIKUCHI, A; KURODA, S; SASAKI, T; KOTANI, K; HIRATA, K; KATAYAMA, M; TAKAI, Y			FUNCTIONAL INTERACTIONS OF STIMULATORY AND INHIBITORY GDP GTP EXCHANGE PROTEINS AND THEIR COMMON SUBSTRATE SMALL GTP-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE BRAIN CYTOSOL; C-TERMINAL REGION; BOTULINUM ADP-RIBOSYLTRANSFERASE; RHO GENE-PRODUCT; REGULATORY PROTEIN; SMG P21; MOLECULAR-CLONING; CATALYZED PHOSPHORYLATION; DISSOCIATION INHIBITOR; CLOSTRIDIUM-BOTULINUM	smg GDS and rho GDI are stimulatory and inhibitory GDP/GTP exchange proteins, respectively, for a group of ras p21-related small GTP-binding proteins (G proteins). rho p21 is a common substrate small G protein for both GDP/GTP exchange proteins. We examined here the functional interactions of these GDP/GTP exchange proteins with rho p21 as a substrate. smg GDS and rho GDI interacted with the GDP-bound form of rho p21 and thereby stimulated and inhibited, respectively, the dissociation of GDP. The inhibitory effect of rho GDI was much stronger than the stimulatory effect of smg GDS. The GDP-bound form of rho p21 formed a complex with rho GDI but not with smg GDS in their simultaneous presence. Since the content of smg GDS was generally less than that of rho GDI in cells, these results suggest that there is some mechanism to release the inhibitory action of rho GDI and to make rho p21 sensitive to the smg GDS action during the conversion of rhoA p21 from the GDP-bound inactive form to the GTP-bound active form in intact cells. On the other hand, rho p2 1 was previously shown to be ADP-ribosylated by bacterial ADP-ribosyltransferases, named C3 and EDIN, at Asn41 in the putative effector region of rho p21. This ADP-ribosylation was inhibited by rho GDI much more efficiently than by smg GDS. These results suggest that rho GDI may mask the putative effector region of rho p21 and thereby inhibit its interaction with the target protein even in the presence of smg GDS. Thus, both smg GDS and rho GDI are important to regulate the rho p21 activity and action in cooperation with each other.	KOBE UNIV,SCH MED,DEPT BIOCHEM,KOBE 650,JAPAN	Kobe University			KURODA, SHINYA/G-4961-2014					ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ARAKI S, 1991, MOL CELL BIOL, V11, P1438, DOI 10.1128/MCB.11.3.1438; ARAKI S, 1990, J BIOL CHEM, V265, P13007; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUN U, 1989, FEBS LETT, V243, P70, DOI 10.1016/0014-5793(89)81220-7; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HATA Y, 1991, J BIOL CHEM, V266, P6571; HIRAOKA K, 1992, BIOCHEM BIOPH RES CO, V182, P921, DOI 10.1016/0006-291X(92)91820-G; HIROYOSHI M, 1991, J BIOL CHEM, V266, P2962; HORI Y, 1991, ONCOGENE, V6, P515; HOSHIJIMA M, 1990, MOL BRAIN RES, V7, P9, DOI 10.1016/0169-328X(90)90067-N; ISOMURA M, 1991, ONCOGENE, V6, P119; ITOH T, 1991, BIOCHEM BIOPH RES CO, V177, P1319, DOI 10.1016/0006-291X(91)90685-Z; KAIBUCHI K, 1991, MOL CELL BIOL, V11, P2873, DOI 10.1128/MCB.11.5.2873; KAWAMURA S, 1991, BIOCHEM BIOPH RES CO, V174, P1095, DOI 10.1016/0006-291X(91)91533-I; KAWATA M, 1989, J BIOL CHEM, V264, P15688; KIKUCHI A, 1988, J BIOL CHEM, V263, P16303; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPETINA EG, 1989, P NATL ACAD SCI USA, V86, P3131, DOI 10.1073/pnas.86.9.3131; MATSUI Y, 1990, MOL CELL BIOL, V10, P4116, DOI 10.1128/MCB.10.8.4116; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MIURA Y, 1992, FEBS LETT, V297, P171, DOI 10.1016/0014-5793(92)80353-I; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; QUILLIAM LA, 1991, J IMMUNOL, V147, P1628; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; SASAKI T, 1991, MOL CELL BIOL, V11, P2909, DOI 10.1128/MCB.11.5.2909; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SHIMIZU K, 1991, BIOCHEM BIOPH RES CO, V175, P199, DOI 10.1016/S0006-291X(05)81220-3; SHIRATAKI H, 1991, J BIOL CHEM, V266, P20672; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUGAI M, 1990, BIOCHEM BIOPH RES CO, V173, P92, DOI 10.1016/S0006-291X(05)81026-5; SUGAI M, 1992, J BIOL CHEM, V267, P2600; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; UEDA T, 1990, J BIOL CHEM, V265, P9373; UEDA T, 1991, BIOCHEMISTRY-US, V30, P909, DOI 10.1021/bi00218a005; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626	46	71	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14611	14615						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634508				2022-12-25	WOS:A1992JF08800021
J	MEDFORD, RM; HYMAN, R; AHMAD, M; ALLEN, JC; PRESSLEY, TA; ALLEN, PD; NADALGINARD, B				MEDFORD, RM; HYMAN, R; AHMAD, M; ALLEN, JC; PRESSLEY, TA; ALLEN, PD; NADALGINARD, B			VASCULAR SMOOTH-MUSCLE EXPRESSES A TRUNCATED NA+,K+-ATPASE ALPHA-1 SUBUNIT ISOFORM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; CA-2+-ATPASE GENE; BETA-SUBUNIT; RAT-BRAIN; ATPASE; PROTEINS; BINDING; FORMS	By regulating transmembrane Na+ and K+ concentrations and membrane potential, the Na+,K+-ATPase plays an important role in regulating cardiac, skeletal, and smooth muscle function. A high degree of amino acid sequence and structural identity characterizes the three M(r) 100,000 Na+,K+-ATPase alpha-subunit isoforms expressed in cardiac and skeletal muscle. Strikingly, vascular smooth muscle utilizes alternative RNA processing of the alpha-1 gene to express a structurally distinct M(r) approximately 65,000 isoform, alpha-1-T (truncated). Analysis of both its mRNA and protein structure reveals that alpha-1-T encodes only the first 554 amino acids of alpha-1 to Gly554, then terminates with an intron-encoded 27-residue peptide. By Western blot analysis, alpha-1-T represents a major, evolutionarily conserved, truncated Na+,K+-ATPase isoform expressed in vascular smooth muscle. This demonstrates an unexpected complexity in the regulation of vascular smooth muscle Na+,K+-ATPase gene expression and suggests that a structurally novel, truncated alpha-subunit may play a role in vascular smooth muscle active ion transport.	EMORY UNIV,SCH MED,DEPT MED,DIV CARDIOL,ATLANTA,GA 30322; BAYLOR COLL MED,HOUSTON,TX 77030; UNIV TEXAS,SCH MED,HOUSTON,TX 77030; HARVARD UNIV,CHILDRENS HOSP,MED CTR,SCH MED,MOLEC & CELLULAR CARDIOL LAB,BOSTON,MA 02115	Emory University; Baylor College of Medicine; University of Texas System; Harvard University; Boston Children's Hospital; Harvard Medical School					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024585, K04HL002305] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-24585, HL-02305] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLEN JC, 1991, CIRC RES, V69, P39, DOI 10.1161/01.RES.69.1.39; ALLEN JC, 1986, AM J PHYSIOL, V250, pC536, DOI 10.1152/ajpcell.1986.250.4.C536; ALLEN JC, 1989, AM J PHYSIOL, V256, pC786, DOI 10.1152/ajpcell.1989.256.4.C786; ALLEN JC, 1987, VASCULAR NEUROEFFECT, P217; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BERK BC, 1988, J CELL PHYSIOL, V137, P391, DOI 10.1002/jcp.1041370302; BOHR BF, 1988, ANN REV PHARM TOXICO, V26, P389; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; EGGERMONT J, 1986, CIRC RES, V62, P266; HARLOW E, 1988, ANTIBODIES LABORATOR; HARRIS WE, 1988, BIOCHIM BIOPHYS ACTA, V942, P236, DOI 10.1016/0005-2736(88)90025-9; HERRERA VLM, 1987, J CELL BIOL, V105, P1855, DOI 10.1083/jcb.105.4.1855; HERRERA VLM, 1988, SCIENCE, V241, P221, DOI 10.1126/science.2838907; IKEDA U, 1991, J BIOL CHEM, V266, P12058; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; KAHN AM, 1988, AM J PHYSIOL, V254, pC441, DOI 10.1152/ajpcell.1988.254.3.C441; KORCZAK B, 1988, J BIOL CHEM, V263, P4813; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LYTTON J, 1988, J BIOL CHEM, V263, P15024; LYTTON J, 1985, J BIOL CHEM, V260, P1177; MCDONOUGH AA, 1990, FASEB J, V4, P1598, DOI 10.1096/fasebj.4.6.2156741; MEDFORD RM, 1984, CELL, V38, P409, DOI 10.1016/0092-8674(84)90496-3; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P59; OHTA T, 1986, P NATL ACAD SCI USA, V83, P2071, DOI 10.1073/pnas.83.7.2071; ORLOWSKI J, 1990, J BIOL CHEM, V265, P3462; ORLOWSKI J, 1988, J BIOL CHEM, V263, P10436; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; SEIDEL CL, 1989, AM J PHYSIOL, V256, pC793, DOI 10.1152/ajpcell.1989.256.4.C793; SHULL GE, 1988, J BIOL CHEM, V263, P8646; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; SWEADNER KJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P185, DOI 10.1016/0304-4157(89)90019-1; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	33	59	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					18308	18312						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1655743				2022-12-25	WOS:A1991GG55300089
J	FUJIMOTO, T; FUJIMURA, K; KURAMOTO, A				FUJIMOTO, T; FUJIMURA, K; KURAMOTO, A			ELECTROPHYSIOLOGICAL EVIDENCE THAT GLYCOPROTEIN-IIB-IIIA COMPLEX IS INVOLVED IN CALCIUM-CHANNEL ACTIVATION ON HUMAN PLATELET PLASMA-MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELOPROLIFERATIVE DISORDERS; CA-2+ INFLUX; ION MOVEMENT; PATCH-CLAMP; FIBRONECTIN; FIBRINOGEN; BINDING; INHIBITION; LIPOSOMES; RECEPTOR	The involvement of platelet glycoprotein (GP) IIb-IIIa complex in calcium channel activity on the plasma membrane was investigated using an electrophysiological approach. Plasma membrane vesicles were prepared from thrombin-stimulated platelets and incorporated into planar lipid bilayers. Voltage-independent Ca2+ channel currents with a conductance of about 10 pS (in 53 mm Ba2+) were observed, in membranes derived from thrombin-stimulated, but not unstimulated platelet membranes. These channel activities were markedly reduced by exposure of membranes to EGTA at 37-degrees-C. This reduction was specifically related to the dissociation of the GPIIb-IIIa complex since preincubation of the membranes with a monoclonal antibody to the GPIIb-IIIa complex (AP-2) could protect the channel activities from the effect of EGTA. Thrombasthenic platelets, which lack the GPIIb-IIIa complex, showed impaired channel activities characterized by decreased open probability and lowered conductance states. Furthermore, when platelets were stimulated by thrombin in the presence of EGTA, AP2, or the synthetic peptide RGDS, to prevent fibrinogen binding to the GPIIb-IIIa complex, open probabilities of the channel currents in these membrane vesicles were also decreased. These results suggest that the GPIIb-IIIa complex is involved in platelet Ca2+ channel activation and that ligand binding to the complex during platelet activation may modify the activation of Ca2+ channels.	HIROSHIMA UNIV,NUCL MED & BIOL RES INST,DEPT INTERNAL MED,KASUMI 1-2-3,MINAMI KU,HIROSHIMA 734,JAPAN	Hiroshima University								BANGA HS, 1986, P NATL ACAD SCI USA, V83, P9197, DOI 10.1073/pnas.83.23.9197; BARBER AJ, 1970, J BIOL CHEM, V245, P6357; BRASS LF, 1985, J BIOL CHEM, V260, P2231; BRASS LF, 1984, J CLIN INVEST, V73, P626, DOI 10.1172/JCI111252; FUJIMOTO T, 1989, ACTA HAEMATOL JAPON, V52, P1542; FUJIMOTO T, 1989, ACTA HAEMATOL JAPON, V52, P118; FUJIMOTO T, 1989, THROMB RES, V53, P99, DOI 10.1016/0049-3848(89)90372-1; FUJIMURA K, 1983, J BIOL CHEM, V258, P247; FUJIMURA K, 1990, THROMB HAEMOSTASIS, V63, P103; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HAVERSTICK DM, 1985, BLOOD, V66, P946; ISENBERG WM, 1987, J CELL BIOL, V104, P1655, DOI 10.1083/jcb.104.6.1655; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAHAUTSMITH MP, 1990, J BIOL CHEM, V265, P10479; MARUYAMA Y, 1987, J PHYSIOL-LONDON, V391, P467, DOI 10.1113/jphysiol.1987.sp016750; PARISE LV, 1987, J BIOL CHEM, V262, P12597; PHILLIPS DR, 1988, BLOOD, V71, P831; PIDARD D, 1983, J BIOL CHEM, V258, P2582; PONCZ M, 1987, J BIOL CHEM, V262, P8476; POWLING MJ, 1985, BLOOD, V66, P731; REUTER H, 1982, NATURE, V297, P501, DOI 10.1038/297501a0; RYBAK ME, 1988, BLOOD, V72, P714; RYBAK MEM, 1989, J BIOL CHEM, V264, P14617; SINIGAGLIA F, 1988, BIOCHEM BIOPH RES CO, V154, P258, DOI 10.1016/0006-291X(88)90678-X; SMITH JS, 1985, NATURE, V316, P446, DOI 10.1038/316446a0; YAMAGUCHI A, 1987, FEBS LETT, V225, P228, DOI 10.1016/0014-5793(87)81163-8; ZSCHAUER A, 1988, NATURE, V334, P703, DOI 10.1038/334703a0	27	63	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16370	16375						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1653231				2022-12-25	WOS:A1991GD63500023
J	MACALLISTER, TW; KELLEY, WL; MIRON, A; STENZEL, TT; BASTIA, D				MACALLISTER, TW; KELLEY, WL; MIRON, A; STENZEL, TT; BASTIA, D			REPLICATION OF PLASMID R6K ORIGIN GAMMA INVITRO - DEPENDENCE ON DUAL INITIATOR PROTEINS AND INHIBITION BY TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI CHROMOSOME; ENZYMATIC REPLICATION; DNA-REPLICATION; RNA-POLYMERASE; 3 ORIGINS; PRIMASE; SEQUENCE; RSF1040; STEP; FUSIONS	We have developed a more efficient in vitro replication system for the plasmid R6K with the objective of dissecting the mechanism of activation of replication origins at a distance. Using this in vitro system we have shown that the activation of replication origin-gamma of R6K is absolutely dependent on two exogenously added initiator proteins: namely the host-encoded DnaA and the plasmid-encoded Pi proteins. Replication was inhibited by novobiocin, suggesting a requirement for DNA gyrase. Surprisingly, rifampicin stimulated in vitro replication significantly, and this stimulation was manifested in the quantitative enhancement of replication without any noticeable qualitative change in the reaction products. This result suggests that transcription at or near the gamma-origin keeps it repressed. Replication intermediates that were allowed to accumulate by dideoxynucleoside triphosphate incorporation were analyzed both by restriction enzyme digestion and by electron microscopy, and both sets of analyses revealed initiation from the gamma-origin resulting in theta-type replication intermediates. Further development of this system should help us to understand how DNA-protein interaction at the gamma-origin/enhancer activates the distal origins alpha and beta.	DUKE UNIV,MED CTR,DEPT MICROBIOL & IMMUNOL,DURHAM,NC 27710	Duke University								BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; CROSA JH, 1980, J BIOL CHEM, V255, P1075; CROSA JH, 1976, J BACTERIOL, V126, P454, DOI 10.1128/JB.126.1.454-466.1976; DIAZ R, 1982, NUCLEIC ACIDS RES, V10, P4687, DOI 10.1093/nar/10.15.4687; DIAZ R, 1984, NUCLEIC ACIDS RES, V12, P5175, DOI 10.1093/nar/12.13.5175; DIGATE RJ, 1988, J BIOL CHEM, V263, P13366; DODSON M, 1989, J BIOL CHEM, V264, P10719; FILUTOWICZ M, 1986, P NATL ACAD SCI USA, V83, P9645, DOI 10.1073/pnas.83.24.9645; FILUTOWICZ M, 1988, NUCLEIC ACIDS RES, V16, P3829, DOI 10.1093/nar/16.9.3829; FILUTOWICZ M, 1985, J MOL BIOL, V187, P225; FULLER RS, 1983, P NATL ACAD SCI-BIOL, V80, P5817, DOI 10.1073/pnas.80.19.5817; FULLER RS, 1981, P NATL ACAD SCI-BIOL, V78, P7370, DOI 10.1073/pnas.78.12.7370; GERMINO J, 1983, CELL, V34, P125, DOI 10.1016/0092-8674(83)90142-3; GERMINO J, 1983, P NATL ACAD SCI-BIOL, V80, P6848, DOI 10.1073/pnas.80.22.6848; INUZUKA M, 1978, BIOCHEMISTRY-US, V17, P2567, DOI 10.1021/bi00606a017; INUZUKA M, 1978, P NATL ACAD SCI USA, V75, P5381, DOI 10.1073/pnas.75.11.5381; INUZUKA M, 1985, FEBS LETT, V181, P236, DOI 10.1016/0014-5793(85)80266-0; INUZUKA N, 1980, J BIOL CHEM, V255, P1071; KELLEY W, 1985, P NATL ACAD SCI USA, V82, P2574, DOI 10.1073/pnas.82.9.2574; KOLTER R, 1978, CELL, V15, P1199, DOI 10.1016/0092-8674(78)90046-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOVETT M, 1975, P NATL ACAD SCI USA, V79, P7664; MASAI H, 1989, J BIOL CHEM, V264, P8082; MASAI H, 1990, J BIOL CHEM, V265, P15134; MASAI H, 1987, P NATL ACAD SCI USA, V84, P4781, DOI 10.1073/pnas.84.14.4781; MCEACHERN MJ, 1989, P NATL ACAD SCI USA, V86, P7942, DOI 10.1073/pnas.86.20.7942; MCMACKEN R, 1988, CANCER CELL, V6, P25; MCMACKEN R, 1987, UCLA S MOL CELL BIOL, V47, P227; MINDEN JS, 1986, J BIOL CHEM, V261, P1906; MUKHERJEE S, 1985, CELL, V43, P189, DOI 10.1016/0092-8674(85)90023-6; MUKHERJEE S, 1988, CELL, V52, P375, DOI 10.1016/S0092-8674(88)80030-8; OGAWA T, 1985, P NATL ACAD SCI USA, V82, P3562, DOI 10.1073/pnas.82.11.3562; ORTEGA S, 1986, NUCLEIC ACIDS RES, V14, P4865, DOI 10.1093/nar/14.12.4865; PINKNEY M, 1988, J MOL BIOL, V203, P927, DOI 10.1016/0022-2836(88)90118-0; SCHNOS M, 1988, CELL, V52, P385, DOI 10.1016/S0092-8674(88)80031-X; SHON M, 1982, J BIOL CHEM, V257, P13823; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STALKER DM, 1983, P NATL ACAD SCI USA, V580, P5500; STERNBERG N, 1981, J MOL BIOL, V150, P487, DOI 10.1016/0022-2836(81)90376-4; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VANDERENDE A, 1985, P NATL ACAD SCI USA, V82, P3954; VONMEYENBURG K, 1979, COLD SPRING HARB SYM, V43, P121, DOI 10.1101/SQB.1979.043.01.018; WICKNER SH, 1987, P NATL ACAD SCI USA, V84, P3668, DOI 10.1073/pnas.84.11.3668	43	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					16056	16062						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1651932				2022-12-25	WOS:A1991GB97700080
J	MURATA, M; WARE, J; RUGGERI, ZM				MURATA, M; WARE, J; RUGGERI, ZM			SITE-DIRECTED MUTAGENESIS OF A SOLUBLE RECOMBINANT FRAGMENT OF PLATELET GLYCOPROTEIN IB-ALPHA-DEMONSTRATING NEGATIVELY CHARGED RESIDUES INVOLVED IN VONWILLEBRAND-FACTOR BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND FACTOR; AMINO-ACID SEQUENCE; IIB/IIIA COMPLEX; IX COMPLEX; DOMAIN; CHAIN; SUBENDOTHELIUM; RISTOCETIN; EXPRESSION; ADHESION	We have expressed in mammalian cells a fragment (residues 1-302) of the alpha-chain of platelet glycoprotein (GP) lb containing the von Willebrand factor- (vWF) binding site. The secreted soluble protein had an apparent molecular mass of 45 kDa and reacted with conformation-dependent monoclonal antibodies that bind only to native GP Ib, thus demonstrating its proper folding. After insolubilization on nitrocellulose membrane, the recombinant GP Ib-alpha fragment bound soluble vWF in the presence of ristocetin or botrocetin with a dissociation constant similar to that exhibited by GP Ib.IX complex on platelets. Moreover, the interaction was blocked by anti-GP Ib monoclonal antibodies known to inhibit vWF binding to platelets. The sequence of GP Ib-alpha between residues 269-287 has a strong net negative charge due to the presence of 10 glutamic or aspartic acid residues; 5 of these are contained in the sequence of a synthetic peptide (residues 251-279) previously shown to inhibit vWF-platelet interaction. In order to evaluate the possible functional role of these acidic residues, we employed site-directed mutagenesis to express two mutant GP Ib-alpha fragments containing asparagine or glutamine instead of aspartic or glutamic acid, respectively. Mutant 1, with substitutions between residues 251-279, failed to bind vWF whether in the presence of ristocetin or botrocetin; in contrast, vWF binding to Mutant 2, with substitutions between residues 280-302, was nearly normal in the presence of ristocetin, but markedly decreased in the presence of botrocetin. Thus, mammalian cells transfected with a truncated cDNA sequence encoding the amino-terminal domain of GP Ib-alpha synthesize a fully functional vWF-binding site; acidic residues in the sequence 252-287 are essential for normal function.	SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, ROON RES CTR ARTERIOSCLEROSIS & THROMBOSIS, COMM VASC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL042846, R01HL042846, R01HL050545] Funding Source: NIH RePORTER; NCRR NIH HHS [RR0833] Funding Source: Medline; NHLBI NIH HHS [R01 HL050545, R01 HL050545-06, HL-42846] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BELLINGER DA, 1987, P NATL ACAD SCI USA, V84, P8100, DOI 10.1073/pnas.84.22.8100; BERNDT MC, 1988, BIOCHEMISTRY-US, V27, P633, DOI 10.1021/bi00402a021; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COLLER BS, 1978, J CLIN INVEST, V61, P1168, DOI 10.1172/JCI109032; DEMARCO L, 1990, J CLIN INVEST, V86, P785, DOI 10.1172/JCI114775; FEDERICI AB, 1989, BRIT J HAEMATOL, V73, P93, DOI 10.1111/j.1365-2141.1989.tb00226.x; FUJIMURA Y, 1991, BIOCHEMISTRY-US, V30, P1957, DOI 10.1021/bi00221a032; FUSTER V, 1978, J CLIN INVEST, V61, P722, DOI 10.1172/JCI108985; HANDA M, 1986, J BIOL CHEM, V261, P2579; JENKINS CSP, 1979, J LAB CLIN MED, V93, P220; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; KATAGIRI Y, 1990, THROMB HAEMOSTASIS, V63, P122; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LOPEZ JA, 1990, CIRCULATION, V82, P597; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5615, DOI 10.1073/pnas.84.16.5615; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MUNSON PJ, 1983, METHOD ENZYMOL, V92, P542; NIIYA K, 1987, BLOOD, V70, P475; Ruggeri Z M, 1991, Prog Hemost Thromb, V10, P35; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SUGIMOTO M, 1991, BIOCHEMISTRY-US, V30, P5202, DOI 10.1021/bi00235a013; TITANI K, 1987, P NATL ACAD SCI USA, V84, P5610, DOI 10.1073/pnas.84.16.5610; VICENTE V, 1988, J BIOL CHEM, V263, P18473; VICENTE V, 1990, J BIOL CHEM, V265, P274; WEISS HJ, 1974, AM J MED, V57, P920, DOI 10.1016/0002-9343(74)90170-3; WEISS HJ, 1978, J LAB CLIN MED, V92, P750; WENGER RH, 1988, BIOCHEM BIOPH RES CO, V156, P389, DOI 10.1016/S0006-291X(88)80853-2	27	102	108	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15474	15480						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1651333				2022-12-25	WOS:A1991GB09700096
J	DELVECCHIO, RL; PILCH, PF				DELVECCHIO, RL; PILCH, PF			PHOSPHATIDYLINOSITOL 4-KINASE IS A COMPONENT OF GLUCOSE TRANSPORTER (GLUT 4)-CONTAINING VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER PLASMA-MEMBRANES; RAT-LIVER; ADIPOSE CELL; KINASE; INSULIN; PURIFICATION; BRAIN; TRANSLOCATION; MECHANISM; PROTEIN	We recently developed a procedure for immunoisolating insulin-responsive membrane vesicles that contain the muscle/fat glucose transporter isoform, GLUT 4, from rat adipocytes. Utilizing this methodology, we are analyzing the components of these vesicles to gain an understanding of how they are regulated by insulin. In this report we identify a phosphatidylinositol (PtdIns) 4-kinase as a constituent of glucose transporter vesicles (GTVs). This kinase has the biochemical and immunological properties of a type II PtdIns 4-kinase as classified by Endeman et al. (Endemann, G., Dunn, S. N., and Cantley, L. C. (1987) Biochemistry 26,6845-6852). A monoclonal antibody, 4C5G, which specifically inhibits the type II PtdIns 4-kinase, suppresses 80% of the GTV-PtdIns 4-kinase activity. In addition, the GTVs-PtdIns 4-kinase is maximally activated by the nonionic detergent Triton X-100, at a concentration of 0.2% and is inhibited by adenosine with a K(i) of approximately 20-30-mu-M. We find that the GTVs do not contain any PtdIns4P 5-kinase or diacylglycerol kinase activities, whereas these activities were detected in the plasma membrane. An analysis of the subcellular distribution of PtdIns 4-kinase activity in the rat adipocyte shows that there are similar levels of activity in GTVs, plasma membranes, and the high and low density microsomal fractions, whereas the mitochondria- and nuclei-containing fractions have less than 5% of the activity seen in other fractions. Low density microsomes were subfractionated by sucrose density gradient centrifugation and PtdIns 4-kinase activity was found to correlate closely with the distribution of membrane protein, indicating that the activity is equally distributed throughout this heterogenous population of membranes. PtdIns 4-kinase activity measured in GTVs, plasma membranes, and low density microsomes, was not affected by prior treatment of the intact adipocytes with 35 nM insulin. We postulate that while the GTV-PtdIns 4-kinase is not regulated by insulin, it may play a role in defining the fusogenic properties necessary to mediate membrane movement between the GTVs, plasma membranes, and microsomes.			DELVECCHIO, RL (corresponding author), BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118, USA.			Pilch, Paul/0000-0003-1997-0499	NIDDK NIH HHS [DK 36424, DK 30245] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036424] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; CAMPBELL CR, 1985, J BIOL CHEM, V260, P948; CAPATINI S, 1989, FEBS LETT, V254, P194; CERBON J, 1986, BIOCHIM BIOPHYS ACTA, V887, P275, DOI 10.1016/0167-4889(86)90155-2; COCKCROFT S, 1985, BIOCHIM BIOPHYS ACTA, V845, P163, DOI 10.1016/0167-4889(85)90173-9; COLLINS CA, 1983, J BIOL CHEM, V258, P2130; CUSHMAN SW, 1970, J CELL BIOL, V46, P326, DOI 10.1083/jcb.46.2.326; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; de Kruijff B., 1985, ENZYMES BIOL MEMBR, P131; EBERHARD DA, 1990, BIOCHEM J, V268, P15, DOI 10.1042/bj2680015; EICHBERG J, 1985, METHOD ENZYMOL, V109, P504; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; ENDEMANN G, 1987, BIOCHEMISTRY-US, V26, P6845, DOI 10.1021/bi00395a039; ENDEMANN GC, 1991, BIOCHEM J, V273, P63, DOI 10.1042/bj2730063; HARWOOD JL, 1969, BIOCHIM BIOPHYS ACTA, V171, P75, DOI 10.1016/0005-2744(69)90107-7; HUSEBYE ES, 1988, BIOCHIM BIOPHYS ACTA, V968, P261, DOI 10.1016/0167-4889(88)90015-8; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; JAMES DE, 1987, J BIOL CHEM, V262, P11817; KATO H, 1989, J BIOL CHEM, V264, P3116; KUROSAWA M, 1986, J IMMUNOL, V136, P616; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCKEEL DW, 1970, J CELL BIOL, V44, P417, DOI 10.1083/jcb.44.2.417; MEUCKLER M, 1990, DIABETES, V39, P6; MONACO ME, 1982, J BIOL CHEM, V257, P2137; OKA Y, 1988, J BIOL CHEM, V263, P13432; PHILLIPS JH, 1973, BIOCHEM J, V136, P579, DOI 10.1042/bj1360579; PILCH PF, 1990, ENDOCRINOLOGY, V126, P3, DOI 10.1210/endo-126-1-3; PORTER FD, 1988, J BIOL CHEM, V263, P8989; RODBELL M, 1964, J BIOL CHEM, V239, P375; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SALTIEL AR, 1987, BIOCHEM J, V241, P759, DOI 10.1042/bj2410759; SEYFRED MA, 1984, J BIOL CHEM, V259, P7666; SIMPSON IA, 1986, ANNU REV BIOCHEM, V55, P1059, DOI 10.1146/annurev.biochem.55.1.1059; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SLOT JW, 1990, FASEB J, V4, P975; SMITH CD, 1983, J BIOL CHEM, V258, P9368; STUBBS EA, 1985, BIOCHIM BIOPHYS ACTA, V958, P247; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TOOKE NE, 1984, BIOCHEM J, V219, P471, DOI 10.1042/bj2190471; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; URUMOW T, 1990, BIOCHIM BIOPHYS ACTA, V1052, P152, DOI 10.1016/0167-4889(90)90070-T; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WHITMAN M, 1988, Biochimica et Biophysica Acta, V948, P327; YAMAKAWA A, 1988, J BIOL CHEM, V263, P17555; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	46	84	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1991	266	20					13278	13283						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FX132	1649187				2022-12-25	WOS:A1991FX13200075
J	HIDAKA, Y; HOTTA, H; NAGATA, Y; IWASAWA, Y; HORIE, M; KAMEI, T				HIDAKA, Y; HOTTA, H; NAGATA, Y; IWASAWA, Y; HORIE, M; KAMEI, T			EFFECT OF A NOVEL SQUALENE EPOXIDASE INHIBITOR, NB-598, ON THE REGULATION OF CHOLESTEROL-METABOLISM IN HEP G2 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; COENZYME-A REDUCTASE; POTENT COMPETITIVE INHIBITOR; HAMSTER OVARY CELLS; HMG-COA REDUCTASE; 3-HYDROXY-3-METHYLGLUTARYL COENZYME; LINE HEP-G2; RAT-LIVER; SIMVASTATIN MK-733; HUMAN FIBROBLASTS	We have reported previously that NB-598 competitively inhibits human squalene epoxidase and strongly inhibits cholesterol synthesis from [C-14]acetate in cultured cells. Furthermore, multiple oral administration of NB-598 decreased serum cholesterol levels in dogs (Horie, M., Tsuchiya, Y., Hayashi, M., Iida, Y., Iwasawa, Y., Nagata, Y., Sawasaki, Y., Fukuzumi, H., Kitani, K., and Kamei, T. (1990) J. Biol. Chem. 265, 18075-18078). In the present study, the effects of NB-598 on 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and low-density-lipoprotein (LDL) receptor were examined using a human hepatoma cell line Hep G2. Incubation of Hep G2 cells with NB-598 for 18 h increased HMG-CoA reductase activity in a dose-dependent manner. However, the increase in activity induced by NB-598 was lower than that induced by L-654, 969 (a potent HMG-CoA reductase inhibitor), although NB-598 inhibited cholesterol synthesis more potently than L-654,969. On the other hand, HMG-CoA reductase mRNA was increased to the same extent by both inhibitors. These results demonstrate that NB-598 does not inhibit the synthesis of non-sterol derivative(s) of mevalonate, which regulate HMG-CoA reductase activity at the post-transcriptional level. NB-598 increased the binding of I-125-LDL to Hep G2 cells. LDL receptor mRNA was also induced by NB-598. In the presence of LDL or cycloheximide, NB-598 did not increase LDL receptor activity. These results demonstrate that the induction of LDL receptor activity by NB-598 is due to increases in mRNA and protein through the inhibition of cholesterol synthesis at the squalene epoxidase step. From these observations, squalene epoxidase inhibitor is expected to be highly effective in the treatment of hypercholesterolemia and also is very useful as a research tool for studying the regulation of cholesterol metabolism.			HIDAKA, Y (corresponding author), BANYU PHARMACEUT CO LTD,CENT RES LABS,2-9-3 SHIMOMEGURO,MEGURO KU,TOKYO 153,JAPAN.							ALBERTS AW, 1980, P NATL ACAD SCI-BIOL, V77, P3957, DOI 10.1073/pnas.77.7.3957; BOOGAARD A, 1987, BIOCHEM J, V241, P345, DOI 10.1042/bj2410345; BROWN MS, 1974, J BIOL CHEM, V249, P789; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN MS, 1978, J BIOL CHEM, V253, P1121; BROWN MS, 1980, J LIPID RES, V21, P505; CHANG TY, 1980, J BIOL CHEM, V255, P7787; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COHEN LH, 1988, BIOCHEM J, V255, P61, DOI 10.1042/bj2550061; COHEN LH, 1984, BIOCHEM J, V222, P35, DOI 10.1042/bj2220035; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; DOUGLAS TJ, 1972, PLANT PHYSIOL, V49, P417, DOI 10.1104/pp.49.3.417; EDWARDS PA, 1979, J LIPID RES, V20, P40; ENDO A, 1976, J ANTIBIOT, V29, P1346, DOI 10.7164/antibiotics.29.1346; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIELDING CJ, 1979, J BIOL CHEM, V254, P8861; GIBBONS GF, 1977, BIOCHEM J, V162, P321, DOI 10.1042/bj1620321; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; GOLDSTEIN JL, 1976, CELL, V7, P85, DOI 10.1016/0092-8674(76)90258-0; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GUPTA A, 1986, J BIOL CHEM, V261, P8348; HAVEKES L, 1983, BIOCHEM J, V214, P951, DOI 10.1042/bj2140951; HIDAKA Y, 1990, J LIPID RES, V31, P2087; HOFFMAN WF, 1986, J MED CHEM, V29, P847; HORIE M, 1990, J BIOL CHEM, V265, P18075; KANDUTSCH AA, 1975, J CELL PHYSIOL, V85, P415, DOI 10.1002/jcp.1040850408; KOVANEN PT, 1981, P NATL ACAD SCI-BIOL, V78, P1194, DOI 10.1073/pnas.78.2.1194; KURIBAYASHI K, 1988, NUCLEIC ACIDS RES S, V19, P61; LISCUM L, 1989, J BIOL CHEM, V264, P11796; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOLOWA DT, 1989, BIOCHEM J, V260, P731, DOI 10.1042/bj2600731; NAGATA Y, 1990, JPN J PHARMACOL, V54, P315, DOI 10.1254/jjp.54.315; NAGATA Y, 1990, BIOCHEM PHARMACOL, V40, P843; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; OSBORNE TF, 1988, J BIOL CHEM, V263, P3380; PANINI SR, 1984, J BIOL CHEM, V259, P7767; PREISS B, 1985, REGULATION HMG COA R; Rodwell V W, 1976, Adv Lipid Res, V14, P1; SATOH T, 1990, J LIPID RES, V31, P2095; SMITH JR, 1988, J BIOL CHEM, V263, P18480; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; WANG SR, 1988, BIOCHIM BIOPHYS ACTA, V961, P351, DOI 10.1016/0005-2760(88)90082-3; YOSHIDA Y, 1985, J PHARMACOBIO-DYNAM, V8, P432; 1982, J AM COLL TOXICOL, V1, P37	44	44	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1991	266	20					13171	13177						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FX132	1649182				2022-12-25	WOS:A1991FX13200060
J	JI, I; JI, TH				JI, I; JI, TH			HUMAN CHORIOGONADOTROPIN BINDS TO A LUTROPIN RECEPTOR WITH ESSENTIALLY NO N-TERMINAL EXTENSION AND STIMULATES CAMP SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE RECEPTOR; EXPRESSION; CLONING; DOMAIN; CDNA; TSH	The lutropin (LH) receptor, which belongs to the family of G-protein coupled receptors, consists of an extracellular hydrophilic N-terminal extension of 341 amino acids and a membrane-embedded C-terminal region of 333 amino acids. This C-terminal region comprises a short N terminus, seven transmembrane domains, three cytoplasmic loops, three exoplasmic loops, and a C terminus. Recently, it was reported that the N-terminal extension of the LH receptor alone or a naturally occurring variant LH receptor similar to the N-terminal extension is capable of binding the hormone with an affinity slightly higher than that of the native receptor. This finding raises a question as to whether the N-terminal extension represents the entire hormone binding site and, if so, how is hormone binding transduced to the activation of a G-protein? In an attempt to answer this important question, we have prepared truncated receptors containing an N-terminal extension as short as 10 amino acids. Surprisingly, the truncated receptors were not only capable of binding the hormone, albeit with low affinities, but also capable of stimulating cAMP synthesis. These results suggest a possibility that the hormone, at least in part, interacts with the membrane embedded C-terminal region and modulates it to activate adenylate cyclase. The low hormone binding affinities of the truncated receptors taken together with high affinity hormone binding to the N-terminal extension of the LH receptor indicate the existence of two or more contact points between the receptor and the hormone.			JI, I (corresponding author), UNIV WYOMING,DEPT MOLEC BIOL,LARAMIE,WY 82071, USA.				NICHD NIH HHS [HD-18702] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018702] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		CHAZENBALK GD, 1990, J BIOL CHEM, V265, P20970; FRAZIER AL, 1990, MOL ENDOCRINOL, V4, P1264, DOI 10.1210/mend-4-8-1264; JI I, 1990, P NATL ACAD SCI USA, V87, P4396, DOI 10.1073/pnas.87.11.4396; JI I, 1981, P NATL ACAD SCI-BIOL, V78, P5465, DOI 10.1073/pnas.78.9.5465; JI I, 1990, GLYCOPROTEIN HORMONE, P355; JI IH, 1985, J BIOL CHEM, V260, P2815; JI IH, 1991, ENDOCRINOLOGY, V128, P2648, DOI 10.1210/endo-128-5-2648; KARPLUS PA, 1985, NATURWISSENSCHAFTEN, V72, P212, DOI 10.1007/BF01195768; KHORANA HG, 1988, J BIOL CHEM, V263, P7439; KOBILKA BK, 1987, J BIOL CHEM, V262, P7321; KOO YB, 1991, ENDOCRINOLOGY, V128, P2297, DOI 10.1210/endo-128-5-2297; LIMBIRD LE, 1984, AM J PHYSIOL, V247, pE59, DOI 10.1152/ajpendo.1984.247.1.E59; LOOSFELT H, 1989, SCIENCE, V245, P525, DOI 10.1126/science.2502844; MACFARLAND KC, 1989, SCIENCE, V245, P494; MISRAHI M, 1990, BIOCHEM BIOPH RES CO, V166, P394, DOI 10.1016/0006-291X(90)91958-U; ODOWD BF, 1989, ANNU REV NEUROSCI, V12, P67, DOI 10.1146/annurev.ne.12.030189.000435; PARMENTIER M, 1989, SCIENCE, V246, P1620, DOI 10.1126/science.2556796; SHELDEN RF, 1987, CURRENT PROTOCOLS MO; SHIN J, 1986, J BIOL CHEM, V261, P7501; SPRENGEL R, 1990, MOL ENDOCRINOL, V4, P525, DOI 10.1210/mend-4-4-525; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; TSAIMORRIS CH, 1990, J BIOL CHEM, V265, P19385; XIE YB, 1990, J BIOL CHEM, V265, P21411	23	93	101	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1991	266	20					13076	13079						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FX132	1649176				2022-12-25	WOS:A1991FX13200045
J	SEO, YS; LEE, SH; HURWITZ, J				SEO, YS; LEE, SH; HURWITZ, J			ISOLATION OF A DNA HELICASE FROM HELA-CELLS REQUIRING THE MULTISUBUNIT HUMAN SINGLE-STRANDED DNA-BINDING PROTEIN FOR ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE T-ANTIGEN; LARGE TUMOR-ANTIGEN; SV40 ORIGIN; SACCHAROMYCES-CEREVISIAE; INVITRO REPLICATION; BACTERIOPHAGE-T4; INITIATION; PURIFICATION; ATPASE; ALPHA	A DNA helicase, dependent on the multisubunit human single-stranded DNA binding protein (HSSB), was isolated from HeLa cells. At low levels of helicase, only the multisubunit SSBs, HSSB and yeast SSB, stimulated DNA helicase activity. At high levels of the helicase Escherichia coli SSB partially substituted for HSSB whereas other SSBs such as T4 gene 32 and adenovirus DNA binding protein did not stimulate the enzyme activity. Maximal activation of helicase activity occurred in the presence of one molecule of HSSB for every 20 nucleotides of single-stranded DNA. The addition of E. coli SSB significantly lowered the amount of HSSB required for strand displacement, suggesting that the HSSB plays at least two roles in the activation of the helicase. One is to bind single-stranded DNA, thereby preventing sequestration of the helicase, the other involves the interaction of the HSSB with the helicase. Monoclonal antibodies that interact with the 70- and 34-kDa subunits of HSSB inhibited its stimulation of the helicase activity. The DNA helicase acted catalytically in displacing duplex DNA and translocated in the 3' to 5' direction. The helicase displaced fragments from both ends of a DNA substrate that contained duplex region at both termini, but the 3' to 5' fragment was displaced 20 times faster than the 5' to 3' fragment. Since this helicase also displaced fully duplex DNA, the release of the 5' to 3' fragment may have occurred by entry of the helicase through the duplex end in a 3' to 5' direction.			SEO, YS (corresponding author), MEM SLOAN KETTERING CANC CTR,SLOAN KETTERING INST,GRAD PROGRAM MOLEC BIOL,NEW YORK,NY 10021, USA.		Seo, Yeonsoo/C-1605-2011					BOROWIEC JA, 1988, EMBO J, V7, P3149, DOI 10.1002/j.1460-2075.1988.tb03182.x; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; CHA TA, 1989, J BIOL CHEM, V264, P12220; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P16, DOI 10.1073/pnas.84.1.16; DEB SP, 1987, J VIROL, V61, P3649, DOI 10.1128/JVI.61.12.3649-3654.1987; GOETZ GS, 1988, J BIOL CHEM, V263, P383; GORBALENYA AE, 1988, NATURE, V333, P22, DOI 10.1038/333022a0; HODGMAN TC, 1988, NATURE, V333, P22, DOI 10.1038/333022b0; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; IKEDA JE, 1981, P NATL ACAD SCI-BIOL, V78, P884, DOI 10.1073/pnas.78.2.884; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; KENNY M K, 1990, Journal of Biological Chemistry, V265, P7693; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LEE SH, 1989, P NATL ACAD SCI USA, V86, P4877, DOI 10.1073/pnas.86.13.4877; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; MATSON SW, 1983, J BIOL CHEM, V258, P4017; MATSUMOTO T, 1990, P NATL ACAD SCI USA, V87, P9712, DOI 10.1073/pnas.87.24.9712; SANGER F, 1978, J MOL BIOL, V125, P225, DOI 10.1016/0022-2836(78)90346-7; SEKI M, 1986, BIOCHEMISTRY-US, V25, P3239, DOI 10.1021/bi00359a024; SEKI M, 1988, BIOCHEMISTRY-US, V27, P1766, DOI 10.1021/bi00405a057; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SMITH KR, 1989, J BIOL CHEM, V264, P6119; STAHL H, 1986, EMBO J, V5, P1939, DOI 10.1002/j.1460-2075.1986.tb04447.x; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; SUNG P, 1987, P NATL ACAD SCI USA, V84, P6045, DOI 10.1073/pnas.84.17.6045; SUNG P, 1987, P NATL ACAD SCI USA, V84, P8951, DOI 10.1073/pnas.84.24.8951; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; TSURIMOTO T, 1989, EMBO J, V8, P3883, DOI 10.1002/j.1460-2075.1989.tb08567.x; VENKATESAN M, 1982, J BIOL CHEM, V257, P2426; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; WIEKOWSKI M, 1988, J BIOL CHEM, V263, P436; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710	38	85	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1991	266	20					13161	13170						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FX132	1649181				2022-12-25	WOS:A1991FX13200059
J	KAGAWA, N; WATERMAN, MR				KAGAWA, N; WATERMAN, MR			EVIDENCE THAT AN ADRENAL-SPECIFIC NUCLEAR-PROTEIN REGULATES THE CAMP RESPONSIVENESS OF THE HUMAN CYP21B (P450C21) GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE STEROID 11-BETA-HYDROXYLASE; RNA POLYMERASE-II; CYCLIC-AMP; 21-HYDROXYLASE GENES; PROMOTER REGION; TRANSCRIPTION; EXPRESSION; ELEMENT; DNA; IDENTIFICATION	Based on competition analysis of gel shift assays utilizing nuclear extracts from the mouse adrenal Y1 cell line, the cAMP-responsive element of the human CYP21B gene (-129/-96 base pairs (bp)) is found to contain two overlapping nuclear protein binding elements. One, - 126/-113 bp, interacts specifically with an adrenal-specific protein factor (ASP) while the other, -119/-110 bp, contains a GC boxlike sequence and binds Sp1. The nucleotide replacements (GG --> CC at -113 and -112 bp) introduced within the sequence -129/-96 bp greatly decreased the binding affinities of both Sp1 and ASP to the fragment and resulted in a loss of cAMP-enhanced transcription of a reporter gene in transient transfection experiments. When the 14-bp ASP-binding sequence was inserted in front of the reporter gene, induced transcription by cAMP was observed that could be increased by multimerization of this -126/-113-bp sequence. The -126/-113-bp fragment revealed specific binding only with nuclear extracts from adrenal Y1 cells among various types of cells tested, indicating that the protein factor ASP is specifically expressed in adrenal cells. The nucleotide replacement (G --> C at -117 bp) of the -126/-113-bp sequence not only abolishes the binding to ASP but also the cAMP-dependent transcription, strongly supporting the hypothesis that ASP is a tissue-specific transacting protein that directly functions as a transcription factor essential to the cAMP-dependent transcription. Furthermore, the -129/-115-bp sequence of the bovine cytochrome P450C21 gene corresponding to the human -126/-113-bp sequence is demonstrated to be functionally conserved with respect to both cAMP-dependent enhancement of transcription and ASP binding.	UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT OBSTET & GYNECOL, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, CECIL H & IDA GREEN CTR REPROD BIOL SCI, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028350] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK28350] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; AHLGREN R, 1990, J BIOL CHEM, V265, P3313; CHUNG BC, 1986, P NATL ACAD SCI USA, V83, P4243, DOI 10.1073/pnas.83.12.4243; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HANDLER JD, 1988, J BIOL CHEM, V263, P13068; HIGASHI Y, 1986, P NATL ACAD SCI USA, V83, P2841, DOI 10.1073/pnas.83.9.2841; HONDA SI, 1990, J BIOCHEM-TOKYO, V108, P1042, DOI 10.1093/oxfordjournals.jbchem.a123303; HUDSON JM, 1989, BIOTECHNIQUES, V7, P812; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KAGAWA N, 1990, J BIOL CHEM, V265, P11299; KOHLER PO, 1971, ACTA ENDOCRINOL-COP, P137; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LUND J, 1990, J BIOL CHEM, V265, P3304; Maniatis T., 1982, MOL CLONING; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MOUW AR, 1989, J BIOL CHEM, V264, P1305; NEBERT DW, 1989, DNA-J MOLEC CELL BIO, V8, P1, DOI 10.1089/dna.1.1989.8.1; PARKER KL, 1986, J BIOL CHEM, V261, P5353; RICE DA, 1989, J BIOL CHEM, V264, P14011; RICE DA, 1990, J BIOL CHEM, V265, P8052; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; WATERMAN MR, 1989, RECENT PROG HORM RES, V45, P533; WESTIN G, 1987, NUCLEIC ACIDS RES, V15, P6787, DOI 10.1093/nar/15.17.6787; WHITE PC, 1986, P NATL ACAD SCI USA, V83, P5111, DOI 10.1073/pnas.83.14.5111	29	56	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					11199	11204						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	1645728				2022-12-25	WOS:A1991FQ77400077
J	ALOUSI, AA; JASPER, JR; INSEL, PA; MOTULSKY, HJ				ALOUSI, AA; JASPER, JR; INSEL, PA; MOTULSKY, HJ			STOICHIOMETRY OF RECEPTOR-GS-ADENYLATE CYCLASE INTERACTIONS	FASEB JOURNAL			English	Note						G-PROTEINS; FORSKOLIN; RECEPTORS	BETA-ADRENERGIC RECEPTORS; S49 LYMPHOMA-CELLS; REGULATORY PROTEIN; BINDING-PROTEIN; MULTIPLE SITES; FORSKOLIN; STIMULATION; MEMBRANES; MECHANISM; AFFINITY	Little is known about the relative stoichiometry of guanine nucleotide-binding (G) proteins relative to the effector systems to which they link. We addressed this question for the stimulatory G protein (G(s)) linked to adenylate cyclase. Forskolin stimulates the catalytic subunit of adenylate cyclase (C), but it has a higher efficacy and potency when C also interacts with the G protein G(s). Accordingly, we measured high-affinity [H-3]forskolin binding to intact cells to assay alpha-s-C complexes. No high-affinity specific binding occurred with unstimulated cells. The beta-adrenergic agonist isoproterenol promoted the binding of [H-3]forskolin to about 3000 sites per cell, suggesting that each receptor on average activates at least several G(s) molecules. Activating G(s) directly with cholera toxin maximally promoted [H-3]forskolin binding to a similar number of sites, suggesting that this is the maximal number of alpha-s-C complexes formed per cell. We conclude that each cell likely contains only a few thousand functional copies of C, and that the availability of C (rather than G(s), which exists in more than 100,000 copies per cell) is likely to be limiting for agonist stimulation of adenylate cyclase activity.	UNIV CALIF SAN DIEGO,DEPT PHARMACOL 0636,LA JOLLA,CA 92093	University of California System; University of California San Diego								BARBER R, 1989, 2 MESSENGERS PHOSPHO, V12, P59; BRANDT DR, 1986, J BIOL CHEM, V261, P1656; DARFLER FJ, 1982, J BIOL CHEM, V257, P1901; DEBLASI A, 1989, TRENDS PHARMACOL SCI, V10, P227, DOI 10.1016/0165-6147(89)90266-6; HAMMOND HK, 1988, J CLIN INVEST, V82, P2168, DOI 10.1172/JCI113840; INSEL PA, 1979, J BIOL CHEM, V254, P6554; INSEL PA, 1983, J BIOL CHEM, V258, P3597; JASPER JR, 1988, J PHARMACOL EXP THER, V244, P820; LAURENZA A, 1987, MOL PHARMACOL, V32, P133; LAURENZA A, 1989, TRENDS PHARMACOL SCI, V10, P442, DOI 10.1016/S0165-6147(89)80008-2; LONGABAUGH JP, 1988, J CLIN INVEST, V81, P420, DOI 10.1172/JCI113335; MORRIS D, 1990, BIOCHEMISTRY-US, V29, P9079, DOI 10.1021/bi00490a027; PEDERSEN SE, 1982, P NATL ACAD SCI-BIOL, V79, P7228, DOI 10.1073/pnas.79.23.7228; RANSNAS LA, 1988, J BIOL CHEM, V263, P9482; RANSNAS LA, 1988, J BIOL CHEM, V263, P17239; RODAN GA, 1984, ADV CYCLIC NUCL PROT, V17, P127; RODBELL M, 1980, NATURE, V284, P17, DOI 10.1038/284017a0; SMIGEL MD, 1986, J BIOL CHEM, V261, P1976; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135	19	139	142	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1991	5	9					2300	2303		10.1096/fasebj.5.9.1650314	http://dx.doi.org/10.1096/fasebj.5.9.1650314			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FP872	1650314				2022-12-25	WOS:A1991FP87200012
J	CHAN, J; WATT, VM				CHAN, J; WATT, VM			EEK AND ERK, NEW MEMBERS OF THE EPH SUBCLASS OF RECEPTOR PROTEIN-TYROSINE KINASES	ONCOGENE			English	Article							PHOSPHOTYROSINE ANTIBODY; GEL-ELECTROPHORESIS; DNA FRAGMENTS; GENE; PDGF; FAMILY; BRAIN; PHOSPHORYLATION; LOCALIZATION; EXPRESSION	We have identified human and rat DNAs encoding two novel members of the eph subclass of putative receptor protein-tyrosine kinases. Rat cDNA clones encoding eek (eph- and elk-related kinase) were isolated from a brain cDNA library probed with DNA encoding the kinase region of the insulin receptor-related receptor. The predicted eek protein contains all the amino acid residues conserved in the catalytic domains of protein-tyrosine kinases and is most similar to two putative receptor protein-tyrosine kinases of the eph subclass, elk (69%) and eph (57%). Human genomic DNAs encoding part of eek (EEK) as well as another putative protein-tyrosine kinase most similar to elk (90%), ERK (elk-related kinase), were isolated and partially characterized. The novel identity of these two eph-family genes was further supported by Southern blot analyses and localization to human chromosome 1. In Northern blot analysis of rat RNA, DNAs encoding rat eek and human ERK hybridized to transcripts most abundant in brain and lung, respectively. These two new members of the eph subclass of receptor protein-tyrosine kinases, eek and erk, may therefore have tissue-specific functions distinct from those of other eph family members.	UNIV TORONTO,DEPT PHYSIOL,MED SCI BLDG,ROOM 3360,1 KINGS COLL CIRCLE,TORONTO M5S 1A8,ONTARIO,CANADA	University of Toronto	WATT, VM (corresponding author), UNIV TORONTO,DEPT PHYSIOL,MED SCI BLDG,ROOM 3360,1 KINGS COLL CIRCLE,TORONTO M5S 1A8,ONTARIO,CANADA.							ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; AULD VJ, 1988, NEURON, V1, P449, DOI 10.1016/0896-6273(88)90176-6; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BUCHBERG AM, 1989, GENETICS, V122, P153; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; EDWARDS AM, 1988, MOL CELL BIOL, V8, P2655, DOI 10.1128/MCB.8.6.2655; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; LAWN RM, 1978, CELL, V15, P1157, DOI 10.1016/0092-8674(78)90043-0; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LETWIN K, 1988, ONCOGENE, V3, P621; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MARU Y, 1988, MOL CELL BIOL, V8, P3770, DOI 10.1128/MCB.8.9.3770; MARU Y, 1990, ONCOGENE, V5, P445; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; NAIRN AC, 1985, ANNU REV BIOCHEM, V54, P931, DOI 10.1146/annurev.bi.54.070185.004435; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; ROBERTS WM, 1988, CELL, V55, P655, DOI 10.1016/0092-8674(88)90224-3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIER P, 1990, CYTOGENET CELL GENET, V54, P80, DOI 10.1159/000132963; SHIER P, 1989, J BIOL CHEM, V264, P14605; SMART JE, 1981, P NATL ACAD SCI-BIOL, V78, P6013, DOI 10.1073/pnas.78.10.6013; SOARES MB, 1985, MOL CELL BIOL, V5, P2090, DOI 10.1128/MCB.5.8.2090; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; WATT VM, 1990, HUM GENET, V85, P651; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	39	58	130	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1991	6	6					1057	1061						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1648701				2022-12-25	WOS:A1991GU62200023
J	KIM, JI; COX, MM; INMAN, RB				KIM, JI; COX, MM; INMAN, RB			ON THE ROLE OF ATP HYDROLYSIS IN RECA PROTEIN-MEDIATED DNA STRAND EXCHANGE .1. BYPASSING A SHORT HETEROLOGOUS INSERT IN ONE DNA SUBSTRATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; GENETIC-RECOMBINATION; PARTIAL DENATURATION; LINEAR DICHROISM; COMPLEXES; BINDING; MECHANISM; FILAMENTS; STOICHIOMETRY; PURIFICATION	RecA protein promotes a substantial DNA strand exchange reaction in the presence of adenosine 5'-O-3-(thio)triphoisphate (ATP-gamma-S) (Menetski, J. P., Bear, D. G., and Kowalczykowski, S. C. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 21-25), calling into question the role of ATP hydrolysis in the strand exchange reaction. Here, we demonstrate that the ATP-gamma-S-mediated reaction can go to completion when the duplex DNA substrate is only 1.3 kilobase pairs in length. The ATP-gamma-S-mediated reaction, however, is completely blocked by a 52-base pair heterologous insertion in either DNA substrate. This same barrier is readily bypassed when ATP replaces ATP-gamma-S. This indicates that at least one function of recA-mediated ATP hydrolysis is to bypass structural barriers in one or both DNA substrates during strand exchange. This suggests that ATP hydrolysis is directly coupled to the branch migration phase of strand exchange, not to promote strand exchange between homologous DNA substrates during recombination, but instead to facilitate the bypass of structural barriers likely to be encountered during recombinational DNA repair.	UNIV WISCONSIN, COLL AGR & LIFE SCI, DEPT BIOCHEM, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032335, R01GM014711, U01GM032335] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-32335, GM-14711] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEDALE WA, 1991, J BIOL CHEM, V266, P6499; BIANCHI ME, 1983, CELL, V35, P511, DOI 10.1016/0092-8674(83)90185-X; BRENNER SL, 1987, J BIOL CHEM, V262, P4011; Cox M.M., 1989, P43; COX MM, 1981, J BIOL CHEM, V256, P4676; COX MM, 1991, MOL MICROBIOL, V5, P1295, DOI 10.1111/j.1365-2958.1991.tb00775.x; COX MM, 1990, BIOL NONSPECIFIC DNA, P171; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; DASGUPTA C, 1982, P NATL ACAD SCI-BIOL, V79, P762, DOI 10.1073/pnas.79.3.762; Davis R., 1980, ADV BACTERIAL GENETI; HOWARDFLANDERS P, 1984, NATURE, V309, P215, DOI 10.1038/309215a0; INMAN RB, 1970, J MOL BIOL, V49, P93, DOI 10.1016/0022-2836(70)90378-5; KIM JI, 1992, J BIOL CHEM, V267, P16444; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; KUBISTA M, 1990, J BIOL CHEM, V265, P18891; LINDSLEY JE, 1990, J BIOL CHEM, V265, P9043; LITTLEWOOD RK, 1982, NUCLEIC ACIDS RES, V10, P1691, DOI 10.1093/nar/10.5.1691; LIVNEH Z, 1982, P NATL ACAD SCI-BIOL, V79, P3171, DOI 10.1073/pnas.79.10.3171; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; LOHMAN TM, 1986, BIOCHEMISTRY-US, V25, P21, DOI 10.1021/bi00349a004; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P21, DOI 10.1073/pnas.87.1.21; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; MULLER B, 1990, J MOL BIOL, V212, P97, DOI 10.1016/0022-2836(90)90307-8; NEUENDORF SK, 1986, J BIOL CHEM, V261, P8276; OGAWA T, 1979, COLD SPRING HARB SYM, V43, P909, DOI 10.1101/SQB.1979.043.01.099; PUGH BF, 1987, J BIOL CHEM, V262, P1337; RADDING CM, 1991, J BIOL CHEM, V266, P5355; ROBERTS JW, 1979, COLD SPRING HARB SYM, V43, P917, DOI 10.1101/SQB.1979.043.01.100; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; ROSSELLI W, 1990, J MOL BIOL, V216, P335, DOI 10.1016/S0022-2836(05)80325-0; Sambrook J, 1989, MOL CLONING LABORATO; SCHUTTE BC, 1987, BIOCHEMISTRY-US, V26, P5616, DOI 10.1021/bi00392a006; SENECOFF JF, 1985, P NATL ACAD SCI USA, V82, P7270, DOI 10.1073/pnas.82.21.7270; TAKAHASHI M, 1989, J MOL BIOL, V205, P137, DOI 10.1016/0022-2836(89)90371-9; TAKAHASHI M, 1991, BIOCHIMIE, V73, P219, DOI 10.1016/0300-9084(91)90205-F; UMLAUF SW, 1990, J BIOL CHEM, V265, P16898; WEST SC, 1981, NATURE, V294, P659, DOI 10.1038/294659a0; WEST SC, 1992, IN PRESS ANN REV BIO; WITKIN EM, 1991, BIOCHIMIE, V73, P133, DOI 10.1016/0300-9084(91)90196-8	40	89	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16438	16443						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1644827				2022-12-25	WOS:A1992JJ45800071
J	SIVARAM, P; KLEIN, MG; GOLDBERG, IJ				SIVARAM, P; KLEIN, MG; GOLDBERG, IJ			IDENTIFICATION OF A HEPARIN-RELEASABLE LIPOPROTEIN-LIPASE BINDING-PROTEIN FROM ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE-FATTY-ACIDS; SULFATE PROTEOGLYCAN; BASEMENT-MEMBRANE; FIBROBLAST GROWTH; SURFACE; RECEPTOR; CULTURE; ASSAY	Triglycerides in circulating plasma lipoproteins are hydrolyzed by lipoprotein lipase (LPL) which is thought to bind to proteoglycans on the luminal endothelial cell surface. Previous studies from this laboratory using LPL-Sepharose affinity chromatography identified a 220-kDa LPL binding proteoglycan. Using ligand blotting with I-125-LPL, we now report a 116-kDa LPL binding protein in plasma membrane preparations of endothelial cells. I-125-LPL binding to this protein was abolished by addition of unlabeled LPL. When the cell surface of endothelial cells was labeled with biotin, a 116-kDa protein was biotinylated. Furthermore, the biotinylated 116-kDa protein bound to LPL-Sepharose and eluted with 0.4 M NaCl suggesting that the 116-kDa LPL binding protein is present on t he cell surface. When detergent extracts of endothelial cells were applied to LPL-Sepharose in the presence of 0.15 M NaCl, the 116-kDa, but not the 220-kDa, protein still bound to LPL-Sepharose. The 116-kDa protein was not labeled with (SO4)-S-35 and eluted from DEAE-cellulose prior to proteoglycans, suggesting that it is not a proteoglycan. However, a 116-kDa endothelial cell surface protein was metabolically labeled with [S-35]methionine. This protein was dissociated from the cell surface by incubating cells with heparin (50 units/ml)-containing buffer. After heparin treatment of endothelial cells, LPL binding to and internalization by the cells decreased >70% compared to control cells. These results suggest that endothelial cells synthesize a heparin-releasable, high affinity 116-kDa LPL binding protein. We postulate that this protein is associated with proteoglycans on luminal endothelial surfaces and mediates LPL binding, internalization, and recycling. We name this protein hrp (heparin-releasable protein)-116.	COLUMBIA UNIV COLL PHYS & SURG, SPECIALIZED CTR RES ARTERIOSCLEROSIS, NEW YORK, NY 10032 USA	Columbia University	SIVARAM, P (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, DEPT MED, 630 W 168TH ST, NEW YORK, NY 10032 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL045095, R01HL045095] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-45095] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aronson N N Jr, 1974, Methods Enzymol, V31, P90; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BENSADOUN A, 1991, ANNU REV NUTR, V11, P217, DOI 10.1146/annurev.nu.11.070191.001245; BIRD TA, 1988, J BIOL CHEM, V263, P12063; CHENG CF, 1981, J BIOL CHEM, V256, P2893; COLE SR, 1987, MOL IMMUNOL, V24, P699, DOI 10.1016/0161-5890(87)90051-4; DANIEL TO, 1983, J BIOL CHEM, V258, P4606; DREFUSS G, 1984, MOL CELL BIOL, V4, P415; ECKEL RH, 1989, NEW ENGL J MED, V320, P1060; Hahn PF, 1943, SCIENCE, V98, P19, DOI 10.1126/science.98.2531.19; KELLER R, 1987, AM J PATHOL, V128, P286; KINSELLA MG, 1988, BIOCHEMISTRY-US, V27, P2136, DOI 10.1021/bi00406a048; KJELLEN L, 1980, J BIOL CHEM, V255, P407; KLINGER MM, 1985, J BIOL CHEM, V260, P4082; KRAEMER PM, 1977, BIOCHEM BIOPH RES CO, V78, P1334, DOI 10.1016/0006-291X(77)91438-3; LIN PH, 1988, ANAL BIOCHEM, V168, P300, DOI 10.1016/0003-2697(88)90322-3; LINDBLOM A, 1989, BIOCHEM J, V261, P145, DOI 10.1042/bj2610145; LINDBLOM A, 1991, BIOCHEM J, V279, P821, DOI 10.1042/bj2790821; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NILSSONEHLE P, 1976, J LIPID RES, V17, P536; OLGEMOLLER B, 1989, BIOL CHEM H-S, V370, P1321, DOI 10.1515/bchm3.1989.370.2.1321; PARTHASARATHY N, 1984, J BIOL CHEM, V259, P2749; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; SAKU T, 1989, J BIOL CHEM, V264, P3514; SAXENA U, 1991, J BIOL CHEM, V266, P17516; SAXENA U, 1989, J BIOL CHEM, V264, P4349; SAXENA U, 1990, BIOCHIM BIOPHYS ACTA, V1043, P161, DOI 10.1016/0005-2760(90)90291-5; SAXENA U, 1991, P NATL ACAD SCI USA, V88, P2254, DOI 10.1073/pnas.88.6.2254; SAXENA U, 1990, J BIOL CHEM, V265, P12880; SHIMADA K, 1981, J CLIN INVEST, V68, P995, DOI 10.1172/JCI110354; SHIMADA K, 1981, BIOCHIM BIOPHYS ACTA, V710, P117; SOCORRO L, 1985, PREP BIOCHEM, V15, P133, DOI 10.1080/10826068508062267; SOUTAR AK, 1986, J BIOL CHEM, V261, P7127; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	34	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16517	16522						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1644832				2022-12-25	WOS:A1992JJ45800082
J	LE, DT; RAPAPORT, SI; RAO, LVM				LE, DT; RAPAPORT, SI; RAO, LVM			RELATIONS BETWEEN FACTOR-VIIA BINDING AND EXPRESSION OF FACTOR-VIIA TISSUE FACTOR CATALYTIC ACTIVITY ON CELL-SURFACES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLACENTAL ANTICOAGULANT PROTEIN; EXTRINSIC PATHWAY; PROCOAGULANT ACTIVITY; BLOOD-COAGULATION; ENDOTHELIAL-CELLS; FACTOR-IX; MECHANISM; INITIATION; INHIBITOR; LINE	The kinetics of the binding of rVIIa to cell surface tissue factor (TF) and the resultant expression of VIIa/TF activity were studied. Binding of I-125-rVIIa (10 nM) to cell surface TF required 30-60 min for saturation, whereas VIIa/TF activity was fully expressed toward factor X (F X) on intact monolayers after only 1 min of incubation. At that time only 10-20% of the total VIIa . TF complexes present at saturation had formed. Freeze-thawing the monolayers before assay increased VIIa/TF activity up to 30-fold, and the time course of its expression was similar to that of TF-specific binding of VIIa to the monolayers. Equilibrium binding revealed a single high affinity binding class of TF sites on intact monolayers for rVIIa with a K(d) of 1.6 nM. Experiments with active-site inhibited rVIIa yielded evidence for two populations of VIIa . TF complexes on intact monolayers: (1) a minor population (<20%) that formed within 1 min of incubation and accounted for all VIIa/TF activity toward F X present on the intact monolayers, and (2) a major population that was inactive toward F X on intact monolayers but which was fully active after the monolayers were lysed. Tissue factor pathway inhibitor (TFPI) . F Xa complexes inhibited the VIIa/TF activity of the first population, i.e. of the complexes active on intact monolayers, half maximally at a concentration of 0.2 nM TFPI. TFPI/Xa also bound to the second population of VIIa . TF complexes on intact monolayers and inhibited their expression of VIIa/TF activity following cell lysis with a half-maximal inhibitory concentration of 2.0 nM. The potential physiologic implications of these findings are discussed.	UNIV CALIF SAN DIEGO,MED CTR,DEPT MED,8423,225 DICKINSON ST,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT PATHOL,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego					NHLBI NIH HHS [HL-27234, HL-42813] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042813, R37HL027234] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALMUS FE, 1989, THROMB HAEMOSTASIS, V62, P1067; ALMUS FE, 1990, BLOOD, V76, P354; ALMUS FE, 1991, BLOOD, V77, P1256; BACH R, 1990, P NATL ACAD SCI USA, V87, P6995, DOI 10.1073/pnas.87.18.6995; BAJAJ SP, 1981, PREP BIOCHEM, V11, P397, DOI 10.1080/00327488108065531; BAUER KA, 1990, BLOOD, V76, P731; BJORKLID E, 1977, BIOCHEM J, V165, P89, DOI 10.1042/bj1650089; BROZE GJ, 1988, BLOOD, V71, P335; BROZE GJ, 1987, P NATL ACAD SCI USA, V84, P1886, DOI 10.1073/pnas.84.7.1886; CALLANDER NS, 1992, J BIOL CHEM, V267, P876; DRAKE TA, 1989, J CELL BIOL, V109, P389, DOI 10.1083/jcb.109.1.389; DRAKE TA, 1989, AM J PATHOL, V134, P1087; FAIR DS, 1987, J BIOL CHEM, V262, P11692; FLECK RA, 1990, THROMB RES, V59, P421, DOI 10.1016/0049-3848(90)90148-6; FUNAKOSHI T, 1987, BIOCHEMISTRY-US, V26, P5572, DOI 10.1021/bi00391a053; KONDO S, 1987, THROMB RES, V48, P449, DOI 10.1016/0049-3848(87)90402-6; LIPFORD GB, 1990, ANAL BIOCHEM, V187, P133, DOI 10.1016/0003-2697(90)90430-H; NEMERSON Y, 1988, BLOOD, V71, P1; NORDFANG O, 1991, BIOCHEMISTRY-US, V30, P10371, DOI 10.1021/bi00107a002; PEDERSEN AH, 1990, J BIOL CHEM, V265, P16786; PLOPLIS VA, 1987, J BIOL CHEM, V262, P9503; RAO LVM, 1988, P NATL ACAD SCI USA, V85, P6687, DOI 10.1073/pnas.85.18.6687; RAO LVM, 1985, BLOOD, V65, P218; RAO LVM, 1984, ANAL BIOCHEM, V136, P357, DOI 10.1016/0003-2697(84)90230-6; RAO LVM, 1987, BLOOD, V69, P645; RAO LVM, 1992, IN PRESS THROMB HAEM; RAO LVM, 1990, CIRCULATION, V82, pA523; SAKAI T, 1989, J BIOL CHEM, V264, P9980; STERN D, 1985, P NATL ACAD SCI USA, V82, P2523, DOI 10.1073/pnas.82.8.2523; TAIT JF, 1989, J BIOL CHEM, V264, P7944; WALSH JD, 1991, THROMB HAEMOSTASIS, V66, P552	31	140	141	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15447	15454						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1639786				2022-12-25	WOS:A1992JG11300031
J	PARK, JG; REDDY, EP				PARK, JG; REDDY, EP			LARGE-SCALE MOLECULAR MAPPING OF HUMAN C-MYB LOCUS - C-MYB PROTOONCOGENE IS NOT INVOLVED IN 6Q- ABNORMALITIES OF LYMPHOID TUMORS	ONCOGENE			English	Article							HUMAN-MALIGNANT MELANOMA; CELL-LINES ML-1; HUMAN CANCER; CYTOGENETIC CHARACTERIZATION; MYELOGENOUS LEUKEMIA; BURKITT-LYMPHOMA; TRANSLOCATION; GENE; DNA; RETINOBLASTOMA	Chromosomal abnormalities in the 6q region have been observed frequently in several T-cell and myeloid leukemias. Interestingly, this region was found to contain three cellular oncogenes, c-myb, c-fyn and c-ros. Several of the tumors that exhibit 6q- abnormalities have also been found to express high levels of c-myb and, in some cases, amplification of the c-myb gene, leading to the suggestion that this gene could tie in proximity to the deletions observed in these tumors. To determine if c-myb gene activation is associated with 6q- abnormalities, we developed a megabase map of the human c-myb locus using pulsed-field gel electrophoresis. We then examined the occurrence of abnormalities near the c-myb gene in several hematopoietic tumor cell lines containing well-characterized 6q- abnormalities. Our results show that no rearrangements or deletions occur within a region of 1.0 Mbp of the c-myb locus in these cell lines. However, several of the cell lines exhibited differential and partial methylation patterns which seem to be prevalent amongst different cell lines.	WISTAR INST, PHILADELPHIA, PA 19104 USA	The Wistar Institute			Reddy, E. Premkumar/F-6233-2011		NCI NIH HHS [CA21124, CAS52009] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA052009, P01CA021124] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARLETTA C, 1987, SCIENCE, V235, P1064, DOI 10.1126/science.3469751; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BLOOMFIELD CD, 1983, CANCER RES, V43, P2975; BROWN WRA, 1986, NATURE, V322, P477, DOI 10.1038/322477a0; CAVENEE WK, 1985, SCIENCE, V228, P501, DOI 10.1126/science.3983638; DALLAFAVERA R, 1983, SCIENCE, V219, P963, DOI 10.1126/science.6401867; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DASGUPTA P, 1989, ONCOGENE, V4, P1201; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GEMMILL RM, 1989, GENOMICS, V4, P28, DOI 10.1016/0888-7543(89)90310-8; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; HARPER ME, 1983, NATURE, V304, P169, DOI 10.1038/304169a0; HAYATA I, 1975, IN VITRO CELL DEV B, V11, P361; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KATHELEEN G, 1986, SOM CELL MOL GEN, V12, P185; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; MAJELLO B, 1986, P NATL ACAD SCI USA, V83, P9636, DOI 10.1073/pnas.83.24.9636; MEESE E, 1989, GENE CHROMOSOME CANC, V1, P88, DOI 10.1002/gcc.2870010114; MITELMAN F, 1984, NATURE, V310, P325, DOI 10.1038/310325a0; MITELMAN F, 1983, CYTOGENET CELL GENET, V36, P1, DOI 10.1159/000131930; NOWELL P, 1983, NATURE, V306, P494, DOI 10.1038/306494a0; NOWELL PC, 1988, FASEB J, V2, P3054, DOI 10.1096/fasebj.2.15.3056765; OHYASHIKI K, 1988, CANCER GENET CYTOGEN, V33, P83, DOI 10.1016/0165-4608(88)90053-2; OHYASHIKI K, 1986, CANCER RES, V46, P3642; OKADA M, 1990, CANCER GENET CYTOGEN, V48, P229, DOI 10.1016/0165-4608(90)90125-T; OSHIMURA HM, 1975, IN VITRO, V11, P361; OSHIMURA M, 1977, CANCER, V40, P1161, DOI 10.1002/1097-0142(197709)40:3<1161::AID-CNCR2820400327>3.0.CO;2-2; PELICCI PG, 1984, SCIENCE, V224, P1117, DOI 10.1126/science.6585957; RABBITTS TH, 1988, TRENDS GENET, V4, P300, DOI 10.1016/0168-9525(88)90106-0; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SMITH SD, 1986, BLOOD, V67, P650; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; TRENT JM, 1989, CANCER RES, V49, P420; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; TRENT JM, 1983, CANCER GENET CYTOGEN, V9, P177, DOI 10.1016/0165-4608(83)90039-0	40	10	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1992	7	8					1603	1609						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1630821				2022-12-25	WOS:A1992JE81300017
J	BRODOWSKY, ID; HAMBERG, M; OLIW, EH				BRODOWSKY, ID; HAMBERG, M; OLIW, EH			A LINOLEIC-ACID (8R)-DIOXYGENASE AND HYDROPEROXIDE ISOMERASE OF THE FUNGUS GAEUMANNOMYCES-GRAMINIS - BIOSYNTHESIS OF (8R)-HYDROXYLINOLEIC ACID AND (7S,8S)-DIHYDROXYLINOLEIC ACID FROM (8R)-HYDROPEROXYLINOLEIC ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID; FATTY-ACIDS; LIQUID-CHROMATOGRAPHY; LAETISARIC ACID; STERIC ANALYSIS; ENZYME-SYSTEM; METABOLISM; CYTOCHROME-P-450; STEREOCHEMISTRY; OXYGENATION	The fungus Gaeumannomyces graminis metabolized linoleic acid extensively to (8R)-hydroperoxylinoleic acid, (8R)-hydroxylinoleic acid, and threo-(7S,8S)-dihydroxylinoleic acid. When G. graminis was incubated with linoleic acid under an atmosphere of oxygen-18, the isotope was incorporated into (8R)-hydroxylinoleic acid and 7,8-dihydroxylinoleic acid. The two hydroxyls of the latter contained either two oxygen-18 or two oxygen-16 atoms, whereas a molecular species that contained both oxygen isotopes was formed in negligible amounts. Glutathione peroxidase inhibited the biosynthesis of 7,8-dihydroxylinoleic acid. These findings demonstrated that the diol was formed from (8R)-hydroperoxylinoleic acid by intramolecular hydroxylation at carbon 7, catalyzed by a hydroperoxide isomerase. The (8R)-dioxygenase appeared to metabolize substrates with a saturated carboxylic side chain and a 9Z-double bond. G. graminis also formed omega-2- and omega-3-hydroxy metabolites of the fatty acids. In addition, linoleic acid was converted to small amounts of nearly (65% R) racemic 10-hydroxy-8,12-octadecadienoic acid by incorporation of atmospheric oxygen. An unstable metabolite, 11-hydroxylinoleic acid, could also be isolated as well as (13R,13S)-hydroxy-(9E,9Z), (11E)-octadecadienoic acids and (9R,9S)-hydroxy(10E), (12E,12Z)-octadecadienoic acids. In summary, G. graminis contains a prominent linoleic acid (8R)-dioxygenase, which differs from the lipoxygenase family of dioxygenases by catalyzing the formation of a hydroperoxide without affecting the double bonds of the substrate.	KAROLINSKA INST,DEPT PHYSIOL CHEM,S-10401 STOCKHOLM 60,SWEDEN	Karolinska Institutet	BRODOWSKY, ID (corresponding author), UPPSALA UNIV,CTR BIOMED,DEPT PHARMACEUT PHARMACOL,POB 591,S-75124 UPPSALA,SWEDEN.			Oliw, Ernst/0000-0002-7986-8130				AIKENS J, 1991, J BIOL CHEM, V266, P15091; Asher MJC, 1981, BIOL CONTROL TAKE AL; BOWERS WS, 1986, SCIENCE, V232, P105, DOI 10.1126/science.232.4746.105; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRASH AR, 1988, P NATL ACAD SCI USA, V85, P3382, DOI 10.1073/pnas.85.10.3382; BRODOWSKY ID, 1992, BIOCHIM BIOPHYS ACTA, V1124, P59, DOI 10.1016/0005-2760(92)90126-G; ELLIOTT WJ, 1986, J BIOL CHEM, V261, P6719; EVANS PH, 1987, ACS SYM SER, V355, P353; GERWICK WH, 1991, ARCH BIOCHEM BIOPHYS, V290, P436, DOI 10.1016/0003-9861(91)90563-X; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; HAMBERG M, 1967, J BIOL CHEM, V242, P5336; HAMBERG M, 1986, BIOCHIM BIOPHYS ACTA, V879, P410, DOI 10.1016/0005-2760(86)90233-X; HAMBERG M, 1971, ANAL BIOCHEM, V43, P515, DOI 10.1016/0003-2697(71)90282-X; HAMBERG M, 1987, BIOCHIM BIOPHYS ACTA, V920, P76, DOI 10.1016/0005-2760(87)90313-4; HAMBERG M, 1991, LIPIDS, V26, P407, DOI 10.1007/BF02536065; HAMMARSTROM S, 1973, ANAL BIOCHEM, V52, P169, DOI 10.1016/0003-2697(73)90342-4; HASLBECK F, 1983, BIOCHIM BIOPHYS ACTA, V750, P185, DOI 10.1016/0005-2760(83)90219-9; HONECK H, 1985, PHARMAZIE, V40, P221; KUHN H, 1987, ANAL BIOCHEM, V160, P24, DOI 10.1016/0003-2697(87)90609-9; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; OLIW EH, 1989, J BIOL CHEM, V264, P17845; OLIW EH, 1983, J CHROMATOGR, V275, P245, DOI 10.1016/S0378-4347(00)84372-8; PORTER TD, 1991, J BIOL CHEM, V266, P13469; RULCO AJ, 1991, ANN REV PHARM TOXICO, V31, P177; SHOUN H, 1985, J BIOCHEM, V97, P755, DOI 10.1093/oxfordjournals.jbchem.a135115; SIH CJ, 1969, J AM CHEM SOC, V91, P3685, DOI 10.1021/ja01041a065; SONG WC, 1991, SCIENCE, V253, P781, DOI 10.1126/science.1876834; WURZENBERGER M, 1984, BIOCHIM BIOPHYS ACTA, V794, P25, DOI 10.1016/0005-2760(84)90293-5; WURZENBERGER M, 1983, BIOCHIM BIOPHYS ACTA, V794, P18	29	94	96	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14738	14745						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634517				2022-12-25	WOS:A1992JF08800038
J	DOMIN, J; ROZENGURT, E				DOMIN, J; ROZENGURT, E			HETEROLOGOUS DESENSITIZATION OF PLATELET-DERIVED GROWTH FACTOR-MEDIATED ARACHIDONIC-ACID RELEASE AND PROSTAGLANDIN SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; PROTEIN KINASE-C; SIGNAL TRANSDUCTION; DNA-SYNTHESIS; MITOGENIC RESPONSE; BOMBESIN FAMILY; FACTOR RECEPTOR; RAS ONCOGENE; VASOPRESSIN; 3T3-CELLS	Prolonged treatment of quiescent Swiss 3T3 cells with vasopressin induced heterologous desensitization of specific early signals stimulated by platelet-derived growth factor (PDGF). PDGF caused a striking dose-dependent release of [H-3]arachidonic acid (EC50 = 2 ng/ml) and prostaglandin E2 (EC50 = 5 ng/ml). These responses are severely attenuated (>85%) by prior exposure to vasopressin in a dose-dependent manner (IC50 = 1.5 nM). Maximal loss of responsiveness occurred after 40 h of vasopressin treatment with a half-maximal desensitization after 11-13 h. The desensitization is dependent upon binding to the V1 receptor, since it can be prevented by the antagonist [Pmp1, O-Me-Tyr2, Arg8]vasopressin. In contrast, stimulation of inositol phosphate accumulation and production of diacylglycerol and phosphatidic acid by PDGF are unchanged. Thus, the observed heterologous desensitization cannot be attributed to an inability to activate phospholipase C. Furthermore, prior exposure to vasopressin did not affect the ability of PDGF to evoke tyrosine phosphorylation of cellular substrates, demonstrating that vasopressin-induced heterologous desensitization causes a block at a point distal to activation of receptor tyrosine kinase activity. Other downstream responses including transient induction of c-fos expression and stimulation of DNA synthesis were attenuated by vasopressin pretreatment. The findings demonstrate a novel mechanism of heterologous cellular desensitization namely, persistent occupancy of a guanine nucleotide-binding protein-coupled receptor, like the V1 type vasopressin receptor, attenuates responsiveness to a polypeptide growth factor like PDGF that initiates responses through a tyrosine kinase receptor.	IMPERIAL CANC RES FUND,POB 123,44 LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND	Cancer Research UK								BENJAMIN CW, 1987, P NATL ACAD SCI USA, V84, P546, DOI 10.1073/pnas.84.2.546; BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BROWN KD, 1984, BIOCHEM BIOPH RES CO, V123, P377, DOI 10.1016/0006-291X(84)90424-8; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; COCHRAN BH, 1985, ADV CANCER RES, V45, P183, DOI 10.1016/S0065-230X(08)60269-9; COLLINS MKL, 1983, P NATL ACAD SCI-BIOL, V80, P1924, DOI 10.1073/pnas.80.7.1924; DICKER P, 1980, NATURE, V287, P607, DOI 10.1038/287607a0; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; FABREGAT I, 1990, BIOCHEM BIOPH RES CO, V167, P161, DOI 10.1016/0006-291X(90)91745-E; GIL J, 1991, J CELL BIOL, V113, P9143; HABENICHT AJR, 1981, J BIOL CHEM, V256, P2329; HASEGAWASASAKI H, 1985, BIOCHEM J, V232, P99, DOI 10.1042/bj2320099; HASEGAWASASAKI H, 1988, J BIOL CHEM, V263; HESKETH TR, 1985, NATURE, V313, P481, DOI 10.1038/313481a0; HESLOP JP, 1986, CELL, V47, P703, DOI 10.1016/0092-8674(86)90513-1; ISSANDOU M, 1990, J BIOL CHEM, V265, P11890; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOPEZRIVAS A, 1984, AM J PHYSIOL, V247, pC156, DOI 10.1152/ajpcell.1984.247.3.C156; LOPEZRIVAS A, 1987, P NATL ACAD SCI USA, V84, P5765; MACDONALD ML, 1988, J BIOL CHEM, V263, P1575; Mehmet H, 1990, GROWTH FACTORS, V3, P83, DOI 10.3109/08977199009108271; MENDOZA SA, 1986, J CELL BIOL, V102, P2223, DOI 10.1083/jcb.102.6.2223; MILLAR JBA, 1990, J BIOL CHEM, V265, P19973; MILLAR JBA, 1989, P NATL ACAD SCI USA, V86, P3204, DOI 10.1073/pnas.86.9.3204; MILLAR JBA, 1990, J BIOL CHEM, V265, P12052; NANBERG E, 1988, EMBO J, V7, P2741, DOI 10.1002/j.1460-2075.1988.tb03128.x; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PARRIES G, 1987, P NATL ACAD SCI USA, V84, P2648, DOI 10.1073/pnas.84.9.2648; RAKE JB, 1991, J BIOL CHEM, V266, P5348; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; ROZENGURT E, 1979, P NATL ACAD SCI USA, V76, P1284, DOI 10.1073/pnas.76.3.1284; ROZENGURT E, 1981, J BIOL CHEM, V256, P716; ROZENGURT E, 1991, EUR J CLIN INVEST, V21, P123, DOI 10.1111/j.1365-2362.1991.tb01801.x; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1983, CELL, V34, P265, DOI 10.1016/0092-8674(83)90157-5; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; SMITH WL, 1989, BIOCHEM J, V259, P315, DOI 10.1042/bj2590315; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; TAKUWA N, 1989, J BIOL CHEM, V264, P7856; TAKUWA N, 1987, J BIOL CHEM, V262, P182; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; WESTERMARK B, 1991, CANCER RES, V51, P5087; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; Woll PJ, 1988, GROWTH FACTORS, V1, P75, DOI 10.3109/08977198809000249; ZACHARY I, 1985, P NATL ACAD SCI USA, V82, P7616, DOI 10.1073/pnas.82.22.7616; ZACHARY I, 1987, J BIOL CHEM, V262, P3947	52	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15217	15223						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634551				2022-12-25	WOS:A1992JF08800104
J	KIM, YT; TABOR, S; CHURCHICH, JE; RICHARDSON, CC				KIM, YT; TABOR, S; CHURCHICH, JE; RICHARDSON, CC			INTERACTIONS OF GENE 2.5 PROTEIN AND DNA-POLYMERASE OF BACTERIOPHAGE-T7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI THIOREDOXIN; ACID REPLICATION INVITRO; STRAND DISPLACEMENT SYNTHESIS; T7 DEOXYRIBONUCLEIC-ACID; DUPLEX DNA; RECOMBINATION; HELICASE; PRIMASE; PURIFICATION; STIMULATION	Bacteriophage T7 gene 2.5 protein has been shown to interact with T7 DNA polymerase (the complex of T7 gene 5 protein and Escherichia coli thioredoxin) by affinity chromatography and fluorescence emission anisotropy. T7 DNA polymerase binds specifically to a resin coupled to gene 2.5 protein and elutes from the resin when the ionic strength of the buffer is raised to 250 mM NaCl. In contrast, T7 gene 5 protein alone binds more weakly to gene 2.5 protein, eluting when the ionic strength of the buffer is 50 mM NaCl. Thioredoxin does not bind to gene 2.5 protein. Steady-state fluorescence emission anisotropy gives a dissociation constant of 1.1 +/- 0.2-mu-M for the complex of gene 2.5 protein and T7 DNA polymerase, with a ratio of gene 2.5 protein to T7 DNA polymerase in the complex of 1:1. Nanosecond emission anisotropic analysis suggests that the complex contains one monomer each of gene 2.5 protein, gene 5 protein, and thioredoxin. The ability of T7 gene 2.5 protein to stimulate the activity and processivity of T7 DNA polymerase is compared with the ability of three other single-stranded DNA-binding proteins: E. coli single-stranded DNA-binding protein, T4 gene 32 protein, and E. coli recA protein. All except E. coli recA protein stimulate the activity and processivity of T7 DNA polymerase; E. coli recA protein inhibits these activities.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,240 LONGWOOD AVE,BOSTON,MA 02115; UNIV TENNESSEE,DEPT BIOCHEM,KNOXVILLE,TN 37996	Harvard University; Harvard Medical School; University of Tennessee System; University of Tennessee Knoxville					NIAID NIH HHS [AI-06045] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI006045, R01AI006045] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARAKI H, 1981, MOL GEN GENET, V183, P66, DOI 10.1007/BF00270140; ARAKI H, 1981, VIROLOGY, V111, P509, DOI 10.1016/0042-6822(81)90353-6; BERNSTEIN JA, 1989, J BIOL CHEM, V264, P13066; BERNSTEIN JA, 1988, P NATL ACAD SCI USA, V85, P396, DOI 10.1073/pnas.85.2.396; BRYANT FR, 1983, BIOCHEMISTRY-US, V22, P3537, DOI 10.1021/bi00284a001; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; FORMOSA T, 1986, CELL, V47, P793, DOI 10.1016/0092-8674(86)90522-2; FORMOSA T, 1983, P NATL ACAD SCI-BIOL, V80, P2442, DOI 10.1073/pnas.80.9.2442; FORMOSA T, 1986, J BIOL CHEM, V261, P6107; GRIPPO P, 1971, J BIOL CHEM, V246, P6867; HAUGLAND RP, 1989, HDB FLUORESCENT PROB, P20; HUBER HE, 1986, J BIOL CHEM, V261, P5006; HUBER HE, 1987, J BIOL CHEM, V262, P16224; HUBERMAN JA, 1971, J MOL BIOL, V62, P39, DOI 10.1016/0022-2836(71)90129-X; KERR C, 1975, VIROLOGY, V65, P281, DOI 10.1016/0042-6822(75)90031-8; KIM YT, 1988, J BIOL CHEM, V263, P13712; KIM YT, 1992, J BIOL CHEM, V267, P15022; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P43; LECHNER RL, 1983, J BIOL CHEM, V258, P1174; MARK DF, 1976, P NATL ACAD SCI USA, V73, P780, DOI 10.1073/pnas.73.3.780; MENDELMAN LV, 1991, J BIOL CHEM, V266, P23240; MODRICH P, 1975, J BIOL CHEM, V250, P5508; MODRICH P, 1975, J BIOL CHEM, V250, P5515; MOLINEUX IJ, 1975, J MOL BIOL, V98, P811, DOI 10.1016/S0022-2836(75)80012-X; MOSIG G, 1983, BACTERIOPHAGE T4, P120; NAKAI H, 1988, J BIOL CHEM, V263, P9818; NOSSAL NG, 1979, J BIOL CHEM, V254, P6032; O'Connor D. V., 1984, TIME CORRELATED SING; OEY JL, 1971, EUR J BIOCHEM, V23, P497, DOI 10.1111/j.1432-1033.1971.tb01646.x; POWLING A, 1974, MOL GEN GENET, V134, P173, DOI 10.1007/BF00268418; RADDING CM, 1991, J BIOL CHEM, V266, P5355; REUBEN RC, 1974, J BIOL CHEM, V249, P3843; REUBEN RC, 1973, P NATL ACAD SCI USA, V70, P1846, DOI 10.1073/pnas.70.6.1846; RICHARDSON CC, 1983, CELL, V33, P315, DOI 10.1016/0092-8674(83)90411-7; SCHERZINGER E, 1973, MOL GEN GENET, V123, P247, DOI 10.1007/BF00271243; TABOR S, 1987, J BIOL CHEM, V262, P16212; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TABOR S, 1989, J BIOL CHEM, V264, P6447; TABOR S, 1986, THIOREDOXIN GLUTARED, P285; WARE WR, 1973, J PHYS CHEM-US, V77, P2038, DOI 10.1021/j100636a003; YONESAKI T, 1985, EMBO J, V4, P3321, DOI 10.1002/j.1460-2075.1985.tb04083.x	41	76	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15032	15040						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634539				2022-12-25	WOS:A1992JF08800078
J	DECRECYLAGARD, V; BOUVET, OMM; LEJEUNE, P; DANCHIN, A				DECRECYLAGARD, V; BOUVET, OMM; LEJEUNE, P; DANCHIN, A			FRUCTOSE CATABOLISM IN XANTHOMONAS-CAMPESTRIS PV CAMPESTRIS - SEQUENCE OF THE PTS OPERON, CHARACTERIZATION OF THE FRUCTOSE-SPECIFIC ENZYMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI PHOSPHOENOLPYRUVATE; SUGAR PHOSPHOTRANSFERASE SYSTEM; NUCLEOTIDE-SEQUENCE; RHODOBACTER-CAPSULATUS; PSEUDOMONAS-AERUGINOSA; TRANSPOSABLE ELEMENTS; GLUCOSE-METABOLISM; GENE; BACTERIA; PHOSPHORYLATION	In Xanthomonas campestris pv. campestris, fructose is transported and phosphorylated into fructose 1-phosphate through a phosphoenolpyruvate-dependent phosphotransferase system. The nucleotide sequence of the fruA gene encoding the phosphotransferase system permease specific of fructose (EII(Fru)) was determined. The fructose 1-phosphate produced by the phosphotransferase system is phosphorylated into fructose 1,6-bisphosphate by a 1-phosphofructokinase. This enzyme was characterized and the corresponding gene (fruK) was sequenced. Sequence comparisons revealed that FruK is a member of a new family of ATP-binding proteins composed of sugar (or sugar-phosphate) kinases. In phosphotransferase system-deficient strains, fructose can still be transported by an unidentified permease. The intracellular fructose is then phosphorylated by a multimeric fructokinase of 135 kDa specific for fructose and inhibited by fructose, fructose 1,6-bisphosphate, and mannose. Several other enzymes of fructose metabolism were assayed and a potential pathway for fructose catabolism is presented.	INST PASTEUR, INSERM,U199,UNITE REGULAT EXPRESS GENET, 28 RUE DOCTEUR ROUX, F-75724 PARIS 15, FRANCE; INST PASTEUR, INSERM, U199, UNITE ENTEROBACTERIES, F-75724 PARIS 15, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			de Crecy-Lagard, Valerie/AAN-8995-2020	Danchin, Antoine/0000-0002-6350-5001				BAUMANN L, 1975, ARCH MICROBIOL, V105, P241, DOI 10.1007/BF00447142; BEUVE A, 1990, J BACTERIOL, V172, P2614, DOI 10.1128/jb.172.5.2614-2621.1990; BLATCH GL, 1990, GENE, V95, P17, DOI 10.1016/0378-1119(90)90408-J; BOUVET OMM, 1987, ANN INST PASTEUR MIC, V138, P3, DOI 10.1016/0769-2609(87)90048-2; BRYAN JK, 1977, ANAL BIOCHEM, V78, P513, DOI 10.1016/0003-2697(77)90111-7; CONRAD R, 1974, BIOCHIM BIOPHYS ACTA, V358, P221, DOI 10.1016/0005-2744(74)90273-3; DALDAL F, 1984, GENE, V28, P337, DOI 10.1016/0378-1119(84)90151-3; DANIELS GA, 1988, J BACTERIOL, V170, P1698, DOI 10.1128/jb.170.4.1698-1703.1988; DECRECYLAGARD V, 1991, IN PRESS MOL GEN GEN; DELOBBE A, 1975, EUR J BIOCHEM, V51, P503; DILLS SS, 1980, MICROBIOL REV, V44, P385, DOI 10.1128/MMBR.44.3.385-418.1980; DURHAM DR, 1982, J BACTERIOL, V149, P534, DOI 10.1128/JB.149.2.534-541.1982; ELFERINK MGL, 1990, J BACTERIOL, V172, P7119, DOI 10.1128/jb.172.12.7119-7125.1990; ERNI B, 1989, FEMS MICROBIOL LETT, V63, P13, DOI 10.1016/0168-6445(89)90004-1; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; GAY P, 1977, EUR J BIOCHEM, V79, P363, DOI 10.1111/j.1432-1033.1977.tb11817.x; GEERSE RH, 1989, MOL GEN GENET, V216, P517, DOI 10.1007/BF00334399; HOPE JN, 1986, J BIOL CHEM, V261, P7663; JACOBSON GR, 1989, FEMS MICROBIOL LETT, V63, P25, DOI 10.1016/0168-6445(89)90005-3; JACOBSON GR, 1979, J BIOL CHEM, V254, P249; Jeanes A., 1961, J APPL POLYM SCI, V5, P519; JONESMOR.MC, 1974, PROC R SOC SER B-BIO, V187, P121, DOI 10.1098/rspb.1974.0066; JOSEPHLIAUZUN E, 1989, GENE, V85, P83, DOI 10.1016/0378-1119(89)90467-8; KORNBERG HL, 1989, FEMS MICROBIOL LETT, V63, P193, DOI 10.1016/0168-6445(89)90024-7; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESSIE TG, 1984, ANNU REV MICROBIOL, V38, P359, DOI 10.1146/annurev.mi.38.100184.002043; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANAYAN R, 1988, J BACTERIOL, V170, P1290, DOI 10.1128/jb.170.3.1290-1296.1988; MANDEL M, 1970, J MOL BIOL, V53, P159, DOI 10.1016/0022-2836(70)90051-3; MEINS M, 1988, J BIOL CHEM, V263, P12986; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; PIELKEN P, 1988, CAN J MICROBIOL, V34, P1333, DOI 10.1139/m88-234; POORMAN RA, 1984, NATURE, V309, P467, DOI 10.1038/309467a0; POSTMA PW, 1980, J BACTERIOL, V141, P476, DOI 10.1128/JB.141.2.476-484.1980; PRENTKI P, 1987, GENE, V61, P91, DOI 10.1016/0378-1119(87)90368-4; PRIOR TI, 1988, J GEN MICROBIOL, V134, P2757; RISLER JL, 1988, J MOL BIOL, V204, P1019, DOI 10.1016/0022-2836(88)90058-7; ROEHL RA, 1982, J BACTERIOL, V149, P897, DOI 10.1128/JB.149.3.897-905.1982; ROSEY EL, 1989, NUCLEIC ACIDS RES, V17, P3980, DOI 10.1093/nar/17.10.3980; SAIER MH, 1971, J BIOL CHEM, V246, P7819; SAIER MH, 1977, BACTERIOL REV, V41, P856, DOI 10.1128/MMBR.41.4.856-871.1977; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schwartz RM, 1978, ATLAS PROTEIN SEQ S3, P353; SERRANO R, 1988, BIOCHIM BIOPHYS ACTA, V947, P1, DOI 10.1016/0304-4157(88)90017-2; SHEPHERD JCW, 1981, P NATL ACAD SCI-BIOL, V78, P1596, DOI 10.1073/pnas.78.3.1596; SUTHERLAND JW, 1979, SOC GENERAL MICROBIO, V29, P107; ULLMANN A, 1983, ADV CYCL NUCL RES<D>, V15, P1; WHITFIELD C, 1982, J GEN MICROBIOL, V128, P981; Williams P. H., 1980, Plant Disease, V64, P736, DOI 10.1094/PD-64-736; WU LF, 1990, J MOL BIOL, V213, P687, DOI 10.1016/S0022-2836(05)80256-6; WU LF, 1990, J BACTERIOL, V172, P7167, DOI 10.1128/jb.172.12.7167-7178.1990; WU LF, 1991, J BACTERIOL, V173, P3117, DOI 10.1128/JB.173.10.3117-3127.1991	55	27	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					18154	18161						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1655739				2022-12-25	WOS:A1991GG55300068
J	TYAGI, SC				TYAGI, SC			SPIN-LABELED NUCLEOTIDE SUBSTRATES FOR DNA-DEPENDENT RNA-POLYMERASE FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION INITIATION; MECHANISM; BINDING; ANALOGS; PURIFICATION; TRIPHOSPHATE; HEMOGLOBIN; SUBUNIT; ACID	New spin-labeled analogs of nucleoside triphosphates, 8-amino(2,2,6,6-tetramethylpiperidine-N-oxyl)adenosine 5'-triphosphate ((8-AmTEMPO)ATP) and 5-amino(2,2,6,6-tetramethylpiperidine-N-oxyl)uridine 5'-triphosphate ((5-AmTEMPO)UTP), with the probe 4-amino(2,2,6,6-tetramethylpiperidine-N-oxyl) (4-AmTEMPO) attached to C-8 of ATP and C-5 of UTP via a secondary amine bond, were synthesized in 50 and 40% yield, respectively. These analogs showed a single spot by thin layer chromatographic analysis. The absorption spectra of (8-AmTEMPO)ATP and (5-AmTEMPO)UTP exhibit maxima at 310 and 265 nm, respectively; their X-band EPR spectra have a typical three-line pattern with lines at 3,221, 3,239, and 3,257 Gauss. The intensity ratios for mid to high field lines of the EPR derivative lines were found to be 1.03 +/- 0.02, 1.08 +/- 0.04, and 1.15 +/- 0.07 for 4-AmTEMPO, (8-AmTEMPO)ATP, and (5-AmTEMPO)UTP, respectively. The immobilization of 4-AmTEMPO bound to C-8 of ATP or bound to C-5 of UTP was observed to be 5 and 11%, respectively, as compared with free 4-AmTEMPO. The initial velocity (s-1) of [H-3]UMP incorporation into RNA in the presence of [H-3]UTP, CTP, GTP, and (8-AmTEMPO)ATP or ATP was measured. The percent incorporation of (8-AmTEMPO)ATP into RNA product by Escherichia coli RNA polymerase using various DNA templates is 68, 66, and 61% for pAR1435 (plasmid containing A1 promoter from T7 DNA), calf thymus DNA, and poly(dA-dT) respectively, as compared with ATP incorporation. The polymerase-catalyzed reaction of (8-AmTEMPO)ATP with (3'-OCH3)UTP yielded 5'-triphosphate delta-amino(2,2,6,6-tetramethylpiperidine-N-oxyl)adenylyl (3'-5')3'-methoxy uridine in the presence of poly(dA-dT). The structure of this spin-labeled dinucleotide was identified by paper chromatographic analysis of the products of phosphodiesterase digestion. These analogs also can be used for the study by EPR spectroscopy of the dynamics of gene transcription catalyzed by RNA polymerases or of other nucleotide-utilizing enzymes.			TYAGI, SC (corresponding author), SUNY STONY BROOK,DEPT BIOCHEM & CELL BIOL,STONY BROOK,NY 11794, USA.							AKERFELDT S, 1959, ACTA CHEM SCAND, V13, P1479, DOI 10.3891/acta.chem.scand.13-1479; BAGSHAW CR, 1972, COLD SPRING HARB SYM, V37, P127; Bayley H, 1977, Methods Enzymol, V46, P69; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; CHAMBERLIN MJ, 1974, ANNU REV BIOCHEM, V43, P721, DOI 10.1146/annurev.bi.43.070174.003445; DARLIX JL, 1971, BIOCHEMISTRY-US, V10, P1525; DERIEMER LH, 1981, BIOCHEMISTRY-US, V20, P1606, DOI 10.1021/bi00509a030; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; GOLDTHWAIT DA, 1970, 1ST LEP C RNA POL TR, P10; GOODY RS, 1971, J AM CHEM SOC, V93, P6252, DOI 10.1021/ja00752a042; HAMPTON A, 1973, BIOCHEMISTRY-US, V12, P1730, DOI 10.1021/bi00733a011; HOPPE J, 1974, EUR J BIOCHEM, V48, P519, DOI 10.1111/j.1432-1033.1974.tb03793.x; Johnston D. E., 1976, RNA POLYMERASE, P413; JOHNSTON LS, 1977, BIOCHEMISTRY-US, V16, P1251, DOI 10.1021/bi00626a001; KAHAN FM, 1962, J BIOL CHEM, V237, P3778; KARLISH SJD, 1976, NATURE, V263, P251, DOI 10.1038/263251a0; KNOWLES JR, 1972, ACCOUNTS CHEM RES, V5, P155, DOI 10.1021/ar50052a006; KUMAR SA, 1981, PROG BIOPHYS MOL BIO, V38, P165, DOI 10.1016/0079-6107(81)90013-4; LASKOWSKI M, 1971, ENZYMES, V4, P276; LOWE PA, 1979, BIOCHEMISTRY-US, V18, P1344, DOI 10.1021/bi00574a034; Maniatis T., 1982, MOL CLONING LABORATO, P86; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MILLER JA, 1979, BIOCHIM BIOPHYS ACTA, V579, P291, DOI 10.1016/0005-2795(79)90056-4; NEUMANN H, 1967, ARCH BIOCHEM BIOPHYS, V122, P354, DOI 10.1016/0003-9861(67)90205-6; OGATA RT, 1971, COLD SPRING HARB SYM, V36, P325, DOI 10.1101/SQB.1972.036.01.043; OGATA RT, 1972, P NATL ACAD SCI USA, V69, P335, DOI 10.1073/pnas.69.2.335; Roeder R.G., 1976, RNA POLYMERASE, P285; SCRUTTON MC, 1971, P NATL ACAD SCI USA, V68, P2497, DOI 10.1073/pnas.68.10.2497; SECRIST JA, 1972, SCIENCE, V175, P656; TONOMURA Y, 1967, J BIOCHEM-TOKYO, V61, P460, DOI 10.1093/oxfordjournals.jbchem.a128569; WARD DC, 1969, J BIOL CHEM, V244, P1228; WILKINSON JAK, 1983, J BIOL CHEM, V258, P3919; WILKINSON JK, 1982, J BIOL CHEM, V257, P4375; YARBROUGH LR, 1979, J BIOL CHEM, V254, P2069; YOUNT RG, 1971, BIOCHEMISTRY-US, V10, P2484, DOI 10.1021/bi00789a009; YOUNT RG, 1975, ADV ENZYMOL RAMB, V43, P1; 1982, EXCELLENCE BIOCH, P11	38	4	4	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					17936	17940						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1655731				2022-12-25	WOS:A1991GG55300037
J	LIU, LW; VU, TKH; ESMON, CT; COUGHLIN, SR				LIU, LW; VU, TKH; ESMON, CT; COUGHLIN, SR			THE REGION OF THE THROMBIN RECEPTOR RESEMBLING HIRUDIN BINDS TO THROMBIN AND ALTERS ENZYME SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ALPHA-THROMBIN; THROMBOMODULIN; ACTIVATION; FIBRINOGEN; COMPLEX	A thrombin receptor has recently been cloned and the sequence deduced. The sequence reveals a thrombin cleavage site that accounts for receptor activation. The receptor also has an acidic region with some similarities to the carboxyl-terminal region of the leech thrombin inhibitor, hirudin. Synthetic peptides corresponding to the receptor cleavage site (residues 38-45), the hirudin-like domain (residues 52-69), and the covalently associated domains (residues 38-64) were evaluated for their ability to bind to thrombin. Peptides 38-45 and 38-64 were competitive inhibitors of thrombin's chromogenic substrate activity (K(i) = 0.96 mM and 0.6-mu-M, respectively. Residues 52-69 altered the chromogenic substrate specificity, resulting in accelerated cleavage of some substrates and inhibited cleavage of others. The same peptide binds to thrombin and alters the fluorescence emission intensity of 5-dimethylaminonaphthalene-1-sulfonyl (dansyl)thrombin in which the dansyl is attached directly to the active site serine (K(d) = 32 +/- 7-mu-M). Residues 52-69 displace the carboxyl-terminal peptide of hirudin, indicating that they share a common binding site in the anion exosite of thrombin. These data suggest that the thrombin receptor has high affinity for thrombin due to the presence of the hirudin-like domain and that this domain alters the specificity of thrombin. This change in specificity may account for the ability of the receptor to serve as an excellent thrombin substrate despite the presence of an Asp residue in the P3 site, which is normally inhibitory to thrombin activity.	OKLAHOMA MED RES FDN,HOWARD HUGHES MED INST,820 NE 15 ST,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,DEPT BIOCHEM,OKLAHOMA CITY,OK 73190; UNIV OKLAHOMA,HLTH SCI CTR,DEPT PATHOL,OKLAHOMA CITY,OK 73190; OKLAHOMA MED RES FDN,CARDIOVASC BIOL RES PROGRAM,OKLAHOMA CITY,OK 73104; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143	Howard Hughes Medical Institute; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Oklahoma Medical Research Foundation; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NHLBI NIH HHS [R01 HL29807, R37 HL30340, HL44907] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL030340, R01HL029807, R01HL044907] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERLINER LJ, 1977, THROMB RES, V12, P15; EHRLICH HJ, 1990, EMBO J, V9, P2367, DOI 10.1002/j.1460-2075.1990.tb07411.x; ESMON NL, 1983, J BIOL CHEM, V258, P2238; GRUTTER MG, 1989, EMBO J, V8, P3467; HORTIN GL, 1991, J BIOL CHEM, V266, P6866; JAKUBOWSKI JA, 1990, BLOOD, V75, P399; LEBONNIEC BF, 1991, IN PRESS P NATL ACAD; MERCOLA DA, 1972, BIOCHEMISTRY-US, V11, P3860, DOI 10.1021/bi00771a005; MUSCI G, 1988, BIOCHEMISTRY-US, V27, P769, DOI 10.1021/bi00402a042; NAITO K, 1991, J BIOL CHEM, V266, P7353; NASKI MC, 1990, J BIOL CHEM, V265, P13484; OWEN WG, 1974, J BIOL CHEM, V249, P594; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; SIMIONESCU N, 1988, ENDOTHELIAL CELL BIO; TSIANG M, 1990, BIOCHEMISTRY-US, V29, P10602, DOI 10.1021/bi00499a005; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WALZ DA, 1986, BIOREGULATORY FUNCTI, V485	17	242	250	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					16977	16980						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1654318				2022-12-25	WOS:A1991GF44500004
J	PONGRATZ, I; STROMSTEDT, PE; MASON, GGF; POELLINGER, L				PONGRATZ, I; STROMSTEDT, PE; MASON, GGF; POELLINGER, L			INHIBITION OF THE SPECIFIC DNA-BINDING ACTIVITY OF THE DIOXIN RECEPTOR BY PHOSPHATASE TREATMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOBIOTIC RESPONSIVE ELEMENTS; MOUSE HEPATOMA-CELLS; HEAT-SHOCK PROTEIN; GLUCOCORTICOID RECEPTOR; HORMONE-BINDING; AH RECEPTOR; DEPENDENT PHOSPHORYLATION; TRANSCRIPTION FACTOR; P-450C GENE; FREE SYSTEM	The dioxin receptor stimulates transcription of the cytochrome P-450IA1 gene in response to dioxin. Exposure of the intracellular dioxin receptor to dioxin leads to a rapid conversion of the receptor from a latent form to a DNA binding species which specifically recognizes dioxin-responsive positive control elements in vitro. In this report, we show that treatment of in vivo or in vitro ligand-activated receptor with potato acid phosphatase significantly reduced or abolished its specific DNA binding activity. This effect was inhibited in the presence of sodium phosphate. In control experiments, the ligand-activated glucocorticoid receptor was not inactivated by phosphatase treatment. Moreover, phosphatase treatment did not induce any detectable degradation of covalently labeled dioxin receptor, arguing against protease contamination as a cause for receptor inactivation. Finally, phosphatase-inactivated dioxin receptor exhibited bona fide levels of ligand binding activity. Taken together, these data suggest that phosphorylation may regulate the DNA binding activity of the ligand-occupied dioxin receptor.			PONGRATZ, I (corresponding author), KAROLINSKA INST,HUDDINGE UNIV HOSP F60,DEPT MED NUTR,S-14186 HUDDINGE,SWEDEN.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003954] Funding Source: NIH RePORTER; NIEHS NIH HHS [ESO 3954] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AURICCHIO F, 1989, J STEROID BIOCHEM, V32, P613, DOI 10.1016/0022-4731(89)90397-X; AURICCHIO F, 1987, EMBO J, V6, P2923, DOI 10.1002/j.1460-2075.1987.tb02596.x; BAGCHI S, 1989, P NATL ACAD SCI USA, V86, P4352, DOI 10.1073/pnas.86.12.4352; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; CARLSTEDTDUKE J, 1987, P NATL ACAD SCI USA, V84, P4437, DOI 10.1073/pnas.84.13.4437; CUTHILL S, 1988, BIOCHEMISTRY-US, V27, P2978, DOI 10.1021/bi00408a047; CUTHILL S, 1991, MOL CELL BIOL, V11, P401, DOI 10.1128/MCB.11.1.401; DENISON MS, 1989, ARCH BIOCHEM BIOPHYS, V273, P458, DOI 10.1016/0003-9861(89)90505-5; DENISON MS, 1988, P NATL ACAD SCI USA, V85, P2528, DOI 10.1073/pnas.85.8.2528; DENNER LA, 1990, J BIOL CHEM, V265, P16548; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FUJISAWASEHARA A, 1988, P NATL ACAD SCI USA, V85, P5859, DOI 10.1073/pnas.85.16.5859; FUJISAWASEHARA A, 1987, NUCLEIC ACIDS RES, V15, P4179, DOI 10.1093/nar/15.10.4179; GUSTAFSSON JA, 1987, ENDOCR REV, V8, P185, DOI 10.1210/edrv-8-2-185; HANKINSON O, 1979, P NATL ACAD SCI USA, V76, P373, DOI 10.1073/pnas.76.1.373; HAPGOOD J, 1989, P NATL ACAD SCI USA, V86, P60, DOI 10.1073/pnas.86.1.60; HOECK W, 1990, J BIOL CHEM, V265, P5403; ISRAEL DI, 1985, J BIOL CHEM, V260, P5648; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; MENDEL DB, 1986, NATURE, V324, P478, DOI 10.1038/324478a0; MIGLIACCIO A, 1989, MOL ENDOCRINOL, V3, P1061, DOI 10.1210/mend-3-7-1061; MYLIN LM, 1990, MOL CELL BIOL, V10, P4623, DOI 10.1128/MCB.10.9.4623; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; NEMOTO T, 1990, J BIOL CHEM, V265, P2269; NEUHOLD LA, 1989, MOL CELL BIOL, V9, P2378, DOI 10.1128/MCB.9.6.2378; OKRET S, 1984, P NATL ACAD SCI-BIOL, V81, P1609, DOI 10.1073/pnas.81.6.1609; PAULSON KE, 1990, MOL CELL BIOL, V10, P1841, DOI 10.1128/MCB.10.5.1841; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; PERDEW GH, 1990, BIOCHEMISTRY-US, V29, P6210, DOI 10.1021/bi00478a014; POELLINGER L, 1989, NATURE, V337, P573, DOI 10.1038/337573a0; POELLINGER L, 1985, ANAL BIOCHEM, V144, P371, DOI 10.1016/0003-2697(85)90130-7; POLAND A, 1986, J BIOL CHEM, V261, P6352; PRYWES R, 1988, P NATL ACAD SCI USA, V85, P7206, DOI 10.1073/pnas.85.19.7206; RAYCHAUDHURI P, 1989, GENE DEV, V3, P620, DOI 10.1101/gad.3.5.620; RUSCONI S, 1987, EMBO J, V6, P1309, DOI 10.1002/j.1460-2075.1987.tb02369.x; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TIENRUNGROJ W, 1987, J BIOL CHEM, V262, P17342; WILHELMSSON A, 1990, EMBO J, V9, P69, DOI 10.1002/j.1460-2075.1990.tb08081.x; WRANGE O, 1986, J BIOL CHEM, V261, P1770; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0	45	101	106	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16813	16817						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1653248				2022-12-25	WOS:A1991GD63500090
J	ISHIJIMA, S; KITA, K; AHMAD, I; ISHIZUKA, T; TAIRA, M; TATIBANA, M				ISHIJIMA, S; KITA, K; AHMAD, I; ISHIZUKA, T; TAIRA, M; TATIBANA, M			EXPRESSION OF RAT PHOSPHORIBOSYLPYROPHOSPHATE SYNTHETASE SUBUNIT-I AND SUBUNIT-II IN ESCHERICHIA-COLI - ISOLATION AND CHARACTERIZATION OF THE RECOMBINANT ISOFORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-LEVEL EXPRESSION; COMPLETE CDNA SEQUENCE; PYROPHOSPHATE SYNTHETASE; 5-PHOSPHORIBOSYL 1-PYROPHOSPHATE; PURIFIED ENZYME; END PRODUCTS; PURIFICATION; LIVER; GENES; INHIBITION	The 34-kDa subunit of rat liver phosphoribosylpyrophosphate synthetase is a mixture of the two highly homologous isoforms, PRS I and PRS II. Heretofore, it was not possible to separate the two. We now describe isolation and characterization of the recombinant isoforms, named rPRS I and rPRS II. The respective rat cDNAs were inserted into vectors constructed from pKK233-2 by replacing its replication origin with that of pGEM-1 and expressed in Escherichia coli. The rPRS I and rPRS II were purified to apparent homogeneity with specific activities of 33,400 and 46,200 milliunits/mg, respectively; these values were at least 2.5-fold higher than the highest value for the mammalian enzyme so far reported. Both isoforms showed a similar dependency on P(i) as an absolute activator. Sulfate partially substituted for P(i). The maximal activities of rPRS I and rPRS II with sulfate were 43 and 7%, respectively, of those seen with P(i). The two isoforms differed in sensitivity to inhibition by ADP and GDP. Inhibition of rPRS I and rPRS II by 0.3 mM ADP was 87 and 54%, respectively, and inhibition by 1 mm GDP was 93 and 24%, respectively. rPRS II was 180-fold more sensitive than rPRS I to heat inactivation at 49-degrees-C.			ISHIJIMA, S (corresponding author), CHIBA UNIV,SCH MED,DEPT BIOCHEM,CHIBA 280,JAPAN.							AKAOKA I, 1981, J RHEUMATOL, V8, P563; AMANN E, 1985, GENE, V40, P183, DOI 10.1016/0378-1119(85)90041-1; ARNVIG K, 1990, EUR J BIOCHEM, V192, P195, DOI 10.1111/j.1432-1033.1990.tb19214.x; BAGNARA AS, 1974, EUR J BIOCHEM, V41, P421, DOI 10.1111/j.1432-1033.1974.tb03283.x; Becker M A, 1979, Adv Enzymol Relat Areas Mol Biol, V49, P281; BECKER MA, 1973, SCIENCE, V179, P1123, DOI 10.1126/science.179.4078.1123; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; FLAKS JG, 1957, J BIOL CHEM, V228, P201; FOX IH, 1972, J BIOL CHEM, V247, P2126; FOX IH, 1971, J BIOL CHEM, V246, P5739; FOX IH, 1971, ANN INTERN MED, V74, P24; HOLMES EW, 1978, HDB EXPT PHARM, V51, P21; HOVEJENSEN B, 1986, J BIOL CHEM, V261, P6765; HOVEJENSEN B, 1982, EUR J BIOCHEM, V126, P327; IIZASA T, 1989, FEBS LETT, V244, P47, DOI 10.1016/0014-5793(89)81159-7; ISHIJIMA S, 1989, NUCLEIC ACIDS RES, V17, P8860, DOI 10.1093/nar/17.21.8860; ISHIJIMA S, 1989, NUCLEIC ACIDS RES, V17, P8859, DOI 10.1093/nar/17.21.8859; KEPPLER D, 1982, METABOLIC COMPARTMEN, P147; KITA K, 1989, J BIOCHEM, V105, P736, DOI 10.1093/oxfordjournals.jbchem.a122737; KORNBERG A, 1955, J BIOL CHEM, V215, P417; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING; MARSTON FAO, 1986, BIOCHEM J, V240, P1, DOI 10.1042/bj2400001; MIKI T, 1987, PROTEIN ENG, V1, P327, DOI 10.1093/protein/1.4.327; ROESSLER BJ, 1990, NUCLEIC ACIDS RES, V18, P193, DOI 10.1093/nar/18.1.193; ROTH DG, 1974, J BIOL CHEM, V249, P291; ROTH DG, 1974, J BIOL CHEM, V249, P297; SATO T, 1987, J BIOCHEM-TOKYO, V101, P525, DOI 10.1093/oxfordjournals.jbchem.a121940; SCHUBERT KR, 1975, J BIOL CHEM, V250, P7492; SONODA T, 1991, J BIOCHEM-TOKYO, V109, P361; SONODA T, 1983, J BIOL CHEM, V258, P9839; SPERLING O, 1972, EUR J CLIN BIOL RES, V17, P703; Switzer R L, 1978, Methods Enzymol, V51, P3; SWITZER RL, 1973, J BIOL CHEM, V248, P1063; SWITZER RL, 1970, J BIOL CHEM, V245, P483; TAIRA M, 1989, BIOCHIM BIOPHYS ACTA, V1007, P203, DOI 10.1016/0167-4781(89)90040-7; TAIRA M, 1987, J BIOL CHEM, V262, P14867; TAIRA M, 1989, SOMAT CELL MOLEC GEN, V15, P29, DOI 10.1007/BF01534667; TATIBANA M, 1972, J BIOCHEM, V72, P549, DOI 10.1093/oxfordjournals.jbchem.a129934; TATIBANA M, 1978, HDB EXPT PHARM, V51, P125; WHITE MN, 1971, J BACTERIOL, V108, P122, DOI 10.1128/JB.108.1.122-131.1971	41	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					15693	15697						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1651917				2022-12-25	WOS:A1991GB97700029
J	SAKATA, J; ABE, Y; UYEDA, K				SAKATA, J; ABE, Y; UYEDA, K			MOLECULAR-CLONING OF THE DNA AND EXPRESSION AND CHARACTERIZATION OF RAT TESTES FRUCTOSE-6-PHOSPHATE, 2-KINASE-FRUCTOSE-2,6-BISPHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFIED BOVINE HEART; AMINO-ACID-SEQUENCE; LIVER 6-PHOSPHOFRUCTO-2-KINASE FRUCTOSE-2,6-BISPHOSPHATASE; PHOSPHOFRUCTOKINASE 2/FRUCTOSE 2,6-BISPHOSPHATASE; BACTERIOPHAGE-T7 RNA-POLYMERASE; DEPENDENT PROTEIN-KINASE; FRUCTOSE 2,6-BISPHOSPHATE; MYOCARDIAL FRUCTOSE-6-PHOSPHATE,2-KINASE; PHOSPHORYLATION SITES; DISTINCT ISOENZYMES	We have isolated and sequenced two overlapping cDNA fragments which could encode the complete amino acid sequence of rat testis fructose-6-phosphate,2-kinase:fructose-2,6-bisphosphatase. Northern blot analysis revealed that the major 2-kilobase mRNA isolated from rat testis hybridized with a cDNA fragment. A full length cDNA, which encoded a protein of 468 amino acids, was constructed and expressed in Escherichia coli. The expressed protein, purified to homogeneity, showed a M(r) of 55,000 by gel electrophoresis under denaturing conditions, compared to the deduced M(r) of 54,023. Fru-6-P,2-kinase:Fru-2,6-bisphosphatase with the same M(r) 55,000 was also present in rat testis extract. The active enzyme was a dimer as judged by molecular sieve filtration. The expressed enzyme was bifunctional with specific activities of 90 and 22 milliunits/mg of the kinase and the phosphatase activities, respectively. Various kinetic constants of the expressed fructose 6-P,2-kinase were K(m)Fru 6-P = 85-mu-M and K(m)ATP = 270-mu-M, and those of fructose 2,6-bisphosphatase were K(m)Fru 2,6-P2 = 21-mu-M and K(i)Fru 6-P = 3.4-mu-M. The enzyme was phosphorylated by Fru-2,6[2-P-32]P2 and also by protein kinase C, but not by cAMP-dependent protein kinase, which is in contrast to the liver and heart isozymes.	UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	SAKATA, J (corresponding author), DEPT VET AFFAIRS MED CTR,PRECLIN SCI UNIT,DALLAS,TX 75216, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016194] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK16194] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALGAIER J, 1988, BIOCHEM BIOPH RES CO, V153, P328, DOI 10.1016/S0006-291X(88)81226-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DARVILLE MI, 1987, FEBS LETT, V224, P317, DOI 10.1016/0014-5793(87)80476-3; DOTTO GP, 1984, J MOL BIOL, V172, P507, DOI 10.1016/S0022-2836(84)80020-0; ELMAGHRABI MR, 1982, J BIOL CHEM, V257, P7603; ELMAGHRABI MR, 1981, BIOCHEM BIOPH RES CO, V101, P1071, DOI 10.1016/0006-291X(81)91858-1; ELMAGHRABI MR, 1984, J BIOL CHEM, V259, P3096; ELMAGHRABI MR, 1982, P NATL ACAD SCI-BIOL, V79, P315, DOI 10.1073/pnas.79.2.315; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FURUYA E, 1982, BIOCHEM BIOPH RES CO, V105, P264, DOI 10.1016/S0006-291X(82)80040-5; FURUYA E, 1982, P NATL ACAD SCI-BIOL, V79, P325, DOI 10.1073/pnas.79.2.325; FURUYA E, 1981, J BIOL CHEM, V256, P7109; KITAJIMA S, 1984, J BIOL CHEM, V259, P6896; KITAJIMA S, 1985, J BIOL CHEM, V266, P13995; KITAMURA K, 1989, J BIOL CHEM, V264, P6344; KITAMURA K, 1989, J BIOL CHEM, V264, P9799; KITAMURA K, 1987, J BIOL CHEM, V262, P679; KITAMURA K, 1988, J BIOL CHEM, V263, P9027; KITAMURA K, 1988, J BIOL CHEM, V263, P16796; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LIVELY MO, 1988, J BIOL CHEM, V263, P839; MURRAY KJ, 1984, J BIOL CHEM, V259, P7673; NARABAYASHI H, 1985, J BIOL CHEM, V260, P9750; RICHARDS CS, 1982, BIOCHEM BIOPH RES CO, V104, P1073, DOI 10.1016/0006-291X(82)91359-6; RIDER MH, 1985, BIOCHEM J, V231, P193, DOI 10.1042/bj2310193; RIDER MH, 1986, BIOCHEM J, V240, P57, DOI 10.1042/bj2400057; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAKAKIBARA R, 1984, J BIOL CHEM, V259, P41; SAKATA J, 1990, P NATL ACAD SCI USA, V87, P4951, DOI 10.1073/pnas.87.13.4951; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STEWART HB, 1985, J BIOL CHEM, V260, P2935; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TANIYAMA M, 1988, BIOCHEM BIOPH RES CO, V157, P949, DOI 10.1016/S0006-291X(88)80966-5; UYEDA K, 1982, MOL CELL BIOCHEM, V48, P97; UYEDA K, 1981, J BIOL CHEM, V256, P8394; VANSCHAFTINGEN E, 1981, BIOCHEM BIOPH RES CO, V103, P362, DOI 10.1016/0006-291X(81)91701-0; VANSCHAFTINGEN E, 1986, EUR J BIOCHEM, V159, P359; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V124, P143; VANSCHAFTINGEN E, 1981, BIOCHEM BIOPH RES CO, V101, P1078	42	107	111	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					15764	15770						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1651918				2022-12-25	WOS:A1991GB97700040
J	BAVIK, CO; ERIKSSON, U; ALLEN, RA; PETERSON, PA				BAVIK, CO; ERIKSSON, U; ALLEN, RA; PETERSON, PA			IDENTIFICATION AND PARTIAL CHARACTERIZATION OF A RETINAL-PIGMENT EPITHELIAL MEMBRANE-RECEPTOR FOR PLASMA RETINOL-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-A; TRANSPORTING PROTEIN; ACID RECEPTOR; RAT-LIVER; CELLS; SERUM; LOCALIZATION; COMPLEX; HOMOLOGY; CLONING	We have developed a membrane binding assay by which we have been able to characterize the interaction between I-125-labeled retinol-binding protein and its receptor in microsome fractions derived from retinal pigment epithelial cells. The binding of retinol-binding protein to the membranes was fast, with a dissociation constant in the range of 31-72 nM, and maximum binding occurred at neutral pH. Receptor binding sites were also found in microsome fractions of liver and kidney, whereas lung and muscle contained few, if any. Chemical cross-linking of retinol-binding protein to the microsomal membranes yielded a major molecular complex of M(r) 86,000 upon sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The protein responsible for binding of retinol-binding protein was identified as a M(r) 63,000 protein using a label transfer cross-linking technique. Further characterization demonstrated that the receptor for retinol-binding protein is a terminally glycosylated membrane protein noncovalently associated with a high molecular weight complex.	Scripps Res Inst, RES INST, DEPT IMMUNOL, LA JOLLA, CA 92037 USA	Scripps Research Institute					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037915] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 37915] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BASU SK, 1978, J BIOL CHEM, V253, P3852; BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BLOMHOFF R, 1985, J BIOL CHEM, V260, P3571; BOK D, 1976, EXP EYE RES, V22, P395, DOI 10.1016/0014-4835(76)90177-9; BOK D, 1984, INVEST OPHTH VIS SCI, V25, P877; Bok D., 1979, RETINAL PIGMENT EPIT, P148; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; DRAYNA D, 1986, J BIOL CHEM, V261, P6535; ELDER JH, 1982, P NATL ACAD SCI-BIOL, V79, P4540, DOI 10.1073/pnas.79.15.4540; ERIKSSON U, 1984, J BIOL CHEM, V259, P3464; Eriksson U, 1990, Subcell Biochem, V16, P365; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GJOEN T, 1987, J BIOL CHEM, V262, P10926; GODOVAC-ZIMMERMANN J, 1985, BIOL CHEM H-S, V366, P431, DOI 10.1515/bchm3.1985.366.1.431; Goodman DS, 1984, RETINOIDS, P41, DOI DOI 10.1016/B978-0-12-658102-7.50008-7; HELENIUS A, 1983, TRENDS BIOCHEM SCI, V8, P245, DOI 10.1016/0968-0004(83)90350-X; HELLER J, 1975, J BIOL CHEM, V250, P3613; HELLER J, 1980, EXP EYE RES, V30, P481, DOI 10.1016/0014-4835(80)90032-9; KATO M, 1984, J CELL BIOL, V98, P1696, DOI 10.1083/jcb.98.5.1696; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LAURENT BC, 1987, CHEM SCRIPTA, V27, P185; LEE KH, 1987, SCIENCE, V235, P1053, DOI 10.1126/science.3493528; LOPEZ C, 1981, BIOCHEM BIOPH RES CO, V103, P919, DOI 10.1016/0006-291X(81)90898-6; MACDONALD PN, 1990, P NATL ACAD SCI USA, V87, P4265, DOI 10.1073/pnas.87.11.4265; MARAMUTSU T, 1976, J BIOL CHEM, V251, P4673; MCGUIRE BW, 1981, ENDOCRINOLOGY, V108, P658, DOI 10.1210/endo-108-2-658; NEWCOMER ME, 1984, EMBO J, V3, P1451, DOI 10.1002/j.1460-2075.1984.tb01995.x; OSTBERG L, 1976, FOLIA BIOL-PRAGUE, V22, P372; PERVAIZ S, 1987, FASEB J, V1, P209, DOI 10.1096/fasebj.1.3.3622999; PETERSON PA, 1971, J BIOL CHEM, V246, P44; PETERSON PA, 1971, J BIOL CHEM, V246, P25; PETERSON PA, 1971, J BIOL CHEM, V246, P34; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PFEFFER BA, 1986, INVEST OPHTH VIS SCI, V27, P101; RASK L, 1979, FEBS LETT, V104, P55, DOI 10.1016/0014-5793(79)81084-4; RASK L, 1983, EXP CELL RES, V143, P91, DOI 10.1016/0014-4827(83)90112-X; RASK L, 1976, J BIOL CHEM, V251, P6360; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHMALE H, 1990, NATURE, V343, P366, DOI 10.1038/343366a0; SHINGLETON JL, 1989, BIOCHEMISTRY-US, V28, P9641, DOI 10.1021/bi00451a015; SIVAPRASADARAO A, 1988, BIOCHEM J, V255, P571; SIVAPRASADARAO A, 1988, BIOCHEM J, V255, P561; SOPRANO DR, 1986, J LIPID RES, V27, P166; SORENSEN P, 1986, J BIOL CHEM, V261, P9094; UNTERMAN RD, 1981, P NATL ACAD SCI-BIOL, V78, P3478, DOI 10.1073/pnas.78.6.3478; VAHLQUIS.A, 1973, J BIOL CHEM, V248, P4040; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	52	120	127	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					14978	14985						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1651317				2022-12-25	WOS:A1991GB09700030
J	ROBINSON, MJ; MARTIN, BA; GOOTZ, TD; MCGUIRK, PR; MOYNIHAN, M; SUTCLIFFE, JA; OSHEROFF, N				ROBINSON, MJ; MARTIN, BA; GOOTZ, TD; MCGUIRK, PR; MOYNIHAN, M; SUTCLIFFE, JA; OSHEROFF, N			EFFECTS OF QUINOLONE DERIVATIVES ON EUKARYOTIC TOPOISOMERASE-II - A NOVEL MECHANISM FOR ENHANCEMENT OF ENZYME-MEDIATED DNA CLEAVAGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OVARY CELL-LINE; DROSOPHILA-MELANOGASTER; ANTIBACTERIAL AGENTS; MITOTIC CHROMOSOMES; RELIGATION REACTION; ANTITUMOR DRUGS; CALF THYMUS; INHIBITION; RESISTANCE; MUTANTS	The effects of two novel quinolone derivatives, CP-67,804 and CP-115,953 (the I-ethyl and 1-cyclopropyl derivatives of 6,8-difluoro-7-(4-hydroxyphenyl)-4-quinolone-3-carboxylic acid, respectively), on the enzymatic activities of Drosophila melanogaster topoisomerase Il were examined. Both drugs enhanced the enzyme's pre- and post-strand passage DNA cleavage activities. CP-67,804 was nearly as potent an enhancer as etoposide, while CP-115,953 was approximately 2 times more potent than this topoisomerase II-targeted antineoplastic drug. In contrast to etoposide, which stabilizes enzyme-DNA cleavage complexes primarily by inhibiting topoisomerase II-mediated DNA religation, neither quinolone impaired the enzyme's ability to religate cleaved DNA. To further assess the characteristics of these unusual quinolone derivatives, the cytotoxic effects of CP-67,804 and CP-115,953 toward wild-type Chinese hamster ovary cells and Vpm(R)-5 cells (an epipodophyllotoxin-resistant Chinese hamster ovary line) were examined. Both quinolones were cytotoxic to the wild-type cells. CP-115,953 was the more potent agent and displayed a level of cytotoxicity similar to that of etoposide. Finally, the Vpm(R)-5 line showed cross-resistance to CP-67,804 (approximately 3.7-fold) and CP-115,953 (approximately 1.3-fold). Although quinolone cross-resistance was less pronounced than observed for etoposide (approximately 12-fold), it indicates that topoisomerase II is a physiological target for CP-67,804 and CP-115,953 in mammalian cells. These findings strongly suggest that these quinolone derivatives represent a novel class of topoisomerase II-targeted drugs which have potential as antineoplastic agents.	VANDERBILT UNIV,MED CTR,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232; PFIZER INC,PFIZER CENT RES,DEPT IMMUNOL & INFECT DIS,GROTON,CT 06340	Vanderbilt University; Pfizer					NCI NIH HHS [T32 CA-09582] Funding Source: Medline; NIGMS NIH HHS [GM-33944] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033944] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; ANDERSEN AH, 1989, BIOCHEMISTRY-US, V28, P6237, DOI 10.1021/bi00441a015; Andriole V., 1988, QUINOLONES, P155; BARRETT JF, 1989, ANTIMICROB AGENTS CH, V33, P1697, DOI 10.1128/AAC.33.10.1697; BERRIOS M, 1985, P NATL ACAD SCI USA, V82, P4142, DOI 10.1073/pnas.82.12.4142; CHEN GL, 1984, J BIOL CHEM, V259, P3560; CHOW KC, 1988, MOL PHARMACOL, V34, P467; DANKS MK, 1988, BIOCHEMISTRY-US, V27, P8861, DOI 10.1021/bi00424a026; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DRLICA K, 1988, BIOCHEMISTRY-US, V27, P2253, DOI 10.1021/bi00407a001; EARNSHAW WC, 1985, J CELL BIOL, V100, P1706, DOI 10.1083/jcb.100.5.1706; EARNSHAW WC, 1985, J CELL BIOL, V100, P1716, DOI 10.1083/jcb.100.5.1716; GALE KC, 1990, BIOCHEMISTRY-US, V29, P9538, DOI 10.1021/bi00493a007; GASSER SM, 1986, J MOL BIOL, V188, P613, DOI 10.1016/S0022-2836(86)80010-9; GILLIGAN PJ, 1986, Patent No. 4623650; GLISSON B, 1986, CANCER RES, V46, P1934; GOOTZ TD, 1990, ANTIMICROB AGENTS CH, V34, P8, DOI 10.1128/AAC.34.1.8; GUPTA RS, 1983, CANCER RES, V43, P1568; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HOOPER DC, 1989, REV INFECT DIS, V11, pS902; HOSHINO K, 1989, ANTIMICROB AGENTS CH, V33, P1816, DOI 10.1128/AAC.33.10.1816; HSIANG YH, 1989, J BIOL CHEM, V264, P9713; HSIANG YH, 1989, MOL PHARMACOL, V36, P371; HUFF AC, 1990, J BIOL CHEM, V265, P20496; HUSSY P, 1986, ANTIMICROB AGENTS CH, V29, P1073, DOI 10.1128/AAC.29.6.1073; LIU LF, 1983, J BIOL CHEM, V258, P5365; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; LOCK RB, 1987, ANTI-CANCER DRUG DES, V2, P151; Maniatis T., 1982, MOL CLONING; MILLER KG, 1981, J BIOL CHEM, V256, P9334; MOREAU NJ, 1990, ANTIMICROB AGENTS CH, V34, P1955, DOI 10.1128/AAC.34.10.1955; NEWPORT J, 1987, CELL, V48, P219, DOI 10.1016/0092-8674(87)90425-9; OOMORI Y, 1988, J ANTIMICROB CHEMOTH, V22, P91, DOI 10.1093/jac/22.Supplement_D.91; OSHEROFF N, 1989, BIOCHEMISTRY-US, V28, P6157, DOI 10.1021/bi00441a005; OSHEROFF N, 1987, BIOCHEMISTRY-US, V26, P4303, DOI 10.1021/bi00388a018; OSHEROFF N, 1989, PHARMACOL THERAPEUT, V41, P223, DOI 10.1016/0163-7258(89)90108-3; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; OSHEROFF N, 1983, J BIOL CHEM, V258, P9536; OSHEROFF N, 1991, IN PRESS BIOESSAYS; POMMIER Y, 1985, BIOCHEMISTRY-US, V24, P6410, DOI 10.1021/bi00344a015; ROBINSON MJ, 1991, BIOCHEMISTRY-US, V30, P1807, DOI 10.1021/bi00221a012; ROBINSON MJ, 1990, BIOCHEMISTRY-US, V29, P2511, DOI 10.1021/bi00462a012; ROSE D, 1990, CELL, V60, P1009, DOI 10.1016/0092-8674(90)90349-J; ROSS W, 1984, CANCER RES, V44, P5857; SANDER M, 1983, J BIOL CHEM, V258, P8421; SHELTON ER, 1983, J BIOL CHEM, V258, P9530; SHEN LL, 1989, J BIOL CHEM, V264, P2973; SHEN LL, 1985, P NATL ACAD SCI USA, V82, P307, DOI 10.1073/pnas.82.2.307; SORENSEN BS, 1990, BIOCHEMISTRY-US, V29, P9507; SULLIVAN DM, 1989, BIOCHEMISTRY-US, V28, P5680, DOI 10.1021/bi00439a051; SUTCLIFFE J, 1990, 90 ANN M AM SOC MICR, P4; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; UEMURA T, 1986, EMBO J, V5, P1003, DOI 10.1002/j.1460-2075.1986.tb04315.x; UEMURA T, 1984, EMBO J, V3, P1737, DOI 10.1002/j.1460-2075.1984.tb02040.x; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WARING MJ, 1981, ANNU REV BIOCHEM, V50, P159, DOI 10.1146/annurev.bi.50.070181.001111; WILSON WR, 1981, MOL PHARMACOL, V20, P404; WOOD ER, 1990, J CELL BIOL, V111, P2839, DOI 10.1083/jcb.111.6.2839; ZECHIEDRICH EL, 1989, BIOCHEMISTRY-US, V28, P6229, DOI 10.1021/bi00441a014; ZIMMER C, 1990, J BASIC MICROB, V30, P209, DOI 10.1002/jobm.3620300312; ZWELLING L A, 1989, Hematologic Pathology, V3, P101; ZWELLINGLA, 1989, J BIOL CHEM, V264, P16411	62	160	164	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14585	14592						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1650363				2022-12-25	WOS:A1991FZ35100074
J	ITO, A; SATO, T; OJIMA, Y; CHEN, LC; NAGASE, H; MORI, Y				ITO, A; SATO, T; OJIMA, Y; CHEN, LC; NAGASE, H; MORI, Y			CALMODULIN DIFFERENTIALLY MODULATES THE INTERLEUKIN 1-INDUCED BIOSYNTHESIS OF TISSUE INHIBITOR OF METALLOPROTEINASES AND MATRIX METALLOPROTEINASES IN HUMAN UTERINE CERVICAL FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ARTICULAR CHONDROCYTES; COLLAGENASE MESSENGER-RNA; ONCOGENE-INDUCED TRANSIN; NECROSIS FACTOR-ALPHA; SYNOVIAL FIBROBLASTS; PROCOLLAGENASE SYNTHESIS; LATENT COLLAGENASE; CELLS; STIMULATION; STROMELYSIN	The effects of a specific calmodulin inhibitor, N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-70 on the synthesis of tissue inhibitor of metalloproteinases (TIMP) and precursor of matrix metalloproteinase 1/tissue collagenase (proMMP-1) and matrix metalloproteinase 3/stromelysin (proMMP-3), were examined using human uterine cervical fibroblasts in culture. When the cells were treated with human recombinant interleukin 1-alpha, the synthesis of TIMP, proMMP-1, and proMMP-3 was greatly enhanced along with the increase in the steady-state levels of mRNAs for respective proteins. The treatment of the cells with human recombinant interleukin 1-alpha and W-7 further augmented the production of proMMPs-I and -3 and the accumulation of their mRNAs. In contrast, TIMP production and its steady-state mRNA level were reduced considerably under these conditions. Similar observations were made with another calmodulin inhibitor, trifluoperazine, but not with N-(6-aminohexyl)-1-naphthalenesulfonamide, the weakest inhibitor for calmodulin. These results indicate that calmodulin is required for the interleukin 1-enhanced synthesis of TIMP but it is a suppressor for the synthesis of proMMPs-1 and -3.	UNIV KANSAS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,KANSAS CITY,KS 66103	University of Kansas; University of Kansas Medical Center	ITO, A (corresponding author), TOKYO COLL PHARM,DEPT BIOCHEM,HACHIOJI,TOKYO 19203,JAPAN.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039189] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39189] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AGGELER J, 1984, J CELL BIOL, V98, P1662, DOI 10.1083/jcb.98.5.1662; BIRD TA, 1986, NATURE, V324, P263, DOI 10.1038/324263a0; BREATHNACH R, 1987, NUCLEIC ACIDS RES, V15, P1139, DOI 10.1093/nar/15.3.1139; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; BUNNING RAD, 1987, BIOCHIM BIOPHYS ACTA, V924, P473, DOI 10.1016/0304-4165(87)90163-2; CAWSTON TE, 1979, ANAL BIOCHEM, V99, P340, DOI 10.1016/S0003-2697(79)80017-2; CIVITELLI R, 1989, ENDOCRINOLOGY, V124, P2928, DOI 10.1210/endo-124-6-2928; DAYER JM, 1986, J CLIN INVEST, V77, P645, DOI 10.1172/JCI112350; DEAN DD, 1989, J CLIN INVEST, V84, P678, DOI 10.1172/JCI114215; DOWER SK, 1986, NATURE, V324, P266, DOI 10.1038/324266a0; FRISCH SM, 1987, J BIOL CHEM, V262, P16300; ITO A, 1988, ARCH BIOCHEM BIOPHYS, V267, P211, DOI 10.1016/0003-9861(88)90025-2; KERR LD, 1988, J BIOL CHEM, V263, P16999; KISHI J, 1985, BIOMED RES-TOKYO, V6, P35; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN CW, 1988, ARCH BIOCHEM BIOPHYS, V264, P351, DOI 10.1016/0003-9861(88)90605-4; MACNAUL KL, 1990, J BIOL CHEM, V265, P17238; MCCACHREN SS, 1989, ARTHRITIS RHEUM, V32, P1539, DOI 10.1002/anr.1780321207; MCCROSKERY PA, 1985, FEBS LETT, V191, P7, DOI 10.1016/0014-5793(85)80983-2; MCDONNELL SE, 1990, MOL CELL BIOL, V10, P4284, DOI 10.1128/MCB.10.8.4284; MIZEL SB, 1981, P NATL ACAD SCI-BIOL, V78, P2474, DOI 10.1073/pnas.78.4.2474; MURPHY G, 1985, J BIOL CHEM, V260, P3079; MURPHY G, 1985, BIOCHIM BIOPHYS ACTA, V839, P214, DOI 10.1016/0304-4165(85)90039-X; NAGASE H, 1981, J BIOL CHEM, V256, P1951; NOLAN JC, 1988, AGENTS ACTIONS, V25, P71, DOI 10.1007/BF01969097; OJIMA Y, 1989, BIOCHIM BIOPHYS ACTA, V1011, P61, DOI 10.1016/0167-4889(89)90079-7; OPPENHEIM JJ, 1986, IMMUNOL TODAY, V7, P45, DOI 10.1016/0167-5699(86)90124-6; OTSUKA K, 1984, EUR J BIOCHEM, V145, P123, DOI 10.1111/j.1432-1033.1984.tb08530.x; POSTLETHWAITE AE, 1988, J CELL BIOL, V106, P311, DOI 10.1083/jcb.106.2.311; SAKYO K, 1986, J PHARMACOBIO-DYNAM, V9, P276, DOI 10.1248/bpb1978.9.276; SAUS J, 1988, J BIOL CHEM, V263, P6742; SCHNYDER J, 1987, J IMMUNOL, V138, P496; STEPHENSON ML, 1987, BIOCHEM BIOPH RES CO, V144, P583, DOI 10.1016/S0006-291X(87)80006-2; SUZUKI K, 1990, BIOCHEMISTRY-US, V29, P10261, DOI 10.1021/bi00496a016; WAHL G, 1983, SCHLEICHER SCHUEL SE, V371	35	47	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13598	13601						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1649824				2022-12-25	WOS:A1991FY02700025
J	MATSUMOTO, Y; WICKNER, RB				MATSUMOTO, Y; WICKNER, RB			YEAST 20-S RNA REPLICON - REPLICATION INTERMEDIATES AND ENCODED PUTATIVE RNA-POLYMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; SELF-CLEAVAGE; SEQUENCE; SPORULATION; EXPRESSION; HAIRPINS; GENOME; HSP26; VIRUS	The 20 S RNA genome is a circular single-stranded replicon, present in most laboratory yeast strains, whose copy number is induced 10,000-fold by transfer of cells to acetate medium without a carbon source. We have sequenced most of the 20 S RNA genome, and the (+) strand has a long open reading frame with the potential to encode a protein with homology to viral RNA-dependent RNA polymerases. The presence of a typical cAMP-dependent phosphorylation site in the putative RNA polymerase suggests that the acetate amplification of the 20 S RNA genome might be mediated by cAMP, a signal known to transmit the same nutritional status information to the sporulation-control system. Our inability to clone across the gap in the sequence suggests either autocatalytic cleavage of the RNA in the reverse transcriptase reaction, an unusual linkage of 5' and 3' ends of a fundamentally linear molecule, or a structure unusually resistant to reverse transcription. The identity of our sequence with that of the accompanying paper (Rodriguez-Cousino, N., Esteban, L. M., and Esteban, R. (1991) J. Biol. Chem. 266, 12772-12778) for W double-stranded RNA (dsRNA) suggests that W is the replicative form of 20 S RNA. The presence of single-stranded (+) and (-) strands and greater than unit length molecules suggests a rolling circle mode of replication as has been suggested for viroids.			MATSUMOTO, Y (corresponding author), NIDDKD,BIOCHEM PHARMACOL LAB,GENET SIMPLE EUKARYOTES SECT,BETHESDA,MD 20892, USA.							BLUMENTHAL T, 1979, ANNU REV BIOCHEM, V48, P525, DOI 10.1146/annurev.bi.48.070179.002521; BOSSIER P, 1989, GENE, V78, P323, DOI 10.1016/0378-1119(89)90234-5; BRUENING G, 1988, RNA GENETICS RETROVI, V2, P127; CHERRY JR, 1989, CELL, V56, P409, DOI 10.1016/0092-8674(89)90244-4; DAVIES C, 1990, VIROLOGY, V177, P216, DOI 10.1016/0042-6822(90)90475-7; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; GARVIK B, 1978, J BACTERIOL, V134, P261, DOI 10.1128/JB.134.1.261-269.1978; GRANKOWSKI N, 1990, BIOCHEM BIOPH RES CO, V167, P471, DOI 10.1016/0006-291X(90)92047-4; HUTCHINS CJ, 1986, NUCLEIC ACIDS RES, V14, P3627, DOI 10.1093/nar/14.9.3627; ICHO T, 1989, J BIOL CHEM, V264, P6716; KADOWAKI K, 1971, J BACTERIOL, V105, P831, DOI 10.1128/JB.105.3.831-836.1971; KADOWAKI K, 1971, J BACTERIOL, V105, P826, DOI 10.1128/JB.105.3.826-830.1971; KAMER G, 1984, NUCLEIC ACIDS RES, V12, P7269, DOI 10.1093/nar/12.18.7269; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; MALONE RE, 1990, CELL, V61, P375, DOI 10.1016/0092-8674(90)90517-I; MATSUMOTO K, 1983, EXP CELL RES, V146, P151, DOI 10.1016/0014-4827(83)90333-6; MATSUMOTO Y, 1990, P NATL ACAD SCI USA, V87, P7628, DOI 10.1073/pnas.87.19.7628; OWENS RA, 1988, RNA GENETICS, V2, P107; RODRIGUEZCOUSINO N, 1991, J BIOL CHEM, V266, P12772; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SUSEK RE, 1989, MOL CELL BIOL, V9, P5265, DOI 10.1128/MCB.9.11.5265; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TUERK C, 1988, P NATL ACAD SCI USA, V85, P1364, DOI 10.1073/pnas.85.5.1364; WANG KS, 1986, NATURE, V323, P508, DOI 10.1038/323508a0; WEJKSNORA PJ, 1978, J BACTERIOL, V134, P246, DOI 10.1128/JB.134.1.246-260.1978; WESOLOWSKI M, 1984, MOL CELL BIOL, V4, P181, DOI 10.1128/MCB.4.1.181; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	28	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1991	266	19					12779	12783						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FV180	1648104				2022-12-25	WOS:A1991FV18000104
J	CHAMPIONARNAUD, P; GESNEL, MC; FOULKES, N; RONSIN, C; SASSONECORSI, P; BREATHNACH, R				CHAMPIONARNAUD, P; GESNEL, MC; FOULKES, N; RONSIN, C; SASSONECORSI, P; BREATHNACH, R			ACTIVATION OF TRANSCRIPTION VIA AP-1 OR CREB REGULATORY SITES IS BLOCKED BY PROTEIN TYROSINE PHOSPHATASES	ONCOGENE			English	Article							HUMAN ESTROGEN-RECEPTOR; EPIDERMAL GROWTH-FACTOR; ROUS-SARCOMA VIRUS; HUMAN-PLACENTA; CYCLIC-AMP; RAT FIBROBLASTS; MESSENGER-RNA; C-JUN; GENE; KINASE	Transcriptional activation endowed by AP-1 or CREB binding sites can be significantly reduced in transient transfection tests by expression from the corresponding cloned cDNAs of protein tyrosine phosphatases. Both the protein tyrosine phosphatase 1B and the T-cell protein tyrosine phosphatase, as well as a novel form of this latter protein generated by an alternative splicing event show this activity. The effect is specific, as none of the protein tyrosine phosphatases alters transcriptional activation by either the estrogen receptor, GAL4, or a GAL4-VP16 fusion protein. Furthermore, the activities of the SV40 early gene promoter and a Moloney murine leukemia virus long terminal repeat promoter are not reduced by these phosphatases. We conclude that a yet to be identified protein phosphorylated on tyrosine is necessary for a full transcriptional response via AP-1 or CREB binding sites.	UNIV NANTES,FAC SCI & TECH,F-44035 NANTES,FRANCE; CHR NANTES,INSERM,U211,F-44035 NANTES,FRANCE; FAC MED STRASBOURG,GENET MOLEC EUCARYOTES LAB,CNRS,INSERM,U184,F-67085 STRASBOURG,FRANCE	Nantes Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	BREATHNACH, R (corresponding author), UNIV NANTES,FAC SCI & TECH,F-44035 NANTES,FRANCE.		Breathnach, Richard/K-7599-2015					ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; CHARBONNEAU H, 1988, P NATL ACAD SCI USA, V85, P7182, DOI 10.1073/pnas.85.19.7182; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P9035; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; COOL DE, 1990, P NATL ACAD SCI USA, V87, P7280, DOI 10.1073/pnas.87.18.7280; COOPER JA, 1983, NATURE, V302, P218, DOI 10.1038/302218a0; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GUAN KL, 1990, P NATL ACAD SCI USA, V87, P1501, DOI 10.1073/pnas.87.4.1501; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KAKIDANI H, 1988, CELL, V52, P161, DOI 10.1016/0092-8674(88)90504-1; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; KOUZARIDES T, 1989, CANCER CELL-MON REV, V1, P71; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LAU KHW, 1989, BIOCHEM J, V257, P23, DOI 10.1042/bj2570023; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MATRISIAN LM, 1986, P NATL ACAD SCI USA, V83, P9413, DOI 10.1073/pnas.83.24.9413; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; MULLER D, 1988, BIOCHEM J, V253, P187, DOI 10.1042/bj2530187; MYLIN LM, 1990, MOL CELL BIOL, V10, P4623, DOI 10.1128/MCB.10.9.4623; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OSTROWSKI LE, 1988, MOL CARCINOGEN, V1, P13, DOI 10.1002/mc.2940010106; Sambrook J, 1989, MOL CLONING LABORATO; SASSONECORSI P, 1990, ONCOGENE, V5, P423; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1988, J BIOL CHEM, V263, P6722; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3; WITTE ON, 1980, NATURE, V283, P826, DOI 10.1038/283826a0; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZENKE M, 1986, EMBO J, V5, P387, DOI 10.1002/j.1460-2075.1986.tb04224.x; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	50	41	41	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1991	6	7					1203	1209						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1650442				2022-12-25	WOS:A1991GV26000016
J	TOURAY, M; RYAN, F; JAGGI, R; MARTIN, F				TOURAY, M; RYAN, F; JAGGI, R; MARTIN, F			CHARACTERIZATION OF FUNCTIONAL INHIBITION OF THE GLUCOCORTICOID RECEPTOR BY FOS/JUN	ONCOGENE			English	Article								We have studied the effects of Fos and Fos/Jun on glucocorticoid induction of hormone-sensitive gene expression. In NIH3T3 cells overexpression of Fos or Fos/Jun by transfection of pSV2-fos and pSV2-jun inhibited glucocorticoid-dependent expression of MMTV LTR-CAT. Expression of p39v-mos had a similar effect on glucocorticoid-dependent reporter gene expression which is most likely mediated by simulation of endogenous Fos. In both cases, this inhibition could be overcome by overexpression of the glucocorticoid receptor (GR) from a transiently transfected expression vector. In receptor deficient CV-1 cells glucocorticoid-dependent reporter gene expression was induced by a range of functional GR truncation mutants. It was established that the C/D domain of the receptor was a sufficient target for inhibition by Fos and Fos/Jun. The C/D domain encompasses the DNA-binding domain, a dimerisation domain and a weak transactivational domain of the GR. When present simultaneously in the cell nucleus Fos and Jun were shown to form a specific and stable protein/protein complex with the glucocorticoid receptor. Finally, it was demonstrated that the GR interacts physically with both Fos and Jun when cotranslated simultaneously in vitro. We propose that this interaction may be the mechanism by which Fos of Fos/Jun bring about inhibition of GR function.	NATL UNIV IRELAND UNIV COLL DUBLIN, DEPT PHARMACOL, DUBLIN 4, IRELAND; UNIV BERN, DEPT CLIN & EXPTL CANC RES, CH-3004 BERN, SWITZERLAND	University College Dublin; University of Bern	MARTIN, F (corresponding author), NATL UNIV IRELAND UNIV COLL DUBLIN, DEPT PHARMACOL, DUBLIN 4, IRELAND.		Ryan, Fergus/B-8407-2012					ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; CATO ACB, 1988, EMBO J, V7, P1403, DOI 10.1002/j.1460-2075.1988.tb02957.x; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; CURRAN T, 1982, J VIROL, V42, P114, DOI 10.1128/JVI.42.1.114-122.1982; DANIELSEN M, 1986, EMBO J, V5, P2513, DOI 10.1002/j.1460-2075.1986.tb04529.x; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; FRISCH SM, 1987, J BIOL CHEM, V262, P16300; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GODOWSKI PJ, 1988, SCIENCE, V241, P812, DOI 10.1126/science.3043662; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GREEN S, 1987, NATURE, V325, P75, DOI 10.1038/325075a0; HAMILTON BJ, 1989, P NATL ACAD SCI USA, V86, P597, DOI 10.1073/pnas.86.2.597; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HERRLICH P, 1989, TRENDS GENET, V5, P112, DOI 10.1016/0168-9525(89)90041-3; HOECK W, 1989, J BIOL CHEM, V264, P14396; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; JAGGI R, 1989, CANCER RES, V49, pS2266; JAGGI R, 1988, J STEROID BIOCHEM, V29, P457, DOI 10.1016/0022-4731(88)90179-3; JAGGI R, 1986, EMBO J, V5, P2609, DOI 10.1002/j.1460-2075.1986.tb04541.x; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MEDCALF RL, 1986, EMBO J, V5, P2217, DOI 10.1002/j.1460-2075.1986.tb04487.x; MORDACQ JC, 1989, GENE DEV, V3, P760, DOI 10.1101/gad.3.6.760; OFFRINGA R, 1988, NUCLEIC ACIDS RES, V16, P10973, DOI 10.1093/nar/16.23.10973; PRATT WB, 1988, J BIOL CHEM, V263, P267; QI M, 1989, MOL ENDOCRINOL, V3, P1279, DOI 10.1210/mend-3-8-1279; RANSONE LJ, 1990, MOL CELL BIOL, V10, P4565, DOI 10.1128/MCB.10.9.4565; RUSCONI S, 1987, EMBO J, V6, P1309, DOI 10.1002/j.1460-2075.1987.tb02369.x; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SCHMID W, 1989, EMBO J, V8, P2257, DOI 10.1002/j.1460-2075.1989.tb08350.x; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SHAW PE, 1989, EMBO J, V8, P2567, DOI 10.1002/j.1460-2075.1989.tb08395.x; TOURAY M, 1991, ONCOGENE, V6, P211; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; VASSALLI JD, 1976, CELL, V8, P271, DOI 10.1016/0092-8674(76)90011-8; VERRIER B, 1986, EMBO J, V5, P913, DOI 10.1002/j.1460-2075.1986.tb04303.x; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	50	81	82	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1991	6	7					1227	1234						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1650443				2022-12-25	WOS:A1991GV26000019
J	YAN, H; CHAO, MV				YAN, H; CHAO, MV			DISRUPTION OF CYSTEINE-RICH REPEATS OF THE P75 NERVE GROWTH-FACTOR RECEPTOR LEADS TO LOSS OF LIGAND-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; HUMAN-MELANOMA CELLS; HUMAN NGF RECEPTOR; MOLECULAR-CLONING; GENE-TRANSFER; PC12 CELLS; NEUROTROPHIC FACTOR; BIOLOGICAL-ACTIVITY; CDNA SEQUENCES; EXPRESSION	Nerve growth factor (NGF) binds to a low affinity cell surface receptor (p75NGFR) which contains four extracellular repeats, rich in cysteine residues and negatively charged. We have made mutations in the receptor cDNA by inserting linkers in specific domains of the receptor. Nearly all the mutations caused a change in the predicted charge, and resulted in either an insertion or deletion in the primary sequence. Stably transfected fibroblasts were assayed for NGF binding by affinity cross-linking with I-125-NGF. Appropriate expression of the mutated receptors was monitored by rosetting with monoclonal antibodies and by metabolic labeling followed by immunoprecipitation. Although the mutant receptors were recognized by monoclonal antibodies, insertions and deletions in the third and fourth cysteine-rich regions of the receptor had a detrimental effect upon NGF binding. Insertions made outside the cysteine-rich region or in the cytoplasmic domain did not inhibit the ability of I-125-NGF to bind to the receptor, as assessed by affinity cross-linking. A chimeric human-rat NGF receptor transfected into fibroblasts indicates that NGF binding and monoclonal antibody recognition sites are separated but contained within the four cysteine repeats.			YAN, H (corresponding author), CORNELL UNIV, MED CTR, COLL MED, DEPT CELL BIOL & ANAT, DIV HEMATOL ONCOL, NEW YORK, NY 10021 USA.			Chao, Moses/0000-0002-6969-3744				BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BUCK CR, 1988, DEV BRAIN RES, V44, P259, DOI 10.1016/0165-3806(88)90224-6; CHANDLER CE, 1984, J BIOL CHEM, V259, P6882; CHAO MV, 1986, SCIENCE, V232, P518, DOI 10.1126/science.3008331; ERNFORS P, 1990, P NATL ACAD SCI USA, V87, P5454, DOI 10.1073/pnas.87.14.5454; ESCANDON E, 1990, DEV BIOL, V142, P293, DOI 10.1016/0012-1606(90)90350-R; FABRICANT RN, 1977, P NATL ACAD SCI USA, V74, P565, DOI 10.1073/pnas.74.2.565; GREEN SH, 1986, J BIOL CHEM, V261, P5316; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GROB PM, 1983, P NATL ACAD SCI-BIOL, V80, P6819, DOI 10.1073/pnas.80.22.6819; GROB PM, 1985, J BIOL CHEM, V260, P8044; HAMAGUCHI M, 1988, MOL CELL BIOL, V8, P3035, DOI 10.1128/MCB.8.8.3035; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEMPSTEAD BL, 1989, RECENT PROG HORM RES, V45, P441; HEMPSTEAD BL, 1989, SCIENCE, V243, P373, DOI 10.1126/science.2536190; HEMPSTEAD BL, 1990, J BIOL CHEM, V265, P9595; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; IBANEZ CF, 1990, EMBO J, V9, P1477, DOI 10.1002/j.1460-2075.1990.tb08265.x; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KWON BS, 1989, P NATL ACAD SCI USA, V86, P1963, DOI 10.1073/pnas.86.6.1963; LANDRETH GE, 1980, P NATL ACAD SCI-BIOL, V77, P4751, DOI 10.1073/pnas.77.8.4751; LARGE TH, 1989, NEURON, V2, P1123, DOI 10.1016/0896-6273(89)90179-7; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LEVIMONTALCINI R, 1987, EMBO J, V6, P1145, DOI 10.1002/j.1460-2075.1987.tb02347.x; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MALLETT S, 1990, EMBO J, V9, P1063, DOI 10.1002/j.1460-2075.1990.tb08211.x; Maniatis T., 1982, MOL CLONING; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MEIER R, 1986, EMBO J, V5, P1489, DOI 10.1002/j.1460-2075.1986.tb04387.x; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; ROSS AH, 1984, P NATL ACAD SCI-BIOL, V81, P6681, DOI 10.1073/pnas.81.21.6681; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHECHTER AL, 1981, CELL, V24, P867, DOI 10.1016/0092-8674(81)90112-4; SEHGAL A, 1989, NUCLEIC ACIDS RES, V17, P5623, DOI 10.1093/nar/17.14.5623; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SONNENFELD KH, 1982, J NEUROSCI RES, V8, P375, DOI 10.1002/jnr.490080226; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; SUTTER A, 1979, J BIOL CHEM, V254, P5972; THOENEN H, 1980, PHYSIOL REV, V60, P1284, DOI 10.1152/physrev.1980.60.4.1284; UPTON C, 1987, VIROLOGY, V160, P20, DOI 10.1016/0042-6822(87)90039-0; WELCHER AA, 1991, P NATL ACAD SCI USA, V88, P159, DOI 10.1073/pnas.88.1.159; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X	49	71	88	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1991	266	18					12099	12104						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FT762	1646820				2022-12-25	WOS:A1991FT76200102
J	VOISIN, T; COUVINEAU, A; ROUYERFESSARD, C; LABURTHE, M				VOISIN, T; COUVINEAU, A; ROUYERFESSARD, C; LABURTHE, M			SOLUBILIZATION AND HYDRODYNAMIC PROPERTIES OF ACTIVE PEPTIDE YY RECEPTOR FROM RAT JEJUNAL CRYPTS - CHARACTERIZATION AS A MR 44,000 GLYCOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; NEUROPEPTIDE-Y; CROSS-LINKING; BINDING-SITES; STRUCTURAL REQUIREMENTS; MEMBRANES; BRAIN; ANTAGONIST; EPITHELIUM; PROTEINS	Peptide YY (PYY) receptors were solubilized from rat jejunal crypts using 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid (CHAPS). The binding of [I-125-Tyr36]monoiodo-PYY ([I-125]PYY) to CHAPS extracts was time-dependent and reversible. The order of potency of PYY-related peptides for inhibiting [I-125]PYY binding was PYY > neuropeptide Y >> pancreatic polypeptide. Scatchard analysis of equilibrium binding data indicated the presence in soluble extracts of a single class of binding sites with a K(d) of 1.02 +/- 0.26 nM and a B(max) of 79 +/- 6 fmol/mg protein. Gel filtration on Sephacryl S-300 and ultracentrifugation on sucrose density gradients of soluble [I-125] PYY-receptor complexes revealed a single binding component with the following hydrodynamic parameters: Stokes radius, 4.43 nm; s20, w, 2.48 S; M(r), 48,000; frictional ratio, 1.82. Solubilized PYY receptors bound specifically to concanavalin A-, wheat germ agglutinin-, and soybean-coupled Sepharose, supporting their glycoproteic nature. After cross-linking with disuccinimidyl suberate, electrophoresis of covalent [I-125]PYY-receptor complexes in membranes or CHAPS extracts revealed the presence of two bands of M(r) 49,000 or 28,000 whose labeling was completely abolished by 1-mu-M unlabeled PYY. The M(r) 49,000 band probably corresponded to the M(r) 48,000 PYY-receptor complex evidenced by hydrodynamic studies. Assuming one molecule of [I-125]PYY (M(r) 4,000) was bound per molecule of receptor, these data show that intestinal PYY receptor consists of a M(r) 44,000 glycoprotein after solubilization with CHAPS. The availability of this CHAPS-soluble receptor from rat jejunum represents a major step toward the purification of this newly characterized receptor.	INSERM, U178, UNITE RECH DIFFERENCIAT & NEUROENDOCRINOL CELLULES, F-94807 VILLEJUIF, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)			LABURTHE, Marc/C-1875-2012; couvineau, alain/G-3641-2013; couvineau, alain/T-3466-2019; voisin, thierry/R-1241-2017	couvineau, alain/0000-0003-2912-5168; couvineau, alain/0000-0003-2912-5168; voisin, thierry/0000-0002-4320-5183				BALASUBRAMANIAM A, 1990, J BIOL CHEM, V265, P14724; BRADFORD M, 1979, ANAL BIOCHEM, V78, P248; BRUNS RF, 1983, ANAL BIOCHEM, V132, P74, DOI 10.1016/0003-2697(83)90427-X; CHANG RSL, 1985, LIFE SCI, V37, P2111, DOI 10.1016/0024-3205(85)90583-1; CLARKE S, 1975, J BIOL CHEM, V250, P5459; COSTA M, 1987, PHYSL GASTROINTESTIN, V1, P1; COUVINEAU A, 1990, J BIOL CHEM, V265, P13386; COUVINEAU A, 1986, J BIOL CHEM, V261, P4482; GIMPL G, 1990, J BIOL CHEM, V265, P18142; HEDO JA, 1984, RECEPTOR PURIFICATIO, V2, P45; Hjelmeland L.M., 1984, MEMBRANES DETERGENTS, P35; HORNE WA, 1986, J BIOL CHEM, V261, P3588; INUI A, 1990, ENDOCRINOLOGY, V127, P934, DOI 10.1210/endo-127-2-934; INUI A, 1989, ENDOCRINOLOGY, V124, P402, DOI 10.1210/endo-124-1-402; LABURTHE M, 1986, ENDOCRINOLOGY, V118, P1910, DOI 10.1210/endo-118-5-1910; LABURTHE M, 1984, EUR J BIOCHEM, V139, P181, DOI 10.1111/j.1432-1033.1984.tb07992.x; LABURTHE M, 1990, TRENDS ENDOCRIN MET, V1, P168, DOI 10.1016/1043-2760(90)90031-W; LABURTHE M, 1988, AM J PHYSIOL, V254, pG457, DOI 10.1152/ajpgi.1988.254.3.G457; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LLUIS F, 1988, GASTROENTEROLOGY, V94, P832, DOI 10.1016/0016-5085(88)90262-4; LUNDBERG JM, 1988, EUR J PHARMACOL, V145, P21, DOI 10.1016/0014-2999(88)90344-5; MANNON PJ, 1989, AM J PHYSIOL, V256, pG637, DOI 10.1152/ajpgi.1989.256.3.G637; MARTIN RG, 1961, J BIOL CHEM, V154, P540; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NALDINI L, 1990, BIOCHEMISTRY-US, V29, P5153, DOI 10.1021/bi00473a022; NGUYEN TD, 1990, J BIOL CHEM, V265, P6416; PRIETO JC, 1979, EUR J BIOCHEM, V96, P229, DOI 10.1111/j.1432-1033.1979.tb13033.x; SERVIN AL, 1989, ENDOCRINOLOGY, V124, P692, DOI 10.1210/endo-124-2-692; SHEIKH SP, 1989, FEBS LETT, V245, P209, DOI 10.1016/0014-5793(89)80223-6; SHEIKH SP, 1989, J BIOL CHEM, V264, P6648; SHEIKH SP, 1990, J BIOL CHEM, V265, P8304; UNDEN A, 1984, EUR J BIOCHEM, V145, P525, DOI 10.1111/j.1432-1033.1984.tb08588.x; VOISIN T, 1990, AM J PHYSIOL, V258, pG753, DOI 10.1152/ajpgi.1990.258.5.G753; VOISIN T, 1990, ANN NY ACAD SCI, V611, P343; WALKER MW, 1988, MOL PHARMACOL, V34, P779; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	36	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					10762	10767						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	1645708				2022-12-25	WOS:A1991FQ77400012
J	LANIER, SM; DOWNING, S; DUZIC, E; HOMCY, CJ				LANIER, SM; DOWNING, S; DUZIC, E; HOMCY, CJ			ISOLATION OF RAT GENOMIC CLONES ENCODING SUBTYPES OF THE ALPHA-2-ADRENERGIC RECEPTOR - IDENTIFICATION OF A UNIQUE RECEPTOR SUBTYPE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTOR; ALPHA-2 ADRENOCEPTOR HETEROGENEITY; BETA-ADRENERGIC-RECEPTOR; H-3 RAUWOLSCINE; ALPHA-2B-ADRENOCEPTOR SUBTYPES; COMPLEMENTARY-DNA; MOLECULAR-CLONING; CELL LINE; EXPRESSION; BINDING	Alpha-2-Adrenergic receptors (alpha-2-AR) exist as subtypes that are expressed in a tissue-specific manner and differ in 1) their ligand recognition properties, 2) their extent of receptor protein glycosylation, and possibly 3) their mechanism of signal transduction. Genomic or cDNA clones encoding three receptor subtypes have been characterized; however, both functional and radioligand binding studies in rodents suggest the existence of a fourth receptor subtype. To isolate the rat genes encoding receptor subtypes we screened a rat genomic library with an oligonucleotide probe encompassing the third membrane span of the human C-4 alpha-2-AR. Two intronless rat genes were isolated that encode distinct receptor subtypes (RG10, RG20). RG10 and RG20 encode proteins of 458 and 450 amino acids, respectively, that are 56% homologous and possess the structural features expected of this class of membrane-bound receptors. RG10 identifies a mRNA species of approximately 2500 nucleotides that is found primarily in brain, whereas RG20 identifies a larger mRNA species (approximately 4000 nucleotides) that is found in several tissues including brain, kidney, and salivary gland. RG10 is 88% homologous to the human C-4-alpha-2-AR and exhibits similar binding properties ([H-3]rauwolscine K(D) = 0.7 +/- 0.3 nM) as determined following transient expression of the receptor in COS-1 cells. RG20 exhibits ligand binding properties distinct from the three receptor subtypes identified by molecular cloning. Saturation binding studies indicate an affinity constant of 15 +/- 1.2 nM for the alpha-2-AR antagonist [H-3]rauwolscine, a value 6-20 times higher than that observed for the three cloned receptor subtypes. In competition binding studies the potency order of competing ligands for RG20 is phentolamine > idazoxan > yohimbine > rauwolscine > prazosin. Of the three previously cloned alpha-2-AR, RG20 is most closely related to the human C-10-alpha-2-AR (89% homology) and is also capable of mediating adenylylcyclase inhibition as determined following its stable expression in NIH-3T3 fibroblasts. However, in contrast to RG20, [H-3]rauwolscine exhibits a K(D) of 2 nM for the C-10 receptor, and the potency order for competing ligands is rauwolscine greater-than-or-equal-to yohimbine > idazoxan > phentolamine > prazosin. RG20 and C-10 are also distinguished by their affinity for SKF-10478 (RG20 K(i) = 531 nM, C-10 K(i) = 101 nm), a compound that may functionally distinguish pre- and postsynaptic alpha-2-AR. These data suggest that RG20 represents a fourth alpha-2-AR subtype distinct from the known alpha-2-A-C receptor subtypes.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,CELLULAR & MOLEC RES LAB,CARDIAC UNIT,JACKSON 13,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital				Lanier, Stephen/0000-0002-2740-7607	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL019259] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS024821, R01NS024821] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-19259] Funding Source: Medline; NINDS NIH HHS [NS-24821] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BOCKAERT J, 1976, J BIOL CHEM, V251, P2653; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BONNER TI, 1989, TRENDS NEUROSCI, V12, P148, DOI 10.1016/0166-2236(89)90054-4; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; BOYAJIAN CL, 1987, J PHARMACOL EXP THER, V241, P1092; BOYAJIAN CL, 1987, J PHARMACOL EXP THER, V241, P1079; BYLUND DB, 1988, TRENDS PHARMACOL SCI, V9, P356, DOI 10.1016/0165-6147(88)90254-4; BYLUND DB, 1988, J PHARMACOL EXP THER, V245, P600; CANTIELLO HF, 1989, J BIOL CHEM, V264, P16000; CHALBERG SC, 1990, MOL CELL BIOCHEM, V97, P161; CHEUNG AH, 1989, MOL PHARMACOL, V34, P132; CHEUNG YC, 1973, BIOCHEM PHARMACOL, V22, P3099; CHEUNG YD, 1982, EUR J PHARMACOL, V84, P79, DOI 10.1016/0014-2999(82)90159-5; CHIASSON B, 1980, LABORATORY ANATOMY W; CONNAUGHTON S, 1990, BRIT J PHARMACOL, V99, P97, DOI 10.1111/j.1476-5381.1990.tb14660.x; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; COTECCHIA S, 1990, J BIOL CHEM, V265, P63; DAYHOFF MO, 1972, ATLAS PROTEIN SEQUEN, V0005; DICKINSON KEJ, 1986, EUR J PHARMACOL, V120, P285, DOI 10.1016/0014-2999(86)90469-3; DIXON RAF, 1986, NATURE, V323, P411; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; EMORINE LJ, 1989, SCIENCE, V245, P1118, DOI 10.1126/science.2570461; FELLER DJ, 1984, J PHARMACOL EXP THER, V228, P275; FINDLAY JBC, 1986, BIOCHEM J, V238, P625, DOI 10.1042/bj2380625; FLORDELLIS CS, 1991, P NATL ACAD SCI USA, V88, P1019, DOI 10.1073/pnas.88.3.1019; FRANKE RR, 1988, J BIOL CHEM, V263, P2119; FRASER CM, 1989, J BIOL CHEM, V264, P11754; GORMAN C, 1985, DNA CLONING, V2, P152; GRAHAM RM, 1986, HEART CARDIOVASCULAR, V2, P1059; GUYER CA, 1990, J BIOL CHEM, V265, P17307; ISOM LL, 1988, ALPHA 2 ADRENERGIC R, P323; KAUFMAN RJ, 1985, P NATL ACAD SCI USA, V82, P689, DOI 10.1073/pnas.82.3.689; KERRY R, 1984, BRIT J PHARMACOL, V81, P91, DOI 10.1111/j.1476-5381.1984.tb10748.x; KOBILKA BK, 1987, P NATL ACAD SCI USA, V84, P46, DOI 10.1073/pnas.84.1.46; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; KOZAK M, 1983, MICROBIOL REV, V47, P1; KUBO T, 1986, NATURE, V323, P411, DOI 10.1038/323411a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANIER SM, 1988, J BIOL CHEM, V263, P14491; Lehninger A.L, 1975, BIOCHEMISTRY-US; LOMASNEY JW, 1990, P NATL ACAD SCI USA, V87, P5094, DOI 10.1073/pnas.87.13.5094; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHMOUDI M, 1989, BIOTECHNIQUES, V7, P331; MCFADZEAN I, 1989, NEURON, V3, P177, DOI 10.1016/0896-6273(89)90030-5; MICHEL AD, 1989, BRIT J PHARMACOL, V98, P890, DOI 10.1111/j.1476-5381.1989.tb14618.x; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURPHY TJ, 1988, J PHARMACOL EXP THER, V244, P571; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; NEYLON CB, 1985, BRIT J PHARMACOL, V85, P349, DOI 10.1111/j.1476-5381.1985.tb08868.x; NORD EP, 1987, J CLIN INVEST, V80, P1755, DOI 10.1172/JCI113268; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; PERALTA EG, 1987, SCIENCE, V236, P600, DOI 10.1126/science.3107123; REGAN JW, 1988, P NATL ACAD SCI USA, V85, P6301, DOI 10.1073/pnas.85.17.6301; ROSENTHAL HE, 1967, ANAL BIOCHEM, V20, P525, DOI 10.1016/0003-2697(67)90297-7; RUBENSTEIN RC, 1987, J BIOL CHEM, V262, P16655; RUFFOLO RR, 1987, N-S ARCH PHARMACOL, V336, P415, DOI 10.1007/BF00164875; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Sambrook J, 1989, MOL CLONING LABORATO; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SUMMERS RJ, 1983, LIFE SCI, V33, P1105, DOI 10.1016/0024-3205(83)90667-7; SWEATT JD, 1985, J BIOL CHEM, V260, P2910; ULRICH S, 1984, J BIOL CHEM, V259, P4111; WEINSHANK R L, 1989, Society for Neuroscience Abstracts, V15, P170; WEINSHANK RL, 1990, MOL PHARMACOL, V38, P681; WEISS ER, 1988, J BIOL CHEM, V263, P6150; YARDEN Y, 1986, P NATL ACAD SCI USA, V83, P6795, DOI 10.1073/pnas.83.18.6795; YOUNG P, 1989, EUR J PHARMACOL, V168, P381, DOI 10.1016/0014-2999(89)90801-7; ZENG DW, 1990, P NATL ACAD SCI USA, V87, P3102, DOI 10.1073/pnas.87.8.3102	70	253	255	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10470	10478						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	1645350				2022-12-25	WOS:A1991FP08600072
J	KELLY, KO; REUVEN, NB; LI, ZW; DEUTSCHER, MP				KELLY, KO; REUVEN, NB; LI, ZW; DEUTSCHER, MP			RNASE PH IS ESSENTIAL FOR TRANSFER-RNA PROCESSING AND VIABILITY IN RNASE-DEFICIENT ESCHERICHIA-COLI-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							POLYNUCLEOTIDE PHOSPHORYLASE; CLONING VECTORS; 3' TERMINUS; TURNOVER; GROWTH; GENE; END; BN	RNase PH is a P(i)-dependent exoribonuclease that can act at the 3' terminus of tRNA precursors in vitro. To obtain information about the function of this enzyme in vivo, the Escherichia coli rph gene encoding RNase PH was interrupted with either a kanamycin resistance or a chloramphenicol resistance cassette and transferred to the chromosome of a variety of RNase-resistant strains. Inactivation of the chromosomal copy of rph eliminated RNase PH activity from extracts and also slowed the growth of many of the strains, particularly ones that already were deficient in RNase T or polynucleotide phosphorylase. Introduction of the rph mutation into a strain already lacking RNases I, II, D, BN, and T resulted in inviability. The rph mutation also had dramatic effects on tRNA metabolism. Using an in vivo suppressor assay we found that elimination of RNase PH greatly decreased the level of su3+ activity in cells deficient in certain of the other RNases. Moreover, in an in vitro tRNA processing system the defect caused by elimination of RNase PH was shown to be the accumulation of a precursor that contained 4-6 additional 3' nucleotides following the -CCA sequence. These data indicate that RNase PH can be an essential enzyme for the processing of tRNA precursors.	UNIV CONNECTICUT, CTR HLTH, DEPT BIOCHEM, FARMINGTON, CT 06030 USA	University of Connecticut			Reuven, Nina/AAM-8711-2020	Reuven, Nina/0000-0003-1569-3818	NIGMS NIH HHS [GM16317] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHA PK, 1983, P NATL ACAD SCI-BIOL, V80, P3301, DOI 10.1073/pnas.80.11.3301; BLOUIN RT, 1983, J BIOL CHEM, V258, P1423; BRENNER S, 1965, J MOL BIOL, V13, P629, DOI 10.1016/S0022-2836(65)80131-0; CUDNY H, 1988, J BIOL CHEM, V263, P1518; DEUTSCHER MP, 1985, P NATL ACAD SCI USA, V82, P6427, DOI 10.1073/pnas.82.19.6427; DEUTSCHER MP, 1988, P NATL ACAD SCI USA, V85, P4710, DOI 10.1073/pnas.85.13.4710; DONOVAN WP, 1986, P NATL ACAD SCI USA, V83, P120, DOI 10.1073/pnas.83.1.120; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; KELLY KO, 1992, J BIOL CHEM, V267, P17153; LARSEN JEL, 1984, GENE, V28, P45, DOI 10.1016/0378-1119(84)90086-6; MCMURRY LM, 1987, J BACTERIOL, V169, P1321, DOI 10.1128/jb.169.3.1321-1324.1987; Miller J. H., 1972, EXPT MOL GENETICS, P433; OST KA, 1991, J BACTERIOL, V173, P5589, DOI 10.1128/jb.173.17.5589-5591.1991; OST KA, 1990, BIOCHIMIE, V72, P813, DOI 10.1016/0300-9084(90)90190-R; PADMANABHA KP, 1991, J BACTERIOL, V173, P1376, DOI 10.1128/jb.173.4.1376-1381.1991; POULSEN P, 1984, EMBO J, V3, P1783, DOI 10.1002/j.1460-2075.1984.tb02046.x; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZANIEWSKI R, 1984, J BIOL CHEM, V259, P1651	19	42	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16015	16018						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1644789				2022-12-25	WOS:A1992JJ45800003
J	ITABE, H; KING, WC; REYNOLDS, CN; GLOMSET, JA				ITABE, H; KING, WC; REYNOLDS, CN; GLOMSET, JA			SUBSTRATE-SPECIFICITY OF A COA-DEPENDENT STEAROYL TRANSACYLASE FROM BOVINE TESTIS MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; RAT-LIVER MICROSOMES; PHOSPHATIDYLCHOLINE; PHOSPHOLIPIDS; CONVERSION; SEPARATION; ACYLATION	We identified a CoA-dependent stearoyl transacylase activity in bovine testis membranes, then examined the enzyme's specificity in mixed micelle systems containing the neutral detergent Triton X-100. The enzyme transferred stearoyl groups from a variety of phospholipids to sn-2-arachidonoyl lysophosphatidic acid (lysoPA), but showed very little palmitoyl transacylase activity. Its ability to transfer stearoyl groups was both donor- and acceptor-dependent. For example, it used weakly acidic phospholipids, such as sn-1-stearoyl-2-acyl species of phosphatidylinositol (PI), as donors, but did not use phosphatidylinositol-4,5-bisphosphate or sn-1-stearoyl-2-arachidonoyl phosphatidylcholine. Moreover, it used sn-2-acyl species of lysoPA and sn-2-arachidonoyl lysoPI as acceptors but did not use sn-2-arachidonoyl species of lysophosphatidylserine, lysophosphatidylethanolamine, or lysophosphatidylcholine. When taken together, our results raise the possibility that sn-1-stearoyl-2-acyl species of PI may be the primary acyl donors in the transacylase reaction in vivo, while sn-2-acyl species of lysoPA may be the primary acyl acceptors. Available evidence suggests that the PA that is formed may subsequently be converted into PI, but the metabolic fate of the other reaction product, sn-2-acyl lysoPI, remains to be determined.	UNIV WASHINGTON,HOWARD HUGHES MED INST,DEPT MED,SL-15,SEATTLE,WA 98195; UNIV WASHINGTON,HOWARD HUGHES MED INST,DEPT BIOCHEM,SEATTLE,WA 98195; UNIV WASHINGTON,REG PRIMATE RES CTR,SEATTLE,WA 98195	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle			板部板部, 洋之/ABC-7746-2020		NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000166] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00166] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; DARNELL JC, 1991, BIOCHIM BIOPHYS ACTA, V1084, P292, DOI 10.1016/0005-2760(91)90071-O; DAVIDSON FM, 1958, BIOCHEM J, V69, P458, DOI 10.1042/bj0690458; Eggstein M., 1974, METHOD ENZYMAT AN, V4, P1825; HESS HH, 1975, ANAL BIOCHEM, V63, P607, DOI 10.1016/0003-2697(75)90388-7; HOLUB BJ, 1976, LIPIDS, V11, P251, DOI 10.1007/BF02544050; JUNEJA LR, 1988, BIOCHIM BIOPHYS ACTA, V960, P334, DOI 10.1016/0005-2760(88)90041-0; JUNEJA LR, 1989, BIOCHIM BIOPHYS ACTA, V1003, P277, DOI 10.1016/0005-2760(89)90233-6; LEPAGE G, 1986, J LIPID RES, V27, P114; MASUZAWA Y, 1989, BIOCHIM BIOPHYS ACTA, V1005, P1, DOI 10.1016/0005-2760(89)90024-6; NAKAGAWA Y, 1986, J CHROMATOGR, V381, P225, DOI 10.1016/S0378-4347(00)83588-4; NAKAGAWA Y, 1989, PROG LIPID RES, V28, P205, DOI 10.1016/0163-7827(89)90013-1; PATTON GM, 1982, J LIPID RES, V23, P190; SIMPSON CMF, 1991, J BIOL CHEM, V266, P15902; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; WALSH JP, 1990, J BIOL CHEM, V265, P4374	17	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15319	15325						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1639778				2022-12-25	WOS:A1992JG11300013
J	ALBRIGHT, JF; OPPENHEIM, JJ				ALBRIGHT, JF; OPPENHEIM, JJ			CONTEMPORARY TOPICS IN IMMUNOLOGY - APPROACHES TO IMMUNOTHERAPY EMERGING FROM BASIC RESEARCH	FASEB JOURNAL			English	Article						T-CELL RECEPTOR MHC PEPTIDE INTERACTIONS; B-CELL TOLERANCE; ANERGY-INFLAMMATORY DISEASE; TRANSGENIC RATS; INTERLEUKIN-10; TRANSFORMING GROWTH FACTOR-BETA	CELL STIMULATORY FACTOR; B-CELLS	The seventh symposium in thc series "Contemporary Topics in Immunology" was held on April 21, 1991, at the FASEB meeting in Atlanta, Georgia. It was sponsored by the National Institute of Allergy and Infectious Diseases, The American Association of Immunologists, and the Clinical Immunology Society. Five topics were discussed by leading researchers in areas of immunology that currently are of exceptional interest and show promise of leading to new advances in the prevention and treatment of human diseases. The topics included: the interactions between immunogenic peptides, class I MHC molecules and T cell receptors; initiation, maintenance, and breakdown of self-tolerance in B lymphocytes; inflammatory disease in HLA-B27 transgenic rats; properties and functions of interleukin-10; and transforming growth factor-beta in reproductive immunology. The exceptional quality of the presentations in this seventh symposium exemplified perfectly the path of basic research that often leads from the laboratory to the clinic.	NCI,FREDERICK CANC RES FACIL,MOLEC IMMUNOREGULAT LAB,FREDERICK,MD 21701	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	ALBRIGHT, JF (corresponding author), NIAID,DIV ALLERGY IMMUNOL & TRANSPLANTAT,BASIC IMMUNOL BRANCH,BETHESDA,MD 20892, USA.							ADELSTEIN S, 1991, SCIENCE, V251, P1223, DOI 10.1126/science.1900950; ALTMAN DJ, 1990, J EXP MED, V172, P1391, DOI 10.1084/jem.172.5.1391; GO NF, 1990, J EXP MED, V172, P1625, DOI 10.1084/jem.172.6.1625; HAMMER RE, 1990, CELL, V63, P1099, DOI 10.1016/0092-8674(90)90512-D; LEE F, 1986, P NATL ACAD SCI USA, V83, P2061, DOI 10.1073/pnas.83.7.2061; VANBLEEK GM, 1990, NATURE, V348, P213	6	3	3	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1992	6	11					2890	2894		10.1096/fasebj.6.11.1644254	http://dx.doi.org/10.1096/fasebj.6.11.1644254			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JJ665	1644254				2022-12-25	WOS:A1992JJ66500002
J	LONGSTREET, M; MILLER, B; HOWE, PH				LONGSTREET, M; MILLER, B; HOWE, PH			LOSS OF TRANSFORMING GROWTH FACTOR-BETA-1 (TGF-BETA-1)-INDUCED GROWTH ARREST AND P34(CDC2) REGULATION IN RAS-TRANSFECTED EPITHELIAL-CELLS	ONCOGENE			English	Article							CDC2 PROTEIN-KINASE; FACTOR-BETA; TGF-BETA; C-MYC; RETINOBLASTOMA PROTEIN; HISTONE-H1 KINASE; INHIBITION; PHOSPHORYLATION; PROLIFERATION; EXPRESSION	Transforming growth factor beta-1 (TGF-beta-1) is a potent inhibitor of mink lung epithelial (CCL64) cell growth in culture. The fact that many transformed epithelial cells have escaped from negative growth control by TGF-beta-1 suggests that transfected epithelial cells may be an appropriate model for investigating the growth-inhibitory mechanism of TGF-beta-1. We transfected CCL64 cells with a mouse c-myc oncogene (pSVc-myc1), a mutated Harvey-ras (Ha-ras) oncogene, or a combination of both. The results indicate that cells transfected with c-myc alone exhibit normal morphology and maintain sensitivity to TGF-beta-1 growth arrest, but are unable to form colonies in soft agar in the presence or absence of FGF-beta-1. Cells transfected with Ha-ras, or co-transfected with c-myc, display a transformed morphology, grow spontaneously under anchorage-independent conditions and acquire a complete resistance to growth inhibition by TGF-beta-1. Affinity cross-linking of [I-125]TGF-beta-1 to cell-surface receptors from these transfectants revealed that all three TGF-beta receptor types were present and no significant differences in [I-125]TGF-beta-1 labeling of these receptors was observed. Since we have previously demonstrated that modulation of p34cdc2 kinase is a marker for TGF-beta-1 growth inhibition, we investigated p34cdc2 activity in the CCL64 transfected clones. The results show that in the control CCL64 cells and in the myc-transfected clones TGF-beta-1 regulation of p34cdc2 activity is maintained. In the ras- and ras + myc-transfected cells p34cdc2 phosphorylation and histone HI kinase activity is significantly increased and regulation by TGF-beta-1 is lost.	CLEVELAND CLIN,RES INST,DEPT CELL BIOL,NC1-145,CLEVELAND,OH 44106	Cleveland Clinic Foundation					NCI NIH HHS [CA-55536] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055536, R29CA055536] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARRETT CB, 1990, MOL CELL BIOL, V10, P310, DOI 10.1128/MCB.10.1.310; BOYD FT, 1989, J BIOL CHEM, V264, P2272; CHANEY WG, 1986, SOMAT CELL MOLEC GEN, V12, P237, DOI 10.1007/BF01570782; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COFFEY RJ, 1986, CANCER RES, V44, P2230; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; HADDOW S, 1991, ONCOGENE, V6, P1465; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HOUCK KA, 1989, ONCOGENE, V4, P19; HOWE PH, 1991, MOL CELL BIOL, V11, P1185, DOI 10.1128/MCB.11.3.1185; HOWE PH, 1990, BIOCHEM J, V266, P537, DOI 10.1042/bj2660537; HOWE PH, 1989, CANCER RES, V49, P6024; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KNABBE C, 1987, CELL, V48, P417, DOI 10.1016/0092-8674(87)90193-0; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEE MG, 1988, NATURE, V333, P676, DOI 10.1038/333676a0; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LEOF EB, 1987, MOL CELL BIOL, V7, P2649, DOI 10.1128/MCB.7.7.2649; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; Maniatis T., 1982, MOL CLONING; MANNING AM, 1991, ONCOGENE, V6, P1471; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MASUI T, 1986, P NATL ACAD SCI USA, V83, P2438, DOI 10.1073/pnas.83.8.2438; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; ROBERTS AB, 1985, P NATL ACAD SCI USA, V82, P119, DOI 10.1073/pnas.82.1.119; SHIPLEY GD, 1986, CANCER RES, V46, P2068; STROM SC, 1991, DIGEST DIS SCI, V5, P642; TAYA Y, 1989, BIOCHEM BIOPH RES CO, V164, P580, DOI 10.1016/0006-291X(89)91759-2; WAKEFIELD LM, 1987, J CELL BIOL, V105, P965, DOI 10.1083/jcb.105.2.965; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; ZENTELLA A, 1991, MOL CELL BIOL, V11, P4952, DOI 10.1128/MCB.11.10.4952	38	49	49	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1992	7	8					1549	1556						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1630817				2022-12-25	WOS:A1992JE81300011
J	ZHANG, W; HU, GY; ESTEY, E; HESTER, J; DEISSEROTH, A				ZHANG, W; HU, GY; ESTEY, E; HESTER, J; DEISSEROTH, A			ALTERED CONFORMATION OF THE P53 PROTEIN IN MYELOID-LEUKEMIA CELLS AND MITOGEN-STIMULATED NORMAL BLOOD-CELLS	ONCOGENE			English	Note							POLYMERASE CHAIN-REACTION; MONOCLONAL-ANTIBODIES; GENE-MUTATIONS; BREAST-CANCER; PHOSPHORYLATION; RETINOBLASTOMA; EXPRESSION; ONCOGENE; OCCUR	Expression of the normal p53 gene promotes cell differentiation, maturation and apoptosis. The mutant p53 gene, which does not function normally, is frequently expressed at elevated levels in tumor cells [for review see Lane, D.P. & Benchimol, S. (1990). Genes Dev., 4, 1-81. We have analysed the expression of and mutational change in the p53 gene in the peripheral blood cells of 49 primary acute myeloid leukemia (AML) patients. The p53 protein levels were elevated in 37 patients (75%) when measured by immunoprecipitation with antibodies PAb1801 and PAb421, which recognize both normal and mutant forms of the protein. The p53 protein from 32 of these 37 patients was immunoprecipitated by PAb240, which recognizes a conformation of p53 protein associated with point mutations. However, point mutations were detected by single-stranded conformation polymorphism (SSCP) assay and direct sequencing in only three patients at codons 178, 245, 273 and 290. Growth stimulation of normal lymphocytes also generated p53 which was immunoprecipitable by PAb240. Thus, alteration of p53 conformation, rather than acquisition of point mutations, could be the mechanism underlying the increased proliferation of myeloid cells in most AML patients.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT HEMATOL,BOX 24,1515 HOLCOMBE BLVD,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center								BAKER SJ, 1990, CANCER RES, V50, P7717; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARTEK J, 1990, ONCOGENE, V5, P893; BENFENATI F, 1990, J BIOL CHEM, V265, P12584; FENAUX P, 1991, BLOOD, V78, P1652; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HU G, 1992, IN PRESS BR J HAEMAT; HURLEY JH, 1990, SCIENCE, V249, P1012, DOI 10.1126/science.2204109; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; KASTAN MB, 1991, CANCER RES, V51, P4279; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MURAKAMI Y, 1991, ONCOGENE, V6, P37; MURPHREE AL, 1984, SCIENCE, V223, P1028, DOI 10.1126/science.6320372; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; STANBRIDGE EJ, 1990, ANNU REV GENET, V24, P615; SUGIMOTO K, 1991, BLOOD, V77, P1153; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	25	93	94	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1992	7	8					1645	1647						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1630824				2022-12-25	WOS:A1992JE81300022
J	PUSHKAREVA, MY; KHAN, WA; ALESSENKO, AV; SAHYOUN, N; HANNUN, YA				PUSHKAREVA, MY; KHAN, WA; ALESSENKO, AV; SAHYOUN, N; HANNUN, YA			SPHINGOSINE ACTIVATION OF PROTEIN-KINASES IN JURKAT T-CELLS - INVITRO PHOSPHORYLATION OF ENDOGENOUS PROTEIN SUBSTRATES AND SPECIFICITY OF ACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; EPIDERMOID CARCINOMA-CELLS; LONG-CHAIN BASES; SPHINGOMYELIN TURNOVER; SIGNAL TRANSDUCTION; HUMAN-PLATELETS; HL-60 CELLS; INHIBITION; DIFFERENTIATION; HEPARIN	Sphingosine displays multiple biochemical and biological effects, in particular inhibition and activation of protein kinases. To determine the predominant interaction of sphingosine with cellular kinases, the effects of sphingosine on endogenous protein phosphorylation in Jurkat T lymphoblastic cells were investigated in vitro. Sphingosine was found to cause prominent phosphorylation of a number of cytosolic proteins ranging in molecular mass from 18 to 165 kDa. Phosphorylation was calcium-independent. Phosphorylation of substrates was increased in response to concentrations of sphingosine as low as 10-mu-M and peaked at concentrations of 20-200-mu-M. Multiple lines of evidence suggested that sphingosine activated more than one protein kinase: 1) the concentration dependence on sphingosine differed from substrate to substrate, 2) phosphorylation of one group of substrates required ATP as the phosphate donor, whereas a second group showed no preference between ATP and GTP, and 3) phosphorylation of some substrates was inhibited by heparin, whereas other substrates were resistant. Activation of these kinases demonstrated a very specific requirement for D-erythro-sphingoid bases. DL-erythro-dihydrosphingosine was partially active, whereas DL-threo-dihydrosphingosine was not. Other related molecules such as stearylamine, sphingomyelin, and C2-ceramide were not active. Sphingosine-activated kinase(s) were distinct from protein kinase C, cyclic nucleotide-activated kinases, and calcium-dependent kinases. These observations demonstrate the existence of multiple sphingosine-activated protein kinases with high specificity for D-erythro-sphingosine, suggesting physiologic regulation of protein phosphorylation by sphingosine.	DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710; ACAD SCI RUSSIA,INST CHEM PHYS,MOSCOW,USSR; BURROUGHS WELLCOME CO,DIV CELL BIOL,RES TRIANGLE PK,NC 27709	Duke University; Russian Academy of Sciences; N.N. Semenov Federal Research Centre for Chemical Physics, Russian Academy of Sciences; Burroughs Wellcome Fund	PUSHKAREVA, MY (corresponding author), DUKE UNIV,MED CTR,DEPT MED,BOX 3355 DUMC,DURHAM,NC 27710, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043825, R37GM043825] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-43825] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ARNOLD RS, 1991, BIOCHEMISTRY-US, V30, P7747, DOI 10.1021/bi00245a011; CASTELLOT JJ, 1989, J CELL BIOL, V109, P3147, DOI 10.1083/jcb.109.6.3147; CONKLING PR, 1989, J BIOL CHEM, V264, P18440; CRISS WE, 1978, CANCER RES, V38, P3532; DAVIS RJ, 1988, J BIOL CHEM, V263, P5373; FAUCHER M, 1988, J BIOL CHEM, V263, P5319; GOLDKORN T, 1991, J BIOL CHEM, V266, P16092; GOUELI SA, 1991, FEBS LETT, V282, P445, DOI 10.1016/0014-5793(91)80533-9; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1987, J BIOL CHEM, V262, P13620; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HATHAWAY GM, 1984, J BIOL CHEM, V259, P7011; HATHAWAY GM, 1980, J BIOL CHEM, V255, P8038; HATHAWAY GM, 1982, CURR TOP CELL REGUL, V21, P101; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; JEFFERSON AB, 1988, J BIOL CHEM, V263, P15241; KIM MY, 1991, J BIOL CHEM, V266, P484; KISS Z, 1990, J BIOL CHEM, V265, P7345; KUENZEL EA, 1985, P NATL ACAD SCI USA, V82, P737, DOI 10.1073/pnas.82.3.737; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVIE Y, 1990, J BIOL CHEM, V265, P3868; LAVIE Y, 1990, FEBS LETT, V277, P7, DOI 10.1016/0014-5793(90)80796-L; LOHSE MJ, 1989, P NATL ACAD SCI USA, V86, P3011, DOI 10.1073/pnas.86.9.3011; MAVIS RD, 1972, J BIOL CHEM, V247, P2835; MCDONALD OB, 1991, J BIOL CHEM, V266, P21773; MERRILL AH, 1989, BIOCHIM BIOPHYS ACTA, V1010, P131, DOI 10.1016/0167-4889(89)90152-3; MERRILL AH, 1986, J BIOL CHEM, V261, P2610; MERRILL AH, 1989, BIOCHEMISTRY-US, V28, P3138, DOI 10.1021/bi00434a004; MORI T, 1980, J BIOL CHEM, V255, P8378; MULLMANN TJ, 1991, J BIOL CHEM, V266, P2013; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; ROSE KM, 1981, J BIOL CHEM, V256, P7468; SAKANE F, 1989, FEBS LETT, V255, P409, DOI 10.1016/0014-5793(89)81134-2; SOHAL PS, 1990, J BIOL CHEM, V265, P11746; TAUZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; WEISS B, 1982, BIOCHEM PHARMACOL, V13, P2217; WILSON E, 1986, J BIOL CHEM, V261, P2616; WRENN RW, 1981, LIFE SCI, V29, P725, DOI 10.1016/0024-3205(81)90026-6; ZHANG H, 1990, J BIOL CHEM, V265, P76; ZHU XX, 1989, J BIOL CHEM, V264, P14556	44	80	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15246	15251						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634554				2022-12-25	WOS:A1992JF08800108
J	VOLLENWEIDER, F; IRMINGER, JC; GROSS, DJ; VILLAKOMAROFF, L; HALBAN, PA				VOLLENWEIDER, F; IRMINGER, JC; GROSS, DJ; VILLAKOMAROFF, L; HALBAN, PA			PROCESSING OF PROINSULIN BY TRANSFECTED HEPATOMA (FAO) CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONSTITUTIVE SECRETORY PATHWAY; MURINE LEUKEMIA-VIRUS; PANCREATIC BETA-CELL; MAMMARY-TUMOR VIRUS; RAT HEPATOCYTES; EXPRESSION; INSULIN; PROALBUMIN; PRECURSOR; CDNA	Rat hepatoma (FAO) cells were stably transfected with the gene encoding either rat proinsulin II (using the DOL retroviral vector) or human proinsulin (using the RSV retroviral vector). Using the DOL vector, production of insulin immunoreactive material was stimulated up to 30-fold by dexamethasone (5 x 10(-7) M). For both proinsulins, fractional release of immunoreactive material relative to cellular content was high, in keeping with the absence of any storage compartment for secretory proteins in these cells. Pulse-chase experiments showed kinetics of release of newly synthesized products in keeping with release via the constitutive pathway. High performance liquid chromatography analysis showed immunoreactivity in the medium distributed between three peaks. For rat proinsulin II, the first coeluted with intact proinsulin; the second coeluted with des-64,65 split proinsulin (the product of endoproteolytic attack between the insulin A-chain and C-peptide followed by trimming of C-terminal basic residues by carboxypeptidase); the third (and minor peak) coeluted with native (fully processed) insulin. For human proinsulin, by contrast, the second peak coeluted with des-31,32 split proinsulin (split and trimmed at the B-chain/C-peptide junction). Analysis of cellular extracts showed intact proinsulin as the major product. The generation of the putative conversion intermediates and insulin was not due to proteolysis of proinsulin after its release but rather to an intracellular event. The data suggest that proinsulin, normally processed in secretory granules and released via the regulated pathway, may also be processed, albeit less efficiently, by the constitutive pathway conversion machinery. The comparison of the sites preferentially cleaved in rat II or human proinsulin suggests cleavage by endoprotease(s) with a preference for R/KXR/KR as substrate.	UNIV GENEVA,MED CTR,LABS RECH LOUIS JEANTET,1 RUE MICHEL SERVET,CH-1211 GENEVA 4,SWITZERLAND; HADASSAH UNIV HOSP,DEPT ENDOCRINOL & METAB,JERUSALEM,ISRAEL; CHILDRENS HOSP MED CTR,DEPT NEUROL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	University of Geneva; Hebrew University of Jerusalem; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School					NIDDK NIH HHS [DK-35292] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035292] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACKER JM, 1990, J BIOL CHEM, V265, P14828; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BATHURST IC, 1987, SCIENCE, V235, P348, DOI 10.1126/science.3541206; BENTLEY AK, 1986, CELL, V45, P343, DOI 10.1016/0092-8674(86)90319-3; BRENNAN SO, 1991, J BIOL CHEM, V266, P21504; BRENNAN SO, 1988, FEBS LETT, V229, P167, DOI 10.1016/0014-5793(88)80819-6; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CELANDER D, 1987, J VIROL, V61, P269, DOI 10.1128/JVI.61.2.269-275.1987; COHEN RM, 1986, METABOLISM, V35, P1137, DOI 10.1016/0026-0495(86)90027-2; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; DUCKWORTH WC, 1988, BIOCHEM J, V255, P277; FOSTER DC, 1990, BIOCHEMISTRY-US, V29, P347, DOI 10.1021/bi00454a007; FULLER RS, 1988, ANNU REV PHYSIOL, V50, P345, DOI 10.1146/annurev.ph.50.030188.002021; FULLER RS, 1989, SCIENCE, V246, P482, DOI 10.1126/science.2683070; GERMAIN D, 1990, MOL ENDOCRINOL, V4, P1572, DOI 10.1210/mend-4-10-1572; GOLD G, 1988, BIOCHEM BIOPH RES CO, V156, P457, DOI 10.1016/S0006-291X(88)80863-5; GROSS D, 1988, FEBS LETT, V241, P205, DOI 10.1016/0014-5793(88)81062-7; GROSS DJ, 1989, J BIOL CHEM, V264, P21486; GROSS DJ, 1989, P NATL ACAD SCI USA, V86, P4107, DOI 10.1073/pnas.86.11.4107; GRUSS P, 1981, P NATL ACAD SCI-BIOL, V78, P133, DOI 10.1073/pnas.78.1.133; HALBAN PA, 1991, DIABETOLOGIA, V34, P767, DOI 10.1007/BF00408349; HALBAN PA, 1990, TRENDS ENDOCRIN MET, V1, P261, DOI 10.1016/1043-2760(90)90007-P; HALBAN PA, 1980, J BIOL CHEM, V255, P6003; HATSUZAWA K, 1990, J BIOL CHEM, V265, P22075; HATZOGLOU M, 1988, J BIOL CHEM, V263, P17798; HEDO JA, 1983, J BIOL CHEM, V258, P20; HERBERT V, 1965, J CLIN ENDOCR METAB, V25, P1375, DOI 10.1210/jcem-25-10-1375; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; Hutton JC, 1990, CURR OPIN CELL BIOL, V2, P1131, DOI 10.1016/0955-0674(90)90167-D; JUDAH JD, 1978, NATURE, V271, P384, DOI 10.1038/271384a0; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; KORNER J, 1991, P NATL ACAD SCI USA, V88, P6834, DOI 10.1073/pnas.88.15.6834; LAUB O, 1983, J BIOL CHEM, V258, P6043; LOMEDICO PT, 1982, P NATL ACAD SCI-BIOL, V79, P5798, DOI 10.1073/pnas.79.19.5798; MISUMI Y, 1984, FEBS LETT, V175, P63, DOI 10.1016/0014-5793(84)80570-0; MISUMI Y, 1991, J BIOL CHEM, V266, P16954; MISUMI Y, 1990, BIOCHEM BIOPH RES CO, V171, P236, DOI 10.1016/0006-291X(90)91382-3; MIZUNO K, 1989, BIOCHEM BIOPH RES CO, V164, P780, DOI 10.1016/0006-291X(89)91527-1; MOORE HPH, 1983, CELL, V35, P531, DOI 10.1016/0092-8674(83)90187-3; ODA K, 1983, EUR J BIOCHEM, V135, P209, DOI 10.1111/j.1432-1033.1983.tb07639.x; ORCI L, 1985, CELL, V42, P671, DOI 10.1016/0092-8674(85)90124-2; OVERHAUSER J, 1985, J VIROL, V54, P133, DOI 10.1128/JVI.54.1.133-144.1985; PODLECKI DA, 1984, DIABETES, V33, P111, DOI 10.2337/diabetes.33.2.111; QUINN D, 1991, J CELL BIOL, V113, P987, DOI 10.1083/jcb.113.5.987; REDDING K, 1991, J CELL BIOL, V113, P527, DOI 10.1083/jcb.113.3.527; REDMAN CM, 1978, J CELL BIOL, V77, P400, DOI 10.1083/jcb.77.2.400; REDMAN CM, 1983, J BIOL CHEM, V258, P3446; RHODES CJ, 1987, J CELL BIOL, V105, P145, DOI 10.1083/jcb.105.1.145; RINGOLD GM, 1975, CELL, V6, P299, DOI 10.1016/0092-8674(75)90181-6; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SHENNAN KIJ, 1991, FEBS LETT, V284, P277, DOI 10.1016/0014-5793(91)80703-6; SIZONENKO SV, 1991, BIOCHEM J, V278, P621, DOI 10.1042/bj2780621; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; THOMAS G, 1988, ANNU REV PHYSIOL, V50, P323; VANDEVEN WJM, 1990, MOL BIOL REP, V14, P265, DOI 10.1007/BF00429896; WEISS MA, 1990, BIOCHEMISTRY-US, V29, P8389, DOI 10.1021/bi00488a028; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9378, DOI 10.1073/pnas.87.23.9378; ZOLLINGER L, 1988, MOL CELL ENDOCRINOL, V58, P31, DOI 10.1016/0303-7207(88)90051-2	62	60	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14629	14636						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634510				2022-12-25	WOS:A1992JF08800024
J	SUZUKI, K; NISHIOKA, J				SUZUKI, K; NISHIOKA, J			A THROMBIN-BASED PEPTIDE CORRESPONDING TO THE SEQUENCE OF THE THROMBOMODULIN-BINDING SITE BLOCKS THE PROCOAGULANT ACTIVITIES OF THROMBIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-C; COAGULATION FACTOR-V; BLOOD-COAGULATION; BOVINE THROMBIN; ALPHA-THROMBIN; COMPLEX; HIRUDIN; INACTIVATION; LOCALIZATION; ANTIBODIES	Thrombomodulin, a cofactor in the thrombin-catalyzed activation of protein C, blocks the procoagulant activities of thrombin such as fibrinogen clotting, Factor V activation, and platelet activation. The binding site for thrombomodulin within human thrombin has been localized at a region comprising residues Thr147-Ser158 of the B-chain of thrombin. The dodecapeptide sequence, TWTANVGKGQPS, corresponding to these residues inhibits thrombin binding to thrombomodulin with an apparent K(i) = 94-mu-M (Suzuki, K., Nishioka, J., and Hayashi, T. (1990) J. Biol. Chem. 265, 13263-13267). We have found that the inhibitory effect of the dodecapeptide on the thrombin-thrombomodulin interaction is sequence-specific, and that residues Asn151, Lys154, and Gln156 are essential for thrombomodulin binding. The dodecapeptide was also found to directly block thrombin procoagulant activities, fibrinogen clotting (concentration for half-maximum inhibition, 385-mu-M). Factor V activation (concentration for half-maximum inhibition, 33-mu-M), and platelet activation (concentration for half-maximum inhibition, 645-mu-M). This peptide did not block thrombin inhibition by anti-thrombin III, but blocked thrombin inhibition by hirudin. These findings suggest that the binding site for thrombomodulin in thrombin is shared with the sites for fibrinogen, Factor V, platelets, and hirudin, and that, therefore, the inhibition of thrombin procoagulant activities by thrombomodulin in part results from blocking of the interaction between thrombin and the procoagulant protein substrates by thrombomodulin.			SUZUKI, K (corresponding author), MIE UNIV,SCH MED,DEPT MOLEC BIOL GENET DIS,TSU,MIE 514,JAPAN.							DODT J, 1984, FEBS LETT, V165, P180, DOI 10.1016/0014-5793(84)80165-9; DODT J, 1990, J BIOL CHEM, V265, P713; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; ESMON CT, 1982, J BIOL CHEM, V257, P7944; ESMON NL, 1983, J BIOL CHEM, V258, P2238; GRUTTER MG, 1990, EMBO J, V9, P2361, DOI 10.1002/j.1460-2075.1990.tb07410.x; HAYASHI T, 1990, J BIOCHEM-TOKYO, V108, P874, DOI 10.1093/oxfordjournals.jbchem.a123295; HAYASHI T, 1990, J BIOL CHEM, V265, P20156; JACKSON CM, 1980, ANNU REV BIOCHEM, V49, P765, DOI 10.1146/annurev.bi.49.070180.004001; JAKUBOWSKI HV, 1986, J BIOL CHEM, V261, P3876; KURACHI K, 1976, BIOCHEMISTRY-US, V15, P368, DOI 10.1021/bi00647a020; LUNDBLAD RL, 1975, BIOCHEM BIOPH RES CO, V66, P482, DOI 10.1016/0006-291X(75)90536-7; MILETICH JP, 1980, ANAL BIOCHEM, V105, P304, DOI 10.1016/0003-2697(80)90462-5; MUSCI G, 1988, BIOCHEMISTRY-US, V27, P769, DOI 10.1021/bi00402a042; NOE G, 1988, J BIOL CHEM, V263, P11729; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; SUZUKI K, 1989, J BIOL CHEM, V264, P4872; SUZUKI K, 1990, J BIOL CHEM, V265, P13263; SUZUKI K, 1983, J BIOL CHEM, V258, P1914; SUZUKI K, 1982, J BIOL CHEM, V257, P6556; TANGEN D, 1973, SCAND J HAEMATOL, V11, P241; TOMA K, 1989, J MOL GRAPHICS, V7, P146, DOI 10.1016/0263-7855(89)80018-9	22	21	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18498	18501						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1655753				2022-12-25	WOS:A1991GJ47200016
J	OPPERT, B; CUNNICK, JM; HURT, D; TAKEMOTO, DJ				OPPERT, B; CUNNICK, JM; HURT, D; TAKEMOTO, DJ			IDENTIFICATION OF THE RETINAL CYCLIC-GMP PHOSPHODIESTERASE INHIBITORY GAMMA-SUBUNIT INTERACTION SITES ON THE CATALYTIC ALPHA-SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; PHOTORECEPTOR CGMP PHOSPHODIESTERASE; AMINO-ACID-SEQUENCE; NUCLEOTIDE PHOSPHODIESTERASES; SYNTHETIC PEPTIDES; CORRESPONDING CDNA; BOVINE RETINA; BETA-SUBUNIT; BINDING; PROTEIN	Retinal rod outer segment phosphodiesterase (PDE) consists of two similar catalytic subunits (alpha and beta) and two identical inhibitory subunits (gamma-2). A trypsin-activated soluble PDE exhibiting the ability to be reinhibited by PDE-gamma was shown by peptide antisera to retain both N and C termini. Synthetic peptides corresponding to residues 16-30, 78-90, 389-403, and 535-563 of PDE-alpha used in a PDE activity assay with trypsin-activated PDE partially prevented inhibition by exogenous PDE-gamma; however, only competitions by peptides 16-30 and 78-90 (corresponding to PDE-alpha 16-30 and 78-90) were concentration-dependent below 100 nmol of peptide. Binding studies using radio-immunoassays and PDE-alpha peptides confirmed that peptides 16-30 and 78-90 (corresponding to PDE-alpha 16-30 and 78-90, respectively) were able to bind PDE-gamma. Additionally, peptides corresponding to the PDE-alpha region 453-534 bound PDE-gamma in the binding assay. This suggests that several regions on PDE-alpha interact with the PDE-gamma inhibitor. While some regions may be involved in binding to PDE-gamma, other sites may be involved in PDE-gamma inhibition of catalytic activity. Our results suggest that the major regions of PDE-alpha that interact with PDE-gamma reside within the N terminus (16-30 and 78-90), with weaker interaction regions within or near the hypothesized catalytic domain (453-563). Sequence analysis of three retinal phosphodiesterases (rod outer segment-alpha, beta, and cone outer segment-alpha') revealed the highest region of dissimilarity in the N and C termini.			OPPERT, B (corresponding author), KANSAS STATE UNIV AGR & APPL SCI, DEPT BIOCHEM, MANHATTAN, KS 66506 USA.		Cunnick, Jess/F-1715-2018		NEI NIH HHS [EY06490] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BAEHR W, 1979, J BIOL CHEM, V254, P1669; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN RL, 1989, P NATL ACAD SCI USA, V86, P4922, DOI 10.1073/pnas.86.13.4922; CHARBONNEAU H, 1986, P NATL ACAD SCI USA, V83, P9308, DOI 10.1073/pnas.83.24.9308; CHARBONNEAU H, 1990, P NATL ACAD SCI USA, V87, P288, DOI 10.1073/pnas.87.1.288; CUNNICK JM, 1990, BIOCHEM J, V271, P721, DOI 10.1042/bj2710721; DETERRE P, 1988, P NATL ACAD SCI USA, V85, P2424, DOI 10.1073/pnas.85.8.2424; FESENKO EE, 1985, NATURE, V313, P310, DOI 10.1038/313310a0; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; GORMAN JJ, 1984, ANAL BIOCHEM, V136, P397, DOI 10.1016/0003-2697(84)90235-5; HURLEY JB, 1982, J BIOL CHEM, V257, P1094; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI T, 1990, P NATL ACAD SCI USA, V87, P293, DOI 10.1073/pnas.87.1.293; Lipkin V M, 1990, Biomed Sci, V1, P305; LIPKIN VM, 1990, BIOORG KHIM+, V16, P118; LIPKIN VM, 1988, FEBS LETT, V234, P287, DOI 10.1016/0014-5793(88)80100-5; LIPKIN VM, 1990, J BIOL CHEM, V265, P12955; LOOKHART GL, 1982, J BIOCHEM BIOPH METH, V7, P15, DOI 10.1016/0165-022X(82)90032-X; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MORRISON DF, 1989, J BIOL CHEM, V264, P11671; OVCHINNIKOV YA, 1987, FEBS LETT, V223, P169, DOI 10.1016/0014-5793(87)80530-6; OVCHINNIKOV YA, 1986, FEBS LETT, V201, P237, DOI 10.1016/0014-5793(86)80616-0; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; SITARAMAYYA A, 1986, BIOCHEMISTRY-US, V25, P651, DOI 10.1021/bi00351a021; Stewart J.M., 1984, SOLID PHASE PEPTIDE, V2nd ed., P85; STROOP SD, 1989, J BIOL CHEM, V264, P13718; STRYER L, 1981, TRENDS BIOCHEM SCI, V6, P245, DOI 10.1016/0968-0004(81)90089-X; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; SUTER M, 1982, J IMMUNOL METHODS, V53, P103, DOI 10.1016/0022-1759(82)90244-7; TAKEMOTO DJ, 1985, BIOCHEM BIOPH RES CO, V132, P438, DOI 10.1016/0006-291X(85)91041-1; THOMPSON WJ, 1971, BIOCHEMISTRY-US, V10, P311; WHALEN MM, 1989, BIOCHEM J, V259, P13, DOI 10.1042/bj2590013; YAMAZAKI A, 1983, J BIOL CHEM, V258, P8188	33	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16607	16613						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1653243				2022-12-25	WOS:A1991GD63500060
J	PAK, Y; RYALS, PE; THOMPSON, GA				PAK, Y; RYALS, PE; THOMPSON, GA			PHOSPHATIDYLINOSITOL GLYCAN FORMATION AND UTILIZATION BY THE CILIATE TETRAHYMENA-MIMBRES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTOZOAN TETRAHYMENA; MEMBRANE-ANCHOR; BIOSYNTHESIS; THERMOPHILA; PYRIFORMIS; PRECURSOR; ANTIGENS	Ryals et al. (Ryals, P. E., Pak, Y., and Thompson, G. A., Jr., (199 1) J. Biol. Chem. 266, 15048-15053) have described and partially characterized phosphatidylinositol glycans (PI glycans) present in Tetrahymena mimbres. We now describe the time course of PI glycan labeling from exogenous [H-3]myristate, [C-14]glucosamine, and [H-3]ethanolamine. Over the first 2-12 h following pulse radioisotope addition a sizeable proportion of the radioactivity associated with the protein pellet remaining after cell delipidation existed as PI glycans. These compounds were distributed throughout the cell, with the largest proportion at 12 h being associated with a fraction containing mitochondria, lysosomes, and peroxisomes. However, by 24 h radioactivity had nearly disappeared from the PI glycans and had become associated with proteins by a process that was almost totally inhibited by cycloheximide or tunicamycin. PI glycans appeared to be incorporated mainly into a protein migrating on sodium dodecyl sulfate-polyacrylamide gel electrophoresis in a relatively broad band with an apparent molecular mass of 24-29 kDa. The exact mobility of the protein band within this molecular weight range was dependent upon the growth temperature of the cells. The apparent molecular masses of the principal PI-anchored proteins formed by other closely related Tetrahymena species varied widely, ranging from 22 to 76 kDa. The PI-anchored proteins may belong to a group of surface proteins known as immobilization antigens. Treatment of 24-h-labeled T. mimbres cells with phosphatidylinositol-specific phospholipase C in vivo released labeled proteins from the cells. Some labeled proteins were present even in the medium of control, non-phospholipase-treated cells. Tetrahymena PI glycans appear to accumulate in a metabolic pool from which they are gradually removed for attachment to externally oriented PI-anchored proteins. Tetrahymena is a versatile system well suited for studying the regulation of PI-anchored protein biochemistry.	UNIV TEXAS, DEPT BOT, AUSTIN, TX 78713 USA	University of Texas System; University of Texas Austin				Pak, Yunbae/0000-0002-8594-5673				BANNO Y, 1987, EXP CELL RES, V170, P259, DOI 10.1016/0014-4827(87)90304-1; BANNON GA, 1986, MOL CELL BIOL, V6, P3240, DOI 10.1128/MCB.6.9.3240; BRUNS PJ, 1971, EXP CELL RES, V65, P445, DOI 10.1016/0014-4827(71)90025-5; BYFIELD JE, 1966, ANAL BIOCHEM, V17, P434, DOI 10.1016/0003-2697(66)90179-5; CAPDEVILLE Y, 1987, BIOCHEM BIOPH RES CO, V147, P1219, DOI 10.1016/S0006-291X(87)80200-0; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DOERDER FP, 1986, J PROTOZOOL, V33, P204, DOI 10.1111/j.1550-7408.1986.tb05590.x; DOERING TL, 1990, J BIOL CHEM, V265, P611; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; HAMBURGER K, 1957, EXP CELL RES, V13, P443, DOI 10.1016/0014-4827(57)90074-5; KRAKOW JL, 1986, J BIOL CHEM, V261, P2147; LOW MG, 1987, BIOCHEM J, V244, P1; MENON AK, 1988, J BIOL CHEM, V263, P1970; MENON AK, 1990, EMBO J, V9, P4249, DOI 10.1002/j.1460-2075.1990.tb07873.x; MEYER EB, 1987, ISOZYMES-CURR T BIOL, V13, P61; NOZAWA Y, 1971, J CELL BIOL, V49, P712, DOI 10.1083/jcb.49.3.712; RYALS PE, 1988, ARCH BIOCHEM BIOPHYS, V266, P408, DOI 10.1016/0003-9861(88)90272-X; RYALS PE, 1991, J BIOL CHEM, V266, P15048; RYALS PE, 1987, BIOCHIM BIOPHYS ACTA, V919, P122, DOI 10.1016/0005-2760(87)90198-6; Williams N.E., 1990, P201	20	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15054	15059						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1651318				2022-12-25	WOS:A1991GB09700041
J	KONISHI, K; VANDOREN, SR; KRAMER, DM; CROFTS, AR; GENNIS, RB				KONISHI, K; VANDOREN, SR; KRAMER, DM; CROFTS, AR; GENNIS, RB			PREPARATION AND CHARACTERIZATION OF THE WATER-SOLUBLE HEME-BINDING DOMAIN OF CYTOCHROME C1 FROM THE RHODOBACTER-SPHAEROIDES BC1 COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOCHEMICAL-REACTION CENTER; RHODOPSEUDOMONAS-SPHAEROIDES; PHOTOSYNTHETIC GROWTH; ELECTRON-TRANSFER; MUTANTS; GENE; PURIFICATION; MITOCHONDRIA; CAPSULATUS; REDUCTASE	The ubiquinol:cytochrome c2 oxidoreductase (bc1 complex) of Rhodobacter sphaeroides consists of four subunits. One of these subunits, cytochrome c1, is the site of interaction with cytochrome c2, a periplasmic protein. In addition, the sequences of the fbcC gene and of the cytochrome c1 subunit that it encodes suggest that the protein should be located on the periplasmic side of the cytoplasmic membrane and that it is anchored to the membrane by a single membrane-spanning alpha-helix located at the carboxyl-terminal end of the polypeptide. Site-directed mutagenesis of the fbcC gene was used to alter the codon for Gln228 to a stop codon. This results in the production of a truncated version of the cytochrome c1 subunit that tacks the membrane anchor at the carboxyl terminus. The bc1 complex fails to assemble properly as a result of this mutation, but the Rb. sphaeroides cells expressing the altered gene contain a water-soluble form of cytochrome c1 in the periplasm. The water-soluble cytochrome c1 was purified and characterized. The amino-terminal sequence is identical with that of the membrane-bound subunit, indicating the signal sequence is properly processed. High pressure liquid chromatography gel filtration chromatography indicates it is monomeric (28 kDa). The heme content and electrochemical properties are similar to those of the intact subunit within the complex. Flash-induced electron transfer kinetics measured using whole cells demonstrated that the water-soluble cytochrome c1 is competent as a reductant for cytochrome c2 within the periplasmic space. These data show that the isolated water-soluble cytochrome c1 retains many of the properties of the membrane-bound subunit of the bc1 complex and, therefore, will be useful for further structural and functional characterization.	UNIV ILLINOIS,DEPT BIOCHEM,URBANA,IL 61801; UNIV ILLINOIS,DEPT CHEM,URBANA,IL 61801; UNIV ILLINOIS,DEPT PHYSIOL & BIOPHYS,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign			; Kramer, David/B-9588-2016	Van Doren, Steven/0000-0003-2838-4598; Kramer, David/0000-0003-2181-6888	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035438, R01GM026305] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35438, GM26305] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS KM, 1990, BIOCHEMISTRY-US, V29, P2645, DOI 10.1021/bi00463a004; ARATA H, 1987, J BIOCHEM-TOKYO, V101, P261, DOI 10.1093/oxfordjournals.jbchem.a121899; CROFTS AR, 1983, BIOCHIM BIOPHYS ACTA, V723, P202, DOI 10.1016/0005-2728(83)90120-2; CROFTS AR, 1986, J BIOENERG BIOMEMBR, V18, P437, DOI 10.1007/BF00743014; DALDAL F, 1986, P NATL ACAD SCI USA, V83, P2012, DOI 10.1073/pnas.83.7.2012; DONOHUE TJ, 1988, BIOCHEMISTRY-US, V27, P1918, DOI 10.1021/bi00406a018; Dutton P L, 1978, Methods Enzymol, V54, P411; FUHROP JH, 1985, PORPHYRINS METALLOPO, P804; GABELLINI N, 1988, J BIOENERG BIOMEMBR, V20, P59, DOI 10.1007/BF00762138; GERHUS E, 1990, J BACTERIOL, V172, P2392, DOI 10.1128/jb.172.5.2392-2400.1990; GONZALEZHALPHEN D, 1988, BIOCHEMISTRY-US, V27, P7021, DOI 10.1021/bi00418a053; HASE T, 1987, J BIOCHEM-TOKYO, V102, P411, DOI 10.1093/oxfordjournals.jbchem.a122068; HASE T, 1987, J BIOCHEM, V102, P401, DOI 10.1093/oxfordjournals.jbchem.a122067; HAUSKA G, 1983, BIOCHIM BIOPHYS ACTA, V726, P97, DOI 10.1016/0304-4173(83)90002-2; JOLIOT P, 1980, J CHIM PHYS PCB, V77, P209, DOI 10.1051/jcp/1980770209; JOLIOT P, 1989, BIOCHIM BIOPHYS ACTA, V975, P336, DOI 10.1016/S0005-2728(89)80341-X; JONES MR, 1990, BIOCHIM BIOPHYS ACTA, V1019, P59, DOI 10.1016/0005-2728(90)90124-M; KEEN NT, 1988, GENE, V70, P191, DOI 10.1016/0378-1119(88)90117-5; KRAMER DM, 1990, THESIS U ILLINOIS; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI Y, 1981, EUR J BIOCHEM, V116, P199, DOI 10.1111/j.1432-1033.1981.tb05319.x; LJUNGDAHL O, 1987, BIOCHIM BIOPHYS ACTA, V891, P227; MARINUS MG, 1983, MOL GEN GENET, V192, P288, DOI 10.1007/BF00327681; MEINHARDT SW, 1984, THESIS U ILLINOIS; PRESS WH, 1989, NUMERICAL RECIPES, P52; PRINCE RC, 1987, BIOCHIM BIOPHYS ACTA, V894, P370, DOI 10.1016/0005-2728(87)90115-0; PRINCE RC, 1986, BIOCHEMISTRY-US, V25, P5208, DOI 10.1021/bi00366a034; PURVIS DJ, 1990, J BIOL CHEM, V265, P1208; ROMISCH J, 1987, CYTOCHROME SYSTEMS, P303; ROTT MA, 1990, J BACTERIOL, V172, P1954, DOI 10.1128/jb.172.4.1954-1961.1990; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; SISTROM WR, 1962, J GEN MICROBIOL, V28, P607, DOI 10.1099/00221287-28-4-607; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1; VANDEYAR MA, 1988, GENE, V65, P129, DOI 10.1016/0378-1119(88)90425-8; WEISS H, 1979, EUR J BIOCHEM, V99, P139, DOI 10.1111/j.1432-1033.1979.tb13240.x; WILSON E, 1987, J BIOL CHEM, V260, P10288; YU L, 1985, J BIOL CHEM, V260, P963; YU L, 1984, J BIOL CHEM, V259, P5752; YUN CH, 1990, EUR J BIOCHEM, V194, P399, DOI 10.1111/j.1432-1033.1990.tb15633.x	39	40	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14270	14276						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1650353				2022-12-25	WOS:A1991FZ35100026
J	WALDO, GL; BOYER, JL; MORRIS, AJ; HARDEN, TK				WALDO, GL; BOYER, JL; MORRIS, AJ; HARDEN, TK			PURIFICATION OF AN ALF4- AND G-PROTEIN BETA-GAMMA-SUBUNIT-REGULATED PHOSPHOLIPASE-C-ACTIVATING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TURKEY ERYTHROCYTE-MEMBRANES; GUANINE-NUCLEOTIDE; ADENYLATE-CYCLASE; ALPHA-SUBUNITS; AFFINITY-CHROMATOGRAPHY; P2Y-PURINERGIC RECEPTOR; COMPONENT; GTP; BRAIN; IDENTIFICATION	A 150-kDa phospholipase C has previously been purified from turkey erythrocytes and has been shown by reconstitution with turkey erythrocyte membranes to be a receptor- and G-protein-regulated enzyme (Morris, A. J., Waldo, G. L., Downes, C. P., and Harden, T. K. (1990) J. Biol. Chem. 265, 13501-13507; Morris, A. J., Waldo, G. L., Downes, C. P., and Harden, T. K. (1990) J. Biol. Chem. 265, 13508-13514). Combination of this 150-kDa protein with phosphoinositide substrate-containing phospholipid vesicles prepared with a cholate extract from purified turkey erythrocyte plasma membranes resulted in conference of AlF4- sensitivity to the purified phospholipase C. Guanosine 5'-3-O-(thio)triphosphate also activated the reconstituted phospholipase C in a manner that was inhibited by guanosine 5'-2-O-(thio)-diphosphate. The magnitude of the AlF4- stimulation was increased with increasing amounts of plasma membrane extract, and was also dependent on the concentration of purified phospholipase C. Using reconstitution of AlF4- sensitivity as an assay, the putative G-protein conferring regulation to the 150-kDa phospholipase C was purified to near homogeneity by sequential chromatography over Q-Sepharose, Sephacryl S-300, octyl-Sepharose, hydroxylapatite, and Mono-Q. Reconstituting activity co-purified with an approximately 43-kDa protein identified by silver staining; lesser amounts of a 35-kDa protein was present in the final purified fractions, as was a minor 40-kDa protein. The 43-kDa protein strongly reacted with antiserum against a 12-amino acid sequence found at the carboxyl terminus of G(q) and G11 the 35-kDa protein strongly reacted with G-protein beta-subunit antiserum, and the 40-kDa protein reacted with antiserum that recognizes G(i3). Immunoprecipitation of the 43-kDa protein resulted in loss of phospholipase C-stimulating activity of the purified fraction. The idea that this is a phospholipase C-regulating G-protein is further supported by the observation that co-reconstitution of G-protein beta-gamma-subunit with the purified phospholipase C-activating fraction resulted in a beta-gamma-subunit-dependent inhibition of AlF4--stimulated phospholipase C activity in the reconstituted preparation.	UNIV N CAROLINA,SCH MED,DEPT PHARMACOL,CB 7365,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine			Morris, Andrew/B-7869-2010		NIGMS NIH HHS [GM38213, GM29536] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029536, R01GM038213, R37GM029536] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BOKOCH GM, 1984, J BIOL CHEM, V259, P3560; BOYER JL, 1989, J BIOL CHEM, V264, P13917; BOYER JL, 1989, J BIOL CHEM, V264, P884; COCKCROFT S, 1985, NATURE, V314, P534, DOI 10.1038/314534a0; CODINA J, 1983, P NATL ACAD SCI-BIOL, V80, P4276, DOI 10.1073/pnas.80.14.4276; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOLDSMITH P, 1987, J BIOL CHEM, V262, P14683; HARDEN TK, 1987, J BIOL CHEM, V262, P9057; HARDEN TK, 1988, BIOCHEM J, V252, P583, DOI 10.1042/bj2520583; HARDEN TK, 1989, INOSITOL LIPIDS CELL, P113; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LITOSCH I, 1985, J BIOL CHEM, V260, P5464; MARTIN MW, 1989, J BIOL CHEM, V264, P19535; MARTIN TFJ, 1989, INOSITOL LIPIDS CELL, P81; MORIARTY TM, 1988, P NATL ACAD SCI USA, V85, P8865, DOI 10.1073/pnas.85.23.8865; MORRIS AJ, 1990, J BIOL CHEM, V265, P13501; MORRIS AJ, 1990, J BIOL CHEM, V265, P13508; MORRIS AJ, 1990, G PROTEINS SIGNAL TR, P61; NEER EJ, 1984, J BIOL CHEM, V259, P4222; NORTHUP JK, 1980, P NATL ACAD SCI-BIOL, V77, P6516, DOI 10.1073/pnas.77.11.6516; PANG IH, 1990, J BIOL CHEM, V265, P18707; PANG IH, 1989, P NATL ACAD SCI USA, V86, P7814, DOI 10.1073/pnas.86.20.7814; Ross E M, 1978, Methods Enzymol, V53, P222; SHAFFNER W, 1973, ANAL BIOCHEM, V56, P502; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STERNWEIS PC, 1981, J BIOL CHEM, V256, P1517; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; STRATHMANN M, 1989, P NATL ACAD SCI USA, V86, P7407, DOI 10.1073/pnas.86.19.7407; TAYLOR SJ, 1990, J BIOL CHEM, V265, P17150	33	128	128	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14217	14225						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1650351				2022-12-25	WOS:A1991FZ35100018
J	HORNE, WA; HAWROT, E; TSIEN, RW				HORNE, WA; HAWROT, E; TSIEN, RW			OMEGA-CONOTOXIN GVIA RECEPTORS OF DISCOPYGE ELECTRIC ORGAN - CHARACTERIZATION OF OMEGA-CONOTOXIN BINDING TO THE NICOTINIC ACETYLCHOLINE-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE CALCIUM CHANNELS; TRANSMITTER RELEASE; SKELETAL-MUSCLE; MONOCLONAL-ANTIBODIES; CA-2+ CHANNELS; CA-CHANNEL; NEURONS; BRAIN; LOCALIZATION; SUBUNIT	A peptide toxin from a Conus marine snail, omega-conotoxin GVIA (omega-CgTx) bas been used extensively as a probe for certain types of neuronal calcium channels. It is often assumed that omega-CgTx interacts with Ca2+ channels exclusively. We have tested this assumption in a study of omega-CgTx-binding sites in the electric organ of Discopyge ommata. Synaptosomal membranes from this tissue contain low affinity omega-CgTx receptor sites (K(d) = 0.6-mu-m) in great abundance (280 pmol/mg of protein), as first reported by Ahmad and Miljanich (Ahmad, S. N., and Miljanich, G. P. (1988) Brain Res. 453, 247-256). However, we find that a large majority of these omega-CgTx-binding sites co-purify with the nicotinic acetylcholine receptor (nAChR) and can be immunoprecipitated by monoclonal antibodies generated against the nAChR of Torpedo. Cross-linking experiments with radiolabeled-omega-CgTx show pronounced specific labeling of the alpha-subunit of the nAChR but not other subunits. Specific omega-CgTx binding to the nAChR is reduced by millimolar Ca2+ but not by alpha- or kappa-bungarotoxin, alpha-conotoxin, or carbamylcholine. Cross-linking experiments also reveal omega-CgTx-binding proteins of 170 and 60 kDa. The characteristics of the 170-kDa protein make it a likely candidate for the alpha-1-subunit of an N-type Ca2+ channel.	STANFORD UNIV,BECKMAN CTR,SCH MED,DEPT MOLEC & CELLULAR PHYSIOL,STANFORD,CA 94305; BROWN UNIV,MOLEC & BIOCHEM PHARMACOL SECT,PROVIDENCE,RI 02912	Stanford University; Brown University					NHLBI NIH HHS [HL 38156] Funding Source: Medline; NINDS NIH HHS [NS 24067] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL038156] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024067] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABE T, 1987, J BIOL CHEM, V262, P9877; ABE T, 1986, NEUROSCI LETT, V71, P203, DOI 10.1016/0304-3940(86)90559-8; AHMAD SN, 1988, BRAIN RES, V453, P247; AOSAKI T, 1989, PFLUG ARCH EUR J PHY, V414, P150, DOI 10.1007/BF00580957; BARHANIN J, 1988, BIOCHEM BIOPH RES CO, V150, P1051, DOI 10.1016/0006-291X(88)90736-X; BEAN BP, 1989, ANNU REV PHYSIOL, V51, P367, DOI 10.1146/annurev.physiol.51.1.367; CHASE BA, 1987, NEUROSCIENCE, V21, P959, DOI 10.1016/0306-4522(87)90051-0; CRUZ LJ, 1987, BIOCHEMISTRY-US, V26, P820, DOI 10.1021/bi00377a024; CRUZ LJ, 1986, J BIOL CHEM, V261, P6230; DEUTCH AY, 1987, P NATL ACAD SCI USA, V84, P8697, DOI 10.1073/pnas.84.23.8697; FOSSET M, 1983, J BIOL CHEM, V258, P6086; FROEHNER SC, 1983, J BIOL CHEM, V258, P7112; GRAY WR, 1988, ANNU REV BIOCHEM, V57, P665, DOI 10.1146/annurev.bi.57.070188.003313; HESS P, 1990, ANNU REV NEUROSCI, V13, P1337; HILLE B, 1989, Q J EXP PHYSIOL CMS, V74, P785, DOI 10.1113/expphysiol.1989.sp003349; JONES OT, 1989, SCIENCE, V244, P1189, DOI 10.1126/science.2543080; KASAI H, 1987, Neuroscience Research, V4, P228, DOI 10.1016/0168-0102(87)90014-9; KERR LM, 1984, NATURE, V308, P282, DOI 10.1038/308282a0; KONGSAMUT S, 1989, ANN NY ACAD SCI, V560, P312, DOI 10.1111/j.1749-6632.1989.tb24112.x; KOYANO K, 1987, EUR J PHARMACOL, V135, P337, DOI 10.1016/0014-2999(87)90683-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUNG AT, 1987, J BIOL CHEM, V262, P7943; LINDSTROM J, 1980, BIOCHEMISTRY-US, V19, P1454, DOI 10.1021/bi00548a029; MARQUEZE B, 1988, MOL PHARMACOL, V34, P87; MCCLESKEY EW, 1987, P NATL ACAD SCI USA, V84, P4327, DOI 10.1073/pnas.84.12.4327; MILLER RJ, 1987, SCIENCE, V235, P46, DOI 10.1126/science.2432656; NGSEE JK, 1990, J NEUROSCI, V10, P317; NISHIUCHI Y, 1986, BIOPOLYMERS, V25, P561; NOWYCKY MC, 1985, NATURE, V316, P440, DOI 10.1038/316440a0; PLUMMER MR, 1989, NEURON, V2, P1453, DOI 10.1016/0896-6273(89)90191-8; ROSENBERG R L, 1987, Society for Neuroscience Abstracts, V13, P1011; RUBSAMEN H, 1978, BIOCHEMISTRY-US, V17, P3818; SMITH SJ, 1988, TRENDS NEUROSCI, V11, P458, DOI 10.1016/0166-2236(88)90199-3; TAKAHASHI M, 1987, P NATL ACAD SCI USA, V84, P5478, DOI 10.1073/pnas.84.15.5478; TSIEN RW, 1988, TRENDS NEUROSCI, V11, P431, DOI 10.1016/0166-2236(88)90194-4; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; WAGNER JA, 1988, J NEUROSCI, V8, P3354; YAMAGUCHI T, 1988, J BIOL CHEM, V263, P9491	38	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13719	13725						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1649828				2022-12-25	WOS:A1991FY02700042
J	MOLLER, DE; BENECKE, H; FLIER, JS				MOLLER, DE; BENECKE, H; FLIER, JS			BIOLOGIC ACTIVITIES OF NATURALLY-OCCURRING HUMAN INSULIN-RECEPTOR MUTATIONS - EVIDENCE THAT METABOLIC EFFECTS OF INSULIN CAN BE MEDIATED BY A KINASE-DEFICIENT INSULIN-RECEPTOR MUTANT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-I; HUMAN-SKIN FIBROBLASTS; TYROSINE KINASE; MONOCLONAL-ANTIBODIES; GLUCOSE TRANSPORTER; ACANTHOSIS NIGRICANS; BETA-SUBUNIT; GENE; RESISTANCE; CELLS	We have studied insulin receptor-mediated signaling in Chinese hamster ovary (CHO) cell transfectants that expressed either of two naturally occurring mutant human insulin receptors: Trp1200 --> Ser1200 and Ala1134 --> Thr1134. Compared with overexpressed normal human insulin receptors, both mutant receptors displayed normal processing and normal binding affinity; however, neither was capable of detectable insulin-stimulated autophosphorylation or tyrosine kinase activity toward endogenous (pp185) or exogenous substrates. Several biologic actions of insulin were evaluated in transfected cells. Compared with neomycin-only transfected CHO cells (CHO-NEO), cells expressing normal receptors demonstrated increased insulin sensitivity for 2-deoxyglucose uptake, [C-14]glucose incorporation into glycogen, [H-3]thymidine incorporation into DNA, and specific gene expression (accumulation of glucose transporter GLUT-1 mRNA). Cells expressing either Ser1200 or Thr1134 receptors showed no increase in insulin-stimulated thymidine incorporation or GLUT-1 mRNA accumulation compared with CHO-NEO. Surprisingly, cells expressing Ser1200 receptors showed increased insulin stimulation of 2-deoxyglucose uptake and glucose incorporation into glycogen compared with CHO-NEO, whereas Thr1134 receptors failed to signal these metabolic responses. We conclude that 1) transfected kinase-deficient insulin receptor mutants derived from insulin-resistant patients have distinct defects in the ability to mediate insulin action in vitro; 2) divergence of insulin signaling pathways may occur at the level of the receptor; and 3) normal activation of the receptor tyrosine kinase by insulin is not necessarily required for signaling of certain important biologic actions.	CHARLES A DANA RES INST,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard University; Harvard Medical School	MOLLER, DE (corresponding author), BETH ISRAEL HOSP,DEPT MED,DIV DIABET,HARVARD THORNDIKE LAB,SL 436,330 BROOKLINE AVE,BOSTON,MA 02215, USA.		Flier, jeffrey/AAG-6223-2019		PHS HHS [28082-10] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ACCILI D, 1989, EMBO J, V8, P2509, DOI 10.1002/j.1460-2075.1989.tb08388.x; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; CHAIKEN RL, 1986, J CLIN ENDOCR METAB, V63, P1181, DOI 10.1210/jcem-63-5-1181; CHOU CK, 1987, J BIOL CHEM, V262, P1842; DEBANT A, 1988, P NATL ACAD SCI USA, V85, P8032, DOI 10.1073/pnas.85.21.8032; DEBANT A, 1989, BIOCHEMISTRY-US, V28, P14, DOI 10.1021/bi00427a003; DEHERREROS AG, 1989, J BIOL CHEM, V264, P9885; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FLIER JS, 1986, P NATL ACAD SCI USA, V83, P664, DOI 10.1073/pnas.83.3.664; FORSAYETH JR, 1987, P NATL ACAD SCI USA, V84, P3448, DOI 10.1073/pnas.84.10.3448; GRUNBERGER G, 1983, BIOCHEM BIOPH RES CO, V115, P560, DOI 10.1016/S0006-291X(83)80181-8; HAWLEY DM, 1989, J BIOL CHEM, V264, P2438; HERRERA R, 1986, J BIOL CHEM, V261, P1980; HOFMANN C, 1989, J BIOL CHEM, V264, P8606; HOFMANN C, 1980, DIABETES, V29, P865, DOI 10.2337/diabetes.29.11.865; HOUSLAY MD, 1989, BIOCHEM SOC T, V17, P627, DOI 10.1042/bst0170627; KADOWAKI T, 1990, P NATL ACAD SCI USA, V87, P658, DOI 10.1073/pnas.87.2.658; KADOWAKI T, 1990, J CLIN INVEST, V86, P254, DOI 10.1172/JCI114693; KADOWAKI T, 1988, SCIENCE, V240, P787, DOI 10.1126/science.2834824; KAHN CR, 1976, NEW ENGL J MED, V294, P739, DOI 10.1056/NEJM197604012941401; KLINKHAMER MP, 1989, EMBO J, V8, P2503, DOI 10.1002/j.1460-2075.1989.tb08387.x; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; MADDUX BA, 1991, J BIOL CHEM, V266, P6731; MCCLAIN DA, 1990, DIABETES CARE, V13, P302, DOI 10.2337/diacare.13.3.302; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MOLLER DE, 1988, NEW ENGL J MED, V319, P1526, DOI 10.1056/NEJM198812083192306; MOLLER DE, 1990, J BIOL CHEM, V265, P14979; MOLLER DE, 1990, MOL ENDOCRINOL, V4, P1183, DOI 10.1210/mend-4-8-1183; MOUNTJOY KG, 1990, ENDOCRINOLOGY, V127, P2025, DOI 10.1210/endo-127-4-2025; MOXHAM CP, 1989, J BIOL CHEM, V264, P13238; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; OBRIEN RM, 1990, DIABETES CARE, V13, P327, DOI 10.2337/diacare.13.3.327; ODAWARA M, 1989, SCIENCE, V245, P66, DOI 10.1126/science.2544998; PERLMAN R, 1989, J BIOL CHEM, V264, P8946; RAFAELOFF R, 1990, DIABETES, V39, pA11; ROTHENBERG PL, 1988, J BIOL CHEM, V263, P15546; SHIMADA F, 1990, LANCET, V335, P1179, DOI 10.1016/0140-6736(90)92695-E; SOOS MA, 1989, BIOCHEM J, V263, P553, DOI 10.1042/bj2630553; STEELEPERKINS G, 1988, J BIOL CHEM, V263, P11486; STUMPO DJ, 1988, J BIOL CHEM, V263, P1611; SUNG CK, 1989, J BIOL CHEM, V264, P18951; TAIRA M, 1989, SCIENCE, V245, P63, DOI 10.1126/science.2544997; WILDEN PA, 1990, P NATL ACAD SCI USA, V87, P3358, DOI 10.1073/pnas.87.9.3358; YAMAMOTOHONDA R, 1990, J BIOL CHEM, V265, P14777; YOKOTA A, 1990, DIABETES S1, V39, pA235; YOSHIMASA Y, 1988, SCIENCE, V240, P784, DOI 10.1126/science.3283938	48	72	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					10995	11001						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	1645719				2022-12-25	WOS:A1991FQ77400047
J	STAUDINGER, R; KNAUS, HG; GLOSSMANN, H				STAUDINGER, R; KNAUS, HG; GLOSSMANN, H			POSITIVE HETEROTROPIC ALLOSTERIC REGULATORS OF DIHYDROPYRIDINE BINDING INCREASE THE CA2+ AFFINITY OF THE L-TYPE CA2+ CHANNEL - STEREOSELECTIVE REVERSAL BY THE NOVEL CA2+ ANTAGONIST BM 20.1140	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PUTATIVE CALCIUM CHANNELS; H-3 NITRENDIPINE BINDING; SKELETAL-MUSCLE; CA-2+ CHANNELS; DILTIAZEM-BINDING; RECOGNITION SITES; SMOOTH-MUSCLE; IDENTIFICATION; RECEPTOR; BENZOTHIAZEPINE	The alpha-1-subunit of the voltage-dependent L-type Ca2+ channel has distinct, allosterically coupled binding domains for drugs from different chemical classes (dihydropyridines, benzothiazepines, phenylalkylamines, diphenylbutylpiperidines). (-)-BM 20.1140 (ethyl-2, 2-di-phenyl-4-(1-pyrrolidino)-5-(2-picolyl)-oxyvalerate) is a novel Ca2+ channel blocker which potently stimulates dihydropyridine binding (K0.5 = 2.98 nM) to brain membranes. This property is shared by (+)-cis-diltiazem, (+)tetrandrine, fostedil and trans-diclofurime, but (-)-BM 20.1140 does not bind in a competitive manner to the sites labeled by (+)-cis-[H-3]diltiazem. (+)-cis-Diltiazem and (-)-BM 20.1140 have differential effects on the rate constants of dihydropyridine binding. (+)-BM 20.1140 reverses the stimulation of the positive allosteric regulators (pA2 value for reversal of (-)-BM 20.1140 stimulation = 7.4, slope 0.72). The underlying molecular mechanism of the potentiation of dihydropyridine binding has been clarified. The K0.5 for free Ca2+ to Stabilize a high affinity binding domain for dihydropyridines on purified L-type channels from rabbit skeletal muscle is 300 nM. (+)-Tetrandine (10-mu-M) increases the affinity 8-fold (K0.5, for free Ca2+ = 30.1 nM) and (+)-BM 20.114 (10-mu-M) inhibits the affinity increase (K0.5 for free Ca2+ = 251 nM). Similar results were obtained with membrane-bound Ca2+-channels from brain tissue which have higher affinity for free Ca2+ (K0.5 for free Ca2+ = 132 nM) and for dihydropyridines compared with skeletal muscle. It is postulated that the dihydropyridine and Ca2+-binding sites are interdependent on the alpha-1-subunit, that the different positive heterotropic allosteric regulators by their differential effects on Ca2+ rate constants) optimize coordination for Ca2+ in the channel pore and, in turn, increase affinity for the dihydropyridines.	UNIV INNSBRUCK, INST BIOCHEM PHARMACOL, PETER MAYR STR 1, A-6020 INNSBRUCK, AUSTRIA	University of Innsbruck			Glossmann, Hartmut/AAL-9790-2020	glossmann, hartmut h./0000-0002-7392-3266				AFFOLTER H, 1986, BIOPHYS J, V49, P767, DOI 10.1016/S0006-3495(86)83703-1; ARUNLAKSHANA O, 1959, BRIT J PHARM CHEMOTH, V14, P48, DOI 10.1111/j.1476-5381.1959.tb00928.x; BABITCH J, 1990, NATURE, V346, P321, DOI 10.1038/346321b0; BOER R, 1989, EUR J PHARM-MOLEC PH, V172, P131, DOI 10.1016/0922-4106(89)90004-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DEPOVER A, 1982, BIOCHEM BIOPH RES CO, V108, P110, DOI 10.1016/0006-291X(82)91838-1; EBATA H, 1990, J BIOL CHEM, V265, P177; EHLERT FJ, 1988, MOL PHARMACOL, V33, P187; FERRY DR, 1982, FEBS LETT, V148, P331, DOI 10.1016/0014-5793(82)80835-1; FERRY DR, 1982, N-S ARCH PHARMACOL, V321, P80, DOI 10.1007/BF00586355; FERRY DR, 1983, BRIT J PHARMACOL, V78, P81; FLECKENSTEIN A, 1977, ANNU REV PHARMACOL, V17, P149, DOI 10.1146/annurev.pa.17.040177.001053; FRIEL DD, 1989, P NATL ACAD SCI USA, V86, P5207, DOI 10.1073/pnas.86.13.5207; GARCIA ML, 1986, J BIOL CHEM, V261, P8146; GLOSSMANN H, 1985, ARZNEIMITTEL-FORSCH, V35-2, P1917; GLOSSMANN H, 1990, REV PHYSIOL BIOCH P, V114, P1; GLOSSMANN H, 1988, VITAM HORM, V44, P155; GLOSSMANN H, 1983, FEBS LETT, V160, P226, DOI 10.1016/0014-5793(83)80972-7; GLOSSMANN H, 1985, METHOD ENZYMOL, V109, P513; GLOSSMANN H, 1983, N-S ARCH PHARMACOL, V323, P279, DOI 10.1007/BF00512465; GOULD RJ, 1982, P NATL ACAD SCI-BIOL, V79, P3656, DOI 10.1073/pnas.79.11.3656; GOULD RJ, 1984, MOL PHARMACOL, V25, P235; GRABNER M, 1991, P NATL ACAD SCI USA, V88, P727, DOI 10.1073/pnas.88.3.727; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOSEY MM, 1988, J MEMBRANE BIOL, V104, P81, DOI 10.1007/BF01870922; Janis RA, 1987, ADV DRUG RES, V16, P309; JOHNSON JD, 1984, BIOPHYS J, V45, P134, DOI 10.1016/S0006-3495(84)84138-7; KASS RS, 1989, AM J CARDIOL, V64, pI35, DOI 10.1016/0002-9149(89)90958-2; KING VF, 1988, J BIOL CHEM, V263, P2238; KNAUS HG, 1990, J BIOL CHEM, V265, P11156; LEE HR, 1985, J PHARMACOL EXP THER, V233, P611; LEUNG AT, 1987, J BIOL CHEM, V262, P7943; LINN T, 1983, Naunyn-Schmiedeberg's Archives of Pharmacology, V324, pR45; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCHOWSKI EM, 1984, J PHARMACOL EXP THER, V230, P607; MIR AK, 1987, J CARDIOVASC PHARM, V9, P469, DOI 10.1097/00005344-198704000-00012; NAITO K, 1989, J BIOL CHEM, V264, P21211; SCHILLING WP, 1988, BIOCHIM BIOPHYS ACTA, V943, P220, DOI 10.1016/0005-2736(88)90554-8; SCHOEMAKER H, 1985, EUR J PHARMACOL, V111, P273; SCHRAMM M, 1983, NATURE, V303, P535, DOI 10.1038/303535a0; SPEDDING M, 1984, N-S ARCH PHARMACOL, V328, P69, DOI 10.1007/BF00496109; STRIESSNIG J, 1986, FEBS LETT, V197, P204, DOI 10.1016/0014-5793(86)80327-1; STRIESSNIG J, 1990, P NATL ACAD SCI USA, V87, P9108, DOI 10.1073/pnas.87.23.9108; STRIESSNIG J, 1990, J BIOL CHEM, V265, P363; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; TSIEN RW, 1987, ANNU REV BIOPHYS BIO, V16, P265; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; VAGHY PL, 1987, J BIOL CHEM, V262, P14337; WANG G, 1990, MOL PHARMACOL, V37, P17	50	31	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					10787	10795						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	1645709				2022-12-25	WOS:A1991FQ77400016
J	DRAPIER, JC; PELLAT, C; HENRY, Y				DRAPIER, JC; PELLAT, C; HENRY, Y			GENERATION OF EPR-DETECTABLE NITROSYL-IRON COMPLEXES IN TUMOR TARGET-CELLS COCULTURED WITH ACTIVATED MACROPHAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ELECTRON-TRANSPORT; MOUSE PERITONEAL-MACROPHAGES; NUCLEAR DOUBLE-RESONANCE; NON-HEME IRON; NITRIC-OXIDE; L-ARGININE; MURINE MACROPHAGES; GUANYLATE-CYCLASE; INTERFERON-GAMMA; NITROGEN-OXIDES	After immunostimulation, murine macrophages oxidize L-arginine into nitric oxide (NO) which acts as an effector molecule. In this study, we attempted to establish whether activated macrophage-derived NO forms paramagnetic complexes in tumor target cells which do not express by themselves the L-arginine:NO pathway. Accordingly, murine L1210 leukemia cells were cocultivated with activated peritonealmacrophages from Bacillus-Calmette-Guerin-infected mice, or activated in vitro with interferon-gamma. In control experiments, macrophages were prevented from producing nitrogen oxides by incubation with N(G)-monomethyl-L-arginine, a specific inhibitor of the L-arginine:NO pathway. After coculture, L1210 cells were removed from adherent macrophage monolayers and analyzed by electron paramagnetic resonance at 77 K. In the L1210 cells cultured with activated macrophages, we detected a signal typical of nitrosyl-iron-sulfur complexes, with g values of 2.041 and 2.015. This signal was not present when L1210 cells were either cultured alone or cocultured with activated macrophages in the presence of N(G)-monomethyl-L-arginine. Mitochondria from activated macrophage-injured L1210 cells also exhibited the signal with g values of 2.041 and 2.015. These results show that when tumor target cells undergo cell-to-cell contact with activated macrophages during culture, the macrophages promote target cell nitrosylation in compartments like mitochondria.	INST CURIE, BIOL SECT, INSERM, U196, F-75005 PARIS, FRANCE; INST CURIE, BIOL SECT, INSERM, U219, F-91405 ORSAY, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie			, pellat-deceunynck/K-8586-2015	, pellat-deceunynck/0000-0002-6287-8148				ADAMS LB, 1990, J IMMUNOL, V144, P2725; ADAMS MWW, 1984, J BIOL CHEM, V259, P7045; ARNOLD WP, 1977, P NATL ACAD SCI USA, V74, P3203, DOI 10.1073/pnas.74.8.3203; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BUTLER AR, 1985, POLYHEDRON, V4, P797, DOI 10.1016/S0277-5387(00)87029-1; BUTLER AR, 1985, INORG CHIM A-BIOINOR, V106, pL7, DOI 10.1016/S0020-1693(00)82246-X; CURRAN RD, 1989, J EXP MED, V170, P1769, DOI 10.1084/jem.170.5.1769; DING A, 1990, J IMMUNOL, V145, P940; DING AH, 1988, J IMMUNOL, V141, P2407; DRAPIER JC, 1988, J IMMUNOL, V140, P2829; DRAPIER JC, 1986, J CLIN INVEST, V78, P790, DOI 10.1172/JCI112642; DRAPIER JC, 1988, EUR J IMMUNOL, V18, P1587, DOI 10.1002/eji.1830181018; FISKUM G, 1980, P NATL ACAD SCI-BIOL, V77, P3430, DOI 10.1073/pnas.77.6.3430; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GRANGER DL, 1990, J CLIN INVEST, V85, P264, DOI 10.1172/JCI114422; GRANGER DL, 1982, J CELL BIOL, V95, P527, DOI 10.1083/jcb.95.2.527; GRANGER DL, 1980, J CLIN INVEST, V65, P357, DOI 10.1172/JCI109679; GREEN SJ, 1990, J IMMUNOL, V144, P278; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.bi.54.070185.005055; Hibbs J B Jr, 1986, Methods Enzymol, V132, P508; HIBBS JB, 1987, J IMMUNOL, V138, P550; HIBBS JB, 1987, SCIENCE, V235, P473, DOI 10.1126/science.2432665; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; HIBBS JB, 1990, INT CONGR SER, V897, P189; HOFFMAN RA, 1990, J IMMUNOL, V145, P2220; IGNARRO LJ, 1990, PHARMACOL TOXICOL, V67, P1, DOI 10.1111/j.1600-0773.1990.tb00772.x; JAMES SL, 1989, J IMMUNOL, V143, P4208; KENNEDY MC, 1987, P NATL ACAD SCI USA, V84, P8854, DOI 10.1073/pnas.84.24.8854; KNOWLES RG, 1989, P NATL ACAD SCI USA, V86, P5159, DOI 10.1073/pnas.86.13.5159; KWON NS, 1989, J BIOL CHEM, V264, P20496; LANCASTER JR, 1990, P NATL ACAD SCI USA, V87, P1223, DOI 10.1073/pnas.87.3.1223; LEPOIVRE M, 1990, J BIOL CHEM, V265, P14143; LIEW FY, 1990, J IMMUNOL, V144, P4794; LOBRUTTO R, 1983, J BIOL CHEM, V258, P7437; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; MCDONALD CC, 1965, J AM CHEM SOC, V87, P3319, DOI 10.1021/ja01093a007; MEYER J, 1981, ARCH BIOCHEM BIOPHYS, V210, P246, DOI 10.1016/0003-9861(81)90186-7; MICHALSKI WP, 1987, ARCH MICROBIOL, V147, P304, DOI 10.1007/BF00463493; MURRAY HW, 1985, J IMMUNOL, V134, P1619; MYERS PR, 1990, NATURE, V345, P161, DOI 10.1038/345161a0; NUSSLER A, 1991, EUR J IMMUNOL, V21, P227, DOI 10.1002/eji.1830210134; PACE JL, 1985, J IMMUNOL, V134, P977; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; PELLAT C, 1990, BIOCHEM BIOPH RES CO, V166, P119, DOI 10.1016/0006-291X(90)91919-J; PETROULEAS V, 1990, BIOCHIM BIOPHYS ACTA, V1015, P131, DOI 10.1016/0005-2728(90)90224-R; SCHOLLER DM, 1979, J BIOL CHEM, V254, P4072; STUEHR DJ, 1989, J EXP MED, V169, P1011, DOI 10.1084/jem.169.3.1011; STUEHR DJ, 1987, J IMMUNOL, V139, P518; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; TAYEH MA, 1989, J BIOL CHEM, V264, P19654; VANIN A F, 1978, Biophysics (English Translation of Biofizika), V23, P479; VANIN AF, 1977, BIOPHYSICS-USSR, V22, P387; VANIN AF, 1987, BIOFIZIKA, V31, P128; WHARTON DC, 1962, ARCH BIOCHEM BIOPHYS, V96, P103, DOI 10.1016/0003-9861(62)90458-7; WHARTON M, 1988, J IMMUNOL, V141, P1311; WOOLUM JC, 1968, BIOCHIM BIOPHYS ACTA, V160, P311, DOI 10.1016/0005-2795(68)90204-3; WOOLUM JC, 1970, BIOCHIM BIOPHYS ACTA, V201, P131, DOI 10.1016/0304-4165(70)90018-8	58	278	288	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10162	10167						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	1645341				2022-12-25	WOS:A1991FP08600028
J	BOCK, PE				BOCK, PE			ACTIVE-SITE-SELECTIVE LABELING OF BLOOD-COAGULATION PROTEINASES WITH FLUORESCENCE PROBES BY THE USE OF THIOESTER PEPTIDE CHLOROMETHYL KETONES .2. PROPERTIES OF THROMBIN DERIVATIVES AS REPORTERS OF PROTHROMBIN FRAGMENT-2 BINDING AND SPECIFICITY OF THE LABELING APPROACH FOR OTHER PROTEINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTITHROMBIN-III; FACTOR-X; BOVINE PROTHROMBIN; CHRISTMAS-FACTOR; ALPHA-THROMBIN; FACTOR-IX; FACTOR-V; ACTIVATION; INHIBITION; ENZYME	The behavior of an array of fluorescent human alpha-thrombin derivatives in reporting binding of the fragment 2 domain of prothrombin was characterized as a representative application of the active-site-selective labeling approach to studies of blood coagulation proteinase regulatory interactions. An array of 16 thrombin derivatives was prepared by affinity labeling of the proteinase active site with the thioester peptide chloromethyl ketones, N(alpha)-[(acetylthio)acetyl]-D-Phe-Pro-Arg-CH2Cl or N(alpha)-[(acetylthio)acetyl]-D-Phe-Phe-Arg-CH2Cl, followed by selective modification of the NH2OH-generated thiol group on the covalently incorporated inhibitors with each of eight thiol-reactive fluorescence probes. The changes in probe fluorescence intensity of the derivatives, signaling changes in the environment of the catalytic site associated with fragment 2 binding, appeared to be a unique and unpredictable function of the structure of the probe and the connecting peptide. These results demonstrated the utility of the labeling approach for overcoming the problem of not being able to predict which fluorescent label will provide the most useful proteinase derivative for investigating an interaction by enabling a greater variety of them to be prepared and screened for those with the most desirable properties. To determine whether the approach could be extended to other proteinases, the specificity of labeling with the fluorescence probe iodoacetamide, 5-(iodoacetamido)fluorescein, by use of the two thioester inhibitors was evaluated for several other blood coagulation proteinases and related trypsin-like enzymes. All of the proteinases were labeled in an active-site-selective manner. The combined results of quantitating the labeling reactions for the proteinase and inhibitor combinations studied thus far showed active-site-specific incorporation of 0.98 +/- 0.10 mol of inhibitor/mol of active sites and 0.92 +/- 0.11 mol of probe/mol of active sites, representing an overall greater-than-or-equal-to 93% site-specificity of labeling. These results demonstrated the broad applicability of the labeling approach for fluorescence studies of proteinases that differ greatly in their catalytic specificities.	AMER RED CROSS,BLOOD SERV,SE MICHIGAN REG RES LAB,DETROIT,MI 48232	American Red Cross					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL038779, R01HL038779] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL38779] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERGER A, 1970, PHILOS T R SOC B, V257, P249, DOI 10.1098/rstb.1970.0024; BOCK PE, 1992, J BIOL CHEM, V267, P14963; BOCK PE, 1988, BIOCHEMISTRY-US, V27, P6633, DOI 10.1021/bi00417a063; BOCK PE, 1989, ARCH BIOCHEM BIOPHYS, V273, P375, DOI 10.1016/0003-9861(89)90496-7; CARLISLE TL, 1990, J BIOL CHEM, V265, P22044; DISCIPIO RG, 1978, J CLIN INVEST, V61, P1528, DOI 10.1172/JCI109073; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P698, DOI 10.1021/bi00623a022; DOYLE MF, 1990, J BIOL CHEM, V265, P10693; HOGG PJ, 1990, J BIOL CHEM, V265, P248; JAKUBOWSKI HV, 1986, J BIOL CHEM, V261, P3876; JOHNSON JD, 1980, J BIOL CHEM, V255, P9635; KETTNER C, 1979, THROMB RES, V14, P969, DOI 10.1016/0049-3848(79)90014-8; KETTNER C, 1981, METHOD ENZYMOL, V80, P826; KETTNER C, 1981, THROMB RES, V22, P645, DOI 10.1016/0049-3848(81)90062-1; KISIEL W, 1979, J BIOL CHEM, V254, P2230; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P9684; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATALLO ZS, 1986, THROMB RES, V43, P507, DOI 10.1016/0049-3848(86)90071-X; LIJNEN HR, 1984, THROMB RES, V34, P431, DOI 10.1016/0049-3848(84)90247-0; LOLLAR P, 1984, ARCH BIOCHEM BIOPHYS, V233, P438, DOI 10.1016/0003-9861(84)90465-X; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P539, DOI 10.1016/0167-4838(83)90272-8; MANN KG, 1981, METHOD ENZYMOL, V80, P286; MORITA T, 1976, J BIOCHEM, V79, P1089, DOI 10.1093/oxfordjournals.jbchem.a131150; MYRMEL KH, 1976, BIOCHEMISTRY-US, V15, P1767, DOI 10.1021/bi00653a027; OLSON ST, 1991, J BIOL CHEM, V266, P6342; OWEN WG, 1974, J BIOL CHEM, V249, P594; Powell J.L., 1986, PROTEINASE INHIBITOR, P55; RIDDLES PW, 1979, ANAL BIOCHEM, V94, P75, DOI 10.1016/0003-2697(79)90792-9; ROSING J, 1988, THROMB HAEMOSTASIS, V60, P355; SCHOEN P, 1987, J BIOL CHEM, V262, P11268; WALKER B, 1985, BIOCHEM J, V230, P645, DOI 10.1042/bj2300645; WALKER FJ, 1979, J BIOL CHEM, V254, P5618; WILLIAMS EB, 1989, J BIOL CHEM, V264, P7536	33	82	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14974	14981						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634536				2022-12-25	WOS:A1992JF08800071
J	CHAVAN, AJ; NEMOTO, Y; NARUMIYA, S; KOZAKI, S; HALEY, BE				CHAVAN, AJ; NEMOTO, Y; NARUMIYA, S; KOZAKI, S; HALEY, BE			NAD+ BINDING-SITE OF CLOSTRIDIUM-BOTULINUM C3 ADP-RIBOSYLTRANSFERASE - IDENTIFICATION OF PEPTIDE IN THE ADENINE RING BINDING DOMAIN USING 2-AZIDO NAD+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHTHERIA-TOXIN; ACTIVE-SITE; PERTUSSIS TOXIN; STAPHYLOCOCCUS-AUREUS; S-1 SUBUNIT; GENE; RIBOSYLATION; DEHYDROGENASE; PURIFICATION; GLUTAMATE	C3 ADP-ribosyltransferase is an exoenzyme produced by certain strains of Clostridium botulinum types C and D, which specifically ADP-ribosylates rho-proteins in eukaryotic cells. Using the photoaffinity probe [alpha-P-32]nicotinamide-2-azidoadenine dinucleotide, we have identified the adenine ring binding domain of the NAD+ binding site. The specificity of labeling was demonstrated by saturation effects and protection by the natural compound at physiologically relevant concentrations. Saturation of labeling was observed at 50-mu-M. Protection experiments indicated an 80% protection of labeling by 100-mu-M NAD+ when protein was photolyzed in the presence of 10-mu-M probe. Trypsin or Staphylococcus aureus V8 protease digestion of the photolabeled protein, along with boronate affinity chromatography and immobilized metal affinity chromatography, was used to specifically isolate the peptide region photolabeled with the probe. The peptide corresponded to Phe9-Gly19 near the N terminus.	UNIV KENTUCKY, LUCILLE P MARKEY CANC CTR 058, 800 ROSE ST, LEXINGTON, KY 40536 USA; KYOTO UNIV, FAC MED, DEPT PHARMACOL, SAKYO KU, KYOTO 606, JAPAN; UNIV OSAKA PREFECTURE, COLL AGR, DEPT VET SCI, SAKAI, OSAKA 591, JAPAN	University of Kentucky; Kyoto University; Osaka Metropolitan University			Watanabe, Mamoru/AHE-0489-2022		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035766] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35766] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKTORIES K, 1987, FEBS LETT, V212, P109, DOI 10.1016/0014-5793(87)81566-1; AKTORIES K, 1988, EUR J BIOCHEM, V172, P445, DOI 10.1111/j.1432-1033.1988.tb13908.x; ANDERSSON L, 1986, ANAL BIOCHEM, V154, P250, DOI 10.1016/0003-2697(86)90523-3; BARBIERI JT, 1988, INFECT IMMUN, V56, P1934, DOI 10.1128/IAI.56.8.1934-1941.1988; CARROLL SF, 1984, P NATL ACAD SCI-BIOL, V81, P3307, DOI 10.1073/pnas.81.11.3307; CARROLL SF, 1987, J BIOL CHEM, V262, P8707; COCKLE SA, 1989, FEBS LETT, V249, P329, DOI 10.1016/0014-5793(89)80652-0; Collier RJ, 1980, MULTIFUNCTIONAL PROT, P261; CORTINA G, 1989, J BIOL CHEM, V264, P17322; DOMENIGHINI M, 1991, MOL MICROBIOL, V5, P23, DOI 10.1111/j.1365-2958.1991.tb01822.x; GALLOWAY TS, 1987, BIOCHEM J, V242, P927, DOI 10.1042/bj2420927; GREENFIELD L, 1983, P NATL ACAD SCI-BIOL, V80, P6853, DOI 10.1073/pnas.80.22.6853; HUGHES NA, 1957, J CHEM SOC, P3733, DOI 10.1039/jr9570003733; INOUE S, 1991, BIOCHEM BIOPH RES CO, V174, P459, DOI 10.1016/0006-291X(91)91438-I; KIM H, 1991, BIOCONJUGATE CHEM, V2, P142, DOI 10.1021/bc00009a002; KIM HT, 1990, J BIOL CHEM, V265, P3636; KING SM, 1991, METHOD ENZYMOL, V196, P449; LAI CY, 1986, ADV ENZYMOL RELAT AR, V58, P110; MADAULE P, 1985, CELL, V41, P31, DOI 10.1016/0092-8674(85)90058-3; Moss J, 1990, ADP RIBOSYLATING TOX; NARUMIYA S, 1988, J BIOL CHEM, V263, P17255; NEMOTO Y, 1991, J BIOL CHEM, V266, P19312; OHASHI Y, 1987, J BIOL CHEM, V262, P1430; POTTER RL, 1983, METHOD ENZYMOL, V91, P613; RANKIN PW, 1989, J BIOL CHEM, V264, P4312; SALVUCCI ME, 1992, BIOCHEMISTRY-US, V31, P4479, DOI 10.1021/bi00133a014; SUGAI M, 1990, BIOCHEM BIOPH RES CO, V173, P92, DOI 10.1016/S0006-291X(05)81026-5; SUGAI M, 1992, J BIOL CHEM, V267, P2600; SYMONS RH, 1968, BIOCHIM BIOPHYS ACTA, V155, P609, DOI 10.1016/0005-2787(68)90205-0; WEISS AA, 1986, ANNU REV MICROBIOL, V40, P661, DOI 10.1146/annurev.micro.40.1.661; YOSHIKAWA M, 1967, TETRAHEDRON LETT, P5065; ZHAO JM, 1988, BIOCHEMISTRY-US, V27, P3398, DOI 10.1021/bi00409a041	32	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14866	14870						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634527				2022-12-25	WOS:A1992JF08800056
J	ARSHAVSKY, VY; GRAYKELLER, MP; BOWNDS, MD				ARSHAVSKY, VY; GRAYKELLER, MP; BOWNDS, MD			CGMP SUPPRESSES GTPASE ACTIVITY OF A PORTION OF TRANSDUCIN EQUIMOLAR TO PHOSPHODIESTERASE IN FROG ROD OUTER SEGMENTS - LIGHT-INDUCED CGMP DECREASES AS A PUTATIVE FEEDBACK MECHANISM OF THE PHOTORESPONSE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; GUANINE-NUCLEOTIDE BINDING; GUANYLATE-CYCLASE; VERTEBRATE PHOTORECEPTORS; RETINAL RODS; PLASMA-MEMBRANE; G-PROTEIN; GUANOSINE 3',5'-CYCLIC-MONOPHOSPHATE; PHOTOEXCITED RHODOPSIN; MOLECULAR MECHANISM	In rod photoreceptor cells, the light response is triggered by an enzymatic cascade that causes cGMP levels to fall: excited rhodopsin (Rho*) --> rod G-protein (transducin, G(t)) --> cGMP-phosphodiesterase (PDE). This results in the closure of plasma membrane channels that are gated by cGMP. PDE activation by G(t) occurs when GDP bound to the alpha-subunit of G(t) (G(t-alpha)) is exchanged with free GTP. The interaction of G(t-alpha)-GTP with the gamma-subunits of PDE releases their inhibitory action and causes cGMP hydrolysis. Inactivation is thought to be caused by subsequent hydrolysis of G(t-alpha)-GTP by an intrinsic G(t)-GTPase activity. Here we report that there are two portions of G(t) in frog rod outer segments (ROS) expressing different rates of GTP hydrolysis: 19.5 +/- 3 mmol of G(t)/mol of Rho, equivalent to that amount which participates in PDE activation, hydrolyzing GTP at a rate of almost-equal-to 0.6 turnover/s ("fast") and the remaining G(t) (80.5 +/- 3 mmol/mol Rho) hydrolyzing GTP at a rate of 0.058 +/- 0.009 turnover/s. Fast GTPase activity is abolished in the presence of cGMP. This effect occurs over the physiological range of cGMP concentration changes in ROS, half-saturating at almost-equal-to 2-mu-M and saturating at 5-mu-M cGMP. cGMP-dependent suppression of GTPase is specific for cGMP; cAMP in millimolar concentration does not affect GTPase, while the poorly hydrolyzable cGMP analogue, 8-bromo-cGMP, mimics the effect. GTPase regulation by cGMP is not affected by Ca2+ over the concentration range 5-500 nM, which spans the physiological changes in cytoplasmic Ca2+ in rod cells. We suggest that the fast cGMP-sensitive GTPase activity is a property of the G(t) that activates PDE. In this model, cGMP serves not only as a messenger of excitation but also modulates GTPase activity, thereby mediating negative feedback regulation of the pathway via PDE turnoff: a light-dependent decrease in cGMP accelerates the hydrolysis of GTP bound to G(t), resulting in the rapid inactivation of PDE.	UNIV WISCONSIN,NEUROSCI TRAINING PROGRAM,MADISON,WI 53706; UNIV WISCONSIN,DEPT ZOOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	ARSHAVSKY, VY (corresponding author), UNIV WISCONSIN,MOLEC BIOL LAB,MADISON,WI 53706, USA.				NEI NIH HHS [EY 00463] Funding Source: Medline; NIGMS NIH HHS [GM 07507] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007507] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARSHAVSKY VY, 1989, FEBS LETT, V250, P353, DOI 10.1016/0014-5793(89)80754-9; ARSHAVSKY VY, 1987, FEBS LETT, V224, P19, DOI 10.1016/0014-5793(87)80414-3; ARSHAVSKY VY, 1985, FEBS LETT, V181, P264, DOI 10.1016/0014-5793(85)80272-6; ARSHAVSKY VY, 1991, BIOPHYS J, V59, pA407; BAEHR W, 1982, J BIOL CHEM, V257, P6452; BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P589; BENNETT N, 1988, BIOCHEMISTRY-US, V27, P1710, DOI 10.1021/bi00405a049; BIERNBAUM MS, 1985, J GEN PHYSIOL, V85, P83, DOI 10.1085/jgp.85.1.83; BIERNBAUM MS, 1979, J GEN PHYSIOL, V74, P649, DOI 10.1085/jgp.74.6.649; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BOWNDS D, 1971, J GEN PHYSIOL, V58, P225, DOI 10.1085/jgp.58.3.225; CALDWELL PC, 1970, CALCIUM CELLULAR FUN, P11; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; CHARBONNEAU H, 1990, P NATL ACAD SCI USA, V87, P288, DOI 10.1073/pnas.87.1.288; COBBS WH, 1985, NATURE, V313, P585, DOI 10.1038/313585a0; COHEN AI, 1988, J GEN PHYSIOL, V92, P731, DOI 10.1085/jgp.92.6.731; COHEN AI, 1978, J GEN PHYSIOL, V71, P595, DOI 10.1085/jgp.71.5.595; COOK NJ, 1987, P NATL ACAD SCI USA, V84, P585, DOI 10.1073/pnas.84.2.585; COTE RH, 1984, J BIOL CHEM, V259, P9635; DETERRE P, 1988, P NATL ACAD SCI USA, V85, P2424, DOI 10.1073/pnas.85.8.2424; DETWILER P B, 1989, Investigative Ophthalmology and Visual Science, V30, P162; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; DRATZ EA, 1987, BIOCHEM BIOPH RES CO, V146, P379, DOI 10.1016/0006-291X(87)90540-7; ERTEL E A, 1991, Biophysical Journal, V59, p534A; FAIN GL, 1990, TRENDS NEUROSCI, V13, P378, DOI 10.1016/0166-2236(90)90023-4; FAIN GL, 1976, J PHYSIOL-LONDON, V261, P71, DOI 10.1113/jphysiol.1976.sp011549; FESENKO EE, 1985, NATURE, V313, P310, DOI 10.1038/313310a0; FLEISCHMAN D, 1979, BIOCHEMISTRY-US, V18, P5060, DOI 10.1021/bi00590a006; FUNG BKK, 1990, BIOCHEMISTRY-US, V29, P2657, DOI 10.1021/bi00463a006; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; GILLESPIE PG, 1989, P NATL ACAD SCI USA, V86, P4311, DOI 10.1073/pnas.86.11.4311; GILLESPIE PG, 1988, J BIOL CHEM, V263, P8133; GILLESPIE PG, 1989, MOL PHARMACOL, V36, P773; GODCHAUX W, 1979, J BIOL CHEM, V254, P7874; GRAYKELLER MP, 1990, J BIOL CHEM, V265, P15323; GRAYKELLER MP, 1991, ASS RES VIS OPHTHAL, V32, P1053; HAKKI S, 1990, BIOCHEMISTRY-US, V29, P1088, DOI 10.1021/bi00456a035; HAMM HE, 1986, BIOCHEMISTRY-US, V25, P4512, DOI 10.1021/bi00364a010; HAMM HE, 1984, J GEN PHYSIOL, V84, P265, DOI 10.1085/jgp.84.2.265; IYENGAR R, 1990, G PROTEINS; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; KILBRIDE P, 1979, J GEN PHYSIOL, V74, P415, DOI 10.1085/jgp.74.3.415; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; KRISHNAN N, 1976, ANAL BIOCHEM, V70, P18, DOI 10.1016/S0003-2697(76)80043-7; LAMBRECHT HG, 1991, EMBO J, V10, P793, DOI 10.1002/j.1460-2075.1991.tb08011.x; LI T, 1990, P NATL ACAD SCI USA, V87, P293, DOI 10.1073/pnas.87.1.293; LIEBMAN PA, 1987, ANNU REV PHYSIOL, V49, P765, DOI 10.1146/annurev.ph.49.030187.004001; LOLLEY RN, 1982, VISION RES, V22, P1481, DOI 10.1016/0042-6989(82)90213-9; MATESIC D, 1987, NATURE, V326, P600, DOI 10.1038/326600a0; MATTHEWS HR, 1985, NATURE, V313, P582, DOI 10.1038/313582a0; MATTHEWS HR, 1988, NATURE, V334, P67, DOI 10.1038/334067a0; MILLER WH, 1982, J GEN PHYSIOL, V80, P103, DOI 10.1085/jgp.80.1.103; MOLDAY RS, 1987, J CELL BIOL, V105, P2589, DOI 10.1083/jcb.105.6.2589; NAKATANI K, 1988, J PHYSIOL-LONDON, V395, P695, DOI 10.1113/jphysiol.1988.sp016942; NAKATANI K, 1988, NATURE, V334, P69, DOI 10.1038/334069a0; NICOL GD, 1989, J GEN PHYSIOL, V94, P233, DOI 10.1085/jgp.94.2.233; PEPE IM, 1989, CELL BIOPHYS, V14, P129, DOI 10.1007/BF02797130; PEPE IM, 1986, FEBS LETT, V203, P73, DOI 10.1016/0014-5793(86)81439-9; PUGH EN, 1990, VISION RES, V30, P1923, DOI 10.1016/0042-6989(90)90013-B; RATTO GM, 1988, J NEUROSCI, V8, P3240; RISPOLI G, 1991, IN PRESS SIGNAL TRAN; ROBINSON PR, 1986, J BIOL CHEM, V261, P313; SHINOZAWA T, 1987, FEBS LETT, V219, P293, DOI 10.1016/0014-5793(87)80238-7; SITARAMAYYA A, 1977, NEUROCHEM RES, V2, P1, DOI 10.1007/BF00966017; SITARAMAYYA A, 1986, BIOCHEMISTRY-US, V25, P5460, DOI 10.1021/bi00367a017; SITARAMAYYA A, 1988, BIOCHEMISTRY-US, V27, P4880, DOI 10.1021/bi00413a044; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; THOMPSON DA, 1990, P NATL ACAD SCI USA, V87, P2201, DOI 10.1073/pnas.87.6.2201; TSIEN RY, 1980, BIOCHIM BIOPHYS ACTA, V599, P623, DOI 10.1016/0005-2736(80)90205-9; TSIEN RY, 1981, J NEUROSCI METH, V4, P73, DOI 10.1016/0165-0270(81)90020-0; VUONG TM, 1990, NATURE, V346, P71, DOI 10.1038/346071a0; WAGNER R, 1988, FEBS LETT, V234, P44, DOI 10.1016/0014-5793(88)81299-7; WENSEL TG, 1988, ENZYME DYNAMICS REGU, P103; WHALEN MM, 1989, BIOCHEM J, V259, P13, DOI 10.1042/bj2590013; WHALEN MM, 1990, BIOCHEM J, V265, P655, DOI 10.1042/bj2650655; WHEELER GL, 1977, NATURE, V269, P822, DOI 10.1038/269822a0; WHEELER GL, 1977, P NATL ACAD SCI USA, V74, P4238, DOI 10.1073/pnas.74.10.4238; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WITT PL, 1984, J GEN PHYSIOL, V84, P251, DOI 10.1085/jgp.84.2.251; WOODRUFF ML, 1982, J GEN PHYSIOL, V80, P537, DOI 10.1085/jgp.80.4.537; WOODRUFF ML, 1979, J GEN PHYSIOL, V73, P629, DOI 10.1085/jgp.73.5.629; YAMANAKA G, 1985, BIOCHEMISTRY-US, V24, P8094, DOI 10.1021/bi00348a039; YAMAZAKI A, 1980, J BIOL CHEM, V255, P1619; YAU KW, 1985, NATURE, V317, P252, DOI 10.1038/317252a0	84	62	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18530	18537						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1655754				2022-12-25	WOS:A1991GJ47200022
J	CALDWELL, KK; LIPS, DL; BANSAL, VS; MAJERUS, PW				CALDWELL, KK; LIPS, DL; BANSAL, VS; MAJERUS, PW			ISOLATION AND CHARACTERIZATION OF 2 3-PHOSPHATASES THAT HYDROLYZE BOTH PHOSPHATIDYLINOSITOL 3-PHOSPHATE AND INOSITOL 1,3-BISPHOSPHATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL GLOMERULOSA CELLS; CEREBRAL-CORTEX SLICES; BOVINE BRAIN; PHOSPHOLIPASE-C; HUMAN PLATELETS; METABOLISM; 1,4,5-TRISPHOSPHATE; KINASE; 1,3,4,5-TETRAKISPHOSPHATE; POLYPHOSPHOINOSITIDES	Inositol-polyphosphate 3-phosphatase catalyzes the hydrolysis of the 3-position phosphate bond of inositol 1,3-bisphosphate (Ins(1,3)P2) to form inositol 1-monophosphate and inorganic phosphate (Bansal, V. S., Inhorn, R. C., and Majerus, P. W. (1987) J. Biol. Chem. 262, 9444-9447). Phosphatidylinositol 3-phosphatase catalyzes the analogous reaction utilizing phosphatidylinositol 3-phosphate (PtdIns(3)P) as substrate to form phosphatidylinositol and inorganic phosphate (Lips, D. L., and Majerus, P. W. (1989) J. Biol. Chem. 264, 19911-19915). We now demonstrate that these enzyme activities are identical. Two forms of the enzyme, designated Type I and II 3-phosphatases, were isolated from rat brain. The Type I 3-phosphatase consisted of a protein doublet that migrated at a relative M(r) of 65,000 upon sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis. The M(r) of this isoform upon size-exclusion chromatography was 110,000, suggesting that the native enzyme is a dimer. The Type II enzyme consisted of equal amounts of an M(r) = 65,000 doublet and an M(r) = 78,000 band upon SDS-polyacrylamide gel electrophoresis. This isoform displayed an M(r) upon size-exclusion chromatography of 147,000, indicating that it is a heterodimer. The Type II 3-phosphatase catalyzed the hydrolysis of Ins(1,3)P2 with a catalytic efficiency of one-nineteenth of that measured for the Type I enzyme, whereas PtdIns(3)P was hydrolyzed by the Type II 3-phosphatase at three times the rate measured for the Type I 3-phosphatase. The M(r) = 65,000 subunits of the two forms of 3-phosphatase appear to be the same based on co-migration on SDS-polyacrylamide gels and peptide maps generated with Staphylococcus aureus protease V8 and trypsin. The peptide map of the M(r) = 78,000 subunit was different from that of the M(r) = 65,000 subunits. Thus, we propose that the differing relative specificities of the Type I and II 3-phosphatases for Ins(1,3)P2 and PtdIns(3)P are due to the presence of the M(r) = 78,000 subunit of the Type II enzyme.	WASHINGTON UNIV,SCH MED,DIV HEMATOL ONCOL,660 S EUCLID AVE,BOX 8125,ST LOUIS,MO 63110	Washington University (WUSTL)					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014147, R37HL016634, T32HL007088, R01HL016634] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 16634, HL 14147, HL 07088] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMES BN, 1960, J BIOL CHEM, V235, P769; AUGER KR, 1989, J BIOL CHEM, V264, P20181; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BAIRD JG, 1990, BIOCHEM J, V267, P835, DOI 10.1042/bj2670835; BALLA T, 1989, J BIOL CHEM, V264, P9386; BALLA T, 1989, J BIOL CHEM, V264, P13605; BANSAL VS, 1990, ANNU REV CELL BIOL, V6, P41, DOI 10.1146/annurev.cellbio.6.1.41; BANSAL VS, 1990, J BIOL CHEM, V265, P1806; BANSAL VS, 1987, J BIOL CHEM, V262, P9444; BATTY IH, 1989, BIOCHEM J, V258, P23, DOI 10.1042/bj2580023; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CATT KJ, 1989, ANNU REV MED, V40, P487; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COUGHLIN SR, 1989, SCIENCE, V243, P1191; CULLEN PJ, 1989, BIOCHEM J, V259, P931, DOI 10.1042/bj2590931; CUNHAMELO JR, 1988, J BIOL CHEM, V263, P14245; CUNNINGHAM TW, 1990, J BIOL CHEM, V265, P21676; DITTMAN WA, 1990, BLOOD, V75, P329; DOUGHNEY C, 1988, BIOCHEM J, V251, P927, DOI 10.1042/bj2510927; HALLCHER LM, 1980, J BIOL CHEM, V255, P896; HOER D, 1988, BIOCHEM BIOPH RES CO, V154, P668, DOI 10.1016/0006-291X(88)90191-X; HOU WM, 1988, BIOCHIM BIOPHYS ACTA, V959, P67; HOWELL S, 1989, EUR J BIOCHEM, V183, P169, DOI 10.1111/j.1432-1033.1989.tb14909.x; HUGHES PJ, 1990, J BIOL CHEM, V265, P9869; INHORN RC, 1987, P NATL ACAD SCI USA, V84, P2170, DOI 10.1073/pnas.84.8.2170; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; KUMADA T, 1987, BLOOD, V71, P728; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPS DL, 1989, J BIOL CHEM, V264, P19911; LIPS DL, 1989, J BIOL CHEM, V264, P8759; MAJERUS PW, 1990, CELL, V63, P459, DOI 10.1016/0092-8674(90)90442-H; MAJERUS PW, 1988, J BIOL CHEM, V263, P3051; MORRISON JF, 1971, J BIOL CHEM, V246, P3992; RANA RS, 1990, PHYSIOL REV, V70, P115, DOI 10.1152/physrev.1990.70.1.115; REBECCHI MJ, 1987, J BIOL CHEM, V262, P12526; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; SERUNIAN LA, 1990, J VIROL, V64, P4718, DOI 10.1128/JVI.64.10.4718-4725.1990; SHIBASAKI F, 1991, J BIOL CHEM, V266, P8108; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; WILKINSON G, 1961, BIOCHEM J, V80, P324, DOI 10.1042/bj0800324	45	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					18378	18386						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1655747				2022-12-25	WOS:A1991GG55300100
J	LAW, SF; MANNING, D; REISINE, T				LAW, SF; MANNING, D; REISINE, T			IDENTIFICATION OF THE SUBUNITS OF GTP-BINDING PROTEINS COUPLED TO SOMATOSTATIN RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE REGULATORY PROTEINS; PURIFIED MUSCARINIC RECEPTORS; RAT NEOCORTICAL NEURONS; PERTUSSIS TOXIN BLOCKS; PITUITARY TUMOR-CELLS; PHOSPHOLIPID-VESICLES; GAMMA-SUBUNITS; BETA-GAMMA; FUNCTIONAL RECONSTITUTION; ACETYLCHOLINE-RECEPTOR	Somatostatin (SRIF) induces its biological effects by interacting with membrane-bound receptors that are linked to cellular effector systems via G proteins. We have studied SRIF receptor-G protein associations by solubilizing the SRIF receptor from rat brain and AtT-20 cells and immunoprecipitating the receptor-G protein complex with peptide-directed antisera against the different subunits of the G protein heterotrimer. Antiserum 8730, which selectively interacts with all G(i-alpha) subtypes, maximally and specifically immunoprecipitated SRIF receptor-G(i-alpha) complexes. To identify the subtypes of G(i-alpha) that are coupled to SRIF receptors, the subtype-selective antisera 3646, 1521, and 1518, which specifically interact with G(i-alpha-1), G(i-alpha-2), and G(i-alpha-3), respectively, were used to immunoprecipitate SRIF receptor-G(i-alpha) complexes. Antiserum 3646 immunoprecipitated SRIF receptor-G(i-alpha-1) complexes from both brain and AtT-20 cells. Antiserum 1521 immunoprecipitated G(i-alpha-2) from both brain and AtT-20 cells but did not immunoprecipitate SRIF receptors from these tissues. Antiserum 1518 immunoprecipitated AtT-20 cell SRIF receptors but uncoupled brain SRIF receptor-G protein complexes. This result was confirmed with another peptide-selective antiserum, SQ, directed against G(i-alpha-3). The findings from these studies indicate that G(i-alpha-1) and G(i-alpha-3) are coupled to SRIF receptors, whereas G(i-alpha-2) is not. Even though brain and AtT-20 cell SRIF receptors were both coupled to G(i-alpha), the receptors from these tissues differed in their coupling to G(o-alpha). Antiserum 2353, which is directed against G(o-alpha), immunoprecipitated SRIF receptors from AtT-20 cells, but did not immunoprecipitate or uncouple SRIF receptor-G protein complexes from rat brain. To determine the beta-subunits associated with the SRIF receptor, antisera directed against G-beta-36 and G-beta-35 were used to immunoprecipitate SRIF receptor-G protein complexes from brain. Peptide-directed antiserum against G-beta-36 selectively immunoprecipitated solubilized brain SRIF receptors. However, antiserum directed against the G-beta-35 subunit did not immunoprecipitate brain SRIF receptors, suggesting that brain SRIF receptors may preferentially associate with G-beta-36. In addition to coimmunoprecipitating with G(i-alpha) and G-beta, brain SRIF receptors coimmunoprecipitated the G protein gamma-subunits, G-gamma-2 and G-gamma-3. These results provide the first evidence that SRIF receptors are coupled to different subunits of G proteins and suggest that selectivity exists in the association of different G protein subunits with the SRIF receptor.			LAW, SF (corresponding author), UNIV PENN,SCH MED,DEPT PHARMACOL,PHILADELPHIA,PA 19104, USA.				NCI NIH HHS [CA39712] Funding Source: Medline; NIGMS NIH HHS [GM 34781] Funding Source: Medline; PHS HHS [45533] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039712] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM034781] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMATRUDA TT, 1988, J BIOL CHEM, V263, P5008; BLUMER KJ, 1990, P NATL ACAD SCI USA, V87, P4363, DOI 10.1073/pnas.87.11.4363; BRAZEAU P, 1972, SCIENCE, V129, P77; CARLSON KE, 1989, J BIOL CHEM, V264, P13298; CERIONE RA, 1986, J BIOL CHEM, V261, P3901; CERIONE RA, 1985, J BIOL CHEM, V260, P1493; CHESSELET MF, 1983, J NEUROSCI, V3, P232; CORTES R, 1988, P NATL ACAD SCI USA, V85, P9351, DOI 10.1073/pnas.85.23.9351; EPELBAUM J, 1986, PROG NEUROBIOL, V27, P63, DOI 10.1016/0301-0082(86)90012-2; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; FONG H, 1987, P NATL ACAD SCI USA, V84, P265; FUNG BKK, 1983, J BIOL CHEM, V258, P495; GAO B, 1987, J BIOL CHEM, V262, P17254; GAO B, 1987, P NATL ACAD SCI USA, V84, P6122, DOI 10.1073/pnas.84.17.6122; GAUTAM N, 1990, P NATL ACAD SCI USA, V87, P7973, DOI 10.1073/pnas.87.20.7973; GAUTAM N, 1989, SCIENCE, V244, P971, DOI 10.1126/science.2499046; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOLDSMITH P, 1988, BIOCHEMISTRY-US, V27, P7085, DOI 10.1021/bi00418a062; HAGA K, 1986, J BIOL CHEM, V261, P133; HAGA K, 1985, NATURE, V316, P731, DOI 10.1038/316731a0; HE HT, 1989, P NATL ACAD SCI USA, V86, P1480, DOI 10.1073/pnas.86.5.1480; HE HT, 1990, MOL PHARMACOL, V37, P614; HILDEBRANDT JD, 1990, J BIOL CHEM, V265, P9825; HSU WH, 1990, J BIOL CHEM, V265, P11220; HUFF RM, 1986, J BIOL CHEM, V261, P1105; JAKOBS KH, 1983, P NATL ACAD SCI-BIOL, V80, P3899, DOI 10.1073/pnas.80.13.3899; JONES DT, 1987, J BIOL CHEM, V262, P14241; KIM D, 1989, NATURE, V337, P557, DOI 10.1038/337557a0; KOCH BD, 1985, J BIOL CHEM, V260, P3138; KUROSE H, 1986, J BIOL CHEM, V261, P6423; LAW S, 1990, J CELL BIOL, V111, P330; MAHY N, 1988, J PHARMACOL EXP THER, V246, P779; MASTERS SB, 1988, SCIENCE, V241, P448, DOI 10.1126/science.2899356; MATESIC DF, 1989, J BIOL CHEM, V264, P21638; MIHARA S, 1987, J PHYSIOL-LONDON, V390, P335, DOI 10.1113/jphysiol.1987.sp016704; MOORE SD, 1988, SCIENCE, V239, P278, DOI 10.1126/science.2892268; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; OHARA K, 1988, MOL PHARMACOL, V33, P290; PITTMAN QJ, 1981, BRAIN RES, V221, P402, DOI 10.1016/0006-8993(81)90791-5; RAYNOR K, 1989, J PHARMACOL EXP THER, V251, P510; REISINE T, 1985, J PHARMACOL EXP THER, V235, P551; REISINE T, 1985, J PHARMACOL EXP THER, V232, P275; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; SENGOLES SE, 1990, J BIOL CHEM, V265, P4507; STERNWEIS PC, 1986, J BIOL CHEM, V261, P631; WANG HL, 1989, P NATL ACAD SCI USA, V86, P9616, DOI 10.1073/pnas.86.23.9616; WANG HL, 1990, NEUROSCIENCE, V38, P335, DOI 10.1016/0306-4522(90)90032-Y; WILLIAMS AG, 1990, BLOOD, V76, P721; WOOLKALIS MJ, 1986, J BIOL CHEM, V261, P3408; YATANI A, 1987, MOL ENDOCRINOL, V1, P283, DOI 10.1210/mend-1-4-283	51	143	150	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					17885	17897						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1655730				2022-12-25	WOS:A1991GG55300030
J	GANDINO, L; MUNARON, L; NALDINI, L; FERRACINI, R; MAGNI, M; COMOGLIO, PM				GANDINO, L; MUNARON, L; NALDINI, L; FERRACINI, R; MAGNI, M; COMOGLIO, PM			INTRACELLULAR CALCIUM REGULATES THE TYROSINE KINASE RECEPTOR ENCODED BY THE MET ONCOGENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; MOLECULAR-CLONING; PROTEIN; PHOSPHORYLATION; INSULIN; CELL; PHOSPHOTYROSINE; THREONINE-654; FIBROBLASTS; PHOSPHATASE	Previous work (Gandino, L., Di Renzo, M. F., Giordano, S., Bussolino, F., and Comoglio, P. M. (1990) Oncogene 5, 721-725) has shown that the tyrosine kinase activity of the receptor encoded by the MET protooncogene is negatively modulated by protein kinase C (PKC). We now show that an increase of intracellular Ca2+ has a similar inhibitory effect in vivo, via a PKC-independent mechanism. In GTL-16 cells the p145MET kinase is overexpressed and constitutively phosphorylated on tyrosine. A rapid and reversible decrease of p145MET tyrosine phosphorylation was induced by treatment with the calcium ionophores A23187 or ionomycin. Experiments performed with the ionophores in absence of extracellular calcium showed that a rise in cytoplasmic Ca2+ concentration to 450 nM (due to release from intracellular stores) resulted in a similar effect. These Ca2+ concentrations had no effect on p145MET autophosphorylation in an in vitro kinase assay. This suggests that the effect of Ca2+ on p145MET tyrosine phosphorylation is not direct but may be mediated by Ca2+-activated protein(s). Involvement of Ca2+-dependent tyrosine phosphatases was ruled out by experiments carried out in presence of Na3VO4. In vivo labeling with [P-32]orthophosphate showed that the rise of intracellular Ca2+ induces serine phosphorylation of p145MET on a specific phosphopeptide. This suggests that Ca2+ negatively modulates p145MET kinase through the phosphorylation of a critical serine residue by a Ca2+-activated serine kinase distinct from PKC.	UNIV TURIN,SCH MED,DEPT BIOMED SCI & ONCOL,C SO M DAZEGLIO 52,I-10126 TURIN,ITALY	University of Turin			Ferracini, Riccardo/AAL-4622-2020; Naldini, Luigi/E-9083-2012	Comoglio, Paolo/0000-0002-7056-5328; munaron, luca/0000-0001-9247-4446; NALDINI, Luigi/0000-0002-7835-527X				BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; COCHET C, 1984, J BIOL CHEM, V259, P2553; COMOGLIO PM, 1984, EMBO J, V3, P483, DOI 10.1002/j.1460-2075.1984.tb01834.x; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; CORPS AN, 1989, CELL REGUL, V1, P75, DOI 10.1091/mbc.1.1.75; DAVIS RJ, 1985, P NATL ACAD SCI USA, V82, P1974, DOI 10.1073/pnas.82.7.1974; DIRENZO MF, 1986, EUR J BIOCHEM, V158, P383; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FRIEDMAN B, 1989, P NATL ACAD SCI USA, V86, P812, DOI 10.1073/pnas.86.3.812; GANDINO L, 1990, ONCOGENE, V5, P721; GIORDANO S, 1988, MOL CELL BIOL, V8, P3510, DOI 10.1128/MCB.8.8.3510; GIORDANO S, 1989, ONCOGENE, V4, P1383; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; JACOBS S, 1983, P NATL ACAD SCI-BIOL, V80, P6211, DOI 10.1073/pnas.80.20.6211; JONES SW, 1989, J BIOL CHEM, V264, P7747; KOSHIO O, 1989, FEBS LETT, V254, P22, DOI 10.1016/0014-5793(89)81001-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN MF, 1988, MOL CELL BIOL, V8, P5477, DOI 10.1128/MCB.8.12.5477; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MOTOYAMA T, 1984, ACTA MED BIOL, V27, P49; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, ONCOGENE, V6, P501; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PONZETTO C, 1991, ONCOGENE, V6, P553; PRAT M, 1991, IN PRESS INT J CANCE; PRITCHARD ML, 1989, BIOCHEM J, V257, P321, DOI 10.1042/bj2570321; ROOME J, 1988, BIOCHEM J, V256, P493, DOI 10.1042/bj2560493; SWOPE SL, 1988, BIOCHEM J, V253, P193, DOI 10.1042/bj2530193; TAKAYAMA S, 1988, J BIOL CHEM, V263, P3440; TEMPEST PR, 1988, BRIT J CANCER, V58, P3, DOI 10.1038/bjc.1988.150; VERHEIJDEN GF, 1990, BIOCHEM J, V271, P215, DOI 10.1042/bj2710215; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZARNEGAR R, 1990, P NATL ACAD SCI USA, V87, P1252, DOI 10.1073/pnas.87.3.1252	39	51	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					16098	16104						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1651934				2022-12-25	WOS:A1991GB97700086
J	ZUPAN, AA; JOHNSON, EM				ZUPAN, AA; JOHNSON, EM			EVIDENCE FOR ENDOCYTOSIS-DEPENDENT PROTEOLYSIS IN THE GENERATION OF SOLUBLE TRUNCATED NERVE GROWTH-FACTOR RECEPTORS BY A875 HUMAN-MELANOMA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; AMINO-ACID-SEQUENCE; PC12 CELLS; MOLECULAR-CLONING; HUMAN-FIBROBLASTS; BINDING-PROTEIN; NGF RECEPTOR; B-CELL; EXPRESSION; RAT	We have identified nerve growth factor receptor (NGFR) on the cell surface and a truncated nerve growth factor receptor (NGFR(t)) in the conditioned medium of NGFR-negative cells that have been transfected with either the gene or the cDNA for the full-length receptor. By using cell surface iodination or metabolic labeling of A875 human melanoma cells, coupled with immunoprecipitation, we have determined the half-life of the cell-associated receptor to be almost-equal-to 7 h. Concomitant with receptor degradation is the accumulation of NGFR(t) in the extracellular medium. Approximately one-fifth of the labeled receptor can be recovered as the truncated species. These data support the hypothesis that NGFR(t) is generated by proteolysis of previously intact receptor. Furthermore, although no specific protease inhibitor assayed could affect this processing, NGFR degradation and truncation were retarded by treatment with: 1) the weak base amines, ammonium chloride or methylamine; 2) the carboxylic ionophore, monensin; or 3) the vacuolar ATPase inhibitor, bafilomycin A1, all agents that dissipate endosomal/lysosomal proton gradients via alternate mechanisms. Incubation of cells at 4-degrees-C precluded NGFR degradation and truncation. The presence of ligand did not alter the time course of receptor truncation.			ZUPAN, AA (corresponding author), WASHINGTON UNIV,SCH MED,DEPT PHARMACOL,ST LOUIS,MO 63110, USA.							AYERLELIEVRE C, 1988, SCIENCE, V240, P1339, DOI 10.1126/science.2897715; BOCCHINI V, 1969, P NATL ACAD SCI USA, V64, P787, DOI 10.1073/pnas.64.2.787; BOTHWELL MA, 1980, CELL, V21, P857, DOI 10.1016/0092-8674(80)90449-3; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; BRAESCHANDERSEN S, 1989, J IMMUNOL, V142, P562; BUXSER S, 1990, J BIOL CHEM, V265, P12701; CASCIOLA LAF, 1989, BIOCHEM J, V262, P681, DOI 10.1042/bj2620681; CHANDLER CE, 1984, J BIOL CHEM, V259, P6882; CHAO MV, 1986, SCIENCE, V232, P418; CREEK KE, 1983, BIOCHEM J, V214, P353, DOI 10.1042/bj2140353; DECKER SJ, 1984, MOL CELL BIOL, V4, P571, DOI 10.1128/MCB.4.4.571; DISTEFANO PS, 1988, P NATL ACAD SCI USA, V85, P270, DOI 10.1073/pnas.85.1.270; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; EVELETH DD, 1988, NEURON, V1, P929, DOI 10.1016/0896-6273(88)90150-X; FABRICANT RN, 1977, P NATL ACAD SCI USA, V74, P565, DOI 10.1073/pnas.74.2.565; GATANAGA T, 1990, LYMPHOKINE RES, V9, P225; GAVIN JR, 1972, SCIENCE, V178, P168, DOI 10.1126/science.178.4057.168; GILMORE T, 1985, CELL, V40, P609, DOI 10.1016/0092-8674(85)90209-0; GIRI JG, 1990, J BIOL CHEM, V265, P17416; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; HERRUP K, 1979, EXP CELL RES, V121, P71, DOI 10.1016/0014-4827(79)90445-2; HOSANG M, 1985, J BIOL CHEM, V260, P655; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; JOHNSTON D, 1984, EXP CELL RES, V152, P179, DOI 10.1016/0014-4827(84)90242-8; KAMPS MP, 1984, NATURE, V310, P589, DOI 10.1038/310589a0; KROMER LF, 1987, SCIENCE, V235, P214, DOI 10.1126/science.3798108; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBIEN TW, 1982, J IMMUNOL, V129, P2287; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; LOW MG, 1987, BIOCHEM J, V244, P1; MACDONALD RG, 1989, J BIOL CHEM, V264, P3256; MARCHALONIS JJ, 1969, BIOCHEM J, V113, P299, DOI 10.1042/bj1130299; MARCHALONIS JJ, 1972, NATURE-NEW BIOL, V235, P240, DOI 10.1038/newbio235240a0; MARSHALL S, 1985, J BIOL CHEM, V260, P4136; MCGUFFIN W L JR, 1976, Endocrinology, V98, P1401; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MYONES BL, 1987, COMPLEMENT INFLAMMAT, V4, P87, DOI 10.1159/000463012; NOPHAR Y, 1990, EMBO J, V9, P3269, DOI 10.1002/j.1460-2075.1990.tb07526.x; NOVICK D, 1989, J EXP MED, V170, P1409, DOI 10.1084/jem.170.4.1409; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RAIVICH G, 1987, NEUROSCIENCE, V20, P23, DOI 10.1016/0306-4522(87)90003-0; ROBB RJ, 1987, J IMMUNOL, V139, P855; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROSENBERG MB, 1988, SCIENCE, V242, P1575, DOI 10.1126/science.3201248; ROSS AH, 1984, P NATL ACAD SCI-BIOL, V81, P6681, DOI 10.1073/pnas.81.21.6681; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHATTEMAN GC, 1988, J NEUROSCI, V8, P860; SEILER M, 1984, BRAIN RES, V300, P33, DOI 10.1016/0006-8993(84)91338-6; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SMITH WC, 1989, MOL ENDOCRINOL, V3, P984, DOI 10.1210/mend-3-6-984; SONNENFELD KH, 1986, CANCER RES, V46, P1446; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; TANIUCHI M, 1986, P NATL ACAD SCI USA, V83, P1950, DOI 10.1073/pnas.83.6.1950; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; THOENEN H, 1980, PHYSIOL REV, V60, P1284, DOI 10.1152/physrev.1980.60.4.1284; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WATANABE N, 1988, J BIOL CHEM, V263, P10262; WEBER W, 1984, SCIENCE, V224, P294, DOI 10.1126/science.6324343; YAN Q, 1988, J NEUROSCI, V8, P3481; ZIMMERMANN A, 1983, EMBO J, V2, P879, DOI 10.1002/j.1460-2075.1983.tb01517.x; ZUPAN AA, 1989, J BIOL CHEM, V264, P11714	61	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15384	15390						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1651328				2022-12-25	WOS:A1991GB09700083
J	THOMPSON, J; NGUYEN, NY; SACKETT, DL; DONKERSLOOT, JA				THOMPSON, J; NGUYEN, NY; SACKETT, DL; DONKERSLOOT, JA			TRANSPOSON-ENCODED SUCROSE METABOLISM IN LACTOCOCCUS-LACTIS - PURIFICATION OF SUCROSE-6-PHOSPHATE HYDROLASE AND GENETIC-LINKAGE TO N5-(L-1-CARBOXYETHYL)-L-ORNITHINE SYNTHASE IN STRAIN K1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOCOCCUS-LACTIS; PHOSPHOTRANSFERASE SYSTEM; NISIN PRODUCTION; NUCLEOTIDE-SEQUENCE; FERMENTING ABILITY; 6-PHOSPHATE HYDROLASE; NADP+ OXIDOREDUCTASE; ANTIBIOTIC NISIN; SUCRASE GENE; MUTANS	Sucrose-6-phosphate hydrolase from Lactococcus lactis subsp. lactis K1-23 (formerly Streptococcus lactis K1-23) has been purified 600-fold to electrophoretic homogeneity. Purification of the enzyme was achieved by DEAE-Sephacel, phosphocellulose P-11, and gel exclusion (Ultrogel AcA 54) chromatography. The purified enzyme (specific activity 31 units/mg) catalyzed the hydrolysis of both 6-O-phosphoryl-alpha-D-glucopyranosyl-1, 2-beta-D-fructofuranoside (sucrose 6-phosphate) and sucrose (K(m) = 0.1 and 100 mM, respectively). Ultracentrifugal analysis of sucrose-6-phosphate hydrolase indicated an M(r) = 52,200. The purified enzyme migrated as a single protein during sodium dodecyl sulfate-polyacrylamide gel electrophoresis (M(r) = 52,000). However, four distinct polypeptides were detected by analytical electrofocusing, and all four species hydrolyzed sucrose and sucrose 6-phosphate. The amino acid composition of sucrose-6-phosphate hydrolase, and the sequence of the first 12 amino acids from the NH2 terminus, have been determined. Hybridization studies with oligonucleotide probes show that the genes for sucrose-6-phosphate hydrolase (scrB), Enzyme II(Scr) of the phosphoenolpyruvate-dependent sucrose:phosphotransferase system (scrA), and N5-(carboxyethyl) ornithine synthase (ceo) are encoded by the same approximately 20-kilobase EcoRI fragment. This fragment is part of a large transposon Tn5306 that also encodes the nisin precursor gene, spaN, and IS904. In L. lactis ATCC 11454, spaN, IS904, scrA, and scrB (but not ceo) are encoded on a related transposon, Tn5307.	NIDDKD, BETHESDA, MD 20892 USA; US FDA, CTR BIOL EVALUAT & RES, DIV CYTOKINE BIOL, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); US Food & Drug Administration (FDA)	THOMPSON, J (corresponding author), NIDR, MICROBIAL ECOL LAB, BLDG 30, RM 528, BETHESDA, MD 20892 USA.							Andrews P, 1970, Methods Biochem Anal, V18, P1, DOI 10.1002/9780470110362.ch1; BLATCH GL, 1990, GENE, V95, P17, DOI 10.1016/0378-1119(90)90408-J; BOIZET B, 1988, GENE, V62, P249, DOI 10.1016/0378-1119(88)90563-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHMAN GW, 1988, J BIOL CHEM, V263, P16260; CHASSY BM, 1979, BIOCHEM BIOPH RES CO, V89, P307, DOI 10.1016/0006-291X(79)90979-3; CROW VL, 1984, J BACTERIOL, V157, P28, DOI 10.1128/JB.157.1.28-34.1984; DAWSON RMC, 1969, DATA BIOCH RES, P625; DODD HM, 1990, J GEN MICROBIOL, V136, P555, DOI 10.1099/00221287-136-3-555; DONKERSLOOT JA, 1990, J BACTERIOL, V172, P4122, DOI 10.1128/jb.172.7.4122-4126.1990; FOUET A, 1986, GENE, V45, P221, DOI 10.1016/0378-1119(86)90258-1; FUCHS PG, 1975, J GEN MICROBIOL, V88, P189, DOI 10.1099/00221287-88-1-189; GABRIEL O, 1969, ANAL BIOCHEM, V27, P545, DOI 10.1016/0003-2697(69)90068-2; GASSON MJ, 1984, FEMS MICROBIOL LETT, V21, P7, DOI 10.1111/j.1574-6968.1984.tb00176.x; GONZALEZ CF, 1985, APPL ENVIRON MICROB, V49, P627, DOI 10.1128/AEM.49.3.627-633.1985; HAANDRIKMAN AJ, 1989, J BACTERIOL, V171, P2789, DOI 10.1128/jb.171.5.2789-2794.1989; HAANES EJ, 1989, J BACTERIOL, V171, P6397, DOI 10.1128/jb.171.12.6397-6408.1989; HARDESTY C, 1987, PLASMID, V18, P142, DOI 10.1016/0147-619X(87)90042-4; HAYAKAWA M, 1986, INFECT IMMUN, V53, P582, DOI 10.1128/IAI.53.3.582-586.1986; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; Hurst A., 1981, ADV APPL MICROBIOL, V27, P85, DOI [10.1016/s0065-2164(08)70342-3, DOI 10.1016/S0065-2164(08)70342-3, 10.1016/S0065-2164(08)70342-3]; KALETTA C, 1989, J BACTERIOL, V171, P1597, DOI 10.1128/jb.171.3.1597-1601.1989; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; Leblanc DJ, 1980, PLASMIDS TRANSPOSONS, P31; LUNSFORD RD, 1986, J BACTERIOL, V166, P426, DOI 10.1128/jb.166.2.426-434.1986; Maniatis T., 1982, MOL CLONING; MILLER SPF, 1987, J BIOL CHEM, V262, P16109; POSTMA PW, 1985, MICROBIOL REV, V49, P232, DOI 10.1128/MMBR.49.3.232-269.1985; SACKETT DL, 1989, ANAL BIOCHEM, V180, P319, DOI 10.1016/0003-2697(89)90439-9; SATO Y, 1989, J BACTERIOL, V171, P263, DOI 10.1128/jb.171.1.263-271.1989; SATO Y, 1988, INFECT IMMUN, V56, P1956, DOI 10.1128/IAI.56.8.1956-1960.1988; Schachman H.K., 1959, ULTRACENTRIFUGATION; SCHMID K, 1988, MOL MICROBIOL, V2, P1, DOI 10.1111/j.1365-2958.1988.tb00001.x; SCHOLLE RR, 1989, GENE, V80, P49, DOI 10.1016/0378-1119(89)90249-7; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPRENGER GA, 1988, J GEN MICROBIOL, V134, P1635; STEELE JL, 1986, APPL ENVIRON MICROB, V51, P57, DOI 10.1128/AEM.51.1.57-64.1986; STMARTIN EJ, 1979, INFECT IMMUN, V24, P865, DOI 10.1128/IAI.24.3.865-868.1979; STMARTIN EJ, 1979, INFECT IMMUN, V26, P487, DOI 10.1128/IAI.26.2.487-491.1979; TARR GE, 1978, ANAL BIOCHEM, V84, P622, DOI 10.1016/0003-2697(78)90086-6; THOMPSON J, 1981, J BACTERIOL, V147, P543, DOI 10.1128/JB.147.2.543-551.1981; THOMPSON J, 1989, J BIOL CHEM, V264, P9592; THOMPSON J, 1986, J BACTERIOL, V167, P522, DOI 10.1128/jb.167.2.522-529.1986; THOMPSON J, 1987, J BACTERIOL, V169, P4147, DOI 10.1128/jb.169.9.4147-4153.1987; THOMPSON J, 1990, CURR MICROBIOL, V20, P239, DOI 10.1007/BF02089417; THOMPSON J, 1988, J BIOL CHEM, V263, P2064; THOMPSON J, 1991, ADV ENZYMOL, V64, P317; TSAI HJ, 1987, APPL ENVIRON MICROB, V53, P352, DOI 10.1128/AEM.53.2.352-357.1987; ZIMMERMAN CL, 1977, ANAL BIOCHEM, V77, P569, DOI 10.1016/0003-2697(77)90276-7	50	35	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14573	14579						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1650362				2022-12-25	WOS:A1991FZ35100072
J	BORIN, M; SIFFERT, W				BORIN, M; SIFFERT, W			FURTHER CHARACTERIZATION OF THE MECHANISMS MEDIATING THE RISE IN CYTOSOLIC FREE NA+ IN THROMBIN-STIMULATED PLATELETS - EVIDENCE FOR INHIBITION OF THE NA+,K+-ATPASE AND FOR NA+ ENTRY VIA A CA2+ INFLUX PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; K+-PUMP ACTIVITY; CA-2+ MOBILIZATION; ADRENERGIC RECEPTORS; ADENYLATE-CYCLASE; CALCIUM CHANNELS; SMOOTH-MUSCLE; SHAPE CHANGE; MONO-VALENT; CELLS	Human platelets were loaded with the fluorescent Na+-sensitive dye sodium-binding benzofuran isophtalate (SBFI), and changes in the fluorescence excited at 345 and 385 nm were analyzed after manipulations that evoked predictable changes in the cytosolic Na+ concentration ([Na+]i). Raising [Na+]i by either gramicidin D or monensin specifically increased the fluorescence excited at 345 nm and decreased that excited at 385 nm. Hence, calculation of changes in the 345/385 nm excitation ratio yields an estimate of actual changes in [Na+]i. A transient activation of Na+/H+ exchange evoked by addition of acidified platelets to buffer, pH 7.4, evoked a transient rise in [Na+]i. The re-establishment of basal [Na+]i could be prevented by ouabain, indicating an involvement of the Na+,K+-ATPase. Upon stimulation by 0.5 unit/ml of thrombin, [Na+]i immediately increased by 16 +/- 4 mm and this rise continued for at least 60 min after addition of agonist, albeit at a lower rate. This latter sustained rise could not be curtailed by scavenging thrombin by means of hirudin. Addition of ouabain or the phorbol ester 12-O-tetradecanoylphorbol-13-acetate induced a comparable slow rise in the 345/385 excitation ratio. This may indicate a protein kinase C-mediated inhibition by thrombin of the Na+,K+-ATPase. In the absence of extracellular Ca2+ (Ca2+o), the [Na+]i gain was augmented to 38 +/- 9 mM. This additional uptake of Na+ was prevented by (i) Mn2+ ions, (ii) La3+ ions, (iii) the blocker of receptor-mediated Ca2+ entry (1-{beta[3-4-methoxyphenyl)propoxyl]-4-methoxyphenethyl}-1H-imidazole hydrochloride), and (iv) by hirudin which reversed receptor occupancy by thrombin. These findings suggest that the additional thrombin-induced [Na+]i gain in the absence of Ca2+o is due to Na+ influx through a Ca2+ entry pathway. The increase in [Na+]i in the presence of Ca2+o results from Na+ influx via Na+/H+ exchange.	MAX PLANCK INST BIOPHYS,KENNEDYALLEE 70,W-6000 FRANKFURT 70,GERMANY	Max Planck Society								ALMERS W, 1984, J PHYSIOL-LONDON, V353, P565, DOI 10.1113/jphysiol.1984.sp015351; BENHAM CD, 1987, NATURE, V328, P275, DOI 10.1038/328275a0; BERTORELLO A, 1989, AM J PHYSIOL, V254, pF9; BORIN M, 1990, J BIOL CHEM, V265, P19543; BORIN ML, 1989, J LIPID MEDIATOR, V1, P257; CLEMENS N, 1990, PFLUG ARCH EUR J PHY, V416, P68, DOI 10.1007/BF00370224; DIVIRGILIO F, 1988, BIOCHEM J, V256, P959, DOI 10.1042/bj2560959; DOYLE VM, 1985, BIOCHEM BIOPH RES CO, V127, P161, DOI 10.1016/S0006-291X(85)80139-X; EVANS CH, 1988, CALCIUM DRUG ACTION, P527; GHIGO D, 1988, BIOCHIM BIOPHYS ACTA, V940, P141, DOI 10.1016/0005-2736(88)90018-1; GIERSCHIK P, 1988, J CARDIOVASC PHARM, V12, pS20; HALLAM TJ, 1985, J PHYSIOL-LONDON, V368, P131, DOI 10.1113/jphysiol.1985.sp015850; HAROOTUNIAN AT, 1989, J BIOL CHEM, V264, P19458; HEIDENREICH KA, 1980, J CYCLIC NUCL PROT, V6, P217; HESS P, 1986, J GEN PHYSIOL, V88, P293, DOI 10.1085/jgp.88.3.293; HOOTMAN SR, 1987, AM J PHYSIOL, V252, pG499, DOI 10.1152/ajpgi.1987.252.4.G499; HWANG SB, 1986, J BIOL CHEM, V261, P532; JAKOBS KH, 1984, J RECEPTOR RES, V4, P443, DOI 10.3109/10799898409042566; KNUDSEN T, 1989, BRIT J PHARMACOL, V98, P1119, DOI 10.1111/j.1476-5381.1989.tb12655.x; LANSMAN JB, 1990, J GEN PHYSIOL, V95, P679, DOI 10.1085/jgp.95.4.679; LANSMAN JB, 1987, NATURE, V325, P811, DOI 10.1038/325811a0; LOWNDES JM, 1990, BIOCHIM BIOPHYS ACTA, V1052, P143, DOI 10.1016/0167-4889(90)90069-P; LYNCH CJ, 1986, J BIOL CHEM, V261, P4551; MAHAUTSMITH MP, 1990, J BIOL CHEM, V265, P10479; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; MOAKE JL, 1970, BIOCHIM BIOPHYS ACTA, V211, P337, DOI 10.1016/0005-2736(70)90106-9; MOTULSKY HJ, 1983, J BIOL CHEM, V258, P3913; NACHSHEN DA, 1984, J GEN PHYSIOL, V83, P941, DOI 10.1085/jgp.83.6.941; NEGULESCU PA, 1990, CELL REGUL, V1, P259, DOI 10.1091/mbc.1.3.259; OKADA K, 1990, BIOCHEM BIOPH RES CO, V173, P224, DOI 10.1016/S0006-291X(05)81045-9; PERT CB, 1974, MOL PHARMACOL, V10, P868; ROSENBERGER LB, 1980, J BIOL CHEM, V255, P820; SAGE SO, 1987, J BIOL CHEM, V262, P16364; SIESS W, 1989, PHYSIOL REV, V69, P58, DOI 10.1152/physrev.1989.69.1.58; SIFFERT W, 1989, BIOCHEM BIOPH RES CO, V161, P1007, DOI 10.1016/0006-291X(89)91343-0; SIFFERT W, 1987, NATURE, V325, P456, DOI 10.1038/325456a0; SIFFERT W, 1989, BIOCHEM J, V258, P521, DOI 10.1042/bj2580521; TSAI BS, 1978, MOL PHARMACOL, V14, P540; VERHOEVEN AJM, 1985, BIOCHEM J, V228, P451, DOI 10.1042/bj2280451; WANG HY, 1990, LIFE SCI, V47, P1419, DOI 10.1016/0024-3205(90)90520-2; YINGST DR, 1988, ANNU REV PHYSIOL, V50, P291, DOI 10.1146/annurev.ph.50.030188.001451; ZAVOICO GB, 1986, J BIOL CHEM, V261, P3160	42	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1991	266	20					13153	13160						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FX132	1649180				2022-12-25	WOS:A1991FX13200058
J	BUELT, MK; SHEKELS, LL; JARVIS, BW; BERNLOHR, DA				BUELT, MK; SHEKELS, LL; JARVIS, BW; BERNLOHR, DA			INVITRO PHOSPHORYLATION OF THE ADIPOCYTE LIPID-BINDING PROTEIN (P15) BY THE INSULIN-RECEPTOR - EFFECTS OF FATTY-ACID ON RECEPTOR KINASE AND SUBSTRATE PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; 3T3-L1 ADIPOCYTES; ESCHERICHIA-COLI; TYROSINE KINASE; CELL-MEMBRANES; PURIFICATION; EXPRESSION; DIFFERENTIATION; IDENTIFICATION; HOMOLOGY	Phosphorylation of the adipocyte lipid-binding protein (ALBP) isolated from 3T3-L1 cells has been studied in vitro utilizing the wheat germ agglutinin-purified 3T3-L1 adipocyte insulin receptor and the soluble kinase domain of the human insulin receptor. Following insulin-stimulated, ATP-dependent autophosphorylation of the wheat germ agglutinin-purified receptor beta-subunit, ALBP was phosphorylated exclusively on tyrosine 19 in the sequence Glu-Asn-Phe-Asp-Asp-Tyr-19, analogous to the substrate phosphorylation consensus sequence observed for several tyrosyl kinases. The concentration of insulin necessary for half-maximal receptor autophosphorylation (K0.5IR) was identical to that necessary for half-maximal ALBP phosphorylation (K0.5ALBP), 10 nM. Kinetic analysis indicated that stimulation of ALBP phosphorylation by insulin was attributable to a 5-fold increase in the V(max) (to 0.33 fmol/min/fmol insulin-binding sites) while the K(m) for ALBP was largely unaffected. By utilizing the soluble kinase domain of the human receptor beta-subunit, the presence of oleate bound to ALBP increased the k(cat)/K(m) greater than 3-fold. Oleate dramatically inhibited autophosphorylation of the 38-kDa fragment of the soluble receptor kinase in a concentration dependent fashion (I0.5 approximately 4-mu-M). The 48-kDa kinase exhibited much less sensitivity to the effects of oleate (I0.5 approximately 190-mu-M). The inhibition of autophosphorylation of the 48-kDa soluble kinase by oleate was reversed by adding saturating levels of ALBP. These results demonstrate that in vitro the murine adipocyte lipid-binding protein is phosphorylated on tyrosine 19 in an insulin-stimulated fashion by the insulin receptor and that the presence of a bound fatty acid on ALBP increases the affinity of insulin receptor for ALBP. Inhibition of insulin receptor kinase activity by unbound fatty acids suggests that the end products of the lipogenic pathway may feedback inhibit the tyrosyl kinase and that fatty acid-binding proteins have the potential to modulate such interaction.	UNIV MINNESOTA,DEPT BIOCHEM,ST PAUL,MN 55108	University of Minnesota System; University of Minnesota Twin Cities								BAXA CA, 1989, BIOCHEMISTRY-US, V28, P8683, DOI 10.1021/bi00448a003; BERNIER M, 1987, P NATL ACAD SCI USA, V84, P1844, DOI 10.1073/pnas.84.7.1844; BERNLOHR DA, 1985, J BIOL CHEM, V260, P5563; BOHMER FD, 1987, J BIOL CHEM, V262, P15137; BUELT MK, 1990, BIOCHEMISTRY-US, V29, P7408, DOI 10.1021/bi00484a008; CHINANDER LL, 1989, J BIOL CHEM, V264, P19564; CISTOLA DP, 1988, BIOCHEMISTRY-US, V27, P1881, DOI 10.1021/bi00406a013; COBB MH, 1989, J BIOL CHEM, V264, P18701; COHEN S, 1980, J BIOL CHEM, V255, P4834; COOPER JA, 1983, CURR TOP MICROBIOL, V107, P125; CUATRECASAS P, 1972, P NATL ACAD SCI USA, V69, P318, DOI 10.1073/pnas.69.2.318; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FROST SC, 1985, J BIOL CHEM, V260, P2646; HERRERA R, 1988, J BIOL CHEM, V263, P5560; HOUSE C, 1984, EUR J BIOCHEM, V140, P363, DOI 10.1111/j.1432-1033.1984.tb08109.x; HRESKO RC, 1988, P NATL ACAD SCI USA, V85, P8835, DOI 10.1073/pnas.85.23.8835; HUNT CR, 1986, P NATL ACAD SCI USA, V83, P3786, DOI 10.1073/pnas.83.11.3786; ISHAQUE A, 1982, J BIOL CHEM, V257, P592; JACOBS S, 1983, J BIOL CHEM, V258, P9581; JONES TA, 1988, EMBO J, V7, P1597, DOI 10.1002/j.1460-2075.1988.tb02985.x; KOHANSKI RA, 1983, J BIOL CHEM, V258, P7460; KOHANSKI RA, 1985, J BIOL CHEM, V260, P5014; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPE PD, 1986, EUR J BIOCHEM, V156, P351, DOI 10.1111/j.1432-1033.1986.tb09590.x; MATARESE V, 1988, J BIOL CHEM, V263, P14544; MATARESE V, 1990, PROG LIPID RES, V28, P245; MAXHAM CP, 1989, J BIOL CHEM, V264, P13238; MORGAN DO, 1987, P NATL ACAD SCI USA, V84, P41, DOI 10.1073/pnas.84.1.41; Mukerjee P., 1971, NSRDSNBS36; NISHIMURA J, 1982, P NATL ACAD SCI-BIOL, V79, P4303, DOI 10.1073/pnas.79.14.4303; Reed B C, 1980, Adv Enzyme Regul, V18, P97, DOI 10.1016/0065-2571(80)90011-4; ROSEN OM, 1988, FEBS LETT, V231, P397, DOI 10.1016/0014-5793(88)80858-5; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; SACCHETTINI JC, 1989, J MOL BIOL, V208, P327, DOI 10.1016/0022-2836(89)90392-6; SACCHETTINI JC, 1986, J BIOL CHEM, V261, P8218; STADTMAUER LA, 1983, J BIOL CHEM, V258, P6682; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; SWEETSER DA, 1987, ANNU REV NUTR, V7, P337, DOI 10.1146/annurev.nu.07.070187.002005; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; WAGGONER DW, 1990, J BIOL CHEM, V265, P11417; WOOTAN MG, 1990, BIOCHEMISTRY-US, V20, P9305	41	44	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1991	266	19					12266	12271						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FV180	1648089				2022-12-25	WOS:A1991FV18000028
J	MYERS, MG; BACKER, JM; SIDDLE, K; WHITE, MF				MYERS, MG; BACKER, JM; SIDDLE, K; WHITE, MF			THE INSULIN-RECEPTOR FUNCTIONS NORMALLY IN CHINESE-HAMSTER OVARY CELLS AFTER TRUNCATION OF THE C-TERMINUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; MONOCLONAL-ANTIBODIES; BETA-SUBUNIT; PROTEIN-KINASE; PHOSPHORYLATION; AUTOPHOSPHORYLATION; REPLACEMENT; BINDING; SITES; ENDOCYTOSIS	We studied the structure and function of the human insulin receptor (IR) and a mutant which lacked the last 43 amino acids of the beta-subunit (IR-DELTA-ct). This deletion removed tyrosine (Tyr1322, Tyr1316) and threonine (Thr1336) phosphorylation sites. In Chinese hamster ovary (CHO) cells, insulin binding to the mutant receptor was normal, and [S-35]methionine labeling indicated that both the IR and IR-DELTA-ct were processed normally; however, the beta-subunit of IR-DELTA-ct was 5 kDa smaller than that of the IR. The time course of insulin-stimulated autophosphorylation of the partially purified IR-DELTA-ct was normal, but the maximum autophosphorylation was reduced 20-30%. Tryptic phosphopeptide mapping confirmed the absence of the C-terminal phosphorylation sites and indicated that phosphorylation of the regulatory region (Tyr1146, Tyr1150, Tyr1151) occurred normally; kinase activity of the IR and IR-DELTA-ct was activated normally by insulin-stimulated autophosphorylation. In the intact CHO cells, insulin-stimulated serine and threonine phosphorylation of the IR-DELTA-ct was reduced 20%, suggesting that most Ser/Thr phosphorylation sites are located outside of the C terminus. During insulin stimulation, the wild-type and mutant insulin receptor activated the phosphatidylinositol 3-kinase. Moreover, insulin itself or human-specific anti-insulin receptor antibodies stimulated glycogen and DNA synthesis equally in both CHO/IR and CHO/IR-DELTA-ct cells. These data suggest that the C terminus plays a minimal role in IR function and signal transmission in CHO cells.	HARVARD UNIV,SCH MED,DEPT MED,JOSLIN DIABET CTR,DIV RES,1 JOSLIN PL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK008126, R29DK038712, R01DK038712, R01DK008126, R55DK038712, P30DK036836] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38712, DK36836, DK08126] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRINDLE NPJ, 1990, BIOCHEM J, V268, P615, DOI 10.1042/bj2680615; CHOU CK, 1987, J BIOL CHEM, V262, P1842; DEBANT A, 1988, P NATL ACAD SCI USA, V85, P8032, DOI 10.1073/pnas.85.21.8032; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; FLORESRIVEROS JR, 1989, J BIOL CHEM, V264, P21557; GOREN HJ, 1987, BIOCHEMISTRY-US, V26, P2374, DOI 10.1021/bi00382a044; HARING HU, 1984, BIOCHEMISTRY-US, V23, P3298, DOI 10.1021/bi00309a028; HAWLEY DM, 1989, J BIOL CHEM, V264, P2438; KARASIK A, 1990, J BIOL CHEM, V265, P10226; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; LEWIS RE, 1990, BIOCHEMISTRY-US, V29, P1807, DOI 10.1021/bi00459a020; LEWIS RE, 1990, J BIOL CHEM, V265, P947; MAEGAWA H, 1988, J BIOL CHEM, V263, P8912; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MCCLAIN DA, 1988, J BIOL CHEM, V263, P8904; RODBARD D, 1980, CANCER, V46, P2907, DOI 10.1002/1097-0142(19801215)46:12+<2907::AID-CNCR2820461433>3.0.CO;2-6; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SOOS MA, 1989, P NATL ACAD SCI USA, V86, P5217, DOI 10.1073/pnas.86.14.5217; STEELEPERKINS G, 1990, J BIOL CHEM, V265, P9458; SUNG CK, 1989, J BIOL CHEM, V264, P18951; THIES RS, 1989, J BIOL CHEM, V264, P12820; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WHITE MF, 1989, J CELL BIOCHEM, V39, P429, DOI 10.1002/jcb.240390409; WHITE MF, 1985, J BIOL CHEM, V260, P9470; WILDEN PA, 1990, P NATL ACAD SCI USA, V87, P3358, DOI 10.1073/pnas.87.9.3358; YU KT, 1984, J BIOL CHEM, V259, P5277	31	86	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10616	10623						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	1645354				2022-12-25	WOS:A1991FP08600092
J	OLASHAW, NE; KUSMIK, W; DANIEL, TO; PLEDGER, WJ				OLASHAW, NE; KUSMIK, W; DANIEL, TO; PLEDGER, WJ			BIOCHEMICAL AND FUNCTIONAL DISCRIMINATION OF PLATELET-DERIVED GROWTH FACTOR-ALPHA AND FACTOR-BETA RECEPTORS IN BALB/C-3T3 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENT DIMERIC FORMS; PHOSPHOLIPASE-C-GAMMA; SWISS 3T3 CELLS; PDGF RECEPTOR; B-CHAIN; DIFFERENT ISOFORMS; TYROSINE KINASE; CDNA CLONING; A-CHAIN; EXPRESSION	Three biologically active isoforms of platelet-derived growth factor (PDGF) exist: PDGF-AB, the predominant form in human platelets; PDGF-BB, the product of the c-sis protooncogene; and PDGF-AA. PDGF-BB and PDGF-AB interact with two distinct PDGF receptors (termed alpha and beta) of similar size, whereas PDGF-AA binds-alpha-receptors only. To dissect-alpha and beta-receptor-mediated signals, we compared the biological activities of PDGF-AA and PDGF-BB in density-arrested BALB/c-3T3 cells, which possess a 4:1 ratio of beta to alpha-receptors, and assessed the contribution of alpha-receptors to PDGF-BB- and PDGF-AB-induced responses. In addition, we describe a convenient method for resolving alpha and beta-receptors on one-dimensional protein gels. This protocol involves treatment of cells with neuraminidase, a desialylating agent, and subsequent in vitro autophosphorylation of solubilized cells, and was used to monitor the presence or absence of alpha and beta-receptors under various experimental conditions. Our data show that although higher concentrations were required, PDGF-AA stimulated DNA synthesis to the same extent as did PDGF-BB. Both isoforms induced inositol phosphate formation, epidermal growth factor transmodulation, and PDGF receptor autophosphorylation; PDGF-AA, however, was less effective than was PDGF-BB even at doses causing maximal mitogenesis. Pretreatment of cells with PDGF-AA for 30-60 min at 37-degrees-C effectively down-regulated alpha-receptors as verified by the absence of desialylated alpha-receptor phosphorylation. Depletion of alpha-receptors did not affect the capacity of PDGF-BB or PDGF-AB to activate the beta-receptor tyrosine kinase, as assessed by tyrosine phosphorylation of an endogenous substrate, or stimulate the formation of inositol phosphates. We suggest that alpha and beta-receptors independently mediate similar biological responses in BALB/c-3T3 cells,and that alpha-receptors are not required for responses induced by PDGF-BB or PDGF-AB.	CREAT BIOMOLECULES INC,HOPKINTON,MA 01748; VANDERBILT UNIV,MED CTR,SCH MED,DEPT NEPHROL,NASHVILLE,TN 37232	Vanderbilt University	OLASHAW, NE (corresponding author), VANDERBILT UNIV,MED CTR,SCH MED,DEPT CELL BIOL,NASHVILLE,TN 37232, USA.				NATIONAL CANCER INSTITUTE [R01CA042713, R01CA042636] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038517] Funding Source: NIH RePORTER; NCI NIH HHS [CA42636, CA42713] Funding Source: Medline; NIDDK NIH HHS [DK38517] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERRIDGE MJ, 1984, BIOCHEM J, V222, P195, DOI 10.1042/bj2220195; BISHAYEE S, 1986, P NATL ACAD SCI USA, V83, P6756, DOI 10.1073/pnas.83.18.6756; BOCKUS BJ, 1984, EXP CELL RES, V153, P186, DOI 10.1016/0014-4827(84)90460-9; BOWENPOPE DF, 1989, J BIOL CHEM, V264, P2502; BOWENPOPE DF, 1982, J BIOL CHEM, V257, P5161; CHIU IM, 1984, CELL, V37, P123; CLAESSONWELSH L, 1987, P NATL ACAD SCI USA, V84, P8796, DOI 10.1073/pnas.84.24.8796; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; CLAESSONWELSH L, 1989, J BIOL CHEM, V264, P1742; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; COLLINS MKL, 1983, J BIOL CHEM, V258, P1689; DANIEL TO, 1986, J BIOL CHEM, V261, P9579; DANIEL TO, 1987, J BIOL CHEM, V262, P9778; DEUEL TF, 1983, SCIENCE, V221, P1348, DOI 10.1126/science.6310754; ESCOBEDO JA, 1988, MOL CELL BIOL, V8, P5126, DOI 10.1128/MCB.8.12.5126; FRANTZ CN, 1980, J CELL PHYSIOL, V105, P439, DOI 10.1002/jcp.1041050308; GRONWALD RGK, 1988, P NATL ACAD SCI USA, V85, P3435, DOI 10.1073/pnas.85.10.3435; HABENICHT AJR, 1981, J BIOL CHEM, V256, P2329; HAMMACHER A, 1988, J BIOL CHEM, V263, P16493; HAMMACHER A, 1988, EUR J BIOCHEM, V176, P179, DOI 10.1111/j.1432-1033.1988.tb14266.x; HAMMACHER A, 1989, EMBO J, V8, P2489, DOI 10.1002/j.1460-2075.1989.tb08385.x; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HELDIN CH, 1982, J BIOL CHEM, V257, P4216; HELDIN CH, 1986, NATURE, V319, P511, DOI 10.1038/319511a0; HERMAN B, 1985, J CELL BIOL, V100, P1031, DOI 10.1083/jcb.100.4.1031; HOSANG M, 1989, J CELL PHYSIOL, V140, P558, DOI 10.1002/jcp.1041400322; JOHNSSON A, 1984, EMBO J, V3, P921, DOI 10.1002/j.1460-2075.1984.tb01908.x; KAZLAUSKAS A, 1988, EMBO J, V7, P3727, DOI 10.1002/j.1460-2075.1988.tb03256.x; KEATING MT, 1987, J BIOL CHEM, V262, P7932; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MATSUI T, 1989, P NATL ACAD SCI USA, V86, P8314, DOI 10.1073/pnas.86.21.8314; MATUOKA K, 1988, SCIENCE, V239, P640, DOI 10.1126/science.2829356; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; NISTER M, 1988, CELL, V52, P791, DOI 10.1016/0092-8674(88)90421-7; OLASHAW NE, 1986, P NATL ACAD SCI USA, V83, P3834, DOI 10.1073/pnas.83.11.3834; OLASHAW NE, 1988, 2ND ADV MESS PHOSPH, V22, P139; PARIS S, 1987, J BIOL CHEM, V262, P1970; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; PLEDGER WJ, 1981, P NATL ACAD SCI-BIOL, V78, P4358, DOI 10.1073/pnas.78.7.4358; SACHINIDIS A, 1990, J BIOL CHEM, V265; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; STROOBANT P, 1984, EMBO J, V3, P2963, DOI 10.1002/j.1460-2075.1984.tb02241.x; SUH PG, 1988, J BIOL CHEM, V263, P14497; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WESTERMARK B, 1986, P NATL ACAD SCI USA, V83, P7197, DOI 10.1073/pnas.83.19.7197; WHARTON W, 1982, P NATL ACAD SCI-BIOL, V79, P5567, DOI 10.1073/pnas.79.18.5567; WRANN M, 1980, SCIENCE, V210, P1363, DOI 10.1126/science.6254158; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	54	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10234	10240						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	1645344				2022-12-25	WOS:A1991FP08600038
J	SWANSON, RV; ZHOU, JH; LEARY, JA; WILLIAMS, T; DELORIMIER, R; BRYANT, DA; GLAZER, AN				SWANSON, RV; ZHOU, JH; LEARY, JA; WILLIAMS, T; DELORIMIER, R; BRYANT, DA; GLAZER, AN			CHARACTERIZATION OF PHYCOCYANIN PRODUCED BY CPCE AND CPCF MUTANTS AND IDENTIFICATION OF AN INTERGENIC SUPPRESSOR OF THE DEFECT IN BILIN ATTACHMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; CYANOBACTERIUM AGMENELLUM-QUADRUPLICATUM; RHODOPHYTE CYANIDIUM-CALDARIUM; CRYSTAL-STRUCTURE ANALYSIS; SITE-SPECIFIC MUTAGENESIS; GAMMA-N-METHYLASPARAGINE; BILIVERDIN-IX-ALPHA; SP STRAIN PCC-6701; BLUE-GREEN-ALGAE; C-PHYCOCYANIN	Mutants of the cyanobacterium Synechococcus sp. PCC 7002 constructed by the insertional inactivation of either the cpcE or cpcF gene produce low levels of spectroscopically detectable phycocyanin. The majority of the phycocyanin produced in these strains appears to lack the alpha-subunit phycocyanobilin (PCB) chromophore (Zhou, J., Gasparich, G. E., Stirewalt, V. L., de Lorimier, R., and Bryant, D. A. (1992) J. Biol. Chem. 267, 16138-16145). Purification of the phycocyanin produced in the mutants revealed two fractions each with an aberrant absorption spectrum. Tryptic peptide maps of the major fraction showed that the alpha-84 PCB peptide was absent. The two PCB peptides derived from the beta-subunit were normal. Tryptic digests of the less abundant phycocyanin fraction contained a family of bilin peptides derived from the alpha-subunit. Several distinct bilin adducts were present. A major component was a mesobiliverdin adduct, a previously described product of the in vitro reaction of PCB and apophycocyanin. The same results were obtained with both the cpcE mutant and the cpcF mutant. In vitro reactions with PCB and the fractions containing apo-alpha-subunit showed that the alpha-84 bilin attachment site was unmodified and competent for adduct formation. Pseudo-revertants of both strains were observed to arise at high frequency. Analysis of the phycocyanin from a cpcE pseudo-revertant, which produced a near wild-type level of phycocyanin with alpha-subunit carrying PCB, revealed a single amino acid substitution, alpha-Tyr129 --> Cys. This residue, which is conserved in all phycocyanins sequenced to date, forms part of the alpha-84 bilin binding site and lies within 5 angstrom of alpha-Cys84. A mutated cpcA gene containing this substitution was constructed by site-directed mutagenesis and transformed, along with cpcB, into a cpcBAC deletion strain containing an insertionally inactivated cpcE. This strain produces high levels of phycocyanin and the majority of the alpha-subunit carries PCB at alpha-Cys84.	UNIV CALIF BERKELEY, DIV BIOCHEM & MOLEC BIOL, STANLEY DONNER ASU, 229 STANLEY HALL, BERKELEY, CA 94720 USA; UNIV CALIF BERKELEY, COLL CHEM, BERKELEY, CA 94720 USA; PENN STATE UNIV, DEPT MOLEC & CELL BIOL, UNIV PK, PA 16802 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University				Swanson, Ronald/0000-0002-6486-2676	NIGMS NIH HHS [GM31625, GM 08352, GM28994] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031625, T32GM008352, R01GM028994] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON LK, 1990, J BACTERIOL, V172, P1297, DOI 10.1128/jb.172.3.1297-1305.1990; ANDERSON LK, 1987, J BACTERIOL, V169, P102, DOI 10.1128/jb.169.1.102-109.1987; ANDERSON LK, 1990, J BACTERIOL, V172, P1289, DOI 10.1128/jb.172.3.1289-1296.1990; ARCIERO DM, 1988, J BIOL CHEM, V263, P18343; ARCIERO DM, 1988, J BIOL CHEM, V263, P18358; ARCIERO DM, 1988, J BIOL CHEM, V263, P18350; BEALE SI, 1991, J BIOL CHEM, V266, P22328; BEALE SI, 1984, PLANT PHYSIOL, V76, P7, DOI 10.1104/pp.76.1.7; BEALE SI, 1991, J BIOL CHEM, V266, P22333; BEALE SI, 1991, J BIOL CHEM, V266, P22341; BEALE SI, 1983, ARCH BIOCHEM BIOPHYS, V227, P279, DOI 10.1016/0003-9861(83)90372-7; BELKNAP WR, 1987, EMBO J, V6, P871, DOI 10.1002/j.1460-2075.1987.tb04833.x; BROWN SB, 1984, BIOCHEM J, V219, P905, DOI 10.1042/bj2190905; BROWN SB, 1981, BIOCHEM J, V194, P137, DOI 10.1042/bj1940137; BRYANT DA, 1985, FEMS MICROBIOL LETT, V29, P343, DOI 10.1111/j.1574-6968.1985.tb00888.x; BRYANT DA, 1978, J BIOL CHEM, V253, P220; BRYANT DA, 1990, ARCH MICROBIOL, V153, P550, DOI 10.1007/BF00245264; BRYANT DA, 1976, ARCH MICROBIOL, V110, P61, DOI 10.1007/BF00416970; BRYANT DA, 1989, LIGHT ENERGY TRANSDU, P62; BRYANT DA, 1991, PHOTOSYNTHETIC APP B, V7, P255; BUZBY JS, 1985, SCIENCE, V230, P805, DOI 10.1126/science.2997920; DELORIMIER R, 1990, ARCH MICROBIOL, V153, P541, DOI 10.1007/BF00245263; DELORIMIER R, 1984, P NATL ACAD SCI-BIOL, V81, P7946; DEMARSAC NT, 1990, FEMS SYMP, V53, P143; DUBBS JM, 1990, THESIS PENNSYLVANIA; DUERRING M, 1991, J MOL BIOL, V217, P577, DOI 10.1016/0022-2836(91)90759-Y; DUERRING M, 1990, J MOL BIOL, V211, P633, DOI 10.1016/0022-2836(90)90270-V; DUMONT ME, 1987, EMBO J, V6, P235, DOI 10.1002/j.1460-2075.1987.tb04744.x; ELHAI J, 1988, GENE, V68, P119, DOI 10.1016/0378-1119(88)90605-1; FREIDENREICH P, 1978, J BIOL CHEM, V253, P212; FRIEDMAN M, 1970, J BIOL CHEM, V245, P3868; Glazer A. N., 1981, The biochemistry of plants. A comprehensive treatise. Volume 8. Photosynthesis., P51; GLAZER AN, 1989, J BIOL CHEM, V264, P1; GLAZER AN, 1973, J BIOL CHEM, V248, P663; HOUMARD J, 1972, P NATL ACAD SCI USA, V69, P3506, DOI 10.1073/pnas.69.12.3506; KLOTZ AV, 1987, J BIOL CHEM, V262, P17350; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAGARIAS JC, 1988, J BIOL CHEM, V263, P12977; MAZEL D, 1988, MOL GEN GENET, V211, P296, DOI 10.1007/BF00330607; NICHOLSON DW, 1989, J BIOL CHEM, V264, P10156; OFFNER GD, 1981, J BIOL CHEM, V256, P2167; ONG LJ, 1987, J BIOL CHEM, V262, P6323; PILOT TJ, 1984, P NATL ACAD SCI-BIOL, V81, P6983, DOI 10.1073/pnas.81.22.6983; SCHIRMER T, 1986, J MOL BIOL, V188, P651, DOI 10.1016/S0022-2836(86)80013-4; SCHIRMER T, 1987, J MOL BIOL, V196, P677, DOI 10.1016/0022-2836(87)90040-4; SHACKLETON CHL, 1991, J CHROMATOGR-BIOMED, V562, P175, DOI 10.1016/0378-4347(91)80576-X; SIDLER W, 1981, H-S Z PHYSIOL CHEM, V362, P611, DOI 10.1515/bchm2.1981.362.1.611; STEVENS SE, 1973, J PHYCOL, V9, P427, DOI 10.1111/j.1529-8817.1973.tb04116.x; STEVENS SE, 1980, P NATL ACAD SCI-BIOL, V77, P6052, DOI 10.1073/pnas.77.10.6052; STUART RA, 1990, J BIOL CHEM, V265, P20210; SWANSON RV, 1991, J BIOL CHEM, V266, P9528; SWANSON RV, 1990, J MOL BIOL, V214, P787, DOI 10.1016/0022-2836(90)90293-U; TROXLER RF, 1966, PLANT PHYSIOL, V41, P491, DOI 10.1104/pp.41.3.491; TROXLER RF, 1981, J BIOL CHEM, V256, P2176; YEH SW, 1986, J PHYS CHEM-US, V90, P4578, DOI 10.1021/j100410a021; ZHOU JH, 1992, J BIOL CHEM, V267, P16138	57	60	70	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16146	16154						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1644802				2022-12-25	WOS:A1992JJ45800028
J	VANRYK, DI; LEE, Y; NAZAR, RN				VANRYK, DI; LEE, Y; NAZAR, RN			UNBALANCED RIBOSOME ASSEMBLY IN SACCHAROMYCES-CEREVISIAE EXPRESSING MUTANT 5-S RIBOSOMAL-RNAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-PROTEIN COMPLEX; KETHOXAL-REACTIVE SITES; INTERNAL CONTROL REGION; HIGHER-ORDER STRUCTURE; 5S RNA; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; RIBONUCLEIC-ACID; THERMOMYCES-LANUGINOSUS; SECONDARY STRUCTURE	Mutant 5 S rRNA genes were expressed in Saccharomyces cerevisiae to further define the function of the ribosomal 5 S RNA. RNA synthesis and utilization were assayed using previously constructed markers which have been shown to be functionally neutral and easily detected by gel electrophoresis. Most mutations were found not to affect the growth rate because they were poorly expressed or could be accommodated effectively in the ribosomal structure. Two of the mutants, Y5A99U56U57 and Y5U90i5 adversely affected cell growth as well as protein synthesis in vitro. Polyribosome profiles in both of these mutants were substantially shorter, and an analysis of the ribosomal subunit composition revealed a significant imbalance with a 25-35% excess in 40 S subunits. Kinetic analyses of RNA labeling indicated very low cellular levels of mutant RNA either because it was poorly expressed (Y5U90i5) or rapidly degraded before being incorporated into mature 60 subunits (Y5A99U56U57). The results suggest that the 5 S RNA is required for the assembly of stable ribosomal 60 S subunits and raise the possibility that this RNA or, more likely, its corresponding ribonucleoprotein complex is critical for subunit assembly or even RNA processing.			VANRYK, DI (corresponding author), UNIV GUELPH, DEPT MOLEC BIOL & GENET, GUELPH N1G 2W1, ONTARIO, CANADA.							ANDERSEN J, 1982, J BIOL CHEM, V257, P9114; AUBERT M, 1973, BIOCHIMIE, V55, P135, DOI 10.1016/S0300-9084(73)80385-2; AZAD AA, 1979, NUCLEIC ACIDS RES, V7, P1913, DOI 10.1093/nar/7.7.1913; BIEKER JJ, 1985, CELL, V40, P119, DOI 10.1016/0092-8674(85)90315-0; BLACK DL, 1985, CELL, V42, P737, DOI 10.1016/0092-8674(85)90270-3; BLOBEL G, 1971, P NATL ACAD SCI USA, V68, P1881, DOI 10.1073/pnas.68.8.1881; BOGENHAGEN DF, 1981, CELL, V24, P261, DOI 10.1016/0092-8674(81)90522-5; CHALLICE JM, 1989, J BIOL CHEM, V264, P20060; Erdmann V A, 1976, Prog Nucleic Acid Res Mol Biol, V18, P45, DOI 10.1016/S0079-6603(08)60586-3; FABER NM, 1981, J MOL BIOL, V146, P223; FOX GE, 1975, NATURE, V256, P505, DOI 10.1038/256505a0; GARRETT RA, 1981, TRENDS BIOCHEM SCI, V6, P137, DOI 10.1016/0968-0004(81)90051-7; GARRETT RA, 1979, J MOL BIOL, V132, P637, DOI 10.1016/0022-2836(79)90379-6; GARRETT RA, 1979, INT REV BIOCHEM, V25, P121; GASIOR E, 1979, J BIOL CHEM, V254, P3965; HANCOCK J, 1982, NUCLEIC ACIDS RES, V10, P1257, DOI 10.1093/nar/10.4.1257; HINNEN A, 1978, P NATL ACAD SCI USA, V75, P1929, DOI 10.1073/pnas.75.4.1929; HORI H, 1976, MOL GEN GENET, V145, P119, DOI 10.1007/BF00269583; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LO AC, 1982, J BIOL CHEM, V257, P3516; LUOMA GA, 1978, P NATL ACAD SCI USA, V75, P4901, DOI 10.1073/pnas.75.10.4901; MCDOUGALL J, 1983, J BIOL CHEM, V258, P5256; MCDOUGALL J, 1987, NUCLEIC ACIDS RES, V15, P161, DOI 10.1093/nar/15.1.161; NAZAR RN, 1991, J BIOL CHEM, V266, P4562; NAZAR RN, 1983, NUCLEIC ACIDS RES, V11, P3155, DOI 10.1093/nar/11.10.3155; NAZAR RN, 1991, BIOCHEM CELL BIOL, V69, P217, DOI 10.1139/o91-033; NISHIKAW.K, 1974, FEBS LETT, V40, P106, DOI 10.1016/0014-5793(74)80904-X; NOLLER HF, 1979, J MOL BIOL, V132, P621, DOI 10.1016/0022-2836(79)90378-4; PEATTIE DA, 1979, P NATL ACAD SCI USA, V76, P1760, DOI 10.1073/pnas.76.4.1760; PICARD B, 1979, P NATL ACAD SCI USA, V76, P241, DOI 10.1073/pnas.76.1.241; PIELER T, 1987, CELL, V48, P91, DOI 10.1016/0092-8674(87)90359-X; RAACKE ID, 1971, P NATL ACAD SCI USA, V68, P2357, DOI 10.1073/pnas.68.10.2357; RUBIN GM, 1973, J BIOL CHEM, V248, P3860; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVINO R, 1990, EMBO J, V9, P2299, DOI 10.1002/j.1460-2075.1990.tb07401.x; STEELE WJ, 1965, J BIOL CHEM, V240, P1742; SZOSTAK JW, 1979, PLASMID, V2, P536, DOI 10.1016/0147-619X(79)90053-2; TANG BZ, 1991, J BIOL CHEM, V266, P6120; Torano A, 1974, Methods Enzymol, V30, P254; Traut R. R., 1980, RIBOSOMES STRUCTURE, P89; VANRYK DI, 1990, J BIOL CHEM, V265, P8377; WAGNER R, 1978, NUCLEIC ACIDS RES, V5, P4065, DOI 10.1093/nar/5.11.4065; WARNER JR, 1982, MOL BIOL YEAST SACCH, P529; WEIDNER H, 1977, NATURE, V266, P193, DOI 10.1038/266193a0; Wettenhall R E, 1974, Methods Enzymol, V30, P186; WILDEMAN AG, 1981, J BIOL CHEM, V256, P5675; WILDEMAN AG, 1982, J BIOL CHEM, V257, P1395; WILLICK GE, 1980, BIOCHEMISTRY-US, V19, P2738, DOI 10.1021/bi00553a031	48	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16177	16181						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1644804				2022-12-25	WOS:A1992JJ45800032
J	LIM, K; CHAE, CB				LIM, K; CHAE, CB			PRESENCE OF A REPRESSOR PROTEIN FOR TESTIS-SPECIFIC H2B (TH2B) HISTONE GENE IN EARLY STAGES OF SPERMATOGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TRANSCRIPTION REGULATORY ELEMENTS; DNA; EXPRESSION; PROMOTER; RNA	The rat testis-specific TH2B histone gene assumes a hypomethylated chromatin structure at all stages of spermatogenesis. However, the TH2B mRNA level is very low in pre-meiotic spermatogenic cells and rises sharply in meiotic pachytene spermatocytes. The low level of TH2B mRNA in pre-meiotic spermatogenic cells appears to be a result of transcriptional repression of the gene by a pre-meiotic cell-specific protein which binds to a site between the TATA element and the transcription initiation site of TH2B gene.	UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020136] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-20136] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BRANSON RE, 1975, ARCH BIOCHEM BIOPHYS, V168, P403, DOI 10.1016/0003-9861(75)90269-6; CHOI YC, 1991, J BIOL CHEM, V266, P20504; CLERMONT Y, 1957, AM J ANAT, V100, P241, DOI 10.1002/aja.1001000205; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HUH NE, 1991, NUCLEIC ACIDS RES, V19, P93, DOI 10.1093/nar/19.1.93; HWANG I, 1990, MOL CELL BIOL, V10, P585, DOI 10.1128/MCB.10.2.585; HWANG IH, 1989, MOL CELL BIOL, V9, P1005, DOI 10.1128/MCB.9.3.1005; KIM YJ, 1987, DEV BIOL, V124, P23, DOI 10.1016/0012-1606(87)90455-6; MEISTRICH M L, 1987, P333; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; Setchell B.P., 1978, THE MAMMALIAN TESTIS; VERNON RG, 1971, CAN J BIOCHEM CELL B, V49, P761, DOI 10.1139/o71-107; WOLGEMUTH DJ, 1985, GAMETE RES, V12, P1, DOI 10.1002/mrd.1120120102	13	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15271	15273						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1639772				2022-12-25	WOS:A1992JG11300004
J	MASLINSKI, W; REMILLARD, B; TSUDO, M; STROM, TB				MASLINSKI, W; REMILLARD, B; TSUDO, M; STROM, TB			INTERLEUKIN-2 (IL-2) INDUCES TYROSINE KINASE-DEPENDENT TRANSLOCATION OF ACTIVE RAF-1 FROM THE IL-2 RECEPTOR INTO THE CYTOSOL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							P70-75 BETA-SUBUNIT; SIGNAL TRANSDUCTION; PROTEIN-KINASE; ALPHA-CHAIN; PHOSPHORYLATION; ACTIVATION; EXPRESSION; DISTINCT; BINDING; INTERNALIZATION	Stimulation of the interleukin-2 (IL-2) receptor results in phosphorylation and activation of cytosolic Raf-1 serine/threonine kinase. Herein, we report that enzymatically active Raf-1 is physically associated with the IL-2 receptor beta-chain (p75) in T-cell blasts. Following stimulation with IL-2, Raf-1 dissociates from the IL-2 receptor complex and translocates to the cytosol. Genistein, a protein tyrosine kinase inhibitor, prevents the dissociation of enzymatically active Raf-1 from the ligand-stimulated IL-2 receptor complex. These data favor a model of IL-2 receptor activation in which an IL-2-activated protein tyrosine kinase phosphorylates the IL-2 receptor and/or receptor-bound Raf-1. Following tyrosine phosphorylation, enzymatically active Raf-1 dissociates from the IL-2 receptor and translocates into the cytosol.	HARVARD UNIV,SCH MED,BOSTON,MA 02115; NEW ENGLAND DEACONESS HOSP,DEACONESS JOSLIN DIV NEPHROL,BOSTON,MA 02215; UNITIKA CENT HOSP,KYOTO,JAPAN	Harvard University; Harvard Medical School	MASLINSKI, W (corresponding author), BETH ISRAEL HOSP,DEPT MED,DIV IMMUNOL,RM RE 319,BOSTON,MA 02215, USA.		Maslinski, Wlodzimierz/T-7078-2019	Maslinski, Wlodzimierz/0000-0001-5597-9373	NCI NIH HHS [UO1 CA 48626] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA048626] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; ASAO H, 1990, J EXP MED, V171, P637, DOI 10.1084/jem.171.3.637; BACCARINI M, 1991, J BIOL CHEM, V266, P10941; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BENEDICT SH, 1987, J IMMUNOL, V139, P1694; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; ETTEHADIEH E, 1992, SCIENCE, V255, P853, DOI 10.1126/science.1311128; FARRAR WL, 1989, J BIOL CHEM, V264, P12562; FERRIS DK, 1989, J IMMUNOL, V143, P870; FUNG MR, 1991, J IMMUNOL, V147, P1253; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HATAKEYAMA M, 1987, J EXP MED, V166, P362, DOI 10.1084/jem.166.2.362; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; KONDO S, 1987, NATURE, V327, P64, DOI 10.1038/327064a0; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; MERIDA I, 1991, J IMMUNOL, V147, P2202; MERIDA I, 1990, J BIOL CHEM, V265, P5690; MILLS GB, 1990, J BIOL CHEM, V265, P3561; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; REMILLARD B, 1991, J BIOL CHEM, V266, P14167; SALTZMAN EM, 1988, J BIOL CHEM, V263, P6959; SHARON M, 1990, P NATL ACAD SCI USA, V87, P4869, DOI 10.1073/pnas.87.12.4869; SMITH KA, 1989, ANNU REV CELL BIOL, V5, P397; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; TESHIGAWARA K, 1987, J EXP MED, V165, P223, DOI 10.1084/jem.165.1.223; TSUDO M, 1989, P NATL ACAD SCI USA, V86, P1982, DOI 10.1073/pnas.86.6.1982; TSUDO M, 1986, P NATL ACAD SCI USA, V83, P9694, DOI 10.1073/pnas.83.24.9694; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; WALDMANN TA, 1989, ANNU REV BIOCHEM, V58, P875, DOI 10.1146/annurev.bi.58.070189.004303; WALDMANN TA, 1991, J BIOL CHEM, V266, P2681; ZMUIDZINAS A, 1991, MOL CELL BIOL, V11, P2794, DOI 10.1128/MCB.11.5.2794	37	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15281	15284						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1639773				2022-12-25	WOS:A1992JG11300007
J	SATO, M; GRASSER, W; HARM, S; FULLENKAMP, C; GORSKI, JP				SATO, M; GRASSER, W; HARM, S; FULLENKAMP, C; GORSKI, JP			BONE ACIDIC GLYCOPROTEIN-75 INHIBITS RESORPTION ACTIVITY OF ISOLATED RAT AND CHICKEN OSTEOCLASTS	FASEB JOURNAL			English	Article						OSTEOCLAST; BONE RESORPTION; POLYMERIZATION; BONE MATRIX; PHOSPHOPROTEINS	VITRONECTIN RECEPTOR; COLLAGENASE PRODUCTION; EXTRACELLULAR-MATRIX; RESORBING AGENTS; CELLS; FIBRONECTIN; BINDING; CULTURE; OSTEOPONTIN; ATTACHMENT	Matrix protein effects on the differentiated activity of osteoclasts were examined in order to understand the functional significance of bone protein interactions with osteoclasts. Bone acidic glycoprotein 75 (BAG 75) from rat calvariae inhibited the resorption of bone by isolated rat osteoclasts with IC50 = 1 nM compared to IC50 = 10 nM for chicken osteoclasts. By contrast, other phosphoproteins similarly isolated from bone were less effective in inhibiting resorption with IC50 = 100 nM osteopontin and IC50 > 100 nM bone sialoprotein. Likewise, RGD-containing matrix proteins vitronectin, thrombospondin, and fibronectin all displayed IC50 greater-than-or-equal-to 100 nM. Mechanistically, 10 nM BAG 75 marginally slowed, but did not block, the association of bone particles with chicken osteoclasts compared with osteopontin or control media. Pretreatment of osteoclasts with 50 nM BAG 75 had no effect on subsequent bone resorption; however, pretreatment of bone with BAG 75 before incubation with osteoclasts reduced the extent of resorption by 55%. These data suggest that a BAG 75/bone surface complex, rather than BAG 75 alone, represents the inhibitory form. Consistent with this hypothesis, direct binding studies provided no evidence of specific, high-affinity receptors on osteoclasts for BAG 75, nor was an excess of BAG 75 (100 nM) able to compete with 0.3 nM sechistatin for osteoclastic a(v)B3-like receptors. However, BAG 75 displayed cooperative binding to tissue fragments and bone particles at concentrations greater than 10 nM, suggesting that BAG 75 self-associates into higher-order species on bone surfaces. Electron microscopy confirmed the time-dependent polymerization of BAG 75 into interconnecting filaments. These data suggest a novel, inhibitory activity for surface-bound BAG 75 on bone resorption that does not appear to involve the osteoclastic a(v)B3-like integrin.	MERCK SHARP & DOHME LTD,DEPT BONE BIOL & OSTEOPOROSIS RES,W POINT,PA 19486; UNIV MISSOURI,SCH BASIC LIFE SCI,DIV MOLEC BIOL & BIOCHEM,KANSAS CITY,MO 64110	Merck & Company; University of Missouri System; University of Missouri Kansas City					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R15AR040923] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR40923] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AKIYAMA SK, 1985, J BIOL CHEM, V260, P4492; AKIYAMA SK, 1985, J BIOL CHEM, V260, P402; BARON R, 1990, PRIMER METABOLIC BON, P3; BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207; BLAIR HC, 1986, J CELL BIOL, V102, P1164, DOI 10.1083/jcb.102.4.1164; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; CHAMBERS TJ, 1985, CELL TISSUE RES, V241, P671; CHAMBERS TJ, 1984, J CELL SCI, V70, P61; CHAMBERS TJ, 1989, BONE MINERAL RES, V6, P1; CONFORTI G, 1990, J BIOL CHEM, V265, P4011; DELAISSE JM, 1985, BIOCHEM BIOPH RES CO, V133, P483, DOI 10.1016/0006-291X(85)90932-5; DELAISSE JM, 1987, BONE, V8, P305, DOI 10.1016/8756-3282(87)90007-X; FOWLER WE, 1983, J ULTRA MOL STRUCT R, V83, P319, DOI 10.1016/S0022-5320(83)90139-9; GORSKI JP, 1990, J BIOL CHEM, V265, P14956; GORSKI JP, 1988, J BIOL CHEM, V263, P15938; GRASSER WA, 1992, IN VITRO IN VIVO AUT; HEATH JK, 1984, BIOCHIM BIOPHYS ACTA, V802, P151, DOI 10.1016/0304-4165(84)90046-1; Heinegard D, 1989, Connect Tissue Res, V21, P3, DOI 10.3109/03008208909049990; HELFRICH MH, 1992, J BONE MINER RES, V7, P335; HORTON MA, 1988, ISI ATLAS-IMMUNOL, V1, P35; JILKA RL, 1984, ENDOCRINE CONTROL BO, P136; JOHANSSON S, 1985, J BIOL CHEM, V260, P1557; KANEHISA J, 1988, BONE, V9, P73, DOI 10.1016/8756-3282(88)90106-8; KIEFFER N, 1991, J CELL BIOL, V113, P451, DOI 10.1083/jcb.113.2.451; LAKKAKORPI PT, 1991, J CELL BIOL, V115, P1179, DOI 10.1083/jcb.115.4.1179; MCABEE DD, 1983, J CELL BIOL, V97, P1515, DOI 10.1083/jcb.97.5.1515; OLDBERG A, 1988, J BIOL CHEM, V263, P19433; OTSUKA K, 1984, EUR J BIOCHEM, V145, P123, DOI 10.1111/j.1432-1033.1984.tb08530.x; POLLARD TD, 1982, CELL MUSCLE MOTILITY, V2, P15; REINHOLT FP, 1990, P NATL ACAD SCI USA, V87, P4473, DOI 10.1073/pnas.87.12.4473; ROULEAU MF, 1988, ENDOCRINOLOGY, V123, P187, DOI 10.1210/endo-123-1-187; SATO M, 1990, J BONE MINER RES, V5, P31, DOI 10.1002/jbmr.5650050107; SATO M, 1990, J CELL BIOL, V111, P1713, DOI 10.1083/jcb.111.4.1713; SATO M, 1990, CELL MOTIL CYTOSKEL, V17, P250, DOI 10.1002/cm.970170311; SATO M, 1989, CELL SHAPE DETERMINA, P329; SHEN V, 1988, J BONE MINER RES, V3, P657; SOMERMAN MJ, 1987, J BONE MINER RES, V2, P259; STREGE DW, 1990, J BONE MINER RES, V5, P963; SUDA T, 1991, PREDICTABLE ADV ORAL, P80; TERMINE JD, 1990, EXP GERONTOL, V25, P217, DOI 10.1016/0531-5565(90)90055-7; TYREE B, 1989, J BONE MINER RES, V4, P877; Vaes G., 1988, CLIN ORTHOP RELAT R, V231, P239; ZAMBONINZALLONE A, 1989, EXP CELL RES, V182, P645, DOI 10.1016/0014-4827(89)90266-8; ZAMBONINZALLONE A, 1983, J ANAT, V137, P57	44	25	25	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1992	6	11					2966	2976		10.1096/fasebj.6.11.1644260	http://dx.doi.org/10.1096/fasebj.6.11.1644260			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JJ665	1644260				2022-12-25	WOS:A1992JJ66500011
J	SCARPETTA, MA; HAWTHORNE, CA; BRUSILOW, WSA				SCARPETTA, MA; HAWTHORNE, CA; BRUSILOW, WSA			CHARACTERIZATION OF SEMI-UNCOUPLED HYBRID ESCHERICHIA-COLI-BACILLUS-MEGATERIUM-F1F0 PROTON-TRANSLOCATING ATPASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED ADENOSINE-TRIPHOSPHATASE; NUCLEAR MAGNETIC-RESONANCE; ESCHERICHIA-COLI-CELLS; ATP-SYNTHASE; UNC OPERON; MITOCHONDRIAL ATPASE; BACILLUS-MEGATERIUM; BETA-SUBUNIT; H+-ATPASE; SCHIZOSACCHAROMYCES-POMBE	Cloned atp genes for the proton-translocating ATPase of the obligate aerobe Bacillus megaterium have been demonstrated to be capable of complementing Escherichia coli ATPase (unc) mutants (Hawthorne, C. A., and Brusilow, W. S. A. (1986) J. Biol. Chem. 261, 5245-5248). To determine the minimum subunit requirements for cross-species complementation, we constructed all combinations of B. megaterium atpA, G, D, and C genes (coding for the alpha, gamma, beta, and epsilon-subunits, respectively) and tested their abilities to complement two uncA (alpha-subunit) and two uncD (beta-subunit) mutants of E. coli. The results indicated that complementation of either uncD mutant required atpD (beta) only. Complementation of one of the uncA (alpha) mutants required atpA, G, and D (alpha, gamma, and beta) and possibly atpE (epsilon) as well. The other uncA mutant was not complemented by any combination of B. megaterium ATPase genes. Complementation of a beta-mutant by atpD (beta) or atpD and C (beta-epsilon) produced cells which could grow aerobically on a nonfermentable carbon source (succinate) but not anaerobically on rich medium containing glucose. These E. coli therefore had become obligate aerobes. The ability to grow anaerobically could be restored to the mutant complemented by atpD alone by growth at pH 7.5 or pH 8 in the presence of 0.1 M potassium.	WAYNE STATE UNIV,SCH MED,DEPT BIOCHEM,DETROIT,MI 48201	Wayne State University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K04AI000882] Funding Source: NIH RePORTER; NIAID NIH HHS [KO4-AI00882] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOUTRY M, 1983, J BIOL CHEM, V258, P5214; BRAGG PD, 1980, EUR J BIOCHEM, V106, P495, DOI 10.1111/j.1432-1033.1980.tb04596.x; BRUSILOW WSA, 1989, J BIOL CHEM, V264, P1528; BRUSILOW WSA, 1983, J BACTERIOL, V155, P1265, DOI 10.1128/JB.155.3.1265-1270.1983; BRUSILOW WSA, 1987, J BACTERIOL, V169, P4984, DOI 10.1128/jb.169.11.4984-4990.1987; COX GB, 1978, BIOCHEM J, V170, P593, DOI 10.1042/bj1700593; DINNIBIER U, 1988, ARCH MICROBIOL, V150, P348, DOI 10.1007/BF00408306; EPSTEIN W, 1980, TRENDS BIOCHEM SCI, V5, P21, DOI 10.1016/S0968-0004(80)80072-7; FALSON P, 1987, BIOCHEM BIOPH RES CO, V148, P1182, DOI 10.1016/S0006-291X(87)80257-7; FOSTER DL, 1982, J BIOL CHEM, V257, P2009; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; FUTAI M, 1980, BIOCHEM BIOPH RES CO, V96, P227, DOI 10.1016/0006-291X(80)91204-8; GAY NJ, 1984, J BACTERIOL, V158, P820, DOI 10.1128/JB.158.3.820-825.1984; GIBSON F, 1977, BIOCHEM J, V164, P193, DOI 10.1042/bj1640193; GROMETELHANAN Z, 1985, J BIOL CHEM, V260, P2635; GUNSALUS RP, 1982, P NATL ACAD SCI-BIOL, V79, P320, DOI 10.1073/pnas.79.2.320; HAWTHORNE CA, 1988, BIOCHEM BIOPH RES CO, V151, P926; HAWTHORNE CA, 1986, J BIOL CHEM, V261, P5245; HSU SY, 1984, BIOCHEMISTRY-US, V23, P988, DOI 10.1021/bi00300a029; HUMBERT R, 1983, J BACTERIOL, V153, P416, DOI 10.1128/JB.153.1.416-422.1983; JAULT JM, 1989, BIOCHEM BIOPH RES CO, V158, P392, DOI 10.1016/S0006-291X(89)80060-9; JONES HM, 1983, J BACTERIOL, V155, P1279, DOI 10.1128/JB.155.3.1279-1287.1983; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAGGIO MB, 1987, J BIOL CHEM, V262, P8981; MESSING J, 1983, METHOD ENZYMOL, V101, P20; Miller J.H., 1972, EXPT MOL GENETICS; NAVON G, 1977, P NATL ACAD SCI USA, V74, P888, DOI 10.1073/pnas.74.3.888; NOUMI T, 1987, FEBS LETT, V213, P381, DOI 10.1016/0014-5793(87)81526-0; PADAN E, 1976, EUR J BIOCHEM, V63, P533, DOI 10.1111/j.1432-1033.1976.tb10257.x; PARSONAGE D, 1987, J BIOL CHEM, V262, P6301; PORTER ACG, 1983, J BACTERIOL, V155, P1271, DOI 10.1128/JB.155.3.1271-1278.1983; RHOADS DB, 1977, J BIOL CHEM, V252, P1394; SEBALD W, 1981, CURR TOP BIOENERG, V12, P1; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SLONCZEWSKI JL, 1981, P NATL ACAD SCI-BIOL, V78, P6271, DOI 10.1073/pnas.78.10.6271; WALDERHAUG MO, 1987, ION TRANSPORT PROCAR, P84; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	38	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18567	18572						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1655755				2022-12-25	WOS:A1991GJ47200028
J	SATO, K; ISHIDA, Y; WAKAMATSU, K; KATO, R; HONDA, H; OHIZUMI, Y; NAKAMURA, H; OHYA, M; LANCELIN, JM; KOHDA, D; INAGAKI, F				SATO, K; ISHIDA, Y; WAKAMATSU, K; KATO, R; HONDA, H; OHIZUMI, Y; NAKAMURA, H; OHYA, M; LANCELIN, JM; KOHDA, D; INAGAKI, F			ACTIVE-SITE OF MU-CONOTOXIN GIIIA, A PEPTIDE BLOCKER OF MUSCLE SODIUM-CHANNELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GEOGRAPHUTOXIN-II; CONUS-GEOGRAPHUS; NA CHANNELS; SAXITOXIN; TETRODOTOXIN; BINDING	The amino acid sequence of mu-conotoxin GIIIA (otherwise called geographutoxin I), a peptide having 22 amino acid residues with three disulfide bridges, was modified by replacing each residue with Ala or Lys to elucidate its active center for blocking sodium channels of skeletal muscle. NMR and CD spectra were virtually identical between native and modified toxins, indicating the similarity of their conformation including disulfide bridges. The inhibitory effect of these modified peptides on twitch contractions of the rat diaphragm showed that Arg at the 13th position and the basicity of the molecule are crucial for the biological action. The segment Lys11-Asp12-Arg13 has been reported to be flexible (Lancelin, J.-M., Kohda, D., Tate, S., Yanagawa, Y., Abe, T., Satake, M., and Inagaki, F. (1991) Biochemistry, in press), and this may represent a clue for the subtle fit of Arg13 to the specific site of sodium channels. Since known ligands to sodium channels, such as tetrodotoxin, anthopleulin-A, etc., contain guanidino groups as a putative binding moiety, Arg may be a general residue for peptide toxins to interact with the receptor site on sodium channels.	HOKKAIDO UNIV, DEPT CHEM, SAPPORO, HOKKAIDO 060, JAPAN; GUNMA UNIV, FAC ENGN, KIRYU, GUNMA 376, JAPAN; TOKYO METROPOLITAN INST MED SCI, DEPT MOLEC PHYSIOL, BUNKYO KU, TOKYO 113, JAPAN	Hokkaido University; Gunma University; Tokyo Metropolitan Institute of Medical Science	SATO, K (corresponding author), MITSUBISHI KASEI INST LIFE SCI, 11 MINAMIOOYA, MACHIDA, TOKYO 194, JAPAN.		Lancelin, Jean-marc/AAC-5686-2019; Kohda, Daisuke/I-4990-2019; Wakamatsu, Kaori/AAQ-9690-2020	Kohda, Daisuke/0000-0001-8234-3776; Wakamatsu, Kaori/0000-0003-1412-5691				BARHANIN J, 1981, J BIOL CHEM, V256, P5764; BEGENISICH T, 1987, ANNU REV BIOPHYS BIO, V16, P247; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; GRAY WR, 1988, ANNU REV BIOCHEM, V57, P665, DOI 10.1146/annurev.bi.57.070188.003313; HIDAKA Y, 1990, FEBS LETT, V264, P29, DOI 10.1016/0014-5793(90)80756-9; KAO CY, 1986, ANN NY ACAD SCI, V479, P52, DOI 10.1111/j.1749-6632.1986.tb15561.x; LANCELIN JM, 1991, IN PRESS BIOCHEMISTR; NAKAMURA H, 1983, EXPERIENTIA, V39, P590, DOI 10.1007/BF01971110; NODA M, 1989, FEBS LETT, V259, P213, DOI 10.1016/0014-5793(89)81531-5; OHIZUMI Y, 1986, J BIOL CHEM, V261, P6149; OHIZUMI Y, 1986, J PHARMACOL EXP THER, V239, P243; OLIVERA BM, 1985, SCIENCE, V230, P1338, DOI 10.1126/science.4071055; OLIVERA BM, 1990, SCIENCE, V249, P257, DOI 10.1126/science.2165278; SATO S, 1983, FEBS LETT, V155, P277, DOI 10.1016/0014-5793(82)80620-0; TORDA AE, 1988, FEBS LETT, V239, P266, DOI 10.1016/0014-5793(88)80931-1; WILLIAMS RJP, 1989, EUR J BIOCHEM, V183, P479, DOI 10.1111/j.1432-1033.1989.tb21076.x; YANAGAWA Y, 1987, J NEUROSCI, V7, P1498	17	111	114	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					16989	16991						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1654319				2022-12-25	WOS:A1991GF44500007
J	VASILETS, LA; OMAY, HS; OHTA, T; NOGUCHI, S; KAWAMURA, M; SCHWARZ, W				VASILETS, LA; OMAY, HS; OHTA, T; NOGUCHI, S; KAWAMURA, M; SCHWARZ, W			STIMULATION OF THE NA+/K+ PUMP BY EXTERNAL [K+] IS REGULATED BY VOLTAGE-DEPENDENT GATING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							(NA+ + K+)-ATPASE; XENOPUS-LAEVIS; ALPHA-SUBUNIT; SEQUENCE; ACTIVATION; TRANSPORT; NA,K-PUMP; CHANNELS; ATPASE; KIDNEY	Wild-type and mutants with a-subunits truncated at the N terminus of Na+/K+ pumps of Torpedo electroplax were expressed in Xenopus oocytes by injection of cRNAs encoding for one of the alpha-subunits and for the beta-subunit. Currents generated by the pump were investigated under voltage clamp in Na+-free solution, a condition where stimulation by external [K+] is the only voltage-dependent and rate-determining step in the pump cycle (Rakowski, R. F., Vasilets, L. A., LaTona, J., and Schwarz, W. (1991) J. Membr. Biol. 121, 177-187). Voltage dependence of the apparent K(m) value for pump stimulation and of maximum transport activity was investigated. Truncation of the intracellular N-terminal end of the alpha-subunit at the trypsin-accessible site (alpha-DELTA-K37, leaving Lys37) leads to nearly complete inhibition of pump current at physiological potentials, whereas ouabain binding capacity is retained indicating an essential involvement of the N-terminal end in the process of ion translocation. Truncation at the N-terminal end leaving Lys28 (alpha-DELTA-K28) or Thr29 (alpha-DELTA-T29) leads to removal of 6 or 7 lysine residues, respectively, and has no effect on maximum transport activity. On the other hand, the mutated pumps with alpha-DELTA-K28 or alpha-DELTA-T29 exhibit more pronounced voltage dependences for stimulation of pump current by external [K+] compared with the wild-type Torpedo pump. In particular, a pronounced increase in voltage dependence of the apparent affinity of pump stimulation is obtained by the removal of the LyS28. The results support the view that the lysine-rich region in the N-terminal end affects the cation binding to the pump molecule and that LyS28 is important.	MAX PLANCK INST BIOPHYS, HEINRICH HOFFMANN STR 7, W-6000 FRANKFURT 71, GERMANY	Max Planck Society				Vasilets, Larisa/0000-0001-5980-4423				DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; FORBUSH B, 1987, J BIOL CHEM, V262, P11116; FORBUSH B, 1988, J BIOL CHEM, V263, P7979; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; HILLE B, 1978, J GEN PHYSIOL, V72, P409, DOI 10.1085/jgp.72.4.409; JORGENSEN PL, 1986, BIOCHIM BIOPHYS ACTA, V860, P570, DOI 10.1016/0005-2736(86)90555-9; JORGENSEN PL, 1980, BIOCHIM BIOPHYS ACTA, V597, P305, DOI 10.1016/0005-2736(80)90108-X; KAWAKAMI K, 1985, NATURE, V316, P733, DOI 10.1038/316733a0; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; NOGUCHI S, 1987, FEBS LETT, V225, P27, DOI 10.1016/0014-5793(87)81125-0; OHTA T, 1991, IN PRESS BIOCH BIOPH; RAKOWSKI RF, 1991, J MEMBRANE BIOL, V121, P177, DOI 10.1007/BF01870531; SCHWARZ W, 1991, SODIUM PUMP STRUCTUR; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; STOCKER M, 1990, P NATL ACAD SCI USA, V87, P8903, DOI 10.1073/pnas.87.22.8903; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; VASILETS LA, 1990, J MEMBRANE BIOL, V118, P131, DOI 10.1007/BF01868470; VERREY F, 1989, AM J PHYSIOL, V256, pF1034, DOI 10.1152/ajprenal.1989.256.6.F1034	18	69	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16285	16288						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1653228				2022-12-25	WOS:A1991GD63500008
J	MCGILL, DL; GUIDOTTI, G				MCGILL, DL; GUIDOTTI, G			INSULIN STIMULATES BOTH THE ALPHA-1 AND THE ALPHA-2 ISOFORMS OF THE RAT ADIPOCYTE (NA+,K+) ATPASE - 2 MECHANISMS OF STIMULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA,K-ATPASE BETA-SUBUNIT; (NA+,K+)-ADENOSINE TRIPHOSPHATASE; MOLECULAR-CLONING; PLASMA-MEMBRANE; TRANSPORT; BRAIN; (NA+,K+)-ATPASE; IDENTIFICATION; SODIUM; FORMS	Results obtained with adipocyte ghosts indicated that the relative pumping activities of the alpha-1 and alpha-2 isoforms of the (Na+,K+) pump depend strongly on intracellular sodium concentration, [Na+]i (McGill, D. (1991) J. Biol. Chem. 266, 15817-15823). Accordingly, [Na+]i was determined in rat adipocytes as a function of ouabain concentration and found to increase gradually as the concentration of ouabain increased. Incubation conditions were therefore designed such that the [Na+]i at 0 M and 10(-5) M ouabain were identical, in order to study the activities of both forms of the pump under identical conditions. Under these conditions, the alpha-2 isozyme accounts for 42% of the total pumping activity; these data prove that the activity of the alpha-2 isozyme is suppressed to a much greater extent than that of the alpha-1 isozyme, in relation to maximally obtainable activities measured in plasma membranes (Lytton J., Lin, J. C., and Guidotti, G. (1985) J. Biol. Chem. 260, 1177-1184). Furthermore, insulin stimulation of Rb-86(+)/K+ uptake in adipocytes results from a 58 and a 128% increase in the activities of the alpha-1 and alpha-2 isozymes (Na+,K+) pump, respectively. In addition, it is shown that under the conditions used to determine the [Na+]i dependence of Rb-86+/K+ uptake into adipocytes (0 mM KCl, various [NaCl]), [Na+]i decreases rapidly upon the addition of KCl/(RbCl)-Rb-86 for the initiation of the uptake measurement. By making uptake measurements quickly after the addition of KCl to eliminate the effect of a decreasing [Na+]i, we demonstrate that the stimulation of the alpha-1 isozyme is due to a small decrease in the K0.5Na+ whereas the stimulation of the alpha-2 isozyme results from a decrease in the K0.5Na+ and an increase in the V(max).	HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138	Harvard University					NIDDK NIH HHS [DK27626] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027626] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRODSKY JL, 1990, AM J PHYSIOL, V258, pC803, DOI 10.1152/ajpcell.1990.258.5.C803; BRODSKY JL, 1990, AM J PHYSIOL, V258, pC812, DOI 10.1152/ajpcell.1990.258.5.C812; CANTLEY L, 1986, TRENDS NEUROSCI, V9, P1, DOI 10.1016/0166-2236(86)90002-0; CANTLEY LC, 1981, CURR TOP BIOENERG, V11, P201; CLAUSEN T, 1977, J PHYSIOL-LONDON, V265, P19, DOI 10.1113/jphysiol.1977.sp011703; CLAUSEN T, 1977, J PHYSIOL-LONDON, V270, P415, DOI 10.1113/jphysiol.1977.sp011959; GLOOR S, 1990, J CELL BIOL, V110, P165, DOI 10.1083/jcb.110.1.165; HSU YM, 1989, BIOCHEMISTRY-US, V28, P569, DOI 10.1021/bi00428a023; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; KAWAKAMI K, 1986, NUCLEIC ACIDS RES, V14, P2833, DOI 10.1093/nar/14.7.2833; KAZAZOGLOU T, 1983, J BIOL CHEM, V258, P2163; LYTTON J, 1985, J BIOL CHEM, V260, P1177; LYTTON J, 1985, J BIOL CHEM, V260, P75; MARTINVASALLO P, 1989, J BIOL CHEM, V264, P4613; MATSUDA T, 1984, J BIOL CHEM, V259, P3858; MCGILL DL, 1991, J BIOL CHEM, V266, P15817; RESH MD, 1980, J BIOL CHEM, V255, P938; RESH MD, 1982, J BIOL CHEM, V257, P1946; RODBELL M, 1967, J BIOL CHEM, V242, P5744; SERRANO R, 1983, FEBS LETT, V156, P11, DOI 10.1016/0014-5793(83)80237-3; SHULL GE, 1986, NATURE, V321, P429, DOI 10.1038/321429a0; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; SHYJAN AW, 1990, P NATL ACAD SCI USA, V87, P1178, DOI 10.1073/pnas.87.3.1178; SWEADNER KJ, 1985, J BIOL CHEM, V260, P1508; SWEADNER KJ, 1979, J BIOL CHEM, V254, P6060; URAYAMA O, 1989, J BIOL CHEM, V264, P8271; URAYAMA O, 1988, BIOCHEM BIOPH RES CO, V156, P796, DOI 10.1016/S0006-291X(88)80914-8; VANDYKE RW, 1983, J BIOL CHEM, V258, P2912	28	66	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					15824	15831						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1651922				2022-12-25	WOS:A1991GB97700047
J	XU, ZH; BUELT, MK; BANASZAK, LJ; BERNLOHR, DA				XU, ZH; BUELT, MK; BANASZAK, LJ; BERNLOHR, DA			EXPRESSION, PURIFICATION, AND CRYSTALLIZATION OF THE ADIPOCYTE LIPID-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID-BINDING; INSULIN-RECEPTOR; CYTOPLASMIC DOMAIN; 3T3-L1 ADIPOCYTES; ESCHERICHIA-COLI; IDENTIFICATION; PHOSPHORYLATION; SEQUENCE	The murine adipocyte lipid binding protein (ALBP/aP2) has been cloned and expressed in Escherichia coli, purified to homogeneity, biochemically characterized, and crystallized for x-ray diffraction study. In the cloning, the ALBP coding region was placed under control of the recA promoter and downstream of the phage T7 g-10 translation enhancer sequence. Nalidixic acid (50-mu-g/ml) induced the expression of ALBP 20-fold over that attained using the pT7 system previously reported (Chinander, L. L., and Bernlohr, D. A. (1989) J. Biol. Chem. 264, 19564-19572). Recombinant ALBP was purified to homogeneity using a combination of pH fractionation, gel filtration, and immobilized metal affinity chromatography. The fluorescent affinity ligand 12-(9-anthroyloxy)oleic acid bound to homogeneous ALBP with an apparent K(d) of 0.5-mu-M. rALBP was devoid of endogenous fatty acid, and oleic acid inhibited cysteine 117 modification by 5,5'-dithiobis-(2-nitrobenzoic acid) indicating integrity of the binding domain. Recombinant ALBP was phosphorylated by the soluble kinase domain of the insulin receptor with a V(max) of 11 nmol.min.mg of kinase and an apparent K(m) of 270-mu-M. Purified protein was crystallized using the hanging drop method with seeding. Crystalline ALBP was orthorhombic with cell dimensions of a = 34.4 angstrom, b = 54.8 angstrom, and c = 76.3 angstrom. The space group was P2(1)2(1)2(1), and there was one molecule per asymmetric unit.	UNIV MINNESOTA, COLL BIOL SCI, DEPT BIOCHEM, 1479 GORTNER AVE, ST PAUL, MN 55108 USA; UNIV MINNESOTA, SCH MED, DEPT BIOCHEM, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities					NIGMS NIH HHS [GM13925] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM013925] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERNIER M, 1987, P NATL ACAD SCI USA, V84, P1844, DOI 10.1073/pnas.84.7.1844; BERNLOHR DA, 1984, P NATL ACAD SCI-BIOL, V81, P5468, DOI 10.1073/pnas.81.17.5468; BOHMER FD, 1987, J BIOL CHEM, V262, P15137; BUELT MK, 1990, BIOCHEMISTRY-US, V29, P7408, DOI 10.1021/bi00484a008; BUELT MK, 1991, J BIOL CHEM, V266, P12266; CHINANDER LL, 1989, J BIOL CHEM, V264, P19564; COBB MH, 1989, J BIOL CHEM, V264, P18701; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; HAHN T, 1983, INT TABLES CRYSTALLO, P40; HERRERA R, 1988, J BIOL CHEM, V263, P5560; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; HRESKO RC, 1988, P NATL ACAD SCI USA, V85, P8835, DOI 10.1073/pnas.85.23.8835; JONES TA, 1988, EMBO J, V7, P1597, DOI 10.1002/j.1460-2075.1988.tb02985.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATARESE V, 1988, J BIOL CHEM, V263, P14544; MATARESE V, 1989, PROG LIPID RES, V28, P245, DOI 10.1016/0163-7827(89)90001-5; McPherson A, 1982, PREPARATION ANAL PRO; OCKNER RK, 1982, J BIOL CHEM, V257, P7872; OCKNER RK, 1974, J CLIN INVEST, V54, P326, DOI 10.1172/JCI107768; OLINS PO, 1990, METHOD ENZYMOL, V185, P115; OSTROVE S, 1990, METHOD ENZYMOL, V182, P371; SACCHETTINI JC, 1989, J MOL BIOL, V208, P327, DOI 10.1016/0022-2836(89)90392-6; SACCHETTINI JC, 1986, J BIOL CHEM, V261, P8281; Sambrook J, 1989, MOL CLONING LABORATO; SULKOWSKI E, 1985, TRENDS BIOTECHNOL, V3, P1, DOI 10.1016/0167-7799(85)90068-X; SUZUKI M, 1982, J NEUROCHEM, V39, P1759, DOI 10.1111/j.1471-4159.1982.tb08017.x	26	54	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14367	14370						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1650358				2022-12-25	WOS:A1991FZ35100041
J	BUXEDA, RJ; NICKELS, JT; BELUNIS, CJ; CARMAN, GM				BUXEDA, RJ; NICKELS, JT; BELUNIS, CJ; CARMAN, GM			PHOSPHATIDYLINOSITOL 4-KINASE FROM SACCHAROMYCES-CEREVISIAE - KINETIC-ANALYSIS USING TRITON X-100 PHOSPHATIDYLINOSITOL-MIXED MICELLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CELL-PROLIFERATION; BOVINE BRAIN; PHOSPHATIDYLSERINE DECARBOXYLASE; SN-1,2-DIACYLGLYCEROL KINASE; RAT-LIVER; PURIFICATION; PHOSPHOLIPASE-A2; DEPENDENCE; SYNTHASE	Phosphatidylinositol 4-kinase (ATP:phosphatidylinositol 4-phosphotransferase, EC 2.7.1.67) was purified from Saccharomyces cerevisiae by an improved procedure over that previously reported (Belunis, C. J., Bae-Lee, M., Kelley, M. J., and Carman, G. M. (1988) J. Biol. Chem. 263, 18897-18903) for the enzyme. The molecular mass of the enzyme was 45 kDa. The 35-kDa protein previously identified as PI 4-kinase was a proteolysis product of the 45-kDa protein. A detailed kinetic analysis of the purified enzyme was performed with Triton X-100/phosphatidylinositol-mixed micelles according to the -surface dilution" (Deems, R. A., Eaton, B. R., and Dennis, E. A. (1975) J. Biol. Chem. 250, 9013-9020) and "dual phospholipid" (Hendrickson, H. S., and Dennis, E. A. (1984) J. Biol. Chem. 259, 5734-5739) kinetic models. Phosphatidylinositol 4-kinase activity followed saturation kinetics with respect to the bulk and surface concentrations of phosphatidylinositol at concentrations of phosphatidylinositol below 0.1 mm. Above 0.1 mm activity was only dependent on the surface concentration of phosphatidylinositol. The enzyme more closely followed the dual phospholipid model where the enzyme associated with Triton X-100 micelles when phosphatidylinositol was present. The interfacial Michaelis constant (K(m)B) for phosphatidylinositol was 0.0036 mol fraction and the dissociation constant (K(s)A) for phosphatidylinositol in the micelle surface was 0.26 mm. The results of glycerol gradient centrifugation studies showed that the enzyme was physically associated with Triton X-100/phosphatidylinositol micelles.	RUTGERS STATE UNIV,COOK COLL,NEW JERSEY AGR EXPT STN,DEPT FOOD SCI,NEW BRUNSWICK,NJ 08903	Rutgers State University New Brunswick					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035655] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-35655] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUGER KR, 1989, J BIOL CHEM, V264, P20181; BAELEE M, 1990, J BIOL CHEM, V265, P7221; BELUNIS CJ, 1988, J BIOL CHEM, V263, P18897; BERRIDGE MJ, 1987, BIOCHIM BIOPHYS ACTA, V907, P33, DOI 10.1016/0304-419X(87)90017-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARMAN GM, 1979, J BIOL CHEM, V254, P8391; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; Cleland W. W, 1970, ENZYMES, V2, P1; COLODZIN M, 1965, J BIOL CHEM, V240, P3771; DAHL C, 1987, P NATL ACAD SCI USA, V84, P4012, DOI 10.1073/pnas.84.12.4012; DAHL JS, 1985, BIOCHEM BIOPH RES CO, V133, P844, DOI 10.1016/0006-291X(85)91211-2; DEEMS RA, 1975, J BIOL CHEM, V250, P9013; DENNIS E A, 1974, Journal of Supramolecular Structure, V2, P682, DOI 10.1002/jss.400020513; Dennis EA, 1983, ENZYMES, P307; DOWHAN W, 1974, J BIOL CHEM, V249, P3079; DOWNES CP, 1990, EUR J BIOCHEM, V193, P1, DOI 10.1111/j.1432-1033.1990.tb19297.x; FISCHL AS, 1986, J BIOL CHEM, V261, P3178; GANONG BR, 1990, BIOCHEMISTRY-US, V29, P6904, DOI 10.1021/bi00481a021; HAID A, 1983, METHOD ENZYMOL, V96, P192; HANNUN YA, 1985, J BIOL CHEM, V260, P39; HENDRICKSON HS, 1984, J BIOL CHEM, V259, P5734; HENDRICKSON HS, 1984, J BIOL CHEM, V259, P5740; HOU WM, 1988, BIOCHIM BIOPHYS ACTA, V959, P67; JONES EW, 1990, METHOD ENZYMOL, V194, P428; KAIBUCHI K, 1986, P NATL ACAD SCI USA, V83, P8172, DOI 10.1073/pnas.83.21.8172; KELLEY MJ, 1987, J BIOL CHEM, V262, P14563; KUCERA GL, 1988, J BIOL CHEM, V263, P12964; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESTER RL, 1968, J BIOL CHEM, V243, P4889; LICHTENBERG D, 1983, BIOCHIM BIOPHYS ACTA, V737, P285, DOI 10.1016/0304-4157(83)90004-7; LIN YP, 1990, J BIOL CHEM, V265, P166; LIPS DL, 1989, J BIOL CHEM, V264, P8759; MCKENZIE MA, 1982, J FOOD BIOCHEM, V6, P77, DOI 10.1111/j.1745-4514.1982.tb00297.x; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; PORTER FD, 1988, J BIOL CHEM, V263, P8989; ROBERTS MF, 1977, P NATL ACAD SCI USA, V74, P1950, DOI 10.1073/pnas.74.5.1950; ROBSON RJ, 1983, ACCOUNTS CHEM RES, V16, P251, DOI 10.1021/ar00091a003; SALTIEL AR, 1987, BIOCHEM J, V241, P759, DOI 10.1042/bj2410759; SCHEIDELER MA, 1989, J BIOL CHEM, V264, P12455; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; STEINER S, 1972, J BACTERIOL, V109, P81, DOI 10.1128/JB.109.1.81-88.1972; TALWALKAR RT, 1973, BIOCHIM BIOPHYS ACTA, V306, P412, DOI 10.1016/0005-2760(73)90180-X; UNO I, 1988, NATURE, V333, P188, DOI 10.1038/333188a0; WALKER DH, 1988, BIOCHEMISTRY-US, V27, P6504, DOI 10.1021/bi00417a046; WALSH JP, 1986, J BIOL CHEM, V261, P5062; WALSH JP, 1986, J BIOL CHEM, V261, P6239; WARNER TG, 1975, J BIOL CHEM, V250, P8004; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YAMAKAWA A, 1988, J BIOL CHEM, V263, P17555; YOUNT RG, 1971, BIOCHEMISTRY-US, V10, P2484, DOI 10.1021/bi00789a009	50	50	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13859	13865						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1649831				2022-12-25	WOS:A1991FY02700065
J	JUSZCZAK, A; AONO, S; ADAMS, MWW				JUSZCZAK, A; AONO, S; ADAMS, MWW			THE EXTREMELY THERMOPHILIC EUBACTERIUM, THERMOTOGA-MARITIMA, CONTAINS A NOVEL IRON-HYDROGENASE WHOSE CELLULAR-ACTIVITY IS DEPENDENT UPON TUNGSTEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RES; ELONGATION FACTOR-TU; SP-NOV REPRESENTS; CLOSTRIDIUM-PASTEURIANUM; PYROCOCCUS-FURIOSUS; HYPERTHERMOPHILIC ARCHAEBACTERIUM; AZOTOBACTER-VINELANDII; SPECTROSCOPIC CHARACTERIZATION; DESULFOVIBRIO-VULGARIS; BACTERIAL EVOLUTION	Thermotoga maritima is the most thermophilic eubacterium currently known and grows up to 90-degrees-C by a fermentative metabolism in which H-2, CO2, and organic acids are end products. It was shown that the production of H-2 is catalyzed by a single hydrogenase located in the cytoplasm. The addition of tungsten to the growth medium was found to increase both the cellular concentration of the hydrogenase and its in vitro catalytic activity by up to 10-fold, but the purified enzyme did not contain tungsten. It is a homotetramer of M(r) 280,000 and contains approximately 20 atoms of Fe and 18 atoms of acid-labile sulfide/monomer. Other transition metals, including nickel (and also selenium), were present in only trace amounts (less than 0.1 atoms/monomer). The hydrogenase was unstable at both 4 and 23-degrees-C, even under anaerobic conditions, but no activity was lost in anaerobic buffer containing glycerol and dithiothreitol. Under these conditions the enzyme was also quite thermostable (t50% approximately 1 h at 90-degrees-C) but extremely sensitive to irreversible inactivation by O2 (t50% approximately 10 s in air). The optimum pH ranges for H-2 evolution and H-2 oxidation were 8.6 - 9.5 and greater-than-or-equal-to 10.4, respectively, and the optimum temperature for catalytic activity was above 95-degrees-C. In contrast to mesophilic Fe hydrogenases, the T. maritima enzyme had very low H-2 evolution activity, did not use T. maritima ferredoxin as an electron donor for H-2 evolution, was inhibited by acetylene but not by nitrite, and exhibited EPR signals typical of [2Fe-2S]1+ clusters. Moreover, the oxidized enzyme did not exhibit the rhombic EPR signal that is characteristic of the catalytic iron-sulfur cluster of mesophilic Fe hydrogenases. These data suggest that T. maritima hydrogenase has a different FeS site and/or mechanism for catalyzing H-2 production. The potential role of tungsten in regulating the activity of this enzyme is discussed.	UNIV GEORGIA,DEPT BIOCHEM,ATHENS,GA 30602; UNIV GEORGIA,CTR METALLOENZYME STUDIES,ATHENS,GA 30602	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia			Aono, Shigetoshi/ABD-7618-2020	Aono, Shigetoshi/0000-0002-2870-3694; Adams, Michael/0000-0002-9796-5014				AASA R, 1970, J CHEM PHYS, V52, P1612, DOI 10.1063/1.1673181; AASA R, 1975, J MAGN RESON, V19, P308, DOI 10.1016/0022-2364(75)90045-1; ACHENBACHRICHTER L, 1987, SYST APPL MICROBIOL, V9, P34, DOI 10.1016/S0723-2020(87)80053-X; ADAMS MWW, 1984, J BIOL CHEM, V259, P7045; ADAMS MWW, 1989, P NATL ACAD SCI USA, V86, P4932, DOI 10.1073/pnas.86.13.4932; ADAMS MWW, 1990, FEMS MICROBIOL LETT, V75, P219, DOI 10.1016/0378-1097(90)90533-V; ADAMS MWW, 1990, BIOCHIM BIOPHYS ACTA, V1020, P115, DOI 10.1016/0005-2728(90)90044-5; ADAMS MWW, 1981, BIOCHIM BIOPHYS ACTA, V594, P105; BACHLEITNER M, 1989, FEMS MICROBIOL LETT, V57, P115, DOI 10.1111/j.1574-6968.1989.tb03231.x; BALCH WE, 1979, MICROBIOL REV, V43, P260, DOI 10.1128/MMBR.43.2.260-296.1979; BRYANT FO, 1989, J BIOL CHEM, V264, P5070; Cammack R, 1988, BIOINORGANIC CHEM NI, P167; CHEN JS, 1977, ANAL BIOCHEM, V79, P157, DOI 10.1016/0003-2697(77)90390-6; CONOVER RC, 1990, J BIOL CHEM, V265, P8533; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; Dutton P L, 1978, Methods Enzymol, V54, P411; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FAUQUE G, 1988, FEMS MICROBIOL LETT, V54, P299, DOI 10.1111/j.1574-6968.1988.tb02748.x; FERNANDEZ VM, 1989, EUR J BIOCHEM, V185, P449, DOI 10.1111/j.1432-1033.1989.tb15135.x; FIALA G, 1986, ARCH MICROBIOL, V145, P56, DOI 10.1007/BF00413027; FILIPIAK M, 1989, EUR J BIOCHEM, V185, P547, DOI 10.1111/j.1432-1033.1989.tb15148.x; GAILLARD J, 1986, BIOCHEMISTRY-US, V25, P464, DOI 10.1021/bi00350a028; HAGEN WR, 1986, FEBS LETT, V203, P59, DOI 10.1016/0014-5793(86)81436-3; HAGEN WR, 1987, EUR J BIOCHEM, V169, P457, DOI 10.1111/j.1432-1033.1987.tb13633.x; HE SH, 1989, BIOCHEM BIOPH RES CO, V161, P127, DOI 10.1016/0006-291X(89)91570-2; HUBER R, 1986, ARCH MICROBIOL, V144, P324, DOI 10.1007/BF00409880; HYMAN MR, 1987, APPL ENVIRON MICROB, V53, P298, DOI 10.1128/AEM.53.2.298-303.1987; HYMAN MR, 1988, ANAL BIOCHEM, V173, P207, DOI 10.1016/0003-2697(88)90181-9; HYMAN MR, 1987, BIOCHEMISTRY-US, V26, P6447, DOI 10.1021/bi00394a023; KLIBANOV AM, 1983, PROCESS BIOCHEM, V8, P13; KOWAL AT, 1989, J BIOL CHEM, V264, P4342; LAKE JA, 1988, NATURE, V327, P348; LINDAHL PA, 1987, J BIOL CHEM, V262, P14945; LINDAHL PA, 1985, J BIOL CHEM, V260, P1160; Linke WF., 1958, SOLUBILITIES INORGAN, V4th ed.; LONDEI P, 1988, J BACTERIOL, V170, P4353, DOI 10.1128/jb.170.9.4353-4360.1988; LOVENBERG W, 1963, J BIOL CHEM, V238, P3899; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MORTENSON LE, 1964, BIOCHIM BIOPHYS ACTA, V81, P71, DOI 10.1016/0926-6569(64)90336-0; MUKUND S, 1990, J BIOL CHEM, V265, P11508; MUKUND S, 1990, IN PRESS J BIOL CHEM, V266; ONATE YA, 1989, J BIOL CHEM, V264, P18386; PATIL DS, 1988, J BIOL CHEM, V263, P18732; PRINCE RC, 1981, BIOCHIM BIOPHYS ACTA, V635, P132, DOI 10.1016/0005-2728(81)90014-1; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; RUPP H, 1978, BIOCHIM BIOPHYS ACTA, V537, P255, DOI 10.1016/0005-2795(78)90509-3; TIBONI O, 1989, SYST APPL MICROBIOL, V12, P127, DOI 10.1016/S0723-2020(89)80002-5; WEBER K, 1972, METHOD ENZYMOL, V26, P2; WHITE H, 1989, EUR J BIOCHEM, V184, P89, DOI 10.1111/j.1432-1033.1989.tb14993.x; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; YAMAMOTO I, 1983, J BIOL CHEM, V258, P1826; ZAMBRANO IC, 1989, J BIOL CHEM, V264, P20974; ZWICKL P, 1990, J BACTERIOL, V172, P4329, DOI 10.1128/jb.172.8.4329-4338.1990	53	67	67	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13834	13841						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1649830				2022-12-25	WOS:A1991FY02700061
J	RUSHMORE, TH; MORTON, MR; PICKETT, CB				RUSHMORE, TH; MORTON, MR; PICKETT, CB			THE ANTIOXIDANT RESPONSIVE ELEMENT - ACTIVATION BY OXIDATIVE STRESS AND IDENTIFICATION OF THE DNA CONSENSUS SEQUENCE REQUIRED FOR FUNCTIONAL-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YA-SUBUNIT GENE; CONTROLLING INDUCIBLE EXPRESSION; AH RECEPTOR COMPLEX; REGULATORY ELEMENTS; INDUCTION; CHLORAMPHENICOL; DAMAGE; LIVER	We have characterized further the antioxidant responsive element (ARE) identified in the 5'-flanking region of the rat glutathione S-transferase Ya subunit gene and the NAD(P)H:quinone reductase gene by mutational and deletion analyses. Our data suggest that the sequence, [GRAPHICS] where N is any nucleotide, represents the core sequence of the ARE required for transcriptional activation by phenolic antioxidants and metabolizable planar aromatic compounds (e.g. beta-naphthoflavone and 3-methylcholanthrene). We also have found that the ARE is responsive to hydrogen peroxide and phenolic antioxidants that undergo redox cycling. These latter data suggest that the ARE is responsive to reactive oxygen species and thus may represent part of a signal transduction pathway that allow eukaryotic cells to sense and respond to oxidative stress.			RUSHMORE, TH (corresponding author), MERCK FROSST CTR THERAPEUT RES,POINTE CLAIRE H9R 4P8,QUEBEC,CANADA.							CLEWELL DB, 1972, J BACTERIOL, V110, P667, DOI 10.1128/JB.110.2.667-676.1972; CLEWELL DB, 1969, P NATL ACAD SCI USA, V62, P1159, DOI 10.1073/pnas.62.4.1159; DELONG MJ, 1987, CARCINOGENESIS, V8, P1549, DOI 10.1093/carcin/8.10.1549; DENISON MS, 1989, J BIOL CHEM, V264, P16478; DENISON MS, 1988, J BIOL CHEM, V263, P17221; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; FUJISAWASEHARA A, 1988, P NATL ACAD SCI USA, V85, P5859, DOI 10.1073/pnas.85.16.5859; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; LEANDERSON P, 1990, CHEM-BIOL INTERACT, V75, P71, DOI 10.1016/0009-2797(90)90023-G; LEWIS JG, 1988, CANCER RES, V48, P4762; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; Mitchell D.B., 1980, J TISSUE CULT METH, V6, P113, DOI 10.1007/BF02082861; NEUBOLD LA, 1989, MOL CELL BIOL, V9, P2378; PAULSON KE, 1990, MOL CELL BIOL, V10, P1841, DOI 10.1128/MCB.10.5.1841; PROCHASKA HJ, 1988, CANCER RES, V48, P4776; PROCHASKA HJ, 1985, P NATL ACAD SCI USA, V82, P8232, DOI 10.1073/pnas.82.23.8232; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; RUSHMORE TH, 1990, J BIOL CHEM, V265, P14648; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; TALALAY P, 1988, P NATL ACAD SCI USA, V85, P8261, DOI 10.1073/pnas.85.21.8261; TARTAGLIA LA, 1989, J MOL BIOL, V210, P709, DOI 10.1016/0022-2836(89)90104-6; TELAKOWSKIHOPKINS CA, 1988, P NATL ACAD SCI USA, V85, P1000, DOI 10.1073/pnas.85.4.1000; VYAS KP, 1983, J BIOL CHEM, V258, P5649; WHITLOCK JP, 1987, PHARMACOL REV, V39, P147	28	1264	1306	4	60	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1991	266	18					11632	11639						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FT762	1646813				2022-12-25	WOS:A1991FT76200036
J	DEMATTEIS, MA; DITULLIO, G; BUCCIONE, R; LUINI, A				DEMATTEIS, MA; DITULLIO, G; BUCCIONE, R; LUINI, A			CHARACTERIZATION OF CALCIUM-TRIGGERED SECRETION IN PERMEABILIZED RAT BASOPHILIC LEUKEMIA-CELLS - POSSIBLE ROLE OF VECTORIALLY ACTING G-PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; CYCLIC-AMP LEVELS; KINASE-C; GUANINE-NUCLEOTIDES; INSULIN-SECRETION; INOSITOL PHOSPHOLIPIDS; BINDING PROTEIN; ACTH-SECRETION; RBL-2H3 CELLS; PHORBOL ESTER	Strong, albeit indirect, evidence suggests that a GTP-binding (G) protein(s) can act directly on the secretory machinery by a post-second messenger mechanism. The type and function of this putative G(e) (exocytosis) protein were investigated in streptolysin-O-permeabilized rat basophilic leukemia (RBL) cells. The exocytotic response to calcium was first characterized both morphologically and biochemically using the release of preloaded [H-3]serotonin as an index of exocytosis. Calcium-induced secretion (EC50 about 3-mu-M) in RBL cells requires ATP (EC50 about 2.5 mM) and is modulated by pH, the optimal value being 7.2. Another requirement for calcium-induced secretion is an activated G protein, since inactivators of G proteins such as GDP-beta-S (EC50 about 800-mu-M) inhibit the secretagogue effect of 10-mu-M free calcium. Conversely, GTP-gamma-S (EC50 about 1-mu-M) and other nonhydrolyzable analogs of GTP, which keep G proteins in a permanently active conformation, potentiate the effect of calcium. GTP-gamma-S alone is without effect. The effect of GTP-gamma-S on exocytosis is apparently not mediated by known second messengers, suggesting that a G(e) protein is involved. Electron microscopic images show that in resting cells, secretory granules are clustered in the perinuclear area, whereas they become scattered upon calcium stimulation. A paradoxical effect of GTP-gamma-S is observed when applied during permeabilization; under these conditions, in fact, the nucleotide inhibits the subsequent secretory response to calcium. The scattering of granules is also inhibited. This effect of GTP-gamma-S is counteracted by coadministration of GTP. These responses to guanine nucleotides are typical of vectorially acting G proteins involved in protein synthesis and in intracellular vesicle transport. Taken together, the data presented suggest that calcium-dependent release requires a vectorially acting G protein controlling the movement of secretory granules. This and alternative models are discussed.			DEMATTEIS, MA (corresponding author), CONSORZIO MARIO NEGRI SUD, IST RIC FARMACOL MARIO NEGRI, NEUROENDOCRINOL LAB, I-66030 SANTA MARIA IMBARO, ITALY.		Luini, Alberto/L-1372-2013	Luini, Alberto/0000-0002-8729-2549; De Matteis, Maria Antonietta/0000-0003-0053-3061; Buccione, Roberto/0000-0001-9210-5261				ACHILLI G, 1985, ANAL BIOCHEM, V148, P1, DOI 10.1016/0003-2697(85)90620-7; ALI H, 1989, J IMMUNOL, V143, P2626; ALI H, 1989, BIOCHIM BIOPHYS ACTA, V1010, P88, DOI 10.1016/0167-4889(89)90188-2; ATHAYDE CM, 1990, EUR J BIOCHEM, V189, P647, DOI 10.1111/j.1432-1033.1990.tb15533.x; AVRAHAM S, 1988, J BIOL CHEM, V263, P7292; BALCH WE, 1989, J BIOL CHEM, V264, P16965; BARROWMAN MM, 1986, NATURE, V319, P504, DOI 10.1038/319504a0; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BITTNER MA, 1986, J BIOL CHEM, V261, P182; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; CHURCHER Y, 1990, CELL REGUL, V1, P337, DOI 10.1091/mbc.1.4.337; COCKCROFT S, 1979, J PHYSIOL-LONDON, V296, P229, DOI 10.1113/jphysiol.1979.sp013002; COLLADOESCOBAR D, 1990, J IMMUNOL, V144, P244; CUNHAMELO JR, 1989, J IMMUNOL, V143, P2617; EBERHARD DA, 1990, BIOCHEM J, V268, P15, DOI 10.1042/bj2680015; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOMPERTS BD, 1990, ANNU REV PHYSIOL, V52, P591; HOLZ RW, 1989, J BIOL CHEM, V264, P5412; HUANG FL, 1989, J BIOL CHEM, V264, P4238; HUANG KP, 1989, TRENDS NEUROSCI, V12, P425, DOI 10.1016/0166-2236(89)90091-X; KANNER BI, 1985, BIOCHIM BIOPHYS ACTA, V816, P403, DOI 10.1016/0005-2736(85)90508-5; KIKKAWA U, 1983, METHOD ENZYMOL, V99, P288; KNIGHT DE, 1982, J MEMBRANE BIOL, V68, P107, DOI 10.1007/BF01872259; KRISHNAMURTHI S, 1989, FEBS LETT, V250, P195, DOI 10.1016/0014-5793(89)80719-7; LEWIS DL, 1986, P NATL ACAD SCI USA, V83, P9035, DOI 10.1073/pnas.83.23.9035; LO TN, 1987, J BIOL CHEM, V262, P4141; LUINI A, 1986, J NEUROSCI, V6, P3128; LUINI A, 1988, CELL MOL NEUROBIOL, V8, P129, DOI 10.1007/BF00712918; LUINI A, 1990, J NEUROCHEM, V54, P30, DOI 10.1111/j.1471-4159.1990.tb13279.x; MAYORGA LS, 1989, CELL REGUL, V1, P113, DOI 10.1091/mbc.1.1.113; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; MORGAN NG, 1987, TRENDS PHARMACOL SCI, V8, P369, DOI 10.1016/0165-6147(87)90092-7; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OTERO AD, 1990, BIOCHEM PHARMACOL, V39, P1399; PHILLIPS DM, 1985, J ULTRA MOL STRUCT R, V90, P105, DOI 10.1016/0889-1605(85)90120-X; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; ULLRICH S, 1988, J BIOL CHEM, V263, P8615; ULLRICH S, 1984, J BIOL CHEM, V259, P4111; VALLAR L, 1987, J BIOL CHEM, V262, P5049; VEGESNA RVK, 1988, MOL PHARMACOL, V33, P537; WHITE KN, 1988, J IMMUNOL, V141, P942	42	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10452	10460						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	1645349				2022-12-25	WOS:A1991FP08600070
J	WEBER, JM; SIRCAR, S; RODRIGUES, M; CAI, FX; HORVATH, J				WEBER, JM; SIRCAR, S; RODRIGUES, M; CAI, FX; HORVATH, J			DOMINANT SUPPRESSION OF ADENOVIRUS MEDIATED TRANSFORMATION AND INSUFFICIENCY OF P105RB BINDING AS A CONDITION FOR ONCOGENIC TRANSFORMATION	ONCOGENE			English	Article							LARGE T-ANTIGENS; RAT-CELLS; METHYLGLYOXAL BIS(GUANYLHYDRAZONE); RETINOBLASTOMA PROTEIN; GENE-PRODUCT; E1A PROTEINS; VIRUS; INTEGRATION; RESISTANT; RETRANSFORMATION	An adenovirus-specific transformation resistant cell line (G2) expressing biologically active E1a proteins and originally isolated as a revertant from Ad2-transformed rat cells (F4), was shown to form stable Rb-E1a and 300K-E1a complexes in immunoprecipitation experiments. Consistent with the transformation resistant phenotype, cell hybrids between G2 and F4 were all nontumorigenic. Retrovirus insertion mutagenesis resulted in tumorigenic cell lines and identified a common locus responsible for the E1a-specific dominant tumor suppressor phenotype of G2 cells.			WEBER, JM (corresponding author), UNIV SHERBROOKE,FAC MED,DEPT MICROBIOL,SHERBROOKE J1H 5N4,QUEBEC,CANADA.							ARMENTANO D, 1987, J VIROL, V61, P1647, DOI 10.1128/JVI.61.5.1647-1650.1987; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CRAIG RW, 1985, P NATL ACAD SCI USA, V82, P2062, DOI 10.1073/pnas.82.7.2062; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GARDELLA T, 1984, J VIROL, V50, P248, DOI 10.1128/JVI.50.1.248-254.1984; HEATON MA, 1988, J CELL PHYSIOL, V136, P133, DOI 10.1002/jcp.1041360117; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LOHUIZEN M, 1989, EMBO J, V8, P133; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; NODA M, 1989, P NATL ACAD SCI USA, V86, P162, DOI 10.1073/pnas.86.1.162; PETERS G, 1990, CELL GROWTH DIFFER, V1, P503; RODRIGUES M, 1989, VIRUS RES, V15, P231; RYAN KW, 1985, MOL CELL BIOL, V5, P3577, DOI 10.1128/MCB.5.12.3577; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; SCHAEFER R, 1988, P NATL ACAD SCI USA, V85, P1590, DOI 10.1073/pnas.85.5.1590; SEIF R, 1977, J VIROL, V24, P721, DOI 10.1128/JVI.24.3.721-728.1977; SHIH CC, 1988, CELL, V53, P531, DOI 10.1016/0092-8674(88)90569-7; SIRCAR S, 1987, CANCER RES, V47, P1339; SIRCAR S, 1988, ONCOGENE, V3, P725; SUGIYAMA A, 1989, P NATL ACAD SCI USA, V86, P9144, DOI 10.1073/pnas.86.23.9144; WEBER JM, 1990, J GEN VIROL, V71, P585, DOI 10.1099/0022-1317-71-3-585; WEBER JM, 1989, CANCER RES, V49, P5779; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0	31	5	5	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1991	6	6					989	993						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1648705				2022-12-25	WOS:A1991GU62200013
J	HUANG, JM; NASR, M; KIM, YH; MATTHEWS, HR				HUANG, JM; NASR, M; KIM, YH; MATTHEWS, HR			GENISTEIN INHIBITS PROTEIN HISTIDINE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATES TYROSINE PHOSPHORYLATION; INOSITOL PHOSPHOLIPID TURNOVER; MOUSE ERYTHROLEUKEMIA-CELLS; LABILE HISTONE PHOSPHATES; DNA STRAND BREAKAGE; NUCLEAR PROTEINS; LEUKEMIA-CELLS; DIFFERENTIATION; INDUCTION; ACTIVATION	Protein histidine kinase was prepared from whole cell extracts of the yeast, Saccharomyces cerevisiae. The enzyme was assayed using either histone H4 or a synthetic peptide corresponding to residues 70 to 102 of histone H4 as an in vitro substrate. With either substrate, both genistein and its solvent, dimethyl sulfoxide (Me2SO), inhibited protein histidine kinase. Me2SO alone gave a cooperative dose-response curve, with inhibition changing from almost zero below 10% Me2SO to 80% at 20% Me2SO with either substrate. Genistein gave a simple dose-response curve with 50% inhibition of protein histidine kinase at 110-mu-M genistein. In experiments with protein histidine kinase, genistein was a noncompetitive inhibitor with respect to ATP, histone H4 or the synthetic peptide, although, in the case of the synthetic peptide, the data were also consistent with competitive inhibition. These data gave K(m) values for both ATP and histone H4 of 15-mu-M, in satisfactory agreement with previously reported values (Huang, J., Wei, Y., Kim, Y., Osterberg, L., and Matthews, H. R. (1991) J. Biol. Chem. 266, 9023-9031). The K(m) for the synthetic peptide was 80-mu-M. The K(I) values were 270 or 310-mu-M measured with histone H4 or the synthetic peptide as substrate, respectively. While these K(I) values are relatively high, relative to published K(I) values for genistein inhibition of protein tyrosine kinases, many reported experiments use genistein at concentrations where inhibition of protein histidine kinase occurs. It is possible that some of the observed effects of genistein in vivo may be due to inhibition of protein histidine kinase.	UNIV CALIF DAVIS, SCH MED, DEPT BIOL CHEM, DAVIS, CA 95616 USA	University of California System; University of California Davis								AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BESTERMAN B, 1990, J EXP ZOOL, V256, P44, DOI 10.1002/jez.1402560107; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; CHEN CC, 1977, BIOCHEMISTRY-US, V16, P4852, DOI 10.1021/bi00641a016; CHEN CC, 1974, BIOCHEMISTRY-US, V13, P3785, DOI 10.1021/bi00715a026; CONSTANTINOU A, 1990, CANCER RES, V50, P2618; FUJITAKI JM, 1981, BIOCHEMISTRY-US, V20, P3658, DOI 10.1021/bi00515a055; GLASER KB, 1990, J BIOL CHEM, V265, P8658; GRANJA C, 1991, J BIOL CHEM, V266, P16277; HILL TD, 1990, SCIENCE, V248, P1660, DOI 10.1126/science.2163545; HONMA Y, 1990, JPN J CANCER RES, V81, P1132, DOI 10.1111/j.1349-7006.1990.tb02524.x; HONMA Y, 1991, CANCER RES, V51, P4649; HUANG JM, 1991, J BIOL CHEM, V266, P9023; HUANG JM, 1990, ANAL BIOCHEM, V188, P114, DOI 10.1016/0003-2697(90)90537-J; HUEBNER VD, 1985, J BIOL CHEM, V260, P6106; KIGUCHI K, 1990, CANCER COMMUN, V2, P271, DOI 10.3727/095535490820874218; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; MAJUMDAR APN, 1990, AM J PHYSIOL, V259, pG626, DOI 10.1152/ajpgi.1990.259.4.G626; MAKISHIMA M, 1991, LEUKEMIA RES, V15, P701, DOI 10.1016/0145-2126(91)90072-2; MARKOVITS J, 1989, CANCER RES, V49, P5111; MATTHEWS HR, 1984, MOL CELL BIOCHEM, V59, P81; MATTHEWS HR, 1991, FASEB J, V5, pA802; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; PESIS KH, 1988, FEBS LETT, V239, P151, DOI 10.1016/0014-5793(88)80563-5; PRICE BD, 1991, MOL CELL BIOL, V11, P3365, DOI 10.1128/MCB.11.6.3365; SMITH DL, 1973, NATURE, V246, P103, DOI 10.1038/246103a0; SMITH DL, 1974, BIOCHEMISTRY-US, V13, P3780, DOI 10.1021/bi00715a025; STOCK JB, 1990, NATURE, V344, P395, DOI 10.1038/344395a0; UCKUN FM, 1991, P NATL ACAD SCI USA, V88, P3589, DOI 10.1073/pnas.88.9.3589; UCKUN FM, 1991, P NATL ACAD SCI USA, V88, P6323, DOI 10.1073/pnas.88.14.6323; UCKUN FM, 1991, J BIOL CHEM, V266; WATANABE T, 1991, CANCER RES, V51, P764; WATANABE T, 1989, EXP CELL RES, V183, P335, DOI 10.1016/0014-4827(89)90394-7; WEI YF, 1990, ANAL BIOCHEM, V190, P188, DOI 10.1016/0003-2697(90)90179-D; WEI YF, 1991, METHOD ENZYMOL, V200, P388; ZWILLER J, 1991, ONCOGENE, V6, P219	36	132	141	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15511	15515						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1639791				2022-12-25	WOS:A1992JG11300041
J	CHEN, JY; JOYCE, PBM; WOLFE, CL; STEFFEN, MC; MARTIN, NC				CHEN, JY; JOYCE, PBM; WOLFE, CL; STEFFEN, MC; MARTIN, NC			CYTOPLASMIC AND MITOCHONDRIAL TRANSFER-RNA NUCLEOTIDYLTRANSFERASE ACTIVITIES ARE DERIVED FROM THE SAME GENE IN THE YEAST SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPLAST TRANSFER-RNA; SPLICED TRANSFER-RNA; XENOPUS OOCYTES; NUCLEAR; PRECURSORS; TRANSCRIPTION; PROTEINS; EXTRACT; ENCODES; IMPORT	ATP (CTP):tRNA-specific tRNA nucleotidyltransferase, is an enzyme required for the synthesis of functional tRNAs in eukaryotic cells. Neither the tRNA genes in the nucleus nor in organelles encode the CCA end, so it must be added post-transcriptionally. The gene that codes for the enzyme that adds the CCA end to nuclear coded tRNAs in Saccharomyces cerevisiae has been isolated (Aebi, M., Kirchner, G., Chen, J.-Y., Vijayraghavan, U., Jacobson, A., Martin, N. C., and Abelson, J. (1990) J. Biol. Chem. 265,16216-16220). We now demonstrate that there is a mitochondrial tRNA nucleotidyltransferase activity in yeast and that it is a matrix enzyme. A comparison of purified mitochondrial enzyme with its cytoplasmic counterpart revealed no differences. These results suggest that proteins responsible for this step in the maturation of tRNAs in the nucleus and mitochondria might be identical and coded by the same nuclear gene. Accumulation of shortened mitochondrial as well as cytoplasmic tRNAs in a strain with a temperature-sensitive tRNA nucleotidyltransferase is consistent with this hypothesis. Alteration of the wild type gene such that amino-terminal truncated proteins are produced leads to a defect in mitochondrial function and a decrease in mitochondrial nucleotidyltransferase activity. This provides a direct demonstration that one gene provides this enzyme activity for the biosynthesis of tRNAs in both the nuclear/cytoplasmic and mitochondrial compartments in yeast.	UNIV LOUISVILLE,DEPT BIOCHEM,LOUISVILLE,KY 40292	University of Louisville			Joyce, Paul/K-3989-2013		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027597] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM27597] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBI M, 1990, J BIOL CHEM, V265, P16216; [Anonymous], 1969, METHODS ENZYMOL; BELTZER JP, 1988, J BIOL CHEM, V263, P368; BREEUWER M, 1990, CELL, V60, P999, DOI 10.1016/0092-8674(90)90348-I; CHATTON B, 1988, J BIOL CHEM, V263, P52; CHEN JY, 1988, J BIOL CHEM, V263, P13677; CHEN JY, 1990, J BIOL CHEM, V265, P16221; CLARK MW, 1987, J CELL BIOL, V105, P1515, DOI 10.1083/jcb.105.4.1515; DEUTSCHER MP, 1972, J BIOL CHEM, V247, P450; DIHANICH ME, 1987, MOL CELL BIOL, V7, P177, DOI 10.1128/MCB.7.1.177; DINGWALL C, 1986, ANNU REV CELL BIOL, V2, P367, DOI 10.1146/annurev.cellbio.2.1.367; DOUGLAS MG, 1986, MICROBIOL REV, V50, P166, DOI 10.1128/MMBR.50.2.166-178.1986; ELLIS SR, 1987, P NATL ACAD SCI USA, V84, P5172, DOI 10.1073/pnas.84.15.5172; GEISSELSODER J, 1987, BIOTECHNIQUES, V5, P786; GILLMAN EC, 1991, MOL CELL BIOL, V11, P2382, DOI 10.1128/MCB.11.5.2382; GREENBERG BM, 1986, PLANT MOL BIOL, V6, P89, DOI 10.1007/BF00027302; GROSJEAN H, 1990, BIOCHIM BIOPHYS ACTA, V1050, P267, DOI 10.1016/0167-4781(90)90179-6; GRUISSEM W, 1983, CELL, V35, P815, DOI 10.1016/0092-8674(83)90114-9; HANCOCK K, 1990, J BIOL CHEM, V265, P19208; HANICJOYCE PJ, 1990, J BIOL CHEM, V265, P13782; HOLLINGSWORTH MJ, 1986, MOL CELL BIOL, V6, P1058, DOI 10.1128/MCB.6.4.1058; HURT EC, 1986, TRENDS BIOCHEM SCI, V11, P204, DOI 10.1016/0968-0004(86)90007-1; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOYCE PBM, 1989, NUCLEIC ACIDS RES, V17, P5461, DOI 10.1093/nar/17.14.5461; KNAPP G, 1978, CELL, V14, P221, DOI 10.1016/0092-8674(78)90109-5; Lambowitz A M, 1979, Methods Enzymol, V59, P421; LI JM, 1989, J CELL BIOL, V109, P1411, DOI 10.1083/jcb.109.4.1411; MANAM S, 1987, J BIOL CHEM, V262, P10272; MARCHFELDER A, 1990, NUCLEIC ACIDS RES, V18, P1401, DOI 10.1093/nar/18.6.1401; MARECHALDROUARD L, 1988, NUCLEIC ACIDS RES, V16, P4777, DOI 10.1093/nar/16.11.4777; MELTON DA, 1980, NATURE, V284, P143, DOI 10.1038/284143a0; MUKERJI SK, 1972, J BIOL CHEM, V247, P481; NATSOULIS G, 1986, CELL, V46, P235, DOI 10.1016/0092-8674(86)90740-3; NISHIKURA K, 1981, J MOL BIOL, V145, P405, DOI 10.1016/0022-2836(81)90212-6; PEEBLES CL, 1979, CELL, V18, P27, DOI 10.1016/0092-8674(79)90350-7; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P657; ROSSET R, 1965, BIOCHIM BIOPHYS ACTA, V108, P376, DOI 10.1016/0005-2787(65)90030-4; SILVER P, 1989, CRIT REV BIOCHEM MOL, V24, P419, DOI 10.3109/10409238909082557; SIMPSON AM, 1989, NUCLEIC ACIDS RES, V17, P5427, DOI 10.1093/nar/17.14.5427; SLUSHER LB, 1991, P NATL ACAD SCI USA, V88, P9789, DOI 10.1073/pnas.88.21.9789; SMITH L, 1955, METHOD ENZYMOL, V2, P735; SOLARI A, 1982, NUCLEIC ACIDS RES, V10, P4397, DOI 10.1093/nar/10.14.4397; SUYAMA Y, 1967, BIOCHEMISTRY-US, V6, P2829, DOI 10.1021/bi00861a025; TOLLEY E, 1975, BIOCHEM GENET, V13, P867, DOI 10.1007/BF00484417; WANG MJ, 1988, EMBO J, V7, P1567, DOI 10.1002/j.1460-2075.1988.tb02981.x; WU M, 1987, J BIOL CHEM, V262, P12275; ZINN AB, 1986, NEW ENGL J MED, V315, P469, DOI 10.1056/NEJM198608213150801	48	41	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14879	14883						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634528				2022-12-25	WOS:A1992JF08800058
J	DESCHEEMAEKER, KA; WYNS, S; NELLES, L; AUWERX, J; NY, T; COLLEN, D				DESCHEEMAEKER, KA; WYNS, S; NELLES, L; AUWERX, J; NY, T; COLLEN, D			INTERACTION OF AP-1-LIKE, AP-2-LIKE, AND SP1-LIKE PROTEINS WITH 2 DISTINCT SITES IN THE UPSTREAM REGULATORY REGION OF THE PLASMINOGEN-ACTIVATOR INHIBITOR-1 GENE MEDIATES THE PHORBOL 12-MYRISTATE 13-ACETATE RESPONSE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR AP-1; CHLORAMPHENICOL ACETYLTRANSFERASE; VENOUS THROMBOSIS; SOMATOSTATIN GENE; BINDING; ELEMENT; DNA; IDENTIFICATION; STIMULATION; ENHANCER	Phorbol 12-myristate 13-acetate induces a 3- and 10-fold induction of chloramphenicol acetyltransferase (CAT) activity in HT1080 and HeLa cells, respectively, following transient transfection of a 336-base pair plasminogen activator inhibitor-1 (PAI-1) promoter fragment linked to a CAT reporter gene. Substitution mutations in the regions encompassing nucleotides -78 to -69 (TGGGTGGGGC) or -61 to -54 (TGAGTTCA), but not in the regions -155 to -149 (TGCCTCA) or -84 to -76 (AGTGAGTGG) reduced this induction. Gel electrophoresis of double-stranded -65 to -50 oligonucleotides of the PAI-1 promoter region and nuclear extracts from Hela cells produced a gel shift pattern similar to that obtained with a AP-1 consensus oligomer, and excess unlabeled AP-1 oligomer reverted binding, suggesting that this region of the PAI-1 promoter is an AP-1-like binding site. Gel electrophoresis of double-stranded -82 to -65 oligonucleotides with HeLa nuclear extracts revealed a gel shift pattern of three bands; Sp1 consensus oligomer competed with the binding to two of these bands and AP-2 consensus sequence oligomer with the binding to the third band. The -82 to -65 oligomer also bound to purified AP-2 and Sp1 proteins. Southwestern blotting of HeLa nuclear extracts revealed that the labeled oligomer spanning region -82 to -65 bound to proteins with molecular masses of 52 and 72 kDa. Consensus AP-2 oligonucleotides competed for binding of the labeled -82 to -65 oligonucleotide to the 52-kDa protein, but consensus Sp-1 oligonucleotides did not compete for binding to the 72-kDa compound. The 72-kDa component binding to the -82 to -65 region may represent a new protein involved in transcriptional regulation.	CATHOLIC UNIV LEUVEN, CTR THROMBOSIS & VASC RES, CAMPUS GASTHUISBERG, B-3000 LOUVAIN, BELGIUM; CATHOLIC UNIV LEUVEN, LEGENDO, B-3000 LOUVAIN, BELGIUM; UMEA UNIV, APPL CELL & MOLEC BIOL UNIT, S-90187 UMEA, SWEDEN	KU Leuven; KU Leuven; Umea University			Auwerx, Johan/ABE-9307-2021	Auwerx, Johan/0000-0002-5065-5393				ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BRUZDZINSKI CJ, 1990, J BIOL CHEM, V265, P2078; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; COLLEN D, 1991, BLOOD, V78, P3114; CRABB DW, 1989, METHOD ENZYMOL, V168, P690; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DEBELLE I, 1991, MOL CELL BIOL, V11, P2752, DOI 10.1128/MCB.11.5.2752; DESCHEEMAEKER KA, 1992, IN PRESS FIBRINOLYSI; EDBROOKE MR, 1989, MOL CELL BIOL, V9, P1908, DOI 10.1128/MCB.9.5.1908; GINSBURG D, 1991, THROMBOLYSIS, P17; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; HAI T, 1988, GENE DEV, V2, P1216, DOI 10.1101/gad.2.10.1216; HAMSTEN A, 1985, NEW ENGL J MED, V313, P1557, DOI 10.1056/NEJM198512193132501; HOEFFLER JP, 1989, MOL ENDOCRINOL, V3, P868, DOI 10.1210/mend-3-5-868; JUHANVAGUE I, 1987, THROMB HAEMOSTASIS, V57, P67; KAGEYAMA R, 1988, P NATL ACAD SCI USA, V85, P5016, DOI 10.1073/pnas.85.14.5016; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KATAI H, 1991, MOL CELL BIOCHEM, V101, P73; KIM CH, 1987, P NATL ACAD SCI USA, V84, P6025, DOI 10.1073/pnas.84.17.6025; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LUSCHER B, 1991, GENE DEV, V2, P1507; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; Maniatis T., 1982, MOL CLONING; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NILSSON IM, 1985, BRIT MED J, V290, P1453, DOI 10.1136/bmj.290.6480.1453; OHLSSON H, 1986, CELL, V45, P35, DOI 10.1016/0092-8674(86)90535-0; PROST E, 1986, GENE, V45, P107, DOI 10.1016/0378-1119(86)90138-1; RICCIO A, 1988, NUCLEIC ACIDS RES, V16, P2805, DOI 10.1093/nar/16.7.2805; SANTELL L, 1988, J BIOL CHEM, V263, P16802; SLIVKA SR, 1991, BIOCHIM BIOPHYS ACTA, V1094, P317, DOI 10.1016/0167-4889(91)90092-C; STRANDBERG L, 1988, EUR J BIOCHEM, V176, P609, DOI 10.1111/j.1432-1033.1988.tb14320.x; STRICKLAND S, 1976, CELL, V9, P231, DOI 10.1016/0092-8674(76)90114-8; VANZONNEVELD AJ, 1988, P NATL ACAD SCI USA, V85, P5525; WESTERHAUSEN DR, 1991, J BIOL CHEM, V266, P1092	39	112	114	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15086	15091						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634545				2022-12-25	WOS:A1992JF08800085
J	NELSON, DA; AGUILARBRYAN, L; BRYAN, J				NELSON, DA; AGUILARBRYAN, L; BRYAN, J			SPECIFICITY OF PHOTOLABELING OF BETA-CELL MEMBRANE-PROTEINS WITH AN I-125 LABELED GLYBURIDE ANALOG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H-3 GLIBENCLAMIDE-BINDING; SENSITIVE POTASSIUM CHANNEL; SULFONYLUREA RECEPTOR; RADIOLIGAND; RAT; PURIFICATION; LIGAND; BRAIN; TUMOR; SITE	The interaction between sulfonylureas and membrane proteins from a hamster insulin-secreting tumor (HIT) cell line has been examined. Four HIT cell membrane proteins were covalently linked to an I-125-labeled glyburide analog by photolabeling. Three photolabeled polypeptides of M(r) 65,000, 55,000, and 30,000 were identified as low affinity "glyburide receptors." These proteins appear to be of similar abundance, when quantitated by photolabeling, with half-maximal displacements (K(i) values) by glyburide, glipizide, and tolbutamide in the low micromolar range. The glyburide analog is more tightly bound to a M(r) 140,000 protein with dissociation constants, determined by filtration binding assays and by photolabeling, of 7 and 9.0 nM, respectively. The labeled analog was displaced from the M(r) 140,000 protein by glyburide, glipizide and tolbutamide with K(i) values of 3.3 nM, 103 nM, and 25-mu-M, respectively, as estimated by photolabeling. Optimal conditions established for visualizing the M(r) 140,000 band on autoradiograms prepared after UV cross-linking and sodium dodecyl sulfate-polyacrylamide gel electrophoresis include irradiating the radioligand-receptor complex at 1.5 J/cm2 at 312 nm, followed by heating samples in pH 9.0 sodium dodecyl sulfate-gel sample buffer. With receptor sites partially occupied (5 nM radioligand), approximately 0.75% of the protein is photocoupled to the radioligand and visualized by autoradiography. Our results confirm that the M(r) 140,000 polypeptide contains the beta-cell high affinity glyburide binding site and show that the second generation sulfonylurea antidiabetic drugs have a selective increase in affinity for this receptor.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	Baylor College of Medicine	NELSON, DA (corresponding author), BAYLOR COLL MED,DEPT MED,1 BAYLOR PL,HOUSTON,TX 77030, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041898, R01DK027635] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK41898, DK27635] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGUILARBRYAN L, 1992, J BIOL CHEM, V267, P14934; AGUILARBRYAN L, 1990, J BIOL CHEM, V265, P8218; BERNARDI H, 1988, P NATL ACAD SCI USA, V85, P9816, DOI 10.1073/pnas.85.24.9816; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CROOKS MJ, 1974, J PHARM PHARMACOL, V26, P304, DOI 10.1111/j.2042-7158.1974.tb09280.x; de Weille J R, 1989, Pflugers Arch, V414 Suppl 1, pS80; ELSAYED YM, 1989, INT J CLIN PHARM TH, V27, P551; FOSSET M, 1988, J BIOL CHEM, V263, P7933; FRENCH JF, 1990, BIOCHEM BIOPH RES CO, V167, P1400, DOI 10.1016/0006-291X(90)90678-G; FRENCH JF, 1991, EUR J PHARM-MOLEC PH, V207, P23, DOI 10.1016/S0922-4106(05)80033-1; GAINES KL, 1988, J BIOL CHEM, V263, P2589; GEISEN K, 1985, ARZNEIMITTEL-FORSCH, V35-1, P707; GERICH JE, 1989, NEW ENGL J MED, V321, P1231; GOPALAKRISHNAN M, 1991, J PHARMACOL EXP THER, V257, P1162; HELLMAN B, 1971, BIOCHEM BIOPH RES CO, V45, P1384, DOI 10.1016/0006-291X(71)90174-4; IKEGAMI H, 1986, ACTA ENDOCRINOL-COP, V111, P528, DOI 10.1530/acta.0.1110528; KAUBISCH N, 1982, BIOCHEM PHARMACOL, V31, P1171, DOI 10.1016/0006-2952(82)90363-X; KRAMER W, 1988, FEBS LETT, V229, P355, DOI 10.1016/0014-5793(88)81155-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUPO B, 1987, EUR J PHARMACOL, V140, P157, DOI 10.1016/0014-2999(87)90801-6; MARTZ A, 1989, J BIOL CHEM, V264, P13672; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; MCPHERSON GA, 1983, COMPUT PROG BIOMED, V17, P107, DOI 10.1016/0010-468X(83)90031-4; MILLER JA, 1991, J PHARMACOL EXP THER, V256, P358; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NIKI I, 1989, PFLUG ARCH EUR J PHY, V415, P47, DOI 10.1007/BF00373140; NIKI I, 1991, BIOCHEM J, V277, P619, DOI 10.1042/bj2770619; PANTEN U, 1989, BIOCHEM PHARMACOL, V38, P1217, DOI 10.1016/0006-2952(89)90327-4; ROBERTSON DW, 1990, J MED CHEM, V33, P3124, DOI 10.1021/jm00174a003; STURGESS NC, 1985, LANCET, V2, P474; ZINI S, 1991, BRAIN RES, V542, P151, DOI 10.1016/0006-8993(91)91010-X	31	50	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14928	14933						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634533				2022-12-25	WOS:A1992JF08800065
J	HERSHKO, A; GANOTH, D; PEHRSON, J; PALAZZO, RE; COHEN, LH				HERSHKO, A; GANOTH, D; PEHRSON, J; PALAZZO, RE; COHEN, LH			METHYLATED UBIQUITIN INHIBITS CYCLIN DEGRADATION IN CLAM EMBRYO EXTRACTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA-URCHIN EGGS; PROTEIN LIGASE; M-PHASE; AFFINITY PURIFICATION; CELL-CYCLE; KINASE; DESTRUCTION; MATURATION; COMPONENT; DIVISION	A derivative of ubiquitin in which amino groups were blocked by reductive methylation was used to study the possible role of the ubiquitin pathway in the cell cycle-programed degradation of cyclin. It was shown previously that methylated ubiquitin can be efficiently ligated to protein substrates, but cannot form polyubiquitin chains. In the well-characterized ubiquitin-dependent proteolytic system from reticulocytes, it was found that rates of protein breakdown obtained with methylated ubiquitin are generally slower than those with ubiquitin; and thus, this derivative can be used, in some cases, as an inhibitor of ubiquitin-dependent protein degradation. The addition of methylated ubiquitin to a cell-free system from fertilized clam oocytes inhibited the degradation of both cyclins A and B. That this was due to specific interference with ubiquitin function was indicated by the observation that the supplementation of excess ubiquitin completely overcame the inhibitory action of methylated ubiquitin on cyclin degradation. These findings suggest that polyubiquitin chain formation is required for cyclin degradation.	TECHNION ISRAEL INST TECHNOL,RAPPAPORT INST RES MED SCI,IL-31096 HAIFA,ISRAEL; FOX CHASE CANC INST,INST CANC,PHILADELPHIA,PA 19111; MARINE BIOL LAB,WOODS HOLE,MA 02543	Technion Israel Institute of Technology; Fox Chase Cancer Center; Marine Biological Laboratory - Woods Hole	HERSHKO, A (corresponding author), TECHNION ISRAEL INST TECHNOL,FAC MED,BIOCHEM UNIT,IL-31096 HAIFA,ISRAEL.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025614] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-25614] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOHLEN P, 1973, ARCH BIOCHEM BIOPHYS, V155, P213, DOI 10.1016/S0003-9861(73)80023-2; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CIECHANOVER A, 1980, P NATL ACAD SCI-BIOL, V77, P1365, DOI 10.1073/pnas.77.3.1365; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HELLER H, 1990, J BIOL CHEM, V265, P6532; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; HERSHKO A, 1988, J BIOL CHEM, V263, P15237; HERSHKO A, 1986, PROG NUCLEIC ACID RE, V33, P19, DOI 10.1016/S0079-6603(08)60019-7; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HOUGH R, 1986, J BIOL CHEM, V261, P2400; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LUCA FC, 1989, J CELL BIOL, V109, P1895, DOI 10.1083/jcb.109.5.1895; MEIJER L, 1988, EXP CELL RES, V174, P116, DOI 10.1016/0014-4827(88)90147-4; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MINSHULL J, 1989, J CELL SCI S, V12, P77; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; RECHSTEINER M, 1987, ANNU REV CELL BIOL, V3, P1, DOI 10.1146/annurev.cb.03.110187.000245; REISS Y, 1990, J BIOL CHEM, V265, P3685; STANDART N, 1987, DEV BIOL, V124, P248, DOI 10.1016/0012-1606(87)90476-3; STANDART NM, 1985, J CELL BIOL, V100, P1968, DOI 10.1083/jcb.100.6.1968	25	217	219	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16376	16379						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1653232				2022-12-25	WOS:A1991GD63500024
J	KUSNER, DJ; AUCOTT, JN; FRANCESCHI, D; SARASUA, MM; SPAGNUOLO, PJ; KING, CH				KUSNER, DJ; AUCOTT, JN; FRANCESCHI, D; SARASUA, MM; SPAGNUOLO, PJ; KING, CH			PROTEASE PRIMING OF NEUTROPHIL SUPEROXIDE PRODUCTION - EFFECTS ON MEMBRANE LIPID ORDER AND LATERAL MOBILITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; FREE FATTY-ACIDS; POLYMORPHONUCLEAR LEUKOCYTES; NADPH OXIDASE; KINASE-C; RESPIRATORY BURST; OXYGEN METABOLITES; NEUTRAL PROTEASES; ENHANCED RELEASE; ACTIVATION	Phagocyte superoxide (O2-) response is primed by a variety of physiologic compounds including the neutrophil secretory proteases cathepsin G and elastase. To study whether protease priming of neutrophil O2- response is related to changes in membrane physical state, we examined enzyme effects on the order and lateral mobility of lipid probes in intact neutrophil membranes. Exposure to cathepsin G (5-mu-g/ml) or elastase (10-mu-g/ml) caused a significant decrease in fluorescence anisotropy of the probe trimethylammonium diphenylhexatriene in neutrophil plasma membranes (0.279 to 0.256 for cathepsin G, 0.274 to 0.256 for elastase, p < 0.02 for both), indicating a decrease in phospholipid chain order in the surface membrane bilayer. Cathepsin G and elastase also caused significant increases in membrane lipid lateral mobility as measured by excimer formation of the fluorescent probe 1-pyrenedecanoic acid (for cathepsin G, a 107% increase, and for elastase, a 44% increase in excimer/monomer fluorescence ratio, p < 0.001). Enzyme effects on membrane structure were dependent on intact proteolytic activity, and were cell specific; the proteases had no effect on lipid order or lateral mobility in liposomes. In corollary studies, the possible association between the physical state of the polymorphonuclear leukocyte membrane and O2- generation was analyzed with the membrane modifying compounds, linoleic acid, ethanol, and cholesterol. Cell exposure to linoleic acid (1-mu-m) caused a significant decrease in lipid order and an increase in lipid lateral mobility along with increased O2- production to N-formyl-Met-Leu-Phe (fMLP) (191%) and phorbol myristate acetate (PMA) (39%), p < 0.02 for each. 3 mm ethanol also augmented O2- response to fMLP (31%) and PMA (48%) and caused a significant decrease in lipid order, but did not affect lipid lateral mobility. Treatment with cholesteryl hemisuccinate (100-mu-g/ml) resulted in increased lipid order and decreased lipid lateral mobility, as well as decreased neutrophil superoxide response to fMLP (-61%, p < 0.00 1) and PMA (-50%, p < 0.02). We then examined whether modulation of membrane physical state may explain the mechanism of action of a known priming agent by studying the effects of low concentrations of a diacylglycerol. Cells treated with 10-mu-M 1-oleoyl-2-acetyl-sn-glycerol had a greater than 8-fold increase in superoxide response to fMLP (p < 0.001) while demonstrating a significant decrease in lipid order (0.289 to 0.281, p < 0.01) and a 50% increase in lipid lateral mobility (p < 0.001). Although proteases and the membrane modifying compounds may have other cellular actions which affect superoxide production, these results suggest that changes in membrane structure can modify oxidative burst activity and may, in part, underlie protease priming of neutrophil superoxide response.	METROHLTH MED CTR,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,UNIV HOSP CLEVELAND,DEPT SURG,CLEVELAND,OH 44106	MetroHealth System; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland	KUSNER, DJ (corresponding author), CASE WESTERN RESERVE UNIV,UNIV HOSP CLEVELAND,DEPT MED,CLEVELAND,OH 44106, USA.			King, Charles/0000-0001-8349-9270	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI024645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020618] Funding Source: NIH RePORTER; NIAID NIH HHS [AI24645] Funding Source: Medline; NIAMS NIH HHS [AR20618] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BADWEY JA, 1989, J BIOL CHEM, V264, P20676; BADWEY JA, 1984, J BIOL CHEM, V259, P7870; BASS DA, 1988, J BIOL CHEM, V263, P19610; BASS DA, 1987, J BIOL CHEM, V262, P6643; BERKOW RL, 1987, J IMMUNOL, V139, P3783; CHONG PLG, 1985, J BIOL CHEM, V260, P4484; CURNUTTE JT, 1987, J BIOL CHEM, V262, P5563; DORING G, 1986, CLIN EXP IMMUNOL, V64, P597; EKLUND EA, 1990, J BIOL CHEM, V265, P8426; FEINSTEIN G, 1975, BIOCHIM BIOPHYS ACTA, V403, P477, DOI 10.1016/0005-2744(75)90076-5; GALLA HJ, 1980, CHEM PHYS LIPIDS, V27, P199, DOI 10.1016/0009-3084(80)90036-5; GENNIS RB, 1989, BIOMEMBRANES MOL STR, P187; GOULD RJ, 1987, MEMBRANE FLUIDITY BI, V3, P257; GUPTE S, 1984, P NATL ACAD SCI-BIOL, V81, P2606, DOI 10.1073/pnas.81.9.2606; GUT J, 1983, J BIOL CHEM, V258, P8588; GUTHRIE LA, 1984, J EXP MED, V160, P1656, DOI 10.1084/jem.160.6.1656; HOUSLAY MD, 1983, CURR TOP MEMBR TRANS, V18, P179; JANOFF A, 1976, J CLIN INVEST, V57, P615, DOI 10.1172/JCI108317; Klebanoff S.J., 1982, ADV HOST DEFENSE MEC, P111; KLEINFELD A, 1987, CURR TOP MEMBR TRANS, V19, P1; KORNECKI E, 1986, J CLIN INVEST, V77, P750, DOI 10.1172/JCI112370; KUHNS DB, 1988, LAB INVEST, V58, P448; KUSNER DJ, 1989, J IMMUNOL, V143, P1696; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P133; LEVI M, 1989, AM J PHYSIOL, V256, pF85, DOI 10.1152/ajprenal.1989.256.1.F85; LISCOVITCH M, 1989, J BIOL CHEM, V264, P1450; MASUDA M, 1987, J IMMUNOL METHODS, V96, P225, DOI 10.1016/0022-1759(87)90318-8; MCPHAIL LC, 1985, J CLIN INVEST, V75, P1735, DOI 10.1172/JCI111884; MCPHAIL LC, 1984, J BIOL CHEM, V259, P5768; MULLER CP, 1983, J IMMUNOL, V131, P1356; NATHAN CF, 1983, J EXP MED, V158, P670, DOI 10.1084/jem.158.3.670; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PETERSON MW, 1988, CLIN RES, V36, pA510; PETTY HR, 1987, BIOCHEMISTRY-US, V26, P6340, DOI 10.1021/bi00394a007; POWERS JC, 1977, BIOCHIM BIOPHYS ACTA, V485, P156, DOI 10.1016/0005-2744(77)90203-0; REHOREK M, 1985, BIOCHEMISTRY-US, V24, P5980, DOI 10.1021/bi00342a044; ROOZEMOND RC, 1987, J IMMUNOL, V139, P1739; SEGAL AW, 1989, J CLIN INVEST, V83, P1785, DOI 10.1172/JCI114083; SHINITZKY M, 1979, P NATL ACAD SCI USA, V76, P5313, DOI 10.1073/pnas.76.10.5313; SHINITZKY M, 1984, PHYSL MEMBRANE FLUID, V1, P1; SHPUNGIN S, 1989, J BIOL CHEM, V264, P9195; SPEER CP, 1984, J IMMUNOL, V133, P2151; SQUIER TC, 1988, J BIOL CHEM, V263, P9177; STORCH J, 1986, BIOCHEMISTRY-US, V25, P1717, DOI 10.1021/bi00355a041; STRAUME M, 1987, BIOCHEMISTRY-US, V26, P5113, DOI 10.1021/bi00390a033; TAKENAWA T, 1982, J BIOCHEM-TOKYO, V91, P793, DOI 10.1093/oxfordjournals.jbchem.a133766; UTSUNOMIYA N, 1986, P NATL ACAD SCI USA, V83, P1877, DOI 10.1073/pnas.83.6.1877; UTSUNOMIYA N, 1986, J BIOL CHEM, V261, P6514; VALENTINO M, 1986, BIOCHEM BIOPH RES CO, V141, P1151, DOI 10.1016/S0006-291X(86)80164-4; VANDERKOOI JM, 1974, BIOCHEMISTRY-US, V13, P4000, DOI 10.1021/bi00716a028; VENGE P, 1975, J IMMUNOL, V115, P1505; WEITZ JI, 1986, J CLIN INVEST, V78, P155, DOI 10.1172/JCI112545; WORTHEN GS, 1988, J IMMUNOL, V140, P3553	53	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16465	16471						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1653237				2022-12-25	WOS:A1991GD63500039
J	FU, W; BEATTIE, DS				FU, W; BEATTIE, DS			ASSEMBLY OF THE IRON-SULFUR PROTEIN INTO THE CYTOCHROME-B-C1, COMPLEX OF YEAST MITOCHONDRIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRECURSOR PROTEINS; C REDUCTASE; PROCESSING PROTEASE; IMPORT RECEPTOR; MEMBRANE; IDENTIFICATION; TRANSLOCATION; UBIQUINOL; SUBUNITS; HSP60	The assembly of the iron-sulfur protein into the cytochrome bc1 complex after import and processing of the precursor form into mitochondria in vitro was investigated by immunoprecipitation of the radiolabeled iron-sulfur protein from detergent-solubilized mitochondria with specific antisera. After import in vitro, the labeled mature form of the iron-sulfur protein was immunoprecipitated by antisera against both the iron-sulfur protein and the entire bc1 complex from mitochondria solubilized with either Triton X-100 or dodecyl maltoside. After sodium dodecyl sulfate solubilization of mitochondria, however, the antiserum against the iron-sulfur protein, but not that against the bc1 complex, immunoprecipitated the radiolabeled iron-sulfur protein. These results suggest that in mitochondria the mature form of the iron-sulfur protein is assembled with other subunits of the bc1 complex that are recognized by the antiserum against the bc1 complex. By contrast, the intermediate and precursor forms of the iron-sulfur protein that accumulated in the matrix when proteolytic processing was blocked with EDTA and omicron-phenanthroline were not efficiently assembled into the bc1 complex. The import and processing of the iron-sulfur protein also occurred in mitochondria lacking either cytochrome b (W-267) or the iron-sulfur protein (JPJ1). The mature form of the iron-sulfur protein was immunoprecipitated by antisera against the bc1 complex or core protein I after import in vitro into these mitochondria, suggesting that the mature form is associated with other subunits of the bc1 complex in these strains.	W VIRGINIA UNIV,SCH MED,DEPT BIOCHEM,MORGANTOWN,WV 26506	West Virginia University								BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; BECKMANN JD, 1987, J BIOL CHEM, V262, P8901; BECKMANN JD, 1989, J BIOL CHEM, V264, P3716; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CRIVELLONE MD, 1988, J BIOL CHEM, V263, P14323; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DOUGLAS MG, 1986, MICROBIOL REV, V50, P166, DOI 10.1128/MMBR.50.2.166-178.1986; FU W, 1990, J BIOL CHEM, V265, P16541; HARNISCH U, 1985, EUR J BIOCHEM, V149, P95, DOI 10.1111/j.1432-1033.1985.tb08898.x; HARTL FU, 1986, CELL, V47, P939, DOI 10.1016/0092-8674(86)90809-3; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HAWLITSCHEK G, 1988, CELL, V53, P795, DOI 10.1016/0092-8674(88)90096-7; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; JAPA S, 1989, ARCH BIOCHEM BIOPHYS, V268, P716, DOI 10.1016/0003-9861(89)90340-8; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; LEWIN AS, 1983, J BIOL CHEM, V258, P6750; MURAKAMI K, 1990, EMBO J, V9, P3201, DOI 10.1002/j.1460-2075.1990.tb07518.x; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; OU WJ, 1989, EMBO J, V8, P2605, DOI 10.1002/j.1460-2075.1989.tb08400.x; PAIN D, 1990, NATURE, V347, P444, DOI 10.1038/347444a0; PFANNER N, 1987, CURR TOP BIOENERG, V15, P177; PFANNER N, 1990, ANNU REV BIOCHEM, V59, P331, DOI 10.1146/annurev.biochem.59.1.331; PFANNER N, 1988, EUR J BIOCHEM, V175, P205, DOI 10.1111/j.1432-1033.1988.tb14185.x; PRASAD TK, 1990, MOL CELL BIOL, V10, P3979, DOI 10.1128/MCB.10.8.3979; ROISE D, 1988, J BIOL CHEM, V263, P4509; SCHAGGER H, 1987, FEBS LETT, V219, P161, DOI 10.1016/0014-5793(87)81210-3; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SCHMIDT B, 1983, J CELL BIOL, V96, P248, DOI 10.1083/jcb.96.1.248; SEN K, 1985, ARCH BIOCHEM BIOPHYS, V242, P393, DOI 10.1016/0003-9861(85)90223-1; SEN K, 1986, ARCH BIOCHEM BIOPHYS, V251, P239, DOI 10.1016/0003-9861(86)90071-8; SIDHU A, 1983, J BIOL CHEM, V258, P2308; SIDHU A, 1983, J BIOL CHEM, V258, P649; SIDHU A, 1982, J BIOL CHEM, V257, P7879; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SOLLNER T, 1990, CELL, V62, P107, DOI 10.1016/0092-8674(90)90244-9; VANLOON APGM, 1987, EMBO J, V6, P2441, DOI 10.1002/j.1460-2075.1987.tb02523.x; VENER K, 1988, SCIENCE, V241, P1307; WIELBURSKI A, 1982, BIOCHEM J, V204, P239, DOI 10.1042/bj2040239; YANG M, 1988, EMBO J, V7, P3857, DOI 10.1002/j.1460-2075.1988.tb03271.x	42	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					16212	16218						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1651936				2022-12-25	WOS:A1991GB97700102
J	HORIUCHI, M; NAKAMURA, N; TANG, SS; BARRETT, G; DZAU, VJ				HORIUCHI, M; NAKAMURA, N; TANG, SS; BARRETT, G; DZAU, VJ			MOLECULAR MECHANISM OF TISSUE-SPECIFIC REGULATION OF MOUSE RENIN GENE-EXPRESSION BY CAMP - IDENTIFICATION OF AN INHIBITORY PROTEIN THAT BINDS NUCLEAR TRANSCRIPTIONAL FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; CYCLIC-AMP; RESPONSIVE ELEMENT; SOMATOSTATIN GENE; ENHANCER; REGION; SALIVA	Renin gene expression in the mouse kidney and submandibular gland (SMG) are differentially regulated by cAMP. In this study, we examined the potential molecular mechanism responsible for this tissue-specific regulation. P-32 end-labeled synthetic oligonucleotide containing mouse renin cAMP-responsive element (CRE) was incubated with kidney nuclear extracts from either control or cAMP-treated mice and analyzed by gel mobility shift assay. Our results demonstrated that cAMP induced a nuclear protein which complexed with the CRE oligonucleotide in a specific manner. This nuclear protein-DNA binding was competed effectively by the oligonucleotide containing human chorionic gonadotropin alpha-subunit CRE but not by the mouse renin DNA fragment from which the CRE was deleted by site-directed mutagenesis. In contrast, no DNA-protein complex formation could be detected when this [P-32]CRE oligonucleotide was incubated with the SMG nuclear extract from control or cAMP-treated mice. However, CRE-binding protein complex formation was demonstrated in the SMG nuclear extract when the incubation was performed in the presence of 0.8% sodium deoxycholate and 1.2% Nonidet P-40, detergents that dissociate protein-protein complexes. Furthermore, in the absence of deoxycholate, we observed that SMG nuclear extract attenuated the binding of the kidney CRE-binding protein to mouse renin CRE in a dose-dependent manner and this inhibitory effect of SMG nuclear extract disappeared in the presence of sodium deoxycholate. This inhibitory nuclear protein in SMG is specific for CRE-binding protein since it does not affect nuclear protein binding to synthetic DNA oligonucleotides of human collagenase AP-1 and human metallothionein AP-2. Our data further suggest that inhibitory nuclear protein is present in lower quantities in other extrarenal tissues, i.e. testes, liver, brain, heart, but is not detectable in the kidney. Taken together, these results suggest that the SMG and certain extrarenal tissues contain nuclear trans-acting factor(s) that interact with CRE-binding protein, thereby interfering with its binding to mouse renin CRE. The presence of this inhibitory protein in the mouse SMG nucleus may contribute to the tissue-specific regulation of the renin gene expression by cAMP.	STANFORD UNIV,MED CTR,SCH MED,FALK CARDIOVASC RES CTR,300 PASTEUR DR,STANFORD,CA 94305; STANFORD UNIV,MED CTR,SCH MED,DIV CARDIOVASC MED,STANFORD,CA 94305	Stanford University; Stanford University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035610, R37HL035610, R01HL035252, R01HL042663] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42663, HL35610, HL35252] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BAEAERLE PA, 1988, SCIENCE, V242, P540; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DEUTSCH PJ, 1987, J BIOL CHEM, V262, P12169; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DZAU VJ, 1987, HYPERTENSION, V9, P36; DZAU VJ, 1986, HDB EXPT CARDIOLOGY, P631; FIELD LJ, 1985, P NATL ACAD SCI USA, V82, P6196, DOI 10.1073/pnas.82.18.6196; GOLDBERG AL, 1981, METHOD ENZYMOL, V80, P680; HAZENMARTIN DJ, 1987, ANAT RECORD, V219, P171, DOI 10.1002/ar.1092190210; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JAMESON JL, 1988, J BIOL CHEM, V263, P9879; KURTZ A, 1986, P NATL ACAD SCI USA, V83, P4769, DOI 10.1073/pnas.83.13.4769; LEE CQ, 1988, P NATL ACAD SCI USA, V85, P4223, DOI 10.1073/pnas.85.12.4223; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LI AKC, 1983, GASTROENTEROLOGY, V84, P949; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MULLINS JJ, 1982, EMBO J, V1, P1461, DOI 10.1002/j.1460-2075.1982.tb01338.x; NAKAMURA N, 1989, P NATL ACAD SCI USA, V86, P56, DOI 10.1073/pnas.86.1.56; PAUL M, 1989, CLIN RES, V37, pA533; PROST E, 1986, GENE, V45, P107, DOI 10.1016/0378-1119(86)90138-1; RICE DA, 1989, J BIOL CHEM, V264, P14011; RYWES R, 1987, MOL CELL BIOL, V7, P3482; SHORT JM, 1986, NATURE, V323, P353; TANG SS, 1990, CLIN RES, V38, pA411; TSUKADA T, 1987, J BIOL CHEM, V262, P8743; WALLACE LJ, 1976, P NATL ACAD SCI USA, V73, P4210, DOI 10.1073/pnas.73.11.4210; YAMAMOTO KK, 1990, CELL, V60, P611, DOI 10.1016/0092-8674(90)90664-Z; YAMAMTO KK, 1988, NATURE, V343, P494	34	57	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					16247	16254						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1651939				2022-12-25	WOS:A1991GB97700107
J	SCHMITT, ME; TRUMPOWER, BL				SCHMITT, ME; TRUMPOWER, BL			THE PETITE PHENOTYPE RESULTING FROM A TRUNCATED COPY OF SUBUNIT-6 RESULTS FROM LOSS OF ASSEMBLY OF THE CYTOCHROME BC1 COMPLEX AND CAN BE SUPPRESSED BY OVEREXPRESSION OF SUBUNIT-9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE CHROMATOGRAPHIC PROCEDURE; SACCHAROMYCES-CEREVISIAE; ELECTRON-TRANSFER; C OXIDOREDUCTASE; YEAST UBIQUINOL; HINGE PROTEIN; CARDIAC CYTOCHROME-C1; EQUILIBRIUM-CONSTANTS; HEART-MITOCHONDRIA; REDUCTASE COMPLEX	Disruption of the gene for subunit 6 of the yeast cytochrome bc1 complex (QCR6) causes a temperature-sensitive petite phenotype in contrast to deletion of the coding region of QCR6, which shows no growth defect. Mitochondria from the petite strain carrying the disruption allele were devoid of ubiquinol-cytochrome c oxidoreductase activity but retained cytochrome c oxidase and oligomycin-sensitive ATPase activities. Optical spectra of cytochromes in mitochondrial membranes from the petite strain lacked a cytochrome b absorption band and had a reduced amount of cytochrome c1. Analysis of mitochondrial translation products showed normal synthesis of cytochrome b. Western analysis of mitochondrial membranes from this disruption strain indicates core protein 1 of the cytochrome bc1 complex is present in normal amounts, while cytochrome c1, the Rieske iron-sulfur protein, subunit 6, and subunit 7 were absent or present in very low amounts. Taken together, these findings indicate a loss of assembly of the cytochrome bc1 complex. High copy suppressors of the disruption strain were selected. Two separate families of suppressors were found. The first contained QCR6. The second family consisted of overlapping clones of a second gene distinct from QCR6. These plasmids contained QCR9, the gene which codes for subunit 9 of the yeast cytochrome bc1 complex. Suppression of the QCR6 disruption strain by overexpression of QCR9 indicates a critical interaction between these two proteins in the assembly of the cytochrome bc1 complex.	DARTMOUTH COLL,HITCHCOCK MED CTR,DARTMOUTH MED SCH,DEPT BIOCHEM,HANOVER,NH 03756	Dartmouth College					NIGMS NIH HHS [GM 20379] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020379, R37GM020379] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECKMANN JD, 1987, J BIOL CHEM, V262, P8901; BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; BOTSTEIN D, 1982, MOL BIOL YEAST SACCH, P607; BROACH JR, 1979, GENE, V8, P121, DOI 10.1016/0378-1119(79)90012-X; CRIVELLONE MD, 1988, J BIOL CHEM, V263, P14323; ENGEL WD, 1983, H-S Z PHYSIOL CHEM, V364, P1753, DOI 10.1515/bchm2.1983.364.2.1753; GONZALEZHALPHEN D, 1988, BIOCHEMISTRY-US, V27, P7021, DOI 10.1021/bi00418a053; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; KIM CH, 1990, FEBS LETT, V266, P78, DOI 10.1016/0014-5793(90)81511-L; KIM CH, 1987, J BIOL CHEM, V262, P8103; King P. V., 1986, FOCUS, V8, P1; KRIAUCIUNAS A, 1989, BIOCHIM BIOPHYS ACTA, V976, P70, DOI 10.1016/S0005-2728(89)80190-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LJUNGDAHL O, 1987, BIOCHIM BIOPHYS ACTA, V891, P227; LJUNGDAHL PO, 1987, THESIS DARTMOUTH COL; Maniatis T., 1982, MOL CLONING; MYERS AM, 1987, J BIOL CHEM, V262, P16822; NEEDLEMAN RB, 1975, ANAL BIOCHEM, V64, P545, DOI 10.1016/0003-2697(75)90466-2; OHTA S, 1987, FEBS LETT, V226, P171, DOI 10.1016/0014-5793(87)80573-2; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; PHILLIPS JD, 1990, J BIOL CHEM, V265, P20813; SCHAGGER H, 1983, H-S Z PHYSIOL CHEM, V364, P307; SCHMITT ME, 1990, J BIOL CHEM, V265, P17005; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SCHOPPINK PJ, 1989, BIOCHIM BIOPHYS ACTA, V974, P192, DOI 10.1016/S0005-2728(89)80372-X; SCHOPPINK PJ, 1988, EUR J BIOCHEM, V173, P115, DOI 10.1111/j.1432-1033.1988.tb13974.x; SCHOPPINK PJ, 1989, THESIS U AMSTERDAM; Sherman F., 1983, METHODS YEAST GENETI; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRUMPOWER BL, 1979, J BIOL CHEM, V254, P8697; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; VANLOON APGM, 1984, EMBO J, V3, P1039, DOI 10.1002/j.1460-2075.1984.tb01924.x; YANG XH, 1986, J BIOL CHEM, V261, P2282	33	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					14958	14963						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1651316				2022-12-25	WOS:A1991GB09700027
J	OVERALL, CM; WRANA, JL; SODEK, J				OVERALL, CM; WRANA, JL; SODEK, J			TRANSCRIPTIONAL AND POSTTRANSCRIPTIONAL REGULATION OF 72-KDA GELATINASE TYPE-IV COLLAGENASE BY TRANSFORMING GROWTH FACTOR-BETA-1 IN HUMAN FIBROBLASTS - COMPARISONS WITH COLLAGENASE AND TISSUE INHIBITOR OF MATRIX METALLOPROTEINASE GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SYNOVIAL FIBROBLASTS; PHORBOL-MYRISTATE ACETATE; MESSENGER-RNA STABILITY; BONE CELL-POPULATIONS; FACTOR-BETA; EXTRACELLULAR-MATRIX; DERMAL FIBROBLASTS; BASEMENT-MEMBRANE; LUNG FIBROBLASTS; HUMAN-PLATELETS	The temporal aspects and mechanisms of the regulation of the matrix metalloproteinase (MMP) 72-kDa gelatinase/type IV collagenase (MMP-2) by transforming growth factor-beta-1 (TGF-beta-1) were investigated in early passage human gingival fibroblasts and compared with the regulation of the genes for collagenase (MMP-1) and TIMP, the tissue inhibitor of MMPs. Northern hybridization analyses revealed that 1.0 ng/ ml TGF-beta-1 increased the abundance of MMP-2 mRNA/ cell approximately 1.5-fold at 24 h, an increase similar to that observed in the level of [S-35]methionine pulse-labeled MMP-2 at 24 h (1.9-fold). At 48 and 72 h, the increase in MMP-2 mRNA abundance remained elevated by 1.5-2.2-fold on a per cell basis whereas TIMP mRNA levels were elevated by up to 3.3-fold. In contrast, the relative levels of collagenase mRNA were reduced by 66-75%. The changes in the MMP-2, collagenase, and TIMP mRNA concentrations in response to TGF-beta-1 were blocked by cycloheximide indicating that protein synthesis was required to mediate the effects of TGF-beta-1 on these mRNA levels. TGF-beta-1 was also found to increase the half-life of the MMP-2 mRNA from approximately 46 to approximately 150 h but did not alter the stability of TIMP mRNA (t1/2 approximately 60 h). Nuclear run-off transcription assays revealed that MMP-2 gene transcription was increased approximately 5-fold 7 h following TGF-beta-1-treatment but returned to control levels by 24 h. In comparison, increased TIMP gene transcription was only detectable after 24 h whereas collagenase gene transcription, although low in control cells, was undetectable at 24 h. Gene transcription, mRNA levels, and message stability of the genes for the extracellular matrix proteins type I collagen and fibronectin were also increased by TGF-beta-1. Thus, the similarity in the control of MMP-2, alpha-1(I) procollagen, and fibronectin expression at the transcriptional and post-transcriptional levels indicates that these genes may share regulatory elements. In comparison, TGF-beta-1 reduced the level of collagenase mRNA and increased the level of TIMP mRNA as a result of altered transcriptional activities, through pathways that required protein synthesis, and without changes in mRNA stability.	UNIV TORONTO,FAC DENT,MRC,PERIODONTAL PHYSIOL GRP,TORONTO M5S 1A8,ONTARIO,CANADA; UNIV TORONTO,DEPT BIOCHEM,TORONTO M5S 1A8,ONTARIO,CANADA	University of Toronto; University of Toronto			Wrana, Jeffrey/F-8857-2013					AGGELER J, 1984, J CELL BIOL, V98, P1662, DOI 10.1083/jcb.98.5.1662; ASSOIAN RK, 1983, J BIOL CHEM, V258, P7155; BRAWERMAN G, 1987, CELL, V48, P5, DOI 10.1016/0092-8674(87)90346-1; BRINCKERHOFF CE, 1986, BIOCHEMISTRY-US, V25, P6378, DOI 10.1021/bi00369a006; CHIANG CP, 1986, J BIOL CHEM, V261, P478; CHIN JR, 1985, J BIOL CHEM, V260, P2367; CLARK SD, 1985, ARCH BIOCHEM BIOPHYS, V241, P36, DOI 10.1016/0003-9861(85)90358-3; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; DEAN DC, 1988, J CELL BIOL, V106, P2159, DOI 10.1083/jcb.106.6.2159; DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; FINE A, 1987, J BIOL CHEM, V262, P3897; FRISCH SM, 1990, ONCOGENE, V5, P75; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; HEINE UI, 1987, J CELL BIOL, V105, P2861, DOI 10.1083/jcb.105.6.2861; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KERR LD, 1988, J BIOL CHEM, V263, P16999; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIHO M, 1986, J CELL BIOL, V103, P2403, DOI 10.1083/jcb.103.6.2403; LEHNERT SA, 1988, DEVELOPMENT, V104, P263; LIOTTA LA, 1986, ANNU REV BIOCHEM, V55, P1037, DOI 10.1146/annurev.biochem.55.1.1037; LUND LR, 1987, EMBO J, V6, P1281, DOI 10.1002/j.1460-2075.1987.tb02365.x; MASSAGUE J, 1987, CELL, V49, P437, DOI 10.1016/0092-8674(87)90443-0; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; MURPHY G, 1985, J BIOL CHEM, V260, P3079; OVERALL CM, 1989, CONNECT TISSUE RES, V20, P289, DOI 10.3109/03008208909023899; OVERALL CM, 1988, BIOCHEM J, V256, P965, DOI 10.1042/bj2560965; OVERALL CM, 1987, ANAL BIOCHEM, V165, P208, DOI 10.1016/0003-2697(87)90221-1; OVERALL CM, 1989, J BIOL CHEM, V264, P1860; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; PENTTINEN RP, 1988, P NATL ACAD SCI USA, V85, P1105, DOI 10.1073/pnas.85.4.1105; RAGHOW R, 1987, J CLIN INVEST, V79, P1285, DOI 10.1172/JCI112950; REDINI F, 1988, BIOCHEM BIOPH RES CO, V155, P786, DOI 10.1016/S0006-291X(88)80564-3; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; ROBERTS AB, 1988, ADV CANCER RES, V51, P107, DOI 10.1016/S0065-230X(08)60221-3; ROBERTS AB, 1981, P NATL ACAD SCI-BIOL, V78, P5339, DOI 10.1073/pnas.78.9.5339; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; SAKSELA O, 1987, J CELL BIOL, V105, P957, DOI 10.1083/jcb.105.2.957; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; SEYEDIN SM, 1985, P NATL ACAD SCI USA, V82, P2267, DOI 10.1073/pnas.82.8.2267; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SPORN MB, 1983, SCIENCE, V219, P1329, DOI 10.1126/science.6572416; STENNER DD, 1986, P NATL ACAD SCI USA, V83, P6892, DOI 10.1073/pnas.83.18.6892; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; STETLERSTEVENSON WG, 1990, J BIOL CHEM, V265, P13933; TUNG PS, 1985, J HISTOCHEM CYTOCHEM, V33, P531, DOI 10.1177/33.6.3889139; WASI S, 1984, CAN J BIOCHEM CELL B, V62, P470, DOI 10.1139/o84-064; WRANA JL, 1988, J CELL BIOL, V106, P915, DOI 10.1083/jcb.106.3.915; WRANA JL, 1989, NUCLEIC ACIDS RES, V17, P10119, DOI 10.1093/nar/17.23.10119; WRANA JL, 1986, EUR J BIOCHEM, V159, P69, DOI 10.1111/j.1432-1033.1986.tb09834.x; WRANA JL, 1991, BIOCHEM J, V273, P523, DOI 10.1042/bj2730523; WRANA JL, 1991, THESIS U TORONTO; WRANA JL, 1991, IN PRESS EUR J BIOCH	54	406	419	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					14064	14071						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1649834				2022-12-25	WOS:A1991FY02700094
J	LUNDIN, M; BALTSCHEFFSKY, H; RONNE, H				LUNDIN, M; BALTSCHEFFSKY, H; RONNE, H			YEAST-PPA2 GENE ENCODES A MITOCHONDRIAL INORGANIC PYROPHOSPHATASE THAT IS ESSENTIAL FOR MITOCHONDRIAL-FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHYLOGENETIC TREES; LIVER-MITOCHONDRIA; DNA; EVOLUTION; SUBUNIT; PURIFICATION; METABOLISM; SEQUENCE; PROTEINS; CLONING	We have cloned a gene encoding a mitochondrial inorganic pyrophosphatase (PPase) in the yeast Saccharomyces cerevisiae by low stringency hybridization to PPA1, the yeast gene for cytoplasmic PPase. The new gene, PPA2, is located on chromosome 13 and encodes a protein whose sequence is 49% identical to the cytoplasmic enzyme. The protein differs from cytoplasmic PPase in that it has a leader sequence enriched in basic and hydroxylated residues, which is typically found in mitochondrial proteins. Yeast cells overproducing PPA2 had a 47-fold increase in mitochondrial PPase activity. This activity was further stimulated 3-fold by the uncoupler carbonyl cyanide p-trifluoromethoxyphenylhydrazone, which suggests that PPA2 is part of an energy-linked enzyme. Using gene disruptions, we found that PPA1 is required for cell growth. In contrast, cells disrupted for PPA2 are viable, but unable to grow on respiratory carbon sources. Fluorescence microscopy revealed that these cells have lost their mitochondrial DNA. We conclude that the mitochondrial PPase encoded by PPA2 is essential for mitochondrial function and maintenance of the mitochondrial genome.	LUDWIG INST CANC RES, CTR BIOMED, S-75123 UPPSALA, SWEDEN	Ludwig Institute for Cancer Research	LUNDIN, M (corresponding author), UNIV STOCKHOLM, ARRHENIUS LABS NAT SCI, DEPT BIOCHEM, S-10691 STOCKHOLM, SWEDEN.			Ronne, Hans/0000-0002-1645-6091				BALTSCHEFFSKY H, 1987, ACTA CHEM SCAND B, V41, P106, DOI 10.3891/acta.chem.scand.41b-0106; BALTSCHEFFSKY H, 1966, SCIENCE, V153, P1120, DOI 10.1126/science.153.3740.1120; BALTSCHEFFSKY H, 1986, CHEM SCRIPTA, V26B, P259; BALTSCHEFFSKY H, 1981, BIOSYSTEMS, V14, P49, DOI 10.1016/0303-2647(81)90021-6; BALTSCHEFFSKY M, 1967, REGUL FUNCT, V11, P277; BALTSCHEFFSKY M, 1984, NEW COMPREHENSIVE BI, V9, P187; BRITTEN CJ, 1989, FEBS LETT, V256, P200, DOI 10.1016/0014-5793(89)81748-X; CHU G, 1986, SCIENCE, V234, P1582, DOI 10.1126/science.3538420; COHEN SA, 1978, J BIOL CHEM, V253, P889; COOPERMAN BS, 1982, METHOD ENZYMOL, V87, P526; Dujon B., 1981, MOL BIOL YEAST SACCH, P505; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; FITCH WM, 1967, SCIENCE, V155, P279, DOI 10.1126/science.155.3760.279; FOX TD, 1983, NATURE, V301, P371, DOI 10.1038/301371a0; GONZALEZ MA, 1986, BIOCHEMISTRY-US, V25, P7179, DOI 10.1021/bi00370a062; GOODMAN M, 1975, NATURE, V253, P603, DOI 10.1038/253603a0; HALESTRAP AP, 1989, BIOCHIM BIOPHYS ACTA, V973, P355, DOI 10.1016/S0005-2728(89)80378-0; ICHIBA T, 1990, J BIOCHEM-TOKYO, V108, P572, DOI 10.1093/oxfordjournals.jbchem.a123244; IWABE N, 1989, P NATL ACAD SCI USA, V86, P9355, DOI 10.1073/pnas.86.23.9355; KAWASAKI I, 1990, NUCLEIC ACIDS RES, V18, P5888, DOI 10.1093/nar/18.19.5888; Kimura MA, 1985, NEUTRAL THEORY MOL E; KOLAKOWSKI LF, 1988, NUCLEIC ACIDS RES, V16, P10441, DOI 10.1093/nar/16.22.10441; KUKKO E, 1982, FEMS MICROBIOL LETT, V15, P309; KURANOVA IP, 1987, BIOKHIMIYA, V53, P1821; LAHTI R, 1983, MICROBIOL REV, V47, P169, DOI 10.1128/MMBR.47.2.169-178.1983; LAHTI R, 1990, BIOCHEMISTRY-US, V29, P5761, DOI 10.1021/bi00476a017; LAHTI R, 1988, J BACTERIOL, V170, P5901, DOI 10.1128/jb.170.12.5901-5907.1988; LAHTI R, 1990, BIOCHIM BIOPHYS ACTA, V1038, P338, DOI 10.1016/0167-4838(90)90246-C; LUNDIN M, 1987, BIOCHIM BIOPHYS ACTA, V890, P279, DOI 10.1016/0005-2728(87)90154-X; MAESHIMA M, 1989, J BIOL CHEM, V264, P20068; MANSUROVA SE, 1989, BIOCHIM BIOPHYS ACTA, V977, P237, DOI 10.1016/S0005-2728(89)80078-7; MASLOWSKI P, 1987, BIOCH PHYSL PFLANZ, V182, P73; NEHLIN JO, 1989, GENE, V85, P313, DOI 10.1016/0378-1119(89)90423-X; NEHLIN JO, 1990, EMBO J, V9, P2891, DOI 10.1002/j.1460-2075.1990.tb07479.x; NELSON GJ, 1969, ANN NY ACAD SCI, V167, P18, DOI 10.1111/j.1749-6632.1969.tb20431.x; NYREN P, 1991, BIOCHEMISTRY-US, V30, P2883, DOI 10.1021/bi00225a022; OCHMAN H, 1987, J MOL EVOL, V26, P74, DOI 10.1007/BF02111283; PRINGLE JR, 1989, METHOD CELL BIOL, V31, P357; QU LH, 1988, J MOL EVOL, V28, P113, DOI 10.1007/BF02143502; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SARAFIAN V, 1989, PLANT PHYSIOL, V91, P34, DOI 10.1104/pp.91.1.34; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SHATTON JB, 1983, ANAL BIOCHEM, V130, P114, DOI 10.1016/0003-2697(83)90657-7; STARK MJR, 1989, YEAST, V5, P35, DOI 10.1002/yea.320050106; TERZYAN SS, 1984, BIOORG KHIM+, V10, P1469; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; VERDIER JM, 1990, YEAST, V6, P271, DOI 10.1002/yea.320060402; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; VOLK SE, 1984, BIOCHIM BIOPHYS ACTA, V791, P198, DOI 10.1016/0167-4838(84)90009-8; VOLK SE, 1983, BIOCHIM BIOPHYS ACTA, V744, P127, DOI 10.1016/0167-4838(83)90081-X; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987	54	162	166	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1991	266	19					12168	12172						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FV180	1648084				2022-12-25	WOS:A1991FV18000012
J	NEEDLEMAN, R; CHANG, M; NI, BF; VARO, G; FORNES, J; WHITE, SH; LANYI, JK				NEEDLEMAN, R; CHANG, M; NI, BF; VARO, G; FORNES, J; WHITE, SH; LANYI, JK			PROPERTIES OF ASP212-]ASN BACTERIORHODOPSIN SUGGEST THAT ASP212 AND ASP85 BOTH PARTICIPATE IN A COUNTERION AND PROTON ACCEPTOR COMPLEX NEAR THE SCHIFF-BASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HALOBACTERIUM-HALOBIUM; PURPLE MEMBRANE; VIBRATIONAL SPECTROSCOPY; CHROMOPHORE PROTEIN; ASPARTIC ACID-96; N-INTERMEDIATE; PUMP; MUTANTS; PH; TRANSLOCATION	The gene coding for bacteriorhodopsin was modified in vitro to replace Asp212 with asparagine and expressed in Halobacterium halobium. X-ray diffraction measurements showed that the major lattice dimension of purple membrane containing the mutated bacteriorhodopsin was the same as wild type. At pH > 7, the ASp212 --> Asn chromophore was blue (absorption maximum at 585 nm) and exhibited a photocycle containing only the intermediates K and L, i.e. a reaction sequence very similar to that of wild-type bacteriorhodopsin at pH < 3 and the blue form of the Asp85 --> Glu protein at pH < 9. Since in the latter cases these effects are attributed to protonation of residue 85, it now appears that removal of the carboxylate of Asp212 has similar consequences as removing the carboxylate of Asp85. However, an important difference is that only Asp85 affects the pKa of the Schiff base. At pH < 7, the ASp2l2 --> Asn protein was purple (absorption maximum at 569 nm) but photoexcitation produced only 15% of the normal amount of M and the transport activity was partial. The reactions of the blue and purple forms after photoexcitation are both quantitatively accounted for by a proposed scheme, K <--> L1 <--> L2 --> BR, but with the addition of an L1 <--> M reaction with unfavorable pKa for Schiff base deprotonation in the purple form. The latter hinders the transient accumulation of M, and the consequent branching at L, allows only partial proton transport activity. The results are consistent with the existence of a complex counterion for the Schiff base proposed earlier (De Groot, H. J. M., Harbison, G. S., Herzfeld, J., and Griffin, R. G. (1989) Biochemistry 28, 3346-3353) and suggest that Asp85, Asp212, and at least one other protonable residue participate in it.	UNIV CALIF IRVINE,DEPT PHYSIOL & BIOPHYS,IRVINE,CA 92717; WAYNE STATE UNIV,SCH MED,DEPT BIOCHEM,DETROIT,MI 48201	University of California System; University of California Irvine; Wayne State University			Lanyi, Janos/C-3808-2011		NIGMS NIH HHS [GM 29498] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM029498, R01GM029498] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLAUROCK AE, 1975, J MOL BIOL, V93, P139, DOI 10.1016/0022-2836(75)90124-2; BOGOMOLNI RA, 1980, BIOCHEMISTRY-US, V19, P2152, DOI 10.1021/bi00551a024; BRAIMAN MS, 1988, BIOCHEMISTRY-US, V27, P8516, DOI 10.1021/bi00423a002; BUTT HJ, 1989, EMBO J, V8, P1657, DOI 10.1002/j.1460-2075.1989.tb03556.x; CLINE SW, 1987, J BACTERIOL, V169, P1341, DOI 10.1128/jb.169.3.1341-1344.1987; DASSARMA S, 1984, P NATL ACAD SCI-BIOL, V81, P125, DOI 10.1073/pnas.81.1.125; DEGROOT HJM, 1990, BIOCHEMISTRY-US, V29, P6873, DOI 10.1021/bi00481a017; DEGROOT HJM, 1989, BIOCHEMISTRY-US, V28, P3346, DOI 10.1021/bi00434a033; DUNACH M, 1990, P NATL ACAD SCI USA, V87, P9873, DOI 10.1073/pnas.87.24.9873; EBREY TG, 1977, J MOL BIOL, V112, P377, DOI 10.1016/S0022-2836(77)80188-5; ELLIOTT A, 1965, J SCI INSTRUM, V422, P312; FODOR SPA, 1988, BIOCHEMISTRY-US, V27, P7097, DOI 10.1021/bi00418a064; GERWERT K, 1990, P NATL ACAD SCI USA, V87, P9774, DOI 10.1073/pnas.87.24.9774; GERWERT K, 1989, P NATL ACAD SCI USA, V86, P4943, DOI 10.1073/pnas.86.13.4943; HENDERSON R, 1975, J MOL BIOL, V93, P123, DOI 10.1016/0022-2836(75)90123-0; HEYN MP, 1975, BIOCHEM BIOPH RES CO, V67, P897, DOI 10.1016/0006-291X(75)90761-5; HOLZ M, 1989, P NATL ACAD SCI USA, V86, P2167, DOI 10.1073/pnas.86.7.2167; KOBAYASHI T, 1983, FEBS LETT, V162, P197, DOI 10.1016/0014-5793(83)81078-3; LAM WL, 1989, P NATL ACAD SCI USA, V86, P5478, DOI 10.1073/pnas.86.14.5478; Lanyi J K, 1979, Methods Enzymol, V56, P398; LANYI JK, 1988, BIOPHYS J, V53, P185, DOI 10.1016/S0006-3495(88)83080-7; MARINETTI T, 1989, P NATL ACAD SCI USA, V86, P529, DOI 10.1073/pnas.86.2.529; MOGI T, 1988, P NATL ACAD SCI USA, V85, P4148, DOI 10.1073/pnas.85.12.4148; MOWERY PC, 1979, BIOCHEMISTRY-US, V18, P4100, DOI 10.1021/bi00586a007; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; NAKANISHI K, 1980, J AM CHEM SOC, V102, P7945, DOI 10.1021/ja00547a028; NI B, 1990, GENE, V90, P169, DOI 10.1016/0378-1119(90)90456-2; Oesterhelt D, 1974, Methods Enzymol, V31, P667; OTTO H, 1990, P NATL ACAD SCI USA, V87, P1018, DOI 10.1073/pnas.87.3.1018; ROTHSCHILD KJ, 1990, J BIOL CHEM, V265, P16985; SPUDICH JL, 1986, BIOPHYS J, V49, P479, DOI 10.1016/S0006-3495(86)83657-8; STERN LJ, 1989, BIOCHEMISTRY-US, V28, P10035, DOI 10.1021/bi00452a023; SUBRAMANIAM S, 1990, P NATL ACAD SCI USA, V87, P1013, DOI 10.1073/pnas.87.3.1013; TITTOR J, 1989, EMBO J, V8, P3477, DOI 10.1002/j.1460-2075.1989.tb08512.x; VARO G, 1990, BIOCHEMISTRY-US, V29, P6858, DOI 10.1021/bi00481a015; VARO G, 1989, BIOPHYS J, V56, P1143, DOI 10.1016/S0006-3495(89)82761-4; VARO G, 1990, BIOCHEMISTRY-US, V29, P3798, DOI 10.1021/bi00467a029; VARO G, 1990, BIOCHEMISTRY-US, V29, P2241, DOI 10.1021/bi00461a006; VARO G, 1990, BIOPHYS J, V59, P313; ZIMANYI L, 1989, BIOCHEMISTRY-US, V28, P5165, DOI 10.1021/bi00438a038	41	175	176	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1991	266	18					11478	11484						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FT762	1646807				2022-12-25	WOS:A1991FT76200014
J	TANAKA, H; HRUSKA, KA; SEINO, Y; MALONE, JD; NISHII, Y; TEITELBAUM, SL				TANAKA, H; HRUSKA, KA; SEINO, Y; MALONE, JD; NISHII, Y; TEITELBAUM, SL			DISASSOCIATION OF THE MACROPHAGE-MATURATIONAL EFFECTS OF VITAMIN-D FROM RESPIRATORY BURST PRIMING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA-CELL-LINE; MONOCYTIC DIFFERENTIATION; HUMAN-NEUTROPHILS; INTACT-CELLS; 1,25-DIHYDROXYVITAMIN-D3; RECEPTOR; PROLIFERATION; ANALOGS; ACTIVATION; INDUCTION	During the process of enhancing monocytic differentiation of the human leukemia line HL-60, 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) also "primes" the cell for respiratory burst by increasing the uptake of Ca2+ across the plasma membrane (Hruska, K. A., Bar-Shavit, Z., Malone, J. D., and Teitelbaum, S. L. (1988) J. Biol. Chem. 263, 16039-16044). The present study asked if the maturational effect of vitamin D is dependent upon this "priming" phenomenon. To this end, we exposed HL-60 to either 1,25(OH)2D3 or its synthetic analogue (1-alpha, 3-beta, 5Z, 7E)-9-10-Secocholesta-5, 7,10(19)-triene-1, 3, 25-triol (22-oxa). We found that 22-oxa induces HL-60 maturation as effectively as does the natural steroid. As expected, 48 h of 1,25(OH)2D3 exposure more than doubles (p < 0.005) HL-60 basal cytosolic Ca2+ and increases inositol triphosphate-sensitive Ca2+ stores approximately 4-fold (p < 0.01). 22-oxa in contrast alters neither Ca2+- nor inositol triphosphate-mobilizable deposits. Moreover, 1,25(OH)2D3 treatment prompts a transient Ca2+ "spike" in response to formyl-methionyl-leucyl-phenylalanine (fMLP) and a marked increase in superoxide (O2-) generation when exposed to the chemotactic peptide (p < 0.01) or phorbol ester (p < 0.02). Treatment with 22-oxa does not enable HL-60 to respond to fMLP with a Ca2+ spike or prime the cell for respiratory burst unless it is co-incubated with the Ca2+ ionophore, ionomycin. Similarly, phorbol ester impacts more profoundly on O2- generation by 1,25(OH)2D3 than 22-oxa preincubated cells (p < 0.02), unless the latter is added with ionomycin. Our findings indicate that the maturational effects of vitamin D sterols are independent of their capacity to prime cells for respiratory burst and that the Ca2+ ionophoretic effects of 1,25(OH)2D3 play a major role in such priming.	WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,DEPT MED,DIV RENAL,ST LOUIS,MO 63110; OKAYAMA UNIV,SCH MED,DEPT PEDIAT,OKAYAMA 700,JAPAN; ST LOUIS UNIV,DEPT MED,ST LOUIS,MO 63103; ST LOUIS UNIV,DEPT PHARMACOL,ST LOUIS,MO 63103; VET ADM MED CTR,ST LOUIS,MO 63106; CHUGAI PHARMACEUT CO LTD,TOKYO 171,JAPAN	Barnes-Jewish Hospital; Washington University (WUSTL); Okayama University; Saint Louis University; Saint Louis University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Chugai Pharmaceutical Co., Ltd.; Roche Holding	TANAKA, H (corresponding author), WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,DEPT PATHOL,216 S KINGSHIGHWAY,ST LOUIS,MO 63110, USA.			Teitelbaum, Steven/0000-0002-4054-6679	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR032087] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR32087] Funding Source: Medline; NIDCR NIH HHS [DE05413] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ABE J, 1987, FEBS LETT, V226, P58, DOI 10.1016/0014-5793(87)80550-1; BABIOR BM, 1984, J CLIN INVEST, V73, P599, DOI 10.1172/JCI111249; BARSHAVIT Z, 1983, P NATL ACAD SCI-BIOL, V80, P5907, DOI 10.1073/pnas.80.19.5907; BARSHAVIT Z, 1981, CALCIFIED TISSUE INT, V33, P673, DOI 10.1007/BF02409507; BARSHAVIT Z, 1986, ENDOCRINOLOGY, V118, P679, DOI 10.1210/endo-118-2-679; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; CLOHISY DR, 1987, J BIOL CHEM, V262, P15922; COOKE E, 1985, BIOCHEM J, V232, P323, DOI 10.1042/bj2320323; HRUSKA KA, 1988, J BIOL CHEM, V263, P16039; HYSLOP PA, 1984, ANAL BIOCHEM, V141, P280, DOI 10.1016/0003-2697(84)90457-3; JAKEN S, 1987, METHOD ENZYMOL, V141, P275; JOHNSTON RB, 1985, FED PROC, V44, P2927; KAHN AJ, 1981, T ASSOC AM PHYSICIAN, V94, P267; KUBODERA N, 1986, CHEM PHARM BULL, V34, P2286; LACEY DL, 1987, J IMMUNOL, V138, P1680; MANGELSDORF DJ, 1984, J CELL BIOL, V98, P391, DOI 10.1083/jcb.98.2.391; MCCARTHY DM, 1983, LEUKEMIA RES, V7, P51, DOI 10.1016/0145-2126(83)90057-7; MCWILLIAMS LT, 1977, P NATL ACAD SCI USA, V74, P1204; MIYAURA C, 1981, BIOCHEM BIOPH RES CO, V102, P937, DOI 10.1016/0006-291X(81)91628-4; MURAYAMA E, 1986, CHEM PHARM BULL, V34, P4410; NIEDEL J, 1979, J BIOL CHEM, V254, P700; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; SMITH EL, 1988, J AM ACAD DERMATOL, V19, P516, DOI 10.1016/S0190-9622(88)70207-8; SNYDERMAN R, 1986, J LEUKOCYTE BIOL, V40, P785, DOI 10.1002/jlb.40.6.785; TANAKA H, 1982, BIOCHEM J, V204, P713, DOI 10.1042/bj2040713; WYMANN MP, 1987, ANAL BIOCHEM, V165, P371, DOI 10.1016/0003-2697(87)90284-3	26	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					10888	10892						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	1645714				2022-12-25	WOS:A1991FQ77400031
J	MILANEZ, S; MURAL, RJ; HARTMAN, FC				MILANEZ, S; MURAL, RJ; HARTMAN, FC			ROLES OF CYSTEINYL RESIDUES OF PHOSPHORIBULOKINASE AS EXAMINED BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINACH PHOSPHORIBULOKINASE; RIBULOSE-5-PHOSPHATE KINASE; DNA; PROTEINS; NONESSENTIALITY; NITROCELLULOSE; ENZYMES; PEPTIDE; BINDING	The Calvin Cycle enzyme phosphoribulokinase is activated in higher plants by the reversible reduction of a disulfide bond, which is located at the active site. To determine the possible contribution of the two regulatory residues (Cys16 and Cys55) to catalysis, site-directed mutagenesis has been used to replace each of them in the spinach enzyme with serine or alanine. The only other cysteinyl residues of the kinase, Cys244 and Cys250, were also replaced individually by serine or alanine. A comparison of specific activities of native and mutant enzymes reveals that substitutions at positions 244 or 250 are inconsequential. The position 16 mutants retain 45-90% of the wild-type activity and display normal K(m) values for both ATP and ribulose 5-phosphate. In contrast, substitution at position 55 results in 85-95% loss of wild-type activity, with less than a 2-fold increase in the K(m) for ATP and a 4-8-fold increase in the K(m) for ribulose 5-phosphate. These results are consistent with moderate facilitation of catalysis by Cys55 and demonstrate that the other three cysteinyl residues do not contribute significantly either to structure or catalysis. The enhanced stability, relative to wild-type enzyme, of the Ser16 mutant protein to a sulfhydryl reagent supports earlier suggestions that Cys16 is the initial target of the oxidative deactivation process.	UNIV TENNESSEE,GRAD SCH BIOMED SCI,OAK RIDGE,TN 37831	University of Tennessee System; University of Tennessee Knoxville	MILANEZ, S (corresponding author), OAK RIDGE NATL LAB,DIV BIOL,PROT ENGN & MOLEC MUTAGENESIS PROGRAM,OAK RIDGE,TN 37831, USA.							ASHTON AR, 1983, THIOREDOXINS STRUCTU, P245; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHANAN BB, 1980, ANNU REV PLANT PHYS, V31, P341, DOI 10.1146/annurev.pp.31.060180.002013; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CRAWFORD NA, 1989, ARCH BIOCHEM BIOPHYS, V271, P223, DOI 10.1016/0003-9861(89)90273-7; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; JAHN R, 1984, P NATL ACAD SCI-BIOL, V81, P1684, DOI 10.1073/pnas.81.6.1684; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; KRIEGER TJ, 1987, ARCH BIOCHEM BIOPHYS, V256, P362, DOI 10.1016/0003-9861(87)90457-7; KRIEGER TJ, 1987, BIOCHIM BIOPHYS ACTA, V915, P112, DOI 10.1016/0167-4838(87)90130-0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARIMER FW, 1990, PROTEIN ENG, V3, P227, DOI 10.1093/protein/3.3.227; MILANEZ S, 1988, GENE, V66, P55, DOI 10.1016/0378-1119(88)90224-7; MILANEZ S, 1990, FASEB J, V4, pA1761; NIYOGI SK, 1986, J BIOL CHEM, V261, P87; OMNAAS J, 1985, ARCH BIOCHEM BIOPHYS, V236, P646, DOI 10.1016/0003-9861(85)90669-1; PONTREMOLI S, 1962, J BIOL CHEM, V237, P643; PORTER MA, 1990, PLANTA, V181, P349, DOI 10.1007/BF00195887; PORTER MA, 1988, J BIOL CHEM, V263, P14846; PORTER MA, 1986, ARCH BIOCHEM BIOPHYS, V245, P14, DOI 10.1016/0003-9861(86)90185-2; PORTER MA, 1988, J BIOL CHEM, V263, P123; PORTER MA, 1986, BIOCHEMISTRY-US, V25, P7314, DOI 10.1021/bi00371a011; PORTER MA, 1990, ARCH BIOCHEM BIOPHYS, V281, P330, DOI 10.1016/0003-9861(90)90452-5; PORTER MA, 1990, J PROTEIN CHEM, V9, P445, DOI 10.1007/BF01024620; RACKER E., 1957, ARCH BIOCHEM AND BIOPHYS, V69, P300, DOI 10.1016/0003-9861(57)90496-4; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SINHA ND, 1984, NUCLEIC ACIDS RES, V12, P4539, DOI 10.1093/nar/12.11.4539; UHLMANN E, 1986, TETRAHEDRON LETT, V27, P1023, DOI 10.1016/S0040-4039(86)80038-7; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; Wishnick M, 1971, METHODS ENZYMOLOGY, V23, P570	31	40	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10694	10699						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	1645355				2022-12-25	WOS:A1991FP08600103
J	TSAI, AYM; ITOH, M; STREULI, M; THAI, T; SAITO, H				TSAI, AYM; ITOH, M; STREULI, M; THAI, T; SAITO, H			ISOLATION AND CHARACTERIZATION OF TEMPERATURE-SENSITIVE AND THERMOSTABLE MUTANTS OF THE HUMAN RECEPTOR-LIKE PROTEIN TYROSINE PHOSPHATASE LAR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; LEUKOCYTE COMMON ANTIGEN; AMINO-ACID REPLACEMENTS; HIGH-LEVEL EXPRESSION; ESCHERICHIA-COLI; LAMBDA-REPRESSOR; CLONED GENES; MUTATIONS; CLONING; MEMBER	Human LAR is a transmembrane receptor-like protein whose cytoplasmic region contains two tandemly duplicated domains homologous to protein tyrosine phosphatases (PTPases). Whereas the membrane-proximal domain I has enzymatic activity, the membrane-distal domain II has no apparent catalytic activity but seems to have a regulatory function. In order to study structure-function relationships of the LAR PTPase, LAR domain I was expressed in Escherichia coli, and mutants that have reduced catalytic activity or reduced thermostability were isolated and characterized. We isolated 18 unique hydroxylamine-induced missense mutations in the LAR domain I segment, of which three were temperature-sensitive. Five additional temperature-sensitive mutations were isolated using N-methyl-N'-nitro-N-nitrosoguanidine. All eight temperature-sensitive mutations are confined within a short segment of the LAR domain I sequence between amino acid positions 1329 and 1407. To examine whether this region is particularly prone to temperature-sensitive mutations, tyrosine at aminoacid position 1379 was changed to a phenylalanine by oligonucleotide-directed mutagenesis. This mutant, Y1379-F, was indeed temperature-sensitive. We also isolated a revertant of a temperature-sensitive mutant. The revertant contained a second-site mutation (C1446-Y) that suppresses several temperature-sensitive mutations and also enhances the folding of LAR protein produced in E. coli.	HARVARD UNIV, SCH MED,DANA FARBER CANC INST,DIV TUMOR IMMUNOL, 44 BINNEY ST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH DENT MED, DEPT PERIODONTOL, CAMBRIDGE, MA 02138 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard School of Dental Medicine; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School			Saito, Haruo/AAF-6113-2019	Saito, Haruo/0000-0001-7891-1689	NCI NIH HHS [CA51132] Funding Source: Medline; NIAID NIH HHS [AI-26598] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051132] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026598] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADELBERG EA, 1965, BIOCHEM BIOPH RES CO, V18, P788, DOI 10.1016/0006-291X(65)90855-7; ALBER T, 1987, BIOCHEMISTRY-US, V26, P3754, DOI 10.1021/bi00387a002; AMANN E, 1985, GENE, V40, P183, DOI 10.1016/0378-1119(85)90041-1; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BOYD D, 1987, P NATL ACAD SCI USA, V84, P8525, DOI 10.1073/pnas.84.23.8525; BROWNSHIMER S, 1990, P NATL ACAD SCI USA, V87, P5148, DOI 10.1073/pnas.87.13.5148; BUSBY S, 1982, J MOL BIOL, V154, P197, DOI 10.1016/0022-2836(82)90060-2; CHARBONNEAU H, 1988, P NATL ACAD SCI USA, V85, P7182, DOI 10.1073/pnas.85.19.7182; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; FOSS K, 1987, GENE, V59, P285, DOI 10.1016/0378-1119(87)90336-2; GUAN KL, 1990, P NATL ACAD SCI USA, V87, P1501, DOI 10.1073/pnas.87.4.1501; HECHT MH, 1984, P NATL ACAD SCI-BIOL, V81, P5685, DOI 10.1073/pnas.81.18.5685; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KLEINA LG, 1990, J MOL BIOL, V212, P295, DOI 10.1016/0022-2836(90)90126-7; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; MARSTON FAO, 1990, METHOD ENZYMOL, V182, P264; MATTHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P4444, DOI 10.1073/pnas.87.12.4444; MILCAREK C, 1972, J MOL BIOL, V68, P303, DOI 10.1016/0022-2836(72)90215-X; NELSON HCM, 1985, CELL, V42, P549, DOI 10.1016/0092-8674(85)90112-6; PAKULA AA, 1986, P NATL ACAD SCI USA, V83, P8829, DOI 10.1073/pnas.83.23.8829; RAETZ CRH, 1975, P NATL ACAD SCI USA, V72, P2274, DOI 10.1073/pnas.72.6.2274; SAITO H, 1991, CELL GROWTH DIFFER, V2, P59; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAP J, 1990, P NATL ACAD SCI USA, V87, P6112, DOI 10.1073/pnas.87.16.6112; SHORTLE D, 1985, GENETICS, V110, P539; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TABOR S, 1989, J BIOL CHEM, V264, P6447; TONKS N K, 1988, Biochemistry, V27, P8695, DOI 10.1021/bi00424a001; TONKS NK, 1988, J BIOL CHEM, V263, P6722	34	62	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10534	10543						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	1645351				2022-12-25	WOS:A1991FP08600081
J	KONDO, K; KOWALSKI, LRZ; INOUYE, M				KONDO, K; KOWALSKI, LRZ; INOUYE, M			COLD SHOCK INDUCTION OF YEAST NSR1 PROTEIN AND ITS ROLE IN PRE-RIBOSOMAL-RNA PROCESSING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-RNA GENES; SMALL NUCLEOLAR RNA; SMALL NUCLEAR-RNA; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; TRANSLATION INITIATION; BACTERIAL RIBOSOMES; HEAT; U3	Yeast NSR1 protein is structurally related to mammalian nucleolin and is involved in ribosome synthesis as described in the preceding paper (Kondo, K., and Inouye, M. (1992) J. Biol. Chem. 267,16252-16258). We report here the regulation of NSR1 gene expression and the effect of nsr1 deletion on growth and pre-rRNA processing after cold shock. A basal level of the transcript was detected at 30-degrees-C only in exponentially growing cells and increased approximately 3-fold after cold shock to 10-degrees-C. NSR1 protein level also increased about 3-fold after the shock. The nsr1 deletion caused a severe growth defect at low temperatures as well as a long growth lag after temperature shift from 30 to 10-degrees-C. Northern hybridization analysis demonstrated that cold shock led to a rapid decrease in the amounts of 27 S, 20 S, and 7 S rRNA precursors in the nsr1 strain, although at 30-degrees-C a major defect was observed only in 20 S pre-rRNA synthesis. Pulse-chase labeling of rRNA showed that pre-rRNA processing in the nsr1 strain was greatly impaired after cold shock. These results demonstrate that the NSR1 protein is required for normal pre-rRNA processing and cell growth in yeast when cells are exposed to abrupt temperature drop.	UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT BIOCHEM, PISCATAWAY, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center								BAYEV AA, 1980, NUCLEIC ACIDS RES, V8, P4919, DOI 10.1093/nar/8.21.4919; GALLWITZ D, 1980, P NATL ACAD SCI-BIOL, V77, P2546, DOI 10.1073/pnas.77.5.2546; GEYL D, 1977, MOL GEN GENET, V152, P331, DOI 10.1007/BF00693088; GOLDSTEIN J, 1990, P NATL ACAD SCI USA, V87, P283, DOI 10.1073/pnas.87.1.283; HARLOW E, 1988, ANTIBODIES LABORATOR; Held W.A., 1974, RIBOSOMES, P193; HUGHES JMX, 1991, EMBO J, V10, P4231, DOI 10.1002/j.1460-2075.1991.tb05001.x; JONES PG, 1987, J BACTERIOL, V169, P2092, DOI 10.1128/jb.169.5.2092-2095.1987; KASS S, 1990, CELL, V60, P897, DOI 10.1016/0092-8674(90)90338-F; KLOOTWIJK J, 1989, METHOD ENZYMOL, V180, P96; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; KONDO K, 1991, J BIOL CHEM, V266, P17537; KONDO K, 1992, J BIOL CHEM, V267, P16252; LEE WC, 1991, J CELL BIOL, V113, P1, DOI 10.1083/jcb.113.1.1; LHOEST J, 1981, EUR J BIOCHEM, V121, P33, DOI 10.1111/j.1432-1033.1981.tb06425.x; LI HV, 1990, MOL CELL BIOL, V10, P1145, DOI 10.1128/MCB.10.3.1145; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MULLERTAUBENBERGER A, 1988, J CELL SCI, V90, P51; NASHIMOT.H, 1970, P NATL ACAD SCI USA, V67, P1440, DOI 10.1073/pnas.67.3.1440; NASHIMOTO H, 1971, J MOL BIOL, V62, P121, DOI 10.1016/0022-2836(71)90135-5; NOMURA M, 1987, COLD SPRING HARB SYM, V52, P653, DOI 10.1101/SQB.1987.052.01.075; ORRICK LR, 1973, P NATL ACAD SCI USA, V70, P1316, DOI 10.1073/pnas.70.5.1316; RUTHER U, 1983, EMBO J, V2, P1791, DOI 10.1002/j.1460-2075.1983.tb01659.x; SACHS AB, 1990, SCIENCE, V247, P1077, DOI 10.1126/science.2408148; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHIMMANG T, 1989, EMBO J, V8, P4015, DOI 10.1002/j.1460-2075.1989.tb08584.x; SCHLESINGER MJ, 1990, J BIOL CHEM, V265, P12111; SETHI N, 1991, MOL CELL BIOL, V11, P5592, DOI 10.1128/MCB.11.11.5592; SHAW MK, 1967, J BACTERIOL, V93, P1332, DOI 10.1128/JB.93.4.1332-1336.1967; SIPOS K, 1991, BIOCHEM BIOPH RES CO, V177, P673, DOI 10.1016/0006-291X(91)91841-Y; TOLLERVEY D, 1985, EMBO J, V4, P3873, DOI 10.1002/j.1460-2075.1985.tb04160.x; TOLLERVEY D, 1987, EMBO J, V6, P4169, DOI 10.1002/j.1460-2075.1987.tb02763.x; TOLLERVEY D, 1991, EMBO J, V10, P573, DOI 10.1002/j.1460-2075.1991.tb07984.x; TRAPMAN J, 1975, EXP CELL RES, V90, P95, DOI 10.1016/0014-4827(75)90361-4; TYC K, 1989, EMBO J, V8, P3113, DOI 10.1002/j.1460-2075.1989.tb08463.x; VELDMAN GM, 1980, NUCLEIC ACIDS RES, V8, P2907, DOI 10.1093/nar/8.13.2907; VELDMAN GM, 1981, NUCLEIC ACIDS RES, V9, P4847, DOI 10.1093/nar/9.19.4847	38	67	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16259	16265						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1644812				2022-12-25	WOS:A1992JJ45800043
J	MEZGUELDI, M; FATTOUM, A; DERANCOURT, J; KASSAB, R				MEZGUELDI, M; FATTOUM, A; DERANCOURT, J; KASSAB, R			MAPPING OF THE FUNCTIONAL DOMAINS IN THE AMINO-TERMINAL REGION OF CALPONIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CALPONIN; T-LIKE PROTEIN; THIN-FILAMENTS; CROSS-LINKING; TROPONIN-T; TROPOMYOSIN-BINDING; CALMODULIN-BINDING; F-ACTIN; CALDESMON; SEQUENCE	Three chymotryptic fragments accounting for almost the entire amino acid sequence of gizzard calponin (Takahashi, K., and Nadal-Ginard, B. (1991) J. Biol. Chem. 266, 13284-13288) were isolated and characterized. They encompass the segments of residues 7-144 (NH2-terminal 13-kDa peptide), 7-182 (NH2-terminal 22-kDa peptide), and 183-292 (COOH-terminal 13-kDa peptide). They arise from the sequential hydrolysis of the peptide bonds at Tyr182-Gly183 and Tyr-144-Ala145 which were protected by the binding of F-actin to calponin. Only the NH2-terminal 13- and 22-kDa fragments were retained by immobilized Ca2+-calmodulin, but only the larger 22 kDa entity cosedimented with F-actin and inhibited, in the absence of Ca2+-calmodulin, the skeletal actomyosin subfragment-1 ATPase activity as the intact calponin. Since the latter peptide differs from the NH2-terminal 13-kDa fragment by a COOH-terminal 38-residue extension, this difference segment appears to contain the actin-binding domain of calponin. Zero-length cross-linked complexes of F-actin and either calponin or its 22-kDa peptide were produced. The total CNBr digest of the F-actin-calponin conjugate was fractionated over immobilized calmodulin. The EGTA-eluted pair of cross-linked actin-calponin peptides was composed of the COOH-terminal actin segment of residues 326-355 joined to the NH2-terminal calponin region of residues 52-168 which seems to contain the major determinants for F-actin and Ca2+-calmodulin binding.	UNIV MONTPELLIER 1, CNRS,CTR RECH BIOCHIM MACROMOLEC,INSERM,U249, ROUTE MENDE,BP 5051, F-34033 MONTPELLIER, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier								ABE M, 1990, J BIOCHEM-TOKYO, V108, P835, DOI 10.1093/oxfordjournals.jbchem.a123289; BARTEGI A, 1990, J BIOL CHEM, V265, P2231; BARTEGI A, 1990, J BIOL CHEM, V265, P15231; BARTEGI A, 1991, BIOPHYS J, V59, pA65; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRYAN J, 1989, J BIOL CHEM, V264, P13873; BRYAN J, 1990, ANN NY ACAD SCI, V599, P100; CHALOVICH JM, 1991, J MUSCLE RES CELL M, V12, P503, DOI 10.1007/BF01738438; CROSBIE R, 1991, J BIOL CHEM, V266, P20001; EISENBERG E, 1974, J BIOL CHEM, V249, P4742; GONG BJ, 1991, J CELL BIOL, V115, P179; GRABAREK Z, 1990, ANAL BIOCHEM, V185, P131, DOI 10.1016/0003-2697(90)90267-D; GRACEFFA P, 1991, J BIOL CHEM, V266, P20305; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HORIUCHI KY, 1991, BIOCHEM BIOPH RES CO, V176, P1487, DOI 10.1016/0006-291X(91)90455-G; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHMAN W, 1991, J MUSCLE RES CELL M, V12, P221, DOI 10.1007/BF01745110; MAKUCH R, 1991, BIOCHEM J, V280, P33, DOI 10.1042/bj2800033; MARSTON SB, 1991, FEBS LETT, V292, P179, DOI 10.1016/0014-5793(91)80862-W; MARSTON SB, 1991, BIOCHEM J, V279, P1; MIMURA N, 1987, J BIOL CHEM, V262, P4717; NAKA M, 1990, BIOCHEM BIOPH RES CO, V171, P933, DOI 10.1016/0006-291X(90)90773-G; NISHIDA W, 1990, FEBS LETT, V268, P165, DOI 10.1016/0014-5793(90)80999-Y; POLZAR B, 1989, EUR J CELL BIOL, V50, P220; SHIRINSKY V, 1991, Journal of Cell Biology, V115, p376A; TAKAHASHI K, 1990, J MUSCLE RES CELL M, V11, P435; TAKAHASHI K, 1986, BIOCHEM BIOPH RES CO, V141, P20, DOI 10.1016/S0006-291X(86)80328-X; TAKAHASHI K, 1988, HYPERTENSION, V11, P620, DOI 10.1161/01.HYP.11.6.620; TAKAHASHI K, 1987, LIFE SCI, V41, P291, DOI 10.1016/0024-3205(87)90151-2; TAKAHASHI K, 1991, J BIOL CHEM, V266, P13284; TAKEUCHI K, 1991, J BIOCHEM, V109, P311; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUNEKAWA S, 1989, FEBS LETT, V250, P493, DOI 10.1016/0014-5793(89)80783-5; VANCOMPERNOLLE K, 1991, J BIOL CHEM, V266, P15427; VANCOMPERNOLLE K, 1990, FEBS LETT, V274, P146, DOI 10.1016/0014-5793(90)81350-W; WINDER SJ, 1990, J BIOL CHEM, V265, P10148; WINDER SJ, 1990, BIOCHEM INT, V22, P335; YIN HL, 1981, J CELL BIOL, V91, P901, DOI 10.1083/jcb.91.3.901	39	93	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15943	15951						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1639822				2022-12-25	WOS:A1992JG11300102
J	PARENTI, P; VILLA, M; HANOZET, GM				PARENTI, P; VILLA, M; HANOZET, GM			KINETICS OF LEUCINE TRANSPORT IN BRUSH-BORDER MEMBRANE-VESICLES FROM LEPIDOPTERAN LARVAE MIDGUT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID TRANSPORT; PHILOSAMIA-CYNTHIA; ORGANIC SOLUTES; CO-TRANSPORT; COTRANSPORT; SYSTEMS; SODIUM; NA+; BINDING; PROLINE	The kinetics of K+-leucine cotransport in the midgut of lepidopteran larvae was investigated using brush border membrane vesicles. Initial rate (3 s) of leucine uptake was determined under experimental conditions similar to those occurring in vivo, i.e. in the presence of DELTA-psi >> 0 (inside negative) and a DELTA-pH of 1.4 units (7.4in/8.80out. Leucine and K+ bind to the carrier according to a sequential mechanism, and the binding of one substrate changed the dissociation constant for the other substrate by a factor of 0.15. Both trans-K+ and trans-leucine were mixed-type inhibitors of leucine uptake. Moreover, a portion of total leucine uptake was K+ independent, and it was competitively inhibited by trans-leucine. We interpret the trans inhibitory effects to mean that the partially loaded K+ only form is virtually unable to translocate across the membrane, whereas the binary complex carrier, leucine, can isomerize from the trans to the cis side of the membrane. However, the K+-independent leucine uptake occurs with a K(eq) > 1, i.e. the efflux route through the partially loaded leucine only form is slower than the rate of isomerization of the unloaded carrier from trans to cis side. Taken together, these results suggest a model in which transport occurs by an iso-random Bi Bi system. Since K+ does not act as a pure competitive activator, this model is different from that proposed for most of the Na+-linked solutes transport agencies and may be related to the broadening of the cation specificity of the amino acid transporters in lepidopteran larvae.			PARENTI, P (corresponding author), UNIV MILAN, DIPARTIMENTO FISIOL & BIOCHIM GEN, VIA CELORIA 26, I-20133 MILAN, ITALY.			PARENTI, PAOLO/0000-0002-9749-4048				ALVARADO F, 1974, BIOCHEMISTRY-US, V13, P2882, DOI 10.1021/bi00711a017; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASSANO G, 1988, J MEMBRANE BIOL, V101, P225, DOI 10.1007/BF01872837; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P188; DOW JAT, 1984, J MEMBRANE BIOL, V77, P223, DOI 10.1007/BF01870571; GECK P, 1976, BIOCHIM BIOPHYS ACTA, V443, P49, DOI 10.1016/0005-2736(76)90490-9; GIORDANA B, 1985, J MEMBRANE BIOL, V88, P45, DOI 10.1007/BF01871212; GIORDANA B, 1989, AM J PHYSIOL, V257, pR494, DOI 10.1152/ajpregu.1989.257.3.R494; GIORDANA B, 1982, BIOCHIM BIOPHYS ACTA, V692, P81, DOI 10.1016/0005-2736(82)90504-1; GULBINSKY JS, 1968, BIOCHEMISTRY-US, V7, P566, DOI 10.1021/bi00842a009; HANOZET GM, 1984, J MEMBRANE BIOL, V81, P233, DOI 10.1007/BF01868716; HANOZET GM, 1980, BIOCHIM BIOPHYS ACTA, V596, P481, DOI 10.1016/0005-2736(80)90139-X; HEINZ E, 1972, BIOCHIM BIOPHYS ACTA, V225, P442, DOI 10.1016/0005-2736(72)90149-6; HOPFER U, 1980, J BIOL CHEM, V255, P4453; KESSLER M, 1983, J MEMBRANE BIOL, V76, P27, DOI 10.1007/BF01871452; MAFFIA M, 1990, BIOCHIM BIOPHYS ACTA, V1027, P8, DOI 10.1016/0005-2736(90)90040-U; MOORE S, 1948, J BIOL CHEM, V176, P367; PARENTI P, 1985, EXPERIENTIA, V41, P1158, DOI 10.1007/BF01951706; SACCHI VF, 1990, J EXP BIOL, V149, P207; SANDERS D, 1986, J MEMBRANE BIOL, V90, P67, DOI 10.1007/BF01869687; SCHULTZ SG, 1970, PHYSIOL REV, V50, P637, DOI 10.1152/physrev.1970.50.4.637; Segel, 1975, ENZYME KINETICS BEHA, P274; SEPULVEDA FV, 1978, J PHYSIOLOGY PARIS, V74, P569; STEVENS BR, 1987, J BIOL CHEM, V262, P6546; TURNER RJ, 1981, BIOCHIM BIOPHYS ACTA, V649, P269, DOI 10.1016/0005-2736(81)90415-6; WIECZOREK H, 1989, J BIOL CHEM, V264, P11143; WRIGHT SH, 1983, J BIOL CHEM, V258, P5456	27	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15391	15397						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1639784				2022-12-25	WOS:A1992JG11300023
J	BARKER, HA				BARKER, HA			THE PATH FROM ACETYLPHOSPHATE TO ACETYL COA	FASEB JOURNAL			English	Editorial Material											BARKER, HA (corresponding author), UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, 401 BARKER HALL, BERKELEY, CA 94720 USA.							BERG P, 1956, J BIOL CHEM, V222, P991; JONES ME, 1953, BIOCHIM BIOPHYS ACTA, V12, P141, DOI 10.1016/0006-3002(53)90133-4; KAPLAN NO, 1948, J BIOL CHEM, V174, P37; LIMANN F, 1945, J BIOL CHEM, V160, P173; LIPMANN F, 1950, J BIOL CHEM, V186, P235; Lipmann F, 1944, J BIOL CHEM, V155, P55; LIPMANN F, 1947, J BIOL CHEM, V167, P869; LIPMANN F, 1954, SCIENCE, V120, P855, DOI 10.1126/science.120.3126.855; Lipmann F, 1941, ADV ENZYMOL REL S BI, V1, P99, DOI 10.1002/9780470122464.ch4; Lipmann F., 1939, COLD SPRING HARB SYM, V7, P248, DOI [10.1101/SQB.1939.007.01.021, DOI 10.1101/SQB.1939.007.01.021]; LYNEN F, 1951, LIEBIGS ANN CHEM, V574, P1; LYNEN F, 1969, PERSPECT BIOL MED, V12, P204; LYNEN F, 1951, ANGEW CHEM-GER EDIT, V63, P47, DOI 10.1002/ange.19510630207; Nachmansohn D, 1943, J NEUROPHYSIOL, V6, P397, DOI 10.1152/jn.1943.6.5.397; NOVELLI GD, 1950, J BIOL CHEM, V182, P213; SNELL EE, 1950, J AM CHEM SOC, V72, P5349, DOI 10.1021/ja01167a546; STADTMAN ER, 1950, J BIOL CHEM, V184, P769; STADTMAN ER, 1949, J BIOL CHEM, V180, P1117; STADTMAN ER, 1951, J BIOL CHEM, V191, P365; STADTMAN ER, 1952, J BIOL CHEM, V196, P527; STADTMAN ER, 1952, J BIOL CHEM, V196, P535	21	2	2	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	1992	6	11					3014	3015		10.1096/fasebj.6.11.1644265	http://dx.doi.org/10.1096/fasebj.6.11.1644265			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JJ665	1644265				2022-12-25	WOS:A1992JJ66500017
J	SOMA, Y; DVONCH, V; GROTENDORST, GR				SOMA, Y; DVONCH, V; GROTENDORST, GR			PLATELET-DERIVED GROWTH FACTOR-AA HOMODIMER IS THE PREDOMINANT ISOFORM IN HUMAN PLATELETS AND ACUTE HUMAN WOUND FLUID	FASEB JOURNAL			English	Article						PLATELETS; PDGF; WOUND REPAIR; ATHEROSCLEROSIS; GROWTH REGULATION	SIMIAN SARCOMA-VIRUS; SMOOTH-MUSCLE CELLS; B-CHAIN; PDGF; RECEPTOR; PURIFICATION; EXPRESSION; MIGRATION; MOLECULES; CLONING	Platelet-derived growth factor (PDGF) is a dimeric protein composed of A- and B-chains (AA, AB, and BB). PDGF purified from human platelets has been shown to bc composed primarily of the AB heterodimer. Immunoblots of total platelet extracts, cell-bound PDGF from the platelet extracts, and acute human wound fluid with PDGF A- and B-chain-specific antisera all demonstrate that the PDGF A-chain is the predominant peptide. Chemotactic and immunochemical assays of chromatographic fractions during PDGF isolation support these observations and demonstrate that PDGF AA can be separated from PDGF AB and BB by ion exchange chromatography. These studies indicate that the AA isoform constitutes the major PDGF dimer contained in human platelets and is the major form present at sites of injury during the acute phase of the wound repair response.	UNIV MIAMI,SCH MED,DEPT CELL BIOL & ANAT R124,1600 NW 10TH AVE,MIAMI,FL 33136; UNIV ALABAMA,SCH MED,DEPT PATHOL,BIRMINGHAM,AL 35294	University of Miami; University of Alabama System; University of Alabama Birmingham					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037223] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37223] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTONIADES HN, 1979, P NATL ACAD SCI USA, V76, P1809, DOI 10.1073/pnas.76.4.1809; ANTONIADES HN, 1981, P NATL ACAD SCI USA, V78, P6314; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; COLLINS T, 1987, NATURE, V328, P621, DOI 10.1038/328621a0; DEUEL TF, 1981, J BIOL CHEM, V256, P8896; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; GRONWALD RGK, 1988, P NATL ACAD SCI USA, V85, P3435, DOI 10.1073/pnas.85.10.3435; GROTENDORST GR, 1981, P NATL ACAD SCI-BIOL, V78, P3669, DOI 10.1073/pnas.78.6.3669; GROTENDORST GR, 1991, J CELL PHYSIOL, V149, P235, DOI 10.1002/jcp.1041490209; GROTENDORST GR, 1987, METHOD ENZYMOL, V147, P144; GROTENDORST GR, 1984, CELL, V36, P279, DOI 10.1016/0092-8674(84)90221-6; GROTENDORST GR, 1984, SOFT HARD TISSUE REP, P20; HAMMACHER A, 1988, J BIOL CHEM, V263, P16493; HELDIN CH, 1985, MOL CELL ENDOCRINOL, V39, P169, DOI 10.1016/0303-7207(85)90061-9; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HELDIN CH, 1981, BIOCHEM J, V193, P907, DOI 10.1042/bj1930907; KAZLAUKAS A, 1988, EMBO J, V7, P1387; KOHLER N, 1974, EXP CELL RES, V87, P297, DOI 10.1016/0014-4827(74)90484-4; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MATSUOKA J, 1989, P NATL ACAD SCI USA, V86, P4416, DOI 10.1073/pnas.86.12.4416; Pencev D, 1988, Oncogene Res, V3, P333; RAINES EW, 1982, J BIOL CHEM, V257, P5154; ROSS R, 1974, P NATL ACAD SCI USA, V71, P1207, DOI 10.1073/pnas.71.4.1207; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; TONG BD, 1987, NATURE, V328, P619, DOI 10.1038/328619a0; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WESTERMARK B, 1983, GROWTH MATURATION FA, P73	28	45	47	1	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1992	6	11					2996	3001		10.1096/fasebj.6.11.1644262	http://dx.doi.org/10.1096/fasebj.6.11.1644262			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JJ665	1644262				2022-12-25	WOS:A1992JJ66500014
J	MURTHY, KGK; MANLEY, JL				MURTHY, KGK; MANLEY, JL			CHARACTERIZATION OF THE MULTISUBUNIT CLEAVAGE-POLYADENYLATION SPECIFICITY FACTOR FROM CALF THYMUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; POLY(A) POLYMERASE; SEQUENCES DOWNSTREAM; AAUAAA SEQUENCE; INVITRO; PRECURSORS; RECOGNITION; PURIFICATION; ACCURATE; PROTEINS	Cleavage-polyadenylation specificity factor (CPSF) is one of five separable factors known to be required for 3' cleavage and polyadenylation of mRNA precursors in vitro. Previous studies have shown that the cleavage and poly(A) addition reactions can be uncoupled in vitro and have suggested that CPSF may be the only factor essential for both of these subreactions. Here we report the purification of CPSF to near homogeneity from calf thymus and show that the purified factor contains three polypeptides of 165, 105, and 70 kDa. These polypeptides cosediment precisely with CPSF activity, which has a sedimentation coefficient of 11.5 S. Consistent with previous reports from our laboratory, purified CPSF does not contain a detectable RNA component, indicating that it is a multisubunit protein and not a small nuclear ribonucleoprotein. Extensively purified bovine CPSF can function with human poly(A) polymerase to bring about AAUAAA-dependent poly(A) addition or with human cleavage factors to catalyze accurate 3' cleavage of a pre-mRNA substrate. UV cross-linking and gel retention analyses demonstrate that highly purified CPSF interacts with one of these cleavage factors, the multisubunit cleavage-stimulation factor, to facilitate stable binding of both to an AAUAAA-containing pre-mRNA. Likewise, evidence is presented indicating that poly(A) polymerase and CPSF can interact directly.	COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027	Columbia University				Manley, James/0000-0002-8341-1459				BARDWELL VJ, 1991, CELL, V65, P125, DOI 10.1016/0092-8674(91)90414-T; BARDWELL VJ, 1990, MOL CELL BIOL, V10, P846, DOI 10.1128/MCB.10.2.846; BIENROTH S, 1991, J BIOL CHEM, V266, P19768; CHRISTOFORI G, 1988, CELL, V54, P875, DOI 10.1016/S0092-8674(88)91263-9; CHRISTOFORI G, 1989, MOL CELL BIOL, V9, P193, DOI 10.1128/MCB.9.1.193; EDMONDS M, 1960, J BIOL CHEM, V235, P1142; EDMONDS M, 1982, ENZYMES, V15, P217; England T E, 1980, Methods Enzymol, V65, P65; GILMARTIN GM, 1991, MOL CELL BIOL, V11, P2432, DOI 10.1128/MCB.11.5.2432; GILMARTIN GM, 1989, GENE DEV, V3, P2180, DOI 10.1101/gad.3.12b.2180; HUMPHREY T, 1988, TRENDS GENET, V4, P243, DOI 10.1016/0168-9525(88)90028-5; JACOB ST, 1983, ENZYMES NUCLEIC ACID, V2, P135; KELLER W, 1991, EMBO J, V10, P4241, DOI 10.1002/j.1460-2075.1991.tb05002.x; LERNER EA, 1981, P NATL ACAD SCI-BIOL, V78, P2737, DOI 10.1073/pnas.78.5.2737; MANLEY JL, 1983, CELL, V33, P595, DOI 10.1016/0092-8674(83)90440-3; MANLEY JL, 1988, BIOCHIM BIOPHYS ACTA, V950, P1, DOI 10.1016/0167-4781(88)90067-X; MANLEY JL, 1985, MOL CELL BIOL, V5, P373, DOI 10.1128/MCB.5.2.373; MOORE CL, 1988, EMBO J, V7, P3159, DOI 10.1002/j.1460-2075.1988.tb03183.x; MOORE CL, 1985, CELL, V41, P845, DOI 10.1016/S0092-8674(85)80065-9; QIAN ZW, 1991, MOL CELL BIOL, V11, P5312, DOI 10.1128/MCB.11.10.5312; RAABE T, 1991, NATURE, V353, P229, DOI 10.1038/353229a0; RYNER LC, 1989, MOL CELL BIOL, V9, P4229, DOI 10.1128/MCB.9.10.4229; RYNER LC, 1989, MOL CELL BIOL, V9, P1759, DOI 10.1128/MCB.9.4.1759; TAKAGAKI Y, 1990, GENE DEV, V4, P2112, DOI 10.1101/gad.4.12a.2112; TAKAGAKI Y, 1988, CELL, V52, P731, DOI 10.1016/0092-8674(88)90411-4; TAKAGAKI Y, 1992, P NATL ACAD SCI USA, V89, P1403, DOI 10.1073/pnas.89.4.1403; TAKAGAKI Y, 1989, GENE DEV, V3, P1711, DOI 10.1101/gad.3.11.1711; TERNS MP, 1989, MOL CELL BIOL, V9, P1435, DOI 10.1128/MCB.9.4.1435; TSIAPALIS CM, 1975, J BIOL CHEM, V250, P4486; VALSAMAKIS A, 1991, P NATL ACAD SCI USA, V88, P2108, DOI 10.1073/pnas.88.6.2108; WAHLE E, 1991, J BIOL CHEM, V266, P3131; WAHLE E, 1991, EMBO J, V10, P4251, DOI 10.1002/j.1460-2075.1991.tb05003.x; WAHLE E, 1992, IN PRESS ANN REV BIO, V61; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; WILUSZ J, 1988, CELL, V52, P221, DOI 10.1016/0092-8674(88)90510-7; WILUSZ J, 1990, MOL CELL BIOL, V10, P1244, DOI 10.1128/MCB.10.3.1244; WILUSZ J, 1988, MOL CELL BIOL, V8, P4477, DOI 10.1128/MCB.8.10.4477; ZARKOWER D, 1986, MOL CELL BIOL, V6, P2317, DOI 10.1128/MCB.6.7.2317	38	148	148	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14804	14811						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634525				2022-12-25	WOS:A1992JF08800047
J	BOSMA, PJ; KOOISTRA, T				BOSMA, PJ; KOOISTRA, T			DIFFERENT INDUCTION OF 2 PLASMINOGEN-ACTIVATOR INHIBITOR-1 MESSENGER-RNA SPECIES BY PHORBOL ESTER IN HUMAN HEPATOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ENDOTHELIAL CELLS; GENE-EXPRESSION; SARCOMA-CELLS; GROWTH-FACTOR; TRANSCRIPTION; SEQUENCE; INSULIN; PROTEIN; INVITRO; IDENTIFICATION	In man, the plasminogen activator inhibitor 1 (PAI-1) gene codes for two mRNA species, one of 3.2 kilobases (kb) and the other of 2.4 kb. We report that the protein kinase C activating phorbol ester, phorbol 12-myristate-13-acetate (PMA), causes a different induction of the two PAI-1 mRNA species in the human hepatoma cell line, HepG2. Upon addition of 100 nM PMA, the level of the 3.2-kb PAI-1 mRNA species increased to 25-fold after 3 h, and then declined rapidly. The level of the 2.4-kb species increased more slowly and reached a maximal 18-fold stimulation after 6 h, followed by a gradual decrease towards control levels. Run-on analysis showed that PMA induces a transient 40-fold increase in PAI-1 gene transcription rate. The relative concentration of the two PAI-1 mRNA species in the nuclei of PMA-treated HepG2 cells shifted towards the 2.4-kb form, suggesting that changes in transcription termination site and/or post-transcriptional nuclear processing might contribute to their different accumulation. Also, the two mRNAs differ in turnover rate, with a half-life of about 0.85 h for the 3.2-kb form and a half-life of about 2.5 h for the 2.4-kb form. By itself, cycloheximide had no effect on PAI-1 gene transcription rate or PAI-1 mRNA levels in HepG2. When added 1 h prior to PMA, however, cycloheximide prevented the induction of PAI-1 mRNA, which suggests that PMA exerts its stimulating transcriptional activity through a newly synthesized regulatory protein. When cycloheximide was added 2 h after PMA, when the PAI-1 gene transcription rate was maximally increased, the two PAI-1 mRNAs reached even higher levels than with PMA alone and maximal mRNA levels were maintained for a much longer period (up to 8 h). Thus, ongoing protein synthesis is required for both the induction and the transient nature of the PMA-induced PAI-1 mRNA accumulation. We conclude that the differential accumulation of the two PAI-1 mRNAs by PMA in serum-starved HepG2 cells is due both to changes in transcription termination and/or post-transcriptional nuclear processing and to differences in half-life between the two mRNAs in a process that requires ongoing protein synthesis.	TNO,GAUBIUS LAB,POB 430,2300 AK LEIDEN,NETHERLANDS	Netherlands Organization Applied Science Research								ALESSI MC, 1988, THROMB HAEMOSTASIS, V60, P491; ANDREASEN PA, 1987, MOL CELL BIOL, V7, P3021, DOI 10.1128/MCB.7.8.3021; BEERS WH, 1975, CELL, V6, P387, DOI 10.1016/0092-8674(75)90188-9; BOSMA PJ, 1988, J BIOL CHEM, V263, P9129; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CICILA GT, 1989, J CELL SCI, V94, P1; COLLEN D, 1980, THROMB HAEMOSTASIS, V43, P77; COLUCCI M, 1985, J CLIN INVEST, V75, P818, DOI 10.1172/JCI111777; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; EMEIS JJ, 1986, J EXP MED, V163, P1260, DOI 10.1084/jem.163.5.1260; ERICKSON LA, 1990, NATURE, V346, P74, DOI 10.1038/346074a0; FORT P, 1987, NUCLEIC ACIDS RES, V15, P5657, DOI 10.1093/nar/15.14.5657; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GELEHRTER TD, 1983, MOL CELL BIOCHEM, V53-4, P11; GINSBURG D, 1986, J CLIN INVEST, V78, P1673, DOI 10.1172/JCI112761; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GROSS JL, 1983, P NATL ACAD SCI-BIOL, V80, P2623, DOI 10.1073/pnas.80.9.2623; HAVEKES L, 1983, BIOCHEM J, V214, P951, DOI 10.1042/bj2140951; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; KNUDSEN BS, 1987, J CLIN INVEST, V80, P1082, DOI 10.1172/JCI113164; KOOISTRA T, 1989, THROMB HAEMOSTASIS, V62, P723; LOSKUTOFF DJ, 1987, BIOCHEMISTRY-US, V26, P3763, DOI 10.1021/bi00387a004; LUCORE CL, 1988, J BIOL CHEM, V263, P15845; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; Maniatis T., 1982, MOL CLONING; MARZLUFF WF, 1984, TRANSCRIPTION TRANSL, P90; MAYER M, 1988, J BIOL CHEM, V263, P15688; MITTLEMAN B, 1983, J MOL BIOL, V165, P461, DOI 10.1016/S0022-2836(83)80213-7; NEVINS JR, 1987, METHOD ENZYMOL, V152, P234; NY T, 1986, P NATL ACAD SCI USA, V83, P6776, DOI 10.1073/pnas.83.18.6776; OSSOWSKI L, 1983, CELL, V35, P611, DOI 10.1016/0092-8674(83)90093-4; PANNEKOEK H, 1986, EMBO J, V5, P2539, DOI 10.1002/j.1460-2075.1986.tb04532.x; POLLANEN J, 1987, J CELL BIOL, V104, P1085, DOI 10.1083/jcb.104.4.1085; PRENDERGAST GC, 1990, MOL CELL BIOL, V10, P1265, DOI 10.1128/MCB.10.3.1265; PRENDERGAST GC, 1989, MOL CELL BIOL, V9, P124, DOI 10.1128/MCB.9.1.124; QUAX PHA, 1990, J BIOL CHEM, V265, P15560; RHEINWALD JG, 1987, J CELL BIOL, V104, P263, DOI 10.1083/jcb.104.2.263; SAWDEY M, 1989, J BIOL CHEM, V264, P10396; SCHLEEF RR, 1988, J BIOL CHEM, V263, P5797; SCHLEUNING WD, 1987, MOL CELL BIOL, V7, P4564, DOI 10.1128/MCB.7.12.4564; SHAW G, 1986, CELL, V46, P559; SPRENGERS ED, 1987, BLOOD, V69, P381; STRICKLAND S, 1976, CELL, V9, P231, DOI 10.1016/0092-8674(76)90114-8; VANDENBERG EA, 1988, THROMB HAEMOSTASIS, V60, P63; VANHINSBERGH VWM, 1988, BLOOD, V72, P1467; VIRJI MAG, 1980, P NATL ACAD SCI-BIOL, V77, P875, DOI 10.1073/pnas.77.2.875	48	68	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					17845	17849						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1655729				2022-12-25	WOS:A1991GG55300024
J	JIANG, ZR; ABAIGAR, LT; HUANG, SH; CAI, B; JONG, AY				JIANG, ZR; ABAIGAR, LT; HUANG, SH; CAI, B; JONG, AY			MOLECULAR CHARACTERIZATION OF SACCHAROMYCES-CEREVISIAE URA6 GENE - DNA-SEQUENCE, MUTAGENESIS ANALYSIS, AND CELL-CYCLE REGULATION RELEVANT TO ITS SUPPRESSION MECHANISM TO CDC8 MUTATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENCODES THYMIDYLATE KINASE; INVITRO MUTAGENESIS; ADENYLATE KINASE; ESCHERICHIA-COLI; YEAST; TRANSCRIPTION; CLONING; SITES	Yeast SOC8 DNA fragment was isolated as a wild type dominant suppressor of cdc8 mutation. We have used Bal31 deletion analysis to define the minimal 1 kilobase HpaI-NcoI DNA element required for complementing the cdc8 mutation. The complementing sequence harbored a multicopy plasmid also enhanced by uridine monophosphate kinase in crude extracts. DNA sequence analysis revealed an open reading frame encoding a protein with a molecular weight of 24,949. Since our SOC8 sequence was identical to that of URA6 gene, which encodes uridine monophosphate kinase, we conclude that SOC8 is allelic with URA6, and we use the term URA6 hereafter. Northern blotting experiments showed that the size of mRNA is about 0.9 kibobases. Primer extension experiments showed multiple transcriptional starting sites primarily located at -160. The size and the deduced amino acid composition are consistent with information obtained from purified uridine monophosphate kinase. Thus, both molecular genetic and biochemical evidence supports a notion that the URA6 is SOC8 encoding a yeast uridine monophosphate kinase. Mutagenesis analysis of its putative nucleotide-binding site, altering essential lysine to glutamic acid, resulted in loss of its uridine monophosphate kinase activity. Complementation analysis studies indicated that the mutated ura6 gene abolished its ability to complement ura6 mutant cells; nor could it suppress cdc8 mutation. Unlike CDC8, the mRNA level of the URA6 gene did not fluctuate throughout the cell cycle; presumably, the temporal order of these two enzymatic activities might be different during cell cycle progression. These data may explain an incomplete suppression of cdc8 by URA6, as previously observed. Taken together, the results support our previous speculation that the suppression of the cdc8 mutation mechanism by URA6 is due to the provision of the trans-acting dTMP kinase activity to complement the cdc8 defect.	UNIV SO CALIF,SCH MED,DEPT PEDIAT & MICROBIOL,LOS ANGELES,CA 90027	University of Southern California					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039436, R29GM039436] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 39436] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNETZEN JL, 1982, J BIOL CHEM, V257, P3026; BERGER A, 1989, EUR J BIOCHEM, V184, P433, DOI 10.1111/j.1432-1033.1989.tb15035.x; BOTSTEIN D, 1985, SCIENCE, V229, P1193, DOI 10.1126/science.2994214; BRUNE M, 1985, NUCLEIC ACIDS RES, V13, P7139, DOI 10.1093/nar/13.19.7139; CHOI WJ, 1989, J BIOL CHEM, V264, P15593; EGNER U, 1987, J MOL BIOL, V195, P649, DOI 10.1016/0022-2836(87)90188-4; HAHN S, 1985, P NATL ACAD SCI USA, V82, P8562, DOI 10.1073/pnas.82.24.8562; HAMILTON R, 1987, NUCLEIC ACIDS RES, V15, P3581, DOI 10.1093/nar/15.8.3581; HARTWELL LH, 1974, BACTERIOL REV, V38, P164, DOI 10.1128/MMBR.38.2.164-198.1974; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; JONG AYS, 1984, J BIOL CHEM, V259, P1052; JONG AYS, 1984, J BIOL CHEM, V259, P4394; KUO CL, 1983, MOL CELL BIOL, V3, P1730, DOI 10.1128/MCB.3.10.1730; LANGFORD CJ, 1984, CELL, V36, P645, DOI 10.1016/0092-8674(84)90344-1; LILJELUND P, 1989, BIOCHEM BIOPH RES CO, V165, P464, DOI 10.1016/0006-291X(89)91093-0; LILJELUND P, 1986, Molecular and General Genetics, V205, P74, DOI 10.1007/BF02428034; MA JJ, 1990, J BIOL CHEM, V265, P19122; MANIATIS T, 1982, MOL CLONING LABORATO, P384; MOLLER W, 1985, FEBS LETT, V186, P1, DOI 10.1016/0014-5793(85)81326-0; NEVINS JR, 1983, ANNU REV BIOCHEM, V52, P441, DOI 10.1146/annurev.bi.52.070183.002301; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCLAFANI RA, 1984, P NATL ACAD SCI-BIOL, V81, P5821, DOI 10.1073/pnas.81.18.5821; Sherman F., 1986, METHODS YEAST GENETI, P163; SMITH GL, 1989, NUCLEIC ACIDS RES, V17, P7581, DOI 10.1093/nar/17.19.7581; SMITH M, 1985, ANNU REV GENET, V19, P423, DOI 10.1146/annurev.genet.19.1.423; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; WHITE JHM, 1987, EXP CELL RES, V171, P223, DOI 10.1016/0014-4827(87)90265-5; ZHOU C, 1990, J BIOL CHEM, V265, P19904; ZHOU C, 1990, BIOTECHNIQUES, V8, P503	31	7	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					18287	18293						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1655742				2022-12-25	WOS:A1991GG55300086
J	SELA, D; RAM, E; ATLAS, D				SELA, D; RAM, E; ATLAS, D			ATP RECEPTOR - A PUTATIVE RECEPTOR-OPERATED CHANNEL IN PC-12 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSORY NEURONS; ADENOSINE-TRIPHOSPHATE; TRANSMITTER RELEASE; EXTRACELLULAR ATP; CALCIUM INFLUX; SMOOTH-MUSCLE; PC12 CELLS; RAT; NEUROTRANSMITTER; ACTIVATION	External ATP induces [H-3]dopamine ([H-3]DA) release in rat pheochromocytoma cells (PC-12 cells). The ATP-induced release is a saturable process with half-effective concentration of EC50 = 80-mu-M. ADP is a poor secretagogue of [H-3]DA (one-sixth of ATP) and AMP is devoid of secretory capabilities. Adenosine and the non-hydrolyzable analogues of ATP, AppNHp and AppCp are ineffective as inducers of [H-3]DA, release, or as inhibitors of the ATP-induced [H-3]DA release. The most potent antagonist of ATP-induced release is Coomassie Blue (IC50 = 25-mu-M), compared to ADP-beta-S (IC50 = 500-mu-M). The overall rank order of potency is ATP > ADP >> AMP > adenosine, which is characteristic of the P2-purinergic receptor. ATP-induced secretion is absolutely Ca2+ dependent, indicating an exocytotic process and is independent of Mg2+ (up to 2 mM) suggesting that the active species is not ATP4-. (a) The ATP-induced Ca-45(2+) influx into the cells is in good correlation to ATP induction of release (IC50 = 80 and 90-mu-M, respectively) and is carried over to ADP which has a diminished ability to induce both release and Ca-45(2+) influx. (b) Divalent cations (Ba2+ > Sr2+ > Ln3+ > Mn2+) replace Ca2+ and support ATP-induced release similar to their effectiveness in supporting bradykinin- and K+ (50 mM)-induced release in PC-12 cells (Weiss, C., Sela, D., and Atlas, D. (1990) Neurosci. Lett. 119, 241-245). Combined together the absolute requirement of [Ca2+]ex for release, inhibition of release by Gd3+ (IC50 = 100-mu-M), Ni2+, and Co2+ (IC50 = 1 mM), and support of release by Ba2+, Sr2+, and Mn2+, we suggest that ATP induces Ca2+ entry via ligand-operated Ca2+ channels as previously suggested for ATP in smooth muscle cells (Benham, C. D., Bolton, T. B., Byren, N. G., and Large, W. A. (1987) J. Physiol. (Lond.) 387, 473-488). No significant inhibition by 1-mu-M verapamil, 10-mu-M nifedipine, or 2 mM Cd2+ argues against ATP activation of voltage-dependent Ca2+ channels as similarly shown for ATP-induced [H-3]noradrenaline release (Inoue, K., Nakazawa, K., Fujimoro, K., and Takanaka, A. (1989) Neurosci. Lett. 106, 294-299). Thus, the widely distributed ATP receptor might play an essential role in Ca2+ homeostasis of the cell by introducing Ca2+ into the cell via specific ligand-gated Ca2+ channels.	HEBREW UNIV JERUSALEM,OTTO LOEWI CTR NEUROBIOL,IL-91904 JERUSALEM,ISRAEL	Hebrew University of Jerusalem	SELA, D (corresponding author), HEBREW UNIV JERUSALEM,DEPT BIOL CHEM,IL-91904 JERUSALEM,ISRAEL.			Sela-Donenfeld, Dalit/0000-0001-7498-061X				APPELL KC, 1989, BIOCHEM J, V263, P11, DOI 10.1042/bj2630011; Atlas D, 1990, Curr Top Cell Regul, V31, P129; AUGUSTINE GJ, 1984, J PHYSIOL-LONDON, V346, P257, DOI 10.1113/jphysiol.1984.sp015020; AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; Bean B P, 1990, Ion Channels, V2, P169; BEAN BP, 1989, IN PRESS J NEUROSCI; BENHAM CD, 1987, J PHYSIOL-LONDON, V387, P473, DOI 10.1113/jphysiol.1987.sp016585; BENHAM CD, 1987, NATURE, V328, P275, DOI 10.1038/328275a0; BIELLMANN JF, 1979, EUR J BIOCHEM, V102, P107, DOI 10.1111/j.1432-1033.1979.tb06268.x; BURNSTOCK G, 1979, PHYSL REGULATORY FUN, P3; CHAREST R, 1985, J BIOL CHEM, V260, P5789; COCKCROFT S, 1979, J PHYSIOL-LONDON, V296, P229, DOI 10.1113/jphysiol.1979.sp013002; DUBYAK GR, 1985, J BIOL CHEM, V260, P653; FASOLATO C, 1990, J BIOL CHEM, V265, P20351; FORSBERG EJ, 1987, P NATL ACAD SCI USA, V84, P5630, DOI 10.1073/pnas.84.16.5630; FRIEL DD, 1988, J GEN PHYSIOL, V91, P1, DOI 10.1085/jgp.91.1.1; FUJIMOTO M, 1981, NEUROSCI LETT, V122, P19; FYFFE REW, 1984, P NATL ACAD SCI-BIOL, V81, P6890, DOI 10.1073/pnas.81.21.6890; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; HARA N, 1990, FEBS LETT, V267, P281, DOI 10.1016/0014-5793(90)80945-F; HOYLE CHV, 1986, EUR J PHARMACOL, V124, P285, DOI 10.1016/0014-2999(86)90229-3; HUME RI, 1986, J NEUROSCI, V6, P681; INOUE K, 1989, NEUROSCI LETT, V106, P294, DOI 10.1016/0304-3940(89)90179-1; JAHR CE, 1983, NATURE, V304, P730, DOI 10.1038/304730a0; KASS GEN, 1990, J BIOL CHEM, V265, P17486; KRISHTAL OA, 1988, BRIT J PHARMACOL, V95, P1057, DOI 10.1111/j.1476-5381.1988.tb11739.x; KRISTAL SM, 1983, NEUROSCI LETT, V35, P41; NAKAZAWA K, 1990, J PHYSIOL-LONDON, V428, P257, DOI 10.1113/jphysiol.1990.sp018211; SALT TE, 1983, NEUROSCI LETT, V35, P53, DOI 10.1016/0304-3940(83)90526-8; SCOPES RK, 1982, PROTEIN PURIFICATION; SHWARTZ L, 1989, BRAIN RES, V503, P102; THOMPSON ST, 1975, P NATL ACAD SCI USA, V72, P669, DOI 10.1073/pnas.72.2.669; WEISS C, 1990, NEUROSCI LETT, V119, P241, DOI 10.1016/0304-3940(90)90843-X; WEISS C, 1991, BRAIN RES, V543, P102, DOI 10.1016/0006-8993(91)91053-4	34	78	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					17990	17994						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1655734				2022-12-25	WOS:A1991GG55300046
J	FIORELLA, PD; NAPOLI, JL				FIORELLA, PD; NAPOLI, JL			EXPRESSION OF CELLULAR RETINOIC ACID BINDING-PROTEIN (CRABP) IN ESCHERICHIA-COLI - CHARACTERIZATION AND EVIDENCE THAT HOLO-CRABP IS A SUBSTRATE IN RETINOIC ACID METABOLISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARCINOMA-CELLS; BOVINE RETINA; RAT TESTIS; RECEPTOR; PURIFICATION; DIFFERENTIATION; AFFINITIES; INVIVO; SKIN; IDENTIFICATION	Cellular retinoic acid binding protein (CRABP) has been expressed efficiently in Escherichia coli from the cDNA of bovine adrenal CRABP and characterized, especially with respect to affinity for endogenous retinoids and a role for it in retinoic acid metabolism. The purified E. coli-expressed CRABP was similar to authentic mammalian CRABP in molecular weight (approximately 14,700), isoelectric point (4.76), absorbance maxima (apo-CRABP, 280 nm; holo-CRABP, 350 and 280 nm with the ratio A350/A280 = 1.8), and in fluorescence excitation (350 nm) and emission spectra (475 nm). The equilibrium dissociation constant, K(d), of E. coli-derived CRABP and all-trans-retinoic acid was 10 +/- 1 nM (mean +/- S.D., n = 4) by retinoid fluorescence and 7 +/- 1 nM (mean +/- S.D., n = 3) by quenching of protein fluorescence, but neither retinol nor retinal bound in concentrations as high as 7-mu-M. All-trans-cyclohexyl ring derivatives of retinoic acid (3,4-didehydro-, 4-hydroxy-, 4-oxo-, 16-hydroxy-4-oxo-, 18-hydroxy-) had affinities similar to that of all-trans-retinoic acid, whereas 13-cis-retinoic acid and 4-oxo- 13-cis-retinoic acid had approximately 25-fold lower affinity. Holo-CRABP was a substrate for retinoic acid catabolism in rat testes microsomes by three criteria: 1) the rate of retinoic acid metabolism with CRABP in excess of retinoic acid exceeded the rate supported by the free retinoic acid; 2) increasing the apo-CRABP did not decrease the rate as predicted if free retinoic acid were the only substrate; and 3) holo-CRABP had a lower Michaelis constant (1.8 nm) for retinoic acid elimination than did free retinoic acid (49 nM). These data indicate a direct role for CRABP in retinoic acid metabolism and suggest a mechanism for discriminating metabolically between all-trans- and 13-cis-retinoids.	SUNY BUFFALO,SCH MED & BIOMED SCI,DEPT BIOCHEM,140 FARBER HALL,BUFFALO,NY 14214	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036870] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK36870] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAILEY JS, 1987, BIOCH CELL BIOL, V66, P750; BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; CLARKE SD, 1989, FASEB J, V3, P2480, DOI 10.1096/fasebj.3.13.2680704; COGAN U, 1976, EUR J BIOCHEM, V65, P71, DOI 10.1111/j.1432-1033.1976.tb10390.x; DALY AK, 1988, BIOCHIM BIOPHYS ACTA, V965, P118, DOI 10.1016/0304-4165(88)90046-3; DOLLE P, 1989, NATURE, V342, P702, DOI 10.1038/342702a0; ERIKSSON U, 1987, J CELL PHYSIOL, V133, P482, DOI 10.1002/jcp.1041330308; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GREEN S, 1986, NATURE, V324, P615, DOI 10.1038/324615a0; HIRSCHELSCHOLZ S, 1989, EUR J CLIN INVEST, V19, P220, DOI 10.1111/j.1365-2362.1989.tb00221.x; HOWARD WB, 1990, BIOCHEM PHARMACOL, V40, P643, DOI 10.1016/0006-2952(90)90568-6; JETTEN AM, 1987, CANCER RES, V47, P3523; JONES TA, 1988, EMBO J, V7, P1597, DOI 10.1002/j.1460-2075.1988.tb02985.x; KEEBLE S, 1989, DEV BIOL, V132, P26, DOI 10.1016/0012-1606(89)90201-7; Lotan R, 1988, Prog Clin Biol Res, V259, P261; LOTAN R, 1980, CANCER RES, V40, P1097; MADANI K, 1986, ARCH DERMATOL RES, V278, P302, DOI 10.1007/BF00407742; MADEN M, 1988, NATURE, V335, P733, DOI 10.1038/335733a0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MCCORMICK AM, 1983, BIOCHEMISTRY-US, V22, P3933, DOI 10.1021/bi00285a032; NAPOLI JL, 1981, BIOCHIM BIOPHYS ACTA, V666, P165, DOI 10.1016/0005-2760(81)90102-8; NAPOLI JL, 1990, CHEM BIOL SYNTHETIC, P229; NOJI S, 1991, NATURE, V350, P83, DOI 10.1038/350083a0; OKUNO M, 1987, BIOCHIM BIOPHYS ACTA, V923, P116, DOI 10.1016/0304-4165(87)90134-6; Ong D, 1980, Methods Enzymol, V67, P288; ONG DE, 1982, J BIOL CHEM, V257, P13385; ONG DE, 1978, J BIOL CHEM, V253, P4551; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; ROSS AC, 1980, J LIPID RES, V21, P100; RUBERTE E, 1991, DEVELOPMENT, V111, P45; Saari J C, 1980, Methods Enzymol, V67, P296; SAARI JC, 1982, J BIOL CHEM, V257, P13329; SAARI JC, 1978, J BIOL CHEM, V253, P6432; SANI BP, 1984, CANCER RES, V44, P190; SANI BP, 1978, BIOCHEM J, V173, P643, DOI 10.1042/bj1730643; SIEGENTHALER G, 1990, BIOCHEM J, V268, P371, DOI 10.1042/bj2680371; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUBEITA HE, 1987, P NATL ACAD SCI USA, V84, P5645; SUNDELIN J, 1985, J BIOL CHEM, V260, P6494; TAKASE S, 1986, ARCH BIOCHEM BIOPHYS, V247, P328, DOI 10.1016/0003-9861(86)90591-6; TROWN PW, 1980, CANCER RES, V40, P212; WANEK N, 1991, NATURE, V350, P81, DOI 10.1038/350081a0; WILLIAMS JB, 1987, ANAL BIOCHEM, V160, P267, DOI 10.1016/0003-2697(87)90046-7; WILLIAMS JB, 1985, P NATL ACAD SCI USA, V82, P4658, DOI 10.1073/pnas.82.14.4658; WINSTON JH, 1989, THESIS SW MED SCH DA; WOLF G, 1984, PHYSIOL REV, V64, P873, DOI 10.1152/physrev.1984.64.3.873; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	51	206	209	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16572	16579						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1653241				2022-12-25	WOS:A1991GD63500055
J	ARGUELLO, JM; KAPLAN, JH				ARGUELLO, JM; KAPLAN, JH			EVIDENCE FOR ESSENTIAL CARBOXYLS IN THE CATION-BINDING DOMAIN OF THE NA,K-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; + K+)-DEPENDENT ATPASE; ALPHA-SUBUNIT; RENAL NA,K-ATPASE; CDNA SEQUENCE; BETA-SUBUNIT; MOLECULAR-CLONING; SUBSTRATE SITE; CATALYTIC SITE; OUTER MEDULLA	Treatment of isolated canine renal Na,K-ATPase with a stable diazomethane analog, 4-(diazomethyl)-7-(diethylamino)-coumarin (DEAC), results in enzyme inactivation. The inactivation rate was dramatically increased when the enzyme was treated with DEAC in the presence of ATP and Mg+ (in imidazole buffer) or P(i) and Mg2+, conditions which produce enzyme phosphorylation. Inactivation in the presence of P(i) and Mg2+ could be partially prevented by Na+ and almost completely prevented by K+. The quantity of DEAC covalently bound to the Na,K-ATPase was determined spectrophotometrically. The extent of inactivation was linearly related to the amount of K-protectable DEAC incorporation. Complete inactivation of ATPase activity occurred with 2.14 +/- 0.18 nmol of DEAC covalently bound/mg of protein. This suggests that only 1 or 2 carboxyl residues/catalytic center (estimated by high affinity ADP binding) are involved in the modification leading to inactivation. The modified enzyme exhibited normal levels of high affinity [H-3]ADP (and hence ATP) binding, thus, the nucleotide-binding domain of the enzyme seems unaffected by the modification. In contrast, under conditions where native enzyme was able to occlude 3.82 nmol of K+ ions/mg of protein, DEAC-modified enzyme occluded only 0.33 nmol of K+ ions. Na+ occlusion by the enzyme (in the presence of oligomycin) was also reduced (by 80%) following treatment with DEAC. Phosphorylation by [P-32]inorganic phosphate and Na+-activated phosphorylation of the modified enzyme with [P-32]ATP yielded reduced levels of phosphoenzyme (about 36%) compared to native enzyme. The DEAC-modified [P-32]phosphoenzyme formed from [P-32]ATP was insensitive to the addition of K+ ions, under conditions which led to the rapid hydrolysis of native phosphoenzyme. Gel electrophoresis of modified protein revealed strong fluorescence labeling of the a-subunit, which was substantially reduced if treatment with DEAC was performed in the presence of K+ ions. Partial tryptic digestion and electrophoretic analysis revealed normal degradation patterns in the presence of ADP (E1 form) but the typical patterns, seen with K+ ions (E2K) or Na+ ions (E1Na) in native enzyme, were absent. A typical E2-like tryptic degradation pattern was seen, however, in the presence of vanadate ions and ouabain, suggesting that the modification does not freeze the enzyme in an E1 conformation and that the enzyme is still able to undergo the E1 E2 conformational transition after modification. Our results suggest that a small number of carboxyl residues in the sodium pump alpha-subunit (perhaps one) are essential for K+ and Na+ binding and stabilizing the occluded enzyme cation forms. Esterification of the carboxyl groups by DEAC inactivates the enzyme. The residues are probably part of the monovalent cation-binding domain and occlusion site in the Na,K-ATPase alpha-subunit.	UNIV PENN,DEPT PHYSIOL,PHILADELPHIA,PA 19104	University of Pennsylvania			Arguello, Jose/D-1997-2012	Arguello, Jose/0000-0003-3940-6297; Kaplan, Jack/0000-0002-7048-6574	NIGMS NIH HHS [GM39500] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039500] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARGUELLO JM, 1990, BIOPHYS J, V57, pA355; ARGUELLO JM, 1990, BIOCHEMISTRY-US, V29, P5775, DOI 10.1021/bi00476a019; ASKARI A, 1982, BIOCHEM BIOPH RES CO, V104, P1447, DOI 10.1016/0006-291X(82)91412-7; BROTHERUS JR, 1981, BIOCHEM BIOPH RES CO, V100, P146, DOI 10.1016/S0006-291X(81)80075-7; CANTLEY LC, 1978, BIOCHEMISTRY-US, V17, P417; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; DEMORAES VLG, 1987, FEBS LETT, V222, P163, DOI 10.1016/0014-5793(87)80212-0; DRAPEAU P, 1980, J BIOL CHEM, V255, P7827; ELLISDAVIES GCR, 1990, J BIOL CHEM, V265, P20570; ESMANN M, 1985, BIOCHEM BIOPH RES CO, V127, P857, DOI 10.1016/S0006-291X(85)80022-X; FARLEY RA, 1984, J BIOL CHEM, V259, P9532; FORBUSH B, 1979, BIOCHEMISTRY-US, V18, P2308, DOI 10.1021/bi00578a027; FORBUSH B, 1987, J BIOL CHEM, V262, P11104; Glynn I. M., 1985, ENZYMES BIOL MEMBR, P35; GLYNN IM, 1982, J PHYSIOL-LONDON, V330, P17, DOI 10.1113/jphysiol.1982.sp014326; GORGA FR, 1985, BIOCHEMISTRY-US, V24, P6783, DOI 10.1021/bi00345a009; ITO K, 1983, CHEM PHARM BULL, V31, P3014; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P53, DOI 10.1016/0005-2736(74)90293-4; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P36, DOI 10.1016/0005-2736(74)90292-2; JORGENSEN PL, 1983, CURR TOP MEMBR TRANS, V19, P377; JORGENSEN PL, 1975, BIOCHIM BIOPHYS ACTA, V401, P399, DOI 10.1016/0005-2736(75)90239-4; KAPLAN JH, 1985, ANNU REV PHYSIOL, V47, P535, DOI 10.1146/annurev.ph.47.030185.002535; KAWAKAMI K, 1986, NUCLEIC ACIDS RES, V14, P2833, DOI 10.1093/nar/14.7.2833; KAWAKAMI K, 1986, J BIOCHEM-TOKYO, V100, P389, DOI 10.1093/oxfordjournals.jbchem.a121726; KAWAKAMI K, 1985, NATURE, V316, P733, DOI 10.1038/316733a0; KIRLEY TL, 1984, BIOCHEM BIOPH RES CO, V125, P767, DOI 10.1016/0006-291X(84)90605-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIANG SM, 1976, BIOCHIM BIOPHYS ACTA, V452, P552, DOI 10.1016/0005-2744(76)90207-2; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNDBLAD RL, 1985, CHEM REAGENTS PROTEI, P105; MATSUI H, 1982, J BIOCHEM-TOKYO, V92, P193, DOI 10.1093/oxfordjournals.jbchem.a133916; NOGUCHI S, 1986, FEBS LETT, V196, P315, DOI 10.1016/0014-5793(86)80270-8; NORBY JG, 1983, CURR TOP MEMBR TRANS, V19, P281; OHTA T, 1986, P NATL ACAD SCI USA, V83, P2071, DOI 10.1073/pnas.83.7.2071; OVCHINNIKOV YA, 1987, FEBS LETT, V217, P111, DOI 10.1016/0014-5793(87)81253-X; PATZELTWENCZLER R, 1975, EUR J BIOCHEM, V53, P301, DOI 10.1111/j.1432-1033.1975.tb04069.x; PATZELTWENCZLER R, 1975, BIOCHIM BIOPHYS ACTA, V403, P538, DOI 10.1016/0005-2744(75)90082-0; PEDEMONTE CH, 1986, J BIOL CHEM, V261, P3632; PEDEMONTE CH, 1986, J BIOL CHEM, V261, P6660; PEDEMONTE CH, 1988, BIOCHEMISTRY-US, V27, P7966, DOI 10.1021/bi00420a056; PEDEMONTE CH, 1990, J AM PHYSL, V258, pC1; POST RL, 1975, J BIOL CHEM, V250, P691; POST RL, 1969, J GEN PHYSIOL, V54, pS306, DOI 10.1085/jgp.54.1.306; ROBINSON JD, 1980, J BIOENERG BIOMEMBR, V12, P165, DOI 10.1007/BF00744681; ROBINSON JD, 1974, FEBS LETT, V38, P325, DOI 10.1016/0014-5793(74)80083-9; SCHNEIDER JW, 1985, P NATL ACAD SCI USA, V82, P6357, DOI 10.1073/pnas.82.18.6357; SCHONER W, 1971, ANGEW CHEM INT EDIT, V10, P882, DOI 10.1002/anie.197108821; SHANISEKLER M, 1988, J BIOL CHEM, V263, P19331; SHULL GE, 1986, NATURE, V321, P429, DOI 10.1038/321429a0; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SKOU JC, 1985, BIOCHIM BIOPHYS ACTA, V819, P119, DOI 10.1016/0005-2736(85)90202-0; STEKHOVEN FMAHS, 1985, BIOCHIM BIOPHYS ACTA, V815, P16, DOI 10.1016/0005-2736(85)90468-7; YAMAGUCHI M, 1983, CURR TOP MEMBR TRANS, V19, P203	53	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14627	14635						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1650364				2022-12-25	WOS:A1991FZ35100080
J	MUELLER, H; WEINGARTEN, R; RANSNAS, LA; BOKOCH, GM; SKLAR, LA				MUELLER, H; WEINGARTEN, R; RANSNAS, LA; BOKOCH, GM; SKLAR, LA			DIFFERENTIAL AMPLIFICATION OF ANTAGONISTIC RECEPTOR PATHWAYS IN NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING REGULATORY PROTEIN; BETA-ADRENERGIC RECEPTORS; SUBUNIT DISSOCIATION; MEDIATED ACTIVATION; CHEMOTACTIC PEPTIDE; HORMONAL ACTIVATION; NATIVE MEMBRANES; FORMYL PEPTIDE; GS PROTEIN; QUANTITATION	In human neutrophils approximately 500 ligand-occupied beta-adrenergic receptors almost completely inhibit the superoxide production generated by at least 50,000 formyl peptide receptors, suggesting a massive amplification of the inhibitory receptor signals. We estimated two stages of amplification. In the first stage, we quantitated the ligand-dependent GTPase activities. For the formyl peptide receptor, the number of phosphates released from GTP in the presence of the saturating ligand is relatively modest, i.e. approximately 1/min/receptor, even though there are approximately 200 G(n) (G(i) type II) proteins/formyl peptide receptor in neutrophil membranes. In contrast, the number of GTPs cleaved in the presence of a beta-adrenergic agonist is approximately 100/min/beta-adrenergic receptor, and there are about 700 G(s)/beta-adrenergic receptor in membranes. Thus the signal of the beta-adrenergic receptor is already massively amplified at the G protein, whereas the signal of the formyl peptide receptor is likely to be amplified at subsequent steps. New kinetic evidence from intact cells and biochemical evidence from permeabilized cells is provided that the second messenger of the inhibitory pathway is cAMP. To estimate the amplification of this step, we determined the cAMP concentration necessary to maximally inhibit superoxide anion production of formyl peptide-stimulated electropermeabilized cells, and we compare these concentrations to previously determined values of cAMP production in neutrophils. We conclude that each receptor may generate up to 10,000 molecules of cAMP.	UNIV NEW MEXICO,SCH MED,900 CAMINO DE SALUD,ALBUQUERQUE,NM 87131; SCRIPPS CLIN & RES FDN,DEPT IMMUNOL,LA JOLLA,CA 92037; GOTHENBURG UNIV,WALLENBERG LAB CARDIOVASC RES,S-41345 GOTHENBURG,SWEDEN	University of New Mexico; Scripps Research Institute; University of Gothenburg					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019032] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM037696] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00833] Funding Source: Medline; NIAID NIH HHS [AI19032] Funding Source: Medline; NIGMS NIH HHS [GM37696] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BJORNSON AB, 1989, J IMMUNOL, V143, P2609; BOKOCH GM, 1988, J CELL BIOL, V106, P1927, DOI 10.1083/jcb.106.6.1927; BOKOCH GM, 1987, J BIOL CHEM, V262, P589; BRANDT DR, 1986, J BIOL CHEM, V261, P1656; BUSSE WW, 1984, J ALLERGY CLIN IMMUN, V73, P404, DOI 10.1016/0091-6749(84)90416-0; CASEY PJ, 1988, J BIOL CHEM, V263, P2577; CRONSTEIN BN, 1985, ANN NY ACAD SCI, V451, P291, DOI 10.1111/j.1749-6632.1985.tb27120.x; FUNG BKK, 1980, P NATL ACAD SCI USA, V77, P250; GRINSTEIN S, 1988, J BIOL CHEM, V263, P1779; IANNONE MA, 1989, J BIOL CHEM, V264, P20177; MAHAN LC, 1986, MOL PHARMACOL, V29, P16; MUELLER H, 1989, J CELL BIOCHEM, V40, P287, DOI 10.1002/jcb.240400305; MUELLER H, 1988, MOL PHARMACOL, V34, P347; RANSNAS LA, 1988, J BIOL CHEM, V263, P9482; RANSNAS LA, 1988, J BIOL CHEM, V263, P17239; RANSNAS LA, 1989, ANAL BIOCHEM, V176, P185, DOI 10.1016/0003-2697(89)90291-1; SEAMON KB, 1986, ADV CYCLIC NUCL PROT, V20, P1; SEDGWICK JB, 1985, CLIN IMMUNOL IMMUNOP, V34, P205, DOI 10.1016/0090-1229(85)90025-X; SELIGMANN BE, 1983, J IMMUNOL, V130, P1902; SIMCHOWITZ L, 1980, J IMMUNOL, V124, P1482; SKLAR LA, 1984, J BIOL CHEM, V259, P5661; SKLAR LA, 1981, J BIOL CHEM, V256, P9909; SKLAR LA, 1987, J BIOL CHEM, V262, P135; SKLAR LA, 1990, BIOCHEMISTRY-US, V29, P313, DOI 10.1021/bi00454a002; SKLAR LA, 1981, P NATL ACAD SCI-BIOL, V78, P7540, DOI 10.1073/pnas.78.12.7540; SMITH CD, 1987, J BIOL CHEM, V262, P6121; TAKENAWA T, 1986, J BIOL CHEM, V261, P1092; TECOMA ES, 1986, J LEUKOCYTE BIOL, V40, P629, DOI 10.1002/jlb.40.5.629; TOLLEY JO, 1987, J LEUKOCYTE BIOL, V42, P43, DOI 10.1002/jlb.42.1.43; WEINGARTEN R, 1990, J BIOL CHEM, V265, P11044	30	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1991	266	20					12939	12943						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FX132	1649171				2022-12-25	WOS:A1991FX13200025
J	DAUM, G; ZANDER, NF; MORSE, B; HURWITZ, D; SCHLESSINGER, J; FISCHER, EH				DAUM, G; ZANDER, NF; MORSE, B; HURWITZ, D; SCHLESSINGER, J; FISCHER, EH			CHARACTERIZATION OF A HUMAN RECOMBINANT RECEPTOR-LINKED PROTEIN TYROSINE PHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE COMMON ANTIGEN; HUMAN-PLACENTA; FAMILY; EXPRESSION; CLONING; MEMBER; CD45	The receptor-linked tyrosine phosphatase RPTP-alpha from human brain (Kaplan, R., Morse, B., Huebner, K., Croce, C., Howk, R., Ravera, M., Ricca, G., Jaye, M., and Schlessinger, J. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 7000-7004) was expressed in insect cells following infection with recombinant baculovirus. Two major forms of the enzyme, with molecular sizes of 98 kDa and 114 kDa, were detected by immunoblot analysis. This heterogeneity could be ascribed to N-linked glycosylation on the basis of two lines of evidence; namely, blockage of glycosylation with tunicamycin in vivo and removal of carbohydrates by endoglycosidase F in vitro. The 114-kDa form was purified to homogeneity by chromatography on Superose 12 and Mono Q. Compared to the low M(r) placenta and T-cell tyrosine phosphatases, RPTP-alpha displayed a low optimum pH of 6 and a high K(m) in the micromolar range toward two artificial substrates (tyrosyl-phosphorylated myelin basic protein and modified lysozyme, respectively). Most effectors had a different and often an opposite influence on phosphatase activity depending on the nature of the substrate and the pH at which the assays were performed. Determination of K(m) and V(max) values for RPTP-alpha suggests that the enzyme could exist in low and high substrate affinity states.	RHONE POULENC RORER BIOTECHNOL INC,KING OF PRUSSIA,PA 19406; NYU MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	New York University	DAUM, G (corresponding author), UNIV WASHINGTON,DEPT BIOCHEM SJ-70,SEATTLE,WA 98195, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK000709] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM042508] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 0709] Funding Source: Medline; NIGMS NIH HHS [GM42508] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALLOU LM, 1986, ENZYMES, V17, P311; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHARBONNEAU H, 1988, P NATL ACAD SCI USA, V85, P7182, DOI 10.1073/pnas.85.19.7182; DUKSIN D, 1982, J BIOL CHEM, V257, P3105; GRACE TDC, 1962, NATURE, V195, P788, DOI 10.1038/195788a0; HARLOW E, 1988, ANTIBODIES LABORATOR; HINK WF, 1970, NATURE, V226, P466, DOI 10.1038/226466b0; KAPLAN R, 1990, P NATL ACAD SCI USA, V87, P7000, DOI 10.1073/pnas.87.18.7000; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; LUSKY M, 1981, NATURE, V293, P79, DOI 10.1038/293079a0; MATTHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P4444, DOI 10.1073/pnas.87.12.4444; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAP J, 1990, P NATL ACAD SCI USA, V87, P6112, DOI 10.1073/pnas.87.16.6112; SHENOLIKAR S, 1990, ADV SEC MESS PHOSPH, V23, P1; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; SUMMERS MD, 1987, TEXAS AGR EXPT STAT, V1555; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; TONKS N K, 1988, Biochemistry, V27, P8695, DOI 10.1021/bi00424a001; TONKS NK, 1990, J BIOL CHEM, V265, P10674; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1988, J BIOL CHEM, V263, P6722; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	27	38	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1991	266	19					12211	12215						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FV180	1648088				2022-12-25	WOS:A1991FV18000020
J	PADH, H; LAVASA, M; STECK, TL				PADH, H; LAVASA, M; STECK, TL			RECONSTITUTION OF THE ASSOCIATION OF ENDOCYTIC VACUOLES AND ACIDOSOMES FROM DICTYOSTELIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISCOIDEUM; ATPASE	In the amoeba, Dictyostelium discoideum, endocytic vacuoles are acidified by proton pumps which reside not in their membranes but in an associated organelle which we call the acidosome. These two organelles can be dissociated in vitro, and we now describe conditions for their functional reassociation. Fluorescein 5-isothiocyanate-dextran was fed to amoebae to report on the pH of their endocytic vacuoles. Following homogenization, the endocytic vacuoles were dissociated from acidosomes by removing Mg2+ and cytosol and purged of their native acidity by transient exposure to nigericin. The endocytic vacuoles could then be reacidified by ATP if first preincubated under these optimized conditions: 30-degrees-C for 30 min in the presence of acidosomes, a 4-fold excess of cytosol, and 5 mm Mg2+ at pH 7.4. Reacidification was observed with early but not late endocytic compartments. Mn2+ and Ca2+ were poor substitutes for Mg2+; albumin did not substitute for cytosol. Neither Ca2+, ATP, nor adenosine 5'-O-(3-thiotriphosphate) affected reconstitution appreciably; guanosine 5'-O-(3-thiotriphosphate) inhibited reacidification by 50% when present during preincubation at 0.1 mm. Warming the cytosol to 50-degrees-C or exposing it to proteases abolished its activity but N-ethylmaleimide did not. Molecular sieving indicated that the cytosolic factor was a macromolecule. We conclude that the specific functional association of acidosomes and endocytic vacuoles can be reconstituted in vitro with soluble proteins plus Mg2+.	UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,920 E 58TH ST,CHICAGO,IL 60637	University of Chicago				Padh, Harish/0000-0003-2305-6229	NIDDK NIH HHS [DK42086] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK042086] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALMERS W, 1990, ANNU REV PHYSIOL, V52, P607, DOI 10.1146/annurev.ph.52.030190.003135; Balch WE, 1990, CURR OPIN CELL BIOL, V2, P634, DOI 10.1016/0955-0674(90)90104-M; Fok A.K., 1990, International Review of Cytology, V123, P61, DOI 10.1016/S0074-7696(08)60671-3; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; GODA Y, 1991, J CELL BIOL, V112, P823, DOI 10.1083/jcb.112.5.823; Holtzman E, 1989, LYSOSOMES; Hubbard AL, 1989, CURR OPIN CELL BIOL, V1, P675, DOI 10.1016/0955-0674(89)90033-1; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MORIYAMA Y, 1989, J BIOL CHEM, V264, P18445; OHKUMA S, 1987, LYSOSOMES THEIR ROLE, P115; PADH H, 1989, J CELL BIOL, V108, P865, DOI 10.1083/jcb.108.3.865; PADH H, 1989, BIOCHIM BIOPHYS ACTA, V982, P271, DOI 10.1016/0005-2736(89)90064-3; PADH H, 1991, J BIOL CHEM, V2665, P5514; REVEL JP, 1985, ANNU REV PHYSIOL, V47, P263; Rodman JS, 1990, CURR OPIN CELL BIOL, V2, P664, DOI 10.1016/0955-0674(90)90108-Q; Wilschut J, 1989, CURR OPIN CELL BIOL, V1, P639, DOI 10.1016/0955-0674(89)90028-8	16	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1991	266	19					12123	12126						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FV180	1648080				2022-12-25	WOS:A1991FV18000003
J	HELIN, K; VELU, T; MARTIN, P; VASS, WC; ALLEVATO, G; LOWY, DR; BEGUINOT, L				HELIN, K; VELU, T; MARTIN, P; VASS, WC; ALLEVATO, G; LOWY, DR; BEGUINOT, L			THE BIOLOGICAL-ACTIVITY OF THE HUMAN EPIDERMAL GROWTH-FACTOR RECEPTOR IS POSITIVELY REGULATED BY ITS C-TERMINAL TYROSINES	ONCOGENE			English	Article							ALTERED AUTOPHOSPHORYLATION SITES; FACTOR EGF RECEPTOR; KINASE-ACTIVITY; SELF-PHOSPHORYLATION; PROTEIN-KINASE; GENE-PRODUCT; INTERNALIZATION; PP60C-SRC; MUTATION; BINDING	The epidermal growth factor receptor (EGF-R) C-terminus contains three conserved tyrosines (Y-1068, Y-1148, Y-1173) which are phosphorylated upon EGF activation. To clarify the functional role of these tyrosines, each has been mutated to phenylalanine and studied as single, double and triple mutants in the full length receptor. EGF-dependent transforming ability of the single point mutants is similar to that of the wild type, while that of double mutants is decreased and an even lower activity is present in the triple mutant. In each bioassay, including EGF-dependent focal transformation, growth in agar and growth in low serum, mutant receptors display a similar hierarchy of activity. The lower activity is intrinsic in the mutants since they are expressed at similar level as the wild type and bind EGF with similar affinity. Deletion mutants lacking the last 19 or 63 amino acids (Velu et al., 1989a) show a similar decline in biological activity when compared to the corresponding point mutants, although the reduction is more pronounced than with the point mutants. Deletion of the last 123 aa, which removes all three tyrosines (Dc123), results in a receptor that is almost inactive biologically. The EGF-R kinase activity is affected by tyrosine substitution since in vitro phosphorylation of exogenous substrates is reduced in the double and triple mutants. Autophosphorylation, in vivo and in vitro, is also reduced, but not totally abolished in the triple point mutant and Dc123 indicating the existence of other autophosphorylation sites. A new site of autophosphorylation is found in the Dc123 mutant. We conclude, therefore, that the tyrosines at the extreme C-terminus positively regulate the biological and transforming activity of the EGF-R, probably via autophosphorylation.	UNIV COPENHAGEN,INST MICROBIOL,OSTER FARIMAGSGADE 2A,DK-1353 COPENHAGEN,DENMARK; NIH,CELLULAR ONCOL LAB,BETHESDA,MD 20892	University of Copenhagen; National Institutes of Health (NIH) - USA	BEGUINOT, L (corresponding author), UNIV COPENHAGEN,INST MICROBIOL,OSTER FARIMAGSGADE 2A,DK-1353 COPENHAGEN,DENMARK.		Helin, Kristian/HDM-8306-2022; Helin, Kristian/K-2526-2019	Helin, Kristian/0000-0003-1975-6097; 				BEGUINOT L, 1984, P NATL ACAD SCI-BIOL, V81, P2384, DOI 10.1073/pnas.81.8.2384; BEGUINOT L, 1985, P NATL ACAD SCI USA, V82, P2774, DOI 10.1073/pnas.82.9.2774; BEGUINOT L, 1986, J BIOL CHEM, V261, P1801; BERTICS PJ, 1988, J BIOL CHEM, V263, P3610; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; CLARK AJL, 1986, BIOCHIM BIOPHYS ACTA, V867, P244, DOI 10.1016/0167-4781(86)90040-0; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; DOWNWARD J, 1985, J BIOL CHEM, V260, P4538; DOWNWARD J, 1984, NATURE, V311, P283; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FELDMAN RA, 1986, MOL CELL BIOL, V6, P1065, DOI 10.1128/MCB.6.4.1065; GILMORE T, 1985, CELL, V40, P609, DOI 10.1016/0092-8674(85)90209-0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HALEY JD, 1989, ONCOGENE, V4, P273; HELIN K, 1991, IN PRESS J BIOL CHEM, V266; HONEGGER A, 1988, EMBO J, V7, P3053, DOI 10.1002/j.1460-2075.1988.tb03170.x; HONEGGER A, 1988, EMBO J, V7, P3045, DOI 10.1002/j.1460-2075.1988.tb03169.x; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HSUAN JJ, 1980, BIOCHEM J, V77, P1311; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAGNI M, 1991, IN PRESS BIOCH J; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; MARTIN P, 1989, CELL, V59, P21, DOI 10.1016/0092-8674(89)90866-0; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGATTO O, 1990, New Biologist, V2, P187; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; VELU TJ, 1989, J CELL BIOCHEM, V39, P153, DOI 10.1002/jcb.240390207; VELU TJ, 1989, MOL CELL BIOL, V9, P1772, DOI 10.1128/MCB.9.4.1772; WALTON GM, 1990, J BIOL CHEM, V265, P1750; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; YACIUK P, 1988, ONCOGENE RES, V3, P207; YAMAMOTO T, 1983, CELL, V34, P225, DOI 10.1016/0092-8674(83)90153-8; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	42	44	48	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1991	6	5					825	832						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT825	1646987				2022-12-25	WOS:A1991GT82500019
J	KOSFELD, MD; FRAZIER, WA				KOSFELD, MD; FRAZIER, WA			IDENTIFICATION OF ACTIVE PEPTIDE SEQUENCES IN THE CARBOXYL-TERMINAL CELL BINDING DOMAIN OF HUMAN THROMBOSPONDIN-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLASMA FIBRONECTIN; PLATELET THROMBOSPONDIN; CARCINOMA-CELLS; MELANOMA-CELLS; ATTACHMENT; SITES; GLYCOPROTEIN; ADHESION; PROTEINS; LAMININ	Thrombospondin (TS) mediates attachment, spreading, and motility of several cell types through at least four cell binding domains: the amino-terminal heparin binding domain, the type I repeats containing the CSVTCG sequence, the RGDA sequence in the last of the type III calcium binding repeats and the carboxyl-terminal cell or platelet binding domain (CBD). The attachment of human melanoma cells (G361) to the COOH-terminal domain is independent of the RGDA sequence and is inhibited by the monoclonal antibody C6.7. To define the cell binding site(s) within this 212-residue COOH-terminal domain, we have synthesized eight overlapping peptides (seven 30-mers and a final 37-mer) representing the entire sequence of the CBD. Several of these peptides are insoluble in aqueous buffers at high concentration. Cell adhesion assays have been devised which employ covalent coupling of peptides in chaotropic solvents to chemically derivatized plastic 96-well plates. Three synthetic peptides, two of which are nonadjacent in the linear sequence, are potent attachment factors for G361 cells. C6.7 blocks adhesion to one of these peptides, whereas sulfated glycoconjugates inhibit adhesion of cells to all three. Polyclonal antibodies raised against the peptides inhibit cell adhesion to the peptides, the recombinant CBD, and to intact TS. The peptides GRGDSP and VTCG are not inhibitory. These sites are thus independent from the type I repeats and the RGDA sequence of TS. Each of the active peptides inhibits cell attachment to the other active peptides as well as to the CBD and to intact TS. This mutual inhibition suggests that the peptides share a common cellular receptor which may contain an associated glycoconjugate chain. These data indicate that the COOH-terminal cell binding domain of TS contains at least two peptide sequences which contribute to the attachment of a wide variety of cells.	WASHINGTON UNIV, SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS, 660 S EUCLID AVE,BOX 8231, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS013269] Funding Source: NIH RePORTER; NIH HHS [NH14147] Funding Source: Medline; NINDS NIH HHS [NS13269] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BORNSTEIN P, 1990, J BIOL CHEM, V265, P16691; BORNSTEIN P, 1991, J BIOL CHEM, V266, P12821; BOWDITCH RD, 1991, J BIOL CHEM, V266, P23323; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; DIXIT VM, 1984, J BIOL CHEM, V259, P100; DIXIT VM, 1985, P NATL ACAD SCI USA, V82, P3472, DOI 10.1073/pnas.82.10.3472; Frazier WA, 1991, CURR OPIN CELL BIOL, V3, P792, DOI 10.1016/0955-0674(91)90052-Z; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; HENNESSY SW, 1989, J CELL BIOL, V108, P729, DOI 10.1083/jcb.108.2.729; HOLT GD, 1990, J BIOL CHEM, V265, P2852; HUMPHRIES MJ, 1986, J CELL BIOL, V103, P2637, DOI 10.1083/jcb.103.6.2637; HUMPHRIES MJ, 1987, J BIOL CHEM, V262, P6886; KOMORIYA A, 1991, J BIOL CHEM, V266, P15075; KOSFELD MD, 1991, J BIOL CHEM, V266, P24257; KOUZIKOLIAKOS K, 1989, J BIOL CHEM, V264, P17971; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; LAWLER J, 1991, J BIOL CHEM, V266, P8039; LEUNG LLK, 1984, J CLIN INVEST, V74, P1764, DOI 10.1172/JCI111595; MAJACK RA, 1988, J CELL BIOL, V106, P415, DOI 10.1083/jcb.106.2.415; MOHRI H, 1988, J BIOL CHEM, V263, P17901; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; RAUGI GJ, 1987, J INVEST DERMATOL, V89, P551, DOI 10.1111/1523-1747.ep12461198; RICH KA, 1990, SCIENCE, V249, P1574, DOI 10.1126/science.2120774; ROBERTS DD, 1985, J BIOL CHEM, V260, P9405; ROBERTS DD, 1987, J CELL BIOL, V104, P131, DOI 10.1083/jcb.104.1.131; ROSE GD, 1978, NATURE, V272, P586, DOI 10.1038/272586a0; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; SKUBITZ APN, 1989, INVAS METAST, V9, P89; SMITH JW, 1990, J BIOL CHEM, V265, P12267; SUN XJ, 1989, J BIOL CHEM, V264, P11288; TARABOLETTI G, 1987, J CELL BIOL, V105, P2409, DOI 10.1083/jcb.105.5.2409; TASHIRO K, 1989, J BIOL CHEM, V264, P16174; TSILIBARY EC, 1988, J BIOL CHEM, V263, P19112; TUSZYNSKI GP, 1992, J CELL BIOL, V116, P209, DOI 10.1083/jcb.116.1.209; TUSZYNSKI GP, 1987, CANCER RES, V47, P4130; VARANI J, 1988, J CLIN INVEST, V81, P1537, DOI 10.1172/JCI113486; VARANI J, 1986, EXP CELL RES, V167, P376, DOI 10.1016/0014-4827(86)90178-3; YABKOWITZ R, 1991, CANCER RES, V51, P3648	39	36	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16230	16236						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1644809				2022-12-25	WOS:A1992JJ45800039
J	MIN, SY; TAPAROWSKY, EJ				MIN, SY; TAPAROWSKY, EJ			V-MYC, BUT NOT MAX, POSSESSES DOMAINS THAT FUNCTION IN BOTH TRANSCRIPTION ACTIVATION AND CELLULAR-TRANSFORMATION	ONCOGENE			English	Article							AVIAN MYELOCYTOMATOSIS VIRUS; DNA-BINDING PROTEINS; HUMAN C-MYC; RETINOBLASTOMA GENE-PRODUCT; LEUCINE ZIPPER; ADENOVIRUS E1A; MULTISTEP TRANSFORMATION; NUCLEAR-LOCALIZATION; NEGATIVE REGULATOR; LARGE-T	Deregulated expression of myc gene family members is associated with the development of malignant neoplasms in several species. Despite the evidence linking expression of this family of nuclear proteins with the proper control of cellular growth and development, the function of the myc protein remains unknown. Intrigued by the observed structural similarity between the myc protein and several eukaryotic transcription factors, we have investigated the ability of the MC29 viral myc protein to activate transcription of a heterologous promoter in C3H10T1/2 cells. Overlapping portions of v-myc coding sequences were inserted 3' to the yeast GAL4 DNA-binding domain and tested for their ability to activate transcription of a chloramphenicol acetyl transferase reporter gene containing GAL4 binding sites. Two transcription activation domains were identified within the amino terminus of v-Myc. The importance of these regions for cellular transformation was examined using ras/myc co-transformation assays. Our results demonstrate that deletion of either of the transcription activation domains, or the DNA-binding and protein oligomerization domains, abolishes the ability of v-Myc to cooperate with Ras to transform C3H10T1/2 cells. Similarly, we investigated whether Max, the protein-binding partner of Myc, also possesses the potential to activate transcription. Interestingly, chimeric GAL4/Max proteins were not functional in our assays, suggesting that the potential of the Myc-Max complex to influence gene expression and function in cellular transformation relies primarily on sequences found within the amino terminus of Myc.	PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus				Min, Soyoung/0000-0001-7511-1520	NATIONAL CANCER INSTITUTE [R01CA042835, R23CA042835] Funding Source: NIH RePORTER; NCI NIH HHS [CA42835] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAMS HD, 1982, CELL, V29, P427, DOI 10.1016/0092-8674(82)90159-3; ARIGA H, 1989, EMBO J, V8, P4273, DOI 10.1002/j.1460-2075.1989.tb08613.x; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; CROUCH DH, 1990, ONCOGENE, V5, P683; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DAVENPORT EA, 1990, MOL CARCINOGEN, V3, P83, DOI 10.1002/mc.2940030206; DAVENPORT EA, 1988, ANTICANCER RES, V8, P959; DEAN M, 1986, J BIOL CHEM, V261, P9161; DENIS N, 1987, EXP CELL RES, V172, P212, DOI 10.1016/0014-4827(87)90107-8; DONNER P, 1982, NATURE, V296, P262, DOI 10.1038/296262a0; FALCONE G, 1985, P NATL ACAD SCI USA, V82, P426, DOI 10.1073/pnas.82.2.426; FIGGE J, 1988, J VIROL, V62, P1814, DOI 10.1128/JVI.62.5.1814-1818.1988; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; IGUCHIARIGA SMM, 1988, EMBO J, V7, P3135, DOI 10.1002/j.1460-2075.1988.tb03180.x; IGVARSSO S, 1990, SEM CANCER BIOL, V1, P359; JAYNES JB, 1986, MOL CELL BIOL, V6, P2855, DOI 10.1128/MCB.6.8.2855; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KADDURAHDAOUK R, 1987, GENE DEV, V1, P347, DOI 10.1101/gad.1.4.347; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KEEGAN L, 1986, SCIENCE, V231, P699, DOI 10.1126/science.3080805; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KERKHOFF E, 1991, ONCOGENE, V6, P93; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; KITCHENER G, 1980, P NATL ACAD SCI-BIOL, V77, P1637, DOI 10.1073/pnas.77.3.1637; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAUTENBERGER JA, 1981, P NATL ACAD SCI-BIOL, V78, P1518, DOI 10.1073/pnas.78.3.1518; LECH K, 1988, CELL, V52, P179, DOI 10.1016/0092-8674(88)90506-5; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIN H, 1991, MOL CELL BIOL, V11, P267, DOI 10.1128/MCB.11.1.267; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PRENDERGAST GC, 1990, MOL CELL BIOL, V10, P1265, DOI 10.1128/MCB.10.3.1265; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P2500, DOI 10.1073/pnas.80.9.2500; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; Sambrook J, 1989, MOL CLONING LABORATO; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHEINESS D, 1978, J VIROL, V28, P600, DOI 10.1128/JVI.28.2.600-610.1978; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; TAPAROWSKY EJ, 1987, CANCER RES, V47, P4125; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YUTZEY KE, 1989, MOL CELL BIOL, V9, P1397, DOI 10.1128/MCB.9.4.1397	63	29	30	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1992	7	8					1531	1540						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1630816				2022-12-25	WOS:A1992JE81300009
J	KIM, YT; TABOR, S; BORTNER, C; GRIFFITH, JD; RICHARDSON, CC				KIM, YT; TABOR, S; BORTNER, C; GRIFFITH, JD; RICHARDSON, CC			PURIFICATION AND CHARACTERIZATION OF THE BACTERIOPHAGE-T7 GENE 2.5 PROTEIN - A SINGLE-STRANDED DNA-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; RECA-PROTEIN; DEOXYRIBONUCLEIC-ACID; T4-GENE 32-PROTEIN; RNA-POLYMERASE; NUCLEIC-ACIDS; 32 PROTEIN; REPLICATION; STIMULATION; RECOMBINATION	Bacteriophage T7 gene 2.5 protein has been purified to homogeneity from cells overexpressing its gene. Native gene 2.5 protein consists of a dimer of two identical subunits of molecular weight 25,562. Gene 2.5 protein binds specifically to single-stranded DNA with a stoichiometry of approximately 7 nucleotides bound per monomer of gene 2.5 protein; binding appears to be noncooperative. Electron microscopic analysis shows that gene 2.5 protein is able to disrupt the secondary structure of single-stranded DNA. The single-stranded DNA is extended into a chain of gene 2.5 protein dimers bound along the DNA. In fluorescence quenching and nitrocellulose filter binding assays, the binding constants of gene 2.5 protein to single-stranded DNA are 1.2 x 10(6) m-1 and 3.8 x 10(6) m-1, respectively. Escherichia coli single-stranded DNA-binding protein and phage T4 gene 32 protein bind to single-stranded DNA more tightly by a factor of 25. Fluorescence spectroscopy suggests that tyrosine residue(s), but not tryptophan residues, on gene 2.5 protein interacts with single-stranded DNA.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,240 LONGWOOD AVE,BOSTON,MA 02115; UNIV N CAROLINA,LINEBERGER CANC RES CTR,CHAPEL HILL,NC 27514; UNIV N CAROLINA,DEPT MICROBIOL & IMMUNOL,CHAPEL HILL,NC 27514	Harvard University; Harvard Medical School; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI006045, R01AI006045] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031819] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-06045] Funding Source: Medline; NIGMS NIH HHS [GM 31819] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alberts B.M., 1971, METHODS ENZYMOL, V21, P198; ALBERTS BM, 1970, NATURE, V227, P1313, DOI 10.1038/2271313a0; ARAKI H, 1981, MOL GEN GENET, V183, P66, DOI 10.1007/BF00270140; ARAKI H, 1981, VIROLOGY, V111, P509, DOI 10.1016/0042-6822(81)90353-6; BENEDICT RC, 1988, J BIOL CHEM, V263, P15513; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN WC, 1990, P NATL ACAD SCI USA, V87, P677, DOI 10.1073/pnas.87.2.677; CARROLL RB, 1975, J MOL BIOL, V91, P275, DOI 10.1016/0022-2836(75)90380-0; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P103, DOI 10.1146/annurev.biochem.55.1.103; CHASE JW, 1980, NUCLEIC ACIDS RES, V8, P3215, DOI 10.1093/nar/8.14.3215; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; FORMOSA T, 1983, P NATL ACAD SCI-BIOL, V80, P2442, DOI 10.1073/pnas.80.9.2442; FUJISAWA H, 1985, NUCLEIC ACIDS RES, V13, P7473, DOI 10.1093/nar/13.20.7473; GUTIERREZ C, 1991, J BIOL CHEM, V266, P2104; HERRICK G, 1976, J BIOL CHEM, V251, P2124; HINKLE DC, 1972, J MOL BIOL, V70, P157, DOI 10.1016/0022-2836(72)90531-1; HUBER HE, 1987, J BIOL CHEM, V262, P16224; HUBERMAN JA, 1971, J MOL BIOL, V62, P39, DOI 10.1016/0022-2836(71)90129-X; KEATING KM, 1988, BIOCHEMISTRY-US, V27, P5240, DOI 10.1021/bi00414a044; KELLY RC, 1976, J BIOL CHEM, V251, P7240; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; KIM YT, 1992, J BIOL CHEM, V267, P15032; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P43; LINDBERG G, 1989, J BIOL CHEM, V264, P12700; LINDENBAUM JO, 1986, J BIOL CHEM, V261, P218; Lohman TM., 1990, BIOL NONSPECIFIC DNA, P131; MATSON SW, 1985, J BIOL CHEM, V260, P2281; MATSON SW, 1983, J BIOL CHEM, V258, P4009; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; MEYER RR, 1990, MICROBIOL REV, V54, P342, DOI 10.1128/MMBR.54.4.342-380.1990; MOLINEUX IJ, 1974, P NATL ACAD SCI USA, V71, P3858, DOI 10.1073/pnas.71.10.3858; MORRICAL SW, 1990, BIOCHEMISTRY-US, V29, P837, DOI 10.1021/bi00455a034; NAKAI H, 1988, J BIOL CHEM, V263, P9831; REGISTER JC, 1986, P NATL ACAD SCI USA, V83, P624, DOI 10.1073/pnas.83.3.624; REUBEN RC, 1974, J BIOL CHEM, V249, P3843; REUBEN RC, 1973, P NATL ACAD SCI USA, V70, P1846, DOI 10.1073/pnas.70.6.1846; RICHARDSON CC, 1983, CELL, V33, P315, DOI 10.1016/0092-8674(83)90411-7; RICHARDSON CC, 1966, J MOL BIOL, V15, P49, DOI 10.1016/S0022-2836(66)80208-5; RUYECHAN WT, 1984, J VIROL, V52, P727, DOI 10.1128/JVI.52.3.727-733.1984; SADOWSKI PD, 1980, MECHANISTIC STUDIES, P941; SANCAR A, 1980, P NATL ACAD SCI-BIOL, V77, P2611, DOI 10.1073/pnas.77.5.2611; SCHERZINGER E, 1973, MOL GEN GENET, V123, P247, DOI 10.1007/BF00271243; SHAMOO Y, 1989, BIOCHEMISTRY-US, V28, P7409, DOI 10.1021/bi00444a039; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SIGAL N, 1972, P NATL ACAD SCI USA, V69, P3537, DOI 10.1073/pnas.69.12.3537; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABOR S, 1987, J BIOL CHEM, V262, P16212; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WHITTIER RF, 1980, ANAL BIOCHEM, V106, P99, DOI 10.1016/0003-2697(80)90123-2; WILLIAMS KR, 1984, J BIOL CHEM, V259, P1804; WILLIAMS KR, 1983, J BIOL CHEM, V258, P3346; WILLIAMS KR, 1990, BIOL NONSPECIFIC DNA, P197; WILLIAMS KR, 1983, BACTERIOPHAGE T4, P82; WOODBURY CP, 1983, BIOCHEMISTRY-US, V22, P4730, DOI 10.1021/bi00289a018	57	85	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15022	15031						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634538				2022-12-25	WOS:A1992JF08800077
J	RONCERO, C; GOODRIDGE, AG				RONCERO, C; GOODRIDGE, AG			HEXANOATE AND OCTANOATE INHIBIT TRANSCRIPTION OF THE MALIC ENZYME AND FATTY-ACID SYNTHASE GENES IN CHICK-EMBRYO HEPATOCYTES IN CULTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE NUCLEAR RECEPTOR; THYROID-HORMONE; SODIUM-BUTYRATE; MESSENGER-RNA; NUTRITIONAL REGULATION; RAT HEPATOCYTES; LIVER-CELLS; CYCLIC-AMP; HISTONE DEACETYLATION; LIPOGENIC ENZYMES	Hexanoate and octanoate inhibit the triiodothyronine (T3)-induced increases in the activities of malic enzyme and fatty acid synthase in chick embryo hepatocytes in culture. Butanoate was less effective as an inhibitor, and palmitate, stearate, and oleate had no effect or small stimulatory effects. Hexanoate and octanoate inhibited the lipogenic enzyme activities at a transcriptional step, and did so within 30 min of addition. Incubation for 2 h in the absence of fatty acid reversed the inhibition of transcription caused by hexanoate. The inhibitory effect of hexanoate was selective because DNA content and transcription of the glyceraldehyde-3-phosphate dehydrogenase and beta-actin genes were not inhibited. Hexanoate-mediated inhibition of transcription rates of the lipogenic genes was not correlated with an inhibition of binding of T3 to its nuclear receptor. 2-Bromooctanoate and carnitine stimulated the T3-induced accumulation of the mRNAs for malic enzyme and fatty acid synthase. The presence of hexanoate stimulated by 2- to 3-fold the increase caused by carnitine, suggesting that hexanoate and carnitine may regulate lipogenic gene expression by a common pathway. Hexanedioate, acetoacetate, beta-hydroxybutyrate, branched chain fatty acids, and branched chain keto acids had little or no effect on abundance of the lipogenic mRNAs. We suggest that the active inhibitor is a metabolite derived from hexanoate or octanoate, possibly an intermediate derived from an acyl-CoA derivative.	UNIV IOWA, DEPT BIOCHEM, IOWA CITY, IA 52242 USA	University of Iowa			Roncero, Cesáreo/H-9039-2015	Roncero, Cesáreo/0000-0001-7608-8553	NIDDK NIH HHS [DK 25295, DK 21954] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMASINO RM, 1986, ANAL BIOCHEM, V152, P304, DOI 10.1016/0003-2697(86)90413-6; AMRI EZ, 1991, J LIPID RES, V32, P1449; ARMSTRONG MK, 1991, BIOCHEM BIOPH RES CO, V177, P1056, DOI 10.1016/0006-291X(91)90645-N; BACK DW, 1986, J BIOL CHEM, V261, P4190; BACK DW, 1986, J BIOL CHEM, V261, P2555; BLAKE WL, 1990, J NUTR, V120, P1727, DOI 10.1093/jn/120.12.1727; BUECHLER KF, 1990, ARCH BIOCHEM BIOPHYS, V281, P233, DOI 10.1016/0003-9861(90)90437-4; CANDIDO EPM, 1978, CELL, V14, P105, DOI 10.1016/0092-8674(78)90305-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE SD, 1990, J NUTR, V120, P625, DOI 10.1093/jn/120.6.625; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COUSENS LS, 1979, J BIOL CHEM, V254, P1716; DISTEL RJ, 1992, J BIOL CHEM, V267, P5937; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; GOLDMAN MJ, 1985, J BIOL CHEM, V260, P4404; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOODRIDG.AG, 1973, J BIOL CHEM, V248, P1932; GOODRIDG.AG, 1973, J BIOL CHEM, V248, P1924; GOODRIDGE AG, 1972, J BIOL CHEM, V247, P6946; GOODRIDGE AG, 1975, FED PROC, V34, P117; GOODRIDGE AG, 1986, ANN NY ACAD SCI, V478, P46, DOI 10.1111/j.1749-6632.1986.tb15520.x; GOODRIDGE AG, 1976, J BIOL CHEM, V251, P3027; GOODRIDGE AG, 1968, BIOCHEM J, V108, P667, DOI 10.1042/bj1080667; GOODRIDGE AG, 1984, ARCH BIOCHEM BIOPHYS, V230, P82, DOI 10.1016/0003-9861(84)90088-2; GREENBAUM AL, 1971, ARCH BIOCHEM BIOPHYS, V143, P617, DOI 10.1016/0003-9861(71)90247-5; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HEERDT BG, 1991, J BIOL CHEM, V266, P19120; INOUE A, 1989, EUR J BIOCHEM, V183, P565, DOI 10.1111/j.1432-1033.1989.tb21085.x; KAMEDA K, 1991, J BIOL CHEM, V266, P419; KRUH J, 1982, MOL CELL BIOCHEM, V42, P65; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LAMPH WW, 1990, P NATL ACAD SCI USA, V87, P4320, DOI 10.1073/pnas.87.11.4320; LAZAR MA, 1990, J BIOL CHEM, V265, P17474; LEDER A, 1975, CELL, V5, P319, DOI 10.1016/0092-8674(75)90107-5; LI QL, 1990, J BIOCHEM-TOKYO, V107, P699, DOI 10.1093/oxfordjournals.jbchem.a123111; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; MA XJ, 1990, J BIOL CHEM, V265, P18435; MAYOREK N, 1985, J BIOL CHEM, V260, P6528; MCKNIGHT GS, 1980, CELL, V22, P469; MCKNIGHT GS, 1979, J BIOL CHEM, V254, P9050; MITSUHASHI T, 1987, J BIOL CHEM, V262, P3993; MORRIS SM, 1982, J BIOL CHEM, V257, P3225; NUMA S, 1965, BIOCHEM Z, V343, P243; PLESKO MM, 1983, J BIOL CHEM, V258, P3738; RAAKA BM, 1979, J BIOL CHEM, V254, P6755; RAAKA BM, 1979, J BIOL CHEM, V254, P3303; RONCERO C, 1992, ARCH BIOCHEM BIOPHYS, V295, P258, DOI 10.1016/0003-9861(92)90516-Y; SALATI LM, 1991, J BIOL CHEM, V266, P4010; SAMUELS HH, 1973, P NATL ACAD SCI USA, V70, P3488, DOI 10.1073/pnas.70.12.3488; SAMUELS HH, 1980, J BIOL CHEM, V255, P2499; SCHIBLER U, 1983, CELL, V33, P501, DOI 10.1016/0092-8674(83)90431-2; SCHULZ H, 1991, BIOCH LIPIDS LIPOPRO, P87; SEALY L, 1978, CELL, V14, P115, DOI 10.1016/0092-8674(78)90306-9; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; STAECKER JL, 1988, J CELL PHYSIOL, V135, P367, DOI 10.1002/jcp.1041350303; STAPLETON SR, 1990, J BIOL CHEM, V265, P18442; UCKER DS, 1984, J BIOL CHEM, V259, P7416; VANDERKLIS FRM, 1989, FEBS LETT, V246, P6, DOI 10.1016/0014-5793(89)80242-X; WIERSINGA WM, 1990, INT J BIOCHEM, V22, P269, DOI 10.1016/0020-711X(90)90339-5; WIERSINGA WM, 1988, METABOLISM, V37, P996, DOI 10.1016/0026-0495(88)90159-X; WINBERRY LK, 1983, J BIOL CHEM, V258, P1337; WISE EM, 1964, P NATL ACAD SCI USA, V52, P1255, DOI 10.1073/pnas.52.5.1255; YUAN ZY, 1988, P NATL ACAD SCI USA, V85, P6328, DOI 10.1073/pnas.85.17.6328	63	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14918	14927						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634532				2022-12-25	WOS:A1992JF08800064
J	DING, W; MENTZER, WC; CAMERON, T; JOHNSON, RM				DING, W; MENTZER, WC; CAMERON, T; JOHNSON, RM			PURIFICATION OF BAND-7.2B, A 31-KDA INTEGRAL PHOSPHOPROTEIN ABSENT IN HEREDITARY STOMATOCYTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEIN PHOSPHORYLATION; ERYTHROCYTE-MEMBRANE; MONOCLONAL-ANTIBODIES; POLYACRYLAMIDE GELS; CELL MEMBRANE; RED-CELLS; BLOOD; RH; POLYPEPTIDE; ANTIGENS	A 31-kDa human erythrocyte integral protein, band 7.2b, has been purified to better than 95% homogeneity. The polypeptide was found to be insoluble in most detergents and was isolated in denatured form by gel filtration in the presence of sodium dodecyl sulfate and preparative electrophoresis. In intact erythrocytes that were equilibrated with P-32(i), band 7.2b was phosphorylated in response to exogenous dibutyryl cAMP. The peptide is also palmitylated, as shown by its incorporation of radioactivity when intact erythrocytes were incubated with [9,10-H-3]palmitic acid. Antisera to band 7.2b were raised in rabbits, and these antibodies cross-react with 31-kDa polypeptides in human liver and kidney. Immunoblots of red cells from a number of other species were negative, with the exception of a cross-reacting 23-kDa polypeptide in rat erythrocyte membranes. Band 7.2b was absent in erythrocyte membranes from an individual with overhydrated hereditary stomatocytes.	WAYNE STATE UNIV, SCH MED, DEPT BIOCHEM, 540 E CANFIELD, DETROIT, MI 48201 USA; UNIV CALIF SAN FRANCISCO, DEPT PEDIAT, SAN FRANCISCO, CA 94143 USA	Wayne State University; University of California System; University of California San Francisco					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL016008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK032094] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-16008] Funding Source: Medline; NIDDK NIH HHS [DK32094] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEUTLER E, 1976, J LAB CLIN MED, V88, P328; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; BLOY C, 1988, MOL IMMUNOL, V25, P925, DOI 10.1016/0161-5890(88)90131-9; BLOY C, 1989, MOL IMMUNOL, V26, P1013, DOI 10.1016/0161-5890(89)90065-5; BLOY C, 1987, BLOOD, V69, P1491; BOIVIN P, 1988, BIOCHEM J, V256, P689, DOI 10.1042/bj2560689; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; CHAILLEY B, 1981, SCAND J HAEMATOL, V27, P365; CONNOR J, 1988, BIOCHEMISTRY-US, V27, P848, DOI 10.1021/bi00403a002; DENKER BM, 1988, J BIOL CHEM, V263, P15634; DEVETTEN MP, 1988, J BIOL CHEM, V263, P18193; DUNBAR BS, 1987, 2 DIMENSIONAL ELECTR, P347; DZANDU JK, 1980, J BIOL CHEM, V255, P6382; EBER SW, 1989, BRIT J HAEMATOL, V72, P452, DOI 10.1111/j.1365-2141.1989.tb07731.x; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; GARAY RP, 1982, BIOCHIM BIOPHYS ACTA, V688, P786, DOI 10.1016/0005-2736(82)90292-9; GRANGER BL, 1982, J CELL BIOL, V92, P299, DOI 10.1083/jcb.92.2.299; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDE WM, 1985, CLIN HAEMATOL, V14, P89; LANDE WM, 1982, J CLIN INVEST, V70, P1273, DOI 10.1172/JCI110726; MARETZKI D, 1990, FEBS LETT, V259, P305, DOI 10.1016/0014-5793(90)80033-F; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MENTZER WC, 1975, BLOOD, V46, P659; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MOORE S, 1982, NATURE, V295, P529, DOI 10.1038/295529a0; MOORE S, 1987, BIOCHEM J, V244, P735, DOI 10.1042/bj2440735; MORLE L, 1989, BRIT J HAEMATOL, V71, P141, DOI 10.1111/j.1365-2141.1989.tb06288.x; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; SABOORI AM, 1988, P NATL ACAD SCI USA, V85, P4042, DOI 10.1073/pnas.85.11.4042; SMITH BL, 1991, J BIOL CHEM, V266, P6407; STAUFENBIEL M, 1986, P NATL ACAD SCI USA, V83, P318, DOI 10.1073/pnas.83.2.318; STECK T L, 1973, Journal of Supramolecular Structure, V1, P220, DOI 10.1002/jss.400010307; Steck T. L., 1974, METHODS MEMBRANE BIO, V2, P245; TALIAN JC, 1983, J CELL BIOL, V97, P1277, DOI 10.1083/jcb.97.4.1277; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TYLER JM, 1980, J BIOL CHEM, V255, P7034; VONDEMBORNE AEGK, 1990, BRIT J HAEMATOL, V75, P254; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WILSON KJ, 1989, PROTEIN SEQUENCING, P22; WOLFE LC, 1978, J BIOL CHEM, V253, P3336; YU J, 1973, Journal of Supramolecular Structure, V1, P233, DOI 10.1002/jss.400010308	41	3	3	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					17826	17831						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1655727				2022-12-25	WOS:A1991GG55300021
J	PEERS, B; MONGET, P; NALDA, MA; VOZ, ML; BERWAER, M; BELAYEW, A; MARTIAL, JA				PEERS, B; MONGET, P; NALDA, MA; VOZ, ML; BERWAER, M; BELAYEW, A; MARTIAL, JA			TRANSCRIPTIONAL INDUCTION OF THE HUMAN PROLACTIN GENE BY CAMP REQUIRES 2 CIS-ACTING ELEMENTS AND AT LEAST THE PITUITARY-SPECIFIC FACTOR PIT-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3',5'-CYCLIC ADENOSINE-MONOPHOSPHATE; THYROTROPIN-RELEASING-HORMONE; NUCLEAR FACTOR CREB; CYCLIC-AMP; GROWTH-HORMONE; RESPONSE ELEMENT; DNA-BINDING; MOLECULAR MECHANISMS; REGULATORY ELEMENTS; PHORBOL ESTER	To identify the cis-acting elements responsible for cAMP stimulation of human prolactin (hPRL) promoter activity, pituitary GC cells were transfected with 5'-deleted hPRL promoters fused to the chloramphenicol acetyltransferase reporter gene. The proximal regulatory region (coordinates -250 to -42) was sufficient to confer strong cAMP stimulation (+/- 25 fold). Further 5' and 3' deletions performed within this proximal region demonstrated that two types of cis-acting elements are involved in the cAMP regulation: (i) the binding sites of the pituitary-specific factor Pit-1, and (ii) the sequence between coordinates -115 and -85 (named fragment A), which contains a TGACG motif. We show by gel-shift and Southwestern experiments that fragment A binds Pit-1 monomer and also a ubiquitous factor that is neither cAMP-responsive element-binding protein nor activator protein-1. Strong cAMP induction was observed when fragment A was juxtaposed to a Pit-1 binding site. That Pit-1 plays an important role was supported further by the finding that the hPRL proximal region conferred cAMP regulation when linked to the herpes simplex virus thymidine kinase promoter only in pituitary GC cells and not in other heterologous cells, which do not express Pit-1. Furthermore, we observed that concatenated Pit-1 binding sites were able to confer cAMP responsiveness to the thymidine kinase promoter in GC cells.	UNIV LIEGE,INST CHIM B6,BIOL MOLEC & GENIE GENET LAB,B-4000 SART,BELGIUM	University of Liege			BELAYEW, Alexandra/D-5205-2013	BELAYEW, Alexandra/0000-0001-5115-2424				ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BERWAER M, 1991, IN PRESS MOL CELL EN; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BOSHART M, 1990, CELL, V61, P905, DOI 10.1016/0092-8674(90)90201-O; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENT GA, 1988, MOL ENDOCRINOL, V2, P792, DOI 10.1210/mend-2-9-792; CAMPER SA, 1985, J BIOL CHEM, V260, P2246; CHRISTOPHE D, 1989, MOL CELL ENDOCRINOL, V64, P5, DOI 10.1016/0303-7207(89)90060-9; COPP RP, 1990, MOL ENDOCRINOL, V3, P790; DANA S, 1989, MOL ENDOCRINOL, V3, P815, DOI 10.1210/mend-3-5-815; DAY RN, 1989, MOL ENDOCRINOL, V3, P3, DOI 10.1210/mend-3-1-3; DECAMILLI P, 1979, NATURE, V278, P252, DOI 10.1038/278252a0; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELSHOLTZ HP, 1986, SCIENCE, V234, P1552, DOI 10.1126/science.3491428; FOX SR, 1990, MOL ENDOCRINOL, V4, P1069, DOI 10.1210/mend-4-7-1069; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; IVERSON RA, 1990, MOL ENDOCRINOL, V4, P1564, DOI 10.1210/mend-4-10-1564; JAMESON JL, 1988, J BIOL CHEM, V263, P9879; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KEECH CA, 1989, MOL ENDOCRINOL, V3, P832, DOI 10.1210/mend-3-5-832; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; LAVERRIERE JN, 1988, ENDOCRINOLOGY, V122, P333, DOI 10.1210/endo-122-1-333; LEMAIGRE FP, 1989, DNA-J MOLEC CELL BIO, V8, P149, DOI 10.1089/dna.1.1989.8.149; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MANGALAM HJ, 1989, GENE DEV, V3, P946, DOI 10.1101/gad.3.7.946; Maniatis T., 1982, MOL CLONING; MANLEY JL, 1984, TRANSCRIPTION TRANSL, P71; MAURER RA, 1981, NATURE, V294, P94, DOI 10.1038/294094a0; MAURER RA, 1987, MOL CELL BIOL, V7, P4247, DOI 10.1128/MCB.7.12.4247; MAURER RA, 1980, J BIOL CHEM, V255, P8092; MCCORMICK A, 1990, NATURE, V345, P829, DOI 10.1038/345829a0; MURDOCH GH, 1982, SCIENCE, V218, P1315, DOI 10.1126/science.6293056; MURDOCH GH, 1985, J BIOL CHEM, V260, P1852; MURDOCH GH, 1982, NATURE, V300, P192, DOI 10.1038/300192a0; PEERS B, 1990, MOL CELL BIOL, V10, P4690, DOI 10.1128/MCB.10.9.4690; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TRUONG AT, 1984, EMBO J, V3, P429, DOI 10.1002/j.1460-2075.1984.tb01824.x; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WATERMAN M, 1985, SCIENCE, V229, P267, DOI 10.1126/science.2990047; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0	52	85	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					18127	18134						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1655738				2022-12-25	WOS:A1991GG55300064
J	NUTTER, LM; NGO, EO; ABULHAJJ, YJ				NUTTER, LM; NGO, EO; ABULHAJJ, YJ			CHARACTERIZATION OF DNA DAMAGE INDUCED BY 3,4-ESTRONE-ORTHO-QUINONE IN HUMAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MICROSOMES; DOUBLE-STRAND BREAKS; CATECHOL ESTROGENS; TOPOISOMERASE-II; INTERCALATING AGENTS; MAMMALIAN-CELLS; NUCLEIC-ACIDS; MITOMYCIN-C; DIETHYLSTILBESTROL; STEROIDS	The DNA damage induced in a human breast cancer cell line treated with 1,5 (10)-estradiene-3,4,17-trione (3,4-estrone-o-quinone; 3,4-EQ) has been measured qualitatively and quantitatively. Single-strand (ss) but not double-strand (ds) DNA breaks were formed in MCF-7 cells treated with 3,4-EQ. The ss DNA breaks formed in MCF-7 cells were partially repaired after incubation of cells in 3,4-EQ-free media for 2 and 4 h (i.e. 33 and 23% repair, respectively, as compared to the ss DNA breaks in cells after a 1-h exposure to 3,4-EQ without a recovery period). The formation of interstrand DNA cross-links was demonstrated in MCF-7 cells exposed to the bifunctional alkylating agent, mitomycin C, but not in those exposed to 3,4-EQ. Protein-linked DNA breaks were detected in MCF-7 cells after exposure to camptothecin and etoposide but not 3,4-EQ, suggesting that the ss DN A breaks induced by 3,4-EQ are unlikely to be mediated via topoisomerases. The induction of ss DNA breaks was detected in the estrogen receptor-negative cell line, BT-20, after exposure to 3,4-EQ. Furthermore, excess estradiol in culture media did not prevent 3,4-EQ-induced ss DNA breaks, suggesting that the DNA damage was not mediated via the estrogen receptor. Evaluation of the newly synthesized quinone analogue, 5,6,7,8-tetrahydro-12-naphthoquinone, in the ss DNA breakage assay revealed that the A and B ring moiety of 3,4-EQ is sufficient to produce ss DNA breaks in MCF-7 cells.	UNIV MINNESOTA, DEPT MED CHEM, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	NUTTER, LM (corresponding author), UNIV MINNESOTA, DEPT PHARMACOL, 435 DELAWARE ST SE, MINNEAPOLIS, MN 55455 USA.				NCI NIH HHS [CA 41269] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA041269] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDULHAJJ YJ, 1985, BIOCHEM BIOPH RES CO, V133, P1078, DOI 10.1016/0006-291X(85)91246-X; ABULHAJJ YJ, 1988, J STEROID BIOCHEM, V31, P107, DOI 10.1016/0022-4731(88)90212-9; ABULHAJJ YJ, 1986, J STEROID BIOCHEM, V25, P245, DOI 10.1016/0022-4731(86)90423-1; ABULHAJJ YJ, 1984, J STEROID BIOCHEM, V21, P621, DOI 10.1016/0022-4731(84)90340-6; BALL P, 1975, J CLIN ENDOCR METAB, V40, P406, DOI 10.1210/jcem-40-3-406; BOLT HM, 1974, J STEROID BIOCHEM, V5, P179, DOI 10.1016/0022-4731(74)90126-5; BRADLEY MO, 1979, NUCLEIC ACIDS RES, V7, P793, DOI 10.1093/nar/7.3.793; BRANSOME ED, 1985, J THEOR BIOL, V112, P97, DOI 10.1016/S0022-5193(85)80118-1; CHEN GL, 1984, J BIOL CHEM, V259, P3560; CHRISEY LA, 1988, J AM CHEM SOC, V110, P644, DOI 10.1021/ja00210a080; CULLINAN EB, 1989, J BIOL CHEM, V264, P16268; DINARDO S, 1982, CELL, V31, P43, DOI 10.1016/0092-8674(82)90403-2; DORR RT, 1985, CANCER RES, V45, P3510; Duax WL, 1980, ESTROGENS ENV, P11; EPE B, 1986, CARCINOGENESIS, V7, P1329, DOI 10.1093/carcin/7.8.1329; GELLERT M, 1981, ANNU REV BIOCHEM, V50, P879, DOI 10.1146/annurev.bi.50.070181.004311; GHAFFARI MA, 1990, J STEROID BIOCHEM, V37, P237, DOI 10.1016/0960-0760(90)90332-F; GLADEK A, 1989, J BIOL CHEM, V264, P16847; GOLDENBERG GJ, 1985, BIOCHEM PHARMACOL, V34, P771, DOI 10.1016/0006-2952(85)90756-7; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; JACOBSOHN MK, 1991, BIOCHIM BIOPHYS ACTA, V1073, P1, DOI 10.1016/0304-4165(91)90175-G; KALWINSKY DK, 1983, CANCER RES, V43, P1592; KALYANARAMAN B, 1989, J BIOL CHEM, V264, P11014; KIRKMAN HADLEY, 1959, NAIL CANCER INST MONOGR, V1, P1; KOHN KW, 1981, DNA REPAIR LABORATOR, P379; KOHN KW, 1979, METHOD CANCER RES, V16, P291; LEHNER AF, 1987, MOL ENDOCRINOL, V1, P377, DOI 10.1210/mend-1-5-377; LEQUESNE PW, 1980, J MED CHEM, V23, P239, DOI 10.1021/jm00177a005; LI JJ, 1983, CANCER RES, V43, P5200; LI JJ, 1984, ARCH TOXICOL, V55, P110, DOI 10.1007/BF00346048; LIEHR JG, 1986, J BIOL CHEM, V261, P6865; LIEHR JG, 1990, FREE RADICAL BIO MED, V8, P415, DOI 10.1016/0891-5849(90)90108-U; LIEHR JG, 1983, MOL PHARMACOL, V23, P278; LUTZ WK, 1979, MUTAT RES, V65, P289, DOI 10.1016/0165-1110(79)90006-X; METZLER M, 1984, ARCH TOXICOL, V55, P104, DOI 10.1007/BF00346047; METZLER M, 1980, ESTROGENS ENV, P293; NAMBARA T, 1971, CHEM PHARM BULL, V19, P1727; NUMAZAWA M, 1979, J STEROID BIOCHEM, V10, P227, DOI 10.1016/0022-4731(79)90240-1; NUMAZAWA M, 1978, BIOCHEM PHARMACOL, V27, P1833, DOI 10.1016/0006-2952(78)90028-X; NUTTER L M, 1990, Proceedings of the American Association for Cancer Research Annual Meeting, V31, P348; NUTTER LM, 1991, BIOCHEM PHARMACOL, V41, P1283, DOI 10.1016/0006-2952(91)90099-Q; PAUL SM, 1977, ENDOCRINOLOGY, V101, P1604, DOI 10.1210/endo-101-5-1604; ROSS WE, 1981, BIOCHIM BIOPHYS ACTA, V654, P129, DOI 10.1016/0005-2787(81)90145-3; ROWE TC, 1986, CANCER RES, V46, P2021; SASAME HA, 1977, BIOCHEM BIOPH RES CO, V78, P919, DOI 10.1016/0006-291X(77)90510-1; SLAGA TJ, 1979, CANCER RES, V39, P67; STUBENRAUCH G, 1976, STEROIDS, V28, P733, DOI 10.1016/0039-128X(76)90010-6; TSIBRIS JCM, 1977, BIOCHEM BIOPH RES CO, V78, P411, DOI 10.1016/0006-291X(77)91269-4; WILLIAMS JG, 1974, STEROIDS, V24, P687, DOI 10.1016/0039-128X(74)90021-X; WILLSON JKV, 1985, CANCER RES, V45, P5281; ZWELLING LA, 1981, BIOCHEMISTRY-US, V20, P6553, DOI 10.1021/bi00526a006; 1979, IARC MONOGRAPHS EVAL, V21, P173	52	113	113	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16380	16386						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1653233				2022-12-25	WOS:A1991GD63500025
J	FLORINI, JR; MAGRI, KA; EWTON, DZ; JAMES, PL; GRINDSTAFF, K; ROTWEIN, PS				FLORINI, JR; MAGRI, KA; EWTON, DZ; JAMES, PL; GRINDSTAFF, K; ROTWEIN, PS			SPONTANEOUS DIFFERENTIATION OF SKELETAL MYOBLASTS IS DEPENDENT UPON AUTOCRINE SECRETION OF INSULIN-LIKE GROWTH FACTOR-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER RIBONUCLEIC-ACID; IGF-I; MUSCLE DIFFERENTIATION; CELL-PROLIFERATION; STIMULATED DIFFERENTIATION; MOUSE MUSCLE; FACTOR-BETA; EXPRESSION; GENE; RECEPTOR	Differentiation of muscle cells to form postmitotic myotubes is usually viewed as being negatively controlled by medium components, sometimes designated "mitogens." However, we have found that a family of mitogenic agents, the insulin-like growth factors (IGFs), are potent stimulators of differentiation in myoblasts which act by inducing expression of the myogenin gene. We show here that this action of the IGFs occurs even when these growth factors are not added to the cell medium; upon transfer to low-serum "differentiation medium," myoblasts begin active expression of the IGF-II gene, at both the mRNA and protein levels. Furthermore, autocrine secretion of IGF-II is essential for the process of terminal differentiation of the cells. These conclusions are based upon four lines of evidence. (1) The rate of spontaneous differentiation in several sublines of myogenic cells correlates with their level of expression of IGF-II. (2) C2 and Sol 8 cells, which secrete high levels of IGF-II, are relatively insensitive to exogenous IGFs, in contrast to L6 lines, which exhibit lower levels of IGF-II gene expression. (3) An antisense oligodeoxyribonucleotide complementary to the first five codons of IGF-II inhibits myogenic differentiation in the absence but not in the presence of exogenous IGF-II. (4) Spontaneous differentiation in response to autocrine IGF-II involves the same mechanism that occurs in cells stimulated by the IGFs, i.e. elevation of expression of the myogenin gene.	WASHINGTON UNIV,SCH MED,DEPT MED,DIV BIOL & BIOL SCI,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT GENET,DIV BIOL & BIOL SCI,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)	FLORINI, JR (corresponding author), SYRACUSE UNIV,DEPT BIOL,130 COLLEGE PL,SYRACUSE,NY 13244, USA.		Rotwein, Peter/R-5783-2019	Rotwein, Peter/0000-0002-9505-1817	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL011551, R37HL011551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008036] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL11551] Funding Source: Medline; NIDDK NIH HHS [DK 42748, R01 DK042748] Funding Source: Medline; NIGMS NIH HHS [GM08036] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADASHI EY, 1988, ENDOCRINOLOGY, V122, P1583, DOI 10.1210/endo-122-4-1583; ALLEN RE, 1989, J CELL PHYSIOL, V138, P311, DOI 10.1002/jcp.1041380213; BEJCEK BE, 1989, SCIENCE, V245, P1496, DOI 10.1126/science.2551043; BELL GI, 1986, NUCLEIC ACIDS RES, V14, P7873, DOI 10.1093/nar/14.20.7873; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CZECH MP, 1989, CELL, V59, P235, DOI 10.1016/0092-8674(89)90281-X; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; DAUGHADAY WH, 1987, METHOD ENZYMOL, V146, P248; DELAHABA G, 1966, P NATL ACAD SCI USA, V56, P1719; DEVOL DL, 1990, AM J PHYSIOL, V259, pE89, DOI 10.1152/ajpendo.1990.259.1.E89; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; ELBADRY OM, 1989, J CLIN INVEST, V84, P829, DOI 10.1172/JCI114243; EWTON DZ, 1984, J CELL PHYSIOL, V120, P263, DOI 10.1002/jcp.1041200302; EWTON DZ, 1988, J BIOL CHEM, V263, P4029; EWTON DZ, 1987, ENDOCRINOLOGY, V120, P115, DOI 10.1210/endo-120-1-115; EWTON DZ, 1981, DEV BIOL, V86, P31, DOI 10.1016/0012-1606(81)90312-2; FLORINI JR, 1984, IN VITRO CELL DEV B, V20, P942; FLORINI JR, 1990, J BIOL CHEM, V265, P13435; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; FLORINI JR, 1986, AM J PHYSIOL, V250, pC771, DOI 10.1152/ajpcell.1986.250.5.C771; FLORINI JR, 1989, ANAL BIOCHEM, V182, P399, DOI 10.1016/0003-2697(89)90614-3; FLORINI JR, 1991, MOL ENDOCRINOL, V5, P718, DOI 10.1210/mend-5-5-718; FLORINI JR, 1989, CELL GROWTH DIVISION, P105; FLORINI JR, 1989, J BIOL CHEM, V256, pC701; FRUNZIO R, 1986, J BIOL CHEM, V261, P7138; HIZUKA N, 1987, J CLIN ENDOCR METAB, V64, P1309, DOI 10.1210/jcem-64-6-1309; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; JENNISCHE E, 1987, ACTA PHYSIOL SCAND, V130, P327, DOI 10.1111/j.1748-1716.1987.tb08144.x; KAMALATI T, 1989, DEVELOPMENT, V106, P283; KEATING MT, 1988, SCIENCE, V239, P914, DOI 10.1126/science.2829358; KONIGSBERG IR, 1963, SCIENCE, V140, P1273, DOI 10.1126/science.140.3573.1273; KONIGSBERG IR, 1971, DEV BIOL, V26, P133, DOI 10.1016/0012-1606(71)90113-8; LAFYATIS R, 1991, IN PRESS MOL CELL BI; LINKHART TA, 1982, COLD SPRINGS HARBOR, V8, P877; LIU LM, 1989, ENDOCRINOLOGY, V124, P3077, DOI 10.1210/endo-124-6-3077; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MOND D, 1989, Q J MATH, V40, P79, DOI 10.1093/qmath/40.1.79; MOORE JW, 1991, IN PRESS DEVELOPMENT; MULLE C, 1988, P NATL ACAD SCI USA, V85, P5728, DOI 10.1073/pnas.85.15.5728; NADALGINARD B, 1978, CELL, V15, P855, DOI 10.1016/0092-8674(78)90270-2; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OLWIN BB, 1988, J CELL BIOL, V107, P761, DOI 10.1083/jcb.107.2.761; QUINN LS, 1990, DEV BIOL, V140, P8, DOI 10.1016/0012-1606(90)90048-N; RAPPOLEE DA, 1991, MODERN CONCEPTS INSU, P3; ROBERTS CT, 1987, MOL ENDOCRINOL, V1, P243, DOI 10.1210/mend-1-3-243; ROTWEIN P, 1988, P NATL ACAD SCI USA, V85, P265, DOI 10.1073/pnas.85.1.265; ROTWEIN P, 1990, DNA CELL BIOL, V9, P725, DOI 10.1089/dna.1990.9.725; SCHMID C, 1984, FEBS LETT, V173, P48, DOI 10.1016/0014-5793(84)81015-7; SHAINBERG A, 1971, DEV BIOL, V25, P1, DOI 10.1016/0012-1606(71)90017-0; SPIZZ G, 1986, J BIOL CHEM, V261, P9483; STEMPIEN MM, 1986, DNA-J MOLEC CELL BIO, V5, P357, DOI 10.1089/dna.1986.5.357; SUSSENBACH JS, 1989, PROG GROWTH FACTOR R, V1, P38; SZEBENYI G, 1991, J BIOL CHEM, V266, P5534; THOMPSON MA, 1990, ENDOCRINOLOGY, V126, P3033, DOI 10.1210/endo-126-6-3033; TOLLEFSEN SE, 1989, P NATL ACAD SCI USA, V86, P1543, DOI 10.1073/pnas.86.5.1543; TOLLEFSEN SE, 1989, J BIOL CHEM, V264, P13810; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477	60	349	361	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					15917	15923						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1651927				2022-12-25	WOS:A1991GB97700061
J	SHARON, G; RABOY, B; PARAG, HA; DIMITROVSKY, D; KULKA, RG				SHARON, G; RABOY, B; PARAG, HA; DIMITROVSKY, D; KULKA, RG			RAD6 GENE-PRODUCT OF SACCHAROMYCES-CEREVISIAE REQUIRES A PUTATIVE UBIQUITIN PROTEIN LIGASE (E3) FOR THE UBIQUITINATION OF CERTAIN PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHORT-LIVED PROTEIN; CONJUGATING ENZYME; AFFINITY PURIFICATION; DEGRADATION; ENCODES; RESOLUTION; SEQUENCE; HISTONES; CLONING; SYSTEM	The RAD6 (UBC2) gene of Saccharomyces cerevisiae which is involved in DNA repair, induced mutagenesis, and sporulation, encodes a ubiquitin-conjugating enzyme (E2). Since the RAD6 gene product can transfer ubiquitin directly to histones in vitro without the participation of a ubiquitin protein ligase (E3), it has been suggested that in vivo it also acts by the unassisted conjugation of ubiquitin to histones or to other target proteins. Here we show that the RAD6 protein can ligate ubiquitin in vitro to a hitherto unknown set of exogenous target proteins (alpha-, beta-, and kappa-casein and beta-lactoglobulin) when supplemented by a putative ubiquitin protein ligase (E3-R) from S. cerevisiae. RAD6 supplemented with E3-R ligates 1 or, sometimes, 2 ubiquitin molecules to the target protein molecule. UBC3 (CDC34) protein in the presence of E3-R has barely detectable activity on the non-histone substrates. Other ubiquitin-conjugating enzymes tested (products of the UBC1 and UBC4 genes) do not cooperate with E3-R in conjugating ubiquitin to the same substrates. Thus, E3-R apparently interacts selectively with RAD6 protein. These findings suggest that some of the in vivo activities of the RAD6 gene may involve E3-R.			SHARON, G (corresponding author), HEBREW UNIV JERUSALEM,ALEXANDER SILBERMAN INST LIFE SCI,DEPT BIOL CHEM,IL-91904 JERUSALEM,ISRAEL.							BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CIECHANOVER A, 1989, TRENDS BIOCHEM SCI, V14, P483, DOI 10.1016/0968-0004(89)90180-1; EIGEL WN, 1984, J DAIRY SCI, V67, P1599, DOI 10.3168/jds.S0022-0302(84)81485-X; FRIEDBERG EC, 1988, MICROBIOL REV, V52, P70, DOI 10.1128/MMBR.52.1.70-102.1988; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; HAAS AL, 1988, J BIOL CHEM, V263, P13258; HELLER H, 1990, J BIOL CHEM, V265, P6532; HERSHKO A, 1988, J BIOL CHEM, V263, P15237; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; JENTSCH S, 1990, TRENDS BIOCHEM SCI, V15, P195, DOI 10.1016/0968-0004(90)90161-4; KUPIEC M, 1984, CURR GENET, V8, P559, DOI 10.1007/BF00395700; MORRISON A, 1988, MOL CELL BIOL, V8, P1179, DOI 10.1128/MCB.8.3.1179; PICKART CM, 1985, J BIOL CHEM, V260, P1573; PICOLOGLOU S, 1990, MOL CELL BIOL, V10, P1017, DOI 10.1128/MCB.10.3.1017; Rechsteiner M., 1988, UBIQUITIN; REISS Y, 1990, J BIOL CHEM, V265, P3685; REYNOLDS P, 1985, P NATL ACAD SCI USA, V82, P168, DOI 10.1073/pnas.82.1.168; REYNOLDS P, 1990, EMBO J, V9, P1423, DOI 10.1002/j.1460-2075.1990.tb08258.x; SCHUSTER T, 1986, CELL, V45, P445, DOI 10.1016/0092-8674(86)90330-2; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SUNG P, 1988, GENE DEV, V2, P1476, DOI 10.1101/gad.2.11.1476; SUNG P, 1990, P NATL ACAD SCI USA, V87, P2695, DOI 10.1073/pnas.87.7.2695; SWERDLOW PS, 1990, MOL CELL BIOL, V10, P4905, DOI 10.1128/MCB.10.9.4905; THOMAS JO, 1975, P NATL ACAD SCI USA, V72, P2626, DOI 10.1073/pnas.72.7.2626; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	29	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					15890	15894						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1651925				2022-12-25	WOS:A1991GB97700057
J	GUY, GR; CHUA, SP; WONG, NS; NG, SB; TAN, YH				GUY, GR; CHUA, SP; WONG, NS; NG, SB; TAN, YH			INTERLEUKIN-1 AND TUMOR-NECROSIS-FACTOR ACTIVATE COMMON MULTIPLE PROTEIN-KINASES IN HUMAN FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAP-BINDING-PROTEIN; NF-KAPPA-B; SIGNAL TRANSDUCTION; RAPID PHOSPHORYLATION; BIOLOGICAL-ACTIVITIES; MOLECULAR-CLONING; FACTOR RECEPTOR; IL-1 RECEPTOR; CYCLIC-AMP; T-CELLS	High resolution two-dimensional gel electrophoresis was used to analyze the signal transduction pathways of tumor necrosis factor (TNF-alpha) and interleukin 1 (IL-1-alpha and -beta) in human fibroblasts. Approximately 450 discrete radioactive spots were electrophoretically resolved from cytosolic extracts of cells prelabeled with P-32. At least 63 of these polypeptides exhibited significant and concordant phosphorylation or dephosphorylation in response to TNF or IL-1, despite the fact that different receptors are involved. Most of these changes concerned serine/threonine residues although enhanced tyrosine phosphorylation of several polypeptides was also observed. Phosphorylation patterns induced by a number of other agonists were compared with the patterns induced by IL-1 and TNF. These included activators of protein kinases C and A, bradykinin (a stimulator of inositol phospholipid hydrolysis), epidermal growth factor, heat-shock, and mellitin (an activator of phospholipase A2). Although each of these agonists induced changes resulting in a distinct pattern of protein phosphorylation, none of these patterns had significant homology with that induced by IL-1 and TNF. Other assays were performed to verify the involvement of specific kinases. Collectively, these data indicate that IL-1 and TNF activate multiple protein kinases viz. a kinase(s) which activates microtubule-associated protein 2 (MAP-2) kinase, a kinase that phosphorylates the cap-binding protein, and a possibly novel serine/threonine protein kinase.			GUY, GR (corresponding author), NATL UNIV SINGAPORE, INST MOLEC & CELL BIOL, 10 KENT RIDGE CRESCENT, SINGAPORE 0511, SINGAPORE.							ABRAHAM RT, 1987, J BIOL CHEM, V262, P2719; ARRIGO AP, 1990, MOL CELL BIOL, V10, P1276, DOI 10.1128/MCB.10.3.1276; BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; BIRD TA, 1989, J IMMUNOL, V142, P126; BIRD TA, 1990, J BIOL CHEM, V265, P235; BOMSZTYK K, 1990, J BIOL CHEM, V265, P9413; BOUCHELOUCHE PN, 1990, CELL SIGNAL, V2, P479; CARROLL GJ, 1986, BRIT J RHEUMATOL, V25, P359; CHEDID M, 1989, J IMMUNOL, V142, P4301; DIDIER M, 1988, J IMMUNOL, V141, P3078; DINARELLO CA, 1989, ADV IMMUNOL, V44, P153, DOI [10.1016/s0065-2776(08)60642-2, 10.1016/S0065-2776(08)60642-2, DOI 10.1016/S0065-2776(08)60642-2]; DOBSON PRM, 1989, J MOL ENDOCRINOL, V2, pR5, DOI 10.1677/jme.0.002R005; DUNCAN R, 1987, J BIOL CHEM, V262, P380; GALLIS B, 1989, J IMMUNOL, V143, P3235; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GOEDDEL DV, 1986, COLD SPRING HARB SYM, V51, P597, DOI 10.1101/SQB.1986.051.01.072; GUY G R, 1990, Progress in Growth Factor Research, V2, P45, DOI 10.1016/0955-2235(90)90009-9; HOHMANN HP, 1989, J BIOL CHEM, V264, P14927; KAUR P, 1988, FEBS LETT, V241, P6, DOI 10.1016/0014-5793(88)81019-6; KIM H, 1979, J CELL BIOL, V80, P266, DOI 10.1083/jcb.80.2.266; KOHNO M, 1986, BIOCHEM J, V238, P451, DOI 10.1042/bj2380451; LAMPHEAR BJ, 1990, J BIOL CHEM, V265, P5333; LE JM, 1987, LAB INVEST, V56, P234; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MACCALLUM SH, 1989, J ENDOCRINOL, V122, P379, DOI 10.1677/joe.0.1220379; MARINO MW, 1989, P NATL ACAD SCI USA, V86, P8417, DOI 10.1073/pnas.86.21.8417; MATSUSHIMA K, 1987, J IMMUNOL, V139, P3367; MIZEL SB, 1990, IMMUNOL TODAY, V11, P390, DOI 10.1016/0167-5699(90)90154-2; MUNOZ E, 1990, J IMMUNOL, V144, P964; OLD LJ, 1988, SCI AM, V258, P59, DOI 10.1038/scientificamerican0588-59; ONEILL LAJ, 1990, IMMUNOL TODAY, V11, P392, DOI 10.1016/0167-5699(90)90155-3; OPPENHEIM JJ, 1986, IMMUNOL TODAY, V7, P45, DOI 10.1016/0167-5699(86)90124-6; PFEFFER LM, 1990, P NATL ACAD SCI USA, V87, P6537, DOI 10.1073/pnas.87.17.6537; PFEFFER LM, 1991, IN PRESS TRENDS BIOC; ROBAYE B, 1989, BIOCHEM BIOPH RES CO, V163, P301, DOI 10.1016/0006-291X(89)92135-9; ROSOFF PM, 1988, CELL, V54, P73, DOI 10.1016/0092-8674(88)90181-X; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHUTZE S, 1989, J BIOL CHEM, V264, P3562; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P959, DOI 10.1128/MCB.9.3.959; SHIRAKAWA F, 1988, P NATL ACAD SCI USA, V85, P8201, DOI 10.1073/pnas.85.21.8201; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; WIJELATH ES, 1988, BIOCHEM BIOPH RES CO, V152, P392, DOI 10.1016/S0006-291X(88)80726-5; YAP WH, 1986, SCIENCE, V234, P355, DOI 10.1126/science.2429366; ZU Y, 1990, BIOCHEMISTRY-US, V29, P1055, DOI 10.1021/bi00456a030	45	189	192	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14343	14352						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1650357				2022-12-25	WOS:A1991FZ35100038
J	KATO, J; LANIERSMITH, KL; CURRIE, MG				KATO, J; LANIERSMITH, KL; CURRIE, MG			CYCLIC-GMP DOWN-REGULATES ATRIAL-NATRIURETIC-PEPTIDE RECEPTORS ON CULTURED VASCULAR ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; ESSENTIAL-HYPERTENSION; GUANYLATE-CYCLASE; LIGAND-BINDING; C-RECEPTORS; RAT; PURIFICATION; ACCUMULATION; PERMEABILITY; STIMULATION	Down-regulation of atrial natriuretic peptide (ANP) receptors was investigated using a cultured bovine pulmonary artery endothelial (CPAE) cell line. Endothelial cells have been shown to possess two subtypes of ANP receptors, a guanylate cyclase-coupled receptor (B-receptor) and a clearance receptor (C-receptor). The treatment with APIII, rat ANP (103-126), at concentrations of 10(-8) to 10(-6) M for 24 h, resulted in a significantly (p < 0.01) greater decrease in maximum I-125-APIII binding to CPAE cells than the identical concentration of API, rat ANP (103-123). APIII at concentrations of 10(-8) to 10(-6) M stimulated cyclic GMP (cGMP) production 3.3-17.5-fold greater than similar concentrations of API. From these findings, we hypothesized that cGMP produced following ANP binding to the B-receptor participates in ANP receptor regulation. M&B 22948, a selective inhibitor of cGMP-specific phosphodiesterase, significantly (p < 0.01) potentiated the effect of both API and APIII on I-125-APIII binding, while M&B 22948 itself had no significant effect on I-125-APIII binding. Treatment of the cells with 1 mM 8-bromo-cGMP also significantly (p < 0.01) decreased I-125--APIII binding to the cells, and a potentiation of this effect was observed by M&B 22948. Scatchard analysis of binding data from 8-bromo-GMP-treated cells showed a significant decrease in B(max) (1.79 +/- 0.15 to 1.20 +/- 0.07 fmol/mg protein, p < 0.05) without a significant change in K(d). Affinity cross-linking of I-125-APIII to 8-bromo-cGMP-treated cells showed a decrease in the labeling of 60- and 70-kDa bands corresponding to the C-receptor. In addition, the APIII-stimulated cGMP response remained unchanged in the 8-bromo-cGMP-treated cells, indicating that the B-receptor was not down-regulated. We conclude that cGMP regulates ANP-binding sites on the endothelial cell and that the evidence indicates that the C-receptor may preferentially be down-regulated by cGMP in CPAE cells.	MONSANTO CO,RES CTR,DEPT HLTH SCI,T3P,800 N LINDBERGH BLVD,ST LOUIS,MO 63167; MED UNIV S CAROLINA,DEPT MOLEC PHARMACOL & EXPTL THERAPEUT,CHARLESTON,SC 29425	Monsanto; Medical University of South Carolina								ALMEIDA FA, 1989, AM J PHYSIOL, V256, pR469, DOI 10.1152/ajpregu.1989.256.2.R469; ANANDSRIVASTAVA MB, 1990, J BIOL CHEM, V265, P8566; ATARASHI K, 1984, SCIENCE, V224, P992, DOI 10.1126/science.6326267; BARON DA, 1989, P NATL ACAD SCI USA, V86, P3394, DOI 10.1073/pnas.86.9.3394; BERGSTRAND H, 1977, MOL PHARMACOL, V13, P38; CHABRIER PE, 1988, J BIOL CHEM, V263, P13199; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; CURRIE MG, 1984, SCIENCE, V223, P67, DOI 10.1126/science.6419347; CURRIE MG, 1983, SCIENCE, V221, P71, DOI 10.1126/science.6857267; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FUJITA T, 1989, BIOCHEM BIOPH RES CO, V159, P734, DOI 10.1016/0006-291X(89)90056-9; FULLER F, 1988, J BIOL CHEM, V263, P9395; HIRATA M, 1989, BIOCHIM BIOPHYS ACTA, V1010, P346, DOI 10.1016/0167-4889(89)90060-8; HIRATA Y, 1989, EUR J PHARMACOL, V164, P603, DOI 10.1016/0014-2999(89)90273-2; HIRATA Y, 1986, BIOCHEM BIOPH RES CO, V138, P405, DOI 10.1016/0006-291X(86)90296-2; HUGHES RJ, 1987, AM J PHYSIOL, V253, pC809, DOI 10.1152/ajpcell.1987.253.6.C809; KATO J, 1987, BIOCHEM BIOPH RES CO, V143, P316, DOI 10.1016/0006-291X(87)90667-X; KOLLENDA MC, 1990, AM J PHYSIOL, V258, pR1084, DOI 10.1152/ajpregu.1990.258.4.R1084; KONDO K, 1985, CLIN EXP HYPERTENS A, V7, P1097, DOI 10.3109/10641968509073577; KUNO T, 1986, J BIOL CHEM, V261, P5817; LANIERSMITH KL, 1990, EUR J PHARMACOL, V178, P105, DOI 10.1016/0014-2999(90)94800-D; LEITMAN DC, 1986, J BIOL CHEM, V261, P1650; LEITMAN DC, 1986, BIOCHIM BIOPHYS ACTA, V885, P74, DOI 10.1016/0167-4889(86)90040-6; LOFTON CE, 1990, BIOCHEM BIOPH RES CO, V172, P793, DOI 10.1016/0006-291X(90)90744-8; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAACK T, 1987, SCIENCE, V238, P675, DOI 10.1126/science.2823385; MARTIN ER, 1989, AM J PHYSIOL, V257, pF649, DOI 10.1152/ajprenal.1989.257.4.F649; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NEEDLEMAN P, 1989, ANNU REV PHARMACOL, V29, P23, DOI 10.1146/annurev.pa.29.040189.000323; RICHARDS AM, 1985, HYPERTENSION, V7, P812, DOI 10.1161/01.HYP.7.5.812; SAGNELLA GA, 1986, LANCET, V1, P179; SCARBOROUGH RM, 1986, J BIOL CHEM, V261, P2960; SCHENK DB, 1987, P NATL ACAD SCI USA, V84, P1521, DOI 10.1073/pnas.84.6.1521; TAKAYANAGI R, 1987, J BIOL CHEM, V262, P12104	34	74	74	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14681	14685						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1650366				2022-12-25	WOS:A1991FZ35100087
J	ANTONINI, G; MALATESTA, F; SARTI, P; BRUNORI, M				ANTONINI, G; MALATESTA, F; SARTI, P; BRUNORI, M			CONTROL OF CYTOCHROME-OXIDASE ACTIVITY - A TRANSIENT SPECTROSCOPY STUDY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTROCHEMICAL-POTENTIAL GRADIENT; C-OXIDASE; ELECTRON-TRANSFER; PHOSPHOLIPID-VESICLES; SUBUNIT-III; PROTON TRANSLOCATION; FLOW-FLASH; MECHANISM; STATE; INTERMEDIATE	The kinetics of cytochrome oxidase reconstituted into small phospholipid vesicles (COV) has been followed by transient optical spectroscopy under steady-state and pre-steady-state conditions, in the presence and absence of ionophores. The effect of valinomycin on the activity of reconstituted cytochrome oxidase is shown to depend on the absolute concentration of the ionophore and on the number of turnovers elapsed by the enzyme; this novel observation, which escaped previous investigations, may account for important differences in results and therefore in interpretation of the mechanism of control of the enzyme activity as between Brunori et al. (Brunori, M., Sarti, P., Colosimo, A., Antonini, G., Malatesta, F., Jones, M. G., and Wilson, M. T. (1985) EMBO J. 4, 2365-2368), Gregory and Ferguson-Miller (Gregory, L., and Ferguson-Miller, S. (1989) Biochemistry 28, 2655-2662) and Capitanio et al. (Capitanio, N., De Nitto, E., Villani, G., Capitanio, G., and Papa, S. (1990) Biochemistry 29, 2939-2944). Quantitative analysis of the optical spectra acquired within 10 ms over a large wavelength and time range (500-650 nm and 5 ms to 60 s) under different experimental conditions, indicates that the electrical component of the transmembrane electro-chemical gradient controls the rate of the internal electron transfer from cytochrome alpha-Cu(A) to cytochrome alpa-3-Cu(B) as well as the cytochrome c to cytochrome alpha-electron transfer. The slow down of cytochrome oxidase activity observed in the presence of valinomycin after several (> 10) turnovers is attributed to alkalinization of the vesicle interior, which affects the internal electron transfer rate. These two mechanisms of control act most likely independently. A "cubic scheme," which illustrates the effect of the electrochemical gradient on two states of cytochrome oxidase characterized by different redox and proton pumping activities is presented and discussed.	UNIV ROME LA SAPIENZA, DEPT BIOCHEM SCI, P ALE ALDO MORO 5, I-00185 ROME, ITALY; CNR, CTR MOLEC BIOL, I-00185 ROME, ITALY; UNIV ROME TOR VERGATA, DEPT EXPTL MED & BIOCHEM SCI, ROME, ITALY	Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); University of Rome Tor Vergata			Sarti, Paolo/D-2946-2009; Malatesta, Francesco/AAT-4757-2020	Antonini, Giovanni/0000-0002-2115-8961; Brunori, Maurizio/0000-0002-7795-1635; Sarti, Paolo/0000-0002-8219-4827				ANTONINI E, 1977, P NATL ACAD SCI USA, V74, P3128, DOI 10.1073/pnas.74.8.3128; ANTONINI G, 1987, J BIOL CHEM, V262, P10077; BRUNORI M, 1983, EMBO J, V2, P2025, DOI 10.1002/j.1460-2075.1983.tb01695.x; BRUNORI M, 1987, EUR J BIOCHEM, V169, P1, DOI 10.1111/j.1432-1033.1987.tb13572.x; BRUNORI M, 1985, EMBO J, V4, P2365, DOI 10.1002/j.1460-2075.1985.tb03940.x; BRUNORI M, 1979, J BIOL CHEM, V254, P769; BRUNORI M, 1981, OXIDASES RELATED RED, P1139; BRZEZINSKI P, 1986, P NATL ACAD SCI USA, V83, P4282, DOI 10.1073/pnas.83.12.4282; CAPITANIO N, 1990, BIOCHEMISTRY-US, V29, P2939, DOI 10.1021/bi00464a008; CASEY RP, 1983, BIOCHEM J, V210, P199; Darley-Usmar V. M., 1987, MITOCHONDRIA PRACTIC; FINEL M, 1986, BIOCHIM BIOPHYS ACTA, V851, P99, DOI 10.1016/0005-2728(86)90253-7; GIBSON QH, 1965, J BIOL CHEM, V240, P2694; GIBSON QH, 1965, J BIOL CHEM, V240, P888; GRAY HB, 1989, BIOCHEMISTRY-US, V28, P7499, DOI 10.1021/bi00445a001; GREENWOOD C, 1976, BIOCHEM J, V157, P591, DOI 10.1042/bj1570591; GREGORY L, 1989, BIOCHEMISTRY-US, V28, P2655, DOI 10.1021/bi00432a044; HILL BC, 1984, BIOCHEM J, V218, P913, DOI 10.1042/bj2180913; HINKLE PC, 1972, J BIOL CHEM, V247, P1338; JENSEN P, 1984, BIOCHEM J, V224, P829, DOI 10.1042/bj2240829; JONES MG, 1984, BIOCHEM J, V220, P57, DOI 10.1042/bj2200057; KOBAYASHI K, 1989, J BIOL CHEM, V264, P7976; MAISONPETERI B, 1989, BIOCHEMISTRY-US, V28, P3156, DOI 10.1021/bi00434a007; MALATESTA F, 1988, ANN NY ACAD SCI, V550, P269, DOI 10.1111/j.1749-6632.1988.tb35342.x; MALATESTA F, 1990, P NATL ACAD SCI USA, V87, P7410, DOI 10.1073/pnas.87.19.7410; MALMSTROM BG, 1985, BIOCHIM BIOPHYS ACTA, V811, P1, DOI 10.1016/0304-4173(85)90002-3; MALMSTROM BG, 1990, CHEM REV, V90, P1247, DOI 10.1021/cr00105a008; MALMSTROM BG, 1989, FEBS LETT, V250, P9, DOI 10.1016/0014-5793(89)80675-1; MCGOVERNMORONEY P, 1984, BIOCHEMISTRY-US, V23, P4991; MORGAN JE, 1989, BIOCHEMISTRY-US, V28, P6975, DOI 10.1021/bi00443a030; MULLER M, 1985, J BIOENERG BIOMEMBR, V17, P385, DOI 10.1007/BF00743111; Nicholls D.G., 1982, BIOENERGETICS INTRO; RAY GB, 1990, BIOCHEMISTRY-US, V29, P3208, DOI 10.1021/bi00465a009; SARTI P, 1985, P NATL ACAD SCI USA, V82, P4876, DOI 10.1073/pnas.82.15.4876; SARTI P, 1983, BIOCHEM J, V209, P81, DOI 10.1042/bj2090081; SARTI P, 1990, J BIOL CHEM, V265, P5554; SARTI P, 1988, ANN NY ACAD SCI, V550, P161, DOI 10.1111/j.1749-6632.1988.tb35332.x; WIKSTROM M, 1979, BIOCHIM BIOPHYS ACTA, V549, P177, DOI 10.1016/0304-4173(79)90014-4; Wikstrom M., 1981, CYTOCHROME OXIDASE S; WILSON MT, 1981, P NATL ACAD SCI-BIOL, V78, P7115, DOI 10.1073/pnas.78.11.7115; WRIGGLESWORTH JM, 1985, J INORG BIOCHEM, V23, P311, DOI 10.1016/0162-0134(85)85040-6; WRIGGLESWORTH JM, 1978, 11TH P FEBS M, V45, P95; Wyman J., 1978, Atti della Accademia Nazionale dei Lincei. Rendiconti, Classe di Scienze Fisiche, Matematiche e Naturali, V64, P409; YONETANI T, 1961, J BIOL CHEM, V236, P1680	44	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1991	266	20					13193	13202						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FX132	1649183				2022-12-25	WOS:A1991FX13200063
J	IKEBUCHI, Y; MASUMOTO, N; TASAKA, K; KOIKE, K; KASAHARA, K; MIYAKE, A; TANIZAWA, O				IKEBUCHI, Y; MASUMOTO, N; TASAKA, K; KOIKE, K; KASAHARA, K; MIYAKE, A; TANIZAWA, O			SUPEROXIDE ANION INCREASES INTRACELLULAR PH, INTRACELLULAR FREE CALCIUM, AND ARACHIDONATE RELEASE IN HUMAN AMNION CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; PROSTAGLANDIN BIOSYNTHESIS; PRETERM LABOR; HEART-CELLS; FATTY-ACIDS; MECHANISMS; MACROPHAGES; GENERATION; INFECTION; INJURY	We determined the effects of superoxide anion, produced by addition of xanthine oxidase to hypoxanthine, on the intracellular pH (pH(i)) and intracellular free calcium concentration ([Ca2+]i) and release of arachidonate in human cultured amnion cells. Superoxide anion induced a prompt increase of pH(i) and subsequent increase of [Ca2+]i. The evoked pH(i) was inhibited by pretreatment with anion channel blockers but not affected by omission of extracellular Na+ or addition of amiloride. The increase of [Ca2+]i was inhibited significantly by the absence of extracellular calcium or by the addition of a calcium channel blocker, cobalt. NH4Cl, which can generally increase pH(i), also increased [Ca2+]i of amnion cells. But the increase of [Ca2+]i induced by the NH4Cl was significantly less than that induced by the amount of superoxide anion causing a similar increase in pH(i). These results show that superoxide anion, crossed through anion channel in membrane, increased [Ca2+]i at least partially via increase of pH(i) and that the calcium mobilization was dependent on both extracellular and intracellular sources. Superoxide anion induced the release of arachidonate in a dose-dependent manner and this induction was inhibited by omission of extracellular calcium. These data suggest that the release of arachidonate was dependent on the increase of [Ca2+]i. We also determined the viability of cells in the presence of superoxide anion by flow cytometry. Superoxide anion at the levels used in these experiments did not change the percentage of viable cells. These findings suggested that superoxide anion may regulate biological functions in amnion cells via pH(i), [Ca2+]i mobilization, and the release of arachidonate without damaging the cells.	OSAKA UNIV,SCH MED,DEPT OBSTET & GYNECOL,1-1-50 FUKUSHIMA,FUKUSHIMA KU,OSAKA 553,JAPAN	Osaka University								BABIOR BM, 1973, J CLIN INVEST, V52, P741, DOI 10.1172/JCI107236; BADWEY JA, 1981, J BIOL CHEM, V256, P2640; BAN C, 1988, ARCH BIOCHEM BIOPHYS, V246, P9; BEJAR R, 1981, OBSTET GYNECOL, V57, P479; BROMBERG Y, 1983, CELL IMMUNOL, V79, P240, DOI 10.1016/0008-8749(83)90067-9; CZERNIECKI BJ, 1989, CARCINOGENESIS, V10, P1769, DOI 10.1093/carcin/10.10.1769; FARBER JL, 1990, LAB INVEST, V62, P670; FLOWER RJ, 1976, BIOCHEM PHARMACOL, V25, P285, DOI 10.1016/0006-2952(76)90216-1; GRINSTEIN S, 1985, BIOCHIM BIOPHYS ACTA, V819, P267, DOI 10.1016/0005-2736(85)90183-X; GROVER AK, 1988, AM J PHYSIOL, V255, pC297, DOI 10.1152/ajpcell.1988.255.3.C297; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HIROSUMI J, 1988, BIOCHEM BIOPH RES CO, V152, P301, DOI 10.1016/S0006-291X(88)80714-9; KANEKO M, 1990, BASIC RES CARDIOL, V85, P45, DOI 10.1007/BF01907013; KIM D, 1987, AM J PHYSIOL, V253, pC137, DOI 10.1152/ajpcell.1987.253.1.C137; LAWSON DL, 1990, J LAB CLIN MED, V115, P541; LUCCHESI BR, 1990, AM J CARDIOL, V65, P141; LYNCH RE, 1978, J BIOL CHEM, V253, P4697; LYNCH RE, 1978, J BIOL CHEM, V253, P1838; MASUMOTO N, 1990, J BIOL CHEM, V265, P22533; MOORE JJ, 1988, ENDOCRINOLOGY, V123, P1771, DOI 10.1210/endo-123-4-1771; MURPHY JG, 1988, AM J PHYSIOL, V254, pH1133, DOI 10.1152/ajpheart.1988.254.6.H1133; MUSGROVE E, 1986, CYTOMETRY, V7, P347, DOI 10.1002/cyto.990070409; OKITA JR, 1983, IN VITRO CELL DEV B, V19, P117; ROMERO R, 1988, CLIN OBSTET GYNECOL, V31, P553, DOI 10.1097/00003081-198809000-00006; ROMERO R, 1989, PROSTAGLANDINS, V37, P13, DOI 10.1016/0090-6980(89)90028-2; ROMERO R, 1989, AM J OBSTET GYNECOL, V161, P336, DOI 10.1016/0002-9378(89)90515-2; SEGAL AW, 1981, NATURE, V290, P406, DOI 10.1038/290406a0; SHIBANUMA M, 1988, J CELL PHYSIOL, V136, P379, DOI 10.1002/jcp.1041360224; SISKIND MS, 1989, AM J PHYSIOL, V256, pC234, DOI 10.1152/ajpcell.1989.256.2.C234; TASAKA K, 1991, OBSTET GYNECOL, V77, P101; ZAKAR T, 1988, J CLIN ENDOCR METAB, V67, P915, DOI 10.1210/jcem-67-5-915	31	99	99	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1991	266	20					13233	13237						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FX132	1649184				2022-12-25	WOS:A1991FX13200068
J	LIU, KE; LIPPARD, SJ				LIU, KE; LIPPARD, SJ			REDOX PROPERTIES OF THE HYDROXYLASE COMPONENT OF METHANE MONOOXYGENASE FROM METHYLOCOCCUS-CAPSULATUS (BATH) - EFFECTS OF PROTEIN-B, REDUCTASE, AND SUBSTRATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							METHYLOSINUS-TRICHOSPORIUM OB3B; MONO-OXYGENASE; ACCEPTOR REDUCTASE; OXIDATION-STATES; II METHANOTROPH; PURIFICATION; CENTERS; BIOLOGY; SYSTEM; NADH	The reduction potentials of the hydroxylase component of the soluble methane monooxygenase from Methylococcus capsulatus (Bath) have been investigated through potentiometric titrations. The potentials were determined by EPR spectroscopic quantitation of the mixed valent hydroxylase as a function of added sodium dithionite in the presence of appropriate mediators. The reduction of the oxidized Fe(III).Fe(III) form to the mixed valent Fe(II).Fe(III) form occurs at 48 mV versus NHE while the potential for the formation of the fully reduced Fe(II).Fe(II) species from the mixed valent form was determined to be -135 mV. Addition of the substrate propylene to the hydroxylase did not have a major effect on the reduction potentials. Introduction of the protein B and the reductase components, however, completely inhibited reduction of the hydroxylase at potential as far negative as -200 mV. Addition of propylene to all three methane monooxygenase components greatly facilitated hydroxylase reduction. Under these conditions, the fully reduced form of the protein was obtained at potentials of > 150 mV. This high redox potential indicates that the oxidized form of the protein is highly reactive, as required for methane oxidation. The present results reveal aspects of how both protein B and substrate can regulate electron transfer into and out of the hydroxylase component of methane monooxygenase.	MIT, DEPT CHEM, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032134, R37GM032134] Funding Source: NIH RePORTER; NCI NIH HHS [CA09112] Funding Source: Medline; NIGMS NIH HHS [GM 32134] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASA R, 1975, J MAGN RESON, V19, P308, DOI 10.1016/0022-2364(75)90045-1; ARMSTRONG FA, 1983, J INORG BIOCHEM, V18, P83, DOI 10.1016/0162-0134(83)85042-9; ARMSTRONG FA, 1991, J INORG BIOCHEM, V266, P540; COLBY J, 1978, BIOCHEM J, V171, P461, DOI 10.1042/bj1710461; COLBY J, 1979, BIOCHEM J, V177, P903, DOI 10.1042/bj1770903; Dalton H, 1985, GAS ENZYMOLOGY, P169, DOI 10.1007/978-94-009-5279-9_12; DAWSON JH, 1986, ADV INORG BIOINORG M, V4, P2; Dutton P L, 1978, Methods Enzymol, V54, P411; ERICSON A, 1988, J AM CHEM SOC, V110, P2330, DOI 10.1021/ja00215a070; FOX BG, 1988, J BIOL CHEM, V263, P10553; FOX BG, 1990, BIOCHEMISTRY-US, V29, P6419, DOI 10.1021/bi00479a013; FOX BG, 1989, J BIOL CHEM, V264, P10023; FOX BG, 1991, J BIOL CHEM, V266, P540; FOX BG, 1988, BIOCHEM BIOPH RES CO, V154, P165, DOI 10.1016/0006-291X(88)90665-1; GREEN J, 1989, J BIOL CHEM, V264, P17698; GREEN J, 1985, J BIOL CHEM, V260, P5795; GREEN J, 1989, BIOCHEM J, V259, P167, DOI 10.1042/bj2590167; GREEN J, 1986, BIOCHEM J, V236, P155, DOI 10.1042/bj2360155; Hanson R. S., 1980, ADV APPL MICROBIOL, V26, P3; HARTMAN JAR, 1987, J AM CHEM SOC, V109, P7387, DOI 10.1021/ja00258a023; HENDRICH MP, 1990, J AM CHEM SOC, V112, P5861, DOI 10.1021/ja00171a029; LIPPARD SJ, 1988, ANGEW CHEM INT EDIT, V27, P344, DOI 10.1002/anie.198803441; LUND J, 1985, EUR J BIOCHEM, V147, P291, DOI 10.1111/j.1432-1033.1985.tb08749.x; LUND J, 1985, EUR J BIOCHEM, V147, P297, DOI 10.1111/j.1432-1033.1985.tb08750.x; Ortiz de Montellano PR, 1986, CYTOCHROME P450 STRU, P217; PRINCE RC, 1988, BIOCHIM BIOPHYS ACTA, V952, P220, DOI 10.1016/0167-4838(88)90119-7; QUE L, 1990, PROG INORG CHEM, V38, P97; RAAG R, 1989, BIOCHEMISTRY-US, V28, P917, DOI 10.1021/bi00428a077; RUZICKA F, 1990, BIOCHEMISTRY-US, V29, P1696, DOI 10.1021/bi00459a005; SNYDER BS, 1989, J AM CHEM SOC, V111, P5214, DOI 10.1021/ja00196a031; TOLMAN WB, 1991, J AM CHEM SOC, V113, P152, DOI 10.1021/ja00001a023; WOODLAND MP, 1986, BIOCHIM BIOPHYS ACTA, V873, P237, DOI 10.1016/0167-4838(86)90050-6; WOODLAND MP, 1984, J BIOL CHEM, V259, P53	33	80	80	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1991	266	20					12836	12839						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FX132	1649166				2022-12-25	WOS:A1991FX13200008
J	ALLEN, GC; KORNBERG, A				ALLEN, GC; KORNBERG, A			THE PRIB GENE ENCODING THE PRIMOSOMAL REPLICATION N-PROTEIN OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DEPENDENT ATPASE; NUCLEOTIDE-SEQUENCE; RNA-POLYMERASE; PURIFICATION; ENZYME; SYSTEM; REGION; OPERON	The gene encoding protein n of the Escherichia coli primosome has been discovered in the rpsF-rpsR-rplI ribosomal protein operon and designated priB. The low copy number of PriB protein and the distinctive codon usage of its gene argue against its being a ribosomal protein. A strain which overproduces PriB was constructed and has been used to purify the protein to homogeneity. The overproduced protein behaves like that purified from wild-type cells.			ALLEN, GC (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT BIOCHEM,STANFORD,CA 94305, USA.				NIGMS NIH HHS [GM07851] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUCKNER R, 1981, MOL GEN GENET, V183, P277, DOI 10.1007/BF00270629; BRUTLAG DL, 1982, NUCLEIC ACIDS RES, V10, P279, DOI 10.1093/nar/10.1.279; BURTON ZF, 1983, CELL, V32, P335, DOI 10.1016/0092-8674(83)90453-1; KORNBERG A, 1982, DNA REPLICATION S, pS105; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE EH, 1990, P NATL ACAD SCI USA, V87, P4620, DOI 10.1073/pnas.87.12.4620; LEE EH, 1991, P NATL ACAD SCI USA, V88, P3029, DOI 10.1073/pnas.88.8.3029; LOW RL, 1982, J BIOL CHEM, V257, P6242; NURSE P, 1990, P NATL ACAD SCI USA, V87, P4615, DOI 10.1073/pnas.87.12.4615; POST LE, 1980, J BIOL CHEM, V255, P4653; SCHNIER J, 1986, MOL GEN GENET, V204, P126, DOI 10.1007/BF00330199; SHLOMAI J, 1980, J BIOL CHEM, V255, P6789; SHLOMAI J, 1980, J BIOL CHEM, V255, P6794; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074	15	24	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1991	266	18					11610	11613						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FT762	1646811				2022-12-25	WOS:A1991FT76200032
J	ROY, G; VILLAR, LM; LAZARO, I; GONZALEZ, M; BOOTELLO, A; GONZALEZPORQUE, P				ROY, G; VILLAR, LM; LAZARO, I; GONZALEZ, M; BOOTELLO, A; GONZALEZPORQUE, P			PURIFICATION AND PROPERTIES OF MEMBRANE AND CYTOSOLIC PHOSPHATIDYLINOSITOL-SPECIFIC PHOSPHOLIPASES-C FROM HUMAN SPLEEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; HUMAN-PLATELET MEMBRANES; GROWTH-FACTOR RECEPTOR; CELL ANTIGEN RECEPTOR; BOVINE BRAIN; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; 2ND MESSENGERS; RAT-LIVER; FORMS	Two phosphatidylinositol-specific phospholipases C (PI-PLC) have been purified from human spleen. PIPLC(m) represents the main activity detected in the membrane, while PI-PLC(c) is the main activity present in the cytoplasm. PI-PLC(m) can be resolved into two peaks of activity of high M(r) (60,000-70,000) and low M(r) (16,000-18,000). High salt concentration ((NH4)2SO4, 2 M) dissociates the high M(r) form yielding the low molecular form and increasing the specific activity. The same effect of dissociation and potentiation of the activity is observed when membranes solubilized by n-octyl glucoside are subjected to the high voltage conditions of an isoelectric focusing run. The purified Pi-PLC(m) has a M(r) of about 18,000 when analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis or gel filtration and a basic pl (9.0-9.2). Purified PI-PLC(c) has a M(r) of 57,000 (sodium dodecyl sulfate-polyacrylamide gel electrophoresis or gel filtration) and a slightly acid pI (6.2). Other characteristics of both enzymes, such as cations dependence, substrate specificity, optimum pH, and kinetic parameters, are also discussed.	HOSP RAMON & CAJAL,SERV INMUNOL,CARRETERA COLMENAR KM 91,E-28034 MADRID,SPAIN	Hospital Universitario Ramon y Cajal			Gonzalez-Muñoz, Miguel/ABG-5151-2020; Roy, Garbiñe/AAG-2570-2021	Gonzalez-Muñoz, Miguel/0000-0002-3957-4955; Roy, Garbiñe/0000-0001-6124-7574; Villar, Luisa M/0000-0002-9067-3668				BALDASSARE JJ, 1989, BIOCHEMISTRY-US, V28, P6010, DOI 10.1021/bi00440a043; BANNO Y, 1987, BIOCHEM J, V248, P95, DOI 10.1042/bj2480095; BANNO Y, 1986, BIOCHEM BIOPH RES CO, V136, P713, DOI 10.1016/0006-291X(86)90498-5; BANNO Y, 1987, BIOCHEM BIOPH RES CO, V146, P861, DOI 10.1016/0006-291X(87)90610-3; BENNETT CF, 1987, J BIOL CHEM, V262, P13789; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; CARTER HR, 1987, BIOCHEM J, V244, P639, DOI 10.1042/bj2440639; FUKUI T, 1988, J BIOL CHEM, V263, P17730; HIRASAWA K, 1985, ANNU REV PHARMACOL, V25, P147, DOI 10.1146/annurev.pharmtox.25.1.147; HOFFMAN SL, 1982, J BIOL CHEM, V257, P14359; HOKIN LE, 1985, ANNU REV BIOCHEM, V54, P205, DOI 10.1146/annurev.biochem.54.1.205; HOMMA Y, 1988, J BIOL CHEM, V263, P6592; KAMISAKA Y, 1986, ARCH BIOCHEM BIOPHYS, V249, P569, DOI 10.1016/0003-9861(86)90035-4; KATSUMATA M, 1986, ANAL BIOCHEM, V154, P676, DOI 10.1016/0003-2697(86)90046-1; KIMURA Y, 1987, J MEMBRANE BIOL, V96, P187, DOI 10.1007/BF01869244; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KUNTZ F, 1973, BIOCHIM BIOPHYS ACTA, V296, P331; LEE KY, 1987, P NATL ACAD SCI USA, V84, P5540, DOI 10.1073/pnas.84.16.5540; LEE MH, 1986, J BIOL CHEM, V261, P4867; MANNE V, 1987, BIOCHEM J, V243, P763, DOI 10.1042/bj2430763; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; NAKANISHI O, 1988, BIOCHEM J, V256, P453, DOI 10.1042/bj2560453; NISHIBE S, 1989, J BIOL CHEM, V264, P10335; NISHIBE S, 1990, P NATL ACAD SCI USA, V87, P424, DOI 10.1073/pnas.87.1.424; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; REBECCHI MJ, 1987, J BIOL CHEM, V262, P12526; REINHOLD JG, 1983, METHODS CLIN CHEM, V1, P88; RYU SH, 1987, P NATL ACAD SCI USA, V84, P6649, DOI 10.1073/pnas.84.19.6649; RYU SH, 1987, J BIOL CHEM, V262, P12511; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; WANG P, 1988, J BIOCHEM-TOKYO, V103, P137, DOI 10.1093/oxfordjournals.jbchem.a122219; WILSON DB, 1984, J BIOL CHEM, V259, P1718	35	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1991	266	18					11495	11501						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FT762	1646808				2022-12-25	WOS:A1991FT76200016
J	LESLIE, CC				LESLIE, CC			KINETIC-PROPERTIES OF A HIGH MOLECULAR MASS ARACHIDONOYL-HYDROLYZING PHOSPHOLIPASE-A2 THAT EXHIBITS LYSOPHOSPHOLIPASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-BOUND PHOSPHOLIPASE-A2; MACROPHAGE CELL-LINE; CYTOSOLIC PHOSPHOLIPASE-A2; PURIFICATION; IDENTIFICATION; ACTIVATION; FORM; ACID	The first step in the production of eicosanoids and platelet-activating factor is the hydrolysis of arachidonic acid from membrane phospholipid by phospholipase A2. We previously purified from the macrophage cell line RAW 264.7 an intracellular phospholipase A2 that preferentially hydrolyzes sn-2-arachidonic acid. The enzyme exhibits a molecular mass of 100 kDa and an isoelectric point of 5.6. When assayed for other activities, the phospholipase A2 was found to exhibit lysophospholipase activity against palmitoyllysoglycerophosphocholine, and both activities copurified to a single band on silver-stained sodium dodecyl sulfate-polyacrylamide gels. An antibody against the macrophage enzyme was found to quantitatively immunoprecipitate both phospholipase A2 and lysophospholipase activities from a crude cytosolic fraction. When the immunoprecipitated material was analyzed on immunoblots, a single band at 100 kDa was evident, further suggesting that a single protein possessed both enzyme activities. When assayed as a function of palmitoyllysoglycerophosphocholine concentration and plotted as a double-reciprocal plot, two different slopes were apparent, corresponding to concentrations above and below the critical micellar concentration (7-mu-M) of the substrate. Above the critical micellar concentration, lysophospholipase exhibited an apparent K(m) of 25-mu-M and a V(max) of 1.5-mu-mol/min/mg. Calcium was not required for lysophospholipase activity, in contrast to phospholipase A2 activity. The enzyme, when assayed as either a phospholipase A2 or lysophospholipase, exhibited nonlinear kinetics beyond 1-2 min despite low substrate conversion. Readdition to more substrate after the activity plateaued did not result in further enzyme activity, ruling out substrate depletion. Readdition of enzyme, however, resulted in another burst of enzyme activity. The results are not consistent with product inhibition, but suggest that the enzyme may be subject to inactivation during catalysis.	UNIV COLORADO, SCH MED, DEPT PATHOL, DENVER, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	LESLIE, CC (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED, DEPT PEDIAT, DIV BASIC SCI, 1400 JACKSON ST, DENVER, CO 80206 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034303] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL034303, HL 34303] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; DIEZ E, 1990, J BIOL CHEM, V265, P14654; DOLE VP, 1960, J BIOL CHEM, V235, P2595; GASSAMADIAGNE A, 1989, J BIOL CHEM, V264, P9470; GRONICH JH, 1990, BIOCHEM J, V271, P37, DOI 10.1042/bj2710037; GRONICH JH, 1988, J BIOL CHEM, V263, P16645; HAYAKAWA M, 1988, J BIOCHEM-TOKYO, V103, P263, DOI 10.1093/oxfordjournals.jbchem.a122258; HAZEN SL, 1990, J BIOL CHEM, V265, P10622; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESLIE CC, 1988, BIOCHIM BIOPHYS ACTA, V963, P476, DOI 10.1016/0005-2760(88)90316-5; LESLIE CC, 1990, METHOD ENZYMOL, V187, P216; LESLIE CC, 1990, BIOCHIM BIOPHYS ACTA, V1045, P261, DOI 10.1016/0005-2760(90)90129-L; LISTER MD, 1988, J BIOL CHEM, V263, P7506; LOEB LA, 1986, J BIOL CHEM, V261, P467; Martonosi, 1985, ENZYMES BIOL MEMBR, V2, P1; OHISHI N, 1987, J BIOL CHEM, V262, P10200; ONO T, 1988, J BIOL CHEM, V263, P5732; STAFFORD RE, 1988, COLLOID SURFACE, V30, P47; ULEVITCH RJ, 1988, J BIOL CHEM, V263, P3079; VANDENBOSCH H, 1980, BIOCHIM BIOPHYS ACTA, V604, P191	22	142	145	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					11366	11371						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	1645732				2022-12-25	WOS:A1991FQ77400101
J	FU, WG; OHANDLEY, S; CUNNINGHAM, RP; JOHNSON, MK				FU, WG; OHANDLEY, S; CUNNINGHAM, RP; JOHNSON, MK			THE ROLE OF THE IRON-SULFUR CLUSTER IN ESCHERICHIA-COLI ENDONUCLEASE-III - A RESONANCE RAMAN-STUDY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING PROTEIN; FE4S4 CLUSTERS; IRE-BP; FERREDOXIN; ACONITASE; THYMINE; ANALOGS; SPECTROSCOPY; MECHANISM; GENE	Resonance Raman spectroscopy has been used to investigate the function and properties of the iron-sulfur cluster in Escherichia coli endonuclease III. Resonance Raman spectra in the Fe-S stretching region are indicative of a [4Fe-4S]2+ cluster with complete cysteinyl sulfur coordination, and vibrational assignments are made by analogy with bacterial ferredoxins. Minor changes in the vibrational frequencies of the modes primarily involving Fe-S(Cys) stretching accompany the binding of the inhibitor thymine glycol or an oligonucleotide containing a reduced apyrimidinic site. These changes are consistent with perturbation of the orientation of the ligating cysteinyl residues and rule out the possibility that the [4Fe-4S] cluster is directly involved with substrate or inhibitor binding. It is concluded that a structural role is most likely for the [4Fe-4S] cluster in endonuclease III.	UNIV GEORGIA, CTR METALLOENZYME STUDIES, ATHENS, GA 30602 USA; SUNY ALBANY, CTR BIOCHEM & BIOPHYS, DEPT BIOL SCI, ALBANY, NY 12222 USA	University System of Georgia; University of Georgia; State University of New York (SUNY) System; State University of New York (SUNY) Albany	FU, WG (corresponding author), UNIV GEORGIA, DEPT CHEM, ATHENS, GA 30602 USA.			O'Handley, Suzanne/0000-0001-8373-0065	NIGMS NIH HHS [GM33806] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033806] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASAHARA H, 1989, BIOCHEMISTRY-US, V28, P4444, DOI 10.1021/bi00436a048; BACKES G, 1991, J AM CHEM SOC, V113, P2055, DOI 10.1021/ja00006a027; BEINERT H, 1989, EUR J BIOCHEM, V186, P5, DOI 10.1111/j.1432-1033.1989.tb15170.x; BREIMER LH, 1984, J BIOL CHEM, V259, P5543; CONOVER RC, 1990, J BIOL CHEM, V265, P8533; CUNNINGHAM RP, 1989, BIOCHEMISTRY-US, V28, P4450, DOI 10.1021/bi00436a049; CZERNUSZEWICZ RS, 1987, J AM CHEM SOC, V109, P7178, DOI 10.1021/ja00257a045; DEMPLE B, 1980, NATURE, V287, P203, DOI 10.1038/287203a0; EMPTAGE MH, 1988, ACS SYM SER, V372, P343; Fasman GD., 1975, HDB BIOCH MOL BIOL N, V1, P589; FRENKEL K, 1981, BIOCHEMISTRY-US, V20, P750, DOI 10.1021/bi00507a014; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; HAN S, 1989, J AM CHEM SOC, V111, P3496, DOI 10.1021/ja00192a002; HENTZE MW, 1991, NUCLEIC ACIDS RES, V19, P1739, DOI 10.1093/nar/19.8.1739; IIDA S, 1970, BIOCHIM BIOPHYS ACTA, V213, P1, DOI 10.1016/0005-2787(70)90002-X; KATCHER HL, 1983, BIOCHEMISTRY-US, V22, P4071, DOI 10.1021/bi00286a013; KOW YW, 1987, BIOCHEMISTRY-US, V26, P8200, DOI 10.1021/bi00399a027; MOULIS JM, 1984, BIOCHEMISTRY-US, V23, P6605, DOI 10.1021/bi00321a050; MOULIS JM, 1988, BIOCHEMISTRY-US, V27, P8712, DOI 10.1021/bi00424a004; ROUAULT TA, 1991, CELL, V64, P881, DOI 10.1016/0092-8674(91)90312-M; SWITZER R L, 1989, Biofactors, V2, P77; THOMSON AJ, 1991, FEBS LETT, V285, P230, DOI 10.1016/0014-5793(91)80807-F	22	71	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16135	16137						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1644800				2022-12-25	WOS:A1992JJ45800026
J	WAGNER, OF; CHRIST, G; WOJTA, J; VIERHAPPER, H; PARZER, S; NOWOTNY, PJ; SCHNEIDER, B; WALDHAUSL, W; BINDER, BR				WAGNER, OF; CHRIST, G; WOJTA, J; VIERHAPPER, H; PARZER, S; NOWOTNY, PJ; SCHNEIDER, B; WALDHAUSL, W; BINDER, BR			POLAR SECRETION OF ENDOTHELIN-1 BY CULTURED ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOREACTIVE ENDOTHELIN; PLASMINOGEN-ACTIVATOR; HUMAN-PLASMA; TRANSPORT; RELEASE	The aim of this study was to determine the permeability of endothelial monolayers for endothelin-1 and a possible directionality of the endothelin-1 secretion process. Human umbilical vein endothelial cells were cultured on acellular amniotic membranes, dividing the tissue culture wells into an apical (luminal) and a basolateral (abluminal) compartment. Whereas in the absence of endothelial monolayers 44.9 +/- 2.3 and 43.5 +/- 2.0% of the unilaterally added endothelin-1 permeated from the apical to the basolateral side and from the basolateral to the apical side, respectively, only 6.5 +/- 0.6 and 6.6 +/- 0.4% diffused in the presence of endothelial cells. Analyzing endothelin-1 secretion, approximately 80% of the total amount of synthesized endothelin-1 was found in the basolateral compartment; thrombin (10 units/ml) stimulated the production of endothelin-1 approximately 2-fold, but did not change the relative distribution of endothelin-1 between the apical and basolateral compartments. In the presence of dexamethasone (10(-7) M), a decrease in the level of endothelin-1 was found in the apical compartment, whereas the total amount of endothelin-1 produced was not affected. Dexamethasone did not influence the permeability of human umbilical vein endothelial cell monolayers for endothelin-1. These results strongly support the hypothesis that endothelin-1 is a local paracrine regulator of vasotone.	UNIV VIENNA, DEPT MED PHYSIOL, DIV CLIN EXPTL PHYSIOL, A-1090 VIENNA, AUSTRIA; UNIV VIENNA, DEPT MED STAT, A-1090 VIENNA, AUSTRIA	University of Vienna; University of Vienna	WAGNER, OF (corresponding author), UNIV VIENNA, DEPT MED 1, DIV CLIN ENDOCRINOL & DIABET MELLITUS, LAZARETTGASSE 14, A-1090 VIENNA, AUSTRIA.		Wojta, Johann/AAC-8433-2020	Wojta, Johann/0000-0002-1282-9276				ANDO K, 1989, FEBS LETT, V245, P164, DOI 10.1016/0014-5793(89)80213-3; BOOYSE FM, 1975, THROMB DIATH HAEMOST, V34, P825, DOI 10.1055/s-0038-1654001; CERNACEK P, 1989, BIOCHEM BIOPH RES CO, V161, P562, DOI 10.1016/0006-291X(89)92636-3; DENUCCI G, 1988, P NATL ACAD SCI USA, V85, P9797; DUNNETT CW, 1955, J AM STAT ASSOC, V50, P1096, DOI 10.2307/2281208; FURIE MB, 1987, J CELL SCI, V88, P161; JAFFE EA, 1973, J CLIN INVEST, V52, P2757, DOI 10.1172/JCI107471; KING GL, 1985, SCIENCE, V227, P1583, DOI 10.1126/science.3883490; KOHNO M, 1990, METABOLISM, V39, P1003, DOI 10.1016/0026-0495(90)90157-8; KOYAMA H, 1989, LANCET, V1, P991; MACCUMBER MW, 1989, P NATL ACAD SCI USA, V86, P7285, DOI 10.1073/pnas.86.18.7285; MASAKI T, 1989, J CARDIOVASC PHARM, V13, pS1, DOI 10.1097/00005344-198900135-00002; MINEO C, 1990, EXP CELL RES, V190, P99, DOI 10.1016/0014-4827(90)90149-5; POHL U, 1989, J CARDIOVASC PHARM, V13, pS188, DOI 10.1097/00005344-198900135-00052; SAITO Y, 1990, NEW ENGL J MED, V322, P205; STEIN O, 1980, BIOCHIM BIOPHYS ACTA, V620, P631, DOI 10.1016/0005-2760(80)90155-1; UNEMORI EN, 1990, J BIOL CHEM, V265, P445; VANHINSBERGH VWM, 1990, BLOOD, V75, P1991; VIERHAPPER H, 1990, CIRCULATION, V81, P1415, DOI 10.1161/01.CIR.81.4.1415; WAGNER OF, 1990, EUR J CLIN INVEST, V20, P502, DOI 10.1111/j.1365-2362.1990.tb01892.x; WOJTA J, 1989, J BIOL CHEM, V264, P2846; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	22	580	586	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16066	16068						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1644793				2022-12-25	WOS:A1992JJ45800015
J	SASAKI, A; GOLDBERG, IJ				SASAKI, A; GOLDBERG, IJ			LIPOPROTEIN-LIPASE RELEASE FROM BFC-1-BETA ADIPOCYTES - EFFECTS OF TRIGLYCERIDE-RICH LIPOPROTEINS AND LIPOLYSIS PRODUCTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ADIPOSE-TISSUE; APOLIPOPROTEIN-C-II; PHOSPHOLIPASE-C; PLASMA-LIPOPROTEINS; INSULIN; CELLS; PHOSPHATIDYLINOSITOL; PROTEOGLYCANS; METABOLISM; DEFICIENCY	Lipoprotein lipase (LPL), synthesized by adipocytes and myocytes, must be transported to the luminal endothelial cell surface where it then interacts with circulating lipoproteins. The first step in this extracellular LPL transport pathway is LPL release from the surface of LPL-synthesizing cells. Because hydrolysis of triglyceride (TG)-rich lipoproteins releases LPL from the apical surface of endothelial cells, we hypothesized that the same substances dissociate LPL from adipocytes. I-125-LPL was bound to the surface of brown adipocytes (BFC-1-beta). LPL binding to the adipocyte surface was greater than to endothelial cell surfaces. Using low concentrations of heparin, more LPL was released from endothelial cells than BFC-1-beta suggesting that the affinity of LPL binding to the adipocytes was greater than LPL affinity for endothelial cells. >3-fold more LPL was released from the cell surface when very low density lipoproteins (VLDL) were added to culture medium containing 3% bovine serum albumin. LPL remaining on the cell surface decreased with VLDL addition. Endogenously produced LPL activity was also released from the cells by VLDL. Low and high density lipoproteins did not release I-125-LPL or LPL activity from the adipocytes. To assess whether lipolysis was necessary for LPL release, BFC-1-beta were incubated with TG-rich lipoproteins from a patient with apoCII deficiency. The apoCII-deficient lipoproteins did not release LPL unless an exogenous source of apoCII was added. Apolipoproteins E and Cs and high molar ratios of oleic acid:bovine serum albumin did not release surface-associated LPL. Lysolecithin (25 and 100-mu-M), but not lecithin, monoglycerides, or diglycerides, released adipocyte surface LPL. Because lysolecithin also released LPL during a 4-degrees-C incubation, cellular metabolic functions are not required for LPL dissociation from the cells. Lysolecithin also inhibited LPL binding to endothelial cells; however, this effect was abrogated by addition of bovine serum albumin. We hypothesize that lipolysis products from TG-rich lipoproteins release adipocyte surface LPL, which can then be transported to the luminal endothelial cell surface.	COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,630 W 168TH ST,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,SPECIALIZED CTR RES ARTERIOSCLEROSIS,NEW YORK,NY 10032	Columbia University; Columbia University					NHLBI NIH HHS [HL 45095, HL 21006] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045095, P50HL021006, R37HL045095] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BELFRAGE P, 1969, J LIPID RES, V10, P341; BRAUN JEA, 1991, AM J PHYSIOL, V260, pE477, DOI 10.1152/ajpendo.1991.260.3.E477; BRECKENRIDGE WC, 1978, NEW ENGL J MED, V298, P1265, DOI 10.1056/NEJM197806082982301; CAMPS L, 1990, AM J PHYSIOL, V258, pC673, DOI 10.1152/ajpcell.1990.258.4.C673; CHAJEKSHAUL T, 1989, BIOCHIM BIOPHYS ACTA, V1014, P178, DOI 10.1016/0167-4889(89)90031-1; CISAR LA, 1989, J BIOL CHEM, V264, P1767; CORNICELLI JA, 1963, ARTERIOSCLEROSIS, V3, P560; DOOLITTLE MH, 1990, J BIOL CHEM, V265, P4570; ECKEL RH, 1981, INT J OBESITY, V5, P571; ECKEL RH, 1984, ENDOCRINOLOGY, V114, P1665, DOI 10.1210/endo-114-5-1665; ECKEL RH, 1989, NEW ENGL J MED, V320, P1060; ECKEL RH, 1987, LIPOPROTEIN LIPASE, P79; FOJO SS, 1989, J CLIN INVEST, V84, P1215, DOI 10.1172/JCI114287; FOREST C, 1987, EXP CELL RES, V168, P218, DOI 10.1016/0014-4827(87)90430-7; FOREST C, 1987, EXP CELL RES, V168, P233, DOI 10.1016/0014-4827(87)90431-9; GARFINKEL AS, 1987, PLASMA LIPOPROTEINS, P335; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HIETANEN E, 1977, J LIPID RES, V18, P480; ISHIHARA M, 1987, J BIOL CHEM, V262, P4708; JONASSON L, 1984, ATHEROSCLEROSIS, V51, P313, DOI 10.1016/0021-9150(84)90179-5; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NICOLL A, 1981, ATHEROSCLEROSIS, V39, P229, DOI 10.1016/0021-9150(81)90073-3; NIEUWENHUIZEN W, 1977, ATHEROSCLEROSIS, V27, P97, DOI 10.1016/0021-9150(77)90029-6; NILSSONE.P, 1973, J BIOL CHEM, V248, P6734; OLIVECRONA T, 1987, J BIOL CHEM, V262, P10748; ONG JM, 1989, J CLIN INVEST, V84, P305, DOI 10.1172/JCI114155; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SAXENA U, 1989, J BIOL CHEM, V264, P4349; SAXENA U, 1991, P NATL ACAD SCI USA, V88, P2254, DOI 10.1073/pnas.88.6.2254; SAXENA U, 1990, J BIOL CHEM, V265, P12880; SCOW RO, 1976, BIOCHIM BIOPHYS ACTA, V431, P538, DOI 10.1016/0005-2760(76)90219-8; SEMB H, 1989, BIOCHEM J, V262, P505, DOI 10.1042/bj2620505; SOCORRO L, 1985, PREP BIOCHEM, V15, P133, DOI 10.1080/10826068508062267; STENDER S, 1981, ARTERIOSCLEROSIS, V1, P38, DOI 10.1161/01.ATV.1.1.38; STEWART JE, 1974, J BIOL CHEM, V249, P904; SWITZER S, 1965, J LIPID RES, V6, P506; WANGIVERSON P, 1980, ATHEROSCLEROSIS, V5, P375; WISE LS, 1978, CELL, V13, P233, DOI 10.1016/0092-8674(78)90192-7; YLAHERTTUALA S, 1988, J LIPID RES, V29, P563; ZOVICH DC, 1991, FASEB J, V5, pA717	40	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15198	15204						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634549				2022-12-25	WOS:A1992JF08800101
J	SPEICHER, DW; WEGLARZ, L; DESILVA, TM				SPEICHER, DW; WEGLARZ, L; DESILVA, TM			PROPERTIES OF HUMAN RED-CELL SPECTRIN HETERODIMER (SIDE-TO-SIDE) ASSEMBLY AND IDENTIFICATION OF AN ESSENTIAL NUCLEATION SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE SPECTRIN; ALPHA-ACTININ; STRUCTURAL DOMAINS; FUNCTIONAL DOMAINS; COMPLETE SEQUENCE; SUBUNIT; CALMODULIN; MEMBRANE; PROTEIN; CDNA	The antiparallel side-to-side association of spectrin alpha and beta-monomers is a two-step process which occurs in seconds even at 0-degrees-C and at low concentrations. Assembly involves initial contact of complementary nucleation sites on each subunit, which are located near the actin binding end of the long, flexible heterodimer rod. The minimum nucleation sites are comprised of approximately four contiguous 106-residue homologous segments or repeats. Three repeats in the nucleation site contain an 8-residue insertion and have the highest homology to the four spectrin-like repeats in alpha-actinin. The adjacent actin binding domain on the beta-subunit and the adjacent EF hand motifs on the alpha-subunit are not required for heterodimer assembly. The nucleation sites probably have a specific lock and key structure which defines the unique side-to-side pairing of the many homologous segments in both subunits. Assembly of spectrin heterodimers is probably most analogous to a zipper. After initial nucleation site binding, the remainder of the subunits quickly associate along their full lengths to reconstitute a normal dimer by supercoiling around each other to form a rope-like, flexible rod. Assembly is terminated if either polypeptide is interrupted by a protease cleavage. Heterozygotic mutations involving either nucleation site are predicted to affect allele incorporation into the mature membrane skeleton.			SPEICHER, DW (corresponding author), WISTAR INST, 3601 SPRUCE ST, ROOM C102, PHILADELPHIA, PA 19104 USA.			Weglarz, Ludmila/0000-0003-4217-5274	NCI NIH HHS [CA10815] Funding Source: Medline; NHLBI NIH HHS [HL38794] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA010815] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038794] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLOISIO N, 1991, J CLIN INVEST, V87, P2169, DOI 10.1172/JCI115250; BARON MD, 1987, J BIOL CHEM, V262, P17623; BENNETT V, 1991, J CLIN INVEST, V87, P1483, DOI 10.1172/JCI115157; COLEMAN TR, 1989, CELL MOTIL CYTOSKEL, V12, P248, DOI 10.1002/cm.970120406; DAVISON MD, 1988, CELL, V52, P159, DOI 10.1016/0092-8674(88)90503-X; DUBREUIL RR, 1989, J CELL BIOL, V109, P2197, DOI 10.1083/jcb.109.5.2197; IMAMURA M, 1988, J BIOL CHEM, V263, P7800; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LITMAN D, 1980, J CELL SCI, V42, P1; MARCHESI SL, 1989, RED BLOOD CELL MEMBR, P77; MAZDZANOWSKI J, 1992, ELECTROPHORESIS, V13, P59, DOI 10.1002/elps.1150130112; MCGOUGH AM, 1990, P NATL ACAD SCI USA, V87, P5208, DOI 10.1073/pnas.87.13.5208; MCGUIRE M, 1988, Hematologic Pathology, V2, P1; Morrow JS, 1989, CURR OPIN CELL BIOL, V1, P23, DOI 10.1016/S0955-0674(89)80032-8; MORROW JS, 1980, P NATL ACAD SCI-BIOL, V77, P6592, DOI 10.1073/pnas.77.11.6592; MOZDZANOWSKI J, 1990, CURRENT RES PROTEIN, P87; PALEK J, 1987, Blood Reviews, V1, P147, DOI 10.1016/0268-960X(87)90031-2; REIM DF, 1992, TECHNIQUES PROTEIN C, P53; SAHR KE, 1990, J BIOL CHEM, V265, P4434; SEARS DE, 1986, BIOCHIM BIOPHYS ACTA, V870, P432, DOI 10.1016/0167-4838(86)90251-7; SHOTTON DM, 1979, J MOL BIOL, V131, P303, DOI 10.1016/0022-2836(79)90078-0; Speicher D.W., 1989, TECHNIQUES PROTEIN C, P24; SPEICHER DW, 1984, NATURE, V311, P177, DOI 10.1038/311177a0; SPEICHER DW, 1982, J BIOL CHEM, V257, P9093; SPEICHER DW, 1986, J CELL BIOCHEM, V30, P245, DOI 10.1002/jcb.240300306; WASENIUS VM, 1987, FEBS LETT, V221, P73, DOI 10.1016/0014-5793(87)80354-X; WINKELMANN JC, 1990, J BIOL CHEM, V265, P11827; YOSHINO H, 1984, J BIOL CHEM, V259, P4496; YURCHENCO PD, 1982, J BIOL CHEM, V257, P9102	30	141	142	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14775	14782						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634521				2022-12-25	WOS:A1992JF08800043
J	SWINNEN, JV; TSIKALAS, KE; CONTI, M				SWINNEN, JV; TSIKALAS, KE; CONTI, M			PROPERTIES AND HORMONAL-REGULATION OF 2 STRUCTURALLY RELATED CAMP PHOSPHODIESTERASES FROM THE RAT SERTOLI-CELL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-AMP PHOSPHODIESTERASE; DEPENDENT PROTEIN-KINASE; FOLLICLE-STIMULATING-HORMONE; RIBONUCLEIC-ACID; NUCLEOTIDE PHOSPHODIESTERASE; ADENOSINE MONOPHOSPHATE; ASTROCYTOMA-CELLS; ESCHERICHIA-COLI; NUCLEAR LOCATION; MESSENGER-RNA	Upon exposure to follicle-stimulating hormone (FSH), the gonadotropin-responsive Sertoli cell expresses increased rolipram-sensitive cAMP-specific phosphodiesterase (cAMP-PDE) activity. To understand the mechanisms leading to this activation, the cAMP-PDEs present in the Sertoli cell were characterized and their regulation studied. Comparison of the conceptual translates of two groups of PDE cDNA clones isolated from a Sertoli cell cDNA library (ratPDE3 and ratPDE4) showed that the encoded proteins were structurally similar, containing a core region of 455 amino acids with a sequence identity of 87%. The amino and carboxyl termini were divergent. Expression of these cDNAs in Escherichia coli and monkey COS-7 cells demonstrated that the encoded cAMP-PDEs had similar affinities for the cAMP substrate and were equally sensitive to a number of PDE inhibitors (rolipram > Ro 20-1724 > cilostamide). FSH stimulation of the Sertoli cell produced an increased rate of transcription of the ratPDE3 gene and elevated mRNA levels for ratPDE3 and to a lesser extent of ratPDE4. The increase in mRNA levels was detected after 1 h of stimulation. Forskolin, cholera toxin, and N6,O2'-dibutyryl cAMP produced a similar increase in rate of transcription and elevated mRNA levels, indicating that this activation is mediated by an increase in intracellular cAMP. RatPDE4 mRNA levels were maximal upon exposure to 10 ng of FSH/ml, whereas ratPDE3 mRNA levels could be further elevated with higher FSH concentrations. The intensity of an immunoreactive band with characteristics identical to a purified cAMP-PDE, correlated with the increased cAMP hydrolytic activity after FSH or dibutyryl cAMP treatment, demonstrating that changes in cAMP-PDE protein levels are involved in this regulation. These data provide evidence that multiple cAMP-PDE forms are expressed in the rat Sertoli cell. Although differences in the pattern of activation of these forms were observed, these data show, that in the rat Sertoli cell, the cAMP-PDE activity is regulated by hormones via a novel mechanism that involves a cAMP-dependent activation of transcription of a PDE gene.	UNIV N CAROLINA, DEPT PEDIAT, REPROD BIOL LABS, CB 7500 MACNIDER 202H, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT PHYSIOL, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill			Swinnen, Johannes V/AAA-2214-2022	Swinnen, Johannes V/0000-0002-7720-5077	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020788] Funding Source: NIH RePORTER; NICHD NIH HHS [HD20788] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BEAVO JA, 1988, ADV SEC MESS PHOSPH, V22, P1; Bernard H U, 1979, Methods Enzymol, V68, P482; BOURNE HR, 1973, SCIENCE, V181, P952, DOI 10.1126/science.181.4103.952; BOURNE HR, 1975, J CELL PHYSIOL, V85, P611, DOI 10.1002/jcp.1040850313; BROWNING ET, 1976, MOL PHARMACOL, V12, P32; BURGLIN TR, 1987, EMBO J, V6, P2617, DOI 10.1002/j.1460-2075.1987.tb02552.x; BUTCHER RW, 1986, J CYCLIC NUCL PROT, V11, P275; Charbonneau H., 1990, CYCLIC NUCLEOTIDE PH, P267; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLICELLI J, 1989, P NATL ACAD SCI USA, V86, P3599, DOI 10.1073/pnas.86.10.3599; CONTI M, 1986, ENDOCRINOLOGY, V118, P901, DOI 10.1210/endo-118-3-901; CONTI M, 1982, ENDOCRINOLOGY, V110, P1189, DOI 10.1210/endo-110-4-1189; CONTI M, 1984, ENDOCRINOLOGY, V114, P2361, DOI 10.1210/endo-114-6-2361; CONTI M, 1983, ENDOCRINOLOGY, V113, P1845, DOI 10.1210/endo-113-5-1845; CONTI M, 1981, BIOCHEM BIOPH RES CO, V98, P1044, DOI 10.1016/0006-291X(81)91216-X; CROWL R, 1985, GENE, V38, P31, DOI 10.1016/0378-1119(85)90200-8; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; DARMIENTO M, 1972, P NATL ACAD SCI USA, V69, P459, DOI 10.1073/pnas.69.2.459; DAVIS RL, 1989, P NATL ACAD SCI USA, V86, P3604, DOI 10.1073/pnas.86.10.3604; DEGERMAN E, 1990, P NATL ACAD SCI USA, V87, P533, DOI 10.1073/pnas.87.2.533; DEMAZANCOURT P, 1988, METHOD ENZYMOL, V159, P766; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GETTYS TW, 1988, J BIOL CHEM, V263, P10359; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GRANT PG, 1988, P NATL ACAD SCI USA, V85, P9071, DOI 10.1073/pnas.85.23.9071; HOUSLAY MD, 1990, CYCLIC NUCLEOTIDE PH, P185; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; LEISER M, 1986, J BIOL CHEM, V261, P5486; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; LYONS RH, 1987, MOL CELL BIOL, V7, P2451, DOI 10.1128/MCB.7.7.2451; MACPHEE CH, 1988, J BIOL CHEM, V263, P10353; MACPHEE CH, 1986, J CYCLIC NUCL PROT, V11, P487; MANGANIELLO V, 1972, P NATL ACAD SCI USA, V69, P269; Manganiello V.C., 1990, CYCLIC NUCLEOTIDE PH, P87; MARCHMONT RJ, 1981, BIOCHEM J, V195, P645, DOI 10.1042/bj1950645; MONACO L, 1986, BIOL REPROD, V35, P258, DOI 10.1095/biolreprod35.2.258; ONALI P, 1981, BIOCHIM BIOPHYS ACTA, V675, P285, DOI 10.1016/0304-4165(81)90239-7; RICHARDSON WD, 1986, CELL, V44, P77, DOI 10.1016/0092-8674(86)90486-1; Sambrook J, 1989, MOL CLONING LABORATO; SCHNEIDER HH, 1986, EUR J PHARMACOL, V127, P105, DOI 10.1016/0014-2999(86)90210-4; SCHWARTZ JP, 1974, P NATL ACAD SCI USA, V71, P3844, DOI 10.1073/pnas.71.10.3844; SHEPARD HM, 1982, DNA-J MOLEC CELL BIO, V1, P125, DOI 10.1089/dna.1.1982.1.125; SMITH EP, 1989, MOL ENDOCRINOL, V3, P954, DOI 10.1210/mend-3-6-954; SWINNEN JV, 1989, P NATL ACAD SCI USA, V86, P8197, DOI 10.1073/pnas.86.21.8197; SWINNEN JV, 1989, P NATL ACAD SCI USA, V86, P5325, DOI 10.1073/pnas.86.14.5325; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; THOMPSON WJ, 1971, BIOCHEMISTRY-US, V10, P311; UZUNOV P, 1973, SCIENCE, V180, P304, DOI 10.1126/science.180.4083.304; VERHOEVEN G, 1981, MOL CELL ENDOCRINOL, V24, P41, DOI 10.1016/0303-7207(81)90077-0; WYCHOWSKI C, 1986, EMBO J, V5, P2569, DOI 10.1002/j.1460-2075.1986.tb04536.x; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0	59	106	111	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					18370	18377						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1655746				2022-12-25	WOS:A1991GG55300099
J	MANN, EA; CROYLE, ML; LINGREL, JB				MANN, EA; CROYLE, ML; LINGREL, JB			IDENTIFICATION OF SEQUENCES MEDIATING INTERLEUKIN-6 INDUCTION OF A RAT T-KININOGEN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; ACUTE-PHASE PROTEINS; TRANSCRIPTION INITIATION; NUCLEAR-PROTEIN; PROMOTER; INFLAMMATION; MUTAGENESIS; EXPRESSION; INTERACT; INVIVO	Interleukin-6 is a pleiotropic cytokine that has a major role in the coordination of the hepatic acute phase response. In order to more fully understand this role, we have examined the interleukin-6 induction of T kininogen, a cysteine protease inhibitor and a major acute phase reactant in the rat. Using deletional analysis and site-directed mutagenesis of T kininogen-chloramphenicol acetyltransferase fusion constructs transfected into HepG2 hepatoma cells, we have identified two similar interleukin-6 response elements within 250 base pairs of the transcription start site. These two response elements are functionally interdependent. The sequences of these two elements match the consensus sequence for the previously described Type B interleukin-6 response element. Interleukin-6 signal transduction via two Type B elements has not been observed previously in vivo. A DNA fragment encompassing these response elements forms the same protein complex with nuclear extracts from both untreated and interleukin-6-treated cells.			MANN, EA (corresponding author), UNIV CINCINNATI,DEPT MOLEC GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267, USA.				NIGMS NIH HHS [GM-10999] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM010999] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ANDERSON KP, 1989, GENE, V81, P119, DOI 10.1016/0378-1119(89)90342-9; ANDERSON KP, 1990, MOL ENDOCRINOL, V4, P543, DOI 10.1210/mend-4-4-543; ANDERSON KP, 1989, NUCLEIC ACIDS RES, V17, P2835, DOI 10.1093/nar/17.7.2835; ANDERSON KP, 1984, ARCH BIOCHEM BIOPHYS, V233, P624, DOI 10.1016/0003-9861(84)90488-0; ANDUS T, 1988, EUR J IMMUNOL, V18, P739, DOI 10.1002/eji.1830180513; BAUMANN H, 1989, IN VITRO CELL DEV B, V25, P115; BIRCH HE, 1986, J BIOL CHEM, V261, P8077; CHEN HM, 1991, J BIOL CHEM, V266, P2946; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FUNG WP, 1987, J BIOL CHEM, V262, P9298; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; GEIGER T, 1988, EUR J IMMUNOL, V18, P717, DOI 10.1002/eji.1830180510; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; ISSHIKI H, 1991, NEW BIOL, V3, P63; KAGEYAMA R, 1987, J BIOL CHEM, V262, P2345; KOJ A, 1974, STRUCTURE FUNCTION P, V1, P73; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; MAJELLO B, 1990, EMBO J, V9, P457, DOI 10.1002/j.1460-2075.1990.tb08131.x; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; OLIVIERO S, 1989, EMBO J, V8, P1145, DOI 10.1002/j.1460-2075.1989.tb03485.x; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; POLI V, 1989, P NATL ACAD SCI USA, V86, P8202, DOI 10.1073/pnas.86.21.8202; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; Sambrook J, 1989, MOL CLONING LABORATO; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; WERNKE G R, 1989, Biophysical Journal, V55, p390A	29	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16931	16934						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1653251				2022-12-25	WOS:A1991GD63500108
J	KENNELLY, PJ; KREBS, EG				KENNELLY, PJ; KREBS, EG			CONSENSUS SEQUENCES AS SUBSTRATE-SPECIFICITY DETERMINANTS FOR PROTEIN-KINASES AND PROTEIN PHOSPHATASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							HEAVY-CHAIN KINASE; SYNTHETIC PEPTIDES; PHOSPHORYLATION SITES; BASIC RESIDUES; SKELETAL-MUSCLE; AMINO-ACID; RAT-LIVER; PURIFICATION; DEPHOSPHORYLATION; IDENTIFICATION		UNIV WASHINGTON,SCH MED,DEPT PHARMACOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	KENNELLY, PJ (corresponding author), VIRGINIA POLYTECH INST & STATE UNIV,DEPT BIOCHEM & NUTR,BLACKSBURG,VA 24061, USA.							AGOSTINIS P, 1990, EUR J BIOCHEM, V189, P235, DOI 10.1111/j.1432-1033.1990.tb15482.x; AITKEN A, 1981, J BIOL CHEM, V256, P3501; BLUMENTHAL DK, 1986, J BIOL CHEM, V261, P8140; BRZESKA H, 1989, J BIOL CHEM, V264, P19340; BRZESKA H, 1990, J BIOL CHEM, V265, P16138; BYLUND DB, 1975, J BIOL CHEM, V250, P6355; CLARKE PR, 1990, EMBO J, V9, P2439, DOI 10.1002/j.1460-2075.1990.tb07420.x; COTE GP, 1987, J BIOL CHEM, V262, P1065; DAILE P, 1974, BIOCHEM BIOPH RES CO, V61, P852, DOI 10.1016/0006-291X(74)90234-4; DOMBRADI V, 1988, COMP BIOCHEM PHYS B, V91, P717, DOI 10.1016/0305-0491(88)90198-8; FERRARI S, 1987, EUR J BIOCHEM, V163, P481, DOI 10.1111/j.1432-1033.1987.tb10894.x; FIOL CJ, 1990, J BIOL CHEM, V265, P6061; FLOTOW H, 1991, J BIOL CHEM, V266, P3724; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; GRAVES DJ, 1983, METHOD ENZYMOL, V99, P268; GRAVES DJ, 1960, J BIOL CHEM, V235, P805; HEMMINGS HC, 1990, J BIOL CHEM, V265, P20369; HOUSE C, 1987, J BIOL CHEM, V262, P772; HUMBLE E, 1975, BIOCHEM BIOPH RES CO, V66, P614, DOI 10.1016/0006-291X(75)90554-9; IKEBE M, 1990, J BIOL CHEM, V265, P17607; KEMP BE, 1975, P NATL ACAD SCI USA, V72, P3448, DOI 10.1073/pnas.72.9.3448; KEMP BE, 1985, J BIOL CHEM, V260, P3355; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KEMP BE, 1977, J BIOL CHEM, V252, P4888; Kemp BE, 1990, PEPTIDES PROTEIN PHO; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; LITCHFIELD DW, 1990, FEBS LETT, V261, P117, DOI 10.1016/0014-5793(90)80650-8; MARAIS RM, 1990, FEBS LETT, V277, P151, DOI 10.1016/0014-5793(90)80831-3; MARIN O, 1986, EUR J BIOCHEM, V160, P239, DOI 10.1111/j.1432-1033.1986.tb09962.x; MICHNOFF CH, 1986, J BIOL CHEM, V261, P8320; MILDVAN AS, 1983, METHOD ENZYMOL, V99, P93; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MULLINAX TR, 1985, ARCH BIOCHEM BIOPHYS, V243, P655, DOI 10.1016/0003-9861(85)90543-0; NOLAN C, 1964, BIOCHEMISTRY-US, V3, P542, DOI 10.1021/bi00892a013; PAYNE ME, 1983, J BIOL CHEM, V258, P2376; PEARSON RB, 1985, J BIOL CHEM, V260, P4471; Pinna L A, 1988, Adv Exp Med Biol, V231, P433; REED J, 1985, BIOCHEMISTRY-US, V24, P2967, DOI 10.1021/bi00333a024; SMALL D, 1977, BIOCHEM BIOPH RES CO, V79, P341, DOI 10.1016/0006-291X(77)90101-2; STRALFORS P, 1985, EUR J BIOCHEM, V149, P295, DOI 10.1111/j.1432-1033.1985.tb08926.x; STULL JT, 1986, ENZYMES, V17, P113; THOMAS MK, 1990, J BIOL CHEM, V265, P14971; THOMAS NE, 1987, BIOCHEMISTRY-US, V26, P4471, DOI 10.1021/bi00388a043; TUAZON PT, 1979, EUR J BIOCHEM, V94, P497, DOI 10.1111/j.1432-1033.1979.tb12918.x; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; ZETTERQVIST O, 1976, BIOCHEM BIOPH RES CO, V70, P696, DOI 10.1016/0006-291X(76)90648-3	46	1182	1213	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					15555	15558						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1651913				2022-12-25	WOS:A1991GB97700001
J	MCGILL, DL				MCGILL, DL			CHARACTERIZATION OF THE ADIPOCYTE GHOST (NA+,K+) PUMP - INSIGHTS INTO THE INSULIN REGULATION OF THE ADIPOCYTE (NA+,K+) PUMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORT ACTIVITY; 2 MOLECULAR-FORMS; RAT ADIPOSE CELL; PLASMA-MEMBRANES; (NA+,K+)-ADENOSINE TRIPHOSPHATASE; SKELETAL-MUSCLE; STIMULATION; (NA+,K+)-ATPASE; TRANSLOCATION; SYSTEMS	The (Na+,K+) ATPase in plasma membranes isolated from rat adipocytes is insensitive to insulin (Lytton J., Lin, J. C., and Guidotti, G. (1985) J. Biol. Chem. 260, 1177-1184). For this reason, the characteristics of the (Na+,K+) pump in adipocyte ghosts, prepared by hypotonic lysis of adipocytes (Rodbell, M. (1967) J. Biol. Chem. 242, 5744-5750), were studied. Herein it is demonstrated that the (Na+,K+) pump in ghosts is identical to that described in isolated plasma membranes, sharing the following characteristics: 1) the K(i) values for ouabain are 1.3 X 10(-7) M and 4.5 X 10(-5) M for the alpha-2 and alpha-1 isozymes, respectively; 2) the K0.5 values for sodium are 11.4 +/- 1.6 and 7.2 +/- 3.8 mM for the alpha-2 and alpha-1 isozymes, respectively; 3) both forms of the (Na+,K+) pump are insensitive to insulin stimulation, presumably because the activities are already maximal. The ghosts are not in an insulin-stimulated state because the activity of the glucose transporter is not increased as it is in ghosts prepared from insulin-treated cells. In addition, presented evidence demonstrates that ghost internal sodium concentration, [Na+]i, is very sensitive to changes in the activity of the (Na+,K+) pump. If the [Na+]i of adipocytes is also very sensitive to the activity of the (Na+,K+) pump, the mechanism of insulin stimulation of the adipocyte (Na+,K+) pump requires reexamination.	HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138	Harvard University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027626] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK27626] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; Aronson N N Jr, 1974, Methods Enzymol, V31, P90; AVRUCH J, 1972, BIOCHIM BIOPHYS ACTA, V288, P27, DOI 10.1016/0005-2736(72)90220-9; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; CANTLEY L, 1986, TRENDS NEUROSCI, V9, P1, DOI 10.1016/0166-2236(86)90002-0; CANTLEY LC, 1981, CURR TOP BIOENERG, V11, P21; CLAUSEN T, 1977, J PHYSIOL-LONDON, V265, P19, DOI 10.1113/jphysiol.1977.sp011703; CLAUSEN T, 1977, J PHYSIOL-LONDON, V270, P415, DOI 10.1113/jphysiol.1977.sp011959; CLAUSEN T, 1969, J BIOL CHEM, V244, P1252; CLAUSEN T, 1970, BIOCHIM BIOPHYS ACTA, V211, P233, DOI 10.1016/0005-2736(70)90096-9; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; FEHLMANN M, 1981, J BIOL CHEM, V256, P7449; FORGAC M, 1985, TOPICS MOL STRUCTURA, V2, P123; GAVRYCK WA, 1975, J PHYSIOL-LONDON, V252, P43, DOI 10.1113/jphysiol.1975.sp011133; HSU YM, 1989, BIOCHEMISTRY-US, V28, P569, DOI 10.1021/bi00428a023; ILLIANO G, 1971, J BIOL CHEM, V246, P2472; JOOST HG, 1988, BIOCHEM J, V249, P155, DOI 10.1042/bj2490155; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; KARNIELI E, 1981, J BIOL CHEM, V256, P4772; KONO T, 1983, RECENT PROG HORM RES, V39, P519; LUDVIGSEN C, 1980, DIABETES, V29, P373, DOI 10.2337/diabetes.29.5.373; LYTTON J, 1985, J BIOL CHEM, V260, P1177; LYTTON J, 1985, J BIOL CHEM, V260, P75; MATTHAEI S, 1988, BIOCHEM J, V251, P491, DOI 10.1042/bj2510491; MCGILL DL, 1991, J BIOL CHEM, V266, P15824; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PILLION DJ, 1978, J SUPRAMOL STR CELL, V8, P269, DOI 10.1002/jss.400080306; RESH MD, 1980, J BIOL CHEM, V255, P938; RESH MD, 1982, J BIOL CHEM, V257, P1946; RODBELL M, 1967, J BIOL CHEM, V242, P5744; RODBELL M, 1967, J BIOL CHEM, V242, P5751; ROSIC NK, 1985, J BIOL CHEM, V260, P6206; ROSSIER BC, 1987, TRENDS BIOCHEM SCI, V12, P483, DOI 10.1016/0968-0004(87)90235-0; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; SIMPSON IA, 1986, ANNU REV BIOCHEM, V55, P1059, DOI 10.1146/annurev.biochem.55.1.1059; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; SWEADNER KJ, 1979, J BIOL CHEM, V254, P6060; WANG C, 1985, P NATL ACAD SCI USA, V82, P3621, DOI 10.1073/pnas.82.11.3621; WHITESELL RR, 1986, J BIOL CHEM, V261, P5090	39	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					15817	15823						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1651921				2022-12-25	WOS:A1991GB97700046
J	NORTHWOOD, IC; GONZALEZ, FA; WARTMANN, M; RADEN, DL; DAVIS, RJ				NORTHWOOD, IC; GONZALEZ, FA; WARTMANN, M; RADEN, DL; DAVIS, RJ			ISOLATION AND CHARACTERIZATION OF 2 GROWTH FACTOR-STIMULATED PROTEIN-KINASES THAT PHOSPHORYLATE THE EPIDERMAL GROWTH-FACTOR RECEPTOR AT THREONINE 669	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEIN-2; GLYCOGEN-SYNTHASE KINASE-3; MYELIN BASIC-PROTEIN; LIGAND-INDUCED INTERNALIZATION; ACTIVATED S6 KINASE; MULTISITE PHOSPHORYLATION; SUBSTRATE-SPECIFICITY; DIRECTED MUTAGENESIS; SWISS 3T3-CELLS; MAP KINASE	A growth factor-stimulated protein kinase activity that phosphorylates the epidermal growth factor (EGF) receptor at Thr669 has been described (Countaway, J. L., Northwood, I. C., and Davis, R. J. (1989) J. Biol. Chem. 264, 10828-10835). Anion-exchange chromatography demonstrated that this protein kinase activity was accounted for by two enzymes. The first peak of activity eluted from the column corresponded to the microtubule- associated protein 2 (MAP2) kinase. However, the second peak of activity was found to be a distinct enzyme. We present here the purification of this enzyme from human tumor KB cells by sequential ion-exchange chromatography. The isolated protein kinase was identified as a 46-kDa protein by polyacrylamide gel electrophoresis and silver staining. Gel filtration chromatography demonstrated that the enzyme was functional in a monomeric state. A kinetic analysis of the purified enzyme was performed at 22-degrees-C using a synthetic peptide substrate based on the primary sequence of the EGF receptor (KREL VEPLT669PSGEAPNQALLR). The K(m(app)) for ATP was 40 +/- 5-mu-M (mean +/- S.D., n = 3). GTP was not found to be a substrate for the purified enzyme. The K(m(app)) for the synthetic peptide substrate was 260 +/- 40-mu-M (mean +/- S.D., n = 3). The V(max(app)) for the isolated protein kinase was determined to be 400-900 nmol/mg/min. The purified enzyme was designated EGF receptor Thr669 (ERT) kinase. It is likely that the MAP2 and ERT kinases account for the phosphorylation of the EGF receptor at Thr669 observed in cultured cells. The marked stimulation of protein kinase activity caused by growth factors indicates that these enzymes may have an important function during signal transduction.	UNIV MASSACHUSETTS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01605	University of Massachusetts System; University of Massachusetts Worcester	NORTHWOOD, IC (corresponding author), UNIV MASSACHUSETTS,SCH MED,HOWARD HUGHES MED INST,PROGRAM MOLEC MED,WORCESTER,MA 01605, USA.				NATIONAL CANCER INSTITUTE [P01CA039240] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037845] Funding Source: NIH RePORTER; NCI NIH HHS [CA39240] Funding Source: Medline; NIGMS NIH HHS [GM37845] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN NG, 1991, J BIOL CHEM, V266, P4220; AHN NG, 1990, J BIOL CHEM, V265, P11487; AHN NG, 1990, J BIOL CHEM, V265, P11495; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOWEN S, 1991, J BIOL CHEM, V266, P1162; CASANELLIE JE, 1982, P NATL ACAD SCI USA, V79, P282; COCHET C, 1984, J BIOL CHEM, V259, P2553; COUNTAWAY JL, 1989, J BIOL CHEM, V264, P10828; COUNTAWAY JL, 1990, J BIOL CHEM, V265, P3407; DAVIS RJ, 1985, P NATL ACAD SCI USA, V82, P1974, DOI 10.1073/pnas.82.7.1974; DAVIS RJ, 1987, J BIOL CHEM, V262, P16041; DAVIS RJ, 1988, J BIOL CHEM, V263, P9462; DAVIS RJ, 1986, J BIOL CHEM, V261, P9034; DECKER SJ, 1990, J BIOL CHEM, V265, P7009; DUGGLEBY RG, 1981, ANAL BIOCHEM, V110, P9, DOI 10.1016/0003-2697(81)90104-4; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; FIOL CJ, 1987, J BIOL CHEM, V262, P14042; FRIEDMAN BA, 1984, P NATL ACAD SCI-BIOL, V81, P3034, DOI 10.1073/pnas.81.10.3034; GLASS DB, 1982, J BIOL CHEM, V257, P1196; GOMEZ N, 1990, FEBS LETT, V271, P119, DOI 10.1016/0014-5793(90)80386-W; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; HEISERMANN GJ, 1988, J BIOL CHEM, V263, P13152; HEISERMANN GJ, 1990, J BIOL CHEM, V265, P12820; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; JENO P, 1988, P NATL ACAD SCI USA, V85, P406, DOI 10.1073/pnas.85.2.406; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KEMP BE, 1985, J BIOL CHEM, V260, P3355; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KUENZEL EA, 1985, P NATL ACAD SCI USA, V82, P737, DOI 10.1073/pnas.82.3.737; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDRETH GE, 1990, J NEUROCHEM, V55, P514, DOI 10.1111/j.1471-4159.1990.tb04165.x; LUND KA, 1990, J BIOL CHEM, V265, P20517; MIYASAKA T, 1990, J BIOL CHEM, V265, P4730; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; NORTHWOOD IC, 1990, P NATL ACAD SCI USA, V87, P6107, DOI 10.1073/pnas.87.16.6107; PEARSON RB, 1971, J BIOL CHEM, V260, P144; PELECH SL, 1987, J BIOL CHEM, V262, P11598; PICTON C, 1982, EUR J BIOCHEM, V124, P37, DOI 10.1111/j.1432-1033.1982.tb05903.x; PIERCE MW, 1981, J BIOL CHEM, V256, P8867; RAY LB, 1988, J BIOL CHEM, V263, P12721; SANGHERA JS, 1990, J BIOL CHEM, V265, P52; SCHLESSINGER J, 1988, BIOCHEMISTRY-US, V27, P3119, DOI 10.1021/bi00409a002; VULLIET PR, 1989, J BIOL CHEM, V264, P16292; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; WOODGETT JR, 1984, BIOCHIM BIOPHYS ACTA, V788, P339, DOI 10.1016/0167-4838(84)90047-5; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479; [No title captured]	53	199	208	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15266	15276						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1651322				2022-12-25	WOS:A1991GB09700068
J	RAO, GN; DEROUX, N; SARDET, C; POUYSSEGUR, J; BERK, BC				RAO, GN; DEROUX, N; SARDET, C; POUYSSEGUR, J; BERK, BC			NA+/H+ ANTIPORTER GENE-EXPRESSION DURING MONOCYTIC DIFFERENTIATION OF HL-60 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							INTRACELLULAR PH; HL-60 CELLS; MESSENGER-RNA; EXCHANGE; GROWTH; ACID; INVOLVEMENT	During differentiation of human promyelocytic HL60 cells into monocytes there are sustained increases in intracellular pH and Na+/H+ antiporter activity. Here we show that increased transcription and expression of the gene for the Na+/H+ antiporter precedes phorbol 12-myristate 13-acetate (PMA)-induced HL60 cell differentiation. PMA increased steady-state Na+/H+ antiporter mRNA levels approximately 50-fold within 8 h (at which time < 15% of cells had differentiated). This increase was due to an increased transcriptional rate as determined by nuclear run on. Immunoprecipitation of [S-35]methionine-labeled Na+/H+ antiporter using an antiporter fusion protein antibody (RP1-c28) showed an equivalent increase in Na+/H+ antiporter protein synthesis. The synthetic diacylglycerol, 1-oleolyl-2-acetylglycerol, an activator of protein kinase C, which unlike PMA did not cause differentiation, failed to induce Na+/H+ antiporter mRNA. Furthermore, inhibition of PMA-induced differentiation by either sphingosine or cycloheximide prevented accumulation of Na+/H+ antiporter mRNA. Together, these findings strongly suggest a close association of Na+/H+ antiporter induction with HL60 cell differentiation. The HL60 cell system is a promising model to study the mechanisms of Na+/H+ antiporter gene regulation and its function in differentiation.	UNIV NICE,CTR BIOCHIM,CNRS,F-06034 NICE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	RAO, GN (corresponding author), EMORY UNIV,SCH MED,DIV CARDIOL,PO DRAWER LL,ATLANTA,GA 30322, USA.			Berk, Bradford/0000-0002-2767-4115				AGARWAL N, 1986, AM J PHYSIOL, V251, pC825, DOI 10.1152/ajpcell.1986.251.5.C825; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BERK BC, 1990, J BIOL CHEM, V265, P19632; BESTERMAN JM, 1985, J BIOL CHEM, V260, P1155; BORON WF, 1983, J GEN PHYSIOL, V81, P29, DOI 10.1085/jgp.81.1.29; CASSEL D, 1985, J CELL PHYSIOL, V122, P178, DOI 10.1002/jcp.1041220203; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COSTACASNELLIE MR, 1988, J BIOL CHEM, V263, P11851; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FRANCHI A, 1986, J BIOL CHEM, V261, P4614; GANZ MB, 1988, AM J PHYSIOL, V254, pF787, DOI 10.1152/ajprenal.1988.254.6.F787; GRINSTEIN S, 1986, AM J PHYSIOL, V251, pC55, DOI 10.1152/ajpcell.1986.251.1.C55; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; GRINSTEIN S, 1988, AM J PHYSIOL, V251, pC272; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HAZAV P, 1989, CANCER RES, V49, P72; KREUTTER D, 1985, J BIOL CHEM, V260, P5979; LADOUX A, 1987, J BIOL CHEM, V262, P811; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; MAHNENSMITH RL, 1985, CIRC RES, V56, P773, DOI 10.1161/01.RES.56.6.773; MERRILL AH, 1986, J BIOL CHEM, V261, P2610; MITCHELL RL, 1986, CELL, V45, P497, DOI 10.1016/0092-8674(86)90281-3; MULLMANN TJ, 1991, J BIOL CHEM, V266, P2013; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; RAO GN, 1990, J BIOL CHEM, V265, P19393; SARDET C, 1990, SCIENCE, V247, P723, DOI 10.1126/science.2154036; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VAIRO G, 1990, J BIOL CHEM, V265, P16929	31	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13485	13488						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1649822				2022-12-25	WOS:A1991FY02700005
J	CLAIRMONT, KB; CZECH, MP				CLAIRMONT, KB; CZECH, MP			EXTRACELLULAR RELEASE AS THE MAJOR DEGRADATIVE PATHWAY OF THE INSULIN-LIKE GROWTH FACTOR-II MANNOSE 6-PHOSPHATE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TRANS-CELLULAR TRANSPORT; IMMUNOELECTRON MICROSCOPY; TRANSFERRIN RECEPTORS; MEDIATED ENDOCYTOSIS; BINDING-PROTEINS; POLYMERIC IGA; BIOSYNTHESIS; SERUM; CELLS; PURIFICATION	The presence of a soluble, truncated form of the IGF-II/Man-6-P receptor in serum has suggested that cleavage from the cell surface may be an initial step in the degradation of this protein (MacDonald, R. G., Tepper, M. A., Clairmont, K. B., Perregaux, S. B., and Czech, M. P. (1989) J. Biol. Chem. 264,3256-3261). In order to test this hypothesis, we pulse-labeled cultured BRL-3A rat liver cells with [S-35]methionine and [S-35]cysteine and measured the fate of labeled receptor at various times after incubation with unlabeled amino acids. It was found that the appearance of labeled IGF-II/Man-6-P receptor in the medium accounts quantitatively for the loss of labeled receptor from the BRL-3A cells. In similar experiments with Chinese hamster ovary cells, L6 rat myoblasts, and chick embryo fibroblasts, labeled receptor from the cell membranes decreases with a time course corresponding to the appearance of soluble receptor in the medium. The release of labeled receptor into the medium can be blocked by the addition of the protease inhibitors aprotinin, chymostatin, or phenylmethylsulfonyl fluoride, but not antipain, leupeptin, and benzamidine. The results are consistent with the hypothesis that the degradation and loss of cellular IGF-II/Man-6-P receptors occurs by a nonlysosomal mechanism involving their proteolysis and removal into the extracellular fluid.	UNIV MASSACHUSETTS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,373 PLANKTAT ST,WORCESTER,MA 01605; UNIV MASSACHUSETTS,SCH MED,MOLEC MED PROGRAM,WORCESTER,MA 01605	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester			Clairmont, Kevin/ABG-6161-2021	Clairmont, Kevin/0000-0003-4198-2437	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030648] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK30648] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BROWN WJ, 1986, J CELL BIOL, V103, P1235, DOI 10.1083/jcb.103.4.1235; CAUSIN C, 1988, BIOCHEM J, V252, P795, DOI 10.1042/bj2520795; CREEK KE, 1983, BIOCHEM J, V214, P353, DOI 10.1042/bj2140353; FLOWERS CH, 1989, J LAB CLIN MED, V114, P368; GEUZE HJ, 1983, CELL, V32, P277, DOI 10.1016/0092-8674(83)90518-4; GEUZE HJ, 1988, J CELL BIOL, V107, P2491, DOI 10.1083/jcb.107.6.2491; GEUZE HJ, 1984, CELL, V37, P195, DOI 10.1016/0092-8674(84)90315-5; GOLDBERG DE, 1983, J CELL BIOL, V97, P1700, DOI 10.1083/jcb.97.6.1700; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GOWER HJ, 1988, CELL, V55, P955, DOI 10.1016/0092-8674(88)90241-3; GRANT KI, 1989, J BIOL CHEM, V265, P4041; GUSSOW D, 1987, IMMUNOL TODAY, V8, P220, DOI 10.1016/0167-5699(87)90170-8; HERINGTON AC, 1986, J CLIN INVEST, V77, P1817, DOI 10.1172/JCI112507; HOPKINS CR, 1983, CELL, V35, P321, DOI 10.1016/0092-8674(83)90235-0; HOPPE CA, 1985, J CELL BIOL, V101, P2113, DOI 10.1083/jcb.101.6.2113; KIESS W, 1987, P NATL ACAD SCI USA, V84, P7720, DOI 10.1073/pnas.84.21.7720; KLAUSNER RD, 1983, P NATL ACAD SCI-BIOL, V80, P2263, DOI 10.1073/pnas.80.8.2263; KONGO Y, 1986, BRIT J HAEMATOL, V64, P277; KYLE JW, 1988, J BIOL CHEM, V263, P16230; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; MACDONALD RG, 1989, J BIOL CHEM, V264, P3256; MACDONALD RG, 1985, J BIOL CHEM, V260, P1357; MOSTOV KE, 1982, J BIOL CHEM, V257, P1816; OPPENHEIMER CL, 1983, J BIOL CHEM, V258, P8539; SAHAGIAN GG, 1983, J BIOL CHEM, V258, P7121; SAHAGIAN GG, 1984, BIOL CELL, V51, P207, DOI 10.1111/j.1768-322X.1984.tb00300.x; SOLARI R, 1984, CELL, V36, P61, DOI 10.1016/0092-8674(84)90074-6; STEIN M, 1987, BIOL CHEM H-S, V368, P937, DOI 10.1515/bchm3.1987.368.2.937; SZTUL ES, 1985, J CELL BIOL, V100, P1255, DOI 10.1083/jcb.100.4.1255; TROWBRIDGE IS, 1989, J LAB CLIN MED, V114, P336	31	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1991	266	19					12131	12134						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FV180	1648081				2022-12-25	WOS:A1991FV18000005
J	LIU, F; FROMM, HJ				LIU, F; FROMM, HJ			P-31 NUCLEAR-MAGNETIC-RESONANCE SPECTROSCOPY STUDIES OF SUBSTRATE AND PRODUCT BINDING TO FRUCTOSE-1,6-BISPHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT LIVER FRUCTOSE-1,6-BISPHOSPHATASE; FRUCTOSE 2,6-BISPHOSPHATE; 1,6-BISPHOSPHATASE; MECHANISM; AMP	The enzymatic hydrolysis of fructose 1,6-bisphosphate (Fru-1,6-P2) to fructose 6-phosphate (Fru-6-P) and inorganic phosphate (P(i)), which is catalyzed by fructose-1,6-bisphosphatase, has been studied by P-31 nuclear magnetic resonance spectroscopy (NMR). At pH 7.5 and 15-degrees-C, the equilibrium constant for the central complex K'(eq) = [E.Fru-6-P.P(i)]/[E.Fru-1,6-P2. H2O] is about 2. This observation is in harmony with results obtained with a number of Bi Bi enzyme systems for the determination of K'(eq) in which a variety of experimental techniques were used (Knowles, J. R. (1980) Annu. Rev. Biochem. 49, 877-919). Significant changes in P-31 NMR chemical shifts were observed for both the substrate, Fru-1,6-P2, and the product, Fru-6-P, when bound to the enzyme relative to ligand free in solution. The chemical shifts of the substrate and product were altered further in the presence of Mg2+, the catalytic divalent metal ion. The chemical shifts caused by the addition of metal ion can be reversed in the presence of trans-1,2-diaminocyclohexane-N,N,N',N'-tetraacetic acid (CDTA) or AMP. In the presence of the metal ion chelator or the nucleotide, the substrate had a chemical shift that was about the same as that observed in the absence of metal ion. On the basis of these observations we suggest that AMP and CDTA exhibit similar effects, i.e. they both remove the catalytic metal ion from the enzyme. This finding is supportive of the suggestion (Scheffler, J. E., and Fromm, H. J. (1986) Biochemistry 25, 6659-6665; Liu, F., and Fromm, H. J. (1990) J. Biol. Chem. 265, 7401-7406) that the role of AMP in the regulation of fructose- 1,6-bisphosphatase is to prevent binding of the divalent metal activator to the enzyme.			LIU, F (corresponding author), IOWA STATE UNIV SCI & TECHNOL,DEPT BIOCHEM & BIOPHYS,AMES,IA 50011, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS010546, R56NS010546] Funding Source: NIH RePORTER; NINDS NIH HHS [NS10546] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BENKOVIC SJ, 1982, ADV ENZYMOL RAMB, V53, P45; CASAZZA JP, 1978, J BIOL CHEM, V254, P4661; CUNNINGHAM AA, 1981, BIOCHEMISTRY-US, V20, P359; GANSON NJ, 1985, J BIOL CHEM, V260, P2837; GRAY GR, 1971, BIOCHEMISTRY-US, V10, P4705, DOI 10.1021/bi00801a017; KE HM, 1990, P NATL ACAD SCI USA, V87, P5243, DOI 10.1073/pnas.87.14.5243; KE HM, 1989, P NATL ACAD SCI USA, V86, P1475, DOI 10.1073/pnas.86.5.1475; KEMP GR, 1990, FRUCTOSE 2 6 BISPHOS, P17; KNOWLES JR, 1980, ANNU REV BIOCHEM, V49, P877, DOI 10.1146/annurev.bi.49.070180.004305; LANG G, 1974, METHOD ENZYMAT AN, V3, P1314; LIU F, 1988, J BIOL CHEM, V263, P9122; LIU F, 1990, J BIOL CHEM, V265, P7401; LIU F, 1990, FRUCTOSE 2 6 BISPHOS, P39; MCGRANE MM, 1983, J BIOL CHEM, V258, P445; NIMMO HG, 1975, BIOCHEM J, V145, P323, DOI 10.1042/bj1450323; OPIE LH, 1967, BIOCHEM J, V104, P353, DOI 10.1042/bj1040353; PONTREMOLI S, 1968, BIOCHEMISTRY-US, V7, P3628, DOI 10.1021/bi00850a041; PONTREMOLI S, 1966, METHOD ENZYMOL, V9, P635; RAO BDN, 1979, J BIOL CHEM, V254, P2689; SCHEFFLER JE, 1986, BIOCHEMISTRY-US, V25, P6659, DOI 10.1021/bi00369a050; STONE SR, 1980, J BIOL CHEM, V255, P3454; TEJWANI GA, 1983, ADV ENZYMOL RAMB, V54, P121; Ulm E H, 1975, Methods Enzymol, V42, P369; VANSCHAFTINGEN E, 1987, ADV ENZYMOL RAMB, V59, P315; WATANABE A, 1968, BIOCHEM BIOPH RES CO, V30, P697, DOI 10.1016/0006-291X(68)90569-X	25	4	4	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1991	266	18					11774	11778						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FT762	1646815				2022-12-25	WOS:A1991FT76200056
J	MOYLE, WR; BERNARD, MP; MYERS, RV; MARKO, OM; STRADER, CD				MOYLE, WR; BERNARD, MP; MYERS, RV; MARKO, OM; STRADER, CD			LEUTROPIN BETA-ADRENERGIC-RECEPTOR CHIMERAS BIND CHORIOGONADOTROPIN AND ADRENERGIC LIGANDS BUT ARE NOT EXPRESSED AT THE CELL-SURFACE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUTEINIZING-HORMONE RECEPTOR; HUMAN CHORIONIC-GONADOTROPIN; MONOCLONAL-ANTIBODIES; CLONING; CDNA; HCG; DOMAIN; GENE; CARBOHYDRATE; MECHANISM	In some G-protein-coupled receptors (e.g. beta-adrenergic receptor (beta-2-AR)), the ligand-binding pocket is contained within the hydrophobic transmembrane domain. In others (e.g. luteinizing hormone receptor (LHR)), the relative roles of the extracellular N-terminal domain and the transmembrane region in hormone binding are unknown. To study the roles of these domains, we prepared vectors encoding the rat LHR N-terminal domain alone (L--), the LHR N-terminal domain fused to the transmembrane and C-terminal domains of the vesicular stomatitis virus-G protein (LVV), the LHR N-terminal domain fused to the transmembrane and C-terminal domains of the hamster beta-2-AR (LAA), and the beta-2-AR N-terminal domain fused to the transmembrane and C-terminal domains of the rat LHR (ALL). Membrane preparations obtained from COS-7 cells expressing the beta-2-AR or LAA bound the beta-adrenergic antagonist I-125-cyanopindolol with equal affinity, confirming the observation that the beta-2-AR transmembrane domain forms the hormone-binding site. Membranes from COS-7 cells transfected with LHR bound I-125 human choriomic gonadotropin (hCG). However, membranes from LAA-, L---, and LVV-transfected cells had low capacity to bind I-125-hCG unless they were solubilized with Triton X-100. The affinity of the detergent-solubilized receptors for I-125-hCG was similar to that of the LHR. We were unable to detect binding of I-125-hCG to ALL in the presence or absence of detergent. These observations suggest that, whereas the transmembrane region of the beta-2-AR is sufficient to bind adrenergic ligands, the N-terminal region of the LHR is required for binding of hCG. Although the N terminus of the LHR is sufficient to bind hCG, both the N terminus and the transmembrane domains of the LHR are required for receptor expression on the cell surface.	MERCK SHARP & DOHME LTD,DEPT MOLEC PHARMACOL & BIOCHEM,RAHWAY,NJ 07065	Merck & Company	MOYLE, WR (corresponding author), RUTGERS STATE UNIV,ROBERT WOOD JOHNSON MED SCH,DEPT OBSTET & GYNECOL,PISCATAWAY,NJ 08854, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD014907, R01HD014907] Funding Source: NIH RePORTER; NICHD NIH HHS [HD14907] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ASCOLI M, 1983, ENDOCRINOLOGY, V113, P2129, DOI 10.1210/endo-113-6-2129; ASCOLI M, 1989, ENDOCR REV, V10, P27, DOI 10.1210/edrv-10-1-27; BERNARD MP, 1990, MOL CELL ENDOCRINOL, V71, pR19, DOI 10.1016/0303-7207(90)90034-6; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; CAMPBELL RK, 1991, P NATL ACAD SCI USA, V88, P760, DOI 10.1073/pnas.88.3.760; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; CRUZ RI, 1987, J CLIN ENDOCR METAB, V64, P433, DOI 10.1210/jcem-64-3-433; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; FINDLAY JBC, 1986, BIOCHEM J, V238, P625, DOI 10.1042/bj2380625; FRAZIER AL, 1990, MOL ENDOCRINOL, V4, P1264, DOI 10.1210/mend-4-8-1264; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; KEUTMANN HT, 1987, P NATL ACAD SCI USA, V84, P2038, DOI 10.1073/pnas.84.7.2038; KORNELUK RG, 1985, GENE, V40, P317, DOI 10.1016/0378-1119(85)90055-1; LOOSFELT H, 1989, SCIENCE, V245, P525, DOI 10.1126/science.2502844; MASU Y, 1987, NATURE, V329, P836, DOI 10.1038/329836a0; MATZUK MM, 1989, BIOL REPROD, V40, P48, DOI 10.1095/biolreprod40.1.48; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MOYLE WR, 1990, J BIOL CHEM, V265, P8511; MOYLE WR, 1975, J BIOL CHEM, V250, P9163; MOYLE WR, 1988, ICSU SHORT REP, V8, P116; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PARMENTIER M, 1989, SCIENCE, V246, P1620, DOI 10.1126/science.2556796; RAJANIEMI HJ, 1989, BIOL REPROD, V40, P1, DOI 10.1095/biolreprod40.1.1; ROCHE PC, 1989, J BIOL CHEM, V264, P4636; ROCHE PC, 1985, ENDOCRINOLOGY, V117, P790, DOI 10.1210/endo-117-2-790; RYAN RJ, 1987, RECENT PROG HORM RES, V43, P383; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SPRENGEL R, 1990, MOL ENDOCRINOL, V4, P525, DOI 10.1210/mend-4-4-525; STRADER CD, 1987, CELL, V49, P855, DOI 10.1016/0092-8674(87)90623-4; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; THOTAKURA NR, 1990, MOL CELL ENDOCRINOL, V70, P263; TSAIMORRIS CH, 1990, J BIOL CHEM, V265, P19385; VUHAILUUTHI MT, 1990, ENDOCRINOLOGY, V127, P2090, DOI 10.1210/endo-127-5-2090; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; XIE YB, 1990, J BIOL CHEM, V265, P21411	35	59	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					10807	10812						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	1645710				2022-12-25	WOS:A1991FQ77400019
J	TAOUIS, M; SHELDON, RS; HILL, RJ; DUFF, HJ				TAOUIS, M; SHELDON, RS; HILL, RJ; DUFF, HJ			CYCLIC AMP-DEPENDENT REGULATION OF THE NUMBER OF [H-3] BATRACHOTOXININ BENZOATE BINDING-SITES ON RAT CARDIAC MYOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE-CYCLASE; SODIUM-CHANNELS; PROTEIN-KINASE; LOCAL-ANESTHETICS; INHIBITION; RECEPTOR; BATRACHOTOXININ; ISOPROTERENOL; ACTIVATION; 20-ALPHA-BENZOATE	We sought to assess the effect of an increase in cAMP on sodium channels on adult rat cardiac ventricular myocytes. Sodium channels were studied with the use of the radiolabeled sodium channel-specific toxin [H-3] batrachotoxinin benzoate ([H-3]BTXB). Forskolin, isoproterenol, prostaglandin E1, cholera toxin, and pertussis toxin each increased cAMP levels and decreased the number of [H-3]BTXB binding sites without changing the affinity of [H-3]BTXB for the sodium channel. The cAMP analog 8-bromo-cyclic AMP (8-Br-cAMP) reduced the number of [H-3]BTXB binding sites from 19 fmol/10(5) cells to 11 fmol/10(5) cells. [H-3]BTXB binding site down-regulation was reversible, cAMP dose-dependent, and time-dependent. To test the hypothesis that the cAMP effect was mediated by cAMP-dependent phosphorylation, we determined the effect of 8-Br-cAMP on [H-3]BTXB binding after preincubation of myocytes with N-(2-(methylamino)ethyl)-5-isoquinolinesulfonamide dihydrochloride (H8), a protein kinase A inhibitor. H8 inhibited 70% of the decrease in the number of [H-3]BTXB binding sites induced by 8-Br-cAMP. Thus increases in intracellular cAMP in cardiac myocytes reversibly induced a decrease in the number of [H-3]BTXB binding sites via cAMP-dependent protein phosphorylation, possibly of the sodium channel.	UNIV CALGARY,DEPT MED,CARDIOVASC RES GRP,3330 HOSP DR NW,CALGARY T2N 4N1,ALBERTA,CANADA	University of Calgary			Taouis, Mohammed/CAA-1797-2022	Taouis, Mohammed/0000-0002-4101-691X; Duff, Henry/0000-0001-9292-5411				CASSEL D, 1977, P NATL ACAD SCI USA, V74, P3307, DOI 10.1073/pnas.74.8.3307; CATTERALL WA, 1981, J BIOL CHEM, V256, P8922; COSTA MRC, 1982, J BIOL CHEM, V257, P7918; CREVELING CR, 1983, MOL PHARMACOL, V23, P350; DELEAN A, 1980, J BIOL CHEM, V255, P7108; FARMER BB, 1983, LIFE SCI, V33, P1, DOI 10.1016/0024-3205(83)90706-3; GILMAN AG, 1984, CELL, V36, P577, DOI 10.1016/0092-8674(84)90336-2; HAYES JS, 1980, J BIOL CHEM, V255, P5113; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HILL RJ, 1989, MOL PHARMACOL, V36, P150; KATADA T, 1986, J BIOL CHEM, V261, P5215; KRYSKI A, 1985, AM J PHYSIOL, V248, pH208, DOI 10.1152/ajpheart.1985.248.2.H208; MOSS J, 1979, ANNU REV BIOCHEM, V48, P581, DOI 10.1146/annurev.bi.48.070179.003053; ONO K, 1989, AM J PHYSIOL, V256, pC1131, DOI 10.1152/ajpcell.1989.256.6.C1131; PARSONS WJ, 1988, MOL PHARMACOL, V34, P37; PEDIGO NW, 1981, J NEUROCHEM, V36, P220, DOI 10.1111/j.1471-4159.1981.tb02397.x; POSTMA SW, 1984, MOL PHARMACOL, V25, P219; ROTHMAN RB, 1982, MOL PHARMACOL, V21, P538; ROTHMAN RB, 1982, MOL PHARMACOL, V21, P548; SCHUBERT B, 1989, SCIENCE, V245, P516, DOI 10.1126/science.2547248; SEAMON KB, 1981, P NATL ACAD SCI-BIOL, V78, P3363, DOI 10.1073/pnas.78.6.3363; SHELDON RS, 1986, MOL PHARMACOL, V30, P617; SHELDON RS, 1987, CIRC RES, V61, P492, DOI 10.1161/01.RES.61.4.492; SHERMAN SJ, 1985, J NEUROSCI, V5, P1570; SIBLEY DR, 1982, J BIOL CHEM, V257, P6351; YANG J, 1990, J NEUROCHEM, V54, P954, DOI 10.1111/j.1471-4159.1990.tb02343.x	26	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10300	10304						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	1645346				2022-12-25	WOS:A1991FP08600049
J	AVIVI, A; ZIMMER, Y; YAYON, A; YARDEN, Y; GIVOL, D				AVIVI, A; ZIMMER, Y; YAYON, A; YARDEN, Y; GIVOL, D			FLG-2, A NEW MEMBER OF THE FAMILY OF FIBROBLAST GROWTH-FACTOR RECEPTORS	ONCOGENE			English	Note							CLONING; GENE	Two genes, flg and bek, have been recently shown to encode receptors for fibroblast growth factors (FGF). Here we report the molecular cloning and sequence of a new member of the FGF receptor family, denoted flg-2, which was isolated from a human keratinocyte cDNA library. The cDNA sequence predicts an extracellular region possessing three immunoglobulin-like domains, a single transmembrane region and a cytoplasmic portion containing the tyrosine kinase domain split by a short inter-kinase segment. The amino acid sequence of flg-2 shows 68% and 64% identity with bek and flg, respectively. The most variable domain among the three genes is the amino-terminal immunoglobulin-like domain. Comparison with the chicken FGF receptor genes suggests that flg-2 is homologous to cek-2, whereas flg and bek are homologous to cek-1 and cek-3, respectively. Analysis of mRNA from various tissues shows that flg-2 is expressed predominantly in skin, brain and lung.	WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science	GIVOL, D (corresponding author), WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL.		YARDEN, YOSEF/K-1467-2012					BOTTARO DP, 1990, J BIOL CHEM, V265, P12767; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; PASQUALE EB, 1990, P NATL ACAD SCI USA, V87, P5812, DOI 10.1073/pnas.87.15.5812; RAZ V, 1991, IN PRESS ONCOGENE; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; RUTA M, 1989, ONCOGENE, V3, P9; SAFRAN A, 1990, ONCOGENE, V5, P635; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YAYON A, 1990, P NATL ACAD SCI USA, V87, P5346, DOI 10.1073/pnas.87.14.5346	19	61	61	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1991	6	6					1089	1092						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1648703				2022-12-25	WOS:A1991GU62200029
J	DEWALD, DB; MASON, HS; MULLET, JE				DEWALD, DB; MASON, HS; MULLET, JE			THE SOYBEAN VEGETATIVE STORAGE PROTEINS VSP-ALPHA AND VSP-BETA ARE ACID-PHOSPHATASES ACTIVE ON POLYPHOSPHATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEMATODE RESISTANT TOMATO; NIGRA SUSPENSION CELLS; PARAVEINAL MESOPHYLL; ASSIMILATE TRANSFER; JASMONIC ACID; POD REMOVAL; PHOSPHOENOLPYRUVATE PHOSPHATASE; TONOPLAST VESICLES; PURIFICATION; GENES	The soybean vegetative storage protein genes (vspA, and vspB) are regulated in a complex manner developmentally and in response to external stimuli such as wounding and water deficit. The proteins accumulate to almost one-half the amount of soluble leaf protein when soybean plants are continually depodded and have been identified as storage proteins because of their abundance and pattern of expression in plant tissues. We have shown that purified VSP homodimers (VSP-alpha and VSP-beta) and heterodimers (VSP-alpha/beta) possess acid phosphatase activity (alpha = 0.3-0.4 units/mg; beta = 2-4 units/mg; alpha/beta = 7-10 units/mg). Specific activities were determined by monitoring o-carboxyphenyl phosphate (0.7 mM) cleavage at pH 5.5 (VSP-alpha) or pH 5.0 (VSPa/beta and VSP-beta) in 0.15 M sodium acetate buffer at 25-degrees-C. These enzymes are active over a broad pH range, maintaining greater than 40% of maximal activity from pH 4.0 to 6.5 and having maximal activity at pH 5.0-5.5. They are inactivated by sodium fluoride, sodium molybdate, and heating at 70-degrees-C for 10 min. These phosphatases can liberate P(i) from several different substrates, including napthyl acid phosphate, carboxyphenyl phosphate, sugar-phosphates, glyceraldehyde 3-phosphate, dihydroxyacetone phosphate, phosphoenolpyruvate, ATP, ADP, PP(i), and short chain polyphosphates. VSP-alpha/beta cleaved phosphoenolpyruvate, ATP, ADP, PP(i), and polyphosphates most efficiently. Apparent K(m) and V(max) values at 25-degrees-C and pH 5.0 were 42-mu-M and 2.0-mu-mol/min/mg, 150-mu-M and 4.2-mu-mol/min/mg, and 420-mu-M and 4.1-mu-mol/min/mg, for tetrapolyphosphate, pyrophosphate, and phosphoenolpyruvate, respectively.	TEXAS A&M UNIV SYST,DEPT BIOCHEM & BIOPHYS,COLLEGE STN,TX 77843	Texas A&M University System; Texas A&M University College Station								AARTS JMMJG, 1991, PLANT MOL BIOL, V16, P647, DOI 10.1007/BF00023429; ANDERSON JM, 1991, J PLANT GROWTH REGUL, V10, P5, DOI 10.1007/BF02279304; ANDERSON JM, 1988, J PLANT GROWTH REGUL, V7, P203, DOI 10.1007/BF02025263; ANDREWS DL, 1988, BIOCHEM J, V252, P199, DOI 10.1042/bj2520199; BECK JL, 1986, BIOCHIM BIOPHYS ACTA, V869, P61, DOI 10.1016/0167-4838(86)90310-9; BLUMWALD E, 1987, PHYSIOL PLANTARUM, V69, P731, DOI 10.1111/j.1399-3054.1987.tb01993.x; BOZARTH CS, 1987, PLANT PHYSIOL, V85, P261, DOI 10.1104/pp.85.1.261; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHRISTELLER JT, 1978, J BIOL CHEM, V253, P1780; Cleland W W, 1979, Methods Enzymol, V63, P103; DUFF SMG, 1991, ARCH BIOCHEM BIOPHYS, V286, P226, DOI 10.1016/0003-9861(91)90033-F; DUFF SMG, 1989, PLANT PHYSIOL, V90, P734, DOI 10.1104/pp.90.2.734; DUFF SMG, 1989, PLANT PHYSIOL, V90, P1275, DOI 10.1104/pp.90.4.1275; ECHEVERRIA E, 1991, PLANT PHYSIOL, V96, P1014, DOI 10.1104/pp.96.4.1014; ERION JL, 1991, PLANT PHYSIOL, V97, P1462, DOI 10.1104/pp.97.4.1462; FRANCESCHI VR, 1991, P NATL ACAD SCI USA, V88, P6745, DOI 10.1073/pnas.88.15.6745; FRANCESCHI VR, 1983, PLANTA, V157, P411, DOI 10.1007/BF00397198; FRANCESCHI VR, 1983, PLANT PHYSIOL, V72, P586, DOI 10.1104/pp.72.2.586; FRANCESCHI VR, 1983, PLANTA, V157, P422, DOI 10.1007/BF00397199; FUJIMOTO S, 1977, AGR BIOL CHEM TOKYO, V41, P599, DOI 10.1080/00021369.1977.10862543; GAMBLE PE, 1989, J BIOL CHEM, V264, P7236; GIBSON DM, 1988, ARCH BIOCHEM BIOPHYS, V260, P503, DOI 10.1016/0003-9861(88)90475-4; KLEID DG, 1981, SCIENCE, V214, P1125, DOI 10.1126/science.6272395; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASON HS, 1988, PLANT MOL BIOL, V11, P845, DOI 10.1007/BF00019524; MASON HS, 1990, PLANT CELL, V2, P569, DOI 10.1105/tpc.2.6.569; MASON HS, 1992, PLANT PHYSIOL, V92, P859; PARK HSC, 1986, PHYTOCHEMISTRY, V25, P351, DOI 10.1016/S0031-9422(00)85479-5; PAUL EM, 1987, PLANT PHYSIOL, V84, P399, DOI 10.1104/pp.84.2.399; PICK U, 1991, PLANT PHYSIOL, V97, P1234, DOI 10.1104/pp.97.3.1234; RANDALL DD, 1971, J BIOL CHEM, V246, P5510; RAPP WD, 1990, THEOR APPL GENET, V79, P785, DOI 10.1007/BF00224246; SPILATRO SR, 1988, PLANT PHYSIOL, V88, P862, DOI 10.1104/pp.88.3.862; SPILATRO SR, 1989, PLANT PHYSIOL, V90, P1387, DOI 10.1104/pp.90.4.1387; STASWICK PE, 1989, PLANT PHYSIOL, V89, P309, DOI 10.1104/pp.89.1.309; STASWICK PE, 1989, PLANT PHYSIOL, V90, P1252, DOI 10.1104/pp.90.4.1252; STASWICK PE, 1991, PLANT PHYSIOL, V96, P130, DOI 10.1104/pp.96.1.130; STASWICK PE, 1990, PLANT CELL, V2, P1, DOI 10.1105/tpc.2.1.1; STASWICK PE, 1988, PLANT PHYSIOL, V87, P25; Steingraber M., 1987, Plant vacuoles. Their importance in solute compartmentation in cells and their applications in plant biotechnology., P417; TABATABAI MA, 1988, PLANT SOIL, V107, P39; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRANBARGER TJ, 1991, PLANT CELL, V3, P973, DOI 10.1105/tpc.3.9.973; ULLAH AHJ, 1988, ARCH BIOCHEM BIOPHYS, V260, P514, DOI 10.1016/0003-9861(88)90476-6; VALLEJOS CE, 1983, ISOZYMES PLANT GEN A, V1, P469; WEISS M, 1991, PLANT PHYSIOL, V97, P1244; WILLIAMSON VM, 1991, PLANT PHYSIOL, V97, P139, DOI 10.1104/pp.97.1.139; WITTENBACH VA, 1982, PLANT PHYSIOL, V70, P1544, DOI 10.1104/pp.70.5.1544; WITTENBACH VA, 1983, PLANT PHYSIOL, V73, P121, DOI 10.1104/pp.73.1.121; WITTENBACH VA, 1983, PLANT PHYSIOL, V73, P125, DOI 10.1104/pp.73.1.125; WOOD HG, 1988, ANNU REV BIOCHEM, V57, P235, DOI 10.1146/annurev.bi.57.070188.001315	52	74	76	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15958	15964						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1639823				2022-12-25	WOS:A1992JG11300104
J	JACKMAN, MP; PARRY, MAA; HOFSTEENGE, J; STONE, SR				JACKMAN, MP; PARRY, MAA; HOFSTEENGE, J; STONE, SR			INTRINSIC FLUORESCENCE CHANGES AND RAPID KINETICS OF THE REACTION OF THROMBIN WITH HIRUDIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-THROMBIN; NUCLEAR MAGNETIC-RESONANCE; RECOMBINANT HIRUDIN; CRYSTAL-STRUCTURE; INHIBITION; COMPLEX; SITE; BINDING; SPECIFICITY; INVESTIGATE	Stopped-flow fluorescence spectroscopy has been used to study the reaction of human alpha-thrombin with recombinant hirudin variant 1 (rhir) at 37-degrees-C and an ionic strength of 0.125 M. A 35% enhancement in intrinsic fluorescence accompanied formation of the thrombin-rhir complex. Over one third of this enhancement corresponded to a structural change that could be induced by binding of either the NH2-terminal fragment (residues 1-51) or the COOH-terminal fragment (residues 52-65) of rhir. Three kinetic steps were detected for reaction of thrombin with rhir. At high rhir concentrations (greater-than-or-equal-to 3-mu-M), two intramolecular steps with observed rate constants of 296 +/- 5 s-1 and 50 +/- 1 s-1 were observed. By using the COOH-terminal fragment of rhir as a competitive inhibitor, it was possible to obtain an estimate of 2.9 x 10(8) M-1 s-1 for the effective association rate constant at low rhir concentrations. At higher ionic strengths, this rate constant was lower, which is consistent with the formation of the initial complex involving an ionic interaction. The mechanism for the reaction of both the COOH- and NH2-terminal fragments of rhir appeared to involve two steps. When thrombin was reacted with the COOH-terminal fragment at high concentrations (greater-than-or-equal-to 6-mu-M), the bimolecular step occurred within the dead time of the spectrometer and only one intramolecular step, with a rate constant of 308 +/- 5 s-1 was observed. At concentrations of NH2-terminal fragment below 50-mu-M, its binding to thrombin appeared to be a bimolecular reaction with an association rate constant of 8.3 x 10(5) m-1 s-1. In the presence of saturating concentrations of the COOH-terminal fragment, a 1.7-fold increase in this rate constant was observed. At concentrations of NH2-terminal fragment greater than 50-mu-M, biphasic reaction traces were observed which suggests a two-step mechanism. By comparing the reaction amplitudes and dissociation constants observed with rhir and its COOH-terminal fragment, it was possible to obtain approximate estimates for the values of the rate constants of different steps in the formation of the rhir-thrombin complex.	UNIV CAMBRIDGE, CTR MRC, DEPT HAEMATOL, HILLS RD, CAMBRIDGE CB2 2QH, ENGLAND; FRIEDRICH MIESCHER INST, CH-4002 BASEL, SWITZERLAND	University of Cambridge; Friedrich Miescher Institute for Biomedical Research								BERLINER LJ, 1985, BIOCHEMISTRY-US, V24, P7005, DOI 10.1021/bi00345a038; BETZ A, 1992, BIOCHEMISTRY-US, V32, P1168; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BODE W, 1990, EUR J BIOCHEM, V193, P175, DOI 10.1111/j.1432-1033.1990.tb19320.x; BRAUN PJ, 1988, BIOCHEMISTRY-US, V27, P6517, DOI 10.1021/bi00417a048; CANTOR CR, 1980, BIOPHYSICAL CHEM 2, P443; CORNISHBOWDEN A, 1976, PRINCIPLES ENZYME KI, P154; DENNIS S, 1990, EUR J BIOCHEM, V188, P61, DOI 10.1111/j.1432-1033.1990.tb15371.x; DIMAIO J, 1990, J BIOL CHEM, V265, P21698; DODT J, 1988, FEBS LETT, V229, P87, DOI 10.1016/0014-5793(88)80803-2; Fenton J W 2nd, 1981, Ann N Y Acad Sci, V370, P468, DOI 10.1111/j.1749-6632.1981.tb29757.x; FENTON JW, 1986, SEMIN THROMB HEMOST, V12, P200, DOI 10.1055/s-2007-1003551; FOLKERS PJM, 1989, BIOCHEMISTRY-US, V28, P2601, DOI 10.1021/bi00432a038; GRUTTER MG, 1990, EMBO J, V9, P2361, DOI 10.1002/j.1460-2075.1990.tb07410.x; Hammes G.G., 1970, ENZYMES, V2, P67; HARUYAMA H, 1989, BIOCHEMISTRY-US, V28, P4301, DOI 10.1021/bi00436a027; Hiromi K., 1979, KINETICS FAST ENZYME; HORTIN GL, 1991, J BIOL CHEM, V266, P6866; JAMESON GW, 1973, BIOCHEM J, V131, P101; KARSHIKOV A, 1992, IN PRESS PROTEIN SCI; LEWIS SD, 1987, BIOCHEMISTRY-US, V26, P7597, DOI 10.1021/bi00398a010; LIU LW, 1991, J BIOL CHEM, V266, P16977; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V185, P269; MARAGANORE JM, 1990, BIOCHEMISTRY-US, V29, P7095, DOI 10.1021/bi00482a021; NASKI MC, 1990, J BIOL CHEM, V265, P13484; NOE G, 1988, J BIOL CHEM, V263, P11729; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; RYDEL TJ, 1991, J MOL BIOL, V221, P583, DOI 10.1016/0022-2836(91)80074-5; SCHMITZ T, 1991, EUR J BIOCHEM, V195, P251, DOI 10.1111/j.1432-1033.1991.tb15701.x; SKRZYPCZAKJANKUN E, 1991, J MOL BIOL, V221, P1379; STONE SR, 1990, NATO ADV SCI I A-LIF, V191, P115; STONE SR, 1991, PROTEIN ENG, V4, P295, DOI 10.1093/protein/4.3.295; STONE SR, 1989, BIOCHEMISTRY-US, V28, P6857, DOI 10.1021/bi00443a012; STONE SR, 1986, BIOCHEMISTRY-US, V25, P4622, DOI 10.1021/bi00364a025; Stone SR, 1992, THROMBIN STRUCTURE F, P219; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; WALLACE A, 1989, BIOCHEMISTRY-US, V28, P10079, DOI 10.1021/bi00452a030; WALLIS RB, 1988, TRENDS PHARMACOL SCI, V9, P425, DOI 10.1016/0165-6147(88)90124-1; WALSMANN P, 1981, PHARMAZIE, V36, P633	40	60	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15375	15383						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1639783				2022-12-25	WOS:A1992JG11300021
J	KANAYA, E; KIKUCHI, M				KANAYA, E; KIKUCHI, M			FOLDING OF HUMAN LYSOZYME INVIVO BY THE FORMATION OF AN ALTERNATIVE DISULFIDE BOND	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; SECRETION; PROTEIN; YEAST; MUTAGENESIS; CHAIN; ISOMERASE	The mutant h-lysozyme, W64CC65A, with Trp64 and Cys65 replaced by Cys and Ala, respectively, was secreted by yeast and purified. Peptide mapping confirmed that W64CC65A contained a nonnative Cys64-Cys81 bond and three native disulfide bonds. The mutant had 2% of the lytic activity of the wild-type lysozyme. The midpoint concentration of the guanidine hydrochloride denaturation curve, the [D]1/2, was 2.7 M for W64CC65A at pH 3.0 and 25-degrees-C, whereas the [D]1/2 for the wild-type h-lysozyme was 2.9 M. These results show that the W64CC65A protein is a compactly folded molecule. Our previous results, using the mutant C81A, indicate that Cys81 is not required for correct folding and activity, whereas Cys65 is indispensable (Taniyama, Y., Yamamoto, Y., Kuroki, R., and Kikuchi, M. (1990) J. Biol. Chem. 65, 7570-7575). Cys64 substituted for Cys65 in W64CC65A, even though the distance between the a-carbons at positions 64 and 81 in the wild-type h-lysozyme is not favorable for forming a disulfide bond. Unlike C81A, the mutant W64CC65/81A, which has the additional substitution of Ala for Cys81, did not fold. These results suggest that the absence of both the Cys64-Cys81 bond and the amino acid residue Trp64 caused the misfolding or destabilization of W64CC65/81A in vivo. It is proposed that the formation of the alternative bond, Cys64-Cys81 is important for the folding of W64CC65A in vivo.	PROT ENGN RES INST,6-2-3 FURUEDAI,SUITA,OSAKA 565,JAPAN									ANDRIA G, 1978, J BIOL CHEM, V253, P2262; ARTYMIUK PJ, 1981, J MOL BIOL, V152, P737, DOI 10.1016/0022-2836(81)90125-X; BERGMAN LW, 1979, J BIOL CHEM, V254, P5690; BERGMAN LW, 1979, J BIOL CHEM, V254, P8869; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FORD LO, 1974, J MOL BIOL, V88, P349, DOI 10.1016/0022-2836(74)90487-2; FURUKAWA K, 1990, Protein Engineering, V3, P353; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; IMOTO T, 1986, J MOL BIOL, V190, P647, DOI 10.1016/0022-2836(86)90250-0; INAKA K, 1991, J BIOL CHEM, V266, P12599; ISHIWATA A, 1991, BIOCHEMISTRY-US, V30, P7766, DOI 10.1021/bi00245a014; KANAYA E, 1990, BIOCHEM BIOPH RES CO, V173, P1194, DOI 10.1016/S0006-291X(05)80912-X; KIDERA A, 1985, J PROTEIN CHEM, V4, P23, DOI 10.1007/BF01025492; KIKUCHI M, 1990, EUR J BIOCHEM, V187, P315, DOI 10.1111/j.1432-1033.1990.tb15307.x; KIKUCHI M, 1988, P NATL ACAD SCI USA, V85, P9411, DOI 10.1073/pnas.85.24.9411; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAMANTIA M, 1991, P NATL ACAD SCI USA, V88, P4453, DOI 10.1073/pnas.88.10.4453; MURAKI M, 1986, AGR BIOL CHEM TOKYO, V50, P713, DOI 10.1080/00021369.1986.10867445; NANJO F, 1988, J BIOCHEM-TOKYO, V104, P255, DOI 10.1093/oxfordjournals.jbchem.a122453; OMURA F, 1991, EUR J BIOCHEM, V198, P477, DOI 10.1111/j.1432-1033.1991.tb16038.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TANIYAMA Y, 1990, J BIOL CHEM, V265, P7570; TANIYAMA Y, 1988, BIOCHEM BIOPH RES CO, V152, P962, DOI 10.1016/S0006-291X(88)80377-2; TANIYAMA Y, 1991, J BIOL CHEM, V266, P6456; TANIYAMA Y, 1990, J BIOL CHEM, V265, P16767; TOHE A, 1973, J BACTERIOL, V113, P727, DOI 10.1128/JB.113.2.727-738.1973; TSOU CL, 1988, BIOCHEMISTRY-US, V27, P1809, DOI 10.1021/bi00406a001; VITA C, 1987, MACROMOL BIORECOGNIT, P51; YOSHIMURA K, 1987, BIOCHEM BIOPH RES CO, V145, P712, DOI 10.1016/0006-291X(87)91023-0	30	11	11	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15111	15115						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634546				2022-12-25	WOS:A1992JF08800089
J	LINARDIC, CM; JAYADEV, S; HANNUN, YA				LINARDIC, CM; JAYADEV, S; HANNUN, YA			BREFELDIN-A PROMOTES HYDROLYSIS OF SPHINGOMYELIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOLGI-APPARATUS; CELL-DIFFERENTIATION; MEMBRANE; PROTEINS; SPHINGOLIPIDS; TURNOVER; ER	The hydrolysis of sphingomyelin (SM) is a key reaction in the "sphingomyelin cycle," which plays a role in the regulation of cell proliferation and differentiation (Okazaki, T., Bell, R. M., and Hannun, Y. A. (1989) J. Biol. Chem. 264, 19076-19080). SM is produced from endoplasmic reticulum-derived ceramide and is delivered to organelle membranes in a regulated manner, presumably through the same endomembrane trafficking system used for sorting and delivery of proteins. Since brefeldin A (BFA) interferes with this endomembrane trafficking system and thus alters normal membrane and organelle distribution, we investigated the effect of BFA on SM levels in HL-60 leukemia cells. BFA caused a dose-dependent decrease of 20-25% in cellular SM levels, with effects observed at concentrations of BFA as low as 0.10-mu-g/ml. BFA effects on SM levels were noted as early as 5 min and were maximal by 20 min, with no further SM hydrolysis observed up to 60 min following treatment with BFA, suggesting the presence of a fixed SM-sensitive pool. BFA did not cause SM hydrolysis at 16-degrees-C, a temperature that inhibits the effects of BFA on endomembrane mixing. The very early effects and temperature dependence of BFA-induced SM hydrolysis suggest that the mechanism of hydrolysis may be closely related to endomembrane mixing. These studies are beginning to define important interrelationships between membrane trafficking and topology, SM metabolism, and cell regulation.	DUKE UNIV,MED CTR,DEPT MED,BOX 3355,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710	Duke University; Duke University					NIGMS NIH HHS [GM43825] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043825, R01GM043825] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRUNING A, 1992, J BIOL CHEM, V267, P5052; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; KIM MY, 1991, J BIOL CHEM, V266, P484; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LIPSKY NG, 1985, J CELL BIOL, V100, P27, DOI 10.1083/jcb.100.1.27; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; NARULA N, 1992, J CELL BIOL, V117, P27, DOI 10.1083/jcb.117.1.27; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; PAGANO RE, 1988, TRENDS BIOCHEM SCI, V13, P202, DOI 10.1016/0968-0004(88)90082-5; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; TAMURA G, 1968, J ANTIBIOT, V21, P160, DOI 10.7164/antibiotics.21.160; VANCE JE, 1991, J BIOL CHEM, V266, P8241; VANECHTEN G, 1990, EUR J CELL BIOL, V51, P135; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5; YOUNG WW, 1990, P NATL ACAD SCI USA, V87, P6838, DOI 10.1073/pnas.87.17.6838	25	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14909	14911						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634530				2022-12-25	WOS:A1992JF08800062
J	OSULLIVAN, MG; CHILTON, FH; HUGGINS, EM; MCCALL, CE				OSULLIVAN, MG; CHILTON, FH; HUGGINS, EM; MCCALL, CE			LIPOPOLYSACCHARIDE PRIMING OF ALVEOLAR MACROPHAGES FOR ENHANCED SYNTHESIS OF PROSTANOIDS INVOLVES INDUCTION OF A NOVEL PROSTAGLANDIN-H SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ARACHIDONIC-ACID METABOLISM; HUMAN-ENDOTHELIAL-CELLS; ENDOPEROXIDE SYNTHASE; PHORBOL ESTER; MESSENGER-RNA; CYCLOOXYGENASE; THROMBOXANE; STIMULATION; INHIBITORS; PROTEIN	We report here that lipopolysaccharide (LPS) priming of rabbit alveolar macrophages leads to amplified synthesis of prostanoids, at least in part, by induction of a novel prostaglandin H synthase (PGH synthase). Rabbit alveolar macrophages were cultured with or without added LPS derived from Escherichia coli 0111:B4 for 4 h and then stimulated with opsonized zymosan (OPZ). LPS priming of alveolar macrophages resulted in enhanced release of thromboxane (TX) upon stimulation with OPZ, when compared to stimulated non-LPS controls. Addition of exogenous arachidonic acid to LPS-primed alveolar macrophages also resulted in increased production of TX. The LPS-induced increase in TX formation, in response to OPZ or arachidonic acid, was abolished by the addition of actinomycin D or cycloheximide during the priming period. Gas chromatography/mass spectrometry analysis indicated that levels of prostaglandins D2, E2, and F2-alpha, along with TX, were augmented in stimulated LPS-primed alveolar macrophages, implicating PGH synthase in the priming process. PGH synthase enzymatic activity, as determined by addition of arachidonic acid to macrophage sonicates, was markedly enhanced in LPS-primed alveolar macrophages. This correlated with increased PGH synthase levels detected by immunoprecipitation of S-35-labeled proteins and by Western blot analysis. Finally, Northern blot analysis using a cDNA probe to the recently described mitogen-inducible mouse PGH synthase revealed strong induction of approximately 4.3-kilobase mRNA in LPS-primed alveolar macrophages. Taken together, these results reveal that induction of a novel PGH synthase, probably the rabbit homologue of PGH synthase-2, plays a role in the enhanced synthesis of prostanoids by LPS-primed alveolar macrophages.			OSULLIVAN, MG (corresponding author), WAKE FOREST UNIV,MED CTR,DEPT MED,INFECT DIS SECT,WINSTON SALEM,NC 27157, USA.			Chilton, Floyd/0000-0002-3686-0198	NHLBI NIH HHS [HL29293] Funding Source: Medline; NIAID NIH HHS [AI-09169] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029293] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI009169, R21AI009169] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADEREM AA, 1986, J EXP MED, V164, P165, DOI 10.1084/jem.164.1.165; BALL HA, 1986, INTENS CARE MED, V12, P116; BNE RC, 1991, ANN INTERN MED, V115, P457; COCHRANE CG, 1987, AM REV RESPIR DIS, V135, P1; DEWITT DL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P121, DOI 10.1016/0005-2760(91)90032-D; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; FAGAN JM, 1986, P NATL ACAD SCI USA, V83, P2771, DOI 10.1073/pnas.83.8.2771; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; FU JY, 1990, J BIOL CHEM, V265, P16737; GLASER KB, 1990, J BIOL CHEM, V265, P8658; HAN JW, 1990, P NATL ACAD SCI USA, V87, P3373, DOI 10.1073/pnas.87.9.3373; IRVINE RF, 1982, BIOCHEM J, V204, P3, DOI 10.1042/bj2040003; KETTELHUT IC, 1987, P NATL ACAD SCI USA, V84, P4273, DOI 10.1073/pnas.84.12.4273; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; LARGEN MT, 1986, J IMMUNOL, V136, P988; LIN AH, 1989, J BIOL CHEM, V264, P17379; MAIER JAM, 1990, J BIOL CHEM, V265, P10805; NAKAMURA T, 1991, BIOCHIM BIOPHYS ACTA, V1085, P191, DOI 10.1016/0005-2760(91)90094-X; OBANION MK, 1991, J BIOL CHEM, V266, P23261; Olson N C, 1988, Mol Aspects Med, V10, P511, DOI 10.1016/0098-2997(88)90024-6; OSULLIVAN MG, 1990, AM J VET RES, V51, P1820; PUERINGER RJ, 1992, AM J PHYSIOL, V262, pL78, DOI 10.1152/ajplung.1992.262.1.L78; ROUZER CA, 1980, P NATL ACAD SCI-BIOL, V77, P4279, DOI 10.1073/pnas.77.7.4279; SALZER WL, 1990, J CLIN INVEST, V85, P1135, DOI 10.1172/JCI114545; TSAI AL, 1990, ADV PROSTAGLANDIN TH, V21, P141; WU KK, 1988, J BIOL CHEM, V263, P19043; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; YOKOYAMA C, 1989, BIOCHEM BIOPH RES CO, V165, P888, DOI 10.1016/S0006-291X(89)80049-X	28	220	220	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14547	14550						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634505				2022-12-25	WOS:A1992JF08800009
J	STRIPP, BR; SAWAYA, PL; LUSE, DS; WIKENHEISER, KA; WERT, SE; HUFFMAN, JA; LATTIER, DL; SINGH, G; KATYAL, SL; WHITSETT, JA				STRIPP, BR; SAWAYA, PL; LUSE, DS; WIKENHEISER, KA; WERT, SE; HUFFMAN, JA; LATTIER, DL; SINGH, G; KATYAL, SL; WHITSETT, JA			CIS-ACTING ELEMENTS THAT CONFER LUNG EPITHELIAL-CELL EXPRESSION OF THE CC10 GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; CLARA CELL; TRANSGENIC MICE; MAMMALIAN LUNG; PROTEIN; MOUSE; PROMOTER; BINDING; RABBIT; ULTRASTRUCTURE	To define cis-acting genetic elements responsible for cell-specific transcriptional regulation of the CC10 gene, DNA sequences spanning nucleotides -2338 to +49 of the rat CC10 gene were linked to a reporter gene coding for chloramphenicol acetyltransferase (CAT). In transient expression assays, CC10 sequences were capable of restricting CAT expression to a human lung adenocarcinoma cell line similar to pulmonary Clara cells. Transgenic mice harboring the hybrid RtCC10-CAT construct expressed high levels of CAT activity specifically within protein extracts of lung and trachea. Transcripts for the CAT reporter gene colocalized with those for the endogenous murine CC10 gene within the airways of transgenic mice. Functional analysis of deletion mutants identified stimulatory, inhibitory, and cell type-specific transcriptional regulatory elements. The results of gel retention and DNaseI protection assays suggest that a transcriptional stimulatory region located between -320 and -175, and a cell type-specific regulatory element located between -175 and +49, result from a series of protein-DNA interactions occurring at -220 to -205 and -128 to -86, respectively. Lung epithelial specific transcriptional regulatory elements described herein will be useful for expression of chimeric genes within epithelial cells lining the trachea, bronchi, and bronchioles of mice.	CHILDRENS HOSP RES FDN,MED CTR,DIV PULM BIOL,ELLAND & BETHESDA AVE,CINCINNATI,OH 45229; UNIV PITTSBURGH,SCH MED,DEPT PATHOL,PITTSBURGH,PA 15261; UNIV CINCINNATI,DEPT MOLEC GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45221	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University System of Ohio; University of Cincinnati			Stripp, Barry/AAI-1467-2021	Stripp, Barry/0000-0003-4348-2137	NHLBI NIH HHS [HL-41496, HL-28193] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041496, R01HL028193] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANGERER LM, 1987, IN SITU HYDRIDIZATIO; ARONOW B, 1989, GENE DEV, V3, P1384, DOI 10.1101/gad.3.9.1384; CROSBY SD, 1991, MOL CELL BIOL, V11, P3835, DOI 10.1128/MCB.11.8.3835; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EVANS MJ, 1978, LAB INVEST, V38, P648; GLASSER SW, 1990, J BIOL CHEM, V265, P21986; GLASSER SW, 1991, AM J PHYSIOL, V261, pL349, DOI 10.1152/ajplung.1991.261.4.L349; GORDON JW, 1987, CELL, V50, P445, DOI 10.1016/0092-8674(87)90498-3; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAGEN G, 1990, NUCLEIC ACIDS RES, V18, P2939, DOI 10.1093/nar/18.10.2939; JACOB GA, 1991, J BIOL CHEM, V266, P22537; KATYAL SL, 1990, PROG R RES, V25, P29; KELSEY GD, 1987, GENE DEV, V1, P161, DOI 10.1101/gad.1.2.161; MANIATIS T, 1982, MOL CLONING LABORATO, P77; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; Miller JH., 1972, EXPT MOL GENETICS; MISSEYANNI A, 1991, NUCLEIC ACIDS RES, V19, P2849, DOI 10.1093/nar/19.11.2849; OREILLY MA, 1988, BIOCHIM BIOPHYS ACTA, V970, P194, DOI 10.1016/0167-4889(88)90179-6; OREILLY MA, 1989, AM J PHYSIOL, V257, pL385, DOI 10.1152/ajplung.1989.257.6.L385; PACK RJ, 1981, J ANAT, V132, P71; PLOPPER CG, 1980, EXP LUNG RES, V1, P171, DOI 10.3109/01902148009069646; PLOPPER CG, 1980, EXP LUNG RES, V1, P139, DOI 10.3109/01902148009069644; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; SANDMOLLER A, 1991, MECH DEVELOP, V34, P57, DOI 10.1016/0925-4773(91)90091-J; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; Walter C A, 1989, Biotechniques, V7, P1065; WAREMBOURG M, 1986, ENDOCRINOLOGY, V119, P1632, DOI 10.1210/endo-119-4-1632; WIKENHEISER KA, 1992, AM J PHYSIOL, V262, pL32, DOI 10.1152/ajplung.1992.262.1.L32; WIRTH T, 1987, NATURE, V329, P174, DOI 10.1038/329174a0; ZHANG DE, 1990, J BIOL CHEM, V265, P3382	31	140	144	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14703	14712						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634515				2022-12-25	WOS:A1992JF08800034
J	RIEDEL, A; RUTHERFORD, AW; HAUSKA, G; MULLER, A; NITSCHKE, W				RIEDEL, A; RUTHERFORD, AW; HAUSKA, G; MULLER, A; NITSCHKE, W			CHLOROPLAST RIESKE CENTER - EPR STUDY ON ITS SPECTRAL CHARACTERISTICS, RELAXATION AND ORIENTATION PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC RESONANCE; IRON-SULFUR CLUSTERS; CYTOCHROME-C OXIDOREDUCTASE; LIPID MODEL MEMBRANE; SPINACH-CHLOROPLASTS; RHODOPSEUDOMONAS-SPHAEROIDES; MITOCHONDRIAL-MEMBRANE; PHTHALATE DIOXYGENASE; RESPIRATORY-CHAIN; PROSTHETIC GROUPS	The spectral parameters, the orientation of the g tensor in two-dimensionally ordered multilayers and the relaxation properties of the Rieske center in purified cytochrome b6f complex from spinach were studied by EPR spectroscopy. A trough at g = 1.76-1.74 was unambiguously identified as the g(x) signal on the basis of the sensitivity of its field position to inhibitors and oxidized plastoquinone. In contrast to previous reports, the orientation of the chloroplast Rieske center was found to be identical to that of its cytochrome bc1 counterpart, provided that non-saturating EPR conditions were applied. Upon onset of microwave saturation, however, the orientation with respect to the ordered multilayers where the g(y) signal (g = 1.9) was maximal, changed drastically and was then similar to the orientation reported previously (Prince R. C., Crowder, M. S., and Bearden, A. J. (1980) Biochim. Biophys. Acta 592, 323-337). The unusually anisotropic saturation behavior of the EPR spectrum was characterized in detail, whereby hitherto controversial results on the spectral parameters of the chloroplast Rieske center could be rationalized. The observed phenomena are discussed on the basis of three tentative models which are able to qualitatively explain the effects.	CENS,DEPT BIOL CELLULAIRE & MOLEC,BIOENERGET SECT,F-91191 GIF SUR YVETTE,FRANCE; UNIV REGENSBURG,INST ZELLBIOL & PFLANZENPHYSIOL,W-8400 REGENSBURG,GERMANY; UNIV REGENSBURG,INST BIOPHYS & PHYS BIOCHEM,W-8400 REGENSBURG,GERMANY	CEA; University of Regensburg; University of Regensburg			Rutherford, Alfred W/A-7831-2019; Nitschke, Wolfgang/C-4812-2012	Rutherford, Alfred W/0000-0002-3124-154X; Nitschke, Wolfgang/0000-0003-2084-3032				BERGSTROM J, 1985, FEBS LETT, V183, P87, DOI 10.1016/0014-5793(85)80959-5; BERTRAND P, 1985, BIOCHIM BIOPHYS ACTA, V831, P261, DOI 10.1016/0167-4838(85)90044-5; BERTRAND P, 1979, BIOCHIM BIOPHYS ACTA, V579, P107, DOI 10.1016/0005-2795(79)90091-6; BLASIE JK, 1978, BIOCHIM BIOPHYS ACTA, V501, P33, DOI 10.1016/0005-2728(78)90093-2; BLUMBERG WE, 1974, ARCH BIOCHEM BIOPHYS, V162, P502, DOI 10.1016/0003-9861(74)90210-0; BRITT RD, 1991, BIOCHEMISTRY-US, V30, P10892; CLINE JF, 1985, J BIOL CHEM, V260, P3251; CROWDER MS, 1982, FEBS LETT, V144, P204, DOI 10.1016/0014-5793(82)80638-8; DEVRIES S, 1979, BIOCHIM BIOPHYS ACTA, V546, P316, DOI 10.1016/0005-2728(79)90049-5; DEVRIES S, 1983, BIOCHIM BIOPHYS ACTA, V723, P91, DOI 10.1016/0005-2728(83)90013-0; ERECINSKA M, 1979, ARCH BIOCHEM BIOPHYS, V192, P80, DOI 10.1016/0003-9861(79)90073-0; FEE JA, 1984, J BIOL CHEM, V259, P124; GURBIEL RJ, 1989, BIOCHEMISTRY-US, V28, P4861, DOI 10.1021/bi00437a051; HAUSKA G, 1986, METHOD ENZYMOL, V126, P271; HAUSKA G, 1983, BIOCHIM BIOPHYS ACTA, V726, P97, DOI 10.1016/0304-4173(83)90002-2; HOOTKINS R, 1983, BIOCHIM BIOPHYS ACTA, V723, P16, DOI 10.1016/0005-2728(83)90004-X; HURT E, 1981, EUR J BIOCHEM, V117, P591; KNAFF DB, 1976, BIOCHIM BIOPHYS ACTA, V430, P244, DOI 10.1016/0005-2728(76)90082-7; LEWIS RJ, 1981, J BIOL CHEM, V256, P543; LIEBL U, 1990, FEBS LETT, V261, P427, DOI 10.1016/0014-5793(90)80608-L; LJUNGDAHL O, 1987, BIOCHIM BIOPHYS ACTA, V891, P227; MALKIN R, 1986, FEBS LETT, V208, P317, DOI 10.1016/0014-5793(86)81041-9; MATSUURA K, 1983, J BIOL CHEM, V258, P1571; MORE C, 1987, J MAGN RESON, V73, P13, DOI 10.1016/0022-2364(87)90221-6; NALECZ MJ, 1985, ARCH BIOCHEM BIOPHYS, V240, P921; NITSCHKE W, 1989, BIOCHIM BIOPHYS ACTA, V974, P223, DOI 10.1016/S0005-2728(89)80376-7; NITSCHKE W, 1987, BIOCHIM BIOPHYS ACTA, V892, P314, DOI 10.1016/0005-2728(87)90235-0; NITSCHKE W, 1987, FEBS LETT, V213, P453, DOI 10.1016/0014-5793(87)81541-7; Nitschke W., 1987, PROGR PHOTOSYNTHESIS, V2, P165; NUGENT JHA, 1987, BIOCHIM BIOPHYS ACTA, V893, P177, DOI 10.1016/0005-2728(87)90037-5; PRINCE RC, 1980, BIOCHIM BIOPHYS ACTA, V592, P323, DOI 10.1016/0005-2728(80)90193-0; PRINCE RC, 1983, BIOCHIM BIOPHYS ACTA, V723, P133, DOI 10.1016/0005-2728(83)90112-3; RICH PR, 1987, BIOCHIM BIOPHYS ACTA, V892, P138, DOI 10.1016/0005-2728(87)90256-8; RIESKE JS, 1964, BIOCHEM BIOPH RES CO, V15, P338, DOI 10.1016/0006-291X(64)90171-8; SAHLIN M, 1986, J MAGN RESON, V67, P135, DOI 10.1016/0022-2364(86)90417-8; SALERNO JC, 1979, BIOCHIM BIOPHYS ACTA, V547, P270, DOI 10.1016/0005-2728(79)90010-0; SALERNO JC, 1983, FEBS LETT, V162, P257, DOI 10.1016/0014-5793(83)80767-4; SALERNO JC, 1977, BIOCHIM BIOPHYS ACTA, V494, P91; SLATER EC, 1980, NATURE, V288, P717, DOI 10.1038/288717a0; TAYLOR CPS, 1977, BIOCHIM BIOPHYS ACTA, V491, P137, DOI 10.1016/0005-2795(77)90049-6; TELSER J, 1987, FEBS LETT, V214, P117, DOI 10.1016/0014-5793(87)80024-8; TELSER J, 1976, FEBS LETT, V70, P73; TRUMPOWER BL, 1979, J BIOL CHEM, V254, P8697; TRUMPOWER BL, 1976, BIOCHEM BIOPH RES CO, V70, P73, DOI 10.1016/0006-291X(76)91110-4; TRUMPOWER BL, 1981, BIOCHIM BIOPHYS ACTA, V639, P129, DOI 10.1016/0304-4173(81)90008-2; VONJAGOW G, 1985, FEBS LETT, V185, P311, DOI 10.1016/0014-5793(85)80929-7; ZANNONI D, 1985, FEBS LETT, V193, P93, DOI 10.1016/0014-5793(85)80086-7	47	47	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					17838	17844						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1655728				2022-12-25	WOS:A1991GG55300023
J	SAXENA, U; KLEIN, MG; GOLDBERG, IJ				SAXENA, U; KLEIN, MG; GOLDBERG, IJ			IDENTIFICATION AND CHARACTERIZATION OF THE ENDOTHELIAL-CELL SURFACE LIPOPROTEIN-LIPASE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; FREE-FATTY-ACIDS; PHOSPHOLIPASE-C; BINDING; MODULATION; THROMBIN; GLYCOSAMINOGLYCANS; INTERNALIZATION; CHROMATOGRAPHY; THROMBOMODULIN	The hydrolysis of triglycerides in plasma lipoproteins is mediated by lipoprotein lipase (LPL) that is bound to vascular endothelial cells. The specific endothelial cell surface protein(s) with which LPL associates has not been characterized. To identify this LPL binding protein(s), radioiodinated cell surface proteins from cultured bovine aortic endothelial cells were chromatographed using bovine LPL-Sepharose. A single radioiodinated protein of apparent molecular mass 220 kDa was specifically retained by the gel and eluted with 0.4 M NaCl. A LPL-binding protein of similar size was obtained after metabolic labeling of the cellular proteoglycans with (SO4)-S-35, indicating that the 220-kDa protein is a proteoglycan. After heparitinase or nitrous acid treatments the molecular mass of the LPL-binding protein decreased to approximately 50 kDa, suggesting that it contains heparin sulfate chains. A 220-kDa protein from the basal cell surface was also identified using LPL-Sepharose chromatography. I-125-LPL was cross-linked to the endothelial cell surface using ethylene glycobis (succinimidylsuccinate). A single ligand-receptor complex, approximately 350 kDa, was obtained. Heparin and unlabeled LPL decreased the cross-linking of radioiodinated LPL to the cell surface receptor. To examine whether the receptor mediates the internalization of cross-linked I-125-LPL, cells containing I-125-LPL complexed to the surface were incubated at either 37 or at 4-degrees-C. The amount of I-125-LPL internalized by the cells was 74% greater at 37-degrees-C than at 4-degrees-C. This suggested that LPL cross-linked to the receptor was internalized in a temperature-dependent manner. Thus, a 220-kDa heparan sulfate proteoglycan functions as an endothelial cell surface receptor for LPL.	COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,SPECIALIZED CTR RES ARTERIOSCLEROSIS,NEW YORK,NY 10032	Columbia University; Columbia University					NHLBI NIH HHS [HL 21006, HL 45095] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL045095, R01HL045095, P50HL021006] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHAJEKSHAUL T, 1989, BIOCHIM BIOPHYS ACTA, V1014, P178, DOI 10.1016/0167-4889(89)90031-1; CHAJEKSHAUL T, 1988, BIOCHIM BIOPHYS ACTA, V963, P183, DOI 10.1016/0005-2760(88)90279-2; CHAJEKSHAUL T, 1988, AM J PHYSIOL, pE247; CHANG CF, 1981, J BIOL CHEM, V256, P12893; CISAR LA, 1989, J BIOL CHEM, V264, P1767; CLEMENT B, 1989, J BIOL CHEM, V264, P12467; DEAGOSTINI AI, 1990, J CELL BIOL, V111, P1293, DOI 10.1083/jcb.111.3.1293; ECKEL RH, 1984, P NATL ACAD SCI-BIOL, V81, P7604, DOI 10.1073/pnas.81.23.7604; ECKEL RH, 1989, NEW ENGL J MED, V320, P1060; FRANSSON LA, 1987, TRENDS BIOCHEM SCI, V12, P406, DOI 10.1016/0968-0004(87)90197-6; GARFINKEL AS, 1987, PLASMA LIPOPROTEINS, P335; GOLDBERG IJ, 1989, J LIPID RES, V30, P1569; HOOK M, 1984, ANNU REV BIOCHEM, V53, P847; JAKUBOWSKI HV, 1986, J BIOL CHEM, V261, P3876; KELLER R, 1987, AM J PATHOL, V128, P286; KINSELLA MG, 1988, BIOCHEMISTRY-US, V27, P2136, DOI 10.1021/bi00406a048; KINSELLA MG, 1988, J BIOL CHEM, V263, P19222; KJELLEN L, 1980, J BIOL CHEM, V255, P407; KLINGER MM, 1985, J BIOL CHEM, V260, P4082; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARCUM JA, 1986, J BIOL CHEM, V261, P7507; MARGELIN D, 1989, INT J BIOCHEM, V21, P761, DOI 10.1016/0020-711X(89)90208-5; OOHIRA A, 1983, J BIOL CHEM, V258, P2014; PREISSNER KT, 1990, J BIOL CHEM, V265, P4915; SAKU T, 1989, J BIOL CHEM, V264, P3514; SANDVIG K, 1990, J BIOL CHEM, V265, P6382; SAVION N, 1989, EUR J CELL BIOL, V49, P350; SAXENA U, 1990, ARTERIOSCLEROSIS, V10, P470, DOI 10.1161/01.ATV.10.3.470; SAXENA U, 1989, J BIOL CHEM, V264, P4349; SAXENA U, 1990, BIOCHIM BIOPHYS ACTA, V1043, P161, DOI 10.1016/0005-2760(90)90291-5; SAXENA U, 1991, P NATL ACAD SCI USA, V88, P2254, DOI 10.1073/pnas.88.6.2254; SAXENA U, 1990, J BIOL CHEM, V265, P12880; SEMB H, 1987, BIOCHIM BIOPHYS ACTA, V921, P104, DOI 10.1016/0005-2760(87)90176-7; SHIMADA K, 1981, J CLIN INVEST, V68, P995, DOI 10.1172/JCI110354; SHIMADA K, 1987, ARTERIOSCLEROSIS, V7, P627, DOI 10.1161/01.ATV.7.6.627; STAUBER GB, 1988, J BIOL CHEM, V263, P19098; WANGIVERSON P, 1980, ATHEROSCLEROSIS, V5, P375; WILLIAMS MP, 1983, BIOCHIM BIOPHYS ACTA, V711, P114; YANAGISHITA M, 1989, J BIOL CHEM, V264, P17551	40	87	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17516	17521						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1654330				2022-12-25	WOS:A1991GF44500080
J	YONEZAWA, N; HOMMA, Y; YAHARA, I; SAKAI, H; NISHIDA, E				YONEZAWA, N; HOMMA, Y; YAHARA, I; SAKAI, H; NISHIDA, E			A SHORT SEQUENCE RESPONSIBLE FOR BOTH PHOSPHOINOSITIDE BINDING AND ACTIN BINDING ACTIVITIES OF COFILIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE BRAIN; PHOSPHOLIPASE-C; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; GELSOLIN; PROTEIN; FILAMENTS; POLYMERIZATION; IDENTIFICATION; PURIFICATION; TROPOMYOSIN	Cofilin is a widely distributed actin-modulating protein that has abilities to bind along the side of F-actin and to depolymerize F-actin. Both abilities of cofilin can be inhibited by phosphoinositides such as phosphatidylinositol, phosphatidylinositol 4-monophosphate, and phosphatidylinositol 4,5-bisphosphate (PIP2). We have previously shown that the synthetic dodecapeptide corresponding to Trp104-Met115 of cofilin is a potent inhibitor of actin polymerization (Yonezawa, N., Nishida, E., Iida, K., Kumagai, H., Yahara, I., and Sakai, H. (1991) J. Biol. Chem. 266, 10485-10489). In this study, we have found that the inhibitory effect of the synthetic dodecapeptide on actin polymerization is canceled specifically by phosphatidylinositol, phosphatidylinositol 4-monophosphate and PIP2. We further show that the dodecapeptide as well as cofilin binds to PIP2 molecules and inhibits PIP2 hydrolysis by phospholipase C. Thus, the actin-binding dodecapeptide sequence of cofilin may constitute a multifunctional domain in cofilin.	UNIV TOKYO,FAC SCI,DEPT BIOPHYS & BIOCHEM,TOKYO 113,JAPAN; TOKYO METROPOLITAN GERIATR HOSP & INST GERONTOL,DEPT BIOSIGNAL RES,TOKYO 173,JAPAN; TOKYO METROPOLITAN INST MED SCI,DEPT CELL BIOL,TOKYO 113,JAPAN	University of Tokyo; Tokyo Metropolitan Institute of Gerontology; Tokyo Metropolitan Institute of Medical Science			Yonezawa, Naoto/F-8300-2011					BAMBURG JR, 1980, FEBS LETT, V121, P178, DOI 10.1016/0014-5793(80)81292-0; BRENNER SL, 1983, J BIOL CHEM, V258, P5013; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; HOMMA Y, 1990, BIOCHEM J, V269, P13, DOI 10.1042/bj2690013; JANMEY PA, 1988, J BIOL CHEM, V263, P16738; JANMEY PA, 1987, J BIOL CHEM, V262, P12228; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; KWIATKOWSKI DJ, 1989, J CELL BIOL, V108, P1717, DOI 10.1083/jcb.108.5.1717; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; MABUCHI I, 1983, J CELL BIOL, V97, P1612, DOI 10.1083/jcb.97.5.1612; MATSUZAKI F, 1988, J BIOL CHEM, V263, P11564; MORIYAMA K, 1990, J BIOL CHEM, V265, P5771; NISHIDA E, 1984, J BIOCHEM-TOKYO, V95, P387, DOI 10.1093/oxfordjournals.jbchem.a134619; NISHIDA E, 1984, BIOCHEMISTRY-US, V23, P5307, DOI 10.1021/bi00317a032; NISHIDA E, 1985, BIOCHEMISTRY-US, V24, P6624, DOI 10.1021/bi00344a049; NISHIDA E, 1985, BIOCHEMISTRY-US, V24, P1160, DOI 10.1021/bi00326a015; NISHIDA E, 1987, P NATL ACAD SCI USA, V84, P5262, DOI 10.1073/pnas.84.15.5262; RYU SH, 1987, J BIOL CHEM, V262, P12511; YIN HL, 1988, J CELL BIOL, V106, P805, DOI 10.1083/jcb.106.3.805; YONEZAWA N, 1985, J BIOL CHEM, V260, P4410; YONEZAWA N, 1990, J BIOL CHEM, V265, P8382; YONEZAWA N, 1991, J BIOL CHEM, V266, P10485	23	151	154	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17218	17221						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1654325				2022-12-25	WOS:A1991GF44500039
J	NAGAYAMA, Y; RUSSO, D; WADSWORTH, HL; CHAZENBALK, GD; RAPOPORT, B				NAGAYAMA, Y; RUSSO, D; WADSWORTH, HL; CHAZENBALK, GD; RAPOPORT, B			11-AMINO ACIDS (LYS-201 TO LYS-211) AND 9-AMINO ACIDS (GLY-222 TO LEU-230) IN THE HUMAN THYROTROPIN RECEPTOR ARE INVOLVED IN LIGAND-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; TSH RECEPTOR; CDNA; HORMONE; AUTOANTIBODIES; MUTAGENESIS; EPITOPES; CHAIN; SITES	Our previous studies involving chimeric thyrotropin-lutropin/choriogonadotropin ( TSH-LH/CG) receptors suggest that multiple segments spanning the entire extracellular domain of the human TSH receptor contribute to the TSH binding site. Nevertheless, the midregion (segment C, amino acid residues 171-260) of the receptor extracellular domain is particularly important in TSH binding. In the present studies, we constructed seven new chimeric receptors in order to analyze segment C in further detail. Seven small segments spanning segment C of the TSH receptor were replaced with the counterpart of the rat LH/CG receptor. These mutant receptors were stably introduced into Chinese hamster ovary cells and were tested for hormone binding and cAMP responsiveness to hormone stimulation. The results indicate that 11 amino acids of the TSH receptor (Lys-201 to Lys-211) and the corresponding region of the LH/CG receptor (Thr-202 to Ile-212) are important for specific TSH and human CG binding, respectively. In addition, nine amino acids of the TSH receptor (Gly-222 to Leu-230) are also involved in TSH binding. A further conclusion from these data is that TSH and human CG bind to partially overlapping sites on their respective receptor molecules.	UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	NAGAYAMA, Y (corresponding author), VET ADM MED CTR,THYROID MOLEC BIOL UNIT,SAN FRANCISCO,CA 94121, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019289, R01DK036182] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-19289, DK-36182] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKAMIZU T, 1990, P NATL ACAD SCI USA, V87, P5677, DOI 10.1073/pnas.87.15.5677; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; FRAZIER AL, 1990, MOL ENDOCRINOL, V4, P1264, DOI 10.1210/mend-4-8-1264; GUSTAFSON TA, 1990, J BIOL CHEM, V265, P18663; HIRAYU H, 1985, MOL CELL ENDOCRINOL, V42, P21, DOI 10.1016/0303-7207(85)90003-6; JANIN J, 1990, J BIOL CHEM, V265, P16027; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAVER WG, 1990, CELL, V61, P553, DOI 10.1016/0092-8674(90)90464-P; LIBERT F, 1989, BIOCHEM BIOPH RES CO, V165, P1250, DOI 10.1016/0006-291X(89)92736-8; LOOSFELT H, 1989, SCIENCE, V245, P525, DOI 10.1126/science.2502844; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MINEGISH T, 1990, BIOCHEM BIOPH RES CO, V172, P1049, DOI 10.1016/0006-291X(90)91552-4; MISRAHI M, 1990, BIOCHEM BIOPH RES CO, V166, P394, DOI 10.1016/0006-291X(90)91958-U; NAGAYAMA Y, 1991, P NATL ACAD SCI USA, V88, P902, DOI 10.1073/pnas.88.3.902; NAGAYAMA Y, 1990, BIOCHEM BIOPH RES CO, V173, P1150, DOI 10.1016/S0006-291X(05)80906-4; NAGAYAMA Y, 1989, BIOCHEM BIOPH RES CO, V165, P1184, DOI 10.1016/0006-291X(89)92727-7; PARMENTIER M, 1989, SCIENCE, V246, P1620, DOI 10.1126/science.2556796; ROBB RJ, 1988, P NATL ACAD SCI USA, V85, P5654, DOI 10.1073/pnas.85.15.5654; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPRENGEL R, 1990, MOL ENDOCRINOL, V4, P525, DOI 10.1210/mend-4-4-525	24	67	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					14926	14930						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1651314				2022-12-25	WOS:A1991GB09700022
J	OSHIMA, T; YOSHIMOTO, T; YAMAMOTO, S; KUMEGAWA, M; YOKOYAMA, C; TANABE, T				OSHIMA, T; YOSHIMOTO, T; YAMAMOTO, S; KUMEGAWA, M; YOKOYAMA, C; TANABE, T			CAMP-DEPENDENT INDUCTION OF FATTY-ACID CYCLOOXYGENASE MESSENGER-RNA IN MOUSE OSTEOBLASTIC CELLS (MC3T3-E1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN ENDOPEROXIDE SYNTHASE; VESICULAR GLAND MICROSOMES; CYCLIC-AMP; GROWTH-FACTOR; COMPLEMENTARY-DNA; G/H SYNTHASE; GENE; STIMULATION; DIFFERENTIATION; CORTICOSTEROIDS	In an osteoblastic cell line, MC3T3-E1, cloned from mouse calvaria, epinephrine stimulated the production of prostaglandin E2 as an essentially sole arachidonate metabolite (Kusaka, M., Oshima, T., Yokota, K., Yamamoto, S., and Kumegawa, M. (1988) Biochim. Biophys. Acta. 972, 339-346). Western and Northern blot analyses showed increases in the enzyme protein and mRNA of fatty acid cyclooxygenase in the epinephrine-treated cells. A rapid cAMP production caused by epinephrine was followed by increases in the activity and mRNA of cyclooxygenase. Both dibutyryl cAMP and 8-bromo-cAMP also increased the level of the cyclooxygenase activity and mRNA. These results suggest that cAMP produced by beta-adrenergic stimulation was responsible for the increased cyclooxygenase mRNA level leading to induction of the cyclooxygenase enzyme. Furthermore, the addition of prostaglandin E2 (the final arachidonate metabolite in the MC3T3-E1 cells) brought about a rapid synthesis of intracellular cAMP followed by increases in the enzyme protein and mRNA of cyclooxygenase.	UNIV TOKUSHIMA, SCH MED, DEPT BIOCHEM, TOKUSHIMA 770, JAPAN; MEIKAI UNIV, SCH DENT, DEPT ORAL ANAT, SAITAMA 35002, JAPAN; NATL CARDIOVASC CTR, RES INST, DEPT PHARMACOL, SUITA, OSAKA 565, JAPAN	Tokushima University; Meikai University; National Cerebral & Cardiovascular Center - Japan								ASANO T, 1984, J PHARMACOL EXP THER, V231, P141; BAILEY JM, 1989, ADV PROSTAG THROMB L, V19, P450; BAILEY JM, 1988, BIOCHEM BIOPH RES CO, V157, P1159, DOI 10.1016/S0006-291X(88)80995-1; BURNSIDE J, 1985, J BIOL CHEM, V260, P2705; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CIMBALA MA, 1982, J BIOL CHEM, V257, P7629; COLLINS S, 1989, P NATL ACAD SCI USA, V86, P4853, DOI 10.1073/pnas.86.13.4853; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; FU JY, 1990, J BIOL CHEM, V265, P16737; HAKEDA Y, 1987, ENDOCRINOLOGY, V121, P1966, DOI 10.1210/endo-121-6-1966; HAYAKAWA Y, 1984, J BIOL CHEM, V259, P9207; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HONMA M, 1977, BIOCHEM MED METAB B, V18, P257, DOI 10.1016/0006-2944(77)90060-6; KLEIN DC, 1970, ENDOCRINOLOGY, V86, P1436, DOI 10.1210/endo-86-6-1436; Kodama HA., 1981, JPN J ORAL BIOL, V23, P899, DOI DOI 10.2330/JORALBIOSCI1965.23.899; KUSAKA M, 1988, BIOCHIM BIOPHYS ACTA, V972, P339, DOI 10.1016/0167-4889(88)90210-8; LANS WEM, 1983, ENZYMES ARACHIDONIC, P203; LIN AH, 1989, J BIOL CHEM, V264, P17379; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MERLIE JP, 1988, J BIOL CHEM, V263, P3550; MIYAMOTO T, 1976, J BIOL CHEM, V251, P2629; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; OHKI S, 1979, J BIOL CHEM, V254, P829; RAZ A, 1989, P NATL ACAD SCI USA, V86, P1657, DOI 10.1073/pnas.86.5.1657; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; SUMITANI K, 1989, ARCH BIOCHEM BIOPHYS, V270, P588, DOI 10.1016/0003-9861(89)90541-9; WU KK, 1988, J BIOL CHEM, V263, P19043; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YAMAMOTO S, 1983, ENZYMES ARACHIDONIC, P171; YOKOTA K, 1986, J BIOL CHEM, V261, P5410; YOKOYAMA C, 1988, FEBS LETT, V231, P347, DOI 10.1016/0014-5793(88)80847-0; YOKOYAMA C, 1989, BIOCHEM BIOPH RES CO, V165, P888, DOI 10.1016/S0006-291X(89)80049-X	34	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13621	13626						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1649827				2022-12-25	WOS:A1991FY02700029
J	MOULD, RM; ROBINSON, C				MOULD, RM; ROBINSON, C			A PROTON GRADIENT IS REQUIRED FOR THE TRANSPORT OF 2 LUMENAL OXYGEN-EVOLVING PROTEINS ACROSS THE THYLAKOID MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE BISPHOSPHATE CARBOXYLASE; PRECURSOR PROTEINS; VESICLES REQUIRES; TRANSIT PEPTIDE; PHOTOSYSTEM-II; SMALL SUBUNIT; CHLOROPLASTS; ATP; TRANSLOCATION; IMPORT	The 33- and 23-kDa proteins of the photosynthetic oxygen-evolving complex are synthesized in the cytosol as larger precursors and transported into the thylakoid lumen via stromal intermediate forms. We have investigated the energetics of protein transport across the thylakoid membrane using import assays that utilize either intact chloroplasts or isolated thylakoids. We have found that the light-driven import of the 23-kDa protein into isolated thylakoids is almost completely inhibited by electron transport inhibitors or by the ionophore nigericin but not by valinomycin. These compounds have similar effects in chloroplast import assays: precursors of both the 33- and 23-kDa proteins are imported and processed to intermediate forms in. the stroma, but transport into the thylakoid lumen is blocked when electron transport is inhibited or nigericin is present. These results indicate that the transport of these proteins across the thylakoid membrane requires a protonmotive force and that the dominant component in this respect is the proton gradient and not the electrical potential.	UNIV WARWICK,DEPT BIOL SCI,COVENTRY CV4 7AL,W MIDLANDS,ENGLAND	University of Warwick								ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN LL, 1985, P NATL ACAD SCI USA, V82, P4384, DOI 10.1073/pnas.82.13.4384; CLINE K, 1985, J BIOL CHEM, V260, P3691; CLINE K, 1989, J BIOL CHEM, V264, P14225; DEVRIJE T, 1987, BIOCHIM BIOPHYS ACTA, V900, P63, DOI 10.1016/0005-2736(87)90278-1; FLUGGE UI, 1986, EUR J BIOCHEM, V160, P563, DOI 10.1111/j.1432-1033.1986.tb10075.x; GELLER BL, 1986, P NATL ACAD SCI USA, V83, P4219, DOI 10.1073/pnas.83.12.4219; GROSSMAN A, 1980, NATURE, V285, P625, DOI 10.1038/285625a0; HAGEMAN J, 1986, NATURE, V324, P567, DOI 10.1038/324567a0; HIGHFIELD PE, 1978, NATURE, V271, P420, DOI 10.1038/271420a0; JAMES HE, 1989, J BIOL CHEM, V264, P19573; JANSEN T, 1987, FEBS LETT, V216, P234, DOI 10.1016/0014-5793(87)80696-8; KEEGSTRA K, 1989, CELL, V56, P247, DOI 10.1016/0092-8674(89)90898-2; KIRWIN PM, 1989, EMBO J, V8, P2251, DOI 10.1002/j.1460-2075.1989.tb08349.x; KIRWIN PM, 1988, J BIOL CHEM, V263, P18128; LAMPPA GK, 1988, J BIOL CHEM, V263, P14996; Mills J. D., 1986, Photosynthesis: energy transduction: a practical approach, P143; OLSEN LJ, 1989, J BIOL CHEM, V264, P6724; PAIN D, 1987, P NATL ACAD SCI USA, V84, P3288, DOI 10.1073/pnas.84.10.3288; PFANNER N, 1985, EMBO J, V4, P2819, DOI 10.1002/j.1460-2075.1985.tb04009.x; ROBINSON C, 1984, EUR J BIOCHEM, V142, P343, DOI 10.1111/j.1432-1033.1984.tb08292.x; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; SMEEKENS S, 1990, TRENDS BIOCHEM SCI, V15, P73, DOI 10.1016/0968-0004(90)90180-J; SUTTON A, 1987, EUR J BIOCHEM, V164, P571, DOI 10.1111/j.1432-1033.1987.tb11165.x; THEG SM, 1989, J BIOL CHEM, V264, P6730; WESTHOFF P, 1985, PLANT MOL BIOL, V4, P137, DOI 10.1007/BF02418761; YAMANE K, 1987, J BIOL CHEM, V262, P2358	28	161	162	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1991	266	19					12189	12193						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FV180	1648086				2022-12-25	WOS:A1991FV18000016
J	LEE, NG; YAMAGUCHI, J; SUBRAMANIAN, KN				LEE, NG; YAMAGUCHI, J; SUBRAMANIAN, KN			EFFICIENT REPLICATION OF PLASMIDS CONTAINING THE SV40 ORIGIN IN N-MYC OVEREXPRESSING HUMAN NEUROBLASTOMA-CELLS	ONCOGENE			English	Article								Using test plasmids containing the SV40 origin, we found a wide spectrum of permissiveness to their replication in different human cell lines. N-myc overexpressing neuroblastoma cells were highly permissive. LA-N-1 neuroblastoma cells were the most permissive of all the cell lines that we tested including the homologous CV-1 or COS-1 monkey kidney cells. Other human cell lines expressing various amounts of c-myc, and the 293 cell line expressing adenovirus E1A and E1B exhibited intermediate levels of permissiveness. T24 and EJ bladder carcinoma cells, which do not express the myc genes, were nonpermissive. Transient expression of c-myc or N-myc from plasmid vectors resulted in a modest stimulation of replication. Replication of test plasmids containing different configurations of the SV40 origin region was activated by the myc proteins. The high efficiency of replication in LA-N-1 cells is due to a combination of reasons including the overproduction of N-myc, high efficiency of expression of the SV40 replication initiator protein large T antigen from a cotransfected expression plasmid (containing the T antigen gene under the RSV LTR control), and other unknown host cell replication stimulatory factors. Replication of test plasmids was not detected in N-myc or c-myc overexpressing cells when the T antigen expression plasmid was not provided, showing that the myc proteins cannot substitute for T antigen in SV40 DNA replication.	UNIV ILLINOIS, DEPT MICROBIOL & IMMUNOL, CHICAGO, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	LEE, NG (corresponding author), UNIV ILLINOIS, DEPT GENET, CHICAGO, IL 60612 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035872] Funding Source: NIH RePORTER; NIGMS NIH HHS [5 R01 GM 35872] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; ALT FW, 1986, COLD SPRING HARB SYM, V51, P931, DOI 10.1101/SQB.1986.051.01.106; ALWINE JC, 1985, MOL CELL BIOL, V5, P1034, DOI 10.1128/MCB.5.5.1034; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BERGSMA DJ, 1982, P NATL ACAD SCI-BIOL, V79, P381, DOI 10.1073/pnas.79.2.381; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BERNARDS R, 1986, CELL, V47, P667, DOI 10.1016/0092-8674(86)90509-X; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BOOKSTEIN R, 1988, P NATL ACAD SCI USA, V85, P2210, DOI 10.1073/pnas.85.7.2210; CHANDRASEKHARAPPA SC, 1987, J VIROL, V61, P2973, DOI 10.1128/JVI.61.10.2973-2980.1987; CLASSON M, 1987, NATURE, V330, P272, DOI 10.1038/330272a0; CLASSON M, 1990, ONCOGENE, V5, P1371; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DELUCIA AL, 1986, J VIROL, V57, P138, DOI 10.1128/JVI.57.1.138-144.1986; DEPINHO RA, 1986, P NATL ACAD SCI USA, V83, P1827, DOI 10.1073/pnas.83.6.1827; Flint S. J, 1981, DNA TUMOR VIRUSES; FRIEDMAN M, 1986, CONTEMP POLICY ISSUE, V4, P1, DOI 10.1111/j.1465-7287.1986.tb00827.x; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GUTIERREZ C, 1987, MOL CELL BIOL, V7, P4594, DOI 10.1128/MCB.7.12.4594; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARTZELL SW, 1984, P NATL ACAD SCI-BIOL, V81, P6335, DOI 10.1073/pnas.81.20.6335; HAYDAY AC, 1984, NATURE, V307, P334, DOI 10.1038/307334a0; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HERTZ GZ, 1986, MOL CELL BIOL, V6, P3513, DOI 10.1128/MCB.6.10.3513; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; IGUCHIARIGA SMM, 1987, EMBO J, V6, P2365, DOI 10.1002/j.1460-2075.1987.tb02513.x; IGUCHIARIGA SMM, 1987, NUCLEIC ACIDS RES, V15, P4889, DOI 10.1093/nar/15.12.4889; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KINGSTON RE, 1984, CANCER CELL, V2, P539; KOHL NE, 1984, SCIENCE, V226, P1335, DOI 10.1126/science.6505694; KOZBOR D, 1984, CANCER RES, V44, P438; KUMAR R, 1988, MOL CELL BIOL, V8, P1509, DOI 10.1128/MCB.8.4.1509; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEBKOWSKI JS, 1985, NATURE, V317, P169, DOI 10.1038/317169a0; LEECHEN GJ, 1986, MOL CELL BIOL, V6, P3086, DOI 10.1128/MCB.6.9.3086; LEWIS ED, 1985, NATURE, V317, P172, DOI 10.1038/317172a0; LI JJ, 1986, MOL CELL BIOL, V6, P1117, DOI 10.1128/MCB.6.4.1117; LUSKY M, 1981, NATURE, V293, P79, DOI 10.1038/293079a0; MCCUTCHAN JH, 1968, JNCI-J NATL CANCER I, V41, P351; NEVINS JR, 1989, ADV VIRUS RES, V37, P35; NISEN PD, 1986, CANCER RES, V46, P6217; PARSONS R, 1990, J VIROL, V64, P509, DOI 10.1128/JVI.64.2.509-518.1990; RALSTON R, 1983, NATURE, V306, P803, DOI 10.1038/306803a0; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHWAB M, 1984, P NATL ACAD SCI-BIOL, V81, P4940, DOI 10.1073/pnas.81.15.4940; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1772, DOI 10.1073/pnas.83.6.1772; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; STUDZINSKI GP, 1986, SCIENCE, V234, P467, DOI 10.1126/science.3532322; TRIFILLIS P, 1990, J VIROL, V64, P1345, DOI 10.1128/JVI.64.3.1345-1347.1990; YANCOPOULOS GD, 1985, P NATL ACAD SCI USA, V82, P5455, DOI 10.1073/pnas.82.16.5455	60	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1991	6	7					1161	1169						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1650440				2022-12-25	WOS:A1991GV26000010
J	SAHEKI, T; MIZUNO, T; IWATA, T; SAITO, Y; NAGASAWA, T; MIZUNO, KU; ITO, F; ITO, T; HAGIWARA, H; HIROSE, S				SAHEKI, T; MIZUNO, T; IWATA, T; SAITO, Y; NAGASAWA, T; MIZUNO, KU; ITO, F; ITO, T; HAGIWARA, H; HIROSE, S			STRUCTURE OF THE BOVINE ATRIAL-NATRIURETIC-PEPTIDE RECEPTOR (TYPE-C) GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANYLATE-CYCLASE; SIGNAL-TRANSDUCTION; ENDOTHELIAL-CELLS; MESSENGER-RNA; PORCINE BRAIN; SEQUENCES; PURIFICATION; FAMILY; DNA; TRANSCRIPTION	The bovine gene encoding the type C atrial natriuretic peptide (ANP) receptor was isolated and characterized. The gene appears to exist as a single copy in the haploid genome and is comprised of eight exons distributed over more than 85 kilobases. The transcription start site was identified by primer extension and ribonuclease protection assay. A "TATA" box-like sequence was found just upstream of the start site (at position -32); however, no CAAT box was apparent. Exon boundaries of the ANP receptor gene correlated well with the functional domain boundaries of the receptor protein; for example, exon 1 contains coding information for a large proportion of the ANP-binding domain and the transmembrane and cytoplasmic domains are encoded by separate exons, namely by exon 7 and exon 8, respectively. These structural features suggest that the organization of the ANP receptor gene reflects the domain structure of the receptor.			SAHEKI, T (corresponding author), TOKYO INST TECHNOL,DEPT BIOL SCI,MEGURO KU,TOKYO 152,JAPAN.							AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BAXTER JD, 1988, BIO-TECHNOL, V6, P529, DOI 10.1038/nbt0588-529; BERGER SL, 1987, METHOD ENZYMOL, V152, P559; BERGER SL, 1987, METHOD ENZYMOL, V152, P629; BLAKE C, 1983, NATURE, V306, P535, DOI 10.1038/306535a0; BOVY PR, 1990, MED RES REV, V10, P115, DOI 10.1002/med.2610100105; CHANG M, 1989, NATURE, V341, P68, DOI 10.1038/341068a0; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; CHINKERS M, 1989, SCIENCE, V245, P1392, DOI 10.1126/science.2571188; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CORDEN J, 1980, SCIENCE, V209, P1406, DOI 10.1126/science.6251548; DEBOLD AJ, 1985, SCIENCE, V230, P767, DOI 10.1126/science.2932797; DEBOLD AJ, 1981, LIFE SCI, V28, P89, DOI 10.1016/0024-3205(81)90370-2; FULLER F, 1988, J BIOL CHEM, V263, P9395; GANNON F, 1979, NATURE, V278, P428, DOI 10.1038/278428a0; GILBERT W, 1985, SCIENCE, V228, P823, DOI 10.1126/science.4001923; GOETZ KL, 1988, AM J PHYSIOL, V254, pE1, DOI 10.1152/ajpendo.1988.254.1.E1; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; INAGAMI T, 1989, J BIOL CHEM, V264, P3043; LAWN RM, 1981, SCIENCE, V212, P1159, DOI 10.1126/science.6165082; LEITMAN DC, 1986, J BIOL CHEM, V261, P1650; LOWE DG, 1989, EMBO J, V8, P1377, DOI 10.1002/j.1460-2075.1989.tb03518.x; MAACK T, 1987, SCIENCE, V238, P675, DOI 10.1126/science.2823385; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NAGATA S, 1980, NATURE, V287, P401, DOI 10.1038/287401a0; OLINS GM, 1988, J BIOL CHEM, V263, P10989; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; REDMOND EM, 1990, FEBS LETT, V269, P157, DOI 10.1016/0014-5793(90)81143-C; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCARBOROUGH RM, 1986, J BIOL CHEM, V261, P2960; SCHENK DB, 1987, P NATL ACAD SCI USA, V84, P1521, DOI 10.1073/pnas.84.6.1521; SCHULZ S, 1989, CELL, V58, P1155, DOI 10.1016/0092-8674(89)90513-8; SHIMONAKA M, 1987, J BIOL CHEM, V262, P5510; SUDOH T, 1990, BIOCHEM BIOPH RES CO, V168, P863, DOI 10.1016/0006-291X(90)92401-K; SUDOH T, 1988, NATURE, V332, P78, DOI 10.1038/332078a0; YAMAGUCHI M, 1990, J BIOL CHEM, V265, P20414	39	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					11122	11125						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	1645726				2022-12-25	WOS:A1991FQ77400065
J	MURRELL, JR; SCHONER, RG; LIEPNIEKS, JJ; ROSEN, HN; MOSES, AC; BENSON, MD				MURRELL, JR; SCHONER, RG; LIEPNIEKS, JJ; ROSEN, HN; MOSES, AC; BENSON, MD			PRODUCTION AND FUNCTIONAL-ANALYSIS OF NORMAL AND VARIANT RECOMBINANT HUMAN TRANSTHYRETIN PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL AMYLOIDOTIC POLYNEUROPATHY; POLYMERASE CHAIN-REACTION; BINDING PRE-ALBUMIN; PREALBUMIN VARIANT; HEREDITARY AMYLOIDOSIS; INDIANA SWISS; DNA; THYROXINE; GENE; POLYMORPHISM	The most common form of hereditary systemic amyloidosis is familial amyloidotic polyneuropathy associated with single amino acid changes in the plasma protein, transthyretin. In addition, there are two variants of transthyretin (Ser6 and Thr109) not associated with familial amyloidotic polyneuropathy but with familial euthyroid hyperthyroxinemia, also an autosomal dominant disorder. In these autosomal dominant diseases, most affected individuals are heterozygous and therefore have hybrid forms of the tetrameric plasma transthyretin. In order to study the structure/function relationships of homozygous variant transthyretins, normal human transthyretin and five variant transthyretins (Gly6 --> Ser, Leu58 --> His, Thr60 --> Ala, Ile84 --> Ser, and Ala109 --> Thr) were produced in Escherichia coli using the expression vector, pCZ11, and site-directed mutagenesis. These recombinant transthyretin (r-TTR) proteins showed the correct size (14 kilodaltons) on sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Western analysis and self-associated into tetramers as determined by size exclusion chromatography. Recombinant normal, Ser6, and Ala60 r-TTRs had an affinity for thyroxine indistinguishable from normal human TTR purified from plasma, whereas His58 and Ser84 r-TTRs had significantly reduced affinity. On the other hand, Thr109 r-TTR had a much higher affinity, probably due to its position within the thyroxine-binding pocket. Expression of mutant transthyretins in E. coli provides the opportunity to study structure/function relationships and amyloid-forming capabilities induced by single amino acid substitutions in the transthyretin molecule.	VET AFFAIRS MED CTR, RHEUMATOL SECT, 583-111RH, 1481 W 10TH ST, RM A772, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, DEPT MOLEC GENET, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, DEPT MED, INDIANAPOLIS, IN 46202 USA; ELI LILLY RES LABS, DIV DIABET RES, INDIANAPOLIS, IN 46202 USA; CHARLES A DANA RES INST, DIABET UNIT, BOSTON, MA 02215 USA; CHARLES A DANA RES INST, THYROID UNIT, BOSTON, MA 02215 USA; BETH ISRAEL HOSP, HARVARD THORNDIKE LABS, BOSTON, MA 02215 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Eli Lilly; Harvard University; Harvard University; Harvard University; Beth Israel Deaconess Medical Center					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018416, R01DK034881] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR20582] Funding Source: Medline; NIDDK NIH HHS [DK34881, DK18416] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALMEIDA MR, 1991, BASIC RES CARDIOL, V86, P567, DOI 10.1007/BF02190707; ALMEIDA MR, 1990, AMYLOID AMYLOIDOSIS, P599; Benson MD, 1989, METABOLIC BASIS INHE, P2439; BLAKE CCF, 1977, NATURE, V268, P115, DOI 10.1038/268115a0; BLAKE CCF, 1978, J MOL BIOL, V121, P339, DOI 10.1016/0022-2836(78)90368-6; BLAKE CCF, 1978, BIOCHEM SOC T, V6, P114; DWULET FE, 1983, BIOCHEM BIOPH RES CO, V114, P657, DOI 10.1016/0006-291X(83)90831-8; DWULET FE, 1986, J CLIN INVEST, V78, P880, DOI 10.1172/JCI112675; FITCH NJS, 1991, J ENDOCRINOL, V129, P309, DOI 10.1677/joe.0.1290309; FURUYA H, 1991, BIOCHEMISTRY-US, V30, P2415, DOI 10.1021/bi00223a017; GOREVIC PD, 1989, J CLIN INVEST, V83, P836, DOI 10.1172/JCI113966; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HAMILTON JA, 1991, AMYLOID AND AMYLOIDOSIS 1990, P579; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; II S, 1991, NEUROLOGY, V41, P893, DOI 10.1212/WNL.41.6.893; JONES LA, 1991, AM J HUM GENET, V48, P979; MAHADIK SP, 1976, ANAL BIOCHEM, V76, P615, DOI 10.1016/0003-2697(76)90355-9; Maniatis T., 1982, MOL CLONING LABORATO, pA840 A851; MOSES AC, 1990, J CLIN INVEST, V86, P2025, DOI 10.1172/JCI114938; NAKAZATO M, 1984, BIOCHEM BIOPH RES CO, V123, P921, DOI 10.1016/S0006-291X(84)80222-3; NICHOLS WC, 1989, GENOMICS, V5, P535, DOI 10.1016/0888-7543(89)90020-7; NORDLIE M, 1988, SCAND J IMMUNOL, V27, P119, DOI 10.1111/j.1365-3083.1988.tb02329.x; REFETOFF S, 1986, J CLIN ENDOCR METAB, V63, P1432, DOI 10.1210/jcem-63-6-1432; SAEKI Y, 1991, BIOCHEM BIOPH RES CO, V180, P380, DOI 10.1016/S0006-291X(05)81304-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARAIVA MJM, 1990, FAMILIAL AMYLOIDOTIC, V3, P107; SCHONER BE, 1986, P NATL ACAD SCI USA, V83, P8506, DOI 10.1073/pnas.83.22.8506; SKARE J, 1990, AM J HUM GENET, V47, pA482; SKARE JC, 1991, CLIN GENET, V39, P6; STEINRAUF LK, 1991, BIOCHEM BIOPH RES CO, V179, P804, DOI 10.1016/0006-291X(91)91888-J; UENO S, 1990, BIOCHEM BIOPH RES CO, V169, P143, DOI 10.1016/0006-291X(90)91445-X; UENO S, 1990, BIOCHEM BIOPH RES CO, V169, P1117, DOI 10.1016/0006-291X(90)92011-N; UENO S, 1991, AMYLOID AND AMYLOIDOSIS 1990, P622; WALLACE MR, 1988, AM J HUM GENET, V43, P182; WALLACE MR, 1985, BIOCHEM BIOPH RES CO, V129, P753, DOI 10.1016/0006-291X(85)91956-4; WALLACE MR, 1986, J CLIN INVEST, V78, P6, DOI 10.1172/JCI112573; WALLACE MR, 1988, J CLIN INVEST, V81, P189, DOI 10.1172/JCI113293; ZON LI, 1989, BIOTECHNIQUES, V7, P696	38	30	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16595	16600						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1644839				2022-12-25	WOS:A1992JJ45800093
J	WALDSCHMIDT, R; SEIFART, KH				WALDSCHMIDT, R; SEIFART, KH			TFIIA IS REQUIRED FOR INVITRO TRANSCRIPTION OF MAMMALIAN U6 GENES BY RNA POLYMERASE-III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACCURATE TRANSCRIPTION; INITIATION-FACTOR; IDENTIFICATION; PURIFICATION; EXPRESSION; ACTIVATION; PROMOTER; DUCK	Transcription factor TFIIA, defined by its role in transcription by RNA polymerase II, is also involved in RNA polymerase III transcription of mammalian U6 small nuclear RNA genes. This finding was substantiated by experimental evidence including (i) extensive copurification of an activity required for U6 transcription with TFIIA, (ii) the comparable molecular dimensions of this activity and TFIIA, (iii) the identical heat stability of both activities, and (iv) functional analyses revealing that TFIIA facilitates the interaction of TFIID with the TATA box of the U6 gene. As was shown previously for TFIID, TFIIA is the second basal transcription factor which could be demonstrated to be involved in gene expression by two different RNA polymerases.	UNIV MARBURG, INST MOLEK BIOL & TUMORFORSCH, LAHNSTR 3, W-3550 MARBURG, GERMANY	Philipps University Marburg								AGARWAL KL, 1972, ANGEW CHEM INT EDIT, V11, P451, DOI 10.1002/anie.197204511; BENECKE BJ, 1975, BIOCHIM BIOPHYS ACTA, V414, P44, DOI 10.1016/0005-2787(75)90124-0; BUNGERT J, 1992, J MOL BIOL, V223, P885, DOI 10.1016/0022-2836(92)90250-N; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; DURING F, 1990, NUCLEIC ACIDS RES, V18, P1225, DOI 10.1093/nar/18.5.1225; EGLY JM, 1984, EMBO J, V3, P2363, DOI 10.1002/j.1460-2075.1984.tb02141.x; FIRE A, 1984, J BIOL CHEM, V259, P2509; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KUNKEL GR, 1986, P NATL ACAD SCI USA, V83, P8575, DOI 10.1073/pnas.83.22.8575; KUNKEL GR, 1991, BIOCHIM BIOPHYS ACTA, V1088, P1, DOI 10.1016/0167-4781(91)90146-D; LOBO SM, 1989, CELL, V58, P55, DOI 10.1016/0092-8674(89)90402-9; LOBO SM, 1991, GENE DEV, V5, P1477, DOI 10.1101/gad.5.8.1477; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REINBERG D, 1987, J BIOL CHEM, V262, P3322; SAMUELS M, 1986, J BIOL CHEM, V261, P2003; SAMUELS M, 1982, J BIOL CHEM, V257, P4419; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SEIFART KH, 1989, J BIOL CHEM, V264, P1702; SIMMEN KA, 1990, NUCLEIC ACIDS RES, V18, P5649, DOI 10.1093/nar/18.19.5649; SIMMEN KA, 1991, EMBO J, V10, P1853, DOI 10.1002/j.1460-2075.1991.tb07711.x; SIMMEN KA, 1992, J MOL BIOL, V223, P873, DOI 10.1016/0022-2836(92)90249-J; SUMIMOTO H, 1990, P NATL ACAD SCI USA, V87, P9158, DOI 10.1073/pnas.87.23.9158; USUDA Y, 1991, EMBO J, V10, P2305, DOI 10.1002/j.1460-2075.1991.tb07767.x; WALDSCHMIDT R, 1991, EMBO J, V10, P2595, DOI 10.1002/j.1460-2075.1991.tb07801.x; WALDSCHMIDT R, 1988, J BIOL CHEM, V263, P13350; WEINGART S, 1989, EUR J BIOCHEM, V183, P145, DOI 10.1111/j.1432-1033.1989.tb14906.x; WINGENDER E, 1986, J BIOL CHEM, V261, P1409	29	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16359	16364						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1644819				2022-12-25	WOS:A1992JJ45800059
J	SHIRINSKY, VP; BIRYUKOV, KG; HETTASCH, JM; SELLERS, JR				SHIRINSKY, VP; BIRYUKOV, KG; HETTASCH, JM; SELLERS, JR			INHIBITION OF THE RELATIVE MOVEMENT OF ACTIN AND MYOSIN BY CALDESMON AND CALPONIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; ATPASE ACTIVITY; LIGHT-CHAIN; CYTOPLASMIC MYOSINS; QUANTITATIVE ASSAY; INVITRO MOVEMENT; HEAVY-MEROMYOSIN; SKELETAL-MUSCLE; PHOSPHORYLATION; BINDING	Contractile activity of myosin II in smooth muscle and non-muscle cells requires phosphorylation of myosin by myosin light chain kinase. in addition, these cells have the potential for regulation at the thin filament level by caldesmon and calponin, both of which bind calmodulin. We have investigated this regulation using in vitro motility assays. Caldesmon completely inhibited the movement of actin filaments by either phosphorylated smooth muscle myosin or rabbit skeletal muscle heavy meromyosin. The amount of caldesmon required for inhibition was decreased when tropomyosin is present. Similarly, calponin binding to actin resulted in inhibition of actin filament movement by both smooth muscle myosin and skeletal muscle heavy meromyosin. Tropomyosin had no effect on the amount of calponin needed for inhibition. High concentrations of calmodulin (10-mu-M) in the presence of calcium completely reversed the inhibition. The nature of the inhibition by the two proteins was markedly different. Increasing caldesmon concentrations resulted in graded inhibition of the movement of actin filaments until complete inhibition of movement was obtained. Calponin inhibited actin sliding in a more "all or none" fashion. As the calponin concentration was increased the number of actin filaments moving was markedly decreased, but the velocity of movement remained near control values.	NHLBI, MOLEC CARDIOL LAB, BLDG 10, RM 8N202, BETHESDA, MD 20892 USA; RUSSIAN ACAD MED SCI, NATL CARDIOL RES CTR, 121552 MOSCOW, USSR	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Medical Research Center of Cardiology; Russian Academy of Medical Sciences			Shirinsky, Vladimir/AAN-3938-2020					ABE M, 1990, J BIOCHEM-TOKYO, V108, P835, DOI 10.1093/oxfordjournals.jbchem.a123289; ADELSTEIN RS, 1982, METHOD ENZYMOL, V85, P298; BRETSCHER A, 1984, J BIOL CHEM, V259, P2873; BRYAN J, 1989, J BIOL CHEM, V264, P13873; CHALOVICH JM, 1987, J BIOL CHEM, V262, P5711; EISENBERG E, 1974, J BIOL CHEM, V249, P4742; HAI CM, 1988, AM J PHYSIOL, V255, pC86, DOI 10.1152/ajpcell.1988.255.1.C86; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, P423; HAYASHI K, 1989, BIOCHEM BIOPH RES CO, V164, P503, DOI 10.1016/0006-291X(89)91748-8; HEMRIC ME, 1988, J BIOL CHEM, V263, P1878; HEMRIC ME, 1990, J BIOL CHEM, V265, P19672; HOMSHER E, 1992, AM J PHYSIOL, V262, pC714, DOI 10.1152/ajpcell.1992.262.3.C714; HONDA H, 1989, J MOL BIOL, V205, P677, DOI 10.1016/0022-2836(89)90313-6; HORIUCHI KY, 1991, BIOCHEM BIOPH RES CO, V176, P1487, DOI 10.1016/0006-291X(91)90455-G; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; KRON SJ, 1991, METHOD ENZYMOL, V196, P399; MAK AS, 1991, J BIOL CHEM, V266, P6678; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; MARSTON SB, 1991, BIOCHEM J, V279, P1; NGAI PK, 1984, J BIOL CHEM, V259, P3656; NGAI PK, 1987, BIOCHEM J, V244, P417, DOI 10.1042/bj2440417; OKAGAKI T, 1991, J BIOCHEM, V109, P858, DOI 10.1093/oxfordjournals.jbchem.a123471; Sellers JR, 1991, CURR OPIN CELL BIOL, V3, P98, DOI 10.1016/0955-0674(91)90171-T; SELLERS JR, 1985, J CELL BIOL, V101, P1897, DOI 10.1083/jcb.101.5.1897; SELLERS JR, 1985, J BIOL CHEM, V260, P5815; Sellers JR, 1987, ENZYMES, V18, ppp381, DOI 10.1016/S1874-6047(08)60264-4; SHEETZ MP, 1986, METHOD ENZYMOL, V134, P531; SHEETZ MP, 1984, J CELL BIOL, V99, P1867, DOI 10.1083/jcb.99.5.1867; SHIRINSKY VP, 1989, FEBS LETT, V251, P65, DOI 10.1016/0014-5793(89)81429-2; SOBUE K, 1991, J BIOL CHEM, V266, P12115; SOBUE K, 1985, BIOCHEM BIOPH RES CO, V132, P645, DOI 10.1016/0006-291X(85)91181-7; SUTHERLAND C, 1989, J BIOL CHEM, V264, P578; TAKAHASHI K, 1986, BIOCHEM BIOPH RES CO, V141, P20, DOI 10.1016/S0006-291X(86)80328-X; TAKAHASHI K, 1991, J BIOL CHEM, V266, P13284; TANAKA T, 1990, EUR J BIOCHEM, V188, P495, DOI 10.1111/j.1432-1033.1990.tb15427.x; TRYBUS KM, 1989, J CELL BIOL, V109, P2887, DOI 10.1083/jcb.109.6.2887; UMEMOTO S, 1990, J BIOL CHEM, V265, P14864; UMEMOTO S, 1989, J BIOL CHEM, V264, P1431; WANG CLA, 1991, J BIOL CHEM, V266, P13958; WARSHAW DM, 1990, J CELL BIOL, V111, P453, DOI 10.1083/jcb.111.2.453; WINDER SJ, 1990, J BIOL CHEM, V265, P10148	42	172	176	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15886	15892						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1639818				2022-12-25	WOS:A1992JG11300094
J	BEHARA, AMP; WESTCOTT, AJ; CHANG, PL				BEHARA, AMP; WESTCOTT, AJ; CHANG, PL			INTRATHYMIC IMPLANTS OF GENETICALLY MODIFIED FIBROBLASTS	FASEB JOURNAL			English	Article						GENE THERAPY; HUMAN GROWTH HORMONE; CYCLOSPORINE-A; THYMUS; TRANSPLANTATION	HUMAN-GENE THERAPY; T-CELL RECEPTOR; ENDOTHELIAL-CELLS; SKIN FIBROBLASTS; CYCLOSPORINE-A; EXPRESSION; TOLERANCE; HEPATOCYTES; DELETIONS; VECTORS	Implantation of autologous rodent fibroblasts genetically altered to express human growth hormone has recently been shown to be a feasible approach to the delivery of new gene products in,somatic gene therapy. However, the novel gene product elicited in its recipients an intense antibody response that would have curtailed the effectiveness of such therapy. The possibility of inducing tolerance to foreign gene product was explored by implanting allogeneic fibroblasts transfected with the human growth hormone gene into rat thymus, a site recently shown to be immunologically privileged and able to induce donor-specific tolerance to transplanted tissues. In the circulation of the implanted rats, human growth hormone was detected at 4-15 ng/ml serum within the first day and subsided to 0.6-9 ng/ml within the first wk in all animals implanted either thymically or intraperitoneally. Within 2-3 wk, high titers of anti-human growth hormone were detected in all animals regardless of the site of implantation. The failure of the thymus to offer immune protection for the foreign antigen was further confirmed when the animals were subsequently challenged with purified human growth hormone. An immediate twofold increase in titer within the first week of challenge was detected in animals previously implanted thymically. In contrast, animals implanted intraperitoneally but treated with short-term daily injection of cyclosporine A (28-41 days) did not mount any significant antibody response to human growth hormone throughout the experiment or even when challenged subsequently at weeks 8-10 with purified growth hormone. In conclusion, implantation of genetically modified fibroblasts in the thymus does not lead to tolerization toward soluble novel gene product secreted by these cells. However, a limited course of cyclosporine A treatment was effective for prolonged suppression of antibody response to novel gene products.	MCMASTER UNIV, MED CTR,DEPT PEDIAT,ROOM HSC 3N18,1200 MAIN ST W, HAMILTON L8N 3Z5, ONTARIO, CANADA; MCMASTER UNIV, DEPT BIOMED SCI, HAMILTON L8N 3Z5, ONTARIO, CANADA; MCMASTER UNIV, DEPT BIOL, HAMILTON L8N 3Z5, ONTARIO, CANADA	McMaster University; McMaster University; McMaster University								ANDERSON WF, 1984, SCIENCE, V226, P401, DOI 10.1126/science.6093246; BENNETT VJ, 1990, MOL BIOL MED, V7, P471; BENNETT VJ, 1991, LIFE SCI, V48, P1455, DOI 10.1016/0024-3205(91)90182-B; BLAESE M, 1991, 8TH INT C HUM GEN WA; BOREL JF, 1976, AGENTS ACTIONS, V6, P468, DOI 10.1007/BF01973261; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; CHANG PL, 1986, EXP CELL RES, V167, P407, DOI 10.1016/0014-4827(86)90181-3; CHANG PL, 1990, MOL BIOL MED, V7, P461; CULVER K, 1991, P NATL ACAD SCI USA, V88, P3155, DOI 10.1073/pnas.88.8.3155; DZIERZAK EA, 1988, NATURE, V331, P35, DOI 10.1038/331035a0; FERRARI G, 1991, SCIENCE, V251, P1363, DOI 10.1126/science.1848369; GARVER RI, 1987, P NATL ACAD SCI USA, V84, P1050, DOI 10.1073/pnas.84.4.1050; GRAHAM FL, 1983, NUCLEIC ACIDS BIOC B, V506, P1; HOBBS HH, 1988, J CLIN INVEST, V81, P909, DOI 10.1172/JCI113402; JENKINS MK, 1988, SCIENCE, V241, P1655, DOI 10.1126/science.3262237; KAHAN BD, 1989, NEW ENGL J MED, V321, P1725; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KUNKEL LM, 1986, NATURE, V322, P73, DOI 10.1038/322073a0; LANCE EM, 1973, ADV IMMUNOL, V17, P1; LEDLEY FD, 1987, P NATL ACAD SCI USA, V84, P5335, DOI 10.1073/pnas.84.15.5335; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MCCORMICK D, 1985, BIO-TECHNOL, V3, P689; MICHIE SA, 1988, J EXP MED, V168, P1929, DOI 10.1084/jem.168.5.1929; OSBORNE WRA, 1988, P NATL ACAD SCI USA, V85, P6851, DOI 10.1073/pnas.85.18.6851; PALMER TD, 1987, P NATL ACAD SCI USA, V84, P1055, DOI 10.1073/pnas.84.4.1055; POSSELT AM, 1990, SCIENCE, V249, P1293, DOI 10.1126/science.2119056; REIS MD, 1989, ADV CANCER RES, V52, P45; REMUZZI G, 1991, LANCET, V337, P750, DOI 10.1016/0140-6736(91)91368-5; SCHALCH DS, 1964, NATURE, V203, P1141, DOI 10.1038/2031141a0; SCHWARTZ RH, 1989, CELL, V57, P1073, DOI 10.1016/0092-8674(89)90044-5; SELDEN RF, 1987, SCIENCE, V236, P714, DOI 10.1126/science.3472348; SHEVACH EM, 1985, ANNU REV IMMUNOL, V3, P397; STLOUIS D, 1988, P NATL ACAD SCI USA, V85, P3150; TEUMER J, 1990, FASEB J, V4, P3245, DOI 10.1096/fasebj.4.14.2227214; WEATHERALL DJ, 1989, METABOLIC BASIS INHE, P2281; WILSON JM, 1989, SCIENCE, V244, P1344, DOI 10.1126/science.2734614; WILSON JM, 1988, P NATL ACAD SCI USA, V85, P4421, DOI 10.1073/pnas.85.12.4421; WILSON JM, 1991, 8TH INT C HUM GEN WA; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; ZWIEBEL JA, 1989, SCIENCE, V243, P220, DOI 10.1126/science.2911735	40	11	14	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1992	6	10					2853	2858		10.1096/fasebj.6.10.1634049	http://dx.doi.org/10.1096/fasebj.6.10.1634049			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JD954	1634049				2022-12-25	WOS:A1992JD95400015
J	DAVID, P; KARLISH, SJD				DAVID, P; KARLISH, SJD			CHARACTERIZATION OF LANTHANIDES AS COMPETITORS OF NA+ AND K+ IN OCCLUSION SITES OF RENAL (NA+,K+)-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM ATPASE; (CA-2+ + MG-2+)-ATPASE; PHOSPHOLIPID-VESICLES; ENERGY-TRANSFER; RB+-OCCLUSION; BINDING-SITE; CALCIUM; LUMINESCENCE; CONFORMATION; NA,K-ATPASE	Lanthanides are useful probes in Ca2+ binding proteins, including sarcoplasmic reticulum (Ca2+,Mg2+) ATPase. Here, we report that lanthanides compete with Rb+ and Na+ for occlusion in renal (Na+,K+)-ATPase. The lanthanides appear to bind at a single site and act as competitive antagonists, without themselves becoming occluded. All lanthanides tested are effective with the order of potencies Pr > Nd > La > Eu > Tb > Ho > Er, but differences are small. The presence of Mg2+ ions does not affect competition of La3+ with Na+ or K+ suggesting that the effects are not exerted via divalent metal sites. Lanthanides compete with Rb+ and Na+ in membranes digested with trypsin so as to produce 19-kDa and smaller fragments of the alpha-chain (Karlish, S. J. D., Goldshleger, R., and Stein, W. D. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 4566-4570), also suggestive of a direct interaction of lanthanides with Na+ and K+ sites. Effects of lanthanides on conformational changes of fluorescein-labeled (Na+,K+)-ATPase are Na+-like. They stabilize the E, state and compete with K+ ions. The K(i) for La3+ is 0.445-mu-M. The apparent affinity in fluorescence assays is proportional to enzyme concentration (K(i) = 32.4*[protein] + 0.445-mu-M La3+), suggesting that lanthanides are also bound nonspecifically (possibly to phospholipids). Direct assays confirm that Tb3+ binding is nonspecific. Measurements of the rate of various conformational transitions show that the rate of E2(K+) --> E1(X) (X = Na+ or La3+) is significantly inhibited by La3+ compared to Na+. La3+ ions also slightly accelerate the rate of the E1 --> E2(K+) conformational transition. The dissociation rate of La3+ has been measured by monitoring the rate of E1(La3+) --> E2(K+). It is 1.741 s-1 at 25-degrees-C. Based on this value, it is unlikely that La3+ ions are stably occluded, consistent with the conclusion from occlusion experiments. In the future, lanthanides bound to monovalent cation sites with high affinity may become useful probes for location and characterization of sites, although it will be necessary to take into account the large amount of nonspecific binding.	WEIZMANN INST SCI,DEPT BIOCHEM,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								BARELA TD, 1976, ANAL BIOCHEM, V71, P351, DOI 10.1016/S0003-2697(76)80004-8; BIRNIR B, 1987, J MEMBRANE BIOL, V100, P221, DOI 10.1007/BF02209153; ESMANN M, 1985, BIOCHEM BIOPH RES CO, V127, P857, DOI 10.1016/S0006-291X(85)80022-X; FUJIMORI T, 1990, J BIOL CHEM, V265, P16262; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; GOLDSHLEGGER R, 1987, J PHYSIOL-LONDON, V387, P331, DOI 10.1113/jphysiol.1987.sp016576; HANEL AM, 1990, BIOCHEMISTRY-US, V29, P5210, DOI 10.1021/bi00473a030; HERRMANN TR, 1988, MOL CELL BIOCHEM, V82, P55; HERRMANN TR, 1986, EUR J BIOCHEM, V158, P555, DOI 10.1111/j.1432-1033.1986.tb09790.x; HIGHSMITH SR, 1983, J BIOL CHEM, V258, P6858; JONA I, 1986, BIOCHEM J, V234, P363, DOI 10.1042/bj2340363; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P35; KARLISH SJD, 1980, J BIOENERG BIOMEMBR, V12, P111, DOI 10.1007/BF00744678; KARLISH SJD, 1990, P NATL ACAD SCI USA, V87, P4566, DOI 10.1073/pnas.87.12.4566; MARTIN RB, 1979, Q REV BIOPHYS, V12, P181, DOI 10.1017/S0033583500002754; MARTIN RB, 1984, METAL IONS BIOL, V17, P2; REPHAELI A, 1986, J BIOL CHEM, V261, P6248; RONJAT M, 1987, J BIOL CHEM, V262, P3146; SCOTT TL, 1984, J BIOL CHEM, V259, P4035; SCOTT TL, 1985, J BIOL CHEM, V260, P4421; SCOTT TL, 1988, MOL CELL BIOCHEM, V82, P51; SHANI M, 1987, BIOCHIM BIOPHYS ACTA, V904, P13, DOI 10.1016/0005-2736(87)90081-2; SHANISEKLER M, 1988, J BIOL CHEM, V263, P19331; SQUIER TC, 1990, J BIOL CHEM, V265, P13713; SQUIER TC, 1987, J BIOL CHEM, V262, P4748; STEWART JMM, 1989, BIOCHEMISTRY-US, V28, P4695, DOI 10.1021/bi00437a028	26	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					14896	14902						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1651313				2022-12-25	WOS:A1991GB09700018
J	HILLERY, CA; SMYTH, SS; PARISE, LV				HILLERY, CA; SMYTH, SS; PARISE, LV			PHOSPHORYLATION OF HUMAN PLATELET GLYCOPROTEIN-IIIA (GPIIIA) - DISSOCIATION FROM FIBRINOGEN RECEPTOR ACTIVATION AND PHOSPHORYLATION OF GPIIIA INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; STIMULATED HUMAN-PLATELETS; INTACT HUMAN-PLATELETS; IIB-IIIA; VITRONECTIN RECEPTOR; PLASMA-MEMBRANES; THROMBIN; COMPLEX; ADHESION; BINDING	Glycoprotein IIb-IIIa (GPIIb-IIIa) is the fibrinogen receptor on activated platelets. GPIIIa is phosphorylated in resting platelets and the incorporation of P-32i increases with platelet activation. To address the functional significance of this modification, the stoichiometry of GPIIIa phosphorylation was determined in resting and activated platelets by estimating the specific activity of metabolic [gamma-P-32] ATP from the specific activity of phosphatidic acid. Approximately 0.01 mol of P/mol of GPIIIa was phosphorylated in resting platelets and 0.03 mol of P/mol of GPIIIa was phosphorylated in thrombin-, phorbol ester-, or U46619-treated platelets. Myosin light chain (MLC) phosphorylation served as a positive control for this method (1.2 mol of P/mol of MLC). Phosphorylation of purified GPIlb-IIIa by human platelet protein kinase C (PKC) resulted in levels of GPIIIa phosphorylation similar to that in platelets (0.05 mol of P/mol of GPIIIa). However, while GPIIIa in platelets was phosphorylated primarily on threonine, purified GPIIIa treated with PKC was phosphorylated primarily on serine. These results suggest that PKC may not directly phosphorylate GPIIIa in intact platelets. Ca 2+/Calmodulin-dependent kinase II phosphorylated purified GPIIIa to higher levels (0.5 mol of P/mol of GPIIIa) with phosphorylation on both threonine and serine. The limited phosphorylation of GPIIIa in intact platelets suggests that this event is unlikely to affect functions involving large populations of GPIIb-IIIa, such as its conversion to a fibrinogen receptor. However, these results may suggest the existence of a more readily phosphorylated subpopulation of GPIIb-IIIa with potentially distinct structural or functional properties.	UNIV N CAROLINA,DEPT PEDIAT,DIV HEMATOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT MED,DIV HEMATOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	HILLERY, CA (corresponding author), UNIV N CAROLINA,SCH MED,CTR THROMBOSIS & HEMOSTASIS,DEPT PHARMACOL,CB 7365,1106 FLOB,CHAPEL HILL,NC 27599, USA.				NHLBI NIH HHS [HL07149-15, R29HL38405] Funding Source: Medline; NIGMS NIH HHS [GM07040] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL038405] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007040] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKKERMAN JWN, 1980, BRIT J HAEMATOL, V44, P291, DOI 10.1111/j.1365-2141.1980.tb01211.x; ALLAN D, 1978, BIOCHIM BIOPHYS ACTA, V508, P277, DOI 10.1016/0005-2736(78)90330-9; BANGA HS, 1986, P NATL ACAD SCI USA, V83, P9197, DOI 10.1073/pnas.83.23.9197; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; BRAY PF, 1990, J BIOL CHEM, V265, P9587; CHATILA TA, 1989, J CELL BIOL, V109, P3435, DOI 10.1083/jcb.109.6.3435; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; CIERNIEWSKI CS, 1989, J BIOL CHEM, V264, P12158; COLLER BS, 1991, BLOOD, V77, P75; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; FERRELL JE, 1989, P NATL ACAD SCI USA, V86, P2234, DOI 10.1073/pnas.86.7.2234; FERRELL JE, 1984, J CELL BIOL, V98, P1992, DOI 10.1083/jcb.98.6.1992; FERRELL JE, 1989, J BIOL CHEM, V264, P20723; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; FITZGERALD LA, 1985, ANAL BIOCHEM, V151, P169, DOI 10.1016/0003-2697(85)90067-3; FOX JEB, 1982, J BIOL CHEM, V257, P4120; FREED E, 1989, EMBO J, V8, P2955, DOI 10.1002/j.1460-2075.1989.tb08445.x; FREED E, 1989, J CELL BIOL, V107, pA152; FUJIMOTO T, 1982, J CLIN INVEST, V69, P1212, DOI 10.1172/JCI110560; HIRST R, 1986, P NATL ACAD SCI USA, V83, P6470, DOI 10.1073/pnas.83.17.6470; HOLMSEN H, 1984, BIOCHEM J, V222, P157, DOI 10.1042/bj2220157; ISENBERG WM, 1987, J CELL BIOL, V104, P1655, DOI 10.1083/jcb.104.6.1655; ITAYA K, 1966, CLIN CHIM ACTA, V14, P361, DOI 10.1016/0009-8981(66)90114-8; KARCZEWSKI J, 1989, J BIOL CHEM, V264, P21322; KAWAMOTO S, 1989, J BIOL CHEM, V264, P2258; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM SCT, 1989, J BIOL CHEM, V264, P3742; LOFTUS JC, 1988, J BIOL CHEM, V263, P11025; MACNICOL M, 1990, J BIOL CHEM, V265, P18055; MARGUERIE GA, 1980, J BIOL CHEM, V255, P154; NEWMAN PJ, 1985, BLOOD, V65, P227; PAINTER RG, 1985, J CELL BIOL, V100, P652, DOI 10.1083/jcb.100.2.652; PARISE LV, 1990, BLOOD, V75, P2363; PARISE LV, 1985, J BIOL CHEM, V260, P698; PHILLIPS DR, 1983, J BIOL CHEM, V258, P240; PHILLIPS DR, 1980, J CELL BIOL, V86, P77, DOI 10.1083/jcb.86.1.77; PHILLIPS DR, 1988, BLOOD, V71, P831; PLOW EF, 1981, J BIOL CHEM, V256, P9477; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; SANO K, 1983, J BIOL CHEM, V258, P2010; SHAW LM, 1990, J CELL BIOL, V110, P2167, DOI 10.1083/jcb.110.6.2167; TSUKUDA M, 1988, BIOCHEM BIOPH RES CO, V155, P1387, DOI 10.1016/S0006-291X(88)81295-6; WEISS HJ, 1989, J CLIN INVEST, V83, P288, DOI 10.1172/JCI113871; WENCELDRAKE JD, 1986, AM J PATHOL, V124, P324; WILSON DB, 1985, J BIOL CHEM, V260, P1046	46	82	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14663	14669						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1650365				2022-12-25	WOS:A1991FZ35100084
J	IKEDA, A; OKUNO, S; FUJISAWA, H				IKEDA, A; OKUNO, S; FUJISAWA, H			STUDIES ON THE GENERATION OF CA2+ CALMODULIN-INDEPENDENT ACTIVITY OF CALMODULIN-DEPENDENT PROTEIN KINASE-II BY AUTOPHOSPHORYLATION - AUTOTHIOPHOSPHORYLATION OF THE ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; MICROTUBULE ASSEMBLY INVITRO; TRYPTOPHAN 5-MONOOXYGENASE; MOLECULAR-CLONING; SMOOTH-MUSCLE; CA-2+-INDEPENDENT ACTIVITY; PHYSICOCHEMICAL PROPERTIES; TYROSINE 3-MONOOXYGENASE; CATALYTIC SUBUNIT; BINDING-PROTEINS	The mechanism for the generation of the Ca2+/calmodulin (CaM)-independent activity of calmodulin-dependent protein kinase II (CaM-kinase II) by autophosphorylation was studied by characterizing the autothiophosphorylated enzyme, which is resistant to hydrolysis. When CaM-kinase II was incubated with adenosine 5'-O-(thiotriphosphate) at 5-degrees-C, the incorporation of thiophosphate into the enzyme occurred rapidly, reaching a maximum level within a few minutes, in parallel with increase in Ca2+/CaM-independent activity. The maximum level was 1 mol of thiophosphate per mol of subunit of the enzyme, and the thiophosphorylation occurred exclusively at Thr286 in the a subunit and Thr287 in the other subunits of the enzyme. These results, taken together, indicate that the autothiophosphorylation of Thr286/Thr287 of each subunit is involved in the generation of the Ca2+/CaM-independent activity. The activity of the autothiophosphorylated enzyme, when assayed in the presence of Ca2+/CaM, showed the same kinetic properties as did the Ca2+/CaM-dependent activity of the original nonphosphorylated enzyme, but when assayed in the absence of Ca2+/CaM, it showed the same V(max) as the Ca2+/CaM-dependent activity but higher K(m) values for protein substrates. Thus, the phosphorylation of Thr286/Thr287 of the subunit of the enzyme by autophosphorylation appears to not only enhance the affinity of its substrate-binding site for the protein substrate, although it is lower than that of the enzyme activated by the binding of CaM, but also convert the active site to the fully active state.			IKEDA, A (corresponding author), ASAHIKAWA MED COLL,DEPT BIOCHEM,ASAHIKAWA 078,JAPAN.							BASS M, 1987, J NEUROCHEM, V49, P1116, DOI 10.1111/j.1471-4159.1987.tb10001.x; BENNETT MK, 1983, J BIOL CHEM, V258, P2735; BENNETT MK, 1987, P NATL ACAD SCI USA, V84, P1794, DOI 10.1073/pnas.84.7.1794; BORISY GG, 1975, ANN NY ACAD SCI, V253, P107, DOI 10.1111/j.1749-6632.1975.tb19196.x; BULLEIT RF, 1988, NEURON, V1, P63, DOI 10.1016/0896-6273(88)90210-3; CONTI MA, 1981, J BIOL CHEM, V256, P3178; Corbin J D, 1974, Methods Enzymol, V38, P287; CORVERA S, 1988, J BIOL CHEM, V263, P3116; COX DE, 1982, J BIOL CHEM, V257, P2728; DEDMAN JR, 1977, J BIOL CHEM, V252, P8415; DEDMAN JR, 1978, J BIOL CHEM, V253, P343; EBASHI S, 1976, J BIOCHEM-TOKYO, V79, P229, DOI 10.1093/oxfordjournals.jbchem.a131052; FONG YL, 1989, J BIOL CHEM, V264, P16759; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; GRAND RJA, 1980, BIOCHEM J, V189, P227, DOI 10.1042/bj1890227; HAAVIK J, 1988, BIOCHIM BIOPHYS ACTA, V953, P142, DOI 10.1016/0167-4838(88)90019-2; HASHIMOTO Y, 1987, ARCH BIOCHEM BIOPHYS, V252, P418, DOI 10.1016/0003-9861(87)90048-8; HASHIMOTO Y, 1988, P NATL ACAD SCI USA, V85, P7001, DOI 10.1073/pnas.85.18.7001; IKEBE M, 1985, J BIOL CHEM, V260, P4547; JOHNS EW, 1967, BIOCHEM J, V104, P78, DOI 10.1042/bj1040078; KARR TL, 1979, J BIOL CHEM, V254, P6107; KATOH T, 1991, BIOCHIM BIOPHYS ACTA, V1091, P205, DOI 10.1016/0167-4889(91)90063-4; KIM H, 1979, J CELL BIOL, V80, P266, DOI 10.1083/jcb.80.2.266; KUMAGAI H, 1986, J BIOCHEM-TOKYO, V99, P521, DOI 10.1093/oxfordjournals.jbchem.a135507; LAI Y, 1986, P NATL ACAD SCI USA, V83, P4253, DOI 10.1073/pnas.83.12.4253; LAI Y, 1987, P NATL ACAD SCI USA, V84, P5710, DOI 10.1073/pnas.84.16.5710; LEE YC, 1984, J BIOL CHEM, V259, P1226; LICKTEIG R, 1988, J BIOL CHEM, V263, P19232; LIN CR, 1987, P NATL ACAD SCI USA, V84, P5962, DOI 10.1073/pnas.84.16.5962; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MERCIER JC, 1971, EUR J BIOCHEM, V23, P41, DOI 10.1111/j.1432-1033.1971.tb01590.x; MILLER SG, 1988, NEURON, V1, P593, DOI 10.1016/0896-6273(88)90109-2; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; OKUNO S, 1990, BIOCHIM BIOPHYS ACTA, V1038, P204, DOI 10.1016/0167-4838(90)90206-U; OKUNO S, 1982, EUR J BIOCHEM, V122, P49, DOI 10.1111/j.1432-1033.1982.tb05846.x; OLIVER D, 1972, BIOCHEM J, V129, P349, DOI 10.1042/bj1290349; PERRIE WT, 1970, BIOCHEM J, V119, P31, DOI 10.1042/bj1190031; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PODELL DN, 1978, BIOCHEM BIOPH RES CO, V81, P176, DOI 10.1016/0006-291X(78)91646-7; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SCHWORER CM, 1986, J BIOL CHEM, V261, P8581; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; THIEL G, 1988, P NATL ACAD SCI USA, V85, P6337, DOI 10.1073/pnas.85.17.6337; TOBIMATSU T, 1989, J BIOL CHEM, V264, P17907; TOBIMATSU T, 1988, J BIOL CHEM, V263, P16082; WATTERSON DM, 1980, J BIOL CHEM, V255, P962; WOODGETT JR, 1987, J BIOL CHEM, V262, P4836; YAMAUCHI T, 1980, FEBS LETT, V116, P141, DOI 10.1016/0014-5793(80)80628-4; YAMAUCHI T, 1983, EUR J BIOCHEM, V132, P15, DOI 10.1111/j.1432-1033.1983.tb07319.x; YAMAUCHI T, 1981, FEBS LETT, V129, P117, DOI 10.1016/0014-5793(81)80769-7; YAMAUCHI T, 1985, BIOCHEM BIOPH RES CO, V129, P213, DOI 10.1016/0006-291X(85)91424-X; YAMAUCHI T, 1984, ARCH BIOCHEM BIOPHYS, V234, P89, DOI 10.1016/0003-9861(84)90327-8; YASUGAWA S, 1988, BIOMED RES-TOKYO, V9, P497	53	70	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1991	266	18					11582	11588						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FT762	1646810				2022-12-25	WOS:A1991FT76200028
J	VLAHOS, CJ; WILHELM, OG; HASSELL, T; JASKUNAS, SR; BANG, NU				VLAHOS, CJ; WILHELM, OG; HASSELL, T; JASKUNAS, SR; BANG, NU			DISULFIDE PAIRING OF THE RECOMBINANT KRINGLE-2 DOMAIN OF TISSUE PLASMINOGEN-ACTIVATOR PRODUCED IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							AMINO-ACID-SEQUENCE; FIBRIN-BINDING; H-1-NMR; PURIFICATION; EXPRESSION; CLONING; CDNA	The kringle-2 domain of tissue plasminogen activator, cloned and expressed in Escherichia coli (Wilhelm, O. G., Jaskunas, S. R., Vlahos, C. J., and Bang, N. U. (1990) J. Biol. Chem. 265, 14606-14611), was internally radiolabeled using [S-35]methionine-cysteine. Following refolding and isolation, the labeled polypeptide was further purified by reverse-phase high performance liquid chromatography. The purified kringle-2 domain was digested with thermolysin, and the resulting peptides were purified by high performance liquid chromatography. Five major peptides containing S-35 were obtained. Amino acid sequence analysis showed that these peptides represented various cleavage products containing one or more of the following disulfides: Cys180-Cys261, Cys201-Cys243, Cys232-Cys256 (sequence numbering based on Pennica et al. (Pennica, D., Holmes, W. E., Kohr, W. J., Hakins, R. N., Vehar, G. A., Ward, C. A., Bennett, W. F., Yelverton E., Seeburg, P. H., Heynecker, H. L., Goeddel, E. V., and Collen, D. (1983) Nature 301, 214-221)). These results confirm that the refolding methodology used produced kringle-2 with the predicted disulfide linkage and, thus, yielded material suitable for structural and functional studies.	LILLY LAB CLIN RES,INDIANAPOLIS,IN 46223; INDIANA UNIV,SCH MED,DEPT MED,INDIANAPOLIS,IN 46223	Indiana University System; Indiana University-Purdue University Indianapolis	VLAHOS, CJ (corresponding author), ELI LILLY & CO,LILLY RES LAB,INDIANAPOLIS,IN 46285, USA.							BANYAI L, 1983, FEBS LETT, V163, P37, DOI 10.1016/0014-5793(83)81157-0; BYEON IJL, 1989, BIOCHEMISTRY-US, V28, P9350, DOI 10.1021/bi00450a016; CLEARY S, 1989, BIOCHEMISTRY-US, V28, P1884, DOI 10.1021/bi00430a068; FOSSEL E T, 1990, Fibrinolysis, V4, P93; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; JACKSON CM, 1980, ANNU REV BIOCHEM, V49, P765, DOI 10.1146/annurev.bi.49.070180.004001; LLINAS M, 1983, EUR J BIOCHEM, V135, P379, DOI 10.1111/j.1432-1033.1983.tb07665.x; MABBUTT BC, 1988, EUR J BIOCHEM, V170, P539, DOI 10.1111/j.1432-1033.1988.tb13733.x; MAGNUSSON S, 1975, PROTEASES BIOL CONTR, P123; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MCMULLEN BA, 1985, J BIOL CHEM, V260, P5328; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; PENNICA D, 1983, NATURE, V301, P214, DOI 10.1038/301214a0; RAMESH V, 1986, EUR J BIOCHEM, V159, P581, DOI 10.1111/j.1432-1033.1986.tb09925.x; SOTTRUPJENSEN L, 1978, PROGR CHEM FIBRINOLY, V3, P191; STEFFENS GJ, 1982, H-S Z PHYSIOL CHEM, V363, P1043, DOI 10.1515/bchm2.1982.363.2.1043; THEWES T, 1987, BIOCHIM BIOPHYS ACTA, V912, P254, DOI 10.1016/0167-4838(87)90096-3; VANZONNEVELD AJ, 1986, J CELL BIOCHEM, V32, P169, DOI 10.1002/jcb.240320302; VERHEIJEN JH, 1986, EMBO J, V5, P3525, DOI 10.1002/j.1460-2075.1986.tb04678.x; WILHELM OG, 1990, J BIOL CHEM, V265, P14606; WIMAN B, 1978, NATURE, V272, P549, DOI 10.1038/272549a0	21	6	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10070	10072						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	1645336				2022-12-25	WOS:A1991FP08600014
J	BARCISZEWSKA, MZ; HUANG, HW; MARSHALL, AG; ERDMANN, VA; BARCISZEWSKI, J				BARCISZEWSKA, MZ; HUANG, HW; MARSHALL, AG; ERDMANN, VA; BARCISZEWSKI, J			BIOCHEMICAL AND NMR-SPECTROSCOPY EVIDENCE FOR A NEW TERTIARY A-U BASE PAIR IN LUPIN RIBOSOMAL 5S RNA STRUCTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGHER-ORDER STRUCTURE; WHEAT-GERM; DYNAMIC CONFORMATION; SPINACH; MODEL; SEEDS	The new model for the tertiary structure of ribosomal 5 S rRNA from plants recently proposed by some of us has been already supported by RNase H digestions in the presence of complementary oligodeoxynucleotides. These results are confirmed now by the new biochemical and NMR spectroscopy data. Diethylpyrocarbonate (DEP) and monoperphthalic acid (MPA) are the reagents with the high specificity toward single-stranded adenosine residues. Our experiments clearly show that under native conditions adenosine 100 (A100) of lupin 5 S rRNA is not available for reaction toward these reagents. However under denaturing conditions this residue reacts with DEP and MPA. The detailed analysis of the lupin 5 S rRNA by NMR spectra provide the data on the specific interaction of A100-U53. Thus, we have seen for the first time the NMR signal due to the A100-U53 tertiary base pair, which as we believe, stabilizes interactions between loops B and E.	POLISH ACAD SCI, INST BIOORGAN CHEM, NOSKOWSKIEGO 12, PL-61704 POZNAN, POLAND; FREE UNIV BERLIN, INST BIOCHEM, W-1000 BERLIN, GERMANY; OHIO STATE UNIV, DEPT CHEM, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, DEPT BIOCHEM, COLUMBUS, OH 43210 USA	Polish Academy of Sciences; Free University of Berlin; Ohio State University; Ohio State University			Barciszewski, Jan/N-9283-2019	Barciszewski, Jan/0000-0001-7766-5594				BARCISZEWSKA M, 1983, BIOCHEM BIOPH RES CO, V114, P1161, DOI 10.1016/0006-291X(83)90684-8; BARCISZEWSKA M, 1986, B ACAD POL SCI, V37, P369; BARCISZEWSKA MZ, 1990, FEBS LETT, V269, P83, DOI 10.1016/0014-5793(90)81124-7; BARCISZEWSKA MZ, 1985, FEBS LETT, V192, P289, DOI 10.1016/0014-5793(85)80127-7; BARCISZEWSKA MZ, 1990, BIOCHIM BIOPHYS ACTA, V1087, P68, DOI 10.1016/0167-4781(90)90122-I; BARCISZEWSKI J, 1988, NUCLEIC ACIDS RES, V16, P685, DOI 10.1093/nar/16.2.685; CHANG LH, 1986, BIOCHEMISTRY-US, V25, P3056, DOI 10.1021/bi00358a048; EGEBJERG J, 1989, J MOL BIOL, V206, P651, DOI 10.1016/0022-2836(89)90573-1; HORE PJ, 1983, J MAGN RESON, V54, P539, DOI 10.1016/0022-2364(83)90335-9; JOACHIMIAK A, 1990, ACTA BIOCHIM POL, V37, P359; JOACHIMIAK A, 1990, INT J BIOL MACROMOL, V12, P321, DOI 10.1016/0141-8130(90)90022-3; KULINSKI T, 1991, NUCLEIC ACIDS RES, V19, P2449, DOI 10.1093/nar/19.9.2449; PEATTIE DA, 1980, P NATL ACAD SCI-BIOL, V77, P4679, DOI 10.1073/pnas.77.8.4679; PIELER T, 1982, P NATL ACAD SCI USA, V79, P7599; PIELER T, 1987, NUCLEIC ACIDS RES, V12, P3115; Reid B R, 1979, Methods Enzymol, V59, P21; ROMBY P, 1990, BIOCHIMIE, V72, P437, DOI 10.1016/0300-9084(90)90068-R; ROMBY P, 1988, BIOCHEMISTRY-US, V27, P4721, DOI 10.1021/bi00413a021; SILBERKLANG M, 1983, NUCLEIC ACIDS RES, V11, P606; VANDERHAAR F, 1971, BIOORG CHEM, V1, P282; WESTHOF E, 1989, J MOL BIOL, V207, P417, DOI 10.1016/0022-2836(89)90264-7; WOLTERS J, 1988, NUCLEIC ACIDS RES, V16, pR1, DOI 10.1093/nar/16.suppl.r1; WU JJ, 1990, BIOCHEMISTRY-US, V29, P1730, DOI 10.1021/bi00459a010	23	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16691	16695						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1644842				2022-12-25	WOS:A1992JJ45800106
J	VANNUFFEL, P; DIGIAMBATTISTA, M; COCITO, C				VANNUFFEL, P; DIGIAMBATTISTA, M; COCITO, C			THE ROLE OF RIBOSOMAL-RNA BASES IN THE INTERACTION OF PEPTIDYLTRANSFERASE INHIBITORS WITH BACTERIAL-RIBOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ERYTHROMYCIN RESISTANCE; B SYNERGIMYCINS; VIRGINIAMYCIN-S; RNA; CHLORAMPHENICOL; MACROLIDES; MUTATIONS; SITES	Synergism of streptogramins A (virginiamycin M, VM) and B (virginiamycin S, VS), peptidyltransferase inhibitors, was explored in EM4/pLC7-21 (wild type) and EM4/pERY (VS-resistant). These bacterial strains contained multicopy plasmids carrying an rrnH operon with wild type (pLC7-21) or mutated (A2058 --> U transversion) 23 S rRNA gene. Ribosomes with wild type and mutated rRNA were both present in EM4/pERY. The latter particles did not bind VS; in the presence of VM, however, high affinity VS binding occurred. As shown previously, VS protected against chemical reagents certain bases in domain V rRNA and VM in the stems flanking this loop. Differences between wild type and mutant ribosomes were observed: A2058, A2059, A2062, and G2505, protected by VS and ERY in EM4/pLC7-21, were unshielded in EM4/pERY. A2062 was shielded by VM in EM4/pERY, not in EM4/pLC7-21, and G2505 of mutant ribosomes became protected by VS when VM was simultaneously present. Induction by VM of a high affinity VS binding site in VS-sensitive and -resistant ribosomes indicates A2058 mutation to entail a conformational change of this site, which is counteracted by VM fixation. Accessibility of A2062 to chemical reagents (unlike behavior of EM4/pERY and EM4/pLC7-21 in the presence of VM) implies different conformations for wild type and mutant ribosomes.	CATHOLIC UNIV LOUVAIN, SCH MED, INST CELL PATHOL, MICROBIOL & GENET UNIT, B-1200 BRUSSELS, BELGIUM	Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel								BARTA A, 1984, P NATL ACAD SCI-BIOL, V81, P3607, DOI 10.1073/pnas.81.12.3607; BISMUTH R, 1988, MACROLIDES SYNERGISM, P187; CHINALI G, 1988, BIOCHIM BIOPHYS ACTA, V951, P42, DOI 10.1016/0167-4781(88)90023-1; CHINALI G, 1984, J BIOL CHEM, V259, P9563; CHINALI G, 1988, BIOCHIM BIOPHYS ACTA, V949, P71, DOI 10.1016/0167-4781(88)90056-5; CHINALI G, 1973, EUR J BIOCHEM, V32, P463, DOI 10.1111/j.1432-1033.1973.tb02629.x; COCITO C, 1975, ANTIBIOTICS, V3, P296; CONTRERAS A, 1977, EUR J BIOCHEM, V74, P549, DOI 10.1111/j.1432-1033.1977.tb11423.x; DIGIAMBATTISTA M, 1987, J BIOL CHEM, V262, P8591; DIGIAMBATTISTA M, 1989, J ANTIMICROB CHEMOTH, V24, P485; DOUTHWAITE S, 1985, P NATL ACAD SCI USA, V82, P8330, DOI 10.1073/pnas.82.24.8330; ETTAYEBI M, 1985, J BACTERIOL, V162, P551, DOI 10.1128/JB.162.2.551-557.1985; Gale E.F., 1981, MOL BASIS ANTIBIOTIC, Vsecond; KENERLEY ME, 1977, J BACTERIOL, V132, P931, DOI 10.1128/JB.132.3.931-949.1977; LAI CJ, 1971, P NATL ACAD SCI USA, V68, P856, DOI 10.1073/pnas.68.4.856; MOAZED D, 1987, BIOCHIMIE, V69, P879, DOI 10.1016/0300-9084(87)90215-X; OAKES M, 1986, STRUCTURE FUNCTION G, P47; PARFAIT R, 1978, MOL GEN GENET, V166, P45, DOI 10.1007/BF00379728; PESTKA S, 1977, MOL MECHANISMS PROTE, P468; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHWARTZ SA, 1971, J BIOL CHEM, V246, P6318; SIGMUND CD, 1982, P NATL ACAD SCI-BIOL, V79, P5602, DOI 10.1073/pnas.79.18.5602; SIGMUND CD, 1988, METHOD ENZYMOL, V164, P673; STERN S, 1988, METHOD ENZYMOL, V164, P481; VANNUFFEL P, 1992, J BIOL CHEM, V267, P8377; VAZQUEZ D, 1975, ANTIBIOTICS, V3, P521; VESTER B, 1987, BIOCHIMIE, V69, P891, DOI 10.1016/0300-9084(87)90217-3	27	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16114	16120						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1644798				2022-12-25	WOS:A1992JJ45800023
J	WELLS, RG; LEE, WS; KANAI, Y; LEIDEN, JM; HEDIGER, MA				WELLS, RG; LEE, WS; KANAI, Y; LEIDEN, JM; HEDIGER, MA			THE 4F2 ANTIGEN HEAVY-CHAIN INDUCES UPTAKE OF NEUTRAL AND DIBASIC AMINO-ACIDS IN XENOPUS OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MONOCLONAL-ANTIBODY 4F2; NA+-DEPENDENT TRANSPORT; CELL-SURFACE ANTIGEN; BROAD-SCOPE SYSTEM; MOUSE BLASTOCYSTS; LYMPHOCYTE-ACTIVATION; STRUCTURAL HOMOLOGY; INHIBITION; RECEPTOR; MEMBRANE	The 4F2 cell surface antigen is a disulfide-linked heterodimer induced during the process of cellular activation and expressed widely in mammalian tissues (Parmacek, M. S., Karpinski, B. A., Gottesdiener, K. M., Thompson, C. B., and Leiden, J. M. (1989) Nucleic Acids Res. 17, 1915-1931). The human heavy chain component, a type II membrane glycoprotein, has 29% identity to the amino acid transport-related protein encoded by the recently cloned rat D2 cDNA. We have demonstrated that Xenopus oocytes injected with in vitro transcribed cRNA from D2 take up cystine and dibasic and neutral amino acids (Wells, R. G., and Hediger, M. A. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 5596-5600). In the present study, we examine the role of the human 4F2 heavy chain in amino acid transport. In vitro transcribed 4F2 cRNA was injected into Xenopus oocytes which were assayed for the uptake of radiolabeled amino acids. Our results show that cRNA from 4F2 stimulates the uptake of dibasic and neutral amino acids into oocytes at levels up to 3-fold higher than for water-injected control oocytes. There is no demonstrable uptake of cystine. Uptake is saturable, with characteristics of high affinity transport, and inhibition data suggest that uptake occurs via a single transporter. Dibasic amino acids are taken up by both 4F2 and D2 cRNA-injected oocytes in a sodium-independent manner. In contrast, 4F2-induced but not D2-induced neutral amino acid uptake has a significant component of sodium dependence. Likewise, neutral amino acids in excess inhibit the 4F2-induced uptake of radiolabeled arginine but not leucine in a sodium-dependent manner. The 4F2-induced uptake we observe most likely represents the activity of a single transport system with some characteristics of systems y+, b0,+, and B0,+. We suggest that 4F2 and D2 represent a new family of proteins which induce amino acid transport with distinct characteristics, possibly functioning as transport activators or regulators.	BETH ISRAEL HOSP,DEPT MED,DIV RENAL,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02115; UNIV MICHIGAN,MED CTR,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,DEPT MED,ANN ARBOR,MI 48109	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan				Hediger, Matthias/0000-0003-1946-027X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043171] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 43171] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5601, DOI 10.1073/pnas.89.12.5601; BRON C, 1986, J IMMUNOL, V137, P397; EISENBARTH GS, 1980, J IMMUNOL, V124, P1237; HAYNES BF, 1981, J IMMUNOL, V126, P1409; HEDIGER MA, 1987, P NATL ACAD SCI USA, V84, P2634, DOI 10.1073/pnas.84.9.2634; HEMLER ME, 1982, J IMMUNOL, V129, P623; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; MICHALAK M, 1986, J BIOL CHEM, V261, P92; PARMACEK MS, 1989, NUCLEIC ACIDS RES, V17, P1915, DOI 10.1093/nar/17.5.1915; POSILLICO JT, 1987, ARCH SURG-CHICAGO, V122, P436; QUACKENBUSH E, 1987, P NATL ACAD SCI USA, V84, P6526, DOI 10.1073/pnas.84.18.6526; TATE SS, 1992, P NATL ACAD SCI USA, V89, P1, DOI 10.1073/pnas.89.1.1; TEIXEIRA S, 1987, J BIOL CHEM, V262, P9574; VANWINKLE LJ, 1988, J BIOL CHEM, V263, P3150; VANWINKLE LJ, 1985, J BIOL CHEM, V260, P2118; VANWINKLE LJ, 1990, BIOCHIM BIOPHYS ACTA, V1025, P215, DOI 10.1016/0005-2736(90)90100-3; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; WELLS RG, 1992, P NATL ACAD SCI USA, V89, P5596, DOI 10.1073/pnas.89.12.5596; WHITE MF, 1985, BIOCHIM BIOPHYS ACTA, V822, P355, DOI 10.1016/0304-4157(85)90015-2; YAGITA H, 1986, CANCER RES, V46, P1478	21	119	121	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15285	15288						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1639774				2022-12-25	WOS:A1992JG11300008
J	KIM, CM; VOGEL, J; JAY, G; RHIM, JS				KIM, CM; VOGEL, J; JAY, G; RHIM, JS			THE HIV TAT GENE TRANSFORMS HUMAN KERATINOCYTES	ONCOGENE			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; EPIDERMAL LANGERHANS CELLS; NEOPLASTIC TRANSFORMATION; KAPOSIS-SARCOMA; VIRUS-INFECTION; AIDS; PSORIASIS; ONCOGENE; LESIONS; INVITRO	Skin disorders are frequently seen in patients with the acquired immune deficiency syndrome (AIDS). Since many of these cutaneous manifestations are accompanied by an early onset of epidermal hyperplasia, the keratinocyte is a candidate for infection by the human immunodeficiency virus (HIV). We now report that the HIV tat gene, under the control of the viral long terminal repeat (LTR), can efficiently transform human keratinocytes in culture. Our finding suggests that this activity of the tat gene may be responsible for the epidermal hyperplasia that accompanies psoriasis and precedes the development of squamous cell and basal cell carcinomas in AIDS patients.	JEROME H HOLLAND LAB,VIROL,ROCKVILLE,MD 20855; NCI,CELL & MOLEC BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Jay, Gregory/C-6346-2013		NATIONAL CANCER INSTITUTE [R01CA053633] Funding Source: NIH RePORTER; NCI NIH HHS [CA53633] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHESEBRO B, 1990, J VIROL, V64, P215, DOI 10.1128/JVI.64.1.215-221.1990; COCKERELL CJ, 1990, J AM ACAD DERMATOL, V22, P1260, DOI 10.1016/0190-9622(90)70172-E; ENSOLI B, 1989, SCIENCE, V243, P223, DOI 10.1126/science.2643161; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; JOHNSON TM, 1985, NEW ENGL J MED, V313, P1415; KANITAKIS J, 1989, AIDS RES HUM RETROV, V5, P293, DOI 10.1089/aid.1989.5.293; Kaplan M H, 1987, Am J Med, V82, P389, DOI 10.1016/0002-9343(87)90435-9; KAPLAN MK, 1987, J AM ACAD DERMATOL, V17, P485; KEATH EJ, 1984, CELL, V39, P339, DOI 10.1016/0092-8674(84)90012-6; KRUEGER G, 1990, J INVEST DERMATOL, V94, P1355; LAZAR AP, 1987, CUTIS, V39, P347; MAHONEY SE, 1991, J CLIN INVEST, V88, P174, DOI 10.1172/JCI115275; MANN DL, 1988, J IMMUNOL, V141, P1131; MATHES BM, 1985, J AM ACAD DERMATOL, V13, P947, DOI 10.1016/S0190-9622(85)70243-5; NIEDT GW, 1985, ARCH PATHOL LAB MED, V109, P727; OVERLY WL, 1987, ANN INTERN MED, V106, P334, DOI 10.7326/0003-4819-106-2-334_1; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; REED JC, 1988, NATURE, V336, P259, DOI 10.1038/336259a0; RHIM JS, 1989, ANTICANCER RES, V9, P1345; RHIM JS, 1985, SCIENCE, V227, P1250, DOI 10.1126/science.2579430; RHIM JS, 1989, ONCOGENE, V4, P1403; SADICK NS, 1990, J AM ACAD DERMATOL, V22, P1270, DOI 10.1016/0190-9622(90)70173-F; SITZ KV, 1987, JAMA-J AM MED ASSOC, V257, P340, DOI 10.1001/jama.257.3.340; SODROSKI J, 1985, SCIENCE, V227, P171, DOI 10.1126/science.2981427; STEIGLEDER GK, 1985, Z HAUTKRANKHEITEN, V60, P1913; STINGL G, 1990, J AM ACAD DERMATOL, V22, P1210, DOI 10.1016/0190-9622(90)70165-E; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; TINDALL B, 1989, J AM ACAD DERMATOL, V20, P587, DOI 10.1016/S0190-9622(89)70068-2; TSCHACHLER E, 1987, J INVEST DERMATOL, V88, P233, DOI 10.1111/1523-1747.ep12525402; VERES G, 1987, SCIENCE, V237, P415, DOI 10.1126/science.3603027; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0; WELCH K, 1984, JAMA-J AM MED ASSOC, V252, P1152, DOI 10.1001/jama.252.9.1152	33	40	41	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1992	7	8					1525	1529						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1630815				2022-12-25	WOS:A1992JE81300008
J	PICKSLEY, SM; MEEK, DW; LANE, DP				PICKSLEY, SM; MEEK, DW; LANE, DP			THE CONFORMATIONAL CHANGE OF A MURINE TEMPERATURE-SENSITIVE P53 PROTEIN IS INDEPENDENT OF A CHANGE IN PHOSPHORYLATION STATUS	ONCOGENE			English	Note							LARGE T-ANTIGEN; MONOCLONAL-ANTIBODY; SIMIAN VIRUS-40; CELL-CYCLE; ACTIVATING MUTATIONS; GENE-PRODUCT; MUTANT P53; 3T3 CELLS; TRANSFORMATION; ONCOGENE	Wild-type and mutant p53 proteins exhibit opposing activities in respectively suppressing and promoting tumour development. In a rat embryo fibroblast cell line transformed with a murine temperature-sensitive p53 gene, p53 functions as a oncogene at 37-degrees-C and as a tumour suppressor at 32-degrees-C [Michalovitz, D., Halevy, O. & Oren, M. (1990). Cell, 62, 671-6801. We have used this cell line to investigate whether this temperature-dependent switching of function involves changes in the phosphorylation of p53 protein. Monoclonal antibodies PAb246 and PAb240 were used to immunoprecipitate metabolically P-32-labelled p53 protein in the `wild-type' or mutant conformation from cells grown at 32-degrees-C or 37-degrees-C. Tryptic phosphopeptide maps were prepared from the isolated `wild-type' and mutant p53 proteins. At 32-degrees-C and 37-degrees-C phosphopeptide maps of the `wild-type' and mutant protein were identical. This demonstrates that the temperature-dependent conformation change, and associated functional change, in the p53 protein does not involve a change in the state of phosphorylation.	UNIV DUNDEE,CANC RES CAMPAIGN,CELL TRANSFORMAT GRP,DUNDEE DD1 4HN,SCOTLAND; UNIV DUNDEE,MRC,PHOSPHORYLAT GRP,DUNDEE DD1 4HN,SCOTLAND	University of Dundee; University of Dundee			Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; BARTEK J, 1990, ONCOGENE, V5, P893; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; MILNER J, 1987, ONCOGENE, V1, P453; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PATCHINSKY T, 1990, ONCOGENE, V5, P1071; SAMAD A, 1986, P NATL ACAD SCI USA, V83, P897, DOI 10.1073/pnas.83.4.897; SCHEIDTMANN KH, 1990, J VIROL, V64, P672, DOI 10.1128/JVI.64.2.672-679.1990; SOUSSI T, 1987, ONCOGENE, V1, P71; STURZBECHER HW, 1987, VIROLOGY, V160, P445; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	25	17	17	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1992	7	8					1649	1651						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1630825				2022-12-25	WOS:A1992JE81300023
J	GROOT, PC; MOEN, CJA; DIETRICH, W; STOYE, JP; LANDER, ES; DEMANT, P				GROOT, PC; MOEN, CJA; DIETRICH, W; STOYE, JP; LANDER, ES; DEMANT, P			THE RECOMBINANT CONGENIC STRAINS FOR ANALYSIS OF MULTIGENIC TRAITS - GENETIC COMPOSITION	FASEB JOURNAL			English	Article						MULTIGENIC TRAITS; RECOMBINANT CONGENIC STRAINS; SIMPLE SEQUENCE REPEATS; GENETIC MAPPING	LINKAGE; MOUSE; MAP	The genetic control of susceptibility to many common diseases, including cancer, is multigenic both in humans and in animals. This genetic complexity has presented a major obstacle in mapping the relevant genes. As a consequence, most geneticists and molecular biologists presently focus on "single gene" diseases. To make the multigenic diseases accessible to genetic and molecular analysis, we developed a novel genetic tool, the recombinant congenic strains (RCS) in the mouse (4). The RC strains are produced by inbreeding of mice of the second backcross generation between two inbred strains, one of which serves as the "donor" and the other as the "background" strain. A series of RCS consists of approximately 20 strains, each carrying a different set of genes: approximately 12.5% genes from the common donor inbred strain, the remaining 87.5% from the common background inbred strain. As the set of donor strain genes in each RC strain is different, the nonlinked genes of the donor strain involved in the control of a multigenic trait, e.g., cancer susceptibility, become distributed into different RC strains where they can be analyzed one by one. Hence, the RCS system transforms a multigenic trait into a series of single gene traits, where each gene contributing to the multigenic control can be mapped and studied separately. Recently we demonstrated that the RCS system is indeed capable of resolving multigenic traits, which are hardly analyzable other-wise, by mapping four new colon tumor susceptibility loci (8; P. C. Groot, C. J. A. Moen, W. Dietrich, L. F. M. van Zutphen, E. S. Lander, and P. Demant, unpublished results). For successful application of the RCS system, extensive genetic characterization of the individual recombinant congenic strains is essential. In this paper we present detailed information about the genetic composition of three series of RC strains on the basis of typing of 120-180 markers distributed along all autosomes. The data indicate that the relative representation of the donor strain genes in the RC strains does not deviate from the theoretical expectation, and that the RC strains achieved a very high degree of genetic homogeneity and for all practical purposes can be considered inbred strains. The density and distribution of markers reported here permits an effective mapping of unknown genes of donor strain origin at almost all autosomal locations. Much of this information has been obtained using the new class of genetic markers, the simple sequence repeat polymorphisms. The extensive application of these PCR-typable markers greatly increases the possibilities of the effective use of the RC strains for mapping of genes involved in multigenic control. The data presented here can be used by investigators interested in functional effects of a specific region of the mouse genome to select RC strains that differ at this region from the background strain. This information is of interest to investigators working with mice, as well as those analyzing a specific region of the human genome and interested in the structure or function of the homologous part of the mouse genome.	NETHERLANDS CANC INST, DIV MOLEC GENET, PLESMANLAAN 121, 1066 CX AMSTERDAM, NETHERLANDS; WHITEHEAD INST, CAMBRIDGE, MA 02142 USA; NATL INST MED RES, LONDON NW7 1AA, ENGLAND	Netherlands Cancer Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute; MRC National Institute for Medical Research				Stoye, Jonathan/0000-0003-3377-323X; Groot, Peter C./0000-0003-3339-1469				AITMAN TJ, 1991, MAMM GENOME, V1, P206, DOI 10.1007/BF00352326; BAILEY DW, 1971, TRANSPLANTATION, V11, P325, DOI 10.1097/00007890-197103000-00013; COLLINS FS, 1992, NAT GENET, V1, P3, DOI 10.1038/ng0492-3; CORNALL RJ, 1991, GENOMICS, V10, P874, DOI 10.1016/0888-7543(91)90175-E; DAVISSON MT, 1989, GENETIC VARIANTS STR, P416; DEMANT P, 1986, IMMUNOGENETICS, V24, P416, DOI 10.1007/BF00377961; DEMANT P, 1989, ADV CANCER RES, V53, P117; DEMANT P, 1992, SEMIN CANCER BIOL, V3, P157; DIETRICH W, IN PRESS GENETICS; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FRANKEL WN, 1990, GENETICS, V124, P221; HEARNE CM, 1991, MAMM GENOME, V1, P273, DOI 10.1007/BF00352339; LANDER ES, 1989, GENETICS, V121, P185; LOVE JM, 1990, NUCLEIC ACIDS RES, V18, P4123, DOI 10.1093/nar/18.14.4123; MCALEER MA, 1992, IN PRESS MAMMALIAN G; MOEN CJA, 1992, ONCOGENE, V7, P563; MOEN CJA, 1991, MAMM GENOME, V1, P217, DOI 10.1007/BF00352328; NADEAU J, 1990, MOUSE GENOME, V87, P55; NAMEN AE, 1988, NATURE, V333, P571, DOI 10.1038/333571a0; RIELE HT, 1992, IN PRESS P NATL ACAD; RISCH N, 1992, SCIENCE, V255, P803, DOI 10.1126/science.1536004; VANHEYNINGEN V, 1985, P NATL ACAD SCI USA, V82, P8592; VANZUTPHEN LFM, 1991, LAB ANIM, V25, P193, DOI 10.1258/002367791780808329; WEBER JL, 1989, AM J HUM GENET, V44, P388; [No title captured]	25	75	75	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1992	6	10					2826	2835		10.1096/fasebj.6.10.1634045	http://dx.doi.org/10.1096/fasebj.6.10.1634045			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JD954	1634045				2022-12-25	WOS:A1992JD95400011
J	VEMURU, RP; DAVIDSON, A; ARAGONA, E; CHOWDHURY, JR; BURK, RD; GUPTA, S				VEMURU, RP; DAVIDSON, A; ARAGONA, E; CHOWDHURY, JR; BURK, RD; GUPTA, S			IMMUNE TOLERANCE TO A DEFINED HETEROLOGOUS ANTIGEN AFTER INTRASPLENIC HEPATOCYTE TRANSPLANTATION - IMPLICATIONS FOR GENE-THERAPY	FASEB JOURNAL			English	Article						HEPATOCYTE TRANSPLANTATION; TRANSGENIC; HEPATITIS-B VIRUS; IMMUNE TOLERANCE; GENE THERAPY	HEPATITIS-B VIRUS; MICROCARRIER-ATTACHED HEPATOCYTES; TRANSGENIC MICE; EXPRESSION; HBSAG; RABBIT; SYSTEM; REGION; CELLS; RATS	Development of a host immune response against gene products expressed by genetically modified cells could be a serious limitation for gene therapy. During examination of whether site-specific differences in antigen presentation could regulate the host immune response, we observed an absence of antibodies against hepatitis B virus surface antigen (HBsAg) when HBsAg producing transgenic hepatocytes were transplanted into the spleen. Intrasplenic transplantation resulted in translocation of a large number of cells into the portal vascular bed and liver sinusoids. In these recipients, HBsAg secreted by the transplanted hepatocytes circulated indefinitely in the blood. In contrast, subcutaneous or intraperitoneal transplantation of the transgenic hepatocytes induced an anti-HBs response, followed by clearance of serum HBsAg. Rechallenge with HBsAg in a highly immunogenic form failed to break the tolerance in intrasplenic hepatocyte recipients even though these animals responded to another antigen (key-hole limpet hemocyanin). Immunization with HBsAg in intraperitoneal recipients of HBsAg producing hepatocytes further elevated anti-HBs titers. Our results indicate that hepatocyte transplantation into the portal vascular bed via injection into the spleen can confer immune tolerance to secreted heterologous antigens. This finding should have important implications for human gene therapy as well as for analyzing the mechanisms of immune tolerance.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, MARION BESSIN LIVER RES CTR, ULLMAN 625, 1300 MORRIS PK AVE, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MED, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT PEDIAT, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MICROBIOL & IMMUNOL, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT OBSTET & GYNECOL, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine					NATIONAL CANCER INSTITUTE [R01CA045476] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK001909, R01DK034357] Funding Source: NIH RePORTER; NCI NIH HHS [CA 45476] Funding Source: Medline; NIDDK NIH HHS [DK 34357, DK 01909] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS TE, 1990, MOL BIOL MED, V7, P341; ARAGONA E, 1990, HEPATOLOGY, V12, P875; ARMENTANO D, 1990, P NATL ACAD SCI USA, V87, P6141, DOI 10.1073/pnas.87.16.6141; BATTISTO JR, 1962, P SOC EXP BIOL MED, V111, P111; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; BURK RD, 1988, J VIROL, V62, P649, DOI 10.1128/JVI.62.2.649-654.1988; CHANG PL, 1990, MOL BIOL MED, V7, P461; CHOWDHURY JR, 1991, SCIENCE, V254, P1802, DOI 10.1126/science.1722351; DEMETRIOU AA, 1986, SCIENCE, V233, P1190, DOI 10.1126/science.2426782; DEMETRIOU AA, 1986, P NATL ACAD SCI USA, V83, P7475, DOI 10.1073/pnas.83.19.7475; Dresser D W, 1968, Adv Immunol, V8, P129, DOI 10.1016/S0065-2776(08)60466-6; FERRY N, 1991, P NATL ACAD SCI USA, V88, P8377, DOI 10.1073/pnas.88.19.8377; GUPTA S, 1992, HEPATOLOGY, V15, P156, DOI 10.1002/hep.1840150126; GUPTA S, 1990, TRANSPLANTATION, V50, P472; GUPTA S, 1991, HEPATOLOGY, V14, P144, DOI 10.1002/hep.1840140124; GUPTA S, 1990, CURRENT HEPATOLOGY, P61; GUPTA S, 1992, CURRENT HEPATOLOGY, P75; HATZOGLOU M, 1990, J BIOL CHEM, V265, P17285; HOSONO M, 1991, CELL IMMUNOL, V136, P373, DOI 10.1016/0008-8749(91)90360-N; ISOBE M, 1992, SCIENCE, V255, P1125, DOI 10.1126/science.1347662; KALEKO M, 1991, HUM GENE THER, V2, P27, DOI 10.1089/hum.1991.2.1-27; LEDLEY FD, 1987, P NATL ACAD SCI USA, V84, P5335, DOI 10.1073/pnas.84.15.5335; MILICH DR, 1985, P NATL ACAD SCI USA, V82, P8168, DOI 10.1073/pnas.82.23.8168; MILICH DR, 1982, J IMMUNOL, V129, P320; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; PENG H, 1988, P NATL ACAD SCI USA, V85, P8146, DOI 10.1073/pnas.85.21.8146; PONDER KP, 1991, P NATL ACAD SCI USA, V88, P1217, DOI 10.1073/pnas.88.4.1217; POSSELT AM, 1990, SCIENCE, V249, P1293, DOI 10.1126/science.2119056; QIN SX, 1990, EUR J IMMUNOL, V20, P2737, DOI 10.1002/eji.1830201231; Schneider W J, 1983, Mol Biol Med, V1, P353; SCHWARTZ RH, 1989, CELL, V57, P1073, DOI 10.1016/0092-8674(89)90044-5; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; STLOUIS D, 1988, P NATL ACAD SCI USA, V85, P3150; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; TOTH LE, 1987, P NATL ACAD SCI USA, V84, P6790, DOI 10.1073/pnas.84.19.6790; VANTWUYVER E, 1991, NEW ENGL J MED, V325, P1210, DOI 10.1056/NEJM199110243251704; VEMURU RP, 1991, HEPATOLOGY, V14, pA96; VEMURU RP, 1991, HEPATOLOGY, V14, pA49; WANDS JR, 1975, J CLIN INVEST, V55, P930, DOI 10.1172/JCI108022; WILSON JM, 1990, P NATL ACAD SCI USA, V87, P8437, DOI 10.1073/pnas.87.21.8437; WILSON JM, 1988, P NATL ACAD SCI USA, V85, P3014, DOI 10.1073/pnas.85.9.3014; WILSON JM, 1988, P NATL ACAD SCI USA, V85, P4421, DOI 10.1073/pnas.85.12.4421; WOLFF JA, 1987, P NATL ACAD SCI USA, V84, P3344, DOI 10.1073/pnas.84.10.3344	43	27	31	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1992	6	10					2836	2842		10.1096/fasebj.6.10.1634046	http://dx.doi.org/10.1096/fasebj.6.10.1634046			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JD954	1634046				2022-12-25	WOS:A1992JD95400012
J	DROZDOFF, V; PLEDGER, WJ				DROZDOFF, V; PLEDGER, WJ			CELLULAR-RESPONSE TO PLATELET-DERIVED GROWTH-FACTOR (PDGF)-AB AFTER DOWN-REGULATION OF PDGF ALPHA-RECEPTORS - EVIDENCE THAT FUNCTIONAL BINDING DOES NOT REQUIRE ALPHA-RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-CHAIN; DIFFERENT ISOFORMS; HUMAN-FIBROBLASTS; PHOSPHOLIPASE-C; SARCOMA-VIRUS; CDNA CLONING; B-CHAIN; EXPRESSION; IDENTIFICATION; PROTEINS	Platelet-derived growth factor (PDGF) and its receptor exist in multiple forms. PDGF exists in three dimeric combinations of A and B subunit chains, which are the products of separate genes. The PDGF receptor is similarly encoded by genes for two distinct receptor proteins, alpha and beta. A recent model proposed PDGF binding involves the association of the two receptor proteins into three possible dimeric forms. An essential prediction of that model is that PDGF alpha-receptors are required for cells to bind and respond to the heterodimeric AB isoform of PDGF. In contrast, we found both binding and functional response to PDGF-AB was retained in Balb/c-3T3 cells after PDGF alpha-receptors had been down-regulated by PDGF-AA pretreatment. The observation that PDGF-AB could still elicit these responses suggests that at 37-degrees-C, PDGF-AB may bind directly to beta-receptors in either monomeric or dimeric forms and that initial receptor activation may occur independently of the formation of alpha-beta-receptor heterodimers.			DROZDOFF, V (corresponding author), VANDERBILT UNIV,MED CTR,SCH MED,DEPT CELL BIOL,NASHVILLE,TN 37232, USA.				NATIONAL CANCER INSTITUTE [R01CA042713, R01CA042636, T32CA009592] Funding Source: NIH RePORTER; NCI NIH HHS [T32-CA09592, CA42636, CA42713] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; BISHAYEE S, 1986, P NATL ACAD SCI USA, V83, P6756, DOI 10.1073/pnas.83.18.6756; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BOWENPOPE DF, 1989, J BIOL CHEM, V264, P2502; BOWENPOPE DF, 1985, METHOD ENZYMOL, V109, P69; BOWENPOPE DF, 1984, P NATL ACAD SCI-BIOL, V81, P2396, DOI 10.1073/pnas.81.8.2396; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; CLAESSONWELSH L, 1989, J BIOL CHEM, V264, P1742; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DANIEL TO, 1985, P NATL ACAD SCI USA, V82, P2684, DOI 10.1073/pnas.82.9.2684; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; DEUEL TF, 1983, SCIENCE, V221, P1348, DOI 10.1126/science.6310754; EK B, 1984, J BIOL CHEM, V259, P1145; GRONWALD RGK, 1988, P NATL ACAD SCI USA, V85, P3435, DOI 10.1073/pnas.85.10.3435; HAMMACHER A, 1988, J BIOL CHEM, V263, P16493; HAMMACHER A, 1989, EMBO J, V8, P2489, DOI 10.1002/j.1460-2075.1989.tb08385.x; HARRINGTON MA, 1985, J CELL BIOCHEM, V27, P67, DOI 10.1002/jcb.240270202; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HELDIN CH, 1982, J BIOL CHEM, V257, P4216; HELDIN CH, 1986, NATURE, V319, P511, DOI 10.1038/319511a0; KAZLAUSKAS A, 1988, EMBO J, V7, P3727, DOI 10.1002/j.1460-2075.1988.tb03256.x; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KEATING MT, 1987, J BIOL CHEM, V262, P7932; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING; MARKWELL MAK, 1982, ANAL BIOCHEM, V125, P427, DOI 10.1016/0003-2697(82)90025-2; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MATSUI T, 1989, P NATL ACAD SCI USA, V86, P8314, DOI 10.1073/pnas.86.21.8314; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NISTER M, 1988, CELL, V52, P791, DOI 10.1016/0092-8674(88)90421-7; OLASHAW NE, 1991, J BIOL CHEM, V266, P10234; SACHINIDIS A, 1990, J BIOL CHEM, V265, P10238; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; STROOBANT P, 1984, EMBO J, V3, P2963, DOI 10.1002/j.1460-2075.1984.tb02241.x; VANZOELEN EJJ, 1989, BIOCHEM J, V262, P549, DOI 10.1042/bj2620549; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WILSON T, 1988, EMBO J, V7, P4193, DOI 10.1002/j.1460-2075.1988.tb03316.x; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	46	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17165	17172						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1654324				2022-12-25	WOS:A1991GF44500032
J	STEINBECK, MJ; HEGG, GG; KARNOVSKY, MJ				STEINBECK, MJ; HEGG, GG; KARNOVSKY, MJ			ARACHIDONATE ACTIVATION OF THE NEUTROPHIL NADPH-OXIDASE - SYNERGISTIC EFFECTS OF PROTEIN PHOSPHATASE INHIBITORS COMPARED WITH PROTEIN-KINASE ACTIVATORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; CELL-FREE SYSTEM; RESPIRATORY BURST OXIDASE; PHORBOL-MYRISTATE ACETATE; ADENINE-DINUCLEOTIDE PHOSPHATE; 2 CYTOSOLIC COMPONENTS; SUPEROXIDE GENERATION; FATTY-ACIDS; POLYMORPHONUCLEAR LEUKOCYTES; SUBCELLULAR-LOCALIZATION	Arachidonate activation of the NADPH-oxidase in intact neutrophils and in a cell-free O2-generation system was compared to synergistic activation in response to arachidonate and agents that effect protein phosphorylation. In intact neutrophils, suboptimal doses of retinal which increase protein phosphorylation, or 4 B-phorbol 12-myristate 13-acetate (PMA) an activator of protein kinase C, induced minimal O2- release, but primed neutrophils to release enhanced amounts of O2- in response to 2.5-mu-M arachidonate. In contrast to retinal or PMA, okadaic acid, a specific inhibitor of serine/threonine protein phosphatases, did not induce any release of O2-, but significantly increased the maximal rate and duration of O2- release in response to arachidonate. In the cell-free system, only arachidonate induced O2- generation. Consistent with previous findings, activation of the cell-free system was dependent of the presence of light membranes, cytosol, NADPH, Mg2+, and 82-mu-M arachidonate. Pretreatment of neutrophils with suboptimal doses of PMA or retinal had little effect on the arachidonate-stimulated release of O2- in cell-free preparations of these cells. However, cytosol (but not light membranes) from PMA or retinal-primed neutrophils was more effective in completing resting membrane NADPH-oxidase activity when compared to cytosol from resting cells. The addition of protein kinase C inhibitors staurosporine and 1-(5-isoquinolinylsulfonyl)-2-methylpiperazine decreased the effectiveness of PMA-primed cytosol to complete the cell-free system, but had little effect on cytosol obtained from cells primed with retinal. The addition of protein phosphatase inhibitors, p-nitrophenyl phosphate or okadaic acid to neutrophil cavitates increased 3-fold the release of O2- in cell-free preparations of these cells. Okadaic acid and p-nitrophenyl phosphate also increased the effectiveness of both cytosol and light membranes to complete the cell-free system when combined with cytosol or light membranes from resting neutrophils, respectively, indicating that both fractions are affected by the inhibition of protein phosphatase activity. These data indicate that increases in protein phosphorylation alone do not lead to the activation of the NADPH-oxidase, but in addition to the requirement of an anionic amphiphile, the release of O2- from intact neutrophils or in the cell-free system is increased by stimulus activation of protein kinase C or more impressively by inhibition of protein phosphatase activity.			STEINBECK, MJ (corresponding author), HARVARD UNIV, SCH MED,DEPT PATHOL,BLDG C2,RM 324, 240 LONGWOOD AVE, BOSTON, MA 02115 USA.				NIDCR NIH HHS [DE-08507] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE008507] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AMBRUSO DR, 1990, J BIOL CHEM, V265, P924; BABIOR BM, 1978, NEW ENGL J MED, V298, P659, DOI 10.1056/NEJM197803232981205; BADWEY JA, 1989, J BIOL CHEM, V264, P14947; BADWEY JA, 1989, J BIOL CHEM, V264, P20676; BADWEY JA, 1984, J BIOL CHEM, V259, P7870; BADWEY JA, 1986, J CELL PHYSIOL, V127, P223, DOI 10.1002/jcp.1041270206; BASS DA, 1987, J BIOL CHEM, V262, P6643; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BOLSCHER BGJM, 1989, J CLIN INVEST, V83, P757, DOI 10.1172/JCI113954; BORREGAARD N, 1984, J BIOL CHEM, V259, P47; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; BROMBERG Y, 1984, CELL IMMUNOL, V88, P213, DOI 10.1016/0008-8749(84)90066-2; BURHAM DN, 1990, J BIOL CHEM, V265, P17550; CALDWELL SE, 1988, J CLIN INVEST, V81, P1485, DOI 10.1172/JCI113480; CLARK RA, 1989, NEW ENGL J MED, V321, P647, DOI 10.1056/NEJM198909073211005; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; COHEN HJ, 1978, J CLIN INVEST, V61, P1081, DOI 10.1172/JCI109007; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COX JA, 1985, J CLIN INVEST, V76, P1932, DOI 10.1172/JCI112190; COX JA, 1987, J IMMUNOL, V138, P1884; CURNUTTE JT, 1989, P NATL ACAD SCI USA, V86, P825, DOI 10.1073/pnas.86.3.825; CURNUTTE JT, 1987, J BIOL CHEM, V262, P5563; CURNUTTE JT, 1985, J CLIN INVEST, V75, P1740, DOI 10.1172/JCI111885; CURNUTTE JT, 1987, ADV HUM GENET, V16, P229; GLASS GA, 1986, J BIOL CHEM, V261, P3247; GRINSTEIN S, 1989, BIOCHEM J, V261, P755, DOI 10.1042/bj2610755; HAYAKAWA T, 1986, J BIOL CHEM, V261, P9109; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HENDERSON LM, 1989, BIOCHEM J, V264, P249, DOI 10.1042/bj2640249; HEYNEMAN RA, 1984, J LEUKOCYTE BIOL, V36, P751, DOI 10.1002/jlb.36.6.751; HEYWORTH PG, 1990, J BIOENERG BIOMEMBR, V22, P1, DOI 10.1007/BF00762842; HEYWORTH PG, 1989, BIOCHEM J, V260, P243, DOI 10.1042/bj2600243; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; IRVINE RF, 1982, BIOCHEM J, V204, P3, DOI 10.1042/bj2040003; KLEINBERG ME, 1990, J BIOL CHEM, V265, P15577; KRAMER IM, 1988, J BIOL CHEM, V263, P2352; LOCHNER JE, 1986, P NATL ACAD SCI USA, V83, P7673, DOI 10.1073/pnas.83.20.7673; MAY WS, 1986, P NATL ACAD SCI USA, V83, P1281, DOI 10.1073/pnas.83.5.1281; MCPHAIL LC, 1985, J CLIN INVEST, V75, P1735, DOI 10.1172/JCI111884; MIYAHARA M, 1988, BIOCHIM BIOPHYS ACTA, V971, P46, DOI 10.1016/S0005-2728(88)80007-0; NAKASHIMA S, 1988, ARCH BIOCHEM BIOPHYS, V261, P375, DOI 10.1016/0003-9861(88)90353-0; NUNOI H, 1988, SCIENCE, V242, P1298, DOI 10.1126/science.2848319; OKAMURA N, 1990, J CLIN INVEST, V85, P1583, DOI 10.1172/JCI114608; OKAMURA N, 1988, J BIOL CHEM, V263, P6777; PONTREMOLI S, 1986, ARCH BIOCHEM BIOPHYS, V250, P23, DOI 10.1016/0003-9861(86)90697-1; QUINN MT, 1989, NATURE, V342, P198, DOI 10.1038/342198a0; ROTROSEN D, 1987, ANNU REV IMMUNOL, V5, P127, DOI 10.1146/annurev.immunol.5.1.127; ROTROSEN D, 1990, J BIOL CHEM, V265, P19910; ROTROSEN D, 1990, J BIOL CHEM, V265, P8745; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; SBARRA AJ, 1959, J BIOL CHEM, V234, P1355; SEGAL AW, 1985, NATURE, V316, P547, DOI 10.1038/316547a0; STEINBECK MJ, 1991, J LEUKOCYTE BIOL, V49, P360, DOI 10.1002/jlb.49.4.360; TAKAI A, 1987, FEBS LETT, V217, P81, DOI 10.1016/0014-5793(87)81247-4; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TANAKA T, 1987, BIOCHEM BIOPH RES CO, V144, P606, DOI 10.1016/S0006-291X(87)80009-8; VOLPP BD, 1988, SCIENCE, V242, P1295, DOI 10.1126/science.2848318	57	52	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16336	16342						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1653230				2022-12-25	WOS:A1991GD63500018
J	ISHIMI, Y; SUGASAWA, K; HANAOKA, F; KIKUCHI, A				ISHIMI, Y; SUGASAWA, K; HANAOKA, F; KIKUCHI, A			REPLICATION OF THE SIMIAN VIRUS-40 CHROMOSOME WITH PURIFIED PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SV40 DNA-REPLICATION; LARGE T-ANTIGEN; INVITRO REPLICATION; TERMINATION REGION; ORIGIN; CHROMATIN; PURIFICATION; NUCLEOSOMES; ENDONUCLEASES; DISPLACEMENT	SV40 chromosomes prepared from infected CV-1 cells were replicated with the purified proteins of SV40 T antigen, HeLa DNA polymerase alpha-primase complex, single-stranded DNA-binding protein, and topoisomerases I and II, all of which have been shown to be essential for SV40 DNA replication in vitro. Replication started near the origin and proceeded bi-directionally. The maximum speed of replication fork movement was 200-300 nucleotides/min, which was similar to the rate of SV40 DNA replication with the same set of proteins. When replication products were digested with micrococcal nuclease, DNA fragments of 160-180 base pairs, which is the typical size of mononucleosomal DNA, were protected. This result indicates that replicated DNA was reconstructed into the nucleosome structure, complexed with parental histones.	INST PHYS & CHEM RES,RADIAT BIOL LAB,WAKO,SAITAMA 35101,JAPAN	RIKEN	ISHIMI, Y (corresponding author), MITSUBISHI KASEI INST LIFE SCI,11 MINAMIOOYA,MACHIDA,TOKYO 194,JAPAN.							BONNEANDREA C, 1990, NATURE, V343, P719, DOI 10.1038/343719a0; CHENG LH, 1989, CELL, V59, P541, DOI 10.1016/0092-8674(89)90037-8; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P16, DOI 10.1073/pnas.84.1.16; DECKER RS, 1987, J BIOL CHEM, V262, P10863; DEPAMPHILIS ML, 1986, PAPOVAVIRIDAE, V1, P99; DODSON M, 1987, SCIENCE, V238, P964, DOI 10.1126/science.2823389; EDENBERG HJ, 1975, ANNU REV GENET, V3, P245; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; GOETZ GS, 1988, J BIOL CHEM, V263, P383; IGOKEMENES T, 1982, ANNU REV BIOCHEM, V51, P89, DOI 10.1146/annurev.bi.51.070182.000513; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; JAKOBOVITS EB, 1980, NATURE, V285, P263, DOI 10.1038/285263a0; LEE SH, 1988, P NATL ACAD SCI USA, V85, P9469, DOI 10.1073/pnas.85.24.9469; LEFFAK IM, 1977, CELL, V12, P837, DOI 10.1016/0092-8674(77)90282-3; LI JJ, 1986, MOL CELL BIOL, V6, P1117, DOI 10.1128/MCB.6.4.1117; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; LOSA R, 1987, CELL, V50, P801, DOI 10.1016/0092-8674(87)90338-2; MURAKAMI Y, 1986, P NATL ACAD SCI USA, V83, P2869, DOI 10.1073/pnas.83.9.2869; MURPHY CI, 1988, J VIROL, V62, P2951, DOI 10.1128/JVI.62.8.2951-2959.1988; PECK LJ, 1983, P NATL ACAD SCI-BIOL, V80, P6206, DOI 10.1073/pnas.80.20.6206; PRELICH G, 1988, CELL, V53, P117, DOI 10.1016/0092-8674(88)90493-X; SARAGOSTI S, 1980, CELL, V20, P65, DOI 10.1016/0092-8674(80)90235-4; SCOTT WA, 1978, CELL, V15, P1511, DOI 10.1016/0092-8674(78)90073-9; SHURE M, 1977, NUCLEIC ACIDS RES, V4, P1183, DOI 10.1093/nar/4.5.1183; SIMANIS V, 1985, VIROLOGY, V144, P88, DOI 10.1016/0042-6822(85)90308-3; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; STILLMAN B, 1986, CELL, V45, P555, DOI 10.1016/0092-8674(86)90287-4; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; SUGASAWA K, 1990, J VIROL, V64, P4820, DOI 10.1128/JVI.64.10.4820-4829.1990; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; SUNDIN O, 1981, CELL, V25, P659, DOI 10.1016/0092-8674(81)90173-2; TAPPER DP, 1979, BIOCHIM BIOPHYS ACTA, V565, P84, DOI 10.1016/0005-2787(79)90084-4; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P609, DOI 10.1128/MCB.9.2.609; VARSHAVSKY AJ, 1978, NUCLEIC ACIDS RES, V5, P3469, DOI 10.1093/nar/5.10.3469; WEAVER DT, 1985, CELL, V41, P565, DOI 10.1016/S0092-8674(85)80029-5; WEINTRAUB H, 1976, CELL, V9, P409, DOI 10.1016/0092-8674(76)90085-4; WEINTRAUB H, 1979, NUCLEIC ACIDS RES, V7, P781, DOI 10.1093/nar/7.3.781; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; YANG L, 1987, P NATL ACAD SCI USA, V84, P950, DOI 10.1073/pnas.84.4.950	42	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					16141	16148						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1651935				2022-12-25	WOS:A1991GB97700092
J	LANGFORD, KG; SHAI, SY; HOWARD, TE; KOVAC, MJ; OVERBEEK, PA; BERNSTEIN, KE				LANGFORD, KG; SHAI, SY; HOWARD, TE; KOVAC, MJ; OVERBEEK, PA; BERNSTEIN, KE			TRANSGENIC MICE DEMONSTRATE A TESTIS-SPECIFIC PROMOTER FOR ANGIOTENSIN-CONVERTING ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MOLECULAR-CLONING; RIBONUCLEIC-ACID; TRANSCRIPTION; TISSUES; ISOZYME; GENES; RAT	There are two isozymes of angiotensin-converting enzyme (ACE), one produced by somatic tissues and a smaller protein synthesized by developing spermatozoa (testis ACE). To investigate the molecular control of testis ACE, we generated mice transgenic for a construct containing a putative testis-specific ACE promoter linked to the Escherichia coli reporter gene encoding beta-galactosidase. The transgenic mice express beta-galactosidase protein and RNA only within the testis. Histochemical analysis of the transgenic mice shows co-localization of beta-galactosidase protein and endogenous ACE within elongating spermatozoa. These studies demonstrate that transcription of testis ACE is controlled by a strong intragenic testis-specific promoter that is contained within a 698-base pair fragment immediately upstream from the transcription start site of testis ACE. Characterization of the testis ACE promoter may provide insights into the molecular mechanisms controlling cell stage-specific gene expression in the male germ line.	EMORY UNIV,DEPT PATHOL & LAB MED,ATLANTA,GA 30322; BAYLOR COLL MED,HOWARD HUGHES MED INST,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,INST MOLEC GENET,HOUSTON,TX 77030	Emory University; Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine				Bernstein, Kenneth/0000-0001-8097-3272; Overbeek, Paul/0000-0001-9784-2084	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK039777, R01DK039777] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK39777] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel FM, 1989, CURRENT PROTOCOLS MO, V1-3; BERNSTEIN KE, 1989, J BIOL CHEM, V264, P11945; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CUSHMAN DW, 1971, BIOCHIM BIOPHYS ACTA, V250, P261, DOI 10.1016/0005-2744(71)90142-2; EHLERS MRW, 1989, BIOCHEMISTRY-US, V28, P5311, DOI 10.1021/bi00439a001; EHLERS MRW, 1989, P NATL ACAD SCI USA, V86, P7741, DOI 10.1073/pnas.86.20.7741; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; HOLLENBERG NK, 1985, AM J MED, V79, P1, DOI 10.1016/0002-9343(85)90072-5; HOWARD TE, 1990, MOL CELL BIOL, V10, P4294, DOI 10.1128/MCB.10.8.4294; KUMAR RS, 1989, J BIOL CHEM, V264, P16754; LATTION AL, 1989, FEBS LETT, V252, P99, DOI 10.1016/0014-5793(89)80897-X; Macgregor G R, 1991, Methods Mol Biol, V7, P217, DOI 10.1385/0-89603-178-0:217; Patchett A A, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P1; PESCHON JJ, 1987, P NATL ACAD SCI USA, V84, P5316, DOI 10.1073/pnas.84.15.5316; ROBINSON MO, 1989, P NATL ACAD SCI USA, V86, P8437, DOI 10.1073/pnas.86.21.8437; SEARLE PF, 1984, MOL CELL BIOL, V4, P1221, DOI 10.1128/MCB.4.7.1221; SOUBRIER F, 1988, P NATL ACAD SCI USA, V85, P9386, DOI 10.1073/pnas.85.24.9386; STEWART TA, 1988, MOL CELL BIOL, V8, P1748, DOI 10.1128/MCB.8.4.1748; TAKETO M, 1991, P NATL ACAD SCI USA, V88, P2065, DOI 10.1073/pnas.88.6.2065; UNGER ER, 1989, CURR TOP MICROBIOL, V143, P21	22	123	126	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					15559	15562						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1651914				2022-12-25	WOS:A1991GB97700002
J	BASU, A; AVADHANI, NG				BASU, A; AVADHANI, NG			STRUCTURAL ORGANIZATION OF NUCLEAR GENE FOR SUBUNIT VB OF MOUSE MITOCHONDRIAL CYTOCHROME-C-OXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTOR GENE; RNA POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; NUCLEOTIDE-SEQUENCE; CATABOLITE REPRESSION; GEL-ELECTROPHORESIS; MOLECULAR-CLONING; CDNA CLONE; CYC1 GENE	We have reported recently the isolation of a cDNA for nuclear encoded subunit Vb of mouse cytochrome c oxidase by screening mouse bone marrow and kidney cDNA libraries. In the present study, this cDNA was used as a probe to screen a mouse genomic library and isolate the complete gene encoding subunit Vb. Southern blot hybridization of mouse genomic DNA with the cDNA probe suggested the occurrence of multiple genes including many retroinserts. Restriction analysis followed by Southern blot hybridization of genomic clones was used to identify the putative retroinserts from the intron containing genes. Of the 10 initial genomic clones isolated, one clone (MG3) showing the most complex hybridization pattern was found to contain the complete gene for subunit Vb. The DNA sequence analysis show that the subunit Vb gene contains four exons of 149, 73, 99, and 189 bases interrupted by three relatively small introns of 520, 165, and 648 nucleotides in a gene spanning about 2.5 kilobase pairs. As determined by a combination of primer extension and S1 protection analyses, the major transcription start site appears to be located 49 nucleotides upstream of the translation initiation codon. The ability of the 5' upstream DNA to initiate transcription was studied using the chloramphenicol acetyltransferase (CAT) expression plasmids in NIH 3T3 cells. Using this system we observed that a segment of the gene spanning nucleotides -574 to +45 can drive the transcription of CAT gene in an orientation dependent manner. The upstream region of subunit Vb gene lacks the TATA and CAAT elements, although it contains several GC rich elements and a pyrimidine rich stretch around the transcription start site.	UNIV PENN, SCH VET MED, DEPT ANIM BIOL, BIOCHEM LABS, PHILADELPHIA, PA 19104 USA	University of Pennsylvania					NIGMS NIH HHS [GM-29037] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029037] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNDT K, 1986, P NATL ACAD SCI USA, V83, P8516, DOI 10.1073/pnas.83.22.8516; BASU A, 1990, BIOCHIM BIOPHYS ACTA, V1087, P98, DOI 10.1016/0167-4781(90)90128-O; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BHAT KS, 1989, BIOCHEMISTRY-US, V28, P763, DOI 10.1021/bi00428a052; BIEWALD R, 1982, H-S Z PHYSIOL CHEM, V363, P1141, DOI 10.1515/bchm2.1982.363.2.1141; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CAO X, 1988, ANN NY ACAD SCI, V550, P337, DOI 10.1111/j.1749-6632.1988.tb35348.x; CAPALDI RA, 1988, TRENDS BIOCHEM SCI, V13, P144, DOI 10.1016/0968-0004(88)90073-4; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; CARTER RS, 1991, IN PRESS ARCH BIOCH; CORDEN J, 1980, SCIENCE, V209, P1406, DOI 10.1126/science.6251548; DAVIES B, 1989, P NATL ACAD SCI USA, V86, P6691, DOI 10.1073/pnas.86.17.6691; DIMAURO S, 1988, J BIOENERG BIOMEMBR, V20, P353, DOI 10.1007/BF00769637; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; DYNAN WS, 1983, CELL, V32, P669, DOI 10.1016/0092-8674(83)90053-3; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; FUNK CD, 1989, P NATL ACAD SCI USA, V86, P2587, DOI 10.1073/pnas.86.8.2587; GLERUM DM, 1988, FEBS LETT, V236, P100, DOI 10.1016/0014-5793(88)80293-X; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUARENTE L, 1984, CELL, V36, P503, DOI 10.1016/0092-8674(84)90243-5; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; KADENBACH B, 1987, CURR TOP BIOENERG, V15, P113; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KAGEYAMA R, 1988, P NATL ACAD SCI USA, V85, P5016, DOI 10.1073/pnas.85.14.5016; KAGEYAMA R, 1988, J BIOL CHEM, V263, P6329; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KENG T, 1987, P NATL ACAD SCI USA, V84, P9113, DOI 10.1073/pnas.84.24.9113; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIGHTOWLERS R, 1990, J BIOL CHEM, V265, P2677; LOMAX MI, 1984, P NATL ACAD SCI-BIOL, V81, P6295, DOI 10.1073/pnas.81.20.6295; MAARSE AC, 1988, NUCLEIC ACIDS RES, V16, P5797, DOI 10.1093/nar/16.13.5797; MAGUIRE DJ, 1986, NUCLEIC ACIDS RES, V14, P1379, DOI 10.1093/nar/14.3.1379; Maniatis T., 1982, MOL CLONING; MERMOD N, 1988, NATURE, V332, P557, DOI 10.1038/332557a0; MULLER RM, 1987, J BIOL CHEM, V262, P6795; PFEIFER K, 1987, CELL, V49, P9, DOI 10.1016/0092-8674(87)90750-1; POYTON RO, 1988, ANN NY ACAD SCI, V550, P289, DOI 10.1111/j.1749-6632.1988.tb35344.x; RIZZUTO R, 1988, GENE, V69, P245, DOI 10.1016/0378-1119(88)90435-0; RIZZUTO R, 1989, J BIOL CHEM, V264, P10595; SACHS MS, 1989, MOL CELL BIOL, V9, P566, DOI 10.1128/MCB.9.2.566; SALBAUM JM, 1988, EMBO J, V7, P2807, DOI 10.1002/j.1460-2075.1988.tb03136.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASSONECORSI P, 1986, TRENDS GENET, V2, P215, DOI 10.1016/0168-9525(86)90233-7; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUSKE G, 1988, DNA-J MOLEC CELL BIO, V7, P163, DOI 10.1089/dna.1988.7.163; SUSKE G, 1987, EUR J BIOCHEM, V168, P233, DOI 10.1111/j.1432-1033.1987.tb13410.x; SUZUKI H, 1989, J BIOL CHEM, V264, P1368; TAKESHIMA H, 1988, J MOL BIOL, V200, P1, DOI 10.1016/0022-2836(88)90328-2; TRAWICK JD, 1989, MOL CELL BIOL, V9, P5350, DOI 10.1128/MCB.9.12.5350; TRUEBLOOD CE, 1988, MOL CELL BIOL, V8, P4537, DOI 10.1128/MCB.8.10.4537; TSUZUKI T, 1987, J MOL BIOL, V198, P21, DOI 10.1016/0022-2836(87)90454-2; VIBERT M, 1989, EUR J BIOCHEM, V181, P33, DOI 10.1111/j.1432-1033.1989.tb14690.x; WEINER AM, 1986, ANNU REV BIOCHEM, V55, P631, DOI 10.1146/annurev.bi.55.070186.003215; YAMADA M, 1990, J BIOL CHEM, V265, P7687; ZEVIANI M, 1988, GENE, V65, P1, DOI 10.1016/0378-1119(88)90411-8; ZEVIANI M, 1987, GENE, V55, P205, DOI 10.1016/0378-1119(87)90281-2	60	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15450	15456						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1651332				2022-12-25	WOS:A1991GB09700093
J	VARGHESE, S; KRONENBERG, HM				VARGHESE, S; KRONENBERG, HM			RAT THYMOSIN-BETA-4 GENE - INTRON-CONTAINING GENE AND MULTIPLE RETROPOSONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; THYMIC HORMONES; DNA-BINDING; CELL-LINES; EXPRESSION; DIFFERENTIATION; LYMPHOCYTES; PSEUDOGENES; TISSUES; CLONING	Thymosin beta-4 (T-beta-4), a 43-residue peptide of uncertain function, is widely distributed in most tissues of vertebrates. Southern blot analysis demonstrated that the rat genome contains many closely related T-beta-4 sequences. Two distinct T-beta-4 sequences were isolated by screening a rat genomic DNA library. Analysis of these clones revealed that they represent T-beta-4 retroposons; they lack introns and contain stretches of poly(A) sequence at their 3' ends and direct repeats flanking the cDNA-like sequences. In order to isolate a T-beta-4 intron-containing gene, DNA fragments that include T-beta-4 introns were generated by polymerase chain reaction, using rat genomic DNA as template. Subsequent Southern blot analysis of rat genomic DNA with intron-specific probes demonstrated the presence of a single T-beta-4 intron-containing gene. Upon screening the rat genomic DNA library with an intron-specific probe, two overlapping clones of the T-beta-4 intron-containing gene were isolated. Further characterization and sequence analysis showed that the rat T-beta-4 intron-containing gene has a 2-kilobase pair-long transcription unit containing two introns. The transcription initiation site and putative regulatory elements of the promoter were identified.	HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	VARGHESE, S (corresponding author), MASSACHUSETTS GEN HOSP,ENDOCRINE UNIT,BOSTON,MA 02114, USA.				NIDDK NIH HHS [DK08351, DK36597] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK008351, R01DK036597] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ATKINSON MJ, 1990, MOL ENDOCRINOL, V4, P69, DOI 10.1210/mend-4-1-69; Ausubel FM, 1989, CURRENT PROTOCOLS MO, V1-3; BAXEVANIS CN, 1987, IMMUNOPHARMACOLOGY, V13, P133, DOI 10.1016/0162-3109(87)90050-6; BENOIST C, 1980, NUCLEIC ACIDS RES, V8, P127, DOI 10.1093/nar/8.1.127; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIES B, 1989, P NATL ACAD SCI USA, V86, P6691, DOI 10.1073/pnas.86.17.6691; DEMAY MB, 1990, P NATL ACAD SCI USA, V87, P369, DOI 10.1073/pnas.87.1.369; ERICKSONVIITANEN S, 1983, ARCH BIOCHEM BIOPHYS, V221, P570, DOI 10.1016/0003-9861(83)90177-7; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GOMEZMARQUEZ J, 1989, J IMMUNOL, V143, P2740; GONDO H, 1987, J IMMUNOL, V139, P3840; GOODALL GJ, 1983, ARCH BIOCHEM BIOPHYS, V221, P598, DOI 10.1016/0003-9861(83)90182-0; GOODALL GJ, 1987, ARCH BIOCHEM BIOPHYS, V256, P402, DOI 10.1016/0003-9861(87)90461-9; HANNAPPEL E, 1985, ARCH BIOCHEM BIOPHYS, V240, P236, DOI 10.1016/0003-9861(85)90028-1; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; LEONARD DGB, 1987, MOL CELL BIOL, V7, P3156, DOI 10.1128/MCB.7.9.3156; LOW TLK, 1981, P NATL ACAD SCI-BIOL, V78, P1162, DOI 10.1073/pnas.78.2.1162; LOW TLK, 1985, METHOD ENZYMOL, V116, P213; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MONTMINY MR, 1990, METABOLISM, V39, P6, DOI 10.1016/0026-0495(90)90198-L; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MUTCHNICK MG, 1988, CLIN IMMUNOL IMMUNOP, V47, P84, DOI 10.1016/0090-1229(88)90147-X; PAZMINO NH, 1978, CANCER TREAT REP, V62, P1749; REBAR RW, 1981, SCIENCE, V214, P669, DOI 10.1126/science.7027442; RUNDIN CM, 1990, J IMMUNOL, V144, P4857; SAFER D, 1991, J BIOL CHEM, V266, P4029; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOBITZ B, 1990, J BIOL CHEM, V265, P15387; SHIMAMURA R, 1990, BLOOD, V76, P977; SHINOMIYA T, 1984, P NATL ACAD SCI-BIOL, V81, P1346, DOI 10.1073/pnas.81.5.1346; SOARES MB, 1985, MOL CELL BIOL, V5, P2090, DOI 10.1128/MCB.5.8.2090; SOMA G, 1985, BIOCHEM BIOPH RES CO, V132, P100, DOI 10.1016/0006-291X(85)90994-5; WEINER AM, 1986, ANNU REV BIOCHEM, V55, P631, DOI 10.1146/annurev.bi.55.070186.003215; WODNARFILIPOWICZ A, 1984, P NATL ACAD SCI-BIOL, V81, P2295, DOI 10.1073/pnas.81.8.2295	40	10	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14256	14261						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1650352				2022-12-25	WOS:A1991FZ35100024
J	BASKIN, G; SCHENKER, S; FROSTO, T; HENDERSON, G				BASKIN, G; SCHENKER, S; FROSTO, T; HENDERSON, G			TRANSFORMING GROWTH-FACTOR BETA-1 INHIBITS EPIDERMAL GROWTH-FACTOR RECEPTOR ENDOCYTOSIS AND DOWN-REGULATION IN CULTURED FETAL-RAT HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; DNA-SYNTHESIS; MEDIATED ENDOCYTOSIS; EGF RECEPTOR; CELLS; EXPRESSION; LIVER; FIBROBLASTS; ANTIBODIES; PARACRINE	Incubation of fetal rat hepatocytes (FRH) with transforming growth factor beta-1 (TGF-beta-1) resulted in growth arrest and a biphasic effect on epidermal growth factor (EGF) receptor. After 2 h of exposure, EGF receptor (EGFR) was reduced by 43%. From 6 to 24 h, TGF-beta-1 exposure resulted in progressive increase in EGFR up to 74% over control. The increased binding was due to increase in high affinity EGF binding sites. FRH grown in medium containing EGF exhibited down-regulated EGFR with loss of high affinity EGF binding sites. With TGF-beta-1 exposure, high affinity EGFR was not down-regulated by EGF. Since down-regulation of EGFR involves internalization, the kinetics of EGF receptor-mediated endocytosis were examined. In TGF-beta-1-exposed FRH, EGF endocytosis was inhibited, with a reduction in the first order rate constant for the process from 0.078 to 0.043 min-1. Despite inhibition of growth, receptor down-regulation, and EGF endocytosis after TGF-beta-1 exposure, EGF-induced receptor autophosphorylation was preserved as demonstrated by [P-32]phosphate-labeling of immunoprecipitated EGFR. These observations provide direct evidence that TGF-beta-1 regulates growth of fetal cells. Further, they suggest that TGF-beta-1 regulates endocytosis of EGF and possibly of other ligands.	UNIV TEXAS, HLTH SCI CTR, DEPT PHARMACOL, SAN ANTONIO, TX 78284 USA	University of Texas System; University of Texas Health San Antonio	BASKIN, G (corresponding author), UNIV TEXAS, HLTH SCI CTR, DEPT MED, 7703 FLOYD CURL DR, SAN ANTONIO, TX 78284 USA.				NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [K02AA000121] Funding Source: NIH RePORTER; NIAAA NIH HHS [5K02AA00121-03] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ASSOIAN RK, 1985, J BIOL CHEM, V260, P9613; BRAUN L, 1988, P NATL ACAD SCI USA, V85, P1539, DOI 10.1073/pnas.85.5.1539; CARR BI, 1986, CANCER RES, V46, P2330; CARR BI, 1989, J CELL BIOCHEM, V39, P477, DOI 10.1002/jcb.240390413; ELLINGSWORTH LR, 1986, J BIOL CHEM, V261, P2362; FENG P, 1986, J BIOL CHEM, V261, P14167; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; HAIGLER HT, 1980, J BIOL CHEM, V255, P1239; HENDERSON GI, 1989, J CLIN INVEST, V84, P1287, DOI 10.1172/JCI114296; KAPUSCINSKI J, 1977, ANAL BIOCHEM, V83, P252, DOI 10.1016/0003-2697(77)90533-4; Klausner R., 1985, ENDOCYTOSIS, P259; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHNERT SA, 1988, DEVELOPMENT, V104, P263; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MIOH H, 1989, J CELL PHYSIOL, V139, P509, DOI 10.1002/jcp.1041390309; MOSES HL, 1981, CANCER RES, V41, P2842; NUGENT MA, 1989, CANCER RES, V49, P3884; OWENSBY DA, 1989, METHOD CELL BIOL, V32, P305; ROBERTS AB, 1981, P NATL ACAD SCI-BIOL, V78, P5339, DOI 10.1073/pnas.78.9.5339; RUSSELL WE, 1988, P NATL ACAD SCI USA, V85, P5126, DOI 10.1073/pnas.85.14.5126; RUSSELL WE, 1988, J CELL PHYSIOL, V135, P253, DOI 10.1002/jcp.1041350212; SPORN MB, 1986, SCIENCE, V233, P532, DOI 10.1126/science.3487831; STOSCHECK CM, 1984, J CELL BIOL, V98, P1048, DOI 10.1083/jcb.98.3.1048; STRAIN AJ, 1987, BIOCHEM BIOPH RES CO, V145, P436, DOI 10.1016/0006-291X(87)91340-4; TAKEHARA K, 1987, CELL, V49, P415, DOI 10.1016/0092-8674(87)90294-7; WHITMAN M, 1989, ANNU REV CELL BIOL, V5, P93; WILCOX JN, 1988, MOL CELL BIOL, V8, P3415, DOI 10.1128/MCB.8.8.3415; WILEY HS, 1982, J BIOL CHEM, V257, P4222	28	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1991	266	20					13238	13242						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FX132	1649185				2022-12-25	WOS:A1991FX13200069
J	HOWARD, EW; BULLEN, EC; BANDA, MJ				HOWARD, EW; BULLEN, EC; BANDA, MJ			PREFERENTIAL INHIBITION OF 72-KDA AND 92-KDA GELATINASES BY TISSUE INHIBITOR OF METALLOPROTEINASES-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKIN FIBROBLAST COLLAGENASE; CAPILLARY ENDOTHELIAL-CELLS; BASEMENT-MEMBRANE COLLAGEN; HUMAN AMNIOTIC MEMBRANE; IV COLLAGENASE; DEGRADING METALLOPROTEINASE; BONE METALLOPROTEINASE; CONNECTIVE TISSUES; CDNA CLONING; V COLLAGEN	Transformed human fibroblasts secrete two structurally and functionally related inhibitors of matrix metalloproteinases, tissue inhibitor of metalloproteinases (TIMP) 1 and 2. In assays measuring the relative inhibitory capability of TIMP-1 and TIMP-2 against autoactivated 72-kDa gelatinase, which consists of two major active peptides and several inactive fragments, TIMP-2 was more effective than TIMP-1. The isolated 42.5-kDa active fragment that formed as a result of the autoactivation of 72-kDa gelatinase showed the greatest preference for TIMP-2; at half-maximal inhibition, TIMP-2 was > 10-fold more effective than TIMP-1. TIMP-2 was also > 2-fold more effective than TIMP-1 at inhibiting 72-kDa gelatinase-TIMP-2 complexes activated with 4- aminophenylmercuric acetate, and > 7-fold more effective than TIMP-1 at inhibiting 92-kDa gelatinase activated with 4-aminophenylmercuric acetate. Furthermore, these active gelatinases preferentially bound I-125-TIMP-2 when incubated with equal amounts of radiolabeled TIMP-1 and TIMP-2. The ratios of I-125-TIMP-2/I-125-TIMP-1 binding to 92-kDa gelatinase, autoactivated 72-kDa gelatinase, and 42.5-kDa fragment were 4.4, 10, and 33, respectively. On the other hand, interstitial collagenase was inhibited by TIMP-1 > 2-fold more effectively than TIMP-2 in assays measuring cleavage of loose collagen fibrils.			HOWARD, EW (corresponding author), UNIV CALIF SAN FRANCISCO,RADIOBIOL & ENVIRONM HLTH LAB,SAN FRANCISCO,CA 94143, USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007106] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR32741] Funding Source: Medline; NIEHS NIH HHS [5-T32-ES07106] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alexander CM, 1989, CURR OPIN CELL BIOL, V1, P974, DOI 10.1016/0955-0674(89)90068-9; APODACA G, 1990, CANCER RES, V50, P2322; BALLIN M, 1988, BIOCHEM BIOPH RES CO, V154, P832, DOI 10.1016/0006-291X(88)90215-X; BARSHAVIT Z, 1985, P NATL ACAD SCI USA, V82, P5380, DOI 10.1073/pnas.82.16.5380; BOONE TC, 1990, P NATL ACAD SCI USA, V87, P2800, DOI 10.1073/pnas.87.7.2800; CARMICHAEL DF, 1986, P NATL ACAD SCI USA, V83, P2407, DOI 10.1073/pnas.83.8.2407; CAWSTON TE, 1983, BIOCHEM J, V211, P313, DOI 10.1042/bj2110313; CAWSTON TE, 1981, METHOD ENZYMOL, V80, P711; CAWSTON TE, 1986, BIOCHEM J, V238, P677, DOI 10.1042/bj2380677; CAWSTON TE, 1981, BIOCHEM J, V195, P159, DOI 10.1042/bj1950159; CAWSTON TE, 1979, ANAL BIOCHEM, V99, P340, DOI 10.1016/S0003-2697(79)80017-2; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; DAVIS GE, 1990, CANCER RES, V50, P1113; DEAN DD, 1984, BIOCHEM J, V218, P277, DOI 10.1042/bj2180277; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; HERRON GS, 1986, J BIOL CHEM, V261, P2814; HERRON GS, 1986, J BIOL CHEM, V261, P2810; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; MAINARDI CL, 1984, COLLAGEN REL RES, V4, P479; MIGNATTI P, 1989, J CELL BIOL, V108, P671, DOI 10.1083/jcb.108.2.671; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; MOOKHTIAR KA, 1986, ANAL BIOCHEM, V158, P322, DOI 10.1016/0003-2697(86)90557-9; MURPHY G, 1985, BIOESSAYS, V2, P55, DOI 10.1002/bies.950020204; MURPHY G, 1989, BIOCHEM J, V261, P1031, DOI 10.1042/bj2611031; MURPHY G, 1985, BIOCHIM BIOPHYS ACTA, V831, P49, DOI 10.1016/0167-4838(85)90148-7; MURPHY G, 1981, BIOCHEM J, V195, P167, DOI 10.1042/bj1950167; OTSUKA K, 1984, EUR J BIOCHEM, V145, P123, DOI 10.1111/j.1432-1033.1984.tb08530.x; SALO T, 1983, J BIOL CHEM, V258, P3058; SELTZER JL, 1981, J BIOL CHEM, V256, P4662; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P1353; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; THOMSON BM, 1987, BIOCHEM BIOPH RES CO, V148, P596, DOI 10.1016/0006-291X(87)90918-1; WELGUS HG, 1985, COLLAGEN REL RES, V5, P167; WELGUS HG, 1983, J BIOL CHEM, V258, P2259; WELGUS HG, 1979, J BIOL CHEM, V254, P1938; Werb Z., 1989, TXB RHEUMATOLOGY, P300; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; ZUCKER S, 1987, BIOCHEM J, V245, P429, DOI 10.1042/bj2450429	39	206	210	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1991	266	20					13070	13075						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FX132	1649175				2022-12-25	WOS:A1991FX13200044
J	WEN, ZL; TAO, X; LAKKIS, F; KIYOKAWA, T; MURPHY, JR				WEN, ZL; TAO, X; LAKKIS, F; KIYOKAWA, T; MURPHY, JR			DIPHTHERIA TOXIN-RELATED ALPHA-MELANOCYTE-STIMULATING HORMONE FUSION TOXIN - INTERNAL IN-FRAME DELETION FROM THR387 TO HIS485 RESULTS IN THE FORMATION OF A HIGHLY POTENT FUSION TOXIN WHICH IS RESISTANT TO PROTEOLYTIC DEGRADATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COOMASSIE BRILLIANT BLUE; CELL-LINE; POLYACRYLAMIDE GELS; ESCHERICHIA-COLI; CYTO-TOXICITY; MELANOTROPIN RECEPTORS; GENETIC CONSTRUCTION; NUCLEOTIDE-SEQUENCE; ADENYLATE-CYCLASE; BETA-MELANOTROPIN	We have previously reported the genetic construction and properties of a fusion protein which was composed of the enzymatically active and membrane translocation domains of the diphtheria toxin and the receptor-specific ligand alpha-melanocyte-stimulating hormone (alpha-MSH) (Murphy, J. R., Bishai, W., Borowski, M., Miyanohara, A., Boyd, J., and Nagle, S. (1986) Proc. Natl. Acad. Sci. U. S. A. 83, 8258-8262). While this fusion toxin was found to be selectively toxic for MSH receptor-bearing cells in vitro, it was subject to profound proteolytic degradation in recombinant Escherichia coli making purification difficult. We now report that the deletion of diphtheria toxin fragment B sequences between Thr387 and His485 results in a protease-resistant form of the fusion toxin, DAB389-alpha-MSH. We show that DAB389-alpha-MSH is expressed in high yield in recombinant Escherichia coli, that it is readily purified from crude bacterial lysates by immunoaffinity and high performance liquid chromatography, and its cytotoxic activity toward both human and murine malignant melanoma cell lines is mediated through the MSH receptor.	BOSTON UNIV HOSP,MED CTR,DEPT MED,BOSTON,MA 02218	Boston University	WEN, ZL (corresponding author), BOSTON UNIV HOSP,MED CTR,EVANS DEPT CLIN RES,BOSTON,MA 02218, USA.				NATIONAL CANCER INSTITUTE [R01CA048626, U19CA048626, R01CA041746, U01CA048626] Funding Source: NIH RePORTER; NCI NIH HHS [CA-41746, V01 CA-48626] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BACHA P, 1988, J EXP MED, V167, P612, DOI 10.1084/jem.167.2.612; BISHAI WR, 1987, J BACTERIOL, V169, P1554, DOI 10.1128/jb.169.4.1554-1563.1987; BISHAI WR, 1987, J BACTERIOL, V169, P5140, DOI 10.1128/jb.169.11.5140-5151.1987; BOQUET P, 1976, P NATL ACAD SCI USA, V73, P4449, DOI 10.1073/pnas.73.12.4449; CHAUDHARY VK, 1987, P NATL ACAD SCI USA, V84, P4538, DOI 10.1073/pnas.84.13.4538; DEXTER TJ, 1987, EXP CELL RES, V27, P143; DIEZEL W, 1972, ANAL BIOCHEM, V48, P617, DOI 10.1016/0003-2697(72)90117-0; DONOVAN JJ, 1981, P NATL ACAD SCI-BIOL, V78, P172, DOI 10.1073/pnas.78.1.172; FULLER BB, 1979, LIFE SCI, V24, P2405, DOI 10.1016/0024-3205(79)90448-X; GERST JE, 1986, MOL CELL ENDOCRINOL, V46, P137; GERST JE, 1987, MOL PHARMACOL, V31, P81; GHANEM GE, 1988, INT J CANCER, V41, P248, DOI 10.1002/ijc.2910410216; GREENFIELD L, 1983, P NATL ACAD SCI-BIOL, V80, P6853, DOI 10.1073/pnas.80.22.6853; HALABAN R, 1983, J CELL BIOL, V97, P480, DOI 10.1083/jcb.97.2.480; ISBERG RR, 1982, CELL, V30, P883, DOI 10.1016/0092-8674(82)90293-8; KACZOREK M, 1983, SCIENCE, V221, P855, DOI 10.1126/science.6348945; KAGAN BL, 1981, P NATL ACAD SCI-BIOL, V78, P4950, DOI 10.1073/pnas.78.8.4950; KAMEYAMA K, 1988, J CELL PHYSIOL, V137, P35, DOI 10.1002/jcp.1041370105; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBERT DT, 1985, PIGMENT CELL 1985, P165; LIU MA, 1988, SCIENCE, V239, P395, DOI 10.1126/science.3257303; LOBERBOUMGALSKI H, 1988, P NATL ACAD SCI USA, V85, P1922; MEYERS CE, 1990, CANCER CHEMOTHERAPY, P356; MIDDLEBROOK JL, 1978, J BIOL CHEM, V253, P7325; MOYA M, 1985, J CELL BIOL, V101, P548, DOI 10.1083/jcb.101.2.548; MURPHY JR, 1986, P NATL ACAD SCI USA, V83, P8258, DOI 10.1073/pnas.83.21.8258; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; PAWELEK JM, 1985, YALE J BIOL MED, V58, P571; PRESTON SF, 1987, P NATL ACAD SCI USA, V84, P5247, DOI 10.1073/pnas.84.15.5247; ROBB M, 1982, INFECT IMMUN, V38, P267, DOI 10.1128/IAI.38.1.267-272.1982; SANDVIG K, 1986, J BIOL CHEM, V261, P1639; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEPPARD JR, 1984, NATURE, V308, P544, DOI 10.1038/308544a0; SIEGALL CB, 1988, P NATL ACAD SCI USA, V85, P9738, DOI 10.1073/pnas.85.24.9738; TATRO JB, 1990, J CLIN INVEST, V85, P1825, DOI 10.1172/JCI114642; TATRO JB, 1990, CANCER RES, V50, P1237; TIEGHEM NV, 1985, PIGMENT CELL 1985, P183; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UCHIDA T, 1971, NATURE-NEW BIOL, V233, P8, DOI 10.1038/newbio233008a0; VARGA JM, 1977, NATURE, V267, P56, DOI 10.1038/267056a0; VARGA JM, 1976, P NATL ACAD SCI USA, V73, P559, DOI 10.1073/pnas.73.2.559; VARGA JM, 1983, TARGETED DRUGS, P73; WILLIAMS DP, 1990, J BIOL CHEM, V265, P11885; WILLIAMS DP, 1987, PROTEIN ENG, V1, P493, DOI 10.1093/protein/1.6.493; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	46	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1991	266	19					12289	12293						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FV180	1648090				2022-12-25	WOS:A1991FV18000031
J	CROOK, T; WREDE, D; VOUSDEN, KH				CROOK, T; WREDE, D; VOUSDEN, KH			P53 POINT MUTATION IN HPV NEGATIVE HUMAN CERVICAL-CARCINOMA CELL-LINES	ONCOGENE			English	Note							HUMAN FORESKIN KERATINOCYTES; HUMAN PAPILLOMAVIRUS TYPE-16; EARLY GENES; CANCER; IMMORTALIZATION; TRANSCRIPTION; ASSOCIATION; EXPRESSION; SEQUENCES; DNAS	Clinical and experimental evidence is consistent with a key role for transforming human papilloma viruses (HPVs) in the aetiology of anogenital carcinoma. Cervical carcinoma does, however, occasionally occur in the absence of HPV sequences (Riou et al., 1990). We have used a direct cDNA/PCR sequencing protocol to analyse the sequence of p53 mRNA expressed by HPV positive and negative cervical carcinoma cell lines. Six cell lines which contain HPV sequences express p53 mRNA which has wild-type sequence throughout conserved boxes 2, 3, 4 and 5. The two HPV negative cell lines (C33a and HT3) express mutant p53 mRNA. In each case the mutation. occurs in an evolutionarily conserved amino acid. Our data suggest that loss of wild-type p53 function is important in development of cervical carcinoma, and that this might be achieved either by mutation within the p53 gene or the presence of a virally encoded p53 binding protein.	SAMARITAN HOSP WOMEN,DEPT GYNAECOL ONCOL,LONDON NW1,ENGLAND		CROOK, T (corresponding author), ST MARYS HOSP,SCH MED,LUDWIG INST CANC RES,NORFOLK PL,LONDON W2 1PG,ENGLAND.							CROOK T, 1991, J VIROL, V65, P505, DOI 10.1128/JVI.65.1.505-510.1991; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PATER MM, 1985, VIROLOGY, V145, P313, DOI 10.1016/0042-6822(85)90164-3; PECORARO G, 1989, P NATL ACAD SCI USA, V86, P563, DOI 10.1073/pnas.86.2.563; RIOU G, 1990, LANCET, V335, P1171; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; SOUSSI T, 1987, ONCOGENE, V1, P71; VOUSDEN KH, 1989, CANCER CELL-MON REV, V1, P43; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WOODWORTH CD, 1989, J VIROL, V63, P159, DOI 10.1128/JVI.63.1.159-164.1989; YEE C, 1985, AM J PATHOL, V119, P361	17	314	317	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1991	6	5					873	875						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT825	1646990				2022-12-25	WOS:A1991GT82500026
J	BETTANY, AJE; EISENSTEIN, RS; MUNRO, HN				BETTANY, AJE; EISENSTEIN, RS; MUNRO, HN			MUTAGENESIS OF THE IRON-REGULATORY ELEMENT FURTHER DEFINES A ROLE FOR RNA SECONDARY STRUCTURE IN THE REGULATION OF FERRITIN AND TRANSFERRIN RECEPTOR EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBUNIT MESSENGER-RNAS; R17 COAT PROTEIN; BINDING-SITE; RESPONSIVE ELEMENTS; HEAVY-SUBUNIT; TRANSLATIONAL REGULATION; UNTRANSLATED REGION; ESCHERICHIA-COLI; COBRA VENOM; IDENTIFICATION	Within the 5'-untranslated region of ferritin mRNAs, there is a conserved region of 28 nucleotides (nt) (the iron regulatory element (IRE)) that binds a protein (the IRE-binding protein (IRE-BP)) involved in the iron regulation of ferritin mRNA translation. We have examined the role of RNA secondary structure on the interaction of the IRE with the IRE-BP. First, the rat light ferritin IRE possesses a structure similar to that of the bullfrog heavy ferritin IRE (Wang, Y.H., Sczekan, S. R., and Theil, E. C. (1990) Nucleic Acids Res. 18, 4463-4468). This includes an extended stem, interrupted at various points by bulge nucleotides and a 6-nt single-stranded loop (CAGUGU) at its top. Computer predictions and mapping results suggest the presence of a 3-nt (UGC) bulge 5 bases 5' of the loop in the rat IRE. Second, disruption of the base pairing in the upper stem alters IRE secondary structure and reduces the affinity with which the IRE-BP binds the IRE. Third, increasing the size of the loop or the distance between the UGC bulge and the loop reduces the IRE/IRE-BP interaction. Our results indicate that several aspects of IRE secondary structure are important for its high affinity binding to the IRE-BP.	TUFTS UNIV, USDA, HUMAN NUTR RES CTR AGING, BOSTON, MA 02111 USA; MIT, DIV TOXICOL, CAMBRIDGE, MA 02139 USA	Tufts University; United States Department of Agriculture (USDA); Massachusetts Institute of Technology (MIT)								AURON PE, 1982, BIOCHEMISTRY-US, V21, P4700, DOI 10.1021/bi00262a028; AZIZ N, 1986, NUCLEIC ACIDS RES, V14, P915, DOI 10.1093/nar/14.2.915; BARTON HA, 1990, J BIOL CHEM, V265, P7000; BHATTACHARYYA A, 1990, NATURE, V343, P484, DOI 10.1038/343484a0; CALNAN BJ, 1991, GENE DEV, V5, P201, DOI 10.1101/gad.5.2.201; CAREY J, 1983, BIOCHEMISTRY-US, V22, P4723, DOI 10.1021/bi00289a017; CASEY JL, 1989, EMBO J, V8, P3693, DOI 10.1002/j.1460-2075.1989.tb08544.x; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CERRETTI DP, 1988, J MOL BIOL, V204, P309, DOI 10.1016/0022-2836(88)90578-5; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; DANDEKAR T, 1991, EMBO J, V10, P1903, DOI 10.1002/j.1460-2075.1991.tb07716.x; EISENSTEIN RS, 1990, ENZYME, V44, P42, DOI 10.1159/000468746; FUERST TR, 1989, J MOL BIOL, V206, P333, DOI 10.1016/0022-2836(89)90483-X; HARRELL CM, 1991, P NATL ACAD SCI USA, V88, P4166, DOI 10.1073/pnas.88.10.4166; HENTZE MW, 1988, GENE, V72, P201, DOI 10.1016/0378-1119(88)90145-X; JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706; JAEGER JA, 1990, METHODS ENZYMOL, V183, P281; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LEIBOLD EA, 1990, NUCLEIC ACIDS RES, V18, P1819, DOI 10.1093/nar/18.7.1819; LOCKARD RE, 1981, NUCLEIC ACIDS RES, V9, P5125, DOI 10.1093/nar/9.19.5125; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; MUNRO HN, 1985, PROTEINS IRON STORAG, P331; MURRAY MT, 1987, P NATL ACAD SCI USA, V84, P7438, DOI 10.1073/pnas.84.21.7438; ROGERS J, 1987, P NATL ACAD SCI USA, V84, P2277, DOI 10.1073/pnas.84.8.2277; ROMANIUK PJ, 1987, BIOCHEMISTRY-US, V26, P1563, DOI 10.1021/bi00380a011; ROMANIUK PJ, 1987, NUCLEIC ACIDS RES, V15, P2737, DOI 10.1093/nar/15.6.2737; ROUAULT TA, 1988, SCIENCE, V241, P1207, DOI 10.1126/science.3413484; ROY S, 1990, GENE DEV, V4, P1365, DOI 10.1101/gad.4.8.1365; SAID B, 1988, NUCLEIC ACIDS RES, V16, P10529, DOI 10.1093/nar/16.22.10529; TANG RS, 1990, BIOCHEMISTRY-US, V29, P5232, DOI 10.1021/bi00474a003; Vournakis J N, 1981, Gene Amplif Anal, V2, P267; WALDEN WE, 1988, P NATL ACAD SCI USA, V85, P9503, DOI 10.1073/pnas.85.24.9503; WANG YH, 1990, NUCLEIC ACIDS RES, V18, P4463, DOI 10.1093/nar/18.15.4463; WEEKS KM, 1991, CELL, V66, P577, DOI 10.1016/0092-8674(81)90020-9; WURST RM, 1978, BIOCHEMISTRY-US, V17, P4493, DOI 10.1021/bi00614a021; ZAHRINGER J, 1976, P NATL ACAD SCI USA, V73, P857, DOI 10.1073/pnas.73.3.857; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	39	81	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16531	16537						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1644834				2022-12-25	WOS:A1992JJ45800084
J	BITTNER, MA; HOLZ, RW				BITTNER, MA; HOLZ, RW			KINETIC-ANALYSIS OF SECRETION FROM PERMEABILIZED ADRENAL CHROMAFFIN CELLS REVEALS DISTINCT COMPONENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CATECHOLAMINE SECRETION; DEPENDENT EXOCYTOSIS; PHORBOL ESTERS; TETANUS TOXIN; MAST-CELLS; RELEASE; CA-2+; CALMODULIN; INFLUX	We have determined that there are components to the time course of Ca2+-dependent secretion from digitonin-permeabilized bovine adrenal chromaffin cells that can be distinguished by Ca2+ sensitivity and ATP dependence. The effects of various Ca2+ concentrations are different on the initial rates and later rates of secretion. The earliest rates (5 s) are half-maximal between 30-100-mu-M Ca2+ and maximal by 300-mu-M Ca2+. Later rates of secretion are maximal by 10-mu-M and decline above 30-mu-M Ca2+. At low Ca2+ concentrations secretion begins after a lag of several seconds. The early rates of secretion (within 1 min) are dependent on the prior effects of MgATP. MgATP primes the cells to secrete. Later rates require the continuous presence of MgATP for optimal secretion. Incubation with low concentrations of Ca2+ increases the ability of MgATP to stimulate subsequent Ca2+-dependent secretion. Preincubation with Ca2+ has no effect on the rapid loss of ATP-independent secretion with time after permeabilization. The data indicate that: 1) as secretion progresses in digitonin-permeabilized cells, different events become rate-limiting; 2) maximal secretion at the early times requires at least 10-fold higher Ca2+ concentrations than at later times; 3) the rate at which Ca2+ initiates secretion is concentration-dependent; and 4) Ca2+ not only triggers the final events in secretion but enhances the ability of ATP to prime secretion.			BITTNER, MA (corresponding author), UNIV MICHIGAN, SCH MED, DEPT PHARMACOL, M6322 MED SCI BLDG 1, ANN ARBOR, MI 48109 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027959] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK27959] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUGUSTINE GJ, 1991, ANN NY ACAD SCI, V635, P365, DOI 10.1111/j.1749-6632.1991.tb36505.x; AUGUSTINE GJ, 1992, J PHYSIOL-LONDON, V450, P247, DOI 10.1113/jphysiol.1992.sp019126; BADER MF, 1986, J BIOL CHEM, V261, P5777; BADER MF, 1989, J BIOL CHEM, V264, P16426; BITTNER MA, 1989, J BIOL CHEM, V264, P10354; BITTNER MA, 1992, J BIOL CHEM, V267, P16226; BITTNER MA, 1986, J BIOL CHEM, V261, P182; BITTNER MA, 1990, J NEUROCHEM, V54, P205, DOI 10.1111/j.1471-4159.1990.tb13302.x; BITTNER MA, 1988, J NEUROCHEM, V51, P451, DOI 10.1111/j.1471-4159.1988.tb01059.x; BITTNER MA, 1989, J NEUROCHEM, V53, P966, DOI 10.1111/j.1471-4159.1989.tb11800.x; BJERRUM J, 1957, STABILITY CONSTANT 1, P422; BROOKS JC, 1983, J NEUROCHEM, V40, P468, DOI 10.1111/j.1471-4159.1983.tb11306.x; CHEEK TR, 1989, FEBS LETT, V247, P429, DOI 10.1016/0014-5793(89)81385-7; CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0; COX JA, 1988, BIOCHEM J, V249, P621, DOI 10.1042/bj2490621; DUNN LA, 1983, J BIOL CHEM, V258, P4989; FENWICK EM, 1982, J PHYSIOL-LONDON, V331, P577, DOI 10.1113/jphysiol.1982.sp014393; HOLZ RW, 1989, J BIOL CHEM, V264, P5412; HOLZ RW, 1982, J NEUROCHEM, V39, P635, DOI 10.1111/j.1471-4159.1982.tb07940.x; HOLZ RW, 1991, ANN NY ACAD SCI, V635, P382, DOI 10.1111/j.1749-6632.1991.tb36506.x; HOWELL TW, 1989, CELL SIGNAL, V1, P157, DOI 10.1016/0898-6568(89)90005-3; KAO LS, 1986, J BIOL CHEM, V261, P4881; KELNER KL, 1986, P NATL ACAD SCI USA, V83, P2998, DOI 10.1073/pnas.83.9.2998; KILHOFFER MC, 1983, MOL CELL BIOCHEM, V51, P33, DOI 10.1007/BF00215584; KNIGHT DE, 1982, J MEMBRANE BIOL, V68, P107, DOI 10.1007/BF01872259; KNIGHT DE, 1985, FEBS LETT, V189, P345, DOI 10.1016/0014-5793(85)81053-X; MARTELL AE, 1974, CRITICAL STABILITY C, V1, P269; NEHER E, 1992, J PHYSIOL-LONDON, V450, P273, DOI 10.1113/jphysiol.1992.sp019127; PORTZEHL H, 1964, BIOCHIM BIOPHYS ACTA, V79, P581, DOI 10.1016/0926-6577(64)90224-4; ROBERTS WM, 1991, ANN NY ACAD SCI, V635, P221, DOI 10.1111/j.1749-6632.1991.tb36494.x; SIMON SM, 1985, BIOPHYS J, V48, P485, DOI 10.1016/S0006-3495(85)83804-2; SONTAG JM, 1988, EUR J CELL BIOL, V46, P316; TATHAM PER, 1989, BIOSCIENCE REP, V9, P99, DOI 10.1007/BF01117516; TERBUSH DR, 1990, J BIOL CHEM, V265, P21179; TERBUSH DR, 1986, J BIOL CHEM, V261, P7099; TERBUSH DR, 1988, J BIOL CHEM, V263, P18873; WILSON SP, 1983, J BIOL CHEM, V258, P4994	37	202	202	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16219	16225						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1644807				2022-12-25	WOS:A1992JJ45800037
J	GILBERT, GE; DRINKWATER, D; BARTER, S; CLOUSE, SB				GILBERT, GE; DRINKWATER, D; BARTER, S; CLOUSE, SB			SPECIFICITY OF PHOSPHATIDYLSERINE-CONTAINING MEMBRANE-BINDING SITES FOR FACTOR-VIII - STUDIES WITH MODEL MEMBRANES SUPPORTED BY GLASS MICROSPHERES (LIPOSPHERES)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR-V; VONWILLEBRAND-FACTOR; PHOSPHOLIPID-VESICLES; HUMAN-PLATELETS; BLOOD-COAGULATION; ENZYME COMPLEXES; MOLECULAR-BASIS; ACTIVATION; PROTEINS; THROMBIN	Factor VIII functions in an enzyme complex upon the activated platelet membrane where phosphatidylserine exposure correlates with expression of receptors for factor VIII. To evaluate the specificity of phosphatidylserine-containing membrane binding sites for factor VIII, we have developed a novel membrane model in which phospholipid bilayers are supported by glass microspheres (lipospheres). The binding of fluorescein-labeled factor VIII to lipospheres with membranes of 15% phosphatidylserine was equivalent to binding to phospholipid vesicles (K(D) = 4.8 nM). Purified von Willebrand factor (vWf), a carrier protein for factor VIII, decreased membrane binding of factor VIII with a K(i) of 10-mu-g/ml. Likewise, normal plasma decreased bound factor VIII by more than 90% whereas plasma lacking vWf decreased the binding of factor VIII by only 20%. Proteolytic activation of factor VIII by thrombin, which releases factor VIII from vWf, increased liposphere binding in the presence of vWf and in the presence of normal plasma. Although factor V is homologous to factor VIII and binds to lipospheres with the same affinity, purified factor V was not an efficient competitor for the membrane binding sites of factor VIII. These results indicate that phosphatidylserine-containing membrane sites have sufficient specificity to select thrombin-activated factor VIII from the range of phospholipid-binding proteins in plasma.	BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	GILBERT, GE (corresponding author), BROCKTON W ROXBURY VET ADM MED CTR,DEPT MED,1400 VFW PKWY,BOSTON,MA 02132, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002587] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL02587] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMAD SS, 1989, J BIOL CHEM, V264, P3244; ANDERSSON LO, 1981, BIOCHEM J, V200, P161, DOI 10.1042/bj2000161; ARAI M, 1989, J CLIN INVEST, V83, P1978, DOI 10.1172/JCI114107; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BARTLES JR, 1982, BIOCHIM BIOPHYS ACTA, V687, P129, DOI 10.1016/0005-2736(82)90538-7; BENTAL O, 1991, BLOOD, V78, P180; BEVERS EM, 1983, BIOCHIM BIOPHYS ACTA, V736, P57, DOI 10.1016/0005-2736(83)90169-4; BLOOM JW, 1987, THROMB RES, V48, P439, DOI 10.1016/0049-3848(87)90401-4; BRIAN AA, 1984, P NATL ACAD SCI-BIOL, V81, P6159, DOI 10.1073/pnas.81.19.6159; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; CHURCH WR, 1984, P NATL ACAD SCI-BIOL, V81, P6934, DOI 10.1073/pnas.81.22.6934; DUFFY E, 1991, BLOOD, V78, P59; FAY PJ, 1991, J BIOL CHEM, V266, P2172; FOSTER PA, 1990, BLOOD, V75, P1999; FOSTER PA, 1988, J BIOL CHEM, V263, P5230; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GEMMELL CH, 1988, BLOOD, V72, P1404; GILBERT GE, 1990, J BIOL CHEM, V265, P815; GILBERT GE, 1991, J BIOL CHEM, V266, P17261; GITSCHIER J, 1984, NATURE, V312, P326, DOI 10.1038/312326a0; HARLOW E, 1988, ANTIBODIES LABORATOR; HAUSER H, 1981, BIOCHIM BIOPHYS ACTA, V650, P21, DOI 10.1016/0304-4157(81)90007-1; HILLEUBANKS DC, 1989, P NATL ACAD SCI USA, V86, P6508, DOI 10.1073/pnas.86.17.6508; KALAFATIS M, 1990, J BIOL CHEM, V265, P21580; KANE WH, 1988, BLOOD, V71, P539; KAUFMAN RJ, 1988, J BIOL CHEM, V263, P6352; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P5714; LAJMANOVICH A, 1981, BIOCHIM BIOPHYS ACTA, V678, P132, DOI 10.1016/0304-4165(81)90056-8; LARSEN E, 1990, CELL, V63, P467, DOI 10.1016/0092-8674(90)90443-I; LOLLAR P, 1991, MAYO CLIN PROC, V66, P524, DOI 10.1016/S0025-6196(12)62395-7; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MANN KG, 1990, BLOOD, V76, P1; NESHEIM M, 1991, J BIOL CHEM, V266, P17815; NESHEIM ME, 1988, J BIOL CHEM, V263, P16467; PITTMAN DD, 1988, P NATL ACAD SCI USA, V85, P2429, DOI 10.1073/pnas.85.8.2429; ROSING J, 1988, BIOCHEMISTRY-US, V27, P8, DOI 10.1021/bi00401a002; SANDBERG H, 1985, THROMB RES, V39, P63, DOI 10.1016/0049-3848(85)90122-7; SIMS PJ, 1986, BLOOD, V68, P556; SIMS PJ, 1988, J BIOL CHEM, V263, P18205; STUBBS JD, 1990, P NATL ACAD SCI USA, V87, P8417, DOI 10.1073/pnas.87.21.8417; TAMM LK, 1985, BIOPHYS J, V47, P105, DOI 10.1016/S0006-3495(85)83882-0; TENDIAN SW, 1991, BIOCHEMISTRY-US, V30, P10991, DOI 10.1021/bi00109a026; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; TRACY PB, 1979, J BIOL CHEM, V254, P354; WOLF P, 1967, BRIT J HAEMATOL, V13, P269, DOI 10.1111/j.1365-2141.1967.tb08741.x; ZOPF D, 1990, NATURE, V346, P87, DOI 10.1038/346087a0	46	85	91	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15861	15868						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1639816				2022-12-25	WOS:A1992JG11300091
J	OSBAKKEN, M; IVANICS, T; ZHANG, DN; MITRA, R; BLUM, H				OSBAKKEN, M; IVANICS, T; ZHANG, DN; MITRA, R; BLUM, H			ISOLATED CARDIOMYOCYTES IN CONJUNCTION WITH NMR-SPECTROSCOPY TECHNIQUES TO STUDY METABOLISM AND ION FLUX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC-RESONANCE SPECTROSCOPY; CITRIC-ACID CYCLE; RAT-HEART; CARDIAC MYOCYTES; C-13 NMR; VASOACTIVE AGENTS; PERFUSED HEART; MUSCLE-CELLS; FREE CALCIUM; ATP	To distinguish cellular from vascular responses to physiological and pathophysiological stimuli, we developed methods to perform NMR spectroscopy on isolated ventricular cardiomyocytes. Isolated adult rat cardiomyocytes, placed in agarose beads and superfused with phosphate-free buffer (Media 199 (GIBCO 400-1100) gassed with 95% O2, 5% CO2), were used to evaluate a variety of cellular processes during different pharmacological and physiological interventions. Bioenergetic function was monitored with P-31 NMR. Intermediary metabolism, gluconeogenesis, and glycolysis were monitored with C-13 NMR. Sodium flux was monitored with Na-23 NMR. Calcium flux was monitored with F-19 NMR in conjunction with an intracellular calcium-chelating agent, 5F-1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid. Creatine kinase kinetics (forward rate constant (K(f)) and flux of phosphocreatine to ATP) were estimated with P-31 NMR saturation transfer data. Various combinations of NMR parameters were monitored simultaneously so that the interaction of metabolism and ion flux could be evaluated. We have demonstrated that it is possible to simultaneously monitor a variety of cellular processes in intact heart cells in real time, without the confounding influences of perfusion, contractile function, and extrinsic blood-borne neurohumoral agents. This model will be useful for longitudinal studies of myocyte metabolism and ion flux.	UNIV PENN, SCH MED, DEPT BIOCHEM BIOPHYS, PHILADELPHIA, PA 19104 USA	University of Pennsylvania	OSBAKKEN, M (corresponding author), UNIV PENN, SCH MED, DEPT MED CARDIOL, PHILADELPHIA, PA 19104 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039208] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL39208] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENTAL M, 1990, EUR J BIOCHEM, V188, P111, DOI 10.1111/j.1432-1033.1990.tb15377.x; BLUM H, 1991, MAGNET RESON MED, V18, P348, DOI 10.1002/mrm.1910180209; BLUMENTHAL MR, 1968, AM J PHYSIOL, V214, P1280, DOI 10.1152/ajplegacy.1968.214.6.1280; BORGERS M, 1988, ANN NY ACAD SCI, V522, P433; BROOKS WM, 1986, J MOL CELL CARDIOL, V18, P149, DOI 10.1016/S0022-2828(86)80467-9; CHANCE EM, 1983, J BIOL CHEM, V258, P3785; CORDIS GA, 1988, J CHROMATOGR, V459, P229, DOI 10.1016/S0021-9673(01)82031-8; DAS AM, 1990, BIOCHEM J, V266, P355, DOI 10.1042/bj2660355; DOELLER JE, 1990, AM J PHYSIOL, V259, pH1851, DOI 10.1152/ajpheart.1990.259.6.H1851; GUPTA RK, 1991, AM J PHYSIOL, V261, pH1155, DOI 10.1152/ajpheart.1991.261.4.H1155; HEADRICK JP, 1990, AM J PHYSIOL, V258, pH617, DOI 10.1152/ajpheart.1990.258.3.H617; HOERTER JA, 1986, CIRC RES, V58, P539, DOI 10.1161/01.RES.58.4.539; HORACKOVA M, 1991, CARDIOVASC RES, V25, P1023, DOI 10.1093/cvr/25.12.1023; HUMPHREY SM, 1991, AM J PHYSIOL, V260, pH6, DOI 10.1152/ajpheart.1991.260.1.H6; IVANICS T, 1991, J APPL CARDIOL, V6, P211; IVANICS T, 1991, J APPL CARDIOL, V6, P283; KAMMERMEIER H, 1988, BASIC RES CARDIOL, V83, P343, DOI 10.1007/BF02005819; KOHLER SJ, 1991, MAGNET RESON MED, V18, P15, DOI 10.1002/mrm.1910180104; KONDRASHOVA MN, 1989, FEBS LETT, V243, P153, DOI 10.1016/0014-5793(89)80119-X; LLOYD TR, 1990, J MOL CELL CARDIOL, V22, P333, DOI 10.1016/0022-2828(90)91466-K; MALLOY CR, 1990, BIOCHEMISTRY-US, V29, P6756, DOI 10.1021/bi00481a002; MALLOY CR, 1987, FEBS LETT, V212, P58, DOI 10.1016/0014-5793(87)81556-9; MARBAN E, 1987, P NATL ACAD SCI USA, V84, P6005, DOI 10.1073/pnas.84.16.6005; MITRA R, 1985, AM J PHYSIOL, V249, P1056, DOI 10.1152/ajpheart.1985.249.5.H1056; NAG AC, 1987, IN VITRO CELL DEV B, V23, P261, DOI 10.1007/BF02623708; NICHOLS CG, 1990, CAN J PHYSIOL PHARM, V68, P183, DOI 10.1139/y90-029; OSBAKKEN M, 1991, CARDIOLOGY, V79, P1, DOI 10.1159/000174851; OSBAKKEN MD, 1989, CLIN RES, V37, pA283; POWELL T, 1980, J PHYSIOL-LONDON, V302, P131; SAKO EY, 1988, J BIOL CHEM, V263, P10600; SEEHOLZER SH, 1985, THESIS U PENNSYLVANI; SEN LY, 1990, CIRC RES, V67, P1182, DOI 10.1161/01.RES.67.5.1182; SERAYDARIAN MW, 1976, J MOL CELL CARDIOL, V8, P669, DOI 10.1016/0022-2828(76)90009-2; SIEGMUND B, 1990, AM J PHYSIOL, V258, pH285, DOI 10.1152/ajpheart.1990.258.2.H285; SIEGMUND B, 1991, AM J PHYSIOL, V260, pH426, DOI 10.1152/ajpheart.1991.260.2.H426; SPRINGER CS, 1988, NMR TECHNIQUES STUDY, P289; STEENBERGEN C, 1990, CIRC RES, V66, P135, DOI 10.1161/01.RES.66.1.135; Taylor D J, 1983, Mol Biol Med, V1, P77; VOLZ A, 1991, J MOL CELL CARDIOL, V23, P161, DOI 10.1016/0022-2828(91)90103-S; WITTENBERG BA, 1985, J BIOL CHEM, V260, P2031; WITTENBERG BA, 1991, BIOPHYS J, V57, pA164; ZWEIER JL, 1987, J BIOL CHEM, V262, P8015	42	14	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15340	15347						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1639780				2022-12-25	WOS:A1992JG11300016
J	WHITE, BH; COHEN, JB				WHITE, BH; COHEN, JB			AGONIST-INDUCED CHANGES IN THE STRUCTURE OF THE ACETYLCHOLINE-RECEPTOR M2 REGIONS REVEALED BY PHOTOINCORPORATION OF AN UNCHARGED NICOTINIC NONCOMPETITIVE ANTAGONIST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY BINDING-SITE; ALPHA-SUBUNIT; H-3 CHLORPROMAZINE; AMINO-ACIDS; ION CHANNEL; TORPEDO-MARMORATA; DELTA-SUBUNIT; ELECTRIC ORGAN; GAMMA-SUBUNIT; BLOCKERS	To characterize structural changes induced in the nicotinic acetylcholine receptor (AChR) by agonists, we have mapped the sites of photoincorporation of the cholinergic noncompetitive antagonist 3-(trifluoromethyl)-3-(m-[I-125]iodophenyl)diazirine ([I-125]TID) in the presence and absence of 50-mu-M carbamylcholine. [I-125]-TID binds to the AChR with similar affinity under both these conditions, but agonist inhibits photoincorporation into all subunits by greater than 75% (White, B. H., Howard, S., Cohen, S. G., and Cohen, J. B. (1991) J. Biol. Chem. 266, 21595-21607). [I-125]TID-labeled sites on the beta- and delta-subunits were identified by amino-terminal sequencing of both cyanogen bromide (CNBr) and tryptic fragments purified by Tricine sodium dodecyl sulfate-polyacrylamide gel electrophoresis followed by reversed-phase high-performance liquid chromatography. In the absence of agonist, [I-125]TID specifically labels homologous aliphatic residues (beta-L-257, delta-L-265, beta-V-261, and delta-V-269) in the M2 region of both subunits. In the presence of agonist, labeling of these residues is reduced approximately 90%, and the distribution of labeled residues is broadened to include a homologous set of serine residues at the amino terminus of M2. In the beta-subunit residues beta-S-250, beta-S-254, beta-L-257, and beta-V-261 are all labeled in the presence of carbamylcholine. This pattern of labeling supports an alpha-helical model for M2 with the labeled face forming the ion channel lumen. The observed redistribution of label in the resting and desensitized states provides the first direct evidence for an agonist-dependent rearrangement of the M2 helices. The efficient labeling of the resting state channel in a region capable of structural change also suggests a plausible model for AChR gating in which the aliphatic residues labeled by [I-125]TID form a permeability barrier to the passage of ions. We also report increased labeling of the M1 region of the delta-subunit in the presence of agonist.	WASHINGTON UNIV, SCH MED, DEPT ANAT & NEUROBIOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL)					NINDS NIH HHS [NS19522, NS-07071] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019522] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABRAMSON SN, 1989, J BIOL CHEM, V264, P12666; BLANTON MP, 1992, BIOCHEMISTRY-US, V31, P3738, DOI 10.1021/bi00130a003; BRAUER AW, 1984, ANAL BIOCHEM, V137, P134, DOI 10.1016/0003-2697(84)90359-2; BRUNNER J, 1989, METHOD ENZYMOL, V172, P628; CHARNET P, 1990, NEURON, V4, P87, DOI 10.1016/0896-6273(90)90445-L; CHIARA D C, 1992, Biophysical Journal, V61, pA106; CLAUDIO T, 1983, P NATL ACAD SCI-BIOL, V80, P1111, DOI 10.1073/pnas.80.4.1111; COHEN JB, 1987, MOL MECHANISMS DESEN, P257; DENNIS M, 1988, BIOCHEMISTRY-US, V27, P2346, DOI 10.1021/bi00407a016; DIPAOLA M, 1990, J BIOL CHEM, V265, P11017; FUROISCORBIN S, 1989, BIOCHIM BIOPHYS ACTA, V984, P339, DOI 10.1016/0005-2736(89)90301-5; GALZI JL, 1990, J BIOL CHEM, V265, P10430; GALZI JL, 1991, ANNU REV PHARMACOL, V31, P37, DOI 10.1146/annurev.pa.31.040191.000345; GIRAUDAT J, 1986, P NATL ACAD SCI USA, V83, P2719, DOI 10.1073/pnas.83.8.2719; GIRAUDAT J, 1987, BIOCHEMISTRY-US, V26, P2410, DOI 10.1021/bi00383a003; GIRAUDAT J, 1989, FEBS LETT, V253, P190, DOI 10.1016/0014-5793(89)80957-3; HEIDMANN T, 1983, BIOCHEMISTRY-US, V22, P3112, DOI 10.1021/bi00282a014; HORROCKS DL, 1975, CLIN CHEM, V21, P370; HUCHO F, 1986, FEBS LETT, V205, P137, DOI 10.1016/0014-5793(86)80881-X; HUCHO F, 1989, FEBS LETT, V257, P17, DOI 10.1016/0014-5793(89)81775-2; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; IMOTO K, 1991, FEBS LETT, V289, P193, DOI 10.1016/0014-5793(91)81068-J; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; KAO PN, 1984, J BIOL CHEM, V259, P1662; KARLIN A, 1991, HARVEY LECT, V85, P71; LEONARD RJ, 1988, SCIENCE, V242, P1578, DOI 10.1126/science.2462281; MCCARTHY MP, 1989, J BIOL CHEM, V264, P10911; MIDDLETON RE, 1991, BIOCHEMISTRY-US, V30, P6987, DOI 10.1021/bi00242a026; MILLER C, 1989, NEURON, V2, P1195, DOI 10.1016/0896-6273(89)90304-8; NODA M, 1982, NATURE, V299, P793, DOI 10.1038/299793a0; NODA M, 1983, NATURE, V302, P528, DOI 10.1038/302528a0; NODA M, 1983, NATURE, V301, P251, DOI 10.1038/301251a0; PEDERSEN SE, 1992, J BIOL CHEM, V267, P10489; PEDERSEN SE, 1990, P NATL ACAD SCI USA, V87, P2785, DOI 10.1073/pnas.87.7.2785; POPOT JL, 1984, PHYSIOL REV, V64, P1162, DOI 10.1152/physrev.1984.64.4.1162; REVAH F, 1990, P NATL ACAD SCI USA, V87, P4675, DOI 10.1073/pnas.87.12.4675; REVAH F, 1991, NATURE, V353, P846, DOI 10.1038/353846a0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SOBEL A, 1977, EUR J BIOCHEM, V80, P215, DOI 10.1111/j.1432-1033.1977.tb11874.x; STROUD RM, 1990, BIOCHEMISTRY-US, V29, P11009, DOI 10.1021/bi00502a001; UNWIN N, 1989, NEURON, V3, P665, DOI 10.1016/0896-6273(89)90235-3; UNWIN N, 1988, J CELL BIOL, V107, P1123, DOI 10.1083/jcb.107.3.1123; VILLARROEL A, 1991, P ROY SOC B-BIOL SCI, V243, P69, DOI 10.1098/rspb.1991.0012; WHITE BH, 1988, BIOCHEMISTRY-US, V27, P8741, DOI 10.1021/bi00424a009; WHITE BH, 1991, J BIOL CHEM, V266, P21595; WHITE BH, 1991, THESIS WASHINGTON U	46	167	167	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15770	15783						14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1639812				2022-12-25	WOS:A1992JG11300079
J	KWONG, YY; HUSAIN, Z; BISWAS, DK				KWONG, YY; HUSAIN, Z; BISWAS, DK			C-HA-RAS GENE MUTATION AND ACTIVATION PRECEDE PATHOLOGICAL-CHANGES IN DMBA-INDUCED INVIVO CARCINOGENESIS	ONCOGENE			English	Article							MULTISTEP CARCINOGENESIS; CELLULAR ONCOGENES; COLORECTAL CANCERS; CARCINOMA; NEOPLASIA; MODEL; DNA	We have previously reported a stage-specific and sequential overexpression of the c-Ha-ras and c-erhB genes in 7, 12-dimethylbenzanthracene (DMBA)-induced in vivo carcinogenesis in hamster buccal pouch epithelium (HBPE). In this investigation, the immunoreactive protein product of the c-Ha-ras gene (p21 protein) was identified in HBPE cells, specifically in treated tissues and cultured cells established after 3 weeks of DMBA treatment. Microscopic examination did not show any histopathological changes in these tissues. The p21 protein was detected in a few selective cells, which were dispersed away from the more densely populated basal layer. The overexpression of the c-Ha-ras gene was accompanied by a point mutation of A --> T in codon 61 (CAA), inducing an amino acid substitution from the wild-type glutamine to leucine in the- peptide. The concurrent molecular modifications preceded any detectable histopathological changes. The cellular morphology and orientation in treated HBPE at this early stage was indistinguishable from the control tissue. Yet the genetic alterations, such as the point mutation and overexpression of the gene, were evident at the predysplastic stage. Amplification and overexpression of the second proto-oncogene, c-erbB, and its product, epidermal growth factor receptor (EGFR), were detected in HBPE cells at the later stages of extensive cell proliferation and invasion. By using double antibodies and two immunoreporter systems, we demonstrated overexpression of both c-Ha-ras and c-erbB genes in the same HBPE cells during this chemically induced in vivo carcinogenesis.	HARVARD UNIV,SCH DENT MED,MOLEC BIOL LAB,188 LONGWOOD AVE,CAMBRIDGE,MA 02138; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV MED,BOSTON,MA 02115	Harvard University; Harvard School of Dental Medicine; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School								Ausubel FM., 1988, CURRENT PROTOCOLS MO; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARBACID M, 1990, EUR J CLIN INVEST, V20, P225, DOI 10.1111/j.1365-2362.1990.tb01848.x; BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; COOPER GM, 1982, SCIENCE, V217, P801, DOI 10.1126/science.6285471; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; HEIM, 1987, CANCER CYTOGENETICS; HUSAIN Z, 1989, P NATL ACAD SCI USA, V86, P1264, DOI 10.1073/pnas.86.4.1264; KUMAR R, 1990, SCIENCE, V248, P1101, DOI 10.1126/science.2188364; KUMAR R, 1990, ONCOGENE, V5, P1271; LAND H, 1983, SCIENCE, V222, P771, DOI 10.1126/science.6356358; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LEON J, 1988, MOL CELL BIOL, V8, P786, DOI 10.1128/MCB.8.2.786; MIYAMOTO S, 1990, MOL CELL BIOL, V10, P1593, DOI 10.1128/MCB.10.4.1593; NUZUM EO, 1990, MOL CARCINOGEN, V3, P287, DOI 10.1002/mc.2940030509; POLVERINI PJ, 1986, LAB INVEST, V54, P432; REDDY EP, 1983, SCIENCE, V220, P1061, DOI 10.1126/science.6844927; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANTOS E, 1984, SCIENCE, V223, P661, DOI 10.1126/science.6695174; SHIH C, 1979, P NATL ACAD SCI USA, V76, P5714, DOI 10.1073/pnas.76.11.5714; SOLT DB, 1988, CARCINOGENESIS, V9, P2173, DOI 10.1093/carcin/9.12.2173; SUKUMAR S, 1990, CANCER CELL-MON REV, V2, P199; VALENZUELA DM, 1986, NUCLEIC ACIDS RES, V14, P843, DOI 10.1093/nar/14.2.843; WONG DTW, 1987, ONCOGENE, V2, P67	31	23	23	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1992	7	8					1481	1489						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1630811				2022-12-25	WOS:A1992JE81300003
J	QUEST, AFG; CHADWICK, JK; WOTHE, DD; MCILHINNEY, RAJ; SHAPIRO, BM				QUEST, AFG; CHADWICK, JK; WOTHE, DD; MCILHINNEY, RAJ; SHAPIRO, BM			MYRISTOYLATION OF FLAGELLAR CREATINE-KINASE IN THE SPERM PHOSPHOCREATINE SHUTTLE IS LINKED TO ITS MEMBRANE ASSOCIATION PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA-URCHIN SPERM; PROTEIN ALPHA-SUBUNIT; CARCINOMA CELL-LINES; TRANSFORMING PROTEIN; ACYLATED PROTEINS; P60SRC; ACID; EXPRESSION; SEQUENCE; MYRISTYLATION	TCK, the flagellar creatine kinase (ATP:creatine N-phosphotransferase) of sperm from the sea urchin Strongylocentrotus purpuratus is a membrane-associated lipophilic protein involved in energy transport. The cDNA derived protein sequence contains a consensus site sufficient for the covalent attachment of myristate. To examine whether TCK was myristoylated, mouse fibroblast Swiss 3T3 and baby hamster kidney cell lines were transfected with a cDNA encoding the entire TCK protein linked to a metallothionein promotor. TCK expression was induced by zinc and paralleled by incorporation of [H-3]myristic acid derived label into the protein. H-3 Label incorporated into TCK was resistant to hydroxylamine treatment. The H-3-labeled material released from TCK by acid methanolysis eluted from a C18 reverse phase high pressure liquid chromatography column at the positions of myristic acid and methylmyristate. Thus, TCK expressed in transfected mammalian cell lines contains authentic myristic acid, covalently attached through amide linkage. [H-3]Myristoyl TCK comigrated on two-dimensional gels with the purified lipophilic isoform TCK II from sea urchins. Furthermore, like TCK II, [H-3]myristoyl TCK associated with phospholipid liposomes, suggesting that myristoylation may mediate the observed membrane association of TCK. Myristoylation of sea urchin sperm flagellar creatine kinase may play a role in confining this enzyme to the flagellum during spermatogenesis.	MRC,ANAT NEUROPHARMACOL UNIT,OXFORD OX1 3TH,ENGLAND; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NATIONAL CANCER INSTITUTE [T32CA009437] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023910] Funding Source: NIH RePORTER; NCI NIH HHS [CA09437] Funding Source: Medline; NIGMS NIH HHS [GM23910] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUSS JE, 1984, MOL CELL BIOL, V4, P2697, DOI 10.1128/MCB.4.12.2697; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; DURNAM DM, 1984, MOL CELL BIOL, V4, P484, DOI 10.1128/MCB.4.3.484; GARBER EA, 1985, MOL CELL BIOL, V5, P2781, DOI 10.1128/MCB.5.10.2781; HALL MN, 1984, CELL, V36, P1057, DOI 10.1016/0092-8674(84)90055-2; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KREIL G, 1981, ANNU REV BIOCHEM, V50, P317, DOI 10.1146/annurev.bi.50.070181.001533; MAGEE AI, 1984, BIOCHIM BIOPHYS ACTA, V798, P156, DOI 10.1016/0304-4165(84)90298-8; MAGEE AI, 1985, EMBO J, V4, P1137, DOI 10.1002/j.1460-2075.1985.tb03751.x; Maniatis T., 1982, MOL CLONING; MANLEY JL, 1989, GENE DEV, V3, P2218, DOI 10.1101/gad.3.12b.2218; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MCILHINNEY RAJ, 1985, EMBO J, V4, P1145, DOI 10.1002/j.1460-2075.1985.tb03752.x; MCILHINNEY RAJ, 1987, BIOCHEM J, V244, P109, DOI 10.1042/bj2440109; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; MUSIL LS, 1988, J CELL BIOL, V107, P1113, DOI 10.1083/jcb.107.3.1113; OLSON EN, 1985, J BIOL CHEM, V260, P3784; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; PALMITER RD, 1983, SCIENCE, V222, P809, DOI 10.1126/science.6356363; PELLMAN D, 1985, P NATL ACAD SCI USA, V82, P1623, DOI 10.1073/pnas.82.6.1623; PERRYMAN MB, 1983, BIOCHIM BIOPHYS ACTA, V747, P284, DOI 10.1016/0167-4838(83)90107-3; QUEST AFG, 1991, J BIOL CHEM, V266, P19803; RESH MD, 1990, NATURE, V346, P84, DOI 10.1038/346084a0; RESH MD, 1989, CELL, V58, P281, DOI 10.1016/0092-8674(89)90842-8; ROTHBLAT GH, 1976, IN VITRO CELL DEV B, V12, P554; SCHATZ G, 1983, CELL, V32, P316, DOI 10.1016/0092-8674(83)90450-6; SCHULTZ AM, 1985, SCIENCE, V227, P427, DOI 10.1126/science.3917576; SEARLE PF, 1985, MOL CELL BIOL, V5, P1480, DOI 10.1128/MCB.5.6.1480; SIMONSEN CC, 1983, P NATL ACAD SCI-BIOL, V80, P2495, DOI 10.1073/pnas.80.9.2495; TOMBES RM, 1987, BIOPHYS J, V52, P75, DOI 10.1016/S0006-3495(87)83190-9; TOMBES RM, 1987, J BIOL CHEM, V262, P16011; TOMBES RM, 1985, CELL, V41, P325, DOI 10.1016/0092-8674(85)90085-6; TOMBES RM, 1988, EXP CELL RES, V178, P307, DOI 10.1016/0014-4827(88)90401-6; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; WALTER P, 1984, CELL, V38, P5, DOI 10.1016/0092-8674(84)90520-8; WOTHE DD, 1990, P NATL ACAD SCI USA, V87, P5203, DOI 10.1073/pnas.87.13.5203	39	28	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15080	15085						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634544				2022-12-25	WOS:A1992JF08800084
J	ALNEMRI, ES; MAKSYMOWYCH, AB; ROBERTSON, NM; LITWACK, G				ALNEMRI, ES; MAKSYMOWYCH, AB; ROBERTSON, NM; LITWACK, G			OVEREXPRESSION AND CHARACTERIZATION OF THE HUMAN MINERALOCORTICOID RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACULOVIRUS EXPRESSION VECTOR; LIVER GLUCOCORTICOID-RECEPTOR; ANTI-IDIOTYPIC ANTIBODY; HEAT-SHOCK PROTEINS; NUCLEAR-LOCALIZATION; PROGESTERONE-RECEPTOR; MONOCLONAL-ANTIBODIES; NUCLEOTIDE-SEQUENCE; COMPLEMENTARY-DNA; STEROID-HORMONES	The full-length human renal mineralocorticoid receptor (hMR) has been overproduced in Spodoptera frugiperda (Sf9) insect cells using baculovirus-mediated expression. The overproduced hMR binds aldosterone with high affinity (K(d) = 1.36 nM) and has high affinity for cortisol, cortexolone, and progesterone. Immunoprecipitation and immunoblot analysis of the recombinant hMR with MR-specific antibodies reveal three major protein bands with molecular masses of 115, 119, and 125 kDa. hMR isoforms show maximal accumulation at 48 h post-infection with the recombinant baculovirus. Maximal aldosterone binding was detected at 24 h rather than at 48 h post-infection, suggesting that the assembly of hMR monomers into the nonactivated steroid-binding receptor complexes and/or their stability deteriorates after 24 h post-infection. It is estimated by specific aldosterone binding that 1.2 x 10(6) hMR molecules are expressed per Sf9 cell (equivalent to 7 pmol/mg of cytosolic protein) at 24 h post-infection. 5-Fold more receptor molecules/cell are expressed but not detected by steroid binding at 48 h post-infection as determined by immunoblot analysis. Using the MR-specific H10E anti-idiotypic monoclonal antibody, immunoprecipitation of cytosol from recombinant baculovirus-infected Sf9 cells pulse-labeled with P-32(i) demonstrated for the first time that the recombinant hMR is highly phosphorylated. The hMR is expressed as 9-10 S oligomeric complexes (Stokes radii almost-equal-to 67-85 angstrom) that are slightly heavier than the unactivated glucocorticoid receptor and can be converted to smaller 4 S receptor monomers (Stokes radii almost-equal-to 25-55 angstrom) by elevated temperature, pH, and ionic strength. Unlike the glucocorticoid receptor, the oligomeric hMR complex can bind DNA-cellulose without prior activation. Finally, indirect immunofluorescence demonstrated that the hMR is expressed primarily as a cytoplasmic protein that can be induced to translocate to the nucleus upon treatment with hormone.	TEMPLE UNIV,HLTH SCI CTR,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University			Alnemri, Emad S/B-4526-2010		NCI NIH HHS [CA-12227] Funding Source: Medline; NIDDK NIH HHS [DK-13531, T-32-DK-07162] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA012227] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007162, R01DK013531] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALNEMRI ES, 1991, J BIOL CHEM, V266, P3925; ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; BAILLY A, 1978, EUR J BIOCHEM, V88, P623, DOI 10.1111/j.1432-1033.1978.tb12489.x; BAULIEU EE, 1987, J CELL BIOCHEM, V35, P161, DOI 10.1002/jcb.240350209; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; Bodine P V, 1990, Receptor, V1, P83; CARSONJURICA MA, 1990, ENDOCR REV, V11, P201, DOI 10.1210/edrv-11-2-201; DAHMER MK, 1984, ANNU REV PHYSIOL, V46, P67; DOUGHERTY JJ, 1982, J BIOL CHEM, V257, P4226; EISEN LP, 1986, ENDOCRINOLOGY, V119, P1419, DOI 10.1210/endo-119-4-1419; ERDOS T, 1970, ANAL BIOCHEM, V37, P244, DOI 10.1016/0003-2697(70)90044-8; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FUNDER JW, 1990, TRENDS ENDOCRIN MET, V1, P145, DOI 10.1016/1043-2760(90)90026-Y; FUXE K, 1985, ENDOCRINOLOGY, V117, P1803, DOI 10.1210/endo-117-5-1803; GOIDL JA, 1977, BIOCHEMISTRY-US, V16, P2125, DOI 10.1021/bi00629a012; GRANDICS P, 1984, J BIOL CHEM, V259, P3173; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GUIOCHONMANTEL A, 1989, CELL, V57, P1147, DOI 10.1016/0092-8674(89)90052-4; HOUSLEY PR, 1984, BIOCHEM ACTION HORM, V11, P347; KING WJ, 1984, NATURE, V307, P745, DOI 10.1038/307745a0; LEESMILLER SP, 1989, J BIOL CHEM, V264, P2431; LEFEVRE B, 1979, BIOCHIM BIOPHYS ACTA, V585, P266, DOI 10.1016/0304-4165(79)90026-6; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; LOMBES M, 1990, P NATL ACAD SCI USA, V87, P1086, DOI 10.1073/pnas.87.3.1086; LOMBES M, 1989, J BIOL CHEM, V264, P2528; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MIGLIACCIO A, 1986, EMBO J, V5, P2867, DOI 10.1002/j.1460-2075.1986.tb04581.x; MILGROM E, 1973, BIOCHEMISTRY-US, V12, P5198, DOI 10.1021/bi00749a029; MILLER LK, 1988, ANNU REV MICROBIOL, V42, P177, DOI 10.1146/annurev.micro.42.1.177; MOGUILEWSKY M, 1980, J STEROID BIOCHEM, V12, P309, DOI 10.1016/0022-4731(80)90285-X; MOORE SK, 1987, GENE, V56, P29, DOI 10.1016/0378-1119(87)90155-7; ORTI E, 1989, J STEROID BIOCHEM, V34, P85, DOI 10.1016/0022-4731(89)90069-1; PATEL PD, 1989, MOL ENDOCRINOL, V3, P1877, DOI 10.1210/mend-3-11-1877; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PERROTAPPLANAT M, 1985, ENDOCRINOLOGY, V116, P1473, DOI 10.1210/endo-116-4-1473; PICARD D, 1990, CELL REGUL, V1, P291, DOI 10.1091/mbc.1.3.291; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; PIKE JW, 1985, BIOCHEM BIOPH RES CO, V131, P378, DOI 10.1016/0006-291X(85)91813-3; PRATT WB, 1987, J CELL BIOCHEM, V35, P51, DOI 10.1002/jcb.240350105; PRATT WB, 1988, HORMONES CANCER, V3, P16; PRIVALSKY ML, 1991, J BIOL CHEM, V266, P1456; RAFESTINOBLIN ME, 1989, J BIOL CHEM, V264, P9304; RAYNAUD JP, 1983, STEROID HORMONE RECE, P140; REBBE NF, 1987, GENE, V53, P235, DOI 10.1016/0378-1119(87)90012-6; ROBERTSON NM, 1987, BIOCHEM J, V246, P55, DOI 10.1042/bj2460055; SANCHEZ ER, 1990, J BIOL CHEM, V265, P22067; SCHLESINGER MJ, 1986, J CELL BIOL, V103, P321, DOI 10.1083/jcb.103.2.321; SCHMIDT TJ, 1986, GLUCOCORTICOID HORMO, P35; SCHULMAN G, 1986, J BIOL CHEM, V261, P2102; SHEPPARD KE, 1987, J STEROID BIOCHEM, V28, P737, DOI 10.1016/0022-4731(87)90406-7; SHERMAN MR, 1984, ANNU REV PHYSIOL, V46, P83; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; SMITH GE, 1983, MOL CELL BIOL, V3, P2156, DOI 10.1128/MCB.3.12.2156; SRINIVASAN G, 1990, MOL ENDOCRINOL, V4, P209, DOI 10.1210/mend-4-2-209; SUMMERS MD, 1987, MANUAL METHODS BACUL, V1555; WELSHONS WV, 1984, NATURE, V307, P747, DOI 10.1038/307747a0; WIKSTROM AC, 1987, ENDOCRINOLOGY, V120, P1232, DOI 10.1210/endo-120-4-1232; WRANGE O, 1983, ENDOCRINOLOGY, V113, P243, DOI 10.1210/endo-113-1-243; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209	61	97	98	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					18072	18081						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1655735				2022-12-25	WOS:A1991GG55300057
J	PEDERSEN, H; SOGAARDANDERSEN, L; HOLST, B; VALENTINHANSEN, P				PEDERSEN, H; SOGAARDANDERSEN, L; HOLST, B; VALENTINHANSEN, P			HETEROLOGOUS COOPERATIVITY IN ESCHERICHIA-COLI - THE CYTR REPRESSOR BOTH CONTACTS DNA AND THE CAMP RECEPTOR PROTEIN WHEN BINDING TO THE DEOP2 PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE ACTIVATOR PROTEIN; CYCLIC-AMP; REGULATORY PROTEINS; NUCLEOTIDE-SEQUENCE; LAC REPRESSOR; SYSTEM; YEAST; VECTORS; INVITRO; CLONING	Promoters in Escherichia coli that are negatively regulated by the CytR repressor are also activated by the cAMP receptor protein (CRP) complexed to cAMP; as a characteristic, these promoters encode two binding sites for the cAMP.CRP complex. Biochemical and genetic studies have shown that CytR relies on interactions with the cAMP.CRP complex in order to bind promoter DNA and repress transcription. Here we have purified CytR to near homogeneity and addressed the question of how it interacts with the deoP2 promoter. Gel retardation and DNase I footprinting analyses show that CytR is a true sequence-specific DNA-binding protein that binds to the sequence between the two CRP sites in deoP2 with a relatively low affinity. In the presence of the cAMP.CRP complex the two protein species bind cooperatively to deoP2, forming a complex in which CytR occupies the sequence between the two DNA bound cAMP.CRP complexes. Furthermore, the inducer (cytidine) does not affect independent DNA binding of CytR, rather the CytR/cAMP.CRP cooperativity is perturbed. These results indicate that CytR binding to deoP2 relies on both repressor-DNA interactions and protein-protein interactions to cAMP.CRP. This combinatorial repression mechanism, in which an activator functions as an adaptor for a repressor that is not capable of blocking transcription on its own, is unprecedented in prokaryotes; it is, however, reminiscent of repression mechanisms found in eukaryotes.	ODENSE UNIV,DEPT MOLEC BIOL,CAMPUSVEJ 55,DK-5230 ODENSE,DENMARK	University of Southern Denmark				Sogaard-Andersen, Lotte/0000-0002-0674-0013; Holst, Bjorn/0000-0002-4517-6881				ADHYA S, 1989, ANNU REV GENET, V23, P227, DOI 10.1146/annurev.genet.23.1.227; ARDITTI RR, 1968, J MOL BIOL, V38, P421, DOI 10.1016/0022-2836(68)90396-3; BENDER A, 1987, CELL, V50, P681, DOI 10.1016/0092-8674(87)90326-6; BERTANI G, 1951, J BACTERIOL, V62, P293, DOI 10.1128/JB.62.3.293-300.1951; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; FRIED MG, 1984, J MOL BIOL, V172, P241, DOI 10.1016/S0022-2836(84)80025-X; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GERLACH P, 1990, MOL MICROBIOL, V4, P479, DOI 10.1111/j.1365-2958.1990.tb00614.x; GHOSAINI LR, 1988, BIOCHEMISTRY-US, V27, P5257, DOI 10.1021/bi00414a046; Hammer-Jespersen K., 1983, METABOLISM NUCLEOTID, P203; HUDSON JM, 1990, J MOL BIOL, V214, P381, DOI 10.1016/0022-2836(90)90188-R; JOHNSTON SA, 1987, CELL, V50, P143, DOI 10.1016/0092-8674(87)90671-4; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; KLEINER D, 1988, J GEN MICROBIOL, V134, P1779; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUE NF, 1987, MOL CELL BIOL, V7, P3446, DOI 10.1128/MCB.7.10.3446; MA L, 1987, CELL, V50, P137; Maniatis T., 1982, MOL CLONING; MARTINUSSEN J, 1989, DNA PROTEIN INTERACT, P31; Maxam A M, 1980, Methods Enzymol, V65, P499; MCKAY DB, 1982, J BIOL CHEM, V257, P9518; PAOB CO, 1984, ANN REV BIOCH, V53, P293; REIDL J, 1989, J BACTERIOL, V171, P4888, DOI 10.1128/jb.171.9.4888-4899.1989; ROLFES RJ, 1988, J BIOL CHEM, V263, P19653; SILVERSTONE AE, 1970, P NATL ACAD SCI USA, V66, P773, DOI 10.1073/pnas.66.3.773; SINGER JT, 1985, J BACTERIOL, V163, P1095, DOI 10.1128/JB.163.3.1095-1100.1985; SOGAARDANDERSEN L, 1991, P NATL ACAD SCI USA, V88, P4921, DOI 10.1073/pnas.88.11.4921; SOGAARDANDERSEN L, 1991, MOL MICROBIOL, V5, P969, DOI 10.1111/j.1365-2958.1991.tb00772.x; SOGAARDANDERSEN L, 1990, MOL MICROBIOL, V4, P1595, DOI 10.1111/j.1365-2958.1990.tb02071.x; SOGAARDANDERSEN L, 1990, J BACTERIOL, V172, P5706, DOI 10.1128/jb.172.10.5706-5713.1990; STRANEY SB, 1987, CELL, V51, P699, DOI 10.1016/0092-8674(87)90093-6; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; VALENTINHANSEN P, 1982, EMBO J, V1, P1049, DOI 10.1002/j.1460-2075.1982.tb01295.x; VALENTINHANSEN P, 1989, MOL MICROBIOL, V3, P1385, DOI 10.1111/j.1365-2958.1989.tb00120.x; VALENTINHANSEN P, 1978, MOL GEN GENET, V159, P191, DOI 10.1007/BF00270893; VALENTINHANSEN P, 1986, NUCLEIC ACIDS RES, V14, P2215, DOI 10.1093/nar/14.5.2215; VALENTINHANSEN P, 1985, GENE MANIPULATION EX, P273; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZUBAY G, 1973, ANNU REV GENET, V7, P267, DOI 10.1146/annurev.ge.07.120173.001411	41	58	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					17804	17808						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1655726				2022-12-25	WOS:A1991GG55300017
J	ALVAREZ, E; NORTHWOOD, IC; GONZALEZ, FA; LATOUR, DA; SETH, A; ABATE, C; CURRAN, T; DAVIS, RJ				ALVAREZ, E; NORTHWOOD, IC; GONZALEZ, FA; LATOUR, DA; SETH, A; ABATE, C; CURRAN, T; DAVIS, RJ			PRO-LEU-SER/THR-PRO IS A CONSENSUS PRIMARY SEQUENCE FOR SUBSTRATE PROTEIN-PHOSPHORYLATION - CHARACTERIZATION OF THE PHOSPHORYLATION OF C-MYC AND C-JUN PROTEINS BY AN EPIDERMAL GROWTH-FACTOR RECEPTOR THREONINE-669 PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELOCYTOMATOSIS VIRUS MC29; TRANSCRIPTIONAL ACTIVATOR PROTEIN; INTERMEDIATE FILAMENT PROTEINS; SITE-DIRECTED MUTAGENESIS; DNA-BINDING DOMAINS; NUCLEOTIDE-SEQUENCE; ONCOGENE JUN; NUCLEAR LAMINA; GENE-PRODUCT; EGF RECEPTOR	A growth factor-stimulated (MAP2-related) protein kinase, ERT, that phosphorylates the epidermal growth factor receptor at Thr669 has been purified from KB human tumor cells by Northwood and co-workers (Northwood, I. C., Gonzalez, F. A., Wartmann, M., Raden, D. L., and Davis, R. J. (1991) J. Biol. Chem. 266, 15266-15276). The ERT protein kinase has a restricted substrate specificity, and the structural determinants employed for substrate recognition by this enzyme have not been defined. As an approach toward understanding the specificity of substrate phosphorylation, we have used an in vitro assay to identify additional substrates for the ERT protein kinase. In this report we describe two novel substrates: (a) the human c-myc protein at Ser62 and (b) the rat c-jun protein at Ser246. Alignment of the primary sequences surrounding the phosphorylation sites located within the epidermal growth factor receptor (Thr669), Myc (Ser62), and Jun (Ser246) demonstrated a marked similarity. The observed consensus sequence was Pro-Leu-Ser/Thr-Pro. We propose that this sequence forms part of a substrate structure that is recognized by the ERT protein kinase.	UNIV MASSACHUSETTS,SCH MED,HOWARD HUGHES MED INST,PROGRAM MOLEC MED,373 PLANTAT ST,WORCESTER,MA 01605; UNIV MASSACHUSETTS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01605; ROCHE INST MOLEC BIOL,DEPT MOLEC ONCOL & VIROL,NUTLEY,NJ 07110	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester			Curran, Tom/F-5234-2018; Curran, Thomas/AAE-7631-2019; Abate-Shen, Cory/O-2520-2014; Curran, Tom/C-1164-2008; Curran, Tom/D-7515-2011; ALVAREZ, ELVIRA/F-2994-2017; ALVAREZ, ELVIRA/S-8977-2019	Curran, Tom/0000-0003-1444-7551; Curran, Thomas/0000-0003-1444-7551; Abate-Shen, Cory/0000-0002-5021-0570; Curran, Tom/0000-0003-1444-7551; ALVAREZ, ELVIRA/0000-0002-9074-3857; 	NCI NIH HHS [CA39240] Funding Source: Medline; NIGMS NIH HHS [GM37845] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA039240] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037845] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABATE C, 1990, CELL GROWTH DIFFER, V1, P455; ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; BEEMON K, 1978, J VIROL, V28, P551, DOI 10.1128/JVI.28.2.551-566.1978; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; COLBY WW, 1983, NATURE, V301, P722, DOI 10.1038/301722a0; COUNTAWAY JL, 1989, J BIOL CHEM, V264, P10828; COUNTAWAY JL, 1990, J BIOL CHEM, V265, P3407; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DAVIS RJ, 1985, P NATL ACAD SCI USA, V82, P1974, DOI 10.1073/pnas.82.7.1974; DAVIS RJ, 1986, J BIOL CHEM, V261, P9034; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FISHER DZ, 1986, P NATL ACAD SCI USA, V83, P6450, DOI 10.1073/pnas.83.17.6450; HATTORI K, 1988, P NATL ACAD SCI USA, V85, P9148, DOI 10.1073/pnas.85.23.9148; HAYASHI K, 1987, NUCLEIC ACIDS RES, V15, P6419, DOI 10.1093/nar/15.16.6419; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; HEISERMANN GJ, 1988, J BIOL CHEM, V263, P13152; HEISERMANN GJ, 1990, J BIOL CHEM, V265, P12820; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; KAN NC, 1984, P NATL ACAD SCI-BIOL, V81, P3000, DOI 10.1073/pnas.81.10.3000; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; Kerppola TK, 1991, CURR OPIN STRUC BIOL, V1, P71, DOI 10.1016/0959-440X(91)90014-K; KITABAYASHI I, 1990, NUCLEIC ACIDS RES, V18, P3400, DOI 10.1093/nar/18.11.3400; KOLAND JG, 1990, BIOCHEM BIOPH RES CO, V166, P90, DOI 10.1016/0006-291X(90)91915-F; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LEGOUY E, 1987, EMBO J, V6, P3359, DOI 10.1002/j.1460-2075.1987.tb02657.x; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MCKEON FD, 1986, NATURE, V319, P463, DOI 10.1038/319463a0; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; NISHIMURA T, 1988, ONCOGENE, V3, P659; NORTHWOOD IC, 1990, P NATL ACAD SCI USA, V87, P6107, DOI 10.1073/pnas.87.16.6107; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P2500, DOI 10.1073/pnas.80.9.2500; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; STRUHL K, 1987, CELL, V50, P841, DOI 10.1016/0092-8674(87)90511-3; SUGIYAMA A, 1989, P NATL ACAD SCI USA, V86, P9144, DOI 10.1073/pnas.86.23.9144; TAYA Y, 1986, EMBO J, V5, P1215, DOI 10.1002/j.1460-2075.1986.tb04349.x; VOGT PK, 1987, P NATL ACAD SCI USA, V84, P3316, DOI 10.1073/pnas.84.10.3316; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; WATSON DK, 1983, P NATL ACAD SCI-BIOL, V80, P3642, DOI 10.1073/pnas.80.12.3642; YOCHEM J, 1987, J MOL BIOL, V195, P233, DOI 10.1016/0022-2836(87)90646-2	57	505	510	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15277	15285						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1651323				2022-12-25	WOS:A1991GB09700069
J	GHOSH, SK; KUSARI, J; BANDYOPADHYAY, SK; SAMANTA, H; KUMAR, R; SEN, GC				GHOSH, SK; KUSARI, J; BANDYOPADHYAY, SK; SAMANTA, H; KUMAR, R; SEN, GC			CLONING, SEQUENCING, AND EXPRESSION OF 2 MURINE 2'-5'-OLIGOADENYLATE SYNTHETASES - STRUCTURE-FUNCTION-RELATIONSHIPS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; ASCITES TUMOR-CELLS; HUMAN 2-5A SYNTHETASE; TREATED HUMAN-CELLS; PROTEIN-KINASE; 2',5'-OLIGOADENYLATE SYNTHETASE; (2'-5')(A)N SYNTHETASE; MESSENGER-RNA; 100-KDA FORMS; INTERFERON	2'-5'-oligoadenylate synthetases constitute a multimember family of interferon-inducible enzymes which need double-stranded RNA as an obligatory cofactor. We have isolated cDNA clones for two new murine synthetases. These two clones, 9-2 and 3-9, encoded proteins of 414 and 363 amino acid residues, respectively, out of which the amino terminal 346 residues were almost identical. They were also very similar to the corresponding regions of human synthetases E16 and E18. On the other hand, the carboxyl-terminal 68 residues of clone 9-2 had no homology with the carboxyl-terminal residues of E18. These murine clones had only 67% amino acid identity with the previously isolated murine synthetase clone L3. 9-2 and 3-9 proteins were expressed efficiently by in vitro transcription and translation of cDNA clones containing the synthetase coding regions preceded by the 5'-untranslated region of the vesicular stomatitis virus NS gene. These in vitro synthetized proteins bound to double-stranded RNA and catalyzed the synthesis of 2'-5' oligoadenylates. A nested set of deletion mutants of the 9-2 clone was produced by restriction digestion and polymerase chain reaction. Functional testing of the corresponding truncated proteins revealed that a region between amino acid residues 104 and 158 was necessary for binding to double-stranded RNA and a region between residues 320 and 344 was necessary for enzyme activity. Moreover substitution of the lysine residue at position 333 by arginine did not affect the enzyme activity.	CLEVELAND CLIN FDN, DEPT MOLEC BIOL, CLEVELAND, OH 44195 USA	Cleveland Clinic Foundation					NIAID NIH HHS [AI-22510] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BENECH P, 1985, NUCLEIC ACIDS RES, V13, P1267; BENECH P, 1985, EMBO J, V4, P2249, DOI 10.1002/j.1460-2075.1985.tb03922.x; CHEBATH J, 1987, J BIOL CHEM, V262, P3852; CHEBATH J, 1987, NATURE, V330, P587, DOI 10.1038/330587a0; CLEMENS MJ, 1978, CELL, V13, P565, DOI 10.1016/0092-8674(78)90329-X; COCCIA EM, 1990, VIROLOGY, V179, P228, DOI 10.1016/0042-6822(90)90292-Y; COHEN B, 1988, EMBO J, V7, P1411, DOI 10.1002/j.1460-2075.1988.tb02958.x; Demaeyer E., 1988, INTERFERONS OTHER RE; DOUGHERTY JP, 1980, J BIOL CHEM, V255, P3813; GALABRU J, 1985, CELL, V43, P685, DOI 10.1016/0092-8674(85)90241-7; GILL DS, 1986, P NATL ACAD SCI USA, V83, P8873, DOI 10.1073/pnas.83.23.8873; HOVANESSIAN AG, 1987, EMBO J, V6, P1273, DOI 10.1002/j.1460-2075.1987.tb02364.x; HOVANESSIAN AG, 1988, J BIOL CHEM, V263, P4945; ICHII Y, 1986, NUCLEIC ACIDS RES, V14, P10117, DOI 10.1093/nar/14.24.10117; ILSON DH, 1986, J INTERFERON RES, V6, P5, DOI 10.1089/jir.1986.6.5; KAMPS MP, 1986, MOL CELL BIOL, V6, P751, DOI 10.1128/MCB.6.3.751; KAMPS MP, 1984, NATURE, V310, P589, DOI 10.1038/310589a0; KERR IM, 1978, P NATL ACAD SCI USA, V75, P256, DOI 10.1073/pnas.75.1.256; KUMAR R, 1988, J VIROL, V62, P3175, DOI 10.1128/JVI.62.9.3175-3181.1988; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEBLEU B, 1976, P NATL ACAD SCI USA, V73, P3107, DOI 10.1073/pnas.73.9.3107; LI SW, 1990, J BIOL CHEM, V265, P5470; LIN SL, 1983, LIFE SCI, V32, P1479, DOI 10.1016/0024-3205(83)90914-1; MARIE I, 1990, J BIOL CHEM, V265, P18601; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; REVEL M, 1986, TRENDS BIOCHEM SCI, V11, P166, DOI 10.1016/0968-0004(86)90134-9; ROBERTS WK, 1976, NATURE, V264, P477, DOI 10.1038/264477a0; SAARMA M, 1986, EXP CELL RES, V166, P229, DOI 10.1016/0014-4827(86)90522-7; SAMANTA H, 1986, J BIOL CHEM, V261, P1849; SAMANTA H, 1980, J BIOL CHEM, V255, P9807; SAMUEL CE, 1988, PROG NUCLEIC ACID RE, V35, P27, DOI 10.1016/S0079-6603(08)60609-1; SAUNDERS ME, 1985, EMBO J, V4, P1761, DOI 10.1002/j.1460-2075.1985.tb03848.x; SEN GC, 1976, NATURE, V264, P370, DOI 10.1038/264370a0; SMEKENSETIENNE M, 1983, EUR J BIOCHEM, V130, P269, DOI 10.1111/j.1432-1033.1983.tb07146.x; STARK GR, 1979, NATURE, V278, P471, DOI 10.1038/278471a0; STLAURENT G, 1983, CELL, V33, P95; SUHADOLNIK RJ, 1990, BIOCHEM BIOPH RES CO, V169, P1198, DOI 10.1016/0006-291X(90)92023-S; TIWARI RK, 1987, EMBO J, V6, P3373, DOI 10.1002/j.1460-2075.1987.tb02659.x; WATHELET M, 1986, FEBS LETT, V196, P113, DOI 10.1016/0014-5793(86)80224-1; WELLS JA, 1984, J BIOL CHEM, V259, P1363; WILLIAMS BRG, 1985, 2 5A SYSTEM; YANG K, 1981, J BIOL CHEM, V256, P9324; ZILBERSTEIN A, 1976, FEBS LETT, V68, P119, DOI 10.1016/0014-5793(76)80418-8; ZULLO JN, 1985, CELL, V43, P793, DOI 10.1016/0092-8674(85)90252-1	45	85	88	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15293	15299						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1651324				2022-12-25	WOS:A1991GB09700071
J	HSU, L; JACKOWSKI, S; ROCK, CO				HSU, L; JACKOWSKI, S; ROCK, CO			ISOLATION AND CHARACTERIZATION OF ESCHERICHIA-COLI K-12-MUTANTS LACKING BOTH 2-ACYLGLYCEROPHOSPHOETHANOLAMINE ACYLTRANSFERASE AND ACYL-ACYL CARRIER PROTEIN SYNTHETASE-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-DERIVED OLIGOSACCHARIDES; FATTY-ACIDS; 2-ACYL LYSOPHOSPHOLIPIDS; TETRACYCLINE RESISTANCE; OUTER-MEMBRANE; PHOSPHOLIPIDS; PHOSPHATIDYLETHANOLAMINE; PURIFICATION; LIPOPROTEIN; DIGLYCERIDE	2-Acyl-glycerophosphoethanolamine (2-acyl-GPE) acyltransferase and acyl-acyl carrier protein (acyl-ACP) synthetase are thought to be dual catalytic activities of a single inner membrane enzyme. A filter disc replica print method for the detection of acyl-ACP synthetase activity by colony fluorography was used to screen a mutagenized population of cells for acyl-ACP synthetase mutants (aas). All aas mutants lacked both acyl-ACP synthetase and 2-acyl-GPE acyltransferase activities in vitro. There was no detectable acyl-CoA-independent incorporation of exogenous fatty acids into phosphatidylethanolamine or the major outer membrane lipoprotein in aas mutants. Exogenous lysophospholipid uptake and acylation was also lacking in aas mutants. Lipoprotein acylation by phospholipids synthesized by the de novo biosynthetic pathway was not affected in aas mutants showing that this gene product was not directly involved in lipoprotein biogenesis. The aas mutants had an altered membrane phospholipid composition and accumulated both 2-acyl-GPE and acylphosphatidylglycerol. Acylphosphatidylglycerol accumulation was due to the transacylase activity of lysophospholipase L2 (the pldB gene product) since aaspldB double mutants accumulated 2-acyl-GPE, but not acylphosphatidylglycerol. The aas allele was mapped to 61 min of the Escherichia coli chromosome, and the deduced gene order in this region was thyA-aas-lysA. The biochemical, physiological, and genetic analyses of aas mutants support the conclusion that 2-acyl-GPE acyltransferase and acyl-ACP synthetase are two activities of the same protein and confirm that this enzyme system participates in membrane phospholipid turnover and governs the acyl-CoA independent incorporation of exogenous fatty acids and lysophospholipids into the membrane.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, CTR HLTH SCI, DEPT BIOCHEM, MEMPHIS, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center			Jackowski, Suzanne/N-8168-2018	Jackowski, Suzanne/0000-0002-6855-1429	NCI NIH HHS [CA-21765] Funding Source: Medline; NIGMS NIH HHS [GM-28035] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028035] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBRIGHT FR, 1973, J BIOL CHEM, V248, P3968; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOCHNER BR, 1980, J BACTERIOL, V143, P926, DOI 10.1128/JB.143.2.926-933.1980; BOOTH BR, 1980, BIOCHEM BIOPH RES CO, V94, P1029, DOI 10.1016/0006-291X(80)90522-7; CHATTOPADHYAY PK, 1977, P NATL ACAD SCI USA, V74, P5318, DOI 10.1073/pnas.74.12.5318; COOPER CL, 1989, J BIOL CHEM, V264, P7384; DOI O, 1975, J BIOL CHEM, V250, P5208; GHRAYEB J, 1984, J BIOL CHEM, V259, P463; HOMMA H, 1981, BIOCHIM BIOPHYS ACTA, V663, P1, DOI 10.1016/0005-2760(81)90189-2; HOMMA H, 1982, J BIOCHEM, V91, P1103, DOI 10.1093/oxfordjournals.jbchem.a133792; HSU L, 1989, J BACTERIOL, V171, P1203, DOI 10.1128/jb.171.2.1203-1205.1989; JACKOWSKI S, 1986, J BIOL CHEM, V261, P1328; KARASAWA K, 1985, J BIOCHEM, V98, P1117, DOI 10.1093/oxfordjournals.jbchem.a135360; KOBAYASHI T, 1984, J BIOCHEM, V96, P137, DOI 10.1093/oxfordjournals.jbchem.a134805; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; MALOY SR, 1981, J BACTERIOL, V145, P1110, DOI 10.1128/JB.145.2.1110-1111.1981; NAKAMURA K, 1982, Journal of Molecular and Applied Genetics, V1, P289; NISHIJIMA M, 1979, J BIOL CHEM, V254, P7837; RAETZ CRH, 1975, P NATL ACAD SCI USA, V72, P2274, DOI 10.1073/pnas.72.6.2274; RAETZ CRH, 1979, J BACTERIOL, V137, P860, DOI 10.1128/JB.137.2.860-868.1979; ROCK CO, 1980, ANAL BIOCHEM, V102, P362, DOI 10.1016/0003-2697(80)90168-2; ROCK CO, 1984, J BIOL CHEM, V259, P6188; ROCK CO, 1979, J BIOL CHEM, V254, P7116; ROCK CO, 1985, J BIOL CHEM, V260, P2720; SCHULMAN H, 1977, J BIOL CHEM, V252, P4250; SINGER M, 1989, MICROBIOL REV, V53, P1; STEWART JCM, 1980, ANAL BIOCHEM, V104, P10, DOI 10.1016/0003-2697(80)90269-9; TIAN GL, 1989, J BACTERIOL, V171, P1987, DOI 10.1128/jb.171.4.1987-1997.1989; WANNER BL, 1986, J MOL BIOL, V191, P39, DOI 10.1016/0022-2836(86)90421-3; WU TT, 1966, GENETICS, V54, P405	30	45	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13783	13788						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1649829				2022-12-25	WOS:A1991FY02700053
J	JOHNSON, JL; INDERMAUR, LW; RAJAGOPALAN, KV				JOHNSON, JL; INDERMAUR, LW; RAJAGOPALAN, KV			MOLYBDENUM COFACTOR BIOSYNTHESIS IN ESCHERICHIA-COLI - REQUIREMENT OF THE CHLB GENE-PRODUCT FOR THE FORMATION OF MOLYBDOPTERIN GUANINE DINUCLEOTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY NITRATE REDUCTASE; CHLORATE-RESISTANT MUTANTS; INVOLVEMENT; INVITRO; RECONSTITUTION; ACTIVATION	The chlorate-resistant mutants of Escherichia coli are affected in the biosynthesis of the molybdenum cofactor and show pleiotropic loss of the activities of those enzymes which require the cofactor. The molybdenum cofactor in all molybdoenzymes other than nitrogenase is a complex of the metal with a unique pterin termed molybdopterin. The molybdenum cofactor in a number of E. coli enzymes has been shown to contain GMP in addition to the metal-molybdopterin complex, with the GMP appended in pyrophosphate linkage to the terminal phosphate ester on the molybdopterin side chain. In this paper, we have examined the biochemistry of the chlB mutant and show that the gene product of the chlB locus is essential for the addition of the GMP moiety to form molybdopterin guanine dinucleotide, a step which occurs late in the cofactor biosynthetic pathway in E. coli. Sensitive techniques were developed for the identification of fluorescent derivatives of molybdopterin and of molybdopterin guanine dinucleotide in extracts of E. coli cells. Wild type cells were shown to contain both molybdopterin and molybdopterin guanine dinucleotide, while cells of chlB mutants were found to contain elevated levels of molybdopterin but no detectable molybdopterin guanine dinucleotide.			JOHNSON, JL (corresponding author), DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710, USA.				NIGMS NIH HHS [GM00091, GM44283] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044283] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMY NK, 1981, J BACTERIOL, V148, P274, DOI 10.1128/JB.148.1.274-282.1981; BASTIAN NR, 1991, J BIOL CHEM, V266, P45; BOXER DH, 1987, J BACTERIOL, V169, P4678, DOI 10.1128/jb.169.10.4678-4685.1987; BOXER DH, 1989, MOL GENETIC ASPECTS, P27; JOHNSON JL, 1990, ARCH BIOCHEM BIOPHYS, V283, P542, DOI 10.1016/0003-9861(90)90681-N; JOHNSON JL, 1990, P NATL ACAD SCI USA, V87, P3190, DOI 10.1073/pnas.87.8.3190; JOHNSON JL, 1984, J BIOL CHEM, V259, P5414; JOHNSON JL, 1991, FEMS MICROBIOL LETT, V77, P213; JOHNSON JL, 1989, J BIOL CHEM, V264, P13440; JOHNSON ME, 1987, J BACTERIOL, V169, P117, DOI 10.1128/jb.169.1.117-125.1987; JOHNSON ME, 1987, J BACTERIOL, V169, P110, DOI 10.1128/jb.169.1.110-116.1987; KRAMER SP, 1987, J BIOL CHEM, V262, P16357; MACGREGOR CH, 1973, J BACTERIOL, V114, P1164, DOI 10.1128/JB.114.3.1164-1176.1973; MILLER JB, 1983, J BACTERIOL, V155, P793, DOI 10.1128/JB.155.2.793-801.1983; PITTERLE DM, 1989, J BACTERIOL, V171, P3373, DOI 10.1128/jb.171.6.3373-3378.1989; Pitterle DM, 1990, FASEB J, V4, pA1957; RIVIERE C, 1975, BIOCHIM BIOPHYS ACTA, V389, P219, DOI 10.1016/0005-2736(75)90317-X; SARACINO L, 1986, EUR J BIOCHEM, V158, P483, DOI 10.1111/j.1432-1033.1986.tb09780.x; STEWART V, 1988, MICROBIOL REV, V52, P190, DOI 10.1128/MMBR.52.2.190-232.1988	19	96	100	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1991	266	19					12140	12145						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FV180	1648082				2022-12-25	WOS:A1991FV18000007
J	DERMASTIA, M; TURK, T; HOLLOCHER, TC				DERMASTIA, M; TURK, T; HOLLOCHER, TC			NITRIC-OXIDE REDUCTASE - PURIFICATION FROM PARACOCCUS-DENITRIFICANS WITH USE OF A SINGLE COLUMN AND SOME CHARACTERISTICS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTRAL AQUEOUS-SOLUTION; NITROSYL HYDRIDE; TRIOXODINITRATE(II); HEMOGLOBIN; INTERMEDIATE; OXIDATION; PROTEINS	Nitric oxide reductase was purified from Paracoccus denitrificans very nearly to homogeneity by a simple method that involved the use of octyl glucoside to solubilize the enzyme from membranes and required a single hydroxyapatite column. The enzyme had specific activities of about 10-mu-mol NO reduced x min-1 x mg-1 at pH 6.5 in an amperometric assay system using phenazine methosulfate/ascorbate as the reducing agent and about 22-mu-mol NO reduced x min-1 x mg-1 at pH 5.0, which is the optimum pH. These values are based on average rates over kinetically complex progress curves and would be about three times greater if based on maximum rate values. The enzyme appeared to be reversibly inhibited by NO(aq) and to have a K(m) too low (probably less-than-or-equal-to 1-mu-M) to measure reliably by the amperometric method. The effective second-order rate constant of the enzyme lay within 1 to 2 orders of magnitude of the diffusion controlled limit. The enzyme was composed of a tight complex of two cytochromes: a cytochrome c (M(r) = 17,500) and a cytochrome b (M(r) = 38,000). The mole ratios of cytochrome c to cytochrome b and M(r) 17,500 peptide to M(r) 38,000 peptide were both about 1.7, and the heme content was about 3 mol/73,000 g (38,000 + 2(17,500)). Each subunit therefore contained only one heme group. The M(r) 38,000 peptide aggregated when heated in the sample buffer used for sodium dodecyl sulfate-polyacrylamide gel electrophoresis. In addition to the ascorbate-based activity, the enzyme showed a little NADH-NO oxidoreductase activity which was not inhibited by antimycin A. The enzyme lost activity with a half-life of about 2 days at 4-degrees-C but could be preserved at -20-degrees-C and in liquid nitrogen. It seemed not to be inactivated by aerobic solutions. These observations, and the recent ones by Carr and Ferguson (Carr, G. J., and Ferguson, S. J. (1990) Biochem. J. 269, 423-429) with a partially purified preparation of nitric oxide reductase, establish that the enzyme from Pa. denitrificans is a cytochrome bc complex which resembles that from Pseudomonas stutzeri (Heiss, B., Frunzke, K., and Zumft, W. G. (1989) J. BacterioL 171, 3288-3297). There would appear to be no functional relationship between nitric oxide reductase and a M(r) = 34,000 peptide of Pa. denitrificans membranes reported previously to be present in purified preparations of a nitric oxide reductase (Hoglen, J., and Hollocher, T. C. (1989) J. Biol. Chem. 264, 7556-7563).	BRANDEIS UNIV, DEPT BIOCHEM, WALTHAM, MA 02254 USA	Brandeis University								BAZYLINSKI DA, 1985, J AM CHEM SOC, V107, P7982, DOI 10.1021/ja00312a031; BAZYLINSKI DA, 1985, J AM CHEM SOC, V107, P7986, DOI 10.1021/ja00312a032; BAZYLINSKI DA, 1985, INORG CHEM, V24, P4285, DOI 10.1021/ic00219a017; CANFIELD RE, 1965, J BIOL CHEM, V240, P1997; CARR GJ, 1989, EUR J BIOCHEM, V179, P683, DOI 10.1111/j.1432-1033.1989.tb14601.x; CARR GJ, 1990, BIOCHEM J, V269, P423, DOI 10.1042/bj2690423; CASSOLY R, 1975, J MOL BIOL, V91, P301, DOI 10.1016/0022-2836(75)90382-4; COSTA C, 1990, FEBS LETT, V276, P67, DOI 10.1016/0014-5793(90)80508-G; DOYLE MP, 1988, J AM CHEM SOC, V110, P593, DOI 10.1021/ja00210a047; FLATMARK T, 1964, ACTA CHEM SCAND, V18, P1517, DOI 10.3891/acta.chem.scand.18-1517; FUHRHOP JH, 1985, PORPHYRINS METALLOPO, P757; GOODHEW CF, 1986, BIOCHIM BIOPHYS ACTA, V852, P288, DOI 10.1016/0005-2728(86)90234-3; GORBUNOFF MJ, 1984, ANAL BIOCHEM, V136, P425, DOI 10.1016/0003-2697(84)90239-2; GORETSKI J, 1988, J BIOL CHEM, V263, P2316; GORETSKI J, 1990, J BIOL CHEM, V265, P889; GORETSKI J, 1990, J BIOL CHEM, V265, P11535; GRATZEL M, 1970, BERICH BUNSEN GESELL, V74, P1003; HEISS B, 1989, J BACTERIOL, V171, P3288, DOI 10.1128/jb.171.6.3288-3297.1989; HOGLEN J, 1989, J BIOL CHEM, V264, P7556; JI XB, 1988, APPL ENVIRON MICROB, V54, P1791, DOI 10.1128/AEM.54.7.1791-1794.1988; KOBAYASHI K, 1990, BIOCHEMISTRY-US, V29, P2080, DOI 10.1021/bi00460a017; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURENT TC, 1964, J CHROMATOGR, V14, P317, DOI 10.1016/S0021-9673(00)86637-6; Lemberg R., 1973, CYTOCHROMES; MASSEY V, 1959, BIOCHIM BIOPHYS ACTA, V34, P255, DOI 10.1016/0006-3002(59)90259-8; PETERSON GL, 1979, ANAL BIOCHEM, V100, P201, DOI 10.1016/0003-2697(79)90222-7; SNYDER SW, 1987, J BIOL CHEM, V262, P6515; STRITTMATTER P, 1956, ENZYMES, V221, P253; VANGELDER BF, 1962, BIOCHIM BIOPHYS ACTA, V58, P593, DOI 10.1016/0006-3002(62)90073-2; WEBER K, 1969, J BIOL CHEM, V244, P4406; YONETANI T, 1968, STRUCTURE FUNCTION C, P289; ZAFIRIOU OC, 1989, J BIOL CHEM, V264, P5694; ZUMFT WG, 1982, BIOCHIM BIOPHYS ACTA, V681, P459, DOI 10.1016/0005-2728(82)90188-8	33	75	75	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					10899	10905						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	1645715				2022-12-25	WOS:A1991FQ77400033
J	YUN, CH; VANDOREN, SR; CROFTS, AR; GENNIS, RB				YUN, CH; VANDOREN, SR; CROFTS, AR; GENNIS, RB			THE USE OF GENE FUSIONS TO EXAMINE THE MEMBRANE TOPOLOGY OF THE L-SUBUNIT OF THE PHOTOSYNTHETIC REACTION CENTER AND OF THE CYTOCHROME-B SUBUNIT OF THE BC1 COMPLEX FROM RHODOBACTER-SPHAEROIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACTERIA; ESCHERICHIA-COLI; RHODOPSEUDOMONAS-SPHAEROIDES; SACCHAROMYCES-CEREVISIAE; CYTOPLASMIC MEMBRANE; MOLECULAR-BASIS; PROTEIN LOCALIZATION; BETA-GALACTOSIDASE; TERMINAL OXIDASE; C REDUCTASE	The topology of the cytochrome b subunit of the bc1 complex from Rhodobacter sphaeroides has been examined by generating gene fusions with alkaline phosphatase. Gene fusions were generated at random locations within the fbcB gene encoding the cytochrome b subunit. These fusion products were expressed in Escherichia coli and were screened for alkaline phosphatase activity on chromogenic plates. 33 in-frame fusions which showed activity were further characterized. The fusion junctions of all those fusions which had a high specific activity were clustered in three regions of the cytochrome b polypeptide, and thus these regions were tentatively assigned as being near the periplasmic surface. The data are consistent with a model containing eight transmembrane helices. In order to explore the validity of the gene fusion approach for a protein not normally expressed in E. coli, the topology of the L-subunit of the photosynthetic reaction center from R. sphaeroides was also explored using phoA gene fusions. A similar protocol was used as with the cytochrome b subunit. The gene fusions with high specific activity were shown to be in regions of the L-subunit polypeptide known to be at or near the periplasmic surface, as defined by the high resolution structure determined by X-ray crystallography. These data demonstrate the utility of this approach for determining membrane protein topology and extend potential applications to include at least some proteins not normally expressed in E. coli.	UNIV ILLINOIS,SCH CHEM SCI,DEPT CHEM,URBANA,IL 61801; UNIV ILLINOIS,DEPT PHYSIOL & BIOPHYS,URBANA,IL 61801; UNIV ILLINOIS,DEPT BIOCHEM,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign				Van Doren, Steven/0000-0003-2838-4598	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026305, R01GM035438] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35438, GM26305] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA Y, 1989, J BIOL CHEM, V264, P437; ALLEN JP, 1987, P NATL ACAD SCI USA, V84, P6162, DOI 10.1073/pnas.84.17.6162; ALLEN JP, 1986, P NATL ACAD SCI USA, V83, P8589, DOI 10.1073/pnas.83.22.8589; ANDREWS KM, 1990, BIOCHEMISTRY-US, V29, P2645, DOI 10.1021/bi00463a004; BOYD D, 1987, P NATL ACAD SCI USA, V84, P8525, DOI 10.1073/pnas.84.23.8525; BRASSEUR R, 1988, J BIOL CHEM, V263, P12571; BRICKMAN E, 1975, J MOL BIOL, V96, P307, DOI 10.1016/0022-2836(75)90350-2; CHEPURI V, 1990, J BIOL CHEM, V265, P12978; CROFTS A, 1987, CYTOCHROME SYSTEMS M, P617; CROFTS AR, 1983, BIOCHIM BIOPHYS ACTA, V723, P202, DOI 10.1016/0005-2728(83)90120-2; CROFTS AR, 1985, ENZYMES BIOL MEMBR, P347; DALDAL F, 1989, EMBO J, V8, P3951, DOI 10.1002/j.1460-2075.1989.tb08578.x; DIRAGO JP, 1989, J BIOL CHEM, V264, P14543; DIRAGO JP, 1988, J BIOL CHEM, V263, P12564; DONOHUE TJ, 1988, BIOCHEMISTRY-US, V27, P1918, DOI 10.1021/bi00406a018; FROSHAUER S, 1988, J MOL BIOL, V200, P501, DOI 10.1016/0022-2836(88)90539-6; GABELLINI N, 1988, J BIOENERG BIOMEMBR, V20, P59, DOI 10.1007/BF00762138; GEORGIOU CD, 1988, J BIOL CHEM, V263, P13130; GOTT P, 1988, MOL MICROBIOL, V2, P655, DOI 10.1111/j.1365-2958.1988.tb00074.x; HARLOW E, 1988, ANTIBODIES LABORATOR; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HAUSKA G, 1988, J BIOENERG BIOMEMBR, V20, P211, DOI 10.1007/BF00768395; HERRERO M, 1988, J BACTERIOL, V170, P54; HICKMAN RK, 1988, J BACTERIOL, V170, P1715, DOI 10.1128/jb.170.4.1715-1720.1988; HOWELL N, 1988, J MOL BIOL, V203, P607, DOI 10.1016/0022-2836(88)90195-7; HOWELL N, 1987, J BIOL CHEM, V262, P2411; ITO K, 1981, CELL, V24, P707, DOI 10.1016/0092-8674(81)90097-0; KEEN NT, 1988, GENE, V70, P191, DOI 10.1016/0378-1119(88)90117-5; KILEY PJ, 1988, MICROBIOL REV, V52, P550; KRIAUCIUNAS A, 1989, BIOCHIM BIOPHYS ACTA, V976, P70, DOI 10.1016/S0005-2728(89)80190-2; LEE C, 1989, J BACTERIOL, V171, P4609, DOI 10.1128/jb.171.9.4609-4616.1989; LUEKING DR, 1978, J BIOL CHEM, V253, P451; Maniatis T., 1982, MOL CLONING; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; MANOIL C, 1990, J BACTERIOL, V172, P1035, DOI 10.1128/jb.172.2.1035-1042.1990; MILLAN J L, 1989, Journal of Bacteriology, V171, P5536; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SARASTE M, 1984, FEBS LETT, V166, P367, DOI 10.1016/0014-5793(84)80114-3; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; VARGA AR, 1989, J BACTERIOL, V171, P5830, DOI 10.1128/jb.171.11.5830-5839.1989; WEBER S, 1988, FEBS LETT, V237, P31, DOI 10.1016/0014-5793(88)80165-0; WIDGER WR, 1984, P NATL ACAD SCI-BIOL, V81, P674, DOI 10.1073/pnas.81.3.674; YANG XH, 1986, J BIOL CHEM, V261, P2282; YUN CH, 1990, EUR J BIOCHEM, V194, P399, DOI 10.1111/j.1432-1033.1990.tb15633.x	46	57	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					10967	10973						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	1645718				2022-12-25	WOS:A1991FQ77400043
J	OKONOGI, K; GETTYS, TW; UHING, RJ; TARRY, WC; ADAMS, DO; PRPIC, V				OKONOGI, K; GETTYS, TW; UHING, RJ; TARRY, WC; ADAMS, DO; PRPIC, V			INHIBITION OF PROSTAGLANDIN-E2-STIMULATED CAMP ACCUMULATION BY LIPOPOLYSACCHARIDE IN MURINE PERITONEAL-MACROPHAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; DEPENDENT PROTEIN-KINASE; ARACHIDONIC-ACID METABOLITES; MULTIPLE MOLECULAR-FORMS; BACTERIAL LIPOPOLYSACCHARIDE; RAT ADIPOCYTES; IA EXPRESSION; ANTIGEN EXPRESSION; HUMAN-MONOCYTES; HUMAN-PLATELETS	Treatment of murine peritoneal macrophages with 100 nM prostaglandin E2 (PGE2) produced a rapid biphasic increase in intracellular cAMP that was maximal at 1 min and sustained through 20 min. Pretreatment of macrophages with 100 ng/ml of lipopolysaccharide (LPS) for 60 min prior to PGE2 decreased the magnitude of cAMP elevation by 50%, accelerated the decrease of cAMP to basal levels, and abolished the sustained phase of cAMP elevation. The effect of LPS was concentration-dependent, with maximal effect at 10 ng/ml in cells incubated in the presence of 5% fetal calf serum and at 1-mu-g/ml in the absence of fetal calf serum. LPS also inhibited cAMP accumulation in cells treated with 100-mu-M forskolin, but the decrease was about half that seen in cells treated with PGE2. LPS concentrations that inhibited cAMP accumulation produced a 30% increase in soluble low K(m) cAMP phosphodiesterase activity while having no effect on particulate phosphodiesterase activity. The nonspecific phosphodiesterase inhibitor, 3-isobutyl-1-methylxanthine, as well as the more specific inhibitors rolipram and Ro-20-1724 were effective in inhibiting soluble phosphodiesterase activity in vitro, producing synergistic elevation of cAMP in PGE2-treated cells, and blocking the ability of LPS to inhibit accumulation of cAMP. Separation of the phosphodiesterase isoforms in the soluble fraction by DEAE chromatography indicated that LPS activated a low K(m) cAMP phosphodiesterase. The enzyme(s) present in this peak could be activated 6-fold by cGMP and were potently inhibited by low micromolar concentrations of Ro-20-1724 and rolipram. Using both membranes from LPS-treated cells and membranes incubated with LPS, no decrease in adenylylcyclase activity could be attributed to LPS. Although effects of LPS on the rate of synthesis of cAMP cannot be excluded, the present evidence is most consistent with a role for phosphodiesterase activation in the inhibitory effects of LPS on cAMP accumulation in murine peritoneal macrophages.	DUKE UNIV,MED CTR,DEPT PATHOL,BOX 3712,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710	Duke University; Duke University			Gettys, Thomas W/N-1964-2017	Gettys, Thomas W/0000-0001-7125-7995	NATIONAL CANCER INSTITUTE [P01CA029589] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK042486] Funding Source: NIH RePORTER; NCI NIH HHS [CA 29589] Funding Source: Medline; NIDDK NIH HHS [DK 42486] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS DO, 1988, INFLAMMATION BASIC P, P471; ADEREM AA, 1986, J EXP MED, V164, P165, DOI 10.1084/jem.164.1.165; ADEREM AA, 1986, P NATL ACAD SCI USA, V83, P5817, DOI 10.1073/pnas.83.16.5817; BEAVO JA, 1990, TRENDS PHARMACOL SCI, V11, P150, DOI 10.1016/0165-6147(90)90066-H; BEAVO JA, 1988, ADV SEC MESS PHOSPH, V2, P1; BONNEY RJ, 1984, CONTEMP TOP IMMUNOBI, V13, P199; BONTA IL, 1982, INT J IMMUNOPHARMACO, V4, P103, DOI 10.1016/0192-0561(82)90057-1; BOURNE HR, 1974, SCIENCE, V184, P19, DOI 10.1126/science.184.4132.19; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brooker G, 1979, Adv Cyclic Nucleotide Res, V10, P1; Buxton I L, 1986, Adv Exp Med Biol, V194, P117; BUXTON ILO, 1985, BIOCHEM INT, V11, P137; DEFRANCO AL, 1987, IMMUNOL REV, V95, P161, DOI 10.1111/j.1600-065X.1987.tb00504.x; DINARELLO CA, 1989, ADV IMMUNOL, V44, P153; FATEMI SH, 1985, CELL MOL BIOL, V31, P153; FATEMI SH, 1985, CELL MOL BIOL, V31, P349; FIGUEIREDO F, 1990, J BIOL CHEM, V265, P12317; GETTYS TW, 1986, AM J PHYSIOL, V251, pE357, DOI 10.1152/ajpendo.1986.251.3.E357; GETTYS TW, 1987, J BIOL CHEM, V262, P333; GETTYS TW, 1988, J BIOL CHEM, V263, P10359; GETTYS TW, 1990, SEC MESS PHOSPHOPROT, V13, P37; GRABER SE, 1988, BIOCHIM BIOPHYS ACTA, V972, P331, DOI 10.1016/0167-4889(88)90209-1; GRABER SE, 1982, J BIOL CHEM, V257, P5414; GRANT PG, 1990, THROMB RES, V59, P105, DOI 10.1016/0049-3848(90)90276-I; HAEFFNERCAVAILLON N, 1985, CELL IMMUNOL, V91, P119, DOI 10.1016/0008-8749(85)90037-1; HAMILTON TA, 1987, J IMMUNOL, V138, P4063; HAZEKI K, 1986, ARCH BIOCHEM BIOPHYS, V246, P772, DOI 10.1016/0003-9861(86)90334-6; KONO T, 1988, METHOD ENZYMOL, V159, P745; MACPHEE CH, 1988, J BIOL CHEM, V263, P10353; MANOGUE KR, 1988, CELLULAR MOL ASPECTS, P123; MARTINS TJ, 1982, J BIOL CHEM, V257, P1973; MUMBY MC, 1982, J BIOL CHEM, V257, P13283; PRPIC V, 1987, J IMMUNOL, V139, P526; REIBMAN J, 1990, CURR TOP MEMBR TRANS, V35, P399; ROSEN A, 1989, J BIOL CHEM, V264, P9118; SCHULTZ RM, 1979, CELL IMMUNOL, V42, P71, DOI 10.1016/0008-8749(79)90222-3; SCOTT WA, 1980, J EXP MED, V152, P324, DOI 10.1084/jem.152.2.324; SHATTUCK RL, 1985, BIOCHEMISTRY-US, V24, P6356, DOI 10.1021/bi00344a006; SMITH CJ, 1989, MOL PHARMACOL, V35, P381; SNYDER DS, 1982, NATURE, V299, P163, DOI 10.1038/299163a0; SNYDERMAN R, 1988, INFLAMMATION BASIC P, P309; STEEG PS, 1982, J IMMUNOL, V129, P2402; TAFFET SM, 1981, J IMMUNOL, V126, P424; Thompson W J, 1979, Adv Cyclic Nucleotide Res, V10, P69; UHING RJ, 1989, AGENTS ACTIONS, V26, P9, DOI 10.1007/BF02126552; UHING RJ, 1990, CURRENT TOPICS MEMBR, V35, P349; VALETTE L, 1990, BIOCHEM BIOPH RES CO, V169, P864, DOI 10.1016/0006-291X(90)91973-V; WALSETH TF, 1979, BIOCHIM BIOPHYS ACTA, V562, P11, DOI 10.1016/0005-2787(79)90122-9; WEIEL JE, 1986, J IMMUNOL, V136, P3012; WEISHAAR RE, 1985, J MED CHEM, V28, P537, DOI 10.1021/jm50001a001; WRIGHT CD, 1990, BIOCHEM PHARMACOL, V40, P699, DOI 10.1016/0006-2952(90)90304-4; YAMAMOTO H, 1987, J IMMUNOL, V139, P3416; YAMAMOTO T, 1983, J BIOL CHEM, V258, P2526; YEM AW, 1981, J IMMUNOL, V127, P2245	54	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10305	10312						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	1645347				2022-12-25	WOS:A1991FP08600050
J	MALHOTRA, K; KIM, ST; WALSH, C; SANCAR, A				MALHOTRA, K; KIM, ST; WALSH, C; SANCAR, A			ROLES OF FAD AND 8-HYDROXY-5-DEAZAFLAVIN CHROMOPHORES IN PHOTOREACTIVATION BY ANACYSTIS-NIDULANS DNA PHOTOLYASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI PHOTOLYASE; ABSOLUTE ACTION SPECTRUM; 2ND CHROMOPHORE; PHOTOCHEMICAL PROPERTIES; STREPTOMYCES-GRISEUS; PYRIMIDINE DIMERS; ENZYME; FLAVIN; PURIFICATION; BINDING	DNA photolyase from the cyanobacterium Anacystis nidulans contains two chromophores, flavin adenine dinucleotide (FADH2) and 8-hydroxy-5-deazaflavin (8-HDF) (Eker, A. P. M., Kooiman, P., Hessels, J. K. C., and Yasui, A. (1990) J. Biol. Chem. 265, 8009-8015). While evidence exists that the flavin chromophore (in FADH2 form) can catalyze photorepair directly and that the 8-HDF chromophore is the major photosensitizer in photoreactivation it was not known whether 8-HDF splits pyrimidine dimer directly or indirectly through energy transfer to FADH2 at the catalytic center. We constructed a plasmid which over-produces the A. nidulans photolyase in Escherichia coli and purified the enzyme from this organism. Apoenzyme was prepared and enzyme containing stoichiometric amounts of either or both chromophores was reconstituted. The substrate binding and catalytic activities of the apoenzyme (apoE), E-FADH2, E-8-HDF, E-FAD(ox)-8-HDF, and E-FADH2-8-HDF were investigated. We found that FAD is required for substrate binding and catalysis and that 8-HDF is not essential for binding DNA, and participates in catalysis only through energy transfer to FADH2. The quantum yields of energy transfer from 8-HDF to FADH2 and of electron transfer from FADH2 to thymine dimer are near unity.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Harvard Medical School	MALHOTRA, K (corresponding author), UNIV N CAROLINA,SCH MED,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM031082, R01GM031082] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31082] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLAVERT KG, 1966, PHOTOCHEMISTRY, P783; EKER AP, 1988, BIOCHEMISTRY-US, V27, P1758, DOI 10.1021/bi00405a056; EKER APM, 1981, PHOTOCHEM PHOTOBIOL, V33, P65, DOI 10.1111/j.1751-1097.1981.tb04298.x; EKER APM, 1986, PHOTOCHEM PHOTOBIOL, V44, P197, DOI 10.1111/j.1751-1097.1986.tb03586.x; EKER APM, 1990, J BIOL CHEM, V265, P8009; EKER APM, 1991, PHOTOCHEM PHOTOBIO S, V53, P175; HAMMALVAREZ S, 1989, J BIOL CHEM, V264, P9649; HEELIS PF, 1986, BIOCHEMISTRY-US, V25, P8163, DOI 10.1021/bi00373a006; HEELIS PF, 1987, BIOCHEMISTRY-US, V26, P4634, DOI 10.1021/bi00389a007; HUSAIN I, 1987, NUCLEIC ACIDS RES, V15, P1109; JOHNSON JL, 1988, P NATL ACAD SCI USA, V85, P2046, DOI 10.1073/pnas.85.7.2046; JORNS MS, 1984, BIOCHEMISTRY-US, V23, P2673, DOI 10.1021/bi00307a021; JORNS MS, 1990, BIOCHEMISTRY-US, V29, P552, DOI 10.1021/bi00454a032; KIENER A, 1989, J BIOL CHEM, V264, P13880; KIM ST, 1991, BIOCHEMISTRY-US, V30, P11262, DOI 10.1021/bi00111a011; KIM ST, 1991, BIOCHEMISTRY-US, V30, P8623, DOI 10.1021/bi00099a019; KIM ST, 1992, P NATL ACAD SCI USA, V89, P900, DOI 10.1073/pnas.89.3.900; KOBAYASHI T, 1989, NUCLEIC ACIDS RES, V17, P4737; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LI YF, 1991, NUCLEIC ACIDS RES, V19, P4885, DOI 10.1093/nar/19.18.4885; MAYERL F, 1990, J BACTERIOL, V172, P6061, DOI 10.1128/jb.172.10.6061-6065.1990; OKAMURA T, 1991, J AM CHEM SOC, V113, P3143, DOI 10.1021/ja00008a050; PAYNE G, 1990, BIOCHEMISTRY-US, V29, P7715, DOI 10.1021/bi00485a021; PAYNE G, 1987, BIOCHEMISTRY-US, V26, P7121, DOI 10.1021/bi00396a038; PAYNE G, 1990, BIOCHEMISTRY-US, V29, P5706, DOI 10.1021/bi00476a010; ROKITA SE, 1984, J AM CHEM SOC, V106, P4589, DOI 10.1021/ja00328a049; SANCAR A, 1984, J BIOL CHEM, V259, P6028; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SANCAR A, 1992, ADV ELECTRON TRANSFE, V2, P215; SANCAR GB, 1987, J BIOL CHEM, V262, P15457; SANCAR GB, 1987, J BIOL CHEM, V262, P492; SVOBODA DL, 1991, THESIS WASHINGTON U; TAKAO M, 1989, PHOTOCHEM PHOTOBIOL, V50, P633, DOI 10.1111/j.1751-1097.1989.tb04319.x; TAKAO M, 1989, J BACTERIOL, V171, P6323, DOI 10.1128/jb.171.11.6323-6329.1989; TAYLOR JS, 1987, J AM CHEM SOC, V109, P6735, DOI 10.1021/ja00256a030; YASUI A, 1988, NUCLEIC ACIDS RES, V16, P4447, DOI 10.1093/nar/16.10.4447	37	62	63	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15406	15411						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1639785				2022-12-25	WOS:A1992JG11300025
J	HATFIELD, PM; VIERSTRA, RD				HATFIELD, PM; VIERSTRA, RD			MULTIPLE FORMS OF UBIQUITIN-ACTIVATING ENZYME E1 FROM WHEAT - IDENTIFICATION OF AN ESSENTIAL CYSTEINE BY INVITRO MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; RNA-POLYMERASE; PROTEIN; EXPRESSION; GENE; PURIFICATION; DNA; CHROMOSOME; MECHANISM	Ubiquitin-activating enzyme, E1, directs the ATP-dependent formation of a thiol ester linkage between itself and ubiquitin. The energy in this bond is ultimately used to attach ubiquitin to various intracellular proteins. We previously reported the isolation of multiple E1s from wheat and the characterization of a cDNA encoding this protein (UBA1). We now report the derived amino acid sequence of two additional members of this gene family (UBA2 and UBA3). Whereas the amino acid sequence of UBA2 is nearly identical to UBA1, the sequence of UBA3 is significantly different. Nevertheless, the protein encoded by UBA3 catalyzes the ATP-dependent activation of ubiquitin in vitro. Comparison of derived amino acid sequences of genes encoding E1 from plant, yeast, and animal tissues revealed 5 conserved cysteine residues, with one potentially involved in thiol ester bond formation. To identify this essential residue, codons corresponding to each of the 5 cysteines in UBA1 were individually altered using site-directed mutagenesis. The mutagenized enzymes were expressed in Escherichia coli and assayed for their ability to activate ubiquitin. Only substitution of the cysteine at position 626 abolishes E1 activity, suggesting that this residue forms the thiol ester linkage with ubiquitin.	UNIV WISCONSIN,DEPT HORT,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison								BIRKETT CR, 1985, FEBS LETT, V187, P211, DOI 10.1016/0014-5793(85)81244-8; CIECHANOVER A, 1982, J BIOL CHEM, V257, P2537; COOK WJ, 1992, J MOL BIOL, V223, P1183, DOI 10.1016/0022-2836(92)90270-T; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FINLEY D, 1984, CELL, V37, P43, DOI 10.1016/0092-8674(84)90299-X; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; GUARINO LA, 1990, P NATL ACAD SCI USA, V87, P409, DOI 10.1073/pnas.87.1.409; HAAS AL, 1982, J BIOL CHEM, V257, P2543; HAAS AL, 1982, J BIOL CHEM, V257, P329; HAAS AL, 1987, J BIOL CHEM, V262, P11315; HANDLEY PM, 1991, P NATL ACAD SCI USA, V88, P258, DOI 10.1073/pnas.88.1.258; HATFIELD PM, 1990, J BIOL CHEM, V265, P15813; HATFIELD PM, 1989, BIOCHEMISTRY-US, V28, P735, DOI 10.1021/bi00428a048; HERSHKO A, 1988, J BIOL CHEM, V263, P15237; HOEFER M, 1991, FEBS LETT, V289, P54, DOI 10.1016/0014-5793(91)80907-K; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; KAY GF, 1991, NATURE, V354, P486, DOI 10.1038/354486a0; KULKA RG, 1988, J BIOL CHEM, V263, P15726; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LOEB KR, 1992, J BIOL CHEM, V267, P7806; MCGRATH JP, 1991, EMBO J, V10, P227, DOI 10.1002/j.1460-2075.1991.tb07940.x; MITCHELL MJ, 1991, NATURE, V354, P483, DOI 10.1038/354483a0; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SULLIVAN ML, 1991, J BIOL CHEM, V266, P23878; SULLIVAN ML, 1990, PLANT PHYSIOL, V94, P710, DOI 10.1104/pp.94.2.710; SUNG P, 1990, P NATL ACAD SCI USA, V87, P2695, DOI 10.1073/pnas.87.7.2695; TONIOLO D, 1988, P NATL ACAD SCI USA, V85, P851, DOI 10.1073/pnas.85.3.851; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; VIERSTRA RD, 1985, J BIOL CHEM, V260, P2015; ZACKSENHAUS E, 1990, EMBO J, V9, P2923, DOI 10.1002/j.1460-2075.1990.tb07483.x	32	68	76	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14799	14803						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634524				2022-12-25	WOS:A1992JF08800046
J	HOWARD, EW; BANDA, MJ				HOWARD, EW; BANDA, MJ			BINDING OF TISSUE INHIBITOR OF METALLOPROTEINASES-2 TO 2 DISTINCT SITES ON HUMAN 72-KDA GELATINASE - IDENTIFICATION OF A STABILIZATION SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST COLLAGENASE INHIBITOR; BRONCHIAL EPITHELIAL-CELLS; RABBIT BONE COLLAGENASE; IV COLLAGENASE; INTERSTITIAL COLLAGENASE; SEQUENCE IDENTIFICATION; CYSTEINE SWITCH; ACTIVATION; FAMILY; EXPRESSION	We have identified a binding site for tissue inhibitors of metalloproteinases 2 (TIMP-2) on human 72-kDa gelatinase that is distinct from the active site. 72-kDa progelatinase is found in a complex with TIMP-2 in the medium of cultured cells and can be activated with organomercurial compounds to yield a gelatinolytic proteinase that remains bound to TIMP-2. Removal of TIMP-2 from 72-kDa progelatinase by reverse-phase high performance liquid chromatography, followed by reconstitution of the progelatinase in neutral pH buffer, results in autocatalytic activation. When samples of autoactivated gelatinase were blotted onto nitrocellulose, then probed with I-125-TIMP-2, we found a 29-kDa peptide that was capable of binding TIMP-2. We isolated this fragment and identified it as the region of gelatinase from amino acid 414 to the carboxyl terminus in the primary amino acid sequence of progelatinase. This portion of the molecule does not contain the putative zinc- or gelatin-binding sites and is proteolytically inactive. Incubation of I-125-TIMP-2 with 72-kDa progelatinase-TIMP-2 complexes resulted in a concentration-dependent exchange of labeled TIMP-2 with unlabeled TIMP-2, in both the presence and absence of the metalloproteinase inhibitor 1,10-phenanthroline. Saturation binding kinetics for the active site of 72-kDa gelatinase were measured in pools of the 43-kDa active fragment that results from the autoactivation of 72-kDa progelatinase; this fragment has no carboxyl-terminal TIMP-2 binding capability. Binding of I-125-TIMP-2 to the active site was completely inhibited by 1,10-phenanthroline. Binding kinetics for the putative stabilization site were determined with isolated 72-kDa progelatinase. In the presence of 1,10-phenanthroline, 72-kDa progelatinase bound I-125-TIMP-2 but not I-125-TIMP-1. Scatchard analysis yielded an approximate dissociation constant (K(d)) of 0.72 nM for the active site and 0.42 nM for the stabilization site.			HOWARD, EW (corresponding author), UNIV CALIF SAN FRANCISCO,RADIOBIOL & ENVIRONM HLTH LAB,SAN FRANCISCO,CA 94143, USA.				NIAMS NIH HHS [AR 32741] Funding Source: Medline	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALEXANDER CM, 1989, CURR OPIN CELL BIOL, V1, P975; BALLIN M, 1988, BIOCHEM BIOPH RES CO, V154, P832, DOI 10.1016/0006-291X(88)90215-X; BIRKEDALHANSEN H, 1987, METHOD ENZYMOL, V144, P140; BROWN PD, 1990, CANCER RES, V50, P6184; CARMICHAEL DF, 1986, P NATL ACAD SCI USA, V83, P2407, DOI 10.1073/pnas.83.8.2407; CAWSTON TE, 1983, BIOCHEM J, V211, P313, DOI 10.1042/bj2110313; CLARK IM, 1989, BIOCHEM J, V263, P201, DOI 10.1042/bj2630201; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; DAVIS GE, 1990, CANCER RES, V50, P1113; DECLERCK YA, 1991, J BIOL CHEM, V266, P3893; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; GRANT GA, 1987, J BIOL CHEM, V262, P5886; HE CS, 1989, P NATL ACAD SCI USA, V86, P2632, DOI 10.1073/pnas.86.8.2632; HOWARD EW, 1991, J BIOL CHEM, V266, P13070; HOWARD EW, 1991, J BIOL CHEM, V266, P13064; HYHTY M, 1990, INT J CANCER, V46, P282; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MOLL UM, 1990, CANCER RES, V50, P6162; MURPHY G, 1989, BIOCHEM J, V261, P1031, DOI 10.1042/bj2611031; MURPHY G, 1989, INT J CANCER, V44, P757, DOI 10.1002/ijc.2910440434; NAGASE H, 1990, BIOCHEMISTRY-US, V29, P5783, DOI 10.1021/bi00476a020; QUANTIN B, 1989, BIOCHEMISTRY-US, V28, P5327, DOI 10.1021/bi00439a004; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SELLERS A, 1979, BIOCHEM BIOPH RES CO, V87, P581, DOI 10.1016/0006-291X(79)91834-5; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P1353; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; STETLERSTEVENSON WG, 1990, J BIOL CHEM, V265, P13933; STRICKLIN GP, 1983, BIOCHEMISTRY-US, V22, P61, DOI 10.1021/bi00270a009; STRICKLIN GP, 1983, J BIOL CHEM, V258, P2252; URA H, 1989, CANCER RES, V49, P4615; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; WELGUS HG, 1985, COLLAGEN REL RES, V5, P167; WELGUS HG, 1983, J BIOL CHEM, V258, P2259; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WILLIAMSON RA, 1990, BIOCHEM J, V268, P267, DOI 10.1042/bj2680267; YAMAGATA S, 1988, BIOCHEM BIOPH RES CO, V151, P158, DOI 10.1016/0006-291X(88)90573-6	39	144	148	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					17972	17977						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1655733				2022-12-25	WOS:A1991GG55300043
J	GILBERT, GE; SIMS, PJ; WIEDMER, T; FURIE, B; FURIE, BC; SHATTIL, SJ				GILBERT, GE; SIMS, PJ; WIEDMER, T; FURIE, B; FURIE, BC; SHATTIL, SJ			PLATELET-DERIVED MICROPARTICLES EXPRESS HIGH-AFFINITY RECEPTORS FOR FACTOR-VIII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT PROTEINS C5B-9; COAGULATION FACTOR-V; LARGE UNILAMELLAR VESICLES; RAPID EXTRUSION PROCEDURE; ACTIVATED HUMAN-PLATELETS; BLOOD-COAGULATION; AMINOPHOSPHOLIPID TRANSLOCASE; PROTHROMBINASE ACTIVITY; PHOSPHOLIPID-VESICLES; PROCOAGULANT ACTIVITY	Factor VIII is a cofactor in the tenase enzyme complex which assembles on the membrane of activated platelets. A critical step in tenase assembly is membrane binding of factor VIII. Platelet membrane factor VIII-binding sites were characterized by flow cytometry using either fluorescein maleimide-labeled recombinant factor VIII or a fluorescein-labeled monoclonal antibody against factor VIII. Following activation by thrombin, most platelets bound factor VIII within 90 s. In addition, over the course of several minutes, membranous vesicles (microparticles) were shed from the platelet plasma membrane and each microparticle bound as much factor VIII as a stimulated platelet. Over 30 min, stimulated platelets (but not microparticles) lost the capacity to bind factor VIII. Factor VIII bound saturably to microparticles from platelets stimulated with thrombin, thrombin plus collagen, or the complement proteins C5b-9. The binding of factor VIII was compared to factor V, a structurally homologous coagulation cofactor. Analysis of microparticle binding kinetics yielded similar on and off rates for factor VIII and factor Va and K(D) values of 2-10 nM. In the presence of 20 nM factor Va, the binding of factor VIII to microparticles was increased, and there was a comparable increase in platelet tenase activity. At higher factor Va concentrations, factor VIII binding and tenase activity were inhibited. Conversely, factor VIII had a similar dose-dependent effect on factor Va binding and platelet prothrombinase activity. Synthetic phospholipid vesicles containing phosphatidylserine competed with microparticles for binding of factor VIII and factor Va. These studies indicate that activated platelets express a transient increase in high affinity receptors for factor VIII, whereas platelet-derived microparticles express a sustained increase in receptors. The binding characteristics of platelet membrane receptors for factor VIII are similar Va.	TUFTS UNIV,NEW ENGLAND MED CTR,CTR HEMOSTASIS & THROMBOSIS RES,SCH MED,DIV HEMATOL ONCOL,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT MED,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02111; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; OKLAHOMA MED RES FDN,CARDIOVASC BIOL RES PROGRAM,OKLAHOMA CITY,OK 73104; OKLAHOMA HLTH SCI CTR,DEPT MED,OKLAHOMA CITY,OK 73104; OKLAHOMA HLTH SCI CTR,DEPT PATHOL,OKLAHOMA CITY,OK 73104; OKLAHOMA HLTH SCI CTR,DEPT MICROBIOL & IMMUNOL,OKLAHOMA CITY,OK 73104; UNIV PENN,SCH MED,DEPT MED,HEMATOL ONCOL SECT,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,HEMATOL ONCOL SECT,PHILADELPHIA,PA 19104	Tufts Medical Center; Tufts University; Tufts University; Tufts University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Pennsylvania; University of Pennsylvania	GILBERT, GE (corresponding author), W ROXBURY VET ADM MED CTR,DEPT MED,HEMATOL ONCOL SECT,1400 VFW PKWY,BOSTON,MA 02132, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL040796, R01HL036946, P01HL042443] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36946, HL40796, HL42443] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABBOTT AJ, 1987, BIOCHEMISTRY-US, V26, P7994, DOI 10.1021/bi00398a067; ABRAMS CS, 1990, BLOOD, V75, P128; ARAI M, 1989, J CLIN INVEST, V83, P1978, DOI 10.1172/JCI114107; BANGHAM AD, 1965, J MOL BIOL, V13, P238, DOI 10.1016/S0022-2836(65)80093-6; BEVERS EM, 1989, BIOCHEMISTRY-US, V28, P2382, DOI 10.1021/bi00432a007; BEVERS EM, 1983, BIOCHIM BIOPHYS ACTA, V736, P57, DOI 10.1016/0005-2736(83)90169-4; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; CHURCH WR, 1984, P NATL ACAD SCI-BIOL, V81, P6934, DOI 10.1073/pnas.81.22.6934; COMFURIUS P, 1990, BIOCHIM BIOPHYS ACTA, V1026, P153, DOI 10.1016/0005-2736(90)90058-V; FAIONI EM, 1988, CIRCULATION S2, V78, P121; FOSTER PA, 1990, BLOOD, V75, P1999; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GILBERT GE, 1990, J BIOL CHEM, V265, P815; GITSCHIER J, 1984, NATURE, V312, P326, DOI 10.1038/312326a0; HARDISTY RM, 1962, THROMB DIATH HAEMOST, V7, P215; HILLEUBANKS DC, 1989, P NATL ACAD SCI USA, V86, P6508, DOI 10.1073/pnas.86.17.6508; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; KANE WH, 1988, BLOOD, V71, P539; KAUFMAN RJ, 1988, J BIOL CHEM, V263, P6352; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P5714; LOLLAR P, 1984, BLOOD, V63, P1303; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; MULLER HP, 1981, BLOOD, V58, P1000; NESHEIM ME, 1988, J BIOL CHEM, V263, P16467; NESHEIM ME, 1989, THROMB HAEMOSTASIS, V62, P35; NEUENSCHWANDER P, 1988, BLOOD, V72, P1761; ROSING J, 1985, BLOOD, V65, P319; SANDBERG H, 1985, THROMB RES, V39, P63, DOI 10.1016/0049-3848(85)90122-7; SHATTIL SJ, 1987, BLOOD, V70, P307; SIMS PJ, 1986, BLOOD, V68, P556; SIMS PJ, 1989, J BIOL CHEM, V264, P17049; SIMS PJ, 1988, J BIOL CHEM, V263, P18205; TAIT JF, 1989, J BIOL CHEM, V264, P7944; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; TRACY PB, 1979, J BIOL CHEM, V254, P354; WIEDMER T, 1986, J BIOL CHEM, V261, P4587; WIEDMER T, 1985, J BIOL CHEM, V260, P8014; WIEDMER T, 1986, BLOOD, V68, P875	39	238	250	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17261	17268						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1654328				2022-12-25	WOS:A1991GF44500046
J	LADROR, US; GOLLAPUDI, L; TRIPATHI, RL; LATSHAW, SP; KEMP, RG				LADROR, US; GOLLAPUDI, L; TRIPATHI, RL; LATSHAW, SP; KEMP, RG			CLONING, SEQUENCING, AND EXPRESSION OF PYROPHOSPHATE-DEPENDENT PHOSPHOFRUCTOKINASE FROM PROPIONIBACTERIUM-FREUDENREICHII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BACILLUS-STEAROTHERMOPHILUS; NUCLEOTIDE-SEQUENCE; GENE; EVOLUTION; PROTEIN; ENZYME	Pyrophosphate-dependent 6-phosphofructo-1-kinase (PP(i)-PFK) from Propionibacterium freudenreichii is a non-allosteric enzyme with properties dissimilar to those of other described phosphofructokinases. The enzyme was cloned into pBluescript, sequenced, and expressed in Escherichia coli at levels 15 times higher than those observed in Propionibacterium. The gene consists of 1215 bases which code for a protein of 404 amino acids and a mass of 43,243 daltons. High G+C in the codon usage (66%) of the gene is consistent with the classification of Propionibacterium in the High-G+C subdivision of the Gram-positive bacteria. While showing no sequence identity to the non-allosteric ATP-dependent phosphofructokinase of E. coli, alignments of the amino acid sequence with other PFKs reveal degrees of identities among the amino halves of the proteins, from 26% between the Propionibacterium and potato PP(i)-PFKs, and 29% between Propionibacterium and E. coli ATP-PFKs. These levels of identities indicate that the amino halves of these proteins are homologous. Identities between the carboxyl half of Propionibacterium PFK and carboxyl halves of other sequences are below 20%, suggesting that the carboxyl half is not homologous. Despite the poor conservation, most of the residues that take part in the binding of fructose-6-P or Mg-PP(i) could be readily identified by analogy to the structure of the E. coli PFK. Both the fructose-6-P and ATP- binding sites are conserved, indicating that PP(i) binds to the homologous site of the E. coli ATP-binding site.	UNIV HLTH SCI CHICAGO MED SCH,DEPT BIOL CHEM,3333 GREEN BAY RD,N CHICAGO,IL 60064	Chicago Medical School					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019912] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK19912] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAZAN JF, 1989, P NATL ACAD SCI USA, V86, P9642, DOI 10.1073/pnas.86.24.9642; CARLISLE SM, 1990, J BIOL CHEM, V265, P18366; CHEVALIER C, 1990, J BACTERIOL, V172, P2693, DOI 10.1128/jb.172.5.2693-2703.1990; DALDAL F, 1984, GENE, V28, P337, DOI 10.1016/0378-1119(84)90151-3; DORIT RL, 1990, SCIENCE, V250, P1377, DOI 10.1126/science.2255907; FRENCH BA, 1987, GENE, V54, P65, DOI 10.1016/0378-1119(87)90348-9; GEHNRICH SC, 1988, J BIOL CHEM, V263, P11755; HUNKAPILLER MW, 1985, PROTEIN SEQUENCER US, V14; KOLB E, 1980, EUR J BIOCHEM, V108, P587, DOI 10.1111/j.1432-1033.1980.tb04754.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVANON D, 1989, DNA-J MOLEC CELL BIO, V8, P733, DOI 10.1089/dna.1989.8.733; Maniatis T., 1982, MOL CLONING; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MULLER M, 1988, ANNU REV MICROBIOL, V42, P465, DOI 10.1146/annurev.mi.42.100188.002341; OBRIEN WE, 1975, J BIOL CHEM, V250, P8690; POORMAN RA, 1984, NATURE, V309, P467, DOI 10.1038/309467a0; REEVES RE, 1976, J BIOL CHEM, V251, P2958; ROGERS DT, 1988, J BIOL CHEM, V263, P6051; SCHIRMER T, 1990, NATURE, V343, P140, DOI 10.1038/343140a0; SHIRAKIHARA Y, 1988, J MOL BIOL, V204, P973, DOI 10.1016/0022-2836(88)90056-3; SNUTCH TP, 1988, GENE, V64, P241, DOI 10.1016/0378-1119(88)90339-3; THORNTON C, 1988, THESIS CASE W RESERV; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987	23	41	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16550	16555						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1653240				2022-12-25	WOS:A1991GD63500052
J	TARBET, EB; STAFFORINI, DM; ELSTAD, MR; ZIMMERMAN, GA; MCINTYRE, TM; PRESCOTT, SM				TARBET, EB; STAFFORINI, DM; ELSTAD, MR; ZIMMERMAN, GA; MCINTYRE, TM; PRESCOTT, SM			LIVER-CELLS SECRETE THE PLASMA FORM OF PLATELET-ACTIVATING-FACTOR ACETYLHYDROLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR PAF ACETYLHYDROLASE; HIGH-DENSITY LIPOPROTEIN; ATHEROSCLEROTIC PATIENTS; LIPID EXTRACT; BOVINE BRAIN; HUMAN-SERUM; RAT-LIVER; DEGRADATION; ACID; 1-ALKYL-2-ACETYL-SN-GLYCERO-3-PHOSPHOCHOLINE	Platelet-activating factor (PAF) is a phospholipid (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) with diverse physiological effects. It has been implicated as a mediator of inflammation, allergy, shock, and thrombosis. Plasma contains an enzyme, PAF acetylhydrolase, that catalyzes the degradation of PAF, and the level of this enzyme may regulate the concentration of PAF in the blood and extracellular spaces under some conditions. Thus, the cellular source(s) of this enzyme and the factors that regulate its synthesis and secretion are issues that may have important physiological and pathological implications. We found that cultures of Hep G2, a human hepatocarcinoma line, secreted PAF acetylhydrolase activity. Optimal secretion occurred in medium that contained serum, and the newly secreted PAF acetylhydrolase was associated with high density and low density lipoproteins (LDL and HDL, respectively), just as the enzyme is in plasma. In the absence of serum, PAF acetylhydrolase was secreted with a particle that had a density similar to HDL. Apolipoproteins B and E were found in the same fractions. We tested the effects of a variety of hormones on the secretion of PAF acetylhydrolase and found that secretion was inhibited by 17-alpha-ethynylestradiol with a maximal effect at 30-mu-M. This may account for the observation of others that estrogens reduce the activity of PAF acetylhydrolase in the plasma. The PAF acetylhydrolase secreted by Hep G2 cells appeared to be identical to the enzyme in human plasma based on substrate specificity, association with LDL and HDL, response to inhibitors, and reactivity with antibodies against the plasma PAF acetylhydrolase. In conclusion, we have demonstrated that hepatocytes in culture secrete a PAF acetylhydrolase that is apparently identical to the plasma form. The secretion is constitutive but may also be regulated in response to hormonal stimulation.	VET AFFAIRS MED CTR, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, DEPT INTERNAL MED, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, DEPT BIOCHEM, SALT LAKE CITY, UT 84112 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	PRESCOTT, SM (corresponding author), UNIV UTAH, NORA ECCLES HARRISON CARDIOVASC RES & TRAINING INS, SALT LAKE CITY, UT 84112 USA.			Tarbet, Bart/0000-0002-4255-9094	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035828] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL35828] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BISSELL DM, 1973, J CELL BIOL, V59, P722; BLANK ML, 1981, J BIOL CHEM, V256, P175; BLANK ML, 1983, BIOCHEM BIOPH RES CO, V113, P666, DOI 10.1016/0006-291X(83)91778-3; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CARTER ME, 1988, CIRCULATION, V78, pA516; DASHTI N, 1987, J LIPID RES, V28, P423; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; ELSTAD MR, 1989, J BIOL CHEM, V264, P8467; FARR RS, 1983, FED PROC, V42, P3120; HAMILTON RL, 1976, J CLIN INVEST, V58, P667, DOI 10.1172/JCI108513; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; MIWA M, 1988, J CLIN INVEST, V82, P1983, DOI 10.1172/JCI113818; MIYAURA S, 1991, IN PRESS LIPIDS; MUELLER HW, 1983, J BIOL CHEM, V258, P6213; OSTERMANN G, 1986, THROMB RES, V44, P303, DOI 10.1016/0049-3848(86)90005-8; OSTERMANN G, 1987, THROMB RES, V47, P279, DOI 10.1016/0049-3848(87)90141-1; OSTERMANN G, 1988, THROMB RES, V52, P529, DOI 10.1016/0049-3848(88)90126-0; Patterson M K Jr, 1979, Methods Enzymol, V58, P141; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; PRITCHARD PH, 1987, BIOCHEM J, V246, P791, DOI 10.1042/bj2460791; PRITCHARD PH, 1985, BLOOD, V66, P1476; RASH JM, 1981, BIOCHIM BIOPHYS ACTA, V666, P294, DOI 10.1016/0005-2760(81)90120-X; SATOH K, 1988, PROSTAGLANDINS, V35, P685, DOI 10.1016/0090-6980(88)90142-6; SATOH K, 1991, J CLIN INVEST, V87, P476, DOI 10.1172/JCI115020; SATOH K, 1989, PROSTAGLANDINS, V37, P673; SISSON JH, 1987, J IMMUNOL, V138, P3918; SMILEY PL, 1991, J BIOL CHEM, V266, P11104; SNYDER F, 1989, ANN NY ACAD SCI, V568, P35; STAFFORINI DM, 1989, P NATL ACAD SCI USA, V86, P2393, DOI 10.1073/pnas.86.7.2393; STAFFORINI DM, 1990, J BIOL CHEM, V265, P9682; STAFFORINI DM, 1991, METHOD ENZYMOL, V197, P411; STAFFORINI DM, 1990, METHOD ENZYMOL, V187, P344; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4223; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4215; STAFFORINI DM, 1991, IN PRESS LIPIDS; STREMLER KE, 1989, J BIOL CHEM, V264, P5331; STREMLER KE, 1991, J BIOL CHEM, V266, P11095; THOMAS DG, 1986, J IMMUNOL METHODS, V89, P239, DOI 10.1016/0022-1759(86)90364-9; TOKUMURA A, 1989, J LIPID RES, V30, P219; TOKUMURA A, 1988, BIOCHEM BIOPH RES CO, V155, P863, DOI 10.1016/S0006-291X(88)80575-8; WARDLOW ML, 1986, J IMMUNOL, V136, P3441; ZANNIS VI, 1981, BIOCHEMISTRY-US, V20, P7089, DOI 10.1021/bi00528a006; ZIMMERMAN GA, 1985, J CLIN INVEST, V76, P2235, DOI 10.1172/JCI112232	45	90	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16667	16673						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1653245				2022-12-25	WOS:A1991GD63500069
J	WHITELAW, ML; HUTCHISON, K; PERDEW, GH				WHITELAW, ML; HUTCHISON, K; PERDEW, GH			A 50-KDA CYTOSOLIC PROTEIN COMPLEXED WITH THE 90-KDA HEAT-SHOCK PROTEIN (HSP90) IS THE SAME PROTEIN COMPLEXED WITH PP60V-SRCHSP90 IN CELLS TRANSFORMED BY THE ROUS-SARCOMA VIRUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOCORTICOID RECEPTOR; MONOCLONAL-ANTIBODIES; CELLULAR PROTEINS; PHOSPHORYLATION; ASSOCIATION; PP60SRC; INVITRO	We have previously shown that a 50-kDa protein is one component of a heteromeric complex immunoprecipitated by the 90-kDa heat shock protein (hsp90) monoclonal antibodies 8D3 and 3G3 (Perdew, G. H., and Whitelaw, M. L. (1991) J. Biol. Chem. 266, 67086713). In this report, we compare the 50-kDa protein with that found in pp60v-src-hsp90-p50 complexes immunoprecipitated from Rous sarcoma virus-transformed cells with antibodies to pp60v-src. S-35 and P-32 labeled p50 proteins from each system were identical in their mobilities by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The profile of N-chlorosuccinimide cleavage products derived from each P-32-labeled p50 protein were also identical when resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. We have developed a mouse monoclonal antibody, 3M/1B5p50, capable of detecting p50 on Western blots. This antibody detected the 50-kDa protein which co-purified with the pa104 pp60v-src mutant of the avian sarcoma virus oncoprotein in 44A rat fibroblasts. We did not detect p50 in association with native glucocorticoid receptor in L cells or with the overexpressed glucocorticoid receptor in Chinese hamster ovary cells. Two experiments utilizing immunochemical staining implied that essentially all cytosolic p50 is associated with hsp90. Firstly, immunoprecipitating hsp90 from Hepa 1 cytosol with monoclonal antibody 3G3 left the cytosol depleted of p50. Secondly, cytosol fractionated by sucrose gradient revealed that p50 cosedimented with hsp90, confirming the existence of p50 only in association with hsp90.	PURDUE UNIV,DEPT FOODS & NUTR,W LAFAYETTE,IN 47907; UNIV MICHIGAN,SCH MED,ANN ARBOR,MI 48109	Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of Michigan System; University of Michigan					NIEHS NIH HHS [ES04869] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R29ES004869, R01ES004869] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADKINS B, 1982, J VIROL, V43, P448, DOI 10.1128/JVI.43.2.448-455.1982; BRUGGE JS, 1982, NATURE, V295, P250, DOI 10.1038/295250a0; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; DALMAN FC, 1989, J BIOL CHEM, V264, P19815; ERHART JC, 1988, ONCOGENE, V3, P595; GAMETCHU B, 1984, ENDOCRINOLOGY, V114, P274, DOI 10.1210/endo-114-1-274; GEARING A, 1985, J IMMUNOL METHODS, V76, P332; GILMORE TD, 1982, MOL CELL BIOL, V2, P199, DOI 10.1128/MCB.2.2.199; JOVE R, 1986, J VIROL, V60, P849, DOI 10.1128/JVI.60.3.849-857.1986; LANE RD, 1985, J IMMUNOL METHODS, V81, P223, DOI 10.1016/0022-1759(85)90207-8; LIPSICH LA, 1982, MOL CELL BIOL, V2, P875, DOI 10.1128/MCB.2.7.875; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LISCHWE MA, 1982, ANAL BIOCHEM, V127, P453, DOI 10.1016/0003-2697(82)90203-2; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; PERDEW GH, 1990, BIOCHEMISTRY-US, V29, P6210, DOI 10.1021/bi00478a014; REXIN M, 1988, FEBS LETT, V241, P234, DOI 10.1016/0014-5793(88)81068-8; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SANCHEZ ER, 1990, J BIOL CHEM, V265, P20123; SMITH DF, 1990, J BIOL CHEM, V265, P3996; TAI PKK, 1986, BIOCHEMISTRY-US, V25, P5269, DOI 10.1021/bi00366a043; VANELDIK LJ, 1981, J BIOL CHEM, V256, P4205; VANNESS J, 1984, P NATL ACAD SCI-BIOL, V81, P7897; ZIEMIECKI A, 1986, VIROLOGY, V151, P265, DOI 10.1016/0042-6822(86)90048-6	24	90	93	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16436	16440						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1653236				2022-12-25	WOS:A1991GD63500034
J	NOLTE, C; EIGENTHALER, M; SCHANZENBACHER, P; WALTER, U				NOLTE, C; EIGENTHALER, M; SCHANZENBACHER, P; WALTER, U			ENDOTHELIAL CELL-DEPENDENT PHOSPHORYLATION OF A PLATELET PROTEIN MEDIATED BY CAMP-ELEVATING AND CGMP-ELEVATING FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RELAXING FACTOR; NITRIC-OXIDE; L-ARGININE; VASCULAR ENDOTHELIUM; CYCLIC-GMP; PROSTACYCLIN; AGGREGATION; BIOSYNTHESIS; VASODILATORS; ACTIVATION	We reported previously that a 46/50-kDa membrane-associated vasodilator-stimulated phosphoprotein (VASP) is phosphorylated in intact human platelets in response to both cGMP- and cAMP-elevating vasodilator drugs and presented evidence that this is mediated by cGMP- and cAMP-dependent protein kinases, respectively. VASP was recently purified and an antibody against it was developed which detects a phosphorylation-induced mobility change of VASP in sodium dodecyl sulfate-polyacrylamide gel electrophoresis (Halbrugge, M., Friedrich, C., Eigenthaler, M., Schanzenbacher, P., and Walter, U. (1990) J. Biol. Chem. 265, 3088-3093). We have now used these methods for the quantitative analysis of VASP phosphorylation during coincubations of human endothelial cells and human platelets. Endothelial cell-derived factors caused the rapid, stoichiometric, and reversible phosphorylation of platelet VASP during these coincubations. Other experiments indicated that the endothelium-derived factors which stimulate VASP phosphorylation are prostacyclin and endothelium-derived relaxing factor whose effects are mediated by cAMP/cAMP-dependent protein kinase and cGMP/cGMP-dependent protein kinase, respectively. The results suggest that VASP phosphorylation is an important component of the inhibitory effects of prostacyclin and endothelium-derived relaxing factor on platelet activation and that VASP phosphorylation is a useful biochemical marker for the interaction of endothelial cells and platelets.	UNIV WURZBURG, MED KLIN, KLIN FORSCHERGRP, JOSEF SCHNEIDER STR 2, W-8700 WURZBURG, GERMANY	University of Wurzburg			Walter, ulrich/W-2478-2017	Walter, ulrich/0000-0001-6784-2307				ALHEID U, 1989, EUR J PHARMACOL, V164, P103, DOI 10.1016/0014-2999(89)90236-7; DENUCCI G, 1988, P NATL ACAD SCI USA, V85, P2334; FURCHGOTT RF, 1984, ANNU REV PHARMACOL, V24, P175, DOI 10.1146/annurev.pa.24.040184.001135; FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; GERSHLICK A H, 1990, Circulation, V81, pI28; GRYGLEWSKI RJ, 1988, HYPERTENSION, V12, P530, DOI 10.1161/01.HYP.12.6.530; HALBRUGGE M, 1989, EUR J BIOCHEM, V185, P41, DOI 10.1111/j.1432-1033.1989.tb15079.x; HALBRUGGE M, 1990, J BIOL CHEM, V265, P3088; HAWKINS DJ, 1988, BIOCHIM BIOPHYS ACTA, V969, P289, DOI 10.1016/0167-4889(88)90064-X; HOGAN JC, 1988, BRIT J PHARMACOL, V94, P1020, DOI 10.1111/j.1476-5381.1988.tb11616.x; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; ISHII K, 1990, EUR J PHARMACOL, V176, P219; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JAFFE EA, 1987, J BIOL CHEM, V262, P8557; MARTIN W, 1985, J PHARMACOL EXP THER, V232, P708; MAYER B, 1989, BIOCHEM BIOPH RES CO, V164, P678, DOI 10.1016/0006-291X(89)91513-1; MONCADA S, 1989, BIOCHEM PHARMACOL, V38, P1709, DOI 10.1016/0006-2952(89)90403-6; MUSTARD J F, 1990, Circulation, V81, pI24; POHL U, 1989, CIRC RES, V65, P1798, DOI 10.1161/01.RES.65.6.1798; RADOMSKI MW, 1987, BRIT J PHARMACOL, V92, P639, DOI 10.1111/j.1476-5381.1987.tb11367.x; REES DD, 1988, EUR J PHARMACOL, V150, P149, DOI 10.1016/0014-2999(88)90761-3; REES DD, 1989, BRIT J PHARMACOL, V96, P418, DOI 10.1111/j.1476-5381.1989.tb11833.x; VANE JR, 1990, NEW ENGL J MED, V323, P27; WALDMANN R, 1989, EUR J PHARMACOL, V159, P317, DOI 10.1016/0014-2999(89)90165-9; WALDMANN R, 1987, EUR J BIOCHEM, V167, P441, DOI 10.1111/j.1432-1033.1987.tb13357.x; Walter U, 1989, REV PHYSL BIOCH PHAR, V113, P41	26	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14808	14812						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1650367				2022-12-25	WOS:A1991FZ35100105
J	HAHNER, L; MCQUILKIN, S; HARRIS, RA				HAHNER, L; MCQUILKIN, S; HARRIS, RA			CEREBELLAR GABA-B RECEPTORS MODULATE FUNCTION OF GABA-A RECEPTORS	FASEB JOURNAL			English	Note						GABA-A RECEPTORS; GABA-B RECEPTORS; CHLORIDE CHANNELS; CEREBELLUM; GUANINE NUCLEOTIDES; PROTEIN PHOSPHORYLATION; PROTEIN KINASE-C; PHOSPHOLIPASE-C	PROTEIN-KINASE-C; INOSITOL PHOSPHATE FORMATION; AMINOBUTYRIC ACID RECEPTORS; CENTRAL-NERVOUS-SYSTEM; RAT CEREBRAL-CORTEX; SYNAPTIC POTENTIALS; CHLORIDE EXCHANGE; FLUX MEASUREMENTS; BRAIN MEMBRANES; SPINAL-CORD	Interactions between GABA(A) and GABA(B) receptors were studied using muscimol-stimulated uptake of Cl-36- by membrane vesicles from mouse cerebellum. Baclofen inhibited muscimol-stimulated Cl-36- uptake and this action was more pronounced with longer flux times (30 vs. 3 s) and after predesensitization of GABA(A) receptors. Baclofen also inhibited Cl-36- flux by cortical membranes but was more effective with cerebellar preparations. The action of baclofen was stereoselective, calcium-dependent, and blocked by the GABA(B) receptor antagonist 2-OH-saclofen. It was mimicked by GTP-gamma-S but not by GDP-beta-S, which suggests that baclofen may be acting via a G protein. The action of baclofen was inhibited by U73122, an inhibitor of phospholipase C. However, the potassium channel blockers tetraethylammonium or Ba2+ did not affect the action of baclofen. The results show that activation of GABA(B) receptors can inhibit the function of GABA(A) receptors and suggest that this action involves either a nondesensitizing subtype of GABA(A) receptor or the rate of recycling of desensitized to nondesensitized receptors. We speculate that this action of baclofen results from activation of phospholipase C and phosphorylation of a subtype of GABA(A) receptor by protein kinase C.	UNIV COLORADO,HLTH SCI CTR,DEPT PHARMACOL,CAMPUS BOX C-236,4200 E 9TH AVE,DENVER,CO 80262; VET ADM MED CTR,DENVER,CO 80220	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NIAAA NIH HHS [AA03527, AA06399] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA006399, P50AA003527, R37AA006399] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		AGEY MW, 1989, BIOCHEMISTRY-US, V28, P4200, DOI 10.1021/bi00436a012; ALLAN AM, 1989, LIFE SCI, V45, P1771, DOI 10.1016/0024-3205(89)90516-X; ALLAN AM, 1991, IN PRESS ALCOHOLISM; BLEASDALE JE, 1990, J PHARMACOL EXP THER, V255, P756; BOWERY N, 1989, TRENDS PHARMACOL SCI, V10, P401, DOI 10.1016/0165-6147(89)90188-0; BROWNING MD, 1990, P NATL ACAD SCI USA, V87, P1315, DOI 10.1073/pnas.87.4.1315; CASH DJ, 1987, BIOCHEMISTRY-US, V26, P7556, DOI 10.1021/bi00398a004; CASH DJ, 1989, J MEMBRANE BIOL, V111, P229, DOI 10.1007/BF01871008; CASTRO E, 1989, J NEUROSCI RES, V23, P290, DOI 10.1002/jnr.490230307; CRAWFORD MLA, 1988, J NEUROCHEM, V51, P1441, DOI 10.1111/j.1471-4159.1988.tb01109.x; CRAWFORD MLA, 1990, BRIT J PHARMACOL, V100, P867, DOI 10.1111/j.1476-5381.1990.tb14106.x; DESARMENIEN M, 1984, BRIT J PHARMACOL, V81, P327, DOI 10.1111/j.1476-5381.1984.tb10082.x; DINGLEDINE R, 1985, J PHYSIOL-LONDON, V366, P387, DOI 10.1113/jphysiol.1985.sp015804; DOLPHIN AC, 1989, BRIT J PHARMACOL, V97, P263, DOI 10.1111/j.1476-5381.1989.tb11950.x; DUTAR P, 1988, NATURE, V332, P156, DOI 10.1038/332156a0; FALCH E, 1982, J NEUROCHEM, V38, P1123, DOI 10.1111/j.1471-4159.1982.tb05357.x; GALLAGHER JP, 1989, J PHYSIOL-LONDON, V418, P367, DOI 10.1113/jphysiol.1989.sp017846; GODFREY PP, 1988, EUR J PHARMACOL, V152, P185, DOI 10.1016/0014-2999(88)90854-0; HARRIS RA, 1985, SCIENCE, V228, P1108, DOI 10.1126/science.2581319; HARRISON NL, 1990, J PHYSIOL-LONDON, V422, P433, DOI 10.1113/jphysiol.1990.sp017993; HARRISON NL, 1988, NEUROSCI LETT, V85, P105, DOI 10.1016/0304-3940(88)90437-5; HOWE JR, 1987, J PHYSIOL-LONDON, V384, P539, DOI 10.1113/jphysiol.1987.sp016469; KAMATCHI GL, 1990, MOL PHARMACOL, V38, P342; KARDOS J, 1990, J NEUROCHEM, V55, P1095, DOI 10.1111/j.1471-4159.1990.tb03110.x; KARDOS J, 1989, BIOCHEM PHARMACOL, V38, P2587, DOI 10.1016/0006-2952(89)90542-X; KERR DIB, 1988, NEUROSCI LETT, V92, P92, DOI 10.1016/0304-3940(88)90748-3; LAI Y, 1986, P NATL ACAD SCI USA, V83, P4253, DOI 10.1073/pnas.83.12.4253; LEIDENHEIMER NJ, 1990, MOL PHARMACOL, V38, P823; LI XH, 1990, NEUROCHEM RES, V15, P725, DOI 10.1007/BF00973654; MEHTA AK, 1990, EUR J PHARMACOL, V182, P473, DOI 10.1016/0014-2999(90)90044-7; NISHIO M, 1990, BRAIN RES, V518, P283, DOI 10.1016/0006-8993(90)90982-H; OLSEN RW, 1978, BRAIN RES, V139, P277, DOI 10.1016/0006-8993(78)90929-0; OLSEN RW, 1990, FASEB J, V4, P1469, DOI 10.1096/fasebj.4.5.2155149; OLSEN RW, 1990, J CHEM NEUROANAT, V3, P59; PRICE GW, 1984, NATURE, V307, P71, DOI 10.1038/307071a0; SIGEL E, 1988, P NATL ACAD SCI USA, V85, P6192, DOI 10.1073/pnas.85.16.6192; WHITING P, 1990, P NATL ACAD SCI USA, V87, P9966, DOI 10.1073/pnas.87.24.9966; YASUI S, 1985, BRAIN RES, V344, P176, DOI 10.1016/0006-8993(85)91206-5	38	43	44	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1991	5	10					2466	2472		10.1096/fasebj.5.10.1648524	http://dx.doi.org/10.1096/fasebj.5.10.1648524			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FW087	1648524				2022-12-25	WOS:A1991FW08700018
J	KANALAS, JJ; MAKKER, SP				KANALAS, JJ; MAKKER, SP			IDENTIFICATION OF THE RAT HEYMANN NEPHRITIS AUTOANTIGEN (GP330) AS A RECEPTOR-SITE FOR PLASMINOGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UROKINASE RECEPTORS; BINDING; ACTIVATOR; ANTIGEN; LIGAND; SYSTEM; THROMBOSPONDIN; GLYCOPROTEIN; DEGRADATION; COMPONENTS	Previous results have demonstrated the binding of a 76- and 80-kDa serum protein to the Heymann nephritis autoantigen, gp330. This 76-kDa serum protein was purified by column chromatography and preparative sodium dodecyl sulfate-polyacrylamide gel electrophoresis. A rabbit polyclonal antibody for the serum protein was produced and used to screen a rat liver cDNA expression library. Sequence analysis of an isolated clone identified the serum protein as plasminogen. Plasminogen was isolated from rat serum by standard techniques, and the binding of plasminogen to gp330 was confirmed by Western analysis. Enzyme-linked immunosorbent assay results demonstrated a time-dependent, saturable, and specifically inhibitable binding of plasminogen to gp330. There was no significant difference in the binding of the two carbohydrate forms of plasminogen to gp330. Plasminogen binding to gp330 could be completely inhibited by the addition of exogenous gp330. This binding could also be partially inhibited by benzamidine but only slightly by the lysine analogue, epsilon-aminocaproic acid. However, even a combination of these two inhibitors could not completely block the binding of plasminogen to gp330 indicating that gp330 may be binding to plasminogen through some other unknown interactions. These results demonstrate that gp330 is a receptor site for plasminogen.			KANALAS, JJ (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT PEDIAT,SAN ANTONIO,TX 78284, USA.				NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM033941] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK040189] Funding Source: NIH RePORTER; NIADDK NIH HHS [R01-AM 33941] Funding Source: Medline; NIDDK NIH HHS [R29-DK 40189] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALOUSI MA, 1969, AM J PATHOL, V54, P47; ARROYAVE CM, 1973, J IMMUNOL, V111, P536; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; CASTELLINO FJ, 1981, METHOD ENZYMOL, V80, P365; DEPOLI P, 1989, BLOOD, V73, P976; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; FORSGREN M, 1987, FEBS LETT, V213, P254, DOI 10.1016/0014-5793(87)81501-6; GAVRILOVIC J, 1989, CELL BIOL INT REP, V13, P367, DOI 10.1016/0309-1651(89)90163-X; GONIAS SL, 1989, BLOOD, V74, P729; HALL SW, 1989, BRAIN RES, V495, P373, DOI 10.1016/0006-8993(89)90231-X; HAMILTON KK, 1985, J CLIN INVEST, V76, P261, DOI 10.1172/JCI111956; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; KANALAS JJ, 1988, J IMMUNOL, V141, P4152; KERJASCHKI D, 1983, J EXP MED, V157, P667, DOI 10.1084/jem.157.2.667; KERJASCHKI D, 1982, P NATL ACAD SCI-BIOL, V79, P5557, DOI 10.1073/pnas.79.18.5557; KNUDSEN KA, 1985, ANAL BIOCHEM, V147, P285, DOI 10.1016/0003-2697(85)90273-8; KOTTGEN E, 1982, FRESEN Z ANAL CHEM, V311, P460, DOI 10.1007/BF00481826; LAWLER JW, 1981, THROMB RES, V22, P267, DOI 10.1016/0049-3848(81)90119-5; LIOTTA LA, 1981, CANCER RES, V41, P4629; MAKKER SP, 1984, LAB INVEST, V50, P287; MANGEL WF, 1990, SCIENCE, V248, P69, DOI 10.1126/science.2108500; MARKUS G, 1978, J BIOL CHEM, V253, P727; MCKAY DG, 1972, AM J PATHOL, V67, P181; MILES LA, 1988, BLOOD, V72, P628; MOONEN G, 1982, NATURE, V298, P753, DOI 10.1038/298753a0; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PLOW EF, 1986, J CELL BIOL, V103, P2411, DOI 10.1083/jcb.103.6.2411; RATNOFF OD, 1967, J EXP MED, V125, P337, DOI 10.1084/jem.125.2.337; SIEFRING GE, 1974, J BIOL CHEM, V249, P1434; STRICKLAND S, 1976, CELL, V9, P231, DOI 10.1016/0092-8674(76)90114-8; THEWES T, 1990, J BIOL CHEM, V265, P3906; VARADI A, 1981, BIOCHEM BIOPH RES CO, V103, P97, DOI 10.1016/0006-291X(81)91665-X; WILSON EL, 1978, INT J CANCER, V22, P390, DOI 10.1002/ijc.2910220405	33	121	123	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					10825	10829						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	1645711				2022-12-25	WOS:A1991FQ77400022
J	LABRAKE, CC; FUNG, LWM				LABRAKE, CC; FUNG, LWM			PHOSPHOLIPID-VESICLES PROMOTE HUMAN HEMOGLOBIN OXIDATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-CELL MEMBRANE; LIPID-PEROXIDATION; PHOSPHATIDYLSERINE VESICLES; ERYTHROCYTE-MEMBRANE; SUPEROXIDE-DISMUTASE; AUTOXIDATION; MECHANISM; LIPOSOMES; HEME; FUSION	We have studied the heme oxidation kinetics of purified human hemoglobin (Hb) in the presence of lipid vesicles of dipalmitoyl phosphatidylcholine and bovine brain phosphatidylserine that exhibited minimal lipid peroxidation. We showed that the lipid vesicles enhanced Hb oxidation and that small unilamellar vesicles (SUVs) exerted a larger effect than large unilamellar vesicles (LUVs). We have determined pseudo first-order rate constants for the initial disappearance of oxygenated ferrous Hb (k0) and for the initial formation of several ferric Hb species (methemoglobin, hemichrome, and choleglobin) in the presence of SUVs and LUVs. k0 and other rate constants depended linearly on lipid-to-hemoglobin molar ratio (lipid/Hb), with k0SUV (h-1) = k0auto (h-1) + 3.7 x 10(-3) x lipid/Hb, and k0LUV (h-1) = k0auto (h-1) + 0.2 x 10(-3) x lipid/Hb, where k0auto is the rate constant for Hb autoxidation in the absence of vesicles. Thus, in the absence of lipid peroxidation products, lipid vesicles themselves promote Hb oxidation by enhancing the rate of Hb oxidation. The enhanced oxidation was inhibited by catalase, but not by butylated hydroxytoluene. The rate constants were independent of Hb concentration, in the range of about 3.1 to 100-mu-M. We suggest that the lipid surface properties, including surface curvature, surface energy, and hydrophobicity, promote hemoglobin oxidation.	LOYOLA UNIV, DEPT CHEM, 6525 N SHERIDAN RD, CHICAGO, IL 60626 USA	Loyola University Chicago					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038361, S15HL041756] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALMOG R, 1991, CHEM PHYS LIPIDS, V60, P93, DOI 10.1016/0009-3084(91)90031-6; ANTONINI E, 1971, HEMOGLOBIN MYOGLOBIN, P18; Aust SD, 1985, CRC HDB METHODS OXYG, P203; BENESCH RE, 1990, J BIOL CHEM, V265, P14881; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRANDL M, 1989, DRUG DEV IND PHARM, V15, P655, DOI 10.3109/03639048909058524; Buege J A, 1978, Methods Enzymol, V52, P302; CALISSANO P, 1972, BIOCHIM BIOPHYS ACTA, V255, P1009, DOI 10.1016/0005-2736(72)90414-2; CANNON JB, 1984, BIOCHEMISTRY-US, V23, P3715, DOI 10.1021/bi00311a022; CAUGHEY WS, 1985, HDB METHODS OXYGEN R, P95; CHIESI M, 1980, BIOCHEMISTRY-US, V19, P2912, DOI 10.1021/bi00554a015; Claiborne A., 1985, CRC HDB METHODS OXYG, P283; CULLIS PR, 1985, BIOCH LIPIDS MEMBRAN, P25; DAS SK, 1980, BRIT J HAEMATOL, V44, P87, DOI 10.1111/j.1365-2141.1980.tb01186.x; DEISSEROTH A, 1970, PHYSIOL REV, V50, P319, DOI 10.1152/physrev.1970.50.3.319; DUNN MF, 1980, BIOCHEMISTRY-US, V19, P718, DOI 10.1021/bi00545a017; DUZGUNES N, 1988, SPECTROSCOPIC MEMBRA; Fridovich I, 1985, CRC HDB METHODS OXYG, P213; FUNG LWM, 1981, BIOCHEMISTRY-US, V20, P7162, DOI 10.1021/bi00528a017; GRAY A, 1991, BLOOD REV, V5, P258, DOI 10.1016/0268-960X(91)90017-7; GUTTERIDGE JMC, 1990, TRENDS BIOCHEM SCI, V15, P129, DOI 10.1016/0968-0004(90)90206-Q; HEBBEL RP, 1988, P NATL ACAD SCI USA, V85, P237, DOI 10.1073/pnas.85.1.237; ITABE H, 1988, BIOCHIM BIOPHYS ACTA, V961, P13; KAUL RK, 1983, KLIN WOCHENSCHR, V61, P831, DOI 10.1007/BF01537457; KAWANISHI S, 1985, J BIOL CHEM, V260, P4622; KIKUGAWA K, 1981, CHEM PHARM BULL, V29, P1382; KIMELBERG HK, 1976, MOL CELL BIOCHEM, V10, P171, DOI 10.1007/BF01731688; KLEIN RA, 1970, BIOCHIM BIOPHYS ACTA, V210, P486, DOI 10.1016/0005-2736(70)90231-2; LIGHT WR, 1990, J BIOL CHEM, V265, P15623; LIGLER FS, 1989, RED CELL, P435; LILLEY GL, 1987, LIFE SCI, V41, P2429, DOI 10.1016/0024-3205(87)90668-0; LORIMER JP, 1987, CHEM SOC REV, V16, P239, DOI 10.1039/cs9871600239; LOUGHREY HC, 1990, BIOCHIM BIOPHYS ACTA, V1028, P73, DOI 10.1016/0005-2736(90)90267-R; MACDONALD RC, 1988, J BIOL CHEM, V263, P10052; MACDONALD RC, 1990, HEPATOLOGY, V4, P1; MACDONALD RC, 1988, MOL MECHANISMS MEMBR, P101; MACDONALD VW, 1982, BIOCHIM BIOPHYS ACTA, V701, P39, DOI 10.1016/0167-4838(82)90309-0; MANSOURI A, 1974, BIOCHEMISTRY-US, V13, P3311, DOI 10.1021/bi00713a021; MARINETTI GV, 1978, J SUPRAMOL STR CELL, V8, P191, DOI 10.1002/jss.400080208; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; MISRA HP, 1972, J BIOL CHEM, V247, P6960; MORRISON GR, 1965, ANAL CHEM, V37, P1124, DOI 10.1021/ac60228a014; OHKI S, 1986, BIOCHIM BIOPHYS ACTA, V861, P177, DOI 10.1016/0005-2736(86)90577-8; OHKI S, 1984, J MEMBRANE BIOL, V77, P265, DOI 10.1007/BF01870574; PAPAHADJOPOULOS D, 1973, Biochimica et Biophysica Acta, V330, P8, DOI 10.1016/0005-2736(73)90280-0; PROTTER MH, 1970, COLLEGE CALCULUS ANA; RABINOVICI R, 1990, CIRC SHOCK, V32, P1; RAUENBUEHLER PB, 1982, BIOCHIM BIOPHYS ACTA, V692, P361, DOI 10.1016/0005-2736(82)90385-6; Riggs A., 1981, Methods in Enzymology, V76, P5; ROSE MY, 1985, J BIOL CHEM, V260, P6632; SADRZADEH SMH, 1984, J BIOL CHEM, V259, P4354; SCHERPHOF G, 1979, BIOCHIM BIOPHYS ACTA, V556, P196, DOI 10.1016/0005-2736(79)90042-7; SHAKLAI N, 1985, BIOCHIM BIOPHYS ACTA, V821, P355, DOI 10.1016/0005-2736(85)90106-3; SHIKAMA K, 1990, BIOL REV, V65, P517, DOI 10.1111/j.1469-185X.1990.tb01236.x; SHIKAMA K, 1984, BIOCHEM J, V223, P279, DOI 10.1042/bj2230279; SHVIRO Y, 1982, BIOCHIM BIOPHYS ACTA, V687, P63, DOI 10.1016/0005-2736(82)90170-5; STEWART JCM, 1980, ANAL BIOCHEM, V104, P10, DOI 10.1016/0003-2697(80)90269-9; SUBBARAO NK, 1991, BIOCHIM BIOPHYS ACTA, V1063, P147, DOI 10.1016/0005-2736(91)90364-E; SZEBENI J, 1988, BIOCHEMISTRY-US, V27, P6425, DOI 10.1021/bi00417a034; SZEBENI J, 1985, BIOCHEMISTRY-US, V24, P2827, DOI 10.1021/bi00333a003; SZEBENI J, 1986, BIOCHIM BIOPHYS ACTA, V857, P139, DOI 10.1016/0005-2736(86)90341-X; SZEBENI J, 1984, BIOCHEM J, V220, P685, DOI 10.1042/bj2200685; SZOKA FC, 1987, CELL FUSION; SZUNDI I, 1980, BIOCHIM BIOPHYS ACTA, V595, P41, DOI 10.1016/0005-2736(80)90245-X; TITOV VY, 1991, B EXP BIOL MED+, V112, P957, DOI 10.1007/BF00841142; VANDENBERG JJM, 1988, BIOCHIM BIOPHYS ACTA, V944, P29, DOI 10.1016/0005-2736(88)90313-6; WALDER JA, 1984, J BIOL CHEM, V259, P238; WALLACE WJ, 1982, J BIOL CHEM, V257, P4966; WALLACE WJ, 1974, FEBS LETT, V43, P33, DOI 10.1016/0014-5793(74)81099-9; WATKINS JA, 1985, BIOCHEM BIOPH RES CO, V132, P742, DOI 10.1016/0006-291X(85)91195-7; WAYS P, 1964, J LIPID RES, V5, P318; WEISS JJ, 1964, NATURE, V202, P83, DOI 10.1038/202083b0; WILSCHUT J, 1981, BIOCHEMISTRY-US, V20, P3126, DOI 10.1021/bi00514a022; WINTERBOURN CC, 1985, ENVIRON HEALTH PERSP, V64, P321, DOI 10.2307/3430020; WINTERBOURN CC, 1975, J LAB CLIN MED, V85, P337; WINTERBOURN CC, 1985, HDB METHODS OXYGEN R, P137; YAMAMOTO Y, 1985, BIOCHIM BIOPHYS ACTA, V819, P29, DOI 10.1016/0005-2736(85)90192-0; ZHANG L, 1991, J BIOL CHEM, V266, P24698	78	24	24	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16703	16711						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1644843				2022-12-25	WOS:A1992JJ45800108
J	HSIEH, CL; MCCLOSKEY, RP; LIEBER, MR				HSIEH, CL; MCCLOSKEY, RP; LIEBER, MR			V(D)J RECOMBINATION ON MINICHROMOSOMES IS NOT AFFECTED BY TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNASE-I SENSITIVITY; IMMUNOGLOBULIN GENES; REARRANGEMENT; CELLS; FRAGMENTS; CHROMATIN; SEQUENCE; REGION; RNA	It has been shown previously by others that transcription is temporally correlated with the onset of V(D)J recombination at the endogenous antigen receptor loci. We have been interested in determining whether this temporal correlation indicates a causal connection between these two processes. We have compared V(D)J recombination minichromosome substrates that have transcripts running through the recombination zone with substrates that do not in a transient transfection assay. In this system, the substrates acquire a minichromosome conformation within the first several hours after transfection. We find that the substrates recombine equally well over a 100-fold range in transcriptional variation. In additional studies, we have taken substrates that have low levels of transcription and inhibited transcription further by methylating the substrate DNA or by treating the cells with a general transcription inhibitor (alpha-amanitin). Although these treatments decrease the level of expression an additional 10-100-fold, there is still no observable effect on V(D)J recombination. Based on these results, we conclude that transcription is not necessary for the V(D)J reaction mechanism and does not alter substrate structure at the DNA level or at the simplest levels of chromatin structure in a way that affects the reaction.	STANFORD UNIV,MED CTR,SCH MED,DEPT PATHOL,EXPTL ONCOL LAB,STANFORD,CA 94305	Stanford University				Lieber, Michael/0000-0001-8809-0909; Lieber, Michael/0000-0003-3700-6345	NIAID NIH HHS [5T32 AI 07290-07] Funding Source: Medline; NIGMS NIH HHS [GM43236] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007290] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACHESON NH, 1978, P NATL ACAD SCI USA, V75, P4754, DOI 10.1073/pnas.75.10.4754; ALT FW, 1987, SCIENCE, V238, P1079, DOI 10.1126/science.3317825; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ENGLER P, 1991, J IMMUNOL, V146, P2826; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERRIER P, 1990, EMBO J, V9, P117, DOI 10.1002/j.1460-2075.1990.tb08087.x; Ferrier P, 1989, INT IMMUNOL, V1, P66, DOI 10.1093/intimm/1.1.66; HESSE JE, 1987, CELL, V49, P775, DOI 10.1016/0092-8674(87)90615-5; HSIEH CL, 1992, EMBO J, V11, P315, DOI 10.1002/j.1460-2075.1992.tb05054.x; HSIEH CL, 1991, MOL CELL BIOL, V11, P3972, DOI 10.1128/MCB.11.8.3972; KESHET I, 1986, CELL, V44, P535, DOI 10.1016/0092-8674(86)90263-1; LIEBER MR, 1987, GENE DEV, V1, P751, DOI 10.1101/gad.1.8.751; MATHER EL, 1983, P NATL ACAD SCI-BIOL, V80, P4689, DOI 10.1073/pnas.80.15.4689; MCGHEE JD, 1981, CELL, V27, P45, DOI 10.1016/0092-8674(81)90359-7; MINIE ME, 1985, MOL CELL BIOL, V6, P4031; PERSIANI DM, 1989, NUCLEIC ACIDS RES, V17, P5339, DOI 10.1093/nar/17.13.5339; SARAGOSTI S, 1980, CELL, V20, P65, DOI 10.1016/0092-8674(80)90235-4; SATO K, 1986, MOL CELL BIOL, V6, P1032, DOI 10.1128/MCB.6.4.1032; SCHLISSEL M, 1991, GENE DEV, V5, P1367, DOI 10.1101/gad.5.8.1367; SCHLISSEL MS, 1991, J EXP MED, V173, P711, DOI 10.1084/jem.173.3.711; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STORB U, 1983, P NATL ACAD SCI-BIOL, V80, P6642, DOI 10.1073/pnas.80.21.6642; STORB U, 1981, BIOCHEMISTRY-US, V20, P990, DOI 10.1021/bi00507a053	24	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15613	15619						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1639801				2022-12-25	WOS:A1992JG11300057
J	NIEHRS, C; HUTTNER, WB; RUTHER, U				NIEHRS, C; HUTTNER, WB; RUTHER, U			INVIVO EXPRESSION AND STOICHIOMETRIC SULFATION OF THE ARTIFICIAL PROTEIN SULFOPHILIN, A POLYMER OF TYROSINE SULFATION SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSYLPROTEIN SULFOTRANSFERASE; SECRETOGRANIN-II; SUBSTRATE; SEQUENCES; PEPTIDES	To gain insight into the structural requirements for tyrosine sulfation in vivo, we have constructed and expressed an artificial gene encoding a polypeptide substrate for tyrosylprotein sulfotransferase. This gene codes for a protein, referred to as sulfophilin, which consists of a 12-times repeated heptapeptide unit corresponding to the identified tyrosine sulfation site of chromogranin B (secretogranin I), Glu-Glu-Pro-Glu-Tyr-Gly-Glu. The gene was fused to the signal sequence of secretogranin II to direct the sulfophilin protein to the secretory pathway. Stable expression of the artificial gene in NIH 3T3 cells resulted in the secretion of sulfated sulfophilin. Analysis of the stoichiometry of sulfation revealed that each of the 12 tyrosyl residues in sulfophilin was sulfated. Remarkably, up to 50% of the total protein-bound tyrosine sulfate secreted by the cells was contained in sulfophilin. The results indicate that the structural information contained in the heptapeptide motif is sufficient for stoichiometric tyrosine sulfation to occur in the living cell.	UNIV HEIDELBERG,INST NEUROBIOL,NEUENHEIMER FELD 364,W-6900 HEIDELBERG,GERMANY; EUROPEAN MOLEC BIOL LAB,CELL BIOL PROGRAMME,W-6900 HEIDELBERG,GERMANY; EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAMME,W-6900 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg; European Molecular Biology Laboratory (EMBL); European Molecular Biology Laboratory (EMBL)			Huttner, Wieland B./P-4080-2018					ANSORGE W, 1989, J BIOCHEM BIOPH METH, V20, P47, DOI 10.1016/0165-022X(89)90080-8; BAEUERLE PA, 1985, J BIOL CHEM, V260, P6434; BENEDUM UM, 1987, EMBO J, V6, P1203, DOI 10.1002/j.1460-2075.1987.tb02355.x; GERDES HH, 1989, J BIOL CHEM, V264, P12009; GERDES HH, 1988, NUCLEIC ACIDS RES, V16, P11811, DOI 10.1093/nar/16.24.11811; HAEUPTLE MT, 1986, NUCLEIC ACIDS RES, V14, P1427, DOI 10.1093/nar/14.3.1427; HILLE A, 1990, EUR J BIOCHEM, V188, P577, DOI 10.1111/j.1432-1033.1990.tb15438.x; HORTIN G, 1986, BIOCHEM BIOPH RES CO, V141, P326, DOI 10.1016/S0006-291X(86)80372-2; HUTTNER W, 1991, Current Biology, V1, P309, DOI 10.1016/0960-9822(91)90094-D; HUTTNER WB, 1984, METHOD ENZYMOL, V107, P200; HUTTNER WB, 1988, ANNU REV PHYSIOL, V50, P363, DOI 10.1146/annurev.ph.50.030188.002051; Huttner WB, 1988, MODERN CELL BIOL, V6, P97; LEE RWH, 1985, P NATL ACAD SCI USA, V82, P6143, DOI 10.1073/pnas.82.18.6143; LEYTE A, 1991, J BIOL CHEM, V266, P740; LIPP J, 1986, CELL, V46, P1103, DOI 10.1016/0092-8674(86)90710-5; NIEHRS C, 1992, EUR J CELL BIOL, V58, P35; NIEHRS C, 1990, EMBO J, V9, P35, DOI 10.1002/j.1460-2075.1990.tb08077.x; NIEHRS C, 1990, J BIOL CHEM, V265, P8525; NIEHRS C, 1990, J BIOL CHEM, V265, P9314; RENSDOMIANO S, 1989, MOL PHARMACOL, V36, P647; STUEBER D, 1984, EMBO J, V3, P3143, DOI 10.1002/j.1460-2075.1984.tb02271.x; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; VARGAS F, 1985, BIOCHEMISTRY-US, V24, P5938, DOI 10.1021/bi00342a037	23	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15938	15942						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1639821				2022-12-25	WOS:A1992JG11300101
J	MCMASTER, CR; CHOY, PC				MCMASTER, CR; CHOY, PC			SERINE REGULATES PHOSPHATIDYLETHANOLAMINE BIOSYNTHESIS IN THE HAMSTER HEART	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACIDS; RAT-LIVER; PHOSPHATIDYLCHOLINE; ETHANOLAMINE; ENZYMES; CELLS; PURIFICATION; PATHWAYS	The role of serine as a precursor and metabolic regulator for phosphatidylethanolamine biosynthesis in the hamster heart was investigated. Hearts were perfused with 50-mu-M [1-H-3]ethanolamine in the presence or absence of serine for up to 60 min. Ethanolamine uptake was attenuated by 0.05-10 mM serine in a noncompetitive manner, and the incorporation of labeled ethanolamine into phosphatidylethanolamine was also inhibited by serine. Analysis of the ethanolamine-containing metabolites in the CDP-ethanolamine pathway revealed that the conversion of ethanolamine to phosphoethanolamine was reduced. The reduction was a result of an inhibition of ethanolamine kinase activity by an elevated pool of intracellular serine. Perfusion of the heart with 1 mM serine caused a 5-fold increase in intracellular serine pool. In order to examine the action of serine on other phosphatidylethanolamine metabolic pathways, hearts were perfused with [1-H-3]glycerol in the presence and absence of serine. Serine did not cause any enhancement of phosphatidylethanolamine hydrolysis. The base-exchange reaction for phosphatidylserine formation or the decarboxylation of phosphatidylserine was not affected by serine perfusion. We conclude that circulating serine plays an important role in the modulation of phosphatidylethanolamine biosynthesis via the CDP-ethanolamine pathway in the hamster heart but does not affect the contribution of the decarboxylase pathway for phosphatidylethanolamine formation.	UNIV MANITOBA,FAC MED,DEPT BIOCHEM & MOLEC BIOL,770 BANNATYNE AVE,WINNIPEG R3E 0W3,MANITOBA,CANADA	University of Manitoba				McMaster, Christopher/0000-0003-0822-5776				ARTHUR G, 1991, BIOCHEM J, V273, P121, DOI 10.1042/bj2730121; BABA S, 1984, CLIN CHIM ACTA, V136, P49, DOI 10.1016/0009-8981(84)90246-8; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; CAO YZ, 1987, J BIOL CHEM, V262, P16927; EXTON JH, 1990, J BIOL CHEM, V265, P1; HEINRIKSON RL, 1984, ANAL BIOCHEM, V136, P65, DOI 10.1016/0003-2697(84)90307-5; KATZ AM, 1982, AM HEART J, V102, P491; KUGE O, 1986, J BIOL CHEM, V261, P5795; LIPTON BA, 1990, J BIOL CHEM, V265, P7195; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAN RYK, 1982, J MOL CELL CARDIOL, V14, P173, DOI 10.1016/0022-2828(82)90115-8; MCMASTER CR, 1992, IN PRESS BIOCH BIOPH; MILAKOFSKY L, 1985, LIFE SCI, V36, P753, DOI 10.1016/0024-3205(85)90195-X; MILLER MA, 1986, J BIOL CHEM, V261, P9753; O KM, 1989, BIOCHEM CELL BIOL, V67, P680; PERRY TL, 1975, J NEUROCHEM, V24, P587, DOI 10.1111/j.1471-4159.1975.tb07680.x; SAMUELSSON B, 1989, J BIOL CHEM, V264, P19469; SCHNEIDER WJ, 1978, EUR J BIOCHEM, V85, P181, DOI 10.1111/j.1432-1033.1978.tb12226.x; SIMELL O, 1989, METABOLIC BASIS INHE, P2497; SUNDLER R, 1975, J BIOL CHEM, V250, P8585; SUNDLER R, 1975, J BIOL CHEM, V250, P3359; SWEELEY CC, 1969, METHOD ENZYMOL, V14, P254; TALLAN HH, 1954, J BIOL CHEM, V211, P927; VANCE DE, 1985, BIOCH LIPIDS MEMBRAN, P242; VOELKER DR, 1984, P NATL ACAD SCI-BIOL, V81, P2669, DOI 10.1073/pnas.81.9.2669; WEINHOLD PA, 1974, BIOCHEMISTRY-US, V13, P5153; WESTALL RG, 1962, AMINO ACID POOLS, P195; XU ZL, 1991, J BIOL CHEM, V266, P2143; YOREK MA, 1985, J BIOL CHEM, V260, P2930; ZELINSKI TA, 1982, J BIOL CHEM, V257, P13201; ZELINSKI TA, 1982, CAN J BIOCHEM CELL B, V60, P817, DOI 10.1139/o82-102	32	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14586	14591						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634506				2022-12-25	WOS:A1992JF08800017
J	OSTEROP, APRM; MEDEMA, RH; BOS, JL; VONDERZON, GCM; MOLLER, DE; FLIER, JS; MOLLER, W; MAASSEN, JA				OSTEROP, APRM; MEDEMA, RH; BOS, JL; VONDERZON, GCM; MOLLER, DE; FLIER, JS; MOLLER, W; MAASSEN, JA			RELATION BETWEEN THE INSULIN-RECEPTOR NUMBER IN CELLS, AUTOPHOSPHORYLATION AND INSULIN-STIMULATED RAS-BULLET-GTP FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; PDGF BETA-RECEPTOR; GLUCOSE-TRANSPORT; SIGNAL TRANSDUCTION; MONOCLONAL-ANTIBODIES; PROTEIN; GAP; ONCOGENES; PHOSPHORYLATION; ACTIVATION	We showed previously that upon insulin stimulation of an insulin receptor overexpressing cell line, most of the p21ras was rapidly converted into the GTP bound state (Burgering, B. M. T., Medema, R. H., Maassen, J. A., Van de Wetering, M. L., Van der Eb, A. J., McCormick, F., and Bos, J. L. (1991) EMBO J. 10, 1103-1109). To determine whether this process also occurs in cells expressing physiologically relevant numbers of insulin receptors, insulin stimulated Ras . GTP formation was quantitated in Chinese hamster ovary (CHO)-derived cell lines expressing varying numbers of insulin receptors. In the parental CHO9 cells, expressing only 5.10(3) insulin receptors, insulin stimulation for 3 min increased Ras . GTP levels with 10%. Upon increasing the number of insulin receptors in these cells, Ras . GTP levels increased almost proportionally until a plateau value of 60% is reached at high receptor numbers. These data show that receptor overexpression is not a prerequisite for insulin-stimulated Ras . GTP formation. The yield of Ras . GTP generated is 0.2-1.0 mol/mol autophosphorylated insulin receptor in CHO9- and NIH3T3-derived cell lines, respectively. These values argue against signal-amplifying processes between the insulin receptor and p21ras. To determine whether receptor autophosphorylation is required for Ras . GTP formation, NIH3T3 cells overexpressing insulin receptors were stimulated with a monoclonal antibody which activates the receptor and subsequent glucose transport without inducing detectable autophosphorylation. Also, CHO cells expressing the mutant Ser1200 receptor, which has markedly impaired tyrosyl autophosphorylation but is capable of mediating insulin-stimulated metabolic effects in CHO cells, were used. In both cases, no Ras . GTP formation was observed. Furthermore, Rat-1-derived cell lines expressing mutant p21ras, which is permanently in the active GTP-bound form, still responded to insulin by increasing the glucose uptake. These results support our hypothesis that Ras . GTP formation is activated by the tyrosyl-phosphorylated insulin receptor and suggest that an active Ras . GTP complex does not mediate metabolic signaling.	SYLVIUS LAB,PROT SYNTH & HORMONE REGULAT LAB,WASSENAARSEWEG 72,2333 AL LEIDEN,NETHERLANDS; UNIV UTRECHT,PHYSIOL CHEM LAB,3521 GG UTRECHT,NETHERLANDS; BETH ISRAEL HOSP,DEPT MED,BOSTON,MA 02215	Leiden University; Leiden University - Excl LUMC; Utrecht University; Harvard University; Beth Israel Deaconess Medical Center			Flier, jeffrey/AAG-6223-2019	Medema, Rene/0000-0002-6754-0381				AKEDO H, 1962, J BIOL CHEM, V237, P118; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BLACKSHEAR PJ, 1991, J BIOL CHEM, V266, P10946; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRUMM AF, 1956, J BIOL CHEM, V220, P713; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; BURGERING BMT, 1989, MOL CELL BIOL, V9, P4312, DOI 10.1128/MCB.9.10.4312; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FLIER JS, 1987, SCIENCE, V235, P1492, DOI 10.1126/science.3103217; FORSAYETH JR, 1987, P NATL ACAD SCI USA, V84, P3448, DOI 10.1073/pnas.84.10.3448; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; LAWRENCE JC, 1978, J BIOL CHEM, V253, P2104; MAASSEN JA, 1988, EUR J BIOCHEM, V172, P725, DOI 10.1111/j.1432-1033.1988.tb13949.x; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MILLER DS, 1989, J BIOL CHEM, V264, P10438; MOLLER DE, 1991, J BIOL CHEM, V266, P10995; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; RIEDEL H, 1986, NATURE, V324, P68, DOI 10.1038/324068a0; SIMPSON IA, 1986, ANNU REV BIOCHEM, V55, P1059, DOI 10.1146/annurev.biochem.55.1.1059; STEELEPERKINS G, 1990, J BIOL CHEM, V265, P9458; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9	37	61	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14647	14653						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634512				2022-12-25	WOS:A1992JF08800026
J	WAHLBERG, J; ALBERT, J; LUNDEBERG, J; COX, S; WAHREN, B; UHLEN, M				WAHLBERG, J; ALBERT, J; LUNDEBERG, J; COX, S; WAHREN, B; UHLEN, M			DYNAMIC CHANGES IN HIV-1 QUASI-SPECIES FROM AZIDOTHYMIDINE (AZT)-TREATED PATIENTS	FASEB JOURNAL			English	Article						POLYMERASE CHAIN REACTION; HUMAN IMMUNODEFICIENCY VIRUS TYPE-1; AZIDOTHYMIDINE RESISTANCE; SOLID-PHASE DNA SEQUENCING	IMMUNODEFICIENCY-VIRUS TYPE-1; POLYMERASE CHAIN-REACTION; ZIDOVUDINE AZT; DNA; MUTATIONS; INVITRO	The emergence of azidothymidine (AZT)-resistant human immunodeficiency virus (HIV) variants in clinical samples was studied by a direct genomic sequencing method. Sequential lymphocyte samples from four patients, who had been treated with AZT for up to 27 months, were shown to gradually accumulate multiple nucleotide changes, some of which are known to be associated with AZT resistance. Several samples were shown to contain mixtures of wild-type and mutated genomes, indicating gradual rather than sudden changes in the HIV-1 quasispecies. These results demonstrate for the first time that automated solid-phase DNA sequencing is a rapid and useful tool for investigation of antiviral drug resistance and suggest that DNA sequencing may be important in routine clinical diagnostics in the future.	ROYAL INST TECHNOL,DEPT BIOCHEM & BIOTECHNOL,TEKNIKRINGEN 32,S-10044 STOCKHOLM 70,SWEDEN; NATL BACTERIOL LAB,DEPT VIROL,S-10521 STOCKHOLM,SWEDEN	Royal Institute of Technology			Uhlen, Mathias/B-3262-2016; Uhlen, Mathias/AAV-8746-2021	Uhlen, Mathias/0000-0002-4858-8056; 				ALBERT J, 1990, J CLIN MICROBIOL, V28, P1560, DOI 10.1128/JCM.28.7.1560-1564.1990; COX SW, 1992, IN PRESS AIDS RES HU; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FITZGIBBON JE, 1991, AIDS RES HUM RETROV, V7, P265, DOI 10.1089/aid.1991.7.265; GIBBS RA, 1989, P NATL ACAD SCI USA, V86, P1919, DOI 10.1073/pnas.86.6.1919; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HULTMAN T, 1991, BIOTECHNIQUES, V10, P84; HULTMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937, DOI 10.1093/nar/17.13.4937; INNIS MA, 1990, PCR PROTOCOLS; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1991, AIDS, V5, P137, DOI 10.1097/00002030-199102000-00002; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; MEYERHANS A, 1989, CELL, V58, P901, DOI 10.1016/0092-8674(89)90942-2; MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096; MYERS G, 1991, HUMAN RETROVIRUSES A; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; SUNDQVIST VA, 1989, J MED VIROL, V29, P170, DOI 10.1002/jmv.1890290305; SYVANEN AC, 1991, GENET ANAL-BIOMOL E, V8, P117, DOI 10.1016/1050-3862(91)90027-O; UHLEN M, 1992, TRENDS BIOTECHNOL, V10, P52, DOI 10.1016/0167-7799(92)90169-V; WAHLBERG J, 1990, P NATL ACAD SCI USA, V87, P6569, DOI 10.1073/pnas.87.17.6569; WAHLBERG J, 1991, AIDS RES HUM RETROV, V7, P983, DOI 10.1089/aid.1991.7.983	21	35	35	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1992	6	10					2843	2847		10.1096/fasebj.6.10.1634047	http://dx.doi.org/10.1096/fasebj.6.10.1634047			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JD954	1634047				2022-12-25	WOS:A1992JD95400013
J	TEASDALE, RD; DAGOSTARO, G; GLEESON, PA				TEASDALE, RD; DAGOSTARO, G; GLEESON, PA			THE SIGNAL FOR GOLGI RETENTION OF BOVINE-BETA-1,4-GALACTOSYLTRANSFERASE IS IN THE TRANSMEMBRANE DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLGLUCOSAMINE (BETA-1-4)GALACTOSYLTRANSFERASE; CELL-SURFACE GALACTOSYLTRANSFERASE; HUMAN-MILK GALACTOSYLTRANSFERASE; ENDOPLASMIC-RETICULUM; MESSENGER-RNA; BREFELDIN-A; ESCHERICHIA-COLI; E1 GLYCOPROTEIN; CDNA; PROTEINS	The expression and localization of bovine beta-1.4-galactosyltransferase (Gal T) has been studied in mammalian cells transfected with Gal T cDNA constructs, and the role of the amino-terminal domains of Gal T in Golgi localization examined. Here we demonstrate that the transmembrane (signal/anchor) domain of bovine Gal T contains a positive Golgi retention signal. Bovine Gal T was characterized in transfected cells with anti-bovine Gal T antibodies, affinity-purified from a rabbit antiserum using a bacterial recombinant fusion protein. These affinity-purified antibodies recognized native bovine Gal T and showed minimum cross-reactivity with Gal T from non-bovine sources. Bovine Gal T cDNA was expressed, as active enzyme, transiently in COS-1 cells and stably in murine L cells, and the product was shown to be localized to the Golgi complex by immunofluorescence using the polypeptide-specific antibodies. A low level of surface bovine Gal T was also detected in the transfected L cells by flow cytometry. The removal of 18 of the 24 amino acids from the cytoplasmic domain of bovine Gal T did not alter the Golgi localization of the product transiently expressed in COS-1 cells or stably expressed in L cells. Both the full-length bovine Gal T and the cytoplasmic domain deletion mutant were N-glycosylated in the transfected L cells, indicating both proteins have the correct N(in)/C(out) membrane orientation. Deletion of both the cytoplasmic and signal/anchor domains of bovine Gal T and incorporation of a cleavable signal sequence resulted in a truncated soluble bovine Gal T that was rapidly secreted (within 1 h) from transfected COS-1 cells. Replacement of the signal/anchor domain of bovine Gal T with the signal/anchor domain of the human transferrin receptor resulted in the transport of the hybrid molecule to the cell surface of transfected COS-1 cells. Furthermore, a hybrid construct containing the signal/anchor domain of Gal T with ovalbumin was efficiently retained in the Golgi complex, whereas ovalbumin anchored to the membrane by the transferrin receptor signal/anchor was expressed at the cell surface of transfected COS-1 cells. Overall, these studies show that the hydrophobic, signal/anchor domain of Gal T is both necessary and sufficient for Golgi localization.	MONASH UNIV, SCH MED, DEPT PATHOL & IMMUNOL, COMMERCIAL RD, PRAHRAN, VIC 3181, AUSTRALIA; ENERGIA NUCL & ENERGIA ALTERNAT, BIOPHYS LAB, I-0006 ROME, ITALY	Monash University; Italian National Agency New Technical Energy & Sustainable Economics Development			Teasdale, Rohan D/B-2538-2009; Teasdale, Rohan/AAD-6698-2019	Teasdale, Rohan D/0000-0001-7455-5269; Teasdale, Rohan/0000-0001-7455-5269; Gleeson, Paul/0000-0002-5336-6503				ANSORGE W, 1983, ELECTROPHORESIS 82, P235; BELTZER JP, 1991, J BIOL CHEM, V266, P973; BENDIAK B, 1990, BIOCHEM BIOPH RES CO, V170, P879, DOI 10.1016/0006-291X(90)92173-W; Beyer T A, 1981, Adv Enzymol Relat Areas Mol Biol, V52, P23; BIRD P, 1987, J CELL BIOL, V105, P2905, DOI 10.1083/jcb.105.6.2905; BRANDLEY BK, 1990, CELL, V63, P861, DOI 10.1016/0092-8674(90)90487-Y; CHILDS RA, 1986, BIOCHEM J, V238, P605, DOI 10.1042/bj2380605; COLLEY K, 1989, 18TH P ANN M SOC COM; COLLEY KJ, 1989, J BIOL CHEM, V264, P17619; CROWE JS, 1991, NUCLEIC ACIDS RES, V19, P184, DOI 10.1093/nar/19.1.184; DAGOSTARO G, 1989, EUR J BIOCHEM, V183, P211, DOI 10.1111/j.1432-1033.1989.tb14915.x; FEIZI T, 1987, BIOCHEM SOC T, V15, P614, DOI 10.1042/bst0150614; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GABATHULER R, 1990, J CELL BIOL, V111, P1803, DOI 10.1083/jcb.111.5.1803; GLEESON PA, 1988, CURR TOP MICROBIOL, V139, P1; GODING JW, 1983, MONOCLONAL ANTIBODIE, P140; HAPER NL, 1988, J BIOL CHEM, V263, P10420; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JOZIASSE DH, 1989, J BIOL CHEM, V264, P14290; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KORNFELD S, 1987, FASEB J, V1, P462, DOI 10.1096/fasebj.1.6.3315809; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI DOI 10.1083/JCB.108.2.229; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN RD, 1990, P NATL ACAD SCI USA, V87, P6674, DOI 10.1073/pnas.87.17.6674; LARSEN RD, 1989, P NATL ACAD SCI USA, V86, P8227, DOI 10.1073/pnas.86.21.8227; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LIPSKY NG, 1985, SCIENCE, V228, P745, DOI 10.1126/science.2581316; LOPEZ LC, 1991, J BIOL CHEM, V266, P15984; MACHAMER CE, 1987, J CELL BIOL, V105, P1205, DOI 10.1083/jcb.105.3.1205; MACHAMER CE, 1990, P NATL ACAD SCI USA, V87, P6944, DOI 10.1073/pnas.87.18.6944; MARCHASE RB, 1988, J CELL BIOCHEM, V36, P453, DOI 10.1002/jcb.240360413; MASRI KA, 1988, BIOCHEM BIOPH RES CO, V157, P657, DOI 10.1016/S0006-291X(88)80300-0; MCCLELLAND A, 1984, CELL, V39, P267, DOI 10.1016/0092-8674(84)90004-7; MCREYNOLDS L, 1978, NATURE, V273, P723, DOI 10.1038/273723a0; MEEK RL, 1982, J BIOL CHEM, V257, P2245; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NAKAZAWA K, 1988, J BIOCHEM-TOKYO, V104, P165, DOI 10.1093/oxfordjournals.jbchem.a122434; NARIMATSU H, 1986, P NATL ACAD SCI USA, V83, P4720, DOI 10.1073/pnas.83.13.4720; ORCI L, 1991, CELL, V64, P1183; OWEN MJ, 1980, J BIOL CHEM, V255, P9678; PAGANO RE, 1989, J CELL BIOL, V109, P2067, DOI 10.1083/jcb.109.5.2067; PAQUET MR, 1984, BIOCHEM J, V218, P745, DOI 10.1042/bj2180745; PARKS GD, 1991, CELL, V64, P777, DOI 10.1016/0092-8674(91)90507-U; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; ROTH J, 1982, J CELL BIOL, V93, P223, DOI 10.1083/jcb.93.1.223; ROTH J, 1985, J CELL BIOL, V100, P118, DOI 10.1083/jcb.100.1.118; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; RUSSO RN, 1990, J BIOL CHEM, V265, P3324; Sambrook J, 1989, MOL CLONING LABORATO; SATO M, 1984, DEV BIOL, V102, P514, DOI 10.1016/0012-1606(84)90219-7; SCHACHTER H, 1986, BIOCHEM CELL BIOL, V64, P163, DOI 10.1139/o86-026; SCHNEIDER C, 1982, J BIOL CHEM, V257, P8516; SHAPER NL, 1985, J CELL BIOCHEM, V28, P229, DOI 10.1002/jcb.240280305; SHAPER NL, 1986, P NATL ACAD SCI USA, V83, P1573, DOI 10.1073/pnas.83.6.1573; SHIN J, 1991, P NATL ACAD SCI USA, V88, P1918, DOI 10.1073/pnas.88.5.1918; SHUR BD, 1982, J BIOL CHEM, V257, P6871; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STROUS GJ, 1986, CRC CR REV BIOCH MOL, V21, P119, DOI 10.3109/10409238609113610; STROUS GJAM, 1982, J BIOL CHEM, V257, P7623; SUGANUMA T, 1991, J HISTOCHEM CYTOCHEM, V39, P299, DOI 10.1177/39.3.1899684; SWIFT AM, 1991, J CELL BIOL, V115, P19, DOI 10.1083/jcb.115.1.19; TASSIN AM, 1985, J CELL BIOL, V101, P630, DOI 10.1083/jcb.101.2.630; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAYER IP, 1971, J BIOL CHEM, V246, P6666; ULRICH JT, 1986, J BIOL CHEM, V261, P7975; YAMAMOTO F, 1990, J BIOL CHEM, V265, P1146	73	138	144	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					4084	4096						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1637374				2022-12-25	WOS:A1992HE60700078
J	ONISHI, A; LIOTTA, LJ; BENKOVIC, SJ				ONISHI, A; LIOTTA, LJ; BENKOVIC, SJ			CLONING AND EXPRESSION OF CHROMOBACTERIUM-VIOLACEUM PHENYLALANINE-HYDROXYLASE IN ESCHERICHIA-COLI AND COMPARISON OF AMINO-ACID-SEQUENCE WITH MAMMALIAN AROMATIC AMINO-ACID HYDROXYLASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-HYDROXYLASE; FUNCTIONAL DOMAINS; SITE; ACTIVATION; PURIFICATION; HOMOLOGY; COMPLEX; ENZYME; CDNA	The complete amino acid sequence (296 amino acids) of Chromobacterium violaceum phenylalanine hydroxylase (PAH) was determined by nucleotide analysis of a DNA clone isolated using both a synthetic oligonucleotide probe based on the NH2-terminal amino acid sequence and an antibody against this enzyme. The ApaL I fragment (approximately 1.9 kilobase pairs) containing the entire PAH gene was subcloned in pBluescript II and induced by isopropyl-beta-D-thiogalactopyranoside. In order to eliminate fusion proteins the XbaI/ClaI fragment which contained the PAH gene from the Bluescript construct was subcloned into pMAC 5-8 containing the TAC promoter. The recombinant protein reacts with antibody raised to authentic C. violaceum PAH and its NH2-terminal 20-amino acid sequence and COOH-terminal amino acid residue were identical with the wild-type protein. Key physical and chemical characteristics of the recombinant protein, i.e. its copper content and Michaelis-Menten parameters, were the same as wild-type. Comparison of amino acid sequences revealed a highly conserved region between C. violaceum PAH and three different mammalian aromatic amino acid hydroxylases. This conserved area may well be a catalytically important domain of these pterin- and metal-requiring aromatic amino acid hydroxylases. The over-expression of C. violaceum PAH in Escherichia coli will facilitate the analysis of the enzyme mechanism by various spectroscopic methods.	PENN STATE UNIV, DEPT CHEM, UNIVERSITY PK, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park								ABITA JP, 1984, J BIOL CHEM, V259, P4560; BRENNEMAN AR, 1964, BIOCHEM BIOPH RES CO, V17, P177, DOI 10.1016/0006-291X(64)90141-X; DAHL HHM, 1986, J BIOL CHEM, V261, P4148; FRIEDMAN PA, 1972, MOL PHARMACOL, V8, P501; FRIEDMAN PA, 1972, J BIOL CHEM, V247, P4165; GRENETT HE, 1987, P NATL ACAD SCI USA, V84, P5530, DOI 10.1073/pnas.84.16.5530; GUROFF G, 1967, J BIOL CHEM, V242, P3641; HERBERT WJ, 1986, HDB EXPT IMMUNOLOGY; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; IWAKI M, 1986, J BIOL CHEM, V261, P2051; KAUFMAN S, 1985, BIOCHEM SOC T, V13, P433, DOI 10.1042/bst0130433; KAUFMAN S, 1974, MOL MECHANISMS OXYGE, P295; KOHZUMA T, 1989, J AM CHEM SOC, V111, P3431, DOI 10.1021/ja00191a052; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDLEY FD, 1985, BIOCHEMISTRY-US, V24, P3389, DOI 10.1021/bi00335a001; LEDLEY FD, 1985, AM J HUM GENET, V37, pA235; LINZEN B, 1985, SCIENCE, V229, P519, DOI 10.1126/science.4023698; Maniatis T., 1982, MOL CLONING; MCCRACKEN J, 1988, J AM CHEM SOC, V110, P1069, DOI 10.1021/ja00212a012; NAKATA H, 1979, J BIOL CHEM, V254, P1829; PEMBER SO, 1989, BIOCHEMISTRY-US, V28, P2124, DOI 10.1021/bi00431a024; PEMBER SO, 1987, METHOD ENZYMOL, V142, P50; PEMBER SO, 1986, BIOCHEMISTRY-US, V25, P6611, DOI 10.1021/bi00369a042; PEMBER SO, 1987, BIOCHEMISTRY-US, V26, P4477, DOI 10.1021/bi00388a045; SHIMAN R, 1980, J BIOL CHEM, V255, P29; SHIMAN R, 1971, J BIOL CHEM, V246, P1330; SHIMAN R, 1985, FOLATES PTERINS, V2, P185; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767	28	33	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18454	18459						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1655752				2022-12-25	WOS:A1991GJ47200011
J	AXELSON, M; MORK, B; EVERSON, GT				AXELSON, M; MORK, B; EVERSON, GT			BILE-ACID SYNTHESIS IN CULTURED HUMAN HEPATOBLASTOMA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATOGRAPHY-MASS SPECTROMETRY; CEREBROTENDINOUS XANTHOMATOSIS; CHENODEOXYCHOLIC ACIDS; CHOLESTENOIC ACIDS; PLASMA; PATHWAYS	Biosynthetic pathways to bile acids have been studied in HepG2 cells, a well-differentiated human hepatoblastoma cell line. Cholesterol metabolites, in total 29, were isolated from culture media and cells by liquid-solid extraction and anion-exchange chromatography and were identified by gas-liquid chromatography-mass spectrometry. The production rates/concentrations of cholic acid (CA) and chenodeoxycholic acid (CDCA) in media from control cells were 71 and 74 ng/10(7) cells/h, respectively. Major bile acid precursors were 3-alpha, 7-alpha, 12-alpha-trihydroxy-5-beta-cholestanoic acid (THCA), 7-alpha, 12-alpha-dihydroxy-3-oxo-4-cholestenoic acid, 7-alpha-hydroxy-3-oxo-4-cholenoic acid, and 7-alpha, 12-alpha-dihydroxy-3-oxo-5-beta-cholanoic acid, their concentrations being 60, 30, 23, and 10 ng/10(7) cells/h, respectively. These and nine other isolated intermediates formed essentially complete metabolic sequences from cholesterol to CA and CDCA. The remaining steroids were metabolites of the intermediates or autooxidation products of cholesterol. These findings and the observed effect of dexamethasone on production rates suggest that in HepG2 cells the major biosynthetic pathways to primary bile acids start with 7-alpha-hydroxylation of cholesterol and oxidation to 7-alpha-hydroxy-4-cholesten-3- one followed by hydroxylation at either the 26 or 12-alpha position. CDCA is formed by the sequence of 26-hydroxylation, oxidation, and degradation of the side chain and A-ring reduction. CA is formed by the sequence of 12-alpha-hydroxylation, 26-hydroxylation, oxidation, and degradation of the side chain and reduction of the A-ring. An alternative pathway to CA included A-ring reduction of the intermediate 7-alpha, 12-alpha-dihydroxy-3-oxo-4-cholestenoic acid to form THCA prior to side chain cleavage. These pathways are not limited to HepG2 cells but may also be important in humans.	KAROLINSKA INST, DEPT PHYSIOL CHEM, S-10401 STOCKHOLM 60, SWEDEN; UNIV COLORADO, HLTH SCI CTR, DEPT MED, DENVER, CO 80262 USA	Karolinska Institutet; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	AXELSON, M (corresponding author), KAROLINSKA HOSP, DEPT CLIN CHEM, S-10401 STOCKHOLM 60, SWEDEN.							ANDERSON KE, 1972, J CLIN INVEST, V51, P112, DOI 10.1172/JCI106780; AXELSON M, 1989, FALK SYMP, V52, P79; AXELSON M, 1981, J CHROMATOGR, V224, P355, DOI 10.1016/S0378-4347(00)80208-X; AXELSON M, 1990, J STEROID BIOCHEM, V36, P631, DOI 10.1016/0022-4731(90)90182-R; AXELSON M, 1989, J LIPID RES, V30, P1883; AXELSON M, 1988, FEBS LETT, V239, P324, DOI 10.1016/0014-5793(88)80944-X; AXELSON M, 1988, J LIPID RES, V29, P629; AXELSON M, 1989, J LIPID RES, V30, P1877; BJORKHEM I, 1981, J LIPID RES, V22, P191; BJORKHEM I, 1985, STEROLS BILE ACIDS, P231; EVERSON GT, 1986, J BIOL CHEM, V261, P2197; EVERSON GT, 1989, 32ND P IUPAC C STOCK, P189; JAVITT NB, 1989, J BIOL CHEM, V264, P10384; KARLAGANIS G, 1980, J LIPID RES, V21, P377; KOVATS E, 1958, HELV CHIM ACTA, V41, P1915, DOI 10.1002/hlca.19580410703; MATOBA N, 1986, J LIPID RES, V27, P1154; SALEN G, 1989, 32ND P IUPAC C STOCK, P190; SETCHELL KDR, 1987, SEMIN LIVER DIS, V7, P85, DOI 10.1055/s-2008-1040568; SKREDE S, 1988, J LIPID RES, V29, P157; SMITH LL, 1981, CHOLESTEROL AUTOOXID, P214; SWELL L, 1980, J LIPID RES, V21, P455	21	53	54	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					17770	17777						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1655725				2022-12-25	WOS:A1991GG55300012
J	HIGUCHI, S; TAMURA, J; GIRI, PR; POLLI, JW; KINCAID, RL				HIGUCHI, S; TAMURA, J; GIRI, PR; POLLI, JW; KINCAID, RL			CALMODULIN-DEPENDENT PROTEIN PHOSPHATASE FROM NEUROSPORA-CRASSA - MOLECULAR-CLONING AND EXPRESSION OF RECOMBINANT CATALYTIC SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCINEURIN-A; DOMAIN; BRAIN; PHOSPHODIESTERASE; IDENTIFICATION; PURIFICATION; ROLES	A cDNA for the catalytic subunit of a calmodulin (CaM)-dependent protein phosphatase was cloned from Neurospora crassa. The open reading frame of 1557 base pairs encoded a protein of M(r) almost-equal-to 59,580 and was followed by a 3'-untranslated region of 363 base pairs including the poly(A) tail. Based on primer extension analysis, the mRNA transcript in vivo was 2403 base pairs. Expression of this CaM-protein phosphatase mRNA was developmentally regulated, being highest during early mycelial growth; production of the corresponding protein followed mRNA with a time lag of 8-12 h. Polymerase chain reaction amplification of genomic DNA revealed three small introns, the positions of which coincided with those in the mouse gene, indicating evolutionary conservation of these structures. The deduced sequence showed almost-equal-to 75% identity with the mammalian homologue, calcineurin, in aligned regions. A region of 40 amino acids preceding the CaM-binding domain was essentially unchanged, suggesting conservation of a crucial interaction site. Three small segments in the carboxyl half of the protein were unrelated to the mammalian gene and may constitute "variable regions" that confer substrate specificity to the enzyme. An active recombinant catalytic subunit was expressed in bacteria and purified by CaM-Sepharose chromatography. This preparation was stimulated 2-3-fold by CaM and showed a p-nitrophenol phosphatase activity equal to that of the bovine brain holoenzyme, although its dephosphorylation of phosphoprotein substrates was markedly different. These findings demonstrate that the catalytic subunit of this phosphatase can exhibit high activity in the absence of its intrinsic Ca2+-binding subunit.			HIGUCHI, S (corresponding author), NIAAA,PHYSIOL & PHARMACOL STUDIES LAB,IMMUNOL SECT,ROCKVILLE,MD 20852, USA.			Polli, Joseph/0000-0003-3812-8985				BILLINGSLEY ML, 1985, P NATL ACAD SCI USA, V82, P7585, DOI 10.1073/pnas.82.22.7585; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; COHEN P, 1988, METHOD ENZYMOL, V159, P427; CYERT MS, 1989, J CELL BIOL, V107, pA841; DAVIS RH, 1986, MICROBIOL REV, V50, P280, DOI 10.1128/MMBR.50.3.280-313.1986; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GUERINI D, 1989, P NATL ACAD SCI USA, V86, P9183, DOI 10.1073/pnas.86.23.9183; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HIGUCHI S, 1990, FASEB J, V4, pA2236; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P297, DOI 10.1111/j.1432-1033.1983.tb07362.x; ITO A, 1989, BIOCHEM BIOPH RES CO, V163, P1492, DOI 10.1016/0006-291X(89)91148-0; KINCAID RL, 1988, METHOD ENZYMOL, V159, P627; KINCAID RL, 1990, J BIOL CHEM, V265, P11312; KINCAID RL, 1988, BIOTECHNIQUES, V6, P42; KINCAID RL, 1984, J BIOL CHEM, V259, P5158; KINCAID RL, 1988, P NATL ACAD SCI USA, V85, P8983, DOI 10.1073/pnas.85.23.8983; KINCAID RL, 1989, CALCIUM PROTEIN SIGN, P347; KLEE CB, 1979, P NATL ACAD SCI USA, V76, P6270, DOI 10.1073/pnas.76.12.6270; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KUNO T, 1989, BIOCHEM BIOPH RES CO, V165, P1352, DOI 10.1016/0006-291X(89)92752-6; LEE DB, 1984, GENETICS, V106, P591; MERAT DL, 1985, J BIOL CHEM, V260, P1053; METZENBERG RL, 1981, NEUROSPORA NEWSL, V28, P20; ORBACH MJ, 1990, J BIOL CHEM, V265, P10981; RIGGS MG, 1986, BIOTECHNIQUES, V4, P310; SCHMID J, 1988, J GEN MICROBIOL, V134, P2623; SILVA EFD, 1989, BIOCHIM BIOPHYS ACTA, V1009, P293, DOI 10.1016/0167-4781(89)90118-8; STEWART AA, 1982, FEBS LETT, V137, P80, DOI 10.1016/0014-5793(82)80319-0; TELLEZINON MT, 1985, BIOCHEM J, V232, P425, DOI 10.1042/bj2320425; VIERULA PJ, 1989, J BIOL CHEM, V264, P1108; Vogel H.J., 1956, MICROB GENET B, V13, P42	32	58	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					18104	18112						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1655737				2022-12-25	WOS:A1991GG55300061
J	KOZUKA, M; ITO, T; HIROSE, S; LODHI, KM; HAGIWARA, H				KOZUKA, M; ITO, T; HIROSE, S; LODHI, KM; HAGIWARA, H			PURIFICATION AND CHARACTERIZATION OF BOVINE LUNG ENDOTHELIN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANES; CLONING; FAMILY; CELL	Endothelin receptor was purified from bovine lung by a rapid and simple two-step procedure: 1) solubilization with the detergent 3[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate and digitonin and 2) affinity chromatography using biotinylated endothelin and avidin-agarose. Starting from 3.5 kg of bovine lung, about 200-mu-g of pure receptor were obtained. Microsequencing of tryptic fragments of the purified protein revealed a high sequence similarity with the rat endothelin ET(B) receptor that has very recently been cloned by expression cloning and shown to be nonselective in terms of the ligand specificity. Purification of the receptor in the presence of low (1 mm) and high (50 mM) concentrations of EDTA yielded, as a major form, 34- and 52-kDa species, respectively, indicating that the lower M(r) species (34 kDa) is a proteolytic product of the 52-kDa species. Interestingly, this metal proteinase-mediated limited proteolysis did not affect the ligand binding properties of the receptor.			KOZUKA, M (corresponding author), TOKYO INST TECHNOL,DEPT BIOL SCI,MEGURO KU,TOKYO 152,JAPAN.							ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; EGUCHI S, 1991, BIOMED RES-TOKYO, V12, P35, DOI 10.2220/biomedres.12.35; HAGIWARA H, 1990, BIOMED RES-TOKYO, V11, P93, DOI 10.2220/biomedres.11.93; HAGIWARA H, 1990, BIOCHEM BIOPH RES CO, V172, P576, DOI 10.1016/0006-291X(90)90712-V; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTIN ER, 1990, J BIOL CHEM, V265, P14044; MASUDA Y, 1989, FEBS LETT, V257, P2088; MIYAZAKI H, 1990, EUR J BIOCHEM, V187, P125, DOI 10.1111/j.1432-1033.1990.tb15285.x; NAKAJO S, 1990, BIOCHEM BIOPH RES CO, V167, P280, DOI 10.1016/0006-291X(90)91762-H; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SCHVARTZ I, 1991, ENDOCRINOLOGY, V128, P126, DOI 10.1210/endo-128-1-126; SIMONSON MS, 1990, FASEB J, V4, P2989, DOI 10.1096/fasebj.4.12.2168326; SUGIURA M, 1989, BIOCHEM BIOPH RES CO, V162, P1396, DOI 10.1016/0006-291X(89)90829-2; WADA K, 1990, BIOCHEM BIOPH RES CO, V167, P251, DOI 10.1016/0006-291X(90)91758-K; WATANABE H, 1989, BIOCHEM BIOPH RES CO, V161, P1252, DOI 10.1016/0006-291X(89)91377-6; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	17	104	105	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16892	16896						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1653249				2022-12-25	WOS:A1991GD63500102
J	LIN, WH; MARCUCCI, KA; RABIN, RA; ROTH, JA				LIN, WH; MARCUCCI, KA; RABIN, RA; ROTH, JA			2-CHLOROADENOSINE DECREASES TYROSYLPROTEIN SULFOTRANSFERASE ACTIVITY IN THE GOLGI-APPARATUS IN PC12 CELLS - EVIDENCE FOR A NOVEL RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; RAT-LIVER; PHEOCHROMOCYTOMA CELLS; TYROSINE SULFATION; ADENOSINE; PROTEINS; LINE; COMPARTMENTATION; MANNOSIDASES; TRANSPORT	In the present studies, we investigated the activity of tyrosylprotein sulfotransferase (TPST) in the Golgi apparatus of PC12 cells and the regulation of this enzyme by 2-chloroadenosine, an adenosine receptor agonist. Studies employing continuous sucrose gradient and trypsinization of the membranes demonstrate that TPST is located on the luminal side of Golgi apparatus in PC12 cells. Treatment of PC12 cells with 2-chloroadenosine results in a dose-dependent decrease of TPST activity which is observable as early as 3 h after initiation of treatment, maximizes at 24-48 h with continuous exposure, and is readily reversible upon removal of the drug. While forskolin, an agent that directly increases intracellular cAMP, has no effect on TPST activity, 2-chloroadenosine equally suppressed the enzyme activity in both the wild type and a protein kinase A-deficient mutant strain of PC12 cells, indicating that such regulation of TPST activity by 2-chloroadenosine was independent of cAMP-dependent protein phosphorylation. This effect of 2-chloroadenosine can be potentiated by an adenosine uptake blocker dipyridamole but cannot be elicited by other adenosine A1 or A2 receptor agonists, further suggesting that TPST activity in PC12 cells is regulated by 2-chloroadenosine via a novel membrane receptor. Incubation of the cells with cycloheximide, a protein synthesis inhibitor, also led to a time- and dose-dependent suppression of TPST activity. At concentrations of cycloheximide that produced maximal inhibition (approximately 50%), cotreatment with 2-chloroadenosine did not lead to a further decrease of the TPST activity. These results suggest that the sensitivity of TPST activity to be controlled by protein synthesis provides a mechanism for regulation of its activity by 2-chloroadenosine.	SUNY BUFFALO,SCH MED & BIOMED SCI,DEPT PHARMACOL & THERAPEUT,102 FARBER HALL,BUFFALO,NY 14260	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS020530] Funding Source: NIH RePORTER; NINDS NIH HHS [NS20530] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAEUERLE PA, 1985, J BIOL CHEM, V260, P6434; BISCHOFF J, 1984, BIOCHEM BIOPH RES CO, V125, P324, DOI 10.1016/S0006-291X(84)80371-X; BOHLEN P, 1973, ARCH BIOCHEM BIOPHYS, V155, P213, DOI 10.1016/S0003-9861(73)80023-2; BRETZ R, 1977, EUR J BIOCHEM, V77, P191; DALY JW, 1985, J MED CHEM, V28, P487, DOI 10.1021/jm00382a018; DICHTER MA, 1977, NATURE, V268, P501, DOI 10.1038/268501a0; DUNPHY WG, 1983, J CELL BIOL, V97, P270, DOI 10.1083/jcb.97.1.270; FUJITA K, 1989, ENVIRON HEALTH PERSP, V80, P127, DOI 10.2307/3430738; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GUROFF G, 1981, J NEUROCHEM, V37, P1431, DOI 10.1111/j.1471-4159.1981.tb06312.x; HORTIN G, 1987, J BIOL CHEM, V262, P3082; HUFFAKER T, 1984, J CELL PHYSIOL, V120, P188, DOI 10.1002/jcp.1041200212; HUTTNER WB, 1988, ANNU REV PHYSIOL, V50, P363, DOI 10.1146/annurev.ph.50.030188.002051; KARP DR, 1983, J BIOL CHEM, V258, P2745; LEE RWH, 1985, P NATL ACAD SCI USA, V82, P6143, DOI 10.1073/pnas.82.18.6143; LEE RWH, 1983, J BIOL CHEM, V258, P1326; LIN WH, 1990, BIOCHEM PHARMACOL, V40, P629; MUTT V, 1971, BIOCHEM J, V125, pP57, DOI 10.1042/bj1250057P; OPHEIM DJ, 1978, J BIOL CHEM, V253, P1017; PATERSON ARP, 1980, MOL PHARMACOL, V18, P40; RABE CS, 1983, J NEUROCHEM, V41, P1623, DOI 10.1111/j.1471-4159.1983.tb00873.x; RABIN RA, 1990, J PHARMACOL EXP THER, V252, P1021; RENSDOMIANO S, 1989, J BIOL CHEM, V264, P899; RENSDOMIANO S, 1989, MOL PHARMACOL, V36, P647; ROTH JA, 1991, IN PRESS J NEUROCHEM; STONE GC, 1987, J NEUROCHEM, V48, P1736, DOI 10.1111/j.1471-4159.1987.tb05731.x; VANBUSKIRK R, 1985, MOL CELL BIOL, V5, P1984, DOI 10.1128/MCB.5.8.1984; VARGAS F, 1985, BIOCHEMISTRY-US, V24, P5938, DOI 10.1021/bi00342a037; WILLIAMS M, 1989, NEUROCHEM INT, V14, P249, DOI 10.1016/0197-0186(89)90051-X; WILLIAMS M, 1987, ANNU REV PHARMACOL, V27, P315; WILLIAMS M, 1987, J NEUROCHEM, V48, P498, DOI 10.1111/j.1471-4159.1987.tb04120.x	31	13	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14457	14463						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1650360				2022-12-25	WOS:A1991FZ35100056
J	LEVADE, T; GATT, S; MARET, A; SALVAYRE, R				LEVADE, T; GATT, S; MARET, A; SALVAYRE, R			DIFFERENT PATHWAYS OF UPTAKE AND DEGRADATION OF SPHINGOMYELIN BY LYMPHOBLASTOID-CELLS AND THE POTENTIAL PARTICIPATION OF THE NEUTRAL SPHINGOMYELINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIEMANN-PICK DISEASE; EPSTEIN-BARR VIRUS; CULTURED HUMAN-FIBROBLASTS; HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; MAGNESIUM-DEPENDENT SPHINGOMYELINASE; LOW-DENSITY LIPOPROTEINS; PLASMA-MEMBRANE; RAT-LIVER; SKIN FIBROBLASTS; HUMAN-BRAIN	The metabolism of sphingomyelin (SPM) was investigated in Epstein-Barr virus-transformed lymphoid cell lines from normal individuals and from patients with Niemann-Pick disease Type A (deficient in the acid, lysosomal sphingomyelinase) and familial hypercholesterolemia (lacking the low density lipoprotein receptor). Cells were incubated with the following radioactive or fluorescent SPMs: [choline-methyl-C-14] SPM, [oleoyl-H-3]SPM, pyrene-propenoyl-SPM (P3:1-SPM), pyrene-butanoyl-SPM (P4-SPM), pyrene-dodecanoyl-SPM (P12-SPM), and pyrene-sulfonylamino-undecanoyl-SPM (PSA11-SPM). Several pathways of uptake and subsequent metabolism of SPM in the lymphoblastoid cells were identified. [choline-methyl-C-14] SPM and the P12-analog, administered to the cells in the presence of lipoproteins, were taken up through the apoB/E receptor-dependent pathway of endocytosis and degraded solely by the lysosomal sphingomyelinase. Under similar conditions, the other sphingomyelins, i.e. [oleoyl-H-3]SPM, P3:1-SPM, P4-SPM, and PSA11-SPM, were taken up by a low density lipoprotein receptor-independent pathway and degraded mostly by a nonlysosomal sphingomyelinase which also catalyzed their hydrolysis in Niemann-Pick cells. In the absence of serum, all sphingomyelins were taken up by an apoB/E receptor-independent pathway and hydrolyzed by a nonlysosomal sphingomyelinase. Indeed, in vitro assays demonstrated the presence, in lymphoblastoid cells, of the neutral magnesium-activated sphingomyelinase, which was also fully active in the Niemann-Pick cells. In conclusion, our observations are consistent with: (i) the existence in lymphoblastoid cells of several pathways for the uptake and subsequent utilization of SPM; (ii) a major role of lipoproteins for the metabolic routing of the SPM; and (iii) the effect of the structure of the fatty acyl residue Of SPM on its possible association with lipoproteins and/or cell membranes.	HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT MEMBRANE BIOCHEM & NEUROCHEM,IL-91010 JERUSALEM,ISRAEL	Hebrew University of Jerusalem	LEVADE, T (corresponding author), CHU RANGUEIL,BIOCHIM LAB,AVE J POULHES,F-31054 TOULOUSE,FRANCE.		Levade, Thierry/O-8948-2014					AHMAD TY, 1985, J LIPID RES, V26, P1160; ALLAN D, 1988, BIOCHEM J, V254, P765, DOI 10.1042/bj2540765; Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; BARENHOLZ Y, 1980, BIOCHIM BIOPHYS ACTA, V604, P129, DOI 10.1016/0005-2736(80)90572-6; BARTOLF M, 1986, J LIPID RES, V27, P57; BEAUDET AL, 1982, BIOCHEM BIOPH RES CO, V105, P14, DOI 10.1016/S0006-291X(82)80004-1; BOHLEN P, 1973, ARCH BIOCHEM BIOPHYS, V155, P213, DOI 10.1016/S0003-9861(73)80023-2; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; CARRE JB, 1989, J NEUROCHEM, V52, P1294, DOI 10.1111/j.1471-4159.1989.tb01878.x; COHEN R, 1984, CHEM PHYS LIPIDS, V35, P371, DOI 10.1016/0009-3084(84)90079-3; EPPLER CM, 1987, LIPIDS, V22, P351, DOI 10.1007/BF02534005; FOLCH J, 1957, J BIOL CHEM, V226, P497; FORTE TM, 1981, LIPIDS, V16, P240, DOI 10.1007/BF02535023; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; Gatt S, 1981, Methods Enzymol, V72, P351; GATT S, 1980, J BIOL CHEM, V255, P3371; Gatt S, 1978, Adv Prostaglandin Thromboxane Res, V3, P1; GATT S, 1976, BIOCHEM BIOPH RES CO, V68, P235, DOI 10.1016/0006-291X(76)90034-6; GATT S, 1978, J NEUROCHEM, V31, P547, DOI 10.1111/j.1471-4159.1978.tb02671.x; GAVER RC, 1965, J AM OIL CHEM SOC, V42, P294, DOI 10.1007/BF02540132; GOLDSTEIN JL, 1974, J BIOL CHEM, V249, P5153; HAMMARSTROM S, 1971, J LIPID RES, V12, P760; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HARTREE EF, 1972, ANAL BIOCHEM, V48, P422, DOI 10.1016/0003-2697(72)90094-2; HO YK, 1976, J EXP MED, V144, P444, DOI 10.1084/jem.144.2.444; HOSTETLER KY, 1979, J LIPID RES, V20, P456; JECKEL D, 1990, FEBS LETT, V261, P155, DOI 10.1016/0014-5793(90)80659-7; KAYDEN HJ, 1976, BIOCHEMISTRY-US, V15, P521, DOI 10.1021/bi00648a011; KISHIMOTO Y, 1983, ENZYMES, V16, P3257; KLAR R, 1988, CLIN CHIM ACTA, V176, P259, DOI 10.1016/0009-8981(88)90185-4; KOVAL M, 1990, J CELL BIOL, V111, P429, DOI 10.1083/jcb.111.2.429; KOVAL M, 1989, J CELL BIOL, V108, P2169, DOI 10.1083/jcb.108.6.2169; KUDOH T, 1983, BIOCHIM BIOPHYS ACTA, V754, P82, DOI 10.1016/0005-2760(83)90084-X; LANGE Y, 1989, J BIOL CHEM, V264, P3786; LECERF J, 1987, BIOCHIM BIOPHYS ACTA, V918, P48, DOI 10.1016/0005-2760(87)90008-7; LEVADE T, 1985, PEDIATR RES, V19, P153, DOI 10.1203/00006450-198501000-00039; LEVADE T, 1986, J CLIN CHEM CLIN BIO, V24, P205; LEVADE T, 1987, BIOCHIM BIOPHYS ACTA, V918, P250, DOI 10.1016/0005-2760(87)90228-1; LEVADE T, 1983, J NEUROCHEM, V40, P1762, DOI 10.1111/j.1471-4159.1983.tb08153.x; LEVADE T, 1988, J INHERIT METAB DIS, V11, P151, DOI 10.1007/BF01799864; LEVADE T, 1984, BIOCHIM BIOPHYS ACTA, V793, P321, DOI 10.1016/0005-2760(84)90337-0; LEVADE T, 1991, BIOCHEM J, V275, P211, DOI 10.1042/bj2750211; LEVADE T, 1985, EUR J BIOCHEM, V149, P405, DOI 10.1111/j.1432-1033.1985.tb08940.x; MALGAT M, 1986, J LIPID RES, V27, P251; MARGGRAF WD, 1984, BIOCHIM BIOPHYS ACTA, V793, P346, DOI 10.1016/0005-2760(84)90248-0; MAZIERE JC, 1984, FEBS LETT, V173, P159, DOI 10.1016/0014-5793(84)81038-8; MAZIERE JC, 1982, BIOCHEM BIOPH RES CO, V108, P1101, DOI 10.1016/0006-291X(82)92113-1; MERRILL AH, 1989, BIOCHIM BIOPHYS ACTA, V1010, P131, DOI 10.1016/0167-4889(89)90152-3; NEGRESALVAYRE A, 1990, BIOCHIM BIOPHYS ACTA, V1045, P224, DOI 10.1016/0005-2760(90)90124-G; NEITZEL H, 1986, HUM GENET, V73, P320, DOI 10.1007/BF00279094; PAGANO RE, 1988, TRENDS BIOCHEM SCI, V13, P202, DOI 10.1016/0968-0004(88)90082-5; RAO BG, 1976, J LIPID RES, V17, P506; SALVAYRE R, 1981, BIOCHIM BIOPHYS ACTA, V659, P445, DOI 10.1016/0005-2744(81)90070-X; SPENCE MW, 1990, BIOCHEM J, V268, P719, DOI 10.1042/bj2680719; SPENCE MW, 1983, J BIOL CHEM, V258, P8595; SPENCE MW, 1979, BRAIN RES, V168, P543, DOI 10.1016/0006-8993(79)90308-1; SPENCE MW, 1989, J BIOL CHEM, V264, P5358; SPENCE MW, 1982, BIOCHIM BIOPHYS ACTA, V719, P162, DOI 10.1016/0304-4165(82)90321-X; SPENCE MW, 1989, METABOLIC BASIS INHE, P1655; SRIPADA PK, 1987, J LIPID RES, V28, P710; STEIN O, 1989, BIOCHIM BIOPHYS ACTA, V1003, P175, DOI 10.1016/0005-2760(89)90252-X; STOFFEL W, 1980, H-S Z PHYSIOL CHEM, V361, P755, DOI 10.1515/bchm2.1980.361.1.755; SUTRINA SL, 1984, BIOCHIM BIOPHYS ACTA, V793, P169, DOI 10.1016/0005-2760(84)90318-7; TOLLEFSON JH, 1988, J LIPID RES, V29, P1593; VANIER MT, 1985, CLIN GENET, V27, P20; White D.A., 1973, FORM FUNCTION PHOSPH	66	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13519	13529						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1649823				2022-12-25	WOS:A1991FY02700013
J	PAROLA, AL; STUMP, DG; PEPPERL, DJ; KRUEGER, KE; REGAN, JW; LAIRD, HE				PAROLA, AL; STUMP, DG; PEPPERL, DJ; KRUEGER, KE; REGAN, JW; LAIRD, HE			CLONING AND EXPRESSION OF A PHARMACOLOGICALLY UNIQUE BOVINE PERIPHERAL-TYPE BENZODIAZEPINE RECEPTOR ISOQUINOLINE BINDING-PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPECIES-DIFFERENCES; CALCIUM CHANNELS; BRAIN MEMBRANES; SITES; PK-11195; HETEROGENEITY; PROLIFERATION; LOCALIZATION; INHIBITION; ANTAGONIST	High affinity binding of isoquinolines, such as PK 11195, is a conserved feature of peripheral-type benzodiazepine receptors (PBR) across species. However, species differences in PBR ligand binding have been described based on the affinity for N1-alkyl-1,4-benzodiazepines, such as Ro5-4864. Ro5-4864 binds with high affinity to the rat receptor but has low affinity for the bovine PBR. Photolabeling with an isoquinoline ligand, [H-3]PK 14105, identifies a 17-kDa protein, the PBR isoquinoline binding protein (PBR/IBP), in both species. To further elucidate the role of the PBR/IBP in determining PBR benzodiazepine and isoquinoline binding characteristics, the bovine PBR/IBP was cloned and expressed. Using a cDNA encoding a rat PBR/IBP to screen a fetal bovine adrenal cDNA library, a bovine cDNA encoding a polypeptide of 169 residues was cloned. The bovine and rat PBR/IBPs had similar hydropathy profiles exhibiting five potential transmembrane domains. Transfecting the cloned bovine PBR/IBP cDNA into COS-7 cells resulted in an 11-fold increase in the density of high affinity [H-3]PK 11195 binding sites which had only low affinity for Ro5-4864. Expression of the bovine PBR/IBP yields a receptor which is pharmacologically distinct from both endogenous COS-7 PBR and the rat PBR based on the affinity for several N1-alkyl-1,4-benzodiazepine ligands. These results suggest the PBR/IBP is the minimal functional component required for PBR ligand binding characteristics and the different protein sequences account for the species differences in PBR benzodiazepine ligand binding.	UNIV ARIZONA,COLL PHARM,DEPT PHARMACOL & TOXICOL,TUCSON,AZ 85721; VANDERBILT UNIV,MED CTR,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232; GEORGETOWN UNIV,SCH MED,FIDIA GEORGETOWN INST NEUROSCI,WASHINGTON,DC 20007	University of Arizona; Vanderbilt University; Georgetown University								ANHOLT RRH, 1985, J PHARMACOL EXP THER, V233, P517; ANHOLT RRH, 1986, J BIOL CHEM, V261, P576; AWAD M, 1987, J NEUROCHEM, V49, P1407, DOI 10.1111/j.1471-4159.1987.tb01007.x; AWAD M, 1989, BIOCHEM PHARMACOL, V38, P3843, DOI 10.1016/0006-2952(89)90594-7; BASILE AS, 1986, MOL BRAIN RES, V1, P127, DOI 10.1016/0169-328X(86)90004-5; BESMAN MJ, 1989, P NATL ACAD SCI USA, V86, P4897, DOI 10.1073/pnas.86.13.4897; BRAESTRUP C, 1977, P NATL ACAD SCI USA, V74, P3805, DOI 10.1073/pnas.74.9.3805; BROADDUS WC, 1990, BRAIN RES, V518, P199, DOI 10.1016/0006-8993(90)90973-F; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DAYHOFF MO, 1978, PROTEINS ATLAS PR S3, V5; DOBLE A, 1987, MOL PHARMACOL, V31, P42; ESHLEMAN AJ, 1989, J NEUROCHEM, V53, P494, DOI 10.1111/j.1471-4159.1989.tb07361.x; HIRSCH JD, 1989, MOL PHARMACOL, V35, P157; HIRSCH JD, 1989, MOL PHARMACOL, V35, P164; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIRD HE, 1989, EUR J PHARMACOL, V171, P25, DOI 10.1016/0014-2999(89)90426-3; LEFUR G, 1983, LIFE SCI, V32, P1839, DOI 10.1016/0024-3205(83)90062-0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCABE RT, 1989, FEBS LETT, V244, P263, DOI 10.1016/0014-5793(89)80541-1; MESTRE M, 1986, LIFE SCI, V39, P329, DOI 10.1016/0024-3205(86)90651-X; MESTRE M, 1986, J CARDIOVASC PHARM, V8, P729; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; PAROLA AL, 1991, LIFE SCI, V48, P757, DOI 10.1016/0024-3205(91)90090-X; PAROLA AL, 1989, J PHARMACOL EXP THER, V250, P1149; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SKOWRONSKI R, 1987, EUR J PHARMACOL, V143, P305, DOI 10.1016/0014-2999(87)90454-7; SNYDER SH, 1990, NEUROCHEM RES, V15, P119, DOI 10.1007/BF00972201; SPRENGEL R, 1989, J BIOL CHEM, V264, P20415; WANG JKT, 1984, P NATL ACAD SCI-BIOL, V81, P753, DOI 10.1073/pnas.81.3.753	32	73	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					14082	14087						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1649835				2022-12-25	WOS:A1991FY02700096
J	KANAYA, S; KATSUDANAKAI, C; IKEHARA, M				KANAYA, S; KATSUDANAKAI, C; IKEHARA, M			IMPORTANCE OF THE POSITIVE CHARGE CLUSTER IN ESCHERICHIA-COLI RIBONUCLEASE HI FOR THE EFFECTIVE BINDING OF THE SUBSTRATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS REVERSE-TRANSCRIPTASE; MURINE LEUKEMIA-VIRUS; SITE-DIRECTED MUTAGENESIS; AMINO-ACID-RESIDUES; RNASE-H; ENZYMATIC CLEAVAGE; DNA-POLYMERASE; MYB ONCOGENE; DOMAIN; SEQUENCE	The handle region (residues 84-99) in ribonuclease HI (RNase HI) from Escherichia coli, which is rich in basic amino acid residues, was altered by alanine-scanning mutagenesis. Fifteen mutant proteins were purified to homogeneity and analyzed for the enzymatic activity. A mutation of either of 2 tryptophan residues at 85 or 90 resulted in a large increase in the K(m) value along with a large decrease in the V(max) value. These values probably resulted from conformational changes introduced by the mutations as indicated by the CD spectra of these mutant proteins. All other mutant enzymes had V(max) values similar to that of the wild-type enzyme. In contrast, replacement of any basic amino acid residue in the handle region, except for lysine 86, yielded proteins whose K(m) values were 3-5-fold higher than the wild-type enzyme. Such effects were shown to be cumulative, suggesting strongly that the cluster of positive charges in the handle region is important for the effective binding of the substrate. Interestingly, the region of human immunodeficiency virus reverse transcriptase with homology to E. coli RNase HI lacks the handle region which may account for the poor RNase H activity of the domain when separated from the polymerase domain.			KANAYA, S (corresponding author), PROT ENGN RES INST,6-2-3 FURUEDAI,SUITA,OSAKA 565,JAPAN.							ARENDES J, 1982, J BIOL CHEM, V257, P4719; ATABEKOV KJ, 1988, FEBS LETT, V232, P96, DOI 10.1016/0014-5793(88)80393-4; BEAUCAGE SL, 1981, TETRAHEDRON LETT, V22, P1859, DOI 10.1016/S0040-4039(01)90461-7; BECERRA SP, 1990, FEBS LETT, V270, P76, DOI 10.1016/0014-5793(90)81238-J; BERKOWER I, 1973, J BIOL CHEM, V248, P5914; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURLEY SK, 1986, J AM CHEM SOC, V108, P7995, DOI 10.1021/ja00285a019; CARL PL, 1980, J BACTERIOL, V144, P28, DOI 10.1128/JB.144.1.28-35.1980; CROUCH R J, 1990, New Biologist, V2, P771; Crouch R. J., 1982, NUCLEASES, P211; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DONISKELLER H, 1979, NUCLEIC ACIDS RES, V7, P179, DOI 10.1093/nar/7.1.179; DOOLITTLE RF, 1989, Q REV BIOL, V64, P1, DOI 10.1086/416128; Goodwin T. W., 1946, BIOCHEM JOUR, V40, P628; HANSEN J, 1988, EMBO J, V7, P239, DOI 10.1002/j.1460-2075.1988.tb02805.x; HAUSEN P, 1970, EUR J BIOCHEM, V14, P278, DOI 10.1111/j.1432-1033.1970.tb00287.x; HOGREFE HH, 1990, J BIOL CHEM, V265, P5561; INOUE H, 1987, FEBS LETT, V215, P327, DOI 10.1016/0014-5793(87)80171-0; ITAYA M, 1990, P NATL ACAD SCI USA, V87, P8587, DOI 10.1073/pnas.87.21.8587; KANAYA S, 1990, BIOCHEM J, V271, P59, DOI 10.1042/bj2710059; KANAYA S, 1989, J BIOL CHEM, V264, P11546; KANAYA S, 1983, J BIOL CHEM, V258, P1276; KANAYA S, 1991, J BIOL CHEM, V266, P6038; KANAYA S, 1990, J BIOL CHEM, V265, P4615; KANEIISHII C, 1990, J BIOL CHEM, V265, P19990; KATAYANAGI K, 1990, NATURE, V347, P306, DOI 10.1038/347306a0; KRUG MS, 1989, P NATL ACAD SCI USA, V86, P3539, DOI 10.1073/pnas.86.10.3539; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIN JG, 1988, J VIROL, V62, P4376, DOI 10.1128/JVI.62.11.4376-4380.1988; LOHMAN TM, 1980, BIOCHEMISTRY-US, V19, P3522, DOI 10.1021/bi00556a017; MANIATIS T, 1982, MOL CLONING LABORATO, P113; METELEV VG, 1988, FEBS LETT, V226, P232, DOI 10.1016/0014-5793(88)81429-7; MILLER HI, 1973, J BIOL CHEM, V248, P2621; Miller J. H., 1972, EXPT MOL GENETICS, P433; MIZRAHI V, 1990, NUCLEIC ACIDS RES, V18, P5359, DOI 10.1093/nar/18.18.5359; OYAMA F, 1989, J BIOL CHEM, V264, P18808; PRASAD VR, 1989, P NATL ACAD SCI USA, V86, P3104, DOI 10.1073/pnas.86.9.3104; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; RATTRAY AJ, 1989, J MOL BIOL, V208, P445, DOI 10.1016/0022-2836(89)90508-1; REPASKE R, 1989, J VIROL, V63, P1460, DOI 10.1128/JVI.63.3.1460-1464.1989; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V87, P8452, DOI 10.1073/pnas.87.21.8452; SCHATZ O, 1990, EMBO J, V9, P1171, DOI 10.1002/j.1460-2075.1990.tb08224.x; SCHATZ O, 1989, FEBS LETT, V257, P311, DOI 10.1016/0014-5793(89)81559-5; STARNES MC, 1989, J BIOL CHEM, V264, P7073; STEIN H, 1969, SCIENCE, V166, P393, DOI 10.1126/science.166.3903.393; TANESE N, 1988, P NATL ACAD SCI USA, V85, P1777, DOI 10.1073/pnas.85.6.1777; VARMUS H, 1988, SCIENCE, V240, P1427, DOI 10.1126/science.3287617; Vesterberg O., 1971, METHODS ENZYMOLOGY, V22, P389; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; WOHRL BM, 1990, BIOCHEMISTRY-US, V29, P10141, DOI 10.1021/bi00496a001; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648	52	117	119	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1991	266	18					11621	11627						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FT762	1646812				2022-12-25	WOS:A1991FT76200034
J	MA, ZM; GRUBB, JH; SLY, WS				MA, ZM; GRUBB, JH; SLY, WS			CLONING, SEQUENCING, AND FUNCTIONAL-CHARACTERIZATION OF THE MURINE 46-KDA MANNOSE 6-PHOSPHATE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-II; LYSOSOMAL-ENZYMES; BOVINE LIVER; LIGAND INTERACTIONS; BETA-GLUCURONIDASE; BINDING; CELLS; EXPRESSION; CDNA; DEFICIENT	We have cloned and sequenced the 2175-nucleotide, full-length cDNA for the mouse 46-kDa Man 6-P receptor (46MPR) and studied its functional properties in stably transfected mouse L cells which do not express the insulin-like growth factor-II receptor/mannose 6-phosphate receptor (IGF-IIR/MPR). The 278-amino acid sequence deduced from the cDNA for the murine 46MPR shows 19 amino acid differences from that of the human 46MPR, none of which are found in the 68-amino acid cytoplasmic tail. Binding of ligand to the murine 46MPR in permeabilized cells showed a pH optimum of 6.5, was completely inhibited by Man 6-P, and was stimulated by divalent cations. Mn2+ was more effective than Ca2+ or Mg2+. Endocytosis was demonstrated at pH 6.5 and was stimulated 4-7-fold by Mn2+. In its responsiveness to divalent cations and its preference for Mn2+, the murine 46MPR resembled the bovine 46MPR more than the human 46MPR. It was even less efficient than the human receptor in its ability to mediate endocytosis in transfected murine cells. It was also no more efficient than the human 46MPR in correcting the sorting defect of IGF-IIR/MPR-deficient mouse L cells. We conclude that the previously observed relative inefficiency of the human 46MPR in sorting enzymes to lysosomes in murine cells is a property of the 46MPR itself and not a manifestation of studying its expression in a heterologous cell line.	ST LOUIS UNIV,SCH MED,EDWARD A DOISY DEPT BIOCHEM & MOLEC BIOL,ST LOUIS,MO 63104	Saint Louis University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034182, R37GM034182] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40163] Funding Source: Medline; NIGMS NIH HHS [GM34182] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHAO HHJ, 1990, EMBO J, V9, P3507, DOI 10.1002/j.1460-2075.1990.tb07559.x; DAHMS NM, 1989, J BIOL CHEM, V264, P11458; DAHMS NM, 1987, CELL, V50, P181, DOI 10.1016/0092-8674(87)90214-5; DUNCAN JR, 1988, J CELL BIOL, V106, P617, DOI 10.1083/jcb.106.3.617; FISCHER HD, 1980, J BIOL CHEM, V255, P5069; GABEL CA, 1983, P NATL ACAD SCI-BIOL, V80, P775, DOI 10.1073/pnas.80.3.775; GARTUNG C, 1985, EMBO J, V4, P1725, DOI 10.1002/j.1460-2075.1985.tb03842.x; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GOLDBERG DE, 1983, J CELL BIOL, V97, P1700, DOI 10.1083/jcb.97.6.1700; HOFLACK B, 1987, J BIOL CHEM, V262, P123; HOFLACK B, 1985, P NATL ACAD SCI USA, V82, P4428, DOI 10.1073/pnas.82.13.4428; HOFLACK B, 1985, J BIOL CHEM, V260, P2008; JUNGHANS U, 1988, FEBS LETT, V237, P81, DOI 10.1016/0014-5793(88)80176-5; KORNFELD S, 1986, J CLIN INVEST, V77, P1, DOI 10.1172/JCI112262; KORNFELD S, 1987, FASEB J, V1, P462, DOI 10.1096/fasebj.1.6.3315809; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KYLE JW, 1988, J BIOL CHEM, V263, P16230; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SJ, 1988, J BIOL CHEM, V263, P3521; LI M, 1990, ARCH BIOCHEM BIOPHYS, V283, P150, DOI 10.1016/0003-9861(90)90625-9; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; LOBEL P, 1988, J BIOL CHEM, V263, P2563; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACDONALD RG, 1988, SCIENCE, V239, P1134, DOI 10.1126/science.2964083; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; NOLAN CM, 1990, CELL REGUL, V1, P197, DOI 10.1091/mbc.1.2.197; NOLAN CM, 1987, J CELL BIOCHEM, V35, P137, DOI 10.1002/jcb.240350207; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; OSHIMA A, 1988, J BIOL CHEM, V263, P2553; POHLMANN R, 1987, P NATL ACAD SCI USA, V84, P5575, DOI 10.1073/pnas.84.16.5575; SAHAGIAN GG, 1981, P NATL ACAD SCI-BIOL, V78, P4289, DOI 10.1073/pnas.78.7.4289; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SPRAGUE J, 1983, J VIROL, V45, P773, DOI 10.1128/JVI.45.2.773-781.1983; STEIN M, 1987, BIOL CHEM H-S, V368, P927, DOI 10.1515/bchm3.1987.368.2.927; STEIN M, 1987, EMBO J, V6, P2677, DOI 10.1002/j.1460-2075.1987.tb02559.x; TONG PY, 1988, J BIOL CHEM, V263, P2585; TONG PY, 1989, J BIOL CHEM, V264, P7962; TONG PY, 1989, J BIOL CHEM, V264, P7970; VONFIGURA K, 1984, EMBO J, V3, P1281, DOI 10.1002/j.1460-2075.1984.tb01963.x; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WAHEED A, 1990, BIOCHEMISTRY-US, V29, P2449, DOI 10.1021/bi00462a003; WAHEED A, 1990, EUR J BIOCHEM, V193, P47, DOI 10.1111/j.1432-1033.1990.tb19302.x; WATANABE H, 1990, P NATL ACAD SCI USA, V87, P8036, DOI 10.1073/pnas.87.20.8036; WENDLAND M, 1989, BIOCHEM J, V260, P201, DOI 10.1042/bj2600201	45	54	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10589	10595						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	1645352				2022-12-25	WOS:A1991FP08600088
J	SONG, WX; VACCA, MF; WELTI, R; RINTOUL, DA				SONG, WX; VACCA, MF; WELTI, R; RINTOUL, DA			EFFECTS OF GANGLIOSIDES GM3 AND DE-N-ACETYL GM3 ON EPIDERMAL GROWTH-FACTOR RECEPTOR KINASE-ACTIVITY AND CELL-GROWTH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3T3 MOUSE FIBROBLASTS; MEDIATED MODULATION; NEU ONCOGENE; TYROSINE PHOSPHORYLATION; TRANSMEMBRANE DOMAIN; POINT MUTATION; PROTEIN; MEMBRANE; GLYCOSPHINGOLIPIDS; DE-N-ACETYL-GM3	Previously it was reported (Bremer, E. G., Schlessinger, J., and Hakomori, S.-I. (1986) J. Biol. Chem. 261, 2434-2440) that ganglioside G(M3) inhibited epidermal growth factor (EGF)-stimulated phosphorylation of the EGF receptor in Triton X-100-treated preparations of human epidermoid carcinoma (A431) cell membranes. In addition, these authors reported that G(M3) inhibited the growth of A431 cells. In contrast, a modified ganglioside, de-N-acetyl G(M3), enhanced the EGF-dependent tyrosine kinase activity of the EGF receptor. In this work and in subsequent studies (Hanai, N., Dohi, T., Nores, G. A., and Hakomori, S.-I. (1988) J. Biol. Chem. 263, 6296-6301), the tyrosine kinase activity of the receptor from A431 cell membranes was assayed in the presence of Triton X-100. In this report, we confirm that G(M3) inhibited and de-N-acetyl G(M3) stimulated EGF receptor autophosphorylation in the presence of Triton X-100. However, in the absence of detergents, ganglioside G(M3) inhibited EGF-stimulated receptor autophosphorylation, whereas de-N-acetyl G(M3) had no effect on EGF-stimulated receptor autophosphorylation. The effects of these gangliosides on receptor autophosphorylation were measured in both A431 cell plasma membranes and in 3T3 cell membranes permeabilized to [P-32]ATP by a freeze-thaw procedure, in intact A431 cells permeabilized with alamethicin, and in intact A431 cells grown in the presence of [P-32]orthophosphate. Thus, the inhibitory effect of G(M3) on receptor autophosphorylation was demonstrated in the presence and in the absence of detergent; the stimulatory effect of de-N-acetyl G(M3) was observed only in the presence of detergent. We also demonstrate that ganglioside G(M3) inhibited EGF-stimulated growth of transfected murine fibroblasts (3T3) that express the gene for human EGF receptor (Velu, T. J., Beguinot, L., Vass, W. C., Zhang, K., Pastan, I., and Lowy, D. R. (1989) J. Cell. Biochem. 39, 153-166). De-N-acetyl ganglioside G(M3) had no effect on the growth of these cells. Growth of control fibroblasts, which lack endogenous EGF receptors (Pruss, R. M., and Herschman, H. R. (1977) Proc. Natl. Acad. Sci. U. S. A. 74, 3918-3921), was not affected by the presence of either ganglioside. Similarly, ganglioside G(M3), but not de-N-acetyl ganglioside G(M3), inhibited the EGF-dependent incorporation of [H-3]thymidine into DNA by transfected fibroblasts. Incorporation of labeled thymidine into DNA of control fibroblasts was not affected by the presence of either ganglioside. These studies indicate that ganglioside G(M3), but not its deacetylated analogue, can affect EGF receptor kinase activity in intact membranes. These effects are consistent with the observed effects of these gangliosides on cell growth and DNA synthesis in human cells and in murine cells expressing the human EGF receptor.	KANSAS STATE UNIV AGR & APPL SCI, DIV BIOL, MANHATTAN, KS 66506 USA; KANSAS STATE UNIV AGR & APPL SCI, DEPT BIOCHEM, MANHATTAN, KS 66506 USA	Kansas State University; Kansas State University				Welti, Ruth/0000-0003-4373-2538				ALBE KR, 1983, EXP CELL RES, V147, P167, DOI 10.1016/0014-4827(83)90281-1; Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; ARIGA T, 1982, J BIOL CHEM, V257, P2230; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BREMER EG, 1984, J BIOL CHEM, V259, P6818; BREMER EG, 1986, J BIOL CHEM, V261, P2434; CHENG YSE, 1981, P NATL ACAD SCI-BIOL, V78, P2388, DOI 10.1073/pnas.78.4.2388; COHEN S, 1982, J BIOL CHEM, V257, P1523; COHEN S, 1983, METHOD ENZYMOL, V99, P379; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; FISHMAN PH, 1972, BIOCHEM BIOPH RES CO, V48, P48, DOI 10.1016/0006-291X(72)90342-7; GENNIS RB, 1989, BIOMEMBRANES MOL STR, P92; HAKOMORI S, 1986, SCI AM, V254, P44, DOI 10.1038/scientificamerican0586-44; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HANAI N, 1988, J BIOL CHEM, V263, P10915; HANAI N, 1987, BIOCHEM BIOPH RES CO, V147, P127, DOI 10.1016/S0006-291X(87)80096-7; HANAI N, 1988, J BIOL CHEM, V263, P6296; ICARDLIEPKALNS C, 1982, J CELL PHYSIOL, V113, P186, DOI 10.1002/jcp.1041130128; IRWIN CC, 1979, ANAL BIOCHEM, V94, P335, DOI 10.1016/0003-2697(79)90369-5; KASHLES O, 1988, P NATL ACAD SCI USA, V85, P9567, DOI 10.1073/pnas.85.24.9567; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; MOMOI T, 1976, BIOCHIM BIOPHYS ACTA, V441, P488; NAOI M, 1974, ANAL BIOCHEM, V58, P571, DOI 10.1016/0003-2697(74)90226-7; NORES GA, 1989, METHOD ENZYMOL, V179, P242; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PRUSS RM, 1977, P NATL ACAD SCI USA, V74, P3918, DOI 10.1073/pnas.74.9.3918; RIEDEL H, 1988, P NATL ACAD SCI USA, V85, P1477, DOI 10.1073/pnas.85.5.1477; RINTOUL DA, 1979, J BIOL CHEM, V254, P70; SCHEEL G, 1985, EUR J BIOCHEM, V153, P29, DOI 10.1111/j.1432-1033.1985.tb09262.x; SCHWARZMANN G, 1978, BIOCHIM BIOPHYS ACTA, V529, P106, DOI 10.1016/0005-2760(78)90108-X; VELU TJ, 1989, J CELL BIOCHEM, V39, P153, DOI 10.1002/jcb.240390207; WEIS FMB, 1990, J BIOL CHEM, V265, P12059; WEST DW, 1984, BIOCHEM J, V219, P181, DOI 10.1042/bj2190181; WIDES RJ, 1990, EUR J BIOCHEM, V189, P637, DOI 10.1111/j.1432-1033.1990.tb15532.x; YARDEN Y, 1985, J BIOL CHEM, V260, P315; YOGEESWARAN G, 1972, J BIOL CHEM, V247, P5146	39	50	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10174	10181						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	1645342				2022-12-25	WOS:A1991FP08600030
J	ALAM, J; SMITH, A				ALAM, J; SMITH, A			HEME-HEMOPEXIN-MEDIATED INDUCTION OF METALLOTHIONEIN GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE HEPATOMA-CELLS; PROTEIN-KINASE-C; I MESSENGER-RNA; TRANSFERRIN RECEPTOR; POSTTRANSCRIPTIONAL REGULATION; TRANSCRIPTIONAL ACTIVATION; ANTIOXIDANT PROTECTION; FERRITIN SYNTHESIS; ZINC-METABOLISM; RAT HEPATOCYTES	Hemopexin-mediated heme transport into mouse hepatoma (Hepa) cells and human promyelocytic (HL-60) cells stimulates the expression of heme oxygenase via transcriptional activation (Alam, J., and Smith, A. (1989) J. Biol. Chem. 264, 17637-17640). Incubation of both these cell types in serum-free medium containing heme-hemopexin is shown here also to increase the steady-state level of metallothionein (MT) mRNA in a time- and dose-dependent manner. Heme-hemopexin is a far more effective inducer (12-fold) of the MT isozyme 1 (MT-1) in Hepa cells than nonprotein-bound heme (4-fold). Apohemopexin has no effect on MT-1 expression, and incubation with heme-hemopexin of mouse L fibroblasts that lack hemopexin receptors does not affect MT-1 expression. Thus, an interaction between the heme-hemopexin complex and its receptor is necessary for increased accumulation of MT-1 transcripts. In vitro nuclear "run-on" analysis indicates that the heme-hemopexin-mediated accumulation of MT-1 mRNA is regulated primarily at the level of initiation of transcription. A highly labile protein is required for constitutive MT-1 gene expression and acts to repress transcription. Transcriptional activation by heme or metals may require decreased concentrations or inactivation of the repressor as well as an additional inducer-specific trans-acting factor. Inhibition of protein synthesis augments the heme-hemopexin-mediated accumulation of MT-1 mRNA. Activation of heme oxygenase (HO) gene transcription by heme requires the synthesis of one (or more) heme-inducible proteins that are labile or become labile upon cycloheximide-sensitive processing or activation. Our comparison of MT and HO points to significant differences in the mechanisms of gene regulation by heme. The concomitant regulation of gene expression of MT-1 and HO in response to heme-hemopexin appears to be a concerted adaptive response of the cells, mediated at the level of the plasma membrane hemopexin receptor, and may relate to the proposed role of MT as an intracellular antioxidant or to a need to sequester zinc which otherwise would compete with iron and occupy sites on regulatory proteins such as the iron-responsive elements.	UNIV MISSOURI, SCH BASIC LIFE SCI, DIV MOLEC BIOL & BIOCHEM, 5100 ROCKHILL RD, KANSAS CITY, MO 64110 USA; ALTON OCHSNER MED FDN & OCHSNER CLIN, DEPT MOLEC GENET, NEW ORLEANS, LA 70121 USA	University of Missouri System; University of Missouri Kansas City; Ochsner Health System					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037463] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-37463] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALAM J, 1989, J BIOL CHEM, V264, P17637; ALAM J, 1989, J BIOL CHEM, V264, P6371; BAUMANN H, 1987, J BIOL CHEM, V262, P9756; BAUMANN H, 1987, BIOCHEM BIOPH RES CO, V146, P1218, DOI 10.1016/0006-291X(87)90778-9; CARMEL N, 1977, ISRAEL J MED SCI, V13, P1182; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CHRONEOS ZC, 1990, FASEB J, V4, pA2281; CIECHANOVER A, 1983, J BIOL CHEM, V258, P9681; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COUSINS RJ, 1988, FASEB J, V2, P2884, DOI 10.1096/fasebj.2.13.2458983; DAVIES DM, 1979, BIOCHEM BIOPH RES CO, V91, P1504, DOI 10.1016/0006-291X(79)91235-X; DURNAM DM, 1981, J BIOL CHEM, V256, P5712; DURNAM DM, 1984, MOL CELL BIOL, V4, P484, DOI 10.1128/MCB.4.3.484; EATON JW, 1982, SCIENCE, V215, P691, DOI 10.1126/science.7036344; ELDER PK, 1984, P NATL ACAD SCI-BIOL, V81, P7476, DOI 10.1073/pnas.81.23.7476; FAILLA ML, 1978, BIOCHIM BIOPHYS ACTA, V538, P435, DOI 10.1016/0304-4165(78)90405-1; FLEET JC, 1990, J NUTR, V120, P1214, DOI 10.1093/jn/120.10.1214; FRIEDMAN RL, 1984, CELL, V38, P745, DOI 10.1016/0092-8674(84)90270-8; GLANVILLE N, 1981, NATURE, V292, P267, DOI 10.1038/292267a0; GOLOS TG, 1987, MOL ENDOCRINOL, V1, P321, DOI 10.1210/mend-1-4-321; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; GUTTERIDGE JMC, 1988, BIOCHEM J, V256, P861, DOI 10.1042/bj2560861; HAGER LJ, 1981, NATURE, V291, P340, DOI 10.1038/291340a0; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; HALLIWELL B, 1986, TRENDS BIOCHEM SCI, V11, P372, DOI 10.1016/0968-0004(86)90207-0; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; HIDALGO J, 1988, AM J PHYSIOL, V255, pE518, DOI 10.1152/ajpendo.1988.255.4.E518; IMBRA RJ, 1987, MOL CELL BIOL, V7, P1358, DOI 10.1128/MCB.7.4.1358; KAGEYAMA H, 1988, CANCER RES, V48, P4795; KARIN M, 1980, NATURE, V286, P295, DOI 10.1038/286295a0; KINGSTON RE, 1987, CURRENT PROTOCOLS MO, P1; KLAUSNER RD, 1984, P NATL ACAD SCI-BIOL, V81, P3005, DOI 10.1073/pnas.81.10.3005; KLEIN ES, 1988, MOL ENDOCRINOL, V2, P1343, DOI 10.1210/mend-2-12-1343; LIN JJ, 1990, BIOCHIM BIOPHYS ACTA, V1050, P146, DOI 10.1016/0167-4781(90)90156-V; MAINES MD, 1976, BIOCHEM J, V154, P125, DOI 10.1042/bj1540125; Marzluff W. F., 1984, TRANSCRIPTION TRANSL, P89; MAY WS, 1987, J BIOL CHEM, V262, P16710; MAYO KE, 1981, J BIOL CHEM, V256, P2621; MCCORMICK CC, 1991, BIOCHEM J, V273, P185, DOI 10.1042/bj2730185; MERRIMAN CR, 1978, P SOC EXP BIOL MED, V157, P669; MEYUHAS O, 1980, GENE, V10, P113, DOI 10.1016/0378-1119(80)90129-8; MORGAN WT, 1988, J BIOL CHEM, V263, P8226; MULLER RM, 1987, J BIOL CHEM, V262, P6795; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; NEBES VL, 1988, BIOCHEM J, V255, P741; OH SH, 1978, AM J PHYSIOL, V234, pE282, DOI 10.1152/ajpendo.1978.234.3.E282; PFEIFER K, 1987, CELL, V49, P9, DOI 10.1016/0092-8674(87)90750-1; PICADOLEONARD J, 1988, J BIOL CHEM, V263, P3240; RANGARAJAN PN, 1989, P NATL ACAD SCI USA, V86, P3963, DOI 10.1073/pnas.86.11.3963; REED RG, 1990, FASEB J, V4, pA2281; ROGERS JT, 1990, J BIOL CHEM, V265, P14572; SCHROEDER JJ, 1990, P NATL ACAD SCI USA, V87, P3137, DOI 10.1073/pnas.87.8.3137; SHIBAHARA S, 1978, ARCH BIOCHEM BIOPHYS, V188, P243, DOI 10.1016/S0003-9861(78)80006-X; SHIBAHARA S, 1987, J BIOL CHEM, V262, P12889; SINCLAIR PR, 1988, BIOCHEM J, V256, P159, DOI 10.1042/bj2560159; SMITH A, 1979, BIOCHEM J, V182, P47, DOI 10.1042/bj1820047; SMITH A, 1991, BIOCHEM J, V276, P417, DOI 10.1042/bj2760417; SMITH A, 1990, EUR J CELL BIOL, V53, P234; SMITH A, 1978, BIOCHEM BIOPH RES CO, V84, P151, DOI 10.1016/0006-291X(78)90276-0; SMITH A, 1981, J BIOL CHEM, V256, P902; SMITH A, 1984, J BIOL CHEM, V259, P2049; SMITH A, 1988, BIOCHEM J, V256, P941, DOI 10.1042/bj2560941; Smith A., 1990, BIOSYNTHESIS HEME CH, P435; SRIVASTAVA G, 1988, J BIOL CHEM, V263, P5202; SUBRAMANIAM M, 1989, NATURE, V340, P64, DOI 10.1038/340064a0; TAKETANI S, 1987, J BIOL CHEM, V262, P4639; THORNALLEY PJ, 1985, BIOCHIM BIOPHYS ACTA, V827, P36, DOI 10.1016/0167-4838(85)90098-6; YOOWARREN H, 1983, P NATL ACAD SCI-BIOL, V80, P3656, DOI 10.1073/pnas.80.12.3656	69	77	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16379	16384						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1644822				2022-12-25	WOS:A1992JJ45800062
J	DAVIE, JR; WYNN, RM; COX, RP; CHUANG, DT				DAVIE, JR; WYNN, RM; COX, RP; CHUANG, DT			EXPRESSION AND ASSEMBLY OF A FUNCTIONAL E1 COMPONENT (ALPHA-2-BETA-2) OF MAMMALIAN BRANCHED-CHAIN ALPHA-KETOACID DEHYDROGENASE COMPLEX IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYRUP URINE DISEASE; DIHYDROLIPOYL TRANSACYLASE COMPONENT; MULTI-SITE PHOSPHORYLATION; ACID DEHYDROGENASE; BOVINE KIDNEY; PYRUVATE-DEHYDROGENASE; SUBUNIT STRUCTURE; Y393N MUTATION; LIVER; PURIFICATION	We have expressed an active recombinant E1 decarboxylase component of the mammalian branched-chain alpha-ketoacid dehydrogenase complex in Escherichia coli by subcloning mature E1-alpha and E1-beta-subunit cDNA sequences into a bacterial expression vector. To permit affinity purification under native conditions, the mature E1-alpha-subunit was fused with the affinity ligand E. coli maltose-binding protein (MBP) through an endoprotease Factor Xa-specific linker peptide. When coexpressed, the MBP-E1-alpha-fusion and E1-beta-subunits were shown to co-purify as a MBP-E1 component that exhibited both E1 activity and binding competence for recombinant branched-chain E2 component. In contrast, in vitro mixing of individually expressed MBP-E1-alpha and E1-beta did not result in assembly or produce E1 activity. Following proteolytic removal of the affinity ligand and linker peptide with Factor Xa, a recombinant E1 species was eluted from a Sephacryl S-300HR sizing column as an enzymatically active 160-kDa species. The latter showed 1:1 subunit stoichiometry, which was consistent with an alpha-2-beta-2 structure. The recovery of this 160-kDa recombinant E1 species (estimated at 0.07% of total lysate protein) was low, with the majority of the recombinant protein lost as insoluble aggregates. Our findings suggest that the concurrent expression of both E1-alpha and E1-beta-subunits in the same cellular compartment is important for assembly of both subunits into a functional E1-alpha-2-beta-2 heterotetramer. By using this co-expression system, we also find that the E1-alpha missense mutation (Tyr-393 --> Asn) characterized in Mennonites with maple syrup urine disease prevents the assembly of soluble E1 heterotetramers.	UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT INTERNAL MED, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Wynn, Richard/0000-0002-1879-2136; Davie, James/0000-0002-0420-6888	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026758, R01DK037373] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-26758, DK-37373] Funding Source: Medline; NIGMS NIH HHS [5-P32 GM-08014] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANG D, 1991, J BIOL CHEM, V266, P24233; BARRERA CR, 1972, ARCH BIOCHEM BIOPHYS, V148, P343, DOI 10.1016/0003-9861(72)90152-X; CHUANG DT, 1988, METHOD ENZYMOL, V166, P146; CHUANG DT, 1984, J BIOL CHEM, V259, P9277; CHUANG DT, 1985, J BIOL CHEM, V260, P3779; COOK KG, 1983, FEBS LETT, V164, P85, DOI 10.1016/0014-5793(83)80024-6; COOK KG, 1985, BIOCHEM J, V225, P731, DOI 10.1042/bj2250731; DAMUNI Z, 1984, P NATL ACAD SCI-BIOL, V81, P4335, DOI 10.1073/pnas.81.14.4335; FATANIA HR, 1983, FEBS LETT, V158, P234, DOI 10.1016/0014-5793(83)80585-7; FISHER CR, 1991, J CLIN INVEST, V88, P1034, DOI 10.1172/JCI115363; FISHER CR, 1991, AM J HUM GENET, V49, P429; FISHER CW, 1989, J BIOL CHEM, V264, P3448; GRIFFIN TA, 1990, J BIOL CHEM, V265, P12104; HEFFELFINGER SC, 1983, BIOCHEMISTRY-US, V22, P5519, DOI 10.1021/bi00293a011; LAU KS, 1982, FEBS LETT, V144, P57, DOI 10.1016/0014-5793(82)80568-1; LAU KS, 1983, FEBS LETT, V160, P149, DOI 10.1016/0014-5793(83)80955-7; LUBBEN TH, 1990, P NATL ACAD SCI USA, V87, P7683, DOI 10.1073/pnas.87.19.7683; MATSUDA I, 1990, BIOCHEM BIOPH RES CO, V172, P646, DOI 10.1016/0006-291X(90)90723-Z; ODESSEY R, 1982, BIOCHEM J, V204, P353, DOI 10.1042/bj2040353; ONO K, 1987, BIOCHEM MED METAB B, V37, P133, DOI 10.1016/0885-4505(87)90019-3; PAXTON R, 1982, J BIOL CHEM, V257, P4433; PETTIT FH, 1978, P NATL ACAD SCI USA, V75, P4881, DOI 10.1073/pnas.75.10.4881; REED LJ, 1980, FEBS S, V60, P47; RIGGS P, 1990, CURRENT PROTOCOLS MO; Sambrook J, 1989, MOL CLONING LABORATO; STEPP LR, 1985, BIOCHEMISTRY-US, V24, P7187, DOI 10.1021/bi00346a026; WYNN RM, 1992, J BIOL CHEM, V267, P1881; WYNN RM, 1992, J BIOL CHEM, V267, P12400; ZHANG B, 1989, J CLIN INVEST, V83, P1425, DOI 10.1172/JCI114033	29	35	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16601	16606						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1644840				2022-12-25	WOS:A1992JJ45800094
J	NOVGORODOV, SA; GUDZ, TI; MILGROM, YM; BRIERLEY, GP				NOVGORODOV, SA; GUDZ, TI; MILGROM, YM; BRIERLEY, GP			THE PERMEABILITY TRANSITION IN HEART-MITOCHONDRIA IS REGULATED SYNERGISTICALLY BY ADP AND CYCLOSPORINE-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; CA-2+-INDUCED MEMBRANE TRANSITION; ADENINE-NUCLEOTIDE POOL; INNER-MEMBRANE; CA-2+-DEPENDENT PORE; ADP/ATP CARRIER; PHOSPHATE; CALCIUM; BINDING; INHIBITION	Heart mitochondria respiring in a sucrose medium containing P(i) show a permeability transition when challenged with Ca2+ and an oxidant such as cumene hydroperoxide. The transition results from the opening of a Ca2+-dependent pore and is evidenced by loss of membrane potential (DELTA-psi) and osmotic swelling due to uptake of sucrose and other solutes. In the absence of oxidant, high concentrations of Ca2+ (100-150-mu-M) are necessary to induce loss of DELTA-psi and initiate swelling. Cyclosporin A delays the loss of DELTA-psi but enhances swelling under these conditions, apparently by promoting better retention of accumulated Ca2+. Cyclosporin A and ADP together restore DELTA-psi in respiring mitochondria that have undergone the permeability transition at levels that are not effective when either is added alone. When the state of the Ca2+-dependent pore is assessed using passive osmotic contraction in response to polyethylene glycol (Haworth, R. A., and Hunter, D. R. (1979) Arch. Biochem. Biophys. 195, 460-467), cyclosporin A is found to be a partial inhibitor of solute now through the open pore. Cyclosporin A decreases the V(max) of passive contraction and increases the K(m) for Ca2+ without affecting the Hill slope. ADP in the presence of carboxyatractyloside closes the pore almost completely even in the presence of 40-mu-M Ca2+. ADP shows mixed type inhibition of the Ca2+-dependent pore, and cyclosporin A increases the affinity of the pore for ADP. It is concluded that cyclosporin A and ADP act synergistically to close the Ca2+-dependent pore of the mitochondrion and that the pore is probably not formed directly from the adenine nucleotide transporter.	OHIO STATE UNIV, DEPT MED BIOCHEM, 1645 NEIL AVE, COLUMBUS, OH 43210 USA; MV LOMONOSOV STATE UNIV, AN BELOZERSKY PHYSICOCHEM BIOL INST, MOSCOW 117234, USSR; MV LOMONOSOV STATE UNIV, FAC BIOL, DEPT BIOPHYS, MOSCOW 117234, USSR; SUNY HLTH SCI CTR, DEPT BIOCHEM & MOLEC BIOL, SYRACUSE, NY 13210 USA	University System of Ohio; Ohio State University; Lomonosov Moscow State University; Lomonosov Moscow State University; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center					NHLBI NIH HHS [HL09364] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALNASSER I, 1986, BIOCHEM J, V239, P19, DOI 10.1042/bj2390019; ALTSCHULD R, 1992, FASEB J, V6, pA400; ALTSCHULD RA, 1987, J BIOL CHEM, V262, P13527; APRILLE JR, 1981, ARCH BIOCHEM BIOPHYS, V212, P689, DOI 10.1016/0003-9861(81)90413-6; ASIMAKIS GK, 1985, AM J PHYSIOL, V249, P1009; ASIMAKIS GK, 1980, ARCH BIOCHEM BIOPHYS, V203, P307, DOI 10.1016/0003-9861(80)90181-2; BEATRICE MC, 1982, J BIOL CHEM, V257, P7161; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; BLOCK MR, 1983, BIOCHEMISTRY-US, V22, P2202, DOI 10.1021/bi00278a022; BRIERLEY GP, 1984, J BIOL CHEM, V259, P4672; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; COELHO JLC, 1980, ARCH BIOCHEM BIOPHYS, V204, P141, DOI 10.1016/0003-9861(80)90016-8; CROMPTON M, 1988, BIOCHEM J, V255, P357; CROMPTON M, 1990, BIOCHEM J, V266, P33, DOI 10.1042/bj2660033; CROMPTON M, 1990, INTRACELLULAR CALCIU, P183; DIERKS T, 1990, BIOCHIM BIOPHYS ACTA, V1028, P268, DOI 10.1016/0005-2736(90)90176-O; FOURNIER N, 1987, J BIOENERG BIOMEMBR, V19, P297, DOI 10.1007/BF00762419; GRIFFITHS EJ, 1991, BIOCHEM J, V274, P611, DOI 10.1042/bj2740611; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; HAWORTH RA, 1980, FED PROC, V39, P1707; HAWORTH RA, 1979, ARCH BIOCHEM BIOPHYS, V195, P460, DOI 10.1016/0003-9861(79)90372-2; HAWORTH RA, 1980, J MEMBRANE BIOL, V54, P231, DOI 10.1007/BF01870239; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P453, DOI 10.1016/0003-9861(79)90371-0; HUNTER DR, 1976, J BIOL CHEM, V251, P5069; JOCELYN PC, 1980, BIOCHIM BIOPHYS ACTA, V590, P1, DOI 10.1016/0005-2728(80)90141-3; JUNG DW, 1992, AM J PHYSIOL, V262, pC1047, DOI 10.1152/ajpcell.1992.262.4.C1047; KAMO N, 1979, J MEMBRANE BIOL, V49, P105, DOI 10.1007/BF01868720; KLINGENBERG M, 1975, EUR J BIOCHEM, V52, P351, DOI 10.1111/j.1432-1033.1975.tb04003.x; KLINGENBERG M, 1989, ARCH BIOCHEM BIOPHYS, V270, P1, DOI 10.1016/0003-9861(89)90001-5; LEHNINGER A L, 1970, Biochemical Journal, V119, P129; LEQUOC K, 1988, ARCH BIOCHEM BIOPHYS, V265, P249, DOI 10.1016/0003-9861(88)90125-7; MCGUINNESS O, 1990, EUR J BIOCHEM, V194, P671, DOI 10.1111/j.1432-1033.1990.tb15667.x; MEISNER H, 1968, J BIOL CHEM, V243, P3631; NOVGORODOV SA, 1990, BIOCHEM BIOPH RES CO, V277, P123; PETRONILLI V, 1989, FEBS LETT, V259, P137, DOI 10.1016/0014-5793(89)81513-3; Pfeiffer D R, 1988, Adv Exp Med Biol, V232, P15; PFEIFFER DR, 1983, BIOCH METABOLIC PROC, P67; REED DJ, 1990, ANNU REV PHARMACOL, V30, P603, DOI 10.1146/annurev.pa.30.040190.003131; SCHEFER U, 1986, ANAL CHEM, V58, P2282, DOI 10.1021/ac00124a036; Segel I. H, 1975, ENZYME KINETICS, P465; SZABO I, 1992, J BIOL CHEM, V267, P2940; SZABO I, 1991, J BIOL CHEM, V266, P3376; SZABO I, 1992, J BIOENERG BIOMEMBR, V24, P111, DOI 10.1007/BF00769537; TONINELLO A, 1983, BIOCHEM BIOPH RES CO, V111, P792, DOI 10.1016/0006-291X(83)91368-2; VIGNAIS PV, 1989, ANION CARRIERS OF MITOCHONDRIAL MEMBRANES, P133; VODYANOY I, 1992, FASEB J, V6, P114; WILSON DE, 1987, BIOCHIM BIOPHYS ACTA, V893, P470, DOI 10.1016/0005-2728(87)90098-3; ZOCCARATO F, 1981, EUR J BIOCHEM, V114, P195, DOI 10.1111/j.1432-1033.1981.tb05136.x	49	143	144	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16274	16282						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1644813				2022-12-25	WOS:A1992JJ45800045
J	PATTANAIK, A; BACHOWSKI, G; LAIB, J; LEMKUIL, D; SHAW, CF; PETERING, DH; HITCHCOCK, A; SARYAN, L				PATTANAIK, A; BACHOWSKI, G; LAIB, J; LEMKUIL, D; SHAW, CF; PETERING, DH; HITCHCOCK, A; SARYAN, L			PROPERTIES OF THE REACTION OF CIS-DICHLORODIAMMINEPLATINUM(II) WITH METALLOTHIONEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED-CELLS; PLATINUM; BINDING; RESISTANCE; ZINC; METABOLISM; TOXICITY; TISSUES; COPPER; METALS	Properties of the reactions of cis-dichlorodiammine Pt(II) and related complexes with zinc metallothionein or apometallothionein have been investigated. During these reactions, platinum binds stoichiometrically to protein sulfhydryl groups and zinc, if present, is displaced. The ammine ligands are also lost in the process, suggesting that Pt(II) has tetrathiolate coordination in metallothionein. This conclusion is supported by extended x-ray absorption-fine structure studies which indicate that there are 4 sulfurs in the first coordination sphere of the platinum centers. The product contains 10 +/- 2 Pt(II) per mol of protein and migrates over Sephadex G-75 as a structure of similar size to zinc metallothionein. The kinetics of reaction are biphasic as monitored by the formation of Pt-thiolate bonds or by the release of zinc from the protein. Both methods yield identical rate laws for the reaction. The first step is independent of Pt(II) concentration but involves the binding of as many as four platinum atoms to the protein with little Pt-sulfhydryl bond formation and without much loss of zine. The second rate process is first order in both zinc or sulfhydryl binding sites and Pt(II). Neither kinetic step is sensitive to the chloride ion concentration over the range 0-0.5 M. However, the reaction is sensitive to pH between 5.5 and 8.0. trans-Dichlorodiammineplatinum(II) reacts with zinc metallothionein with similar kinetics.	UNIV WISCONSIN, DEPT CHEM, CHEM BLDG, MILWAUKEE, WI 53201 USA; MCMASTER UNIV, HAMILTON L8S 4L8, ONTARIO, CANADA; W ALLIS MEM HOSP, IND TOXICOL LAB, MILWAUKEE, WI 53227 USA	University of Wisconsin System; University of Wisconsin Milwaukee; McMaster University					NIEHS NIH HHS [ES-O4026] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004026] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANDREWS PA, 1987, CANCER CHEMOTH PHARM, V19, P149; ARSENIEV A, 1988, J MOL BIOL, V201, P637, DOI 10.1016/0022-2836(88)90644-4; BAKKA A, 1981, TOXICOL APPL PHARM, V61, P215, DOI 10.1016/0041-008X(81)90411-7; BASOLO F, 1972, MECHANISMS INORGANIC, pCH5; Bevington P. R., 1969, DATA REDUCTION ERROR, P235; BOHLEN P, 1973, ARCH BIOCHEM BIOPHYS, V155, P213, DOI 10.1016/S0003-9861(73)80023-2; BONGERS J, 1988, J INORG BIOCHEM, V34, P55, DOI 10.1016/0162-0134(88)85017-7; BONGERS J, 1990, INORG CHEM, V30, P515; DEDON PC, 1987, BIOCHEM PHARMACOL, V36, P1955, DOI 10.1016/0006-2952(87)90494-1; EASTMAN A, 1986, BIOCH MECHANISMS PLA, P91; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; ENDRESEN L, 1983, CANCER RES, V43, P2918; HAMILTON TC, 1985, BIOCHEM PHARMACOL, V34, P2583, DOI 10.1016/0006-2952(85)90551-9; HITCHCOCK AP, 1986, INORG CHIM A-BIOINOR, V124, P101, DOI 10.1016/S0020-1693(00)86033-8; KELLEY SL, 1988, SCIENCE, V241, P1813, DOI 10.1126/science.3175622; KRAKER A, 1985, BIOCHEM BIOPH RES CO, V130, P786, DOI 10.1016/0006-291X(85)90485-1; LAIB JE, 1985, BIOCHEMISTRY-US, V24, P1977, DOI 10.1021/bi00329a027; LI TY, 1980, P NATL ACAD SCI-BIOL, V77, P6334, DOI 10.1073/pnas.77.11.6334; LI TY, 1981, BIOCHEM J, V193, P441, DOI 10.1042/bj1930441; LIM MC, 1976, J INORG NUCL CHEM, V38, P1911, DOI 10.1016/0022-1902(76)80121-2; MANAKA RC, 1978, CHEM-BIOL INTERACT, V22, P353, DOI 10.1016/0009-2797(78)90139-4; MCPARTLIN EM, 1969, ACTA CRYSTALL B-STRU, VB 25, P1659, DOI 10.1107/S0567740869004481; MINKEL DT, 1980, BIOCHEM J, V191, P475, DOI 10.1042/bj1910475; NAGANUMA A, 1987, CANCER RES, V47, P983; NETTESHEIM DG, 1985, BIOCHEMISTRY-US, V24, P6744, DOI 10.1021/bi00345a003; NIELSON KB, 1984, J BIOL CHEM, V259, P4941; ONOSAKA S, 1982, TOXICOLOGY, V23, P11, DOI 10.1016/0300-483X(82)90037-3; ONOSAKA S, 1986, TOXICOLOGY, V38, P261, DOI 10.1016/0300-483X(86)90142-3; PETERING DH, 1984, ENVIRON HEALTH PERSP, V54, P73; PETERING DH, 1984, ANTICANCER INTERFERO, pCH7; ROBINS AB, 1973, CHEM-BIOL INTERACT, V6, P35, DOI 10.1016/0009-2797(73)90084-7; ROSENBERG B, 1980, MET IONS BIOL SYST, V11, P127; RUSH RM, 1954, ANAL CHEM, V26, P1345, DOI 10.1021/ac60092a024; SHAW CF, 1990, INORG CHEM, V29, P403, DOI 10.1021/ic00328a012; SHERMAN SE, 1987, CHEM REV, V87, P1153, DOI 10.1021/cr00081a013; UJJANI B, 1986, BIOCHEM J, V233, P99, DOI 10.1042/bj2330099; VASAK M, 1983, MET IONS BIOL SYST, V15, P213; WEBB M, 1979, CHEM BIOCH BIOL CADM, pCH6; ZELAZOWSKI AJ, 1984, ARCH BIOCHEM BIOPHYS, V229, P246	39	80	81	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16121	16128						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1644799				2022-12-25	WOS:A1992JJ45800024
J	PENTLAND, AP; MORRISON, AR; JACOBS, SC; HRUZA, LL; HEBERT, JS; PACKER, L				PENTLAND, AP; MORRISON, AR; JACOBS, SC; HRUZA, LL; HEBERT, JS; PACKER, L			TOCOPHEROL ANALOGS SUPPRESS ARACHIDONIC-ACID METABOLISM VIA PHOSPHOLIPASE INHIBITION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-E; PROSTAGLANDIN SYNTHESIS; LIPID-PEROXIDATION; ALPHA-TOCOPHEROL; MECHANISM; INJURY; STABILIZATION; BIOSYNTHESIS; SYNTHASE; CA-2+	Alpha-tocopherol and three derivatives in which the phytol chain is modified or deleted were examined for their effect on cultured keratinocyte arachidonic acid metabolism. 2,2,5,7,8-Pentamethyl-6-hydroxychromane (PMC), in which the phytol chain is replaced by a methyl group, inhibited basal, bradykinin (BK)- and A23187-stimulated prostaglandin E2 (PGE2) synthesis with an apparent K(i) of 1.3-mu-M. The K(i) of the analogue with six carbon atoms in the side chain (C6) was 5-mu-M while that of the C11 analogue was 10-mu-M. No effect of alpha-tocopherol was observed. The mechanism of inhibition was studied using PMC. The effect of PMC on phospholipase and cyclooxygenase activity was assayed using stable isotope mass measurements of PGE2 formation, which assesses arachidonate release and cyclooxygenase metabolism simultaneously. BK-stimulated formation of PGE2, derived from endogenous phospholipid, was decreased 60% by 5-mu-M PMC and eliminated by 50-mu-M PMC, compared with controls. No difference in PGE2 formed from exogenous arachidonic acid was observed, indicating no effect of PMC on cyclooxygenase activity. In contrast, no effect of 5-mu-M PMC was observed on BK-stimulated [H-3]arachidonic acid release from prelabeled cultures. The capacity of PMC to inhibit phospholipase activity in vitro was also assessed. PMC inhibited hydrolysis of phospholipid substrate by up to 60%. These results suggest that alpha-tocopherol analogues with alterations in the phytol chain inhibit eicosanoid synthesis by preferential inhibition of phospholipase.	WASHINGTON UNIV, SCH MED, DEPT MED, DIV NEPHROL, ST LOUIS, MO 63110 USA; UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, MEMBRANE BIOENERGET GRP, BERKELEY, CA 94720 USA	Washington University (WUSTL); University of California System; University of California Berkeley	PENTLAND, AP (corresponding author), WASHINGTON UNIV, SCH MED,DEPT MED,DIV DERMATOL,660 S EUCLID, BOX 8123, ST LOUIS, MO 63110 USA.				NIAMS NIH HHS [K04 AR01849, AR40574] Funding Source: Medline; NIDDK NIH HHS [DK38111] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K04AR001849, R01AR040574] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038111] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAKALOVA RA, 1988, P NATL ACAD SCI USA, V299, P1008; BECKMAN JK, 1987, J BIOL CHEM, V262, P1479; BURTON GW, 1986, ACCOUNTS CHEM RES, V19, P194, DOI 10.1021/ar00127a001; COYNE DW, 1992, IN PRESS AM J PHYSL; DICCIANNI MB, 1991, BIOCHEMISTRY-US, V30, P9090, DOI 10.1021/bi00101a026; DOUGLAS CE, 1986, BIOCHIM BIOPHYS ACTA, V876, P639, DOI 10.1016/0005-2760(86)90053-6; ERIN AN, 1986, BRAIN RES, V398, P85, DOI 10.1016/0006-8993(86)91253-9; GAMACHE DA, 1988, BIOCHIM BIOPHYS ACTA, V958, P116, DOI 10.1016/0005-2760(88)90252-4; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEMLER ME, 1980, J BIOL CHEM, V255, P6253; KAGAN V, 1990, BIOL OXIDATION SYSTE, P1; KAGAN VE, 1989, ANN NY ACAD SCI, V570, P121; KAGAN VE, 1990, BIOCHEM PHARMACOL, V40, P2403, DOI 10.1016/0006-2952(90)90080-5; KARPEN CW, 1982, DIABETES, V31, P947, DOI 10.2337/diacare.31.11.947; MALGAROLI A, 1987, J CELL BIOL, V105, P2145, DOI 10.1083/jcb.105.5.2145; MARKEY CM, 1987, J BIOL CHEM, V262, P6266; MARSHALL PJ, 1987, J BIOL CHEM, V262, P3510; PANGANAMALA RV, 1982, ANN NY ACAD SCI, V393, P376, DOI 10.1111/j.1749-6632.1982.tb31277.x; PENTLAND AP, 1990, J CLIN INVEST, V86, P566, DOI 10.1172/JCI114746; PENTLAND AP, 1986, J CLIN INVEST, V77, P246, DOI 10.1172/JCI112283; PENTLAND AP, 1991, AM J PHYSIOL, V261, pR543, DOI 10.1152/ajpregu.1991.261.3.R543; REDDANNA P, 1985, FEBS LETT, V193, P39, DOI 10.1016/0014-5793(85)80075-2; SAKAMOTO W, 1991, PROSTAG LEUKOTR ESS, V44, P89, DOI 10.1016/0952-3278(91)90188-B; SEN A, 1991, BIOCHEMISTRY-US, V30, P4516, DOI 10.1021/bi00232a021; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; WEI EP, 1982, J NEUROSURG, V56, P695, DOI 10.3171/jns.1982.56.5.0695; WUWANG CY, 1987, PROSTAG LEUKOTR ESS, V26, P291, DOI 10.1016/0262-1746(87)90038-2	28	59	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15578	15584						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1639798				2022-12-25	WOS:A1992JG11300052
J	ROWAN, AD; MASON, P; MACH, L; MORT, JS				ROWAN, AD; MASON, P; MACH, L; MORT, JS			RAT PROCATHEPSIN-B - PROTEOLYTIC PROCESSING TO THE MATURE FORM INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER CATHEPSIN-B; AMINO-ACID-SEQUENCES; CYSTEINE PROTEINASE; NEUTROPHIL ELASTASE; THIOL PROTEINASE; ASCITIC FLUID; HUMAN SPUTUM; ALPHA-FACTOR; CYSTATIN-C; PURIFICATION	Expression of rat procathepsin B in yeast led to the secretion of both the latent and mature forms of the enzyme. Culture in the presence of a cysteine proteinase inhibitor prevented this processing. We have expressed and purified a mutant form of rat procathepsin B whose active-site cysteine residue has been changed to a serine, and which also lacks the glycosylation site in the mature region of the protein. This non-active mutant protein was secreted essentially in an unprocessed form. The purified protein has been incubated with a variety of proteinases, and results indicate that cathepsins D and L, as well as mature cathepsin B itself, can produce a processed (single-chain) form of cathepsin B from this precursor. Amino-terminal sequencing of these processed forms has revealed that they are all elongated by a few residues with respect to the mature form found in vivo. The action of a combination of cathepsin B with dipeptidylpeptidase I produced a single-chain form of cathepsin B with the correct amino terminus. This work has also shown that the processing of procathepsin B to a single-chain form can be an autocatalytic process, in at least an intermolecular manner.	SHRINERS HOSP CRIPPLED CHILDREN,JOINT DIS LAB,1529 CEDAR AVE,MONTREAL H3G 1A6,QUEBEC,CANADA; MCGILL UNIV,DEPT SURG,MONTREAL H3G 1A6,QUEBEC,CANADA	McGill University; McGill University				Mach, Lukas/0000-0001-9013-5408				ARONSON NN, 1978, BIOCHEM J, V171, P759, DOI 10.1042/bj1710759; BARRETT AJ, 1976, ANAL BIOCHEM, V76, P374, DOI 10.1016/0003-2697(76)90298-0; BARRETT AJ, 1973, BIOCHEM J, V131, P809, DOI 10.1042/bj1310809; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BOND JS, 1980, BIOCHEM J, V189, P17, DOI 10.1042/bj1890017; BUTTLE DJ, 1988, BIOCHEM J, V254, P693, DOI 10.1042/bj2540693; BUTTLE DJ, 1990, SCAND J CLIN LAB INV, V50, P509, DOI 10.3109/00365519009089165; BUTTLE DJ, 1991, BIOCHEM J, V276, P325, DOI 10.1042/bj2760325; CHAN SJ, 1986, P NATL ACAD SCI USA, V83, P7721, DOI 10.1073/pnas.83.20.7721; CHOW TYK, 1988, DNA PROTEIN ENG TECH, V1, P72; Dean R T, 1976, Essays Biochem, V12, P1; DENOBEL JG, 1991, YEAST, V7, P313, DOI 10.1002/yea.320070402; DOCHERTY K, 1984, J BIOL CHEM, V259, P6041; ERNST JF, 1986, DNA-J MOLEC CELL BIO, V5, P483, DOI 10.1089/dna.1.1986.5.483; FELLEISEN R, 1990, EMBO J, V9, P371, DOI 10.1002/j.1460-2075.1990.tb08120.x; FRUTON JS, 1971, ENZYMES, P119; FULLER RS, 1988, ANNU REV PHYSIOL, V50, P345, DOI 10.1146/annurev.ph.50.030188.002021; GRUBB A, 1990, BIOL CHEM H-S, V371, P137; HANEWINKEL H, 1987, J BIOL CHEM, V262, P12351; HASNAIN S, J BIOL CHEM, V267, P4713; HUANG JS, 1979, J BIOL CHEM, V254, P1405; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; KING J, 1971, J MOL BIOL, V62, P465, DOI 10.1016/0022-2836(71)90148-3; KIRSCHKE H, 1977, ACTA BIOL MED GER, V36, P185; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE X, 1990, J BIOL CHEM, V265, P5950; MACH L, 1992, BIOCHEM J, V282, P577, DOI 10.1042/bj2820577; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCDONALD JK, 1986, MAMMALIAN PROTEINASE, V2; MCDONALD JK, 1977, PROTEINASES MAMMALIA, P314; MORT JS, 1986, BIOCHEM J, V233, P57, DOI 10.1042/bj2330057; MORT JS, 1981, J HISTOCHEM CYTOCHEM, V29, P649, DOI 10.1177/29.5.6788835; MORT JS, 1981, BIOCHIM BIOPHYS ACTA, V662, P173, DOI 10.1016/0005-2744(81)90027-9; MORT JS, 1983, BIOCHIM BIOPHYS ACTA, V755, P369, DOI 10.1016/0304-4165(83)90240-4; MORT JS, 1985, INTRACELLULAR PROTEI, P243; NISHIMURA Y, 1988, ARCH BIOCHEM BIOPHYS, V261, P64, DOI 10.1016/0003-9861(88)90104-X; NISHIMURA Y, 1990, ACTA HISTOCHEM CYTOC, V23, P53, DOI 10.1267/ahc.23.53; NISHIMURA Y, 1987, BIOCHEM BIOPH RES CO, V148, P254, DOI 10.1016/0006-291X(87)91103-X; RECKLIES AD, 1982, CANCER RES, V42, P1026; RITONJA A, 1985, FEBS LETT, V181, P169, DOI 10.1016/0014-5793(85)81136-4; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SEGUNDO BS, 1985, P NATL ACAD SCI USA, V82, P2320, DOI 10.1073/pnas.82.8.2320; SHERMAN F, 1986, LABORATORY COURSE MA; TAKIO K, 1983, P NATL ACAD SCI-BIOL, V80, P3666, DOI 10.1073/pnas.80.12.3666; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERNET T, 1991, J BIOL CHEM, V266, P21451	48	181	184	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15993	15999						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1639824				2022-12-25	WOS:A1992JG11300109
J	RUGGERI, B; ZHANG, SY; CAAMANO, J; DIRADO, M; FLYNN, SD; KLEINSZANTO, AJP				RUGGERI, B; ZHANG, SY; CAAMANO, J; DIRADO, M; FLYNN, SD; KLEINSZANTO, AJP			HUMAN PANCREATIC CARCINOMAS AND CELL-LINES REVEAL FREQUENT AND MULTIPLE ALTERATIONS IN THE P53 AND RB-1 TUMOR-SUPPRESSOR GENES	ONCOGENE			English	Article							HUMAN PROSTATE CARCINOMA; HUMAN BREAST-CANCER; RETINOBLASTOMA GENE; LUNG-CANCER; MONOCLONAL-ANTIBODIES; POLYPOSIS-COLI; OVARIAN-CANCER; EXPRESSION; MUTATIONS; TRANSFORMATION	The molecular pathology of human pancreatic cancer is poorly understood, particularly with regard to the role of known tumor-suppressor genes. We have examined the expression of the p53 and Rb-1 tumor-suppressor genes in seven human pancreatic carcinoma cell lines and 10 primary pancreatic carcinomas. Examination of the Rb-1 gene by Northern hybridization and immunoprecipitation analyses revealed the absence of Rb-1 protein expression in two cell lines. Moreover, regions of absent nuclear staining in two primary pancreatic carcinomas were detected by immunohistochemical analysis. Investigation of p53 by Southern, Northern, immunohistochemical and immunoprecipitation analyses revealed multiple abnormalities, including gross rearrangements in two cell lines, the absence of detectable p53 transcript in two cell lines and a truncated transcript in one line. Six cell lines overexpressed p53 protein, while one line revealed the absence of p53 product by immunohistochemical and immunoprecipitation analyses. Sequence analysis of exons 5-8 of the p53 gene confirmed these analyses, revealing missense mutations in all seven cell lines in codons 181, 220, 248, 249, 265, 272 and 273. Of 10 mutations identified, nine were transitions and 50% were in codon 273. Immunohistochemical analyses of frozen primary pancreatic carcinomas revealed positive nuclear staining for p53 in 40% of cases. Mutations were identified in codons 238 and 286 and in intron 9 in several representative specimens. Alterations in the p53 and Rb-1 genes may be important features in the development of human pancreatic cancer.	FOX CHASE CANC INST,INST CANC RES,DEPT PATHOL,7701 BURHOLME AVE,PHILADELPHIA,PA 19111; YALE UNIV,SCH MED,DEPT PATHOL,NEW HAVEN,CT 06510	Fox Chase Cancer Center; Yale University			Klein-Szanto, A./E-6218-2010; Caamano, Jorge/O-7530-2019; Caamano, Jorge/I-6778-2012	Caamano, Jorge/0000-0003-3530-7056; Caamano, Jorge/0000-0003-3530-7056	NCI NIH HHS [CA-06927, CA-09035-16] Funding Source: Medline; NCRR NIH HHS [RR-05895] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005895] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARTEK J, 1991, ONCOGENE, V6, P1699; BARTEK J, 1990, ONCOGENE, V5, P893; BARTON CM, 1991, BRIT J CANCER, V64, P1076, DOI 10.1038/bjc.1991.467; BOOKSTEIN R, 1990, P NATL ACAD SCI USA, V87, P7762, DOI 10.1073/pnas.87.19.7762; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BOS JL, 1989, CANCER RES, V49, P4682; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; CAAMANO J, 1991, IN PRESS AM J PATHOL; CANCE WG, 1990, NEW ENGL J MED, V323, P1457, DOI 10.1056/NEJM199011223232105; CELLO JP, 1989, GASTROINTESTINAL DIS, P1872; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHIBA I, 1990, ONCOGENE, V5, P1603; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIDOFF AM, 1991, P NATL ACAD SCI USA, V88, P5006, DOI 10.1073/pnas.88.11.5006; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GRAJOWER MM, 1983, ANN INTERN MED, V98, P111, DOI 10.7326/0003-4819-98-1-111_2; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GRUNEWALD K, 1989, INT J CANCER, V43, P1037, DOI 10.1002/ijc.2910430614; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HALL PA, 1990, J PATHOL, V161, P195, DOI 10.1002/path.1711610305; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HENSEL CH, 1990, CANCER RES, V50, P3067; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HOLLINGSWORTH RE, 1991, J NATL CANCER I, V83, P91, DOI 10.1093/jnci/83.2.91; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JAGELMAN DG, 1987, CANCER GENET CYTOGEN, V27, P319, DOI 10.1016/0165-4608(87)90014-8; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KONDOLEON S, 1987, NUCLEIC ACIDS RES, V15, P10605, DOI 10.1093/nar/15.24.10605; KORC M, 1986, P NATL ACAD SCI USA, V83, P5141, DOI 10.1073/pnas.83.14.5141; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEHMAN TA, 1991, CANCER RES, V51, P4090; LEMOINE NR, 1990, BAILLIERE CLIN GASTR, V4, P815, DOI 10.1016/0950-3528(90)90021-8; LEMOINE NR, 1992, J PATHOL, V166, P7, DOI 10.1002/path.1711660103; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI SB, 1991, J NATL CANCER I, V83, P637, DOI 10.1093/jnci/83.9.637; LYNCH HT, 1985, BRIT J CANCER, V52, P271, DOI 10.1038/bjc.1985.187; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARKS JR, 1991, CANCER RES, V51, P2979; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MICHELASSI F, 1989, Italian Journal of Surgical Sciences, V19, P341; MILLER CW, 1990, CANCER RES, V50, P7950; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P5707, DOI 10.1093/nar/16.12.5707; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OKAMOTO A, 1991, CANCER RES, V51, P5632; POSTON GJ, 1991, GUT, V32, P800, DOI 10.1136/gut.32.7.800; Sambrook J, 1989, MOL CLONING LABORATO; Shew J.-Y., 1989, ONCOGENE RES, V1, P205; SMIT VTHBM, 1988, NUCLEIC ACIDS RES, V16, P7773, DOI 10.1093/nar/16.16.7773; SMITH JJ, 1987, P NATL ACAD SCI USA, V84, P7567, DOI 10.1073/pnas.84.21.7567; SOUSSI T, 1990, ONCOGENE, V5, P945; STRATTON MR, 1990, ONCOGENE, V5, P1297; TADA M, 1990, CANCER-AM CANCER SOC, V66, P930, DOI 10.1002/1097-0142(19900901)66:5<930::AID-CNCR2820660519>3.0.CO;2-W; TAKAHASHI T, 1990, J CLIN INVEST, V86, P363, DOI 10.1172/JCI114710; VARLEY JM, 1989, ONCOGENE, V4, P725; VARLEY JM, 1991, ONCOGENE, V6, P413; WASYLYSHYN ML, 1991, SURGERY, V110, P265; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x	74	176	177	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1992	7	8					1503	1511						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1630814				2022-12-25	WOS:A1992JE81300006
J	BOCK, PE				BOCK, PE			ACTIVE-SITE-SELECTIVE LABELING OF BLOOD-COAGULATION PROTEINASES WITH FLUORESCENCE PROBES BY THE USE OF THIOESTER PEPTIDE CHLOROMETHYL KETONES .1. SPECIFICITY OF THROMBIN LABELING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-THROMBIN; FACTOR-XA; FACTOR-VA; CONFORMATIONAL SENSITIVITY; PROTHROMBINASE COMPLEX; PHOSPHOLIPID SURFACE; ANTITHROMBIN-III; INACTIVATION; BINDING; MEIZOTHROMBIN	In a, new strategy for labeling the active sites of serine proteinases with fluorescence probes (Bock, P. E. (1988) Biochemistry 27, 6633-6639), a thioester peptide chloromethyl ketone inhibitor is incorporated into the enzyme active center and used to produce a unique thiol group which provides a site for selective chemical modification with any one of many thiol-reactive fluorescence probes. This approach was developed to increase the opportunities for identifying fluorescent proteinase derivatives that act as reporters of binding interactions by allowing a large number of derivatives, representing a broad range of probe spectral properties, to be readily prepared. In the studies described here, the specificity of the labeling approach was evaluated quantitatively for the labeling of human alpha and beta/gamma-thrombin with the thioester peptide chloromethyl ketones, N(alpha)-[(acetylthio)acetyl]-D-Phe-Pro-Arg-CH2Cl and N(alpha)-[(acetylthio)acetyl]-D-Phe-Phe-Arg-CH2Cl, and the thiol-reactive fluorescence probe, 5-(iodoacetamido)fluorescein. Irreversible inactivation of thrombin by the inhibitors was accompanied by incorporation of 0.98 +/- 0.06 mol/mol of the thioester group into the active site, independent of a 470-fold difference between the thioester peptide chloromethyl ketones in the bimolecular rate constants of alpha-thrombin affinity labeling. Subsequent mild treatment of the covalent thrombin-inhibitor complexes with NH2OH in the presence of 5-(iodoacetamido)fluorescein resulted in generation of the thiol group together with its selective modification and incorporation of 0.96 +/- 0.07 mol of probe/mol of active sites. The incorporated label was localized to a 9000 molecular weight region of a and beta/gamma-thrombin containing the catalytic-site histidine residue. Evaluation of competing, side reactions showed that they did not significantly compromise the active site specificity of labeling. These results demonstrated equivalent, active-site-selective fluorescence probe labeling of alpha and beta/gamma-thrombin by use of either of the thioester peptide chloromethyl ketones, with a site specificity of greater-than-or-equal-to 94%.	AMER RED CROSS, BLOOD SERV, SE MICHIGAN REG RES LAB, DETROIT, MI 48232 USA	American Red Cross					NHLBI NIH HHS [HL-38779] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038779, R29HL038779] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMSTRONG SA, 1990, J BIOL CHEM, V265, P6210; BOCK PE, 1988, BIOCHEMISTRY-US, V27, P6633, DOI 10.1021/bi00417a063; BOCK PE, 1992, J BIOL CHEM, V267, P14974; BOCK PE, 1989, ARCH BIOCHEM BIOPHYS, V273, P375, DOI 10.1016/0003-9861(89)90496-7; BOISSEL JP, 1984, J BIOL CHEM, V259, P5691; Bornstein P, 1977, Methods Enzymol, V47, P132; BOSKOVIC DS, 1990, J BIOL CHEM, V265, P10497; BRAUN PJ, 1988, THROMB RES, V50, P273, DOI 10.1016/0049-3848(88)90228-9; BROZE GJ, 1984, J CLIN INVEST, V73, P933, DOI 10.1172/JCI111317; BUTKOWSKI RJ, 1977, J BIOL CHEM, V252, P4942; CHANG JY, 1986, BIOCHEM J, V240, P797, DOI 10.1042/bj2400797; CRAIG PA, 1989, J BIOL CHEM, V264, P5452; DANIELS SB, 1983, J BIOL CHEM, V258, P5046; DUNCAN RJS, 1983, ANAL BIOCHEM, V132, P68, DOI 10.1016/0003-2697(83)90426-8; ELION J, 1986, ANN NY ACAD SCI, V485, P16, DOI 10.1111/j.1749-6632.1986.tb34564.x; FENTON JW, 1974, THROMB RES, V4, P809, DOI 10.1016/0049-3848(74)90024-3; FENTON JW, 1977, J BIOL CHEM, V252, P3587; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; KETTNER C, 1979, THROMB RES, V14, P969, DOI 10.1016/0049-3848(79)90014-8; KETTNER C, 1981, METHOD ENZYMOL, V80, P826; KETTNER C, 1978, BIOCHEMISTRY-US, V17, P4778, DOI 10.1021/bi00615a027; KETTNER C, 1981, THROMB RES, V22, P645, DOI 10.1016/0049-3848(81)90062-1; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P9684; KRISHNASWAMY S, 1990, J BIOL CHEM, V265, P3708; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIJNEN HR, 1984, THROMB RES, V34, P431, DOI 10.1016/0049-3848(84)90247-0; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P558, DOI 10.1016/0167-4838(83)90273-X; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P539, DOI 10.1016/0167-4838(83)90272-8; MANN KG, 1981, METHOD ENZYMOL, V80, P286; MANN KG, 1990, BLOOD, V76, P1; MILETICH JP, 1978, J BIOL CHEM, V253, P6908; NESHEIM M, 1986, J BIOL CHEM, V261, P3214; NIENABER VL, 1991, THROMB HAEMOSTASIS, V65, P40; Orsi B A, 1979, Methods Enzymol, V63, P159; Powell J.L., 1986, PROTEINASE INHIBITOR, P55; RIDDLES PW, 1979, ANAL BIOCHEM, V94, P75, DOI 10.1016/0003-2697(79)90792-9; SHISHIKURA F, 1987, J BIOL CHEM, V262, P3123; TAIT JF, 1982, ARCH BIOCHEM BIOPHYS, V216, P133, DOI 10.1016/0003-9861(82)90197-7; TIAN WX, 1982, BIOCHEMISTRY-US, V21, P1028, DOI 10.1021/bi00534a031; WALKER B, 1985, BIOCHEM J, V230, P645, DOI 10.1042/bj2300645; WILLIAMS EB, 1989, J BIOL CHEM, V264, P7536; 1980, POLYACRYLAMIDE GEL E, P54	42	46	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14963	14973						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634535				2022-12-25	WOS:A1992JF08800070
J	LEE, JY; HIROSE, M				LEE, JY; HIROSE, M			PARTIALLY FOLDED STATE OF THE DISULFIDE-REDUCED FORM OF HUMAN SERUM-ALBUMIN AS AN INTERMEDIATE FOR REVERSIBLE DENATURATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC TRYPSIN-INHIBITOR; MOLTEN-GLOBULE STATE; CIRCULAR-DICHROISM; CONFORMATIONAL STATES; IMMUNOLOGICAL PROBE; SECONDARY STRUCTURE; BOVINE; PROTEINS; OVOTRANSFERRIN; SPECTROSCOPY	The conformation of the fully disulfide-reduced state of human serum albumin was investigated by tryptophan fluorescence spectrum, CD analyses, and size-exclusion chromatography. Both the reduction of the native disulfide-bonded form under nondenaturing conditions and the refolding of the urea-denatured disulfide-reduced form under reduced conditions yielded almost exactly the same disulfide-reduced state with partially folded unique conformation that was clearly distinguished from either the native or fully denatured state. In addition, the interconversion between the urea-denatured reduced form and the partially folded reduced form was reversible with each other; by reoxidation, the partially folded reduced form was converted to the disulfide-bonded form. The conformation of disulfide-reduced serum albumin was highly variable depending on pH and ionic strength conditions. Thus, we concluded that the disulfide-reduced state with partially folded variable conformation is involved in the reversible interconversion between the denatured reduced form and the native disulfide-bonded form of human serum albumin.	KYOTO UNIV, FOOD SCI RES INST, UJI, KYOTO 611, JAPAN	Kyoto University				Hirose, Masaaki/0000-0003-2672-4384				BEYCHOK S, 1966, SCIENCE, V154, P1288, DOI 10.1126/science.154.3754.1288; BOS OJM, 1989, J BIOL CHEM, V264, P953; BURTON SJ, 1989, EUR J BIOCHEM, V179, P379, DOI 10.1111/j.1432-1033.1989.tb14564.x; CORBETT RJT, 1984, BIOCHEMISTRY-US, V23, P1888, DOI 10.1021/bi00303a047; DAMODARAN S, 1986, INT J PEPT PROT RES, V27, P589; DARBY NJ, 1991, FEBS LETT, V279, P61, DOI 10.1016/0014-5793(91)80251-W; DOLGIKH DA, 1981, FEBS LETT, V136, P311, DOI 10.1016/0014-5793(81)80642-4; ERA S, 1985, INT J PEPT PROT RES, V26, P575; GALAT A, 1981, BIOCHEMISTRY-US, V20, P594, DOI 10.1021/bi00506a023; GOTO Y, 1990, BIOCHEMISTRY-US, V29, P3480, DOI 10.1021/bi00466a009; GOTO Y, 1990, P NATL ACAD SCI USA, V87, P573, DOI 10.1073/pnas.87.2.573; GOTO Y, 1989, BIOCHEMISTRY-US, V28, P945, DOI 10.1021/bi00429a004; GOTO Y, 1982, J MOL BIOL, V156, P911, DOI 10.1016/0022-2836(82)90147-4; GOTO Y, 1990, J MOL BIOL, V214, P803, DOI 10.1016/0022-2836(90)90334-I; HIROSE M, 1991, J BIOL CHEM, V266, P1463; HIROSE M, 1989, J BIOL CHEM, V264, P16867; JOHANSON KO, 1981, J BIOL CHEM, V256, P445; KITABATAKE N, 1988, AGR BIOL CHEM TOKYO, V52, P967; KOSEN PA, 1983, BIOCHEMISTRY-US, V22, P2433, DOI 10.1021/bi00279a020; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; LAPANJE S, 1969, CROAT CHEM ACTA, V41, P115; OE H, 1986, AGR BIOL CHEM TOKYO, V50, P2469, DOI 10.1080/00021369.1986.10867773; OHGUSHI M, 1983, FEBS LETT, V164, P21, DOI 10.1016/0014-5793(83)80010-6; PETERS T, 1985, ADV PROTEIN CHEM, V37, P161, DOI 10.1016/S0065-3233(08)60065-0; SEETHARAMA A, 1982, MOL CELL BIOCHEM, V44, P129; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; SUN SF, 1989, INT J PEPT PROT RES, V34, P46; TAKAHASHI N, 1991, J BIOCHEM-TOKYO, V109, P846, DOI 10.1093/oxfordjournals.jbchem.a123469; TAKAHASHI N, 1992, IN PRESS J BIOL CHEM; TANFORD C, 1967, J AM CHEM SOC, V89, P729, DOI 10.1021/ja00980a001; TEALE JM, 1977, J BIOL CHEM, V252, P4521; TEALE JM, 1976, J BIOL CHEM, V251, P4609; TEALE JM, 1976, J BIOL CHEM, V251, P4603; WHITE FH, 1982, BIOCHEMISTRY-US, V21, P967, DOI 10.1021/bi00534a023	34	84	89	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14753	14758						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634518				2022-12-25	WOS:A1992JF08800040
J	ZHANG, WG; BROOKS, RL; SILVERSIDES, DW; WEST, BL; LEIDIG, F; BAXTER, JD; EBERHARDT, NL				ZHANG, WG; BROOKS, RL; SILVERSIDES, DW; WEST, BL; LEIDIG, F; BAXTER, JD; EBERHARDT, NL			NEGATIVE THYROID-HORMONE CONTROL OF HUMAN GROWTH-HORMONE GENE-EXPRESSION IS MEDIATED BY 3'-UNTRANSLATED 3'-FLANKING DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PITUITARY-TUMOR-CELLS; RESPONSE ELEMENT; GLUCOCORTICOID RECEPTOR; RNA-POLYMERASE; BINDING PROTEIN; C-JUN; RAT; PROMOTER; TRANSCRIPTION; SEQUENCE	The intact human growth hormone (hGH) gene is negatively regulated by triiodothyronine (T3) treatment in transfected rat pituitary tumor cells. We now demonstrate that this responsiveness is mediated by a negative thyroid hormone response element (nTRE) localized to the proximal 3'-untranslated/3'-flanking region (3'-UT/FR). This region binds thyroid hormone receptors specifically and with high affinity. nTRE function was promoter-dependent, since it suppressed the activity of a positive TRE in the human chorionic somatomammotropin promoter, partially repressed activity of the herpes simplex virus TK promoter, but did not function with the human actin or Rous sarcoma virus promoters. T3 treatment did not alter transcript termination sites nor selectively affect the stability of transcripts containing the hGH 3'-UT/FR when transcription was blocked by actinomycin D treatment. The function of the nTRE depended on its location in the 3'-UT/FR; it was inactive when positioned downstream of the simian virus 40 (SV40) 3'-UT/FR, and it acted as a positive TRE when placed upstream of the hGH promoter. These results demonstrate a novel localization of a TRE with unique properties which suggests expanded mechanisms by which thyroid hormone receptors can affect gene expression.	MAYO CLIN & MAYO FDN,DEPT MED,ENDOCRINE RES UNIT,4-407 ALFRED,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT MOLEC BIOL BIOCHEM,ROCHESTER,MN 55905; UNIV CALIF SAN FRANCISCO,DEPT MED,METAB RES UNIT,SAN FRANCISCO,CA 94143	Mayo Clinic; Mayo Clinic; University of California System; University of California San Francisco				West, Brian/0000-0002-5320-3691	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041206, R01DK041842] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK41842, DK41206] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; APRILETTI JW, 1988, J BIOL CHEM, V263, P9409; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; BRENT GA, 1988, MOL ENDOCRINOL, V2, P792, DOI 10.1210/mend-2-9-792; CARR FE, 1989, MOL ENDOCRINOL, V3, P706; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CATTINI PA, 1986, J BIOL CHEM, V261, P3367; CATTINI PA, 1987, NUCLEIC ACIDS RES, V15, P1297, DOI 10.1093/nar/15.3.1297; CONNELLY S, 1989, MOL CELL BIOL, V9, P5254, DOI 10.1128/MCB.9.11.5254; DARLING DS, 1989, MOL ENDOCRINOL, V3, P1359, DOI 10.1210/mend-3-9-1359; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; EASTMAN A, 1987, BIOTECHNIQUES, V5, P731; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; LAMPH WW, 1990, P NATL ACAD SCI USA, V87, P4320, DOI 10.1073/pnas.87.11.4320; LAVIN TN, 1988, J BIOL CHEM, V263, P9418; LEIDIG F, 1992, J BIOL CHEM, V267, P913; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MARTIAL JA, 1977, P NATL ACAD SCI USA, V74, P1816, DOI 10.1073/pnas.74.5.1816; MARTIAL JA, 1979, SCIENCE, V205, P602, DOI 10.1126/science.377496; MORIN A, 1990, MOL CELL ENDOCRINOL, V71, P261, DOI 10.1016/0303-7207(90)90031-3; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NELSON C, 1986, NATURE, V322, P557, DOI 10.1038/322557a0; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NORMAN MF, 1989, J BIOL CHEM, V264, P12063; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; PAVCO PA, 1990, J BIOL CHEM, V265, P9960; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SAP J, 1990, EMBO J, V9, P887, DOI 10.1002/j.1460-2075.1990.tb08186.x; SCHAUFELE F, 1990, J BIOL CHEM, V265, P17189; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SKARNES WC, 1988, J MOL BIOL, V203, P609; SLATER EP, 1985, MOL CELL BIOL, V5, P2984, DOI 10.1128/MCB.5.11.2984; SPENCER CA, 1990, ONCOGENE, V5, P777; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; SU W, 1990, P NATL ACAD SCI USA, V87, P5504, DOI 10.1073/pnas.87.14.5504; TANSEY WP, 1991, J BIOL CHEM, V266, P9805; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZILZ ND, 1990, J BIOL CHEM, V265, P8136	45	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15056	15063						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634542				2022-12-25	WOS:A1992JF08800081
J	GASBARRINI, A; BORLE, AB; FARGHALI, H; BENDER, C; FRANCAVILLA, A; VANTHIEL, D				GASBARRINI, A; BORLE, AB; FARGHALI, H; BENDER, C; FRANCAVILLA, A; VANTHIEL, D			EFFECT OF ANOXIA ON INTRACELLULAR ATP, NA+(I), CA2+(I), MG2+(I), AND CYTOTOXICITY IN RAT HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC FREE CALCIUM; FREE CA-2+; PLASMA-MEMBRANE; LIVER-CELL; EXTRACELLULAR CALCIUM; CEREBRAL-ISCHEMIA; MAMMALIAN-CELLS; HYPOXIC INJURY; BLEB FORMATION; FREE MAGNESIUM	The effects of anoxia were studied in freshly isolated rat hepatocytes maintained in agarose gel threads and perfused with Krebs-Henseleit bicarbonate buffer (KHB). Cytosolic free calcium (Ca2+i) was measured with aequorin, intracellular sodium (Na+i) with SBFI, intracellular pH (pH(i)) with BCECF, lactic dehydrogenase (LDH) by the increase in NADH absorbance during lactate oxidation to pyruvate, ATP by P-31 NMR spectroscopy in real time, and intracellular free Mg2+ (Mg2+i) from the chemical shift of beta-ATP relative to alpha-ATP in the NMR spectra. Anoxia was induced by perfusing the cells with KHB saturated with 95% N2, 5% CO2. After 1 h of anoxia, beta-ATP fell 66%, and 85% after 2 h, while the P(i)/ATP ratio increased 10-fold from 2.75 to 28.3. Under control conditions, the resting cytosolic free calcium was 127 +/- 6 nM. Anoxia increased Ca2+i in two distinct phases: a first rise occurred within 15 min and reached a mean value of 389 +/- 35 nM (p < 0.001). A second peak reached a maximum value of 1.45 +/- 0.12-mu-M (p < 0.001) after 1 h. During the first hour of anoxia, Na+i increased from 15.9 +/- 2.4 mM to 32.2 +/- 1.2 mM (p < 0.001), Mg2+i doubled from 0.51 +/- 0.05 to 1.12 +/- 0.01 mM (p < 0.001), and pH(i) decreased from 7.41 +/- 0.03 to 7.06 +/- 0.1 (p < 0.001). LDH release doubled during the first hour and increased 6-fold during the second hour of anoxia. Upon reoxygenation, ATP, Ca2+i, Mg2+i, Na+i, and LDH returned near the control levels within 45 min. To determine whether the increased LDH release was related to the rise in Ca2+i, and whether the increased Ca2+i was caused by Ca2+ influx, the cells were perfused with Ca2+-free KHB (+ 0.1 mM EGTA) during the anoxic period. After 2 h of anoxia in Ca2+-free medium, beta-ATP again fell 90%, but Ca2+i, after the first initial peak, fell below control levels, and LDH release increased only 2.7-fold. During reoxygenation, Ca2+i, ATP, Na+i, and LDH returned near the control levels within 45 min. These results suggest that the rise in Ca2+i induced by anoxia is caused by an influx of Ca2+ from the extracellular fluid, and that LDH release and cell injury may be related to the resulting rise in Ca2+i.	UNIV PITTSBURGH,SCH MED,DEPT PHYSIOL,PITTSBURGH,PA 15261; UNIV PITTSBURGH,SCH MED,DEPT SURG,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh			Farghali, Hassan/K-6582-2017	Farghali, Hassan/0000-0001-6467-9532	NCRR NIH HHS [P41RR03631] Funding Source: Medline; NIAAA NIH HHS [AA04425] Funding Source: Medline; NIADDK NIH HHS [AM39789] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR003631] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R37AA004425, R01AA004425] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ALLEN DG, 1983, J PHYSIOL-LONDON, V335, P555, DOI 10.1113/jphysiol.1983.sp014550; ALLSHIRE A, 1987, BIOCHEM J, V244, P381, DOI 10.1042/bj2440381; AW TY, 1987, AM J PHYSIOL, V252, pC362, DOI 10.1152/ajpcell.1987.252.4.C362; BARRY WH, 1987, CIRC RES, V61, P726, DOI 10.1161/01.RES.61.5.726; BERNSTEIN J, 1985, RES COMMUN CHEM PATH, V47, P3; Blinks J.R., 1978, Methods in Enzymology, V57, P292; Blinks J. R., 1985, BIOLUMINESCENCE CHEM, V2, P185; BLINKS JR, 1978, LIFE SCI, V22, P1237, DOI 10.1016/0024-3205(78)90092-9; Borle A B, 1986, Methods Enzymol, V124, P90; BORLE AB, 1986, AM J PHYSIOL, V251, pC323, DOI 10.1152/ajpcell.1986.251.2.C323; BORLE AB, 1982, SCIENCE, V217, P252, DOI 10.1126/science.6806904; BORLE AB, 1990, AM J PHYSIOL, V259, pC19, DOI 10.1152/ajpcell.1990.259.1.C19; CHIEN KR, 1977, AM J PATHOL, V88, P539; COBBOLD PH, 1984, NATURE, V312, P444, DOI 10.1038/312444a0; COLCA JR, 1983, BIOCHIM BIOPHYS ACTA, V729, P176, DOI 10.1016/0005-2736(83)90483-2; CORKEY BE, 1986, J BIOL CHEM, V261, P2567; CURRIN RT, 1991, FASEB J, V5, P207, DOI 10.1096/fasebj.5.2.2004664; ELMOFTY SK, 1975, AM J PATHOL, V79, P579; EPSTEIN FH, 1985, NEW ENGL J MED, V312, P159; FARBER JL, 1990, ENVIRON HEALTH PERSP, V84, P107, DOI 10.2307/3430711; FARGHALI H, 1990, 9TH ANN SCI M SOC MA, V2, P957; FARISS MW, 1985, SCIENCE, V227, P751, DOI 10.1126/science.3918345; GASBARRINI A, 1990, HEPATOLOGY, V12, P1010; GASBARRINI A, 1991, Gastroenterology, V100, pA745; GASBARRINI A, 1991, Gastroenterology, V100, pA744; GOLIGORSKY MS, 1986, MINER ELECTROL METAB, V12, P363; GOLIGORSKY MS, 1988, MINER ELECTROL METAB, V14, P58; GREENBERG JH, 1990, STROKE, V21, P72; HARMAN AW, 1990, BIOCHEM BIOPH RES CO, V170, P477, DOI 10.1016/0006-291X(90)92116-H; HEMS DA, 1970, BIOCHEM J, V120, P105, DOI 10.1042/bj1200105; HEXUM T, 1970, BIOCHIM BIOPHYS ACTA, V212, P322, DOI 10.1016/0005-2744(70)90213-5; IWASA T, 1983, BIOCHIM BIOPHYS ACTA, V731, P229, DOI 10.1016/0005-2736(83)90013-5; JEWELL SA, 1982, SCIENCE, V217, P1257, DOI 10.1126/science.7112127; JOHNSON JD, 1987, TOXICOL APPL PHARM, V88, P212; KAUPPINEN RA, 1988, NEUROSCIENCE, V27, P175, DOI 10.1016/0306-4522(88)90228-X; KORETSUNE Y, 1990, CIRCULATION, V82, P528, DOI 10.1161/01.CIR.82.2.528; KORETSUNE Y, 1990, AM J PHYSIOL, V258, pH9, DOI 10.1152/ajpheart.1990.258.1.H9; KUSUOKA H, 1990, CIRC RES, V66, P1268, DOI 10.1161/01.RES.66.5.1268; LEE JA, 1988, PFLUG ARCH EUR J PHY, V413, P83, DOI 10.1007/BF00581232; LEMASTERS JJ, 1990, ENVIRON HEALTH PERSP, V84, P83, DOI 10.2307/3430708; LEMASTERS JJ, 1987, NATURE, V325, P79; LUTAYA G, 1983, BIOCHEM J, V214, P645, DOI 10.1042/bj2140645; MALLOY CR, 1986, BIOCHIM BIOPHYS ACTA, V885, P1, DOI 10.1016/0167-4889(86)90032-7; MARBAN E, 1990, CIRC RES, V66, P1255, DOI 10.1161/01.RES.66.5.1255; MCCOY CE, 1988, J CLIN INVEST, V82, P1326, DOI 10.1172/JCI113734; MICHAELIS EK, 1983, J BIOL CHEM, V258, P6101; MOULE SK, 1990, BIOCHIM BIOPHYS ACTA, V1031, P383, DOI 10.1016/0304-4157(90)90016-6; NAKAO M, 1974, ANN NY ACAD SCI, V242, P24, DOI 10.1111/j.1749-6632.1974.tb19076.x; NAYLER WG, 1987, INT J CARDIOL, V15, P267, DOI 10.1016/0167-5273(87)90332-9; NICOTERA P, 1986, J BIOL CHEM, V261, P4628; NICOTERA P, 1988, TOXICOLOGY, V52, P55, DOI 10.1016/0300-483X(88)90196-5; NICOTERA P, 1989, FASEB J, V3, P59, DOI 10.1096/fasebj.3.1.2910738; NIEMINEN AL, 1988, CELL CALCIUM, V9, P237, DOI 10.1016/0143-4160(88)90004-8; NISHIDA T, 1986, BIOCHEMISTRY-US, V106, P533; OKUNO F, 1983, RES COMMUN CHEM PATH, V39, P437; ORRENIUS S, 1989, TRENDS PHARMACOL SCI, V10, P281, DOI 10.1016/0165-6147(89)90029-1; PEDERSON PL, 1991, BIOENERGETICS, V6, P243; RAJU B, 1989, AM J PHYSIOL, V256, pC540, DOI 10.1152/ajpcell.1989.256.3.C540; SAKAIDA I, 1991, J BIOL CHEM, V266, P717; SCHANNE FAX, 1986, J BIOL CHEM, V261, P9886; Sharma RJ, 1978, BIOCHEM SOC T, V6, P1319, DOI 10.1042/bst0061319; SHARMA RJ, 1980, BIOCHIM BIOPHYS ACTA, V630, P414, DOI 10.1016/0304-4165(80)90290-1; SILVER IA, 1990, J GEN PHYSIOL, V95, P837, DOI 10.1085/jgp.95.5.837; SMITH GL, 1988, CIRC RES, V62, P1223, DOI 10.1161/01.RES.62.6.1223; SMITH MT, 1981, SCIENCE, V213, P1257, DOI 10.1126/science.7268433; SNOWDOWNE KW, 1984, AM J PHYSIOL, V247, pC396, DOI 10.1152/ajpcell.1984.247.5.C396; SNOWDOWNE KW, 1985, J BIOL CHEM, V260, P1619; SNOWDOWNE KW, 1985, J MOL CELL CARDIOL, V17, P233, DOI 10.1016/S0022-2828(85)80006-7; STEENBERGEN C, 1987, CIRC RES, V60, P700, DOI 10.1161/01.RES.60.5.700; STRUBELT O, 1988, RES COMMUN CHEM PATH, V61, P327; STUDER RK, 1982, J BIOL CHEM, V257, P7987; SWANLJUNG P, 1973, BIOCHIM BIOPHYS ACTA, V305, P519, DOI 10.1016/0005-2728(73)90073-X; THEEN J, 1982, AM J PHYSIOL, V342, pE182; UEMATSU D, 1989, STROKE, V20, P1531, DOI 10.1161/01.STR.20.11.1531; UEMATSU D, 1988, ANN NEUROL, V24, P420, DOI 10.1002/ana.410240311; WATTS JA, 1990, J CARDIOVASC PHARM, V15, P44, DOI 10.1097/00005344-199001000-00007	76	192	193	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6654	6663						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1637381				2022-12-25	WOS:A1992HM05300033
J	REHFUSS, RP; WALTON, KM; LORIAUX, MM; GOODMAN, RH				REHFUSS, RP; WALTON, KM; LORIAUX, MM; GOODMAN, RH			THE CAMP-REGULATED ENHANCER-BINDING PROTEIN ATF-1 ACTIVATES TRANSCRIPTION IN RESPONSE TO CAMP-DEPENDENT PROTEIN KINASE-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LEUCINE ZIPPER STRUCTURE; RAT SOMATOSTATIN GENE; CYCLIC-AMP; CDNA CLONES; CATALYTIC SUBUNIT; ELEMENT; DNA; PROMOTER; IDENTIFICATION; EXPRESSION	Many promoters respond transcriptionally to elevated levels of cAMP through the cAMP-responsive enhancer (CRE). Several proteins have been characterized which bind to the CRE and presumably modulate CRE-dependent transcription. Of these CRE-binding proteins, only CREB has been shown to be activated by cAMP-dependent protein kinase A (PKA), and as such, CREB represents the only basis for our understanding of cAMP-regulated transcriptional activity. In this report, we describe the complete cDNA sequence of another CRE-binding protein, ATF-1. This protein contains a consensus phosphorylation site for PKA and shares extensive homology with CREB in the region surrounding and carboxyl-terminal to the PKA site. ATF-1 does not contain sequences homologous to the glutamine-rich amino-terminal domain found in CREB, however. ATF-1, like CREB, is expressed in a wide variety of cell types, and ATF-1 is capable of dimerizing with CREB. Both ATF-1 homodimers and ATF-1/CREB heterodimers bind to the CRE but not to the related phorbol ester response element. ATF-1 is as active as CREB in its ability to mediate the transcriptional effects of PKA, and, because ATF-1 has a smaller effect on basal expression, it is actually more responsive than CREB to cAMP. These findings indicate that CREB is not unique in its ability to mediate cAMP-dependent transcriptional regulation.	OREGON HLTH SCI UNIV,VOLLUM INST ADV BIOMED RES,3181 SW SAM JACKSON PK RD,PORTLAND,OR 97201	Oregon Health & Science University					NATIONAL CANCER INSTITUTE [R01CA037370] Funding Source: NIH RePORTER; NCI NIH HHS [CA37370] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDRISANI OM, 1989, P NATL ACAD SCI USA, V86, P2181, DOI 10.1073/pnas.86.7.2181; ANDRISANI OM, 1988, MOL CELL BIOL, V8, P1947, DOI 10.1128/MCB.8.5.1947; BERKOWITZ LA, 1990, P NATL ACAD SCI USA, V87, P5258, DOI 10.1073/pnas.87.14.5258; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; GAIRE M, 1990, NUCLEIC ACIDS RES, V18, P3467, DOI 10.1093/nar/18.12.3467; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOODMAN RH, 1990, ANNU REV NEUROSCI, V13, P111, DOI 10.1146/annurev.neuro.13.1.111; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LEE KAW, 1987, EMBO J, V6, P1345, DOI 10.1002/j.1460-2075.1987.tb02374.x; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MAURER RA, 1989, J BIOL CHEM, V264, P6870; MEINKOTH JL, 1991, MOL CELL BIOL, V511, P1759; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; QUINN PG, 1988, MOL CELL BIOL, V8, P3467, DOI 10.1128/MCB.8.8.3467; RIABOWOL KT, 1988, NATURE, V336, P83, DOI 10.1038/336083a0; Sambrook J, 1989, MOL CLONING LABORATO; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHORT JM, 1986, J BIOL CHEM, V261, P9721; SILVER BJ, 1987, P NATL ACAD SCI USA, V84, P2198, DOI 10.1073/pnas.84.8.2198; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x	29	215	218	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18431	18434						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1655749				2022-12-25	WOS:A1991GJ47200006
J	LI, M; JOURDIAN, GW				LI, M; JOURDIAN, GW			ISOLATION AND CHARACTERIZATION OF THE 2 GLYCOSYLATION ISOFORMS OF LOW-MOLECULAR-WEIGHT MANNOSE 6-PHOSPHATE RECEPTOR FROM BOVINE TESTIS - EFFECT OF CARBOHYDRATE COMPONENTS ON LIGAND-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASCITES TUMOR-CELLS; LYSOSOMAL-ENZYMES; LINKED OLIGOSACCHARIDES; PHASEOLUS-VULGARIS; LECTIN; GLYCOPEPTIDES; PURIFICATION; ERYTHROGLYCAN; BIOSYNTHESIS; LOCALIZATION	Low molecular weight mannose 6-phosphate receptor from bovine testis exhibits two isoforms on sodium dodecyl sulfate-polyacrylamide gel electrophoresis with M(r) values of 45,000 (MPR-2A) and 41,000 (MPR-2B), respectively. Each isoform was purified to near homogeneity by the sequential application of differential centrifugation and affinity chromatography. The isoforms contain a common polypeptide core, but differ in their carbohydrate content. Treatment with specific endoglycosidases demonstrated that each isoform contains two high mannose and/or hybrid and two complex N-linked oligosaccharide chains. The results obtained from treatment of each isoform with endo-beta-galactosidase and neuraminidases and from lectin affinity chromatography reveal that MPR-2A contains a linear polylactosamine sequence(s) comprised of approximately 5 lactosamine units. A majority of the outer branches of the complex chains associated with MPR-2A are terminated with sialic acid residues. In contrast, MPR-2B lacks a polylactosamine sequence and a majority of the outer branches of the complex chains are terminated with galactose residues. MPR-2A exhibited a lower affinity than MPR-2B for mannose 6-phosphate-containing ligands. Treatment of MPR-2A with endo-beta-galactosidase and/or neuraminidases followed by affinity chromatography revealed that polylactosamine and sialic acid residues impair the ability of MPR-2A to bind ligands.	UNIV MICHIGAN, SCH MED, DEPT BIOL CHEM, ROOM 4633, KRESGE 1, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH MED, DEPT INTERNAL MED, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR010531] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 10531] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BAS M, 1984, J BIOL CHEM, V259, P12557; Cassidy JT, 1966, METHODS ENZYMOL, V8, P680; CHAO HHJ, 1990, EMBO J, V9, P3507, DOI 10.1002/j.1460-2075.1990.tb07559.x; CUMMINGS RD, 1982, J BIOL CHEM, V257, P13421; CUMMINGS RD, 1984, J BIOL CHEM, V259, P6253; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; DAHMS NM, 1987, CELL, V50, P181, DOI 10.1016/0092-8674(87)90214-5; DISTLER JJ, 1987, METHOD ENZYMOL, V138, P504; ECKHARDT AE, 1983, BIOCHEMISTRY-US, V22, P5290, DOI 10.1021/bi00292a007; FUJIWARA M, 1987, ANAL BIOCHEM, V166, P72, DOI 10.1016/0003-2697(87)90547-1; FUKUDA M, 1985, Biochimica et Biophysica Acta, V780, P119; FUKUDA MN, 1985, J BIOL CHEM, V260, P6623; GALBRAIT.W, 1972, BIOCHEMISTRY-US, V11, P3976, DOI 10.1021/bi00771a022; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HILLE A, 1989, J BIOL CHEM, V264, P13460; HOFLACK B, 1985, J BIOL CHEM, V260, P2008; IRIMURA T, 1983, CARBOHYD RES, V120, P187, DOI 10.1016/0008-6215(83)88016-1; JARNEFELT J, 1978, J BIOL CHEM, V253, P8006; KAIZU T, 1982, J BIOL CHEM, V257, P8272; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI E, 1980, ARCH BIOCHEM BIOPHYS, V199, P393, DOI 10.1016/0003-9861(80)90295-7; LI M, 1989, GLYCOCONJUGATE J, V6, P388; LI M, 1989, METHOD ENZYMOL, V179, P304; MATHER JP, 1980, BIOL REPROD, V23, P243, DOI 10.1095/biolreprod23.1.243; MATSUMOT.I, 1969, BIOCHIM BIOPHYS ACTA, V194, P180, DOI 10.1016/0005-2795(69)90193-7; MERKLE RK, 1987, METHOD ENZYMOL, V138, P232; MILLER RL, 1987, METHOD ENZYMOL, V138, P527; MURPHY LA, 1977, J BIOL CHEM, V252, P4739; OBRIEN DA, 1989, ENDOCRINOLOGY, V125, P2973, DOI 10.1210/endo-125-6-2973; OSAWA T, 1987, ANNU REV BIOCHEM, V56, P21, DOI 10.1146/annurev.biochem.56.1.21; OSAWA T, 1989, 10TH P INT S GLYC JE, P91; PAULSON JC, 1982, J BIOL CHEM, V257, P2734; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PERINI F, 1981, ANAL BIOCHEM, V123, P357; POHLMANN R, 1987, P NATL ACAD SCI USA, V84, P5575, DOI 10.1073/pnas.84.16.5575; SCUDDER P, 1983, BIOCHEM J, V213, P485, DOI 10.1042/bj2130485; STEIN M, 1987, BIOL CHEM H-S, V368, P927, DOI 10.1515/bchm3.1987.368.2.927; STEIN M, 1987, BIOL CHEM H-S, V368, P937, DOI 10.1515/bchm3.1987.368.2.937; STEIN M, 1987, EMBO J, V6, P2677, DOI 10.1002/j.1460-2075.1987.tb02559.x; THOTAKURA NR, 1987, METHOD ENZYMOL, V138, P350; VANDENEIJNDEN DH, 1988, J BIOL CHEM, V263, P12461; VANDENEIJNDEN DH, 1983, J BIOL CHEM, V258, P3435; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WENDLAND M, 1991, J BIOL CHEM, V266, P4598; YAMASHITA K, 1987, J BIOL CHEM, V262, P1602; YAMASHITA K, 1983, J BIOL CHEM, V258, P4753; YARIV J, 1972, METHOD ENZYMOL, V28, P356	47	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17621	17630						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1654332				2022-12-25	WOS:A1991GF44500095
J	ENDO, K; BORER, CH; TSUJIMOTO, Y				ENDO, K; BORER, CH; TSUJIMOTO, Y			MODULATION OF LFA-1 SURFACE-ANTIGEN EXPRESSION BY ACTIVATED H-RAS BUT NOT C-MYC ONCOGENE IN EBV-INFECTED HUMAN B-LYMPHOBLAST CELLS	ONCOGENE			English	Article							BURKITTS-LYMPHOMA; ADHESION RECEPTORS; MOLECULAR-CLONING; DOWN-REGULATION; BETA-SUBUNIT; GENE; FAMILY; VIRUS; P150,95; PROTEIN	The lymphocyte-associated antigen 1 (LFA-1) involved in a wide range of cellular adhesion-dependent immunological functions, including interaction of cytotoxic T lymphocytes with their target, is implicated in tumorigenesis. The modulation of the LFA-1 antigen expression was studied in Epstein-Barr virus (EBV)-immortalized human B-lymphoblastoid cell lines, transfected with human oncogenes, H-ras and c-myc. We observed by flow cytometry that the activated H-ras (EJ) gene, but not its normal counterpart, consistently enhanced LFA-1 expression. The RNA analysis revealed that induction of the LFA-1 surface antigen by the EJ gene occurred through the level of the alpha-chain but not the beta-chain mRNA of LFA-1. The LFA-1 molecules induced by the EJ gene were functional; cells with the EJ gene revealed an elevated level of homocytic cellular adhesion, which was blocked by the anti-LFA-1 monoclonal antibody. Flow cytometry analysis indicated that the modulation of the LFA-1 antigen expression was a phenomenon specific to the EJ gene. The high levels of expression of c-myc and blc-2 gene did not affect LFA-1 antigen expression. The system used here provides a tool by which the signal transduction pathway involving the H-ras gene and the molecular mechanism of LFA-1 gene expression can be genetically dissected.	WISTAR INST, 3601 SPRUCE ST, PHILADELPHIA, PA 19104 USA	The Wistar Institute					NATIONAL CANCER INSTITUTE [R01CA051864, R01CA050551] Funding Source: NIH RePORTER; NCI NIH HHS [CA-51864, CA-50551] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BILLAUD M, 1987, LANCET, V2, P1327; CHANG EH, 1982, NATURE, V297, P479, DOI 10.1038/297479a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLAYBERGER C, 1987, LANCET, V2, P533; CORBI AL, 1988, J EXP MED, V167, P1597, DOI 10.1084/jem.167.5.1597; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; INGHIRAMI G, 1990, SCIENCE, V250, P682, DOI 10.1126/science.2237417; KEIZER GD, 1985, EUR J IMMUNOL, V15, P1142, DOI 10.1002/eji.1830151114; KISHIMOTO TK, 1989, ADV IMMUNOL, V46, P149, DOI 10.1016/S0065-2776(08)60653-7; KISHIMOTO TK, 1987, CELL, V48, P681, DOI 10.1016/0092-8674(87)90246-7; LOMBARDI L, 1987, CELL, V49, P161, DOI 10.1016/0092-8674(87)90556-3; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MASUCCI MG, 1987, P NATL ACAD SCI USA, V84, P4567, DOI 10.1073/pnas.84.13.4567; MICHELSON AM, 1983, P NATL ACAD SCI-BIOL, V80, P472, DOI 10.1073/pnas.80.2.472; MIYAMOTO C, 1985, P NATL ACAD SCI USA, V82, P7232, DOI 10.1073/pnas.82.21.7232; NASI S, 1990, ONCOGENE, V5, P117; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PATARROYO M, 1988, INT J CANCER, V41, P901, DOI 10.1002/ijc.2910410623; PULCIANI S, 1982, P NATL ACAD SCI-BIOL, V79, P2845, DOI 10.1073/pnas.79.9.2845; ROONEY CM, 1985, NATURE, V317, P629, DOI 10.1038/317629a0; ROOSSIEN FF, 1990, CANCER RES, V50, P3509; ROTHLEIN R, 1986, J IMMUNOL, V137, P1270; ROUSSET F, 1989, J IMMUNOL, V143, P1490; SANCHEZMADRID F, 1983, J EXP MED, V158, P1785, DOI 10.1084/jem.158.6.1785; SEREMETIS S, 1989, SCIENCE, V243, P660, DOI 10.1126/science.2536954; SHAW S, 1986, NATURE, V323, P262, DOI 10.1038/323262a0; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TSUJIMOTO Y, 1989, P NATL ACAD SCI USA, V86, P1958, DOI 10.1073/pnas.86.6.1958; TSUJIMOTO Y, 1989, ONCOGENE, V4, P1331; YATES J, 1984, P NATL ACAD SCI-BIOL, V81, P3806, DOI 10.1073/pnas.81.12.3806	31	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1991	6	8					1391	1396						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1653411				2022-12-25	WOS:A1991GX27200015
J	ISOGAI, Y; SHIRO, Y; NASUDAKOUYAMA, A; IIZUKA, T				ISOGAI, Y; SHIRO, Y; NASUDAKOUYAMA, A; IIZUKA, T			SUPEROXIDE PRODUCTION BY CYTOCHROME-B558 PURIFIED FROM NEUTROPHILS IN A RECONSTITUTED SYSTEM WITH AN EXOGENOUS REDUCTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CHRONIC GRANULOMATOUS-DISEASE; RESPIRATORY BURST OXIDASE; PURIFICATION; ACTIVATION; OXYGEN; CHAIN; NADPH; COMPONENTS; MECHANISM; ENZYME	Cytochrome b558, which is considered to be an essential component of the phagocytic superoxide (O2-)-generating system, was highly purified from porcine neutrophils. The isolated cytochrome was resolved into two polypeptides with molecular masses of 60-90 and 19 kDa on sodium dodecyl sulfate-polyacrylamide gel electrophoresis. For enzymatic reduction of purified cytochrome b558, we utilized hepatic NADPH-cytochrome P450 reductase purified from rat liver microsomes. More than 80% of the cytochrome was reduced by incubation with the reductase and NADPH under the anaerobic condition, and was quickly reoxidized by the air. As indicated by measurement of oxygen consumption, the purified cytochrome catalytically reduced oxygen at a rate equal to approximately 30% of the activity of the phorbol myristate acetate-activated cells on the basis of cytochrome b558 content. Electron paramagnetic resonance study with a spin trapping agent 5,5-dimethyl-1-pyrroline-1-oxide demonstrated that O2- is the exclusive primary product in the reduction of oxygen by the cytochrome. This gives direct evidence that cytochrome b558 functions as the terminal oxidizing enzyme in the O2--generating system of neutrophils. This also establishes a new functional class of heme proteins that catalyzes one-electron reduction of molecular oxygen.			ISOGAI, Y (corresponding author), INST PHYS & CHEM RES,HIROSAWA 2-1,WAKO,SAITAMA 35101,JAPAN.		Shiro, Yoshitsugu Y/J-3757-2014	Shiro, Yoshitsugu Y/0000-0003-0695-8327; Isogai, Yasuhiro/0000-0001-6905-4208				BABIOR BM, 1978, NEW ENGL J MED, V298, P659, DOI 10.1056/NEJM197803232981205; BADWEY JA, 1980, ANNU REV BIOCHEM, V49, P695, DOI 10.1146/annurev.bi.49.070180.003403; BROMBERG Y, 1985, J BIOL CHEM, V260, P3539; CROSS AR, 1985, BIOCHEM J, V226, P881, DOI 10.1042/bj2260881; CROSS AR, 1982, BIOCHEM J, V204, P479, DOI 10.1042/bj2040479; CURNUTTE JT, 1989, P NATL ACAD SCI USA, V86, P825, DOI 10.1073/pnas.86.3.825; CURNUTTE JT, 1987, J BIOL CHEM, V262, P6450; DINAUER MC, 1987, NATURE, V327, P717, DOI 10.1038/327717a0; GLASS GA, 1986, J BIOL CHEM, V261, P3247; IIZUKA T, 1985, J BIOL CHEM, V260, P2049; IYANAGI T, 1981, BIOCHEMISTRY-US, V20, P1722, DOI 10.1021/bi00510a004; KAKINUMA K, 1987, J BIOL CHEM, V262, P12316; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAKINO R, 1986, J BIOL CHEM, V261, P1444; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; PARKOS CA, 1988, P NATL ACAD SCI USA, V85, P3319, DOI 10.1073/pnas.85.10.3319; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; SEGAL AW, 1987, NATURE, V326, P88, DOI 10.1038/326088a0; SEGAL AW, 1989, J CLIN INVEST, V83, P1785, DOI 10.1172/JCI114083; TANAKA T, 1990, J BIOL CHEM, V265, P18717; TANAKA T, 1988, J BIOL CHEM, V263, P13670; TEAHAN C, 1987, NATURE, V327, P720, DOI 10.1038/327720a0; UENO I, 1989, J BIOCHEM-TOKYO, V105, P905, DOI 10.1093/oxfordjournals.jbchem.a122777; VOLPP BD, 1988, SCIENCE, V242, P1295, DOI 10.1126/science.2848318; YAMAGUCHI T, 1989, J BIOL CHEM, V264, P112; YEA CM, 1990, BIOCHEM J, V265, P95, DOI 10.1042/bj2650095	26	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13481	13484						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1649821				2022-12-25	WOS:A1991FY02700004
J	NAKAGAWA, N; ARAB, N; GHISHAN, FK				NAKAGAWA, N; ARAB, N; GHISHAN, FK			CHARACTERIZATION OF THE DEFECT IN THE NA+-PHOSPHATE TRANSPORTER IN VITAMIN-D-RESISTANT HYPOPHOSPHATEMIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANE; X-LINKED HYPOPHOSPHATEMIA; XENOPUS-LAEVIS OOCYTES; CO-TRANSPORTER; MESSENGER-RNA; RICKETS; EXPRESSION; ACID; 1,25-DIHYDROXYVITAMIN-D3; VESICLES	Hypophosphatemic vitamin D-resistant rickets is the most common form of vitamin D-resistant rickets in man. The hypophosphatemic mouse model (Hyp) is phenotypically, and biochemically similar to the human disease. Biochemically, hypophosphatemia is the hallmark of this disorder. The cause of the hypophosphatemia is thought to be secondary to a defect in the renal and/or intestinal Na+-phosphate transporter. The current studies were designed to investigate and characterize the localization of the defect in the Na+-phosphate transporter in this disorder. Phosphate uptake by renal brush border membrane vesicles (BBMV) showed a significant decrease in the slope of the initial rate of phosphate uptake in (Hyp) compared with control mice (0.009 versus 0.0 1 3, respectively). The slopes representing initial rates of phosphate uptake by jejunal BBMV were similar in (Hyp) and control mice (0.004 and 0.004, respectively). Kinetics of jejunal Na+-dependent phosphate uptake showed a V(max) of 0.63 +/- 0.12 and 0.64 +/- 0.12 nmol/mg protein/ 15 s in (Hyp) and control mice, respectively, whereas K(m) values were 0.12 +/- 0.08 and 0.2 +/- 0.11 mM respectively. Similar kinetic analysis in the kidney showed a V(max) of 0.32 +/- 0.06 and 1.6 +/- 0.1 (p < 0.0 1) and K(m) of 0.07 +/- 0.06 and 0.39 +/- 0.05 (p < 0.02) in (Hyp) and control mice, respectively. Na+-dependent D-glucose uptake by BBMVs of intestine and kidney showed typical overshoot phenomena in (Hyp) and control mice. In order to explore these findings further, Na+-phosphate transporter expression from intestine and kidney, was accomplished by microinjection of 50 ng of poly(A)+ RNA into Xenopus laevis oocytes. Na+-dependent phosphate uptake was expressed 6 days after the microinjection of intestinal and kidney poly(A)+ RNA from control mice. However, expression of the transporter from (Hyp) mice occurred only from the intestine, and not from the kidney. The decrease in the expression of the Na+-dependent phosphate transporter was not secondary to accelerated efflux of phosphate or decreased metabolism in oocytes injected with poly(A)+ RNA from (Hyp) mice. Alpha-Methyl-D-glucose was expressed equally from the kidneys of (Hyp) and control mice. The combined results of brush border membrane and X. laevis oocyte studies suggest that the cause of hypophosphatemia in (Hyp) mice is secondary to a defect in coding for the phosphate transporter, resulting in diminished activity and/or function of the Na+-dependent phosphate transporter in the kidney, but not in the intestine. Alternatively, the diminished expression could be secondary to a decrease in mRNA concentration for the Na+-phosphate co-transporter.	VANDERBILT UNIV,DEPT PEDIAT GASTROENTEROL,MED CTR N,S-4322,21ST & GARLAND ST,NASHVILLE,TN 37232; VANDERBILT UNIV,MED CTR,DEPT MOLEC PHYSIOL & BIOPHYS,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033209, R37DK033209] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 33209-08] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALMAHROUQ HA, 1991, J BIOL CHEM, V266, P1422; BARNARD JA, 1985, J CLIN INVEST, V75, P869, DOI 10.1172/JCI111785; BEAMER WG, 1980, ENDOCRINOLOGY, V106, P1949, DOI 10.1210/endo-106-6-1949; BEAUFAY H, 1974, J CELL BIOL, V61, P188, DOI 10.1083/jcb.61.1.188; CHAN JCM, 1980, PEDIATRICS, V66, P445; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COWGILL LD, 1979, J CLIN INVEST, V63, P1203, DOI 10.1172/JCI109415; EICKER EM, 1976, P NATL ACAD SCI USA, V73, P4667; GHISHAN FK, 1985, AM J PHYSIOL, V248, pG87, DOI 10.1152/ajpgi.1985.248.1.G87; GIASSON SD, 1977, PFLUG ARCH EUR J PHY, V371, P33, DOI 10.1007/BF00580769; GLORIEUX FH, 1976, PEDIATR RES, V10, P691, DOI 10.1203/00006450-197610070-00012; HEDIGER MA, 1987, P NATL ACAD SCI USA, V84, P2634, DOI 10.1073/pnas.84.9.2634; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MEYER RA, 1989, J BONE MINER RES, V4, P493; ODOHERTY PJA, 1977, ENDOCRINOLOGY, V101, P1325, DOI 10.1210/endo-101-4-1325; Rasmussen H., 1983, METABOLIC BASIS INHE, V5th, P1743; SARTHY V, 1986, MOL BRAIN RES, V1, P97, DOI 10.1016/0169-328X(86)90025-2; SCHARSCHMIDT BF, 1979, J LAB CLIN MED, V93, P790; SZCZEPANSKAKONKEL M, 1987, J BIOL CHEM, V262, P8000; TENENHOUSE HS, 1978, KIDNEY INT, V14, P236, DOI 10.1038/ki.1978.115; TENENHOUSE HS, 1979, CAN J BIOCHEM CELL B, V57, P938, DOI 10.1139/o79-114; WERNER A, 1990, J BIOL CHEM, V265, P12331	23	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13616	13620						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1649826				2022-12-25	WOS:A1991FY02700028
J	HILL, MA; KAUFMANN, K; OTERO, J; PREISS, J				HILL, MA; KAUFMANN, K; OTERO, J; PREISS, J			BIOSYNTHESIS OF BACTERIAL GLYCOGEN - MUTAGENESIS OF A CATALYTIC SITE RESIDUE OF ADP-GLUCOSE PYROPHOSPHORYLASE FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALLOSTERIC ACTIVATOR SITE; INHIBITOR-BINDING SITE(S); COVALENT MODIFICATION; STRUCTURAL CHARACTERIZATION; ADPGLUCOSE SYNTHETASE; PHENOTYPIC SELECTION; NUCLEOTIDE-SEQUENCE; ADENYLATE KINASE; SYNTHASE; PHOSPHATE	Site-directed mutagenesis was used to explore the role of Lys-195 in ADP-glucose pyrophosphorylase from Escherichia coli. This residue, which is conserved in every bacterial and plant source sequenced to date, was originally identified as a potential catalytic site residue by covalent modification studies. Mutation of Lys-195 to glutamine produces an enzyme whose K(m) for glucose 1-phosphate is 600-fold greater than that measured for the wild-type enzyme. The effect on glucose 1-phosphate is very specific since kinetic constants measured for ATP, Mg2+, and the allosteric activator, fructose 1,6-bisphosphate, are unchanged relative to those measured for the wild-type enzyme. Furthermore, the catalytic rate constant, k(cat), for the glutamine mutant is similar to that of the wild-type enzyme. Taken together, the results suggest a role for Lys-195 in binding of glucose 1-phosphate and exclude its role as a participant in the rate-determining step(s) in the catalytic reaction mechanism. To further study the effect of charge, shape, size, and hydrophobicity of the amino acid residue at position 195, a series of mutants were prepared including arginine, histidine, isoleucine, and glutamic acid. In every case, the kinetic constants measured for ATP, Mg2+, and fructose 1,6-bisphosphate were similar to wild-type constants, reinforcing the notion that this residue is responsible for a highly localized effect at the glucose 1-phosphate-binding site and also suggesting that the protein can accommodate a wide range of substitutions at this position without losing its global folding properties. Thermal stability measurements corroborate this finding. The mutations did, however, produce a range of glucose I-phosphate K(m) values from 100- to 10,000-fold greater than wild-type, which indicate that both size and charge properties of lysine are essential for proper binding of glucose 1-phosphate at the catalytic site. AMP binding was also affected by the nature of the mutation at position 195. A model for glucose 1-phosphate, ATP, and AMP binding is presented.			HILL, MA (corresponding author), MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022835, R37AI022835] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 22835] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON JM, 1989, J BIOL CHEM, V264, P12238; BAECKER PA, 1983, J BIOL CHEM, V258, P5084; GENTNER N, 1968, J BIOL CHEM, V243, P5882; HAUGEN TH, 1979, J BIOL CHEM, V254, P127; KUMAR A, 1989, J BIOL CHEM, V264, P10464; KUMAR A, 1988, J BIOL CHEM, V263, P14634; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LARSEN CE, 1986, J BIOL CHEM, V261, P5402; LARSEN CE, 1986, BIOCHEMISTRY-US, V25, P4371, DOI 10.1021/bi00363a029; LEE YM, 1986, ARCH BIOCHEM BIOPHYS, V244, P585, DOI 10.1016/0003-9861(86)90627-2; LEE YM, 1986, J BIOL CHEM, V261, P1058; LEUNG PSC, 1987, J BACTERIOL, V169, P4355, DOI 10.1128/jb.169.9.4355-4360.1987; OKITA TW, 1981, J BIOL CHEM, V256, P6944; OZAKI H, 1972, METHOD ENZYMOL, V28, P409; PARSONS TF, 1978, J BIOL CHEM, V253, P7638; PARSONS TF, 1978, J BIOL CHEM, V253, P6197; PAULE MR, 1971, J BIOL CHEM, V246, P4602; PREISS J, 1966, J BIOL CHEM, V5, P1833; REINSTEIN J, 1990, BIOCHEMISTRY-US, V29, P7451, DOI 10.1021/bi00484a014; ROMEO T, 1989, J BACTERIOL, V171, P2773, DOI 10.1128/jb.171.5.2773-2782.1989; SHEU KFR, 1979, BIOCHEMISTRY-US, V18, P5548, DOI 10.1021/bi00592a004; WILKINSON G, 1961, BIOCHEM J, V80, P324, DOI 10.1042/bj0800324	23	43	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1991	266	19					12455	12460						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FV180	1648099				2022-12-25	WOS:A1991FV18000057
J	BAETSCHER, M; SCHMIDT, E; SHIMIZU, A; LEDER, P; FISHMAN, MC				BAETSCHER, M; SCHMIDT, E; SHIMIZU, A; LEDER, P; FISHMAN, MC			SV40 T-ANTIGEN TRANSFORMS CALCITONIN CELLS OF THE THYROID BUT NOT CGRP-CONTAINING NEURONS IN TRANSGENIC MICE	ONCOGENE			English	Article							LARGE TUMOR-ANTIGEN; C-MYC; GENE; EXPRESSION; CARCINOMA; ONCOGENE; BRAIN	Neurons are postmitotic for the adult life of animals. Tumors rarely, if ever, arise from neurons in the adult, although they do from other cells from the same lineage, such as the neuroendocrine C cells of the thyroid. We have found that 2 kb of the calcitonin gene-related peptide (CGRP)/calcitonin gene suffices to target expression to CGRP-containing neurons, such as those in the dorsal root ganglia (DRG), and to the clacitonin-secreting C cells of the thyroid. Using this promoter we have examined the effect of two potentially transforming oncogenes in these two different populations. Overexpression of c-myc for periods of up to two years does not transform either cell type, whereas SV40 Tag causes early onset medullary thyroid carcinoma, but does not transform the dorsal root ganglia neurons. This suggests that as part of the terminal differentiation process of these neurons, the cessation of mitosis is accompanied by a relative refractoriness to oncogenes that may transform other cells of the same lineage.	HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,DEV BIOL LAB,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,CARDIOVASC RES CTR,BOSTON,MA 02114; HOWARD HUGHES MED INST,BOSTON,MA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Howard Hughes Medical Institute	FISHMAN, MC (corresponding author), MASSACHUSETTS GEN HOSP,DEV BIOL LAB,MGH E,149 13TH ST,4TH FLOOR,BOSTON,MA 02129, USA.							AMARA SG, 1982, NATURE, V298, P240, DOI 10.1038/298240a0; AMARA SG, 1984, MOL CELL BIOL, V4, P2151, DOI 10.1128/MCB.4.10.2151; BAETGE EE, 1988, P NATL ACAD SCI USA, V85, P3648, DOI 10.1073/pnas.85.10.3648; BARASCH JM, 1987, J NEUROSCI, V7, P2874; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BRINSTER RL, 1984, CELL, V37, P367, DOI 10.1016/0092-8674(84)90367-2; CHAPMAN CR, 1985, PAIN, V22, P1, DOI 10.1016/0304-3959(85)90145-9; CORY S, 1988, ANNU REV IMMUNOL, V6, P25; DEBUSTROS A, 1990, MOL CELL BIOL, V10, P1773, DOI 10.1128/MCB.10.4.1773; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEGROOT LJ, 1979, ENDOCRINOLOGY, V2; DeLellis R A, 1981, Methods Achiev Exp Pathol, V10, P190; DELELLIS RA, 1978, AM J CLIN PATHOL, V70, P587, DOI 10.1093/ajcp/70.4.587; EFRAT S, 1988, NEURON, V1, P605, DOI 10.1016/0896-6273(88)90110-9; GOLDMAN SA, 1983, P NATL ACAD SCI-BIOL, V80, P2390, DOI 10.1073/pnas.80.8.2390; GRAZIADEI PPC, 1979, NEUROSCIENCE, V4, P713, DOI 10.1016/0306-4522(79)90002-2; HAMMANG JP, 1990, NEURON, V4, P775, DOI 10.1016/0896-6273(90)90204-S; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HOGAN B, 1986, MANIPULATING MOUSE E; JOHANNESSEN JV, 1978, HUM PATHOL, V9, P385, DOI 10.1016/S0046-8177(78)80025-2; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LANFORD RE, 1984, CELL, V37, P801, DOI 10.1016/0092-8674(84)90415-X; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; REYNOLDS RK, 1988, P NATL ACAD SCI USA, V85, P3135, DOI 10.1073/pnas.85.9.3135; ROSENFELD MG, 1983, NATURE, V304, P129, DOI 10.1038/304129a0; RUPPERT C, 1986, EMBO J, V5, P1897, DOI 10.1002/j.1460-2075.1986.tb04442.x; RUPPERT JM, 1986, AM J SURG PATHOL, V10, P513, DOI 10.1097/00000478-198607000-00009; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; TRIGGS SM, 1977, ACTA ENDOCRINOL-COP, V85, P84	31	27	27	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1991	6	7					1133	1138						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1650439				2022-12-25	WOS:A1991GV26000006
J	CHOI, HS; LI, BS; LIN, Z; HUANG, LE; LIU, AYC				CHOI, HS; LI, BS; LIN, Z; HUANG, LE; LIU, AYC			CAMP AND CAMP-DEPENDENT PROTEIN-KINASE REGULATE THE HUMAN HEAT-SHOCK PROTEIN-70 GENE PROMOTER ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN HSP70 PROMOTER; TRANSCRIPTION FACTOR ATF; ELEMENT-BINDING-PROTEIN; CYCLIC-AMP; DNA-BINDING; SOMATOSTATIN GENE; RESPONSE ELEMENT; PREINITIATION COMPLEX; DIPLOID FIBROBLASTS; ACTIVATION INVITRO	The theme of this study is an evaluation of the involvement of cAMP and cAMP-dependent protein kinase (PKA) in the regulation of the human heat shock protein (hsp) 70 gene promoter. Expression of a highly specific protein inhibitor of PKA (pRSVPKI) inhibited the basal as well as heat- and cadmium-induced expression of the cotransfected pHBCAT, a human hsp 70 promoter-driven reporter gene; this inhibition was dependent on the amount of pRSVPKI used. The effect of an expression vector of the R(I) regulatory subunit of PKA, pMTREV, was similar to that of pRSVPKI; pMTREV inhibited both the basal as well as the heat-induced expression of pHBCAT. The specificity of effects of these expression vectors was demonstrated by the lack of effect of a mutant PKI gene and by the unaffected expression of a reference gene (pRSV-beta-gal) under these conditions. Analysis of the effects of dibutyryl cAMP (1 mM), forskolin (10-mu-M), and 8-Br-cAMP (1 mM) on the transient expression of pHBCAT showed that these cAMP-elevating agents stimulated the hsp 70 promoter activity, whereas cAMP (1 mM) was without effect. Chloramphenicol acetyltransferase gene constructs with truncated or mutated hsp 70 promoter were used to define the cis-acting DNA element(s) that confer this cAMP stimulation; the heat induced (42-degrees-C) expression was used as a control. Mutation of the adenovirus transcription factor element (pLSN-40/-26) greatly reduced the basal level of expression; forskolin had little or no effect on this adenovirus transcription factor-minus promoter, although the promoter activity was very heat inducible. The absence of a functional heat shock consensus element (HSE) in the construct pLSPNWT rendered the promoter heat insensitive; this construct was forskolin responsive although the magnitude of this stimulation was reduced when compared with that of a control construct with HSE. These results were corroborated by studies using consensus sequence of ATF (ATFE) and HSE as competitors to titrate our cellular factors that may interact with these elements. We showed that cotransfection with ATFE and HSE depressed the basal (37-degrees-C) expression of pHBCAT by 25 and 60%, respectively. The heat-induced expression of pHBCAT was not significantly affected by the cotransfection of ATFE and was reduced by 60% when HSE was cotransfected. ATFE and HSE reduced the forskolin-induced pHBCAT expression by 70 and 40%, respectively. The implications of these findings as they relate to the action of cAMP and cAMP-dependent protein kinase in the control of heat shock gene expression are discussed.	RUTGERS STATE UNIV, DEPT BIOL SCI, PISCATAWAY, NJ 08855 USA	Rutgers State University New Brunswick				Huang, Eric/0000-0002-6444-1708; Liu, Alice Y./0000-0002-6984-1671				ANDRISANI OM, 1988, MOL CELL BIOL, V8, P1947, DOI 10.1128/MCB.8.5.1947; BERKOWITZ LA, 1990, P NATL ACAD SCI USA, V87, P5258, DOI 10.1073/pnas.87.14.5258; BOORSTEIN WR, 1990, EMBO J, V9, P2543, DOI 10.1002/j.1460-2075.1990.tb07435.x; CHERRY JR, 1989, CELL, V56, P409, DOI 10.1016/0092-8674(89)90244-4; CHOI HS, 1990, J BIOL CHEM, V265, P18005; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; CORTES P, 1988, GENE DEV, V2, P975, DOI 10.1101/gad.2.8.975; DAY RN, 1989, J BIOL CHEM, V264, P431; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; GALLO GJ, 1991, MOL CELL BIOL, V11, P281, DOI 10.1128/MCB.11.1.281; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GLINEUR C, 1990, GENE DEV, V4, P1663, DOI 10.1101/gad.4.10.1663; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENE JM, 1990, MOL CELL BIOL, V10, P1319, DOI 10.1128/MCB.10.4.1319; GREENE JM, 1987, MOL CELL BIOL, V7, P3646, DOI 10.1128/MCB.7.10.3646; GROVE JR, 1989, J BIOL CHEM, V264, P19506; GROVE JR, 1987, SCIENCE, V238, P530; HAI T, 1988, CELL, V54, P1043, DOI 10.1016/0092-8674(88)90119-5; HAI T, 1988, GENE DEV, V2, P1216, DOI 10.1101/gad.2.10.1216; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HENSOLD JO, 1990, MOL CELL BIOL, V10, P1600, DOI 10.1128/MCB.10.4.1600; HICKEY E, 1989, MOL CELL BIOL, V9, P2615, DOI 10.1128/MCB.9.6.2615; HOEFFLER WK, 1988, CELL, V53, P907, DOI 10.1016/S0092-8674(88)90409-6; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; HURST HC, 1987, GENE DEV, V1, P1132, DOI 10.1101/gad.1.10.1132; JOHNSTON RN, 1988, SCIENCE, V242, P1551, DOI 10.1126/science.3201244; KAO HT, 1985, MOL CELL BIOL, V5, P628, DOI 10.1128/MCB.5.4.628; LAMPH WW, 1990, P NATL ACAD SCI USA, V87, P4320, DOI 10.1073/pnas.87.11.4320; LARSON JS, 1988, NATURE, V335, P372, DOI 10.1038/335372a0; LEGAGNEUX V, 1990, EUR J BIOCHEM, V193, P121, DOI 10.1111/j.1432-1033.1990.tb19312.x; LIN YS, 1988, P NATL ACAD SCI USA, V85, P3396, DOI 10.1073/pnas.85.10.3396; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; LIU AYC, 1989, BIOCHEM BIOPH RES CO, V162, P1302, DOI 10.1016/0006-291X(89)90815-2; LIU AYC, 1989, J BIOL CHEM, V264, P12037; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; MCKNIGHT GS, 1988, RECENT PROG HORM RES, V44, P307; MERINO A, 1989, J BIOL CHEM, V264, P21266; MILARSKI KL, 1986, P NATL ACAD SCI USA, V83, P9517, DOI 10.1073/pnas.83.24.9517; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MORIMOTO RI, 1989, STRESS INDUCED PROTE, P83; NEVINS JR, 1982, CELL, V29, P913, DOI 10.1016/0092-8674(82)90453-6; POTEAT HT, 1990, J VIROL, V64, P1264, DOI 10.1128/JVI.64.3.1264-1270.1990; PRIVES C, 1990, CELL, V61, P735, DOI 10.1016/0092-8674(90)90179-I; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; SASSONECORSI P, 1988, P NATL ACAD SCI USA, V85, P7192, DOI 10.1073/pnas.85.19.7192; SCHLESINGERMJ, 1982, HEAT SHOCK BACTERIA; SIMON MC, 1987, MOL CELL BIOL, V7, P2884, DOI 10.1128/MCB.7.8.2884; SORGER PK, 1987, NATURE, V329, P81, DOI 10.1038/329081a0; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443; WILLIAMS GT, 1989, MOL CELL BIOL, V9, P2574, DOI 10.1128/MCB.9.6.2574; WILLIAMS GT, 1990, MOL CELL BIOL, V10, P3125, DOI 10.1128/MCB.10.6.3125; WU B, 1985, MOL CELL BIOL, V5, P330, DOI 10.1128/MCB.5.2.330; WU BJ, 1985, P NATL ACAD SCI USA, V82, P6070, DOI 10.1073/pnas.82.18.6070; WU BJ, 1987, P NATL ACAD SCI USA, V84, P2203, DOI 10.1073/pnas.84.8.2203; WU BJ, 1986, P NATL ACAD SCI USA, V83, P629, DOI 10.1073/pnas.83.3.629; WU JC, 1989, J BIOL CHEM, V264, P9989; XIAO H, 1986, MOL CELL BIOL, V6, P3200, DOI 10.1128/MCB.6.9.3200	60	79	81	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1991	266	18					11858	11865						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FT762	1646817				2022-12-25	WOS:A1991FT76200068
J	KYRIAKIS, JM; BRAUTIGAN, DL; INGEBRITSEN, TS; AVRUCH, J				KYRIAKIS, JM; BRAUTIGAN, DL; INGEBRITSEN, TS; AVRUCH, J			PP54 MICROTUBULE-ASSOCIATED PROTEIN-2 KINASE REQUIRES BOTH TYROSINE AND SERINE THREONINE PHOSPHORYLATION FOR ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GROWTH-FACTOR; S6 KINASE; INSULIN; ACTIVATION; INVIVO; FORMS	pp54 microtubule-associated protein-2 (MAP-2) kinase, a recently discovered protein serine/threonine kinase (Kyriakis, J., and Avruch, J. (1990) J. Biol. Chem. 265, 17355-17363), is shown to contain immunoreactive phosphotyrosine residues. Treatment with recombinant rat brain protein tyrosine phosphatase-1 deactivates pp54 MAP-2 kinase, concomitant with the removal of phosphotyrosine residues. Protein (serine/threonine) phosphatase-1 also deactivates pp54 MAP-2 kinase in a specific fashion. pp54 MAP-2-kinase joins pp42 MAP-2 kinase and cdc2/maturation-promoting factor as one of only three serine/threonine protein kinases known to be regulated by phosphorylation at both tyrosine and, independently, at serine/threonine residues. In view of these shared regulatory properties, a role for pp54 MAP-2 kinase in the control of cell division is likely.	MASSACHUSETTS GEN HOSP,DIABET UNIT,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,MED SERV,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; BROWN UNIV,DIV BIOL & MED,PROVIDENCE,RI 02912; IOWA STATE UNIV SCI & TECHNOL,DEPT ZOOL & GENET,AMES,IA 50011	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Brown University; Iowa State University					NHLBI NIH HHS [HL07680] Funding Source: Medline; NIDDK NIH HHS [DK41513, DK41762] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041762, R01DK041513] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BRAUTIGAN DL, 1989, ARCH BIOCHEM BIOPHYS, V275, P44, DOI 10.1016/0003-9861(89)90348-2; ERIKSON E, 1989, J BIOL CHEM, V264, P13711; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; GAUN K, 1990, P NATL ACAD SCI USA, V87, P1501; HABENICHT AJR, 1981, J BIOL CHEM, V256, P2329; HOWELL BW, 1991, MOL CELL BIOL, V11, P568, DOI 10.1128/MCB.11.1.568; JONES SW, 1989, J BIOL CHEM, V264, P7747; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; LEVINE L, 1989, J IMMUNOL METHODS, V124, P239, DOI 10.1016/0022-1759(89)90360-8; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MORRISON DK, 1989, CELL, V58, P641; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PRICE DJ, 1990, P NATL ACAD SCI USA, V87, P7944, DOI 10.1073/pnas.87.20.7944; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; STERN DF, 1991, MOL CELL BIOL, V11, P987, DOI 10.1128/MCB.11.2.987; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0	23	102	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10043	10046						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	1645334				2022-12-25	WOS:A1991FP08600007
J	BITTNER, MA; HOLZ, RW				BITTNER, MA; HOLZ, RW			A TEMPERATURE-SENSITIVE STEP IN EXOCYTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL-MEDULLARY CELLS; BOVINE CHROMAFFIN CELLS; PROTEIN-KINASE-C; CATECHOLAMINE SECRETION; PHORBOL ESTER; CALCIUM	We have examined the temperature sensitivity of exocytosis in digitonin-permeabilized chromaffin cells. The time course of secretion is markedly slowed by incubating the cells at 18-degrees-C rather than 27-degrees-C. We have previously shown that secretion has both ATP-dependent and ATP-independent components (Holz, R. W., Bittner, M. A., Peppers, S. C., Senter, R. A., and Eberhard, D. A. (1989) J. Biol. Chem. 264, 5412-5419). Reducing the temperature has no effect on ATP-independent secretion. However, cold (18-degrees-C) greatly slows the ability of ATP to stimulate secretion. The ATP-requiring priming step itself is not affected by reducing the temperature since an effect of ATP can be seen after permeabilization at 18-degrees-C if the cells are subsequently stimulated to secrete at 27-degrees-C. When cells are permeabilized at 27-degrees-C with ATP and then stimulated by Ca2+ in the absence of ATP, the secretion which was primed by ATP during the permeabilization step is inhibited 75% at 18-degrees-C. Similar results are seen when ATP-dependent priming is enhanced by low concentrations of Ca2+. Thus, the temperature-sensitive step occurs after ATP and Ca2+ act to prime the cell. The temperature-sensitive step is likely to be the overall rate-limiting step during the later phase of secretion, when the ATP-dependent priming process is limiting.			BITTNER, MA (corresponding author), UNIV MICHIGAN, SCH MED, DEPT PHARMACOL, M6322 MED SCI BLDG 1, ANN ARBOR, MI 48109 USA.				NIDDK NIH HHS [R01 DK27959] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027959] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BITTNER MA, 1992, J BIOL CHEM, V267, P16219; BJERRUM J, 1957, STABILITY CONSTANT 1, P422; BROCKLEHURST KW, 1985, BIOCHEM J, V228, P35, DOI 10.1042/bj2280035; DUNN LA, 1983, J BIOL CHEM, V258, P4989; EBERHARD DA, 1990, BIOCHEM J, V268, P15, DOI 10.1042/bj2680015; HOLZ RW, 1989, J BIOL CHEM, V264, P5412; KAO LS, 1984, J NEUROCHEM, V43, P590, DOI 10.1111/j.1471-4159.1984.tb00940.x; KNIGHT DE, 1983, FEBS LETT, V160, P98, DOI 10.1016/0014-5793(83)80944-2; KNIGHT DE, 1983, Q J EXP PHYSIOL CMS, V68, P123, DOI 10.1113/expphysiol.1983.sp002691; KNIGHT DE, 1979, J PHYSIOL-LONDON, V298, pP41; MARTELL AE, 1974, CRITICAL STABILITY C, V1, P269; POCOTTE SL, 1985, P NATL ACAD SCI USA, V82, P930, DOI 10.1073/pnas.82.3.930; PORTZEHL H, 1964, BIOCHIM BIOPHYS ACTA, V79, P581, DOI 10.1016/0926-6577(64)90224-4; TERBUSH DR, 1990, J BIOL CHEM, V265, P21179; WILSON SP, 1983, J BIOL CHEM, V258, P4994; WU YN, 1991, BIOCHIM BIOPHYS ACTA, V1092, P384, DOI 10.1016/S0167-4889(97)90016-1	16	75	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16226	16229						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1644808				2022-12-25	WOS:A1992JJ45800038
J	HORI, N; IWAI, S; INOUE, H; OHTSUKA, E				HORI, N; IWAI, S; INOUE, H; OHTSUKA, E			PHOTOAFFINITY-LABELING OF T4 ENDONUCLEASE-V WITH A SUBSTRATE CONTAINING A PHENYLDIAZIRINE DERIVATIVE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; GENE; OLIGODEOXYRIBONUCLEOTIDES; T4-ENDONUCLEASE-V; IDENTIFICATION; SEQUENCE; PROBES; DNA	T4 endonuclease V recognizes thymine photodimers in DNA duplexes and, in a two-step reaction, cleaves the glycosyl linkage of the 5'-side thymidine and the phosphodiester linkage. To determine the amino acid residues responsible for binding thymine photodimers, a photoaffinity reagent, 4-(1-azi-2,2,2-trifluoroethyl)-benzoate, was linked to the aminoalkylphosphonate of a thymine photodimer in a 14-mer duplex. The reactive substrate was treated with the enzyme under UV light (365 nm). The nascent enzyme and the modified enzyme were treated with lysyl endopeptidase, and the peptide maps were compared. Three peptides from the C terminus were found to interact with the reactive oligonucleotide to various extents. The three modified peptides were isolated and analyzed by Edman degradation. The amino acid residues Gly-133, Tyr-129, and Thr-89 were partially linked with the reactive substrate and may be involved in the binding of thymine photodimers.			HORI, N (corresponding author), HOKKAIDO UNIV,FAC PHARMACEUT SCI,SAPPORO,HOKKAIDO 060,JAPAN.							[Anonymous], 1985, DNA REPAIR; AOKI D, 1990, EMBO J, V9, P3171, DOI 10.1002/j.1460-2075.1990.tb07515.x; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; BRUNNER J, 1980, J BIOL CHEM, V255, P3313; CATALANO CE, 1990, BIOCHEMISTRY-US, V29, P3612, DOI 10.1021/bi00467a004; CHOLLET A, 1985, NUCLEIC ACIDS RES, V13, P1529, DOI 10.1093/nar/13.5.1529; GANESAN AK, 1986, BIOCHEMISTRY-US, V25, P5751, DOI 10.1021/bi00367a060; HATANAKA Y, 1990, FEBS LETT, V260, P27, DOI 10.1016/0014-5793(90)80057-P; HATANAKA Y, 1989, BIOORG CHEM, V17, P482, DOI 10.1016/0045-2068(89)90048-5; IKEHARA M, 1984, P NATL ACAD SCI-BIOL, V81, P5956, DOI 10.1073/pnas.81.19.5956; INAOKA T, 1989, J BIOL CHEM, V264, P2609; ISHIDA M, 1990, BIOCHEMISTRY-US, V29, P3817, DOI 10.1021/bi00468a002; LLOYD RS, 1989, PROTEINS, V6, P128, DOI 10.1002/prot.340060204; MILLER PS, 1983, NUCLEIC ACIDS RES, V11, P5188; MORIKAWA K, 1992, SCIENCE, V256, P523, DOI 10.1126/science.1575827; MORIKAWA K, 1988, J MOL BIOL, V202, P683, DOI 10.1016/0022-2836(88)90298-7; Murov S. L, 1973, HDB PHOTOCHEMISTRY; NAKABEPPU Y, 1981, P NATL ACAD SCI-BIOL, V78, P2742, DOI 10.1073/pnas.78.5.2742; NASSAL M, 1983, LIEBIGS ANN CHEM, P1510; RECINOS A, 1988, BIOCHEMISTRY-US, V27, P1832, DOI 10.1021/bi00406a006; REESE CB, 1978, TETRAHEDRON LETT, P2727; STEINUM AL, 1986, NUCLEIC ACIDS RES, V14, P3763, DOI 10.1093/nar/14.9.3763; STUMP DG, 1988, BIOCHEMISTRY-US, V27, P1839, DOI 10.1021/bi00406a007; VALERIE K, 1984, NUCLEIC ACIDS RES, V12, P8085, DOI 10.1093/nar/12.21.8085	24	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15591	15594						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1639800				2022-12-25	WOS:A1992JG11300054
J	TANIGUCHI, M; IWAMOTO, T; NAKASHIMA, I; NAKAYAMA, A; OHBAYASHI, M; MATSUYAMA, M; TAKAHASHI, M				TANIGUCHI, M; IWAMOTO, T; NAKASHIMA, I; NAKAYAMA, A; OHBAYASHI, M; MATSUYAMA, M; TAKAHASHI, M			ESTABLISHMENT AND CHARACTERIZATION OF A MALIGNANT MELANOCYTIC TUMOR-CELL LINE EXPRESSING THE RET ONCOGENE	ONCOGENE			English	Article							RECEPTOR TYROSINE KINASES; PROTEINS; CLONING; PI3-KINASE; PRODUCTS; DOMAINS; GENE	We established a cell line (designated Mel-ret) from a melanocytic tumor developed in a metallothionein/ret transgenic mouse. Unlike primary melanocytic tumors, which did not show malignant features, when the Met-ret cells were transplanted into nude mice they invaded into surrounding tissues and had metastatic ability. Although the Ret proteins were expressed at similar levels in the cell fine and the primary tumors, the level of tyrosine phosphorylation in the Mel-ret cells was much higher than that in the primary tumors. In particular, an 85-kDa tyrosine-phosphorylated band was specifically detected in the Mel-ret cells. These results suggest that the increase in tyrosine phosphorylation may be responsible for malignant transformation of the Mel-ret cells. Immunofluorescence and cell fractionation studies showed that the Ret proteins and most of tyrosine-phosphorylated proteins in the Mel-ret cells localized in the membrane fraction. No activation of phosphatidyl-inositol-3 kinase (PI-3 kinase), a target protein for several tyrosine kinases, was detected in the Mel-ret cells.	NAGOYA UNIV,SCH MED,DEPT PATHOL,65 TSURUMAI CHO,SHOWA KU,NAGOYA,AICHI 466,JAPAN; NAGOYA UNIV,SCH MED,DEPT IMMUNOL,NAGOYA,AICHI 466,JAPAN	Nagoya University; Nagoya University			Takahashi, Masahide/AAN-4770-2020; TAKAHASHI, Masahide/I-7244-2014	Takahashi, Masahide/0000-0002-2803-2683; 				ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; HAMAGUCHI M, 1988, MOL CELL BIOL, V8, P3035, DOI 10.1128/MCB.8.8.3035; IWAMOTO T, 1991, EMBO J, V10, P3167, DOI 10.1002/j.1460-2075.1991.tb04878.x; LIOTTA LA, 1986, P NATL ACAD SCI USA, V83, P3302, DOI 10.1073/pnas.83.10.3302; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; SCHULTZ RM, 1988, CANCER RES, V48, P5539; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; TAKAHASHI M, 1991, ONCOGENE, V6, P297; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TANIGUCHI M, 1991, BIOCHEM BIOPH RES CO, V181, P416, DOI 10.1016/S0006-291X(05)81435-4	11	25	25	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1992	7	8					1491	1496						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1630812				2022-12-25	WOS:A1992JE81300004
J	FABRE, E; THARAUD, C; GAILLARDIN, C				FABRE, E; THARAUD, C; GAILLARDIN, C			INTRACELLULAR TRANSIT OF A YEAST PROTEASE IS RESCUED BY TRANSCOMPLEMENTATION WITH ITS PRODOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKALINE EXTRACELLULAR PROTEASE; TRANSFORMING GROWTH FACTOR-BETA-1; YARROWIA-LIPOLYTICA; ESCHERICHIA-COLI; PRO-SEQUENCE; SUBTILISIN; PROPEPTIDE; SECRETION; REQUIREMENT; PRECURSORS	The alkaline extracellular protease (AEP) of the yeast Yarrowia lipolytica is synthesized as a preproprotein. The precursor undergoes a complex maturation during its intracellular transit, successively involving signal peptide cleavage, dipeptidyl aminopeptidase processing, and cleavage at a dibasic site which results in the extracellular release of the active enzyme. It was previously shown that various deletions within the proregion affect the intracellular transit of the protease. Prodeleted precursors are translocated and have their signal sequences removed, but they accumulate in the secretion apparatus. We show here that the secretion of partially active proteins is restored when the prodomain is supplied in trans as an independent peptide. The secretion rescue and maturation processing that are reconstituted by the free propeptide do not reach wild type efficiency. The results of pulse-chase experiments indicate that a rate-limiting step occurs during the intracellular transit of the rescued precursors, before Kex2p proteolytic cleavage. This delayed maturation seems to be responsible for an overall slower release of the rescued polypeptides. Propeptide and AEP were secreted in equimolar amounts by both wild type and trans-complemented strains, but none could be detected in the supernatant when expressed alone. These experiments suggest that the prodomain of AEP initially acts as a crucial folding aid for the early secretory transit of the translocated precursor. They further suggest that the prodomain is also required for a second structural change of the AEP precursor during its activation.	INRA,CNRS,GENET MICROORGANISMES LAB,F-78850 THIVERVAL GRIGNON,FRANCE	Centre National de la Recherche Scientifique (CNRS); INRAE; UDICE-French Research Universities; Universite Paris Saclay				FABRE, Emmanuelle/0000-0002-0009-4604				BUSSEY H, 1988, YEAST, V4, P17, DOI 10.1002/yea.320040103; CAPLAN S, 1991, J BACTERIOL, V173, P627, DOI 10.1128/jb.173.2.627-635.1991; COLL M, 1991, EMBO J, V10, P1; DAVIDOW LS, 1987, J BACTERIOL, V169, P4621, DOI 10.1128/jb.169.10.4621-4629.1987; DAVIS RW, 1980, ADV BACTERIAL GENET, P116; FABRE E, 1991, J BIOL CHEM, V266, P3782; GAILLARDIN C, 1987, CURR GENET, V11, P369, DOI 10.1007/BF00378179; GENTRY LE, 1990, BIOCHEMISTRY-US, V29, P6851, DOI 10.1021/bi00481a014; GRAY AM, 1990, SCIENCE, V247, P1328, DOI 10.1126/science.2315700; IKEMURA H, 1988, J BIOL CHEM, V263, P12959; IKEMURA H, 1987, J BIOL CHEM, V262, P7859; KISER J, 1991, BIOCHEM BIOPH RES CO, V174, P586; KLIONSKY DJ, 1988, MOL CELL BIOL, V8, P2105, DOI 10.1128/MCB.8.5.2105; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATOBA S, 1988, MOL CELL BIOL, V8, P4904, DOI 10.1128/MCB.8.11.4904; MATOBA S, 1989, J BIOL CHEM, V264, P6037; MCCRACKEN AA, 1989, J BIOL CHEM, V264, P20843; MIYAZONO K, 1991, EMBO J, V10, P1091, DOI 10.1002/j.1460-2075.1991.tb08049.x; NEURATH H, 1989, TRENDS BIOCHEM SCI, V14, P268, DOI 10.1016/0968-0004(89)90061-3; NICAUD JM, 1989, J BIOTECHNOL, V12, P285, DOI 10.1016/0168-1656(89)90048-5; OGRYDZIAK DM, 1982, J GEN MICROBIOL, V128, P1225; OHTA Y, 1991, MOL MICROBIOL, V5, P1507, DOI 10.1111/j.1365-2958.1991.tb00797.x; SEVARINO KA, 1989, CELL, V57, P11, DOI 10.1016/0092-8674(89)90167-0; SHA X, 1991, J CELL BIOL, V114, P827, DOI 10.1083/jcb.114.4.827; SILEN JL, 1989, J BACTERIOL, V171, P1320, DOI 10.1128/jb.171.3.1320-1325.1989; SILEN JL, 1989, NATURE, V341, P462, DOI 10.1038/341462a0; SUTER U, 1991, EMBO J, V10, P2395, DOI 10.1002/j.1460-2075.1991.tb07778.x; VALLS LA, 1990, J CELL BIOL, V111, P361, DOI 10.1083/jcb.111.2.361; WANDERSMAN C, 1989, MOL MICROBIOL, V3, P1825, DOI 10.1111/j.1365-2958.1989.tb00169.x; WINTHER JR, 1991, P NATL ACAD SCI USA, V88, P9330, DOI 10.1073/pnas.88.20.9330; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0	32	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15049	15055						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634541				2022-12-25	WOS:A1992JF08800080
J	SONNENBURG, WK; MULLANEY, PJ; BEAVO, JA				SONNENBURG, WK; MULLANEY, PJ; BEAVO, JA			MOLECULAR-CLONING OF A CYCLIC GMP-STIMULATED CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE CDNA - IDENTIFICATION AND DISTRIBUTION OF ISOZYME VARIANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EXPRESSION; CGMP-BINDING; PURIFICATION; DNA; SPECIFICITY; HYDROLYSIS; INHIBITORS; CHANNEL; DOMAIN; LIVER	We have cloned a 4.2-kilobase pair (kb) cDNA that encodes the cyclic GMP-stimulated phosphodiesterase (cGS PDE) from a bovine adrenal cortex library. The 921-residue polypeptide deduced from the cDNA nucleotide sequence is nearly identical with the complete amino acid sequence of the cGS PDE purified from a soluble bovine heart extract. Moreover, PPD-S49 cells transfected with the cGS PDE cDNA express a soluble cAMP hydrolytic activity that is enhanced by cGMP. Total RNA isolated from several bovine tissues were screened for cGS PDE transcript by Northern blot analysis. The cGS PDE cDNA appears to hybridize to a single 4.5-4.6-kb mRNA species. Although the cGS PDE mRNA is most abundant in the adrenal cortex, it is also concentrated in the adrenal medulla and heart and in anatomically distinct regions of the brain and kidney. A mRNA species encoding a putative variant cGS PDE isoform was detected by RNase protection. Total RNA isolated from adrenal cortex, adrenal medulla, liver, kidney, trachea, lung, spleen, and T-lymphocytes completely protected a 452-base riboprobe encoding 100 residues of the adrenal cortex cGS PDE amino terminus. In contrast, RNAs isolated from brain (cerebral cortex, hippocampus, and basal ganglia) protected only 268 bases of this riboprobe. The RNase protection pattern of this same probe using heart RNA showed major bands at both 268 and 452 bases, suggesting that two different cGS PDE mRNA species are expressed. These results indicate that the cGS PDE is widely expressed in a variety of tissues. Moreover, these studies suggest that at least one different cGS PDE isoform having a structurally distinct amino-terminal domain is expressed in brain and heart.	UNIV WASHINGTON, DEPT PHARMACOL, SJ-30, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle					NATIONAL EYE INSTITUTE [R01EY008197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007441] Funding Source: NIH RePORTER; NEI NIH HHS [EY-08197] Funding Source: Medline; NIDDK NIH HHS [DK-07441] Funding Source: Medline; PHS HHS [DL-21723] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Ausubel FM, 1987, CURRENT PROTOCOLS MO, V1-5; BEAVO J, 1990, CYCLIC NUCLEOTIDE PH, V2; BEAVO JA, 1988, ADV SEC MESS PHOSPH, V22, P1; BEAVO JA, 1971, J BIOL CHEM, V246, P3841; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BOURNE HR, 1975, J CELL PHYSIOL, V85, P611, DOI 10.1002/jcp.1040850313; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHARBONNEAU H, 1986, P NATL ACAD SCI USA, V83, P9308, DOI 10.1073/pnas.83.24.9308; CHARBONNEAU H, 1990, P NATL ACAD SCI USA, V87, P288, DOI 10.1073/pnas.87.1.288; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONTI M, 1990, CYCLIC NUCLEOTIDE PH, V2, P243; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; ERNEUX C, 1981, EUR J BIOCHEM, V115, P503; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GILLESPIE PG, 1989, P NATL ACAD SCI USA, V86, P4311, DOI 10.1073/pnas.86.11.4311; GILLESPIE PG, 1988, J BIOL CHEM, V263, P8133; GRANT PG, 1990, THROMB RES, V59, P105, DOI 10.1016/0049-3848(90)90276-I; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LEE MA, 1988, J CLIN INVEST, V82, P388, DOI 10.1172/JCI113610; LETRONG H, 1990, BIOCHEMISTRY-US, V29, P10280; LEVINSON A, 1984, Journal of Molecular and Applied Genetics, V2, P507; LIPKIN VM, 1990, J BIOL CHEM, V265, P12955; MACFARLAND RT, 1991, J BIOL CHEM, V266, P136; MANGANIELLO V, 1990, CYCLIC NUCLEOTIDE PH, V2, P61; Maniatis T., 1982, MOL CLONING; MARTINS TJ, 1982, J BIOL CHEM, V257, P1973; MIOT F, 1985, EUR J BIOCHEM, V149, P59, DOI 10.1111/j.1432-1033.1985.tb08893.x; MURASHIMA S, 1990, BIOCHEMISTRY-US, V29, P5285, DOI 10.1021/bi00474a010; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SIMMONS MA, 1988, MOL PHARMACOL, V33, P664; STROOP SD, 1989, J BIOL CHEM, V264, P13718; WADA H, 1987, J BIOL CHEM, V262, P13938; WATSON CJ, 1985, DNA CLONING PRACTICA, V1, P79; WERNET W, 1989, FEBS LETT, V251, P191, DOI 10.1016/0014-5793(89)81453-X; WHALIN ME, 1988, BIOCHIM BIOPHYS ACTA, V972, P79; WHALIN MW, 1990, PURINES IN CELLULAR SIGNALLING, P323; YAMAMOTO T, 1983, J BIOL CHEM, V258, P2526; YAMAMOTO T, 1983, J BIOL CHEM, V258, P4173	42	96	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17655	17661						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1654333				2022-12-25	WOS:A1991GF44500099
J	MATSON, SW; MORTON, BS				MATSON, SW; MORTON, BS			ESCHERICHIA-COLI DNA HELICASE-I CATALYZES A SITE-SPECIFIC AND STRAND-SPECIFIC NICKING REACTION AT THE F-PLASMID ORIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRAI GENE-PRODUCT; SEX FACTOR-F; UNWINDING ENZYME; ORIGIN; SEQUENCE; LOCATION; PROTEIN; PURIFICATION; SEPARATION; NUCLEOTIDE	A site- and strand-specific nick, introduced in the F plasmid origin of transfer, initiates conjugal DNA transfer during bacterial conjugation. Recently, molecular genetic studies have suggested that DNA helicase 1, which is known to be encoded on the F plasmid, may be involved in this nicking reaction (Traxler, B. A., and Minkley, E. G., Jr. (1988) J. Mol. Biol. 204, 205-209). We have demonstrated this site- and strand-specific nicking event using purified helicase I in an in vitro reaction. The nicking reaction requires a superhelical DNA substrate containing the F plasmid origin of transfer, Mg2+ and helicase I. The reaction is protein concentration-dependent but, under the conditions used, only 50-70% of the input DNA substrate is converted to the nicked species. Genetic data (Everett, R., and Willetts, N. (1980) J. Mol. Biol. 136, 129-150) have also suggested the involvement of a second F-encoded protein, the TraY protein, in the oriT nicking reaction. Unexpectedly, the in vitro nicking reaction does not require the product of the F plasmid traY gene. The implications of this result are discussed. The phosphodiester bond interrupted by helicase I has been shown to correspond exactly to the site nicked in vivo suggesting that helicase I is the site- and strand-specific nicking enzyme that initiates conjugal DNA transfer. Thus, helicase I is a bifunctional protein which catalyzes site- and strand-strand specific nicking of the F plasmid in addition to the previously characterized duplex DNA unwinding (helicase) reaction.	UNIV N CAROLINA,CURRICULUM GENET,CHAPEL HILL,NC 27514	University of North Carolina; University of North Carolina Chapel Hill	MATSON, SW (corresponding author), UNIV N CAROLINA,DEPT BIOL,CHAPEL HILL,NC 27599, USA.							ABDELMONEM M, 1976, EUR J BIOCHEM, V65, P441, DOI 10.1111/j.1432-1033.1976.tb10359.x; ABDELMONEM M, 1977, J MOL BIOL, V110, P667, DOI 10.1016/S0022-2836(77)80083-1; ABDELMONEM M, 1983, P NATL ACAD SCI-BIOL, V80, P4659, DOI 10.1073/pnas.80.15.4659; ABDELMONEM M, 1976, EUR J BIOCHEM, V65, P431, DOI 10.1111/j.1432-1033.1976.tb10358.x; BARBOUR SD, 1967, J MOL BIOL, V28, P373, DOI 10.1016/S0022-2836(67)80016-0; BENZ I, 1990, EUR J BIOCHEM, V189, P267, DOI 10.1111/j.1432-1033.1990.tb15486.x; BOUCK N, 1970, J BACTERIOL, V102, P688, DOI 10.1128/JB.102.3.688-701.1970; BRADSHAW HD, 1990, J BACTERIOL, V172, P4127, DOI 10.1128/jb.172.7.4127-4131.1990; EVERETT R, 1980, J MOL BIOL, V136, P129, DOI 10.1016/0022-2836(80)90309-5; EVERETT R, 1982, EMBO J, V1, P747, DOI 10.1002/j.1460-2075.1982.tb01241.x; JOHNSON D, 1981, J MOL BIOL, V153, P187, DOI 10.1016/0022-2836(81)90273-4; KINGSMAN A, 1978, J MOL BIOL, V122, P287, DOI 10.1016/0022-2836(78)90191-2; KLINE BC, 1971, BIOCHEMISTRY-US, V10, P4975, DOI 10.1021/bi00802a022; KUHN B, 1979, J BIOL CHEM, V254, P1343; LAHUE EE, 1990, J BACTERIOL, V172, P1385, DOI 10.1128/jb.172.3.1385-1391.1990; LAHUE EE, 1988, J BIOL CHEM, V263, P3208; MANIATIS T, 1982, MOL CLONING LABORATO, P91; MANNING PA, 1982, J BACTERIOL, V150, P76, DOI 10.1128/JB.150.1.76-88.1982; MULLINEAUX P, 1985, PLASMIDS BACTERIA, P605; PANSEGRAU W, 1990, J BIOL CHEM, V265, P10637; PANSEGRAU W, 1990, P NATL ACAD SCI USA, V87, P6555, DOI 10.1073/pnas.87.17.6555; SHORTLE D, 1983, METHOD ENZYMOL, V100, P457; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; THOMPSON R, 1984, EMBO J, V3, P1175, DOI 10.1002/j.1460-2075.1984.tb01947.x; THOMPSON TL, 1989, J MOL BIOL, V207, P505, DOI 10.1016/0022-2836(89)90460-9; TRAXLER BA, 1987, J BACTERIOL, V169, P3251, DOI 10.1128/jb.169.7.3251-3259.1987; TRAXLER BA, 1988, J MOL BIOL, V204, P205, DOI 10.1016/0022-2836(88)90609-2; WESSEL R, 1990, EUR J BIOCHEM, V189, P277, DOI 10.1111/j.1432-1033.1990.tb15487.x; WILLETTS N, 1979, MOL GEN GENET, V169, P325, DOI 10.1007/BF00382278; WILLETTS N, 1980, ANNU REV GENET, V14, P41, DOI 10.1146/annurev.ge.14.120180.000353; WILLETTS N, 1987, ESCHERICHIA COLI SAL, P1110; WILLETTS NS, 1984, MICROBIOL REV, V48, P21	32	90	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					16232	16237						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1651938				2022-12-25	WOS:A1991GB97700105
J	DING, JP; KOELLNER, G; GRUNERT, HP; SAENGER, W				DING, JP; KOELLNER, G; GRUNERT, HP; SAENGER, W			CRYSTAL-STRUCTURE OF RIBONUCLEASE-T1 COMPLEXED WITH ADENOSINE 2'-MONOPHOSPHATE AT 1.8-A RESOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; LEAST-SQUARES REFINEMENT; X-RAY STRUCTURE; ACID COMPLEX; 3-DIMENSIONAL STRUCTURE; 1.9-A RESOLUTION; MOLECULAR-DYNAMICS; HISTIDINE-RESIDUES; PROTEIN STRUCTURES; BINDING	Ribonuclease T1 was purified from an Escherichia coli overproducing strain and co-crystallized with adenosine 2'-monophosphate (2'-AMP) by microdialysis against 50% (v/v) 2-methyl-2,4-pentanediol in 20 mM sodium acetate, 2 mM calcium acetate, pH 4.2. The crystals have orthorhombic space group P2(1)2(1)2(1), with cell dimensions a = 48.93(1), b = 46.57(4), c = 41.04(2) angstrom; Z = 4 and V = 93520 angstrom3. The crystal structure was determined on the basis of the isomorphous structure of uncomplexed RNase T1 (Martinez-Oyanedel et al. (1991) submitted for publication) and refined by least squares methods using stereochemical restraints. The refinement was based on F(hkl) of 7,445 reflections with F(o) greater-than-or-equal-to 1-sigma(F(o)) in the resolution range of 10-1.8 angstrom, and converged at a crystallographic R factor of 0.149. The phosphate group of 2'-AMP is tightly hydrogen-bonded to the side chains of the active site residues Tyr38, His40, Glu58, Arg77, and His92, comparable with vanadate binding in the respective complex (Kostrewa, D., Choe, H.-W., Heinemann, U., and Saenger, W. (1989) Biochemistry 28, 7592-7600) and different from the complex with guanosine 2'-monophosphate (Arni, R., Heinemann, U., Tokuoka, R., and Saenger, W. (1988) J. Biol. Chem. 263, 15358-15368) where the phosphate does not interact with Arg77 and His92. The adenosine moiety is not located in the guanosine recognition site but stacked on Gly74 carbonyl and His92 imidazole, which serve as a subsite, as shown previously (Lenz, A., Cordes, F., Heinemann, U., and Saenger, W. (1991) J. Biol. Chem. 266, 7661-7667); in addition, there are hydrogen bonds adenine N6H . . . O Gly74 (minor component of three-center hydrogen bond) and adenosine O5' . . . O-delta Asn36. These binding interactions readily explain why RNase T1 has some affinity for 2'-AMP. The molecular structure of RNase T1 is only marginally affected by 2'-AMP binding. Its ''empty'' guanosine-binding site features a flipped Asn43-Asn44 peptide bond and the side chains of Tyr45, Glu46 adopt conformations typical for RNase T1 not involved in guanosine binding. The side chains of amino acids LeU26, Ser35, Asp49, Val78 are disordered. The disorder of Val78 is of interest since this amino acid is located in a hydrophobic cavity, and the disorder appears to be correlated with an ''empty'' guanosine-binding site. The two Asp15 carboxylate oxygens and six water molecules coordinate a Ca2+ ion 8-fold in the form of a square antiprism.	FREE UNIV BERLIN,INST KRISTALLOG,TAKUSTR 6,W-1000 BERLIN 33,GERMANY	Free University of Berlin								ALTONA C, 1972, J AM CHEM SOC, V94, P8205, DOI 10.1021/ja00778a043; ARATA Y, 1979, BIOCHEMISTRY-US, V18, P18, DOI 10.1021/bi00568a003; ARNI R, 1987, ACTA CRYSTALLOGR B, V43, P548, DOI 10.1107/S0108768187097337; ARNI R, 1988, J BIOL CHEM, V263, P15358; BROWN RS, 1985, BIOCHEMISTRY-US, V24, P4785, DOI 10.1021/bi00339a012; CAMPBELL MK, 1971, BIOCHIM BIOPHYS ACTA, V232, P427, DOI 10.1016/0005-2787(71)90597-1; COOK WJ, 1977, METAL LIGAND INTER 2, P231; Egami F, 1980, Mol Biol Biochem Biophys, V32, P250; FINZEL BC, 1987, J APPL CRYSTALLOGR, V20, P53, DOI 10.1107/S0021889887087144; HEINEMANN U, 1980, EUR J BIOCHEM, V109, P109, DOI 10.1111/j.1432-1033.1980.tb04774.x; HEINEMANN U, 1982, NATURE, V299, P27, DOI 10.1038/299027a0; Heinemann U., 1989, PROTEIN NUCLEIC ACID, P111; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HENDRICKSON WA, 1980, COMPUTING CRYSTALLOG; HIRONO S, 1990, J MOL BIOL, V212, P197, DOI 10.1016/0022-2836(90)90315-D; HUBBARD R, 1985, MED RES COUNC G B LA; INAGAKI F, 1981, J BIOCHEM-TOKYO, V89, P1185; IRIE M, 1964, J BIOCHEM-TOKYO, V56, P495, DOI 10.1093/oxfordjournals.jbchem.a128026; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KAWATA Y, 1990, EUR J BIOCHEM, V187, P255, DOI 10.1111/j.1432-1033.1990.tb15303.x; KELLER E, 1988, SCHAKAL 88; KOEPKE J, 1989, J MOL BIOL, V206, P475, DOI 10.1016/0022-2836(89)90495-6; KOSTREWA D, 1989, BIOCHEMISTRY-US, V28, P7592, DOI 10.1021/bi00445a014; LENZ A, 1991, J BIOL CHEM, V266, P7661; LENZ A, 1991, IN PRESS ACTA CRYS B; LESK AM, 1982, SCIENCE, V216, P539, DOI 10.1126/science.7071602; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; OSHIMA T, 1971, J BIOCHEM-TOKYO, V70, P197, DOI 10.1093/oxfordjournals.jbchem.a129621; OSTERMAN HL, 1979, BIOCHEMISTRY-US, V18, P1984, DOI 10.1021/bi00577a021; QUAAS R, 1988, EUR J BIOCHEM, V173, P617, DOI 10.1111/j.1432-1033.1988.tb14043.x; SHERIFF S, 1987, J APPL CRYSTALLOGR, V20, P55, DOI 10.1107/S0021889887087132; SMITH JL, 1986, BIOCHEMISTRY-US, V25, P5018, DOI 10.1021/bi00366a008; SOBER HA, 1970, HDB BIOCH SELECTED D, pG59; SUGIO S, 1985, FEBS LETT, V183, P115, DOI 10.1016/0014-5793(85)80966-2; SUGIO S, 1985, FEBS LETT, V181, P129, DOI 10.1016/0014-5793(85)81127-3; SUGIO S, 1988, J BIOCHEM-TOKYO, V103, P354, DOI 10.1093/oxfordjournals.jbchem.a122274; SUSSMAN JL, 1985, METHOD ENZYMOL, V115, P271; SUSSMAN JL, 1977, PROTEIN-STRUCT FUNCT, V1, P370; Takahashi K., 1982, ENZYMES, V15, p435 468; YU HA, 1985, ACTA CRYSTALLOGR B, V41, P191, DOI 10.1107/S0108768185001926; 1988, DISCOVER USER MANUAL	42	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15128	15134						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1651320				2022-12-25	WOS:A1991GB09700051
J	YOKOYAMA, N; WANG, JH				YOKOYAMA, N; WANG, JH			DEMONSTRATION AND PURIFICATION OF MULTIPLE BOVINE BRAIN AND BOVINE LUNG CALMODULIN-STIMULATED PHOSPHATASE ISOZYMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; DEPENDENT PROTEIN PHOSPHATASE; MONOCLONAL-ANTIBODIES; BINDING-PROTEIN; CALCINEURIN-A; LIMITED PROTEOLYSIS; CELLULAR-REGULATION; SUBUNIT-A; ACTIVATION; CHROMATOGRAPHY	Calmodulin (CaM)-stimulated phosphatase in bovine brain or bovine lung CaM-binding protein fractions were fractionated on a heparin-Sepharose column into three activity peaks, designated in order of column elution as the brain peak I (BPI), peak II (BPII), and peak III (BPIII) or the lung peak I (LPI), peak II (LPII), and peak III (LPIII) phosphatases, respectively. The pooled individual peak fractions were further purified on a fast protein liquid chromatography Superose 12 column. Analysis of the purified samples by sodium dodecyl sulfate-polyacrylamide gel electrophoresis revealed that they all contained major peptides corresponding to alpha and beta-subunits of the brain CaM-stimulated phosphatase. The phosphatases had similar specific activities and were similarly stimulated by Ni2+, Mn2+, Mg2+ + Ca2+, and CaM. They showed differential reactivity on immunotransblots with an a subunit-specific monoclonal antibody VJ6, which reacted strongly toward BPI and weakly toward BPIII and LPI, but showed no reactivity toward BPII, LPII, and LPIII. Each of the alpha-subunits of the purified phosphatases had a distinct V8 protease and chymotrypsin peptide map. The results suggest that both bovine brain and bovine lung contain multiple CaM-stimulated phosphatase isozymes. The suggestion of three mammalian brain CaM-stimulated phosphatase isozymes is in agreement with the results of recent molecular cloning studies (Kuno, T., Takeda, T., Hirai, M., Ito, A., Mukai, H., and Tanaka, C. (1989) Biochem. Biophys. Res. Commun. 165, 1352-1358; Guerini, D., and Klee, C. B. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 9183-9187; da Cruz e Silva, E. F., and Cohen, P. T. W. (1989) Biochim. Biophys. Acta 1009, 293-296). The successful purification of the individual isozymes may facilitate the elucidation of molecular basis and physiological significance of the isozymes.	UNIV CALGARY,CELL REGULAT GRP,CALGARY T2N 4N1,ALBERTA,CANADA	University of Calgary	YOKOYAMA, N (corresponding author), UNIV CALGARY,DEPT MED BIOCHEM,CALGARY T2N 4N1,ALBERTA,CANADA.							BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; ESILVA EFD, 1989, BIOCHIM BIOPHYS ACTA, V1009, P293; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; GUERINI D, 1989, P NATL ACAD SCI USA, V86, P9183, DOI 10.1073/pnas.86.23.9183; GUPTA RC, 1985, FEBS LETT, V190, P104, DOI 10.1016/0014-5793(85)80437-3; HUBBARD MJ, 1989, BIOCHEMISTRY-US, V28, P1868, DOI 10.1021/bi00430a066; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P297, DOI 10.1111/j.1432-1033.1983.tb07362.x; ITO A, 1989, BIOCHEM BIOPH RES CO, V163, P1492, DOI 10.1016/0006-291X(89)91148-0; KING MM, 1983, BIOCHEM BIOPH RES CO, V114, P955, DOI 10.1016/0006-291X(83)90653-8; KLEE CB, 1979, P NATL ACAD SCI USA, V76, P6270, DOI 10.1073/pnas.76.12.6270; KLEE CB, 1983, METHOD ENZYMOL, V102, P227; KRINKS MH, 1985, FED PROC, V44, P707; KUNO T, 1989, BIOCHEM BIOPH RES CO, V165, P1352, DOI 10.1016/0006-291X(89)92752-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM HYP, 1987, HYBRIDOMA, V6, P77, DOI 10.1089/hyb.1987.6.77; LI HC, 1984, J BIOL CHEM, V259, P8801; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PALLEN CJ, 1986, J BIOL CHEM, V261, P6115; PALLEN CJ, 1984, J BIOL CHEM, V259, P6134; PALLEN CJ, 1988, CALCIUM BINDING PROT, V1, P51; RICHMAN PG, 1978, J BIOL CHEM, V253, P6323; SHARMA RK, 1986, J BIOL CHEM, V261, P1322; SHARMA RK, 1984, J BIOL CHEM, V259, P9248; SHARMA RK, 1979, J BIOL CHEM, V254, P4276; STANKER LH, 1985, J IMMUNOL METHODS, V76, P157, DOI 10.1016/0022-1759(85)90488-0; STEWART AA, 1982, FEBS LETT, V137, P80, DOI 10.1016/0014-5793(82)80319-0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4305; WALLACE RW, 1979, J BIOL CHEM, V254, P377; WALLACE RW, 1980, BIOCHEMISTRY-US, V19, P1831, DOI 10.1021/bi00550a016; WANG JH, 1990, MOL PHARM CELL REGUL, V2, P19; WINKLER MA, 1984, P NATL ACAD SCI-BIOL, V81, P3054, DOI 10.1073/pnas.81.10.3054; YOKOYAMA N, 1990, J BIOL CHEM, V265, P8170	33	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14822	14829						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1650368				2022-12-25	WOS:A1991FZ35100107
J	DHARIWAL, KR; BLACK, CDV; LEVINE, M				DHARIWAL, KR; BLACK, CDV; LEVINE, M			SEMIDEHYDROASCORBIC ACID AS AN INTERMEDIATE IN NOREPINEPHRINE BIOSYNTHESIS IN CHROMAFFIN GRANULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOPAMINE BETA-MONOOXYGENASE; ENZYME-BOUND COPPER; ASCORBIC-ACID; ELECTRON-TRANSFER; REDUCTION; MEMBRANE; CELLS; RESONANCE; OXIDATION; ATP	We investigated whether semidehydroascorbic acid was an intermediate in norepinephrine synthesis in chromaffin granules and in electron transfer across the chromaffin granule membrane. Semidehydroascorbic acid was measured in intact granules by electron spin resonance. In the presence of intragranular but not extragranular ascorbic acid, semidehydroascorbic acid was formed within granules in direct relationship to dopamine beta-monooxygenase activity. However, semidehydroascorbic acid was not generated when granules were incubated with epinephrine instead of the substrate dopamine, with dopamine beta-monooxygenase inhibitors, without oxygen, and when intragranular ascorbic acid was depleted. Experiments using the impermeant paramagnetic broadening agents [K3[Cr(C2O4)3].3H2O] and Ni(en)3(NO3)2 provided further evidence that semidehydroascorbic acid was generated only within granules. We also investigated semidehydroascorbic acid formation in the presence of intragranular and extragranular ascorbic acid. Under these conditions, semidehydroascorbic acid was formed on both sides of the granule membrane, and formation was coupled to dopamine beta-monooxygenase activity. These data indicate that dopamine beta-monooxygenase is reduced by single electron transfer from intragranular ascorbic acid, that transmembrane electron transfer occurs by single electron transfer, and that transmembrane electron transfer is directly coupled to formation of intragranular semidehydroascorbic acid via dopamine beta-monooxygenase activity.	NCI,DIV CANC TREATMENT,RADIAT ONCOL BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	DHARIWAL, KR (corresponding author), NIDDKD,CELL BIOL & GENET LAB,BETHESDA,MD 20892, USA.							BAIOAR JC, 1939, INORG SYNTHESIS, V1, P35; BEERS MF, 1986, J BIOL CHEM, V261, P2529; BUETTNER GR, 1990, FREE RADICAL RES COM, V10, P5, DOI 10.3109/10715769009145927; DHARIWAL KR, 1989, J BIOL CHEM, V264, P15404; DHARIWAL KR, 1991, J BIOL CHEM, V266, P5384; FRIEDMAN S, 1965, J BIOL CHEM, V240, P4763; HARTMAN BK, 1972, PHARMACOL REV, V24, P311; KAUFMAN S, 1965, PHARMACOL REV, V17, P71; LADURON PM, 1975, FEBS LETT, V52, P132, DOI 10.1016/0014-5793(75)80654-5; LEVIN EY, 1960, J BIOL CHEM, V235, P2080; LEVINE M, 1985, J BIOL CHEM, V260, P5598; LEVINE M, 1985, J BIOL CHEM, V260, P2942; LEVINE M, 1988, J BIOL CHEM, V263, P19353; LEVINE M, 1986, J BIOL CHEM, V261, P7347; LEWIN S, 1976, VITAMIN C ITS MOL BI, P5; LJONES T, 1979, FEBS LETT, V108, P25, DOI 10.1016/0014-5793(79)81170-9; LJONES T, 1978, FEBS LETT, V92, P81, DOI 10.1016/0014-5793(78)80726-1; NAGATSU T, 1973, BIOCH CATECHOLAMINES, pCH1; NJUS D, 1983, J BIOL CHEM, V258, P27; POLLARD HB, 1976, J BIOL CHEM, V251, P4544; POLLARD HB, 1978, ANAL BIOCHEM, V86, P761, DOI 10.1016/0003-2697(78)90805-9; SAMUNI A, 1986, P NATL ACAD SCI USA, V83, P7593, DOI 10.1073/pnas.83.20.7593; SAMUNI A, 1988, J BIOL CHEM, V263, P13797; SKOTLAND T, 1980, BIOCHIM BIOPHYS ACTA, V630, P30, DOI 10.1016/0304-4165(80)90134-8; SKOTLAND T, 1979, INORG PERSPECT BIOL, V2, P151; SRIVASTAVA M, 1984, J BIOL CHEM, V259, P8072; TERLAND O, 1975, FEBS LETT, V59, P52, DOI 10.1016/0014-5793(75)80339-5; WAKEFIELD LM, 1982, FED PROC, V41, P893; WAKEFIELD LM, 1986, J BIOL CHEM, V261, P9746; WAKEFIELD LM, 1986, J BIOL CHEM, V261, P9739; WASHKO PW, 1989, ANAL BIOCHEM, V181, P276, DOI 10.1016/0003-2697(89)90243-1; WEIS W, 1975, ANN NY ACAD SCI, V258, P190, DOI 10.1111/j.1749-6632.1975.tb29279.x; WINKLER H, 1970, BIOCHEM J, V118, P3093; YAMAZAKI I, 1961, BIOCHIM BIOPHYS ACTA, V50, P62, DOI 10.1016/0006-3002(61)91060-5; YAMAZAKI I, 1977, FREE RADICALS BIOL, V3, P183	35	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1991	266	20					12908	12914						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FX132	1649168				2022-12-25	WOS:A1991FX13200021
J	RAMANUJAM, KS; SEETHARAM, S; DAHMS, NM; SEETHARAM, B				RAMANUJAM, KS; SEETHARAM, S; DAHMS, NM; SEETHARAM, B			FUNCTIONAL EXPRESSION OF INTRINSIC FACTOR-COBALAMIN RECEPTOR BY RENAL PROXIMAL TUBULAR EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANINE KIDNEY-CELLS; AFFINITY CHROMATOGRAPHY; PROTEINS; LINE; TRANSPORT; IDENTIFICATION; PURIFICATION; SURFACE; DOG; RAT	Previous studies from our laboratory (Seetharam, B., Levine, J. S., Ramasamy, M., and Alpers, D. H. (1988) J. Biol. Chem. 263, 4443-4449; Fyfe, J. C., Ramanujam, K. S., Ramaswamy, K., Patterson, D. F., and Seetharam, B. (1991) J. Biol. Chem. 266, 4489-4494) have identified and isolated a 230-kDa receptor from rat and canine kidney which binds with high affinity [Co-57]cyanocobalamin (Cbl) complexed to gastric intrinsic factor (IF). Although these studies have identified a renal receptor which binds intrinsic factor-cobalamin (IFCR), it is not known whether the binding is specific for IF-Cbl and whether renal cells internalize [Co-57]Cbl bound to IF and transport [Co-57]Cbl across the cell. Using a variety of renal cells, our results show that IF-[Co-57]Cbl binding activity is detected in proximal tubular-derived epithelial cells from opossum (OK) and porcine kidney (LLC-PK1) but not in distal tubular-derived cells from canine kidney cells (MDCK). Metabolic labeling studies with Tran S-35-label confirmed the presence of a 230-kDa IFCR in OK and LLC-PK1 cells. Cell surface labeling and binding studies demonstrated that IFCR is targeted to the apical membrane. This apical expression of IFCR in OK cells is inhibited by the microtubule-disruptive drugs, colchicine and nocodazole. Opossum kidney cells when grown on culture inserts are polarized and transport [Co-57]Cbl only when bound to IF and not to other Cbl binders. Furthermore, the transport of [Co-57]Cbl occurred unidirectionally from the apical to the basolateral surface. Treatment of cells with colchicine or nocodazole inhibited the surface binding of IF-[Co-57]Cbl as well as the transcytosis of [Co-57]Cbl by 70-75%. IFCR retained intracellularly by incubation of cells with colchicine or nocodazole is degraded by leupeptin-sensitive proteases. Based on these results, we suggest that proximal tubular-derived epithelial cells transport [CO-57]Cbl bound to IF in a saturable way via receptor-mediated endocytosis.	MED COLL WISCONSIN,DEPT MED,DIV GASTROENTEROL,DIV GI,MACC FUND CTR,RM 6061,MILWAUKEE,WI 53226; MED COLL WISCONSIN,DEPT BIOCHEM,MILWAUKEE,WI 53226	Medical College of Wisconsin; Medical College of Wisconsin					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026638] Funding Source: NIH RePORTER; NIDDK NIH HHS [NIDDK 26638] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACHLER C, 1989, J CELL BIOL, V109, P1179; ALLEN RH, 1973, J BIOL CHEM, V248, P3670; ALLEN RH, 1973, J BIOL CHEM, V248, P3660; BATT RM, 1989, AM J PHYSIOL, V256, pG517, DOI 10.1152/ajpgi.1989.256.3.G517; BATT RM, 1989, AM J PHYSIOL, V257, pG9344; BULLER HA, 1987, J BIOL CHEM, V262, P17206; COUDRIER E, 1988, KIDNEY INT, V34, P309, DOI 10.1038/ki.1988.183; DANIELSEN EM, 1984, BIOCHEM J, V221, P1; EILERS U, 1989, J CELL BIOL, V108, P13, DOI 10.1083/jcb.108.1.13; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FULLER S, 1984, CELL, V38, P65, DOI 10.1016/0092-8674(84)90527-0; FYFE JC, 1991, J BIOL CHEM, V266, P4489; GOTTLIEB C, 1965, BLOOD-J HEMATOL, V25, P875, DOI 10.1182/blood.V25.6.875.875; GRAEVE L, 1990, J BIOL CHEM, V265, P1216; GRASBECK R, 1982, LANCET, V1, P1330; HAGEDORN CH, 1977, GASTROENTEROLOGY, V73, P1019; HERBERT V, 1961, J CLIN INVEST, V40, P1978, DOI 10.1172/JCI104423; HOOPER DC, 1973, J CLIN INVEST, V52, P3074, DOI 10.1172/JCI107506; KESSLER M, 1978, BIOCHIM BIOPHYS ACTA, V506, P136, DOI 10.1016/0005-2736(78)90440-6; KOUVONEN I, 1981, J BIOL CHEM, V256, P154; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE JS, 1984, J CELL BIOL, V98, P1111, DOI 10.1083/jcb.98.3.1111; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maack T, 1985, KIDNEY PHYSL PATHOPH, P1773; MALSTROM K, 1987, BIOCHIM BIOPHYS ACTA, V902, P269, DOI 10.1016/0005-2736(87)90305-1; MCKUSICK VA, 1988, MENDELIAN INHERITANC, P1129; OJAKIAN GK, 1988, J CELL BIOL, V107, P2377, DOI 10.1083/jcb.107.6.2377; PINTO M, 1983, BIOL CELL, V47, P323; RABITO CA, 1983, J BIOL CHEM, V258, P2543; RAMANUJAM KS, 1991, AM J PHYSIOL, V260, pG416, DOI 10.1152/ajpgi.1991.260.3.G416; RAMANUJAM KS, 1990, BIOCHIM BIOPHYS ACTA, V1030, P157, DOI 10.1016/0005-2736(90)90251-I; RINDLER MJ, 1979, J CELL BIOL, V81, P635, DOI 10.1083/jcb.81.3.635; RINDLER MJ, 1987, J CELL BIOL, V104, P231, DOI 10.1083/jcb.104.2.231; SEETHARAM B, 1981, J BIOL CHEM, V256, P3785; SEETHARAM B, 1985, NUTR REV, V43, P97, DOI 10.1111/j.1753-4887.1985.tb06875.x; SEETHARAM B, 1988, J BIOL CHEM, V263, P4443; WAHLSTEDT V, 1985, J LAB CLIN MED, V106, P439	37	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1991	266	20					13135	13140						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FX132	1649178				2022-12-25	WOS:A1991FX13200055
J	MCNAMARA, PT; HARRINGTON, RE				MCNAMARA, PT; HARRINGTON, RE			CHARACTERIZATION OF INHERENT CURVATURE IN DNA LACKING POLYADENINE RUNS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYZED RING-CLOSURE; ESCHERICHIA-COLI; CURVED DNA; B-DNA; REPLICATION ORIGIN; KINETOPLAST DNA; ADENINE TRACTS; HELICAL TWIST; A-DNA; SEQUENCE	Sequence-directed DNA curvature is most commonly associated with AA dinucleotides in the form of polyadenine runs. We demonstrate inherent curvature in DNA which lacks AA/TT dinucleotides using the criteria of polyacrylamide gel mobility and efficiency of DNA cyclization. These studies are based upon two 21-base pair synthetic DNA fragments designed to exhibit fixed curvature according to deflections made to the helical axis by non-AA dinucleotide stacks. Repeats of these sequences display anomalously slow migration in polyacrylamide gels. Moreover, both sequences describe helical conformations that are closed into circles by DNA ligase at much smaller sizes than is typical of nondeformed DNA. Chemical cleavage of these DNA molecules with hydroxyl radical is also consistent with local variation in helical conformation at specific dinucleotide steps.			MCNAMARA, PT (corresponding author), UNIV NEVADA,DEPT BIOCHEM,RENO,NV 89557, USA.				NATIONAL CANCER INSTITUTE [T32CA009563] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033435] Funding Source: NIH RePORTER; NCI NIH HHS [T32CA09563] Funding Source: Medline; NIGMS NIH HHS [GM 33435] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABAGYAN RA, 1990, NUCLEIC ACIDS RES, V18, P989, DOI 10.1093/nar/18.4.989; ANDERSON JN, 1986, NUCLEIC ACIDS RES, V14, P8513, DOI 10.1093/nar/14.21.8513; BOSHOY A, 1991, P NATL ACAD SCI USA, V88, P2312; BOSSI L, 1984, CELL, V39, P643, DOI 10.1016/0092-8674(84)90471-9; BRACCO L, 1989, EMBO J, V8, P4289, DOI 10.1002/j.1460-2075.1989.tb08615.x; BRAHMS S, 1990, NUCLEIC ACIDS RES, V18, P1559, DOI 10.1093/nar/18.6.1559; BURKHOFF AM, 1987, CELL, V48, P935, DOI 10.1016/0092-8674(87)90702-1; BURKHOFF AM, 1988, NATURE, V331, P445; CALLADINE CR, 1982, J MOL BIOL, V161, P343, DOI 10.1016/0022-2836(82)90157-7; COLLIS CM, 1989, NUCLEIC ACIDS RES, V17, P9447, DOI 10.1093/nar/17.22.9447; CONS BMG, 1989, NUCLEIC ACIDS RES, V17, P5447, DOI 10.1093/nar/17.14.5447; DICKERSON RE, 1983, J MOL BIOL, V166, P419, DOI 10.1016/S0022-2836(83)80093-X; DREW HR, 1984, J MOL BIOL, V176, P535, DOI 10.1016/0022-2836(84)90176-1; DREW HR, 1984, CELL, V37, P491, DOI 10.1016/0092-8674(84)90379-9; GOODMAN SD, 1989, NATURE, V341, P251, DOI 10.1038/341251a0; GOURSE RL, 1986, CELL, V44, P197, DOI 10.1016/0092-8674(86)90498-8; HAGERMAN PJ, 1988, ANNU REV BIOPHYS BIO, V17, P265; HAGERMAN PJ, 1984, P NATL ACAD SCI-BIOL, V81, P4632, DOI 10.1073/pnas.81.15.4632; HAGERMAN PJ, 1990, J MOL BIOL, V212, P351, DOI 10.1016/0022-2836(90)90130-E; HAGERMAN PJ, 1990, ANNU REV BIOCHEM, V59, P755, DOI 10.1146/annurev.biochem.59.1.755; HUSAIN I, 1988, P NATL ACAD SCI USA, V85, P2558, DOI 10.1073/pnas.85.8.2558; JACOBSON H, 1950, J CHEM PHYS, V18, P1600, DOI 10.1063/1.1747547; KABSCH W, 1982, NUCLEIC ACIDS RES, V10, P1097, DOI 10.1093/nar/10.3.1097; KOEPSEL RR, 1986, SCIENCE, V233, P1316, DOI 10.1126/science.3749879; KOO HS, 1986, NATURE, V320, P501, DOI 10.1038/320501a0; KOO HS, 1990, BIOCHEMISTRY-US, V29, P4227, DOI 10.1021/bi00469a027; KUNKEL GR, 1981, NUCLEIC ACIDS RES, V9, P6869, DOI 10.1093/nar/9.24.6869; LEVENE SD, 1986, BIOCHEMISTRY-US, V25, P3988, DOI 10.1021/bi00362a003; Maniatis T., 1982, MOL CLONING; MCCALL M, 1986, NATURE, V322, P661, DOI 10.1038/322661a0; MILTON DL, 1990, NUCLEIC ACIDS RES, V18, P817, DOI 10.1093/nar/18.4.817; MILTON DL, 1988, NUCLEIC ACIDS RES, V16, P3931, DOI 10.1093/nar/16.9.3931; MUZARD G, 1990, EMBO J, V9, P1289, DOI 10.1002/j.1460-2075.1990.tb08238.x; NADEAU JG, 1989, P NATL ACAD SCI USA, V86, P2622, DOI 10.1073/pnas.86.8.2622; NELSON HCM, 1987, NATURE, V330, P221, DOI 10.1038/330221a0; OHYAMA T, 1989, NUCLEIC ACIDS RES, V17, P3845, DOI 10.1093/nar/17.10.3845; RADIC MZ, 1987, CELL, V50, P1101, DOI 10.1016/0092-8674(87)90176-0; RYDER K, 1986, CELL, V44, P719, DOI 10.1016/0092-8674(86)90838-X; SARMA MH, 1988, BIOCHEMISTRY-US, V27, P3423, DOI 10.1021/bi00409a045; SCHLEIF R, 1988, SCIENCE, V241, P1182, DOI 10.1126/science.2842864; SHLYAKHTENKO YS, 1990, MOL BIOL MOSC, V24, P79; SHORE D, 1983, J MOL BIOL, V170, P983, DOI 10.1016/S0022-2836(83)80199-5; SHORE D, 1983, J MOL BIOL, V170, P957, DOI 10.1016/S0022-2836(83)80198-3; SHORE D, 1981, P NATL ACAD SCI-BIOL, V78, P4833, DOI 10.1073/pnas.78.8.4833; SIMPSON RT, 1979, NUCLEIC ACIDS RES, V6, P1387, DOI 10.1093/nar/6.4.1387; TAYLOR WH, 1990, J MOL BIOL, V212, P363, DOI 10.1016/0022-2836(90)90131-5; TRAVERS A, 1987, NATURE, V327, P280, DOI 10.1038/327280a0; TRIFONOV EN, 1988, UNUSUAL DNA STRUCTUR, P173; TULLIUS TD, 1987, TRENDS BIOCHEM SCI, V12, P297, DOI 10.1016/0968-0004(87)90145-9; TULLIUS TD, 1985, SCIENCE, V230, P679, DOI 10.1126/science.2996145; ULANOVSKY L, 1986, P NATL ACAD SCI USA, V83, P862, DOI 10.1073/pnas.83.4.862; ULANOVSKY LE, 1987, NATURE, V326, P720, DOI 10.1038/326720a0; WANG AHJ, 1982, P NATL ACAD SCI-BIOL, V79, P3968, DOI 10.1073/pnas.79.13.3968; Waterborg J. H., 1989, Access, V8, P14; WATERBORG JH, 1987, ANAL BIOCHEM, V162, P430, DOI 10.1016/0003-2697(87)90415-5; ZAHN K, 1987, SCIENCE, V236, P416, DOI 10.1126/science.2951850; ZAHN K, 1985, NATURE, V317, P451, DOI 10.1038/317451a0	57	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1991	266	19					12548	12554						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FV180	1648100				2022-12-25	WOS:A1991FV18000070
J	REUE, K; LEETE, TH				REUE, K; LEETE, TH			GENETIC-VARIATION IN MOUSE APOLIPOPROTEIN-A-IV DUE TO INSERTION AND DELETION IN A REGION OF TANDEM REPEATS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DEGRADATION; HIGH-DENSITY LIPOPROTEINS; HUMAN MITOCHONDRIAL-DNA; HUMAN-PLASMA; GENUS MUS; EVOLUTION; POLYMORPHISM; MICE; RAT; EXPRESSION	We have detected three unique apolipoprotein A-IV (apoA-IV) charge isoforms in strains of commensal mice. The cDNA sequences for one representative of each isoform (Mus domesticus strains C57BL/6J and 129/J and Mus castaneus) revealed a polymorphism within a series of four imperfect repeats encoding the sequence Glu-Gln-Ala/Val-Gln. Insertions or deletions of 12 nucleotides within this repetitive region have given rise to three genotypes characterized by three (129), four (C57BL/6), or five (M. castaneus) copies of the repeat unit. To ascertain the extent of this variation among other species of the Mus genus, we sequenced this region of apoA-IV cDNAs from eight additional M. domesticus inbred strains and from five wild-derived Mus species. All eight additional M. domesticus strains examined had four repeat units, as found in C57BL/6. Among wild-derived mice, however, one species (Mus spretus) had three repeats, two species (Mus cookii and Mus cervicolor) had four repeats, and two species (Mus hortulanus and Mus minutoides) had five repeats. A lack of correlation between the number of repeat units and the phylogeny of Mus species indicates that independent mutations may have occurred throughout the evolution of specific mouse lineages. We suggest that the repetitive nature of the polymorphic sequence may predispose this region to slippage errors during DNA replication, resulting in frequent deletion/insertion mutations.	UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles	REUE, K (corresponding author), VET ADM WADSWORTH MED CTR,WILSHIRE & SAWTELLE BLVDS,BLDG 113,RM 312,LOS ANGELES,CA 90073, USA.				NHLBI NIH HHS [HL 28481] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL028481] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BARTER PJ, 1988, BIOCHEM J, V254, P179, DOI 10.1042/bj2540179; BOGUSKI MS, 1984, P NATL ACAD SCI-BIOL, V81, P5021, DOI 10.1073/pnas.81.16.5021; BONHOMME F, 1986, CURR TOP MICROBIOL, V127, P19; BONHOMME F, 1984, BIOCHEM GENET, V22, P275, DOI 10.1007/BF00484229; BONHOMME F, 1989, GENETIC VARIANTS STR, P649; BRESLOW JL, 1988, PHYSIOL REV, V68, P85, DOI 10.1152/physrev.1988.68.1.85; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAAR IO, 1988, MOL CELL BIOL, V8, P802, DOI 10.1128/MCB.8.2.802; DICKINSON DP, 1984, GENETICS, V108, P651; DOOLITTLE MH, 1990, J BIOL CHEM, V265, P16380; DVORIN E, 1986, J BIOL CHEM, V261, P5714; EFTRATIADIS A, 1980, CELL, V21, P653; ELSHOURBAGY NA, 1987, J BIOL CHEM, V262, P7973; FERRELL RE, 1990, J LIPID RES, V31, P131; FERRIS SD, 1983, GENETICS, V105, P681; GOLDBERG IJ, 1990, J BIOL CHEM, V265, P4266; GORDON JI, 1984, J BIOL CHEM, V259, P468; HADDAD IA, 1986, J BIOL CHEM, V261, P3268; ISHIDA BY, 1989, MONOGRAPHS HUMAN GEN, V12, P189; JIAO S, 1990, J LIPID RES, V31, P467; JONES CW, 1982, J MOL EVOL, V19, P87, DOI 10.1007/BF02100227; KAMBOH MI, 1987, AM J HUM GENET, V41, P119; KARATHANASIS SK, 1986, BIOCHEMISTRY-US, V25, P3962, DOI 10.1021/bi00361a034; KELLY JH, 1985, ANNU REV GENET, V19, P273, DOI 10.1146/annurev.genet.19.1.273; LAGROST L, 1989, J LIPID RES, V30, P1525; LEBOEUF RC, 1990, J LIPID RES, V31, P91; LI WH, 1988, J LIPID RES, V29, P245; LOHSE P, 1990, J BIOL CHEM, V265, P10061; LOHSE P, 1990, J BIOL CHEM, V265, P12734; LUSIS AJ, 1988, J LIPID RES, V29, P397; LUSIS AJ, 1987, J BIOL CHEM, V262, P7594; LUSIS AJ, 1983, J BIOL CHEM, V258, P5071; MARZLUFF WF, 1988, TRENDS BIOCHEM SCI, V13, P49, DOI 10.1016/0968-0004(88)90027-8; MENZEL HJ, 1990, HUM GENET, V84, P344; MENZEL HJ, 1988, HUM GENET, V79, P368; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORSE HC, 1981, MOUSE BIOMEDICAL RES, V1, P1; PAIGEN B, 1987, P NATL ACAD SCI USA, V82, P8085; RAGHOW R, 1987, TRENDS BIOCHEM SCI, V12, P358, DOI 10.1016/0968-0004(87)90165-4; SCHON EA, 1989, SCIENCE, V244, P346, DOI 10.1126/science.2711184; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; STEIN O, 1986, BIOCHIM BIOPHYS ACTA, V878, P7, DOI 10.1016/0005-2760(86)90337-1; STEINMETZ A, 1990, J BIOL CHEM, V265, P7859; STEINMETZ A, 1985, J BIOL CHEM, V260, P2258; TSENG-CRANK J, 1988, Molecular Biology and Evolution, V5, P442; VANDENMAAGDENBERG AMJM, 1989, BIOCHEM BIOPH RES CO, V165, P851, DOI 10.1016/S0006-291X(89)80044-0; WARDELL MR, 1989, J BIOL CHEM, V264, P21205; WEINBERG RB, 1990, J BIOL CHEM, V265, P18372; WEISGRABER KH, 1978, BIOCHEM BIOPH RES CO, V85, P287, DOI 10.1016/S0006-291X(78)80041-2; WILLIAMS SC, 1986, MOL CELL BIOL, V6, P3807, DOI 10.1128/MCB.6.11.3807; WILLIAMS SC, 1989, J BIOL CHEM, V264, P19009; WRISCHNIK LA, 1987, NUCLEIC ACIDS RES, V15, P529, DOI 10.1093/nar/15.2.529; WU AL, 1979, J BIOL CHEM, V254, P7316; YANG CY, 1989, BIOCHIM BIOPHYS ACTA, V1002, P231, DOI 10.1016/0005-2760(89)90292-0	56	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1991	266	19					12715	12721						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FV180	1648102				2022-12-25	WOS:A1991FV18000095
J	SLESAREV, AI; ZAITZEV, DA; KOPYLOV, VM; STETTER, KO; KOZYAVKIN, SA				SLESAREV, AI; ZAITZEV, DA; KOPYLOV, VM; STETTER, KO; KOZYAVKIN, SA			DNA TOPOISOMERASE-III FROM EXTREMELY THERMOPHILIC ARCHAEBACTERIA - ATP-INDEPENDENT TYPE-I TOPOISOMERASE FROM DESULFUROCOCCUS-AMYLOLYTICUS DRIVES EXTENSIVE UNWINDING OF CLOSED CIRCULAR DNA AT HIGH-TEMPERATURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECA PROTEIN-BINDING; ESCHERICHIA-COLI; REVERSE GYRASE; DUPLEX DNA; SUPERHELICAL DNA; PBR322 DNA; INVITRO; RECOMBINATION; SULFOLOBUS; CLEAVAGE	A second type I topoisomerase was purified from the extremely thermophilic archaebacterium Desulfurococcus amylolyticus. In contrast to the previously described reverse gyrase from this organism, the novel enzyme designated as Dam topoisomerase III is an ATP-independent relaxing topoisomerase. It is a monomer with M(r) 108,000, as determined by electrophoresis under denaturing conditions and by size exclusion chromatography. Dam topoisomerase III, like other bacterial type I topoisomerases, absolutely requires Mg2+ for activity and is specific for single-stranded DNA. At 60-80-degrees-C, it relaxes negatively but not positively supercoiled DNA and is inhibited by single-stranded M13 DNA. At 95-degrees-C, the enzyme unwinds both positively and negatively supercoiled substrates and produces extensively unwound form I* and I** DNA. The peculiarities of DNA topoisomerization at high temperatures are discussed.	ACAD SCI USSR,INST MOLEC GENET,MOSCOW 123182,USSR; RE KAVETSKY ONCOL PROBLEMS INST,KIEV 252127,UKRAINE,USSR	Russian Academy of Sciences; National Academy of Sciences Ukraine; Kavetsky Institute of Experimental Pathology, Oncology & Radiobiology of NASU	SLESAREV, AI (corresponding author), UNIV REGENSBURG,LEHRSTUHL MIKROBIOL,UNIV STR 31,W-8400 REGENSBURG,GERMANY.			Kozyavkin, Sergei/0000-0001-5605-5113				AGUILERA A, 1990, MOL CELL BIOL, V10, P1439, DOI 10.1128/MCB.10.4.1439; AUSTIN CA, 1990, FEBS LETT, V266, P115, DOI 10.1016/0014-5793(90)81520-X; BAKER TA, 1986, CELL, V45, P53, DOI 10.1016/0092-8674(86)90537-4; BALCH WE, 1976, APPL ENVIRON MICROB, V32, P781, DOI 10.1128/AEM.32.6.781-791.1976; BLISKA JB, 1987, J MOL BIOL, V194, P205, DOI 10.1016/0022-2836(87)90369-X; BONCH-OSMOLOVSKAYA E A, 1988, Mikrobiologiya, V57, P94; BONCHOSMOLOVSKAIA EA, 1986, DOKL AKAD NAUK SSSR+, V290, P1259; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROCK TD, 1972, ARCH MIKROBIOL, V84, P54, DOI 10.1007/BF00408082; Champoux JJ, 1990, DNA TOPOLOGY ITS BIO, P217; CHARBONNIER F, 1990, 1990 INT M THERM TOD, P96; CHUNG TDY, 1989, P NATL ACAD SCI USA, V86, P9431, DOI 10.1073/pnas.86.23.9431; CONLEY EC, 1990, J BIOL CHEM, V265, P10156; DEAN F, 1982, COLD SPRING HARB SYM, V47, P411; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P16, DOI 10.1073/pnas.84.1.16; DEAN FB, 1985, J BIOL CHEM, V260, P4984; DEPEW RE, 1975, P NATL ACAD SCI USA, V72, P4275, DOI 10.1073/pnas.72.11.4275; DIGATE RJ, 1989, J BIOL CHEM, V264, P17924; DIGATE RJ, 1988, J BIOL CHEM, V263, P13366; FEICK R, 1985, CHEM PHYSICS ANTENNA, V42, P74; FINK GR, 1989, CELL, V58, P225, DOI 10.1016/0092-8674(89)90832-5; FORTERRE P, 1985, EMBO J, V4, P2123, DOI 10.1002/j.1460-2075.1985.tb03902.x; GELLERT M, 1981, ANNU REV BIOCHEM, V50, P879, DOI 10.1146/annurev.bi.50.070181.004311; HEUKESHOVEN J, 1984, CHROMATOGRAPHIA, V19, P95, DOI 10.1007/BF02687724; IWABUCHI MA, 1983, J BIOL CHEM, V258, P2394; JAXEL C, 1989, EMBO J, V8, P3135, DOI 10.1002/j.1460-2075.1989.tb08466.x; KATO J, 1990, CELL, V63, P394; KIKUCHI A, 1984, NATURE, V309, P677, DOI 10.1038/309677a0; Kikuchi A, 1990, DNA TOPOLOGY ITS BIO, P285; KIRKEGAARD K, 1985, J MOL BIOL, V185, P625, DOI 10.1016/0022-2836(85)90075-0; KIRKEGAARD K, 1984, COLD SPRING HARB SYM, V49, P411, DOI 10.1101/SQB.1984.049.01.047; KOVALSKY OI, 1990, NUCLEIC ACIDS RES, V18, P2801, DOI 10.1093/nar/18.9.2801; KOZYAVKIN SA, 1987, J BIOMOL STRUCT DYN, V5, P119, DOI 10.1080/07391102.1987.10506380; KUNG VT, 1977, J BIOL CHEM, V252, P5398; LEE FS, 1985, NUCLEIC ACIDS RES, V13, P1665, DOI 10.1093/nar/13.5.1665; LEE JW, 1990, BIOCHEMISTRY-US, V29, P7666, DOI 10.1021/bi00485a016; Maniatis T., 1982, MOL CLONING; MARIANS KJ, 1987, J BIOL CHEM, V262, P10362; MAXWELL A, 1986, ADV PROTEIN CHEM, V38, P68; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MINDEN JS, 1986, J BIOL CHEM, V261, P1906; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; NADAL M, 1988, BIOCHEMISTRY-US, V27, P9102, DOI 10.1021/bi00426a006; NAKASU S, 1985, EMBO J, V4, P2705, DOI 10.1002/j.1460-2075.1985.tb03990.x; OSHEROFF N, 1989, PHARMACOL THERAPEUT, V41, P223, DOI 10.1016/0163-7258(89)90108-3; PANYUTIN I, 1985, J BIOMOL STRUCT DYN, V2, P1221, DOI 10.1080/07391102.1985.10507634; PANYUTIN IG, 1989, NUCLEIC ACIDS RES, V17, P8257, DOI 10.1093/nar/17.20.8257; PARADA CA, 1989, J BIOL CHEM, V264, P15120; PUGH BF, 1989, J MOL BIOL, V205, P487, DOI 10.1016/0022-2836(89)90219-2; PUGH BF, 1987, J BIOL CHEM, V262, P1326; PUGH BF, 1987, J BIOL CHEM, V262, P1337; SCHOELLMANN G, 1963, BIOCHEMISTRY-US, V2, P252, DOI 10.1021/bi00902a008; SHIBATA T, 1987, J BIOL CHEM, V262, P10419; SIEDLECKI J, 1983, NUCLEIC ACIDS RES, V11, P1523, DOI 10.1093/nar/11.5.1523; SLESAREV A, 1990, 20TH FEBS M BUD, P309; SLESAREV AI, 1990, J BIOMOL STRUCT DYN, V7, P935, DOI 10.1080/07391102.1990.10508533; SLESAREV AI, 1988, EUR J BIOCHEM, V173, P395, DOI 10.1111/j.1432-1033.1988.tb14012.x; SRIVENUGOPAL KS, 1984, BIOCHEMISTRY-US, V23, P1899, DOI 10.1021/bi00304a002; STECK TR, 1984, CELL, V36, P1081, DOI 10.1016/0092-8674(84)90058-8; STETTLER UH, 1979, J MOL BIOL, V131, P21, DOI 10.1016/0022-2836(79)90299-7; SVEJSTRUP JQ, 1990, J BIOL CHEM, V265, P12529; TSE YC, 1980, J BIOL CHEM, V255, P5560; VENGEROVA T I, 1979, Molekulyarnaya Biologiya (Moscow), V13, P1303; VOSBERG HP, 1985, CURR TOP MICROBIOL, V114, P19; WALLIS JW, 1989, CELL, V58, P409, DOI 10.1016/0092-8674(89)90855-6; Wang J. C., 1990, DNA TOPOLOGY ITS BIO, P321; Wang J.C., 1979, MOL GENETICS, P65, DOI [10.1016/B978-0-12-684403-0.50009-5., DOI 10.1016/B978-0-12-684403-0.50009-5]; WANG JC, 1971, J MOL BIOL, V55, P523, DOI 10.1016/0022-2836(71)90334-2; WANG JC, 1990, CELL, V62, P403, DOI 10.1016/0092-8674(90)90002-V; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WANG JC, 1981, ENYZMES A, V14, P331; WU AM, 1983, P NATL ACAD SCI-BIOL, V80, P1256, DOI 10.1073/pnas.80.5.1256; ZHANG H, 1990, P NATL ACAD SCI USA, V87, P9078, DOI 10.1073/pnas.87.23.9078	73	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1991	266	19					12321	12328						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FV180	1648092				2022-12-25	WOS:A1991FV18000036
J	HADCOCK, JR; PORT, JD; MALBON, CC				HADCOCK, JR; PORT, JD; MALBON, CC			CROSS-REGULATION BETWEEN G-PROTEIN-MEDIATED PATHWAYS - ACTIVATION OF THE INHIBITORY PATHWAY OF ADENYLYLCYCLASE INCREASES THE EXPRESSION OF BETA-2-ADRENERGIC RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC RECEPTORS; ADENYLATE-CYCLASE SYSTEM; MESSENGER-RNA LEVELS; INDUCED UP-REGULATION; SMOOTH-MUSCLE CELLS; STEADY-STATE LEVELS; DOWN-REGULATION; ELECTROPHORETIC TRANSFER; NITROCELLULOSE SHEETS; PROLONGED INCUBATION	Cross-regulation from the stimulatory (G(s-alpha)-mediated) to the inhibitory (G(i-alpha)-mediated) pathways controlling adenylylcyclase has been described (Hadcock, J. R., Ros, M., Watkins, D. C., and Malbon, C. C. (1990) J. Biol. Chem. 265, 14784-14790). The extent to which cross-regulation occurs from inhibitory to stimulatory pathways for adenylylcyclase was explored. Persistent activation of the inhibitory pathway of adenylylcyclase by the Al-adenosine receptor agonist (-)-N6(R-phenylisopropyl)adenosine (PIA) in hamster smooth muscle DDT, MF-2 cells enhanced the stimulatory pathway of adenylylcyclase and its activation by the beta-2-adrenergic receptor agonist isoproterenol. PIA treatment (48 h) of cells increased isoproterenol-stimulated adenylylcyclase by 2-fold. In addition, the ED50 for stimulation of adenylylcyclase by isoproterenol decreased 50-fold to approximately 1 nm. Persistent activation of cells with PIA increased beta-2-adrenergic receptor number in a time- and dose-dependent manner. The steady-state levels of beta-2-adrenergic receptors (radioligand binding and immunoblotting) and receptor mRNA levels increased by more than 70%, while the half-life of the receptor (24 h) was unaltered. Both A1-adenosine receptor binding and G(i-alpha-2) levels declined by half in cells persistently activated with PIA. Although G(i-alpha-2) mRNA levels and the relative rate of synthesis of G(i-alpha-2) protein upon persistent activation of the inhibitory pathway were found to increase, a decrease in the half-life of G(i-alpha-2) from approximately 75 h in naive cells to approximately 40 h in cells provides the basis for the decline in G(i-alpha-2) levels. The steady-State level of mRNA and half-life of G(s-alpha) protein were unaltered in persistently activated cells. Thus, activation of the inhibitory pathway of adenylylcyclase cross-regulates the stimulatory, hormone-sensitive adenylylcyclase system by: (i) up-regulating beta-2-adrenergic receptors and enhancing the activation of the stimulatory adenylylcyclase pathway and (ii) down-regulating elements of the inhibitory adenylylcyclase pathway (G(i-alpha-2) and A1-adenosine receptor binding).			HADCOCK, JR (corresponding author), SUNY STONY BROOK,HLTH SCI CTR,SCH MED,DEPT PHARMACOL,DIABET & METAB DIS RES PROGRAM,STONY BROOK,NY 11794, USA.		malbon, craig/ABF-3604-2020	Port, Jonathan D./0000-0001-7048-3544	NIDDK NIH HHS [DK30111, DK25410, T32 DK07521] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007521, R01DK030111, R01DK025410] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAHOUTH SW, 1988, MOL PHARMACOL, V34, P318; BRANN MR, 1987, FEBS LETT, V222, P191, DOI 10.1016/0014-5793(87)80218-1; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLINS S, 1988, J BIOL CHEM, V263, P9067; COLLINS S, 1989, P NATL ACAD SCI USA, V86, P4853, DOI 10.1073/pnas.86.13.4853; ERICKSON PF, 1982, J IMMUNOL METHODS, V51, P241, DOI 10.1016/0022-1759(82)90263-0; FELDMAN AM, 1988, J CLIN INVEST, V82, P189, DOI 10.1172/JCI113569; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GILMAN AG, 1984, CELL, V36, P577, DOI 10.1016/0092-8674(84)90336-2; GREEN A, 1987, J BIOL CHEM, V262, P15702; GREEN A, 1990, J BIOL CHEM, V265, P5206; HADCOCK JR, 1988, P NATL ACAD SCI USA, V85, P8415, DOI 10.1073/pnas.85.22.8415; HADCOCK JR, 1990, J BIOL CHEM, V265, P14784; HADCOCK JR, 1988, P NATL ACAD SCI USA, V85, P5021, DOI 10.1073/pnas.85.14.5021; HADCOCK JR, 1989, J BIOL CHEM, V264, P13956; HADCOCK JR, 1989, J BIOL CHEM, V264, P19928; HADCOCK JR, 1989, AM J PHYSIOL, V256, pC457, DOI 10.1152/ajpcell.1989.256.3.C457; HOFFMAN BB, 1986, J CLIN INVEST, V78, P185, DOI 10.1172/JCI112550; JOHNSON GL, 1989, ENDOCR REV, V10, P317, DOI 10.1210/edrv-10-3-317; JONES DT, 1987, J BIOL CHEM, V262, P14241; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LONGABAUGH JP, 1989, MOL PHARMACOL, V36, P681; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHAN LC, 1987, ANNU REV PHARMACOL, V27, P215; MALBON CC, 1985, J BIOL CHEM, V260, P2558; MANAITIS T, 1982, MOL CLONING LABORATO; MORRIS GM, 1991, J BIOL CHEM, V266, P2233; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; RAMKUMAR V, 1990, MOL PHARMACOL, V37, P149; Ramkumar V, 1988, Prog Drug Res, V32, P195; RAPIEJKO PJ, 1989, J BIOL CHEM, V264, P16183; REITHMANN C, 1990, MOL PHARMACOL, V37, P631; RICH KA, 1984, J BIOL CHEM, V259, P7893; ROS M, 1989, BIOCHEM J, V260, P271, DOI 10.1042/bj2600271; SAKAUE M, 1990, FASEB J, V4, P1126; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SCARPACE PJ, 1985, MOL PHARMACOL, V28, P495; SIBLEY DR, 1985, NATURE, V317, P124, DOI 10.1038/317124a0; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; SMITH DE, 1987, J CELL BIOL, V105, P771, DOI 10.1083/jcb.105.2.771; STEINBERG RA, 1978, CELL, V15, P1351, DOI 10.1016/0092-8674(78)90060-0; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wang H Y, 1990, Receptor, V1, P13; WANG HY, 1989, BIOCHEM J, V263, P519, DOI 10.1042/bj2630519; WANG HY, 1989, J BIOL CHEM, V264, P14424; WATKINS DC, 1989, BIOCHEM BIOPH RES CO, V165, P929, DOI 10.1016/0006-291X(89)92692-2; WATKINS DC, 1989, J BIOL CHEM, V264, P4186	48	86	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1991	266	18					11915	11922						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FT762	1646818				2022-12-25	WOS:A1991FT76200077
J	HICKEY, DR; BERGHUIS, AM; LAFOND, G; JAEGER, JA; CARDILLO, TS; MCLENDON, D; DAS, G; SHERMAN, F; BRAYER, GD; MCLENDON, G				HICKEY, DR; BERGHUIS, AM; LAFOND, G; JAEGER, JA; CARDILLO, TS; MCLENDON, D; DAS, G; SHERMAN, F; BRAYER, GD; MCLENDON, G			ENHANCED THERMODYNAMIC STABILITIES OF YEAST ISO-1-CYTOCHROMES-C WITH AMINO-ACID REPLACEMENTS AT POSITION-5I AND POSITION-102	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESOLUTION 3-DIMENSIONAL STRUCTURE; CYTOCHROME-C; PROTEIN CONFORMATION; FERRICYTOCHROME-C; STAPHYLOCOCCAL NUCLEASE; GENETIC-ANALYSIS; MUTANTS; SUBSTITUTIONS; REQUIREMENTS; DENATURATION	We have determined the structures and thermodynamic stabilities of the wild type Asn-52 and unusually thermostable mutant Ile-52 yeast iso-1-cytochromes c (Das, G., Hickey, D. R. McLendon, D., McLendon, G., and Sherman, F. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 496-499). Although both structures were similar, Water-166, buried within the wild type protein, is excluded from the Ile-52 mutant, which substantially reorganizes the local hydrogen bonding. Wild type Cys-102 was replaced with alanine or serine to eliminate dimerization in vitro. The Cys-102 (wild type), Ala-102, and Ser-102 proteins were equally stable, whereas the chemically modified Cys-102-SCH3 Was less stable. The order of stability observed with replacements at positions 52 and 102 was as follows: Ile-52 Ala-102 > Ala-52 Ala-102 > Asn-52 Ala-102 ("normal") > Gly-52 Ala-102. No significant stabilization was attributed to potential energy interactions expressed as helix-forming propensities of replacements at position 52. A high correlation between differences in free energy changes and transfer free energies suggests hydrophobic interactions are the main factor for enhancing stability in the Ile-52 mutant. Additional possible contributions to the thermostability of the Ile-52 variant are energetic effects due to packing and hydrogen bonding changes surrounding position 52.	UNIV ROCHESTER,DEPT CHEM,ROCHESTER,NY 14627; UNIV BRITISH COLUMBIA,DEPT BIOCHEM,VANCOUVER V6T 1W5,BC,CANADA; UNIV ROCHESTER,SCH MED & DENT,DEPT BIOCHEM,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,DEPT BIOPHYS,ROCHESTER,NY 14642	University of Rochester; University of British Columbia; University of Rochester; University of Rochester			Berghuis, Albert M/A-6495-2008	Berghuis, Albert/0000-0002-2663-025X	NIGMS NIH HHS [R01 GM12702] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM012702] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; BRYANT C, 1985, BIOCHEMISTRY-US, V24, P3459, DOI 10.1021/bi00335a011; BUSHNELL GW, 1990, J MOL BIOL, V214, P585, DOI 10.1016/0022-2836(90)90200-6; CHEN BL, 1989, BIOCHEMISTRY-US, V28, P685, DOI 10.1021/bi00428a041; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P211, DOI 10.1021/bi00699a001; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; DAS G, 1989, P NATL ACAD SCI USA, V86, P496, DOI 10.1073/pnas.86.2.496; Donovan J W, 1973, Methods Enzymol, V27, P497; EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0; ERNST JF, 1985, J BIOL CHEM, V260, P3225; FAUCHERE JL, 1983, EUR J MED CHEM, V18, P369; GRIKO YV, 1988, P NATL ACAD SCI USA, V85, P3293; HAMPSEY DM, 1988, FEBS LETT, V231, P275, DOI 10.1016/0014-5793(88)80834-2; HAMPSEY DM, 1986, J BIOL CHEM, V261, P3259; Hendrickson W. A., 1981, BIOMOLECULAR STRUCTU, V1, P43; HICKEY DR, 1988, J BIOL CHEM, V263, P18298; HOLZSCHU D, 1987, J BIOL CHEM, V262, P7125; KAMINSKY LS, 1973, BIOCHEMISTRY-US, V12, P2215, DOI 10.1021/bi00736a006; KELLIS JT, 1989, BIOCHEMISTRY-US, V28, P4914, DOI 10.1021/bi00437a058; LEUNG CJ, 1989, J MOL BIOL, V206, P783, DOI 10.1016/0022-2836(89)90585-8; LOUIE GV, 1989, J MOL BIOL, V210, P313, DOI 10.1016/0022-2836(89)90333-1; LOUIE GV, 1990, J MOL BIOL, V214, P527, DOI 10.1016/0022-2836(90)90197-T; LOUIE GV, 1988, J MOL BIOL, V199, P295, DOI 10.1016/0022-2836(88)90315-4; LUMRY R, 1966, BIOPOLYMERS, V4, P917, DOI 10.1002/bip.1966.360040808; LUNTZ TL, 1989, P NATL ACAD SCI USA, V86, P3524, DOI 10.1073/pnas.86.10.3524; MATTHEWS BW, 1987, BIOCHEMISTRY-US, V26, P6885, DOI 10.1021/bi00396a001; MONTONAGA K, 1965, J BIOCHEM-TOKYO, V57, P29; NOJIMA H, 1977, J MOL BIOL, V116, P429, DOI 10.1016/0022-2836(77)90078-X; PETROCHILO E, 1977, BIOCHEM BIOPH RES CO, V79, P364, DOI 10.1016/0006-291X(77)90166-8; POLASTRO E, 1976, BIOCHIM BIOPHYS ACTA, V446, P310, DOI 10.1016/0005-2795(76)90121-5; PRIVALOV PL, 1974, J MOL BIOL, V86, P665, DOI 10.1016/0022-2836(74)90188-0; RAMDAS L, 1986, BIOCHEMISTRY-US, V25, P6952, DOI 10.1021/bi00370a032; Schechter E, 1967, BIOPOLYMERS, V5, P788; SCHELLMAN JA, 1978, BIOPOLYMERS, V17, P1305, DOI 10.1002/bip.1978.360170515; SCHWEINGRUBER ME, 1979, J BIOL CHEM, V254, P4132; SHERMAN F, 1974, GENETICS, V77, P255; SHORTLE D, 1988, BIOCHEMISTRY-US, V27, P4761, DOI 10.1021/bi00413a027; SHORTLE D, 1985, GENETICS, V110, P539; SREENATHAN BR, 1971, BIOCHEM BIOPH RES CO, V42, P1122, DOI 10.1016/0006-291X(71)90021-0; TANFORD C, 1962, J AM CHEM SOC, V84, P4240, DOI 10.1021/ja00881a009; TSONG TY, 1974, J BIOL CHEM, V249, P1988; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001; ZUNIGA EH, 1983, BIOCHEMISTRY-US, V22, P1430, DOI 10.1021/bi00275a017	43	74	74	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1991	266	18					11686	11694						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FT762	1646814				2022-12-25	WOS:A1991FT76200043
J	OSTMAN, A; ANDERSSON, M; HELLMAN, U; HELDIN, CH				OSTMAN, A; ANDERSSON, M; HELLMAN, U; HELDIN, CH			IDENTIFICATION OF 3 AMINO-ACIDS IN THE PLATELET-DERIVED GROWTH-FACTOR (PDGF) B-CHAIN THAT ARE IMPORTANT FOR BINDING TO THE PDGF BETA-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN SARCOMA-VIRUS; FACTOR A-CHAIN; HUMAN-FIBROBLASTS; EXPRESSION; CDNA; LOCALIZATION; DIMERIZATION; GENE; ESTABLISHES; MUTAGENESIS	Platelet-derived growth factor (PDGF) is a disulfide-linked dimeric protein composed of two homologous polypeptide chains denoted A and B. Two types of PDGF receptor, alpha and beta, have been characterized. Whereas PDGF-AA binds only to PDGF alpha-receptors, PDGF-BB binds to both receptor types with high affinity. To map the regions of the PDGF B-chain that confer its ability to bind with high affinity to the PDGF beta-receptor, we expressed PDGF A/B-chain chimeras in COS cells and analyzed them with regard to PDGF alpha-and beta-receptor binding. A systematic analysis revealed that replacement of Asn-115, Arg-154, and Ile-158 of the PDGF B-chain with the corresponding A-chain amino acids led to a dramatic decrease in the affinity for the beta-receptor. Conversely, introduction of B-chain amino acids into the A-chain in the region spanning from Asn-115 to Ile-158 yielded a product with high affinity for the beta-receptor. These data thus indicate that Asn-115, Arg-154, and Ile-158 are likely to be part of the active site of the PDGF B-chain.			OSTMAN, A (corresponding author), BIOMED CTR,LUDWIG INST CANC RES,BOX 595,S-751 UPPSALA,SWEDEN.							BECKMANN MP, 1988, SCIENCE, V241, P1346, DOI 10.1126/science.2842868; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; BYWATER M, 1988, MOL CELL BIOL, V8, P2753, DOI 10.1128/MCB.8.7.2753; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; GIESE N, 1990, MOL CELL BIOL, V10, P5496, DOI 10.1128/MCB.10.10.5496; HAMMACHER A, 1989, EMBO J, V8, P2489, DOI 10.1002/j.1460-2075.1989.tb08385.x; HANNINK M, 1986, MOL CELL BIOL, V6, P1304, DOI 10.1128/MCB.6.4.1304; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HELDIN CH, 1981, EXP CELL RES, V136, P255, DOI 10.1016/0014-4827(81)90003-3; JOSEPHS SF, 1984, SCIENCE, V223, P487, DOI 10.1126/science.6318322; KING CR, 1985, P NATL ACAD SCI USA, V82, P5295, DOI 10.1073/pnas.82.16.5295; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAROCHELLE WJ, 1990, SCIENCE, V248, P1541, DOI 10.1126/science.2163109; LAROCHELLE WJ, 1989, MOL CELL BIOL, V9, P3538, DOI 10.1128/MCB.9.8.3538; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; OSTMAN A, 1988, J BIOL CHEM, V263, P16202; Ostman A, 1989, GROWTH FACTORS, V1, P271, DOI 10.3109/08977198908998003; ROBBINS KC, 1983, NATURE, V305, P605, DOI 10.1038/305605a0; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; TRUETT MA, 1985, DNA-J MOLEC CELL BIO, V4, P333, DOI 10.1089/dna.1985.4.333; VOGEL S, 1989, BIOCHEMISTRY-US, V28, P2961, DOI 10.1021/bi00433a033; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	27	44	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10073	10077						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	1645337				2022-12-25	WOS:A1991FP08600015
J	ONG, G; SIKORA, K; GULLICK, WJ				ONG, G; SIKORA, K; GULLICK, WJ			INACTIVATION OF THE RETINOBLASTOMA GENE DOES NOT LEAD TO LOSS OF TGF-BETA RECEPTORS OR RESPONSE TO TGF-BETA IN BREAST-CANCER CELL-LINES	ONCOGENE			English	Note							TRANSFORMING GROWTH-FACTOR; INHIBITION; EXPRESSION; PATTERN; PRODUCT		HAMMERSMITH HOSP,ICRF,ONCOL GRP,CYCLOTRON BLDG,DU CANE RD,LONDON W12 0HS,ENGLAND	Imperial College London	GULLICK, WJ (corresponding author), HAMMERSMITH HOSP,ICRF,ONCOL GRP,CYCLOTRON BLDG,DU CANE RD,LONDON W12 0HS,ENGLAND.							CHAMBARD JC, 1988, J CELL PHYSIOL, V135, P101, DOI 10.1002/jcp.1041350114; CHEIFETZ S, 1987, CELL, V48, P409, DOI 10.1016/0092-8674(87)90192-9; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GREEN MR, 1989, CELL, V56, P1, DOI 10.1016/0092-8674(89)90975-6; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; KNABBE C, 1987, CELL, V48, P417, DOI 10.1016/0092-8674(87)90193-0; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LIKE B, 1986, J BIOL CHEM, V261, P3426; MASSAGUE J, 1987, CELL, V49, P437, DOI 10.1016/0092-8674(87)90443-0; MASSAGUE J, 1985, J BIOL CHEM, V260, P2636; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SHIPLEY GD, 1985, P NATL ACAD SCI USA, V82, P4147, DOI 10.1073/pnas.82.12.4147; SILBERSTEIN GB, 1987, SCIENCE, V237, P291, DOI 10.1126/science.3474783; WAKEFIELD LM, 1987, J CELL BIOL, V105, P965, DOI 10.1083/jcb.105.2.965; XU HJ, 1989, ONCOGENE, V4, P807	17	37	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1991	6	5					761	763						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT825	1646985				2022-12-25	WOS:A1991GT82500011
J	GOODWIN, EC; ROTTMAN, FM				GOODWIN, EC; ROTTMAN, FM			THE 3'-FLANKING SEQUENCE OF THE BOVINE GROWTH-HORMONE GENE CONTAINS NOVEL ELEMENTS REQUIRED FOR EFFICIENT AND ACCURATE POLYADENYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' END FORMATION; MESSENGER-RNA; POLY(A) SITE; DOWNSTREAM ELEMENTS; POINT MUTATIONS; AAUAAA; CLEAVAGE; INVITRO; SIGNAL; CELLS	In addition to the conserved AAUAAA hexanucleotide, GU- and U-rich sequences in the 3'-nanking region are thought to be critical for efficient polyadenylation. The 3'-flanking sequence requirements for efficient and accurate polyadenylation of the bovine growth hormone (bGH) gene were determined by quantitative S1 nuclease analysis of transcripts derived from various bGH 3' deletions and block mutations transiently transfected into COS-1 cells. Though the bGH 3'-flanking sequence contains a portion of the putative GU efficiency element, we find that mutation of this element leads to a marginal decrease in efficiency similar to that from mutation of other sequences that do not contain recognizable GU- or U-rich motifs. The data are consistent with a diffuse efficiency element in the bGH polyadenylation signal rather than a discrete element as is thought to exist in other mammalian signals. We have also determined that a region from 18 to 27 nucleotides downstream of the cleavage site contains sequences required for correctly positioning the cleavage site.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT MOLEC BIOL & MICROBIOL, CLEVELAND, OH 44106 USA	Case Western Reserve University					NIDDK NIH HHS [DK-32770] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032770] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARDWELL VJ, 1991, CELL, V65, P125, DOI 10.1016/0092-8674(91)90414-T; BERGET SM, 1984, NATURE, V309, P179, DOI 10.1038/309179a0; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; CAMPER SA, 1985, J BIOL CHEM, V260, P2246; CONWAY L, 1987, EMBO J, V6, P4177, DOI 10.1002/j.1460-2075.1987.tb02764.x; DARNELL JE, 1982, NATURE, V297, P365, DOI 10.1038/297365a0; GIL A, 1987, CELL, V49, P399, DOI 10.1016/0092-8674(87)90292-3; GREEN TL, 1988, MOL CELL BIOL, V8, P1839, DOI 10.1128/MCB.8.4.1839; HART RP, 1985, MOL CELL BIOL, V5, P2975, DOI 10.1128/MCB.5.11.2975; LEVITT N, 1989, GENE DEV, V3, P1019, DOI 10.1101/gad.3.7.1019; LITTAUER UZ, 1982, PROG NUCLEIC ACID RE, V27, P53, DOI 10.1016/S0079-6603(08)60597-8; Maniatis T., 1982, MOL CLONING; MASON PJ, 1986, CELL, V46, P263, DOI 10.1016/0092-8674(86)90743-9; MCDEVITT MA, 1986, EMBO J, V5, P2907, DOI 10.1002/j.1460-2075.1986.tb04586.x; MCLAUCHLAN J, 1985, NUCLEIC ACIDS RES, V13, P1347, DOI 10.1093/nar/13.4.1347; MONTELL C, 1983, NATURE, V305, P600, DOI 10.1038/305600a0; MUNROE D, 1990, GENE, V91, P151, DOI 10.1016/0378-1119(90)90082-3; PETERSON ML, 1991, MOL CELL BIOL, V11, P2324, DOI 10.1128/MCB.11.4.2324; PFARR DS, 1986, DNA-J MOLEC CELL BIO, V5, P115, DOI 10.1089/dna.1986.5.115; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; QIAN ZW, 1991, MOL CELL BIOL, V11, P5312, DOI 10.1128/MCB.11.10.5312; SETZER D, 1990, NUCLEIC ACIDS RES, V11, P4175; SHEETS MD, 1989, GENE DEV, V3, P1401, DOI 10.1101/gad.3.9.1401; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; WICKENS M, 1984, SCIENCE, V226, P1045, DOI 10.1126/science.6208611; WILUSZ J, 1989, NUCLEIC ACIDS RES, V17, P3899, DOI 10.1093/nar/17.10.3899; WOYCHIK RP, 1984, P NATL ACAD SCI-BIOL, V81, P3944, DOI 10.1073/pnas.81.13.3944; ZARKOWER D, 1988, J BIOL CHEM, V263, P5780; ZHANG F, 1986, MOL CELL BIOL, V6, P4611, DOI 10.1128/MCB.6.12.4611	29	73	93	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16330	16334						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1644817				2022-12-25	WOS:A1992JJ45800054
J	SJOBERG, ER; MANZI, AE; KHOO, KH; DELL, A; VARKI, A				SJOBERG, ER; MANZI, AE; KHOO, KH; DELL, A; VARKI, A			STRUCTURAL AND IMMUNOLOGICAL CHARACTERIZATION OF O-ACETYLATED GD2 - EVIDENCE THAT GD2 IS AN ACCEPTOR FOR GANGLIOSIDE O-ACETYLTRANSFERASE IN HUMAN-MELANOMA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOMBARDMENT MASS-SPECTROMETRY; RAT-LIVER GOLGI; PERFORMANCE LIQUID-CHROMATOGRAPHY; PROTON-TRANSLOCATING ATPASE; EMBRYONAL CARCINOMA-CELLS; DE-ORTHO-ACETYLATION; PROTEIN-KINASE-C; SIALIC ACIDS; MONOCLONAL-ANTIBODY; 9-O-ACETYL-N-ACETYLNEURAMINIC ACID	We have shown previously that Golgi-enriched vesicles from the human melanoma cell line Melur can transfer [H-3]acetate from [acetyl-H-3]acetyl-CoA to endogenous G(D3) to form [acetyl-H-3]O-acetyl-G(D3) (Manzi, A. E., Sjoberg, E. R., Diaz, S., and Varki, A. (1990) J. Biol. Chem. 265, 13091-13103). Applying the same approach in the human melanoma cell line M21, label was found in [acetyl-H-3]O-acetyl-G(D3) and also in a species co-migrating with unsubstituted G(D3) on TLC. Both were sialidase-sensitive and alkali-labile, indicating incorporation as [H-3]O-acetyl esters on sialic acids. Immunological reactivity, sialidase sensitivity, chromatographic behavior, and the known ganglioside pattern of M21 cells suggested that the slower migrating species might be [acetyl-H-3]O-acetyl-G(D2). Sialic acids released from this labeled molecule by sialidase showed esterification with [H-3]acetate at both C7 and C9 hydroxyls. Lipid extracts from cells metabolically labeled with [H-3]galactose showed a corresponding ganglioside, which upon alkali treatment yielded a species migrating with G(D2). Analysis of purified ganglioside by high performance thin layer chromatography immuno-overlays, fast atom bombardment-mass spectrometry in positive and negative ion modes, periodate oxidation resistance, linkage analysis by permethylation and gas chromatography-mass spectrometry, and 500 MHz H-1 NMR was consistent with the following structure: 9-OAc-Neu5Ac-alpha-2-8Neu5Ac-alpha-2-3(GalNAc-beta-1-4) Gal-beta-1-4Gluc-beta-1-1'ceramide Total gangliosides from M21 were analyzed by high performance thin layer chromatography immuno-overlay with monoclonal antibodies D1.1, JONES, 27A, and 8A2, all known to, or suspected of reacting with 9-O-acetylated gangliosides. The first three bound well to 9-O-acetyl-G(D3) and a slower migrating 9-O-acetylated ganglioside, which was distinct from 9-O-acetyl-G(D2). Antibody 8A2 reacted weakly with purified 9-O-acetyl-G(D2) and strongly with two other 9-O-acetylated gangliosides migrating slower than 9-O-acetyl-G(D2). Thus, the family of O-acetylated gangliosides in melanoma cells is much more complex than previously appreciated.	UNIV CALIF SAN DIEGO, DEPT CHEM, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR CANC, LA JOLLA, CA 92093 USA; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, DEPT BIOCHEM, LONDON SW7 2AY, ENGLAND	University of California System; University of California San Diego; University of California System; University of California San Diego; Imperial College London			Khoo, Kay-Hooi/E-1989-2019	Khoo, Kay-Hooi/0000-0003-2906-406X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI023287] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032373] Funding Source: NIH RePORTER; NIAID NIH HHS [P01 AI 23287] Funding Source: Medline; NIGMS NIH HHS [R01-GM32373] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDO S, 1989, J BIOL CHEM, V264, P3478; ARAKI N, 1990, HISTOCHEMISTRY, V93, P453, DOI 10.1007/BF00266400; AUBRY J, 1991, 11TH INT S GLYC TOR; BARKER E, 1991, CANCER RES, V51, P144; BEVILACQUA M, 1991, CELL, V67, P233, DOI 10.1016/0092-8674(91)90174-W; BJORNDAL H, 1970, CARBOHYD RES, V15, P339, DOI 10.1016/S0008-6215(00)80450-4; BJORNDAL H, 1970, ANGEW CHEM INT EDIT, V9, P610, DOI 10.1002/anie.197006101; BLUM AS, 1987, P NATL ACAD SCI USA, V84, P8716, DOI 10.1073/pnas.84.23.8716; BREMER EG, 1984, J BIOL CHEM, V259, P6818; CHAN KFJ, 1989, J BIOL CHEM, V264, P18632; CHERESH DA, 1984, P NATL ACAD SCI-BIOL, V81, P5767, DOI 10.1073/pnas.81.18.5767; CHERESH DA, 1987, J CELL BIOL, V105, P1163, DOI 10.1083/jcb.105.3.1163; CHERESH DA, 1984, SCIENCE, V225, P844, DOI 10.1126/science.6206564; CHERESH DA, 1984, J BIOL CHEM, V259, P7453; CHERESH DA, 1986, J CELL BIOL, V102, P688, DOI 10.1083/jcb.102.3.688; CONSTANTINEPATON M, 1986, NATURE, V324, P459, DOI 10.1038/324459a0; DABROWSKI J, 1980, CHEM PHYS LIPIDS, V26, P187, DOI 10.1016/0009-3084(80)90006-7; DAS KK, 1991, J BIOL CHEM, V266, P5238; DEKAN G, 1990, AM J PATHOL, V137, P913; DIAZ S, 1989, J BIOL CHEM, V264, P19416; DIAZ S, 1985, ANAL BIOCHEM, V150, P32, DOI 10.1016/0003-2697(85)90438-5; DIPPOLD WG, 1985, EUR J CANCER CLIN ON, V21, P907, DOI 10.1016/0277-5379(85)90106-3; DIXON SJ, 1987, J CELL BIOL, V105, P1153, DOI 10.1083/jcb.105.3.1153; DRAZBA J, 1991, DEV BIOL, V145, P154, DOI 10.1016/0012-1606(91)90221-N; DRZENIEK R, 1973, HISTOCHEM J, V5, P271, DOI 10.1007/BF01004994; DUBOIS C, 1990, J BIOL CHEM, V265, P2797; FREDDO L, 1986, NEUROLOGY, V36, P454, DOI 10.1212/WNL.36.4.454; FUKUDA MN, 1985, J BIOL CHEM, V260, P6623; FUKUDA MN, 1986, J BIOL CHEM, V261, P5145; GASA S, 1983, J BIOL CHEM, V258, P876; GHIDONI R, 1980, J BIOL CHEM, V255, P6990; GOWDA DC, 1984, H-S Z PHYSIOL CHEM, V365, P1247, DOI 10.1515/bchm2.1984.365.2.1247; GROSS SK, 1980, J NEUROCHEM, V34, P1351, DOI 10.1111/j.1471-4159.1980.tb11215.x; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HANNUN YA, 1987, SCIENCE, V235, P670, DOI 10.1126/science.3101176; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HARA S, 1989, ANAL BIOCHEM, V179, P162, DOI 10.1016/0003-2697(89)90218-2; HAVERKAMP J, 1977, H-S Z PHYSIOL CHEM, V358, P1609, DOI 10.1515/bchm2.1977.358.2.1609; HAVERKAMP J, 1977, FEBS LETT, V73, P215, DOI 10.1016/0014-5793(77)80984-8; HAVERKAMP J, 1982, EUR J BIOCHEM, V122, P305, DOI 10.1111/j.1432-1033.1982.tb05881.x; HAVERKAMP J, 1975, H-S Z PHYSIOL CHEM, V356, P1575, DOI 10.1515/bchm2.1975.356.2.1575; HIGA HH, 1989, J BIOL CHEM, V264, P19427; HIRABAYASHI Y, 1991, J BIOL CHEM, V266, P10268; HOLTHOFER H, 1991, LAB INVEST, V65, P548; HOUGHTON AN, 1985, P NATL ACAD SCI USA, V82, P1242, DOI 10.1073/pnas.82.4.1242; HOUGHTON AN, 1986, SEMIN ONCOL, V13, P165; IBER H, 1991, EUR J BIOCHEM, V195, P115, DOI 10.1111/j.1432-1033.1991.tb15683.x; ISOBE R, 1989, ANAL BIOCHEM, V177, P296, DOI 10.1016/0003-2697(89)90055-9; ITO M, 1989, METHOD ENZYMOL, V179, P488; IWASAKI M, 1990, J BIOL CHEM, V265, P2596; JOHNSTONE SR, 1988, J NEUROCHEM, V51, P1655, DOI 10.1111/j.1471-4159.1988.tb01138.x; KAMERLING JP, 1987, EUR J BIOCHEM, V162, P601, DOI 10.1111/j.1432-1033.1987.tb10681.x; KANNAGI R, 1987, METHOD ENZYMOL, V138, P3, DOI 10.1016/0076-6879(87)38003-6; KITAGAWA S, 1989, J BIOL CHEM, V264, P16149; KOERNER TAW, 1983, BIOCHEMISTRY-US, V22, P2687, DOI 10.1021/bi00280a015; KOERNER TAW, 1983, BIOCHEMISTRY-US, V22, P2676, DOI 10.1021/bi00280a014; Kundu S K, 1981, Methods Enzymol, V72, P185, DOI 10.1016/S0076-6879(81)72012-3; LADISCH S, 1984, J CLIN INVEST, V74, P2074, DOI 10.1172/JCI111631; LADISCH S, 1987, J CLIN INVEST, V79, P1879, DOI 10.1172/JCI113031; LEDEEN RW, 1982, METHOD ENZYMOL, V83, P139; LEVINE JM, 1984, J NEUROSCI, V4, P820; MAGNANI JL, 1982, METHOD ENZYMOL, V83, P235; MANZI AE, 1990, ANAL BIOCHEM, V188, P20, DOI 10.1016/0003-2697(90)90523-C; MANZI AE, 1990, J BIOL CHEM, V265, P8094; MANZI AE, 1990, J BIOL CHEM, V265, P13091; MARCUS DM, 1984, MOL IMMUNOL, V21, P1083, DOI 10.1016/0161-5890(84)90118-4; MARKWELL MAK, 1981, P NATL ACAD SCI-BIOL, V78, P5406, DOI 10.1073/pnas.78.9.5406; MASSERINI M, 1988, BIOCHEMISTRY-US, V27, P7973, DOI 10.1021/bi00420a057; MCLEAN RL, 1971, J BIOL CHEM, V246, P803; MORIYAMA Y, 1989, J BIOL CHEM, V264, P18445; MUELLER BM, 1990, P NATL ACAD SCI USA, V87, P5702, DOI 10.1073/pnas.87.15.5702; MUJOO K, 1989, CANCER RES, V49, P2857; NUDELMAN E, 1982, J BIOL CHEM, V257, P2752; OTERO RM, 1988, J NEUROSCI, V8, P564; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; POHLENTZ G, 1988, P NATL ACAD SCI USA, V85, P7044, DOI 10.1073/pnas.85.19.7044; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; PRESTI D, 1989, J NEUROIMMUNOL, V22, P233, DOI 10.1016/0165-5728(89)90021-0; RAJ SV, 1988, J CLIN ONCOL, V6, P1636; REIVREN J, 1990, J CELL BIOL, V111, P74; RIBONI L, 1986, J BIOL CHEM, V261, P8514; RITTER G, 1990, CANCER RES, V50, P1403; ROGERS GN, 1986, J BIOL CHEM, V261, P5947; ROSEMAN S, 1970, CHEM PHYS LIPIDS, V5, P270, DOI 10.1016/0009-3084(70)90024-1; SCARSDALE JN, 1990, BIOCHEMISTRY-US, V29, P9843, DOI 10.1021/bi00494a014; SCHAUER R, 1987, METHOD ENZYMOL, V138, P611; SCHAUER R, 1982, ADV CARBOHYD CHEM BI, V40, P131, DOI 10.1016/S0065-2318(08)60109-2; Schauer R., 1982, CELL BIOL MONOGRAPHS, V10; SCHLOSSHAUER B, 1988, J NEUROSCI, V8, P580; SCHWARZMANN G, 1990, BIOCHEMISTRY-US, V29, P10865, DOI 10.1021/bi00501a001; SONNINO S, 1982, ADV EXP MED BIOL, V152, P55; SPARROW JR, 1988, J NEUROSCI RES, V21, P398, DOI 10.1002/jnr.490210231; SPIEGEL S, 1989, J BIOL CHEM, V264, P16512; STALLCUP WB, 1989, DEV BIOL, V132, P212, DOI 10.1016/0012-1606(89)90218-2; STELLNER K, 1973, ARCH BIOCHEM BIOPHYS, V155, P464, DOI 10.1016/0003-9861(73)90138-0; STULTS CLM, 1989, METHOD ENZYMOL, V179, P167; SVENNERHOLM L, 1989, BIOCHIM BIOPHYS ACTA, V1005, P109, DOI 10.1016/0005-2760(89)90175-6; THURIN J, 1985, J BIOL CHEM, V260, P4556; TSUJI S, 1988, J BIOCHEM, V104, P498, DOI 10.1093/oxfordjournals.jbchem.a122498; TYRRELL D, 1991, P NATL ACAD SCI USA, V88, P10372, DOI 10.1073/pnas.88.22.10372; USUKI S, 1988, J BIOL CHEM, V263, P10595; VARKI A, 1984, ANAL BIOCHEM, V137, P236, DOI 10.1016/0003-2697(84)90377-4; VARKI A, 1980, J EXP MED, V152, P532, DOI 10.1084/jem.152.3.532; VARKI A, 1991, CELL, V65, P65, DOI 10.1016/0092-8674(91)90408-Q; VARKI A, 1983, J BIOL CHEM, V258, P2465; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; VLASAK R, 1987, VIROLOGY, V160, P419, DOI 10.1016/0042-6822(87)90013-4; YOUNG GPH, 1988, P NATL ACAD SCI USA, V85, P9590, DOI 10.1073/pnas.85.24.9590	108	60	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16200	16211						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1644805				2022-12-25	WOS:A1992JJ45800035
J	XU, X; KANTROWITZ, ER				XU, X; KANTROWITZ, ER			THE IMPORTANCE OF ASPARTATE-327 FOR CATALYSIS AND ZINC-BINDING IN ESCHERICHIA-COLI ALKALINE-PHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; SITE-SPECIFIC MUTAGENESIS; AMINO-ACID-SEQUENCE; DNA-POLYMERASE-I; PHENOTYPIC SELECTION; MECHANISM; RESOLUTION; CLONING; CDNA; GENE	In order to investigate the function of Asp-327, a bidentate ligand of one of the zinc atoms in Escherichia coli alkaline phosphatase, and the importance of this zinc atom in catalysis, site-specific mutagenesis was used to convert Asp-327 to either asparagine or alanine. The 10(7)-fold decrease in the k(cat)/K(m) ratio observed for the Asp-327 --> Ala enzyme compared to the wild-type enzyme indicates that the side chain of Asp-327 is important for zinc binding at the M1 site. However, only one of the two carboxyl oxygens of Asp-327 is essential for zinc binding, since the Asp-327 --> Asn enzyme shows approximately the same hydrolysis activity as the wild-type enzyme. The fact that the enzymatic activity of this mutant enzyme shows a dependence on zinc concentration suggests that the other carboxyl oxygen or the negative charge on the side chain of Asp-327 is important in binding of the zinc at the M1 site. However, the zinc hydroxyl must still be appropriately positioned to attack the phosphoserine in the Asp-327 --> Asn enzyme; therefore, the negative charge and at least one carboxyl oxygen of the side chain are not directly involved in positioning or deprotonating the zinc hydroxyl. P-31 NMR studies indicate that the Asp-327 --> Asn enzyme exhibits transphosphorylation activity at both pH 8.0 and pH 10.0, but at a reduced level compared to the wild-type enzyme. The biphasic production of 2,4-dinitrophenylate in the pre-steady-state kinetics of the mutant enzymes at pH 5.5 suggests that the breaking of the phosphoenzyme covalent complex is rate-limiting for both mutant enzymes. These results suggest that the main function of the zinc atom at the M1 site in catalysis involves decomposition of the phosphoenzyme covalent complex and that it may be important in helping to stabilize the alcohol leaving group.	BOSTON COLL, DEPT CHEM, CHESTNUT HILL, MA 02167 USA	Boston College					NIGMS NIH HHS [GM42833] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042833] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON RA, 1976, BIOCHEMISTRY-US, V15, P3710, DOI 10.1021/bi00662a011; ANDERSON RA, 1975, P NATL ACAD SCI USA, V72, P2989, DOI 10.1073/pnas.72.8.2989; APPLEBUR.ML, 1970, J BIOL CHEM, V245, P4968; APPLEBURY ML, 1969, J BIOL CHEM, V244, P308; ATHERTON FR, 1945, J CHEM SOC, P382, DOI 10.1039/jr9450000382; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BERGER J, 1987, P NATL ACAD SCI USA, V84, P695, DOI 10.1073/pnas.84.3.695; BLOCH W, 1974, J BIOL CHEM, V249, P1760; BLOCH W, 1980, BIOCHEMISTRY-US, V19, P5008, DOI 10.1021/bi00563a012; BLOCH W, 1973, J BIOL CHEM, V248, P5794; BLOCH W, 1978, J BIOL CHEM, V253, P6211; BOSRON WF, 1977, BIOCHEMISTRY-US, V16, P610, DOI 10.1021/bi00623a009; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADSHAW RA, 1981, P NATL ACAD SCI-BIOL, V78, P3473, DOI 10.1073/pnas.78.6.3473; CHAIDAROGLOU A, 1988, BIOCHEMISTRY-US, V27, P8338, DOI 10.1021/bi00422a008; CHANG CN, 1986, GENE, V44, P121; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; CHLEBOWSKI JF, 1972, J BIOL CHEM, V247, P6007; COLEMAN JE, 1983, J BIOL CHEM, V258, P386; COLEMAN JE, 1983, ADV ENZYMOL RELAT AR, V55, P351; DAYAN J, 1964, BIOCHIM BIOPHYS ACTA, V81, P620, DOI 10.1016/0926-6569(64)90154-3; DERBYSHIRE V, 1988, SCIENCE, V240, P199, DOI 10.1126/science.2832946; ENGSTROM L, 1962, BIOCHIM BIOPHYS ACTA, V56, P606, DOI 10.1016/0006-3002(62)90616-9; FERNLEY HN, 1966, NATURE, V212, P1435, DOI 10.1038/2121435a0; GAREN A, 1960, BIOCHIM BIOPHYS ACTA, V38, P470, DOI 10.1016/0006-3002(60)91282-8; GETTINS P, 1983, J BIOL CHEM, V258, P408; GETTINS P, 1983, J BIOL CHEM, V258, P396; GETTINS P, 1985, J BIOL CHEM, V260, P2875; HARRIS MI, 1968, J BIOL CHEM, V243, P5063; HOUGH E, 1989, NATURE, V338, P357, DOI 10.1038/338357a0; HULETT FM, 1991, J BIOL CHEM, V266, P1077; HULL WE, 1976, BIOCHEMISTRY-US, V15, P1547, DOI 10.1021/bi00652a028; KAM W, 1985, P NATL ACAD SCI USA, V82, P8715, DOI 10.1073/pnas.82.24.8715; KANEKO Y, 1987, GENE, V58, P137; KIM EE, 1990, CLIN CHIM ACTA, V186, P175, DOI 10.1016/0009-8981(90)90035-Q; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; KIRBY AJ, 1966, J AM CHEM SOC, V88, P1823, DOI 10.1021/ja00960a048; KO SHD, 1967, J AM CHEM SOC, V89, P7139, DOI 10.1021/ja01002a068; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; PLOCKE DJ, 1962, BIOCHEMISTRY-US, V1, P373, DOI 10.1021/bi00909a001; Reid T.W., 1971, ENZYMES, V4, P373; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARTZ JH, 1963, P NATL ACAD SCI USA, V49, P722, DOI 10.1073/pnas.49.5.722; SCHWARTZ JH, 1961, P NATL ACAD SCI USA, V47, P1996, DOI 10.1073/pnas.47.12.1996; SIMPSON RT, 1968, BIOCHEMISTRY-US, V7, P4343, DOI 10.1021/bi00852a029; SOWADSKI J M, 1983, Journal of Molecular Biology, V170, P575, DOI 10.1016/S0022-2836(83)80162-4; SOWADSKI JM, 1985, J MOL BIOL, V186, P417, DOI 10.1016/0022-2836(85)90115-9; THIEDE MA, 1988, P NATL ACAD SCI USA, V85, P319, DOI 10.1073/pnas.85.2.319; TRENTHAM DR, 1968, BIOCHEM J, V106, P455, DOI 10.1042/bj1060455; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WEISS MJ, 1986, P NATL ACAD SCI USA, V83, P7182, DOI 10.1073/pnas.83.19.7182; WILSON IB, 1964, J BIOL CHEM, V239, P4182; XU X, 1991, BIOCHEMISTRY-US, V30, P7789, DOI 10.1021/bi00245a018	55	19	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16244	16251						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1644810				2022-12-25	WOS:A1992JJ45800041
J	CORREAS, I; DIAZNIDO, J; AVILA, J				CORREAS, I; DIAZNIDO, J; AVILA, J			MICROTUBULE-ASSOCIATED PROTEIN-TAU IS PHOSPHORYLATED BY PROTEIN-KINASE-C ON ITS TUBULIN BINDING DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; ALZHEIMER-DISEASE; NEUROFIBRILLARY TANGLES; DEPENDENT KINASE; ANTIGENIC DETERMINANTS; REPEATED SEQUENCE; MOUSE-BRAIN; RAT-BRAIN; LOCALIZATION; IDENTIFICATION	We have analyzed the in vitro phosphorylation of tau protein by Ca2+/calmodulin-dependent protein kinase, protein kinase C, cAMP-dependent protein kinase, casein kinase II, and proline-directed serine/threonine protein kinase. These kinases phosphorylate tau protein in sites localized in different regions of the molecule, as determined by peptide mapping analyses. Focusing on the phosphorylation of tau by protein kinase C, it was calculated as an incorporation of 4 mol of phosphate/mol of tau. Limited proteolysis assays suggest that the phosphorylation sites could be located within the tubulin-binding domain. Direct phosphorylation of synthetic peptides corresponding to the cysteine-containing tubulin-binding region present in both fetal and adult tau isoforms demonstrates that serine 313 is modified by protein kinase C. Phosphorylation of the synthetic peptide by protein kinase C diminishes its binding to tubulin, as compared with the unphosphorylated peptide.			CORREAS, I (corresponding author), UNIV AUTONOMA MADRID, FAC CIENCIAS, CTR BIOL MOLEC, E-28049 MADRID, SPAIN.		Diaz-Nido, Javier/L-2371-2013; Avila, Jesus/I-2610-2015; Correas, Isabel/O-4061-2018	Diaz-Nido, Javier/0000-0002-0927-7925; Avila, Jesus/0000-0002-6288-0571; Correas, Isabel/0000-0002-2286-186X				ALCAZAR A, 1988, NEUROCHEM RES, V13, P829, DOI 10.1007/BF00970750; AOKI C, 1985, J NEUROSCI, V5, P2465; AVILA J, 1991, BIOCHEM J, V274, P621, DOI 10.1042/bj2740621; BANCHER C, 1989, BRAIN RES, V477, P90, DOI 10.1016/0006-8993(89)91396-6; BAUDIER J, 1987, J BIOL CHEM, V262, P17577; BAUDIER J, 1987, J BIOL CHEM, V262, P17584; BINDER LI, 1986, ANN NY ACAD SCI, V466, P145, DOI 10.1111/j.1749-6632.1986.tb38392.x; CLEVELAND DW, 1977, J MOL BIOL, V116, P227, DOI 10.1016/0022-2836(77)90214-5; CORREAS I, 1990, BIOCHEM J, V269, P61, DOI 10.1042/bj2690061; CORREAS I, 1991, ALZHEIMERS DISEASE : BASIC MECHANISMS, DIAGNOSIS AND THERAPEUTIC STRATEGIES, P199; DEDMAN JR, 1977, J BIOL CHEM, V252, P8415; DIAZNIDO J, 1988, MOL CELL BIOCHEM, V79, P73, DOI 10.1007/BF00229400; DIAZNIDO J, 1990, J NEUROCHEM, V54, P211, DOI 10.1111/j.1471-4159.1990.tb13303.x; DRUBIN DG, 1984, J CELL BIOL, V98, P1090, DOI 10.1083/jcb.98.3.1090; DRUBIN DG, 1986, J CELL BIOL, V103, P2739, DOI 10.1083/jcb.103.6.2739; ENNULAT DJ, 1989, J BIOL CHEM, V264, P5327; FLAMENT S, 1990, BRAIN RES, V516, P15, DOI 10.1016/0006-8993(90)90891-E; FRIEDRICH P, 1990, NEUROSCIENCE, V35, P1, DOI 10.1016/0306-4522(90)90115-K; GOEDERT M, 1989, EMBO J, V8, P393, DOI 10.1002/j.1460-2075.1989.tb03390.x; GOEDERT M, 1988, P NATL ACAD SCI USA, V85, P4051, DOI 10.1073/pnas.85.11.4051; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; GRUNDKEIQBAL I, 1986, J BIOL CHEM, V261, P6084; HERNANDEZ MA, 1987, J NEUROCHEM, V48, P84, DOI 10.1111/j.1471-4159.1987.tb13130.x; HERZOG W, 1978, EUR J BIOCHEM, V92, P1, DOI 10.1111/j.1432-1033.1978.tb12716.x; HIMMLER A, 1989, MOL CELL BIOL, V9, P1381, DOI 10.1128/MCB.9.4.1381; HIMMLER A, 1989, MOL CELL BIOL, V9, P1389, DOI 10.1128/MCB.9.4.1389; HOSHI M, 1988, EUR J BIOCHEM, V174, P225, DOI 10.1111/j.1432-1033.1988.tb14086.x; HOSHI M, 1987, FEBS LETT, V217, P237, DOI 10.1016/0014-5793(87)80670-1; IHARA Y, 1986, J BIOCHEM-TOKYO, V99, P1807, DOI 10.1093/oxfordjournals.jbchem.a135662; IQBAL K, 1989, P NATL ACAD SCI USA, V86, P5646, DOI 10.1073/pnas.86.14.5646; ISHIGURO K, 1988, J BIOCHEM-TOKYO, V104, P319, DOI 10.1093/oxfordjournals.jbchem.a122465; JACOBSON GR, 1973, J BIOL CHEM, V248, P6583; JOLY JC, 1990, BIOCHEMISTRY-US, V29, P8916, DOI 10.1021/bi00490a006; JOLY JC, 1989, J CELL BIOL, V109, P2289, DOI 10.1083/jcb.109.5.2289; KANAI Y, 1989, J CELL BIOL, V109, P1173, DOI 10.1083/jcb.109.3.1173; KELLY PT, 1987, J NEUROCHEM, V49, P1927, DOI 10.1111/j.1471-4159.1987.tb02456.x; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KOSE A, 1990, BRAIN RES, V518, P209, DOI 10.1016/0006-8993(90)90974-G; Kosik KS, 1990, CURR OPIN CELL BIOL, V2, P101, DOI 10.1016/S0955-0674(05)80038-9; KOSIK KS, 1989, NEURON, V2, P1389, DOI 10.1016/0896-6273(89)90077-9; KOSIK KS, 1988, NEURON, V1, P817, DOI 10.1016/0896-6273(88)90129-8; KOSIK KS, 1986, P NATL ACAD SCI USA, V83, P4044, DOI 10.1073/pnas.83.11.4044; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE G, 1988, SCIENCE, V239, P285, DOI 10.1126/science.3122323; LEE G, 1989, NEURON, V2, P1615, DOI 10.1016/0896-6273(89)90050-0; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LEWIS SA, 1988, SCIENCE, V242, P936, DOI 10.1126/science.3142041; LICHTENBERG B, 1988, NATURE, V334, P359, DOI 10.1038/334359a0; LINDWALL G, 1984, J BIOL CHEM, V259, P5301; LIPTON SA, 1989, TRENDS NEUROSCI, V12, P265, DOI 10.1016/0166-2236(89)90026-X; MACCIONI RB, 1989, ARCH BIOCHEM BIOPHYS, V275, P568, DOI 10.1016/0003-9861(89)90403-7; MACCIONI RB, 1988, EMBO J, V7, P1957, DOI 10.1002/j.1460-2075.1988.tb03033.x; MATTSON MP, 1988, BRAIN RES REV, V13, P179, DOI 10.1016/0165-0173(88)90020-3; MATTSON MP, 1988, J NEUROSCI, V8, P2087; NIETO A, 1988, BIOCHEM BIOPH RES CO, V154, P660, DOI 10.1016/0006-291X(88)90190-8; NUKINA N, 1986, J BIOCHEM-TOKYO, V99, P1541, DOI 10.1093/oxfordjournals.jbchem.a135625; OLWIN BB, 1983, METHOD ENZYMOL, V102, P148; PAPASOZOMENOS SC, 1987, CELL MOTIL CYTOSKEL, V8, P210, DOI 10.1002/cm.970080303; PIERRE M, 1983, BIOCHEM BIOPH RES CO, V115, P212, DOI 10.1016/0006-291X(83)90991-9; SCHULMAN H, 1984, J CELL BIOL, V99, P11, DOI 10.1083/jcb.99.1.11; SERRANO L, 1985, EUR J BIOCHEM, V153, P595, DOI 10.1111/j.1432-1033.1985.tb09342.x; STEINER B, 1990, EMBO J, V9, P3539, DOI 10.1002/j.1460-2075.1990.tb07563.x; TSUYAMA S, 1986, J BIOL CHEM, V261, P4110; WALSH MP, 1984, BIOCHEM J, V224, P117, DOI 10.1042/bj2240117; WICHE G, 1991, INT REV CYTOL, V124, P217; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4506, DOI 10.1073/pnas.85.12.4506; WOOD JG, 1986, P NATL ACAD SCI USA, V83, P4040, DOI 10.1073/pnas.83.11.4040; YAMAMOTO H, 1985, J NEUROCHEM, V44, P759, DOI 10.1111/j.1471-4159.1985.tb12880.x; YAMAMOTO H, 1983, J NEUROCHEM, V41, P1119, DOI 10.1111/j.1471-4159.1983.tb09060.x	70	163	165	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15721	15728						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1639808				2022-12-25	WOS:A1992JG11300072
J	DUBIK, D; SHIU, RPC				DUBIK, D; SHIU, RPC			MECHANISM OF ESTROGEN ACTIVATION OF C-MYC ONCOGENE EXPRESSION	ONCOGENE			English	Article							HUMAN-BREAST-CANCER; DEOXYRIBONUCLEIC-ACID BINDING; RAT PROLACTIN GENE; RESPONSIVE ELEMENT; TRANSCRIPTIONAL ACTIVATION; PROTO-ONCOGENE; SINGLE DOMAIN; DNA-BINDING; PS2 GENE; RECEPTOR	The estrogen receptor complex is a known trans-acting factor that regulates transcription of specific genes through an interaction with a specific estrogen-responsive cis-acting element (ERE). In previous studies we have shown that in estrogen-responsive human breast cancer cells estrogen rapidly activates c-myc expression. This activated expression occurs through enhanced transcription and does not require the synthesis of new protein intermediates; therefore, an ERE is present in the human c-myc gene regulatory region. To localize the ERE, constructs containing varying lengths of the c-myc 5'-flanking region ranging from - 2327 to + 25 (relative to the PI promoter) placed adjacent to the chloramphenicol acetyl transferase reporter gene (CAT) were prepared. They were used in transient transfection studies in MCF-7 and HeLa cells co-transfected with an estrogen receptor expression vector. These studies reveal that at] constructs containing the P2 promoter region exhibited estrogen-regulated CAT expression and that a 116-bp region upstream and encompassing the P2 TATA box is necessary for this activity. Analysis of this 116-bp region failed to identify a cis-acting element with sequences resembling the consensus ERE; however, co-transfection studies with mutant estrogen receptor expression vectors showed that the DNA-binding domain of the receptor is essential for estrogen-regulated CAT gene expression. We have also observed that anti-estrogen receptor complexes can weakly trans-activate from this 116-bp region but fail to do so from the ERE-containing ApoVLDLII-CAT construct. To explain these results we propose a new mechanism of estrogen trans-activation in the c-myc gene promoter.	UNIV MANITOBA, DEPT PHYSIOL, WINNIPEG R3E 0W3, MANITOBA, CANADA	University of Manitoba								BASERGA R, 1984, EXP CELL RES, V151, P1, DOI 10.1016/0014-4827(84)90349-5; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERRY M, 1989, P NATL ACAD SCI USA, V86, P1218, DOI 10.1073/pnas.86.4.1218; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; CALLAHAN R, 1989, JNCI-J NATL CANCER I, V81, P1780, DOI 10.1093/jnci/81.23.1780; CARSONJURICA MA, 1990, ENDOCR REV, V11, P201, DOI 10.1210/edrv-11-2-201; CATO ACB, 1988, MOL CELL BIOL, V8, P5323, DOI 10.1128/MCB.8.12.5323; CATTINI PA, 1987, NUCLEIC ACIDS RES, V15, P1297, DOI 10.1093/nar/15.3.1297; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DELLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P6497, DOI 10.1073/pnas.79.21.6497; DUBIK D, 1987, CANCER RES, V47, P6517; DUBIK D, 1988, J BIOL CHEM, V263, P12705; GARCIA I, 1989, CANCER RES, V49, P6675; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOWLEY PM, 1983, METHOD ENZYMOL, V101, P387; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; LANG JC, 1988, BRIT J CANCER, V58, P62; LIPP M, 1987, MOL CELL BIOL, V7, P1393, DOI 10.1128/MCB.7.4.1393; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARCU KB, 1988, CURR TOP MICROBIOL, V141, P253; MARCU KB, 1987, BIOESSAYS, V6, P28, DOI 10.1002/bies.950060108; MARIANICOSTANTINI R, 1988, CANCER RES, V48, P199; MARTINEZ E, 1987, EMBO J, V6, P3719, DOI 10.1002/j.1460-2075.1987.tb02706.x; NUNEZ AM, 1989, EMBO J, V8, P823, DOI 10.1002/j.1460-2075.1989.tb03443.x; PENTECOST BT, 1990, MOL ENDOCRINOL, V4, P1000, DOI 10.1210/mend-4-7-1000; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; REMMERS EF, 1986, EMBO J, V5, P899, DOI 10.1002/j.1460-2075.1986.tb04301.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTOS GF, 1988, J BIOL CHEM, V263, P9565; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SLATER EP, 1990, MOL ENDOCRINOL, V4, P604, DOI 10.1210/mend-4-4-604; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; WALKER P, 1984, NUCLEIC ACIDS RES, V12, P8611, DOI 10.1093/nar/12.22.8611; WATERMAN ML, 1988, MOL ENDOCRINOL, V2, P14, DOI 10.1210/mend-2-1-14; WATSON PH, 1991, CANCER RES, V51, P3996; WU X, 1991, 73RD END SOC PROGR A	43	282	288	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1992	7	8					1587	1594						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1630819				2022-12-25	WOS:A1992JE81300015
J	EYCHENE, A; BARNIER, JV; APIOU, F; DUTRILLAUX, B; CALOTHY, G				EYCHENE, A; BARNIER, JV; APIOU, F; DUTRILLAUX, B; CALOTHY, G			CHROMOSOMAL ASSIGNMENT OF 2 HUMAN B-RAF(RMIL) PROTOONCOGENE LOCI - B-RAF-1 ENCODING THE P94(BRAF RMIL) AND B-RAF-2, A PROCESSED PSEUDOGENE	ONCOGENE			English	Note							RAF FAMILY; C-MIL; B-RAF; KINASE; TRANSDUCTION; EXPRESSION; RETROVIRUS; SEQUENCE; GENES; VIRUS	The B-raf gene is the human homolog of the avian c-Rmil proto-oncogene encoding a 94-kDa serine/threonine kinase detected in avian cells. We have previously shown that this protein contains amino-terminal sequences not found in other proteins of the mil/raf gene family. These sequences are encoded by three exons in the avian genome. We report that these three exons are conserved in the human B-raf gene and that they encode an amino acid sequence similar to that of the avian c-Rmil gene, indicating that in both avian and mammalian species the product of the B-raf/c-Rmil gene is a 94-kDa protein. We also identified two human B-raf loci: B-raf-1, located on chromosome 7q34, which encodes the functional B-raf/Rmil gene product, and B-raf-2, an inactive processed pseudogene located on chromosome Xq13.	CTR UNIV ORSAY,INST CURIE,CNRS,URA 1443,F-91405 ORSAY,FRANCE; INST CURIE,CNRS,URA 620,F-75231 PARIS 05,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie			Eychene, Alain/M-8838-2017	EYCHENE, Alain/0000-0002-6818-7225				BONNER T, 1984, SCIENCE, V223, P71, DOI 10.1126/science.6691137; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; EYCHENE A, 1989, NUCLEIC ACIDS RES, V17, P1250, DOI 10.1093/nar/17.3.1250; EYCHENE A, 1992, IN PRESS ONCOGENE; FELDER MP, 1991, J VIROL, V65, P3633, DOI 10.1128/JVI.65.7.3633-3640.1991; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; HUEBNER K, 1986, P NATL ACAD SCI USA, V83, P3934, DOI 10.1073/pnas.83.11.3934; IKAWA S, 1988, MOL CELL BIOL, V8, P2651, DOI 10.1128/MCB.8.6.2651; LEMIEUX N, 1992, IN PRESS CYTOGENET C; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; Maniatis T, 1989, DECONTAMINATION DILU; MARX M, 1988, EMBO J, V7, P3369, DOI 10.1002/j.1460-2075.1988.tb03209.x; RAPP UR, 1991, ONCOGENE, V6, P495; REEVES BR, 1989, ONCOGENE, V4, P373; SANGER F, 1981, SCIENCE, V214, P1205, DOI 10.1126/science.7302589; SITHANANDAM G, 1990, ONCOGENE, V5, P1775; STORM SM, 1990, ONCOGENE, V5, P345; VANIN EF, 1984, BIOCHIM BIOPHYS ACTA, V782, P231, DOI 10.1016/0167-4781(84)90057-5; VIEGASPEQUIGNOT E, 1978, ANN GENET-PARIS, V21, P122	19	38	43	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1992	7	8					1657	1660						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1630826				2022-12-25	WOS:A1992JE81300025
J	BURANT, CF; TAKEDA, J; BROTLAROCHE, E; BELL, GI; DAVIDSON, NO				BURANT, CF; TAKEDA, J; BROTLAROCHE, E; BELL, GI; DAVIDSON, NO			FRUCTOSE TRANSPORTER IN HUMAN SPERMATOZOA AND SMALL-INTESTINE IS GLUT5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GLUCOSE TRANSPORTER; LOCALIZATION; ERYTHROCYTE	We recently reported that the glucose transporter isoform, GLUT5, is expressed on the brush border membrane of human small intestinal enterocytes (Davidson, N. O., Hausman, A. M. L., Ifkovits, C. A., Buse, J. B., Gould, G. W., Burant, C. F., and Bell, G. I. (1992) Am. J. Physiol. 262, C795-C800). To define its role in sugar transport, human GLUT5 was expressed in Xenopus oocytes and its substrate specifiicity and kinetic properties determined. GLUT5 exhibits selectivity for fructose transport, as determined by inhibition studies, with a K(m) of 6 mM. In addition, fructose transport by GLUT5 is not inhibited by cytochalasin B, a competitive inhibitor of facilitative glucose transporters. RNA and protein blotting studies showed the presence of high levels of GLUT5 mRNA and protein in human testis and spermatozoa, and immunocytochemical studies localize GLUT5 to the plasma membrane of mature spermatids and spermatozoa. The biochemical properties and tissue distribution of GLUT5 are consistent with a physiological role for this protein as a fructose transporter.	UNIV CHICAGO, DEPT BIOCHEM & MOLEC BIOL, CHICAGO, IL 60637 USA; UNIV CHICAGO, HOWARD HUGHES MED INST, CHICAGO, IL 60637 USA; INSERM, U178, F-94807 VILLEJUIF, FRANCE	University of Chicago; Howard Hughes Medical Institute; University of Chicago; Institut National de la Sante et de la Recherche Medicale (Inserm)	BURANT, CF (corresponding author), UNIV CHICAGO, DEPT MED, 5841 S MARYLAND AVE, MC1027, CHICAGO, IL 60637 USA.		Burant, Charles/GPC-5690-2022	Burant, Charles/0000-0001-9189-5003	NHLBI NIH HHS [HL-02166] Funding Source: Medline; NIDDK NIH HHS [DK-42086, DK-20595] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K04HL002166] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020595, P30DK042086] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAUR H, 1977, EUR J BIOCHEM, V74, P397, DOI 10.1111/j.1432-1033.1977.tb11404.x; BROWN CR, 1983, J CELL BIOL, V96, P256, DOI 10.1083/jcb.96.1.256; BURANT CF, 1991, RECENT PROG HORM RES, V47, P343; CARRUTHERS A, 1990, PHYSIOL REV, V70, P1135, DOI 10.1152/physrev.1990.70.4.1135; DAVIDSONNO, 1992, AM J PHYSIOL, V262, pC795; GLANDER HJ, 1978, ANDROLOGIA, V10, P69; GOULD GW, 1991, BIOCHEMISTRY-US, V30, P5139, DOI 10.1021/bi00235a004; Greep, 1977, HISTOLOGY, P979; KAYANO T, 1990, J BIOL CHEM, V265, P13276; KING APJ, 1991, BIOCHEMISTRY-US, V30, P11546, DOI 10.1021/bi00113a009; ORCI L, 1989, SCIENCE, V245, P295, DOI 10.1126/science.2665080; PETERSON RN, 1977, BIOL REPROD, V17, P198, DOI 10.1095/biolreprod17.2.198; PETERSON RN, 1975, HUMAN SEMEN FERTILIT, P176; PTERSON RN, 1977, FERTIL STERIL, V28, P257; ROGERS BJ, 1990, BIOL REPROD, V43, P1064, DOI 10.1095/biolreprod43.6.1064; SHAFRIR E, 1991, NESTLE NUTR WORKS SE, V25, P131; SIGRISTNELSON K, 1974, BIOCHIM BIOPHYS ACTA, V367, P179; THORENS B, 1990, AM J PHYSIOL, V259, pC279; THORENS B, 1990, AM J PHYSIOL, V259, pC286; WRIGHT EM, 1991, J CLIN INVEST, V88, P1435, DOI 10.1172/JCI115451	20	446	454	0	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14523	14526						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634504				2022-12-25	WOS:A1992JF08800003
J	BUSSOLINO, F; SIRONI, M; BOCCHIETTO, E; MANTOVANI, A				BUSSOLINO, F; SIRONI, M; BOCCHIETTO, E; MANTOVANI, A			SYNTHESIS OF PLATELET-ACTIVATING-FACTOR BY POLYMORPHONUCLEAR NEUTROPHILS STIMULATED WITH INTERLEUKIN-8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; PERIPHERAL-BLOOD GRANULOCYTES; PROTEIN KINASE-C; ENDOTHELIAL-CELLS; DE-GRANULATION; FACTOR PAF; FUNCTIONAL EXPRESSION; HUMAN-MONOCYTES; FACTOR-ALPHA; RELEASE	Human interleukin-8 (IL-8) was evaluated for its capability to induce the synthesis and release of platelet-activating factor (PAF) from human polymorphonuclear neutrophils (PMN). IL-8 promotes in a dose-dependent fashion (1-100 ng/ml) a rapid synthesis of PAF, which is only partially released. The synthesis of PAF is preceded by the activation of acetyl-CoA: 1-alkyl-2-lyso-sn-glycero-3-phosphocholine acetyltransferase, suggesting that IL-8 activates the "remodeling pathway" of PAF synthesis. By thin layer chromatography and reverse-phase high pressure liquid chromatography, we demonstrated that PAF synthesized by human PMN stimulated with IL-8 is heterogeneous: the 2-acetylated phospholipids having the biological and physicochemical characteristics of PAF include the 1-0-alkyl form, which is produced in large extent (51%), and the 1-acyl form (20%). The analysis of the individual molecular species of radyl chain indicated nine peaks, 16:0 and 18:0 being the predominant forms. These results identify PAF as a direct product of IL-8 stimulation in PMN.	IST RIC FARMACOL MARIO NEGRI,I-20100 MILAN,ITALY	Istituto di Ricerche Farmacologiche Mario Negri IRCCS	BUSSOLINO, F (corresponding author), DIPARTIMENTO GENET BIOL & CHIM MED,VIA SANTENA 5 BIS,I-10126 TURIN,ITALY.		Mantovani, Alberto/HCI-7449-2022; Bussolino, Federico/AES-3951-2022; Sironi, Marina/AAB-5757-2020; Bussolino, Federico/K-2500-2016	Mantovani, Alberto/0000-0001-5578-236X; Sironi, Marina/0000-0002-3342-1149; Bussolino, Federico/0000-0002-5348-1341				BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; BAULDRY SA, 1991, J IMMUNOL, V146, P1277; BAZZONI F, 1991, J EXP MED, V173, P771, DOI 10.1084/jem.173.3.771; BETZ SJ, 1980, J IMMUNOL, V125, P2756; BLANK ML, 1982, RES COMMUN CHEM PATH, V38, P3; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRAQUET P, 1987, PHARMACOL REV, V39, P97; BUSSOLINO F, 1986, J CLIN INVEST, V77, P2027, DOI 10.1172/JCI112532; BUSSOLINO F, 1989, J BIOL CHEM, V264, P21711; BUSSOLINO F, 1986, J BIOL CHEM, V261, P6502; CAMUSSI G, 1987, J EXP MED, V166, P1390, DOI 10.1084/jem.166.5.1390; CAMUSSI G, 1989, EUR J BIOCHEM, V182, P661, DOI 10.1111/j.1432-1033.1989.tb14876.x; CAMUSSI G, 1981, IMMUNOLOGY, V42, P191; CAROLAN EJ, 1990, J IMMUNOL, V145, P2561; CHILTON FH, 1982, J BIOL CHEM, V257, P5402; CHILTON FH, 1988, J BIOL CHEM, V263, P5260; COLOTTA F, 1987, J EXP MED, V165, P1224, DOI 10.1084/jem.165.4.1224; DAHINDEN CA, 1989, J EXP MED, V170, P1787, DOI 10.1084/jem.170.5.1787; DEMOPOULOS CA, 1979, J BIOL CHEM, V254, P9355; DENICHILO MO, 1991, J BIOL CHEM, V266, P4896; DUBOIS C, 1989, J IMMUNOL, V143, P964; DUBRAVEC DB, 1990, P NATL ACAD SCI USA, V87, P6758, DOI 10.1073/pnas.87.17.6758; FURUTA R, 1989, J BIOCHEM-TOKYO, V106, P436, DOI 10.1093/oxfordjournals.jbchem.a122870; GOETZL EJ, 1980, BIOCHEM BIOPH RES CO, V94, P881, DOI 10.1016/0006-291X(80)91317-0; GUPTA CM, 1977, P NATL ACAD SCI USA, V74, P4315, DOI 10.1073/pnas.74.10.4315; HANAHAN DJ, 1980, J BIOL CHEM, V255, P5514; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; LACASSE C, 1991, J LEUKOCYTE BIOL, V49, P245, DOI 10.1002/jlb.49.3.245; LEE TC, 1984, J BIOL CHEM, V259, P5526; LEE TH, 1984, J CLIN INVEST, V74, P1922, DOI 10.1172/JCI111612; LEVI R, 1989, BIOCHEM BIOPH RES CO, V161, P1341, DOI 10.1016/0006-291X(89)91390-9; LINDEMANN A, 1989, J CLIN INVEST, V83, P1308, DOI 10.1172/JCI114016; LOPEZ AF, 1986, J CLIN INVEST, V78, P1220, DOI 10.1172/JCI112705; MCINTYRE TM, 1987, J BIOL CHEM, V262, P15370; MIZOGUCHI Y, 1991, J GASTROEN HEPATOL, V6, P283, DOI 10.1111/j.1440-1746.1991.tb01479.x; MUELLER HW, 1983, J BIOL CHEM, V258, P6213; MUELLER HW, 1984, J BIOL CHEM, V259, P4554; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NATHAN CF, 1989, BLOOD, V73, P301; OFLAHERTY JT, 1983, RES COMMUN CHEM PATH, V39, P291; OFLAHERTY JT, 1981, AM J PATHOL, V105, P107; OFLAHERTY JT, 1985, J CELL PHYSIOL, V122, P229, DOI 10.1002/jcp.1041220211; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PACCAUD JP, 1990, BIOCHEM BIOPH RES CO, V166, P187, DOI 10.1016/0006-291X(90)91929-M; PATTON GM, 1982, J LIPID RES, V23, P190; POUBELLE PE, 1991, IMMUNOLOGY, V72, P181; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; RAMESHA CS, 1987, J IMMUNOL, V138, P1559; RICHES DWH, 1990, J IMMUNOL, V145, P3062; ROUBIN R, 1987, CLIN EXP IMMUNOL, V70, P484; SALEM P, 1990, J IMMUNOL, V144, P1338; SATOUCHI K, 1985, BIOCHEM BIOPH RES CO, V128, P1409, DOI 10.1016/0006-291X(85)91097-6; SHAAFI RI, 1988, PROG ALLERGY, V42, P1; SHAW JO, 1981, J IMMUNOL, V127, P1250; SISSON JH, 1987, J IMMUNOL, V138, P3918; SNYDER F, 1987, PLATELET ACTIVATING; STEWART AG, 1990, P NATL ACAD SCI USA, V87, P3251; TESSNER TG, 1987, J BIOL CHEM, V262, P12660; TESSNER TG, 1989, J BIOL CHEM, V264, P4794; TETTA C, 1990, INT ARCH ALLER A IMM, V91, P244, DOI 10.1159/000235124; TRIGGIANI M, 1990, J IMMUNOL, V144, P4773; VALONE FH, 1988, J IMMUNOL, V141, P3945; WAKU K, 1972, J BIOCHEM-TOKYO, V72, P149, DOI 10.1093/oxfordjournals.jbchem.a129880; WANG JM, 1987, J IMMUNOL, V138, P1469; WEINTRAUB ST, 1985, BIOCHEM BIOPH RES CO, V129, P868, DOI 10.1016/0006-291X(85)91972-2; WEISBART RH, 1985, NATURE, V314, P361, DOI 10.1038/314361a0; WIRTHMUELLER U, 1991, BIOCHEM BIOPH RES CO, V176, P972, DOI 10.1016/0006-291X(91)90377-J; WIRTHMUELLER U, 1989, J IMMUNOL, V142, P3213; WORTHEN GS, 1988, J IMMUNOL, V140, P3553; YAMAZAKI M, 1989, P NATL ACAD SCI USA, V86, P5791, DOI 10.1073/pnas.86.15.5791; ZAVOICO GB, 1989, J IMMUNOL, V142, P3993	72	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14598	14603						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634507				2022-12-25	WOS:A1992JF08800019
J	NOHARA, K; SUZUKI, M; INAGAKI, F; SANO, T; KAYA, K				NOHARA, K; SUZUKI, M; INAGAKI, F; SANO, T; KAYA, K			A NOVEL DISIALOGANGLIOSIDE IN RAT SPLEEN LYMPHOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES; GANGLIOSIDES; DIFFERENTIATION; HL-60; LIVER; GD3	A novel ganglioside has been identified as the predominant disialoganglioside of the lymphocytes prepared from rat spleen. The ganglioside was isolated from rat spleen and characterized by compositional analysis, methylation analysis, sialidase hydrolysis, proton NMR spectroscopy, and negative ion fast atom bombardment mass spectrometry. The structure was determined as follows. [GRAPHICS] This ganglioside is a unique derivative of N-acetyllactosaminyl-G(M1). The three monosialogangliosides containing N-acetyllactosaminyl-G(M1) structure, which had been originally isolated from rat spleen (Nohara, K., Suzuki, M., Inagaki, F., Ito, H., and Kaya, K. (1990) J. Biol. Chem. 265, 14335-14339), were also found in the lymphocytes and were hardly detected in the spleen remnant tissue depleted of single cells. On the other hand, G(D1C)(NeuGc,NeuGC) (IV3(NeuGc-alpha-2-8NeuGc)-Gg4Cer), the overwhelmingly predominant gangLioside of rat thymocytes (Nohara, K., Suzuki, M., Inagaki, F., and Kaya, K. (1991) J. Biochem. (Tokyo) 110, 274-278), was demonstrated to be only a minor component of the gangliosides of the spleen Lymphocytes. These results suggested that G(D1c) is characteristic for the immature T lineage lymphoid cells and the gangliosides having lactosaminyl-G(M1) structure are specific for other populations of the lymphocytes in rat.	NATL INST ENVIRONM STUDIES,DIV ENVIRONM CHEM,YATABE,IBARAKI 305,JAPAN; TOKYO METROPOLITAN INST MED SCI,DEPT MEMBRANE BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN; TOKYO METROPOLITAN INST MED SCI,DEPT MOLEC PHYSIOL,TOKYO 113,JAPAN	National Institute for Environmental Studies - Japan; Tokyo Metropolitan Institute of Medical Science; Tokyo Metropolitan Institute of Medical Science	NOHARA, K (corresponding author), NATL INST ENVIRONM STUDIES,DIV ENVIRONM HLTH SCI,YATABE,IBARAKI 305,JAPAN.							BARTOSZEWICZ Z, 1986, CARBOHYD RES, V151, P77, DOI 10.1016/S0008-6215(00)90331-8; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HBU S, 1986, ZOKU SEIKAGAKU JIKKE, V5, P169; HERSEY P, 1989, CELL IMMUNOL, V119, P263, DOI 10.1016/0008-8749(89)90243-8; INAGAKI F, 1987, FEBS LETT, V212, P91, DOI 10.1016/0014-5793(87)81563-6; MARCUS DM, 1984, MOL IMMUNOL, V21, P1083, DOI 10.1016/0161-5890(84)90118-4; NAKAMURA K, 1991, J BIOCHEM-TOKYO, V110, P832, DOI 10.1093/oxfordjournals.jbchem.a123667; NOHARA K, 1990, J BIOCHEM, V108, P684, DOI 10.1093/oxfordjournals.jbchem.a123263; NOHARA K, 1990, J BIOL CHEM, V265, P14335; NOHARA K, 1991, J BIOCHEM-TOKYO, V110, P274, DOI 10.1093/oxfordjournals.jbchem.a123570; NOHARAUCHIDA K, 1987, J BIOCHEM-TOKYO, V102, P923, DOI 10.1093/oxfordjournals.jbchem.a122133; NOJIRI H, 1986, P NATL ACAD SCI USA, V83, P782, DOI 10.1073/pnas.83.3.782; NOJIRI H, 1988, J BIOL CHEM, V263, P7443; OFFNER H, 1987, J IMMUNOL, V139, P3295; ROKUKAWA C, 1982, J BIOCHEM-TOKYO, V92, P1481, DOI 10.1093/oxfordjournals.jbchem.a134072; SVENNERHOLM L, 1957, BIOCHIM BIOPHYS ACTA, V24, P604, DOI 10.1016/0006-3002(57)90254-8; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; WELTE K, 1987, J IMMUNOL, V139, P1763; YU RK, 1970, J LIPID RES, V11, P506	19	14	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14982	14986						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634537				2022-12-25	WOS:A1992JF08800072
J	BRUGGER, CH; STALLWOOD, D; PAUL, S				BRUGGER, CH; STALLWOOD, D; PAUL, S			ISOLATION OF A LOW-MOLECULAR MASS VASOACTIVE-INTESTINAL-PEPTIDE BINDING-PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT LUNG MEMBRANES; ADENYLATE-CYCLASE SYSTEM; HYDRODYNAMIC CHARACTERIZATION; POLYPEPTIDE VIP; RECEPTORS; SOLUBILIZATION; NEUROPEPTIDES; AUTOANTIBODY; SECRETIN; FAMILY	A vasoactive intestinal peptide (VIP) binding protein was purified in active form by detergent solubilization of lung membranes, gel filtration, VIP-Sepharose affinity chromatography, reverse phase high performance liquid chromatography, and anion exchange chromatography. The mass of this protein was estimated at 18 kDa by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and 17 kDa by gel filtration. The binding of VIP by this protein was inhibited by Mg2+, covalent cross-linking of [Tyr10-I-125]VIP to the protein produced two radioactive bands at 22 and 26 kDa identified by electrophoresis, and the purified protein exhibited saturable and high affinity binding of VIP and the related neuropeptide, rat growth hormone releasing factor.	UNIV NEBRASKA,MED CTR,DEPT PHARMACOL,OMAHA,NE 68198; UNIV NEBRASKA,MED CTR,DEPT BIOCHEM,OMAHA,NE 68198; UNIV NEBRASKA,MED CTR,DEPT INTERNAL MED,OMAHA,NE 68198	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K04HL002217, R01HL044126, R01HL040348] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL40348, HL44126, HL02217] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUGIGIER S, 1987, ANN NY ACAD SCI, V493, P579; BISSONNETTE BM, 1984, AM J PHYSIOL, V246, pG710, DOI 10.1152/ajpgi.1984.246.6.G710; CHATELAIN P, 1983, PFLUG ARCH EUR J PHY, V397, P100, DOI 10.1007/BF00582046; COUVINEAU A, 1986, J BIOL CHEM, V261, P4482; COUVINEAU A, 1986, J NEUROCHEM, V47, P1461; COUVINEU A, 1990, J BIOL CHEM, V22, P13386; DICKINSON KEJ, 1986, PEPTIDES, V7, P791, DOI 10.1016/0196-9781(86)90097-5; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; ELBATTARI A, 1988, J BIOL CHEM, V263, P17685; MALENCIK DA, 1983, BIOCHEMISTRY-US, V22, P1995, DOI 10.1021/bi00277a040; MALHOTRA RK, 1988, J BIOL CHEM, V263, P2123; MITRIUS JC, 1985, ADV CYCLIC NUCL PROT, V19, P57; NGUYEN TD, 1986, BIOCHEMISTRY-US, V25, P361, DOI 10.1021/bi00350a013; OETTLING G, 1990, CANCER LETT, V50, P203, DOI 10.1016/0304-3835(90)90266-Z; PATTHI S, 1987, J BIOL CHEM, V262, P15740; PAUL S, 1986, PEPTIDES, V7, P147, DOI 10.1016/0196-9781(86)90177-4; PAUL S, 1987, J BIOL CHEM, V262, P158; PAUL S, 1989, SCIENCE, V244, P1158, DOI 10.1126/science.2727702; PAUL S, 1990, J IMMUNOL, V145, P1196; PAUL S, 1988, ANN NY ACAD SCI, V547, P282; PROVOW S, 1987, ENDOCRINOLOGY, V120, P2442, DOI 10.1210/endo-120-6-2442; ROBBERECHT P, 1981, BIOCHIM BIOPHYS ACTA, V678, P76, DOI 10.1016/0304-4165(81)90049-0; ROSSELIN G, 1986, PEPTIDES, V7, P89, DOI 10.1016/0196-9781(86)90170-1; SAID SI, 1984, PEPTIDES, V5, P143, DOI 10.1016/0196-9781(84)90197-9; SAID SI, 1987, AM REV RESPIR DIS, V136, pS52, DOI 10.1164/ajrccm/136.6_Pt_2.S52; SCHRAMM M, 1984, SCIENCE, V225, P1350, DOI 10.1126/science.6147897; SVOBODA M, 1988, EUR J BIOCHEM, V176, P707, DOI 10.1111/j.1432-1033.1988.tb14334.x; WONG YH, 1989, J NEUROCHEM, V52, P999, DOI 10.1111/j.1471-4159.1989.tb01840.x; WOOD CL, 1985, J BIOL CHEM, V260, P1243; ZYSK JR, 1986, J BIOL CHEM, V261, P6781	30	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					18358	18362						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1655745				2022-12-25	WOS:A1991GG55300097
J	FROST, RA; TSENG, L				FROST, RA; TSENG, L			INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN-1 IS PHOSPHORYLATED BY CULTURED HUMAN ENDOMETRIAL STROMAL CELLS AND MULTIPLE PROTEIN-KINASES INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN AMNIOTIC-FLUID; IGF-I; MONOCLONAL-ANTIBODIES; FOLLICULAR-FLUID; CARRIER PROTEIN; PREGNANCY; SERUM; IDENTIFICATION; HORMONE; RADIOIMMUNOASSAY	The insulin-like growth factor-binding protein IGF-BP1 is a major secretory protein of human endometrial stromal cells decidualized in culture. Anion exchange chromatography and nondenaturing gel electrophoresis showed IGF-BP1 to exist in five electrophoretically and chromatographically distinct isoforms. IGF-BP1 variants migrated as a quintet on nondenaturing polyacrylamide gels and as a single band (28 kDa) on sodium dodecyl sulfate-polyacrylamide gels. Alkaline phosphatase treatment reduced the IGF-BP1 variants to a single band. Cells incubated with [P-32]orthophosphate for 12 h secreted four P-32-labeled IGF-BP1 phosphovariants, and their migration coincided with those bands that were eliminated by alkaline phosphatase treatment. In cells treated with medroxyprogesterone acetate and relaxin, the concentration of phosphorylated IGF-BP1 was increased dramatically as compared with controls. All the phosphovariants were confirmed to be IGF-BP1 by their ability to be supershifted on nondenaturing polyacrylamide gels after binding a monoclonal antibody to IGF-BP1. Thin layer electrophoresis of IGF-BP1 acid hydrolysates showed IGF-BP1 to be phosphorylated exclusively on serine. Non-phosphorylated IGF-BP1 was phosphorylated by the catalytic subunit of the cAMP-dependent protein kinase and casein kinase II in vitro. This suggests that IGF-BP1 may be a substrate of multiple protein kinases in vivo.	SUNY STONY BROOK, HLTH SCI CTR, DEPT OBSTET & GYNECOL, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	FROST, RA (corresponding author), SUNY STONY BROOK, HLTH SCI CTR, PROGRAM CELLULAR & DEV BIOL, LIFE SCI 350, STONY BROOK, NY 11794 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD019247] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-19247] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BACHRACH LK, 1991, ENDOCRINOLOGY, V128, P1967, DOI 10.1210/endo-128-4-1967; Baxter R C, 1989, Prog Growth Factor Res, V1, P49, DOI 10.1016/0955-2235(89)90041-0; BELL SC, 1985, BRIT J OBSTET GYNAEC, V92, P793, DOI 10.1111/j.1471-0528.1985.tb03048.x; BELL SC, 1989, AM J REPROD IMMUNOL, V20, P87, DOI 10.1111/j.1600-0897.1989.tb00645.x; BELL SC, 1991, J CLIN ENDOCR METAB, V72, P1014, DOI 10.1210/jcem-72-5-1014; BELL SC, 1985, J REPROD FERTIL, V74, P261; BELL SC, 1986, BRIT J OBSTET GYNAEC, V93, P909, DOI 10.1111/j.1471-0528.1986.tb08007.x; BLUM WF, 1989, ENDOCRINOLOGY, V125, P766, DOI 10.1210/endo-125-2-766; BUSBY WH, 1988, J BIOL CHEM, V263, P14203; BUSBY WH, 1989, ENDOCRINOLOGY, V125, P773, DOI 10.1210/endo-125-2-773; CHOCHINOV RH, 1976, J CLIN ENDOCR METAB, V42, P983, DOI 10.1210/jcem-42-5-983; CLEMMONS DR, 1991, MODERN CONCEPTS INSU, P475; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DEMELLOW JSM, 1988, BIOCHEM BIOPH RES CO, V156, P199, DOI 10.1016/S0006-291X(88)80824-6; ELGIN RG, 1987, P NATL ACAD SCI USA, V84, P3254, DOI 10.1073/pnas.84.10.3254; FEIGE JJ, 1989, P NATL ACAD SCI USA, V86, P3174, DOI 10.1073/pnas.86.9.3174; FROST RA, 1990, 72ND ANN M END SOC B, P72; GIUDICE LC, 1990, J CLIN ENDOCR METAB, V71, P1330, DOI 10.1210/jcem-71-5-1330; GIUDICE LC, 1990, J CLIN ENDOCR METAB, V71, P806, DOI 10.1210/jcem-71-4-806; HALTIWANGER RS, 1990, J BIOL CHEM, V265, P2563; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; HOSSENLOPP P, 1986, ANAL BIOCHEM, V154, P138, DOI 10.1016/0003-2697(86)90507-5; HOSSENLOPP P, 1986, FEBS LETT, V208, P439, DOI 10.1016/0014-5793(86)81065-1; HOSSENLOPP P, 1990, J CLIN ENDOCR METAB, V71, P797, DOI 10.1210/jcem-71-4-797; HUHTALA ML, 1986, BIOCHEM BIOPH RES CO, V141, P263, DOI 10.1016/S0006-291X(86)80363-1; HUI HZ, 1990, J CLIN ENDOCR METAB, V71, P889; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; KNAUER DJ, 1980, P NATL ACAD SCI-BIOL, V77, P7252, DOI 10.1073/pnas.77.12.7252; KOISTINEN R, 1987, CLIN CHIM ACTA, V164, P293, DOI 10.1016/0009-8981(87)90304-4; LEE YL, 1988, MOL ENDOCRINOL, V2, P404, DOI 10.1210/mend-2-5-404; LIU HC, 1979, ENDOCRINOLOGY, V104, P1674, DOI 10.1210/endo-104-6-1674; LUO K, 1990, ONCOGENE, V5, P921; OSHEROFF PL, 1990, J BIOL CHEM, V265, P9396; POVOA G, 1984, EUR J BIOCHEM, V144, P199, DOI 10.1111/j.1432-1033.1984.tb08449.x; RASHIDBAIGI A, 1985, J BIOL CHEM, V260, P8514; Rechler M. M., 1990, PEPTIDE GROWTH FACTO, P263; RUTANEN EM, 1988, BIOCHEM BIOPH RES CO, V152, P208, DOI 10.1016/S0006-291X(88)80701-0; RUTANEN EM, 1982, AM J OBSTET GYNECOL, V144, P460, DOI 10.1016/0002-9378(82)90254-X; RUTANEN EM, 1986, ENDOCRINOLOGY, V118, P1067, DOI 10.1210/endo-118-3-1067; SCOTT CD, 1985, ENDOCRINOLOGY, V116, P1094, DOI 10.1210/endo-116-3-1094; SHIMASAKI S, 1990, J BIOL CHEM, V265, P2198; SMITH JA, 1987, CURRENT PROTOCOLS MO; TABIBZADEH SS, 1989, J IMMUNOL, V142, P3134; WAITES GT, 1990, J ENDOCRINOL, V124, P333, DOI 10.1677/joe.0.1240333; ZAPF J, 1975, ARCH BIOCHEM BIOPHYS, V168, P638, DOI 10.1016/0003-9861(75)90296-9	45	90	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					18082	18088						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1655736				2022-12-25	WOS:A1991GG55300058
J	GARDLIK, S; RAJAGOPALAN, KV				GARDLIK, S; RAJAGOPALAN, KV			THE MECHANISMS OF INACTIVATION OF SULFITE OXIDASE BY PERIODATE AND ARSENITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLYBDENUM COFACTOR; DEMOLYBDOSULFITE OXIDASE; INVITRO RECONSTITUTION; THIONE PHOTOCHEMISTRY; XANTHINE-OXIDASE; ALPHA-DITHIONE; RAT-LIVER; MOLYBDOPTERIN; PURIFICATION; DINUCLEOTIDE	The inactivation of sulfite oxidase, a molybdoenzyme containing the Mo cofactor, by arsenite and periodate was investigated. In contrast to ferricyanide (Gardlik, S., and Rajagopalan, K. V. (1991) J. Biol. Chem. 266, 4889-4895), neither of these reagents causes oxidation of the pterin ring of the Mo cofactor. Instead, inactivation by these reagents appears to involve attack on sulfhydryl groups at the active site of the enzyme. The inactivation of sulfite oxidase by arsenite was shown to be dependent on the presence Of O2 and on the enzymatic oxidation of arsenite to arsenate. The inactivation was preventable by the presence of sulfite, or by the use of cytochrome c as the electron acceptor instead Of O2. It is concluded that inactivation by arsenite is the result of arsenite displacement of Mo during enzymatic oxidation of arsenite to arsenate, when Mo transiently breaks its bond to protein or molybdopterin sulfhydryl(s) in order to provide a site for transfer of electrons to O2. Data indicate that arsenite is properly oriented to displace Mo only once every 20,800 turnovers, thus accounting for the slow rate of inactivation by this reagent. Inactivation of sulfite oxidase by periodate is believed to occur as the result of direct attack of periodate on the thiolate ligands of Mo, either those of the protein and/or molybdopterin, leading to Mo loss. Treatment of enzyme with even low levels of periodate resulted in loss of Mo and both sulfite:cytochrome c and sulfite:O2 activities. Molybdopterin of periodate-inactivated enzyme retained the ability to reconstitute nitrate reductase apoprotein in nit-1 extracts and the ability to reduce dichlorophenolindophenol, indicating that the pterin ring had not been oxidized.			GARDLIK, S (corresponding author), DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA.				NIGMS NIH HHS [GM00091] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; AMY NK, 1979, J BACTERIOL, V140, P114, DOI 10.1128/JB.140.1.114-124.1979; COHEN HJ, 1971, J BIOL CHEM, V246, P374; COHEN HJ, 1971, J BIOL CHEM, V246, P359; FLEISCHMAN JB, 1962, ARCH BIOCHEM BIOPHYS, P174; GARDLIK S, 1991, J BIOL CHEM, V266, P4889; GARDLIK S, 1990, J BIOL CHEM, V265, P13047; GARDNER CD, 1985, MOLYBDENUM ENZYMES, P343; GEOGHEGAN KF, 1980, J BIOL CHEM, V255, P1429; GRUBER S, 1990, J AM CHEM SOC, V112, P8179, DOI 10.1021/ja00178a059; JOHNSON JL, 1990, ARCH BIOCHEM BIOPHYS, V283, P542, DOI 10.1016/0003-9861(90)90681-N; JOHNSON JL, 1990, P NATL ACAD SCI USA, V87, P3190, DOI 10.1073/pnas.87.8.3190; JOHNSON JL, 1982, P NATL ACAD SCI-BIOL, V79, P6856, DOI 10.1073/pnas.79.22.6856; JOHNSON JL, 1977, J BIOL CHEM, V252, P4994; JOHNSON JL, 1977, J BIOL CHEM, V252, P2017; JOHNSON JL, 1984, J BIOL CHEM, V259, P5414; JOHNSON JL, 1976, J CLIN INVEST, V58, P543, DOI 10.1172/JCI108499; JONES HP, 1977, J BIOL CHEM, V252, P4988; KESSLER DL, 1974, BIOCHIM BIOPHYS ACTA, V370, P399, DOI 10.1016/0005-2744(74)90101-6; KESSLER DL, 1972, J BIOL CHEM, V247, P6566; KRAMER SP, 1987, J BIOL CHEM, V262, P16357; KRAMER SP, 1987, THESIS DUKE U; KUSTERS W, 1973, J AM CHEM SOC, V95, P2383; KUSTERS W, 1974, J AM CHEM SOC, V96, P3502, DOI 10.1021/ja00818a025; LIU TY, 1977, PROTEINS, V3, P239; NEZLIN RS, 1970, BIOCH ANTIBODIES, P139; RIPPA M, 1981, J BIOL CHEM, V256, P451; SCHULZ R, 1983, J AM CHEM SOC, V105, P4519, DOI 10.1021/ja00352a004; ZAHLER WL, 1968, J BIOL CHEM, V243, P716	29	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16627	16632						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1653244				2022-12-25	WOS:A1991GD63500063
J	NOGIMORI, K; HUGHES, PJ; GLENNON, MC; HODGSON, ME; PUTNEY, JW; SHEARS, SB				NOGIMORI, K; HUGHES, PJ; GLENNON, MC; HODGSON, ME; PUTNEY, JW; SHEARS, SB			PURIFICATION OF AN INOSITOL (1,3,4,5)-TETRAKISPHOSPHATE 3-PHOSPHATASE ACTIVITY FROM RAT-LIVER AND THE EVALUATION OF ITS SUBSTRATE-SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1,3,4-TRISPHOSPHATE PHOSPHORYLATION; HUMAN-PLATELETS; METABOLISM; PHOSPHATES; 1,3,4,5-TETRAKISPHOSPHATE; 1,4,5-TRISPHOSPHATE; CELLS; HEXAKISPHOSPHATE; BRAIN; 1,3,4,5,6-PENTAKISPHOSPHATE	Hepatic inositol (1,3,4,5)-tetrakisphosphate 3-phosphatase activity was detected in a 100,000 x g soluble fraction and a detergent-solubilized particulate fraction. Activity in both fractions increased up to 40-fold after anion-exchange chromatography due to removal of endogenous inhibitors (Hodgson, M. E., and Shears, S. B. (1990) Biochem. J. 267, 831-834); at this stage the detergent-solubilized particulate activity comprised over 90% of total activity. The particulate phosphatase was further purified by affinity chromatography using heparin-agarose and red-agarose. The latter column resolved two peaks of enzyme activity (designated 1 and 2 by their order of elution from the column). Their proportions varied between experiments, but peak 2 generally predominated and so this was further purified by hydroxylapatite chromatography. The final preparation was typically 38,000-fold purified with a 7% yield. The apparent molecular mass of this enzyme was 66 kDa, as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and gel filtration. The enzyme had little or no affinity for the following: inositol (1,3,4,6)-tetrakisphosphate, inositol (1,3,4)-trisphosphate, inositol (1,3)-bisphosphate, inositol (3,4)-bisphosphate, and para-nitrophenylphosphate. At pH 7.4 the K(m) for inositol (1,3,4,5)-tetrakisphosphate was 130 nM and the V(max) was 4250 nmol/mg protein/min. The purified enzyme also dephosphorylated inositol (1,3,4,5,6)-pentakisphosphate to inositol (1,4,5,6)-tetrakisphosphate (K(m) = 40 nM, V(max) = 211 nmol/mg protein/min), and inositol hexakisphosphate to at least five isomers of inositol pentakisphosphate (K(m) = 0.3 nM, V(max) = 12 nmol/mg protein/min). The latter affinity is the highest yet defined for an enzyme involved in inositol phosPhate metabolism. Determinations of IC50 values, and Dixon plots, revealed that with the (1,3,4,5)-tetrakisphosphate as substrate, the pentakis- and hexakisphosphates were potent competitive inhibitors; the K(i) values (25 and 0.5 nM, respectively) were similar to their substrate K(m) values. The kinetic properties of this enzyme, as well as estimates of the cellular levels of its potential substrates, indicate that inositol pentakisphosphate and inositol hexakisphosphate are likely to be the preferred substrates in vivo.	NIEHS,CELLULAR & MOLEC PHARMACOL LAB,INOSITOL LIPID SECT,RES TRIANGLE PK,NC 27709	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)			Putney, James W/F-7247-2019; Shears, Stephen B/C-6335-2019	Putney, James W/0000-0002-3379-4789; Shears, Stephen B/0000-0001-7309-8916; Hodgson, Elizabeth/0000-0002-2089-2689				Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; BALLA T, 1989, J BIOL CHEM, V264, P9386; BANSAL VS, 1987, J BIOL CHEM, V262, P9444; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARPENTER D, 1989, BIOCHEM SOC T, V17, P3, DOI 10.1042/bst0170003; CONNOLLY TM, 1985, J BIOL CHEM, V260, P7868; CULLEN PJ, 1989, BIOCHEM J, V259, P931, DOI 10.1042/bj2590931; CUNHAMELO JR, 1988, J BIOL CHEM, V263, P14245; DEAN NM, 1987, BIOCHEM J, V242, P361, DOI 10.1042/bj2420361; DOUGHNEY C, 1988, BIOCHEM J, V251, P927, DOI 10.1042/bj2510927; HANSEN CA, 1987, J BIOL CHEM, V262, P17319; HANSEN CA, 1988, FEBS LETT, V236, P53, DOI 10.1016/0014-5793(88)80284-9; HAWKINS PT, 1990, BIOCHEM BIOPH RES CO, V167, P819, DOI 10.1016/0006-291X(90)92099-L; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; HODGSON ME, 1990, BIOCHEM J, V267, P831, DOI 10.1042/bj2670831; HOER A, 1990, BIOCHEM J, V270, P715; HOER D, 1988, BIOCHEM BIOPH RES CO, V154, P668, DOI 10.1016/0006-291X(88)90191-X; HOWELL S, 1989, EUR J BIOCHEM, V183, P169, DOI 10.1111/j.1432-1033.1989.tb14909.x; HUGHES PJ, 1990, J BIOL CHEM, V265, P9869; ISAACKS RE, 1976, ARCH BIOCHEM BIOPHYS, V173, P114, DOI 10.1016/0003-9861(76)90240-X; Kirk CJ., 1990, PEPTIDE HORMONE ACTI, P151; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATTINGLY RR, 1991, J BIOL CHEM, V266, P15144; MCINTOSH RP, 1990, BIOCHEM J, V268, P141, DOI 10.1042/bj2680141; MENNITI FS, 1990, J BIOL CHEM, V265, P11167; OBERDISSE E, 1990, J BIOL CHEM, V265, P726; PHILLIPPY BQ, 1988, ANAL BIOCHEM, V175, P162, DOI 10.1016/0003-2697(88)90374-0; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; SHEARS SB, 1990, CELL SIGNAL, V2, P191, DOI 10.1016/0898-6568(90)90023-4; SHEARS SB, 1989, BIOCHEM J, V260, P313, DOI 10.1042/bj2600313; SHEARS SB, 1989, J BIOL CHEM, V264, P19879; SPENCER CEL, 1990, METHODS INOSITIDE RE, P39; STEPHENS LR, 1990, NATURE, V346, P580, DOI 10.1038/346580a0; STEPHENS LR, 1988, BIOCHEM J, V249, P283, DOI 10.1042/bj2490283; SZWERGOLD BS, 1987, BIOCHEM BIOPH RES CO, V149, P874, DOI 10.1016/0006-291X(87)90489-X	36	65	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16499	16506						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1653239				2022-12-25	WOS:A1991GD63500044
J	RONDON, IJ; MACMILLAN, LA; BECKMAN, BS; GOLDBERG, MA; SCHNEIDER, T; BUNN, HF; MALTER, JS				RONDON, IJ; MACMILLAN, LA; BECKMAN, BS; GOLDBERG, MA; SCHNEIDER, T; BUNN, HF; MALTER, JS			HYPOXIA UP-REGULATES THE ACTIVITY OF A NOVEL ERYTHROPOIETIN MESSENGER-RNA BINDING-PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-LINE; IDENTIFICATION; EXPRESSION; MECHANISM; FERRITIN; FETUS; GENE	The mechanisms which control the production of erythropoietin (Epo) remain enigmatic. Recent data suggest that the half-time of Epo messenger RNA (mRNA) is increased by hypoxia in Hep 3B cells, a human hepatoma line. The post-transcriptional regulation of other rapidly degraded mRNAs is mediated by sequence-specific mRNA binding proteins. In order to determine if Epo mRNA specific binding proteins exist, we probed cytosolic lysates from Hep 3B cells and mouse tissues with radiolabeled Epo RNA. A cytosolic protein that binds specifically to Epo RNA was identified in the Epo-producing, hepatoblastoma Hep 3B cell line by gel mobility shift assay. This protein was identified in both normoxic and hypoxic cells and bound specifically to a 120-base fragment of the 3'-untranslated region (3'-UTR) of Epo mRNA. Binding was competed with unlabeled Epo RNA, but not with granulocyte-macrophage colony-stimulating factor RNA. Ultraviolet light cross-linked Epo RNA-protein complexes migrated as two bands of 70 and 135-140 kD on sodium dodecyl sulfate-polyacrylamide gels. Binding activity was markedly increased in brain and spleen lysates from mice subjected to 24 h of hypoxia. Therefore, the post-transcriptional regulation of Epo expression in response to hypoxia may in part be due to the interaction of Epo RNA with its specific binding protein.	TULANE UNIV,SCH MED,DEPT PHARMACOL,NEW ORLEANS,LA 70112; TULANE UNIV,SCH MED,DEPT PATHOL,NEW ORLEANS,LA 70112; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV HEMATOL,BOSTON,MA 02115	Tulane University; Tulane University; Harvard University; Brigham & Women's Hospital; Harvard Medical School					NCI NIH HHS [CA-01427] Funding Source: Medline; NIDDK NIH HHS [DK-41234, DK-01401] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA001427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041234, K12DK001401] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; GILLIS P, 1991, J BIOL CHEM, V266, P3172; GOLDBERG MA, 1991, BLOOD, V77, P271; GOLDBERG MA, 1987, P NATL ACAD SCI USA, V84, P7972, DOI 10.1073/pnas.84.22.7972; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; GOLDBERG MA, 1990, ERYTHROPOIETIN CLIN, P59; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; JACOBS K, 1985, NATURE, V313, P806, DOI 10.1038/313806a0; JACOBSON AB, 1984, NUCLEIC ACIDS RES, V12, P45, DOI 10.1093/nar/12.1Part1.45; JACOBSON LO, 1957, NATURE, V179, P633, DOI 10.1038/179633a0; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MARCINIAK RA, 1990, P NATL ACAD SCI USA, V87, P3624, DOI 10.1073/pnas.87.9.3624; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; NIELSEN OJ, 1987, BLOOD, V70, P1904; SHERWOOD JB, 1987, BLOOD, V69, P1053; SHOEMAKER CB, 1986, MOL CELL BIOL, V6, P849, DOI 10.1128/MCB.6.3.849; SPIVAK JL, 1986, INT J CELL CLONING, V4, P139, DOI 10.1002/stem.5530040302; THEIL EC, 1990, J BIOL CHEM, V265, P4771; TURNER DH, 1987, COLD SPRING HARB SYM, V52, P123, DOI 10.1101/SQB.1987.052.01.017; UENO M, 1988, BIOCHEM BIOPH RES CO, V154, P773, DOI 10.1016/0006-291X(88)90207-0; WALDEN WE, 1988, P NATL ACAD SCI USA, V85, P9503, DOI 10.1073/pnas.85.24.9503; ZANJANI ED, 1974, J LAB CLIN MED, V83, P281; ZANJANI ED, 1977, J LAB CLIN MED, V89, P640	24	107	114	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16594	16598						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1653242				2022-12-25	WOS:A1991GD63500058
J	MELLGREN, RL				MELLGREN, RL			PROTEOLYSIS OF NUCLEAR PROTEINS BY MU-CALPAIN AND M-CALPAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTICATALYTIC PROTEINASE; PROTEASE; CELLS; INACTIVATION; INHIBITOR; COMPLEX; ENZYME; SYSTEM; KINASE	Purified calpains are capable of proteolyzing several high M, nuclear proteins and solubilizing a histone H1 kinase activity from rat liver nuclei upon exposure to 10(6) - 10(-5) M Ca2+. Major nuclear substrates displayed apparent molecular masses of 200, 130, 120, and 60 kDa on Coomassie Blue-stained SDS-PAGE gels. The nuclear proteins and the H1 kinase were released from Triton-treated nuclei following incubation with buffer containing 0.5 m NaCl. They therefore appeared to be internal nuclear matrix proteins. The nuclear Hl kinase activity solubilized by incubation with m-calpain was eluted in the void volume of a Bio-Gel A-1.5m column, indicating an apparent mass greater than 1,500 kDa. Treatment of the calpain-solubilized kinase with 0.5 M NaCl dissociated it to a form having an apparent mass of 300 kDa (Stokes radius = 5.6 nm), suggesting that the 300-kDa kinase is released from nuclei by calpain treatment as a large complex containing other internal matrix proteins. Purified human erythrocyte-mu-calpain was capable of proteolyzing the nuclear matrix proteins at 10(-6) M Ca2+. In contrast, human erythrocyte multicatalytic protease complex produced little cleavage of the nuclear proteins. Proteolysis of nuclear proteins by either mu-calpain or m-calpain was inhibited by calpastatin. These experiments suggest a physiologic role for the calpains in the turnover of nuclear proteins.			MELLGREN, RL (corresponding author), MED COLL OHIO, DEPT PHARMACOL & THERAPEUT, TOLEDO, OH 43699 USA.				NHLBI NIH HHS [HL-36573] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036573] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; DAYTON WR, 1976, BIOCHEMISTRY-US, V15, P2159, DOI 10.1021/bi00655a020; FOX JEB, 1985, ADV EXP MED BIOL, V192, P201; GANOTH D, 1988, J BIOL CHEM, V263, P12412; Goll D E, 1985, Prog Clin Biol Res, V180, P151; KAUFMANN SH, 1984, EXP CELL RES, V155, P477, DOI 10.1016/0014-4827(84)90208-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MELLGREN RL, 1988, BIOCHIM BIOPHYS ACTA, V954, P154, DOI 10.1016/0167-4838(88)90066-0; MELLGREN RL, 1990, BIOCHIM BIOPHYS ACTA, V1040, P28, DOI 10.1016/0167-4838(90)90142-3; MELLGREN RL, 1990, BIOCHEM BIOPH RES CO, V168, P589, DOI 10.1016/0006-291X(90)92361-3; MELLGREN RL, 1987, FASEB J, V1, P110, DOI 10.1096/fasebj.1.2.2886390; MELLGREN RL, 1986, ARCH BIOCHEM BIOPHYS, V246, P233, DOI 10.1016/0003-9861(86)90468-6; MELLGREN RL, 1988, PREP BIOCHEM, V18, P183, DOI 10.1080/00327488808062520; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MINSHULL J, 1989, J CELL SCI, P77; Murachi T, 1980, Adv Enzyme Regul, V19, P407; MURRAY AW, 1989, J CELL SCI, P65; PICARD A, 1985, DEV BIOL, V109, P311, DOI 10.1016/0012-1606(85)90458-0; RIVETT AJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P1, DOI 10.1016/0003-9861(89)90558-4; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SALO DC, 1990, J BIOL CHEM, V265, P11919; SANDERS C, 1977, BIOCHEM BIOPH RES CO, V78, P1034, DOI 10.1016/0006-291X(77)90525-3; SCHOLLMEYER JE, 1988, SCIENCE, V240, P911, DOI 10.1126/science.2834825; SHOEMAN RL, 1980, INTRACELLULAR CALCIU, P191; SHOJIKASAI Y, 1988, P NATL ACAD SCI USA, V85, P146, DOI 10.1073/pnas.85.1.146; SILLEN LG, 1964, SPECIAL PUBLICATION, V17; SUZUKI K, 1988, ADV ENZYME REGUL, V27, P153; TANAKA K, 1990, CELL STRUCT FUNCT, V15, P127, DOI 10.1247/csf.15.127; TOKES ZA, 1989, J BIOL CHEM, V264, P15059; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; WILK S, 1983, J NEUROCHEM, V40, P842, DOI 10.1111/j.1471-4159.1983.tb08056.x	31	75	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13920	13924						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1649832				2022-12-25	WOS:A1991FY02700073
J	WU, WG; CHI, LM; YANG, TS; FANG, SY				WU, WG; CHI, LM; YANG, TS; FANG, SY			FREEZING OF PHOSPHOCHOLINE HEADGROUP IN FULLY HYDRATED SPHINGOMYELIN BILAYERS AND ITS EFFECT ON THE DYNAMICS OF NONFREEZABLE WATER AT SUBZERO TEMPERATURES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; DIPALMITOYLPHOSPHATIDYLCHOLINE BILAYERS; SPIN RELAXATION; LINE-SHAPES; HEAD-GROUP; PHOSPHOLIPIDS; SPECTROSCOPY; CONFORMATION; LECITHIN; H-2-NMR	Differential scanning calorimetry (DSC) and nuclear magnetic resonance (NMR) spectroscopy are applied to characterize the nonfreezable water molecules in fully hydrated D2O/sphingomyelin at temperatures below 0-degrees-C. Upon cooling, DSC thermogram displays two thermal transitions peaked at -11 and -34-degrees-C. The high-temperature exothermic transition corresponds to the freezing of the bulk D2O, and the low-temperature transition, which has not previously been reported, can be ascribed to the freezing of the phosphocholine headgroup in the lipid bilayer. The dynamics of nonfreezable water are also studied by H-2 NMR T1 (spin-lattice relaxation time) and T2e (spin-spin relaxation time obtained by two pulse echo) measurements at 30.7 MHz and at temperatures down to -110-degrees-C. The temperature dependence of the T1 relaxation time is characterized by a distinct minimum value of 2.1 +/-0.1 ms at -30-degrees-C. T2e is discontinuous at temperature around -70-degrees-C, indicating another freezing-like event for the bound water at this temperature. Analysis of the relaxation data suggest that nonfreezable water undergoes both fast and slow motions at characteristic NMR time scales. The slow motions are affected when the lipid headgroup freezes.			WU, WG (corresponding author), NATL TSING HUA UNIV,INST LIFE SCI,HSINCHU 30043,TAIWAN.							ANGELL CA, 1983, ANNU REV PHYS CHEM, V34, P593, DOI 10.1146/annurev.pc.34.100183.003113; BARENHOLZ Y, 1980, BIOCHIM BIOPHYS ACTA, V604, P129, DOI 10.1016/0005-2736(80)90572-6; BLOOM M, 1980, CAN J PHYS, V58, P1510, DOI 10.1139/p80-196; CALSTROM G, 1989, J PHYS CHEM-US, V93, P3287; CAMPBELL RF, 1979, J PHYS CHEM-US, V83, P525, DOI 10.1021/j100467a020; CASILLAS N, 1989, LANGMUIR, V5, P384, DOI 10.1021/la00086a017; DAVIS JH, 1983, BIOCHIM BIOPHYS ACTA, V737, P117, DOI 10.1016/0304-4157(83)90015-1; FINER EG, 1974, CHEM PHYS LIPIDS, V12, P1, DOI 10.1016/0009-3084(74)90064-4; GRIFFIN RG, 1976, J AM CHEM SOC, V98, P851, DOI 10.1021/ja00419a044; GRIFFIN RG, 1978, BIOCHEMISTRY-US, V17, P2718, DOI 10.1021/bi00607a004; HALLE B, 1981, J CHEM PHYS, V75, P1928, DOI 10.1063/1.442218; HARMON JF, 1978, J PHYS CHEM-US, V82, P1938, DOI 10.1021/j100506a017; HERZFELD J, 1978, BIOCHEMISTRY-US, V17, P2711, DOI 10.1021/bi00607a003; JACKSON JA, 1964, J CHEM PHYS, V41, P4008, DOI 10.1063/1.1725860; JANIAK MJ, 1979, J BIOL CHEM, V254, P6068; KOENIG SH, 1969, J BIOL CHEM, V244, P3283; LANG EW, 1984, J CHEM PHYS, V81, P3820, DOI 10.1063/1.448164; PAULS KP, 1985, EUR BIOPHYS J BIOPHY, V12, P1, DOI 10.1007/BF00254089; POPE JM, 1981, BIOPHYS J, V35, P509, DOI 10.1016/S0006-3495(81)84806-0; QUIST PO, 1988, J CHEM SOC FARAD T 1, V84, P1033, DOI 10.1039/f19888401033; SHIRLEY WM, 1982, J AM CHEM SOC, V104, P2910, DOI 10.1021/ja00374a034; WITTEBORT RJ, 1987, J CHEM PHYS, V86, P5411, DOI 10.1063/1.452565; WITTEBORT RJ, 1988, J AM CHEM SOC, V110, P5668, DOI 10.1021/ja00225a013; WOESSNER DE, 1962, J CHEM PHYS, V36, P1, DOI 10.1063/1.1732274; WU WG, 1981, LIPIDS, V16, P820, DOI 10.1007/BF02535036; WU WG, 1990, BIOCHIM BIOPHYS ACTA, V1026, P225, DOI 10.1016/0005-2736(90)90068-Y	26	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13602	13606						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1649825				2022-12-25	WOS:A1991FY02700026
J	FURUKAWA, KI; OHSHIMA, N; TAWADAIWATA, Y; SHIGEKAWA, M				FURUKAWA, KI; OHSHIMA, N; TAWADAIWATA, Y; SHIGEKAWA, M			CYCLIC-GMP STIMULATES NA+/CA2+ EXCHANGE IN VASCULAR SMOOTH-MUSCLE CELLS IN PRIMARY CULTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CALCIUM EXCHANGE; MEMBRANE CA-2+ PUMP; DEPENDENT PROTEIN-KINASE; GUANOSINE-MONOPHOSPHATE; NA+-CA-2+ EXCHANGE; RAT AORTA; MECHANISM; VESICLES; PHOSPHATIDYLINOSITOL; PHOSPHORYLATION	We examined the effect of cGMP on Na+/Ca2+ exchange in rat aortic smooth muscle cells (VSMCs) in primary culture. The intracellular Ca2+ concentration ([Ca 2+]i) was raised by adding ionomycin to VSMCs incubated at high extracellular pH (pH(o)) (pH(o) = 8.8) and high extracellular Mg2+ (Mg2+o) (Mg2+o = 20 mM), conditions that inhibit activity of the sarcolemmal Ca2+ pump. Ca-45(2+) efflux observed under these conditions was mostly extracellular Na+ (Na+o)-dependent and thus presumably catalyzed by the Na+/Ca2+ exchanger. Brief treatment of VSMCs with 8-bromo-cGMP or atrial natriuretic peptide increased this Na+(o)-dependent Ca-45(2+) efflux by about 50%. The 8-bromo-cGMP treatment did not significantly influence total cell Na+, membrane potential, and cell pH. Conversely, when VSMCs were loaded with Na+ and then exposed to a Na+o-free medium, the rate of Ca-45(2+) uptake into VSMCs increased as cell Na+ increased. Prior treatment of VSMCs with 8-bromo-cGMP accelerated Ca-45(2+) uptake by up to 60% without influencing Na+ loading itself. Treatment of VSMCs with 25-mu-M 2,5-di-(tert-butyl)-1,4-benzohydroquinone, an inhibitor of the sarcoplasmic reticulum Ca2+-ATPase, induced a transient elevation of [Ca2+]i. 8-Bromo-cGMP stimulated the rate of recovery phase of this Ca2+ transient measured in the high pH(o)/high Mg2+o medium. All these results indicate that cGMP stimulates Na+/Ca2+ exchange in VSMCs.	NATL CARDIOVASC CTR, RES INST, DEPT MOLEC PHYSIOL, SUITA, OSAKA 565, JAPAN	National Cerebral & Cardiovascular Center - Japan								ABDELLATIF AA, 1986, PHARMACOL REV, V38, P227; ASHIDA T, 1987, J PHYSIOL-LONDON, V392, P617, DOI 10.1113/jphysiol.1987.sp016800; BLAUSTEIN MP, 1989, SODIUM CALCIUM EXCHA, P208; CARONI P, 1983, EUR J BIOCHEM, V132, P451, DOI 10.1111/j.1432-1033.1983.tb07383.x; CHAMLEY JH, 1977, CELL TISSUE RES, V177, P503; DIPOLO R, 1987, BIOCHIM BIOPHYS ACTA, V897, P347, DOI 10.1016/0005-2736(87)90432-9; DiPolo R, 1989, SODIUM CALCIUM EXCHA; FURUKAWA K, 1989, J BIOCHEM, V106, P1068, DOI 10.1093/oxfordjournals.jbchem.a122966; FURUKAWA KI, 1989, J BIOL CHEM, V264, P4844; FURUKAWA KI, 1988, J BIOL CHEM, V263, P8058; HIRATA M, 1990, J BIOL CHEM, V265, P1268; IGNARRO LJ, 1985, ANNU REV PHARMACOL, V25, P171, DOI 10.1146/annurev.pharmtox.25.1.171; IMAI S, 1990, J BIOCHEM-TOKYO, V107, P755, DOI 10.1093/oxfordjournals.jbchem.a123121; KAHN AM, 1988, AM J PHYSIOL, V254, pC441, DOI 10.1152/ajpcell.1988.254.3.C441; KASS GEN, 1989, J BIOL CHEM, V264, P15192; KIMURA J, 1987, J PHYSIOL-LONDON, V384, P199, DOI 10.1113/jphysiol.1987.sp016450; KOBAYASHI S, 1985, SCIENCE, V229, P553, DOI 10.1126/science.3927484; KURTZ I, 1987, J BIOL CHEM, V262, P4516; MOORE GA, 1987, FEBS LETT, V224, P331, DOI 10.1016/0014-5793(87)80479-9; MORGAN JP, 1984, J PHYSIOL-LONDON, V357, P539, DOI 10.1113/jphysiol.1984.sp015516; MURAD F, 1986, J CLIN INVEST, V78, P1, DOI 10.1172/JCI112536; POPESCU LM, 1985, EUR J PHARMACOL, V107, P393, DOI 10.1016/0014-2999(85)90269-9; RAPOPORT RM, 1986, CIRC RES, V58, P407, DOI 10.1161/01.RES.58.3.407; RASHATWAR SS, 1987, P NATL ACAD SCI USA, V84, P5685, DOI 10.1073/pnas.84.16.5685; REEVES JP, 1984, J BIOL CHEM, V259, P7733; SCHEID CR, 1984, AM J PHYSIOL, V246, pC431, DOI 10.1152/ajpcell.1984.246.5.C431; SCHWARTZ SM, 1986, CIRC RES, V58, P427, DOI 10.1161/01.RES.58.4.427; SIMS PJ, 1974, BIOCHEMISTRY-US, V13, P3315, DOI 10.1021/bi00713a022; SLAUGHTER RS, 1989, BIOCHEMISTRY-US, V28, P3995, DOI 10.1021/bi00435a055; SMITH JB, 1990, AM J PHYSIOL, V259, pC302, DOI 10.1152/ajpcell.1990.259.2.C302; SMITH JB, 1987, J BIOL CHEM, V262, P17455; TAMURA H, 1986, AM J PHYSIOL, V250, pC939, DOI 10.1152/ajpcell.1986.250.6.C939; TWORT CHC, 1988, CIRC RES, V62, P961, DOI 10.1161/01.RES.62.5.961; VIGNE P, 1988, J BIOL CHEM, V263, P8078; VROLIX M, 1988, BIOCHEM J, V255, P855, DOI 10.1042/bj2550855; WAKABAYASHI S, 1981, BIOCHIM BIOPHYS ACTA, V642, P158, DOI 10.1016/0005-2736(81)90146-2	36	115	117	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1991	266	19					12337	12341						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FV180	1648093				2022-12-25	WOS:A1991FV18000038
J	NASSI, P; NEDIANI, C; LIGURI, G; TADDEI, N; RAMPONI, G				NASSI, P; NEDIANI, C; LIGURI, G; TADDEI, N; RAMPONI, G			EFFECTS OF ACYLPHOSPHATASE ON THE ACTIVITY OF ERYTHROCYTE-MEMBRANE CA-2+ PUMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; HORSE MUSCLE ACYLPHOSPHATASE; CALCIUM-TRANSPORT; SKELETAL-MUSCLE; CALMODULIN; ACTIVATOR; CA-2+-ATPASE; STIMULATION; VESICLES; PHOSPHORYLATION	Acylphosphatase, purified from human erythrocytes, actively hydrolyzes the acylphosphorylated intermediate of human red blood cell membrane Ca2+-ATPase. This effect occurred with acylphosphatase amounts (up to 10 units/mg membrane protein) that fall within the physiological range. Furthermore, a very low K(m) value, 3.41 +/- 1.16 (S.E.) nM, suggests a high affinity in acylphosphatase for the phosphoenzyme intermediate, which is consistent with the small number of Ca2+-ATPase units in human erythrocyte membrane. Acylphosphatase addition to red cell membranes resulted in a significant increase in the rate of ATP hydrolysis. Maximal stimulation (about 2-fold over basal) was obtained at 2 units/mg membrane protein, with a concomitant decrease in apparent K(m) values for both Ca2+ and ATP. Conversely, similar amounts of acylphosphatase significantly decreased (by about 30%) the rate of Ca2+ transport into inside-out red cell membrane vesicles, albeit that reduced apparent K(m) values for Ca2+ and ATP were also observed in this case. A stoichiometry of 2.04 Ca2+/ATP hydrolyzed was calculated in the absence of acylphosphatase; in the presence of acylphosphatase optimal concentration, this ratio was reduced to 0.9. Acylphosphatase activity, rather than just protein, was essential for all the above effects. Taken together these findings suggest that, because of its hydrolytic activity on the phosphoenzyme intermediate, acylphosphatase reduces the efficiency of the erythrocyte membrane Ca2+ pump. A possible mechanism for this effect is that the phosphoenzyme is hydrolyzed before its transport work can be accomplished.			NASSI, P (corresponding author), UNIV FLORENCE,DIPARTIMENTO SCI BIOCHIM,VIALE MORGAGNI 50,I-50134 FLORENCE,ITALY.		Nediani, Chiara/R-2201-2019; Nediani, Chiara/AAO-8919-2020	Nediani, Chiara/0000-0003-3190-3539; Taddei, Niccolo/0000-0003-2513-1018				ADAMO HP, 1988, J BIOL CHEM, V263, P17548; BEISENHERZ G, 1955, Z NATURFORSCH B, V8, P555; BERTI A, 1977, ITAL J BIOCHEM, V26, P377; CAMICI G, 1976, EXPERIENTIA, V32, P5345; CAPPUGI G, 1980, J BIOL CHEM, V255, P6868; DAVIS FB, 1983, J CLIN INVEST, V71, P579, DOI 10.1172/JCI110803; GARRAHAN PJ, 1969, J PHYSIOL-LONDON, V202, P305, DOI 10.1113/jphysiol.1969.sp008813; HOKIN LE, 1965, P NATL ACAD SCI USA, V54, P177, DOI 10.1073/pnas.54.1.177; LIGURI G, 1987, MECH AGEING DEV, V39, P59, DOI 10.1016/0047-6374(87)90086-8; LIGURI G, 1986, BIOCHEMISTRY-US, V25, P8089, DOI 10.1021/bi00372a044; LUTHRA MG, 1980, BIOCHIM BIOPHYS ACTA, V633, P299, DOI 10.1016/0304-4165(80)90416-X; MACINTYRE JD, 1978, BIOCHIM BIOPHYS ACTA, V510, P373, DOI 10.1016/0005-2736(78)90037-8; MANAO G, 1988, J PROTEIN CHEM, V7, P417, DOI 10.1007/BF01024889; MANAO G, 1985, ARCH BIOCHEM BIOPHYS, V241, P418, DOI 10.1016/0003-9861(85)90565-X; MAULDIN D, 1980, BIOCHEM J, V187, P507, DOI 10.1042/bj1870507; MUALLEM S, 1981, BIOCHIM BIOPHYS ACTA, V647, P73, DOI 10.1016/0005-2736(81)90296-0; NASSI P, 1985, BIOCHEM MED METAB B, V34, P166, DOI 10.1016/0006-2944(85)90107-3; RAMPONI G, 1966, EXPERIENTIA, V22, P705, DOI 10.1007/BF01901326; RAMPONI G, 1967, EXPERIENTIA, V23, P1019, DOI 10.1007/BF02136422; RAMPONI G, 1961, G BIOCH, V10, P189; ROUFOGALIS BD, 1979, CAN J PHYSIOL PHARM, V57, P1331, DOI 10.1139/y79-199; SARKADI B, 1978, FEBS LETT, V89, P78, DOI 10.1016/0014-5793(78)80526-2; SCHARFF O, 1978, BIOCHIM BIOPHYS ACTA, V509, P67, DOI 10.1016/0005-2736(78)90008-1; Steck T L, 1974, Methods Enzymol, V31, P172; STEFANI M, 1981, ARCH BIOCHEM BIOPHYS, V208, P37, DOI 10.1016/0003-9861(81)90120-X; THAKAR JH, 1985, ANAL BIOCHEM, V144, P94, DOI 10.1016/0003-2697(85)90088-0; WAISMAN DM, 1981, J BIOL CHEM, V256, P409; WANG KKW, 1988, ARCH BIOCHEM BIOPHYS, V260, P696, DOI 10.1016/0003-9861(88)90498-5	28	48	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					10867	10871						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	1645713				2022-12-25	WOS:A1991FQ77400028
J	CHAMOW, SM; KOGAN, TP; PEERS, DH; HASTINGS, RC; BYRN, RA; ASHKENAZI, A				CHAMOW, SM; KOGAN, TP; PEERS, DH; HASTINGS, RC; BYRN, RA; ASHKENAZI, A			CONJUGATION OF SOLUBLE CD4 WITHOUT LOSS OF BIOLOGICAL-ACTIVITY VIA A NOVEL CARBOHYDRATE-DIRECTED CROSS-LINKING REAGENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-INFECTED CELLS; BINDING-SITE; DISULFIDE BONDS; PROTEIN; EXPRESSION; MOLECULES; FRAGMENTS; INVITRO; FORM	Chemical conjugates of recombinant soluble CD4 (sCD4) with toxins, or with antibodies that activate cytotoxic T cells, can be used to direct selective killing of human immunodeficiency virus (HIV)-infected cells. This approach takes advantage of the ability of sCD4 to bind with high affinity to gp120, the envelope protein of HIV-1, which is expressed on actively infected cells. However, conjugation of sCD4 via reagents that target amino groups may reduce its affinity for gp120, since at least one such group is important for gp120 binding. Here, we describe a novel cross-linking reagent which enables the conjugation of sCD4 via its carbohydrate moieties rather than its free amino groups. This heterobifunctional reagent, 4-(4-N-maleimidophenyl)-butyric acid hydrazide (MPBH), combines a nucleophilic hydrazide with an electrophilic maleimide, thereby allowing coupling of carbohydrate-derived aldehydes to free thiols. We describe conditions by which MPBH is coupled selectively to the sialic acid residues of sCD4, and exemplify the use of MPBH by conjugating sCD4 to hemoglobin and to beta-galactosidase. We show that, whereas conjugation of sCD4 via amino groups markedly reduces its gp120 binding affinity, conjugation via the carbohydrate chains using MPBH does not affect binding. Moreover, we demonstrate the ability of a sCD4-MPBH-fluorescein conjugate to label HIV-infected human CEM cells selectively. These results indicate that, by targeting its carbohydrate moieties, sCD4 can be cross-linked to other molecules without compromising its function. The approach described here can be useful for glycoproteins in which amino groups, but not carbohydrates, are important for function. More generally, this approach can be considered for use in cross-linking glycoconjugates to compounds which either contain thiols, or to which thiols can be added.	GENENTECH INC, DEPT PULM RES, SAN FRANCISCO, CA 94080 USA; GENENTECH INC, DEPT BIOORGAN CHEM, SAN FRANCISCO, CA 94080 USA; HARVARD UNIV, NEW ENGLAND DEACONESS HOSP, SCH MED, DIV HEMATOL ONCOL, BOSTON, MA 02215 USA	Roche Holding; Genentech; Roche Holding; Genentech; Harvard University; Harvard Medical School	CHAMOW, SM (corresponding author), GENENTECH INC, DEPT PROC SCI, 460 PT SAN BRUNO BLVD, SAN FRANCISCO, CA 94080 USA.		Ashkenazi, Avi/ABG-2712-2020	Ashkenazi, Avi/0000-0002-6890-4589				ASHKENAZI A, 1990, P NATL ACAD SCI USA, V87, P7150, DOI 10.1073/pnas.87.18.7150; BERG J, 1991, P NATL ACAD SCI USA, V88, P4723, DOI 10.1073/pnas.88.11.4723; BERGER EA, 1988, P NATL ACAD SCI USA, V85, P2357, DOI 10.1073/pnas.85.7.2357; BYRN RA, 1990, NATURE, V344, P667, DOI 10.1038/344667a0; CAPON DJ, 1990, CURR OPIN IMMUNOL, V2, P433, DOI 10.1016/0952-7915(89)90156-8; CAPON DJ, 1989, NATURE, V337, P525, DOI 10.1038/337525a0; CARLSSON J, 1978, BIOCHEM J, V173, P723, DOI 10.1042/bj1730723; CHAMOW SM, 1990, BIOCHEMISTRY-US, V29, P9885, DOI 10.1021/bi00494a019; CHAUDHARY VK, 1988, NATURE, V335, P369, DOI 10.1038/335369a0; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DEEN KC, 1988, NATURE, V331, P82, DOI 10.1038/331082a0; DUNCAN RJS, 1983, ANAL BIOCHEM, V132, P68, DOI 10.1016/0003-2697(83)90426-8; DUZGUNES N, 1992, J CELL BIOCH SE, V16, P77; FISHER RA, 1988, NATURE, V331, P76, DOI 10.1038/331076a0; GHETIE V, 1991, P NATL ACAD SCI USA, V88, P5690, DOI 10.1073/pnas.88.13.5690; HARRIS RJ, 1990, EUR J BIOCHEM, V188, P291, DOI 10.1111/j.1432-1033.1990.tb15402.x; HEINDEL ND, 1991, BIOCONJUGATE CHEM, V2, P427, DOI 10.1021/bc00012a008; HOWELL DN, 1985, J IMMUNOL, V134, P971; HUSSEY RE, 1988, NATURE, V331, P78, DOI 10.1038/331078a0; IDZIOREK T, 1991, AIDS RES HUM RETROV, V7, P529, DOI 10.1089/aid.1991.7.529; JI TH, 1983, METHOD ENZYMOL, V91, P580; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDAU NR, 1988, NATURE, V334, P159, DOI 10.1038/334159a0; MADDON PJ, 1987, P NATL ACAD SCI USA, V84, P9155, DOI 10.1073/pnas.84.24.9155; MADDON PJ, 1985, CELL, V42, P93, DOI 10.1016/S0092-8674(85)80105-7; MARTIN FJ, 1981, BIOCHEMISTRY-US, V20, P4229, DOI 10.1021/bi00517a043; MARTIN FJ, 1982, J BIOL CHEM, V257, P286; MATSUKURA M, 1989, P NATL ACAD SCI USA, V86, P4244, DOI 10.1073/pnas.86.11.4244; MEANS GE, 1971, CHEM MODIFICATION PR, P110; O'Sullivan M J, 1981, Methods Enzymol, V73, P147; OSHANNESSY DJ, 1987, J IMMUNOL METHODS, V99, P153, DOI 10.1016/0022-1759(87)90120-7; RICHARDSON NE, 1988, P NATL ACAD SCI USA, V85, P6102, DOI 10.1073/pnas.85.16.6102; RODWELL JD, 1986, P NATL ACAD SCI USA, V83, P2632, DOI 10.1073/pnas.83.8.2632; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SMITH DH, 1987, SCIENCE, V238, P1704, DOI 10.1126/science.3500514; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPELLMAN MW, 1991, BIOCHEMISTRY-US, V30, P2395, DOI 10.1021/bi00223a015; TILL MA, 1988, SCIENCE, V242, P1166, DOI 10.1126/science.2847316; TRAUNECKER A, 1989, NATURE, V339, P68, DOI 10.1038/339068a0; TRAUNECKER A, 1988, NATURE, V331, P84, DOI 10.1038/331084a0; TRAUT RR, 1973, BIOCHEMISTRY-US, V12, P3266, DOI 10.1021/bi00741a019; VANLENTEN L, 1971, J BIOL CHEM, V246, P1889; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; Webb RR, 1990, BIOCONJUGATE CHEM, V1, P96, DOI 10.1021/bc00002a002; WILCHEK M, 1990, METHOD ENZYMOL, V184, P123; WINKLER G, 1991, AIDS RES HUM RETROV, V7, P393, DOI 10.1089/aid.1991.7.393; ZARA JJ, 1991, ANAL BIOCHEM, V194, P156, DOI 10.1016/0003-2697(91)90163-N; ZEIRA M, 1991, P NATL ACAD SCI USA, V88, P4409, DOI 10.1073/pnas.88.10.4409; ZETTLMEISSL G, 1990, DNA CELL BIOL, V9, P347, DOI 10.1089/dna.1990.9.347	50	38	69	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15916	15922						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1639820				2022-12-25	WOS:A1992JG11300098
J	WHITE, AL; GRAHAM, DL; LEGROS, J; PEASE, RJ; SCOTT, J				WHITE, AL; GRAHAM, DL; LEGROS, J; PEASE, RJ; SCOTT, J			OLEATE-MEDIATED STIMULATION OF APOLIPOPROTEIN-B SECRETION FROM RAT HEPATOMA-CELLS - A FUNCTION OF THE ABILITY OF APOLIPOPROTEIN-B TO DIRECT LIPOPROTEIN ASSEMBLY AND ESCAPE PRESECRETORY DEGRADATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; ENDOPLASMIC-RETICULUM; MESSENGER-RNA; HEPG2 CELLS; FATTY-ACIDS; FAMILIAL HYPOBETALIPOPROTEINEMIA; INTRACELLULAR DEGRADATION; PLASMA-LIPOPROTEINS; OLEIC-ACID; PRE-GOLGI	Physiological concentrations of oleate stimulate apolipoprotein (apo) B-containing lipoprotein secretion from HepG2 cells without increasing apoB mRNA levels. The purpose of this study was to determine whether oleate acts by increasing translation of apoB mRNA or through posttranslational effects on the apoB protein. To address the mechanism of oleate-stimulated secretion of apoB, a series of carboxyl terminally truncated apoB constructs was made. Each contained the SV40 early promoter, the apoB 5'-untranslated region, and SV40 polyadenylation signals. Any difference in the response to oleate between endogenous apoB and the proteins encoded by the constructs or between the constructs themselves should thus depend on the protein sequence. Stable transformants were established for each of the constructs in the rat hepatoma cell line McArdle-RH7777. The effect of oleate on secretion of the apoB protein products was determined by labeling with [S-35]methionine, immunoprecipitation, and sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Carboxyl-terminal truncation of apoB41 resulted in a loss of the ability of apoB secretion to respond to oleate. Ultracentrifugation of secreted proteins on continuous CsCl gradients from 1.0-1.4 g/ml revealed that this correlated with a decrease in the ability of apoB to be recovered as a buoyant lipoprotein particle. Addition of oleate decreased the densities at which the short forms of apoB secreted as lipoproteins were recovered. Pulse-chase analysis of the secretion of apoB100 and of the truncated proteins revealed that they all underwent rapid posttranslational intracellular degradation. We conclude that oleate has no effect on the translation of apoB mRNA but promotes the secretion of apoB-containing lipoproteins by reducing presecretory degradation of those forms of apoB that can produce buoyant lipoproteins.	CLIN RES CTR,MRC,DIV MOLEC MED,HARROW HA1 3UJ,MIDDX,ENGLAND	Medical Research Council Clinical Trials Unit								ALEXANDER CA, 1976, J CELL BIOL, V69, P241, DOI 10.1083/jcb.69.2.241; AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; BARTLETT SM, 1988, BIOCHEM J, V249, P37, DOI 10.1042/bj2490037; BELLQUINT J, 1981, BIOCHEM BIOPH RES CO, V99, P700, DOI 10.1016/0006-291X(81)91800-3; BEYNEN AC, 1981, BIOCHIM BIOPHYS ACTA, V665, P1, DOI 10.1016/0005-2760(81)90224-1; BOOGAERTS JR, 1984, AM J PHYSIOL, V246, pE77, DOI 10.1152/ajpendo.1984.246.1.E77; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BOSTROM K, 1988, J BIOL CHEM, V263, P4434; CARDIN AD, 1984, J BIOL CHEM, V259, P8522; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; CHRISTOFORI G, 1988, CELL, V54, P875, DOI 10.1016/S0092-8674(88)91263-9; CIANFLONE KM, 1990, J LIPID RES, V31, P2045; COLE TG, 1982, J LIPID RES, V23, P81; COLLINS DR, 1988, NUCLEIC ACIDS RES, V16, P8361, DOI 10.1093/nar/16.17.8361; DAVIS RA, 1979, J BIOL CHEM, V254, P2010; DAVIS RA, 1982, J BIOL CHEM, V257, P908; DAVIS RA, 1985, J BIOL CHEM, V260, P4137; DIXON JL, 1991, J BIOL CHEM, V266, P5080; DUERDEN JM, 1989, BIOCHEM J, V263, P937, DOI 10.1042/bj2630937; ELOVSON J, 1981, P NATL ACAD SCI-BIOL, V78, P157, DOI 10.1073/pnas.78.1.157; ERICKSON SK, 1986, J LIPID RES, V27, P875; FINE MB, 1960, AM J PHYSIOL, V199, P403, DOI 10.1152/ajplegacy.1960.199.3.403; GIBBONS GF, 1990, BIOCHEM J, V268, P1; Goldstein JL, 1983, METABOLIC BASIS INHE, P672; GORDON RS, 1957, J CLIN INVEST, V36, P810, DOI 10.1172/JCI103486; GRAHAM DL, 1991, BIOCHEMISTRY-US, V30, P5616, DOI 10.1021/bi00236a040; HEIMBERG M, 1963, BIOCHEM PHARMACOL, V12, P392, DOI 10.1016/0006-2952(63)90067-4; HERSCOVITZ H, 1991, P NATL ACAD SCI USA, V88, P7313, DOI 10.1073/pnas.88.16.7313; HERSHEY NB, 1991, ANN REV BIOCH, V91, P717; KANE JP, 1983, ANNU REV PHYSIOL, V45, P637, DOI 10.1146/annurev.ph.45.030183.003225; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG CA, 1990, J LIPID RES, V31, P2079; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUSIS AJ, 1985, P NATL ACAD SCI USA, V82, P4597, DOI 10.1073/pnas.82.14.4597; MANIATIS T, 1982, MOL CLONING LABORATO, P90; MOOS M, 1983, EMBO J, V2, P757, DOI 10.1002/j.1460-2075.1983.tb01496.x; PATSCH W, 1986, J BIOL CHEM, V261, P9603; PATSCH W, 1983, J CLIN INVEST, V72, P371, DOI 10.1172/JCI110977; PEASE RJ, 1991, NATURE, V353, P448, DOI 10.1038/353448a0; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; PULLINGER CR, 1989, J LIPID RES, V30, P1065; PULLINGER CR, 1985, BIOCHIM BIOPHYS ACTA, V833, P44, DOI 10.1016/0005-2760(85)90251-6; SALAM WH, 1988, BIOCHEM J, V251, P809, DOI 10.1042/bj2510809; SATO R, 1990, J BIOL CHEM, V265, P11880; Siegel S., 2009, NONPARAMETRIC STAT B, V2nd; SPARKS CE, 1986, METABOLISM, V35, P1128, DOI 10.1016/0026-0495(86)90026-0; SPARKS JD, 1990, J BIOL CHEM, V265, P8854; TANABE S, 1989, IN VITRO CELL DEV B, V25, P1129; TAYLOR JA, 1984, BIOCHIM BIOPHYS ACTA, V769, P171, DOI 10.1016/0005-2736(84)90020-8; THRIFT RN, 1986, J LIPID RES, V27, P236; VANHARKEN DR, 1969, J BIOL CHEM, V244, P2278; WETTESTEN M, 1985, EUR J BIOCHEM, V149, P461, DOI 10.1111/j.1432-1033.1985.tb08947.x; YANG CY, 1986, NATURE, V323, P738, DOI 10.1038/323738a0; YAO ZM, 1991, J BIOL CHEM, V266, P3300; YOUNG SG, 1987, J CLIN INVEST, V79, P1831, DOI 10.1172/JCI113025; YOUNG SG, 1990, J CLIN INVEST, V85, P933, DOI 10.1172/JCI114522	60	144	145	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15657	15664						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1639804				2022-12-25	WOS:A1992JG11300063
J	JONES, MH; NAKAMURA, Y				JONES, MH; NAKAMURA, Y			DELETION MAPPING OF CHROMOSOME-3P IN FEMALE GENITAL-TRACT MALIGNANCIES USING MICROSATELLITE POLYMORPHISMS	ONCOGENE			English	Article							RENAL-CELL CARCINOMA; PRIMARY BREAST-CANCER; SHORT ARM; SIMPLE SEQUENCES; OVARIAN-CANCER; LUNG-CANCER; DNA MARKERS; HETEROZYGOSITY; ALLELOTYPE; PROGRESSION	We have constructed deletion maps of chromosome 3p for cancers of the female genital tract (uterine endometrium, uterine cervix and ovary). The tumours were tested for loss of heterozygosity using CA-repeat polymorphisms. The high degree of informativeness of these markers allowed the construction of detailed deletion maps from a relatively small number of samples. A common region of deletion was identified at chromosome 3p13-21.1 in endometrial cancer and at 3p13-14.3 in cervical cancer; 5 out of 13 (38%) endometrial cancers and six out of eight (75%) cervical cancers showed loss of heterozygosity at these regions. In ovarian cancer a separate common region of deletion was identified at 3p21.1-22; two out of four (50%) ovarian cancers had alleles deleted at this region. These data suggest the presence of a tumour-suppressor gene(s) for endometrial and cervical cancer at 3p13-21.3 and a separate gene at 3p21.1-22 that is involved in the carcinogenesis of ovarian cancer.	JAPANESE FDN CANC RES,INST CANC,DEPT BIOCHEM,1-37-1 KAMI IKEBUKURO,TOSHIMA KU,TOKYO 170,JAPAN	Japanese Foundation for Cancer Research				Jones, Michael/0000-0002-2251-1990				ANGLARD P, 1991, CANCER RES, V51, P1071; BRAUCH H, 1990, GENE CHROMOSOME CANC, V1, P240, DOI 10.1002/gcc.2870010309; DEVILEE P, 1989, GENOMICS, V5, P554, DOI 10.1016/0888-7543(89)90023-2; EHLEN T, 1990, ONCOGENE, V5, P219; JONES MH, 1992, IN PRESS GENES CHROM; JONES MH, 1992, IN PRESS HUM MOL GEN; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KOVACS G, 1988, P NATL ACAD SCI USA, V85, P1571, DOI 10.1073/pnas.85.5.1571; LITT M, 1989, AM J HUM GENET, V44, P397; LOTHE RA, 1989, GENOMICS, V5, P134, DOI 10.1016/0888-7543(89)90097-9; MORITA R, 1991, CANCER RES, V51, P820; NAKAMURA Y, 1987, SCIENCE, V325, P939; PATHAK S, 1982, NEW ENGL J MED, V301, P592; SATO T, 1991, CANCER RES, V51, P5794; SATO T, 1991, CANCER RES, V51, P5118; SATO T, 1990, CANCER RES, V50, P7184; SMEETS DFCM, 1986, HUM GENET, V72, P215, DOI 10.1007/BF00291880; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; TAUTZ D, 1984, NUCLEIC ACIDS RES, V12, P4127, DOI 10.1093/nar/12.10.4127; TAUTZ D, 1989, NUCLEIC ACIDS RES, V17, P6463, DOI 10.1093/nar/17.16.6463; TRENT JM, 1985, CANCER GENET CYTOGEN, V14, P153, DOI 10.1016/0165-4608(85)90226-2; WANG N, 1984, CANCER GENET CYTOGEN, V11, P479, DOI 10.1016/0165-4608(84)90028-1; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WHANGPENG J, 1984, CANCER GENET CYTOGEN, V11, P91, DOI 10.1016/0165-4608(84)90102-X; YAMAKAWA K, 1991, GENOMICS, V9, P536, DOI 10.1016/0888-7543(91)90421-A; YAMAKAWA K, 1991, CANCER RES, V51, P4707; YAMAKAWA K, 1991, GENOMICS, V11, P565, DOI 10.1016/0888-7543(91)90063-K; YOKOJAMA S, 1992, IN PRESS CANCER RES, V52; YOKOTA J, 1989, CANCER RES, V49, P3598	30	106	107	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1992	7	8					1631	1634						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1630822				2022-12-25	WOS:A1992JE81300020
J	PORTER, RK; SCOTT, JM; BRAND, MD				PORTER, RK; SCOTT, JM; BRAND, MD			CHOLINE TRANSPORT INTO RAT-LIVER MITOCHONDRIA - CHARACTERIZATION AND KINETICS OF A SPECIFIC TRANSPORTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYLCARNITINE TRANSLOCASE; S-ADENOSYLMETHIONINE; RUTHENIUM RED; INHIBITION; BETAINE; DEHYDROGENASE; METABOLISM; DEFICIENCY; COMPLEX; QUININE	Rat liver mitochondria possess a specific choline transporter in the inner membrane. The transporter shows saturable kinetics at high membrane potential with a K(m) of 220-mu-M and a V(max) of 0.4 nmol/mg of protein/min at pH 7.0 and 25-degrees-C. At physiological concentrations of choline, the rate of choline uptake by the transporter shows a linear dependence on membrane potential; uptake is distinct from the nonspecific cation diffusion process. Hemicholinium-3, hemicholinium-15, quinine, and quinidine, all analogues of choline, are high affinity competitive inhibitors of choline transport with K(i) values of 17, 55, 15, and 127-mu-M, respectively. The choline transporter is distinct from other known mitochondrial transporters. Rat heart mitochondria do not appear to possess a choline transporter. Evidence suggests that the transporter is an electrophoretic uniporter. Analogue studies have shown that the hydroxyl and the quaternary ammonium groups of choline are necessary for binding to the transporter. A comparison of molecular models of choline and the high affinity inhibitors has provided evidence for the preferred conformation of choline for binding to the transporter. The presence of a choline transporter in the mitochondrial inner membrane provides a potential site for control of choline oxidation and hence supply of endogenous betaine.	UNIV DUBLIN TRINITY COLL,DEPT BIOCHEM,DUBLIN 2,IRELAND	Trinity College Dublin	PORTER, RK (corresponding author), UNIV CAMBRIDGE,DEPT BIOCHEM,TENNIS COURT RD,CAMBRIDGE CB2 1QW,ENGLAND.		Brand, Martin D/A-9423-2012	Brand, Martin D/0000-0003-4418-6153; Porter, Richard/0000-0001-9854-5161				ALLEN FH, 1983, ACCOUNTS CHEM RES, V16, P146, DOI 10.1021/ar00089a001; BIANCHI G, 1964, J BIOL CHEM, V239, P3947; BROWN GC, 1986, BIOCHEM J, V234, P75, DOI 10.1042/bj2340075; BROWN GC, 1988, BIOCHEM J, V252, P473, DOI 10.1042/bj2520473; BRYLA J, 1976, FEBS LETT, V72, P331, DOI 10.1016/0014-5793(76)80998-2; Chappell J. B., 1972, SUBCELLULAR COMPONEN, P77; CORNISHB.A, 1974, BIOCHEM J, V137, P143, DOI 10.1042/bj1370143; CYBULSKI RL, 1977, BIOCHEMISTRY-US, V16, P5116, DOI 10.1021/bi00642a026; DERIDDER JJ, 1973, BIOCHIM BIOPHYS ACTA, V291, P557, DOI 10.1016/0005-2736(73)90507-5; DERIDDER JJ, 1973, BIOCHIM BIOPHYS ACTA, V325, P397, DOI 10.1016/0005-2728(73)90200-4; DERIDDER JJM, 1976, BIOCHIM BIOPHYS ACTA, V449, P236, DOI 10.1016/0005-2728(76)90136-5; DERIDDER JJM, 1975, BIOCHIM BIOPHYS ACTA, V408, P112, DOI 10.1016/0005-2728(75)90003-1; DIWAN JJ, 1986, BIOCHEM BIOPH RES CO, V135, P830, DOI 10.1016/0006-291X(86)91003-X; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; ELFORD BC, 1990, J PHYSIOL-LONDON, V426, pP100; FEINBERG RH, 1967, J BIOL CHEM, V242, P4614; FINKELSTEIN JD, 1974, METABOLISM, V23, P387, DOI 10.1016/0026-0495(74)90057-2; FINKELSTEIN JD, 1990, J NUTR BIOCHEM, V1, P228, DOI 10.1016/0955-2863(90)90070-2; GARLID KD, 1986, J BIOL CHEM, V261, P1529; GORNALL AG, 1949, J BIOL CHEM, V177, P751; GROEN AK, 1982, J BIOL CHEM, V257, P2754; GROSSMAN EB, 1989, AM J PHYSIOL, V256, pF107; HAFNER RP, 1991, BIOCHEM J, V275, P75, DOI 10.1042/bj2750075; HALESTRAP AP, 1974, BIOCHEM J, V138, P313, DOI 10.1042/bj1380313; HAUBRICH DR, 1981, BIOCHEM PHARMACOL, V30, P2993, DOI 10.1016/0006-2952(81)90265-3; HOFFMAN DR, 1979, CAN J BIOCHEM CELL B, V57, P56, DOI 10.1139/o79-007; IDELLWENGER JA, 1981, J BIOL CHEM, V256, P5597; JOHNSON RN, 1973, BIOCHEM J, V134, P769, DOI 10.1042/bj1340769; KEATING JN, 1991, LANCET, V337, P935, DOI 10.1016/0140-6736(91)91570-K; KIEHL R, 1980, BIOCHEMISTRY-US, V19, P541, DOI 10.1021/bi00544a023; LANDFALD B, 1986, J BACTERIOL, V165, P849, DOI 10.1128/jb.165.3.849-855.1986; LAYZER RB, 1978, NEUROLOGY, V28, P485; LERNER J, 1989, COMP BIOCHEM PHYS C, V93, P1, DOI 10.1016/0742-8413(89)90002-9; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; LUMB M, 1983, BIOCHIM BIOPHYS ACTA, V756, P354, DOI 10.1016/0304-4165(83)90345-8; MATSUZAWA T, 1974, J BIOCHEM, V75, P601, DOI 10.1093/oxfordjournals.jbchem.a130428; MCGIVAN JD, 1977, BIOCHEM J, V162, P147, DOI 10.1042/bj1620147; MCKEEVER MP, 1991, CLIN SCI, V81, P551, DOI 10.1042/cs0810551; MEIJER AJ, 1970, FEBS LETT, V8, P41, DOI 10.1016/0014-5793(70)80220-4; MITCHELL AD, 1979, J ANIM SCI, V49, P764, DOI 10.2527/jas1979.493764x; MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405; MOORE CL, 1971, BIOCHEM BIOPH RES CO, V42, P298, DOI 10.1016/0006-291X(71)90102-1; MURTHY MSR, 1984, J BIOL CHEM, V259, P9082; PALMIERI F, 1972, EUR J BIOCHEM, V29, P408, DOI 10.1111/j.1432-1033.1972.tb02003.x; PARVIN R, 1978, J BIOL CHEM, V253, P1944; QIU ZH, 1990, SCI CHINA SER B, V33, P955; REED KC, 1974, BIOCHEM J, V140, P143, DOI 10.1042/bj1400143; ROBINSON BH, 1972, J MEMBRANE BIOL, V7, P391, DOI 10.1007/BF01867928; SCARPA A, 1973, J GEN PHYSIOL, V62, P756, DOI 10.1085/jgp.62.6.756; SCOTT JM, 1981, LANCET, V2, P334; SCOTT JM, 1979, CHEM BIOL PTERIDINES, P335; SEBALD W, 1981, CURR TOP BIOENERG, V12, P1; SMOLIN LA, 1981, J PEDIATR-US, V99, P467, DOI 10.1016/S0022-3476(81)80352-6; TSUGE H, 1980, BIOCHIM BIOPHYS ACTA, V614, P274, DOI 10.1016/0005-2744(80)90217-X; TYLER DD, 1977, BIOCHEM J, V166, P571, DOI 10.1042/bj1660571; TYLER DD, 1966, ARCH BIOCHEM BIOPHYS, V115, P373, DOI 10.1016/0003-9861(66)90287-6; VANDERWESTHUYZE.J, 1982, LIFE SCI, V31, P325; VANDERWESTHUYZEN J, 1984, J NUTR, V114, P1106, DOI 10.1093/jn/114.6.1106; VIGNAIS PV, 1971, FEBS LETT, V13, P28, DOI 10.1016/0014-5793(71)80656-7; WEIR DG, 1988, J NEUROCHEM, V51, P1949, DOI 10.1111/j.1471-4159.1988.tb01184.x; WILKEN DR, 1970, BIOCHIM BIOPHYS ACTA, V216, P305, DOI 10.1016/0005-2728(70)90222-7; Zeisel S.H., 1988, MODERN NUTR HLTH DIS, P440	62	49	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14637	14646						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634511				2022-12-25	WOS:A1992JF08800025
J	THON, VJ; VIGNERONLESENS, C; MARIANNEPEPIN, T; MONTREUIL, J; DECQ, A; RACHEZ, C; BALL, SG; CANNON, JF				THON, VJ; VIGNERONLESENS, C; MARIANNEPEPIN, T; MONTREUIL, J; DECQ, A; RACHEZ, C; BALL, SG; CANNON, JF			COORDINATE REGULATION OF GLYCOGEN-METABOLISM IN THE YEAST SACCHAROMYCES-CEREVISIAE - INDUCTION OF GLYCOGEN BRANCHING ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID CONTROL; NUCLEOTIDE-SEQUENCE; 2 FORMS; SYNTHASE; GENE; DNA; PHOSPHORYLASE; INTERCONVERSION; PURIFICATION; SYSTEM	The yeast glycogen branching enzyme (EC 2.4.1.18) is shown to be induced in batch culture simultaneously with the onset of intracellular glycogen accumulation. The branching enzyme structural gene (GLC3) has been cloned. Its predicted amino acid sequence is very similar to procaryotic branching enzymes. Northern analysis indicates that GLC3 mRNA abundance increases in late exponential growth phase coincident with glycogen accumulation. Disruption of the branching enzyme structural gene establishes that branching enzyme activity is an absolute requirement for maximal glycogen synthesis.	UNIV MISSOURI, SCH MED M642, DEPT MOLEC MICROBIOL & IMMUNOL, COLUMBIA, MO 65212 USA; UNIV SCI & TECH LILLE FLANDRES ARTOIS, CHIM BIOL LAB, CNRS, UNITE MIXTE RECH 111, F-59655 VILLENEUVE DASCQ, FRANCE	University of Missouri System; University of Missouri Columbia; Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille			Rachez, Christophe/GLR-0102-2022	Cannon, John/0000-0001-6698-176X; Rachez, Christophe/0000-0001-8502-4738; Ball, Steven/0000-0003-1629-1650	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM040326, R01GM040326] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40326] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAECKER PA, 1986, J BIOL CHEM, V261, P8738; BAI G, 1990, J BIOL CHEM, V265, P7843; BHATTACHARYYA MK, 1990, CELL, V60, P115, DOI 10.1016/0092-8674(90)90721-P; BOTSTEIN D, 1979, GENE, V8, P17, DOI 10.1016/0378-1119(79)90004-0; BOYER CD, 1978, CARBOHYD RES, V61, P321, DOI 10.1016/S0008-6215(00)84492-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown B. I., 1966, METHOD ENZYMOL, V8, P395; BROWN DH, 1961, P NATL ACAD SCI USA, V47, P479, DOI 10.1073/pnas.47.4.479; CAMERON S, 1988, CELL, V53, P555, DOI 10.1016/0092-8674(88)90572-7; CANNON JF, 1990, J BIOL CHEM, V265, P11897; CARABAZA A, 1990, BIOCHEM J, V268, P401, DOI 10.1042/bj2680401; CARLE GF, 1985, P NATL ACAD SCI USA, V82, P3756, DOI 10.1073/pnas.82.11.3756; CHESTER VE, 1968, J GEN MICROBIOL, V51, P47, DOI 10.1099/00221287-51-1-49; DAMOTTE M, 1968, BIOCHEM BIOPH RES CO, V32, P916, DOI 10.1016/0006-291X(68)90114-9; FARKAS I, 1990, J BIOL CHEM, V265, P20879; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRANCOIS J, 1988, EUR J BIOCHEM, V174, P561, DOI 10.1111/j.1432-1033.1988.tb14135.x; FRANCOIS J, 1988, EUR J BIOCHEM, V174, P551, DOI 10.1111/j.1432-1033.1988.tb14134.x; GUNJA ZH, 1960, BIOCHEM J, V75, P441, DOI 10.1042/bj0750441; GUNJA-SMITH Z, 1977, Journal of Bacteriology, V130, P818; HENIKOFF S, 1984, GENE, V28, P352; HERS HG, 1976, ANNU REV BIOCHEM, V45, P167, DOI 10.1146/annurev.bi.45.070176.001123; HINNEBUSCH AG, 1984, P NATL ACAD SCI-BIOL, V81, P6442, DOI 10.1073/pnas.81.20.6442; HINNEBUSCH AG, 1983, P NATL ACAD SCI-BIOL, V80, P5374, DOI 10.1073/pnas.80.17.5374; HWANG PK, 1989, MOL CELL BIOL, V9, P1659, DOI 10.1128/MCB.9.4.1659; HWANG PK, 1986, NATURE, V324, P80, DOI 10.1038/324080a0; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KIEL JAKW, 1990, GENE, V89, P77, DOI 10.1016/0378-1119(90)90208-9; LILLIE SH, 1980, J BACTERIOL, V143, P1384, DOI 10.1128/JB.143.3.1384-1394.1980; Maniatis T., 1982, MOL CLONING; MORTIMER RK, 1989, YEAST, V5, P321, DOI 10.1002/yea.320050503; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROTHMAN LB, 1969, BIOCHEMISTRY-US, V8, P3332, DOI 10.1021/bi00836a030; ROTHMANDENES LB, 1970, P NATL ACAD SCI USA, V66, P967, DOI 10.1073/pnas.66.3.967; ROWEN DW, 1992, MOL CELL BIOL, V12, P22, DOI 10.1128/MCB.12.1.22; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHERMAN F, 1986, LABORATORY COURSE MA; SIKORSKI RS, 1989, GENETICS, V122, P19; SWINTON SJ, 1989, FOOD BIOTECHNOL, V3, P197, DOI 10.1080/08905438909549708	39	57	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15224	15228						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634552				2022-12-25	WOS:A1992JF08800105
J	RYSER, HJP; MANDEL, R; GHANI, F				RYSER, HJP; MANDEL, R; GHANI, F			CELL-SURFACE SULFHYDRYLS ARE REQUIRED FOR THE CYTOTOXICITY OF DIPHTHERIA-TOXIN BUT NOT OF RICIN IN CHINESE-HAMSTER OVARY CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LOW PH; DISULFIDE; ENTRY; RECEPTOR; ENDOCYTOSIS; MUTANT	A previous study on cleavage of disulfide bonds in endocytosed model compounds had shown that an initial phase of cleavage was totally inhibited by membrane-impermeant sulfhydryl inhibitors and thus was mediated by cell surface sulfhydryls (Feener, E. P., Shen, W.-C., and Ryser, H. J.-P. (1990) J. Biol. Chem. 265, 18780-18785). This paper uses the same inhibitors (5,5'-dithiobis(2-nitrobenzoic acid) and p-chloromercuriphenylsulfonic acid) to examine the role of surface sulfhydryls in the cytotoxicity of diphtheria toxin (DT). Since the interchain disulfide of endocytosed DT must be cleaved prior to translocation of chain A from endosomes to cytoplasm, it was postulated that surface sulfhydryls might mediate the cleavage of that disulfide bond as well. Both sulfhydryl blockers did indeed markedly inhibit DT cytotoxicity. This effect was not due to inactivation of unbound DT, inhibition of receptor-mediated endocytosis, or impairment of acidification of endosomes. We conclude that cell surface sulfhydryls susceptible to blockage by 5,5'-dithiobis(2-nitrobenzoic acid) and p-chloromercuriphenylsulfonic acid are required for the cytotoxicity of DT and, most likely, for the reductive cleavage of DT's interchain disulfides. Ricin cytotoxicity was not decreased; this is consistent with the view that ricin reaches the cytoplasm from a late endocytic structure and with the finding that endocytosed disulfides are also cleaved in a cell fraction containing elements of the Golgi apparatus (Feener, E. P., Shen, W.-C., and Ryser, H. J.-P. (1990) J. Biol. Chem. 265, 18780-18785).			RYSER, HJP (corresponding author), BOSTON UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02118, USA.				NCI NIH HHS [CA-14551] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA014551] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CLARK S, 1983, J BIOL CHEM, V258, P1434; DRAPER RK, 1980, J CELL BIOL, V87, P849, DOI 10.1083/jcb.87.3.849; FEENER EP, 1990, J BIOL CHEM, V265, P18780; GALLOWAY CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3334, DOI 10.1073/pnas.80.11.3334; GILLILAND DG, 1981, J BIOL CHEM, V256, P2731; GONZALEZNORIEGA A, 1980, J CELL BIOL, V85, P839, DOI 10.1083/jcb.85.3.839; LEWIS MS, 1986, J BIOL CHEM, V261, P11572; MANDEL R, 1991, IN PRESS J CELL PHYS; MARNELL MH, 1984, J CELL BIOL, V99, P1907, DOI 10.1083/jcb.99.6.1907; MOEHRING JM, 1983, INFECT IMMUN, V41, P998, DOI 10.1128/IAI.41.3.998-1009.1983; MOSKAUG JO, 1987, J BIOL CHEM, V262, P10339; OLSNES S, 1976, J BIOL CHEM, V251, P3985; ROBBINS AR, 1983, J CELL BIOL, V96, P1064, DOI 10.1083/jcb.96.4.1064; RYSER HJP, 1988, J CELL PHYSIOL, V135, P277, DOI 10.1002/jcp.1041350215; SANDVIG K, 1981, J BIOL CHEM, V256, P9068; SANDVIG K, 1980, J CELL BIOL, V87, P828, DOI 10.1083/jcb.87.3.828; SHEN WC, 1985, J BIOL CHEM, V260, P905; VANDEURS B, 1986, J CELL BIOL, V102, P39; WRIGHT HT, 1984, J BIOL CHEM, V259, P1649; WRIGHT HT, 1987, ARCH BIOCHEM BIOPHYS, V256, P280, DOI 10.1016/0003-9861(87)90447-4	20	74	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18439	18442						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1655751				2022-12-25	WOS:A1991GJ47200008
J	SHIBATA, H; ROBINSON, FW; SODERLING, TR; KONO, T				SHIBATA, H; ROBINSON, FW; SODERLING, TR; KONO, T			EFFECTS OF OKADAIC ACID ON INSULIN-SENSITIVE CAMP PHOSPHODIESTERASE IN RAT ADIPOCYTES - EVIDENCE THAT INSULIN MAY STIMULATE THE ENZYME BY PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; FAT-CELLS; GLUCOSE-TRANSPORT; ADIPOSE-TISSUE; INHIBITORS; ACTIVATION; LIPOLYSIS; HORMONE; METABOLISM; AGENTS	Okadaic acid, a potent inhibitor of Type 1 and Type 2A protein phosphatases, was used to investigate the mechanism of insulin action on membrane-bound low K(m) cAMP phosphodiesterase in rat adipocytes. Upon incubation of cells with 1-mu-M okadaic acid for 20 min, phosphodiesterase was stimulated 3.7- to 3.9-fold. This stimulation was larger than that elicited by insulin (2.5- to 3.0-fold). Although okadaic acid enhanced the effect of insulin, the maximum effects of the two agents were not additive. When cells were pretreated with 1-(5-isoquinolinylsulfonyl)-2-methylpiperazine (H-7) (see below), the level of phosphodiesterase stimulation by okadaic acid was rendered smaller, similar to that attained by insulin. In cells that had been treated with 2 mM KCN, okadaic acid (like insulin) failed to stimulate phosphodiesterase, suggesting that ATP was essential. Also, as reported previously, the effect of insulin on phosphodiesterase was reversed upon exposure of hormone-treated cells to KCN. This deactivation of previously-stimulated phosphodiesterase was blocked by okadaic acid, but not by insulin. The above KCN experiments were carried out with cells in which A-kinase activity was minimized by pretreatment with H-7. Okadaic acid mildly stimulated basal glucose transport and, at the same time, strongly inhibited the action of insulin thereon. It is suggested that insulin may stimulate phosphodiesterase by promoting its phosphorylation and that the hormonal effect may be reversed by a protein phosphatase which is sensitive to okadaic acid. The hypothetical protein kinase thought to be involved in the insulin-dependent stimulation of phosphodiesterase appears to be more H-7-resistant than A-kinase.	VANDERBILT UNIV,MED CTR,SCH MED,DEPT MOLEC PHYSIOL & BIOPHYS,NASHVILLE,TN 37232	Vanderbilt University					NIDDK NIH HHS [DK 06725, DK17808, DK 19925] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK017808, R01DK006725, R01DK019925] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Biolojan C., 1988, BIOCHEM J, V256, P283; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTCHER RW, 1966, J BIOL CHEM, V241, P1652; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; CORBIN JD, 1972, J BIOL CHEM, V247, P3736; CZECH MP, 1988, J BIOL CHEM, V263, P11017; DEGERMAN E, 1990, P NATL ACAD SCI USA, V87, P533, DOI 10.1073/pnas.87.2.533; DOLE VP, 1960, J BIOL CHEM, V235, P2595; ELKS ML, 1984, ENDOCRINOLOGY, V115, P1262, DOI 10.1210/endo-115-4-1262; GETTYS TW, 1988, J BIOL CHEM, V263, P10359; GOTO Y, 1990, FASEB J, V4, pA2078; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; KIECHLE FL, 1981, FEBS LETT, V133, P279, DOI 10.1016/0014-5793(81)80524-8; KONO T, 1975, J BIOL CHEM, V250, P7826; KONO T, 1983, RECENT PROG HORM RES, V39, P519; KONO T, 1977, J BIOL CHEM, V252, P2226; KONO T, 1973, J BIOL CHEM, V248, P7417; LAWRENCE JC, 1990, J BIOL CHEM, V265, P19768; LOTEN EG, 1980, J BIOL CHEM, V255, P7838; MACPHEE CH, 1988, J BIOL CHEM, V263, P10353; MAKINO H, 1980, J BIOL CHEM, V255, P7845; MAKINO H, 1980, J BIOL CHEM, V255, P7850; NAKAGAWA F, 1985, J ANTIBIOT, V38, P823, DOI 10.7164/antibiotics.38.823; PAWLSON LG, 1974, P NATL ACAD SCI USA, V71, P1639, DOI 10.1073/pnas.71.5.1639; ROBINSON FW, 1989, J BIOL CHEM, V264, P16458; RODBELL M, 1964, J BIOL CHEM, V239, P375; SHIBATA H, 1990, BIOCHEM BIOPH RES CO, V167, P614, DOI 10.1016/0006-291X(90)92069-C; SHIBATA H, 1990, BIOCHEM BIOPH RES CO, V170, P533, DOI 10.1016/0006-291X(90)92124-I; SHIBATA H, 1991, ARCH BIOCHEM BIOPHYS, V285, P97, DOI 10.1016/0003-9861(91)90333-E; SHIBATA S, 1982, J PHARMACOL EXP THER, V223, P135; SMITH CJ, 1989, MOL PHARMACOL, V35, P381; SODERLING TR, 1973, J BIOL CHEM, V248, P1822; TACHIBANA K, 1981, J AM CHEM SOC, V103, P2469, DOI 10.1021/ja00399a082; TAKAI A, 1987, FEBS LETT, V217, P81, DOI 10.1016/0014-5793(87)81247-4; TOYODA N, 1987, J BIOL CHEM, V262, P2737; VEGA FV, 1980, ARCH BIOCHEM BIOPHYS, V203, P167, DOI 10.1016/0003-9861(80)90165-4; ZINMAN B, 1974, J BIOL CHEM, V249, P2182	39	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					17948	17953						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1655732				2022-12-25	WOS:A1991GG55300039
J	ASTROM, A; TAVAKKOL, A; PETTERSSON, U; CROMIE, M; ELDER, JT; VOORHEES, JJ				ASTROM, A; TAVAKKOL, A; PETTERSSON, U; CROMIE, M; ELDER, JT; VOORHEES, JJ			MOLECULAR-CLONING OF 2 HUMAN CELLULAR RETINOIC ACID-BINDING PROTEINS (CRABP) - RETINOIC ACID-INDUCED EXPRESSION OF CRABP-II BUT NOT CRABP-I IN ADULT HUMAN SKIN INVIVO AND IN SKIN FIBROBLASTS INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; HUMAN KERATINOCYTES; CDNA CLONE; RECEPTOR; DIFFERENTIATION; RAT; PURIFICATION; MODULATION; GROWTH; CELLS	Cellular retinoic acid binding proteins (CRABP) are low molecular weight proteins whose precise function remains unknown. To investigate the role of CRABP in human skin we have cloned the human CRABP-II cDNA as well as the coding region of human CRABP-I. The predicted amino acid sequences of human CRABP-I and CRABP-II demonstrated a 99.3 and 93.5% identity to mouse CRABP-I and CRABP-II, respectively. CRABP-I transcripts were undetectable in adult human epidermis by RNA blot hybridization, while the CRABP-II cDNA probe detected an approximately 1.2-kilobase mRNA transcript. External application of 0.1% retinoic acid cream in vivo for 16 h resulted in a 16-fold induction of CRABP-II transcripts, while CRABP-I mRNA remained undetectable. Expression of CRABP-II, but not CRABP-I mRNA, was also markedly increased (> 15-fold) by retinoic acid treatment of fibroblasts cultured from human skin, whereas no significant induction of CRABP-II mRNA was observed in human lung fibroblasts. Human CRABP-II but not CRABP-I mRNA was significantly increased by agents which are known to induce keratinocyte differentiation in vitro. The marked inducibility of the CRABP-II gene is compatible with the idea that this isoform is important in retinoic acid-mediated regulation of human skin growth and differentiation.			ASTROM, A (corresponding author), UNIV MICHIGAN,DEPT DERMATOL,KRESGE I,R6558,ANN ARBOR,MI 48109, USA.							ASSELINEAU D, 1989, DEV BIOL, V133, P322, DOI 10.1016/0012-1606(89)90037-7; BAILEY JS, 1988, J BIOL CHEM, V263, P9326; BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BOYCE ST, 1986, IN VITRO MODELS CANC, V3, P245; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; EICHELE G, 1989, TRENDS GENET, V5, P246, DOI 10.1016/0168-9525(89)90096-6; ELDER JT, 1991, J INVEST DERMATOL, V96, P425, DOI 10.1111/1523-1747.ep12469889; ELDER JT, 1990, J INVEST DERMATOL, V94, P19, DOI 10.1111/1523-1747.ep12873313; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLOYD EE, 1989, MOL CELL BIOL, V9, P4846, DOI 10.1128/MCB.9.11.4846; GIGUERE V, 1990, P NATL ACAD SCI USA, V87, P6233, DOI 10.1073/pnas.87.16.6233; HARPER RA, 1979, SCIENCE, V204, P526, DOI 10.1126/science.432659; HIRSCHELSCHOLZ S, 1989, EUR J CLIN INVEST, V19, P220, DOI 10.1111/j.1365-2362.1989.tb00221.x; KITAMOTO T, 1988, BIOCHEM BIOPH RES CO, V157, P1302, DOI 10.1016/S0006-291X(88)81016-7; KOPAN R, 1989, J CELL BIOL, V109, P295, DOI 10.1083/jcb.109.1.295; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LI E, 1986, P NATL ACAD SCI USA, V83, P5779, DOI 10.1073/pnas.83.16.5779; LIPPMAN SM, 1989, PHARMACOL THERAPEUT, V40, P107, DOI 10.1016/0163-7258(89)90078-8; MADEN M, 1988, NATURE, V335, P733, DOI 10.1038/335733a0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Maniatis T., 1982, MOL CLONING; NILSSON MHL, 1988, EUR J BIOCHEM, V173, P45, DOI 10.1111/j.1432-1033.1988.tb13964.x; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PILLAI S, 1990, J CELL PHYSIOL, V143, P294, DOI 10.1002/jcp.1041430213; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIEGENTHALER G, 1987, ARCH DERMATOL, V123, pA1690, DOI 10.1001/archderm.123.12.1690a; SIEGENTHALER G, 1988, EXP CELL RES, V178, P114, DOI 10.1016/0014-4827(88)90383-7; SIEGENTHALER G, 1986, J INVEST DERMATOL, V86, P42, DOI 10.1111/1523-1747.ep12283788; SPORN MB, 1983, CANCER RES, V43, P3034; STONER CM, 1989, CANCER RES, V49, P1497; SUMMERBELL D, 1990, TRENDS NEUROSCI, V13, P142, DOI 10.1016/0166-2236(90)90006-V; SUNDELIN J, 1985, J BIOL CHEM, V260, P6488; TAKASE S, 1986, ARCH BIOCHEM BIOPHYS, V247, P328, DOI 10.1016/0003-9861(86)90591-6; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; VOORHEES JJ, 1972, ARCH DERMATOL, V105, P695, DOI 10.1001/archderm.105.5.695; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	37	207	213	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17662	17666						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1654334				2022-12-25	WOS:A1991GF44500100
J	YAMAGUCHI, M; HATEFI, Y				YAMAGUCHI, M; HATEFI, Y			MITOCHONDRIAL ENERGY-TRANSDUCING NICOTINAMIDE NUCLEOTIDE TRANSHYDROGENASE - PURIFICATION AND PROPERTIES OF THE PROTEINASE K-BISECTED ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATIVE BACTERIORHODOPSIN STRUCTURE; 2 CHYMOTRYPTIC FRAGMENTS; BEEF-HEART MITOCHONDRIA; ESCHERICHIA-COLI; REGENERATION; SEQUENCE; MEMBRANE; CLEAVAGE; SITES	The mitochondrial proton-translocating nicotinamide nucleotide transhydrogenase is embedded in the inner membrane as a homodimer of monomer M(r) = 109,288. Its N-terminal 430 residues and C-terminal 200 residues protrude into the matrix, whereas its central 400 residues appear to intercalate into the inner membrane as 14 hydrophobic clusters of about 20 residues each (Yamaguchi, M., and Hatefi, Y. (1991) J. Biol. Chem. 266, 5728-5735). Treatment of mitoplasts (mitochondria denuded of outer membrane) with several proteolytic enzymes cleaves the transhydrogenase into a 72-kDa N-terminal and a 37-kDa C-terminal fragment. The cleavage site of proteinase K was determined to be Ala690-Ala691 (see above reference), which is located in a small loop of the transhydrogenase exposed on the cytosolic side of the inner membrane. This paper shows that the bisected transhydrogenase can be purified from proteinase K-treated mitoplasts with retention of greater-than-or-equal-to 85% transhydrogenase activity. The inactivation rate of the bisected enzyme by trypsin and N-ethylmaleimide was altered in the presence of NADP and NADPH, suggesting substrate-induced conformation changes similar to those reported previously for the intact transhydrogenase. Also, like the intact enzyme, proteoliposomes of the bisected transhydrogenase were capable of membrane potential formation and internal acidification coupled to NADPH --> NAD transhydrogenation. The properties of the bisected transhydrogenase have been discussed in relation to those of the two-subunit Escherichia coli transhydrogenase, the bisected lac permease (via gene restriction), and the fragmented and reconstituted bacteriorhodopsin.	Scripps Res Inst, RES INST, DEPT MOLEC & EXPTL MED, DIV BIOCHEM, LA JOLLA, CA 92037 USA	Scripps Research Institute					NIGMS NIH HHS [GM24887] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024887] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CLARKE DM, 1986, EUR J BIOCHEM, V158, P647, DOI 10.1111/j.1432-1033.1986.tb09802.x; EYTAN GD, 1987, J BIOL CHEM, V262, P5008; FISHER R. R., 1982, PYRIDINE NUCLEOTIDE, P279; GORNALL AG, 1949, J BIOL CHEM, V177, P751; HATEFI Y, 1961, ARCH BIOCHEM BIOPHYS, V94, P148, DOI 10.1016/0003-9861(61)90022-4; KABACK HR, 1990, TRENDS BIOCHEM SCI, V15, P309; KREBS JJR, 1979, J BIOL CHEM, V254, P5308; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CP, 1989, BIOCHIM BIOPHYS ACTA, V1000, P371, DOI 10.1016/S0006-3002(89)80032-0; LIAO MJ, 1984, J BIOL CHEM, V259, P4200; LIAO MJ, 1983, J BIOL CHEM, V258, P9949; LOW H, 1963, BIOCHIM BIOPHYS ACTA, V69, P361, DOI 10.1016/0006-3002(63)91269-1; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PHELPS DC, 1984, BIOCHEMISTRY-US, V23, P4475, DOI 10.1021/bi00314a037; POPOT JL, 1986, EMBO J, V5, P3039, DOI 10.1002/j.1460-2075.1986.tb04603.x; RYDSTROM J, 1977, BIOCHIM BIOPHYS ACTA, V463, P155, DOI 10.1016/0304-4173(77)90007-6; TREWHELLA J, 1986, EMBO J, V5, P3045, DOI 10.1002/j.1460-2075.1986.tb04604.x; WAKABAYASHI S, 1987, BIOCHEM INT, V15, P915; YAGI T, 1984, BIOCHEMISTRY-US, V23, P1029, DOI 10.1021/bi00300a035; YAMAGUCHI M, 1990, BIOENERGETICS, P39; YAMAGUCHI M, 1991, J BIOL CHEM, V266, P5728; YAMAGUCHI M, 1988, J BIOL CHEM, V263, P2761; YAMAGUCHI M, 1990, BIOCHEMISTRY-US, V29, P4136, DOI 10.1021/bi00469a017; YAMAGUCHI M, 1989, BIOCHEMISTRY-US, V28, P6050, DOI 10.1021/bi00440a049	24	6	6	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17020	17025						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1654321				2022-12-25	WOS:A1991GF44500012
J	CHANG, CF; GUTIERREZ, LM; MUNDINAWEILENMANN, C; HOSEY, MM				CHANG, CF; GUTIERREZ, LM; MUNDINAWEILENMANN, C; HOSEY, MM			DIHYDROPYRIDINE-SENSITIVE CALCIUM CHANNELS FROM SKELETAL-MUSCLE .2. FUNCTIONAL-EFFECTS OF DIFFERENTIAL PHOSPHORYLATION OF CHANNEL SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; 1,4-DIHYDROPYRIDINE RECEPTOR; CA-2+ CHANNEL; PURIFIED RECEPTOR; BLOCKERS; MODULATION; PEPTIDE; MONOPHOSPHATE; MEMBRANE; ALPHA-1	Dihydropyridine-sensitive Ca2+ channels from skeletal muscle are multisubunit proteins and are regulated by protein phosphorylation. The purpose of this study was to determine: 1) which subunits are the preferential targets of various protein kinases when the channels are phosphorylated in vitro in their native membrane-bound state and 2) the consequences of these phosphorylations in functional assays. Using as substrates channels present in purified transverse (T) tubule membranes, cAMP-dependent protein kinase (PKA), protein kinase C (PKC), and a multifunctional Ca2+/calmodulin-dependent protein kinase (CaM protein kinase) preferentially phosphorylated the 165-kDa alpha-1 subunit to an extent that was 2-5-fold greater than the 52-kDa beta-subunit. A protein kinase endogenous to the skeletal muscle membranes preferentially phosphorylated the beta-peptide and showed little activity toward the alpha-1 subunit; however, the extent of phosphorylation was low. Reconstitution of partially purified channels into liposomes was used to determine the functional consequences of phosphorylation by these kinases. Phosphorylation of channels by PKA or PKC resulted in an activation of the channels that was observed as increases in both the rate and extent of Ca2+ influx. However, phosphorylation of channels by either the CaM protein kinase or the endogenous kinase in T-tubule membranes was without effect. Phosphorylation did not affect the sensitivities of the channels toward the dihydropyridines. Taken together, the results demonstrate that the alpha-1 subunit is the preferred substrate of PKA, PKC, and CaM protein kinase when the channels are phosphorylated in the membrane-bound state and that phosphorylation of the channels by PKA and PKC, but not by CaM protein kinase or an endogenous T-tubule membrane protein kinase, results in activation of the dihydropyridine-sensitive Ca2+ channels from skeletal muscle.	NORTHWESTERN UNIV,SCH MED,DEPT PHARMACOL,303 E CHICAGO AVE,CHICAGO,IL 60611	Northwestern University			Gutierrez, Luis/K-8633-2014	Gutierrez, Luis/0000-0002-0512-7858	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL023306, R01HL023306] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL23306] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARREOLA J, 1987, J PHYSIOL-LONDON, V393, P307, DOI 10.1113/jphysiol.1987.sp016825; CHANG CF, 1990, BIOCHEM BIOPH RES CO, V172, P751, DOI 10.1016/0006-291X(90)90738-9; CHANG FC, 1988, J BIOL CHEM, V263, P18929; CURTIS BM, 1985, P NATL ACAD SCI USA, V82, P2528, DOI 10.1073/pnas.82.8.2528; DEJONGH KS, 1989, P NATL ACAD SCI USA, V86, P8585; FOSSET M, 1983, J BIOL CHEM, V258, P6086; GUTIERREZ LM, 1991, J BIOL CHEM, V266, P16387; HOSEY MM, 1986, P NATL ACAD SCI USA, V83, P3733, DOI 10.1073/pnas.83.11.3733; HOSEY MM, 1988, J MEMBRANE BIOL, V104, P81, DOI 10.1007/BF01870922; HOSEY MM, 1987, BIOCHEM BIOPH RES CO, V147, P1137; IMAGAWA T, 1987, J BIOL CHEM, V262, P8333; JAHN H, 1988, EUR J BIOCHEM, V178, P535, DOI 10.1111/j.1432-1033.1988.tb14480.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI Y, 1990, J BIOL CHEM, V265, P20839; LEUNG AT, 1987, J BIOL CHEM, V262, P7943; LEUNG AT, 1988, J BIOL CHEM, V263, P994; MOCZYDLOWSKI EG, 1983, BIOCHIM BIOPHYS ACTA, V732, P412, DOI 10.1016/0005-2736(83)90058-5; MUNDINA-WEILENMANN C, 1991, Biophysical Journal, V59, p88A; MUNDINAWEILENMANN C, 1991, J BIOL CHEM, V266, P4067; NASTAINCZYK W, 1987, EUR J BIOCHEM, V169, P137, DOI 10.1111/j.1432-1033.1987.tb13590.x; NUMOKI K, 1989, P NATL ACAD SCI USA, V86, P6816; OCALLAHAN CM, 1988, J BIOL CHEM, V263, P17342; OCALLAHAN CM, 1988, BIOCHEMISTRY-US, V27, P6071, DOI 10.1021/bi00416a036; REUTER H, 1983, NATURE, V301, P569, DOI 10.1038/301569a0; ROHRKASTEN A, 1988, J BIOL CHEM, V263, P15325; SIEBER M, 1987, EUR J BIOCHEM, V167, P117, DOI 10.1111/j.1432-1033.1987.tb13311.x; SUGDEN PH, 1976, BIOCHEM J, V159, P409, DOI 10.1042/bj1590409; TAKAHASHI M, 1987, P NATL ACAD SCI USA, V84, P5478, DOI 10.1073/pnas.84.15.5478; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TSIEN RW, 1986, J MOL CELL CARDIOL, V18, P691, DOI 10.1016/S0022-2828(86)80941-5; VAGHY PL, 1987, J BIOL CHEM, V262, P14337; WOODGETT JR, 1987, J BIOL CHEM, V262, P4836	32	76	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16395	16400						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1653234				2022-12-25	WOS:A1991GD63500027
J	AROETI, B; HENIS, YI				AROETI, B; HENIS, YI			ACCUMULATION OF SENDAI VIRUS GLYCOPROTEINS IN CELL-CELL CONTACT REGIONS AND ITS ROLE IN CELL-FUSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE PHOTOBLEACHING RECOVERY; FUSED HUMAN-ERYTHROCYTES; LATERAL MOBILITY; INFLUENZA HEMAGGLUTININ; ENVELOPE PROTEINS; MEMBRANES; PENETRATION; LIPOSOMES; SURFACE; BINDING	Lateral motion of the viral envelope proteins in the target cell membrane was shown recently to be essential for cell fusion by Sendai virus (Henis, Y. I., Herman-Barhom, Y., Aroeti, B., and Gutman, 0. (1989) J. Biol. Chem. 264, 17119-17125). To explore the mechanism that gives rise to this requirement, we have now investigated the distribution of Sendai virus envelope proteins (F, the fusion protein, and HN, the hemagglutinin/neuraminidase protein) on human erythrocytes in the course of fusion, using fluorescence microscopy and image analysis. In these studies, both the F and the HN proteins were found to accumulate in cell-cell contact regions, on the time scale of the fusion process. We propose that migration of the viral glycoproteins to cell contact regions and accumulation at the contact sites are essential parts of the fusion mechanism and form the basis to the requirement for their lateral motion in the fusion event.	TEL AVIV UNIV, GEORGE S WISE FAC LIFE SCI, DEPT BIOCHEM, IL-69978 TEL AVIV, ISRAEL	Tel Aviv University				Henis, Yoav/0000-0002-1408-3877				AROETI B, 1986, BIOCHEMISTRY-US, V25, P4588, DOI 10.1021/bi00364a020; AROETI B, 1990, BIOCHEMISTRY-US, V29, P9119, DOI 10.1021/bi00491a004; AROETI B, 1988, BIOCHEMISTRY-US, V27, P5654, DOI 10.1021/bi00415a039; BRECKENRIDGE LJ, 1987, NATURE, V328, P814, DOI 10.1038/328814a0; CHOPPIN PW, 1980, REV INFECT DIS, V2, P40; ELLENS H, 1990, BIOCHEMISTRY-US, V29, P9697, DOI 10.1021/bi00493a027; GETHING MJ, 1978, P NATL ACAD SCI USA, V75, P2737, DOI 10.1073/pnas.75.6.2737; GITMAN AG, 1984, J BIOL CHEM, V259, P9813; HARTER C, 1989, J BIOL CHEM, V264, P6459; HENIS YI, 1985, EXP CELL RES, V160, P514, DOI 10.1016/0014-4827(85)90198-3; HENIS YI, 1989, J BIOL CHEM, V264, P17119; HOEKSTRA D, 1989, BIOSCIENCE REP, V9, P273, DOI 10.1007/BF01114682; HSU M, 1982, P NATL ACAD SCI-BIOL, V79, P5862, DOI 10.1073/pnas.79.19.5862; KATZIR Z, 1989, BIOCHEMISTRY-US, V28, P6400, DOI 10.1021/bi00441a036; MAEDA T, 1979, EXP CELL RES, V123, P333, DOI 10.1016/0014-4827(79)90475-0; MARSH M, 1989, ADV VIRUS RES, V36, P107, DOI 10.1016/S0065-3527(08)60583-7; MCCLOSKEY MA, 1986, J CELL BIOL, V102, P2185, DOI 10.1083/jcb.102.6.2185; NAKANISHI M, 1982, EXP CELL RES, V142, P95, DOI 10.1016/0014-4827(82)90413-X; NOVICK SL, 1988, P NATL ACAD SCI USA, V85, P7433, DOI 10.1073/pnas.85.20.7433; OZAWA M, 1979, VIROLOGY, V99, P197, DOI 10.1016/0042-6822(79)90055-2; PERETZ H, 1974, J CELL BIOL, V63, P1, DOI 10.1083/jcb.63.1.1; Poste G., 1978, CELL SURF REV, V5, P305; RIMON G, 1984, BIOCHIM BIOPHYS ACTA, V775, P283, DOI 10.1016/0005-2736(84)90182-2; SPRUCE AE, 1989, NATURE, V342, P555, DOI 10.1038/342555a0; STEGMANN T, 1989, ANNU REV BIOPHYS BIO, V18, P187, DOI 10.1146/annurev.bb.18.060189.001155; WHITE JM, 1990, ANNU REV PHYSIOL, V52, P675, DOI 10.1146/annurev.ph.52.030190.003331; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0	27	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					15845	15849						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1651923				2022-12-25	WOS:A1991GB97700050
J	TAN, JL; SPUDICH, JA				TAN, JL; SPUDICH, JA			CHARACTERIZATION AND BACTERIAL EXPRESSION OF THE DICTYOSTELIUM MYOSIN LIGHT CHAIN KINASE CDNA - IDENTIFICATION OF AN AUTOINHIBITORY DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CALMODULIN-BINDING DOMAIN; CATALYTIC SUBUNIT; ESCHERICHIA-COLI; CYCLIC-GMP; DISCOIDEUM; SEQUENCE; PHOSPHORYLATION; RECOGNITION; SITE	A full-length cDNA corresponding to the Dictyostelium myosin light chain kinase gene has been isolated and characterized. Sequence analysis of the cDNA confirms conserved protein kinase subdomains and reveals that the Dictyostelium sequence is highly homologous to those of calcium/calmodulin-dependent protein kinases, including myosin light chain kinases from higher eukaryotes. Despite the high homologies to calcium/calmodulin-dependent protein kinases, there is no recognizable calmodulin-binding domain within the Dicytostelium sequence. However, the Dictyostelium myosin light chain kinase possesses a putative auto-inhibitory domain near its carboxyl terminus. To further characterize this domain, the full-length enzyme as well as a truncated form lacking this domain were expressed in bacterial cells and purified. The full-length enzyme expressed in bacteria exhibits essentially the same biochemical characteristics as the enzyme isolated from Dictyostelium. The truncated form however exhibits a V(max) that is approximately ten times greater than that of the native enzyme. In addition, unlike the native kinase and the full-length kinase expressed in bacteria, the truncated enzyme does not undergo autophosphorylation. These results suggest that the Dictyostelium enzyme, like myosin light chain kinases from higher eukaryotes, is regulated by an autoinhibitory domain but that the specific molecular signals necessary for activation of the Dictyostelium enzyme are entirely distinct.	STANFORD UNIV,MED CTR,SCH MED,DEPT DEV BIOL,STANFORD,CA 94305	Stanford University	TAN, JL (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT CELL BIOL,STANFORD,CA 94305, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM046551, R01GM046551] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 46551] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGCHI IC, 1989, J BIOL CHEM, V264, P15843; BENIAN GM, 1989, NATURE, V342, P45, DOI 10.1038/342045a0; BENNETT MK, 1987, P NATL ACAD SCI USA, V84, P1794, DOI 10.1073/pnas.84.7.1794; BLUMENTHAL DK, 1985, P NATL ACAD SCI USA, V82, P3187, DOI 10.1073/pnas.82.10.3187; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; CLARKE M, 1980, J BACTERIOL, V141, P397, DOI 10.1128/JB.141.1.397-400.1980; COLBRAN RJ, 1990, J BIOL CHEM, V265, P11213; CONTI MA, 1981, J BIOL CHEM, V256, P3178; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; ERICKSONVIITANEN S, 1987, METHOD ENZYMOL, V139, P455; FRANKEL S, 1990, J BIOL CHEM, V265, P17980; FRANKEL S, 1991, P NATL ACAD SCI USA, V88, P1192, DOI 10.1073/pnas.88.4.1192; GOLDHAGEN H, 1986, MOL CELL BIOL, V6, P1851, DOI 10.1128/MCB.6.5.1851; GRIFFITH LM, 1987, J CELL BIOL, V104, P1309, DOI 10.1083/jcb.104.5.1309; GUERRIERO V, 1986, BIOCHEMISTRY-US, V25, P8372, DOI 10.1021/bi00374a007; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HATHAWAY DR, 1979, P NATL ACAD SCI USA, V76, P1653, DOI 10.1073/pnas.76.4.1653; HERRING BP, 1990, J BIOL CHEM, V265, P1724; IKEBE M, 1987, J BIOL CHEM, V262, P13828; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KEMP BE, 1987, J BIOL CHEM, V262, P2542; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUKAS TJ, 1986, BIOCHEMISTRY-US, V25, P1458, DOI 10.1021/bi00354a041; Maniatis T., 1982, MOL CLONING; MARSHAK DR, 1984, BIOCHEMISTRY-US, V23, P2891, DOI 10.1021/bi00308a007; MATO JM, 1977, P NATL ACAD SCI USA, V74, P2348, DOI 10.1073/pnas.74.6.2348; NISHIKAWA M, 1984, J BIOL CHEM, V259, P8429; OLSEN NJ, 1990, P NATL ACAD SCI USA, V87, P2284; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PATTON BL, 1990, J BIOL CHEM, V265, P11204; PEARSON RB, 1988, SCIENCE, V241, P970, DOI 10.1126/science.3406746; ROOS W, 1976, FEBS LETT, V68, P170, DOI 10.1016/0014-5793(76)80429-2; SHOEMAKER MO, 1990, J CELL BIOL, V111, P1107, DOI 10.1083/jcb.111.3.1107; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; STULL JT, 1986, ENZYMES, V17, P113; TAKIO K, 1985, BIOCHEMISTRY-US, V24, P6028, DOI 10.1021/bi00343a002; TAN JL, 1990, J BIOL CHEM, V265, P13818; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; WARRICK HM, 1988, NUCLEIC ACIDS RES, V16, P6617, DOI 10.1093/nar/16.14.6617; WURSTER B, 1977, FEBS LETT, V76, P141, DOI 10.1016/0014-5793(77)80139-7; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	44	54	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					16044	16049						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1651931				2022-12-25	WOS:A1991GB97700078
J	ROHLFS, RJ; HILLE, R				ROHLFS, RJ; HILLE, R			INTRAMOLECULAR ELECTRON-TRANSFER IN TRIMETHYLAMINE DEHYDROGENASE FROM BACTERIUM W3A1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COVALENTLY BOUND COENZYME; IRON-SULFUR FLAVOPROTEIN; MILK XANTHINE-OXIDASE; DIMETHYLAMINE DEHYDROGENASE; METHYLOTROPHIC BACTERIA; PROSTHETIC GROUPS; FLAVIN; SUBSTRATE; CLUSTER	Reductive optical/EPR titrations of trimethylamine dehydrogenase with sodium dithionite have been performed, indicating that the equilibrium distribution of reducing equivalents between the covalently bound FMN and 4Fe/4S centers in partially reduced trimethylamine dehydrogenase is pH-dependent. In the case of two-electron reduced enzyme, formation of fully reduced flavin with oxidized iron-sulfur is favored below pH 7.5, whereas above pH 8 formation of flavin semiquinone with reduced iron-sulfur is preferred. The rates of electron transfer between the sites have been measured with the stopped-flow rapid mixing technique using a pH jump. The observed rate constants fall in the range of 200 s-1 to 1000 s-1 at 25-degrees-C with the larger values occurring at higher values of final pH. The values of the rate constants depend on the final pH and are independent of observation wavelength. The temperature dependencies of these reactions give linear Arrhenius plots with activation energies in the range of 12 to 16 kcal/mol, consistent with prototropic equilibria being associated with electron transfer. The pH dependence of EPR spectral line widths for the flavin semiquinone and static optical spectra suggest that the semiquinone form of flavin present at pH 10 is anionic, whereas the neutral form is present at pH 7. The observed rate constants at 25-degrees-C are greater-than-or-equal-to 100-fold larger than k(cat) for this enzyme and indicate that intramolecular electron transfer is not intrinsically rate-limiting in overall catalysis.	OHIO STATE UNIV,DEPT MED BIOCHEM,COLUMBUS,OH 43210	Ohio State University								ANDERSON RF, 1986, J BIOL CHEM, V261, P5870; ANDERSON RF, 1987, FLAVINS FLAVOPROTEIN, P279; BARBER MJ, 1988, BIOCHEM J, V256, P657, DOI 10.1042/bj2560657; BELLAMY HD, 1989, J BIOL CHEM, V264, P11887; Bevington PR, 1969, DATA REDUCTION ERROR; BHATTACHARYYA A, 1983, BIOCHEMISTRY-US, V22, P5270, DOI 10.1021/bi00292a005; COLBY J, 1973, BIOCHEM J, V132, P101, DOI 10.1042/bj1320101; DRAPER RD, 1968, ARCH BIOCHEM BIOPHYS, V125, P802, DOI 10.1016/0003-9861(68)90517-1; EHRENBERG A, 1967, EUR J BIOCHEM, V2, P286, DOI 10.1111/j.1432-1033.1967.tb00137.x; FOUST GP, 1969, ANAL BIOCHEM, V27, P530, DOI 10.1016/0003-2697(69)90066-9; HEMMERICH P, 1964, HELV CHIM ACTA, V47, P464, DOI 10.1002/hlca.19640470214; HILL CL, 1977, P NATL ACAD SCI USA, V74, P547, DOI 10.1073/pnas.74.2.547; HILLE R, 1986, J BIOL CHEM, V261, P1241; KASPRZAK AA, 1983, BIOCHEM J, V211, P535, DOI 10.1042/bj2110535; LAND EJ, 1969, BIOCHEMISTRY-US, V8, P2117, DOI 10.1021/bi00833a050; LEHMAN TC, 1990, BIOCHEMISTRY-US, V29, P10594, DOI 10.1021/bi00499a004; LIM LW, 1986, J BIOL CHEM, V261, P5140; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MASSEY V, 1966, BIOCHEMISTRY-US, V5, P3181, DOI 10.1021/bi00874a016; Massey V, 1980, BIOCHEM SOC T, V8, P246, DOI 10.1042/bst0080246; PALMER G, 1969, J BIOL CHEM, V244, P2614; PORRAS AG, 1982, J BIOL CHEM, V257, P1617; STANKOVICH MT, 1987, FLAVINS FLAVOPROTEIN, P687; STEENKAMP DJ, 1982, BIOCHEM J, V207, P233, DOI 10.1042/bj2070233; STEENKAMP DJ, 1982, BIOCHEM J, V207, P241, DOI 10.1042/bj2070241; STEENKAMP DJ, 1978, BIOCHEM J, V169, P361, DOI 10.1042/bj1690361; STEENKAMP DJ, 1976, BIOCHEM BIOPH RES CO, V71, P1289, DOI 10.1016/0006-291X(76)90794-4; STEENKAMP DJ, 1978, J BIOL CHEM, V253, P2812; STEENKAMP DJ, 1976, BIOCHIM BIOPHYS ACTA, V429, P705, DOI 10.1016/0005-2744(76)90319-3; STEENKAMP DJ, 1978, J BIOL CHEM, V253, P4086; STEENKAMP DJ, 1978, J BIOL CHEM, V253, P2818; STEENKAMP DJ, 1978, MECHANISMS OXIDIZING, P127; STEVENSON RC, 1986, BIOCHIM BIOPHYS ACTA, V869, P81, DOI 10.1016/0167-4838(86)90313-4; SWOBODA BENNETT E. P., 1966, J BIOL CHEM, V241, P3409	35	33	33	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15244	15252						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1651321				2022-12-25	WOS:A1991GB09700065
J	ANDERSON, RF; PATEL, KB; VOJNOVIC, B				ANDERSON, RF; PATEL, KB; VOJNOVIC, B			ABSORPTION-SPECTRA OF RADICAL FORMS OF 2,4-DIHYDROXYBENZOIC ACID, A SUBSTRATE FOR P-HYDROXYBENZOATE HYDROXYLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENOL HYDROXYLASE; ELECTROPHILIC ATTACK; DERIVATIVES; OXYGENASES; OXIDATION; FLAVIN	Combined optical and conductimetric measurements in aqueous solution indicate that at high pH (greater-than-or-equal-to 10).OH radicals react with the phenoxide form of 2,4-dihydroxybenzoic acid to form transiently phenoxyl radicals and a small amount of hydroxycyclohexadienyl (HCHD) radicals by 150 ns. The respective yields of 88 and 12% of the total .OH radical yield were deduced from conductance and optical changes as well as from studies using a low potential reductant. The HCHD radical possesses a pK(a) of 8.0 +/- 0.1 and the constructed spectrum of the deprotonated forms of HCHD has a lambda-max at 420 nm with a minimum extinction coefficient of approximately 7250 M-1 cm-1. The red shift in lambda-max and increase in extinction coefficient compared to the revised spectral properties of the protonated form of the HCHD radical (lambda-max at 390 nm with extinction coefficient of approximately 4500 M-1 cm-1), together with the pK(a) of the HCHD radical, provide an explanation for the pH-dependent spectral changes of the so-called highly absorbing intermediate II species, observed in the functioning of the enzyme p-hydroxybenzoate hydroxylase. These results add further to the evidence in support of the proposal that intermediate II is composed of species which absorb similarly to the flavin 4(a)-hydroxide and a form of the substrate/product such as the HCHD radical (Anderson, R. F., Patel, K. B., and Stratford, M. R. L. (1987) J. Biol. Chem. 262, 17475-17479).			ANDERSON, RF (corresponding author), MT VERNON HOSP,CANC RES CAMPAIGN,GRAY LAB,POB 100,NORTHWOOD HA6 2JR,MIDDX,ENGLAND.		Vojnovic, Borivoj/AAV-4756-2021	Vojnovic, Borivoj/0000-0001-9013-3816				ALFASSI ZB, 1985, J PHYS CHEM-US, V89, P3359, DOI 10.1021/j100261a040; Anderson R F, 1988, Prog Clin Biol Res, V274, P167; ANDERSON RF, 1987, J BIOL CHEM, V262, P17475; ANDERSON RF, 1990, J BIOL CHEM, V265, P1952; ANDERSON RF, 1987, J CHEM SOC FARAD T 1, V83, P3177, DOI 10.1039/f19878303177; BRUICE TC, 1984, FLAVINS FLAVOPROTEIN, P45; DETMER K, 1985, J BIOL CHEM, V260, P5998; ENTSCH B, 1976, J BIOL CHEM, V251, P2550; FROST JW, 1981, J AM CHEM SOC, V103, P5242, DOI 10.1021/ja00407a052; KLEIN GW, 1978, RADIAT PHYS CHEM, V11, P167, DOI 10.1016/0146-5724(78)90078-X; NEUJAHR HY, 1973, EUR J BIOCHEM, V35, P386, DOI 10.1111/j.1432-1033.1973.tb02851.x; SCHOPFER LM, 1991, J BIOL CHEM, V266, P13080; STEENKEN S, 1982, J PHYS CHEM-US, V86, P3661, DOI 10.1021/j100215a033; STEENKEN S, 1979, J PHYS CHEM-US, V83, P1134, DOI 10.1021/j100472a005; VOJNOVIC B, 1986, RADIAT PHYS CHEM, V27, P363; VOJNOVIC B, 1983, THESIS U LONDON; WESSIAK A, 1984, J BIOL CHEM, V259, P2547; WESSIAK A, 1983, J AM CHEM SOC, V105, P4809, DOI 10.1021/ja00352a045; 1960, LANDOLTBORNSTEIN ZAH, V7, P257	19	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1991	266	20					13086	13090						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FX132	1649177				2022-12-25	WOS:A1991FX13200047
J	WANGE, RL; SMRCKA, AV; STERNWEIS, PC; EXTON, JH				WANGE, RL; SMRCKA, AV; STERNWEIS, PC; EXTON, JH			PHOTOAFFINITY-LABELING OF 2 RAT-LIVER PLASMA-MEMBRANE PROTEINS WITH [P-32] GAMMA-AZIDOANILIDO GTP IN RESPONSE TO VASOPRESSIN - IMMUNOLOGICAL IDENTIFICATION AS ALPHA-SUBUNITS OF THE GQ CLASS OF G-PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BINDING REGULATORY PROTEINS; PHOSPHOLIPASE-C ACTIVITY; GUANINE-NUCLEOTIDE; ALPHA-1-ADRENERGIC RECEPTOR; INOSITOL TRISPHOSPHATE; ADENYLATE-CYCLASE; ANGIOTENSIN-II; PURIFICATION; HORMONE; CALCIUM	Two proteins have been identified in rat liver plasma membranes that bind a photoreactive GTP analogue, [P-32]gamma-azidoanilido GTP, in response to incubation with the Ca2+-mobilizing agonist, vasopressin. The labeled proteins possess apparent molecular masses of 42 and 43 kDa. Their labeling requires Mg2+ and can be inhibited by GTP, its analogues, and GDP but not by other nucleotides. Vasopressin-stimulated labeling is attenuated by a V, receptor-selective antagonist. The concentration of vasopressin required to stimulate labeling is in the same range (EC50 = 4 nm) as that required for activation of GTPase and phosphoinositide-specific phospholipase C activities in liver plasma membranes. Immunodetection and immunoprecipitation of the [P-32]gamma-azidoanilido GTP-labeled 42- and 43-kDa proteins with antisera raised against peptide sequences in alpha-q indicate that these proteins are members of the recently described G(q) class of G proteins.	VANDERBILT UNIV,MED CTR,SCH MED,HOWARD HUGHES MED INST,NASHVILLE,TN 37232; UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	Howard Hughes Medical Institute; Vanderbilt University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	WANGE, RL (corresponding author), VANDERBILT UNIV,MED CTR,SCH MED,DEPT PHARMACOL,NASHVILLE,TN 37232, USA.			Wange, Ronald/0000-0001-9593-3572	NIGMS NIH HHS [GM40919, GM31954, GM07628] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040919, T32GM007628, R01GM031954] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BOYER JL, 1989, TRENDS PHARMACOL SCI, V10, P360, DOI 10.1016/0165-6147(89)90008-4; COCKCROFT S, 1987, TRENDS BIOCHEM SCI, V12, P75, DOI 10.1016/0968-0004(87)90035-1; EXTON JH, 1988, FASEB J, V2, P2670, DOI 10.1096/fasebj.2.11.2456243; EXTON JH, 1988, HEPATOLOGY, V8, P152, DOI 10.1002/hep.1840080129; EXTON JH, 1988, REV PHYSL BIOCH PHAR, V111, P118; FAWZI AB, 1990, BIOCHEMISTRY-US, V29, P3804, DOI 10.1021/bi00467a030; FITZGERALD TJ, 1986, J BIOL CHEM, V261, P6871; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; IM MJ, 1990, J BIOL CHEM, V265, P18952; IM MJ, 1990, J BIOL CHEM, V265, P18944; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LITOSCH I, 1985, J BIOL CHEM, V260, P5464; LYNCH CJ, 1985, MOL PHARMACOL, V28, P93; LYNCH CJ, 1989, J CLIN INVEST, V83, P2050, DOI 10.1172/JCI114116; MANNING M, 1987, PEPTIDES 1986, P459; Michell R H, 1979, Biochem Soc Trans, V7, P861; OFFERMANS S, 1990, FEBS LETT, V260, P14, DOI 10.1016/0014-5793(90)80054-M; PANG IH, 1990, J BIOL CHEM, V265, P18707; PFEUFFER T, 1977, J BIOL CHEM, V252, P7224; PRPIC V, 1984, J BIOL CHEM, V259, P1382; SCHAFER R, 1988, BIOCHEM BIOPH RES CO, V155, P1051, DOI 10.1016/S0006-291X(88)80603-X; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; STRATHMANN M, 1989, P NATL ACAD SCI USA, V86, P7407, DOI 10.1073/pnas.86.19.7407; TAYLOR SJ, 1987, BIOCHEM J, V248, P791, DOI 10.1042/bj2480791; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TAYLOR SJ, 1990, J BIOL CHEM, V265, P17150; UHING RJ, 1985, FEBS LETT, V188, P317, DOI 10.1016/0014-5793(85)80394-X; UHING RJ, 1986, J BIOL CHEM, V261, P2140	34	102	103	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1991	266	18					11409	11412						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FT762	1646803				2022-12-25	WOS:A1991FT76200002
J	BHUTADA, A; WASSYNGER, WW; ISMAILBEIGI, F				BHUTADA, A; WASSYNGER, WW; ISMAILBEIGI, F			DEXAMETHASONE MARKEDLY INDUCES NA,K-ATPASE MESSENGER RNA-BETA-1 IN A RAT-LIVER CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+-K+-ATPASE; BETA-SUBUNIT; 5'-FLANKING REGION; GENE-EXPRESSION; ALPHA-SUBUNIT; SODIUM-PUMP; RNAS; NA+,K+-ATPASE; ABUNDANCE; INDUCTION	Exposure of Clone 9 cells, a "nontransformed' rat liver cell line, to 10(-8) M dexamethasone resulted at 3 h in 1.8 +/- 0.2- and 40 +/- 5-fold increases in mRNA-alpha-1 and mRNA-beta-1 content, respectively, an effect that was not mimicked by 10(-8) M aldosterone. The increments in mRNA-alpha-1 and mRNA-beta-1 abundances in total cell RNA were half-maximal at 5 x 10(-9) M dexamethasone and persisted for more than 24 h. Na,K-ATPase activity, however, increased only slightly (by 9%) at 24 h. The induction of mRNA-beta-1 by dexamethasone was not prevented by the presence of cycloheximide. mRNA-beta-1 abundance increased earlier in the nuclear RNA pool (becoming apparent within 45 min) than in the cytoplasmic RNA pool, consistent with a precursor-product relationship. Moreover, putative pre-mRNA-beta-1 bands of approximately 4,600 and approximately 12,000 nucleotides accumulated in the nRNA pool after 1 h of exposure to dexamethasone. Incubation in the presence of dexamethasone for 3 h enhanced the incorporation of [H-3]uridine into total cell mRNA-alpha-1 and mRNA-beta-1 by 1.3- and 12-fold, respectively. In nuclear run-on assays, however, transcription of mRNA-alpha-1 and mRNA-beta-1 was not altered after 30 min of exposure to 10(-8) M dexamethasone. The abundance of mRNA-beta-1 in rat liver also increased markedly (> 30-fold) in rats treated with the hormone for 6 h. We conclude that dexamethasone causes an induction of Na,K-ATPase subunit mRNAs, an effect that is markedly greater for mRNA-beta-1 than for mRNA-alpha-1. The increases in subunit mRNA content, however, are associated with, at most, a small increase in Na,K-ATPase activity, suggesting that the increments in mRNA abundances, especially that of mRNA-beta-1, do not play a determining role in the regulation of Na,K-ATPase activity in these cells.			BHUTADA, A (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, DEPT MED, 630 W 168TH ST, NEW YORK, NY 10032 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039835] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-39835] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUMANN H, 1983, J BIOL CHEM, V258, P563; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BHUTADA A, 1990, J GEN PHYSIOL, V96, pA24; BHUTADA A, 1990, AM J PHYSIOL, V258, pC1044, DOI 10.1152/ajpcell.1990.258.6.C1044; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FENG B, 1990, J BIOL CHEM, V265, P18702; GEERING K, 1990, J MEMBRANE BIOL, V115, P109, DOI 10.1007/BF01869450; GICK GG, 1990, J MEMBRANE BIOL, V115, P273, DOI 10.1007/BF01868642; GICK GG, 1988, J BIOL CHEM, V263, P16610; GICK GG, 1990, AM J PHYSIOL, V258, pC544, DOI 10.1152/ajpcell.1990.258.3.C544; GLOOR S, 1990, J CELL BIOL, V110, P165, DOI 10.1083/jcb.110.1.165; HOROWITZ B, 1990, J BIOL CHEM, V265, P4189; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; LANE LK, 1989, GENOMICS, V5, P445, DOI 10.1016/0888-7543(89)90008-6; LESCALEMATYS L, 1990, J BIOL CHEM, V265, P17935; MCDONOUGH AA, 1990, FASEB J, V4, P1598, DOI 10.1096/fasebj.4.6.2156741; NOGUCHI S, 1990, J BIOL CHEM, V265, P15991; NOGUCHI S, 1987, FEBS LETT, V225, P27, DOI 10.1016/0014-5793(87)81125-0; ORLOWSKI J, 1990, J BIOL CHEM, V265, P3462; PRESSLEY TA, 1988, AM J PHYSIOL, V255, pC252, DOI 10.1152/ajpcell.1988.255.2.C252; Sambrook J., 1982, MOL CLONING LAB MANU, V1; SCHMALZING G, 1990, J GEN PHYSIOL, V96, pA91; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; SHULL MM, 1990, GENOMICS, V6, P451, DOI 10.1016/0888-7543(90)90475-A; SHYJAN AW, 1990, J BIOL CHEM, V265, P5166; SNEDECOR GW, 1976, STATISTICAL METHODS, P1; TAKEYASU K, 1989, CURR TOP MEMBR TRANS, V34, P143; TAORMINO JP, 1990, J BIOL CHEM, V265, P4116; YAGAWA Y, 1990, BIOCHIM BIOPHYS ACTA, V1049, P286, DOI 10.1016/0167-4781(90)90099-N; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; YOUNG RM, 1987, BIOCHEM BIOPH RES CO, V145, P52, DOI 10.1016/0006-291X(87)91286-1; YOUNG RM, 1987, J BIOL CHEM, V262, P4905	33	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					10859	10866						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	1645712				2022-12-25	WOS:A1991FQ77400027
J	FRANGAKIS, MV; OHMSTEDE, CA; SAHYOUN, N				FRANGAKIS, MV; OHMSTEDE, CA; SAHYOUN, N			A BRAIN-SPECIFIC CA2+/CALMODULIN-DEPENDENT PROTEIN-KINASE (CAM KINASE-GR) IS REGULATED BY AUTOPHOSPHORYLATION - RELEVANCE TO NEURONAL CA2+ SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING PROTEIN; CA-2+ CALMODULIN; MECHANISM; SITES; PHOSPHORYLATION; ACTIVATION; DOMAIN	A neuronal Ca2+/calmodulin-dependent protein kinase (CaM kinase-Gr) undergoes autophosphorylation on a serine residue(s) in response to Ca2+ and calmodulin. Phosphate incorporation leads to the formation of a Ca2+-independent (autonomous) activity state, as well as potentiation of the Ca2+/calmodulin-dependent response. The autonomous enzyme activity of the phosphorylated enzyme approximately equals the Ca2+/calmodulin-stimulated activity of the unphosphorylated enzyme, but displays diminished affinity toward ATP and the synthetic substrate, syntide-2. The K(m)(app) for ATP and syntide-2 increased 4.3- and 1.7-fold, respectively. Further activation of the autonomous enzyme by Ca2+/calmodulin yields a marked increase in the affinity for ATP and peptide substrate such that the K(m)(app) for ATP and syntide-2 decreased by 14- and 8-fold, respectively. Both autophosphorylation and the addition of Ca2+/calmodulin are required to produce the maximum level of enzyme activation and to increase substrate affinity. Unlike Ca2+/calmodulin-dependent protein kinase type II that is dephosphorylated by the Mg2+-independent phosphoprotein phosphatases 1 and 2A, CaM kinase-Gr is dephosphorylated by a Mg2+-dependent phosphoprotein phosphatase that may be related to the type 2C enzyme. Dephosphorylation of CaM kinase-Gr reverses the effects of autophosphorylation on enzyme activity. A comparison between the autophosphorylation and dephosphorylation reactions of CaM kinase-Gr and Ca2+/calmodulin-dependent protein kinase type II provides useful insights into the operation of Ca2+-sensitive molecular switches.			FRANGAKIS, MV (corresponding author), WELLCOME RES LABS, RES TRIANGLE PK, NC 27709 USA.							BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COHEN P, 1989, J BIOL CHEM, V264, P21435; COLBRAN RJ, 1989, BIOCHEM J, V258, P313, DOI 10.1042/bj2580313; COLBRAN RJ, 1990, J BIOL CHEM, V265, P11213; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; EARNSHAW WC, 1987, J CELL BIOL, V105, P1479, DOI 10.1083/jcb.105.4.1479; FONG YL, 1989, J BIOL CHEM, V264, P16759; HASHIMOTO Y, 1987, J BIOL CHEM, V262, P8051; JACOBS S, 1986, J BIOL CHEM, V261, P934; JENSEN KF, 1991, P NATL ACAD SCI USA, V88, P2850, DOI 10.1073/pnas.88.7.2850; JENSEN KF, 1991, IN PRESS P NATL ACAD; KURET J, 1985, J BIOL CHEM, V260, P6427; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI Y, 1986, P NATL ACAD SCI USA, V83, P4253, DOI 10.1073/pnas.83.12.4253; LEVINE H, 1985, BIOCHEM BIOPH RES CO, V131, P1212, DOI 10.1016/0006-291X(85)90220-7; LEVINE H, 1985, P NATL ACAD SCI USA, V82, P287, DOI 10.1073/pnas.82.2.287; LLINAS R, 1985, P NATL ACAD SCI USA, V82, P3035, DOI 10.1073/pnas.82.9.3035; LOU LL, 1986, P NATL ACAD SCI USA, V83, P9497, DOI 10.1073/pnas.83.24.9497; LOU LL, 1989, J NEUROSCI, V9, P2020; MILLER SG, 1988, NEURON, V1, P593, DOI 10.1016/0896-6273(88)90109-2; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; MYAMOTO E, 1990, ADV SEC MESS PHOSPH, V24, P212; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; OHMSTEDE CA, 1989, J BIOL CHEM, V264, P5866; OHMSTEDE CA, 1990, FASEB J, V4, pA2078; ONO T, 1989, J BIOL CHEM, V264, P2081; ONO T, 1985, J BIOCHEM-TOKYO, V98, P1455, DOI 10.1093/oxfordjournals.jbchem.a135414; PATTON BL, 1990, J BIOL CHEM, V265, P11204; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SAHYOUN NE, 1981, P NATL ACAD SCI USA, V80, P3646; SCHULMAN H, 1989, TRENDS BIOCHEM SCI, V14, P62, DOI 10.1016/0968-0004(89)90045-5; SCHULMAN H, 1988, ADV SEC MESS PHOSPH, V22, P39; SCHWORER CM, 1988, J BIOL CHEM, V263, P13486; SCHWORER CM, 1986, J BIOL CHEM, V261, P8581; SIKELA JM, 1989, GENOMICS, V4, P21, DOI 10.1016/0888-7543(89)90309-1; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; THIEL G, 1988, P NATL ACAD SCI USA, V85, P6337, DOI 10.1073/pnas.85.17.6337	37	59	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					11309	11316						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	1645731				2022-12-25	WOS:A1991FQ77400093
J	KOGA, J; ADACHI, T; HIDAKA, H				KOGA, J; ADACHI, T; HIDAKA, H			PURIFICATION AND CHARACTERIZATION OF INDOLEPYRUVATE DECARBOXYLASE - A NOVEL ENZYME FOR INDOLE-3-ACETIC-ACID BIOSYNTHESIS IN ENTEROBACTER-CLOACAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE DECARBOXYLASE; THIAMINE PYROPHOSPHATE; INDOLE-3-PYRUVIC ACID; D-TRYPTOPHAN; CARBOXYLASE; SPECIFICITY; METABOLISM; LIVER; IAA	Indolepyruvate decarboxylase, a key enzyme for indole-3-acetic acid biosynthesis, was found in extracts of Enterobacter cloacae. The enzyme catalyzes the decarboxylation of indole-3-pyruvic acid to yield indole-3-acetaldehyde and carbon dioxide. The enzyme was purified to apparent homogeneity from Escherichia coli cells harboring the genetic locus for this enzyme obtained from E. cloacae. The results of gel filtration experiments showed that indolepyruvate decarboxylase is a tetramer with an M(r) of 240,000. In the absence of thiamine pyrophosphate and Mg2+ the active tetramers dissociate into inactive monomers and dimers. However, the addition of thiamine pyrophosphate and Mg2+ to the inactive monomers and dimers results in the formation of active tetramers. These results indicate that the thiamine pyrophosphate-Mg2+ complex functions in the formation of the tetramer, which is the enzymatically active holoenzyme. The enzyme exhibited decarboxylase activity with indole-3-pyruvic acid and pyruvic acid as substrates, but no decarboxylase activity was apparent with L-tryptophan, indole-3-lactic acid, beta-phenylpyruvic acid, oxalic acid, oxaloacetic acid, and acetoacetic acid. The K(m) values for indole-3-pyruvic acid and pyruvic acid were 15-mu-M and 2.5 mM, respectively. These results indicate that indole-3-acetic acid biosynthesis in E. cloacae is mediated by indolepyruvate decarboxylase, which has a high specificity and affinity for indole-3-pyruvic acid.			KOGA, J (corresponding author), MEIJI SEIKA KAISHA LTD,BIO SCI LABS,5-3-1 CHIYODA,SAITAMA 35002,JAPAN.			Koga, Jinichiro/0000-0003-2106-9894				ATSUMI S, 1980, PLANT CELL PHYSIOL, V21, P1227, DOI 10.1093/oxfordjournals.pcp.a076121; BAIS R, 1972, J BIOL CHEM, V247, P3255; BARDEN RE, 1972, J BIOL CHEM, V247, P1323; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAZZULO JJ, 1969, BIOCHEM J, V112, P747, DOI 10.1042/bj1120747; FRIDOVICH I, 1963, J BIOL CHEM, V238, P592; GAMBORG OL, 1963, CAN J BIOCHEM PHYS, V41, P1733; GARCIATABARES F, 1987, APPL MICROBIOL BIOT, V25, P502; GIBSON RA, 1972, J EXP BOT, V23, P381, DOI 10.1093/jxb/23.2.381; GOUNARIS AD, 1975, BIOCHIM BIOPHYS ACTA, V405, P492, DOI 10.1016/0005-2795(75)90114-2; GOUNARIS AD, 1971, J BIOL CHEM, V246, P1302; Green DE, 1941, J BIOL CHEM, V138, P327; GUNSALUS IC, 1955, METHOD ENZYMOL, V2, P170, DOI 10.1016/S0076-6879(55)02182-4; JUNI E, 1968, ARCH BIOCHEM BIOPHYS, V127, P79, DOI 10.1016/0003-9861(68)90204-X; KAPER JM, 1958, BIOCHIM BIOPHYS ACTA, V30, P401, DOI 10.1016/0006-3002(58)90065-9; KEECH DB, 1967, J BIOL CHEM, V242, P1983; KENTEN RH, 1952, BIOCHEM J, V50, P360, DOI 10.1042/bj0500360; KOGA J, 1991, MOL GEN GENET, V226, P10, DOI 10.1007/BF00273581; KOGA J, 1991, AGR BIOL CHEM TOKYO, V55, P701, DOI 10.1080/00021369.1991.10870678; KOGA J, 1991, SCI REP MEIJI SEIKA, V30, P35; LAW DM, 1987, PHYSIOL PLANTARUM, V70, P626, DOI 10.1111/j.1399-3054.1987.tb04316.x; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; MCCLURE WR, 1971, J BIOL CHEM, V246, P3569; MCQUEENMASON SJ, 1989, PLANT CELL PHYSIOL, V30, P999; MOORE TC, 1968, ARCH BIOCHEM BIOPHYS, V127, P613, DOI 10.1016/0003-9861(68)90269-5; PARIS CG, 1981, J BACTERIOL, V145, P257, DOI 10.1128/JB.145.1.257-265.1981; SCHMITT A, 1966, H-S Z PHYSIOL CHEM, V347, P18, DOI 10.1515/bchm2.1966.347.1.18; SHELDRAKE AR, 1973, BIOL REV, V48, P509, DOI 10.1111/j.1469-185X.1973.tb01568.x; SHIMAZONO H, 1957, J BIOL CHEM, V227, P151; SINGER TP, 1952, J BIOL CHEM, V196, P375; TRUELSEN TA, 1972, PHYSIOL PLANTARUM, V26, P289, DOI 10.1111/j.1399-3054.1972.tb01110.x; TRUELSEN TA, 1973, PHYSIOL PLANTARUM, V28, P67, DOI 10.1111/j.1399-3054.1973.tb01152.x; ULLRICH J, 1966, BIOCHIM BIOPHYS ACTA, V115, P595	33	74	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15823	15828						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1639814				2022-12-25	WOS:A1992JG11300086
J	AVENT, ND; BUTCHER, SK; LIU, W; MAWBY, WJ; MALLINSON, G; PARSONS, SF; ANSTEE, DJ; TANNER, MJA				AVENT, ND; BUTCHER, SK; LIU, W; MAWBY, WJ; MALLINSON, G; PARSONS, SF; ANSTEE, DJ; TANNER, MJA			LOCALIZATION OF THE C-TERMINI OF THE RH (RHESUS) POLYPEPTIDES TO THE CYTOPLASMIC FACE OF THE HUMAN ERYTHROCYTE-MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-CELL MEMBRANE; ANION TRANSPORT PROTEIN; RH(D) POLYPEPTIDE; ANTIGENS; IDENTIFICATION; POLYMORPHISM; ORIENTATION; SEQUENCE; CLONING	We have raised a rabbit antiserum to a synthetic peptide corresponding to the C terminus (residues 400-416) of the Rh30A polypeptide. The rabbit antiserum reacted with the Rh30B (D30) polypeptide in addition to the Rh30A (C/c and/or E/e) polypeptide(s), indicating that these proteins share homology at their C termini. The antiserum did not react with erythrocyte membranes from an individual with Rh(null) syndrome. The rabbit antiserum immunoprecipitated Rh polypeptides from erythrocyte membranes and alkali-stripped membranes, but not from intact erythrocytes. Treatment of intact red cells with carboxypeptidase Y did not affect the reactivity of the antiserum, whereas treatment of alkali-stripped and unsealed erythrocyte ghost membranes resulted in the loss of antibody binding. Carboxypeptidase A treatment of intact erythrocytes and alkali-stripped membranes had no effect on antibody binding, indicating that the C-terminal domains of the Rh polypeptides contain lysine, arginine, proline, or histidine residues. These results show that the C termini of the Rh polypeptides are located toward the cytoplasmic face of the erythrocyte membrane. Treatment of intact radioiodinated erythrocytes with bromelain followed by immunoprecipitation with monoclonal anti-D gave a band of M(r) 24,000-25,000, indicating that the Rh30B (D30) polypeptide is cleaved at an extracellular domain close to the N or C terminus, with loss of the major radioiodinated domain. Immunoblotting of bromelain treated D-positive erythrocyte membranes with the rabbit antiserum to the C-terminal peptide revealed a new band of M(r) 6000-6500, indicating that the extracellular bromelain cleavage site is located near the C terminus of the molecule. The band of M(r) 6000-6500 was not obtained in erythrocyte membranes derived from bromelain treated D-negative erythrocytes. Erythrocytes of the rare -D- phenotype appear to either totally lack, or have gross alterations in, the Cc/Ee polypeptide(s), since the bromelain treatment of these cells resulted in the total loss of staining in the M(r) 35,000-37,000 region and the concomitant appearance of the new band of M(r) 6000-6500.	UNIV BRISTOL,DEPT BIOCHEM,BRISTOL BS8 1TD,AVON,ENGLAND; BRISTOL POLYTECH,DEPT BIOL,BRISTOL BS16 1QY,ENGLAND	University of Bristol; University of West England	AVENT, ND (corresponding author), INT BLOOD GRP REFERENCE LAB,SOUTHMEAD RD,BRISTOL BS10 5ND,ENGLAND.		Anstee, David/AAE-9231-2020					AGRE P, 1991, BLOOD, V78, P551, DOI 10.1182/blood.V78.3.551.bloodjournal783551; Atherton E., 1981, J CHEM SOC P1, V1, P538; AVENT N, 1988, BIOCHEM J, V251, P499, DOI 10.1042/bj2510499; AVENT ND, 1990, BIOCHEM J, V271, P821, DOI 10.1042/bj2710821; AVENT ND, 1988, BIOCHEM J, V256, P1043, DOI 10.1042/bj2561043; BLOY C, 1990, J BIOL CHEM, V265, P21482; BLOY C, 1988, BLOOD, V72, P661; BRUNS GAP, 1989, CYTOGENET CELL GENET, V51, P67, DOI 10.1159/000132781; CHERIFZAHAR B, 1991, HUM GENET, V86, P398, DOI 10.1007/BF00201843; CHERIFZAHAR B, 1990, P NATL ACAD SCI USA, V87, P6243, DOI 10.1073/pnas.87.16.6243; COLIN Y, 1991, BLOOD, V78, P2747; DEVETTEN MP, 1988, J BIOL CHEM, V263, P18193; DRYLAND A, 1986, J CHEM SOC P1, V1, P125; GAHMBERG CG, 1984, J IMMUNOL, V133, P334; GAHMBERG CG, 1982, FEBS LETT, V140, P93, DOI 10.1016/0014-5793(82)80528-0; Gardner B, 1991, Transfus Med, V1, P77, DOI 10.1111/j.1365-3148.1991.tb00013.x; GREEN FA, 1967, IMMUNOCHEMISTRY, V4, P247, DOI 10.1016/0019-2791(67)90186-3; GREEN FA, 1965, VOX SANG, V10, P32, DOI 10.1111/j.1423-0410.1965.tb04317.x; GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; Hayashi R, 1977, Methods Enzymol, V47, P84; KISFALUDY L, 1983, SYNTHESIS-STUTTGART, P325; KNORR R, 1989, TETRAHEDRON LETT, V30, P1927, DOI 10.1016/S0040-4039(00)99616-3; KRAHMER M, 1987, FEBS LETT, V226, P105, DOI 10.1016/0014-5793(87)80560-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEBERMAN DM, 1987, BIOCHIM BIOPHYS ACTA, V903, P37, DOI 10.1016/0005-2736(87)90153-2; MACGEOCH C, 1992, CYTOGENET CELL GENET, V59, P261, DOI 10.1159/000133264; MALLINSON G, 1986, BIOCHEM J, V234, P649, DOI 10.1042/bj2340649; MALLINSON G, 1990, TRANSFUSION, V30, P222, DOI 10.1046/j.1537-2995.1990.30390194341.x; MOLLISON PL, 1987, BLOOD TRANSFUSION CL; MOORE S, 1982, NATURE, V295, P529, DOI 10.1038/295529a0; MOORE S, 1987, BIOCHEM J, V244, P735, DOI 10.1042/bj2440735; RIDGWELL K, 1984, FEBS LETT, V174, P7, DOI 10.1016/0014-5793(84)81066-2; RIDGWELL K, 1983, BIOCHEM J, V213, P267, DOI 10.1042/bj2130267; RIDGWELL K, 1992, IN PRESS BIOCH J; SABOORI AM, 1988, P NATL ACAD SCI USA, V85, P4042, DOI 10.1073/pnas.85.11.4042; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SUYAMA K, 1990, BLOOD, V75, P255; SUYAMA K, 1988, BLOOD, V72, P1622; SUYAMA K, 1992, BLOOD, V79, P808; SUYAMA K, 1991, BLOOD, V77, P411; TIPPETT P, 1987, BLOOD GROUP SYSTEMS, P25; TSCHESCHE H, 1977, METHOD ENZYMOL, V247, P73; WAINWRIGHT SD, 1989, BIOCHEM J, V258, P211, DOI 10.1042/bj2580211	44	56	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15134	15139						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634548				2022-12-25	WOS:A1992JF08800092
J	OKAMURA, N; TAJIMA, Y; ONOE, S; SUGITA, Y				OKAMURA, N; TAJIMA, Y; ONOE, S; SUGITA, Y			PURIFICATION OF BICARBONATE-SENSITIVE SPERM ADENYLYLCYCLASE BY 4-ACETAMIDO-4'-ISOTHIOCYANOSTILBENE-2,2'-DISULFONIC ACID-AFFINITY CHROMATOGRAPHY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRAIN ADENYLATE-CYCLASE; ANION TRANSPORT; CATALYTIC SUBUNIT; MAMMALIAN SPERM; SEMINAL PLASMA; PORCINE SPERM; IDENTIFICATION; MEMBRANES; PROTEIN; SPERMATOZOA	Anion transport inhibitors, such as SITS (4-acetamido-4'-isothiocyanostilbene-2,2'-disulfonic acid) and heparin, inhibit reversibly the bicarbonate-sensitive adenylylcyclase of porcine sperm plasma membrane. In the light of this, SITS- and heparin-affinity chromatographies were applied in order to purify sperm adenylylcyclase. SITS-Affi-Gel 102 binds proteins extracted from the porcine cauda epididymal sperm plasma membrane by Lubrol-PX, more selectively than heparin-agarose. However, recovery of adenylylcyclase activity is higher when heparin-agarose is used. The hormone-sensitive liver adenylylcyclase, which is less sensitive to bicarbonate than sperm enzyme, has less affinity for these affinity resins than sperm enzyme. Adenylylcyclase can be purified to apparent homogeneity on two-dimensional gel electrophoresis (isoelectric focusing/sodium dodecyl sulfate-polyacrylamide gel electrophoresis) from the Lubrol-PX extract of the purified sperm plasma membrane by using SITS-affinity chromatography at the first step of the purification followed by preparative isoelectric focusing and gel filtration. The molecular weight and pI of the purified enzyme are 46,300 and 6.9, respectively. The purified enzyme activity is highly dependent on Mn2+. Bicarbonate activates even the purified enzyme both by decreasing K(m) and by increasing V(max).	SAGA MED SCH HOSP, CLIN LAB, SAGA 849, JAPAN	Saga University	OKAMURA, N (corresponding author), UNIV TSUKUBA, INST BASIC MED SCI, TSUKUBA, IBARAKI 305, JAPAN.							BHATTACHARYYA A, 1988, GAMETE RES, V19, P123, DOI 10.1002/mrd.1120190203; CLARKE S, 1975, J BIOL CHEM, V250, P5459; COUSSEN F, 1985, P NATL ACAD SCI USA, V82, P6736, DOI 10.1073/pnas.82.20.6736; GARBERS DL, 1982, J BIOL CHEM, V257, P8980; GARTY NB, 1987, FEBS LETT, V218, P148, DOI 10.1016/0014-5793(87)81036-0; GROSS MK, 1987, J BIOL CHEM, V262, P8672; HILDEBRANDT JD, 1985, ENDOCRINOLOGY, V116, P1357, DOI 10.1210/endo-116-4-1357; HYNE RV, 1979, BIOL REPROD, V21, P1135, DOI 10.1095/biolreprod21.5.1135; JOHNSON RA, 1985, J BIOL CHEM, V260, P114; KOPF GS, 1986, J BIOL CHEM, V261, P7327; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LEE MA, 1986, BIOL REPROD, V34, P349, DOI 10.1095/biolreprod34.2.349; LIPKIN VM, 1989, FEBS LETT, V254, P69, DOI 10.1016/0014-5793(89)81011-7; LORENSON MY, 1981, J BIOL CHEM, V256, P2802; MACARA IG, 1983, CELL MEMBR METH REV, V1, P41; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; NEER EJ, 1981, J BIOL CHEM, V256, P5497; NEER EJ, 1974, J BIOL CHEM, V249, P6527; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OKAMURA N, 1985, J BIOL CHEM, V260, P9699; OKAMURA N, 1988, BIOCHEM BIOPH RES CO, V157, P1280, DOI 10.1016/S0006-291X(88)81013-1; OKAMURA N, 1983, J BIOL CHEM, V258, P3056; OKAMURA N, 1990, BIOCHIM BIOPHYS ACTA, V1035, P83, DOI 10.1016/0304-4165(90)90177-X; PASSOW H, 1986, REV PHYSIOL BIOCH P, V103, P61; PFEUFFER E, 1985, P NATL ACAD SCI USA, V82, P3086, DOI 10.1073/pnas.82.10.3086; PIMPLIKAR SW, 1986, J BIOL CHEM, V261, P9770; RAMJEESINGH M, 1981, BIOCHIM BIOPHYS ACTA, V641, P173, DOI 10.1016/0005-2736(81)90581-2; ROSS EM, 1980, ANNU REV BIOCHEM, V49, P553, DOI 10.1146/annurev.bi.49.070180.002533; SMIGEL MD, 1986, J BIOL CHEM, V261, P1976; STENGEL D, 1984, ANN NY ACAD SCI, V438, P18, DOI 10.1111/j.1749-6632.1984.tb38272.x; STENGEL D, 1982, J BIOL CHEM, V257, P818; STENGEL D, 1986, EUR J BIOCHEM, V161, P241, DOI 10.1111/j.1432-1033.1986.tb10148.x; TAJIMA Y, 1990, BIOCHIM BIOPHYS ACTA, V1034, P326, DOI 10.1016/0304-4165(90)90059-6; VISCONTI PE, 1990, BIOCHIM BIOPHYS ACTA, V1054, P231, DOI 10.1016/0167-4889(90)90246-A; YEAGER RE, 1985, BIOCHEMISTRY-US, V24, P3776, DOI 10.1021/bi00335a054	35	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					17754	17759						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1655724				2022-12-25	WOS:A1991GG55300009
J	CASADEVALL, N; LACOMBE, C; MULLER, O; GISSELBRECHT, S; MAYEUX, P				CASADEVALL, N; LACOMBE, C; MULLER, O; GISSELBRECHT, S; MAYEUX, P			MULTIMERIC STRUCTURE OF THE MEMBRANE ERYTHROPOIETIN RECEPTOR OF MURINE ERYTHROLEUKEMIA-CELLS (FRIEND-CELLS) - CROSS-LINKING OF ERYTHROPOIETIN WITH THE SPLEEN FOCUS-FORMING VIRUS ENVELOPE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROID-CELLS; DIMETHYL-SULFOXIDE; ESCHERICHIA-COLI; ONE-STEP; GLYCOPROTEIN; DIFFERENTIATION; IDENTIFICATION; GENE; BINDING; EXPRESSION	In erythroleukemia cells infected with the polycythemia strain of the Friend virus complex, erythropoietin could be cross-linked mainly to a protein of 63 kDa when using disuccinimidyl suberate. In contrast, erythropoietin in other erythroleukemia cells cross-linked to two proteins of 85 and 100 kDa. When native erythropoietin receptor complexes were immunoprecipitated, the 63-kDa erythropoietin-cross-linked protein could be precipitated both by antibodies directed against the intracellular part of the cloned chain of the erythropoietin receptor and by antibodies directed against the envelope proteins of the Friend virus. However, after denaturation of the complexes, the 63-kDa protein was only precipitated by antibodies directed against the envelope proteins of the Friend virus. Enzymatic deglycosylation confirmed that erythropoietin was cross-linked with the envelope protein of the defective virus and bidimensional diagonal gel electrophoresis analyses showed that some of the erythropoietin cross-linked envelope proteins were dimerized by disulfide bonds. Thus, the main erythropoietin-receptor complex in the plasma membrane of these cells consisted of a molecule of the cloned chain of the erythropoietin receptor noncovalently associated with one or two disulfide-bonded molecule(s) of the envelope protein of the defective virus. Moreover, our results also showed that the viral envelope protein associated with the cloned chain of the erythropoietin receptor at a site distinct from the erythropoietin binding site.	HOP COCHIN, INSERM, U152, ICGM, 27 RUE FAUBOURG ST JACQUES, F-75674 PARIS 14, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier								BEDOUELLE H, 1988, EUR J BIOCHEM, V171, P541, DOI 10.1111/j.1432-1033.1988.tb13823.x; BROUDY VC, 1988, P NATL ACAD SCI USA, V85, P6513, DOI 10.1073/pnas.85.17.6513; CLEMENT JM, 1989, CR ACAD SCI III-VIE, V308, P401; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DRESLER S, 1979, J VIROL, V30, P564, DOI 10.1128/JVI.30.2.564-575.1979; DUPLAY P, 1984, J BIOL CHEM, V259, P606; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; GLINIAK BC, 1989, J VIROL, V63, P3561, DOI 10.1128/JVI.63.9.3561-3568.1989; GODING JW, 1981, P NATL ACAD SCI-BIOL, V78, P4530, DOI 10.1073/pnas.78.7.4530; HARRISON PR, 1978, CELL, V14, P61, DOI 10.1016/0092-8674(78)90301-X; IKAWA Y, 1976, GANN, V67, P767; KABAT D, 1989, CURR TOP MICROBIOL, V148, P1; KITAMURA T, 1989, BLOOD, V73, P375; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ KT, 1989, BLOOD, V73, P1476; LI JP, 1987, J VIROL, V61, P2782, DOI 10.1128/JVI.61.9.2782-2792.1987; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; MACHIDA CA, 1985, VIROLOGY, V144, P158, DOI 10.1016/0042-6822(85)90314-9; MANIATIS T, 1982, MOL CLONING LABORATO, P466; MAYEUX P, 1987, J BIOL CHEM, V262, P13985; MAYEUX P, 1990, EUR J BIOCHEM, V194, P271, DOI 10.1111/j.1432-1033.1990.tb19453.x; MAYEUX P, 1990, FEBS LETT, V269, P167, DOI 10.1016/0014-5793(90)81145-E; OSTERTAG W, 1972, NATURE-NEW BIOL, V239, P231, DOI 10.1038/newbio239231a0; PINTER A, 1989, VIROLOGY, V173, P136, DOI 10.1016/0042-6822(89)90229-8; RUTA M, 1983, P NATL ACAD SCI-BIOL, V80, P4704, DOI 10.1073/pnas.80.15.4704; SASAKI R, 1987, EUR J BIOCHEM, V168, P43, DOI 10.1111/j.1432-1033.1987.tb13384.x; SAWYER ST, 1987, P NATL ACAD SCI USA, V84, P3690, DOI 10.1073/pnas.84.11.3690; TODOKORO K, 1988, BIOCHIM BIOPHYS ACTA, V943, P326, DOI 10.1016/0005-2736(88)90564-0; TOJO A, 1987, BIOCHEM BIOPH RES CO, V148, P443, DOI 10.1016/0006-291X(87)91131-4; WEISS TL, 1989, J BIOL CHEM, V264, P1804; WOGNUM AW, 1990, BLOOD, V76, P697; WOLFF L, 1988, J VIROL, V62, P2158, DOI 10.1128/JVI.62.6.2158-2163.1988; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139	33	65	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					16015	16020						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1651930				2022-12-25	WOS:A1991GB97700074
J	GINTY, DD; GLOWACKA, D; DEFRANCO, C; WAGNER, JA				GINTY, DD; GLOWACKA, D; DEFRANCO, C; WAGNER, JA			NERVE GROWTH FACTOR-INDUCED NEURONAL DIFFERENTIATION AFTER DOMINANT REPRESSION OF BOTH TYPE-I AND TYPE-II CAMP-DEPENDENT PROTEIN-KINASE ACTIVITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PC12 PHEOCHROMOCYTOMA CELLS; CYCLIC-AMP; ORNITHINE DECARBOXYLASE; GENE-EXPRESSION; RAT PHEOCHROMOCYTOMA; NEURITE OUTGROWTH; BINDING PROTEINS; FREE-EXTRACTS; PHOSPHORYLATION; INHIBITOR	Clonal PC12 lines deficient in cAMP-dependent protein kinase (PKA) were made by stably expressing mutant regulatory subunits (RI) of PKA that are deficient in cAMP binding (Correll, L. A., Woodford, T. A., Corbin, J. D., Mellon, P. L., and McKnight, G. S. (1989) J. Biol. Chem. 264, 16672-16678). Expression of the mutant RIs repressed cAMP-dependent activation of both PKAI and PKAII while having no effects on the cAMP binding to either free RI or RII or the level of catalytic subunit protein. These data suggest that RI and RII compete for the same pool of catalytic subunit and that the level of PKAI and PKAII are interdependent. We have used these cell lines to examine the requirement for PKA in mediating the effects of nerve growth factor (NGF) and agents that are thought to act exclusively via cAMP-dependent pathways. While several responses to cAMP were strongly compromised in these lines, NGF-dependent responses were comparable in parental and PKA-deficient cells, including: 1) protein phosphorylation, 2) transcriptional induction of the immediate early gene egr1, 3) expression of the gene for GAP-43, 4) induction of ornithine decarboxylase activity, and 5) formation of neurites. Furthermore, transient expression of the cAMP-dependent protein kinase inhibitor (RSVPKI; Day, R. N., Walder, J. A., and Maurer, R. A. (1989) J. Biol. Chem. 264, 431-436) blocked cAMP, but not NGF, induction of regulatory elements derived from the gene for egr1. These experiments support the idea that NGF can regulate neuronal differentiation by pathways that are independent of cAMP-activatable PKA.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	GINTY, DD (corresponding author), HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA.				NCI NIH HHS [CA40929] Funding Source: Medline; NINDS NIH HHS [NS08764] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040929] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS008764] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADY MJ, 1990, J NEUROCHEM, V54, P1034, DOI 10.1111/j.1471-4159.1990.tb02354.x; CHAN BL, 1989, P NATL ACAD SCI USA, V86, P1756, DOI 10.1073/pnas.86.6.1756; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHO KO, 1989, MOL CELL BIOL, V9, P135, DOI 10.1128/MCB.9.1.135; CONTRERAS ML, 1987, J NEUROCHEM, V48, P1466, DOI 10.1111/j.1471-4159.1987.tb05687.x; CORRELL LA, 1989, J BIOL CHEM, V264, P16672; CREMINS J, 1986, J CELL BIOL, V103, P887, DOI 10.1083/jcb.103.3.887; DAMON DH, 1990, J CELL BIOL, V110, P1333, DOI 10.1083/jcb.110.4.1333; DAMON DH, 1990, J CELL BIOL, V111, P507; DAY RN, 1989, J BIOL CHEM, V264, P431; DJURHUUS R, 1981, ANAL BIOCHEM, V113, P352, DOI 10.1016/0003-2697(81)90088-9; FEDEROFF HJ, 1988, J BIOL CHEM, V263, P19290; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIOL CJ, 1987, J BIOL CHEM, V262, P14042; FUJITA K, 1989, ENVIRON HEALTH PERSP, V80, P127, DOI 10.2307/3430738; GLOWACKA D, 1990, J NEUROSCI RES, V25, P453, DOI 10.1002/jnr.490250403; GOLUBEVA EE, 1989, FEBS LETT, V247, P232, DOI 10.1016/0014-5793(89)81341-9; GOTTESMAN MM, 1980, CELL, V22, P329, DOI 10.1016/0092-8674(80)90342-6; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GUNNING PW, 1981, J CELL BIOL, V89, P240, DOI 10.1083/jcb.89.2.240; HALEGOUA S, 1980, CELL, V22, P571, DOI 10.1016/0092-8674(80)90367-0; HALEGOUA S, 1991, CURR TOP MICROBIOL, V165, P119; HAMA T, 1986, P NATL ACAD SCI USA, V83, P2353, DOI 10.1073/pnas.83.8.2353; HATANAKA H, 1978, FEBS LETT, V92, P313, DOI 10.1016/0014-5793(78)80777-7; HAYCOCK JW, 1990, J BIOL CHEM, V265, P11682; HEASLEY LE, 1989, MOL PHARMACOL, V35, P331; HOFMANN F, 1975, J BIOL CHEM, V250, P7795; HUFFAKER T, 1984, J CELL PHYSIOL, V120, P188, DOI 10.1002/jcp.1041200212; KALMAN D, 1990, NEURON, V4, P355, DOI 10.1016/0896-6273(90)90048-K; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KARNS LR, 1987, SCIENCE, V236, P597, DOI 10.1126/science.2437653; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; LANDRETH GE, 1987, NEUROCHEM RES, V12, P943, DOI 10.1007/BF00966317; LECAM A, 1981, J BIOL CHEM, V256, P933; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MASIAKOWSKI P, 1988, P NATL ACAD SCI USA, V85, P1277, DOI 10.1073/pnas.85.4.1277; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; RACE HM, 1985, J NEUROCHEM, V44, P1588, DOI 10.1111/j.1471-4159.1985.tb08799.x; RAE PA, 1979, P NATL ACAD SCI USA, V76, P1896, DOI 10.1073/pnas.76.4.1896; ROSEN OM, 1975, J BIOL CHEM, V250, P7788; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SCHUBERT D, 1977, P NATL ACAD SCI USA, V74, P2579, DOI 10.1073/pnas.74.6.2579; SCHUBERT D, 1978, NATURE, V273, P718, DOI 10.1038/273718a0; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; STEINBERG RA, 1979, CELL, V18, P719, DOI 10.1016/0092-8674(79)90126-0; SUGDEN PH, 1976, BIOCHEM J, V159, P423, DOI 10.1042/bj1590423; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443; THOENEN H, 1980, PHYSIOL REV, V60, P1284, DOI 10.1152/physrev.1980.60.4.1284; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANBUSKIRK R, 1985, MOL CELL BIOL, V5, P1984, DOI 10.1128/MCB.5.8.1984; VOLONTE C, 1989, J CELL BIOL, V109, P2395, DOI 10.1083/jcb.109.5.2395; VULLIET PR, 1989, J BIOL CHEM, V264, P16292; WALSH DA, 1971, J BIOL CHEM, V246, P1977; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3682	56	111	111	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15325	15333						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1651325				2022-12-25	WOS:A1991GB09700075
J	GRAFF, JM; RAJAN, RR; RANDALL, RR; NAIRN, AC; BLACKSHEAR, PJ				GRAFF, JM; RAJAN, RR; RANDALL, RR; NAIRN, AC; BLACKSHEAR, PJ			PROTEIN-KINASE-C SUBSTRATE AND INHIBITOR CHARACTERISTICS OF PEPTIDES DERIVED FROM THE MYRISTOYLATED ALANINE-RICH C-KINASE SUBSTRATE (MARCKS) PROTEIN-PHOSPHORYLATION SITE DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAP-JUNCTION PROTEIN; MYELIN BASIC-PROTEIN; PROMINENT CELLULAR SUBSTRATE; MOLECULAR-CLONING; INDEPENDENT PATHWAYS; CALMODULIN BINDING; REGULATORY DOMAIN; BOVINE BRAIN; CA-2+; EXPRESSION	The phosphorylation sites in the myristoylated alanine-rich C kinase substrate or MARCKS protein consist of four serines contained within a conserved, basic region of 25 amino acids, termed the phosphorylation site domain. A synthetic peptide comprising this domain was phosphorylated by both protein kinase C and its catalytic fragment with high affinity and apparent positive cooperativity. Tryptic phosphopeptides derived from the peptide appeared similar to phosphopeptides derived from the phosphorylated intact protein. The peptide was phosphorylated by cAMP- and cGMP-dependent protein kinases with markedly lower affinities. In peptides containing only one of the four serines, with the other three serines replaced by alanine, the affinities for protein kinase C ranged from 25 to 60 nM with Hill constants between 1.8 and 3.0. The potential pseudosubstrate peptide, in which all four serines were replaced by alanines, inhibited protein kinase C phosphorylation of histone or a peptide substrate with an IC50 of 100-200 nM with apparently non-competitive kinetics; it also inhibited the catalytic fragment of protein kinase C with a K(i) of 20 nM, with kinetics of the mixed type. The peptide did not significantly inhibit the cAMP- and cGMP-dependent protein kinases. It inhibited Ca2+/calmodulin-dependent protein kinases I, II, and III by competing with the kinases for calmodulin. In addition, the peptide inhibited the Ca2+/calmodulin-independent activity of a proteolytic fragment of Ca2+/calmodulin protein kinase II, with an IC50 almost-equal-to 5-mu-M. Thus, the phosphorylation site domain peptide of the MARCKS protein is a high affinity substrate for protein kinase C in vitro; the cognate peptide containing no serines is a potent but not completely specific inhibitor of both protein kinase C and its catalytic fragment.	DUKE UNIV,MED CTR,DEPT MED,DIV ENDOCRINOL METAB & GENET,DIABET & METAB SECT,BOX 3897,DURHAM,NC 27710; HOWARD HUGHES MED INST LABS,DURHAM,NC 27710; ROCKEFELLER UNIV,MOLEC & CELLULAR NEUROSCI LAB,NEW YORK,NY 10021; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; Rockefeller University; Duke University			Blackshear, Perry J./C-6206-2019	Blackshear, Perry J./0000-0002-9561-8529; Nairn, Angus/0000-0002-7075-0195	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007171] Funding Source: NIH RePORTER; NIGMS NIH HHS [2T32-GM-07171] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERT KA, 1987, P NATL ACAD SCI USA, V84, P7046, DOI 10.1073/pnas.84.20.7046; BEYER EC, 1987, J CELL BIOL, V105, P2621, DOI 10.1083/jcb.105.6.2621; BLACKSHEAR PJ, 1984, METHOD ENZYMOL, V104, P237; BLACKSHEAR PJ, 1985, J BIOL CHEM, V260, P3304; BLACKSHEAR PJ, 1987, J BIOL CHEM, V262, P7774; BLACKSHEAR PJ, 1986, MECHANISMS INSULIN A, P211; BLACKSHEAR PJ, 1988, AM J MED SCI, V31, P231; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cleland W, 1983, CONT ENZYME KINETICS, P253; COLBRAN RJ, 1989, J BIOL CHEM, V264, P4800; CZERNIK AJ, 1987, P NATL ACAD SCI USA, V84, P7518, DOI 10.1073/pnas.84.21.7518; FERRARI S, 1985, FEBS LETT, V184, P72, DOI 10.1016/0014-5793(85)80656-6; FRIEIFELDER D, 1982, PHYSICAL BIOCH, P491; GRAFF JM, 1989, MOL ENDOCRINOL, V3, P1903, DOI 10.1210/mend-3-11-1903; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; GRAFF JM, 1989, J BIOL CHEM, V264, P11912; GRAND RJA, 1979, BIOCHEM J, V177, P521, DOI 10.1042/bj1770521; HALSEY DL, 1987, J BIOL CHEM, V262, P2234; HANNUN YA, 1986, J BIOL CHEM, V261, P7184; HARLAN DM, 1991, J BIOL CHEM, V266, P14399; HOUSE C, 1987, J BIOL CHEM, V262, P772; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HUANG KP, 1986, BIOCHEM BIOPH RES CO, V139, P320, DOI 10.1016/S0006-291X(86)80116-4; KACZMAREK LK, 1980, P NATL ACAD SCI-BIOL, V77, P7487, DOI 10.1073/pnas.77.12.7487; KEMP BE, 1976, P NATL ACAD SCI USA, V73, P1038, DOI 10.1073/pnas.73.4.1038; KENNELLY PJ, 1987, J BIOL CHEM, V262, P11958; KIM JY, 1991, BIOPHYS J, V60, P135, DOI 10.1016/S0006-3495(91)82037-9; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KWIATKOWSKI AP, 1989, BIOCHEMISTRY-US, V28, P5380, DOI 10.1021/bi00439a010; MCGUINNESS TL, 1985, J BIOL CHEM, V260, P1696; MCILROY BK, 1991, J BIOL CHEM, V266, P4959; MOCHLYROSEN D, 1987, J BIOL CHEM, V262, P2291; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; NAIRN AC, 1987, J BIOL CHEM, V262, P17299; NAKADATE T, 1987, J BIOL CHEM, V262, P11507; Neet K E, 1980, Methods Enzymol, V64, P192; NEET KE, 1983, CONT ENZYME KINETICS, P267; NIEDEL J E, 1986, P47; NISHIZUKA Y, 1984, SCIENCE, V225, P1365, DOI 10.1126/science.6147898; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OBRIAN CA, 1984, BIOCHEM BIOPH RES CO, V124, P296, DOI 10.1016/0006-291X(84)90951-3; PAUL DL, 1986, J CELL BIOL, V103, P123, DOI 10.1083/jcb.103.1.123; RAMACHANDRAN C, 1984, J BIOL CHEM, V259, P3495; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; ROZENGURT E, 1983, P NATL ACAD SCI USA, V80, P6858; SAEZ J C, 1990, Journal of Cell Biology, V111, p154A; SAEZ JC, 1990, EUR J BIOCHEM, V192, P263, DOI 10.1111/j.1432-1033.1990.tb19223.x; Segel IH, 1975, ENZYME KINETICS, P346; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; TURNER RS, 1984, J NEUROCHEM, V43, P1257; TURNER RS, 1985, J BIOL CHEM, V260, P1503; WALTER U, 1980, J BIOL CHEM, V255, P3757; WHITTAKER J, 1987, P NATL ACAD SCI USA, V84, P5237, DOI 10.1073/pnas.84.15.5237; WOODGETT JR, 1987, J BIOL CHEM, V262, P4836; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; WOODGETT JR, 1987, CELL MEMBRANES METHO, V3, P215	57	111	128	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14390	14398						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1650359				2022-12-25	WOS:A1991FZ35100045
J	RAPUANO, M; ROSEN, OM				RAPUANO, M; ROSEN, OM			PHOSPHORYLATION OF THE INSULIN-RECEPTOR BY A CASEIN KINASE-I-LIKE ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; PHORBOL ESTERS INCREASE; RABBIT SKELETAL-MUSCLE; ATP-BINDING SITE; SERINE KINASE; BETA-SUBUNIT; TYROSINE PHOSPHORYLATION; RAT ADIPOCYTES; IM-9 CELLS; PURIFICATION	A serine protein kinase that phosphorylates the beta-subunit of the insulin receptor has been partially purified 5,000-fold from HeLa cell membranes. The enzyme has been purified by ion-exchange and hydroxylapatite chromatography and sucrose gradient centrifugation; it has an apparent molecular weight of 36,000-43,000 daltons. It exhibits the following properties: (a) it catalyzes the phosphorylation of the autophosphorylated insulin receptor more efficiently than the nonautophosphorylated insulin receptor, (b) it decreases insulin receptor phosphorylation of tubulin but has no effect on insulin receptor phosphorylation of microtubule-associated proteins or reduced and carboxyamidomethylated lysozyme. The enzyme also phosphorylates casein and ribosomal protein S6 and shares many properties with casein kinase I: (a) similar molecular weight, (b) utilization of ATP but not GTP as phosphoryl donor, and (c) sensitivity to inhibition by heparin. Based on several criteria the receptor serine kinase is neither protein kinase C nor the cAMP-dependent protein kinase.	MEM SLOAN KETTERING CANC CTR,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035158] Funding Source: NIH RePORTER; NIDDK NIH HHS [5R37DK 35158-06] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHMAD Z, 1984, J BIOL CHEM, V259, P3420; BALLOTTI R, 1986, BIOCHEM BIOPH RES CO, V139, P179, DOI 10.1016/S0006-291X(86)80096-1; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; BOLLAG GE, 1986, P NATL ACAD SCI USA, V83, P5822, DOI 10.1073/pnas.83.16.5822; CHOU CK, 1987, J BIOL CHEM, V262, P1842; COBB MH, 1983, J BIOL CHEM, V258, P2472; CRESTFIELD AM, 1963, J BIOL CHEM, V238, P622; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; GANGULY S, 1985, CURR TOP CELL REGUL, V27, P83; GAZZANO H, 1983, BIOCHEM J, V216, P575, DOI 10.1042/bj2160575; HARING H, 1986, J BIOL CHEM, V261, P3869; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; ITARTE E, 1979, J BIOL CHEM, V254, P4052; JACOBS S, 1986, J BIOL CHEM, V261, P934; JACOBS S, 1983, P NATL ACAD SCI-BIOL, V80, P6211, DOI 10.1073/pnas.80.20.6211; KADOWAKI T, 1985, J BIOL CHEM, V260, P4016; KASUGA M, 1982, J BIOL CHEM, V257, P9891; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KOHANSKI RA, 1986, BIOCHEM BIOPH RES CO, V134, P1312, DOI 10.1016/0006-291X(86)90393-1; KOLAROV J, 1988, J BIOL CHEM, V263, P10613; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS RE, 1990, J BIOL CHEM, V265, P947; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MORGAN DO, 1987, P NATL ACAD SCI USA, V84, P41, DOI 10.1073/pnas.84.1.41; PANG DT, 1985, J BIOL CHEM, V260, P7131; PENDERGAST AM, 1985, J BIOL CHEM, V260, P1769; PETRUZZELLI L, 1984, P NATL ACAD SCI-BIOL, V81, P3327, DOI 10.1073/pnas.81.11.3327; PETRUZZELLI LM, 1982, P NATL ACAD SCI USA, V79, P6972; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; ROTH RA, 1983, SCIENCE, V219, P299, DOI 10.1126/science.6849137; ROTH RA, 1987, DIABETES, V36, P123, DOI 10.2337/diabetes.36.1.123; RUSSELL DS, 1987, J BIOL CHEM, V262, P11833; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SHIA MA, 1983, BIOCHEMISTRY-US, V22, P717, DOI 10.1021/bi00273a001; SIBLEY DR, 1986, P NATL ACAD SCI USA, V83, P9408, DOI 10.1073/pnas.83.24.9408; SIEGEL TW, 1981, J BIOL CHEM, V256, P9266; SINGH TJ, 1984, J BIOL CHEM, V259, P2857; SMITH DM, 1988, BIOCHEM J, V256, P903, DOI 10.1042/bj2560903; STADTMAUER L, 1986, J BIOL CHEM, V261, P3402; STETLER DA, 1985, BIOCHEMISTRY-US, V24, P5163, DOI 10.1021/bi00340a031; TABARINI D, 1987, BIOCHEM BIOPH RES CO, V144, P891, DOI 10.1016/S0006-291X(87)80048-7; TAKAYAMA S, 1988, J BIOL CHEM, V263, P3440; TAKAYAMA S, 1984, P NATL ACAD SCI-BIOL, V81, P7797, DOI 10.1073/pnas.81.24.7797; TUAZON PT, 1985, J CELL BIOCHEM, V28, P159, DOI 10.1002/jcb.240280208; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VANDEWERVE G, 1985, BIOCHEM J, V225, P523, DOI 10.1042/bj2250523; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; YANAGITA Y, 1987, P NATL ACAD SCI USA, V84, P925, DOI 10.1073/pnas.84.4.925; YU KT, 1984, J BIOL CHEM, V259, P5277; ZICK Y, 1983, BIOCHEM BIOPH RES CO, V116, P1129, DOI 10.1016/S0006-291X(83)80260-5	52	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1991	266	20					12902	12907						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FX132	1649167				2022-12-25	WOS:A1991FX13200020
J	LEVINE, BA; ELLIS, L				LEVINE, BA; ELLIS, L			DELETION OF APPROXIMATELY 10 KDA FROM THE CARBOXYL TERMINUS OF A SOLUBLE APPROXIMATELY 48-KDA INSULIN-RECEPTOR PROTEIN-TYROSINE KINASE RESULTS IN SLOWER RATES OF DIPHOSPHORYLATION OF A SERIES OF DODECAPEPTIDE SUBSTRATES - AN ASSESSMENT BY H-1-NMR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC DOMAIN; BETA-SUBUNIT; AUTOPHOSPHORYLATION; PHOSPHORYLATION; RESIDUES; CELLS; SITES; 2-DEOXYGLUCOSE; IDENTIFICATION; EXPRESSION	Autophosphorylation of a soluble approximately 48-kDa derivative of the insulin receptor protein-tyrosine kinase is accompanied by an increase in its specific activity towards exogenous substrates. In the present study, we have utilized H-1 NMR to compare the order and rate of mono- and diphosphorylation of multiple tyrosine residues in a series of synthetic dodecapeptide substrates (based on the receptor sequence, which includes major sites of autophosphorylation (RRDIYETDYYRK), with substitution(s) at positions 6 and/or 7 based on residue size and/or charge) by the approximately 48-kDa enzyme and by a approximately 38-kDa enzyme generated by tryptic deletion of approximately 10 kDa from the carboxyl terminus of the approximately 48-kDa protein. Both enzymes exhibit a marked order and progression of phosphorylation of peptide tyrosine residues; for each peptide, phosphorylation initiates and proceeds to completion first on tyrosine 9, followed by phosphorylation on tyrosine 10. Although removal of the carboxyl terminus does not affect the rate of monophosphorylation of these peptides on tyrosine 9, the smaller enzyme exhibits a slower rate of diphosphorylation (at tyrosine 10), as compared with the approximately 48-kDa enzyme.	UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,5323 HARRY HINES BLVD,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV OXFORD,INORGAN CHEM LAB,OXFORD OX1 3QR,ENGLAND; UNIV OXFORD,OXFORD CTR MOLEC SCI,OXFORD OX1 3QR,ENGLAND	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Oxford; University of Oxford								COBB MH, 1989, J BIOL CHEM, V264, P18701; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ELLIS L, 1987, MOL ENDOCRINOL, V1, P15, DOI 10.1210/mend-1-1-15; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ELLIS L, 1988, J VIROL, V62, P1634, DOI 10.1128/JVI.62.5.1634-1639.1988; FLORESRIVEROS JR, 1989, J BIOL CHEM, V264, P21557; HERRERA R, 1988, J BIOL CHEM, V263, P5560; LEVINE BA, 1991, J BIOL CHEM, V266, P3565; LEVINE BA, 1991, J BIOL CHEM, V266, P13405; TAVARE JM, 1988, BIOCHEM J, V252, P607, DOI 10.1042/bj2520607; TAVARE JM, 1991, J BIOL CHEM, V266, P1390; TAVARE JM, 1988, BIOCHEM J, V253, P783, DOI 10.1042/bj2530783; TORNQVIST HE, 1987, J BIOL CHEM, V262, P10212; TORNQVIST HE, 1988, J BIOL CHEM, V263, P350; WHITE MF, 1988, J BIOL CHEM, V263, P2969; ZHANG B, 1991, J BIOL CHEM, V266, P990	16	4	4	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1991	266	19					12369	12371						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FV180	1648094				2022-12-25	WOS:A1991FV18000043
J	SEEDORF, K; FELDER, S; MILLAUER, B; SCHLESSINGER, J; ULLRICH, A				SEEDORF, K; FELDER, S; MILLAUER, B; SCHLESSINGER, J; ULLRICH, A			ANALYSIS OF PLATELET-DERIVED GROWTH-FACTOR RECEPTOR DOMAIN FUNCTION USING A NOVEL CHIMERIC RECEPTOR APPROACH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; SIGNAL TRANSDUCTION; PDGF RECEPTOR; CYTOPLASMIC DOMAINS; EGF-RECEPTOR; PROTEINS; INSULIN; INSERT; CELLS; DNA	A chimeric receptor consisting of an epidermal growth factor (EGF) receptor ligand-binding domain and platelet-derived growth factor (PDGF) receptor transmembrane and cytoplasmic signalling domains has been constructed and shown to be fully functional in phosphorylation, mitogenesis, transformation, Ca2+ release, and pH change assays. Expression of this receptor in EGF receptor-deficient, PDGF-responsive NIH 3T3 cells allows the activation of PDGF signalling pathways by EGF. This system was used to examine the function of kinase insertion sequences (KIS). While a mutant with a KIS deletion of 83 amino acids displayed a significant but reduced ability to induce mitogenic, transforming, and Ca2+ release responses in transfected cells, deletion of 20 additional amino acids resulted in abolishment of such activities. This differential loss of signalling potential correlated with the reduced or abolished potential of these receptor mutants to phosphorylate cellular substrates such as PLC-gamma. Our results suggest an integral role for KIS in PDGF receptor cytoplasmic domain conformation and an involvement in substrate interaction, but provide no evidence for an exclusive role of KIS in the mediation of biological signals.	RORER BIOTECHNOL INC,KING OF PRUSSIA,PA 19406; NYU MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	New York University	SEEDORF, K (corresponding author), MAX PLANCK INST BIOCHEM,DEPT MOLEC BIOL,W-8033 MARTINSRIED,GERMANY.							ADELMAN JP, 1983, DNA-J MOLEC CELL BIO, V2, P183, DOI 10.1089/dna.1983.2.183; ALT FW, 1978, J BIOL CHEM, V253, P1357; BELLOT F, 1990, IN PRESS J CELL BIOL; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COUGHLIN SR, 1989, SCIENCE, V243, P1191; EATON DL, 1986, BIOCHEMISTRY-US, V25, P8343, DOI 10.1021/bi00374a001; ESCOBEDO JA, 1988, NATURE, V335, P85, DOI 10.1038/335085a0; FENDLY BM, 1990, CANCER RES, V50, P1550; GORMAN CM, 1989, VIROLOGY, V171, P377, DOI 10.1016/0042-6822(89)90605-3; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; IVES HE, 1987, P NATL ACAD SCI USA, V84, P1950, DOI 10.1073/pnas.84.7.1950; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KRIS RM, 1985, CELL, V40, P619, DOI 10.1016/0092-8674(85)90210-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMMERS R, 1989, EMBO J, V8, P1369, DOI 10.1002/j.1460-2075.1989.tb03517.x; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; MESSING J, 1981, NUCLEIC ACIDS RES, V9, P309, DOI 10.1093/nar/9.2.309; MOOLENAAR WH, 1988, EMBO J, V7, P707, DOI 10.1002/j.1460-2075.1988.tb02866.x; RIEDEL H, 1986, NATURE, V324, P68, DOI 10.1038/324068a0; RIEDEL H, 1989, EMBO J, V8, P2943, DOI 10.1002/j.1460-2075.1989.tb08444.x; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SEVERINSSON L, 1990, MOL CELL BIOL, V10, P801, DOI 10.1128/MCB.10.2.801; TAYLOR GR, 1989, EMBO J, V8, P2029, DOI 10.1002/j.1460-2075.1989.tb03611.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	31	28	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1991	266	19					12424	12431						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FV180	1648098				2022-12-25	WOS:A1991FV18000052
J	VANLEEUWEN, CCM; POSTMA, E; VANDENBROEK, PJA; VANSTEVENINCK, J				VANLEEUWEN, CCM; POSTMA, E; VANDENBROEK, PJA; VANSTEVENINCK, J			PROTON-MOTIVE FORCE-DRIVEN D-GALACTOSE TRANSPORT IN PLASMA-MEMBRANE VESICLES FROM THE YEAST KLUYVEROMYCES-MARXIANUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C OXIDASE; SACCHAROMYCES-CEREVISIAE; GLUCOSE-TRANSPORT; STREPTOCOCCUS-CREMORIS; CONTINUOUS-CULTURE; ESCHERICHIA-COLI; KINETICS; PURIFICATION; REQUIREMENT; MECHANISM	Galactose transport was studied in membrane vesicles, prepared by fusion of plasma membranes from the yeast Kluyveromyces marxianus with proteoliposomes containing beef heart cytochrome c oxidase as a proton-motive force-generating system. Sugar transport studies performed under nonenergized conditions revealed that, even at high protein to phospholipid ratios, not all vesicles contained a D-galactose-specific transporter. The amount of vesicles containing an active carrier proved to be proportional to the amount of plasma membrane protein present in the fusion mixture. By addition of a suitable electron donor system a proton-motive force of -160 mV could be generated, inside alkaline and negative. Moreover, D-galactose accumulation was observed. It was found that D-galactose accumulation was highly dependent on the phospholipid composition of the vesicles, whereas generation of a proton-motive force was not. Best results were obtained with vesicles prepared with Escherichia coli phospholipid, giving a galactose accumulation of 14 times. Uphill transport could be established under conditions where only the pH gradient or the electrical gradient was present. Moreover, kinetic analysis of the galactose transport activity in energized vesicles revealed influx with a K(m) value of 540-mu-M, which is in good agreement with the apparent affinity constant obtained with whole cells. These results establish that galactose transport of K. marxianus is a proton-motive force-driven process. Moreover it demonstrates that plasma membrane vesicles co-reconstituted with cytochrome c oxidase are a valuable resource for the analysis of proton-motive force-driven sugar transport systems of yeast.	SYLVIUS LAB, DEPT MED BIOCHEM, POB 9503, 2300 RA LEIDEN, NETHERLANDS; ZAADUNIE BV, 1600 AA ENKHUIZEN, NETHERLANDS	Leiden University; Leiden University - Excl LUMC								CALAHORRA M, 1987, BIOCHIM BIOPHYS ACTA, V899, P229, DOI 10.1016/0005-2736(87)90404-4; CALAHORRA M, 1989, FEBS LETT, V247, P235, DOI 10.1016/0014-5793(89)81342-0; Cartwright C.P., 1989, YEASTS, V3, P5; CHEN CC, 1984, J BIOL CHEM, V259, P150; CHRISTENSEN MS, 1972, J BACTERIOL, V110, P1190, DOI 10.1128/JB.110.3.1190-1205.1972; CLEMENT NR, 1981, BIOCHEMISTRY-US, V20, P1534, DOI 10.1021/bi00509a019; DEBRUIJNE AW, 1988, BIOCHIM BIOPHYS ACTA, V939, P569, DOI 10.1016/0005-2736(88)90104-6; DEVRIJ W, 1986, EUR J BIOCHEM, V156, P431; DRIESSEN AJM, 1987, J BIOL CHEM, V262, P12438; DRIESSEN AJM, 1988, BIOCHEMISTRY-US, V27, P865, DOI 10.1021/bi00403a005; DRIESSEN AJM, 1985, P NATL ACAD SCI USA, V82, P7555, DOI 10.1073/pnas.82.22.7555; EDDY AA, 1982, ADV MICROB PHYSIOL, V23, P1, DOI 10.1016/S0065-2911(08)60335-5; FRANZUSOFF AJ, 1983, J BIOL CHEM, V258, P3608; GASNIER B, 1987, BIOCHIM BIOPHYS ACTA, V903, P425, DOI 10.1016/0005-2736(87)90049-6; GOFFEAU A, 1981, BIOCHIM BIOPHYS ACTA, V639, P197, DOI 10.1016/0304-4173(81)90010-0; Hanes CS, 1932, BIOCHEM J, V26, P1406, DOI 10.1042/bj0261406; HOEKSTRA D, 1984, BIOCHEMISTRY-US, V23, P5675, DOI 10.1021/bi00319a002; KREUTZFELDT C, 1984, SWISS BIOTECHNOL, V2, P24; LOLKEMA JS, 1982, BIOCHIM BIOPHYS ACTA, V681, P85, DOI 10.1016/0005-2728(82)90281-X; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAIR T, 1988, BIOCHEM INT, V17, P593; ONGJOCO R, 1987, J BACTERIOL, V169, P2926, DOI 10.1128/jb.169.7.2926-2931.1987; OPEKAROVA M, 1987, FEBS LETT, V213, P45, DOI 10.1016/0014-5793(87)81462-X; POSTMA E, 1989, YEAST, V5, P159, DOI 10.1002/yea.320050305; POSTMA E, 1990, J BACTERIOL, V172, P2871, DOI 10.1128/jb.172.6.2871-2876.1990; POSTMA E, 1988, J GEN MICROBIOL, V134, P1109; RAMOS J, 1989, J BACTERIOL, V171, P3539, DOI 10.1128/jb.171.6.3539-3544.1989; SHINBO T, 1978, ARCH BIOCHEM BIOPHYS, V187, P414, DOI 10.1016/0003-9861(78)90052-8; UCHIDA E, 1988, METHOD ENZYMOL, V157, P544; VANDERWILDEN W, 1973, Z NATURFORSCH C, VC 28, P416; VANURK H, 1989, J GEN MICROBIOL, V135, P2399; VIITANEN P, 1986, METHOD ENZYMOL, V125, P429; YONETANI T, 1961, J BIOL CHEM, V236, P1680; YU CA, 1975, J BIOL CHEM, V250, P1383	34	29	29	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1991	266	19					12146	12151						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FV180	1648083				2022-12-25	WOS:A1991FV18000008
J	PANDOLFI, PP; GRIGNANI, F; ALCALAY, M; MENCARELLI, A; BIONDI, A; LOCOCO, F; GRIGNANI, F; PELICCI, PG				PANDOLFI, PP; GRIGNANI, F; ALCALAY, M; MENCARELLI, A; BIONDI, A; LOCOCO, F; GRIGNANI, F; PELICCI, PG			STRUCTURE AND ORIGIN OF THE ACUTE PROMYELOCYTIC LEUKEMIA MYL/RAR-ALPHA CDNA AND CHARACTERIZATION OF ITS RETINOID-BINDING AND TRANSACTIVATION PROPERTIES	ONCOGENE			English	Article							HUMAN ESTROGEN-RECEPTOR; THYROID-HORMONE; ACID RECEPTOR; TRANSCRIPTIONAL ACTIVATION; FUNCTIONAL DOMAINS; RESPONSIVE ELEMENT; NUCLEAR RECEPTORS; GENE; DIFFERENTIATION; CELLS	Acute promyelocytic leukemia (APL) is characterized by the 15;17 chromosomal translocation. Cloning experiments have established that the chromosome 17 breakpoint maps to the RAR-alpha and the 15 to the myl locus. The resulting chimeric gene is transcribed as a myl/RAR-alpha fusion mRNA. By isolating both normal myl and APL myl/RAR-alpha cDNAs, we showed that the myl/RAR-alpha mRNA encodes for a putative fusion protein with a molecular weight of about 103 kDa, which is made up of 530 amino acids derived from the myl N-terminus and 402 amino acids originating from the RAR-alpha C-terminus. The protein includes the RAR-alpha DNA and retinoid-binding regions but lacks the A portion of the N-terminal region (A/B region) which is thought to contain one of the RAR-alpha transactivation domains. The myl/RAR-alpha protein acted as a retinoid-inducible transcription factor with both ligand-independent repressor and ligand-dependent activator functions in transactivation experiments of a retinoic acid-responsive gene. Myl/RAR-alpha exerted this dual function three times more effectively than RAR-alpha exerted this dual function three times more effectively than RAR-alpha and had about 10-fold greater affinity for RA than RAR-alpha. Comparison of myl/RAR-alpha genomic and cDNA sequences from the same case demonstrated that both chromosome 15 and 17 breakpoints occurred within introns and the myl and RAR-alpha sequences are spliced in the same polyadenylated RNA.	UNIV PERUGIA,MONTELUCE POLICLIN,IST CLIN MED 1,I-06100 PERUGIA,ITALY; UNIV MILAN,OSPED S GERARDO,PEDIATR CLIN,I-20052 MONZA,ITALY; UNIV ROME,DEPT BIOPATOL,DIV EMATOL,I-00161 ROME,ITALY	University of Perugia; San Gerardo Hospital; University of Milan; Sapienza University Rome	PELICCI, PG (corresponding author), UNIV PERUGIA,MONTELUCE POLICLIN,IST CLIN MED 1,I-06100 PERUGIA,ITALY.		Grignani, Francesco/AAC-2565-2022; Biondi, Andrea/K-9997-2016; Pelicci, Pier Giuseppe/AAL-6572-2020; Biondi, Andrea/AAX-1865-2020; Alcalay, Myriam/B-3182-2016	Biondi, Andrea/0000-0002-6757-6173; Alcalay, Myriam/0000-0002-5558-4272				ALCALAY M, 1991, P NATL ACAD SCI USA, V88, P1977, DOI 10.1073/pnas.88.5.1977; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BRAND NJ, 1990, NUCLEIC ACIDS RES, V18, P6799, DOI 10.1093/nar/18.23.6799; BREITMAN TR, 1981, BLOOD, V57, P1000; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; CASTAIGNE S, 1990, BLOOD, V76, P1704; CHOMIENNE C, 1990, BLOOD, V76, P1710; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DEVERNEUIL H, 1990, NUCLEIC ACIDS RES, V18, P4489; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; LOCOCO F, 1991, BLOOD, V77, P1657; LONGO L, 1990, ONCOGENE, V5, P1557; LONGO L, 1990, J EXP MED, V172, P1571, DOI 10.1084/jem.172.6.1571; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; MENGER H, 1988, BLOOD, V72, P567; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MITELMAN F, 1988, CATALOG CHROMOSOME A; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; ROWLEY JD, 1977, LANCET, V1, P549; Sambrook J, 1989, MOL CLONING LABORATO; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; SULTAN C, 1973, BRIT J HAEMATOL, V24, P255, DOI 10.1111/j.1365-2141.1973.tb05746.x; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; TICKLE C, 1982, NATURE, V296, P564, DOI 10.1038/296564a0; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TORA L, 1988, NATURE, V333, P185, DOI 10.1038/333185a0; TORA L, 1988, EMBO J, V7, P3771, DOI 10.1002/j.1460-2075.1988.tb03261.x; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0	43	340	344	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1991	6	7					1285	1292						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1650447				2022-12-25	WOS:A1991GV26000027
J	GEIGER, M; PRIGLINGER, U; GRIFFIN, JH; BINDER, BR				GEIGER, M; PRIGLINGER, U; GRIFFIN, JH; BINDER, BR			URINARY PROTEIN-C INHIBITOR - GLYCOSAMINOGLYCANS SYNTHESIZED BY THE EPITHELIAL KIDNEY-CELL LINE TCL-598 ENHANCE ITS INTERACTION WITH UROKINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-3; HUMAN-PLASMA; MONOCLONAL-ANTIBODIES; ANTITHROMBIN-III; PURIFICATION; HEPARIN; BINDING; FIBRINOLYSIS; KALLIKREIN; IDENTITY	Protein C inhibitor (PCI), also known as plasminogen activator inhibitor 3, inhibits a variety of serine proteases by forming sodium dodecyl sulfate-stable 1:1 complexes. In purified systems PCI is only a weak inhibitor of urokinase. Nevertheless, complexes between PCI and urokinase are found in appreciable amounts in native human urine. Since PCI activity is stimulated by heparin and other glycosaminoglycans, we investigated the presence of stimulating glycosaminoglycans on cells lining the urinary tract. We chose the epithelial kidney tumor cell line TCL-598 as a model and isolated metabolically labeled glycosaminoglycans. TCL-598 incorporated [S-35]sulfate into high M(r) components (M(r) > 200,000 and almost-equal-to 75,000) as judged from sodium dodecyl sulfate-polyacrylamide gel electrophoresis and autoradiography of cell extracts; the M(r) > 200,000 component bound specifically to PCI-Sepharose 4B and was eluted either with heparin (5 mg/ml) or with NaCl (2.0 M). Treatment of this PCI-binding material with chondroitinase ABC, but not with chondroitinase AC or heparitinase, abolished binding to PCI-Sepharose, confirming the glycosaminoglycan nature of this material and suggesting the involvement of dermatan sulfate in binding. These glycosaminoglycans eluted from PCI-Sepharose stimulated urokinase inhibition by PCI in a dose-dependent way and enhanced complex formation of I-125-urokinase and PCI as did in control experiments dermatan sulfate from porcine skin and from bovine mucosa. Our results suggest that PCI activity might be regulated also in vivo by the presence or absence of stimulating glycosaminoglycans; dermatan sulfate-containing glycosaminoglycans associated with kidney cells might be responsible for stimulation of the urokinase inhibitory activity of PCI in the urinary tract; the type of glucosaminoglycans might furthermore regulate enzyme specificity of PCI.	Scripps Res Inst, RES INST, LA JOLLA, CA 92037 USA	Scripps Research Institute	GEIGER, M (corresponding author), UNIV VIENNA, CLIN EXPTL PHYSIOL LAB, SCHWARZSPANIERSTR 17, A-1090 VIENNA, AUSTRIA.			Geiger, Margarethe/0000-0003-2021-5319	NHLBI NIH HHS [HL-31950] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031950] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		COLLEN D, 1986, THROMB HAEMOSTASIS, V56, P415; ESPANA F, 1989, THROMB RES, V55, P369, DOI 10.1016/0049-3848(89)90069-8; GARDINER JE, 1984, THROMB RES, V36, P197, DOI 10.1016/0049-3848(84)90219-6; GEIGER M, 1988, Fibrinolysis, V2, P183, DOI 10.1016/0268-9499(88)90011-2; GEIGER M, 1988, FASEB J, V2, P2263, DOI 10.1096/fasebj.2.7.3350241; GEIGER M, 1989, THROMB HAEMOSTASIS, V61, P86; GEIGER M, 1989, BLOOD, V74, P722; GEIGER M, 1990, Fibrinolysis, V4, P178; HATTEY E, 1987, THROMB RES, V45, P485, DOI 10.1016/0049-3848(87)90311-2; HEEB MJ, 1987, J BIOL CHEM, V262, P15813; HEEB MJ, 1989, BLOOD, V73, P446; HEINEGARD D, 1987, METHOD ENZYMOL, V144, P319; KAZAMA Y, 1987, THROMB RES, V48, P179, DOI 10.1016/0049-3848(87)90414-2; KOHNO T, 1984, BIO-TECHNOL, V2, P628, DOI 10.1038/nbt0784-628; KRUITHOF EKO, 1987, BLOOD, V69, P460; LAEMMLE B, 1986, THROMB RES, V41, P747; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURELL M, 1989, THROMB HAEMOSTASIS, V62, P885; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARCUM JA, 1986, J BIOL CHEM, V261, P7507; MARLAR RA, 1980, J CLIN INVEST, V66, P1186, DOI 10.1172/JCI109952; MCGUIRE EA, 1987, J BIOL CHEM, V262, P169; MEIJERS JCM, 1988, BIOCHEMISTRY-US, V27, P4231, DOI 10.1021/bi00412a005; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; SHIMADA K, 1987, ARTERIOSCLEROSIS, V7, P627, DOI 10.1161/01.ATV.7.6.627; STERN D, 1985, J CLIN INVEST, V75, P272, DOI 10.1172/JCI111685; STIEF TW, 1987, BIOL CHEM H-S, V368, P1427, DOI 10.1515/bchm3.1987.368.2.1427; STUMP DC, 1986, J BIOL CHEM, V261, P2759; STUMP DC, 1986, J BIOL CHEM, V261, P1267; SUZUKI K, 1987, J BIOL CHEM, V262, P611; SUZUKI K, 1983, J BIOL CHEM, V258, P163; SUZUKI K, 1985, PROTEIN C BIOCH MED, P43; SUZUKI K, 1984, J BIOCHEM-TOKYO, V95, P184; WOJTA J, 1986, THROMB HAEMOSTASIS, V55, P347	34	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1991	266	18					11851	11857						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FT762	1646816				2022-12-25	WOS:A1991FT76200067
J	MAEHAMA, T; TAKAHASHI, K; OHOKA, Y; OHTSUKA, T; UI, M; KATADA, T				MAEHAMA, T; TAKAHASHI, K; OHOKA, Y; OHTSUKA, T; UI, M; KATADA, T			IDENTIFICATION OF A BOTULINUM C3-LIKE ENZYME IN BOVINE BRAIN THAT CATALYZES ADP-RIBOSYLATION OF GTP-BINDING PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ISLET-ACTIVATING PROTEIN; RHO-GENE-PRODUCT; PERTUSSIS TOXIN; CLOSTRIDIUM-BOTULINUM; GUANINE-NUCLEOTIDE; TURKEY ERYTHROCYTES; ADENYLATE-CYCLASE; RIBOSYLTRANSFERASE; SUBSTRATE; PURIFICATION	A novel enzyme activity was found in bovine brain cytosol that transfers the ADP-ribosyl moiety of NAD to proteins with M(r) values of 22,000 and 25,000. The substrates were the same GTP-binding proteins serving as the substrate of an ADP-ribosyltransferase C3 which was produced by a type C strain of Clostridium botulinum. The brain enzyme was partially purified from the cytosol and had a molecular mass of approximately 20,000 on a gel filtration column. The brain endogenous enzyme displayed unique properties similar to those observed with botulinum C3 enzyme. The enzyme activity was markedly stimulated by a protein factor that had been initially found in the cytosol as an activator for botulinum C3-catalyzed ADP-ribosylation (Ohtsuka, T., Nagata, K., Iiri, T., Nozawa, Y., Ueno, K., Ui, M., and Katada, T. (1989) J. Biol. Chem. 264, 15000-15005). The activity of the brain enzyme was also affected by certain types of detergents or phospholipids. The substrate of the brain enzyme was specific for GTP-binding proteins serving as the substrate of botulinum C3 enzyme; the alpha-subunits of trimeric GTP-binding proteins which served as the substrate of cholera or pertussis toxin were not ADP-ribosylated by the endogenous enzyme. Thus, this is the first report showing an endogenous enzyme in mammalian cells that catalyzes ADP-ribosylation of small molecular weight GTP-binding proteins.	TOKYO INST TECHNOL,DEPT LIFE SCI,YOKOHAMA,KANAGAWA 227,JAPAN; UNIV TOKYO,FAC PHARMACEUT SCI,DEPT PHYSIOL CHEM,TOKYO 113,JAPAN	Tokyo Institute of Technology; University of Tokyo			Maehama, Tomohiko/AAX-8926-2020; Maehama, Tomohiko/HGB-4896-2022	Maehama, Tomohiko/0000-0002-9685-2317				AKTORIES K, 1987, FEBS LETT, V212, P109, DOI 10.1016/0014-5793(87)81566-1; AKTORIES K, 1987, BIOCHEM J, V247, P363, DOI 10.1042/bj2470363; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRAUN U, 1989, FEBS LETT, V243, P70, DOI 10.1016/0014-5793(89)81220-7; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; IIRI T, 1989, J BIOL CHEM, V264, P21394; KATADA T, 1986, J BIOL CHEM, V261, P8182; KATADA T, 1987, FEBS LETT, V213, P353, DOI 10.1016/0014-5793(87)81521-1; KIKUCHI A, 1988, J BIOL CHEM, V263, P16303; KOBAYASHI I, 1989, FEBS LETT, V257, P177, DOI 10.1016/0014-5793(89)81815-0; MAEHAMA T, 1990, FEBS LETT, V263, P376, DOI 10.1016/0014-5793(90)81418-N; MOSS J, 1980, J BIOL CHEM, V255, P5838; NARUMIYA S, 1988, J BIOL CHEM, V263, P17255; NISHIKI T, 1990, BIOCHEM BIOPH RES CO, V167, P265, DOI 10.1016/0006-291X(90)91760-P; OHTSUKA T, 1989, J BIOL CHEM, V264, P15000; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PETERSON JE, 1990, J BIOL CHEM, V265, P17062; ROOF DJ, 1985, J BIOL CHEM, V260, P6242; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; SAYHAN O, 1986, BIOCHEM BIOPH RES CO, V139, P1210, DOI 10.1016/S0006-291X(86)80306-0; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SEKINE A, 1989, J BIOL CHEM, V264, P8602; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; TANIGAWA Y, 1984, J BIOL CHEM, V259, P2022; TANUMA S, 1989, BIOCHIM BIOPHYS ACTA, V1010, P246, DOI 10.1016/0167-4889(89)90168-7; TANUMA S, 1988, J BIOL CHEM, V263, P5458; TSAI SC, 1988, J BIOL CHEM, V263, P1768; UI M, 1984, TRENDS PHARMACOL SCI, V5, P277, DOI 10.1016/0165-6147(84)90444-9; YOST DA, 1983, J BIOL CHEM, V258, P4926	31	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10062	10065						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	1645335				2022-12-25	WOS:A1991FP08600012
J	WEISEL, JW; NAGASWAMI, C; VILAIRE, G; BENNETT, JS				WEISEL, JW; NAGASWAMI, C; VILAIRE, G; BENNETT, JS			EXAMINATION OF THE PLATELET MEMBRANE GLYCOPROTEIN-IIB-IIIA COMPLEX AND ITS INTERACTION WITH FIBRINOGEN AND OTHER LIGANDS BY ELECTRON-MICROSCOPY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VONWILLEBRAND-FACTOR; ALPHA-CHAIN; FIBRONECTIN RECEPTOR; RECOGNITION SITE; DISULFIDE BONDS; GAMMA-CHAIN; GPIIB-IIIA; BINDING; INTEGRIN; ADHESION	The platelet integrin, glycoprotein IIb-IIIa (GPIIb-IIIa), is a calcium-dependent heterodimer that binds fibrinogen, von Willebrand factor, and fibronectin after platelet activation. We examined GPIIb-IIIa alone and bound to these ligands by electron microscopy after rotary shadowing with platinum/tungsten. We found, as observed previously, that in the presence of detergent and 2 mM Ca2+, GPIIb-IIIa consists of an 8 x 12-nm globular head with two 18-nm flexible tails extending from one side. We also found that in the presence of EDTA, GPIIb-IIIa dissociates into two similar comma-shaped subunits, each containing a portion of the globular head and a single tail. Using monoclonal antibodies to GPIIb, GPIIIa, and the GPIIb-IIIa heterodimer, we found that the tails contained the carboxyl termini of each subunit, while the nodular head was composed of amino-terminal segments of both subunits. Electron microscopy of GPIIb-IIIa bound to fibrinogen revealed a highly specific interaction of the nodular head of GPIIb-IIIa with the distal end of the trinodular fibrinogen molecule and with the tails of GPIIb-IIIa extended laterally at an angle of almost-equal-to 98-degrees with respect to the long axis of fibrinogen. When a GPIIb-IIIa was bound to each end of a single fibrinogen, the tails were oriented to opposite sides of fibrinogen, enabling fibrinogen to bridge two adjacent platelets. Electron microscopy of GPIIb-IIIa bound to fibronectin revealed GPIIb/IIIa-binding sites approximately two-thirds of the distance from the amino terminus of each end of the fibronectin molecule, while GPIIb-IIIa was found to bind to von Willebrand factor protomers along a rod-like region near the central nodule of the molecule.	UNIV PENN, SCH MED, HEMATOL ONCOL SECT, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT MED, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	WEISEL, JW (corresponding author), UNIV PENN, SCH MED, DEPT ANAT, PHILADELPHIA, PA 19104 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL040387, R01HL030954] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL40387, HL30954] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENNETT JS, 1983, P NATL ACAD SCI-BIOL, V80, P2417, DOI 10.1073/pnas.80.9.2417; BENNETT JS, 1988, J BIOL CHEM, V263, P12948; CALVETE JJ, 1991, BIOCHEM J, V274, P63, DOI 10.1042/bj2740063; CALVETE JJ, 1989, BIOCHEM J, V261, P551, DOI 10.1042/bj2610551; CARRELL NA, 1985, J BIOL CHEM, V260, P1743; DOOLITTLE RF, 1979, NATURE, V280, P464, DOI 10.1038/280464a0; DSOUZA SE, 1991, NATURE, V350, P66, DOI 10.1038/350066a0; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; ERICKSON HP, 1983, ANN NY ACAD SCI, V408, P146, DOI 10.1111/j.1749-6632.1983.tb23242.x; FOWLER WE, 1985, J CLIN INVEST, V76, P1491, DOI 10.1172/JCI112129; FOWLER WE, 1979, J MOL BIOL, V134, P241, DOI 10.1016/0022-2836(79)90034-2; GAILIT J, 1988, J BIOL CHEM, V263, P12927; GARTNER TK, 1985, J BIOL CHEM, V260, P1891; KELLY T, 1987, J BIOL CHEM, V262, P17189; KLOCZEWIAK M, 1984, BIOCHEMISTRY-US, V23, P1767, DOI 10.1021/bi00303a028; MOON DG, 1990, AM J PHYSIOL, V259, pC611, DOI 10.1152/ajpcell.1990.259.4.C611; NACHMAN RL, 1982, J CLIN INVEST, V69, P263, DOI 10.1172/JCI110448; NERMUT MV, 1988, EMBO J, V7, P4093, DOI 10.1002/j.1460-2075.1988.tb03303.x; NIEWIAROWSKI S, 1989, BIOCHIM BIOPHYS ACTA, V983, P91, DOI 10.1016/0005-2736(89)90384-2; PARISE LV, 1985, J BIOL CHEM, V260, P1750; PARISE LV, 1985, J BIOL CHEM, V260, P698; PEERSCHKE EIB, 1987, BLOOD, V69, P950; PHILLIPS DR, 1988, BLOOD, V71, P831; PLOW EF, 1987, BLOOD, V70, P110; PONCZ M, 1987, J BIOL CHEM, V262, P8476; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; RAO SPS, 1991, J MOL BIOL, V222, P89, DOI 10.1016/0022-2836(91)90739-S; RUDEE ML, 1981, ULTRAMICROSCOPY, V17, P193; RUGGERI ZM, 1987, BLOOD, V70, P895; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; SANTORO SA, 1987, CELL, V48, P867, DOI 10.1016/0092-8674(87)90083-3; SCHULLEK J, 1984, J CLIN INVEST, V73, P421, DOI 10.1172/JCI111228; SILVER SM, 1987, BLOOD, V69, P1031; SKAER RJ, 1979, J ULTRA MOL STRUCT R, V69, P28, DOI 10.1016/S0022-5320(79)80040-4; SLAYTER H, 1985, J BIOL CHEM, V260, P8559; STEINER B, 1989, J BIOL CHEM, V264, P13102; WALL J, 1983, ANN NY ACAD SCI, V408, P164, DOI 10.1111/j.1749-6632.1983.tb23243.x; WEISEL JW, 1985, SCIENCE, V230, P1388, DOI 10.1126/science.4071058; WEISS HJ, 1986, BLOOD, V67, P322; WILLIAMS RC, 1983, ANN NY ACAD SCI, V408, P180, DOI 10.1111/j.1749-6632.1983.tb23244.x; ZIMRIN AB, 1988, J CLIN INVEST, V81, P1470, DOI 10.1172/JCI113478	44	265	276	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16637	16643						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1644841				2022-12-25	WOS:A1992JJ45800099
J	BABU, A; SU, H; RYU, YJ; GULATI, J				BABU, A; SU, H; RYU, YJ; GULATI, J			DETERMINATION OF RESIDUE SPECIFICITY IN THE EF-HAND OF TROPONIN-C FOR CA2+ COORDINATION, BY GENETIC-ENGINEERING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEINS; SKELETAL-MUSCLE; REFINED STRUCTURE; SITE-III; CALMODULIN; CONTRACTION; AFFINITY; CRYSTAL; RESOLUTION; MUTANTS	Utilizing protein engineering of troponin C (TnC), combined with the physiology of skinned fibers, the present study sought to delineate the mechanisms for metal ion coordination and sensitivity in the sites (EF-hands) that execute the Ca2+ switch for contraction. A total TnC-encoding gene comprising multiple target sequences for restriction enzymes was synthesized, furnishing a pliant molecular handle to manipulate sites I and II in the NH2 terminus of the protein. Of the six positions (X, Y, Z, -Y, -X, and -Z) essential for metal ion chelation in a typical EF-hand, invariably the X position has aspartate, and -Z position has glutamate. In the X position of site II, mutation of aspartate for either glutamate (gamma-carboxylate) or asparagine (same side chain length as aspartate) yielded functionally inactive proteins with concomitantly diminished Ca2+ binding capacity. Similarly, in -Z position (site I), neither aspartate nor glutamine were compatible in exchange for the conserved glutamate. In contrast, for the Y coordinate of site II, a preference for asparagine comparable to that for wild-type aspartate was detected, but glutamate was impermissible. Evidently, physicochemical and steric factors both are critical in governing the mechanism for metal ion chelation in TnC in a physiological milieu. Furthermore, the findings manifest that the quaternary structure of hydrated TnC restrains the EF-hands during on-off operation of the Ca2+ switch.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT PHYSIOL & BIOPHYS,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine	BABU, A (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MED,DIV CARDIOL,MOLEC PHYSIOL LAB,BRONX,NY 10461, USA.			Akella, Aravind/0000-0002-3396-7598	NHLBI NIH HHS [HL37412] Funding Source: Medline; NIAMS NIH HHS [AR33736] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL037412] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR033736] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BABU A, 1988, J BIOL CHEM, V263, P15485; BABU A, 1987, J BIOL CHEM, V262, P5815; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; CASPAR DLD, 1963, ADV PROTEIN CHEM, V18, P37; CHEN Q, 1988, FEBS LETT, V228, P22, DOI 10.1016/0014-5793(88)80576-3; COLLINS JH, 1991, J MUSCLE RES CELL M, V12, P3, DOI 10.1007/BF01781170; FERRETTI L, 1986, P NATL ACAD SCI USA, V83, P599, DOI 10.1073/pnas.83.3.599; FUJIMORI K, 1990, NATURE, V345, P182, DOI 10.1038/345182a0; FUJISAWA T, 1989, J BIOCHEM-TOKYO, V105, P377, DOI 10.1093/oxfordjournals.jbchem.a122672; GARIEPY J, 1983, FEBS LETT, V160, P1, DOI 10.1016/0014-5793(83)80924-7; GRABAREK Z, 1986, J BIOL CHEM, V261, P608; GULATI J, 1989, FEBS LETT, V248, P5, DOI 10.1016/0014-5793(89)80420-X; GULATI J, 1991, J PHYSIOL-LONDON, V441, P305, DOI 10.1113/jphysiol.1991.sp018753; GULATI J, 1992, MODULATION CARDIAC C; HEIDORN DB, 1988, BIOCHEMISTRY-US, V27, P909, DOI 10.1021/bi00403a011; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; HUBBARD SR, 1988, J BIOL CHEM, V263, P4151; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; MARSDEN BJ, 1988, BIOCHEMISTRY-US, V27, P4198, DOI 10.1021/bi00411a043; MOSS RL, 1992, CIRC RES, V70, P865, DOI 10.1161/01.RES.70.5.865; OGAWA Y, 1985, J BIOCHEM-TOKYO, V97, P1011, DOI 10.1093/oxfordjournals.jbchem.a135143; POTTER JD, 1982, CALCIUM CELL FUNCTIO, V2, P145; PUTKEY JA, 1989, J BIOL CHEM, V264, P12370; SATYSHUR KA, 1988, J BIOL CHEM, V263, P1628; SHAW GS, 1991, BIOCHEMISTRY-US, V30, P8339, DOI 10.1021/bi00098a009; SHENG ZL, 1990, J BIOL CHEM, V265, P21554; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; SZEBENYI DME, 1986, J BIOL CHEM, V261, P8761; XU GQ, 1988, J BIOL CHEM, V263, P13962; ZOT A, 1986, ANNU REV BIOPHYS BIO, V16, P535; [No title captured]	32	85	86	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15469	15474						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1639788				2022-12-25	WOS:A1992JG11300035
J	BRUGGEMAN, LA; BURBELO, PD; YAMADA, Y; KLOTMAN, PE				BRUGGEMAN, LA; BURBELO, PD; YAMADA, Y; KLOTMAN, PE			A NOVEL SEQUENCE IN THE TYPE-IV COLLAGEN PROMOTER BINDS NUCLEAR PROTEINS FROM ENGELBRETH-HOLM-SWARM TUMOR	ONCOGENE			English	Article							HEAD-TO-HEAD; BASEMENT-MEMBRANE; EXTRACELLULAR-MATRIX; TRANSCRIPTIONAL REGULATION; BIDIRECTIONAL PROMOTER; GENE-REGULATION; CHAIN; CELLS; IDENTIFICATION; ALPHA-1(IV)	The production of extracellular matrix proteins is an important element of tumor formation, and alterations in matrix protein metabolism may be critical to the process of tumor metastasis. Abundant expression of type IV collagen, the major structural protein of the basement membrane, is characteristic of the Engelbreth-Holm-Swarm (EHS) mouse sarcoma. In the present study, we evaluated mechanisms of transcriptional regulation of type IV collagen genes by analysing nuclear factors that bind to the promoter region. Gel mobility-shift assays indicated that specific proteins from EHS tumor bound the promoter and generated several unique shift patterns. The specific sequences to which these proteins bound were determined using DNAase I protection assays. DNA-binding proteins protected two regions from DNAase I digestion. The first region was similar to a GC box, the binding site for the transcription factor Spl. The other footprint was a 30-bp region that contained the novel sequence motif, `CCCTCCC' present in several other extracellular matrix promoters. Nuclear extracts isolated from tissues that variably express type IV collagen bound to this protected sequence with distinctly different shift patterns. Furthermore, in highly expressing tissues, unlabeled oligonucleotides containing the `CCCTCCC' motif effectively inhibited nuclear protein binding with the entire promoter. Thus, it is likely that a novel protein or protein complex binds to these sequences. Furthermore, these sequences appear to be unique to the genes that encode basement membrane proteins, suggesting a specific role in their regulation.	NIH,DEV BIOL LAB,9000 ROCKVILLE PIKE,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA			Burbelo, Peter D./B-1027-2009					ABEL T, 1989, NATURE, V341, P24, DOI 10.1038/341024a0; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BACHINGER HP, 1982, J BIOL CHEM, V257, P9796; BRUGGEMAN LA, 1991, AM J KIDNEY DIS, V18, P134, DOI 10.1016/S0272-6386(12)80305-2; BURBELO PD, 1990, J BIOL CHEM, V265, P4839; BURBELO PD, 1988, P NATL ACAD SCI USA, V85, P9679, DOI 10.1073/pnas.85.24.9679; DEAN DC, 1989, MOL CELL BIOL, V9, P1498, DOI 10.1128/MCB.9.4.1498; DYAN WS, 1985, NATURE, V316, P774; DYNAN WS, 1989, CELL, V58, P1, DOI 10.1016/0092-8674(89)90393-0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GUNWAR S, 1990, J BIOL CHEM, V265, P5466; HOSTIKKA SL, 1990, P NATL ACAD SCI USA, V87, P1606, DOI 10.1073/pnas.87.4.1606; INGBER DE, 1989, CELL, V58, P803, DOI 10.1016/0092-8674(89)90928-8; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KALLUNKI T, 1991, J BIOL CHEM, V266, P221; KAYTES P, 1988, J BIOL CHEM, V263, P19274; KILLEN PD, 1988, J BIOL CHEM, V263, P12310; KLEINMAN HK, 1987, DEV BIOL, V122, P373, DOI 10.1016/0012-1606(87)90302-2; LIOTTA LA, 1983, LAB INVEST, V49, P636; MARTIN GR, 1987, ANNU REV CELL BIOL, V3, P57, DOI 10.1146/annurev.cellbio.3.1.57; MEYERS JC, 1987, COLLAGEN REL RES, V7, P149; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORRISON KE, 1991, J BIOL CHEM, V266, P34; OGAWA K, 1988, J BIOL CHEM, V263, P8384; OGAWA K, 1986, CANCER, V58, P269, DOI 10.1002/1097-0142(19860715)58:2<269::AID-CNCR2820580212>3.0.CO;2-7; ORKIN RW, 1977, J EXP MED, V145, P204, DOI 10.1084/jem.145.1.204; OSBORNE TF, 1987, P NATL ACAD SCI USA, V84, P3614, DOI 10.1073/pnas.84.11.3614; PATEL RS, 1987, EMBO J, V6, P2565, DOI 10.1002/j.1460-2075.1987.tb02545.x; POSCHL E, 1988, EMBO J, V7, P2687, DOI 10.1002/j.1460-2075.1988.tb03122.x; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RUTKA JT, 1987, CAN J NEUROL SCI, V14, P25; SAKR WA, 1987, HUM PATHOL, V18, P1043, DOI 10.1016/S0046-8177(87)80221-6; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SOININEN R, 1988, J BIOL CHEM, V263, P17217; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; TIMPL R, 1986, INT REV EXP PATHOL, V29, P1	36	24	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1992	7	8					1497	1502						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1630813				2022-12-25	WOS:A1992JE81300005
J	ESTES, PA; COOKE, NE; LIEBHABER, SA				ESTES, PA; COOKE, NE; LIEBHABER, SA			A NATIVE RNA SECONDARY STRUCTURE CONTROLS ALTERNATIVE SPLICE-SITE SELECTION AND GENERATES 2 HUMAN GROWTH-HORMONE ISOFORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; EXON SEQUENCES; U2 SNRNP; GENE; DNA; INVITRO; INTRON; TRANSCRIPTS; EXPRESSION; PRECURSORS	Consensus sequences at the splice donor, splice acceptor, and lariat branch point regions are necessary but insufficient determinants of splice-site selection in nuclear precursor mRNAs. Sequences outside of these regions can have a significant effect on the utilization of splice sites. Although the mode of action of such sequences is undefined in most cases, higher order RNA structures have been suggested as a potential contributor to splice-site selection. During a detailed analysis of the splicing patterns of the human growth hormone transcript, we located 2 bases in the vicinity of the exon 3 major splice-acceptor site (B) which facilitate the utilization of a competing downstream acceptor (B'). The effects of a series of site-specific mutations on the splicing pattern demonstrate that these 2 bases function by stabilizing a specific stem-loop structure in the native transcript. This defined secondary structure selectively encompasses the upstream B splice-acceptor site together with its lariat branch point region. Increasing the predicted stability of this stem by point mutations results in a corresponding shift in splicing towards the alternative B' splice-acceptor site. These results indicate that a specific secondary structure within the native human growth hormone transcript controls the relative utilization of two competing splice-acceptor sites with the consequent generation of two functionally distinct hormone isoforms.	UNIV PENN,SCH MED,DEPT GENET,ROOM 437A CURIE BLVD,PHILADELPHIA,PA 19104; UNIV PENN,HOWARD HUGHES MED INST,PHILADELPHIA,PA 19104; UNIV PENN,DEPT BIOL,PHILADELPHIA,PA 19104; UNIV PENN,DEPT MED,PHILADELPHIA,PA 19104	University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania					NICHD NIH HHS [HD 25147] Funding Source: Medline; NIH HHS [MOD 1-1015] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD025147] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		CHEBLI K, 1989, MOL CELL BIOL, V9, P4852, DOI 10.1128/MCB.9.11.4852; COOKE NE, 1988, J BIOL CHEM, V263, P9001; COOKE NE, 1988, J CLIN INVEST, V82, P270, DOI 10.1172/JCI113582; DENOTO FM, 1981, NUCLEIC ACIDS RES, V9, P3719, DOI 10.1093/nar/9.15.3719; DOMENJOUD L, 1991, MOL CELL BIOL, V11, P4581, DOI 10.1128/MCB.11.9.4581; DORVAL BC, 1991, SCIENCE, V252, P1823, DOI 10.1126/science.2063195; EPERON LP, 1988, CELL, V54, P393, DOI 10.1016/0092-8674(88)90202-4; EPERON LP, 1986, NATURE, V324, P280, DOI 10.1038/324280a0; ESTES PA, 1990, J BIOL CHEM, V265, P19863; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREEN MR, 1986, ANNU REV GENET, V20, P671, DOI 10.1146/annurev.ge.20.120186.003323; HWANG LHS, 1984, MOL CELL BIOL, V4, P2289, DOI 10.1128/MCB.4.11.2289; Lewis U J, 1980, Recent Prog Horm Res, V36, P477; LIBRI D, 1991, SCIENCE, V252, P1842, DOI 10.1126/science.2063196; LIU CP, 1979, P NATL ACAD SCI USA, V76, P4503, DOI 10.1073/pnas.76.9.4503; MANIATIS T, 1987, NATURE, V325, P673, DOI 10.1038/325673a0; MARDON HJ, 1987, NUCLEIC ACIDS RES, V15, P7725, DOI 10.1093/nar/15.19.7725; MUNROE SH, 1988, EMBO J, V7, P2523, DOI 10.1002/j.1460-2075.1988.tb03100.x; NELSON KK, 1988, GENE DEV, V2, P319, DOI 10.1101/gad.2.3.319; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PARKER R, 1987, CELL, V49, P229, DOI 10.1016/0092-8674(87)90564-2; PERUCHO M, 1980, CELL, V22, P309, DOI 10.1016/0092-8674(80)90178-6; REED R, 1986, CELL, V46, P681, DOI 10.1016/0092-8674(86)90343-0; REED R, 1988, GENE DEV, V2, P1268, DOI 10.1101/gad.2.10.1268; RUSKIN B, 1988, CELL, V52, P207, DOI 10.1016/0092-8674(88)90509-0; Sambrook J., 1982, MOL CLONING LAB MANU, V1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEIF I, 1979, NUCLEIC ACIDS RES, V6, P3387, DOI 10.1093/nar/6.10.3387; SHARP PA, 1987, SCIENCE, V235, P766, DOI 10.1126/science.3544217; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SOLNICK D, 1985, CELL, V43, P667, DOI 10.1016/0092-8674(85)90239-9; SOLNICK D, 1987, MOL CELL BIOL, V7, P3194, DOI 10.1128/MCB.7.9.3194; SOMASEKHAR MB, 1985, NUCLEIC ACIDS RES, V13, P5591, DOI 10.1093/nar/13.15.5591; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TINOCO I, 1973, NATURE-NEW BIOL, V246, P40, DOI 10.1038/newbio246040a0; TURNER DH, 1988, ANNU REV BIOPHYS BIO, V17, P167; WATAKABE A, 1989, NUCLEIC ACIDS RES, V17, P8159, DOI 10.1093/nar/17.20.8159; WIERINGA B, 1984, CELL, V37, P915, DOI 10.1016/0092-8674(84)90426-4; WU J, 1989, GENE DEV, V3, P1553, DOI 10.1101/gad.3.10.1553; ZHUANG Y, 1989, Proceedings of the National Academy of Sciences of the United States of America, V86, P2752, DOI 10.1073/pnas.86.8.2752; ZHUANG Y, 1989, GENE DEV, V3, P1545, DOI 10.1101/gad.3.10.1545; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	43	68	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14902	14908						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634529				2022-12-25	WOS:A1992JF08800061
J	HERTZBERG, MS; BENTAL, O; FURIE, B; FURIE, BC				HERTZBERG, MS; BENTAL, O; FURIE, B; FURIE, BC			CONSTRUCTION, EXPRESSION, AND CHARACTERIZATION OF A CHIMERA OF FACTOR-IX AND FACTOR-X - THE ROLE OF THE 2ND EPIDERMAL GROWTH-FACTOR DOMAIN AND SERINE PROTEASE DOMAIN IN FACTOR-VA BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; COAGULATION FACTOR-XA; VITAMIN-K; PROTHROMBINASE COMPLEX; BLOOD-COAGULATION; ENZYME COMPLEXES; GLUTAMIC-ACID; EGF DOMAIN; ACTIVATION; PROTEINS	The prothrombinase complex, which catalyzes the conversion of prothrombin to thrombin, consists of activated Factor X, Factor Va, a membrane surface and Ca2+. To examine the structures that support Factor Va binding to Factor X, we used in vitro mutagenesis to construct a chimeric molecule that includes regions of Factor IX and Factor X. This chimera (IX(Gla,E1)X(E2,SP)) was prepared from cDNA encoding the second epidermal growth factor (EGF) and serine protease domains of Factor X linked downstream from the cDNA encoding the signal peptide, propeptide, Gla domain, and first EGF domain of Factor IX. The cDNAs encoding the Factor IX/X chimera and wild-type Factor X were each expressed in Chinese hamster ovary cells and the secreted proteins purified by affinity chromatography using polyclonal anti-Factor X antibodies. The chimera migrated as a single major band corresponding to a molecular weight of 68,000. By Western blotting, the chimeric protein stained with both polyclonal anti-Factor X and anti-Factor IX antibodies. Gamma-carboxyglutamic acid analysis demonstrated near complete carboxylation of both the wild-type Factor X and the Factor IX/X chimera. Compared with Factor X, the rate of zymogen activation of the Factor IX/X chimera was about 50% that of Factor X when activated by Factor IXa, Factor VIIIa, phospholipid, and Ca2+. The enzyme form of the Factor IX/X chimera, activated Factor IX/X, generated using the coagulant protein of Russell's viper venom, expressed full amidolytic activity compared with Factor Xa. The activated Factor IX/X chimera had about 14% of the activity of Factor Xa when employed in a prothrombinase assay; this activity reached 100% with increasing concentrations of Factor Va. A binding assay was employed to test the ability of the active site-inactivated Factor IX/Xa chimera to inhibit the binding of Factor Xa to the Factor Va-phospholipid complex, thus inhibiting the activation of prothrombin to thrombin. In this assay the active site-inactivated form of the chimera competed with Factor Xa completely but with decreased affinity for the Factor Va-phospholipid complex. These data indicate that the second EGF domain and the serine protease domain of Factor Xa are sufficient to interact with Factor Va. The Factor IX/X chimera is a good substrate for the tenase complex; the defective enzymatic activity of the activated Factor IX/X chimera can be accounted for by its decreased affinity for Factor Va relative to Factor Xa.	NEW ENGLAND MED CTR,DIV HEMATOL ONCOL,CTR HEMOSTASIS & THROMBOSIS RES,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT MED,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02111	Tufts Medical Center; Tufts University; Tufts University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL018834, R37HL018834] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42433, HL18834] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENTAL O, 1991, BLOOD S, V78, pA180; BLOOM JW, 1989, THROMB RES, V54, P261, DOI 10.1016/0049-3848(89)90084-4; CHEN PS, 1956, J BIOL CHEM, V252, P1756; CHOO KH, 1982, NATURE, V299, P178, DOI 10.1038/299178a0; Dacie J., 1984, PRACTICAL HAEMATOLOG, V6th; FUJIKAWA K, 1972, BIOCHEMISTRY-US, V11, P4892, DOI 10.1021/bi00776a003; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; FURIE B, 1982, J BIOL CHEM, V257, P3875; GREEN PM, 1989, EMBO J, V8, P1067, DOI 10.1002/j.1460-2075.1989.tb03474.x; HUBER P, 1990, CIRCULATION, V82, P365; Innis MA, 1990, PCR PROTOCOLS GUIDE; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KAUFMAN RJ, 1986, J BIOL CHEM, V261, P9622; KOTKOW KJ, 1992, IN PRESS METHODS ENZ; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P8977; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P3823; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; KURACHI K, 1982, P NATL ACAD SCI-BIOL, V79, P6461, DOI 10.1073/pnas.79.21.6461; KUWADA M, 1981, ANAL BIOCHEM, V117, P259, DOI 10.1016/0003-2697(81)90720-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEYTUS SP, 1984, P NATL ACAD SCI-BIOL, V81, P3699, DOI 10.1073/pnas.81.12.3699; LIN SW, 1990, J BIOL CHEM, V265, P144; LOLLAR P, 1984, ARCH BIOCHEM BIOPHYS, V233, P438, DOI 10.1016/0003-9861(84)90465-X; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MANN KG, 1990, BLOOD, V76, P1; MCCRACKEN AA, 1984, BIOTECHNIQUES    MAR, P82; NELSESTUEN GL, 1974, J BIOL CHEM, V249, P6347; NELSESTUEN GL, 1978, BIOCHEMISTRY-US, V17, P2134, DOI 10.1021/bi00604a017; NESHEIM ME, 1981, J BIOL CHEM, V256, P9874; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; NEUENSCHWANDER P, 1988, BLOOD, V72, P1761; PERSSON E, 1991, J BIOL CHEM, V266, P2453; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; ROSING J, 1980, J BIOL CHEM, V255, P274; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SKOGEN WF, 1984, J BIOL CHEM, V259, P2306; STENFLO J, 1974, P NATL ACAD SCI USA, V71, P2730, DOI 10.1073/pnas.71.7.2730; SZOKA F, 1980, BIOCHIM BIOPHYS ACTA, V601, P559, DOI 10.1016/0005-2736(80)90558-1; SZOKA F, 1978, P NATL ACAD SCI USA, V75, P4194, DOI 10.1073/pnas.75.9.4194; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; VANRIJN JLML, 1984, BIOCHEMISTRY-US, V23, P4557, DOI 10.1021/bi00315a008; WILDGOOSE P, 1988, BIOCHEM BIOPH RES CO, V152, P1207, DOI 10.1016/S0006-291X(88)80413-3	42	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14759	14766						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634519				2022-12-25	WOS:A1992JF08800041
J	TAKEUCHI, Y; YANAGISHITA, M; HASCALL, VC				TAKEUCHI, Y; YANAGISHITA, M; HASCALL, VC			METABOLIC PATHWAYS OF HEPARAN-SULFATE PROTEOGLYCANS IN A RAT PARATHYROID CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; CULTURE; TRANSPORT; CALCIUM	The distribution of heparan sulfate (HS) proteoglycans in clonal rat parathyroid cells is regulated by the extracellular Ca2+ concentration, which is a principal factor for parathyroid cell function (Takeuchi, Y., Sakaguchi, K., Yanagishita, M., Aurbach, G. D., and Hascall, V. C. (1990) J. Biol. Chem. 265, 13661-13668). Increasing the concentration of extracellular Ca2+ in the physiological range redistributes HS proteoglycans from the cell surface to an intracellular compartment. We have now examined effects of the extracellular Ca2+ concentration on the metabolism of the HS proteoglycans in detail using [S-35]sulfate metabolic labeling-chase experiments. Two distinct metabolic pathways were demonstrated: (i) the intracellular generation of HS chains from HS proteoglycans in prelysosomal compartments followed by their release into the medium (pathway 1), and (ii) intracellular generation of HS oligosaccharides from HS chains in prelysosomal compartments, which are eventually degraded into free sulfate in lysosomes (pathway 2). The HS oligosaccharides were exclusively present within the cells, whereas HS chains were found primarily in the medium. The cells do not internalize either HS proteoglycans or HS chains from the medium. These observations indicate that these two degradation pathways are independent. In addition to these pathways, approximately 15% of the HS proteoglycans were released into the medium as a proteoglycan form. Treatment of cells with chloroquine, a lysosomotropic agent, did not affect generation of HS chains but inhibited conversion of HS chains to HS oligosaccharides or to free sulfate and resulted in the release of HS chains from the cells. The drug did not affect metabolic pathway 1. The extracellular Ca2+ concentration did not alter these intracellular degradation pathways for HS proteoglycans in the parathyroid cells. Thus, extracellular Ca2+ appears to regulate only the distribution of HS proteoglycans between the cell surface and intracellular compartments, and the process of cycling between these compartments when extracellular Ca2+ is low.	NIDR,BONE RES BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)								BROWN EM, 1982, MINER ELECTROL METAB, V8, P130; CUSHMAN SW, 1985, FED PROC, V43, P2251; FRANSSON LA, 1989, HEPARIN, P115; GALLAGHER JT, 1986, BIOCHEM J, V236, P313, DOI 10.1042/bj2360313; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PIEPKORN M, 1989, J BIOL CHEM, V264, P8662; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SAKAGUCHI K, 1991, J BIOL CHEM, V266, P7270; SAKAGUCHI K, 1987, P NATL ACAD SCI USA, V84, P3269, DOI 10.1073/pnas.84.10.3269; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; TAKEUCHI Y, 1990, BIOCHEM J, V266, P15, DOI 10.1042/bj2660015; TAKEUCHI Y, 1990, J BIOL CHEM, V265, P13661; WILEMAN T, 1985, BIOCHEM J, V232, P1; YANAGISHITA M, 1985, J BIOL CHEM, V260, P5445; YANAGISHITA M, 1984, J BIOL CHEM, V259, P270; YANAGISHITA M, 1989, J BIOL CHEM, V264, P15714; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	22	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14677	14684						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634513				2022-12-25	WOS:A1992JF08800030
J	PYERITZ, RE				PYERITZ, RE			A REVOLUTION IN MEDICINE LIKE NO OTHER	FASEB JOURNAL			English	Review							CLINICAL GENETICS; MUTATIONS; DISEASE		JOHNS HOPKINS UNIV, SCH MED, CTR MED GENET, BALTIMORE, MD 21287 USA	Johns Hopkins University			Pyeritz, Reed/A-1364-2010					ANDERSON WF, 1992, SCIENCE, V256, P808, DOI 10.1126/science.1589762; [Anonymous], 1989, METABOLIC BASIS INHE, V34, P253; ASLANIDIS C, 1992, NATURE, V355, P548, DOI 10.1038/355548a0; BAGASRA O, 1992, NEW ENGL J MED, V326, P1385, DOI 10.1056/NEJM199205213262103; BALL DM, 1992, FASEB J, V6, P2818, DOI 10.1096/fasebj.6.10.1386046; BERNHARDT BA, 1987, AM J HUM GENET, V41, P559; BERNHARDT BA, 1992, AM J HUM GENET, V50, P84; BILLINGS PR, 1992, AM J HUM GENET, V50, P476; BROWN MD, 1992, FASEB J, V6, P2791, DOI 10.1096/fasebj.6.10.1634041; BRUENING W, 1992, NAT GENET, V1, P144, DOI 10.1038/ng0592-144; BUXTON J, 1992, NATURE, V355, P547, DOI 10.1038/355547a0; CARSON DA, 1992, FASEB J, V6, P2800, DOI 10.1096/fasebj.6.10.1634042; CASKEY CT, 1992, SCIENCE, V256, P784, DOI 10.1126/science.1589758; CHILDS B, 1992, MEDICINE, V71, P102, DOI 10.1097/00005792-199203000-00005; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; COOPER DN, 1990, HUM GENET, V85, P55; Courteau J, 1991, Science, V254, P201, DOI 10.1126/science.1925577; CROW J, 1992, FASEB J, V6; DALTON TA, 1992, AM J MED, V92, P183, DOI 10.1016/0002-9343(92)90110-W; DIETZ HC, 1991, NATURE, V352, P337, DOI 10.1038/352337a0; DIETZ HC, 1992, IN PRESS P NATL ACAD; EISENSTEIN BI, 1990, NEW ENGL J MED, V322, P178; ENGEL E, 1991, AM J MED GENET, V40, P432, DOI 10.1002/ajmg.1320400411; FEARON ER, 1992, FASEB J, V6, P2783, DOI 10.1096/fasebj.6.10.1321771; FLUGELMAN MY, 1992, CIRCULATION, V85, P1110, DOI 10.1161/01.CIR.85.3.1110; FOST N, 1992, FASEB J, V6, P2813, DOI 10.1096/fasebj.6.10.1634044; FRIEDMANN T, 1989, SCIENCE, V244, P1275, DOI 10.1126/science.2660259; GERSHON ES, 1990, TRENDS GENET, V6, P282, DOI 10.1016/0168-9525(90)90233-V; GIBBS RA, 1989, P NATL ACAD SCI USA, V86, P1919, DOI 10.1073/pnas.86.6.1919; GREEN JBA, 1991, TRENDS GENET, V7, P245, DOI 10.1016/0168-9525(91)90323-I; GROOT PC, 1992, FASEB J, V6, P2826, DOI 10.1096/fasebj.6.10.1634045; GUTIERREZ AA, 1992, LANCET, V339, P715, DOI 10.1016/0140-6736(92)90606-4; HALL JG, 1988, AM J HUM GENET, V43, P355; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Hall JG, 1991, CURR OPIN GENET DEV, V1, P34, DOI 10.1016/0959-437X(91)80038-N; HANDYSIDE AH, 1989, LANCET, V1, P347; HARLEY HG, 1992, NATURE, V355, P545, DOI 10.1038/355545a0; HAYDEN MR, 1991, AM J MED GENET, V40, P515, DOI 10.1002/ajmg.1320400430; HEALY B, 1991, HUM GENE THER, V3, P51; HIGUCHI M, 1991, P NATL ACAD SCI USA, V88, P7405, DOI 10.1073/pnas.88.16.7405; HOLTZMAN NA, 1992, FASEB J, V6, P2806, DOI 10.1096/fasebj.6.10.1634043; HUMPHRIES P, 1992, SCIENCE, V256, P804, DOI 10.1126/science.1589761; KAN YW, 1992, JAMA-J AM MED ASSOC, V267, P1532, DOI 10.1001/jama.267.11.1532; KNIGHT SJL, 1992, AM J MED GENET, V43, P217, DOI 10.1002/ajmg.1320430135; KOSIK KS, 1992, SCIENCE, V256, P780, DOI 10.1126/science.1589757; KUO WL, 1991, AM J HUM GENET, V49, P112; LEE B, 1991, NATURE, V352, P330, DOI 10.1038/352330a0; LUNGU O, 1992, JAMA-J AM MED ASSOC, V267, P2493, DOI 10.1001/jama.267.18.2493; MAGENIS RE, 1990, AM J MED GENET, V35, P333, DOI 10.1002/ajmg.1320350307; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MASLEN CL, 1991, NATURE, V352, P334, DOI 10.1038/352334a0; MATHIAS SL, 1991, SCIENCE, V254, P1808, DOI 10.1126/science.1722352; MCINTOSH I, 1992, FASEB J, V6, P2775, DOI 10.1096/fasebj.6.10.1378801; MCKUSICK VA, 1992, AM J HUM GENET, V50, P663; MCKUSICK VA, 1992, ON LINE MENDELIAN IN; MERLINO GT, 1991, FASEB J, V5, P2996, DOI 10.1096/fasebj.5.14.1752364; MILUNSKY A, 1992, AM J HUM GENET, V50, P643; NATOWICZ MR, 1992, AM J HUM GENET, V50, P465; NEEL JV, 1947, MEDICINE, V26, P115, DOI 10.1097/00005792-194705000-00001; OBERLE I, 1992, AM J MED GENET, V43, P224, DOI 10.1002/ajmg.1320430136; OLEE T, 1991, J CLIN INVEST, V88, P193, DOI 10.1172/JCI115277; PEARSON PL, 1991, SCIENCE, V254, P214, DOI 10.1126/science.1925578; PLAUTZ G, 1991, CIRCULATION, V83, P578, DOI 10.1161/01.CIR.83.2.578; PYERITZ RE, 1989, J AM COLL CARDIOL, V13, P1458, DOI 10.1016/0735-1097(89)90333-1; PYERITZ RE, 1989, AM J MED GENET, V34, P124, DOI 10.1002/ajmg.1320340120; ROSSITER BJF, 1991, FASEB J, V5, P21, DOI 10.1096/fasebj.5.1.1846832; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; SHOFFNER JM, 1991, ANN NEUROL, V30, P332, DOI 10.1002/ana.410300304; SIDRANSKY D, 1992, SCIENCE, V256, P102, DOI 10.1126/science.1566048; SMEETS DFCM, 1992, NEW ENGL J MED, V326, P807, DOI 10.1056/NEJM199203193261206; SOBELL JL, 1992, GENOMICS, V12, P1, DOI 10.1016/0888-7543(92)90398-C; SOMMER SS, 1992, FASEB J, V6, P2767, DOI 10.1096/fasebj.6.10.1634040; TAYLOR CR, 1992, NEW ENGL J MED, V326, P1436, DOI 10.1056/NEJM199205213262118; VIRCHOW R, 1877, GENERAL PATHOLOGY BA, P69; WALLACE MR, 1991, NATURE, V353, P864, DOI 10.1038/353864a0; WEXLER NS, 1992, FASEB J, V6, P2820, DOI 10.1096/fasebj.6.10.1386047; WILSON GN, 1992, AM J MED GENET, V42, P187, DOI 10.1002/ajmg.1320420211; WRIGHT AF, 1992, TRENDS GENET, V8, P85, DOI 10.1016/0168-9525(92)90195-A; 1992, JAMA-J AM MED ASSOC, V267, P2609	79	5	5	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1992	6	10					2761	2766		10.1096/fasebj.6.10.1634038	http://dx.doi.org/10.1096/fasebj.6.10.1634038			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JD954	1634038				2022-12-25	WOS:A1992JD95400001
J	GROVE, RI; MAZZUCCO, CE; RADKA, SF; SHOYAB, M; KIENER, PA				GROVE, RI; MAZZUCCO, CE; RADKA, SF; SHOYAB, M; KIENER, PA			ONCOSTATIN-M UP-REGULATES LOW-DENSITY-LIPOPROTEIN RECEPTORS IN HEPG2 CELLS BY A NOVEL MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-HYDROXY-3-METHYLGLUTARYL COENZYME; FAMILIAL HYPERCHOLESTEROLEMIA; MEDIATED ENDOCYTOSIS; GROWTH-REGULATOR; LDL RECEPTORS; CHOLESTEROL; MACROPHAGES; REDUCTASE; PHOSPHORYLATION; IDENTIFICATION	Oncostatin M is a growth regulatory protein secreted by macrophages and activated T lymphocytes. In a hepatoma cell line (HepG2) the polypeptide very potently increased low density lipoprotein (LDL) uptake with an EC50 of 0.1-0.2 nM. The stimulation of LDL uptake was detectable by 2 h, was maximal by 8 h, and remained elevated through 20 h of oncostatin M incubation. In a similar fashion, oncostatin M also increased the number of cell surface LDL receptors by a mechanism that was inhibited by cycloheximide or the protein kinase C inhibitor H-7. Oncostatin M stimulation of LDL uptake and receptor protein occurred regardless of the state of cholesterol-dependent regulation of HepG2 LDL receptor (i.e. cells incubated in medium containing lipoproteins responded to the same extent as did cells incubated in the absence of lipoproteins). No significant effects were observed on sterol synthesis over 8 h or on DNA synthesis over 24 h. Oncostatin M induced rapid alterations in HepG2 phospholipid metabolism. Within 5-15 min there was a 20-50% increase in incorporation of P-32 into several classes of phospholipids, including the phosphoinositides. Radiolabeled diacylglycerol levels were elevated 20% by 2 min and nearly 50% by 15 min. In addition, the polypeptide induced rapid increases (within 1 min) in phosphorylation of HepG proteins on tyrosine residues. Stimulation of both phosphotyrosine and LDL receptor up-regulation by oncostatin M was decreased by the tyrosine kinase inhibitor genistein. We propose that oncostatin M up-regulates HepG2 LDL receptor expression by a mechanism that includes stimulation of a tyrosine kinase followed by generation of phospholipid-related second messengers.			GROVE, RI (corresponding author), BRISTOL MYERS SQUIBB PRI,ONCOGEN DIV,3005 1ST AVE,SEATTLE,WA 98121, USA.							AUWERX JH, 1989, MOL CELL BIOL, V9, P2298, DOI 10.1128/MCB.9.6.2298; BEG ZH, 1986, ARCH BIOCHEM BIOPHYS, V244, P310, DOI 10.1016/0003-9861(86)90120-7; BEISIEGEL U, 1981, J BIOL CHEM, V256, P1923; BILHEIMER DW, 1983, P NATL ACAD SCI-BIOL, V80, P4124, DOI 10.1073/pnas.80.13.4124; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CAI HJ, 1988, BIOCHIM BIOPHYS ACTA, V959, P334; CHAIT A, 1980, P NATL ACAD SCI-BIOL, V77, P4084, DOI 10.1073/pnas.77.7.4084; GARNICK MB, 1989, CLIN RES, V37, P260; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; GROVE RI, 1990, CIRCULATION, V82, P326; GROVE RI, 1990, J LEUKOCYTE BIOL, V48, P38, DOI 10.1002/jlb.48.1.38; HUI DY, 1981, J BIOL CHEM, V256, P5646; KAMPS MP, 1988, ONCOGENE, V2, P305; KINGSLEY DM, 1984, P NATL ACAD SCI-BIOL, V81, P5454, DOI 10.1073/pnas.81.17.5454; KOVANEN PT, 1987, AM HEART J, V113, P464, DOI 10.1016/0002-8703(87)90615-6; LINSLEY PS, 1989, J BIOL CHEM, V264, P4282; MOLOWA DT, 1989, BIOCHEM J, V260, P731, DOI 10.1042/bj2600731; MOSLEY ST, 1989, J LIPID RES, V30, P1411; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; NATHAN CF, 1987, J CLIN INVEST, V79, P319, DOI 10.1172/JCI112815; NIMER SD, 1988, JAMA-J AM MED ASSOC, V260, P3297, DOI 10.1001/jama.260.22.3297; PITAS RE, 1981, ARTERIOSCLEROSIS, V1, P177, DOI 10.1161/01.ATV.1.3.177; REYNOLDS GD, 1985, SURV SYN PATHOL RES, V4, P389; RUSSELL DW, 1983, P NATL ACAD SCI-BIOL, V80, P7501, DOI 10.1073/pnas.80.24.7501; SPADY DK, 1985, P NATL ACAD SCI USA, V82, P4526, DOI 10.1073/pnas.82.13.4526; TODDERUD G, 1990, SCIENCE, V249, P296, DOI 10.1126/science.2374928; YOKODE M, 1990, SCIENCE, V250, P1273, DOI 10.1126/science.2244210; ZARLING JM, 1986, P NATL ACAD SCI USA, V83, P9739, DOI 10.1073/pnas.83.24.9739	29	94	97	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					18194	18199						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1655740				2022-12-25	WOS:A1991GG55300073
J	THOMPSON, WJ; TAN, BH; STRADA, SJ				THOMPSON, WJ; TAN, BH; STRADA, SJ			ACTIVATION OF RABBIT LIVER HIGH-AFFINITY CAMP (TYPE-IV) PHOSPHODIESTERASE BY A VANADYL-GLUTATHIONE COMPLEX - CHARACTERIZATION OF THE ROLE OF THE SULFHYDRYL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-AMP PHOSPHODIESTERASE; DEPENDENT PROTEIN-KINASE; NUCLEOTIDE PHOSPHODIESTERASE; RAT ADIPOCYTES; PLASMA-MEMBRANE; INSULIN CONTROL; PURIFICATION; PHOSPHORYLATION; STIMULATION; HORMONE	Activation of rabbit liver microsomal high affinity cAMP phosphodiesterase (Type IV PDE) by vanadylglutathione complexes was studied as a possible model of insulin stimulation of the enzyme in a cell-free system. The effect of VO.2GSH activation of PDE was a 21-fold decrease in the IC50 value for cGMP inhibition and a 2.6-fold increase in the V(max) of the higher affinity cAMP catalytic site. Cyclic AMP and cGMP substrate affinities and cGMP hydrolysis were unaffected by VO.2GSH activation. Selective Type IV PDE inhibitors and cGMP analogs indicated that VO.2GSH complexes activated the cGMP-inhibitable form of the Type IV PDE activities which co-localized in hepatic microsomes. The Type IV PDE activating complex appears to consist minimally of vanadyl ion and 2 oxidized electron donor compounds. The components of the electron donor required to achieve an enzyme activation complex are: 1) a free-SH group as the electron donor for vanadate reduction and 2) a minimum structure of cysteamine (NH2-CH2-CH2-SH). Maximal activation of the enzyme required near 2:1 molar ratios of either glutathione or cysteamine mixed with sodium orthovanadate. Active vanadyl-cysteamine complexes were isolated by reverse- phase high performance liquid chromatography. Tungsten, niobium, and tantalum, but not manganese, chromium, or molybdenum, substituted for vanadium to form enzyme-activating complexes with glutathione. VO.RSH complex activation occured rapidly upon addition to microsomes and was reversible. We conclude from these studies that VO.RSH complexes and insulin activate the same form of Type IV PDE in rabbit liver microsomes; our findings are discussed with respect to the involvement of a possible electron transfer enzyme oxidation in the activation mechanism.			THOMPSON, WJ (corresponding author), UNIV SO ALABAMA,COLL MED,DEPT PHARMACOL,MOBILE,AL 36688, USA.				NIGMS NIH HHS [GM 33538] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033538] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APPLEMAN MM, 1984, ADV CYCLIC NUCL PROT, V16, P149; BEAVO JA, 1990, TRENDS PHARMACOL SCI, V11, P150, DOI 10.1016/0165-6147(90)90066-H; BEEBE SJ, 1985, J BIOL CHEM, V260, P5781; BOYLES S, 1988, EUR J BIOCHEM, V174, P303; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUECH M, 1984, TOXICOLOGY, V31, P283, DOI 10.1016/0300-483X(84)90109-4; CHALLISS RAJ, 1987, BIOCHEM PHARMACOL, V36, P357, DOI 10.1016/0006-2952(87)90294-2; CHENG K, 1985, ANNU REV PHYSIOL, V47, P405; CLELAND WW, 1967, ADV ENZYMOL RAMB, V29, P1; CORBIN JD, 1986, J BIOL CHEM, V261, P1208; CORNISHBOWDEN A, 1979, FUNDAMENTALS ENZYME, P76; DEGANI H, 1981, BIOCHEMISTRY-US, V20, P5795, DOI 10.1021/bi00523a023; DEGERMAN E, 1987, J BIOL CHEM, V262, P5797; DELFERT DM, 1985, ARCH BIOCHEM BIOPHYS, V241, P665, DOI 10.1016/0003-9861(85)90593-4; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; DUBYAK GR, 1980, J BIOL CHEM, V255, P5306; EPSTEIN PM, 1982, ARCH BIOCHEM BIOPHYS, V218, P119, DOI 10.1016/0003-9861(82)90327-7; ERDMANN E, 1984, BIOCHEM PHARMACOL, V33, P945, DOI 10.1016/0006-2952(84)90498-2; ERNEUX C, 1981, EUR J BIOCHEM, V115, P503; ERNEUX C, 1985, J CYCLIC NUCL PROT, V10, P463; Fleischer S, 1974, Methods Enzymol, V31, P6; GETTYS TW, 1988, J BIOL CHEM, V263, P10359; GRANT PG, 1988, P NATL ACAD SCI USA, V85, P9071, DOI 10.1073/pnas.85.23.9071; GREEN A, 1986, BIOCHEM J, V238, P663, DOI 10.1042/bj2380663; HEYLIGER CE, 1985, SCIENCE, V227, P1474, DOI 10.1126/science.3156405; HOUSLAY MD, 1984, ADV CYCLIC NUCL PROT, V16, P159; KIECHLE FL, 1981, FEBS LETT, V133, P279, DOI 10.1016/0014-5793(81)80524-8; KONO T, 1975, J BIOL CHEM, V250, P7826; LAVIS VR, 1970, J BIOL CHEM, V245, P23; LOTEN EG, 1978, J BIOL CHEM, V253, P746; LOTEN EG, 1986, INT J BIOCHEM, V18, P847, DOI 10.1016/0020-711X(86)90063-7; MACARA IG, 1980, TRENDS BIOCHEM SCI, V5, P92, DOI 10.1016/0968-0004(80)90256-X; MACAULAY SL, 1983, ARCH BIOCHEM BIOPHYS, V225, P130, DOI 10.1016/0003-9861(83)90015-2; MACPHEE CH, 1988, J BIOL CHEM, V263, P10353; MAJOR GN, 1983, INT J BIOCHEM, V15, P217, DOI 10.1016/0020-711X(83)90068-X; NECHAY BR, 1986, FASEB J, V45, P123; PYNE NJ, 1987, BIOCHEM J, V242, P33, DOI 10.1042/bj2420033; SALTIEL AR, 1986, SCIENCE, V233, P967, DOI 10.1126/science.3016898; Senft G, 1968, Diabetologia, V4, P322, DOI 10.1007/BF01211766; SHECHTER Y, 1990, DIABETES, V39, P1, DOI 10.2337/diabetes.39.1.1; SMITH CJ, 1989, MOL PHARMACOL, V35, P381; SMOAKE JA, 1989, LIFE SCI, V45, P2255, DOI 10.1016/0024-3205(89)90067-2; SOUNESS JE, 1985, J CYCLIC NUCL PROT, V10, P383; STRADA SJ, 1984, ADV CYCLIC NUCLEOTID, V16, pR6; TAMURA S, 1984, J BIOL CHEM, V259, P6650; Thompson W J, 1979, Adv Cyclic Nucleotide Res, V10, P69; THOMPSON WJ, 1973, BIOCHEMISTRY-US, V12, P1889, DOI 10.1021/bi00734a008; THOMPSON WJ, 1988, FASEB J, V2, pA1041; WEBER HW, 1982, J BIOL CHEM, V257, P5339; WHITSON RH, 1982, BIOCHIM BIOPHYS ACTA, V714, P279, DOI 10.1016/0304-4165(82)90335-X; YAMAMOTO T, 1984, BIOCHEMISTRY-US, V23, P670, DOI 10.1021/bi00299a013	51	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17011	17019						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1654320				2022-12-25	WOS:A1991GF44500011
J	HAGIWARA, T; OHSAKO, S; YAMAUCHI, T				HAGIWARA, T; OHSAKO, S; YAMAUCHI, T			STUDIES ON THE REGULATORY DOMAIN OF CA-2+ CALMODULIN-DEPENDENT PROTEIN KINASE-II BY EXPRESSION OF MUTATED CDNAS IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTSYNAPTIC DENSITY PROTEIN; FUNCTIONAL-ANALYSIS; SYNAPTIC JUNCTIONS; MOLECULAR-CLONING; RNA-POLYMERASE; ALPHA-SUBUNIT; AUTOPHOSPHORYLATION; BRAIN; BINDING; IDENTIFICATION	The cDNAs encoding the alpha and beta-subunits of Ca2+/calmodulin-dependent protein kinase II (CaM kinase II) were ligated into the bacterial expression vector pET and expressed in Escherichia coli. The bacterially expressed-alpha and beta-subunits exhibited Ca2+/calmodulin-dependent activity and were easily purified to apparent homogeneity from cell extracts. To determine the minimum size required for catalytic activity and the properties of the calmodulin-binding domain, mutated CaM kinase II cDNAs were expressed in E. coli and the enzymatic property of expressed proteins was examined. The replacement of Thr-286 of the alpha-subunit with the negatively charged amino acid Asp or that of Arg-283 with the neutral amino acid Gly induced the partially Ca2+ independent activity. The mutant enzymes alpha-I(DELTA-283-478) and alpha-II(DELTA-359-478), which truncated the C-terminal region of the alpha-subunit, exhibited CaM kinase II activity and the activities of alpha-I(DELTA-283-478) and alpha-II(DELTA-359-478) were completely independent of and partially dependent on Ca2+ and calmodulin, respectively. However, the truncated protein alpha(DELTA-250-478), which was only 33 amino acids shorter than the alpha-I(DELTA-283-478) protein had no enzymatic activity, indicating that alpha-I(DELTA-283-478) was close to the minimum size of the active form. The mutant enzyme alpha(DELTA-291-315), which lacked the calmodulin-binding domain exhibited Ca2+ independent activity. The molecular mass was, however, smaller than that expected from the amino acid sequence. The mutant enzyme alpha(DELTA-304-315), which lacked the C-terminal half of the calmodulin-binding domain of the alpha-subunit, however, exhibited Ca2+-independent activity without a reduction in molecular size, indicating that residues 304-315 of the a subunit constituted the core calmodulin-binding domain.	TOKYO METROPOLITAN INST NEUROSCI,DEPT CELL BIOL,FUCHU,TOKYO 183,JAPAN	Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science								BENNETT MK, 1983, J BIOL CHEM, V258, P2735; BENNETT MK, 1987, P NATL ACAD SCI USA, V84, P1794, DOI 10.1073/pnas.84.7.1794; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BLUMENTHAL DK, 1985, P NATL ACAD SCI USA, V82, P3187, DOI 10.1073/pnas.82.10.3187; COLBRAN RJ, 1989, BIOCHEM J, V258, P313, DOI 10.1042/bj2580313; COLBRAN RJ, 1988, J BIOL CHEM, V263, P18145; COLBRAN RJ, 1989, J BIOL CHEM, V264, P4800; DEDMAN JR, 1977, J BIOL CHEM, V252, P8415; FONG YL, 1989, J BIOL CHEM, V264, P16759; GOLDENRING JR, 1983, J BIOL CHEM, V258, P2632; GOLDENRING JR, 1984, J NEUROCHEM, V42, P1077, DOI 10.1111/j.1471-4159.1984.tb12713.x; HANLEY RM, 1987, SCIENCE, V237, P293, DOI 10.1126/science.3037704; HASHIMOTO Y, 1987, ARCH BIOCHEM BIOPHYS, V252, P418, DOI 10.1016/0003-9861(87)90048-8; HASHIMOTO Y, 1987, J BIOL CHEM, V262, P8051; KELLY PT, 1987, J NEUROCHEM, V49, P1927, DOI 10.1111/j.1471-4159.1987.tb02456.x; KELLY PT, 1984, P NATL ACAD SCI-BIOL, V81, P945, DOI 10.1073/pnas.81.3.945; KELLY PT, 1988, P NATL ACAD SCI USA, V85, P4991, DOI 10.1073/pnas.85.14.4991; KENNEDY MB, 1983, P NATL ACAD SCI-BIOL, V80, P7357, DOI 10.1073/pnas.80.23.7357; KRAMER W, 1984, NUCLEIC ACIDS RES, V12, P9441, DOI 10.1093/nar/12.24.9441; KWIATKOWSKI AP, 1989, BIOCHEMISTRY-US, V28, P5380, DOI 10.1021/bi00439a010; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI Y, 1986, P NATL ACAD SCI USA, V83, P4253, DOI 10.1073/pnas.83.12.4253; LEVINE H, 1987, EUR J BIOCHEM, V168, P481, DOI 10.1111/j.1432-1033.1987.tb13442.x; LIN CR, 1987, P NATL ACAD SCI USA, V84, P5962, DOI 10.1073/pnas.84.16.5962; MCGUINNESS TL, 1985, J BIOL CHEM, V260, P1696; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; MILLER SG, 1985, J BIOL CHEM, V260, P9039; NAIRN AC, 1985, ANNU REV BIOCHEM, V54, P931, DOI 10.1146/annurev.bi.54.070185.004435; OHSAKO S, 1991, J BIOCHEM-TOKYO, V109, P137, DOI 10.1093/oxfordjournals.jbchem.a123334; OHSAKO S, 1990, BIOCHEM BIOPH RES CO, V170, P705, DOI 10.1016/0006-291X(90)92148-S; PAYNE ME, 1988, J BIOL CHEM, V263, P7190; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SAITOH T, 1985, J CELL BIOL, V100, P835, DOI 10.1083/jcb.100.3.835; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWORER CM, 1988, J BIOL CHEM, V263, P13486; SCHWORER CM, 1986, J BIOL CHEM, V261, P8581; SHIELDS SM, 1984, J NEUROCHEM, V43, P1599, DOI 10.1111/j.1471-4159.1984.tb06084.x; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; THIEL G, 1988, P NATL ACAD SCI USA, V85, P6337, DOI 10.1073/pnas.85.17.6337; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALMANN R, 1990, BIOCHEMISTRY-US, V29, P1679; WAXHAM MN, 1989, J BIOL CHEM, V264, P7477; WAXHAM MN, 1990, P NATL ACAD SCI USA, V87, P1273, DOI 10.1073/pnas.87.4.1273; YAMAUCHI T, 1983, EUR J BIOCHEM, V132, P15, DOI 10.1111/j.1432-1033.1983.tb07319.x; YAMAUCHI T, 1989, J BIOL CHEM, V264, P19108	45	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16401	16408						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1653235				2022-12-25	WOS:A1991GD63500028
J	CHIN, JE; TAVARE, JM; ELLIS, L; ROTH, RA				CHIN, JE; TAVARE, JM; ELLIS, L; ROTH, RA			EVIDENCE FOR HYBRID RODENT AND HUMAN INSULIN-RECEPTORS IN TRANSFECTED CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GROWTH FACTOR-I; TYROSINE KINASE; SUBSTRATE PHOSPHORYLATION; BETA-SUBUNIT; 2-DEOXYGLUCOSE; HETEROGENEITY; REPLACEMENT; MECHANISMS; MUTATIONS; ANTIBODY	Chinese hamster ovary cells and NIH 3T3 cells overexpressing mutant human insulin receptors were examined for the presence of hybrid receptors composed of human and rodent insulin receptors. In the present studies, most of the endogenous rodent receptors were found to be immunoprecipitated from the transfected cells but not the parental cells with a monoclonal antibody specific for human receptor. These data indicate that in these transfected cells, most of the endogenous rodent receptors are in a hybrid complex with the overexpressed human receptor. These results together with the in vitro studies of Treadway et al. (Treadway, J. L., Morrison, B. D., Soos, M. A., Siddle, K., Olefsky, J., Ullrich, A., McClain, D. A., and Pessin, J. E. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 214-218) showing that hybrid receptors exhibit transdominant inhibition explain the prior finding indicating that overexpression of defective insulin receptors interferes with the normal signaling of endogenous receptors.	STANFORD UNIV,MED CTR,SCH MED,DEPT PHARMACOL,STANFORD,CA 94305; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235	Stanford University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIDDK NIH HHS [DK41765, DK34926, DK40511] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034926, R37DK034926, R01DK040511, R01DK041765] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHOU CK, 1987, J BIOL CHEM, V262, P1842; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; EBINA Y, 1985, P NATL ACAD SCI USA, V82, P8014, DOI 10.1073/pnas.82.23.8014; ELLIS L, 1987, MOL ENDOCRINOL, V1, P15, DOI 10.1210/mend-1-1-15; ELLIS L, 1986, P NATL ACAD SCI USA, V83, P8137, DOI 10.1073/pnas.83.21.8137; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ELLIS L, 1986, COLD SPRING HARB SYM, V51, P773, DOI 10.1101/SQB.1986.051.01.090; FLORESRIVEROS JR, 1989, J BIOL CHEM, V264, P21557; GOLDSTEIN BJ, 1990, MOL ENDOCRINOL, V4, P235, DOI 10.1210/mend-4-2-235; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; MAEGAWA H, 1988, J BIOL CHEM, V263, P12629; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MORGAN DO, 1986, P NATL ACAD SCI USA, V83, P328, DOI 10.1073/pnas.83.2.328; MOXHAM CP, 1989, J BIOL CHEM, V264, P13238; OLSON TS, 1989, FASEB J, V3, P1618, DOI 10.1096/fasebj.3.5.2537774; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; ROTH RA, 1988, COLD SPRING HARB SYM, V53, P537, DOI 10.1101/SQB.1988.053.01.062; SHII K, 1986, P NATL ACAD SCI USA, V83, P4147, DOI 10.1073/pnas.83.12.4147; SOOS MA, 1989, BIOCHEM J, V263, P553, DOI 10.1042/bj2630553; SOOS MA, 1990, BIOCHEM J, V270, P383, DOI 10.1042/bj2700383; STUMPO DJ, 1991, J BIOL CHEM, V266, P455; TAYLOR SI, 1990, DIABETES CARE, V13, P257, DOI 10.2337/diacare.13.3.257; TREADWAY JL, 1991, P NATL ACAD SCI USA, V88, P214, DOI 10.1073/pnas.88.1.214; TREADWAY JL, 1989, J BIOL CHEM, V264, P21450; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WHITTAKER J, 1990, DIABETES CARE, V13, P576, DOI 10.2337/diacare.13.6.576; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YONEZAWA K, 1991, MOL ENDOCRINOL, V5, P194, DOI 10.1210/mend-5-2-194	32	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					15587	15590						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1651915				2022-12-25	WOS:A1991GB97700009
J	ANDRES, DA; RHODES, JD; MEISEL, RL; DIXON, JE				ANDRES, DA; RHODES, JD; MEISEL, RL; DIXON, JE			CHARACTERIZATION OF THE CARBOXYL-TERMINAL SEQUENCES RESPONSIBLE FOR PROTEIN RETENTION IN THE ENDOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUMINAL ER PROTEINS; NEUROPEPTIDE-Y; SECRETION; PITUITARY; COMPARTMENT; PATHWAY; SYSTEM; SIGNAL; CELLS; YEAST	The COOH-terminal sequence KDEL has been shown to be essential for the retention of several proteins in the lumen of the endoplasmic reticulum (Munro S., and Pelham, H. R. B. (1987) Cell 48, 899-907; Pelham, H. R. B. (1988) EMBO J. 7, 913-918; Mazzarella; R. A., Srinivasan, M., Haugejorden, S. M., and Green, M. (1990) J. Biol. Chem. 265, 1092-1101). We have previously demonstrated that variants to the KDEL retention signal, particularly at the initial two positions of the tetrapeptide, can be made without affecting its ability to direct intracellular retention when appended to the neuropeptide Y precursor (pro-NPY) (Andres, D. A., Dickerson, I. M., and Dixon, J. E. (1990) J. Biol. Chem. 265, 5952-5955). To further investigate the nature of the KDEL retention signal, oligonucleotide-directed mutagenesis and transfection was used to generate stable mouse anterior pituitary AtT-20 cell lines expressing pro-NPY mutants with variants of the KDEL sequence added to their direct carboxyl terminus. Analyses of dibasic processing and indirect immunofluorescent microscopy of AtT-20 subclones were consistent with the retention of the pro-NPY mutants bearing the COOH-terminal extensions QDEL, KEDL, or KDEI within the endoplasmic reticulum. A change in the final amino acid of the tetrapeptide from Leu to Val abolished retention completely, and the peptide hormone was processed and secreted. These results indicate that only a limited number of conservative changes can be made to the final two positions of the tetrapeptide without abolishing activity and suggest a highly specific interaction of the retention signal and the KDEL receptor.	PURDUE UNIV,DEPT PSYCHOL SCI,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus	ANDRES, DA (corresponding author), PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907, USA.				NIDDK NIH HHS [NIDDKD 18849] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018849] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDRES DA, 1990, J BIOL CHEM, V265, P5952; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; DAVIES GE, 1970, P NATL ACAD SCI USA, V66, P651, DOI 10.1073/pnas.66.3.651; DICKERSON IM, 1987, J BIOL CHEM, V262, P13646; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GRAY TS, 1986, LIFE SCI, V38, P389, DOI 10.1016/0024-3205(86)90061-5; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; LEWIS MJ, 1990, CELL, V61, P1359, DOI 10.1016/0092-8674(90)90699-F; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; MAY V, 1986, ENDOCRINOLOGY, V118, P1284, DOI 10.1210/endo-118-4-1284; MAZZARELLA RA, 1990, J BIOL CHEM, V265, P1094; MINTH CD, 1984, P NATL ACAD SCI-BIOL, V81, P4577, DOI 10.1073/pnas.81.14.4577; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; ORCI L, 1987, CELL, V51, P1039, DOI 10.1016/0092-8674(87)90590-3; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PELHAM HRB, 1988, EMBO J, V7, P1757, DOI 10.1002/j.1460-2075.1988.tb03005.x; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO SM, 1970, ENDOCRINOLOGY, V122, P68; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; SWANK RT, 1971, ANAL BIOCHEM, V39, P462, DOI 10.1016/0003-2697(71)90436-2; VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0; WAND GS, 1987, ENDOCRINOLOGY, V120, P953, DOI 10.1210/endo-120-3-953; WIGLER M, 1978, CELL, V14, P729; ZAGOURAS P, 1989, J CELL BIOL, V109, P2633, DOI 10.1083/jcb.109.6.2633	28	63	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14277	14282						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1650354				2022-12-25	WOS:A1991FZ35100027
J	TSEDINH, YC				TSEDINH, YC			ZINC(II) COORDINATION IN ESCHERICHIA-COLI DNA TOPOISOMERASE-I IS REQUIRED FOR CLEAVABLE COMPLEX-FORMATION WITH DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING DOMAIN; POLY(ADP-RIBOSE) POLYMERASE; PROTEIN; FINGERS; MUTAGENESIS; RECOGNITION; SITE; TYROSINE; BREAKS	Escherichia coli DNA topoisomerase I catalyzes relaxation of negatively supercoiled DNA. The reaction proceeds through a covalent intermediate, the cleavable complex, in which the DNA is cleaved and the enzyme is linked to the DNA via a phosphotyrosine linkage. Each molecule of E. coli DNA topoisomerase I has been shown to have three tightly bound zinc(II) ions required for relaxation activity (Tse-Dinh, Y.-C., and Beran-Steed, R. K. (1988) J. Biol. Chem. 263, 15857-15859). It is shown here that Cd(II) could replace Zn(II) in reconstitution of active enzyme from apoprotein. The role of metal was analyzed by studying the partial reactions. The apoenzyme was deficient in sodium dodecyl sulfate- induced cleavage of supercoiled PM2 phage DNA. Formation of covalent complex with linear single-stranded DNA was also reduced in the absence of metal. However, the cleavage of small oligonucleotide was not affected, and the apoenzyme could religate the covalently bound oligonucleotide to another DNA molecule. Assay of noncovalent complex formation by retention of 5'-labeled DNA on filters showed that the apoenzyme was not inhibited in noncovalent binding to DNA. It is proposed that zinc(II) coordination in E. coli DNA topoisomerase I is required for the transition of the noncovalent complex with DNA to the cleavable state.			TSEDINH, YC (corresponding author), NEW YORK MED COLL, DEPT BIOCHEM & MOLEC BIOL, VALHALLA, NY 10595 USA.				NIGMS NIH HHS [GM42774] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERG JM, 1990, J BIOL CHEM, V265, P6513; BERG JM, 1990, ANNU REV BIOPHYS BIO, V19, P405; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; DEPEW RE, 1978, J BIOL CHEM, V253, P511; DOMANICO PL, 1988, BIOCHEMISTRY-US, V27, P6365, DOI 10.1021/bi00417a026; DOOLITTLE RF, 1986, NATURE, V323, P451, DOI 10.1038/323451a0; DRLICA K, 1990, TRENDS GENET, V6, P433, DOI 10.1016/0168-9525(90)90306-Q; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FREEDMAN LP, 1988, NATURE, V334, P543, DOI 10.1038/334543a0; IKEJIMA M, 1990, J BIOL CHEM, V265, P21907; KLEVAN L, 1983, BIOCHIM BIOPHYS ACTA, V745, P175, DOI 10.1016/0167-4838(83)90046-8; KLUG A, 1987, TRENDS BIOCHEM SCI, V12, P464, DOI 10.1016/0968-0004(87)90231-3; LIU LF, 1979, J BIOL CHEM, V254, P1082; LYNN RM, 1989, PROTEINS, V6, P231, DOI 10.1002/prot.340060305; MENISSIERDEMURCIA J, 1989, J MOL BIOL, V210, P229, DOI 10.1016/0022-2836(89)90302-1; NADLER SG, 1990, J BIOL CHEM, V265, P10389; NAVARATNAM S, 1989, J BIOL CHEM, V264, P16067; PAN T, 1990, BIOCHEMISTRY-US, V29, P3023, DOI 10.1021/bi00464a019; PAN T, 1989, P NATL ACAD SCI USA, V86, P3145, DOI 10.1073/pnas.86.9.3145; STERNGLANZ R, 1981, P NATL ACAD SCI USA, V82, P4374; TAO P, 1990, P NATL ACAD SCI USA, V87, P2077, DOI 10.1073/pnas.87.6.2077; THOMAS CA, 1979, ANAL BIOCHEM, V93, P158, DOI 10.1016/S0003-2697(79)80130-X; TSE Y, 1980, CELL, V22, P269, DOI 10.1016/0092-8674(80)90174-9; TSE YC, 1980, J BIOL CHEM, V255, P5560; TSEDINH YC, 1983, NUCLEIC ACIDS RES, V11, P8691, DOI 10.1093/nar/11.24.8691; TSEDINH YC, 1988, J BIOL CHEM, V263, P15857; TSEDINH YC, 1986, J BIOL CHEM, V261, P931; UCHIDA K, 1987, BIOCHEM BIOPH RES CO, V148, P617, DOI 10.1016/0006-291X(87)90921-1; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; ZUMSTEIN L, 1986, J MOL BIOL, V191, P333, DOI 10.1016/0022-2836(86)90130-0	30	39	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14317	14320						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1650356				2022-12-25	WOS:A1991FZ35100034
J	YIU, KC; HUANG, DP; CHAN, MKM; FOO, W				YIU, KC; HUANG, DP; CHAN, MKM; FOO, W			THE PHYSICAL STATE OF HUMAN PAPILLOMAVIRUS TYPE-16 DNA IN CERVICAL CARCINOMAS OF HONG-KONG CHINESE	ONCOGENE			English	Article							GENITAL TUMORS; CELL-LINES; MOLECULAR ANALYSIS; INTEGRATION SITES; SEQUENCES; GENE; P53; TRANSFORMATION; E6; IDENTIFICATION	The presence of human papillomavirus (HPV) in 15 cervical carcinoma specimens obtained from Hong Kong Chinese patients was analyzed by Southern blot hybridization studies. In nine (60%) of them, HPV 16 genomes were detected, while two others (13.3%) were found to harbor HPV DNA of unknown type closely related to HPV 16. All of them were classified as squamous cell carcinomas according to WHO guidelines. In addition, the presence of HPV 18 was shown in another two (13.3%) squamous cell carcinoma samples. Among the nine tumors harboring HPV 16, four specimens (44.4%) have HPV in integrated forms, while four others (44.4%) have HPV in episomal forms. The simultaneous presence of both episomal and integrated forms was demonstrated in the remaining tissue sample (11.2%). The result obtained here indicates a strong association between HPV infection and cervical carcinogenesis in Hong Kong Chinese, with HPV 16 prevalent in squamous cell carcinoma. Moreover, the persistence of HPV 16 episomes in some of the tumor specimens suggests that extrachromosomal HPV DNA, possibly acting synergistically with other oncogenic factors, is also capable of inducing cervical cancer.	CHINESE UNIV HONG KONG, PRINCE WALES HOSP, DEPT ANAT & CELLULAR PATHOL, SHA TIN, HONG KONG; QUEEN ELIZABETH HOSP, INST RADIOL & ONCOL, KOWLOON, HONG KONG	Chinese University of Hong Kong; Prince of Wales Hospital								ANDERSON MC, 1987, HAINES TAYLOR OBSTET, P255; ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; BAKER CC, 1987, J VIROL, V61, P962, DOI 10.1128/JVI.61.4.962-971.1987; CANNIZZARO LA, 1988, CANCER GENET CYTOGEN, V33, P93, DOI 10.1016/0165-4608(88)90054-4; CHOO KB, 1989, J VIROL, V63, P782, DOI 10.1128/JVI.63.2.782-789.1989; CHOO KB, 1987, J MED VIROL, V21, P101, DOI 10.1002/jmv.1890210202; DANOS O, 1984, J INVEST DERMATOL, V83, pS7, DOI 10.1111/1523-1747.ep12281115; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DILUCA D, 1986, J GEN VIROL, V67, P583, DOI 10.1099/0022-1317-67-3-583; DOEBERITZ MV, 1988, CANCER RES, V48, P3780; DURST M, 1987, P NATL ACAD SCI USA, V84, P1070, DOI 10.1073/pnas.84.4.1070; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELAWADY MK, 1987, VIROLOGY, V159, P389, DOI 10.1016/0042-6822(87)90478-8; FERENCZY A, 1987, BLAUSTEINS PATHOLOGY, P177; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUKUSHIMA M, 1985, CANCER RES, V45, P3252; GISSMANN L, 1984, J INVEST DERMATOL, V83, pS26, DOI 10.1111/1523-1747.ep12281143; HAUSEN HZ, 1988, MOL CARCINOGEN, V1, P147, DOI 10.1002/mc.2940010302; HAUSEN HZ, 1989, CANCER RES, V49, P4677; HOWLEY PM, 1988, AM J MED, V85, P155; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KOSS L G, 1987, Applied Pathology, V5, P7; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MCCANCE DJ, 1983, BRIT MED J, V287, P784, DOI 10.1136/bmj.287.6395.784; POPESCU NC, 1987, CYTOGENET CELL GENET, V44, P58, DOI 10.1159/000132342; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; SCHNEIDERMAUNOURY S, 1987, J VIROL, V61, P3295, DOI 10.1128/JVI.61.10.3295-3298.1987; SMITH PP, 1989, INT J CANCER, V44, P1124, DOI 10.1002/ijc.2910440631; TANAKA A, 1989, J VIROL, V63, P1465, DOI 10.1128/JVI.63.3.1465-1469.1989; WATANABE S, 1989, J VIROL, V63, P965, DOI 10.1128/JVI.63.2.965-969.1989; WATTS SL, 1984, SCIENCE, V225, P634, DOI 10.1126/science.6330900; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YIU KC, 1990, ANTICANCER RES, V10, P917	33	2	2	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1991	6	8					1339	1342						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1653409				2022-12-25	WOS:A1991GX27200007
J	KAMIBAYASHI, C; ESTES, R; SLAUGHTER, C; MUMBY, MC				KAMIBAYASHI, C; ESTES, R; SLAUGHTER, C; MUMBY, MC			SUBUNIT INTERACTIONS CONTROL PROTEIN PHOSPHATASE-2A - EFFECTS OF LIMITED PROTEOLYSIS, N-ETHYLMALEIMIDE, AND HEPARIN ON THE INTERACTION OF THE B-SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL-T-ANTIGEN; DNA-REPLICATION INVITRO; MEDIUM TUMOR-ANTIGEN; LIGHT CHAIN KINASE; PHOSPHOPROTEIN PHOSPHATASE; OKADAIC ACID; STRUCTURAL CHARACTERIZATION; SUBSTRATE-SPECIFICITY; TYPE-2A PHOSPHATASE; POLYACRYLAMIDE GELS	Protein phosphatase 2A consists of a heterotrimeric complex composed of a catalytic subunit (C) and two associated subunits (A and B). Limited tryptic digestion of the heterotrimeric ABC form resulted in the selective degradation of the M(r) = 55,000 B subunit to a 48-kDa polypeptide. The cleavage sites were determined to be within a 3-7-kDa region of the COOH terminus. Proteolysis led to dissociation of the B subunit from the enzyme complex and correlated with an increase in cardiac myosin light chain, smooth muscle myosin light chain peptide, and Leu-Arg-Arg-Ala-Ser-Leu-Gly (Kemptide) phosphatase activity. Purification of the digestion products and native gel electrophoresis indicated that dissociation of the B subunit was responsible for the increase in phosphatase activity. Kinetic analyses with several substrates revealed that dissociation of the B subunit resulted in a 2-7-fold increase in V(max) and a 1.6-5 fold increase in K(m). Proteolytic dissociation of the B subunit increased the sensitivity of protein phosphatase 2A to inhibition by okadaic acid. Inhibition of the trypsinized enzyme was very similar to that observed for the purified AC form of protein phosphatase 2A. Incubation of the ABC complex with N-ethylmaleimide resulted in dissociation of the C subunit and generation of an AB complex. Selective release of the C subunit indicated that the B subunit interacts directly with the A subunit and that one or more free sulfhydryls are required to maintain the heterotrimeric structure of protein phosphatase 2A. Treatment of the enzyme with heparin resulted in an increase in specific activity that was due to the release of the B subunit from the complex. These results provide evidence that the B subunit binds directly to the A subunit to modulate enzyme activity and substrate specificity and that the COOH-terminal region of this protein is important for interaction with the AC complex. Dissociation of the B subunit by polyanionic substances related to heparin may represent a mechanism for regulating the activity of this enzyme.	UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,5323 HARRY HINES BLVD,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NHLBI NIH HHS [HL31107, HL17669] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL017669, R01HL031107] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BLISS CI, 1970, STATISTICS BIOL, P167; BLUMENTHAL DK, 1982, BIOCHEMISTRY-US, V21, P2386, DOI 10.1021/bi00539a017; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN SC, 1989, J BIOL CHEM, V264, P7267; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; CORNISHB.A, 1974, BIOCHEM J, V137, P143, DOI 10.1042/bj1370143; CSORTOS C, 1990, BIOCHEM BIOPH RES CO, V169, P559, DOI 10.1016/0006-291X(90)90367-V; DILLS WL, 1975, BIOCHEM BIOPH RES CO, V62, P70, DOI 10.1016/S0006-291X(75)80406-2; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; FELIX MA, 1990, EMBO J, V9, P675, DOI 10.1002/j.1460-2075.1990.tb08159.x; FISHER PA, 1977, J BIOL CHEM, V252, P6528; GLASS DB, 1978, ANAL BIOCHEM, V87, P566, DOI 10.1016/0003-2697(78)90707-8; GRUSSENMEYER T, 1987, J VIROL, V61, P3902, DOI 10.1128/JVI.61.12.3902-3909.1987; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; IMAOKA T, 1983, J BIOL CHEM, V258, P1526; JOSHI B, 1990, J VIROL, V64, P5649, DOI 10.1128/JVI.64.11.5649-5651.1990; KEMP BE, 1977, J BIOL CHEM, V252, P4888; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE TH, 1991, CELL, V64, P415, DOI 10.1016/0092-8674(91)90649-J; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MICHNOFF CH, 1986, J BIOL CHEM, V261, P8320; MUMBY MC, 1987, J BIOL CHEM, V262, P6257; MUMBY MC, 1985, J BIOL CHEM, V260, P3763; NUNNALLY MH, 1985, J BIOL CHEM, V260, P1020; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PATO MD, 1986, J BIOL CHEM, V261, P3770; PATO MD, 1990, ARCH BIOCHEM BIOPHYS, V276, P116, DOI 10.1016/0003-9861(90)90017-S; PELECH S, 1985, EUR J BIOCHEM, V148, P245, DOI 10.1111/j.1432-1033.1985.tb08832.x; RUNDELL K, 1987, J VIROL, V61, P1240, DOI 10.1128/JVI.61.4.1240-1243.1987; SCOTT CW, 1989, MOL ENDOCRINOL, V3, P1815, DOI 10.1210/mend-3-11-1815; SHACTERNOIMAN E, 1983, J BIOL CHEM, V258, P4214; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; TITANJI VPK, 1977, BIOCHIM BIOPHYS ACTA, V481, P140, DOI 10.1016/0005-2744(77)90145-0; TUNG HYL, 1985, EUR J BIOCHEM, V148, P253, DOI 10.1111/j.1432-1033.1985.tb08833.x; USU H, 1988, J BIOL CHEM, V263, P3752; VIRSHUP DM, 1989, EMBO J, V8, P3891, DOI 10.1002/j.1460-2075.1989.tb08568.x; VIRSHUP DM, 1989, P NATL ACAD SCI USA, V86, P3584, DOI 10.1073/pnas.86.10.3584; WALTER G, 1989, P NATL ACAD SCI USA, V86, P8669, DOI 10.1073/pnas.86.22.8669; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988	43	79	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1991	266	20					13251	13260						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FX132	1649186				2022-12-25	WOS:A1991FX13200071
J	WANG, EH; PRIVES, C				WANG, EH; PRIVES, C			DNA HELICASE AND DUPLEX DNA FRAGMENT UNWINDING ACTIVITIES OF POLYOMA AND SIMIAN VIRUS-40 LARGE T-ANTIGEN DISPLAY SIMILARITIES AND DIFFERENCES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE-TUMOR-ANTIGEN; TEMPERATURE-SENSITIVE MUTANTS; REPLICATION INVITRO; SV40 ORIGIN; VIRAL-DNA; GENE-EXPRESSION; POLYMERASE-ALPHA; ATPASE ACTIVITY; BINDING SITE; PROTEIN	We have characterized the biochemical activities of purified polyoma (Py) large T antigen (T Ag) that was capable of mediating the replication of a plasmid containing the Py origin (ori(+) DNA) in mouse cell extracts. We report here that like the T Ag encoded by simian virus 40 (SV40), Py T Ag has DNA helicase and double-stranded DNA fragment unwinding activities. Py T Ag displaced DNA fragments greater than 1,600 nucleotides which were annealed to complementary sequences in single-stranded M13 by translocating in the 3' to 5' direction. Both helicase and double-stranded DNA fragment unwinding reactions were completely dependent upon NTP hydrolysis, displaying a strong preference for ATP and dATP. At low T Ag concentrations, significantly more Py ori(+) DNA fragment was unwound compared with a fragment lacking the replication origin. However, at higher ratios of Py T Ag to DNA, equivalent to those used in replication reactions, unwinding of both ori-containing and -lacking fragments was equally efficient. This is in contrast to SV40 T Ag which exhibited a more stringent requirement for SV40 origin sequences under similar conditions. Furthermore, some of the nucleotides that supported the helicase and unwinding activities of Py T Ag were different from those for the same SV40 T Ag reactions. We have also observed that in contrast to the very poor replication of linear SV40 ori(+) DNA by SV40 T Ag in human cell extracts, linear Py ori(+) DNA was replicated efficiently in mouse cell extracts by Py T Ag. However, despite the fact that linear Py ori(+), SV40 ori(+), and ori(-) DNA fragments could be unwound with comparable efficiency by Py T Ag, only fragments containing the Py replication origin were replicated in vitro. These results suggest that the initiation of DNA synthesis at the Py origin of replication requires features in addition to unwinding of the template.	COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027	Columbia University					NCI NIH HHS [CA26905] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA026905] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALFANO C, 1989, J BIOL CHEM, V264, P10699; BOROWIEC JA, 1988, EMBO J, V7, P3149, DOI 10.1002/j.1460-2075.1988.tb03182.x; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; CHOU JY, 1974, J VIROL, V14, P116, DOI 10.1128/JVI.14.1.116-124.1974; CLARK R, 1981, J BIOL CHEM, V256, P1854; CLERTANT P, 1982, J BIOL CHEM, V257, P6300; COWIE A, 1984, J VIROL, V52, P750, DOI 10.1128/JVI.52.3.750-760.1984; COWIE A, 1986, J VIROL, V57, P505, DOI 10.1128/JVI.57.2.505-514.1986; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P8981, DOI 10.1073/pnas.84.24.8981; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P16, DOI 10.1073/pnas.84.1.16; DELUCIA AL, 1983, J VIROL, V46, P143, DOI 10.1128/JVI.46.1.143-150.1983; DEPAMPHILIS ML, 1986, PAPOVAVIRIDAE, V1, P99; DORNREITER I, 1990, EMBO J, V9, P3329, DOI 10.1002/j.1460-2075.1990.tb07533.x; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; FRANCKE B, 1973, VIROLOGY, V55, P127, DOI 10.1016/S0042-6822(73)81014-1; FRIEDMAN M, 1986, CONTEMP POLICY ISSUE, V4, P1, DOI 10.1111/j.1465-7287.1986.tb00827.x; GAUDRAY P, 1980, EUR J BIOCHEM, V109, P553, DOI 10.1111/j.1432-1033.1980.tb04827.x; GOETZ GS, 1988, J BIOL CHEM, V263, P383; HERTZ GZ, 1986, MOL CELL BIOL, V6, P3513, DOI 10.1128/MCB.6.10.3513; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; JONES KA, 1984, CELL, V36, P155, DOI 10.1016/0092-8674(84)90084-9; KELLY TJ, 1988, J BIOL CHEM, V263, P17889; KENNY M K, 1990, Journal of Biological Chemistry, V265, P7693; KERN FG, 1985, MOL CELL BIOL, V5, P2070, DOI 10.1128/MCB.5.8.2070; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; LOEBER G, 1989, J VIROL, V63, P4426, DOI 10.1128/JVI.63.10.4426-4430.1989; LORIMER HE, 1991, J VIROL, V65, P687, DOI 10.1128/JVI.65.2.687-699.1991; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MILLER DW, 1986, GENETIC ENG PRINCIPL, V8, P277; MILLER LK, 1988, ANNU REV MICROBIOL, V42, P177, DOI 10.1146/annurev.micro.42.1.177; MURAKAMI Y, 1986, P NATL ACAD SCI USA, V83, P6347, DOI 10.1073/pnas.83.17.6347; OREILLY DR, 1988, J VIROL, V62, P3109, DOI 10.1128/JVI.62.9.3109-3119.1988; PALLAS DC, 1986, J VIROL, V60, P1075, DOI 10.1128/JVI.60.3.1075-1084.1986; PEDEN K, 1988, VIROLOGY, V168, P13; PRIVES C, 1982, J VIROL, V43, P73, DOI 10.1128/JVI.43.1.73-82.1982; RICE WC, 1987, J VIROL, V61, P1712, DOI 10.1128/JVI.61.5.1712-1716.1987; SCHEFFNER M, 1989, NUCLEIC ACIDS RES, V17, P93, DOI 10.1093/nar/17.1.93; SCHELLER A, 1982, CELL, V29, P375, DOI 10.1016/0092-8674(82)90154-4; SCHELLER A, 1985, J VIROL, V54, P532, DOI 10.1128/JVI.54.2.532-545.1985; SEKI M, 1990, BIOCHEMISTRY-US, V29, P1003, DOI 10.1021/bi00456a024; SMALE ST, 1986, MOL CELL BIOL, V6, P4077, DOI 10.1128/MCB.6.11.4077; SOEDA E, 1980, NATURE, V283, P445, DOI 10.1038/283445a0; STAHL H, 1986, EMBO J, V5, P1939, DOI 10.1002/j.1460-2075.1986.tb04447.x; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; TEGTMEYER P, 1972, J VIROL, V10, P591, DOI 10.1128/JVI.10.4.591-598.1972; TOOZE J, 1981, MOL BIOL TUMOR VIR 2, P61; TRAUT W, 1988, MOL CELL BIOL, V8, P903, DOI 10.1128/MCB.8.2.903; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P3839, DOI 10.1128/MCB.9.9.3839; TWIGG AJ, 1980, NATURE, V283, P216, DOI 10.1038/283216a0; VELDMAN GM, 1985, MOL CELL BIOL, V5, P649, DOI 10.1128/MCB.5.4.649; VIRSHUP DM, 1989, P NATL ACAD SCI USA, V86, P3584, DOI 10.1073/pnas.86.10.3584; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WIEKOWSKI M, 1988, J BIOL CHEM, V263, P436; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710; WOLD MS, 1989, J BIOL CHEM, V264, P2801; WOLD MS, 1987, P NATL ACAD SCI USA, V84, P3643, DOI 10.1073/pnas.84.11.3643; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; YAMAGUCHI M, 1986, P NATL ACAD SCI USA, V83, P1646, DOI 10.1073/pnas.83.6.1646	60	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1991	266	19					12668	12675						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FV180	1648101				2022-12-25	WOS:A1991FV18000088
J	LU, D; THOMPSON, JD; GORSKI, GK; RICE, NR; MAYER, MG; YUNIS, JJ				LU, D; THOMPSON, JD; GORSKI, GK; RICE, NR; MAYER, MG; YUNIS, JJ			ALTERATIONS AT THE REL LOCUS IN HUMAN LYMPHOMA	ONCOGENE			English	Article							NF-KAPPA-B; DNA-BINDING SUBUNIT; C-REL; V-REL; RETICULOENDOTHELIOSIS VIRUS; PROTO-ONCOGENE; MESSENGER-RNA; NUCLEOTIDE-SEQUENCE; GENE-EXPRESSION; CELL-LINE	The rel proto-oncogene has been mapped to chromosome region 2p11.2-14, a site associated with nonrandom rearrangements in non-Hodgkin's lymphoma. We have characterized an abnormal rel mRNA from a cell line derived from a diffuse large cell lymphoma, in which the evolutionarily conserved N-terminal half of the rel coding region was fused with the C-terminal coding region of an unrelated gene. In addition, rearrangement or amplification of the rel locus was found in the lymphomatous tissue of two follicular and one diffuse large cell lymphoma. The findings suggest involvement of rel in the pathogenesis of large cell lymphoma.	HAHNEMANN UNIV,SCH MED,DEPT NEOPLAST DIS,DIV HUMAN GENET & MOLEC BIOL,PHILADELPHIA,PA 19102; NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,FREDERICK,MD 21702	Drexel University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	YUNIS, JJ (corresponding author), HAHNEMANN UNIV,SCH MED,DEPT NEOPLAST DIS,DIV HUMAN GENET & MOLEC BIOL,PHILADELPHIA,PA 19102, USA.				OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101, CA3314] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BLOOMFIELD CD, 1983, CANCER RES, V43, P2975; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BRENNAND J, 1983, J BIOL CHEM, V258, P9593; BROWNELL E, 1988, ONCOGENE, V3, P93; BROWNELL E, 1988, ONCOGENE, V2, P527; BROWNELL E, 1985, MOL CELL BIOL, V5, P2826, DOI 10.1128/MCB.5.10.2826; BROWNELL E, 1989, ONCOGENE, V4, P935; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GELINAS C, 1988, ONCOGENE, V3, P349; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; GOLLIN SM, 1986, CANCER GENET CYTOGEN, V20, P331, DOI 10.1016/0165-4608(86)90092-0; GRUMONT RJ, 1989, ONCOGENE RES, V4, P1; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; HECHT BK, 1985, CANCER GENET CYTOGEN, V14, P205, DOI 10.1016/0165-4608(85)90186-4; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOELZER JD, 1980, VIROLOGY, V100, P462, DOI 10.1016/0042-6822(80)90536-X; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KARATHANASIS SK, 1983, P NATL ACAD SCI-BIOL, V80, P6147, DOI 10.1073/pnas.80.20.6147; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KLEIN E, 1968, CANCER RES, V28, P1300; KUBONISHI I, 1986, CANCER, V58, P1453, DOI 10.1002/1097-0142(19861001)58:7<1453::AID-CNCR2820580713>3.0.CO;2-B; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LOMBARDI L, 1987, CELL, V49, P161, DOI 10.1016/0092-8674(87)90556-3; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MINOWADA J, 1982, MALIGNANT LYMPHOMAS, P53; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARTZ RC, 1988, VIROLOGY, V165, P182, DOI 10.1016/0042-6822(88)90671-X; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STEPHENS RM, 1983, P NATL ACAD SCI-BIOL, V80, P6229, DOI 10.1073/pnas.80.20.6229; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; THEILEN GH, 1966, J NATL CANCER I, V37, P731; TONEGUZZO F, 1986, MOL CELL BIOL, V6, P703, DOI 10.1128/MCB.6.2.703; TSUJIMOTO Y, 1989, P NATL ACAD SCI USA, V86, P1958, DOI 10.1073/pnas.86.6.1958; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; YATES J, 1984, P NATL ACAD SCI-BIOL, V81, P3806, DOI 10.1073/pnas.81.12.3806; YUNIS JJ, 1989, NEW ENGL J MED, V320, P1047, DOI 10.1056/NEJM198904203201605; YUNIS JJ, 1987, NEW ENGL J MED, V316, P79, DOI 10.1056/NEJM198701083160204	52	109	110	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1991	6	7					1235	1241						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1650444				2022-12-25	WOS:A1991GV26000020
J	GUPTE, SS; OLSON, JW; RUYECHAN, WT				GUPTE, SS; OLSON, JW; RUYECHAN, WT			THE MAJOR HERPES-SIMPLEX VIRUS TYPE-1 DNA-BINDING PROTEIN IS A ZINC METALLOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SINGLE-STRANDED-DNA; GENE-32 PROTEIN; POLYMERASE; ICP8; BACTERIOPHAGE-T4; IDENTIFICATION; REPLICATION; EXPRESSION; INHIBITION; MUTANTS	The primary amino acid sequence of the major herpes simplex virus type 1 (HSV-1) -infected cell polypeptide 8 (ICP8) deduced from the DNA sequence of the unique long open reading frame 29 (UL29 ORF) contains a potential metal-binding domain of the form Cys-X2-5-Cys-X2-15-A-X2-4-A where A may be either histidine or cysteine and X is any amino acid. The putative metal-binding sequence in ICP8 encompasses residues 499-512 as follows: -C-N-L-C-T-F-D-T-R-H-A-C-V-H-. Atomic absorption analysis of several preparations of ICP8 indicates the presence of 1 mol of zinc/mol of protein. The zinc is resistant to removal by dialysis against concentrations of EDTA which deplete zinc from alcohol dehydrogenase. The bound zinc can be removed by reaction with the reversible sulfhydryl reagent p-hydroxymercurimethylsulfonate and the zinc-depleted protein transiently retains DNA binding activity. Digestion of both native and zinc-depleted ICP8 with V8 protease indicates that the bound zinc is required for the structural integrity of the protein.			GUPTE, SS (corresponding author), UNIFORMED SERV UNIV HLTH SCI,DEPT BIOCHEM,BETHESDA,MD 20814, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022468] Funding Source: NIH RePORTER; NIAID NIH HHS [AI22468] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P103, DOI 10.1146/annurev.biochem.55.1.103; CONLEY AJ, 1981, J VIROL, V37, P413; DRUM DE, 1969, BIOCHEMISTRY-US, V8, P3783, DOI 10.1021/bi00837a044; FOOTE JW, 1982, ANALYST, V107, P1229, DOI 10.1039/an9820701229; GAO M, 1988, VIROLOGY, V163, P319, DOI 10.1016/0042-6822(88)90272-3; GAO M, 1989, J VIROL, V63, P5258, DOI 10.1128/JVI.63.12.5258-5267.1989; GAUSS P, 1987, P NATL ACAD SCI USA, V84, P8515, DOI 10.1073/pnas.84.23.8515; GIEDROC DP, 1987, BIOCHEMISTRY-US, V26, P5251, DOI 10.1021/bi00391a007; GIEDROC DP, 1986, P NATL ACAD SCI USA, V83, P8452, DOI 10.1073/pnas.83.22.8452; GODOWSKI PJ, 1986, P NATL ACAD SCI USA, V83, P256, DOI 10.1073/pnas.83.2.256; GOTTLIEB J, 1990, J VIROL, V64, P5976, DOI 10.1128/JVI.64.12.5976-5987.1990; HERNANDEZ TR, 1990, J BIOL CHEM, V265, P11227; HONESS RW, 1974, J VIROL, V14, P8, DOI 10.1128/JVI.14.1.8-19.1974; KNIPE DM, 1982, J VIROL, V44, P736, DOI 10.1128/JVI.44.2.736-741.1982; KOPS AD, 1988, CELL, V55, P857, DOI 10.1016/0092-8674(88)90141-9; KOWACZYKOWSKI SC, 1981, ENZYMES, V14, P337; LEE CK, 1985, J VIROL, V54, P731, DOI 10.1128/JVI.54.3.731-738.1985; LEINBACH SS, 1988, VIROLOGY, V166, P10; LITTLER E, 1983, J GEN VIROL, V64, P983, DOI 10.1099/0022-1317-64-5-983; LOWRY OH, 1951, J BIOL CHEM, V193, P265; ODONNELL ME, 1987, J BIOL CHEM, V262, P4260; OLIVO PD, 1988, CANCER CELL, V6, P43; ORBERG PK, 1987, J VIROL, V61, P1136, DOI 10.1128/JVI.61.4.1136-1146.1987; POWELL KL, 1981, J VIROL, V39, P894, DOI 10.1128/JVI.39.3.894-902.1981; POWELL KL, 1976, INTERVIROLOGY, V7, P225, DOI 10.1159/000149955; QUINN JP, 1985, NUCLEIC ACIDS RES, V13, P8143, DOI 10.1093/nar/13.22.8143; RIORDAN JF, 1988, METHOD ENZYMOL, V158, P3, DOI 10.1016/0076-6879(88)58041-2; RUYECHAN WT, 1986, J VIROL, V59, P31, DOI 10.1128/JVI.59.1.31-36.1986; RUYECHAN WT, 1983, J VIROL, V46, P661, DOI 10.1128/JVI.46.2.661-666.1983; RUYECHAN WT, 1984, J VIROL, V52, P727, DOI 10.1128/JVI.52.3.727-733.1984; RUYECHAN WT, 1988, J VIROL, V62, P810, DOI 10.1128/JVI.62.3.810-817.1988; WANG YS, 1990, J VIROL, V64, P2082, DOI 10.1128/JVI.64.5.2082-2089.1990; WELLER SK, 1983, J VIROL, V45, P354, DOI 10.1128/JVI.45.1.354-366.1983; WU CA, 1988, J VIROL, V62, P435, DOI 10.1128/JVI.62.2.435-443.1988	35	35	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1991	266	18					11413	11416						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FT762	1646804				2022-12-25	WOS:A1991FT76200003
J	ERICSSON, J; SCALLEN, TJ; CHOJNACKI, T; DALLNER, G				ERICSSON, J; SCALLEN, TJ; CHOJNACKI, T; DALLNER, G			INVOLVEMENT OF STEROL CARRIER PROTEIN-2 IN DOLICHOL BIOSYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MICROSOMES; CHOLESTEROL-BIOSYNTHESIS; ESTERIFICATION; PYROPHOSPHATE; PURIFICATION; SUPERNATANT; CONVERSION; PHOSPHATE; SQUALENE	The effect of sterol carrier protein-2 (SCP-2) on dolichol biosynthesis by rat liver microsomes was investigated. cis-Prenyltransferase activity was stimulated 7-fold in the presence of 5-mu-g of purified SCP-2/mg of microsomal protein, which was similar to the increase obtained by adding detergent. The polyisoprenoid pattern obtained in the presence of SCP-2 was the same as that present in rat liver, in contrast to the pattern appearing upon incubation of microsomes with detergent, which gave shorter polyisoprenoids. Like SCP-2, the cytosolic fraction from rat liver also stimulated cis-prenyltransferase. Incubation with cytosol pretreated with anti-SCP-2 showed no stimulatory effect and led to the accumulation of shorter polyisoprenoids. SCP-2 had no appreciable effect on polyprenol alpha-saturase, dolichol kinase, dolichyl phosphate phosphatase, or acyl-CoA:dolichol acyltransferase. The results demonstrate that SCP-2 greatly stimulates and may regulate the condensation reactions mediated by cis-prenyltransferase in the process of dolichol biosynthesis and permits polymerization of the polyisoprenoid to its natural chain length.	KAROLINSKA INST,HUDDINGE HOSP,CLIN RES CTR,DIV MED CELL & NEUROBIOL,S-14186 HUDDINGE,SWEDEN; UNIV NEW MEXICO,SCH MED,DEPT BIOCHEM,ALBUQUERQUE,NM 87131; POLISH ACAD SCI,INST BIOCHEM & BIOPHYS,PL-02532 WARSAW,POLAND	Karolinska Institutet; University of New Mexico; Polish Academy of Sciences; Institute of Biochemistry & Biophysics - Polish Academy of Sciences	ERICSSON, J (corresponding author), UNIV STOCKHOLM,DEPT BIOCHEM,S-10691 STOCKHOLM,SWEDEN.		Ericsson, Johan/AAA-6664-2020	Ericsson, Johan/0000-0003-1186-6574	NIDDK NIH HHS [DK-10,628] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK010628] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAIR WL, 1984, J BIOL CHEM, V259, P4441; ADAIR WL, 1983, BIOCHIM BIOPHYS ACTA, V208, P532; APPELKVIST EL, 1989, EUR J BIOCHEM, V185, P503, DOI 10.1111/j.1432-1033.1989.tb15142.x; BLOCH K, 1985, BIOCH LIPIDS MEMBRAN, P1; BUTKO P, 1990, BIOCHEMISTRY-US, V29, P4070, DOI 10.1021/bi00469a007; CHEN Z, 1988, ARCH BIOCHEM BIOPHYS, V266, P98, DOI 10.1016/0003-9861(88)90240-8; CHOJNACKI T, 1988, BIOCHEM J, V251, P1; EGGENS I, 1982, BIOCHIM BIOPHYS ACTA, V686, P77, DOI 10.1016/0005-2736(82)90153-5; EKSTROM TJ, 1987, J BIOL CHEM, V262, P4090; EKSTROM TJ, 1984, J BIOL CHEM, V259, P460; ERICSSON J, 1987, ANAL BIOCHEM, V167, P222, DOI 10.1016/0003-2697(87)90156-4; FUJII H, 1982, BIOCHIM BIOPHYS ACTA, V712, P716; GAVEY KL, 1981, J BIOL CHEM, V256, P2993; GAVEY KL, 1978, J BIOL CHEM, V253, P5470; GAYLOR JL, 1983, BIOSYNTHESIS ISOPREN, V1, P481; GORNALL AG, 1949, J BIOL CHEM, V177, P751; HEMMING FW, 1983, BIOSYNTHESIS ISOPREN, V2, P305; JOHNSON RC, 1974, ARCH BIOCHEM BIOPHYS, V164, P502, DOI 10.1016/0003-9861(74)90060-5; KEENAN RW, 1976, BIOCHEMISTRY-US, V15, P1586, DOI 10.1021/bi00652a032; MANKOWSKI T, 1976, BIOCHEMISTRY-US, V15, P2125, DOI 10.1021/bi00655a015; NOLAND BJ, 1980, J BIOL CHEM, V255, P4282; PINTER KG, 1964, J LIPID RES, V5, P273; POPJAK G, 1962, J BIOL CHEM, V237, P56; SAGAMI H, 1989, BIOCHIM BIOPHYS ACTA, V1002, P218, DOI 10.1016/0005-2760(89)90290-7; SCALLEN TJ, 1974, FED PROC, V33, P1733; SCALLEN TJ, 1971, J BIOL CHEM, V246, P224; SCHROEDER F, 1990, J BIOL CHEM, V265, P151; TAKAHASHI I, 1980, J BIOL CHEM, V255, P4539; TAKAHASHI I, 1982, J BIOCH, V89, P1527; TECEN TT, 1957, J BIOL CHEM, V266, P921; TOLLBOM O, 1988, J BIOL CHEM, V263, P1347; TRZASKOS JM, 1983, BIOCHIM BIOPHYS ACTA, V751, P52, DOI 10.1016/0005-2760(83)90256-4; VAHOUNY GV, 1984, BIOCHEM BIOPH RES CO, V122, P509, DOI 10.1016/S0006-291X(84)80062-5; VAHOUNY GV, 1983, J BIOL CHEM, V258, P1731; ZILVERSMIT DB, 1984, J LIPID RES, V25, P1563	35	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10602	10607						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	1645353				2022-12-25	WOS:A1991FP08600090
J	HUPE, DJ; BOLTZ, R; COHEN, CJ; FELIX, J; HAM, E; MILLER, D; SODERMAN, D; VANSKIVER, D				HUPE, DJ; BOLTZ, R; COHEN, CJ; FELIX, J; HAM, E; MILLER, D; SODERMAN, D; VANSKIVER, D			THE INHIBITION OF RECEPTOR-MEDIATED AND VOLTAGE-DEPENDENT CALCIUM ENTRY BY THE ANTIPROLIFERATIVE L-651,582	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; SUPEROXIDE ANION GENERATION; HUMAN-NEUTROPHILS; INOSITOL 1,4,5-TRISPHOSPHATE; SIGNAL TRANSDUCTION; MOBILIZING LIGANDS; HUMAN-LEUKOCYTES; GROWTH-FACTOR; ION CHANNELS; ACTIVATION	L-651,582, 5-amino-[4-(4-chlorobenzoyl)-3,5-dichlorobenzyl]-1,2,3-triazole-4-carboxamide, an antiproliferative and antiparasitic agent previously shown to affect Ca-45(2+) uptake into mammalian cells, inhibits both receptor-mediated and voltage-dependent calcium entryin well characterized in vitro systems. Indo 1 fluorescence measurements of cytosolic calcium levels indicate that the drug has no effect on the initial transient release of internal stores of calciumstimulated by fMet-Leu-Phe in rat polymorphonuclear leukocytes. Itdoes decrease the levels maintained subsequently, however, indicating blockage of calcium influx through receptor-operated channels. L-651,582 also blocks the stimulation of leukotriene B4 (LTB4) production by fMet-Leu-Phe with an IC50 = 0.5-mu-g/ml equal to that for calcium entry inhibition. The LTB4 inhibition is likely due to calcium entry inhibition since L-651,582 does not inhibit calmodulin or enzymes producing arachidonate metabolites. L-651,582 also inhibits potassium-stimulated Ca-45(2+) influx into GH3 cells with an IC50 of 0.5-mu-g/ml, indicating a block of voltagegated L-type calcium channels. Patch voltage clamp measurements of current through L- and T-type calcium in guinea pig atrial cells also indicate that L-651,582 is a calcium antagonist. Block of L-type calcium channels is voltage-dependent, and the apparent dissociation constant for the high affinity state is 0.2-mu-g/ml. The IC50 for block of T-type calcium channels is 1.4-mu-g/ml. The inhibition of cellular proliferation and the production of arachidonate metabolites by L-651,582 may be the result of the nearly equipotent block of receptor-operated and voltage-gated calcium channels.	MERCK INST THERAPEUT RES, DEPT ENZYMOL, RAHWAY, NJ 07065 USA; MERCK INST THERAPEUT RES, DEPT IMMUNOL, RAHWAY, NJ 07065 USA; MERCK INST THERAPEUT RES, DEPT MEMBRANE BIOCHEM & BIOPHYS, RAHWAY, NJ 07065 USA	Merck & Company; Merck & Company; Merck & Company								BEAN BP, 1989, ANNU REV PHYSIOL, V51, P367, DOI 10.1146/annurev.physiol.51.1.367; BEAN BP, 1984, P NATL ACAD SCI-BIOL, V81, P6388, DOI 10.1073/pnas.81.20.6388; BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BERRIDGE MJ, 1984, BIO-TECHNOL, V2, P541, DOI 10.1038/nbt0684-541; Bochis R. J., 1986, Patent No. [4590201A, 4590201]; BOSMA M, 1988, J CELL PHYSIOL, V135, P317, DOI 10.1002/jcp.1041350220; BURGESS GM, 1985, BIOCHEM J, V232, P237, DOI 10.1042/bj2320237; CHAN TCK, 1989, J CELL PHYSIOL, V141, P461, DOI 10.1002/jcp.1041410303; CHAND N, 1986, AGENTS ACTIONS, V17, P407, DOI 10.1007/BF01965507; DILLON SB, 1987, J BIOL CHEM, V262, P11546; EGAN RW, 1979, J BIOL CHEM, V254, P3295; EVANS JF, 1985, BIOCHIM BIOPHYS ACTA, V840, P43, DOI 10.1016/0304-4165(85)90160-6; FRACE AM, 1989, P NATL ACAD SCI USA, V86, P2511, DOI 10.1073/pnas.86.7.2511; HANNUN YA, 1985, J BIOL CHEM, V260, P39; HESKETH TR, 1988, J BIOL CHEM, V263, P11879; HESS P, 1990, ANNU REV NEUROSCI, V13, P337, DOI 10.1146/annurev.ne.13.030190.002005; HUPE DJ, 1991, J PHARMACOL EXP THER, V256, P462; HUPE DJ, 1990, J CELL PHYSIOL, V144, P457, DOI 10.1002/jcp.1041440313; HUPE DJ, 1989, Patent No. 4847257; JOUVINMARCHE E, 1983, EUR J PHARMACOL, V89, P19, DOI 10.1016/0014-2999(83)90603-9; KING VF, 1989, J BIOL CHEM, V264, P5633; KOHN EC, 1990, J NATL CANCER I, V82, P54, DOI 10.1093/jnci/82.1.54; KORCHAK HM, 1988, J BIOL CHEM, V263, P11090; KORCHAK HM, 1988, J BIOL CHEM, V263, P11098; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; LEWIS RS, 1989, CELL REGUL, V1, P99, DOI 10.1091/mbc.1.1.99; MATSUNAGA H, 1988, AM J PHYSIOL, V255, pC442, DOI 10.1152/ajpcell.1988.255.4.C442; MATTESON DR, 1986, J GEN PHYSIOL, V87, P161, DOI 10.1085/jgp.87.1.161; MERRITT JE, 1989, J BIOL CHEM, V264, P1522; MILLER DK, 1985, J IMMUNOL METHODS, V81, P169, DOI 10.1016/0022-1759(85)90202-9; Naccache P.H., 1985, CALMODULIN ANTAGONIS, P149; NARAHASHI T, 1988, CALCIUM DRUG ACTIONS, P255; NISHIZUKA Y, 1984, RECENT PROG HORM RES, V40, P301; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PUTNEY JW, 1989, FASEB J, V3, P1899, DOI 10.1096/fasebj.3.8.2542110; RASMUSSEN H, 1984, PHYSIOL REV, V64, P938, DOI 10.1152/physrev.1984.64.3.938; RINK TJ, 1990, FEBS LETT, V268, P381, DOI 10.1016/0014-5793(90)81290-5; ROUZER CA, 1986, P NATL ACAD SCI USA, V83, P857, DOI 10.1073/pnas.83.4.857; ROUZER CA, 1985, P NATL ACAD SCI USA, V82, P6040, DOI 10.1073/pnas.82.18.6040; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SANGUINETTI MC, 1984, CIRC RES, V55, P336, DOI 10.1161/01.RES.55.3.336; SCHEIBEL LW, 1987, P NATL ACAD SCI USA, V84, P7310, DOI 10.1073/pnas.84.20.7310; SCHRAMM M, 1988, CALCIUM DRUG ACTIONS, P90; SHAAFI RI, 1985, CALCIUM BIOL SYSTEMS, P137; TRUETT AP, 1988, P NATL ACAD SCI USA, V85, P1549, DOI 10.1073/pnas.85.5.1549; VEIGL ML, 1983, BIOCHIM BIOPHYS ACTA, V738, P21, DOI 10.1016/0304-419X(84)90018-0; VERGHESE MW, 1987, J IMMUNOL, V138, P4374; VONTSCHARNER V, 1986, NATURE, V324, P369, DOI 10.1038/324369a0; WHEELER LA, 1987, J BIOL CHEM, V262, P6531; WHITFIELD JF, 1987, CANCER METAST REV, V5, P205, DOI 10.1007/BF00046999; YONEDA T, 1985, CANCER RES, V45, P398	54	73	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10136	10142						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	1645340				2022-12-25	WOS:A1991FP08600024
J	BOSMA, PJ; CHOWDHURY, JR; HUANG, TJ; LAHIRI, P; ELFERINK, RPJO; VANES, HHG; LEDERSTEIN, M; WHITINGTON, PF; JANSEN, PLM; CHOWDHURY, NR				BOSMA, PJ; CHOWDHURY, JR; HUANG, TJ; LAHIRI, P; ELFERINK, RPJO; VANES, HHG; LEDERSTEIN, M; WHITINGTON, PF; JANSEN, PLM; CHOWDHURY, NR			MECHANISMS OF INHERITED DEFICIENCIES OF MULTIPLE UDP-GLUCURONOSYLTRANSFERASE ISOFORMS IN 2 PATIENTS WITH CRIGLER-NAJJAR SYNDROME, TYPE-I	FASEB JOURNAL			English	Article						UDP-GLUCURONOSYLTRANSFERASE; CRIGLER-NAJJAR SYNDROME; TYPE-I; EXON SKIPPING; BILIRUBIN; 4-NITROPHENOL; SEQUENCE ABNORMALITY; MULTIPLE ISOFORM DEFICIENCY	URIDINE-DIPHOSPHATE GLUCURONOSYLTRANSFERASE; IMPROVED ASSAY; RNA; ENZYME; RATS; DNA	Crigler-Najjar syndrome, type I (CN-I) is a potentially lethal disorder characterized by severe unconjugated hyperbilirubinemia resulting from a recessively inherited deficiency of hepatic UDP-glucuronosyl-transferase (UGT) activity toward bilirubin (B-UGT). Two forms of B-UGT exist in human liver. mRNAs for these two forms and that for another isoform with activity toward simple phenols (P-UGT) have unique 5' regions, but their 3' regions are identical. The three mRNA species are derived from a single locus; the unique 5' regions are encoded by single unique exons and the identical 3' regions consist of four consecutive exons that are shared by all three isoforms. In this paper, we determined genetic lesions in two CN-I patients with deficiency of hepatic B-UGT and P-UGT activities. In one patient, there was a C-->T substitution in exon 4 (common region) predicting the substitution of a serine residue with a phenylalanine residue; this mutation was present in the identical region of B-UGT and P-UGT mRNAs. In the other patient, a C-->T substitution in exon 2 (common region) of the B-UGT/P-UGT locus resulted in a premature stop codon. This exon (132 nt) was absent in heptic B-UGT and P-UGT mRNAs of this patient due to exon skipping during pre-mRNA processing. Sequence abnormality of three distinct mRNA species explains the abnormality of multiple UGT isoforms in these patients. Presence of identical abnormalities in the common regions of the three mRNAs is consistent with the finding that the common 3' regions of the two B-UGT mRNAs and the P-UGT mRNA are encoded by four shared exons.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,MARION BESSIN LIVER RES CTR,ULLMAN 625,1300 MORRIS PK AVE,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MED,BRONX,NY 10461; UNIV AMSTERDAM,ACAD MED CTR,DEPT GASTROENTEROL & LIVER DIS,1105 AZ AMSTERDAM,NETHERLANDS; UNIV CHICAGO,SCH MED,DEPT PEDIAT,CHICAGO,IL 60637	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University of Amsterdam; Academic Medical Center Amsterdam; University of Chicago			Jansen, Peter LM/I-4509-2013		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035652, R01DK039137, R01DK034357, R37DK035652] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 35652, R01-DK 39137, R01-DK 34357] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOSMA PJ, 1992, HEPATOLOGY, V15, P941, DOI 10.1002/hep.1840150531; Burchell B, 1981, Methods Enzymol, V77, P188; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chowdhury J. R., 1986, BILE PIGMENTS JAUNDI, P317; CHOWDHURY JR, 1982, J CLIN INVEST, V69, P595, DOI 10.1172/JCI110486; CHOWDHURY JR, 1990, PRINCIPLES PRACTICE, P1135; CHOWDHURY JR, 1991, J BIOL CHEM, V266, P18294; CRIGLER JF, 1952, PEDIATRICS, V10, P169; DAAR IO, 1988, MOL CELL BIOL, V8, P802, DOI 10.1128/MCB.8.2.802; Dutton G., 1980, GLUCURONIDATION DRUG, P3; DUTTON GJ, 1981, METHOD ENZYMOL, V97, P383; ELAWADY M, 1990, J BIOL CHEM, V265, P10752; HARDING D, 1988, P NATL ACAD SCI USA, V85, P8381, DOI 10.1073/pnas.85.22.8381; IRSHAID YM, 1987, MOL PHARMACOL, V31, P27; JANSEN PLM, 1992, IN PRESS HEPATOLOGY; KAUFMAN SS, 1986, HEPATOLOGY, V6, P1259, DOI 10.1002/hep.1840060606; LEAKEY JEA, 1978, BIOCHEM J, V175, P1119, DOI 10.1042/bj1751119; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANIATIS T, 1982, MOL CLONING LABORATO, P280; RAO GS, 1976, ANAL BIOCHEM, V74, P35, DOI 10.1016/0003-2697(76)90307-9; RITTER JK, 1992, J BIOL CHEM, V267, P3257; RITTER JK, 1991, J BIOL CHEM, V266, P1043; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHALABY F, 1990, P NATL ACAD SCI USA, V87, P2652, DOI 10.1073/pnas.87.7.2652; TREISMAN R, 1983, NATURE, V302, P591, DOI 10.1038/302591a0; URLAUB G, 1989, MOL CELL BIOL, V9, P2868, DOI 10.1128/MCB.9.7.2868; VANES HHG, 1990, J CLIN INVEST, V85, P1199, DOI 10.1172/JCI114553; VANES HHG, 1988, CELLULAR MOL ASPECTS, P193; [No title captured]	30	102	105	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1992	6	10					2859	2863		10.1096/fasebj.6.10.1634050	http://dx.doi.org/10.1096/fasebj.6.10.1634050			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JD954	1634050				2022-12-25	WOS:A1992JD95400016
J	SANAL, O; LANGE, E; TELATAR, M; SOBEL, E; SALAZARNOVAK, J; ERSOY, F; MORRISON, A; CONCANNON, P; TOLUN, A; GATTI, RA				SANAL, O; LANGE, E; TELATAR, M; SOBEL, E; SALAZARNOVAK, J; ERSOY, F; MORRISON, A; CONCANNON, P; TOLUN, A; GATTI, RA			ATAXIA-TELANGIECTASIA - LINKAGE ANALYSIS OF CHROMOSOME-11Q22-23 MARKERS IN TURKISH FAMILIES	FASEB JOURNAL			English	Article						AT GENES; GENETIC HETEROGENEITY; COMPLEMENTATION GROUPS; MONTE-CARLO ANALYSIS	REGION; MAP	To further pinpoint the location of the genes for ataxia-telangiectasia on the long arm of chromosome 11, we performed linkage analysis and analysis of recombinants of genetic haplotypes on 14 Turkish families with ataxia-telangiectasia, 12 of which were consanguineous. These studies used more than 25 polymorphic genetic markers spanning a region of the long arm of chromosome 11 that is larger than 50 cm. Seven markers gave significant LOD scores to AT: CJ5, DRD2, CJ208, S144, CD3E, PBGD, and S147, as did haplotypes created with pairs of markers DRD2/CJ5 and S144/CJ208, giving recombination fractions (0) of 0.00, 0.00, 0.05, 0.08, 0.03, 0.09, 0.07, 0.00, and 0.06, respectively. Monte Carlo analysis of these 14 Turkish families indicated the best location for a single AT gene to be within a 6 cm sex-averaged (3 cm male-specific) interval defined by STMY and CJ77; this was three times more likely than the next most likely location (peak III) at the DRD2 locus. The analysis also revealed a peak (peak II) between S147 and S133, which may represent the complementation group D gene. Recombinant analysis of haplotypes also localized an AT locus to the STMY-CJ77 interval. Taken together, these results suggest that at least two distinct AT loci exist (ATA and ATD) at 11q22-23, with perhaps a third locus, ATC, located very near to the ATA gene. This genetic heterogeneity further complicates plans to isolate the major ATA and ATC genes and to begin identifying AT carriers in the general population.	UNIV CALIF LOS ANGELES, SCH MED, DEPT PATHOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT BIOMATH, LOS ANGELES, CA 90024 USA; HACETTEPE UNIV, DEPT PEDIAT, ANKARA, TURKEY; BOGAZICI UNIV, DEPT BIOL, ISTANBUL, TURKEY; VIRGINIA MASON RES CTR, SEATTLE, WA 98101 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Hacettepe University; Bogazici University; Virginia Mason Medical Center			Tolun, Aslihan/AAS-2250-2020	Tolun, Aslihan/0000-0002-0328-6046; Concannon, Patrick/0000-0002-5801-1859; Sobel, Eric/0000-0002-1718-0031				CHARMLEY P, 1990, GENOMICS, V6, P316, DOI 10.1016/0888-7543(90)90572-C; FOROUD T, 1991, AM J HUM GENET, V49, P1263; GATTI RA, 1991, MEDICINE, V70, P99, DOI 10.1097/00005792-199103000-00003; GATTI RA, 1988, NATURE, V336, P577, DOI 10.1038/336577a0; JASPERS NGJ, 1988, CYTOGENET CELL GENET, V49, P259, DOI 10.1159/000132673; JULIER C, 1990, GENOMICS, V7, P335, DOI 10.1016/0888-7543(90)90167-S; KAPP LN, 1992, IN PRESS AM J HUM GE, V50; KOMATSU K, 1990, MUTAT RES, V235, P59, DOI 10.1016/0921-8777(90)90058-D; LANGE K, 1991, AM J HUM GENET, V49, P1320; MCCONVILLE CM, 1990, NUCLEIC ACIDS RES, V18, P4335, DOI 10.1093/nar/18.15.4335; SANAL O, 1990, AM J HUM GENET, V47, P860; Sedgwick R, 1991, HDB CLIN NEUROLOGY, P347; SOBEL E, 1992, IN PRESS AM J HUM GE; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; ZIV Y, 1991, GENOMICS, V9, P373, DOI 10.1016/0888-7543(91)90268-J	15	14	15	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1992	6	10					2848	2852		10.1096/fasebj.6.10.1634048	http://dx.doi.org/10.1096/fasebj.6.10.1634048			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JD954	1634048				2022-12-25	WOS:A1992JD95400014
J	GUAN, KL; DIXON, JE				GUAN, KL; DIXON, JE			EVIDENCE FOR PROTEIN-TYROSINE-PHOSPHATASE CATALYSIS PROCEEDING VIA A CYSTEINE-PHOSPHATE INTERMEDIATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE-COMMON ANTIGEN; PHOSPHOTYROSYL-PROTEIN; VIRULENCE DETERMINANT; ACID-PHOSPHATASE; HUMAN-PLACENTA; PURIFICATION; DISTINCT; CLONING; FAMILY; BRAIN	A recombinant protein-tyrosine-phosphatase has been expressed in Escherichia coli and purified to a single band by sodium dodecyl sulfate-polyacrylamide gel electrophoresis using affinity chromatography. When the phosphatase was allowed to react with P-32-labeled substrates and then rapidly denaturated, a P-32-labeled phosphoprotein could be visualized by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Transient formation of a P-32-labeled phosphoprotein was observed, and the P-32-labeled protein disappeared as substrate was consumed. In the presence of P-32-labeled p-nitrophenyl phosphate, 0.27 mol of phosphate was incorporated per mol of protein-tyrosine-phosphatase. Site-directed mutagenesis of a catalytically essential cystine residue (position 215) in the recombinant protein resulted in an inactive enzyme, and no phosphoprotein was formed. The P-32-labeled phosphoprotein showed a maximum lability between pH 2.5 and 3.5 and was rapidly decomposed in the presence of iodine. These properties, along with additional site-directed mutations, suggest that the protein-tyrosine-phosphatase forms a covalent thiol phosphate linkage between Cys215 and phosphate.	PURDUE UNIV,WALTHER CANC INST,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Walther Cancer Institute	GUAN, KL (corresponding author), PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907, USA.		Guan, Kun-Liang/ADK-7088-2022		PHS HHS [18849] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AKERFELDT S, 1960, ACTA CHEM SCAND, V14, P1980, DOI 10.3891/acta.chem.scand.14-1980; BOLIN I, 1988, MOL MICROBIOL, V2, P237, DOI 10.1111/j.1365-2958.1988.tb00025.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNSHIMER S, 1990, P NATL ACAD SCI USA, V87, P5148, DOI 10.1073/pnas.87.13.5148; BRUNATI AM, 1985, BIOCHEM BIOPH RES CO, V133, P929, DOI 10.1016/0006-291X(85)91225-2; CHARBONNEAU H, 1988, P NATL ACAD SCI USA, V85, P7182, DOI 10.1073/pnas.85.19.7182; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; CHERNOFF J, 1983, ARCH BIOCHEM BIOPHYS, V226, P517, DOI 10.1016/0003-9861(83)90321-1; CLAIR G, 1986, BIOCHEM BIOPH RES CO, V137, P566; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; DISABATO G, 1961, J AM CHEM SOC, V83, P4393, DOI 10.1021/ja01482a024; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; FOULKES JG, 1983, J BIOL CHEM, V258, P431; GENTLEMAN S, 1984, BIOCHIM BIOPHYS ACTA, V798, P53, DOI 10.1016/0304-4165(84)90009-6; GHOSH SS, 1986, SCIENCE, V231, P145, DOI 10.1126/science.3510454; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GUAN KL, 1990, P NATL ACAD SCI USA, V87, P1501, DOI 10.1073/pnas.87.4.1501; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HERR EB, 1957, BIOCHIM BIOPHYS ACTA, V25, P219, DOI 10.1016/0006-3002(57)90456-0; HORLEIN D, 1982, BIOCHEMISTRY-US, V21, P5577; JENCKS WP, 1965, J AM CHEM SOC, V87, P3199, DOI 10.1021/ja01092a035; JONES SW, 1989, J BIOL CHEM, V264, P7747; KAPLAN R, 1990, P NATL ACAD SCI USA, V87, P7000, DOI 10.1073/pnas.87.18.7000; LEIS JF, 1985, ARCH BIOCHEM BIOPHYS, V239, P320, DOI 10.1016/0003-9861(85)90694-0; MATTHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P4444, DOI 10.1073/pnas.87.12.4444; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; NELSON RL, 1984, MOL CELL BIOL, V4, P1003, DOI 10.1128/MCB.4.6.1003; OKADA M, 1986, BIOCHEM J, V239, P155, DOI 10.1042/bj2390155; PAS HH, 1988, BIOCHEMISTRY-US, V27, P5835, DOI 10.1021/bi00416a002; PIGIET V, 1978, J BIOL CHEM, V253, P1910; Plimmer RHA, 1941, BIOCHEM J, V35, P461, DOI 10.1042/bj0350461; RALPH SJ, 1987, EMBO J, V6, P1251, DOI 10.1002/j.1460-2075.1987.tb02361.x; SCHWARTZ JH, 1961, P NATL ACAD SCI USA, V47, P1996, DOI 10.1073/pnas.47.12.1996; SHRINER CL, 1984, J BIOL CHEM, V259, P1383; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; SWARUP G, 1982, J BIOL CHEM, V257, P7298; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1988, J BIOL CHEM, V263, P6722; TUNG HYL, 1987, ANAL BIOCHEM, V161, P412; VANETTEN RL, 1982, ANN NY ACAD SCI, V390, P27; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZHANG ZY, 1991, J BIOL CHEM, V266, P1516; ZHANG ZY, 1990, THESIS PURDUE U	46	459	473	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17026	17030						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1654322				2022-12-25	WOS:A1991GF44500013
J	WANG, CJ; TAI, HH				WANG, CJ; TAI, HH			MONOCLONAL ANTIIDIOTYPIC ANTIBODIES TO PLATELET-ACTIVATING-FACTOR (PAF) AND THEIR INTERACTION WITH PAF RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE ANTIBODIES; INSULIN-RECEPTOR; BINDING; MEDIATOR; ACETHER; CHOLINE; RABBIT	Monoclonal anti-idiotypic antibodies (3C3F3E4 and 10D3F8H7) that interact with platelet activating factor (PAF) receptors were generated using an auto-anti-idiotypic approach by immunizing mice with an aldehydic analog of PAF coupled to bovine thyroglobulin. The resulting hybridomas were screened for anti-idiotypic antibody (anti-anti-PAF) with F(ab')2 fragments of affinity-purified polyclonal rabbit anti-PAF antibody. These antibodies displayed internal image properties of PAF and were considered as Ab2-beta according to the following criteria: (a) they bound to F(ab')2 fragments of the affinity-purified rabbit polyclonal anti-PAF antibody that had high affinity for PAF; (b) they inhibited [H-3]PAF binding to rabbit polyclonal anti-PAF antibody and its F(ab')2 fragment in a concentration-dependent manner; (c) they displaced [H-3]PAF from the anti-PAF antibody/[H-3]PAF complex specifically; (d) they inhibited [H-3]PAF binding to PAF receptors on rabbit platelet membranes dose dependently; (e) they displaced [H-3]PAF from the [H-3]PAF/PAF receptor complex specifically; and (f) they stimulated rabbit platelets to aggregate, and this aggregation could be inhibited or totally blocked by specific PAF receptor antagonists WEB 2086 and SRI 63-441. All of the above are consistent with the first successful production of monoclonal antibodies that mimic PAF and interact specifically with the PAF binding domain of PAF receptors on rabbit platelet membranes.	UNIV KENTUCKY,COLL PHARM,DIV MED CHEM & PHARMACEUT,LEXINGTON,KY 40536	University of Kentucky								ABOOD LG, 1987, P NATL ACAD SCI USA, V84, P6587, DOI 10.1073/pnas.84.18.6587; BENVENISTE J, 1977, NATURE, V269, P170, DOI 10.1038/269170a0; BENVENISTE J, 1974, NATURE, V249, P581, DOI 10.1038/249581a0; BRAQUET P, 1987, PHARMACOL REV, V39, P97; CASALSSTENZEL J, 1987, IMMUNOPHARMACOLOGY, V3, P7; CAYANIS E, 1986, J BIOL CHEM, V261, P5094; CLEVELAND WL, 1983, NATURE, V305, P56, DOI 10.1038/305056a0; COURAUD JY, 1985, J BIOL CHEM, V260, P9461; DEMOPOULOS CA, 1979, J BIOL CHEM, V254, P9355; ELAZAR Z, 1988, LIFE SCI, V42, P1987, DOI 10.1016/0024-3205(88)90498-5; ELIAS D, 1984, J BIOL CHEM, V259, P6416; GAULTON GN, 1986, ANNU REV IMMUNOL, V4, P253, DOI 10.1146/annurev.iy.04.040186.001345; GODFROID JJ, 1980, FEBS LETT, V116, P161, DOI 10.1016/0014-5793(80)80633-8; GRAMSCH C, 1988, J BIOL CHEM, V263, P5853; HILL BL, 1988, ENDOCRINOLOGY, V122, P2840, DOI 10.1210/endo-122-6-2840; HOMCY CJ, 1982, J CLIN INVEST, V69, P1147, DOI 10.1172/JCI110550; HWANG SB, 1986, J BIOL CHEM, V261, P3720; HWANG SB, 1990, J LIPID MEDIATOR, V2, P123; HWANG SB, 1985, BIOCHEM BIOPH RES CO, V128, P972, DOI 10.1016/0006-291X(85)90142-1; INARREA P, 1984, EUR J PHARMACOL, V105, P309, DOI 10.1016/0014-2999(84)90623-X; JAEGGI C, 1986, Patent No. 178261; JERNE NK, 1982, EMBO J, V1, P243, DOI 10.1002/j.1460-2075.1982.tb01154.x; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; KLOPROGGE E, 1984, BIOCHEM J, V223, P901, DOI 10.1042/bj2230901; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KU HH, 1987, J IMMUNOL, V139, P2376; LINTHICUM DS, 1988, ANTIIDIOTYPES RECEPT, P1; LOMBES M, 1989, J BIOL CHEM, V264, P2528; REILLY TM, 1986, J IMMUNOL, V137, P597; SCHREIBER AB, 1980, P NATL ACAD SCI-BIOL, V77, P7385, DOI 10.1073/pnas.77.12.7385; SEGE K, 1978, P NATL ACAD SCI USA, V75, P2445; SHECHTER Y, 1984, J BIOL CHEM, V259, P6411; SNYDER F, 1985, MED RES REV, V5, P107, DOI 10.1002/med.2610050105; VALONE FH, 1983, IMMUNOLOGY, V48, P141; VARGAFTIG BB, 1983, TRENDS PHARMACOL SCI, V4, P341, DOI 10.1016/0165-6147(83)90433-9; WANG CJ, 1990, CHEM PHYS LIPIDS, V55, P265, DOI 10.1016/0009-3084(90)90164-M; WANG CJ, 1991, IN PRESS LIPIDS; WASSERMANN NH, 1982, P NATL ACAD SCI-BIOL, V79, P4810, DOI 10.1073/pnas.79.15.4810	38	7	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1991	266	19					12372	12378						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FV180	1648095				2022-12-25	WOS:A1991FV18000044
J	SALO, T; LYONS, JG; RAHEMTULLA, F; BIRKEDALHANSEN, H; LARJAVA, H				SALO, T; LYONS, JG; RAHEMTULLA, F; BIRKEDALHANSEN, H; LARJAVA, H			TRANSFORMING GROWTH FACTOR-BETA-1 UP-REGULATES TYPE-IV COLLAGENASE EXPRESSION IN CULTURED HUMAN KERATINOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE COLLAGEN; FACTOR-BETA; EXTRACELLULAR-MATRIX; TGF-BETA; MESSENGER-RNA; CELL-PROLIFERATION; ENDOTHELIAL-CELLS; HUMAN-FIBROBLASTS; LUNG FIBROBLASTS; CARCINOMA-CELLS	During the wound healing process lysis of basement membranes precedes keratinocyte migration into the wound bed. We studied, in vitro, whether this degradation of basement membranes could be regulated by transforming growth factor-beta-1 (TGF-beta-1), which is known to accelerate wound healing in vivo. Transforming growth factor-beta-l was found to increase the expression of both 92- and 72-kDa type IV collagenases (gelatinases) in cultured human mucosal and dermal keratinocytes. The 92-kDa enzyme predominated in both unstimulated and stimulated cultures. The 92-kDa form was stimulated over 5-fold, and the other form by a factor of 2-3. This increase in the synthesis of type IV collagenases was associated with a marked increase in the mRNA levels of these enzymes as well. The induction of the 92-kDa enzyme was similar in culture medium containing either 0.15 or 1.2 mm calcium chloride. Rat mucosal keratinocytes secreted only 92-kDa type IV collagenase, the secretion of which was not regulated by TGF-beta-1. Also, TGF-beta-1 did not cause any significant induction (maximum about 1.2-fold) of either type IV collagenase in human gingival fibroblasts. The induction levels of both collagenases in human keratinocytes were independent of the type of the extracellular matrix the cells were grown on. However, the basement membrane matrix (Matrigel) activated about half of the 92-kDa type to its 84-kDa active form. The data suggest that TGF-beta-1 has a specific function in up-regulating the expression of type IV collagenases in human keratinocytes, offering a possible explanation of how keratinocytes detach from basement membranes prior to the migration over the wound bed.	UNIV OULU,DEPT ORAL SURG,SF-90220 OULU,FINLAND; UNIV ALABAMA,SCH DENT,DEPT ORAL BIOL,BIRMINGHAM,AL 35294; UNIV TURKU,DEPT PERIODONT,SF-20520 TURKU 52,FINLAND	University of Oulu; University of Alabama System; University of Alabama Birmingham; University of Turku			, tuula/ABG-2051-2021; Lyons, Guy/B-1319-2012; Larjava, Hannu/GRO-4325-2022	Lyons, Guy/0000-0002-4835-4663; 	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE008228, R01DE006028] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE-06028, DE-08228, DE-09466] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AHMAD I, 1990, Biotechniques, V8, P164; AKHURST RJ, 1988, NATURE, V331, P363, DOI 10.1038/331363a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BASSOLS A, 1988, J BIOL CHEM, V263, P3039; BIRKEDALHANSEN H, 1987, METHOD ENZYMOL, V144, P140; BLOOD CH, 1990, BIOCHIM BIOPHYS ACTA, V1032, P89, DOI 10.1016/0304-419X(90)90014-R; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; DILORENZO TP, 1990, J CELL SCI, V96, P115; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; EMONARD H, 1990, INVAS METAST, V10, P170; FESSLER LI, 1984, J BIOL CHEM, V259, P9783; GARBISA S, 1986, J BIOL CHEM, V261, P2369; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; HARRIS ED, 1984, COLLAGEN REL RES, V4, P493; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; HIBBS MS, 1987, J CLIN INVEST, V80, P1644, DOI 10.1172/JCI113253; HUHTALA P, 1990, J BIOL CHEM, V265, P11077; HUHTALA P, 1990, GENOMICS, V6, P554, DOI 10.1016/0888-7543(90)90486-E; IGNOTZ RA, 1987, J BIOL CHEM, V262, P6443; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KESKIOJA J, 1988, J BIOL CHEM, V263, P3111; KVENG W, 1989, ANAL BIOCHEM, V182, P16; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LAIHO M, 1986, EXP CELL RES, V164, P399, DOI 10.1016/0014-4827(86)90038-8; LEOF EB, 1986, P NATL ACAD SCI USA, V83, P2453, DOI 10.1073/pnas.83.8.2453; LIN HY, 1987, J BIOL CHEM, V262, P6823; LYONS RM, 1990, EUR J BIOCHEM, V187, P467, DOI 10.1111/j.1432-1033.1990.tb15327.x; MADRI JA, 1988, J CELL BIOL, V106, P1375, DOI 10.1083/jcb.106.4.1375; MASSAGUE J, 1987, CELL, V49, P437, DOI 10.1016/0092-8674(87)90443-0; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MULLER G, 1987, P NATL ACAD SCI USA, V84, P5600, DOI 10.1073/pnas.84.16.5600; MURPHY G, 1989, BIOCHEM J, V258, P463, DOI 10.1042/bj2580463; MURPHY G, 1985, BIOCHIM BIOPHYS ACTA, V831, P49, DOI 10.1016/0167-4838(85)90148-7; MUSTOE TA, 1987, SCIENCE, V237, P1333, DOI 10.1126/science.2442813; NICKOLOFF BJ, 1988, AM J PATHOL, V132, P543; OGRADY RL, 1984, ANAL BIOCHEM, V140, P490, DOI 10.1016/0003-2697(84)90199-4; OKEEFE EJ, 1985, J INVEST DERMATOL, V85, P125, DOI 10.1111/1523-1747.ep12276531; OVERALL CM, 1989, J BIOL CHEM, V264, P1860; PIERCE GF, 1989, J CELL BIOL, V109, P429, DOI 10.1083/jcb.109.1.429; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; SALO T, 1985, J BIOL CHEM, V260, P8526; SALO T, 1983, J BIOL CHEM, V258, P3058; SELTZER JL, 1989, J BIOL CHEM, V264, P3822; SHIPLEY GD, 1985, P NATL ACAD SCI USA, V82, P4147, DOI 10.1073/pnas.82.12.4147; SPORN MB, 1986, SCIENCE, V233, P532, DOI 10.1126/science.3487831; Stenn K.S., 1988, MOL CELLULAR BIOL WO, P321; STEVENSON GA, 1985, BIOSCIENCE REP, V5, P1071, DOI 10.1007/BF01119628; TRYGGVASON K, 1987, BIOCHIM BIOPHYS ACTA, V907, P191, DOI 10.1016/0304-419X(87)90006-0; WELGUS HG, 1990, J BIOL CHEM, V265, P13521; WIKNER NE, 1988, J INVEST DERMATOL, V91, P207, DOI 10.1111/1523-1747.ep12464997; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WOODLEY DT, 1986, J INVEST DERMATOL, V86, P418, DOI 10.1111/1523-1747.ep12285689	54	289	294	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1991	266	18					11436	11441						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FT762	1646806				2022-12-25	WOS:A1991FT76200009
J	SIMON, D; KNOWLES, BB; WEITH, A				SIMON, D; KNOWLES, BB; WEITH, A			ABNORMALITIES OF CHROMOSOME-1 AND LOSS OF HETEROZYGOSITY ON 1P IN PRIMARY HEPATOMAS	ONCOGENE			English	Article							HUMAN HEPATOCELLULAR-CARCINOMA; HEPATITIS-B VIRUS; CELL-LINE; HUMAN NEUROBLASTOMAS; C-MYC; GENE; INTEGRATION; LIVER; HETEROCHROMATIN; EXPRESSION	Cytogenetic analysis of eight human hepatoma-derived cell lines and one primary hepatocellular carcinoma biopsy revealed multiple chromosome abnormalities; however, only chromosome 1 was consistently affected by rearrangements. Pseudopolysomy 1 as well as chromosome 1 deletions and/or translocations that resulted in loss of the distal 1p region from at least one copy of chromosome 1 were observed in all but one of the cell lines analysed. Molecular analyses of tumor-derived and normal genomic DNA from six cases of hepatocellular carcinoma and from two of hepatoblastoma, using a panel of chromosome 1p-specific DNA probes indicated allelic loss in the distal 1p region in five of the six hepatocellular carcinomas but not in either hepatoblastoma. These results suggest the location of a gene in the distal 1p region whose functional loss may be involved in hepatocellular carcinogenesis.	WISTAR INST,3601 SPRUCE ST,PHILADELPHIA,PA 19104; RES INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA	The Wistar Institute; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	KNOWLES, BB (corresponding author), WISTAR INST,3601 SPRUCE ST,PHILADELPHIA,PA 19104, USA.			Knowles, Barbara B./0000-0002-2597-5619	NCI NIH HHS [CA10815, CA37725] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA010815] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; ALEXANDER JJ, 1976, S AFR MED J, V50, P2124; ATKIN NB, 1986, CANCER GENET CYTOGEN, V21, P279, DOI 10.1016/0165-4608(86)90206-2; BEASLEY RP, 1981, LANCET, V2, P1129; BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; BUETOW KH, 1989, P NATL ACAD SCI USA, V86, P8852, DOI 10.1073/pnas.86.22.8852; CHANG C, 1983, MOL CELL BIOL, V3, P1133, DOI 10.1128/MCB.3.6.1133; CHATTERJEE B, 1989, MUTAT RES, V210, P49, DOI 10.1016/0027-5107(89)90043-2; DETHE H, 1987, NATURE, V330, P667, DOI 10.1038/330667a0; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; FOUREL G, 1990, NATURE, V347, P294, DOI 10.1038/347294a0; HSU TY, 1988, CELL, V55, P627, DOI 10.1016/0092-8674(88)90221-8; HUH N, 1981, GANN, V72, P178; JEFFREYS AJ, 1988, NATURE, V332, P278, DOI 10.1038/332278a0; KEICHLESCHWARTZ M, 1990, GENE CHROMOSOME CANC, V1, P312; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; MARTINSSON T, 1989, GENE CHROMOSOME CANC, V1, P67, DOI 10.1002/gcc.2870010111; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; OBRIEN SJ, 1990, GENETIC MAPS; PINTO MR, 1985, CANCER GENET CYTOGEN, V18, P11, DOI 10.1016/0165-4608(85)90033-0; ROBINSON WS, 1989, CANCER DETECT PREV, V14, P245; ROGLER CE, 1985, SCIENCE, V230, P219; ROONEY DE, 1971, HUMAN CYTOGENETICS P, V2, P971; SEABRIGH.M, 1971, LANCET, V2, P971; SIMON D, 1986, LAB INVEST, V55, P657; SIMON D, 1982, INT J CANCER, V30, P27, DOI 10.1002/ijc.2910300106; SIMON D, 1985, CYTOGENET CELL GENET, V39, P116, DOI 10.1159/000132118; SIMON D, 1990, CANCER GENET CYTOGEN, V45, P255, DOI 10.1016/0165-4608(90)90091-N; Simon D.R., UNPUB; SMUZNESS W, 1978, PROG MED VIROL, V24, P40; STEVENSON D, 1987, HEPATOLOGY, V7, P1291, DOI 10.1002/hep.1840070619; SUMNER AT, 1972, EXP CELL RES, V75, P304, DOI 10.1016/0014-4827(72)90558-7; TADA M, 1990, CANCER RES, V40, P1122; TAKADA S, 1989, ONCOGENE, V4, P189; TSUDA H, 1990, P NATL ACAD SCI USA, V87, P6791, DOI 10.1073/pnas.87.17.6791; TWIST EM, 1981, J VIROL, V37, P239, DOI 10.1128/JVI.37.1.239-243.1981; WANG HP, 1988, CYTOGENET CELL GENET, V48, P72, DOI 10.1159/000132593; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WEITH A, 1989, GENE CHROMOSOME CANC, V1, P159, DOI 10.1002/gcc.2870010209; WUU KD, 1987, CANCER GENET CYTOGEN, V26, P279, DOI 10.1016/0165-4608(87)90062-8; YASWEN P, 1985, MOL CELL BIOL, V5, P780, DOI 10.1128/MCB.5.4.780	42	153	156	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1991	6	5					765	770						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT825	1646986				2022-12-25	WOS:A1991GT82500012
J	HILL, LE; MEHEGAN, JP; BUTTERS, CA; TOBACMAN, LS				HILL, LE; MEHEGAN, JP; BUTTERS, CA; TOBACMAN, LS			ANALYSIS OF TROPONIN-TROPOMYOSIN BINDING TO ACTIN - TROPONIN DOES NOT PROMOTE INTERACTIONS BETWEEN TROPOMYOSIN MOLECULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; COOPERATIVE EQUILIBRIUM BINDING; CARDIAC THIN FILAMENT; MYOSIN SUBFRAGMENT-1; ALPHA-TROPOMYOSIN; F-ACTIN; NONPOLYMERIZABLE TROPOMYOSIN; LABELED TROPOMYOSIN; PARTIAL EXTRACTION; CRYSTAL-STRUCTURE	The binding of tropomyosin to actin and troponin-tropomyosin to actin was analyzed according to a linear lattice model which quantifies two parameters: K(o), the affinity of the ligand for an isolated site on the actin filament, and y, the fold increase in affinity when binding is contiguous to an occupied site (cooperativity). Tropomyosin-actin binding is very cooperative (y = 90-137). Troponin strengthens tropomyosin-actin binding greatly but, surprisingly, does so solely by an 80-130-fold increase in K(o), while cooperativity actually decreases. Additionally, troponin complexes containing TnT subunits with deletions of either amino acids 1-69 (troponin70-259) or 1-158 (troponin159-259) were examined. Deletion of amino acids 1-69 had only small effects on K(o) and y, despite this peptide's location spanning the joint between adjacent tropomyosins. Ca2+ reduced K(o) by half for both troponin and troponin70-159 and had no detectable effect on cooperativity. Troponin159-259 had much weaker effects on tropomyosin-actin binding than did troponin70-259 and had no effect at all in the presence of Ca2+. This suggests the importance of Ca2+-insensitive interactions between tropomyosin and troponin T residues 70-159. Cooperativity was slightly lower for troponin159-259 than tropomyosin alone, suggesting that the globular head region of troponin affects tropomyosin-tropomyosin interactions along the thin filament.	UNIV IOWA, COLL MED, DEPT BIOCHEM, IOWA CITY, IA 52242 USA	University of Iowa	HILL, LE (corresponding author), UNIV IOWA, COLL MED, DEPT INTERNAL MED, IOWA CITY, IA 52242 USA.				NHLBI NIH HHS [HL38834] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038834, R29HL038834] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Battey, 1986, BASIC METHODS MOL BI; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDT PW, 1987, J MOL BIOL, V195, P885, DOI 10.1016/0022-2836(87)90492-X; BREITBART RE, 1985, CELL, V41, P67, DOI 10.1016/0092-8674(85)90062-5; CHO YJ, 1990, J BIOL CHEM, V265, P538; EBASHI S, 1965, J BIOCHEM-TOKYO, V58, P107, DOI 10.1093/oxfordjournals.jbchem.a128157; FLICKER PF, 1982, J MOL BIOL, V162, P495, DOI 10.1016/0022-2836(82)90540-X; HEALD RW, 1988, J BIOL CHEM, V263, P5254; HEELEY DH, 1987, J BIOL CHEM, V262, P9971; HEELEY DH, 1989, J BIOL CHEM, V264, P2424; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; Hill T. L., 1985, COOPERATIVITY THEORY; HILL TL, 1980, P NATL ACAD SCI-BIOL, V77, P3186, DOI 10.1073/pnas.77.6.3186; HILL TL, 1983, BIOPHYS J, V44, P383, DOI 10.1016/S0006-3495(83)84312-4; HILL TL, 1983, P NATL ACAD SCI-BIOL, V80, P60, DOI 10.1073/pnas.80.1.60; HITCHCOCKDEGREGORI SE, 1990, J MOL BIOL, V214, P885, DOI 10.1016/0022-2836(90)90343-K; HITCHCOCKDEGREGORI SE, 1987, J BIOL CHEM, V262, P9730; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; HUXLEY HE, 1972, COLD SPRING HARB SYM, V37, P341; INGRAHAM RH, 1984, J BIOL CHEM, V259, P9544; INGRAHAM RH, 1985, BIOCHEMISTRY-US, V24, P5221, DOI 10.1021/bi00340a040; ISHII Y, 1991, J BIOL CHEM, V266, P6894; ISHII Y, 1987, BIOCHEMISTRY-US, V26, P4922, DOI 10.1021/bi00390a005; JACKSON P, 1975, BIOCHEM J, V151, P85, DOI 10.1042/bj1510085; MAK AS, 1983, J BIOL CHEM, V258, P4330; Maniatis T., 1982, MOL CLONING; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MEHEGAN JP, 1991, J BIOL CHEM, V266, P966; MILLIGAN RA, 1990, NATURE, V348, P217, DOI 10.1038/348217a0; MORRIS EP, 1984, BIOCHEMISTRY-US, V23, P2214, DOI 10.1021/bi00305a018; MOSS RL, 1985, J GEN PHYSIOL, V86, P585, DOI 10.1085/jgp.86.4.585; MOSS RL, 1986, J GEN PHYSIOL, V87, P761, DOI 10.1085/jgp.87.5.761; OHTSUKI I, 1984, J BIOCHEM, V95, P1337, DOI 10.1093/oxfordjournals.jbchem.a134740; PAN BS, 1991, J BIOL CHEM, V266, P12432; PEARLSTONE JR, 1983, J BIOL CHEM, V258, P2534; PHILLIPS GN, 1986, J MOL BIOL, V192, P111, DOI 10.1016/0022-2836(86)90468-7; POTTER JD, 1982, METHOD ENZYMOL, V85, P241; POTTER JD, 1974, BIOCHEMISTRY-US, V13, P2697, DOI 10.1021/bi00710a007; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TOBACMAN LS, 1988, J BIOL CHEM, V263, P2668; TOBACMAN LS, 1986, BIOCHEMISTRY-US, V25, P798, DOI 10.1021/bi00352a010; TOBACMAN LS, 1987, J BIOL CHEM, V262, P4059; TOBACMAN LS, 1987, BIOCHEMISTRY-US, V26, P492, DOI 10.1021/bi00376a022; TOBACMAN LS, 1990, J BIOL CHEM, V265, P931; WEGNER A, 1979, J MOL BIOL, V131, P839, DOI 10.1016/0022-2836(79)90204-3; WEGNER A, 1981, BIOCHEMISTRY-US, V20, P5633, DOI 10.1021/bi00522a043; WHITE SP, 1987, NATURE, V325, P826, DOI 10.1038/325826a0; WILLIAMS DL, 1988, BIOCHEMISTRY-US, V27, P6987, DOI 10.1021/bi00418a048; ZASEDATELEV A S, 1971, Molekulyarnaya Biologiya (Moscow), V5, P245	51	90	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16106	16113						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1644797				2022-12-25	WOS:A1992JJ45800022
J	ORR, JW; KERANEN, LM; NEWTON, AC				ORR, JW; KERANEN, LM; NEWTON, AC			REVERSIBLE EXPOSURE OF THE PSEUDOSUBSTRATE DOMAIN OF PROTEIN-KINASE-C BY PHOSPHATIDYLSERINE AND DIACYLGLYCEROL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ACTIVATION; MEMBRANES; SEQUENCE	The lipid activators of protein kinase C, phosphatidylserine and diacylglycerol, induce a reversible conformational change that exposes the auto-inhibitory pseudosubstrate domain of the enzyme. The pseudosubstrate domain of beta-II protein kinase C is cleaved after the first residue, arginine 19, by the endoproteinase Arg-C only when the kinase is bound to the activating lipid phosphatidylserine. Exposure of this residue is markedly enhanced by diacylglycerol. In contrast, the pseudosubstrate domain is not cleaved in the absence of lipids, when protein kinase C is bound to non-activating acidic lipids, when the kinase has autophosphorylated on the amino terminus, or after dilution of the activating lipids. This work reveals specificity in the interaction of protein kinase C with phosphatidylserine since only this phospholipid causes the specific conformational change detected in the regulatory domain of the enzyme, and demonstrates that allosteric regulators expose the intramolecular auto-inhibitory domain of a kinase.	INDIANA UNIV,DEPT CHEM,BLOOMINGTON,IN 47405	Indiana University System; Indiana University Bloomington					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043154, R37GM043154] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 43154] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES GFL, 1974, J BIOL CHEM, V249, P634; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BELL RM, 1991, J BIOL CHEM, V266, P4661; CHAKRAVARTHY BR, 1991, ANAL BIOCHEM, V196, P144, DOI 10.1016/0003-2697(91)90130-L; CORBIN JD, 1978, J BIOL CHEM, V253, P3997; FLINT AJ, 1990, SCIENCE, V249, P408, DOI 10.1126/science.2377895; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; KAIBUCHI K, 1989, J BIOL CHEM, V264, P13489; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; LEE MH, 1989, J BIOL CHEM, V264, P14797; LEE MH, 1991, BIOCHEMISTRY-US, V30, P1041, DOI 10.1021/bi00218a023; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; MAKOWSKE M, 1989, J BIOL CHEM, V264, P16155; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MOSIOR M, 1991, BIOPHYS J, V60, P149, DOI 10.1016/S0006-3495(91)82038-0; MURAKAMI K, 1986, J BIOL CHEM, V261, P5424; NEWTON AC, 1989, J BIOL CHEM, V264, P14909; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4667, DOI 10.1021/bi00134a019; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4661, DOI 10.1021/bi00134a018; PEARS CJ, 1990, EUR J BIOCHEM, V194, P89, DOI 10.1111/j.1432-1033.1990.tb19431.x; POEHLING HM, 1981, ELECTROPHORESIS, V2, P141, DOI 10.1002/elps.1150020304; PRICE DJ, 1991, J BIOL CHEM, V266, P16281; SCHAEFFER E, 1989, CELL, V57, P403, DOI 10.1016/0092-8674(89)90915-X; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; WALKER JM, 1988, J BIOL CHEM, V263, P4537	27	181	181	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15263	15266						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1639770				2022-12-25	WOS:A1992JG11300002
J	ROFF, CF; PASTUSZYN, A; STRAUSS, JF; BILLHEIMER, JT; VANIER, MT; BRADY, RO; SCALLEN, TJ; PENTCHEV, PG				ROFF, CF; PASTUSZYN, A; STRAUSS, JF; BILLHEIMER, JT; VANIER, MT; BRADY, RO; SCALLEN, TJ; PENTCHEV, PG			DEFICIENCIES IN SEX-REGULATED EXPRESSION AND LEVELS OF 2 HEPATIC STEROL CARRIER PROTEINS IN A MURINE MODEL OF NIEMANN-PICK TYPE-C DISEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; LIPID TRANSFER PROTEIN; TEMPERATURE-SENSITIVE DEFECTS; OVARY CELL MUTANTS; RAT-LIVER; CHOLESTEROL STORAGE; CULTURED FIBROBLASTS; ESTERIFICATION; SEQUENCE; DISORDER	Hepatic sterol carrier protein-2 (SCP2) and sterol carrier protein-X (SCP(x)) levels in normal and in mutant Niemann-Pick Type C mice were determined by immunoblotting with antiserum against rat SCP2. A 14-kDa protein (SCP2) Was detected in the cytosol fraction and a 58-kDa protein (SCP(x)) was found in both cytosolic and organellar fractions. Expression of hepatic SCP(x) protein was developmentally regulated in a sex-specific pattern. The amounts of organelle-associated SCP(x) increased 4-fold during sexual development of normal males but decreased dramatically during development of normal females. Levels of hepatic SCP2 increased much less dramatically during sexual maturation of normal males and females. Adult Niemann-Pick Type C mice were deficient in both hepatic SCP(x) and SCP2. The deficit in SCP(x) in affected males reflected a failure to increase hepatic SCP(x) levels during sexual maturation. In affected males SCP(x) remained at levels found in immature mice. Affected male and female mice were also unable to maintain levels of hepatic SCP2. The level of SCP2 was near normal in affected immature males and subnormal in affected immature females. During sexual maturation hepatic SCP2 declined in affected animals.	UNIV NEW MEXICO,SCH MED,DEPT BIOCHEM,ALBUQUERQUE,NM 87131; UNIV PENN,SCH MED,DEPT OBSTET & GYNECOL,PHILADELPHIA,PA 19104; DUPONT MERCK PHARMACEUT CO,WILMINGTON,DE 19880; FAC MED LYON SUD OULLINS,INSERM,U189,F-69921 OULLINS,FRANCE; FAC MED LYON SUD OULLINS,DEPT BIOCHEM,F-69921 OULLINS,FRANCE	University of New Mexico; University of Pennsylvania; DuPont; Institut National de la Sante et de la Recherche Medicale (Inserm)	ROFF, CF (corresponding author), NINCDS,DEV & METAB NEUROL BRANCH,BLDG 10,RM 3D-12,BETHESDA,MD 20892, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD006274] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK010628] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-06274] Funding Source: Medline; NIDDK NIH HHS [DK-10628] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAKER ME, 1991, DNA CELL BIOL, V10, P695, DOI 10.1089/dna.1991.10.695; BILLHEIMER JT, 1990, DNA CELL BIOL, V9, P159, DOI 10.1089/dna.1990.9.159; BILLHEIMER JT, 1990, SUBCELLULAR BIOCH, P301; BLANCHETTEMACKIE EJ, 1988, P NATL ACAD SCI USA, V85, P8022, DOI 10.1073/pnas.85.21.8022; BRADY RO, 1983, SPHINGOMYELIN LIPIDO, P831; BUTKO P, 1990, BIOCHEMISTRY-US, V29, P4070, DOI 10.1021/bi00469a007; CHANDERBHAN R, 1983, BIOCHEM BIOPH RES CO, V117, P702, DOI 10.1016/0006-291X(83)91654-6; CHANDERBHAN R, 1982, J BIOL CHEM, V257, P8928; CHANDERBHAN RF, 1986, ENDOCR RES, V12, P351, DOI 10.3109/07435808609035445; FUJIKI Y, 1989, J BIOCHEM, V106, P1126, DOI 10.1093/oxfordjournals.jbchem.a122977; GAVEY KL, 1981, J BIOL CHEM, V256, P2993; HE ZG, 1991, DNA CELL BIOL, V10, P559, DOI 10.1089/dna.1991.10.559; KELLER GA, 1989, J CELL BIOL, V108, P1353, DOI 10.1083/jcb.108.4.1353; KRUTH HS, 1986, J BIOL CHEM, V261, P6769; LISCUM L, 1989, J CELL BIOL, V108, P1625, DOI 10.1083/jcb.108.5.1625; LISCUM L, 1987, J BIOL CHEM, V262, P17002; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCLEAN MP, 1989, ENDOCRINOLOGY, V125, P1337, DOI 10.1210/endo-125-3-1337; MONCECCHI D, 1991, J BIOL CHEM, V266, P9885; MORI T, 1991, P NATL ACAD SCI USA, V88, P4338, DOI 10.1073/pnas.88.10.4338; MORRIS HR, 1988, BIOCHEM BIOPH RES CO, V154, P476, DOI 10.1016/0006-291X(88)90711-5; NOLAND BJ, 1980, J BIOL CHEM, V255, P4282; PENTCHEV PG, 1985, P NATL ACAD SCI USA, V82, P8247, DOI 10.1073/pnas.82.23.8247; PENTCHEV PG, 1986, J BIOL CHEM, V261, P6775; PENTCHEV PG, 1986, J BIOL CHEM, V261, P2772; PENTCHEV PG, 1987, FASEB J, V1, P40, DOI 10.1096/fasebj.1.1.3609608; PENTCHEV PG, 1984, J BIOL CHEM, V259, P5784; PENTCHEV PG, 1980, BIOCHIM BIOPHYS ACTA, V619, P669, DOI 10.1016/0005-2760(80)90116-2; Pentchev PG, 1980, 2ND INT S ENZ THER G, P225; RENNERT H, 1991, BIOCHEMISTRY-US, V30, P11280, DOI 10.1021/bi00111a013; ROFF CF, 1990, J CELL BIOL, V110, P1023, DOI 10.1083/jcb.110.4.1023; ROFF CF, 1986, J CELL BIOL, V103, P2283, DOI 10.1083/jcb.103.6.2283; ROME LH, 1979, CELL, V17, P143, DOI 10.1016/0092-8674(79)90302-7; SCALLEN TJ, 1985, CHEM PHYS LIPIDS, V38, P239, DOI 10.1016/0009-3084(85)90019-2; SEEDORF U, 1991, J BIOL CHEM, V266, P630; SOKOL J, 1988, J BIOL CHEM, V263, P3411; SOKOL J, 1988, BIOCHIM BIOPHYS ACTA, V263, P123; SUZUKI Y, 1990, CELL STRUCT FUNCT, V15, P301, DOI 10.1247/csf.15.301; TANAKA T, 1984, ENDOCRINOLOGY, V114, P533, DOI 10.1210/endo-114-2-533; TRZECIAK WH, 1987, J BIOL CHEM, V262, P3713; VAHOUNY GV, 1984, BIOCHEM BIOPH RES CO, V122, P509, DOI 10.1016/S0006-291X(84)80062-5; VAHOUNY GV, 1983, J BIOL CHEM, V258, P1731; VAHOUNY GV, 1987, ADV LIPID RES, V22, P83; VANAMERONGEN A, 1987, BIOCHIM BIOPHYS ACTA, V919, P149, DOI 10.1016/0005-2760(87)90201-3; VANDERKRIFT TP, 1985, BIOCHIM BIOPHYS ACTA, V812, P387, DOI 10.1016/0005-2736(85)90313-X; VANHEUSDEN GPH, 1985, BIOCHIM BIOPHYS ACTA, V846, P21, DOI 10.1016/0167-4889(85)90105-3; WANDERS RJA, 1988, J NEUROL SCI, V88, P1, DOI 10.1016/0022-510X(88)90203-1; YAMAMOTO R, 1991, P NATL ACAD SCI USA, V88, P463, DOI 10.1073/pnas.88.2.463	48	44	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15902	15908						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1639819				2022-12-25	WOS:A1992JG11300096
J	KUSSICK, SJ; COOPER, JA				KUSSICK, SJ; COOPER, JA			PHOSPHORYLATION AND REGULATORY EFFECTS OF THE CARBOXY TERMINUS OF A DROSOPHILA-SRC HOMOLOG	ONCOGENE			English	Article							ROUS-SARCOMA VIRUS; TYROSINE PHOSPHORYLATION; C-SRC; TRANSFORMING PROTEIN; CELL-TRANSFORMATION; NUCLEOTIDE-SEQUENCE; RETROVIRUS VECTORS; GENE-PRODUCT; PP60C-SRC; ACTIVATION	The kinase activities of the vertebrate src family members are repressed by phosphorylation of a tyrosine residue in the carboxy-terminal `tail' of these molecules. To explore whether the tail of an invertebrate src homolog might also serve a regulatory function, we examined the ability of the carboxy terminus of a Drosophila src homolog (p62D), which contains a tyrosine homologous to those in the vertebrate src family members, to regulate the following molecules in mammalian fibroblasts: (1) a chimeric protein, p60CD, containing the amino terminus and catalytic domains of chicken p60c-src joined to the C-terminus of p62D; and (2) full-length p62D itself. By a variety of criteria p60CD appears to be a partially, rather than fully, repressed form of p60c-src. Phosphopeptide mapping indicates that partial repression correlates with partial phosphorylation of the tyrosine in the p62D tail of the chimera. Phosphorylation of the tail may also regulate full-length p62D. Expression of p62D in fibroblasts does not affect cell morphology or the overall abundance of tyrosine-phosphorylated proteins. The molecule is phosphorylated at its C-terminal tyrosine (Tyr-547), but not at its in vitro autophosphorylation sites, suggesting that it is catalytically repressed in fibroblasts. Expression of a truncated p62D mutant lacking Tyr-547 is associated with a clear alteration in cellular morphology and a two- to threefold increase in cellular phosphotyrosine levels. These results suggest that phosphorylation of the C-terminal tyrosine of the tail of an invertebrate src-like kinase can repress the activity of adjacent catalytic domains.	UNIV WASHINGTON,SCH MED,FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98195	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	KUSSICK, SJ (corresponding author), UNIV WASHINGTON,SCH MED,DEPT PATHOL,1124 COLUMBIA ST,SEATTLE,WA 98195, USA.				NCI NIH HHS [CA-41072] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA041072, R37CA041072] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEEMON K, 1978, J VIROL, V28, P551, DOI 10.1128/JVI.28.2.551-566.1978; BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CARTWRIGHT CA, 1986, MOL CELL BIOL, V6, P1562, DOI 10.1128/MCB.6.5.1562; CHENG SH, 1988, MOL CELL BIOL, V8, P1736, DOI 10.1128/MCB.8.4.1736; COBB BS, 1991, MOL CELL BIOL, V11, P5832, DOI 10.1128/MCB.11.12.5832; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; COUSSENS PM, 1985, MOL CELL BIOL, V5, P2753, DOI 10.1128/MCB.5.10.2753; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; HARVEY R, 1989, MOL CELL BIOL, V9, P3647, DOI 10.1128/MCB.9.9.3647; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; HOFFMANN FM, 1983, CELL, V35, P393, DOI 10.1016/0092-8674(83)90172-1; IBA H, 1985, MOL CELL BIOL, V5, P1058, DOI 10.1128/MCB.5.5.1058; KAMPS MP, 1986, MOL CELL BIOL, V6, P751, DOI 10.1128/MCB.6.3.751; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; KUSICK SJ, 1991, NATO ASI SERIES H, V56, P295; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MACAULEY A, 1988, MOL CELL BIOL, V8, P3560, DOI 10.1128/MCB.8.8.3560; MACAULEY A, 1990, New Biologist, V2, P828; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MILLER AD, 1986, SOMAT CELL MOLEC GEN, V12, P175, DOI 10.1007/BF01560664; NEMETH SP, 1989, MOL CELL BIOL, V9, P1109, DOI 10.1128/MCB.9.3.1109; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; PARSONS SJ, 1986, J VIROL, V59, P755, DOI 10.1128/JVI.59.3.755-758.1986; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SCHWARTZ DE, 1983, CELL, V32, P853, DOI 10.1016/0092-8674(83)90071-5; SIMON MA, 1985, CELL, V42, P831, DOI 10.1016/0092-8674(85)90279-X; SMART JE, 1981, P NATL ACAD SCI-BIOL, V78, P6013, DOI 10.1073/pnas.78.10.6013; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; YACIUK P, 1986, MOL CELL BIOL, V6, P2807, DOI 10.1128/MCB.6.8.2807	38	7	7	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1992	7	8					1577	1586						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1630818				2022-12-25	WOS:A1992JE81300014
J	IYENGAR, V; ALBAUGH, GP; LOHANI, A; NAIR, PP				IYENGAR, V; ALBAUGH, GP; LOHANI, A; NAIR, PP			HUMAN STOOLS AS A SOURCE OF VIABLE COLONIC EPITHELIAL-CELLS	FASEB JOURNAL			English	Article						EPITHELIAL CELLS; HUMAN STOOLS; COUNTERCURRENT CENTRIFUGAL ELUTRIATION	RENEWAL; LOCALIZATION; CULTURE	Human stools consist of a mixture of undigested food residues, colonic microflora, and cellular components shed from the walls of the gastrointestinal tract. The cellular components are made up mostly of terminally differentiated colonic epithelial cells. Using a combination of Percoll density gradient centrifugation and countercurrent centrifugal elutriation, it is now possible to recover these cells as an enriched fraction from fresh human stools. Cells can be visualized on heat-fixed smears of the enriched fractions stained with modified Wright's stain. The enrichment process is optimized by following the segregation of eukaryotic cells as determined by an ELISA technique using monoclonal antibodies against human double-stranded DNA. This work, demonstrating the feasibility of isolating intact colonic cells from stools, has important applications as a noninvasive approach to the biology of exfoliated cells from the gastrointestinal tract.	USDA,BELTSVILLE HUMAN NUTR RES CTR,LIPID NUTR LAB,BLDG 308,BELTSVILLE,MD 20705; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT BIOCHEM,BALTIMORE,MD 21205	United States Department of Agriculture (USDA); Johns Hopkins University				Nair, Padmanabhan/0000-0002-8925-1193				ALBAUGH GP, 1989, J CELL BIOL, V107, pA575; CHANG WWL, 1971, AM J ANAT, V131, P73, DOI 10.1002/aja.1001310105; COLE JW, 1961, GASTROENTEROLOGY, V41, P122; EASTWOOD GL, 1977, GASTROENTEROLOGY, V72, P962; FARAJISHADAN F, 1989, ANAL BIOCHEM, V177, P259, DOI 10.1016/0003-2697(89)90049-3; GRIMES A, 1988, ANAL BIOCHEM, V172, P436, DOI 10.1016/0003-2697(88)90466-6; HAGEMANN RF, 1977, CELL TISSUE KINET, V10, P3, DOI 10.1111/j.1365-2184.1977.tb00278.x; HENRY JB, 1979, CLIN DIAGNOSIS MANAG, P788; HOLGERSSON J, 1988, BIOCHIMIE, V70, P1565, DOI 10.1016/0300-9084(88)90292-1; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; IYENGAR V, 1990, FASEB J, V4, pA1165; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LIPKIN M, 1963, J CLIN INVEST, V42, P767, DOI 10.1172/JCI104769; MACDONALD WC, 1964, GASTROENTEROLOGY, V46, P405; MAZUMDER A, 1978, J NATL CANCER I, V60, P915, DOI 10.1093/jnci/60.4.915; MESSIER B, 1960, AM J ANAT, V106, P247, DOI 10.1002/aja.1001060305; MOYER MP, 1984, SCIENCE, V224, P1445, DOI 10.1126/science.6328655; MOYER MP, 1983, P SOC EXP BIOL MED, V174, P12; MUKHERJEE A, 1981, CELL BIOL INT REP, V5, P409, DOI 10.1016/0309-1651(81)90011-4; PANT KD, 1987, NUCL MED BIOL, V14, P81, DOI 10.1016/0883-2897(87)90136-X; PATNAIK R, 1981, CELL DIFFER DEV, V10, P147, DOI 10.1016/0045-6039(81)90035-X; RADIO SJ, 1989, ARCH PATHOL LAB MED, V133, P333; SHORTER RG, 1964, AM J DIG DIS, V9, P760, DOI 10.1007/BF02231983; STEPHEN AM, 1980, NATURE, V284, P283, DOI 10.1038/284283a0; STRAGAND JJ, 1977, AM J CLIN NUTR, V30, P918, DOI 10.1093/ajcn/30.6.918; WILEY EL, AM J CLIN PATHOL, V76, P806	26	62	79	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1991	5	13					2856	2859		10.1096/fasebj.5.13.1655550	http://dx.doi.org/10.1096/fasebj.5.13.1655550			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GJ471	1655550				2022-12-25	WOS:A1991GJ47100015
J	GHOSH, G; BRUNIE, S; SCHULMAN, LH				GHOSH, G; BRUNIE, S; SCHULMAN, LH			TRANSITION-STATE STABILIZATION BY A PHYLOGENETICALLY CONSERVED TYROSINE RESIDUE IN METHIONYL-TRANSFER RNA-SYNTHETASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; AMINO-ACID-ACTIVATION; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; ENZYME; RESOLUTION; MECHANISM; INTERMEDIATE; RECOGNITION; LIGANDS	The crystal structure of a fully biologically active monomeric form of Escherichia coli methionyl-tRNA synthetase (MetRS) complexed with ATP has recently been reported (Brunie, S., Zelwer, C., and Risler, J.-L., (1990) J. Mol. Biol. 216, 411-424), revealing details of the active site of the enzyme, including the location of amino acid residues potentially involved in substrate binding. In the present paper, the role of 3 active site residues in interaction with methionine, ATP, and tRNA(fMet) and in catalysis of methionyl-adenylate has been explored using site-directed mutagenesis. Lys142 is located near the ribose of ATP in the MetRS.ATP cocrystal. Mutation of this residue to Ala caused a 5-fold decrease in k(cat)/K(m) for ATP-PP(i) exchange, indicating some contribution of the lysine side chain to the specificity of the enzyme. Mutation of Tyr359 to Ala produced a 14-fold increase in the K(m) for ATP with only a small (2-3-fold) change in the other kinetic parameters, indicating that the major role of this residue is in formation of the initial complex with ATP and/or in stabilization of the methionyl-adenylate reaction intermediate. Mutation of the adjacent residue Tyr358 to Ala had no effect on the K(m) values for methionine or ATP but produced nearly a 2000-fold decrease in the rate of ATP-PP(i) exchange. This mutation also dramatically reduced the rate of pyrophosphorolysis of the isolated MetRS.Met-AMP complex on addition of pyrophosphate without increasing the K(m) for PP(i). None of the mutations affected the K(m) for tRNA(fMet) in the aminoacylation reaction. The results suggest that Tyr358 may enhance the rate of methionyl-adenylate formation by binding to the alpha-phosphate of ATP in the transition state. Interaction of Tyr358 and Tyr359 with ATP during the course of the reaction requires a significant change in the conformation of this region of the active site compared to the structure found in the MetRS.ATP complex. Such a shift is consistent with an induced-fit mechanism for methionine activation. Primary sequence comparisons of methionine-specific enzymes from yeast and bacterial sources reveals that Tyr358 is conserved in all of the known MetRS sequences.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT DEV BIOL & CANC,BRONX,NY 10461; ECOLE POLYTECH,CNRS,URA 240,BIOCHIM LAB,F-91128 PALAISEAU,FRANCE	Yeshiva University; Albert Einstein College of Medicine; Centre National de la Recherche Scientifique (CNRS); Institut Polytechnique de Paris					NCI NIH HHS [P30CA13330] Funding Source: Medline; NIGMS NIH HHS [GM16995] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM016995] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARKER DG, 1982, EUR J BIOCHEM, V127, P449; BARKER DG, 1982, FEBS LETT, V145, P191, DOI 10.1016/0014-5793(82)80165-8; BHAT TN, 1982, J MOL BIOL, V158, P699, DOI 10.1016/0022-2836(82)90255-8; BLANQUET S, 1972, EUR J BIOCHEM, V24, P461, DOI 10.1111/j.1432-1033.1972.tb19707.x; BLANQUET S, 1975, J MOL BIOL, V94, P1, DOI 10.1016/0022-2836(75)90401-5; BRICK P, 1989, J MOL BIOL, V208, P83, DOI 10.1016/0022-2836(89)90090-9; BRICK P, 1987, J MOL BIOL, V194, P287, DOI 10.1016/0022-2836(87)90376-7; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNIE S, 1990, J MOL BIOL, V216, P411, DOI 10.1016/S0022-2836(05)80331-6; BURBAUM JJ, 1990, PROTEINS, V7, P99, DOI 10.1002/prot.340070202; CASSIO D, 1971, EUR J BIOCHEM, V20, P283, DOI 10.1111/j.1432-1033.1971.tb01393.x; DARDEL F, 1984, J BACTERIOL, V160, P1115, DOI 10.1128/JB.160.3.1115-1122.1984; ERIANI G, 1991, NUCLEIC ACIDS RES, V19, P265, DOI 10.1093/nar/19.2.265; FASIOLO F, 1985, J BIOL CHEM, V260, P5571; FAYAT G, 1977, BIOCHEMISTRY-US, V16, P2570, DOI 10.1021/bi00630a039; Fersht A, 1985, ENZYME STRUCTURE MEC, P104; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; FERSHT AR, 1988, BIOCHEMISTRY-US, V27, P1581, DOI 10.1021/bi00405a028; FERSHT AR, 1987, BIOCHEMISTRY-US, V26, P8031, DOI 10.1021/bi00399a001; GHOSH G, 1990, BIOCHEMISTRY-US, V29, P2220, DOI 10.1021/bi00461a003; HENDRICKSON WA, 1980, COMPUTING CRYSTALLOG; HOU YM, 1991, P NATL ACAD SCI USA, V88, P976, DOI 10.1073/pnas.88.3.976; HOUNTONDJI C, 1985, BIOCHEMISTRY-US, V24, P1175, DOI 10.1021/bi00326a018; HOUNTONDJI C, 1986, BIOCHIMIE, V68, P1071, DOI 10.1016/S0300-9084(86)80181-X; HYAFIL F, 1976, BIOCHEMISTRY-US, V15, P3678, DOI 10.1021/bi00662a006; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANGDON SP, 1979, NATURE, V281, P320, DOI 10.1038/281320a0; LEATHERBARROW RJ, 1987, BIOCHEMISTRY-US, V26, P8524, DOI 10.1021/bi00400a005; MECHULAM Y, 1991, J MOL BIOL, V217, P465, DOI 10.1016/0022-2836(91)90750-Z; NUREKI O, 1991, J BIOL CHEM, V266, P3268; PERONA JJ, 1991, P NATL ACAD SCI USA, V88, P2903, DOI 10.1073/pnas.88.7.2903; RISLER JL, 1981, NATURE, V292, P383; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; SCHULMAN LH, 1983, P NATL ACAD SCI-BIOL, V80, P6755, DOI 10.1073/pnas.80.22.6755; Soll D., 1974, ENZYMES, V10, P489; SOMERVILLE CR, 1977, J MOL BIOL, V111, P77, DOI 10.1016/S0022-2836(77)80133-2; TZAGOLOFF A, 1989, EUR J BIOCHEM, V179, P365, DOI 10.1111/j.1432-1033.1989.tb14562.x; WALLER JP, 1971, FEBS LETT, V16, P186, DOI 10.1016/0014-5793(71)80128-X; WELLS TNC, 1989, BIOCHEMISTRY-US, V28, P9201, DOI 10.1021/bi00449a036; WILKINSON AJ, 1983, BIOCHEMISTRY-US, V22, P3581, DOI 10.1021/bi00284a007; ZELWER C, 1982, J MOL BIOL, V155, P63, DOI 10.1016/0022-2836(82)90492-2	41	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17136	17141						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1654323				2022-12-25	WOS:A1991GF44500028
J	LANDGRAF, W; REGULLA, S; MEYER, HE; HOFMANN, F				LANDGRAF, W; REGULLA, S; MEYER, HE; HOFMANN, F			OXIDATION OF CYSTEINES ACTIVATES CGMP-DEPENDENT PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; BINDING-SITES; BOVINE HEART; CYCLIC-GMP; CAMP; AUTOPHOSPHORYLATION; LUNG; IDENTIFICATION; MECHANISM; AFFINITY	The functional significance of the oxidation/reduction state of sulfhydryl groups of cGMP-dependent protein kinase (cGMP kinase) was studied at 30-degrees-C using different metal ions as oxidizing agents. Mn2+, Zn2+, Fe2+, Ni2+, and Co2+ failed to activate cGMP kinase, whereas Cu2+, Cu+, Fe3+, Hg2+, and Ag+ activated cGMP kinase by oxidation with an activity ratio (-cGMP/+cGMP) of about 0.7. The activation was not caused by degradation of the enzyme to a cGMP-independent constitutively active form. Reduction of the Cu2+-activated and gel-filtered enzyme with dithiothreitol lowered the activity ratio in the absence of cGMP to 0.17. Oxidation did not change the kinetic and binding parameters of cGMP kinase significantly but reduced the number of titratable sulfhydryl groups from 9.5 +/- 0.7 to 6.0 +/- 0.4 cysteines/75-kDa subunit. The free cysteinyl residues of the native and Cu2+-oxidized cGMP kinase were labeled with 4-dimethylaminoazobenzene-4'-iodoacetamide or N-(7-dimethylamino-4-methyl-3-coumarinyl)maleimide. Tryptic peptides of the labeled proteins were isolated and sequenced. The cysteinyl residues oxidized by Cu2+ were identified as disulfide bonds between Cys-117 and Cys-195 and Cys-312 and Cys-518, respectively. Cu2+ activation of cGMP kinase was prevented by mild carboxymethylation of the reduced enzyme with iodoacetamide, which apparently modified these four cysteinyl groups. The results show that cGMP kinase is activated by the formation of at least one intrachain disulfide bridge.	RUHR UNIV BOCHUM,BIOCHEM SUPRAMOLEK SYST ABT,W-4630 BOCHUM,GERMANY	Ruhr University Bochum	LANDGRAF, W (corresponding author), TECH UNIV MUNICH,INST PHARMACOL & TOXIKOL,W-8000 MUNICH 40,GERMANY.		Landgraf, Wolfgang/AAD-2624-2019	Landgraf, Wolfgang/0000-0001-5321-7164				AITKEN A, 1984, BIOCHIM BIOPHYS ACTA, V790, P219, DOI 10.1016/0167-4838(84)90025-6; ATHERTON E, 1983, J CHEM SOC CHEM COMM, V19, P1060; BHATNAGAR D, 1985, BIOCHEMISTRY-US, V24, P1122, DOI 10.1021/bi00326a009; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAMSON HN, 1982, J BIOL CHEM, V257, P575; CHANG JY, 1983, BIOCHEM J, V211, P163, DOI 10.1042/bj2110163; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; CORBIN JD, 1983, J BIOL CHEM, V258, P1391; DOSKELAND SO, 1987, J BIOL CHEM, V262, P3534; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FIRST EA, 1989, BIOCHEMISTRY-US, V28, P3598, DOI 10.1021/bi00434a067; FIRST EA, 1988, J BIOL CHEM, V263, P5176; FOSTER JL, 1981, J BIOL CHEM, V256, P5029; GILL GN, 1977, J BIOL CHEM, V252, P6443; GOPALAKRISHNA R, 1989, P NATL ACAD SCI USA, V86, P6758, DOI 10.1073/pnas.86.17.6758; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEIL WG, 1987, EUR J BIOCHEM, V168, P117, DOI 10.1111/j.1432-1033.1987.tb13395.x; HOFMANN F, 1985, EUR J BIOCHEM, V147, P361, DOI 10.1111/j.1432-1033.1985.tb08758.x; HOFMANN F, 1983, EUR J BIOCHEM, V130, P599, DOI 10.1111/j.1432-1033.1983.tb07191.x; HOFMANN F, 1978, BIOCHEM BIOPH RES CO, V49, P1100; JIMENEZ JS, 1982, BIOCHEMISTRY-US, V21, P1623, DOI 10.1021/bi00536a024; LANDGRAF W, 1986, EUR J BIOCHEM, V154, P113, DOI 10.1111/j.1432-1033.1986.tb09365.x; LANDGRAF W, 1990, BIOCHEMISTRY-US, V29, P9921, DOI 10.1021/bi00494a024; LANDGRAF W, 1989, EUR J BIOCHEM, V181, P643, DOI 10.1111/j.1432-1033.1989.tb14771.x; LANDGRAF W, 1991, N-S ARCH PHARMACOL, V343, pR35; LINCOLN TM, 1978, J BIOL CHEM, V253, P6002; MONKEN CE, 1980, J BIOL CHEM, V255, P7067; MUNSON PJ, 1983, METHOD ENZYMOL, V92, P543; PETERS KA, 1977, BIOCHEMISTRY-US, V16, P5691, DOI 10.1021/bi00645a007; PURI RN, 1985, BIOCHEMISTRY-US, V24, P6508, DOI 10.1021/bi00344a030; SWIDEREK K, 1988, EUR J BIOCHEM, V176, P335, DOI 10.1111/j.1432-1033.1988.tb14286.x; TAKAI Y, 1975, J BIOL CHEM, V250, P4690; TAKAI Y, 1976, J BIOL CHEM, V251, P1481; TAKIO K, 1983, J BIOL CHEM, V258, P5531; TAKIO K, 1984, BIOCHEMISTRY-US, V23, P4207, DOI 10.1021/bi00313a030; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; WEBER IT, 1989, BIOCHEMISTRY-US, V28, P6122, DOI 10.1021/bi00440a059; WERNET W, 1989, FEBS LETT, V251, P191, DOI 10.1016/0014-5793(89)81453-X; WOLFE L, 1989, J BIOL CHEM, V264, P7734; WOLFE L, 1989, J BIOL CHEM, V264, P4157; YAMAMOTO K, 1977, ANAL BIOCHEM, V79, P83, DOI 10.1016/0003-2697(77)90381-5	41	56	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16305	16311						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1653229				2022-12-25	WOS:A1991GD63500013
J	NISTER, M; CLAESSONWELSH, L; ERIKSSON, A; HELDIN, CH; WESTERMARK, B				NISTER, M; CLAESSONWELSH, L; ERIKSSON, A; HELDIN, CH; WESTERMARK, B			DIFFERENTIAL EXPRESSION OF PLATELET-DERIVED GROWTH-FACTOR RECEPTORS IN HUMAN-MALIGNANT GLIOMA CELL-LINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN SARCOMA-VIRUS; DIFFERENT DIMERIC FORMS; A-TYPE RECEPTOR; B-TYPE RECEPTOR; PDGF-RECEPTOR; HUMAN-FIBROBLASTS; MESSENGER-RNAS; CDNA CLONING; GENES; PROTEIN	Glioma cells in culture express platelet-derived growth factor (PDGF) A- and B-chains and secrete PDGF-like activity that is mainly PDGF-AA. In this work, we show that the PDGF alpha- and beta-receptors are independently expressed in human malignant glioma cells. We also define three different receptor phenotypes that are related to the morphology of glioma cells: cells with only alpha-receptors, only beta-receptors, or with both types of receptors. By the help of Northern blot analyses, I-125-PDGF-binding experiments, and immunoprecipitations the receptors are shown to be structurally normal PDGF receptors, except for minor variations in size that probably are due to differences in glycosylation. PDGF-BB induces DNA synthesis in cells of all three receptor phenotypes, whereas PDGF-AA or PDGF-AB has this effect only on cells with alpha- or with alpha- and beta-receptors. I-125-PDGF-AB binds with high affinity and down-regulates beta-receptors only in cells where alpha-receptors are present in addition to beta-receptors. Thus, the different functional capacities of PDGF isoforms on glioma cells fit with their known receptor-binding specificities and are compatible with the hypothesis that the isoforms act by inducing dimeric receptor complexes. When data on PDGF A- and B-chains, as well as alpha- and beta-receptor expression are compiled and the pattern of receptor binding specificity is taken into account, the majority of glioma cell lines are found to have a phenotype that makes autocrine stimulation possible.	LUDWIG INST CANC RES,CTR BIOMED,S-75124 UPPSALA,SWEDEN	Ludwig Institute for Cancer Research	NISTER, M (corresponding author), UNIV HOSP UPPSALA,DEPT PATHOL,S-75185 UPPSALA,SWEDEN.							BETSHOLTZ C, 1984, J CELL PHYSIOL, V118, P203, DOI 10.1002/jcp.1041180213; BLOCK LH, 1989, P NATL ACAD SCI USA, V86, P2388, DOI 10.1073/pnas.86.7.2388; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BONGCAMRUDLOFF E, 1991, CANCER RES, V51, P1553; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; CLAESSONWELSH L, 1989, J BIOL CHEM, V264, P1742; DEINHARDT F, 1980, VIRAL ONCOLOGY, P357; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; EVA A, 1982, NATURE, V295, P116, DOI 10.1038/295116a0; GRONWALD RGK, 1988, P NATL ACAD SCI USA, V85, P3435, DOI 10.1073/pnas.85.10.3435; HAMMACHER A, 1989, BIOCHEM J, V264, P15, DOI 10.1042/bj2640015; HAMMACHER A, 1988, J BIOL CHEM, V263, P16493; HAMMACHER A, 1988, EUR J BIOCHEM, V176, P179, DOI 10.1111/j.1432-1033.1988.tb14266.x; HAMMACHER A, 1989, EMBO J, V8, P2489, DOI 10.1002/j.1460-2075.1989.tb08385.x; HARSH GR, 1990, J NEURO-ONCOL, V8, P1; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HELDIN CH, 1989, EUR J BIOCHEM, V184, P487, DOI 10.1111/j.1432-1033.1989.tb15041.x; HELDIN CH, 1990, GROWTH FACTORS DIFFE, P267; HELDIN NE, 1988, P NATL ACAD SCI USA, V85, P9302, DOI 10.1073/pnas.85.23.9302; HELDIN P, 1991, EXP CELL RES, V193, P364, DOI 10.1016/0014-4827(91)90108-7; HOSANG M, 1989, J CELL PHYSIOL, V140, P558, DOI 10.1002/jcp.1041400322; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; JOHNSSON A, 1985, NATURE, V317, P438, DOI 10.1038/317438a0; KAZLAUSKAS A, 1988, EMBO J, V7, P3727, DOI 10.1002/j.1460-2075.1988.tb03256.x; LEVEEN P, 1990, INT J CANCER, V46, P1066, DOI 10.1002/ijc.2910460620; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MATSUI T, 1989, P NATL ACAD SCI USA, V86, P8314, DOI 10.1073/pnas.86.21.8314; MAXWELL M, 1990, INT J CANCER, V46, P16, DOI 10.1002/ijc.2910460106; NISTER M, 1988, CANCER RES, V48, P3910; NISTER M, 1987, CANCER RES, V47, P4953; NISTER M, 1986, CANCER RES, V46, P332; NISTER M, 1988, CELL, V52, P791, DOI 10.1016/0092-8674(88)90421-7; NISTER M, 1984, P NATL ACAD SCI-BIOL, V81, P926, DOI 10.1073/pnas.81.3.926; Ostman A, 1989, GROWTH FACTORS, V1, P271, DOI 10.3109/08977198908998003; PRINGLE N, 1989, EMBO J, V8, P1049, DOI 10.1002/j.1460-2075.1989.tb03472.x; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SIEGBAHN A, 1990, J CLIN INVEST, V85, P916, DOI 10.1172/JCI114519; SMITS A, 1991, IN PRESS P NATL ACAD; Smits A, 1989, GROWTH FACTORS, V2, P1, DOI 10.3109/08977198909069076; WANG JL, 1990, INT J CANCER, V46, P772, DOI 10.1002/ijc.2910460504; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; Westermark B, 1989, Prog Growth Factor Res, V1, P253, DOI 10.1016/0955-2235(89)90014-8; WESTERMARK B, 1990, P NATL ACAD SCI USA, V87, P128, DOI 10.1073/pnas.87.1.128; YARDEN Y, 1986, NATURE, V323, P266	48	169	173	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16755	16763						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1653246				2022-12-25	WOS:A1991GD63500081
J	MAST, AE; ENGHILD, JJ; NAGASE, H; SUZUKI, K; PIZZO, SV; SALVESEN, G				MAST, AE; ENGHILD, JJ; NAGASE, H; SUZUKI, K; PIZZO, SV; SALVESEN, G			KINETICS AND PHYSIOLOGICAL RELEVANCE OF THE INACTIVATION OF ALPHA-1-PROTEINASE INHIBITOR, ALPHA-1-ANTICHYMOTRYPSIN, AND ANTITHROMBIN-III BY MATRIX METALLOPROTEINASES-1 (TISSUE COLLAGENASE), METALLOPROTEINASES-2 (72-KDA GELATINASE TYPE-IV COLLAGENASE), AND METALLOPROTEINASES-3 (STROMELYSIN)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONNECTIVE-TISSUE; HUMAN-PLASMA; HUMAN ALPHA-2-MACROGLOBULIN; CLEAVAGE SITES; REACTIVE SITE; PROTEOLYTIC INACTIVATION; BONE METALLOPROTEINASE; FIBROBLAST COLLAGENASE; PROTEINASE-INHIBITORS; SYNOVIAL FIBROBLASTS	Serpins encompass a superfamily of proteinase inhibitors that regulate many of the serine proteinases involved in inflammation and hemostasis. In vitro, many serpins are catalytically inactivated by proteinases that they do not inhibit, leading to the concept of proteolytic down-regulation of serpin inhibitory capacity. The extent to which down-regulation of serpin activity occurs in vivo is debated, since little is known of the rates at which the process occurs. To address this debate, we have measured the rates of inactivation of three serpins, alpha-1-proteinase inhibitor (alpha-1-PI), alpha-1-antichymotrypsin (alpha-1-ACT), and antithrombin III (ATIII), by three human matrix metalloproteinases (MMPs -1, -2, and -3) thought to be involved in tissue destruction and repair. Our object was to establish a working kinetic model which can be used to predict whether serpin inactivation by these proteinases is likely to occur in vivo. We determined the rates of inactivation of these three serpins by each of the MMPs and compared these to rates of inhibition of the MMPs by an endogenous inhibitor, alpha-2-macroglobulin. An equation designed to predict the extent of substrate hydrolyzed by an enzyme in the presence of an enzyme inhibitor gave the following predictions of the inactivation in vivo: (i) ATIII is unlikely to be inactivated by the MMPs. (ii) MMP-2 (72-kDa gelatinase/type IV collagenase) is unlikely to inactivate any of the three serpins. (iii) MMP-1 (tissue collagenase) will inactivate alpha-1-PI and alpha-1-ACT only when its concentration saturates that of its controlling inhibitors. (iv) MMP-3 (stromelysin) may inactivate small amounts of alpha-1-PI and more significant amounts of alpha-1-ACT, even in the presence of its controlling inhibitors. Any physiologic or pathologic inactivation of these serpins by these MMPs that occurs in vivo will probably be due to MMP-3, and will likely only take place in tissues and inflammatory loci where the concentration of MMP inhibitors is depressed.	DUKE UNIV,MED CTR,DEPT PATHOL,BOX 3712,DURHAM,NC 27710; UNIV KANSAS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,KANSAS CITY,KS 66103	Duke University; University of Kansas; University of Kansas Medical Center				Enghild, Jan Johannes/0000-0001-9292-9172	NHLBI NIH HHS [HL-24066] Funding Source: Medline; NIAMS NIH HHS [AR-39189] Funding Source: Medline; NIGMS NIH HHS [GM-38860] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024066, R37HL024066] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039189] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038860] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANDA MJ, 1988, J BIOL CHEM, V263, P4481; BANDA MJ, 1987, J CLIN INVEST, V79, P1314, DOI 10.1172/JCI112955; BIETH JG, 1984, BIOCHEM MED METAB B, V32, P387, DOI 10.1016/0006-2944(84)90046-2; BOONE TC, 1990, P NATL ACAD SCI USA, V87, P2800, DOI 10.1073/pnas.87.7.2800; BROWER MS, 1982, J BIOL CHEM, V257, P9849; BURY AF, 1981, J CHROMATOGR, V213, P491, DOI 10.1016/S0021-9673(00)80500-2; CARRELL R, 1985, TRENDS BIOCHEM SCI, V10, P20, DOI 10.1016/0968-0004(85)90011-8; Carrell R.W, 1986, PROTEINASE INHIBITOR, P403; CARRELL RW, 1985, NATURE, V317, P730, DOI 10.1038/317730a0; Cawston T.E., 1986, PROTEINASE INHIBITOR, P589; CAWSTON TE, 1990, BIOCHEM J, V269, P183, DOI 10.1042/bj2690183; CAWSTON TE, 1986, FEBS LETT, V209, P9, DOI 10.1016/0014-5793(86)81074-2; CHASE T, 1970, METHOD ENZYMOL, V19, P20; CHIN JR, 1985, J BIOL CHEM, V260, P2367; DESROCHERS PE, 1988, J CLIN INVEST, V81, P1646, DOI 10.1172/JCI113500; ENGHILD JJ, 1989, J BIOL CHEM, V264, P8779; Fersht A., 1985, ENZYME STRUCTURE MEC, P99; GALLOWAY WA, 1983, BIOCHEM J, V209, P741, DOI 10.1042/bj2090741; GEORGE PM, 1984, LANCET, V2, P1426; HASTY KA, 1990, J BIOL CHEM, V265, P11421; HERRON GS, 1986, J BIOL CHEM, V261, P2814; HIBBS MS, 1985, J BIOL CHEM, V260, P2493; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; IMBER MJ, 1981, J BIOL CHEM, V256, P8134; ITO A, 1988, ARCH BIOCHEM BIOPHYS, V267, P211, DOI 10.1016/0003-9861(88)90025-2; JANOFF A, 1985, AM REV RESPIR DIS, V132, P417; JOCHUM M, 1981, H-S Z PHYSIOL CHEM, V362, P103, DOI 10.1515/bchm2.1981.362.1.103; JOHNSON D, 1979, J BIOL CHEM, V254, P4022; JOHNSON DA, 1986, J BIOL CHEM, V261, P4748; JORDAN RE, 1989, J BIOL CHEM, V264, P10493; KNAUPER V, 1990, FEBS LETT, V263, P355, DOI 10.1016/0014-5793(90)81412-H; KRESS LF, 1979, J BIOL CHEM, V254, P5317; MAST AE, 1991, BIOCHEMISTRY-US, V320, P1723; MORII M, 1983, J BIOL CHEM, V258, P2749; MORII M, 1983, BIOCHEM BIOPH RES CO, V111, P438, DOI 10.1016/0006-291X(83)90325-X; MURPHY G, 1985, BIOESSAYS, V2, P55, DOI 10.1002/bies.950020204; MURPHY G, 1985, BIOCHIM BIOPHYS ACTA, V831, P49, DOI 10.1016/0167-4838(85)90148-7; NAGASE H, 1990, BIOCHEMISTRY-US, V29, P5783, DOI 10.1021/bi00476a020; OKADA Y, 1990, EUR J BIOCHEM, V194, P721, DOI 10.1111/j.1432-1033.1990.tb19462.x; OKADA Y, 1986, J BIOL CHEM, V261, P14245; OKADA Y, 1988, BIOCH J TOKYO, V254, P7314; PANNELL R, 1974, BIOCHEMISTRY-US, V13, P5439, DOI 10.1021/bi00723a031; PETERSEN TE, 1978, PHYSL INHIBITORS BLO, P43; REDDY VY, 1989, J BIOL CHEM, V264, P13801; SALVESEN G, 1989, ELASTIN ELASTASES, P95; Salvesen G, 1989, PROTEOLYTIC ENZYMES, P83; SALVESEN GS, 1985, J BIOL CHEM, V260, P2432; SAUS J, 1988, J BIOL CHEM, V263, P6742; SCHMID TM, 1986, J BIOL CHEM, V261, P4184; SCHWARTZ RS, 1908, AM J MED S3B, V87, P53; SELTZER JL, 1989, J BIOL CHEM, V264, P3822; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P393; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; SUZUKI K, 1990, BIOCHEMISTRY-US, V29, P10261, DOI 10.1021/bi00496a016; THALER E, 1975, BRIT J HAEMATOL, V31, P233, DOI 10.1111/j.1365-2141.1975.tb00853.x; TIAN WX, 1982, BIOCHEMISTRY-US, V21, P1028, DOI 10.1021/bi00534a031; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; VISSERS MCM, 1988, J CLIN INVEST, V82, P706, DOI 10.1172/JCI113651; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WELGUS HG, 1981, J BIOL CHEM, V256, P9511; Werb Z., 1989, TXB RHEUMATOLOGY, P300; WEWERS MD, 1987, NEW ENGL J MED, V316, P1055, DOI 10.1056/NEJM198704233161704; WINYARD PG, 1991, FEBS LETT, V279, P91, DOI 10.1016/0014-5793(91)80258-5	63	139	141	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					15810	15816						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1651920				2022-12-25	WOS:A1991GB97700045
J	KESSLER, M; BENASHER, E; RESENKOV, O; HATINI, V; BENGAL, E; ALONI, Y				KESSLER, M; BENASHER, E; RESENKOV, O; HATINI, V; BENGAL, E; ALONI, Y			A 21-BASE PAIR DNA FRAGMENT DIRECTS TRANSCRIPTION ATTENUATION WITHIN THE SIMIAN VIRUS-40 LATE LEADER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; ADENOSINE-DEAMINASE GENE; C-MYC GENE; PREMATURE TERMINATION; MESSENGER-RNA; SEQUENCE REQUIREMENTS; TRYPTOPHAN OPERON; ESCHERICHIA-COLI; ANIMAL VIRUSES; EXPRESSION	Transcription through the late simian virus 40 (SV40) sequences have been examined in vivo and in vitro for identifying attenuation signals involved in regulating late RNA transcription. In addition to the previously identified and characterized attenuator 1 situated 93 nucleotides downstream from the major late transcription start site, a second attenuator, attenuator 2, situated 55 nucleotides downstream from it, has been identified. Attenuated transcripts mapping to this site have been observed in vivo as well as in several different in vitro transcription systems. The signal inducing transcription attenuation has been localized to a 21-base pair DNA fragment and has been found to function independently of the promoter directing transcription or its distance from the transcription start site. Furthermore, this attenuator, unlike that preceding it, does not include a region of dyad symmetry or A + T-rich sequences. Also, similar to the adenovirus 2 attenuator, but in contrast to SV40 attenuator 1, the block to elongation at the SV40 attenuator 2 appears to be modulated by the general transcription factors. It is concluded that in SV40 there are at least two types of attenuators: one that is dependent on RNA secondary structure and a second that is sequence specific and is modulated, at least in part, by the general transcription factors.			KESSLER, M (corresponding author), WEIZMANN INST SCI,DEPT MOLEC GENET & VIROL,IL-76100 REHOVOT,ISRAEL.			Hatini, Victor/0000-0003-4264-574X	NATIONAL CANCER INSTITUTE [R01CA014995] Funding Source: NIH RePORTER; NCI NIH HHS [CA14995] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALONI Y, 1985, CRC CR REV BIOCH MOL, V18, P327, DOI 10.3109/10409238509086785; BENASHER E, 1984, J VIROL, V52, P266, DOI 10.1128/JVI.52.1.266-276.1984; BENDER TP, 1987, SCIENCE, V237, P1473, DOI 10.1126/science.3498214; BENGAL E, 1989, J BIOL CHEM, V264, P18926; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; BENGAL E, 1989, J BIOL CHEM, V264, P9791; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; COLLINS PL, 1987, P NATL ACAD SCI USA, V84, P5134, DOI 10.1073/pnas.84.15.5134; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; England T E, 1980, Methods Enzymol, V65, P65; FLORES O, 1990, J BIOL CHEM, V265, P5629; FORT P, 1987, NUCLEIC ACIDS RES, V15, P5657, DOI 10.1093/nar/15.14.5657; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; HAY N, 1982, CELL, V29, P183, DOI 10.1016/0092-8674(82)90102-7; HAY N, 1984, NUCLEIC ACIDS RES, V121, P1401; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; KERPPOLA TK, 1990, BIOCHEMISTRY-US, V29, P269, DOI 10.1021/bi00453a037; KESSLER M, 1989, J BIOL CHEM, V264, P9785; KESSLER M, 1984, J VIROL, V52, P277, DOI 10.1128/JVI.52.1.277-280.1984; LAU LF, 1982, P NATL ACAD SCI USA, V84, P8306; LAUB O, 1976, VIROLOGY, V75, P346, DOI 10.1016/0042-6822(76)90033-7; LAUB O, 1975, J VIROL, V16, P1171, DOI 10.1128/JVI.16.5.1171-1183.1975; LEBOWITZ P, 1979, CURR TOP MICROBIOL I, V87, P42; MAA MC, 1990, J BIOL CHEM, V265, P12513; MADERIOUS A, 1984, P NATL ACAD SCI-BIOL, V81, P5931, DOI 10.1073/pnas.81.19.5931; MANLEY JL, 1984, TRANSCRIPTION TRANSL, P71; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MOK M, 1984, MOL CELL BIOL, V4, P2031, DOI 10.1128/MCB.4.10.2031; MORGAN WD, 1983, J BIOL CHEM, V258, P9553; PIATAK M, 1981, J MOL BIOL, V153, P589, DOI 10.1016/0022-2836(81)90409-5; PLATT T, 1981, CELL, V24, P10, DOI 10.1016/0092-8674(81)90496-7; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; RAMAMURTHY V, 1990, MOL CELL BIOL, V10, P1484, DOI 10.1128/MCB.10.4.1484; RAPPAPORT J, 1987, J BIOL CHEM, V262, P5227; REINBERG D, 1987, J BIOL CHEM, V262, P3322; RESNEKOV O, 1989, J BIOL CHEM, V264, P9953; RESNEKOV O, 1988, GENE, V72, P91, DOI 10.1016/0378-1119(88)90130-8; RESNEKOV O, 1989, P NATL ACAD SCI USA, V86, P12, DOI 10.1073/pnas.86.1.12; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; Seiberg M, 1987, Virus Genes, V1, P97; SKERNES WC, 1988, J MOL BIOL, V203, P153; SKOLNIKDAVID H, 1983, EMBO J, V2, P179, DOI 10.1002/j.1460-2075.1983.tb01402.x; SKOLNIKDAVID H, 1984, THESIS WEIZMANN I SC, P1; TOOHEY MG, 1989, GENE DEV, V3, P265, DOI 10.1101/gad.3.3.265; WU AM, 1981, P NATL ACAD SCI-BIOL, V78, P2913, DOI 10.1073/pnas.78.5.2913; YANOFSKY C, 1981, NATURE, V289, P751, DOI 10.1038/289751a0	47	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1991	266	20					13019	13027						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FX132	1649173				2022-12-25	WOS:A1991FX13200037
J	LEVINE, BA; TAVARE, JM; ALEJOS, E; CLACK, B; SAYED, N; ELLIS, L				LEVINE, BA; TAVARE, JM; ALEJOS, E; CLACK, B; SAYED, N; ELLIS, L			AUTOPHOSPHORYLATION OF SOLUBLE INSULIN-RECEPTOR PROTEIN-TYROSINE KINASES - H-1-NMR SPECTRAL CHANGES OBSERVED DURING PHOSPHORYLATION OF MOBILE TYROSINE RESIDUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC DOMAIN; CELLS; IDENTIFICATION; EXPRESSION; SITES	Autophosphorylation of a soluble approximately 48-kDa derivative of the insulin receptor protein-tyrosine kinase occurs at multiple tyrosine residues (analogous to tyrosines 1158, 1162, and 1163 in the kinase homology region of the native receptor and tyrosines 1328 and 1334 in the carboxyl-terminal tail) and is accompanied by an increase in the specific activity of the enzyme toward exogenous substrates. A comparison of H-1 NMR spectra of approximately 48- and approximately 38-kDa forms of enzyme (the latter generated by tryptic deletion of approximately 10 kDa from the carboxyl terminus of the approximately 48-kDa protein) allows a correlation of observed mobile tyrosine resonances to two of the known sites of autophosphorylation (residues 1328 and 1334). Furthermore, spectra acquired during autophosphorylation of the approximately 48-kDa enzyme reveal a rapid downfield shift in the resonances of these mobile tail tyrosines consistent with their phosphorylation (as confirmed by two-dimensional tryptic phosphopeptide mapping performed under identical conditions). This experimental strategy now provides a means by which to monitor protein-tyrosine kinase autophosphorylation in solution in real time.	UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,5323 HARRY HINES BLVD,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV OXFORD,INORGAN CHEM LAB,OXFORD OX1 3QR,ENGLAND; UNIV OXFORD,OXFORD CTR MOLEC SCI,OXFORD OX1 3QR,ENGLAND	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Oxford; University of Oxford								COBB MH, 1989, J BIOL CHEM, V264, P18701; DALGARNO DC, 1983, BIOSCIENCE REP, V3, P443, DOI 10.1007/BF01121955; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ELLIS L, 1987, MOL ENDOCRINOL, V1, P15, DOI 10.1210/mend-1-1-15; ELLIS L, 1988, J VIROL, V62, P1634, DOI 10.1128/JVI.62.5.1634-1639.1988; Ernst R. R., 1987, PRINCIPLES NUCL MAGN; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HERRERA R, 1988, J BIOL CHEM, V263, P5560; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; Jardetzky O., 1981, NMR MOL BIOL; LEVINE BA, 1991, J BIOL CHEM, V266, P3565; TAVARE JM, 1988, BIOCHEM J, V252, P607, DOI 10.1042/bj2520607; TAVARE JM, 1991, J BIOL CHEM, V266, P1390; TAVARE JM, 1988, BIOCHEM J, V253, P783, DOI 10.1042/bj2530783; TORNQVIST HE, 1987, J BIOL CHEM, V262, P10212; TORNQVIST HE, 1988, J BIOL CHEM, V263, P350; WHITE MF, 1988, J BIOL CHEM, V263, P2969; Wuthrich K., 1986, NMR PROTEINS NUCL AC	18	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1991	266	20					13405	13410						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FX132	1649190				2022-12-25	WOS:A1991FX13200094
J	SHO, K; OKAJIMA, F; MAJID, MA; KONDO, Y				SHO, K; OKAJIMA, F; MAJID, MA; KONDO, Y			RECIPROCAL MODULATION OF THYROTROPIN ACTIONS BY P1-PURINERGIC AGONISTS IN FRTL-5 THYROID-CELLS - INHIBITION OF CAMP PATHWAY AND STIMULATION OF PHOSPHOLIPASE C-CA2+ PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION SYSTEMS; ISLET-ACTIVATING PROTEIN; PERTUSSIS TOXIN; CYCLIC-AMP; CA-2+ MOBILIZATION; IODIDE EFFLUX; PHOSPHOINOSITIDE TURNOVER; ADENYLATE-CYCLASE; GROWTH; RECEPTOR	In FRTL-5 thyroid cells, thyrotropin (TSH) stimulates I- efflux in association with phospholipase C activation and Ca2+ mobilization. TSH also stimulates DNA synthesis, accompanied by cAMP accumulation. Significant activation of the phospholipase C-Ca2+ pathway requires 10-100 nM TSH a concentration 10(3) to 10(4) times higher than necessary to stimulate the cAMP pathway. When the P1-purinergic agonist, phenylisopropyladenosine (PIA) is added to the reaction medium, the former pathway is markedly enhanced, whereas the latter pathway is inhibited. As a result, in the presence of PIA, both TSH-induced pathways are activated at similar TSH concentrations. These PIA actions are completely reversed by a prior treatment of cells with islet-activating protein (IAP), pertussis toxin. When adenosine deaminase is added to the reaction medium, TSH-induced cAMP accumulation is significantly enhanced, suggesting an autocrine action of adenosine. In IAP-treated cells, the level of TSH-induced cAMP accumulation reaches that of deaminase-treated control cells, and no further increase is observed when adenosine deaminase is added. We conclude that in the thyroid, either an neural or autocrine adenosine signal, mediated by an IAP-sensitive G-protein, switches TSH signal transduction from the cAMP pathway to the phospholipase C-Ca2+ pathway.			SHO, K (corresponding author), GUNMA UNIV,INST ENDOCRINOL,DEPT PHYS BIOCHEM,MAEBASHI,GUNMA 371,JAPAN.							AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; BJORKMAN U, 1988, ENDOCRINOLOGY, V122, P488; BONE EA, 1986, ENDOCRINOLOGY, V119, P2193, DOI 10.1210/endo-119-5-2193; BOYER JL, 1989, J BIOL CHEM, V264, P13917; COCKCROFT S, 1987, TRENDS BIOCHEM SCI, V12, P75, DOI 10.1016/0968-0004(87)90035-1; CORDA D, 1985, J BIOL CHEM, V260, P9230; EALEY PA, 1987, J ENDOCRINOL, V114, P199, DOI 10.1677/joe.0.1140199; EKHOLM R, 1981, MOL CELL ENDOCRINOL, V24, P141, DOI 10.1016/0303-7207(81)90056-3; FIELD JB, 1987, BIOCHEM J, V247, P519, DOI 10.1042/bj2470519; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; GREEN WL, 1987, THYROID, P1; HONMA M, 1977, BIOCHEM MED METAB B, V18, P257, DOI 10.1016/0006-2944(77)90060-6; IGARASHI Y, 1980, BIOCHEM BIOPH RES CO, V97, P759, DOI 10.1016/0006-291X(80)90329-0; JIN S, 1986, ENDOCRINOLOGY, V119, P802, DOI 10.1210/endo-119-2-802; LAURENT E, 1987, MOL CELL ENDOCRINOL, V52, P273, DOI 10.1016/0303-7207(87)90055-4; MOSES AC, 1989, ENDOCRINOLOGY, V125, P2758, DOI 10.1210/endo-125-5-2758; NAZAREA M, 1991, EUR J PHARM-MOLEC PH, V206, P47, DOI 10.1016/0922-4106(91)90145-8; OKAJIMA F, 1990, J BIOL CHEM, V265, P21741; OKAJIMA F, 1989, FEBS LETT, V253, P132, DOI 10.1016/0014-5793(89)80945-7; OKAJIMA F, 1988, ENDOCRINOLOGY, V123, P1035, DOI 10.1210/endo-123-2-1035; OKAJIMA F, 1989, FEBS LETT, V248, P145, DOI 10.1016/0014-5793(89)80450-8; OKAJIMA F, 1989, J BIOL CHEM, V264, P13029; OKAJIMA F, 1987, J BIOL CHEM, V262, P13483; PHILP NJ, 1986, FEBS LETT, V202, P193, DOI 10.1016/0014-5793(86)80685-8; RANI CSS, 1985, BIOCHEM BIOPH RES CO, V131, P1041, DOI 10.1016/0006-291X(85)90195-0; RANI CSS, 1989, ENDOCRINOLOGY, V125, P1889, DOI 10.1210/endo-125-4-1889; RASPE E, 1986, BIOCHEM BIOPH RES CO, V141, P569, DOI 10.1016/S0006-291X(86)80211-X; ROGER P, 1988, J CLIN ENDOCR METAB, V66, P1158, DOI 10.1210/jcem-66-6-1158; ROMEO HE, 1986, J AUTONOM NERV SYST, V17, P63, DOI 10.1016/0165-1838(86)90044-5; ROMEO HE, 1988, ENDOCRINOLOGY, V122, P2527, DOI 10.1210/endo-122-6-2527; SHO K, 1989, ENDOCRINOLOGY, V124, P598, DOI 10.1210/endo-124-2-598; TAGUCHI M, 1988, ENDOCRINOLOGY, V123, P2019, DOI 10.1210/endo-123-4-2019; TRAMONTANO D, 1986, ENDOCRINOLOGY, V119, P940, DOI 10.1210/endo-119-2-940; UI M, 1984, TRENDS PHARMACOL SCI, V5, P277, DOI 10.1016/0165-6147(84)90444-9; VALENTE WA, 1983, ENDOCRINOLOGY, V112, P71, DOI 10.1210/endo-112-1-71; VANSANDE J, 1990, MOL CELL ENDOCRINOL, V74, pR1, DOI 10.1016/0303-7207(90)90209-Q; WEISS SJ, 1984, ENDOCRINOLOGY, V114, P1108, DOI 10.1210/endo-114-4-1108	38	78	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1991	266	19					12180	12184						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FV180	1648085				2022-12-25	WOS:A1991FV18000014
J	LIDHOLM, DA; GUDMUNDSSON, GH; BOMAN, HG				LIDHOLM, DA; GUDMUNDSSON, GH; BOMAN, HG			A HIGHLY REPETITIVE, MARINER-LIKE ELEMENT IN THE GENOME OF HYALOPHORA-CECROPIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPOSABLE ELEMENT; DROSOPHILA-MAURITIANA; GERM LINE; EXCISION; CHROMOSOMES; MOS	A highly repetitive DNA element, homologous to the mariner transposon of Drosophila mauritiana was found in the intron of the gene for cecropin A, an antibacterial peptide from the Cecropia moth. The mariner-like elements (MLE) represent a homogeneous population with a copy number of about 1000/genome. Sequencing analysis showed it to be 1255 base pairs long, including 38-base pair terminal inverted repeats. The MLE contains a defective reading frame. Nevertheless, the putative product is clearly homologous to the predicted translation product encoded by mariner. In consonance is also the fact that the inverted repeats are highly conserved between the two elements and that the overall DNA homology is 48%. Since the mariner element is present in several Drosophila species closely related to Drosophila melanogaster and since MLE is present in the lepidopteran Cecropia, a route of horizontal transfer is indicated rather than vertical transmission from a common ancestor. This suggests the possible use of mariner for the construction of an interspecies vector.			LIDHOLM, DA (corresponding author), UNIV STOCKHOLM, DEPT MICROBIOL, S-10691 STOCKHOLM, SWEDEN.		Gudmundsson, Gudmundur H/K-9178-2015	Gudmundsson, Gudmundur H/0000-0001-5793-0565				Berg DE, 1989, MOBILE DNA; BRYAN GJ, 1987, SCIENCE, V235, P1636, DOI 10.1126/science.3029874; BRYAN GJ, 1988, SCIENCE, V240, P215, DOI 10.1126/science.2832948; BURKE DD, 1976, J INSECT PHYSIOL, V22, P791, DOI 10.1016/0022-1910(76)90246-8; ENGELS WR, 1983, ANNU REV GENET, V17, P313, DOI 10.1146/annurev.ge.17.120183.001531; FEDOROFF NV, 1989, MOBILE DNA, P375; GUDMUNDSSON GH, 1991, J BIOL CHEM, V266, P11510; HARTL DL, 1989, MOBILE DNA, P531; HAYMER DS, 1986, DEV GENET, V6, P281; JACOBSON JW, 1990, GENET RES, V55, P153, DOI 10.1017/S0016672300025465; JACOBSON JW, 1986, P NATL ACAD SCI USA, V83, P8684, DOI 10.1073/pnas.83.22.8684; LEMEUNIER F, 1984, CHROMOSOMA, V89, P343, DOI 10.1007/BF00331251; LIDHOLM DA, 1987, FEBS LETT, V226, P8, DOI 10.1016/0014-5793(87)80540-9; MEDHORA MM, 1988, EMBO J, V7, P2185, DOI 10.1002/j.1460-2075.1988.tb03057.x; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Shapiro JA, 1983, MOBILE GENETIC ELEME, P329, DOI DOI 10.1016/B978-0-12-638680-6.50012-0; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; XANTHOPOULOS KG, 1988, EUR J BIOCHEM, V172, P371, DOI 10.1111/j.1432-1033.1988.tb13896.x; YOUNG MW, 1979, P NATL ACAD SCI USA, V76, P6274, DOI 10.1073/pnas.76.12.6274; [No title captured]	20	69	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1991	266	18					11518	11521						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FT762	1646809				2022-12-25	WOS:A1991FT76200019
J	MENDEZ, AJ; ORAM, JF; BIERMAN, EL				MENDEZ, AJ; ORAM, JF; BIERMAN, EL			PROTEIN-KINASE-C AS A MEDIATOR OF HIGH-DENSITY-LIPOPROTEIN RECEPTOR-DEPENDENT EFFLUX OF INTRACELLULAR CHOLESTEROL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-SKIN FIBROBLASTS; CULTURED FIBROBLASTS; PLASMA-MEMBRANE; CELL-SURFACE; SPHINGOSINE INHIBITION; SIGNAL TRANSDUCTION; HUMAN-PLATELETS; BINDING; INTERNALIZATION; IDENTIFICATION	The interaction of high density lipoproteins (HDL) with the HDL receptor stimulates the translocation of cholesterol from intracellular pools to the plasma membrane where the cholesterol becomes available for removal by appropriate acceptors. The role of signal transduction through protein kinase C in HDL receptor-dependent cholesterol translocation and efflux was examined using cholesterol-loaded cultured human skin fibroblasts. Treatment of cells with HDL3 activated protein kinase C, demonstrated by a transient increase in membrane associated kinase activity. Kinase activation appeared to be dependent on binding of HDL3 to the HDL receptor, since tetranitromethane-modified HDL3, which does not bind to the receptor, was without effect. Translocation of intracellular sterol to the plasma membrane was stimulated by treatment of cells with the protein kinase C activators, dioctanoylglycerol and phorbol myristic acetate, and the calcium ionophore A23187. Conversely, treatment of cells with sphingosine, a protein kinase C inhibitor, reduced HDL3-mediated translocation and efflux of intracellular sterols. However, sphingosine had no effect on efflux of labeled cholesterol derived from the plasma membrane. Down-regulation of cellular protein kinase C activity by long term incubation with phorbol esters also inhibited HDL3-mediated efflux of intracellular sterols and abolished the ability of sphingosine to further inhibit HDL3-mediated efflux. These studies support the conclusion that HDL receptor-mediated translocation and efflux of intracellular cholesterol occurs through activation of protein kinase C.	UNIV WASHINGTON,DEPT MED,DIV METAB ENDOCRINOL & NUTR,RG-26,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018645, R01HL031194] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-18645, HL-31194] Funding Source: Medline; NIDDK NIH HHS [DK-02456] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AVIRAM M, 1989, J LIPID RES, V30, P65; BEISBROECK R, 1983, J CLIN INVEST, V71, P525; BELLINI F, 1984, BIOCHIM BIOPHYS ACTA, V777, P209, DOI 10.1016/0005-2736(84)90422-X; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BRASAEMLE DL, 1990, J LIPID RES, V31, P103; BRINTON EA, 1985, ARTERIOSCLEROSIS, V5, P329, DOI 10.1161/01.ATV.5.4.329; BRINTON EA, 1986, J BIOL CHEM, V261, P495; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; DANIELS RJ, 1981, J BIOL CHEM, V256, P4978; DEGRELLA RF, 1982, J BIOL CHEM, V257, P4256; DELBART C, 1989, CIRCULATION S, V80, P487; DUELL PB, 1988, ARTERIOSCLEROSIS, V8, pA570; FIDGE NH, 1985, J BIOL CHEM, V260, P3570; FIELDING C J, 1981, Proceedings of the National Academy of Sciences of the United States of America, V78, P3911, DOI 10.1073/pnas.78.6.3911; FIELDING CJ, 1982, MED CLIN N AM, V66, P363, DOI 10.1016/S0025-7125(16)31425-0; FOLCH J, 1957, J BIOL CHEM, V226, P497; GLOMSET JA, 1968, J LIPID RES, V9, P155; GRAHAM DL, 1987, J BIOL CHEM, V262, P7439; HAHM KS, 1983, J LIPID RES, V27, P877; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1987, J BIOL CHEM, V262, P13620; HARA A, 1978, ANAL BIOCHEM, V90, P420, DOI 10.1016/0003-2697(78)90046-5; HO AK, 1988, J BIOL CHEM, V263, P9292; LANGE Y, 1983, J BIOL CHEM, V258, P5130; LANGE Y, 1984, J BIOL CHEM, V259, P4624; LEDBETTER JA, 1986, J IMMUNOL, V136, P3945; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MENDEZ AJ, 1990, ARTERIOSCLEROSIS, V10, pA768; MERRILL AH, 1989, BIOCHIM BIOPHYS ACTA, V1010, P131, DOI 10.1016/0167-4889(89)90152-3; MERRILL AH, 1989, BIOCHEMISTRY-US, V28, P3138, DOI 10.1021/bi00434a004; MILLER NE, 1984, ATHEROSCLEROSIS MECH, P156; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OPPENHEIMER MJ, 1988, J BIOL CHEM, V263, P19318; OPPENHEIMER MJ, 1987, ARTERIOSCLEROSIS, V7, P325, DOI 10.1161/01.ATV.7.4.325; Oram J F, 1986, Methods Enzymol, V129, P645; ORAM JF, 1987, J BIOL CHEM, V262, P2405; ORAM JF, 1983, J CLIN INVEST, V72, P1611, DOI 10.1172/JCI111120; ORAM JF, 1983, ARTERIOSCLEROSIS, V3, P420, DOI 10.1161/01.ATV.3.5.420; ORAM JF, 1981, J BIOL CHEM, V256, P8348; ORAM JF, 1991, IN PRESS ARTERIOSCLE, V11; PHILLIPS MC, 1987, BIOCHIM BIOPHYS ACTA, V906, P223, DOI 10.1016/0304-4157(87)90013-X; SCHMITZ G, 1985, EMBO J, V4, P2773, DOI 10.1002/j.1460-2075.1985.tb04003.x; SLOTTE JP, 1987, J BIOL CHEM, V262, P12904; STEIN O, 1976, BIOCHIM BIOPHYS ACTA, V431, P347, DOI 10.1016/0005-2760(76)90155-7; THOMAS TP, 1987, METHOD ENZYMOL, V141, P399; URBANI L, 1990, J BIOL CHEM, V265, P1919; WEISGRABER KH, 1980, J LIPID RES, V21, P316	47	240	249	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10104	10111						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	1645339				2022-12-25	WOS:A1991FP08600020
J	ZHENG, B; WOO, CF; KUO, JF				ZHENG, B; WOO, CF; KUO, JF			MITOTIC ARREST AND ENHANCED NUCLEAR-PROTEIN PHOSPHORYLATION IN HUMAN LEUKEMIA K562 CELLS BY OKADAIC ACID, A POTENT PROTEIN PHOSPHATASE INHIBITOR AND TUMOR PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BLACK SPONGE TOXIN; SMOOTH-MUSCLE; M-PHASE; KINASE; INVOLVEMENT; ADIPOCYTES; SIGNAL; CDC2	We investigated the effects of the non-phorbol tumor promoter okadaic acid on human leukemia K562 cells. It was found that okadaic acid potently and reversibly inhibited cell growth, with a nearly complete inhibition of thymidine uptake seen at about 10 nM. The cytotoxicity of okadaic acid was characterized by a marked mitotic arrest of the cells exhibiting scattered chromosomes and abnormal anaphase-like structures, a phenomenon distinct from the typical metaphase arrest caused by colchicine. Okadaic acid (10-1,000 nM) greatly stimulated phosphorylation of a number of nuclear proteins in K562 cells. Phosphorylation of many of the same proteins was also stimulated by 12-O-tetradecanoylphorbol-13-O-acetate, a protein kinase C activator. The present findings, consistent with recent reports that okadaic acid is a potent inhibitor of protein phosphatases 1 and 2A (PP1 and PP2A) shown to be essential for normal mitosis, provided evidence for the first time that okadaic acid inhibition of PP1/PP2A resulted in enhanced nuclear protein phosphorylation and subsequent mitotic arrest.			ZHENG, B (corresponding author), EMORY UNIV, SCH MED, DEPT PHARMACOL, ATLANTA, GA 30322 USA.				NCI NIH HHS [CA-36777] Funding Source: Medline; NHLBI NIH HHS [HL-15696] Funding Source: Medline; NINDS NIH HHS [NS-17608] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA036777] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL015696, R37HL015696] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017608] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; ASHIZAWA N, 1989, BIOCHEM BIOPH RES CO, V162, P971, DOI 10.1016/0006-291X(89)90768-7; AXTON JM, 1990, CELL, V63, P33, DOI 10.1016/0092-8674(90)90286-N; BASTIAN FO, 1988, J CLIN MICROBIOL, V26, P2124, DOI 10.1128/JCM.26.10.2124-2126.1988; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COHEN P, 1989, J BIOL CHEM, V264, P21435; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; FUKUNAGA K, 1989, J BIOL CHEM, V264, P21830; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HELFMAN DM, 1983, CANCER RES, V43, P2955; HESCHELER J, 1988, PFLUG ARCH EUR J PHY, V412, P248, DOI 10.1007/BF00582504; KARAKI H, 1989, BRIT J PHARMACOL, V98, P590, DOI 10.1111/j.1476-5381.1989.tb12633.x; KINOSHITA N, 1990, CELL, V63, P405, DOI 10.1016/0092-8674(90)90173-C; KISS Z, 1987, BIOCHEM J, V248, P649, DOI 10.1042/bj2480649; LAWRENCE JC, 1990, J BIOL CHEM, V265, P19768; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PEWITT EB, 1990, J BIOL CHEM, V265, P20747; PICARD A, 1989, J CELL BIOL, V109, P3347, DOI 10.1083/jcb.109.6.3347; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; TACHIBANA K, 1981, J AM CHEM SOC, V103, P2469, DOI 10.1021/ja00399a082; TAKAI A, 1987, FEBS LETT, V217, P81, DOI 10.1016/0014-5793(87)81247-4; TAYLOR EW, 1965, J CELL BIOL, V25, P145, DOI 10.1083/jcb.25.1.145	28	58	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10031	10034						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	1645333				2022-12-25	WOS:A1991FP08600004
J	KIM, JI; COX, MM; INMAN, RB				KIM, JI; COX, MM; INMAN, RB			ON THE ROLE OF ATP HYDROLYSIS IN RECA PROTEIN-MEDIATED DNA STRAND EXCHANGE .2. 4-STRAND EXCHANGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENETIC-RECOMBINATION; ESCHERICHIA-COLI; DUPLEX DNA; LINEAR DICHROISM; MOLECULES; MECHANISM; FILAMENTS; COMPLEXES; STOICHIOMETRY; PURIFICATION	RecA protein promotes a substantial DNA strand exchange reaction in the presence of adenosine 5'-O3-(thio)triphosphate (ATP-gamma-S) (Menetski et al., 1990), calling into question the role of ATP hydrolysis in this reaction. We demonstrate here that the ATP-gamma-S-mediated process is restricted to homologous strand exchange reactions involving three strands. In four-strand exchanges between a gapped duplex circle and a second linear duplex, joint molecules are formed in the gap but are not extended into the four-strand region when ATP-gamma-S is present. This result provides evidence that one function of ATP hydrolysis in the recA system is to facilitate reciprocal DNA strand exchange involving four strands. Implications with respect to the role of four-stranded pairing intermediates and the mechanistic relationship between three- and four-strand exchange reactions are discussed.	UNIV WISCONSIN, COLL AGR & LIFE SCI, DEPT BIOCHEM, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032335, U01GM032335, R01GM014711] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-14711, GM-32335] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEDALE WA, 1991, J BIOL CHEM, V266, P6499; CASSUTO E, 1980, P NATL ACAD SCI-BIOL, V77, P3962, DOI 10.1073/pnas.77.7.3962; CONLEY EC, 1990, J BIOL CHEM, V265, P10156; CONLEY EC, 1989, CELL, V56, P987, DOI 10.1016/0092-8674(89)90632-6; COX MM, 1981, J BIOL CHEM, V256, P4676; COX MM, 1990, BIOL NONSPECIFIC DNA, P171; COX MM, 1987, UCLA S MOL CELL BIOL, V47, P597; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; CUNNINGHAM RP, 1980, CELL, V20, P223, DOI 10.1016/0092-8674(80)90250-0; DASGUPTA C, 1981, CELL, V25, P507, DOI 10.1016/0092-8674(81)90069-6; Davis R., 1980, ADV BACTERIAL GENETI; EGGLESTON AK, 1991, BIOCHIMIE, V73, P163, DOI 10.1016/0300-9084(91)90199-B; HONIGBERG SM, 1988, CELL, V54, P525, DOI 10.1016/0092-8674(88)90074-8; HOWARDFLANDERS P, 1984, NATURE, V309, P215, DOI 10.1038/309215a0; HSIEH P, 1990, GENE DEV, V4, P1951, DOI 10.1101/gad.4.11.1951; INMAN RB, 1970, J MOL BIOL, V49, P93, DOI 10.1016/0022-2836(70)90378-5; JAIN SK, 1992, IN PRESS J BIOL CHEM; KIM JI, 1992, J BIOL CHEM, V267, P16438; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; KUBISTA M, 1990, J BIOL CHEM, V265, P18891; LINDSLEY JE, 1989, J MOL BIOL, V205, P695, DOI 10.1016/0022-2836(89)90315-X; LINDSLEY JE, 1990, J BIOL CHEM, V265, P10164; LOHMAN TM, 1986, BIOCHEMISTRY-US, V25, P21, DOI 10.1021/bi00349a004; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P21, DOI 10.1073/pnas.87.1.21; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; MULLER B, 1990, J MOL BIOL, V212, P97, DOI 10.1016/0022-2836(90)90307-8; RADDING CM, 1991, J BIOL CHEM, V266, P5355; RAO BJ, 1990, J MOL BIOL, V213, P789, DOI 10.1016/S0022-2836(05)80264-5; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; ROSSELLI W, 1990, J MOL BIOL, V216, P335, DOI 10.1016/S0022-2836(05)80325-0; Sambrook J, 1989, MOL CLONING LABORATO; SENECOFF JF, 1985, P NATL ACAD SCI USA, V82, P7270, DOI 10.1073/pnas.82.21.7270; TAKAHASHI M, 1989, J MOL BIOL, V205, P137, DOI 10.1016/0022-2836(89)90371-9; TAKAHASHI M, 1991, BIOCHIMIE, V73, P219, DOI 10.1016/0300-9084(91)90205-F; UMLAUF SW, 1990, J BIOL CHEM, V265, P16898	35	61	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16444	16449						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1644828				2022-12-25	WOS:A1992JJ45800072
J	KNOPS, J; LIEBERBURG, I; SINHA, S				KNOPS, J; LIEBERBURG, I; SINHA, S			EVIDENCE FOR A NONSECRETORY, ACIDIC DEGRADATION PATHWAY FOR AMYLOID PRECURSOR PROTEIN IN 293 CELLS - IDENTIFICATION OF A NOVEL, 22-KDA, BETA-PEPTIDE-CONTAINING INTERMEDIATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ALZHEIMERS-DISEASE; LOCALIZATION; CLEAVAGE	We have analyzed the metabolic pathway of maturation of APP751 in stably transfected 293 cells, in the presence of either of the cysteine protease inhibitors leupeptin or E-64. Metabolic labeling, followed by immunoprecipitation at various times in the chase with a rabbit polyclonal antibody (anti-BX6) specific to the carboxyl-terminal end of amyloid precursor protein (APP), revealed the accumulation of a novel approximately 22-kDa carboxyl-terminal fragment (22-CTF) in the inhibitor-treated cells. This fragment, which was not detectable in untreated cells, was immunoprecipitated by four separate antibodies to the carboxyl-terminal region of APP as well as by polyclonal and monoclonal antibodies specific to the first 16 amino acids of the beta-peptide domain. Antibodies to the amino-terminal end of APP do not, however, recognize the fragment. Co-treatment of the inhibitor-treated cells with either of the lysosomotropic agents chloroquine or ammonium chloride completely blocked the generation of this fragment but did not significantly affect APP maturation or secretion. All, however, slowed the intracellular turnover of the cell-associated, approximately 9-kDa carboxyl-terminal fragment (c-CTF) produced during constitutive secretion. Densitometric analyses of these results suggest that this non-secretory pathway of APP degradation, mediated by cysteine proteases in an intracellular acidic compartment, accounts for approximately 70% of total APP metabolism and that a key processing intermediate in this pathway is a 22-kDa, beta-peptide-containing APP carboxyl-terminal fragment. It is possible that inefficient degradation of such an intermediate leads to the formation of aggregating beta-peptide.	ATHENA NEUROSCI, 800-F GATEWAY BLVD, S SAN FRANCISCO, CA 94080 USA									ANDERSON JP, 1991, NEUROSCI LETT, V128, P126, DOI 10.1016/0304-3940(91)90775-O; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COLE GM, 1989, NEUROCHEM RES, V14, P933, DOI 10.1007/BF00965926; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; HAASS C, 1991, J NEUROSCI, V11, P3783; LOWERY DE, 1991, J BIOL CHEM, V266, P19842; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TAMAOKA A, 1992, P NATL ACAD SCI USA, V89, P1345, DOI 10.1073/pnas.89.4.1345; WANG R, 1991, J BIOL CHEM, V266, P16906; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3	15	56	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16022	16024						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1644790				2022-12-25	WOS:A1992JJ45800005
J	NGAI, SM; HODGES, RS				NGAI, SM; HODGES, RS			BIOLOGICALLY IMPORTANT INTERACTIONS BETWEEN SYNTHETIC PEPTIDES OF THE N-TERMINAL REGION OF TROPONIN-I AND TROPONIN-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; AMINO-ACID-SEQUENCE; INHIBITORY REGION; CROSS-LINKING; PROTEOLYTIC FRAGMENTS; CALCIUM-BINDING; MAGNETIC-RESONANCE; REGULATORY DOMAIN; CONTRACTION; TROPOMYOSIN	The interaction between troponin I and troponin C plays a critical role in the regulation of muscle contraction. In this study the interaction between troponin C (TnC) and the N-terminal region of TnI was investigated by the synthesis of three TnI peptides (residues 1-40/Rp, 10-40, and 20-40). The regulatory peptide (Rp) on binding to TnC prevents the ability of TnC to release the inhibition of the acto-SI-tropomyosin ATPase activity caused by TnI or the TnI inhibitory peptide (IP), residues 104-115. A stable complex between TnC and Rp in the presence of Ca2+ was demonstrated by polyacrylamide gel electrophoresis in the presence of 6 M urea. Rp was able to displace TnI from a preformed TnI.TnC complex. In the absence of Ca2+, Rp was unable to maintain a complex with TnC in benign conditions of polyacrylamide gel electrophoresis which demonstrates the Ca2+-dependent nature of this interaction. Size-exclusion chromatography demonstrated that the TnC.Rp complex consisted of a 1:1 complex. The results of these studies have shown that the N-terminal region of TnI (1-40) plays a critical role in modulating the Ca2+-sensitive release of TnI inhibition by TnC.	UNIV ALBERTA,DEPT BIOCHEM,EDMONTON T6G 2H7,ALBERTA,CANADA; UNIV ALBERTA,MED RES COUNCIL CANADA,PROT STRUCT & FUNCT GRP,EDMONTON T6G 2H7,ALBERTA,CANADA	University of Alberta; University of Alberta			Ngai, Sai Ming/S-4898-2018	Ngai, Sai Ming/0000-0002-4484-2483				BURKE TWL, 1991, HIGH PERFORMANCE LIQ, P643; CACHIA PJ, 1986, BIOCHEMISTRY-US, V25, P3553, DOI 10.1021/bi00360a013; CACHIA PJ, 1983, BIOCHEMISTRY-US, V22, P4145, DOI 10.1021/bi00286a024; CHEUNG H C, 1989, Biophysical Journal, V55, p122A; CHONG PCS, 1981, J BIOL CHEM, V256, P5071; CHONG PCS, 1983, FEBS LETT, V153, P372, DOI 10.1016/0014-5793(83)80646-2; CHONG PCS, 1982, J BIOL CHEM, V257, P2549; DALGARNO DC, 1982, FEBS LETT, V150, P54, DOI 10.1016/0014-5793(82)81303-3; Ebashi S, 1968, Prog Biophys Mol Biol, V18, P123, DOI 10.1016/0079-6107(68)90023-0; EVANS JS, 1980, J INORG BIOCHEM, V12, P227, DOI 10.1016/S0162-0134(00)80204-4; GARIEPY J, 1983, FEBS LETT, V160, P1, DOI 10.1016/0014-5793(83)80924-7; GRABAREK Z, 1981, J BIOL CHEM, V256, P3121; GRABAREK Z, 1986, J BIOL CHEM, V261, P608; HEAD JF, 1974, BIOCHEM J, V137, P145, DOI 10.1042/bj1370145; HEIDORN DB, 1988, BIOCHEMISTRY-US, V27, P909, DOI 10.1021/bi00403a011; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; HODGES R S, 1988, Peptide Research, V1, P19; HODGES RS, 1991, HIGH PERFORMANCE LIQ, P773; KATAYAMA E, 1982, J BIOCHEM-TOKYO, V91, P1449, DOI 10.1093/oxfordjournals.jbchem.a133835; KOBAYASHI T, 1991, J BIOL CHEM, V266, P13746; LAN JQ, 1989, BIOCHEMISTRY-US, V28, P7380, DOI 10.1021/bi00444a035; LEAVIS PC, 1978, J BIOL CHEM, V253, P5452; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; LESZYK J, 1988, BIOCHEMISTRY-US, V27, P6983, DOI 10.1021/bi00418a047; LESZYK J, 1990, BIOCHEMISTRY-US, V29, P299, DOI 10.1021/bi00453a041; LESZYK J, 1987, BIOCHEMISTRY-US, V26, P7035, DOI 10.1021/bi00396a027; MANT CT, 1987, CHROMATOGRAPHIA, V24, P565, DOI 10.1007/BF02688546; MCCUBBIN ND, 1973, BIOCHEMISTRY-US, V2, P428; NOZAKI S, 1980, CHEM LETT, P345, DOI 10.1246/cl.1980.345; PARKER JMR, 1985, J PROTEIN CHEM, V3, P465; PATO MD, 1981, J BIOL CHEM, V256, P593; PERRY SV, 1975, S CALCIUM TRANSPORT, P431; ROSENFELD SS, 1985, J BIOL CHEM, V260, P252; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SUNDARALINGAM M, 1985, SCIENCE, V227, P945, DOI 10.1126/science.3969570; SWENSON CA, 1992, IN PRESS BIOCHEMISTR; SYSKA H, 1976, BIOCHEM J, V153, P375, DOI 10.1042/bj1530375; TALBOT JA, 1979, J BIOL CHEM, V254, P3720; TALBOT JA, 1981, J BIOL CHEM, V256, P2374; TALBOT JA, 1981, J BIOL CHEM, V256, P2798; TAO T, 1986, BIOCHEMISTRY-US, V25, P7633, DOI 10.1021/bi00371a054; VANEYK JE, 1991, BIOCHEMISTRY-US, V30, P9974, DOI 10.1021/bi00105a023; VANEYK JE, 1988, J BIOL CHEM, V263, P1726; VANEYK JE, 1987, BIOCHEM CELL BIOL, V65, P982; WANG CLA, 1987, J BIOL CHEM, V262, P9636; WANG ZY, 1990, J BIOL CHEM, V265, P4953; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; WEEKS RA, 1978, BIOCHEM J, V173, P449, DOI 10.1042/bj1730449; WILKINSON JM, 1975, BIOCHEM J, V149, P493, DOI 10.1042/bj1490493; WILKINSON JM, 1978, NATURE, V271, P31, DOI 10.1038/271031a0; YAGI K, 1967, BIOCHEM BIOPH RES CO, V29, P331, DOI 10.1016/0006-291X(67)90458-5; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	52	39	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15715	15720						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1639807				2022-12-25	WOS:A1992JG11300071
J	SEI, Y; ARORA, PK; SKOLNICK, P; PAUL, IA				SEI, Y; ARORA, PK; SKOLNICK, P; PAUL, IA			SPATIAL-LEARNING IMPAIRMENT IN A MURINE MODEL OF AIDS	FASEB JOURNAL			English	Article						SPATIAL LEARNING AND MEMORY; HUMAN IMMUNODEFICIENCY VIRUS; HIV-1; AIDS; AIDS DEMENTIA COMPLEX; MICE	INDUCED IMMUNODEFICIENCY SYNDROME; MICE; RETROVIRUS; INFECTION; VIRUS; ANTIDEPRESSANTS; LOCALIZATION; BRAINS; MAIDS	Mice infected with an immunosuppressive murine leukemia virus (MuLV) mixture, LP-BM5, displayed profound and selective deficits in spatial learning in a modified Morris water maze. These deficits appeared before the appearance of gross neurological impairment or histopathological changes in the central nervous system. Thus, LP-BM5-infected mice displayed deficits in several aspects of trained performance compared to controls. Furthermore, a failure to exhibit any evidence of task acquisition in this maze was observed almost twice as frequently (P < 0.0005) in infected mice as in uninfected controls. Moreover, in the absence of gross visual, motoric, or motivational impairment, LP-BM5 MuLV-infected animals exhibited neither the target directed search pattern nor the spatial preference characteristic of controls. The spatial learning and memory deficit described here is the first report of cognitive impairment accompanying viral-induced immunosuppression in a nonprimate species.	NIDDK,NEUROSCI LAB,BLDG 8,ROOM 111,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								ANDERS KH, 1986, AM J PATHOL, V124, P537; AZIZ DC, 1989, NATURE, V338, P505, DOI 10.1038/338505a0; BRIONI JD, 1990, BRAIN RES, V522, P227, DOI 10.1016/0006-8993(90)91465-S; BULLER RML, 1987, J VIROL, V61, P383, DOI 10.1128/JVI.61.2.383-387.1987; CHATTOPADHYAY SK, 1989, P NATL ACAD SCI USA, V86, P3862, DOI 10.1073/pnas.86.10.3862; CHATTOPADHYAY SK, 1991, J VIROL, V65, P4232, DOI 10.1128/JVI.65.8.4232-4241.1991; DUNHAM NW, 1956, J AM PHARM ASSOC, V3, P112; EPSTEIN LG, 1985, AIDS RES, V1, P447; GLOWA JR, 1992, BRAIN RES, V570, P49, DOI 10.1016/0006-8993(92)90562-N; HARTLEY JW, 1989, J VIROL, V63, P1223, DOI 10.1128/JVI.63.3.1223-1231.1989; HO DD, 1989, ANN INTERN MED, V107, P828; HUANG M, 1989, SCIENCE, V246, P1614, DOI 10.1126/science.2480643; JOHNSON RT, 1988, FASEB J, V2, P2970, DOI 10.1096/fasebj.2.14.2846395; JOLICOEUR P, 1991, FASEB J, V5, P2398, DOI 10.1096/fasebj.5.10.2065888; KLINKEN SP, 1988, J IMMUNOL, V140, P1123; KLINMAN DM, 1989, J IMMUNOL, V142, P1144; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; MOSIER DE, 1985, J EXP MED, V161, P766, DOI 10.1084/jem.161.4.766; NAVIA BA, 1986, ANN NEUROL, V19, P517, DOI 10.1002/ana.410190602; PORSOLT RD, 1977, ARCH INT PHARMACOD T, V229, P327; PRICE RW, 1988, SCIENCE, V239, P586, DOI 10.1126/science.3277272; SEI Y, 1992, J NEUROIMMUNOL, V37, P131, DOI 10.1016/0165-5728(92)90164-G; SELIGMAN MEP, 1975, J COMP PHYSIOL PSYCH, V88, P542, DOI 10.1037/h0076431; SHAW GM, 1985, SCIENCE, V227, P177, DOI 10.1126/science.2981429; STERU L, 1985, PSYCHOPHARMACOLOGY, V85, P367, DOI 10.1007/BF00428203; UPCHURCH M, 1988, HARM BIOCH BEHAV, V29, P325; WEHNER JM, 1989, PHARMACOL BIOCHEM BE, V32, P543, DOI 10.1016/0091-3057(89)90194-9; WILEY CA, 1986, P NATL ACAD SCI USA, V83, P7089, DOI 10.1073/pnas.83.18.7089	28	51	51	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1992	6	11					3008	3013		10.1096/fasebj.6.11.1644264	http://dx.doi.org/10.1096/fasebj.6.11.1644264			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JJ665	1644264				2022-12-25	WOS:A1992JJ66500016
J	BENNETT, DL; BAILYES, EM; NIELSEN, E; GUEST, PC; RUTHERFORD, NG; ARDEN, SD; HUTTON, JC				BENNETT, DL; BAILYES, EM; NIELSEN, E; GUEST, PC; RUTHERFORD, NG; ARDEN, SD; HUTTON, JC			IDENTIFICATION OF THE TYPE-2 PROINSULIN PROCESSING ENDOPEPTIDASE AS PC2, A MEMBER OF THE EUKARYOTE SUBTILISIN FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-SECRETORY GRANULES; YEAST KEX2; CHROMOGRANIN-A; GENE ENCODES; CELL-LINE; PROTEINS; CLEAVAGE; SEQUENCE; SITE; ENDOPROTEASE	Enzymological studies have implicated two Ca2+-dependent endopeptidases in the conversion of proinsulin to insulin; a type 1 activity which cleaves on the C-terminal side of Arg31-Arg32 and a type 2 activity which cleaves C-terminally to Lys64-Arg65 in the proinsulin sequence. The possibility that these enzymes are related to the recently discovered family of mammalian subtilisin-like gene products (furin, PC2, and PC3) and the yeast propheromone-converting enzyme (KEX-2), was investigated. Degenerate oligonucleotide primers flanking the putative catalytic domain within this gene family were used in a polymerase chain reaction to amplify related sequences from rat insulinoma cDNA. One major product of 700 base pairs was obtained which was >99% identical to the corresponding rat PC2 sequence. This cDNA was subcloned into the bacterial expression vector pGEX-3X to generate a recombinant protein for antibody production. Western blot analysis showed the immunoreactivity was prominent in neuroendocrine tissues as a 65-kDa protein. It was concentrated in secretory granule-enriched fractions of insulinoma tissue, where it was present as a readily solubilized monomeric protein. Deglycosylation studies using endoglycosidase H and N-glycanase showed that the 65-kDa protein was comprised of approximately 9% carbohydrate, consistent with the presence of three consensus sequences for N-linked glycosylation in rat PC2. The immunoreactivity co-eluted with the type 2 proinsulin endopeptidase on gel filtration and ion-exchange chromatography and the antisera specifically immunoprecipitated type 2 activity from insulin granule extracts. N-terminal sequence analysis of the immunoreactive protein gave two sequences which corresponded to residues 109-112 and 112-119 of rat PC2. This indicated that posttranslational processing of PC2 itself occurs C-terminally to basic amino acids to produce the mature enzyme. It is concluded that PC2 is the type 2 endopeptidase involved in proinsulin conversion. Localization of PC2 immunoreactivity to other tissues of the diffuse neuroendocrine system suggests that the type 2 endopeptidase also functions in the processing of precursor forms of other prohormones and polypeptide neurotransmitters.	ADDENBROOKES HOSP,DEPT CLIN BIOCHEM,HILLS RD,CAMBRIDGE CB2 2QR,ENGLAND; NOVO NORDISK,DK-28800 BAGSVAERD,DENMARK	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge				guest, paul/0000-0002-5030-7137	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAILYES EM, 1992, IN PRESS BIOCH J; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BEK E, 1990, BIOCHEMISTRY-US, V29, P178, DOI 10.1021/bi00453a024; BENTLEY AK, 1986, CELL, V45, P345; BLOOMQUIST BT, 1991, MOL ENDOCRINOL, V5, P2014, DOI 10.1210/mend-5-12-2014; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNAN SO, 1991, J BIOL CHEM, V266, P21504; BRENNAN SO, 1988, FEBS LETT, V229, P167, DOI 10.1016/0014-5793(88)80819-6; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; BULLER HA, 1989, BIOCHEM J, V263, P249; CHRISTIE DL, 1991, J BIOL CHEM, V266, P15679; DAVIDSON HW, 1987, BIOCHEM J, V246, P279, DOI 10.1042/bj2460279; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; DOCHERTY K, 1982, ANNU REV PHYSIOL, V44, P625, DOI 10.1146/annurev.ph.44.030182.003205; DOCHERTY K, 1989, J BIOL CHEM, V264, P18335; FALKENSAMMER G, 1985, NEUROSCIENCE, V14, P735, DOI 10.1016/0306-4522(85)90323-9; FULLER RS, 1988, ANNU REV PHYSIOL, V50, P345, DOI 10.1146/annurev.ph.50.030188.002021; GUEST PC, 1989, BIOCHEM J, V257, P431, DOI 10.1042/bj2570431; GUEST PC, 1991, BIOCHEM J, V274, P73, DOI 10.1042/bj2740073; GUEST PC, 1991, ENDOCRINOLOGY, V129, P734, DOI 10.1210/endo-129-2-734; HAKES DJ, 1991, ENDOCRINOLOGY, V129, P3053, DOI 10.1210/endo-129-6-3053; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; Hutton JC, 1990, CURR OPIN CELL BIOL, V2, P1131, DOI 10.1016/0955-0674(90)90167-D; HUTTON JC, 1982, DIABETOLOGIA, V23, P365; HUTTON JC, 1988, ENDOCRINOLOGY, V122, P1014, DOI 10.1210/endo-122-3-1014; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDBERG I, 1991, PEPTIDE BIOSYTHESIS, P00141; MACKIN RB, 1991, ENDOCRINOLOGY, V129, P2263, DOI 10.1210/endo-129-4-2263; Maniatis T., 1982, MOL CLONING; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MISUMI Y, 1990, NUCLEIC ACIDS RES, V18, P6719, DOI 10.1093/nar/18.22.6719; MIZUNO K, 1989, BIOCHEM BIOPH RES CO, V164, P780, DOI 10.1016/0006-291X(89)91527-1; MIZUNO K, 1988, BIOCHEM BIOPH RES CO, V156, P246, DOI 10.1016/S0006-291X(88)80832-5; RHODES CJ, 1989, BIOCHEM J, V258, P305, DOI 10.1042/bj2580305; RHOLAM M, 1986, FEBS LETT, V207, P1, DOI 10.1016/0014-5793(86)80002-3; ROEBROEK AJM, 1986, MOL BIOL REP, V11, P117, DOI 10.1007/BF00364823; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SLEEP D, 1990, BIO-TECHNOL, V8, P42, DOI 10.1038/nbt0190-42; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SMITH D, 1988, GENE, V65, P31; THIM L, 1986, P NATL ACAD SCI USA, V83, P6766, DOI 10.1073/pnas.83.18.6766; THOMAS G, 1988, ANNU REV PHYSIOL, V50, P323; THOMAS G, 1988, SCIENCE, V241, P226, DOI 10.1126/science.3291117; THORNE BA, 1989, J BIOL CHEM, V264, P3545; THORNE BA, 1991, J BIOL CHEM, V266, P13607; VANDENOUWELAND AMW, 1990, NUCLEIC ACIDS RES, V18, P664, DOI 10.1093/nar/18.3.664; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9378, DOI 10.1073/pnas.87.23.9378; ZOLLINGER L, 1990, BIOCHEM CELL BIOL, V68, P635, DOI 10.1139/o90-090	52	155	155	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15229	15236						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634553				2022-12-25	WOS:A1992JF08800106
J	FRANKE, RR; SAKMAR, TP; GRAHAM, RM; KHORANA, HG				FRANKE, RR; SAKMAR, TP; GRAHAM, RM; KHORANA, HG			STRUCTURE AND FUNCTION IN RHODOPSIN - STUDIES OF THE INTERACTION BETWEEN THE RHODOPSIN CYTOPLASMIC DOMAIN AND TRANSDUCIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; BOVINE RHODOPSIN; MONOCLONAL-ANTIBODIES; VISUAL RHODOPSIN; MEMBRANE; GENE; ARRANGEMENT; SPECIFICITY; EXPRESSION; RECEPTORS	Structural requirements for the activation of transducin by rhodopsin have been studied by site-specific mutagenesis of bovine rhodopsin. A variety of single amino acid replacements and amino acid insertions and deletions of varying sizes were carried out in the two cytoplasmic loops CD (amino acids 134-151) and EF (amino acids 231-252). Except for deletion mutant DELTA-137-150, all the mutants bound 11-cis-retinal and displayed normal spectral characteristics. Deletion mutant A236-239 in loop EF caused a 50% reduction of transducin activation, whereas deletion mutant DELTA-244-249 and the larger deletions in loop EF abolished transducin activation. An 8-amino acid deletion in the cytoplasmic loop CD as well as a replacement of 13 amino acids with an unrelated sequence showed no transducin activation. Several single amino acid substitutions also caused significant reduction in transducin activation. The conserved charged pair Glu-134/Arg-135 in the cytoplasmic loop CD was required for transducin activation; its reversal or neutralization abolished transducin activation. Three amino acid replacements in loop EF (S240A, T243V, and K248L) resulted in significant reduction in transducin activation. We conclude that 1) both the cytoplasmic loops CD and EF are required for transducin activation, and 2) effective functional interaction between rhodopsin and transducin involves relatively large peptide sequences in the cytoplasmic loops.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; MIT,DEPT CHEM,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)			Sakmar, Thomas P/D-1833-2015	Sakmar, Thomas P/0000-0002-2836-8953	NHLBI NIH HHS [HI 11479] Funding Source: Medline; NIGMS NIH HHS [GM 28289] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028289, R37GM028289] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMUS G, 1991, VISION RES, V31, P17, DOI 10.1016/0042-6989(91)90069-H; ARGOS P, 1982, EUR J BIOCHEM, V128, P565; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; DEGRIP WJ, 1982, METHOD ENZYMOL, V81, P256; DOI T, 1990, P NATL ACAD SCI USA, V87, P4991, DOI 10.1073/pnas.87.13.4991; FERRETTI L, 1986, P NATL ACAD SCI USA, V83, P599, DOI 10.1073/pnas.83.3.599; FRANKE RR, 1988, J BIOL CHEM, V263, P2119; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; GANTER UM, 1989, BIOCHEMISTRY-US, V28, P5954, DOI 10.1021/bi00440a036; HARGRAVE PA, 1983, BIOPHYS STRUCT MECH, V9, P235, DOI 10.1007/BF00535659; HONG K, 1972, P NATL ACAD SCI USA, V69, P2617, DOI 10.1073/pnas.69.9.2617; KAUFMAN RJ, 1985, P NATL ACAD SCI USA, V82, P689, DOI 10.1073/pnas.82.3.689; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KUBO T, 1988, FEBS LETT, V241, P119, DOI 10.1016/0014-5793(88)81043-3; KUHN H, 1981, BIOCHEMISTRY-US, V20, P2410; MOLDAY RS, 1983, BIOCHEMISTRY-US, V22, P653, DOI 10.1021/bi00272a020; NATHANS J, 1983, CELL, V34, P807, DOI 10.1016/0092-8674(83)90537-8; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; OVCHINNIKOV YA, 1983, BIOORG KHIM+, V9, P1331; OVCHINNIKOV YA, 1987, TRENDS BIOCHEM SCI, V12, P434, DOI 10.1016/0968-0004(87)90210-6; OVCHINNIKOV YA, 1982, BIOORG KHIM+, V8, P1424; PALCZEWSKI K, 1989, BIOCHEMISTRY-US, V28, P8764, DOI 10.1021/bi00448a013; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; WANG JK, 1980, BIOCHEMISTRY-US, V19, P5111, DOI 10.1021/bi00563a027; WEISS ER, 1988, J BIOL CHEM, V263, P6150; WONG SKF, 1990, J BIOL CHEM, V265, P6219; YOSHIZAWA T, 1963, NATURE, V197, P1279, DOI 10.1038/1971279a0	29	242	243	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14767	14774						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634520				2022-12-25	WOS:A1992JF08800042
J	ZOON, KC; MILLER, D; BEKISZ, J; NEDDEN, DZ; ENTERLINE, JC; NGUYEN, NY; HU, RQ				ZOON, KC; MILLER, D; BEKISZ, J; NEDDEN, DZ; ENTERLINE, JC; NGUYEN, NY; HU, RQ			PURIFICATION AND CHARACTERIZATION OF MULTIPLE COMPONENTS OF HUMAN LYMPHOBLASTOID INTERFERON-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LEUKOCYTE INTERFERON; AMINO-ACID-SEQUENCE; MONOCLONAL-ANTIBODY; CELLS; HOMOGENEITY; FAMILY; GENES	Twenty-two components of human interferon-alpha (IFN-alpha) derived from Sendai virus-induced Namalwa cells were purified by sequential immunoadsorbent affinity chromatography using four monoclonal antibody affinity columns followed by ultrafiltration and reversed-phase high-performance liquid chromatography. The specific activity ranged from 0.2 to 2.6 x 10(8) IU/mg protein on Madin-Darby bovine kidney cells, 0.3 to 4.6 x 10(8) IU/mg protein on human WISH cells, and 10(4) to 7 x 10(5) units/mg protein on mouse L929 cells. The apparent molecular weights of the components ranged from 17,500 to 23,300 using nonreducing sodium dodecyl polyacrylamide-gel electrophoresis and 17,500 to 27,600 using reducing sodium dodecyl polyacylamide-gel electrophoresis. The amino-terminal amino acid sequences were similar among the components as well as to those reported for the cloned human IFN-alpha genes (Pestka, S. (1986) Methods Enzymol. 119, 3-14). However, four components, f, i, l, and m, have amino-terminal amino acid sequences which appear to be unique when compared to those predicted from the cDNA clones. One component, pre-a, has a potential N-linked glycosylation site on the Asn of residues 2 through 4, Asn-Leu-Ser.			ZOON, KC (corresponding author), US FDA,CTR BIOL EVALUAT & RES,DIV CYTOKINE BIOL,BLDG 29A,RM 2D20,8800 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.							ALLEN G, 1982, BIOCHEM J, V207, P397, DOI 10.1042/bj2070397; ALLEN G, 1980, NATURE, V287, P408, DOI 10.1038/287408a0; ARNHEITER H, 1981, NATURE, V294, P278, DOI 10.1038/294278a0; ARNHEITER H, 1983, P NATL ACAD SCI-BIOL, V80, P2539, DOI 10.1073/pnas.80.9.2539; BERG K, 1980, SCAND J IMMUNOL, V11, P489, DOI 10.1111/j.1365-3083.1980.tb00017.x; BOSE S, 1976, J BIOL CHEM, V251, P1659; FANTES KH, 1980, BIOCH CHARACTERIZATI, P343; FEINSTEIN SI, 1985, MOL CELL BIOL, V5, P510, DOI 10.1128/MCB.5.3.510; GOEDDEL DV, 1981, NATURE, V290, P20, DOI 10.1038/290020a0; GOEDDEL DV, 1980, NATURE, V287, P411, DOI 10.1038/287411a0; HAUPTMANN R, 1985, NUCLEIC ACIDS RES, V13, P4739, DOI 10.1093/nar/13.13.4739; HOBBS DS, 1982, J BIOL CHEM, V257, P4071; LABDON JE, 1984, ARCH BIOCHEM BIOPHYS, V232, P422, DOI 10.1016/0003-9861(84)90558-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY WP, 1981, P NATL ACAD SCI-BIOL, V78, P6186, DOI 10.1073/pnas.78.10.6186; LUND B, 1985, J INTERFERON RES, V5, P229, DOI 10.1089/jir.1985.5.229; MANTEI N, 1980, GENE, V10, P1, DOI 10.1016/0378-1119(80)90137-7; MEURS E, 1983, ANN INST PASTEUR VIR, V134, P361, DOI 10.1016/S0769-2617(83)80009-4; MILLER D M, 1990, Journal of Interferon Research, V10, pS6; PESTKA S, 1985, PHARMACOL THERAPEUT, V29, P299, DOI 10.1016/0163-7258(85)90006-3; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PESTKA S, 1986, METHOD ENZYMOL, V119, P3; RUBINSTEIN M, 1981, ARCH BIOCHEM BIOPHYS, V210, P307, DOI 10.1016/0003-9861(81)90194-6; RUBINSTEIN M, 1979, P NATL ACAD SCI USA, V76, P640, DOI 10.1073/pnas.76.2.640; SECHER DS, 1980, NATURE, V285, P446, DOI 10.1038/285446a0; WEBB DSA, 1989, CELL IMMUNOL, V124, P158, DOI 10.1016/0008-8749(89)90119-6; WECK PK, 1981, J GEN VIROL, V57, P233, DOI 10.1099/0022-1317-57-1-233; WEINTRAUB H, 1975, CELL, V6, P85, DOI 10.1016/0092-8674(75)90077-X; YONEHARA S, 1981, J BIOL CHEM, V256, P3770; Zoon K C, 1987, BIOL INTERFER SYST P, P567; ZOON KC, 1982, J INTERFERON RES, V2, P253, DOI 10.1089/jir.1982.2.253; ZOON KC, 1979, P NATL ACAD SCI USA, V76, P5601, DOI 10.1073/pnas.76.11.5601; ZOON KC, 1980, SCIENCE, V207, P527, DOI 10.1126/science.7352260; ZOON KC, 1978, J CLIN MICROBIOL, V7, P44; ZOON KC, 1986, BIOL INTERFERON SYST, P55; ZOON KC, 1985, BIOL INTERFERON SYST, P61; ZOON KC, 1984, HDB EXPT PHARM, V71, P79	37	50	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15210	15216						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634550				2022-12-25	WOS:A1992JF08800103
J	GIVOL, I; GREENHOUSE, JJ; HUGHES, SH; EWERT, DL				GIVOL, I; GREENHOUSE, JJ; HUGHES, SH; EWERT, DL			RETROVIRUSES THAT EXPRESS DIFFERENT RAS MUTANTS CAUSE DIFFERENT TYPES OF TUMORS IN CHICKENS	ONCOGENE			English	Article								We have used replication-competent retroviral vectors to express avian and murine ras genes in cultured chick embryo fibroblasts (CEF) and in chickens. Since the viral vectors are identical, it is possible to compare the oncogenic potential of the ras genes directly. The normal (12 gly) form of chicken c-Ha-ras is not oncogenic in vivo, nor does high-level expression transform CEF. Expression of murine v-ras or modified forms of chicken c-Ha-ras with either lysine or glutamine at position 12 transforms CEF and causes tumors in birds. However, the oncogenic potential of the transforming ras genes is different, the viruses that express the genes with lysine and glutamine at position 12 cause a distinct spectrum of tumors.	NCI, FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM, POB B, FREDERICK, MD 21702 USA; NIAID, IMMUNOREGULAT LAB, BETHESDA, MD 20892 USA; WISTAR INST, PHILADELPHIA, PA 19104 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); The Wistar Institute					NCI NIH HHS [N01-CO-74101, CA39000] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039000] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTCZAK M, 1990, J VIROL, V64, P1451, DOI 10.1128/JVI.64.4.1451-1458.1990; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BROWN K, 1990, P NATL ACAD SCI USA, V87, P538, DOI 10.1073/pnas.87.2.538; DEFEO D, 1981, P NATL ACAD SCI-BIOL, V78, P3328, DOI 10.1073/pnas.78.6.3328; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; HUGHES S, 1984, VIROLOGY, V136, P89, DOI 10.1016/0042-6822(84)90250-2; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; LACAL JC, 1984, P NATL ACAD SCI-BIOL, V81, P5305, DOI 10.1073/pnas.81.17.5305; PAPAGEORGE AG, 1986, MOL CELL BIOL, V6, P1843, DOI 10.1128/MCB.6.5.1843; PULCIANI S, 1985, MOL CELL BIOL, V5, P2836, DOI 10.1128/MCB.5.10.2836; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; WESTAWAY D, 1986, EMBO J, V5, P301, DOI 10.1002/j.1460-2075.1986.tb04213.x; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373	16	8	8	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1992	7	1					141	146						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1632878				2022-12-25	WOS:A1992HC22700019
J	BLANK, JL; ROSS, AH; EXTON, JH				BLANK, JL; ROSS, AH; EXTON, JH			PURIFICATION AND CHARACTERIZATION OF 2 G-PROTEINS THAT ACTIVATE THE BETA-1 ISOZYME OF PHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPASE-C - IDENTIFICATION AS MEMBERS OF THE GQ CLASS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING REGULATORY PROTEINS; LIVER PLASMA-MEMBRANES; GUANINE-NUCLEOTIDE; ALPHA-SUBUNITS; POLYPHOSPHOINOSITIDE PHOSPHODIESTERASE; PERTUSSIS TOXIN; IMMUNOLOGICAL IDENTIFICATION; TYROSINE PHOSPHORYLATION; AFFINITY-CHROMATOGRAPHY; TURKEY ERYTHROCYTES	Plasma membranes from bovine liver contain a phosphatidylinositol 4,5-bisphosphate-specific phospholipase C (PLC) activity that is activated by guanine nucleotides. The G-proteins involved retained their ability to activate bovine brain PLC-beta-1 in a guanosine 5'-O-(3-thiotriphosphate) (GTP-gamma-S)-dependent manner following extraction from the membranes with cholate and reconstitution with phospholipids. This reconstitution assay was used to purify the G-proteins by chromatography on heparin-Sepharose, DEAE-Sephacel, octyl-Sepharose, hydroxylapatite, Mono Q, and Sephacryl S-300 gel filtration. Gel electrophoresis showed that two alpha-subunits with molecular mass of 42 and 43 kDa were isolated to a high degree of purity, together with a beta-subunit. Neither alpha-subunit was a substrate for pertussis toxin-catalyzed ADP-ribosylation. Gel filtration of the final activity indicated an apparent molecular mass of 95 kDa, suggesting the presence of an alpha-beta-gamma-heterotrimer. Immunological data revealed that the 42- and 43-kDa proteins were related to alpha-subunits of the G(q) class recently purified from brain (Pang, I.-H., and Sternweis, P. C. (1990) J. Biol. Chem. 265, 18707-18712) and identified by molecular cloning (Strathmann, M., and Simon, M. I. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 9113-9117). The activation of PLC-beta-1 by the purified G-protein preparation was specific for nonhydrolyzable guanine nucleotides, the efficacy decreasing in order GTP-gamma-S > guanylimidodiphosphate > guanylyl(beta,gamma-methylene)-diphosphonate. Half-maximal activation required 4-mu-M GTP-gamma-S suggesting that the affinity of the G-proteins for GTP analogues is low. The GTP-gamma-S-dependent activation of PLC-beta-1 required millimolar Mg2+ and was inhibited by guanosine 5'-O-(2-thiodiphosphate) and by excess beta-gamma-subunits. Aluminum fluoride also activated PLC-beta-1 in the presence of the G-proteins. The G-proteins were inactive toward PLC-gamma-1 or PLC-delta-1. In summary, these findings identify two G-protein activators of PLC-beta-1 that have the properties of heterotrimeric G-proteins and are members of the G(q) class.	VANDERBILT UNIV, MED CTR, SCH MED, HOWARD HUGHES MED INST, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, MED CTR, SCH MED, DEPT MOLEC PHYSIOL & BIOPHYS, NASHVILLE, TN 37232 USA	Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University								ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BLACKMORE PF, 1985, J BIOL CHEM, V260, P4477; CANTAU B, 1980, J RECEPTOR RES, V1, P137, DOI 10.3109/10799898009044096; CARLSON KE, 1989, J BIOL CHEM, V264, P13298; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; COCKCROFT S, 1987, BIOCHEM J, V241, P409, DOI 10.1042/bj2410409; COCKCROFT S, 1987, TRENDS BIOCHEM SCI, V12, P75, DOI 10.1016/0968-0004(87)90035-1; COCKCROFT S, 1985, NATURE, V314, P534, DOI 10.1038/314534a0; CROOKE ST, 1989, CELL CALCIUM, V10, P309, DOI 10.1016/0143-4160(89)90057-2; FAIN JN, 1990, BIOCHIM BIOPHYS ACTA, V1053, P81, DOI 10.1016/0167-4889(90)90029-D; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; FONG HKW, 1988, P NATL ACAD SCI USA, V85, P3066, DOI 10.1073/pnas.85.9.3066; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HARDEN TK, 1990, AM REV RESPIR DIS, V141, pS119, DOI 10.1164/ajrccm/141.3_Pt_2.S119; HOLBROOK SR, 1989, P NATL ACAD SCI USA, V86, P1751, DOI 10.1073/pnas.86.6.1751; KRIZ R, 1990, CIBA F SYMP, V150, P112; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LITOSCH I, 1985, J BIOL CHEM, V260, P5464; LYNCH CJ, 1989, J CLIN INVEST, V83, P2050, DOI 10.1172/JCI114116; MAJERUS PW, 1990, CELL, V63, P459, DOI 10.1016/0092-8674(90)90442-H; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MATSUOKA M, 1988, P NATL ACAD SCI USA, V85, P5384, DOI 10.1073/pnas.85.15.5384; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MORIARTY TM, 1990, NATURE, V343, P79, DOI 10.1038/343079a0; MORRIS AJ, 1990, J BIOL CHEM, V265, P13501; MORRIS AJ, 1990, J BIOL CHEM, V265, P13508; MUMBY S, 1988, J BIOL CHEM, V263, P2020; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; NISHIBE S, 1990, P NATL ACAD SCI USA, V87, P424, DOI 10.1073/pnas.87.1.424; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; PANG IH, 1990, J BIOL CHEM, V265, P18707; PANG IH, 1989, P NATL ACAD SCI USA, V86, P7814, DOI 10.1073/pnas.86.20.7814; PRICE SR, 1989, BIOCHEMISTRY-US, V28, P3803, DOI 10.1021/bi00435a027; PRPIC V, 1984, J BIOL CHEM, V259, P1382; RANA RS, 1990, PHYSIOL REV, V70, P115, DOI 10.1152/physrev.1990.70.1.115; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RYU SH, 1987, P NATL ACAD SCI USA, V84, P6649, DOI 10.1073/pnas.84.19.6649; RYU SH, 1987, J BIOL CHEM, V262, P12511; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; STRATHMANN M, 1989, P NATL ACAD SCI USA, V86, P7407, DOI 10.1073/pnas.86.19.7407; TAYLOR SJ, 1987, BIOCHEM J, V248, P791, DOI 10.1042/bj2480791; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TAYLOR SJ, 1990, J BIOL CHEM, V265, P17150; UHING RJ, 1986, J BIOL CHEM, V261, P2140; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WANGE RL, 1991, J BIOL CHEM, V266, P11409	50	176	177	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					18206	18216						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1655741				2022-12-25	WOS:A1991GG55300075
J	KINTANAR, A; METZLER, CM; METZLER, DE; SCOTT, RD				KINTANAR, A; METZLER, CM; METZLER, DE; SCOTT, RD			NMR OBSERVATION OF EXCHANGEABLE PROTONS OF PYRIDOXAL-PHOSPHATE AND HISTIDINE-RESIDUES IN CYTOSOLIC ASPARTATE-AMINOTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; PIG-HEART; SPECTRA; MITOCHONDRIAL; H-1-NMR; ISOENZYMES; SUBSTRATE; COENZYME; PROTEINS; BINDING	Observation of the 93-kDa cytosolic aspartate aminotransferase by 500-MHz H-1 NMR spectroscopy in H2O has revealed a series of resonances in the 10-18 ppm range arising from exchangeable protons. One of these (peak A) has been assigned to the proton bound to the ring nitrogen of the coenzyme pyridoxal 5'-phosphate. A second (peak B) is assigned to H143 which participates in a chain of hydrogen bonds that includes also the coenzyme-bound proton. There is a mutual nuclear Overhauser effect between these two resonances. Peaks A and B respond to changes in pH and to interaction of the enzyme with coenzyme derivatives and inhibitors. Peak A moves from 15.4 to 17.4 ppm as the pH is lowered, while peak B moves in the opposite direction from 14.7 to 13.7 ppm, both with an apparent pKa of 6.15. This pKa is associated with deprotonation of the imine nitrogen at the Schiff base linkage of the coenzyme with K258 of the enzyme. In spectra of enzyme containing pyridoxamine 5'-phosphate, peak A is observed at 16.5 ppm and peak B is at 13.9 ppm over a broad pH range. Peaks A and B are found at 17.8 and 14.0 ppm, respectively, for the enzyme complex with glutarate. When alpha-methylaspartate is added to the enzyme several new resonances appear in the spectrum, which are attributed to formation of the external aldimine. The position of peak A in spectra of various forms of the enzyme is interpreted to reflect the electronic distribution in the coenzyme ring. Several other peaks in this region of the spectrum also are sensitive to changes in pH or the addition of inhibitors. Some possible assignments of these resonances are discussed.	IOWA STATE UNIV SCI & TECHNOL, CHEM INSTRUMENT SERV, AMES, IA 50011 USA	Iowa State University	KINTANAR, A (corresponding author), IOWA STATE UNIV SCI & TECHNOL, DEPT BIOCHEM & BIOPHYS, AMES, IA 50011 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK001549] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK01549] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARNONE A, 1985, TRANSAMINASES, P326; Arnone A, 1985, TRANSAMINASES, P138; BENECKY MJ, 1985, J BIOL CHEM, V260, P1671; CAMPBELL ID, 1984, BIOL SPECTROSCOPY, P162; CASSELS R, 1978, EUR J BIOCHEM, V92, P81, DOI 10.1111/j.1432-1033.1978.tb12725.x; CHENG S, 1971, J BIOL CHEM, V246, P3623; Christen P, 1985, TRANSAMINASES; DOONAN S, 1975, BIOCHEM J, V149, P497, DOI 10.1042/bj1490497d; EICHELE G, 1979, J MOL BIOL, V135, P513, DOI 10.1016/0022-2836(79)90451-0; FASELLA P, 1966, BIOCHEMISTRY-US, V5, P197, DOI 10.1021/bi00865a026; FONDA ML, 1970, J BIOL CHEM, V245, P2709; FURBISH FS, 1969, BIOCHEMISTRY-US, V8, P5169, DOI 10.1021/bi00840a071; HAMMES GG, 1968, BIOCHEMISTRY-US, V7, P1519, DOI 10.1021/bi00844a039; HARUTYUNYAN EG, 1985, TRANSAMINASES, P164; HAYASHI H, 1990, ANNU REV BIOCHEM, V59, P87, DOI 10.1146/annurev.biochem.59.1.87; HIGAKI T, 1991, BIOCHEMISTRY-US, V30, P2519, DOI 10.1021/bi00223a032; IVANOV VI, 1969, ADV ENZYMOL RAMB, V32, P21; Jansonius J.N., 1987, BIOL MACROMOLECULES, P187; JENKINS WT, 1957, J AM CHEM SOC, V79, P2655, DOI 10.1021/ja01567a086; JENKINS WT, 1965, J BIOL CHEM, V240, P2907; JENKINS WT, 1966, J BIOL CHEM, V241, P5667; JENKINS WT, 1966, J BIOL CHEM, V241, P2845; JENKINS WT, 1980, ARCH BIOCHEM BIOPHYS, V205, P579, DOI 10.1016/0003-9861(80)90141-1; JIN P, 1989, THESIS IOWA STATE U; KALLEN RG, 1985, TRANSAMINASES, P37; KIICK DM, 1983, BIOCHEMISTRY-US, V22, P375, DOI 10.1021/bi00271a022; KORPELA T, 1987, BIOCH VITAMIN B6; Korytnyk W, 1979, Methods Enzymol, V62, P454; KURAMITSU S, 1991, IN PRESS P INT S VIT; MARTINEZ.M, 1973, J BIOL CHEM, V248, P2153; MARTINEZCARRION M, 1967, J BIOL CHEM, V242, P2397; MCPHALEN CA, 1987, BIOCH VITAMIN B6, P99; MEHTA PK, 1989, EUR J BIOCHEM, V186, P249, DOI 10.1111/j.1432-1033.1989.tb15202.x; METZLER CM, 1987, ANAL BIOCHEM, V166, P313, DOI 10.1016/0003-2697(87)90580-X; METZLER CM, 1988, J MOL BIOL, V203, P197, DOI 10.1016/0022-2836(88)90102-7; METZLER DE, 1955, J AM CHEM SOC, V77, P2431, DOI 10.1021/ja01614a022; MORINO Y, 1986, BIOCHEMISTRY-US, V25, P1917, DOI 10.1021/bi00356a013; MORINO Y, 1990, ANN NY ACAD SCI, V585, P32, DOI 10.1111/j.1749-6632.1990.tb28039.x; MORINO Y, 1984, J BIOL CHEM, V259, P3877; MORINO Y, 1984, CHEM BIOL ASPECTS VI, P255; OVCHINNIKOV YA, 1973, FEBS LETT, V29, P31, DOI 10.1016/0014-5793(73)80008-0; ROBILLAR.G, 1974, J MOL BIOL, V86, P519, DOI 10.1016/0022-2836(74)90178-8; SCOTT RD, 1985, BIOCHEMISTRY-US, V24, P7668, DOI 10.1021/bi00347a026; SCOTT RD, 1991, IN PRESS P INT S VIT; SILVA MM, 1990, 14TH ANN M AM CRYST, V18, P69; SKLENAR V, 1987, J MAGN RESON, V74, P469, DOI 10.1016/0022-2364(87)90269-1; STOESZ JD, 1979, BIOCHEMISTRY-US, V18, P4669, DOI 10.1021/bi00588a030; VELICK SF, 1962, J BIOL CHEM, V237, P2109; VERGE D, 1979, FEBS LETT, V100, P265, DOI 10.1016/0014-5793(79)80348-8; WAGNER G, 1983, J AM CHEM SOC, V105, P5948, DOI 10.1021/ja00356a056; WUTHRICH K, 1986, NMR PROTEINS NUCLEIC, P28; Yang B I, 1979, Methods Enzymol, V62, P528; YANO T, 1991, J BIOL CHEM, V266, P6079	53	32	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17222	17229						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1654326				2022-12-25	WOS:A1991GF44500040
J	HUHTALA, P; TUUTTILA, A; CHOW, LT; LOHI, J; KESKIOJA, J; TRYGGVASON, K				HUHTALA, P; TUUTTILA, A; CHOW, LT; LOHI, J; KESKIOJA, J; TRYGGVASON, K			COMPLETE STRUCTURE OF THE HUMAN GENE FOR 92-KDA TYPE-IV COLLAGENASE - DIVERGENT REGULATION OF EXPRESSION FOR THE 92-KILODALTON AND 72-KILODALTON ENZYME GENES IN HT-1080 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE COLLAGEN; EPIDERMAL GROWTH-FACTOR; FIBROBLAST COLLAGENASE; RAT FIBROBLASTS; INDUCED TRANSIN; ONCOGENE; METALLOPROTEINASES; STROMELYSIN; MATRIX; FAMILY	The complete structure of the human gene for 92-kDa type IV collagenase was determined. Two overlapping genomic clones spanning 26 kilobases (kb) of genomic DNA were shown to contain the entire 7.7-kb structural gene together with 15 and 3.5 kb of 5'-end and 3'-end flanking regions, respectively. The 92-kDa type IV collagenase gene contains 13 exons as does the 72-kDa type IV collagenase gene. All intron locations of the 92-kDa enzyme gene coincided with intron locations in the 72-kDa enzyme gene. Exons 5, 6, and 7 which were 174, 174, and 177 base pairs long, respectively, each encoded one complete internal repeat which resembles the collagen-binding domains of fibronectin. The sequence coding for a unique 48-residue segment in the 92-kDa type IV collagenase that has no counterpart in other metalloproteinases was not present in a separate exon, but was contained in exon 9 which also codes for sequences with homology to the other metalloproteinases. The initiation site for transcription was determined by primer extension analysis. Sequencing analysis of 599 base pairs of the 5'-end flanking region showed that the promoter does not have a TATA motif, but a TTAAA sequence at position -29 to -25. A CAAT motif was not observed but there was one GC box. Two putative 12-O-tetradecanoyl-phorbol-13-acetate (TPA) response elements, that might serve as binding sites for the transcription factor AP-1 and a consensus sequence of a transforming growth factor beta-1 (TGF-beta-1) inhibitory element were found in the promoter region. Gelatinase assay of enzyme secreted by cultured human fibrosarcoma cells (HT-1080) revealed only low levels of 92-kDa type IV collagenase activity, whereas considerable activity of the 72-kDa enzyme was present. Northern hybridization analysis confirmed these findings. Treatment of the HT-1080 cells with TPA resulted in induction of the secretion of 92-kDa type IV collagenase activity. This induction could not be significantly inhibited by concomitant incubation with TGF-beta-1. TPA and TGF, 61 did not markedly affect the activities of the 72-kDa enzyme. The activities of the secreted 92- and 72-kDa enzymes by HT-1080 cells correlated with the amounts of mRNA as estimated by Northern analyses.	UNIV OULU,BIOCTR,SF-90570 OULU,FINLAND; UNIV OULU,DEPT BIOCHEM,SF-90570 OULU,FINLAND; UNIV ROCHESTER,SCH MED & DENT,DEPT BIOCHEM,ROCHESTER,NY 14642; UNIV HELSINKI,DEPT VIROL,SF-00290 HELSINKI 29,FINLAND; UNIV HELSINKI,DEPT DERMATOL,SF-00290 HELSINKI 29,FINLAND	University of Oulu; Finland National Institute for Health & Welfare; University of Oulu; University of Rochester; University of Helsinki; University of Helsinki					PHS HHS [36200] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALITALO K, 1980, EUR J BIOCHEM, V109, P247, DOI 10.1111/j.1432-1033.1980.tb04790.x; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BREATHNACH R, 1987, NUCLEIC ACIDS RES, V15, P1139, DOI 10.1093/nar/15.3.1139; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOW LT, 1979, J MOL BIOL, V134, P265, DOI 10.1016/0022-2836(79)90036-6; COLLIER IE, 1988, J BIOL CHEM, V263, P10711; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; FESSLER LI, 1984, J BIOL CHEM, V259, P9783; FINI ME, 1987, BIOCHEMISTRY-US, V26, P6156, DOI 10.1021/bi00393a032; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; HARRIS ED, 1984, COLLAGEN REL RES, V4, P493; HASTY KA, 1990, J BIOL CHEM, V265, P11421; HIBBS MS, 1985, J BIOL CHEM, V260, P2493; HUHTALA P, 1990, J BIOL CHEM, V265, P11077; HUHTALA P, 1990, GENOMICS, V6, P554, DOI 10.1016/0888-7543(90)90486-E; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LOPATA MA, 1983, CELL, V32, P713, DOI 10.1016/0092-8674(83)90057-0; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MULLER D, 1988, BIOCHEM J, V253, P187, DOI 10.1042/bj2530187; MURPHY G, 1989, BIOCHEM J, V258, P463, DOI 10.1042/bj2580463; MURPHY G, 1981, BIOCHEM J, V195, P167, DOI 10.1042/bj1950167; QUINONES S, 1989, J BIOL CHEM, V264, P8339; SALO T, 1985, J BIOL CHEM, V260, P8526; SALO T, 1983, J BIOL CHEM, V258, P3058; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; TRYGGVASON K, 1987, BIOCHIM BIOPHYS ACTA, V907, P191, DOI 10.1016/0304-419X(87)90006-0; WHITHAM SE, 1986, BIOCHEM J, V240, P913, DOI 10.1042/bj2400913; WILHELM SM, 1987, P NATL ACAD SCI USA, V84, P6725, DOI 10.1073/pnas.84.19.6725; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; YAMADA Y, 1980, CELL, V22, P887, DOI 10.1016/0092-8674(80)90565-6	34	337	355	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16485	16490						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1653238				2022-12-25	WOS:A1991GD63500042
J	BAHOUTH, SW				BAHOUTH, SW			THYROID-HORMONES TRANSCRIPTIONALLY REGULATE THE BETA-1-ADRENERGIC RECEPTOR GENE IN CULTURED VENTRICULAR MYOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC RECEPTORS; RAT CARDIAC MYOCYTES; MESSENGER-RNA LEVELS; HEART-CELLS; BETA-2-ADRENERGIC RECEPTORS; RESPONSE ELEMENTS; RIBONUCLEIC-ACID; BINDING; TRIIODOTHYRONINE; IDENTIFICATION	Exposure of ventricular myocytes in primary culture to triiodothyronine (T3) increased the number of beta-1-adrenergic receptors per cell by 2.1 +/- 0.3-fold (n = 7) within 48 h. Immunoblots of membranes prepared from myocytes revealed a marked increase by T3 in the 64-kDa species of the beta-1-adrenergic receptor. Steady-state levels of beta-1- and beta-2-adrenergic receptor mRNAs quantified by DNA-excess solution hybridization were 0.26 +/- 0.06 and 0.81 +/- 0.05 amol of beta-adrenergic receptor mRNA/-mu-g of total cellular RNA, respectively (n = 4). beta-1-Adrenergic receptor mRNA increased to 0.90 +/- 0.07 amol/mu-g RNA by 2-4 h after exposure to T3 and then declined by 6 h to twice that of control cells. Beta-2-Adrenergic receptor mRNA levels were unaffected by T3. Northern blot hybridization also showed a rapid and sustained increase of 2.2 +/- 0.4-fold (n = 4) in beta-1-adrenergic receptor mRNA. The rate of beta-1-adrenergic receptor gene transcription assessed by nuclear run-on transcription assays increased by 3.4 +/- 0.4-fold in cells treated for 30 min with T3. Ventricular cells contained nuclear T3 receptors and mRNAs of c-erbA genes that encode T3 binding proteins. These studies indicate that thyroid hormones regulate the cardiac beta-adrenergic receptor-adenylate cyclase system by controlling the rate of transcription of the beta-1-adrenergic receptor gene. This regulation involves nuclear T3 receptors and appears to be exerted in a tissue-specific manner.			BAHOUTH, SW (corresponding author), UNIV TENNESSEE,CTR HLTH SCI,COLL MED,DEPT PHARMACOL,MEMPHIS,TN 38163, USA.							BAHOUTH SW, 1987, BIOCHEM J, V248, P557, DOI 10.1042/bj2480557; BAHOUTH SW, 1991, CLIN BIOTECHNOL, V3, P101; BILEZIKIAN JP, 1983, ENDOCR REV, V4, P378, DOI 10.1210/edrv-4-4-378; BLONDEL B, 1971, EXPERIENTIA, V27, P356, DOI 10.1007/BF02138197; BOWMAN LH, 1987, DEV BIOL, V119, P152, DOI 10.1016/0012-1606(87)90217-X; BURNSIDE J, 1990, J BIOL CHEM, V265, P2500; BUXTON ILO, 1985, CIRC RES, V56, P126, DOI 10.1161/01.RES.56.1.126; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COLLINS S, 1990, J BIOL CHEM, V265, P19330; COLLINS S, 1988, J BIOL CHEM, V263, P9067; COLLINS S, 1989, P NATL ACAD SCI USA, V86, P4853, DOI 10.1073/pnas.86.13.4853; CUBERO A, 1984, J BIOL CHEM, V259, P1344; DAVIES AO, 1984, ANNU REV PHYSIOL, V46, P119; DILLMANN WH, 1983, J BIOL CHEM, V258, P7738; DILLMANN WH, 1989, ANNU REV MED, V40, P373; ELKS ML, 1985, ENDOCRINOLOGY, V117, P947, DOI 10.1210/endo-117-3-947; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FRIELLE T, 1988, TRENDS NEUROSCI, V11, P321, DOI 10.1016/0166-2236(88)90095-1; FRIELLE T, 1987, P NATL ACAD SCI USA, V84, P7920, DOI 10.1073/pnas.84.22.7920; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HADCOCK JR, 1988, P NATL ACAD SCI USA, V85, P8415, DOI 10.1073/pnas.85.22.8415; HADCOCK JR, 1988, P NATL ACAD SCI USA, V85, P5021, DOI 10.1073/pnas.85.14.5021; HADCOCK JR, 1989, J BIOL CHEM, V264, P19928; IM JH, 1984, J MOL CELL CARDIOL, V16, P867, DOI 10.1016/S0022-2828(84)80023-1; KLEIN I, 1984, AM J MED, V76, P167, DOI 10.1016/0002-9343(84)90768-X; KOENIG RJ, 1989, NATURE, V337, P859; KUPFER LE, 1986, N-S ARCH PHARMACOL, V334, P275, DOI 10.1007/BF00508782; LAZAR MA, 1988, MOL ENDOCRINOL, V2, P893, DOI 10.1210/mend-2-10-893; LAZAR MA, 1990, J CLIN INVEST, V86, P1777, DOI 10.1172/JCI114906; LEFKOWITZ RJ, 1988, J BIOL CHEM, V263, P4993; LIBBY P, 1984, J MOL CELL CARDIOL, V16, P803, DOI 10.1016/S0022-2828(84)80004-8; LIMAS C, 1987, CIRC RES, V61, P824, DOI 10.1161/01.RES.61.6.824; MACHIDA CA, 1990, J BIOL CHEM, V265, P12960; MALBON CC, 1988, TRENDS PHARMACOL SCI, V9, P33, DOI 10.1016/0165-6147(88)90240-4; MALBON CC, 1988, BIOCHEM BIOPH RES CO, V154, P676, DOI 10.1016/0006-291X(88)90192-1; MURRAY MB, 1988, J BIOL CHEM, V263, P12770; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; OPPENHEIMER JH, 1987, ENDOCR REV, V8, P288, DOI 10.1210/edrv-8-3-288; ORLOWSKI J, 1990, J BIOL CHEM, V265, P3462; PINSON A, 1987, HEART CELL CULTURE, V1; POLIKAR R, 1990, J AM COLL CARDIOL, V15, P94, DOI 10.1016/0735-1097(90)90182-O; ROBINSON RB, 1987, HEART CELL CULTURE, V2, P143; SAMBROOK J, 1989, MOL CLONING LABORATO, V1; SAMUELS HH, 1973, P NATL ACAD SCI USA, V70, P3488, DOI 10.1073/pnas.70.12.3488; SAMUELS HH, 1988, J CLIN INVEST, V81, P957, DOI 10.1172/JCI113449; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SANTOS A, 1988, MOL ENDOCRINOL, V2, P992; STILES GL, 1984, PHYSIOL REV, V64, P661, DOI 10.1152/physrev.1984.64.2.661; THOMPSON CC, 1987, SCIENCE, V237, P1610, DOI 10.1126/science.3629259; TSAI JS, 1978, NATURE, V275, P138, DOI 10.1038/275138a0; WANG HY, 1989, J BIOL CHEM, V264, P14424; WILLIAMS DL, 1986, METHOD ENZYMOL, V128, P671	53	113	116	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					15863	15869						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1651924				2022-12-25	WOS:A1991GB97700053
J	BIANCHINI, L; WOODSIDE, M; SARDET, C; POUYSSEGUR, J; TAKAI, A; GRINSTEIN, S				BIANCHINI, L; WOODSIDE, M; SARDET, C; POUYSSEGUR, J; TAKAI, A; GRINSTEIN, S			OKADAIC ACID, A PHOSPHATASE INHIBITOR, INDUCES ACTIVATION AND PHOSPHORYLATION OF THE NA+/H+ ANTIPORT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; INTRACELLULAR PH; CYTOPLASMIC PH; GROWTH-FACTORS; H+ EXCHANGER; CELLS; AMILORIDE; MEMBRANE; LYMPHOCYTES; FIBROBLASTS	We determined the effect of okadaic acid (OA), a potent phosphoprotein phosphatase inhibitor, on the intracellular pH (pH(i)) of rat thymic lymphocytes and human bladder carcinoma cells. OA induced a rapid and sustained cytosolic alkalinization. This pH(i) increase was Na-dependent and was inhibited by 5,N-disubstituted analogs of amiloride, indicating mediation by the Na+/H+ antiport. As described for other stimulants, such as mitogens and hypertonic challenge, activation of the antiport by OA is attributable to an upward shift in its pH(i) dependence. Accordingly, the alkalinization produced by the phosphatase inhibitor was not additive with that induced osmotically. Activation of the antiport by OA was accompanied by a marked increase in phosphoprotein accumulation, revealing the presence of active protein kinases in otherwise unstimulated cells. We considered the possibility that phosphorylation of the antiport itself or of an ancillary protein is responsible for activation of Na+/H+ exchange. Consistent with this notion, the alkalinization induced by OA was absent in ATP depleted cells. More importantly, immunoprecipitation experiments demonstrated increased phosphorylation of the antiport following treatment with OA. We conclude that, upon inhibition of phosphoprotein phosphatase activity, constitutively active kinases induce the activation of Na+/H+ exchange, possibly by direct phosphorylation of the antiport.	HOSP SICK CHILDREN,DIV CELL BIOL,555 UNIV AVE,TORONTO M5G 1X8,ONTARIO,CANADA; UNIV NICE,CNRS,CTR BIOCHIM,F-06034 NICE,FRANCE; NAGOYA UNIV,DEPT PHYSIOL,NAGOYA,AICHI 466,JAPAN	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Nagoya University								ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ARONSON PS, 1982, NATURE, V299, P161, DOI 10.1038/299161a0; ARONSON PS, 1985, ANNU REV PHYSIOL, V47, P545, DOI 10.1146/annurev.ph.47.030185.002553; BAROIN A, 1984, J PHYSIOL-LONDON, V356, P21, DOI 10.1113/jphysiol.1984.sp015450; BENOS DJ, 1982, AM J PHYSIOL, V242, pC131, DOI 10.1152/ajpcell.1982.242.3.C131; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; CASSEL D, 1986, J BIOL CHEM, V261, P5460; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P464; GELFAND EW, 1986, J BIOL CHEM, V261, P1520; GOMEZ N, 1990, FEBS LETT, V271, P119, DOI 10.1016/0014-5793(90)80386-W; GOTOH Y, 1990, EUR J BIOCHEM, V193, P671, DOI 10.1111/j.1432-1033.1990.tb19385.x; GRINSTEIN S, 1988, J BIOL CHEM, V263, P1779; GRINSTEIN S, 1987, J BIOL CHEM, V262, P15277; GRINSTEIN S, 1984, J GEN PHYSIOL, V83, P341, DOI 10.1085/jgp.83.3.341; GRINSTEIN S, 1986, J MEMBRANE BIOL, V90, P1, DOI 10.1007/BF01869680; GRINSTEIN S, 1989, PHYSIOL REV, V69, P417, DOI 10.1152/physrev.1989.69.2.417; GRINSTEIN S, 1985, P NATL ACAD SCI USA, V82, P1429, DOI 10.1073/pnas.82.5.1429; GRINSTEIN S, 1984, AM J PHYSIOL, V247, pC293, DOI 10.1152/ajpcell.1984.247.3.C293; GRINSTEIN S, 1985, J CELL BIOL, V101, P269, DOI 10.1083/jcb.101.1.269; HAAVIK J, 1989, FEBS LETT, V251, P36, DOI 10.1016/0014-5793(89)81424-3; HAYSTEAD TAJ, 1990, EUR J BIOCHEM, V187, P199, DOI 10.1111/j.1432-1033.1990.tb15295.x; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HIDAKA H, 1980, MOL PHARMACOL, V17, P66; KAWAMOTO S, 1984, BIOCHEM BIOPH RES CO, V125, P258, DOI 10.1016/S0006-291X(84)80362-9; KONG SK, 1989, BIOCHEM BIOPH RES CO, V165, P131, DOI 10.1016/0006-291X(89)91044-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALLEMAIN G, 1984, J BIOL CHEM, V259, P4313; MIYASAKA T, 1990, BIOCHEM BIOPH RES CO, V168, P1237, DOI 10.1016/0006-291X(90)91161-K; MOOLENAAR WH, 1986, ANNU REV PHYSIOL, V48, P363; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; OWEN NE, 1982, BIOCHEM BIOPH RES CO, V109, P762, DOI 10.1016/0006-291X(82)92005-8; RAY LB, 1988, J BIOL CHEM, V263, P12721; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; ROTIN D, 1989, CANCER RES, V49, P205; SARDET C, 1990, SCIENCE, V247, P723, DOI 10.1126/science.2154036; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SHIBATA S, 1982, J PHARMACOL EXP THER, V223, P135; TACHIBANA K, 1981, J AM CHEM SOC, V103, P2469, DOI 10.1021/ja00399a082; TANAKA T, 1982, MOL PHARMACOL, V22, P408; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012	45	119	119	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15406	15413						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1651331				2022-12-25	WOS:A1991GB09700086
J	TAN, A; VANDENBROEK, L; VANBOECKEL, S; PLOEGH, H; BOLSCHER, J				TAN, A; VANDENBROEK, L; VANBOECKEL, S; PLOEGH, H; BOLSCHER, J			CHEMICAL MODIFICATION OF THE GLUCOSIDASE INHIBITOR 1-DEOXYNOJIRIMYCIN - STRUCTURE-ACTIVITY-RELATIONSHIPS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; INTESTINAL EPITHELIAL-CELLS; ENDOPLASMIC-RETICULUM; SECRETORY GLYCOPROTEINS; SYNCYTIUM FORMATION; MANNOSIDASE-I; MEMBRANE; CASTANOSPERMINE; DERIVATIVES; DEOXYNOJIRIMYCIN	The ability of the glucosidase inhibitor 1-deoxynojirimycin (dNM) and a series of N-alkylated dNM derivatives to interfere with biosynthesis, transport, and maturation of the glycoprotein alpha-1-antitrypsin in HepG2 cells was investigated. Inhibition of endoplasmic reticulum glucosidase I and II by dNM and its derivatives resulted in an intracellular accumulation of alpha-1-antitrypsin with glucose-containing high mannose type oligosaccharides (precursor). N-alkylation of dNM increased its potency in inhibiting endoplasmic reticulum glucosidases, as determined from the concentration required for half maximal inhibition. N-Alkylated derivatives of dNM were better able to inhibit glucosidase I than glucosidase II (deduced from the number of glucose residues retained in Endo H-releasable oligosaccharides). The inhibition of glucosidase activity imposed by alkylated dNM derivatives was less easily reversed than that by dNM, an effect most pronounced for N-methyl-dNM. Branching of the alkyl group of dNM derivatives decreased the inhibitory potency. Although dNM and its derivatives interfered strongly with intracellular oligosaccharide processing, they did not completely block N-glycan maturation of alpha-1-antitrypsin even at the highest concentrations tested.	NETHERLANDS CANC INST,DIV CELLULAR BIOCHEM,PLESMANLAAN 121,1066 CX AMSTERDAM,NETHERLANDS; ORGANON INT BV,SCI DEV GRP,5340 BH OSS,NETHERLANDS	Netherlands Cancer Institute			Bolscher, Jan/ABF-6102-2021	Bolscher, Jan/0000-0001-5669-6164				BOESHAGEN H, 1989, Patent No. 315017; BOLLEN M, 1989, EUR J BIOCHEM, V181, P775, DOI 10.1111/j.1432-1033.1989.tb14792.x; BROXTERMAN HJG, 1987, RECL TRAV CHIM PAY B, V106, P571; BURKE B, 1984, EMBO J, V3, P551, DOI 10.1002/j.1460-2075.1984.tb01845.x; CHIBA S, 1988, BIOCHEMISTRY-US, V27, P1564, DOI 10.1021/bi00405a025; DOBBERSTEIN B, 1979, CELL, V17, P759, DOI 10.1016/0092-8674(79)90316-7; ELBEIN AD, 1984, ARCH BIOCHEM BIOPHYS, V235, P579, DOI 10.1016/0003-9861(84)90232-7; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; FLEET GWJ, 1988, FEBS LETT, V237, P128, DOI 10.1016/0014-5793(88)80185-6; FLEET GWJ, 1988, TETRAHEDRON LETT, V29, P3603, DOI 10.1016/0040-4039(88)85305-X; FODDY L, 1988, EUR J BIOCHEM, V175, P291, DOI 10.1111/j.1432-1033.1988.tb14196.x; GROSS V, 1983, J BIOL CHEM, V258, P2203; GRUTERS RA, 1987, NATURE, V330, P74, DOI 10.1038/330074a0; HENDRY D, 1988, TETRAHEDRON, V44, P6143, DOI 10.1016/S0040-4020(01)89804-5; HETTKAMP H, 1984, EUR J BIOCHEM, V142, P85, DOI 10.1111/j.1432-1033.1984.tb08253.x; HUBBARD SC, 1979, J BIOL CHEM, V254, P4568; HUGHES RC, 1987, BIOCHEM J, V247, P537, DOI 10.1042/bj2470537; INOUYE S, 1968, TETRAHEDRON, V23, P2125; JUNGE B, 1981, Patent No. 4260622; KARPAS A, 1988, P NATL ACAD SCI USA, V85, P9229, DOI 10.1073/pnas.85.23.9229; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LEGLER G, 1985, BIOL CHEM H-S, V366, P1113, DOI 10.1515/bchm3.1985.366.2.1113; LEMANSKY P, 1984, J BIOL CHEM, V259, P129; LODISH HF, 1984, J CELL BIOL, V98, P1720, DOI 10.1083/jcb.98.5.1720; MOORE SEH, 1990, J BIOL CHEM, V265, P13104; NEEFJES JJ, 1989, J BIOL CHEM, V264, P10271; PEYRIERAS N, 1983, EMBO J, V2, P823, DOI 10.1002/j.1460-2075.1983.tb01509.x; ROMERO PA, 1985, BIOCHEM J, V226, P733, DOI 10.1042/bj2260733; ROMERO PA, 1985, FEBS LETT, V183, P29, DOI 10.1016/0014-5793(85)80947-9; SAUNIER B, 1982, J BIOL CHEM, V257, P4155; SCHWEDEN J, 1986, ARCH BIOCHEM BIOPHYS, V248, P335, DOI 10.1016/0003-9861(86)90429-7; SNIDER MD, 1986, J CELL BIOL, V103, P265, DOI 10.1083/jcb.103.1.265; TYMS AS, 1987, LANCET, V2, P1025; WALKER BD, 1987, P NATL ACAD SCI USA, V84, P8120, DOI 10.1073/pnas.84.22.8120; YAMASHITA K, 1982, METHOD ENZYMOL, V83, P105	35	71	76	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14504	14510						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1650361				2022-12-25	WOS:A1991FZ35100063
J	IKEDA, U; HYMAN, R; SMITH, TW; MEDFORD, RM				IKEDA, U; HYMAN, R; SMITH, TW; MEDFORD, RM			ALDOSTERONE-MEDIATED REGULATION OF NA+,K+-ATPASE GENE-EXPRESSION IN ADULT AND NEONATAL RAT CARDIOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED KIDNEY-CELLS; NA-K-ATPASE; COLLECTING TUBULE; MINERALOCORTICOID RECEPTOR; VENTRICULAR CELLS; EPITHELIAL-CELLS; THYROID-HORMONE; BETA-SUBUNIT; HEART-CELLS; NA,K-ATPASE	By altering the Na+/K+ electrochemical gradient, Na+,K+-ATPase activity profoundly influences cardiac cell excitability and contractility. The recent finding of mineralocorticoid hormone receptors in the heart implies that Na+,K+-ATPase gene expression, and hence cardiac function, is regulated by aldosterone, a corticosteroid hormone associated with certain forms of hypertension and classically involved in regulating Na+,K+-ATPase gene expression and transepithelial Na+ transport in tissues such as the kidney. The regulation by aldosterone of the major cardiac Na+,K+-ATPase isoform genes, alpha-1 and beta-1, were studied in adult and neonatal rat ventricular cardiocytes grown in defined serum-free media. In both cell types, aldosterone-induced a rapid and sustained 3-fold induction in alpha-1 mRNA accumulation within 6 h. Beta-1 mRNA was similarly induced. alpha-1 mRNA induction occurred over the physiological range with an EC50 of 1-2 nm, consistent with binding of aldosterone to the high affinity mineralocorticoid hormone receptor. In adult cardiocytes, this was associated with a 36% increase in alpha-subunit protein accumulation and an increase in Na+K+-ATPase transport activity. Aldosterone did not alter the 3-h half-life of alpha-1 mRNA, indicating an induction of alpha-1 mRNA synthesis. Aldosterone-dependent alpha-1 mRNA accumulation was not blocked by the protein synthesis inhibitor cycloheximide, whereas amiloride inhibited both an aldosterone-dependent increase in intracellular Na+ ([Na+]i) and alpha-1 mRNA accumulation. This demonstrates that aldosterone directly stimulates Na+,K+-ATPase alpha-1 subunit mRNA synthesis and protein accumulation in cardiac cells throughout development and suggests that the heart is a mineralocorticoid-responsive organ. An early increase in [Na+]i may be a proximal event in the mediation of the hormone effect.	EMORY UNIV,SCH MED,DEPT MED,DIV CARDIOL,319 WOODRUFF MEM BLDG,PO DRAWER LL,ATLANTA,GA 30322; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV CARDIOVASC,BOSTON,MA 02115	Emory University; Harvard University; Brigham & Women's Hospital; Harvard Medical School					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036141] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL36141] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; BARLETBAS C, 1988, P NATL ACAD SCI USA, V85, P1707, DOI 10.1073/pnas.85.5.1707; BINDER HJ, 1989, J PHYSIOL-LONDON, V410, P425, DOI 10.1113/jphysiol.1989.sp017542; BLOCH KD, 1986, CELL, V47, P695, DOI 10.1016/0092-8674(86)90512-X; CATO ACB, 1988, J CELL BIOL, V106, P2119, DOI 10.1083/jcb.106.6.2119; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; DOUCET A, 1988, KIDNEY INT, V34, P749, DOI 10.1038/ki.1988.245; FANESTIL DD, 1981, ANNU REV PHYSIOL, V43, P637, DOI 10.1146/annurev.ph.43.030181.003225; FINKEL Y, 1986, PEDIATR RES, V20, P242, DOI 10.1203/00006450-198603000-00009; FUNDER JW, 1973, ENDOCRINOLOGY, V93, P1300, DOI 10.1210/endo-93-6-1300; GLOOR S, 1990, J CELL BIOL, V110, P165, DOI 10.1083/jcb.110.1.165; HEGYVARY C, 1977, EXPERIENTIA, V33, P1280, DOI 10.1007/BF01920133; HERRERA VLM, 1988, SCIENCE, V241, P221, DOI 10.1126/science.2838907; IKEDA U, 1990, CARDIOSCIENCE, V1, P225; IKEDA U, 1988, CIRCULATION, V78, P242; JORGENSEN PL, 1982, BIOCHIM BIOPHYS ACTA, V694, P27, DOI 10.1016/0304-4157(82)90013-2; KIM D, 1986, AM J PHYSIOL, V250, pC32, DOI 10.1152/ajpcell.1986.250.1.C32; KIM D, 1984, CIRC RES, V55, P39, DOI 10.1161/01.RES.55.1.39; KIM D, 1984, J CLIN INVEST, V74, P1481, DOI 10.1172/JCI111561; LASKI ME, 1983, J CLIN INVEST, V72, P2050, DOI 10.1172/JCI111170; LIN ZY, 1989, GENE DEV, V3, P986, DOI 10.1101/gad.3.7.986; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTINVASALLO P, 1989, J BIOL CHEM, V264, P4613; MARVER D, 1985, BIOCHEM ACTION HORM, V12, P385; MCKNIGHT GS, 1979, CELL, V14, P403; MEDFORD RM, 1983, J BIOL CHEM, V258, P1063; MEDFORD RM, 1990, CIRCULATION, V82, P535; ORLOWSKI J, 1990, J BIOL CHEM, V265, P3462; ORLOWSKIJ, 1988, J BIOL CHEM, V263, P10436; PEARCE P, 1987, CLIN EXP PHARMACOL P, V14, P859, DOI 10.1111/j.1440-1681.1987.tb02422.x; PETTY KJ, 1981, J CLIN INVEST, V68, P1514, DOI 10.1172/JCI110405; PRATT RD, 1984, BIOCHIM BIOPHYS ACTA, V805, P405, DOI 10.1016/0167-4889(84)90024-7; RINGOLD GM, 1977, P NATL ACAD SCI USA, V74, P2879, DOI 10.1073/pnas.74.7.2879; SCHENK DB, 1984, J BIOL CHEM, V259, P14941; STOKES JB, 1981, KIDNEY INT, V20, P340, DOI 10.1038/ki.1981.144; SWEADNER KJ, 1980, NEW ENGL J MED, V302, P777, DOI 10.1056/NEJM198004033021404; TAPSCOTT SJ, 1989, SCIENCE, V245, P532, DOI 10.1126/science.2547249; VERREY F, 1987, J CELL BIOL, V104, P1231, DOI 10.1083/jcb.104.5.1231; VERREY F, 1989, MOL ENDOCRINOL, V3, P1369, DOI 10.1210/mend-3-9-1369; WALSHREITZ MM, 1984, AM J PHYSIOL, V247, pC321, DOI 10.1152/ajpcell.1984.247.5.C321	41	117	118	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1991	266	18					12058	12066						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FT762	1646819				2022-12-25	WOS:A1991FT76200097
J	NAGGERT, J; NARASIMHAN, ML; DEVEAUX, L; CHO, HS; RANDHAWA, ZI; CRONAN, JE; GREEN, BN; SMITH, S				NAGGERT, J; NARASIMHAN, ML; DEVEAUX, L; CHO, HS; RANDHAWA, ZI; CRONAN, JE; GREEN, BN; SMITH, S			CLONING, SEQUENCING, AND CHARACTERIZATION OF ESCHERICHIA-COLI THIOESTERASE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID SYNTHETASE; RAT MAMMARY-GLAND; EXPRESSION; PROTEINS; PURIFICATION; SPECIFICITY; REGION; GENE; SITE	The gene (tesB) encoding Escherichia coli thioesterase II, a low-abundance enzyme of unknown physiological function which can hydrolyze a broad range of acyl-CoA thioesters, has been localized by transposon mutagenesis, cloned and sequenced. A two-cistron construct containing both the lac and tesB promoters was used successfully to overexpress the 286-residue polypeptide. The recombinant enzyme constituted up to 25% of the soluble proteins of E. coli and was readily purified to homogeneity as a tetramer of approximately 120,000 Da. Amino-terminal sequence analysis and electrospray ionization mass spectrometry confirmed the identity of the thioesterase and revealed that the amino-terminal formyl-methionine had been removed yielding a subunit species of average molecular mass 31,842 Da. The protein does not contain the GXSXG motif found characteristically in animal thioesterases which function as chain-terminating enzymes in fatty acid synthesis and exhibits no sequence similarity with these or any other known proteins. Activity of the recombinant enzyme was inhibited by iodoacetamide and diethylpyrocarbonate. The carboxamidomethylated residue was identified as histidine 58, and a role for this amino acid in catalysis is suggested. E. coli strains having a large deletion within the genomic tesB gene grew normally but retained a low level of thioesterase activity toward decanoyl-CoA. This residual activity indicates the presence of an additional decanoyl-CoA hydrolase in E. coli. Overexpression of the recombinant enzyme, under control of the lac promoter, did not alter the fatty acids synthesized by E. coli at any stage of cell growth and the physiological role of this enzyme remains an enigma.	CHILDRENS HOSP,OAKLAND RES INST,747 52ND ST,OAKLAND,CA 94609; OTSUKA AMER PHARMACEUT INC,ROCKVILLE,MD 20850; UNIV ILLINOIS,DEPT MICROBIOL,URBANA,IL 61801; UNIV ILLINOIS,DEPT BIOCHEM,URBANA,IL 61801; VG MASSLAB LTD,ALTRINCHAM WA14 6RZ,ENGLAND	Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign			Cronan, John/V-6626-2019		NIAID NIH HHS [AI 15650] Funding Source: Medline; NIDDK NIH HHS [DK 16073, DK34400] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015650, R37AI015650] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016073, R01DK034400] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barnes E M Jr, 1975, Methods Enzymol, V35, P102, DOI 10.1016/0076-6879(75)35144-6; BARNES EM, 1968, J BIOL CHEM, V243, P2955; BAYLEY SA, 1988, BIO-TECHNOL, V6, P1219, DOI 10.1038/nbt1088-1219; BLANCHE PJ, 1981, BIOCHIM BIOPHYS ACTA, V665, P408, DOI 10.1016/0005-2760(81)90253-8; BONNER WM, 1972, J BIOL CHEM, V247, P3123; DEVEAUX LC, 1985, J BACTERIOL, V162, P888, DOI 10.1128/JB.162.3.888-896.1985; GRIBSKOV M, 1984, NUCLEIC ACIDS RES, V12, P539, DOI 10.1093/nar/12.1Part2.539; GUYER MS, 1983, METHOD ENZYMOL, V101, P363; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; HOHN B, 1980, GENE, V11, P291, DOI 10.1016/0378-1119(80)90069-4; Hohn B, 1979, Methods Enzymol, V68, P299; ISHHOROWICZ D, 1981, NUCLEIC ACIDS RES, V9, P2989, DOI 10.1093/nar/9.13.2989; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIBERTINI LJ, 1978, J BIOL CHEM, V253, P1393; MULLIGAN ME, 1984, NUCLEIC ACIDS RES, V12, P789, DOI 10.1093/nar/12.1Part2.789; NAGGERT J, 1987, BIOCHEM J, V243, P597, DOI 10.1042/bj2430597; NARASHIMHAN ML, 1986, J BACTERIOL, V165, P911, DOI 10.1128/jb.165.3.911-917.1986; SAITO H, 1963, BIOCHIM BIOPHYS ACTA, V72, P619, DOI 10.1016/0926-6550(63)90386-4; SANCAR A, 1979, J BACTERIOL, V137, P692, DOI 10.1128/JB.137.1.692-693.1979; SCHONER BE, 1984, P NATL ACAD SCI-BIOL, V81, P5403, DOI 10.1073/pnas.81.17.5403; Smith S, 1981, Methods Enzymol, V71 Pt C, P181, DOI 10.1016/0076-6879(81)71026-7; Smith S, 1981, Methods Enzymol, V71 Pt C, P188, DOI 10.1016/0076-6879(81)71027-9; SMITH S, 1979, ARCH BIOCHEM BIOPHYS, V196, P88, DOI 10.1016/0003-9861(79)90554-X; SPENCER AK, 1978, J BIOL CHEM, V253, P5922; WIHAN SC, 1985, J BACTERIOL, V161, P1219; WITKOWSKA HE, 1990, J BIOL CHEM, V265, P5662; YANG SY, 1985, J BIOL CHEM, V260, P2862; YOSHIDA H, 1989, BIOCHIMIE, V71, P687, DOI 10.1016/0300-9084(89)90163-6	31	83	150	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					11044	11050						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	1645722				2022-12-25	WOS:A1991FQ77400054
J	SHUMAN, S				SHUMAN, S			SITE-SPECIFIC INTERACTION OF VACCINIA VIRUS TOPOISOMERASE-I WITH DUPLEX DNA - MINIMAL DNA SUBSTRATE FOR STRAND CLEAVAGE INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SUPERCOILED DNA; SV40 DNA; SEQUENCE; MUTAGENESIS; CLONING; BINDING; GENE; RESOLUTION; BREAKAGE	Purified vaccinia virus DNA topoisomerase I forms a cleavable complex with duplex DNA at a conserved sequence element 5'(C/T)CCTT down in the incised DNA strand. DNase I footprint studies show that vaccinia topoisomerase protects the region around the site of covalent adduct formation from nuclease digestion. On the cleaved DNA strand, the protected region extends from +13 to -13 (+1 being the site of cleavage). On the noncleaved strand, the protected region extends from +13 to -9. Similar nuclease protection is observed for a mutant topoisomerase (containing a Tyr --> Phe substitution at the active site amino acid 274) that is catalytically inert and does not form the covalent intermediate. Thus, vaccinia topoisomerase is a specific DNA binding protein independent of its competence in transesterification. By studying the cleavage of a series of 12-mer DNA duplexes in which the position of the CCCTT down motif within the substrate is systematically phased, the "minimal' substrate for cleavage has been defined; cleavage requires six nucleotides upstream of the cleavage site and two nucleotides downstream of the site. An analysis of the cleavage of oligomer substrates mutated singly in the CCCTT sequence reveals a hierarchy of mutational effects based on position within the pentamer motif and the nature of the sequence alteration.			SHUMAN, S (corresponding author), SLOAN KETTERING MEM CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042498] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42498-02] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUER WR, 1977, P NATL ACAD SCI USA, V74, P1841, DOI 10.1073/pnas.74.5.1841; BEEN MD, 1984, NUCLEIC ACIDS RES, V12, P3097, DOI 10.1093/nar/12.7.3097; BEEN MD, 1984, J MOL BIOL, V180, P515, DOI 10.1016/0022-2836(84)90025-1; BJORNSTI MA, 1987, P NATL ACAD SCI USA, V84, P8971, DOI 10.1073/pnas.84.24.8971; BUSK H, 1987, NATURE, V327, P638, DOI 10.1038/327638a0; Champoux JJ, 1990, DNA TOPOLOGY ITS BIO, P217; DARPA P, 1988, P NATL ACAD SCI USA, V85, P2543, DOI 10.1073/pnas.85.8.2543; DEAN F, 1983, COLD SPRING HARB SYM, V47, P769; DIGATE RJ, 1989, J BIOL CHEM, V264, P17924; EDWARDS KA, 1982, NUCLEIC ACIDS RES, V10, P2565, DOI 10.1093/nar/10.8.2565; KIM YC, 1990, SCIENCE, V249, P1307, DOI 10.1126/science.2399465; KIRKEGAARD K, 1985, J MOL BIOL, V185, P625, DOI 10.1016/0022-2836(85)90075-0; LYNN RM, 1989, P NATL ACAD SCI USA, V86, P3559, DOI 10.1073/pnas.86.10.3559; MCCLARIN JA, 1986, SCIENCE, V234, P1526, DOI 10.1126/science.3024321; MORHAM SG, 1990, GENE DEV, V4, P515, DOI 10.1101/gad.4.4.515; SHAFFER R, 1987, J BIOL CHEM, V262, P9309; SHUMAN S, 1991, J BIOL CHEM, V266, P1796; SHUMAN S, 1988, J BIOL CHEM, V263, P16401; SHUMAN S, 1990, J BIOL CHEM, V265, P17826; SHUMAN S, 1987, P NATL ACAD SCI USA, V84, P7478, DOI 10.1073/pnas.84.21.7478; SHUMAN S, 1989, VIROLOGY, V170, P302, DOI 10.1016/0042-6822(89)90384-X; SHUMAN S, 1989, P NATL ACAD SCI USA, V86, P9793, DOI 10.1073/pnas.86.24.9793; STEVNSNER T, 1989, J BIOL CHEM, V264, P10110; SVEJSTRUP JQ, 1990, J BIOL CHEM, V265, P12529; TAPPER DP, 1981, NUCLEIC ACIDS RES, V9, P6787, DOI 10.1093/nar/9.24.6787; THOMSEN B, 1987, EMBO J, V6, P1817, DOI 10.1002/j.1460-2075.1987.tb02436.x; TRASK DK, 1983, NUCLEIC ACIDS RES, V11, P2779, DOI 10.1093/nar/11.9.2779; TSE YC, 1980, J BIOL CHEM, V255, P5560; TSEDINH YC, 1983, NUCLEIC ACIDS RES, V11, P8691, DOI 10.1093/nar/11.24.8691; TSEDINH YC, 1988, J BIOL CHEM, V263, P15857; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZUMSTEIN L, 1986, J MOL BIOL, V191, P333, DOI 10.1016/0022-2836(86)90130-0	32	83	110	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					11372	11379						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	1645733				2022-12-25	WOS:A1991FQ77400102
J	RAMEH, LE; ARMELIN, MCS				RAMEH, LE; ARMELIN, MCS			T-ANTIGENS ROLE IN POLYOMAVIRUS TRANSFORMATION - C-MYC BUT NOT C-FOS OR C-JUN EXPRESSION IS A TARGET FOR MIDDLE-T	ONCOGENE			English	Article							PHOSPHATIDYLINOSITOL KINASE-ACTIVITY; EARLY-RESPONSE GENES; GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; ONCOGENIC TRANSFORMATION; MOLECULAR-CLONING; PP60C-SRC KINASE; TRANSGENIC MICE; PHOSPHOLIPASE-C; EARLY PROTEINS	Polyoma virus (Py) causes neoplastic transformation in vitro and multiple tumors in vivo. The role played by large and middle T antigens (LT, MT) and their mechanisms of action are focused here. Py-transformed Balb-3T3 cells become independent of platelet-derived growth factor (PDGF) for growth. JE, c-fos, c-jun and c-myc are 'immediate early' genes induced in response to PDGF. To test whether these cellular genes play a role in malignant transformation by Py, we generated a number of transfectant cell lines overexpressing LT, MT or both. Characterization of these cell lines revealed that: (a) MT but not LT causes morphological transformation, ability to grow in PDGF-free plasma medium and ability to grow in agarose suspension; (b) cooperation between LT and MT is evident in vitro, however, high and simultaneous LT and MT expression does not warrant tumorigenic potential; (c) MT expression does not correlate with tumorigenic potential but alters the probability of eliciting tumors; (d) JE and c-myc (but not c-fos or c-jun) are constitutively expressed in MT transfectants. MT induction is followed by c-myc induction 1.5 h later. We conclude that some of the 'immediate-early' genes may play pivotal roles in Py transformation.	UNIV SAO PAULO,INST QUIM,DEPT BIOQUIM,CP 20780,BR-01498 SAO PAULO,BRAZIL	Universidade de Sao Paulo	ARMELIN, MCS (corresponding author), UNIV SAO PAULO,INST QUIM,DEPT BIOQUIM,CP 20780,BR-01498 SAO PAULO,BRAZIL.							ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ARMELIN HA, 1973, P NATL ACAD SCI USA, V70, P2702, DOI 10.1073/pnas.70.9.2702; ARMELIN MCS, 1985, COLD SPRING HARBOR C, V3, P195; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BAUTCH VL, 1987, CELL, V51, P529, DOI 10.1016/0092-8674(87)90122-X; BENJAMIN T, 1990, VIROLOGY, P317; BOUCHARD L, 1984, VIROLOGY, V135, P53, DOI 10.1016/0042-6822(84)90116-8; CHENG SH, 1988, EMBO J, V7, P3845, DOI 10.1002/j.1460-2075.1988.tb03270.x; CHERINGTON V, 1986, P NATL ACAD SCI USA, V83, P4307, DOI 10.1073/pnas.83.12.4307; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; EK B, 1982, NATURE, V295, P419, DOI 10.1038/295419a0; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GELINAS C, 1989, VIROLOGY, V170, P193, DOI 10.1016/0042-6822(89)90366-8; GLENN GM, 1990, J VIROL, V64, P2193, DOI 10.1128/JVI.64.5.2193-2201.1990; GORGA FR, 1990, J VIROL, V64, P105, DOI 10.1128/JVI.64.1.105-112.1990; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; ITO Y, 1977, P NATL ACAD SCI USA, V74, P4666, DOI 10.1073/pnas.74.10.4666; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; KAPLAN DR, 1985, MOL CELL BIOL, V5, P1795, DOI 10.1128/MCB.5.7.1795; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P3624, DOI 10.1073/pnas.83.11.3624; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; METCALF D, 1987, EMBO J, V6, P3703, DOI 10.1002/j.1460-2075.1987.tb02704.x; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; MUSER J, 1989, ONCOGENE, V4, P1433; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; RAPTIS L, 1985, MOL CELL BIOL, V5, P2476, DOI 10.1128/MCB.5.9.2476; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; ROLLINS BJ, 1988, P NATL ACAD SCI USA, V85, P3738, DOI 10.1073/pnas.85.11.3738; SONOBE MH, 1991, IN PRESS ONCOGENE; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WELHAM MJ, 1990, ONCOGENE, V5, P161; WHITMAN M, 1988, Biochimica et Biophysica Acta, V948, P327; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; WILLIAMS RL, 1989, CELL, V57, P1053, DOI 10.1016/0092-8674(89)90343-7; ZARBL H, 1987, CELL, V51, P357, DOI 10.1016/0092-8674(87)90632-5; ZULLO J, 1987, P NATL ACAD SCI USA, V84, P1210, DOI 10.1073/pnas.84.5.1210	55	21	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1991	6	6					1049	1056						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1648700				2022-12-25	WOS:A1991GU62200022
J	LINDSEY, GG; THOMPSON, P				LINDSEY, GG; THOMPSON, P			S(T)PXX MOTIFS PROMOTE THE INTERACTION BETWEEN THE EXTENDED N-TERMINAL TAILS OF HISTONE H2B WITH LINKER DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URCHIN SPERM CHROMATIN; CORE-HISTONE; PARTICLE; SEQUENCE; PROTEINS	The assembly of hybrid core particles onto long chicken DNA with histone H2B in the chicken histone octamer replaced with either wheat histone H2B(2) or sea urchin sperm histone H2B(1) or H2B(2) is described. All these histone H2B variants have N-terminal extensions of between 18 and 20 amino acids, although only those from sea urchin sperm have S(T)PXX motifs present. Whereas chicken histone octamers protected 167 base pairs (bp) (representing two full turns) of DNA against micrococcal nuclease digestion (Lindsey, G. G., Orgeig, S., Thompson, P., Davies, N., and Maeder, D. L. (1991) J. Mol. Biol. 218, 805-813), all the hybrid histone octamers protected an additional 17-bp DNA against nuclease digestion. This protection was more marked in the case of hybrid octamers containing sea urchin sperm histone H2B variants and similar to that described previously (Lindsey, G. G., Orgeig, S., Thompson, P., Davies, N., and Maeder, D. L. (1991) J. Mol. Biol. 218, 805-813) for hybrid histone octamers containing wheat histone H2A variants all of which also have S(T)PXX motifs present. Continued micrococcal nuclease digestion reduced the length of DNA associated with the core particle via 172-, 162-, and 152-bp intermediates until the 146-bp core particle was obtained. These DNA lengths were approximately 5 bp or half a helical turn longer than those reported previously for stripped chicken chromatin and for core particles containing histone octamers reconstituted using "normal" length histone H2B variants. This protection pattern was also found in stripped sea urchin sperm chromatin, demonstrating that the assembly/digestion methodology reflects the in vivo situation. The interaction between the N-terminal histone H2B extension and DNA of the "linker" region was confirmed by demonstrating that stripped sea urchin sperm chromatin precipitated between 120 and 500 mm NaCl in a manner analogous to unstripped chromatin whereas stripped chicken chromatin did not. Tryptic digestion to remove all the histone tails abolished this precipitation as well as the protection of DNA outside of the 167-bp core particle against nuclease digestion.			LINDSEY, GG (corresponding author), UNIV CAPE TOWN,DEPT BIOCHEM,RONDEBOSCH 7700,SOUTH AFRICA.							BOHM L, 1984, BIOSCIENCE REP, V4, P365, DOI 10.1007/BF01122502; BOHM L, 1982, EUR J BIOCHEM, V123, P299, DOI 10.1111/j.1432-1033.1982.tb19767.x; BRANDT WF, 1988, EUR J BIOCHEM, V173, P547, DOI 10.1111/j.1432-1033.1988.tb14033.x; CLARK DJ, 1990, J MOL BIOL, V211, P883, DOI 10.1016/0022-2836(90)90081-V; HILL CS, 1990, EUR J BIOCHEM, V187, P145, DOI 10.1111/j.1432-1033.1990.tb15288.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDSEY GG, 1985, FEBS LETT, V192, P230, DOI 10.1016/0014-5793(85)80113-7; LINDSEY GG, 1990, BIOCHIM BIOPHYS ACTA, V1049, P9, DOI 10.1016/0167-4781(90)90077-F; LINDSEY GG, 1989, BIOCHIM BIOPHYS ACTA, V1009, P257, DOI 10.1016/0167-4781(89)90111-5; LINDSEY GG, 1991, J MOL BIOL, V218, P805, DOI 10.1016/0022-2836(91)90268-B; LINDSEY GG, 1983, FEBS LETT, V155, P301, DOI 10.1016/0014-5793(82)80625-X; LINDSEY GG, 1982, FEBS LETT, V145, P131, DOI 10.1016/0014-5793(82)81221-0; Maniatis T., 1982, MOL CLONING; OLINS AL, 1976, NUCLEIC ACIDS RES, V3, P3271, DOI 10.1093/nar/3.12.3271; SAHASRABUDDHE CG, 1977, NUCLEIC ACIDS RES, V4, P853, DOI 10.1093/nar/4.4.853; SIMPSON RT, 1978, BIOCHEMISTRY-US, V17, P5524, DOI 10.1021/bi00618a030; STRICKLAND M, 1981, FEBS LETT, V135, P86, DOI 10.1016/0014-5793(81)80949-0; SUZUKI M, 1989, J MOL BIOL, V207, P61, DOI 10.1016/0022-2836(89)90441-5; THOMAS JO, 1986, EUR J BIOCHEM, V154, P343, DOI 10.1111/j.1432-1033.1986.tb09403.x; VONHOLT C, 1989, METHOD ENZYMOL, V170, P428; Zweidler A, 1978, Methods Cell Biol, V17, P223, DOI 10.1016/S0091-679X(08)61145-0	21	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14622	14628						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634509				2022-12-25	WOS:A1992JF08800023
J	TREMETHICK, DJ; FROMMER, M				TREMETHICK, DJ; FROMMER, M			PARTIAL-PURIFICATION, FROM XENOPUS-LAEVIS OOCYTES, OF AN ATP-DEPENDENT ACTIVITY REQUIRED FOR NUCLEOSOME SPACING INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPACED CHROMATIN; ASSEMBLY INVITRO; CORE PARTICLE; TRANSCRIPTION COMPLEX; DNA-REPLICATION; REPEAT LENGTH; HISTONE; PROTEIN; YEAST; EXTRACTS	A critical feature of chromatin with regard to structure and function is the regular spacing of nucleosomes. In vivo, spacing of nucleosomes occurs in at least two steps, but the mechanism is not understood. In this report, we have mimicked the two-step process in vitro. A novel spacing activity has been partially purified from Xenopus laevis ovaries. When this activity is added, either at the beginning or at the end of a nucleosomal assembly reaction, it can convert a DNA template consisting of irregularly spaced nucleosomes into a chromatin structure made up of regularly spaced nucleosomes with a repeat length of about 165 base pairs. The reaction requires ATP. Histone H1 is able to increase the nucleosomal repeat from 165 to 190 base pairs. This two-step increase in nucleosomal repeat length suggests that both the spacing activity and histone H1 contribute to generating repeat lengths of greater than 165 base pairs and that their contributions may be additive. Alternatively, the critical step in the spacing reaction may not be the formation of the 165-base pair repeat but may be the sliding of nucleosomes or the reorganization of the octamer structure induced by the spacing activity.	CSIRO,DIV BIOMOLEC ENGN,MOLEC BIOL LAB,N RYDE,NSW 2113,AUSTRALIA; ROYAL PRINCE ALFRED HOSP,KANEMATSU LABS,CAMPERDOWN,NSW 2050,AUSTRALIA	Commonwealth Scientific & Industrial Research Organisation (CSIRO); University of Sydney	TREMETHICK, DJ (corresponding author), AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,POB 334,CANBERRA,ACT 2601,AUSTRALIA.			Tremethick, David/0000-0001-5274-8078				ALMER A, 1986, EMBO J, V5, P2689, DOI 10.1002/j.1460-2075.1986.tb04552.x; ALMOUZNI G, 1988, EMBO J, V7, P665, DOI 10.1002/j.1460-2075.1988.tb02861.x; ALMOUZNI G, 1990, NUCLEIC ACIDS RES, V18, P5767, DOI 10.1093/nar/18.19.5767; ALMOUZNI G, 1988, EMBO J, V7, P4355, DOI 10.1002/j.1460-2075.1988.tb03334.x; ALMOUZNI G, 1991, MOL CELL BIOL, V11, P655, DOI 10.1128/MCB.11.2.655; ANNUNZIATO AT, 1982, BIOCHEMISTRY-US, V21, P5431, DOI 10.1021/bi00265a008; BANERJEE S, 1990, MOL CELL BIOL, V10, P2863, DOI 10.1128/MCB.10.6.2863; CERTA U, 1984, NUCLEIC ACIDS RES, V12, P7975, DOI 10.1093/nar/12.21.7975; DILWORTH SM, 1988, BIOESSAYS, V9, P44, DOI 10.1002/bies.950090203; DILWORTH SM, 1987, CELL, V51, P1009, DOI 10.1016/0092-8674(87)90587-3; DREW HR, 1987, J MOL BIOL, V197, P485, DOI 10.1016/0022-2836(87)90560-2; EARNSHAW WC, 1980, CELL, V21, P373, DOI 10.1016/0092-8674(80)90474-2; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; FEDOR MJ, 1988, J MOL BIOL, V204, P109, DOI 10.1016/0022-2836(88)90603-1; FOTEDAR R, 1989, P NATL ACAD SCI USA, V86, P6459, DOI 10.1073/pnas.86.17.6459; GRUSS C, 1990, EMBO J, V9, P2911, DOI 10.1002/j.1460-2075.1990.tb07482.x; HILL CS, 1991, EMBO J, V10, P1939, DOI 10.1002/j.1460-2075.1991.tb07720.x; JORCANO JL, 1979, BIOCHEMISTRY-US, V18, P768, DOI 10.1021/bi00572a005; KLEINSCHMIDT JA, 1990, EMBO J, V9, P1309, DOI 10.1002/j.1460-2075.1990.tb08240.x; KLEINSCHMIDT JA, 1991, EMBO J, V10, P3043, DOI 10.1002/j.1460-2075.1991.tb07855.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1990, TRENDS GENET, V6, P406, DOI 10.1016/0168-9525(90)90301-L; LOHR D, 1977, BIOCHEMISTRY-US, V16, P463, DOI 10.1021/bi00622a020; LUND T, 1987, EUR J BIOCHEM, V166, P21, DOI 10.1111/j.1432-1033.1987.tb13477.x; MARVIN KW, 1990, J BIOL CHEM, V265, P19839; MEERSSEMAN G, 1991, J MOL BIOL, V220, P89, DOI 10.1016/0022-2836(91)90383-H; PEDERSON DS, 1986, ANNU REV CELL BIOL, V2, P117, DOI 10.1146/annurev.cellbio.2.1.117; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; RODRIGUEZCAMPOS A, 1989, J MOL BIOL, V209, P135, DOI 10.1016/0022-2836(89)90177-0; RUIZCARRILLO A, 1979, P NATL ACAD SCI USA, V76, P3284, DOI 10.1073/pnas.76.7.3284; SAPP M, 1990, J BIOL CHEM, V265, P9357; SESSA G, 1990, NUCLEIC ACIDS RES, V18, P5449, DOI 10.1093/nar/18.18.5449; SHIMAMURA A, 1988, MOL CELL BIOL, V8, P4257, DOI 10.1128/MCB.8.10.4257; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; SMITH S, 1991, EMBO J, V10, P971, DOI 10.1002/j.1460-2075.1991.tb08031.x; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; STEIN A, 1984, J MOL BIOL, V178, P341, DOI 10.1016/0022-2836(84)90148-7; STEIN A, 1988, J MOL BIOL, V203, P1029, DOI 10.1016/0022-2836(88)90127-1; SUN JM, 1990, EMBO J, V9, P1651, DOI 10.1002/j.1460-2075.1990.tb08285.x; TREMETHICK D, 1990, J BIOL CHEM, V265, P5014; TREMETHICK DJ, 1986, J BIOL CHEM, V261, P6986; VANDONGEN WMAM, 1983, CELL DIFFER DEV, V12, P257, DOI 10.1016/0045-6039(83)90021-0; WEINTRAUB H, 1978, NUCLEIC ACIDS RES, V5, P1179, DOI 10.1093/nar/5.4.1179; WOLFFE A P, 1990, New Biologist, V2, P211; WOLFFE AP, 1991, J CELL SCI, V99, P201; WORCEL A, 1978, CELL, V15, P969, DOI 10.1016/0092-8674(78)90280-5; ZUCKER K, 1990, J BIOL CHEM, V265, P14487	47	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15041	15048						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634540				2022-12-25	WOS:A1992JF08800079
J	TESSNER, TG; ROCK, CO; KALMAR, GB; CORNELL, RB; JACKOWSKI, S				TESSNER, TG; ROCK, CO; KALMAR, GB; CORNELL, RB; JACKOWSKI, S			COLONY-STIMULATING FACTOR-I REGULATES CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE MESSENGER-RNA LEVELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MITOGENIC GROWTH-FACTORS; MACROPHAGE CELL-LINE; C-MYC-GENE; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; PHOSPHOLIPASE-C; DNA-SYNTHESIS; RAS ONCOGENE; 3T3 CELLS; FOS; HYDROLYSIS	Growth factor regulation of phosphatidylcholine (PtdCho) metabolism during the G1 stage of the cell cycle was investigated in the colony-stimulating factor 1 (CSF-1)-dependent murine macrophage cell-line BAC1.2F5. The transient removal of CSF-1 arrested the cells in G1. Incorporation of [H-3]choline into PtdCho was stimulated significantly 1 h after growth factor addition to quiescent cells. Metabolic labeling experiments pointed to CTP:phosphocholine cytidylyltransferase (CT) as the rate-controlling enzyme for PtdCho biosynthesis in BAC1.2F5 cells. The amount of CT mRNA increased 4-fold within 15 min of CSF-1 addition and remained elevated for 2 h. The rise in CT mRNA levels was accompanied by a 50% increase in total CT specific activity in cell extracts within 4 h after the addition of CSF-1. CSF-1-dependent elevation of CT mRNA content was neither attenuated nor superinduced by the inhibition of protein synthesis with cycloheximide. The rate of CT mRNA turnover decreased in the presence of CSF-1 indicating that message stabilization was a key factor in determining the levels of CT mRNA. These data point to increased CT mRNA abundance as a component in growth factor-stimulated PtdCho synthesis.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, 322 N LAUDERDALE, POB 318, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, CTR HLTH SCI, DEPT BIOCHEM, MEMPHIS, TN 38163 USA; SIMON FRASER UNIV, DEPT CHEM BIOCHEM, BURNABY V5A 1S6, BC, CANADA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; Simon Fraser University			Jackowski, Suzanne/N-8168-2018	Jackowski, Suzanne/0000-0002-6855-1429	NCI NIH HHS [CA21765, T32 CA09346] Funding Source: Medline; NIGMS NIH HHS [GM45737] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009346, P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045737] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DIAZLAVIADA I, 1990, EMBO J, V9, P3907, DOI 10.1002/j.1460-2075.1990.tb07611.x; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAMILTON JA, 1989, J CELL PHYSIOL, V141, P618, DOI 10.1002/jcp.1041410321; JACKOWSKI S, 1990, J BIOL CHEM, V265, P6611; JAMIL H, 1990, J BIOL CHEM, V265, P4332; KAHANA C, 1984, P NATL ACAD SCI-BIOL, V81, P3645, DOI 10.1073/pnas.81.12.3645; KALMAR GB, 1990, P NATL ACAD SCI USA, V87, P6029, DOI 10.1073/pnas.87.16.6029; KAPLAN O, 1991, J BIOL CHEM, V266, P3688; KATZ A, 1987, MOL CELL BIOL, V7, P2641, DOI 10.1128/MCB.7.7.2641; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; LARRODERA P, 1990, CELL, V61, P1113, DOI 10.1016/0092-8674(90)90074-O; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LOPEZBARAHONA M, 1990, J BIOL CHEM, V265, P9022; Maniatis T., 1982, MOL CLONING; MORGAN C, 1987, J CELL PHYSIOL, V130, P420, DOI 10.1002/jcp.1041300316; MULLER R, 1985, NATURE, V314, P546, DOI 10.1038/314546a0; PELECH SL, 1982, J BIOL CHEM, V257, P4198; PELECH SL, 1981, J BIOL CHEM, V256, P8283; PELECH SL, 1984, BIOCHIM BIOPHYS ACTA, V779, P217, DOI 10.1016/0304-4157(84)90010-8; PELECH SL, 1989, TRENDS BIOCHEM SCI, V14, P28, DOI 10.1016/0968-0004(89)90086-8; RAGHOW R, 1987, TRENDS BIOCHEM SCI, V12, P358, DOI 10.1016/0968-0004(87)90165-4; ROONEY SA, 1990, BIOCHIM BIOPHYS ACTA, V1044, P385, DOI 10.1016/0005-2760(90)90085-C; SANGHERA JS, 1989, J BIOL CHEM, V264, P1215; SARIBAN E, 1988, MOL CELL BIOL, V8, P340, DOI 10.1128/MCB.8.1.340; SCHWARZBAUM S, 1984, J IMMUNOL, V132, P1158; SLEIGHT R, 1983, J BIOL CHEM, V258, P831; SOHLA PS, 1990, J BIOL CHEM, V265, P11746; STANLEY ER, 1977, J BIOL CHEM, V252, P4305; TEEGARDEN D, 1990, J BIOL CHEM, V265, P6042; TIJBURG LBM, 1989, BIOCHIM BIOPHYS ACTA, V1004, P1, DOI 10.1016/0005-2760(89)90206-3; TUSHINSKI RJ, 1985, J CELL PHYSIOL, V122, P221, DOI 10.1002/jcp.1041220210; VANCE DE, 1989, PHOSPHATIDYLCHOLINE, P225; VANCE DE, 1989, PHOSPHATIDYLCHOLINE, P33; VOELKER DR, 1984, P NATL ACAD SCI-BIOL, V81, P2669, DOI 10.1073/pnas.81.9.2669; VOELKER DR, 1982, BIOCHEMISTRY-US, V21, P2753, DOI 10.1021/bi00540a027; WARDEN CH, 1985, J BIOL CHEM, V260, P6006; WARDEN CH, 1984, BIOCHIM BIOPHYS ACTA, V792, P270, DOI 10.1016/0005-2760(84)90194-2; WATKINS JD, 1990, J BIOL CHEM, V265, P2190; WEINHOLD PA, 1991, J BIOL CHEM, V266, P6093; YAO ZM, 1990, J BIOL CHEM, V265, P4326	45	65	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16261	16264						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1653227				2022-12-25	WOS:A1991GD63500002
J	KELLEY, WL; BASTIA, D				KELLEY, WL; BASTIA, D			CONFORMATIONAL-CHANGES INDUCED BY INTEGRATION HOST FACTOR AT ORIGIN GAMMA OF R6K AND COPY NUMBER CONTROL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION INITIATOR PROTEIN; ESCHERICHIA-COLI CHROMOSOME; SITE-SPECIFIC RECOMBINATION; DNA-BINDING PROTEIN; PLASMID R6K; FACTOR IHF; BACTERIOPHAGE-LAMBDA; NUCLEOTIDE-SEQUENCE; ATTACHMENT SITE; COMPLEX	We have investigated the role of integration host factor (IHF) in the replication of plasmid R6K by studying the maintenance of the plasmid in a strain of Escherichia coli that lacks both subunits of IHF and in an isogenic wild type strain and found that all three origins, alpha, beta, and gamma, were functional in the absence of IHF; however, loss of IHF reduced the copy number of those replicons initiating solely from ori-gamma by 5-fold. Concomitant loss of direct repeats within the origin that bind the R6K replication initiator protein, Pi, resulted in a further reduction in copy number. Using gel mobility shift analysis, we showed that IHF bound specifically only to one site within the A/T rich region of the minimal origin adjacent to the Pi binding sites. The origin region possessed no intrinsic DNA curvature although IHF induced a strong bend upon binding. Combination footprinting with different orders of addition of Pi and IHF suggested that there was no cooperativity between the two proteins with regard to DNA binding. Hydroxyl-radical footprinting revealed hypersensitive asymmetric periodic cleavage sites within the origin region in the presence of IHF that extended over 200 base pairs and a localized perturbation of cleavage chemistry. The presence of periodic cleavages was dependent upon the presence of the wild type R6K origin sequence and was not observed when the IHF binding site was positioned adjacent to a heterologous sequence. We observed that the conformational changes induced by IHF upon binding to the R6K origin were negatively correlated with the observed decrease in copy number, and therefore, origin conformation altered by protein-DNA interaction may play an important role in the regulation of replication initiation.	DUKE UNIV,MED CTR,DEPT MICROBIOL & IMMUNOL,DURHAM,NC 27710	Duke University								ALFANO C, 1989, J BIOL CHEM, V264, P10699; BAKER TA, 1986, CELL, V45, P53, DOI 10.1016/0092-8674(86)90537-4; BIEK DP, 1989, J BACTERIOL, V171, P2066, DOI 10.1128/jb.171.4.2066-2074.1989; BIEK DP, 1989, J BACTERIOL, V171, P2056, DOI 10.1128/jb.171.4.2056-2065.1989; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; CRAIG NL, 1984, CELL, V39, P707, DOI 10.1016/0092-8674(84)90478-1; CROSA JH, 1978, J MOL BIOL, V124, P443, DOI 10.1016/0022-2836(78)90181-X; CROSA JH, 1980, J BIOL CHEM, V255, P1075; DOSON M, 1989, J BIOL CHEM, V264, P10719; ECKDAHL TT, 1990, NUCLEIC ACIDS RES, V18, P1609, DOI 10.1093/nar/18.6.1609; FILUTOWICZ M, 1988, NUCLEIC ACIDS RES, V16, P3829, DOI 10.1093/nar/16.9.3829; FRIEDMAN DI, 1988, CELL, V55, P545, DOI 10.1016/0092-8674(88)90213-9; FUNNELL BE, 1987, J BIOL CHEM, V262, P10327; FUNNELL BE, 1988, P NATL ACAD SCI USA, V85, P6657, DOI 10.1073/pnas.85.18.6657; GAMAS P, 1986, MOL GEN GENET, V204, P85, DOI 10.1007/BF00330192; GERMINO J, 1983, CELL, V34, P125, DOI 10.1016/0092-8674(83)90142-3; GERMINO J, 1982, P NATL ACAD SCI-BIOL, V79, P5475, DOI 10.1073/pnas.79.18.5475; GERMINO J, 1983, CELL, V32, P131, DOI 10.1016/0092-8674(83)90503-2; GERMINO J, 1984, P NATL ACAD SCI-BIOL, V81, P4692, DOI 10.1073/pnas.81.15.4692; Gibson T.J., 1984, THESIS CAMBRIDGE U E; GOODMAN SD, 1989, NATURE, V341, P251, DOI 10.1038/341251a0; GOODRICH JA, 1990, NUCLEIC ACIDS RES, V18, P4993, DOI 10.1093/nar/18.17.4993; GREENSTEIN D, 1988, P NATL ACAD SCI USA, V85, P6262, DOI 10.1073/pnas.85.17.6262; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HERTZBERG RP, 1984, BIOCHEMISTRY-US, V23, P3934, DOI 10.1021/bi00312a022; INUZUKA N, 1980, J BIOL CHEM, V255, P1071; KIM SH, 1990, CELL, V63, P773, DOI 10.1016/0092-8674(90)90143-3; KOLTER R, 1978, CELL, V15, P1199, DOI 10.1016/0092-8674(78)90046-6; KOLTER R, 1978, COLD SPRING HARB SYM, V43, P91; KOSTURKO LD, 1989, NUCLEIC ACIDS RES, V17, P317, DOI 10.1093/nar/17.1.317; KULA MR, 1976, BIOCHEM BIOPH RES CO, V69, P389, DOI 10.1016/0006-291X(76)90534-9; LANDY A, 1989, ANNU REV BIOCHEM, V58, P913, DOI 10.1146/annurev.biochem.58.1.913; LEONG JM, 1985, J BIOL CHEM, V260, P4468; Maniatis T., 1982, MOL CLONING; MARINI JC, 1982, P NATL ACAD SCI-BIOL, V79, P7664, DOI 10.1073/pnas.79.24.7664; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MONK M, 1972, J BACTERIOL, V109, P971, DOI 10.1128/JB.109.3.971-978.1972; MUKHERJEE S, 1988, P NATL ACAD SCI USA, V85, P6287, DOI 10.1073/pnas.85.17.6287; MUKHERJEE S, 1985, CELL, V43, P189, DOI 10.1016/0092-8674(85)90023-6; NASH HA, 1981, J BIOL CHEM, V256, P9246; NASH HA, 1990, TRENDS BIOCHEM SCI, V15, P222, DOI 10.1016/0968-0004(90)90034-9; NASH HA, 1987, J BACTERIOL, V169, P4124, DOI 10.1128/jb.169.9.4124-4127.1987; OGURA T, 1990, MOL GEN GENET, V220, P197; PATEL I, 1986, CELL, V47, P785, DOI 10.1016/0092-8674(86)90521-0; PATEL I, 1987, CELL, V51, P455, DOI 10.1016/0092-8674(87)90641-6; POLACZEK P, 1990, New Biologist, V2, P265; PRENTKI P, 1987, NUCLEIC ACIDS RES, V15, P10060, DOI 10.1093/nar/15.23.10060; ROBERTSON CA, 1988, J BIOL CHEM, V263, P3554; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNOS M, 1988, CELL, V52, P385, DOI 10.1016/S0092-8674(88)80031-X; SHON M, 1982, J BIOL CHEM, V257, P13823; STALKER DM, 1982, J MOL BIOL, V161, P33, DOI 10.1016/0022-2836(82)90276-5; STENZEL TT, 1987, CELL, V49, P709, DOI 10.1016/0092-8674(87)90547-2; TAYLOR DE, 1988, NUCLEIC ACIDS RES, V16, P9056, DOI 10.1093/nar/16.18.9056; THOMPSON JF, 1987, J MOL BIOL, V195, P481, DOI 10.1016/0022-2836(87)90177-X; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; TIMMIS K, 1975, P NATL ACAD SCI USA, V72, P2242, DOI 10.1073/pnas.72.6.2242; TRAVERS AA, 1990, CELL, V60, P177, DOI 10.1016/0092-8674(90)90729-X; TULLIUS TD, 1986, P NATL ACAD SCI USA, V83, P5469, DOI 10.1073/pnas.83.15.5469; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; VOCKE C, 1985, THESIS DUKE U DURHAM; WORK TS, 1979, LABORATORY TECHNIQUE, V7, P348; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; YANG CC, 1989, CELL, V57, P869, DOI 10.1016/0092-8674(89)90801-5	67	28	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					15924	15937						14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1651928				2022-12-25	WOS:A1991GB97700062
J	SIMPSON, CMF; ITABE, H; REYNOLDS, CN; KING, WC; GLOMSET, JA				SIMPSON, CMF; ITABE, H; REYNOLDS, CN; KING, WC; GLOMSET, JA			SWISS 3T3 CELLS PREFERENTIALLY INCORPORATE SN-2-ARACHIDONOYL MONOACYLGLYCEROL INTO SN-1-STEAROYL-2-ARACHIDONOYL PHOSPHATIDYLINOSITOL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MICROSOMES; PERFORMANCE LIQUID-CHROMATOGRAPHY; ACYLTRANSFERASE; METABOLISM; SEPARATION; DIACYLGLYCEROL; PHOSPHOLIPIDS; KINASE	The sn-1-stearoyl-2-arachidonoyl phospholipids of animal cells appear to be formed by special mechanisms. To determine whether monoacylglycerol (MG) incorporation pathways are involved we incubated quiescent Swiss 3T3 cells with [H-3]glycerol-labeled sn-2-arachidonoyl MG, then analyzed the radioactive cell lipids that accumulated. We also examined cell homogenates to identify enzyme activities that might promote the incorporation of sn-2-arachidonoyl MG into other cell lipids. The cell incubation experiments demonstrated rapid labeling of several lipids, including diacylglycerol, lysophosphatidic acid, phosphatidic acid, and phosphatidylinositol. They also demonstrated selective labeling of sn-1-stearoyl-2-arachidonoyl species of phosphatidylinositol, phosphatidylethanolamine, and phosphatidylserine. The cell homogenate experiments identified an sn-2-acyl MG acyltransferase activity, an MG kinase activity that phosphorylates sn-2-arachidonoyl MG in preference to sn-2-oleoyl MG, and a stearoyl-specific acyl transferase activity that converts sn-2-arachidonoyl lysophosphatidic acid into sn-1-stearoyl-2-arachidonoyl phosphatidic acid. The results also showed that this stearoyl transferase could act with other enzymes to convert sn-2-arachidonoyl lysophosphatidic acid into sn-1-stearoyl-2-arachidonoyl phosphatidylinositol. The combined results indicate that Swiss 3T3 cells incorporate sn-2-arachidonoyl MG into phospholipids by at least two different pathways, including one that specifically forms sn-1-stearoyl-2-arachidonoyl phosphatidylinositol.	UNIV WASHINGTON,HOWARD HUGHES MED INST,DEPT MED,SEATTLE,WA 98195; UNIV WASHINGTON,REG PRIMATE RES CTR,SEATTLE,WA 98195; UNIV WASHINGTON,HOWARD HUGHES MED INST,DEPT BIOCHEM,SEATTLE,WA 98195	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle			板部板部, 洋之/ABC-7746-2020		NCRR NIH HHS [RR 00166] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000166] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AKESSON B, 1970, BIOCHIM BIOPHYS ACTA, V210, P15, DOI 10.1016/0005-2760(70)90057-3; BISHOP WR, 1988, ANNU REV CELL BIOL, V4, P579, DOI 10.1146/annurev.cb.04.110188.003051; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLEMAN RA, 1986, J BIOL CHEM, V261, P224; DAWIDOWICZ EA, 1987, ANNU REV BIOCHEM, V56, P43, DOI 10.1146/annurev.bi.56.070187.000355; GLOMSET JA, 1990, DYNAMICS BIOGENESIS, V40, P65; HABENICHT AJR, 1981, J BIOL CHEM, V256, P2329; HILL EE, 1968, J BIOL CHEM, V243, P4440; Holub B J, 1978, Adv Lipid Res, V16, P1; HOLUB BJ, 1971, J LIPID RES, V12, P699; HOLUB BJ, 1981, BIOCHIM BIOPHYS ACTA, V664, P221, DOI 10.1016/0005-2760(81)90044-8; HOLUB BJ, 1979, LIPIDS, V14, P529, DOI 10.1007/BF02533526; JOHNSTON JM, 1977, LIPID METABOLISM MAM, P151; KANOH H, 1969, BIOCHIM BIOPHYS ACTA, V176, P756; LANDS WEM, 1982, J BIOL CHEM, V257, P4968; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYNCH DV, 1988, ADV MEMBRANE FLUIDIT, V3, P323; MACDONALD ML, 1988, J BIOL CHEM, V263, P1584; MASUZAWA Y, 1989, BIOCHIM BIOPHYS ACTA, V105, P1; NAKAGAWA Y, 1983, J LIPID RES, V24, P1268; NAKAGAWA Y, 1989, ARCH BIOCHEM BIOPHYS, V268, P559, DOI 10.1016/0003-9861(89)90323-8; NAKAGAWA Y, 1986, J CHROMATOGR, V381, P225, DOI 10.1016/S0378-4347(00)83588-4; ORAM JF, 1980, J BIOL CHEM, V255, P475; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; SANSBURY K, 1989, J LIPID RES, V30, P1251; SHIM YH, 1989, BIOCHEM CELL BIOL, V67, P233, DOI 10.1139/o89-035; SKIPSKI VP, 1964, BIOCHEM J, V90, P374, DOI 10.1042/bj0900374; SLOTBOOM AJ, 1970, CHEM PHYS LIPIDS, V4, P15, DOI 10.1016/0009-3084(70)90059-9; THOMPSON GA, 1989, BIOCHEM SOC T, V17, P286, DOI 10.1042/bst0170286; THOMPSON GA, 1984, PHYSL MEMBRANE FLUID, V1, P99; Yamashita S, 1981, Methods Enzymol, V71 Pt C, P528; YANG SF, 1967, J BIOL CHEM, V242, P477; 1990, PROPHET STATISTICS R	34	48	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					15902	15909						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1651926				2022-12-25	WOS:A1991GB97700059
J	KNAFF, DB; HIRASAWA, M; AMEYIBOR, E; FU, WG; JOHNSON, MK				KNAFF, DB; HIRASAWA, M; AMEYIBOR, E; FU, WG; JOHNSON, MK			SPECTROSCOPIC EVIDENCE FOR A [3FE-4S] CLUSTER IN SPINACH GLUTAMATE SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC CIRCULAR-DICHROISM; GIGAS FERREDOXIN-II; IRON-SULFUR; AZOTOBACTER-VINELANDII; ESCHERICHIA-COLI; CHLAMYDOMONAS-REINHARDII; THERMUS-THERMOPHILUS; BINDING; PURIFICATION; MOSSBAUER	The combination of low temperature EPR, magnetic circular dichroism, and resonance Raman spectroscopies reveals the presence of a single [3Fe-4S]+,0 center as the sole iron-sulfur prosthetic group in glutamate synthase from spinach leaves. The electronic, magnetic, and structural properties of the oxidized and reduced cluster are analogous with those of similar clusters in bacterial ferredoxins. It was not possible to convert the [3Fe-4S] cluster to a [4Fe-4S] cluster by incubating with iron under reducing conditions. Taken together with the published amino acid sequence data for plant and bacterial glutamate synthases, this suggests that the [3Fe-4S] cluster is not an isolation artifact resulting from oxidative degradation of a [4Fe-4S] cluster. The likelihood that a [3Fe-4S] cluster is an intrinsic component of all plant and bacterial glutamate synthases is discussed.	UNIV GEORGIA,DEPT CHEM,ATHENS,GA 30602; TEXAS TECH UNIV,DEPT CHEM & BIOCHEM,LUBBOCK,TX 79409; UNIV GEORGIA,CTR METALLOENZYME STUDIES,ATHENS,GA 30602	University System of Georgia; University of Georgia; Texas Tech University System; Texas Tech University; University System of Georgia; University of Georgia					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033806] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33806] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASA R, 1975, J MAGN RESON, V19, P308, DOI 10.1016/0022-2364(75)90045-1; ACKRELL BAC, 1991, IN PRESS CRIT REV BI; BEINERT H, 1983, ARCH BIOCHEM BIOPHYS, V222, P333, DOI 10.1016/0003-9861(83)90531-3; BENNETT DE, 1987, BIOCHIM BIOPHYS ACTA, V911, P71, DOI 10.1016/0167-4838(87)90272-X; BOTELLA JR, 1988, PLANT PHYSIOL, V87, P255, DOI 10.1104/pp.87.1.255; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUSCHI M, 1988, FEMS MICROBIOL LETT, V54, P155, DOI 10.1111/j.1574-6968.1988.tb02741.x; CONOVER RC, 1990, J BIOL CHEM, V265, P8533; EMPTAGE MH, 1980, J BIOL CHEM, V255, P1793; GALVAN F, 1984, PLANTA, V162, P180, DOI 10.1007/BF00410216; GUERRERO MG, 1981, ANNU REV PLANT PHYS, V32, P169, DOI 10.1146/annurev.pp.32.060181.001125; HAGEN WR, 1985, BIOCHIM BIOPHYS ACTA, V828, P369, DOI 10.1016/0167-4838(85)90318-8; HAMILTON CL, 1989, J BIOL CHEM, V264, P11650; HEMMILA IA, 1978, BIOCHEM J, V173, P45, DOI 10.1042/bj1730045; HIRASAWA M, 1986, BIOCHIM BIOPHYS ACTA, V851, P23, DOI 10.1016/0005-2728(86)90244-6; HIRASAWA M, 1989, BIOCHIM BIOPHYS ACTA, V977, P150, DOI 10.1016/S0005-2728(89)80065-9; HIRASAWA M, 1991, ARCH BIOCHEM BIOPHYS, V286, P171, DOI 10.1016/0003-9861(91)90024-D; HIRASAWA M, 1984, J BIOCHEM, V95, P983, DOI 10.1093/oxfordjournals.jbchem.a134725; JOHNSON MK, 1987, BIOCHIM BIOPHYS ACTA, V911, P81, DOI 10.1016/0167-4838(87)90273-1; JOHNSON MK, 1983, J AM CHEM SOC, V105, P6671, DOI 10.1021/ja00360a022; JOHNSON MK, 1985, BIOCHEM BIOPH RES CO, V131, P653, DOI 10.1016/0006-291X(85)91287-2; JOHNSON MK, 1988, ACS SYM SER, V372, P326; KISSINGER CR, 1988, J AM CHEM SOC, V110, P8721, DOI 10.1021/ja00234a038; KNAFF DB, 1991, BIOCHIM BIOPHYS ACTA, V1056, P93, DOI 10.1016/S0005-2728(05)80277-4; LEA P J, 1978, Nature (London), V275, P741; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARQUEZ AJ, 1986, INT J BIOCHEM, V18, P531, DOI 10.1016/0020-711X(86)90164-3; MILLER RE, 1972, J BIOL CHEM, V247, P7407; OLIVER G, 1987, GENE, V60, P1, DOI 10.1016/0378-1119(87)90207-1; PAPAEFTHYMIOU V, 1987, J AM CHEM SOC, V109, P4703, DOI 10.1021/ja00249a037; RENDINA AR, 1980, THESIS U WISCONSIN; ROBBINS AH, 1989, P NATL ACAD SCI USA, V86, P3639, DOI 10.1073/pnas.86.10.3639; ROBBINS AH, 1989, PROTEINS, V5, P289, DOI 10.1002/prot.340050406; SAKAKIBARA H, 1991, J BIOL CHEM, V266, P2028; STOUT CD, 1988, J BIOL CHEM, V263, P9256; STOUT GH, 1988, P NATL ACAD SCI USA, V85, P1020, DOI 10.1073/pnas.85.4.1020; TROTTA PP, 1974, P NATL ACAD SCI USA, V71, P4607, DOI 10.1073/pnas.71.11.4607	37	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15080	15084						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1651319				2022-12-25	WOS:A1991GB09700045
J	ANESKIEVICH, BJ; HAIMOVICH, B; BOETTIGER, D				ANESKIEVICH, BJ; HAIMOVICH, B; BOETTIGER, D			PHOSPHORYLATION OF INTEGRIN IN DIFFERENTIATING TS-ROUS SARCOMA VIRUS-INFECTED MYOGENIC CELLS	ONCOGENE			English	Article							FIBRONECTIN-RECEPTOR COMPLEX; MONOCLONAL-ANTIBODIES; TYROSINE PHOSPHORYLATION; EXOGENOUS FIBRONECTIN; MUSCLE MORPHOGENESIS; SKELETAL-MUSCLE; CSAT ANTIGEN; CHICK-EMBRYO; MYOBLASTS; PROTEIN	The differentiation of primary myogenic cultures requires the attachment of the cells to an extracellular matrix substrate using an integrin family receptor. These integrin receptors can be phosphorylated on both their alpha and beta chains, and it has been postulated that phosphorylation regulates the receptor function. Quail myogenic clones transformed with ts-LA24A differentiated into mature myotubes following a temperature shift to non-permissive temperature which inactivates the viral src kinas. Phosphorylation of integrin beta-1 chain and of at least one alpha chain was detected on both serine and tyrosine. An additional alpha chain(s) with a mobility similar to alpha 5 was not phosphorylated at either temperature. Following the induction of differentiation by a temperature shift, there was a marked decrease in integrin phosphorylation of both alpha and beta integrin chains. This decrease was more prominent for serine than for tyrosine, suggesting that src could not be the only kinase involved. The drop in integrin phosphorylation correlated with the initiation of differentiation, suggesting that integrin phosphorylation could be at least part of the mechanism by which myogenic differentiation is blocked by v-src.	UNIV PENN,SCH MED,DEPT MICROBIOL,36TH ST & HAMILTON WALK,PHILADELPHIA,PA 19104	University of Pennsylvania					NATIONAL CANCER INSTITUTE [R01CA049866, R01CA030383] Funding Source: NIH RePORTER; NCI NIH HHS [CA 30383, CA 49866, CA 16503] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; ALEMA S, 1987, ADV CANCER RES, V49, P1, DOI 10.1016/S0065-230X(08)60792-7; BISCHOFF R, 1967, J CELL BIOL, V36, P111; BOETTIGER D, 1989, UCLA S MOL CELLULAR, P57; BOZYCZKO D, 1989, EXP CELL RES, V183, P72, DOI 10.1016/0014-4827(89)90419-9; BUCK CA, 1986, J CELL BIOL, V103, P2421, DOI 10.1083/jcb.103.6.2421; CARLEY WW, 1981, J CELL BIOL, V97, P797; CHEN LB, 1977, CELL, V37, P357; CHEN WT, 1986, J CELL BIOL, V103, P1649, DOI 10.1083/jcb.103.5.1649; CHI JC, 1975, P NATL ACAD SCI USA, V72, P4999, DOI 10.1073/pnas.72.12.4999; CHI JCH, 1975, J CELL BIOL, V67, P523, DOI 10.1083/jcb.67.3.523; CHIQUET M, 1979, J BIOL CHEM, V254, P5475; CHIQUET M, 1981, DEV BIOL, V88, P220, DOI 10.1016/0012-1606(81)90166-4; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DAMSKY CH, 1985, J CELL BIOL, V100, P1528, DOI 10.1083/jcb.100.5.1528; DARRIBERE T, 1990, J CELL BIOL, V110, P1813, DOI 10.1083/jcb.110.5.1813; DUBAND JL, 1988, FEBS LETT, V230, P181, DOI 10.1016/0014-5793(88)80667-7; FALCONE G, 1984, EMBO J, V3, P1327, DOI 10.1002/j.1460-2075.1984.tb01971.x; FISZMAN MY, 1975, NATURE, V254, P429, DOI 10.1038/254429a0; FOSTER RF, 1987, DEV BIOL, V122, P11, DOI 10.1016/0012-1606(87)90327-7; FURCHT LT, 1978, CELL, V13, P263, DOI 10.1016/0092-8674(78)90195-2; GEORGEWEINSTEIN M, 1988, DEV BIOL, V125, P34, DOI 10.1016/0012-1606(88)90056-5; HAIMOVICH B, 1991, CELL REGUL, V2, P271, DOI 10.1091/mbc.2.4.271; HAUSCHKA SD, 1966, P NATL ACAD SCI USA, V55, P119, DOI 10.1073/pnas.55.1.119; HIRST R, 1986, P NATL ACAD SCI USA, V83, P6470, DOI 10.1073/pnas.83.17.6470; HOLTZER H, 1975, P NATL ACAD SCI USA, V72, P4051, DOI 10.1073/pnas.72.10.4051; HYNES RO, 1989, J CELL BIOL, V109, P409, DOI 10.1083/jcb.109.1.409; JAFFREDO T, 1988, DEVELOPMENT, V103, P431; KAUSHAL V, 1986, ANAL BIOCHEM, V157, P291, DOI 10.1016/0003-2697(86)90629-9; KELLIE S, 1987, BIOCHEM SOC T, V15, P791, DOI 10.1042/bst0150791; KIENY M, 1984, J EXP ZOOL, V232, P327, DOI 10.1002/jez.1402320220; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN ZY, 1989, GENE DEV, V3, P986, DOI 10.1101/gad.3.7.986; MENKO AS, 1987, CELL, V51, P51, DOI 10.1016/0092-8674(87)90009-2; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; OCALAN M, 1988, DEV BIOL, V125, P158, DOI 10.1016/0012-1606(88)90068-1; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; ROMAN J, 1989, J CELL BIOL, V108, P2529, DOI 10.1083/jcb.108.6.2529; STOKER AW, 1984, MOL CELL BIOL, V4, P1508, DOI 10.1128/MCB.4.8.1508; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; TAMKUN JW, 1986, CELL, V46, P271, DOI 10.1016/0092-8674(86)90744-0; TAPLEY P, 1989, ONCOGENE, V4, P325; WEBER K, 1974, COLD SPRING HARB SYM, V39, P363, DOI 10.1101/SQB.1974.039.01.047; WYKE JA, 1973, VIROLOGY, V54, P152	44	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1991	6	8					1381	1390						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1653410				2022-12-25	WOS:A1991GX27200014
J	SMITH, CJ; VASTA, V; DEGERMAN, E; BELFRAGE, P; MANGANIELLO, VC				SMITH, CJ; VASTA, V; DEGERMAN, E; BELFRAGE, P; MANGANIELLO, VC			HORMONE-SENSITIVE CYCLIC GMP-INHIBITED CYCLIC-AMP PHOSPHODIESTERASE IN RAT ADIPOCYTES - REGULATION OF INSULIN-DEPENDENT AND CAMP-DEPENDENT ACTIVATION BY PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; GLYCOGEN-SYNTHASE; ADIPOSE-TISSUE; FAT-CELLS; LIPOLYSIS; ATP; PURIFICATION; PARTICULATE; STIMULATION; ANALOGS	In (PO4)-P-32-labeled adipocytes, isoproterenol (ISO) or physiologically relevant concentrations of insulin rapidly increased phosphorylation of a particulate 135-kDa protein which has been identified as a cGMP-inhibited "low K(m)" cAMP phosphodiesterase (CGI-PDE) by several criteria, including selective immunoprecipitation with anti-CGI-PDE IgG (Degerman, E., Smith, C. J., Tornqvist, H., Vasta, V., Belfrage, P., and Manganiello, V. C. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 533-537). The time courses and concentration dependences for phosphorylation of CGI-PDE by ISO and insulin correlated with CGI-PDE activation in the presence of these agents; effects of ISO were somewhat more rapid than those of insulin. Adenosine deaminase, which metabolizes the adenylate cyclase inhibitor adenosine, also rapidly induced phosphorylation and activation of CGI-PDE. Phenylisopropyladenosine (an adenosine deaminase-resistant adenosine analog) prevented or reversed both adenosine deaminase-stimulated phosphorylation and activation of CGI-PDE (IC50 almost-equal-to 0.2 nM). Incubation of adipocytes with 0.1 nM insulin in the presence of ISO rapidly produced 30-200% greater activation and phosphorylation of CGI-PDE than the expected added effects of insulin and ISO individually; both effects preceded the insulin-induced decreases in protein kinase A activity and inhibition of lipolysis. These and other results indicate that CGI-PDE can be phosphorylated at distinct sites and activated by cAMP-dependent and insulin-dependent serine kinase(s), that the activation state of CGI-PDE reflects its relative phosphorylation state, and that synergistic phosphorylation/activation of CGI-PDE may be important in the antilipolytic action of insulin.	UNIV FLORENCE,DEPT BIOCHEM,I-50121 FLORENCE,ITALY; UNIV LUND,DEPT MED & PHYSIOL CHEM 4,S-22100 LUND,SWEDEN	University of Florence; Lund University	SMITH, CJ (corresponding author), NHLBI,CELLULAR METAB LAB,BLDG 10,RM 5N-307,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.							ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BEEBE SJ, 1985, J BIOL CHEM, V260, P5781; CZECH MP, 1988, J BIOL CHEM, V263, P11017; DEGERMAN E, 1990, P NATL ACAD SCI USA, V87, P533, DOI 10.1073/pnas.87.2.533; DEGERMAN E, 1988, SEC MESS PHOSPHOPROT, V12, P171; DEGERMAN E, 1987, J BIOL CHEM, V262, P5797; DENT P, 1989, FEBS LETT, V248, P67, DOI 10.1016/0014-5793(89)80433-8; DOOLITTLE MH, 1991, IN PRESS ANAL BIOCH; Fain J.N, 1980, BIOCHEM ACTION HORM, V3, P119; FLOTOW H, 1989, J BIOL CHEM, V264, P9126; FRANCIS SH, 1982, MOL CELL BIOCHEM, V42, P109; GETTYS TW, 1987, J BIOL CHEM, V262, P333; GETTYS TW, 1988, J BIOL CHEM, V263, P10359; GRANT PG, 1988, P NATL ACAD SCI USA, V85, P9071, DOI 10.1073/pnas.85.23.9071; HONNOR RC, 1985, J BIOL CHEM, V260, P5122; HONNOR RC, 1985, J BIOL CHEM, V260, P5130; HOPKIRK TJ, 1986, BIOCHIM BIOPHYS ACTA, V885, P195, DOI 10.1016/0167-4889(86)90089-3; HUANG KP, 1983, J BIOL CHEM, V258, P7094; LONDOS C, 1978, P NATL ACAD SCI USA, V75, P5362, DOI 10.1073/pnas.75.11.5362; LONNROTH P, 1986, BIOCHEM BIOPH RES CO, V141, P1157, DOI 10.1016/S0006-291X(86)80165-6; MACPHEE CH, 1988, J BIOL CHEM, V263, P10353; MANGANIELLO VC, 1987, J CYCLIC NUCLEOTIDE, V11, P497; MANGANIELLO VC, 1986, MECHANISMS INSULIN A, P123; RAMAKRISHNA S, 1989, BIOCHEMISTRY-US, V28, P856, DOI 10.1021/bi00428a067; ROACH PJ, 1990, FASEB J, V4, P2961, DOI 10.1096/fasebj.4.12.2168324; ROBINSON FW, 1989, J BIOL CHEM, V264, P16458; SHIBATA H, 1990, BIOCHEM BIOPH RES CO, V167, P614, DOI 10.1016/0006-291X(90)92069-C; SMITH CJ, 1989, MOL PHARMACOL, V35, P381	28	111	113	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1991	266	20					13385	13390						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FX132	1649189				2022-12-25	WOS:A1991FX13200091
J	NISHIMOTO, I; OGATA, E; OKAMOTO, T				NISHIMOTO, I; OGATA, E; OKAMOTO, T			GUANINE NUCLEOTIDE-BINDING PROTEIN INTERACTING BUT UNSTIMULATING SEQUENCE LOCATED IN INSULIN-LIKE GROWTH FACTOR-II RECEPTOR - ITS AUTOINHIBITORY CHARACTERISTICS AND STRUCTURAL DETERMINANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTOR; PERTUSSIS-TOXIN; BOVINE SPLEEN; IGF-II; CELLS; DOMAINS; LINKAGE	RVGLVRGEKARKGK (peptide 14) from residues 2410-2423 of the human insulin-like growth factor II receptor (IGF-IIR) directly activates adenylylcyclase-inhibitory guanine nucleotide-binding proteins (G(i) proteins) whereas RGEKARKGK (peptide 9) has no stimulatory action. However, peptide 9 inhibited the actions of peptide 14 on both GDP release from and guanosine 5'-O-(3-thiotriphosphate) (GTP-gamma-S) binding to G(i-2) in an aqueous system. Peptide 9 also inhibited peptide 14-induced G(i-1) activation with a similar profile. The peptide 9 action was competitive for peptide 14 action and determined by the first arginine residue and the C-terminal RKGK. In reconstituted IGF-IIR-G(i-2) vesicles, peptide 9 blocked the G protein stimulation by IGF-II with a potency similar to that observed in the action of peptide 9 on peptide 14; and peptide 9-induced inhibition was also observed in IGF-IIR-G(i-1) vesicles. In pertussis toxin-treated K562 cell membranes supplemented with G(i-2), peptide 9 inhibited IGF-II-induced reduction in pertussis toxin-catalyzed ADP-ribosylation of G(i-2) with an IC50 of 30-mu-M. This inhibitory effect of peptide 9 was competitive for the concentration of these IGF-IIR-positive/IGF-I receptor-negative cell membranes. Therefore, peptide 9 inhibits the G(i)-activating function of IGF-IIR possibly by interacting with the putative peptide 14 recognition site of G(i) proteins. The significance of this sequence is discussed.			NISHIMOTO, I (corresponding author), UNIV TOKYO,SCH MED,DEPT INTERNAL MED 4,LIFE SCI LAB,3-28-6 MEJIRO DAI,BUNKYO KU,TOKYO 112,JAPAN.							BLANCHARD MM, 1988, MOL CELL ENDOCRINOL, V56, P235, DOI 10.1016/0303-7207(88)90066-4; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; KATADA T, 1987, FEBS LETT, V213, P353, DOI 10.1016/0014-5793(87)81521-1; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KOJIMA I, 1988, BIOCHEM BIOPH RES CO, V154, P9, DOI 10.1016/0006-291X(88)90642-0; KUBO T, 1988, FEBS LETT, V241, P119, DOI 10.1016/0014-5793(88)81043-3; MORISHITA R, 1990, BIOCHEM BIOPH RES CO, V172, P249, DOI 10.1016/S0006-291X(05)80201-3; MORISHITA R, 1989, BIOCHEM BIOPH RES CO, V161, P1280, DOI 10.1016/0006-291X(89)91381-8; MURAYAMA Y, 1990, J BIOL CHEM, V265, P17456; NISHIMOTO I, 1989, J BIOL CHEM, V264, P14029; NISHIMOTO I, 1987, J BIOL CHEM, V262, P12120; NOLAN CM, 1990, CELL REGUL, V1, P197, DOI 10.1091/mbc.1.2.197; OKAMOTO T, 1991, J BIOL CHEM, V266, P1085; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; OKAMOTO T, 1990, BIOCHEM BIOPH RES CO, V168, P1201, DOI 10.1016/0006-291X(90)91156-M; RECHLER MM, 1985, ANNU REV PHYSIOL, V47, P425; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; TALLY M, 1987, BIOCHEM BIOPH RES CO, V148, P811, DOI 10.1016/0006-291X(87)90948-X; WEISS ER, 1988, J BIOL CHEM, V263, P6150	21	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1991	266	19					12747	12751						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FV180	1648103				2022-12-25	WOS:A1991FV18000099
J	HAMMARBERG, B; TALLY, M; SAMUELSSON, E; WADENSTEN, H; HOLMGREN, E; HARTMANIS, M; HALL, K; UHLEN, M; MOKS, T				HAMMARBERG, B; TALLY, M; SAMUELSSON, E; WADENSTEN, H; HOLMGREN, E; HARTMANIS, M; HALL, K; UHLEN, M; MOKS, T			CHARACTERIZATION OF AN EXTENDED FORM OF RECOMBINANT HUMAN INSULIN-LIKE GROWTH FACTOR-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAPHYLOCOCCAL PROTEIN-A; ESCHERICHIA-COLI; IGF-II; PURIFICATION; RECEPTOR; SEQUENCE; VARIANT; EXPRESSION; BINDING; SERUM	To investigate the biological role of variants of human insulin-like growth factor II (IGF-II), an extended form designated IGF-IIE21, with a molecular mass of 9.8 kDa, was produced in Escherichia coli as a stable and soluble secreted fusion protein. After site-specific cleavage of the affinity purified fusion protein, followed by purification using ion exchange and reversed phase chromatography, it could be demonstrated that IGF-IIE21 and IGF-II have similar or identical activities according to radioimmunoassay and radioreceptor assay. However, IGF-IIE21 showed only 1% growth promotion activity as compared with IGF-II in a clonal expansion assay using human K562 cells which lacks IGF-I receptors. These results suggest that this extended variant of IGF-II can bind to the receptor but has limited growth promoting activity.	ROYAL INST TECHNOL,DEPT BIOCHEM & BIOTECHNOL,S-10044 STOCKHOLM 70,SWEDEN; KAROLINSKA INST,DEPT ENDOCRINOL,S-10401 STOCKHOLM 60,SWEDEN; KABIGEN AB,S-11287 STOCKHOLM,SWEDEN	Royal Institute of Technology; Karolinska Institutet			Uhlen, Mathias/AAV-8746-2021; Uhlen, Mathias/B-3262-2016	Uhlen, Mathias/0000-0002-4858-8056; Holmgren, Erik/0000-0002-2656-1864				ADAMS SO, 1983, NATURE, V302, P150, DOI 10.1038/302150a0; BELL GI, 1984, NATURE, V310, P775, DOI 10.1038/310775a0; BENNETT A, 1983, J CLIN ENDOCR METAB, V57, P609, DOI 10.1210/jcem-57-3-609; BLUNDELL TL, 1978, P NATL ACAD SCI USA, V75, P180, DOI 10.1073/pnas.75.1.180; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; DULL TJ, 1984, NATURE, V310, P777, DOI 10.1038/310777a0; ENBERG G, 1984, ACTA ENDOCRINOL-COP, V107, P164, DOI 10.1530/acta.0.1070164; GOWAN LK, 1987, ENDOCRINOLOGY, V121, P449, DOI 10.1210/endo-121-2-449; GRODBERG J, 1988, J BACTERIOL, V170, P1245, DOI 10.1128/jb.170.3.1245-1253.1988; HAMMARBERG B, 1989, P NATL ACAD SCI USA, V86, P4367, DOI 10.1073/pnas.86.12.4367; HAMMARBERG B, 1990, J BIOTECHNOL, V14, P423, DOI 10.1016/0168-1656(90)90123-S; HAMPTON B, 1989, J BIOL CHEM, V264, P19155; HASELBACHER G, 1982, ENDOCRINOLOGY, V110, P1822, DOI 10.1210/endo-110-5-1822; HASELBACHER GK, 1985, P NATL ACAD SCI USA, V82, P2153, DOI 10.1073/pnas.82.7.2153; HOGSET A, 1990, J BIOL CHEM, V265, P7338; JANSEN M, 1985, FEBS LETT, V179, P243, DOI 10.1016/0014-5793(85)80527-5; KIESS W, 1988, J BIOL CHEM, V263, P9339; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING; MOKS T, 1987, BIOCHEMISTRY-US, V26, P5239, DOI 10.1021/bi00391a005; MOKS T, 1987, BIO-TECHNOL, V5, P379, DOI 10.1038/nbt0487-379; MOSES AC, 1980, P NATL ACAD SCI-BIOL, V77, P3649, DOI 10.1073/pnas.77.6.3649; NILSSON B, 1987, PROTEIN ENG, V1, P107, DOI 10.1093/protein/1.2.107; RINDERKNECHT E, 1978, FEBS LETT, V89, P283, DOI 10.1016/0014-5793(78)80237-3; TALLY M, 1987, BIOCHEM BIOPH RES CO, V147, P1206, DOI 10.1016/S0006-291X(87)80198-5; TALLY M, 1987, BIOCHEM BIOPH RES CO, V148, P811, DOI 10.1016/0006-291X(87)90948-X; TALLY M, 1989, THESIS KAROLINSKA I; VIEIRA J, 1982, GENE, V19, P269; ZUMSTEIN PP, 1985, P NATL ACAD SCI USA, V82, P3169, DOI 10.1073/pnas.82.10.3169	29	18	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					11058	11062						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	1645723				2022-12-25	WOS:A1991FQ77400056
J	SMILEY, PL; STREMLER, KE; PRESCOTT, SM; ZIMMERMAN, GA; MCINTYRE, TM				SMILEY, PL; STREMLER, KE; PRESCOTT, SM; ZIMMERMAN, GA; MCINTYRE, TM			OXIDATIVELY FRAGMENTED PHOSPHATIDYLCHOLINES ACTIVATE HUMAN NEUTROPHILS THROUGH THE RECEPTOR FOR PLATELET-ACTIVATING-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYHEMOGLOBIN-INDUCED PEROXIDATION; BOVINE BRAIN; FACTOR ACETYLHYDROLASE; MYOCARDIAL ISCHEMIA; DE-GRANULATION; LIPID EXTRACT; HUMAN-PLASMA; GUINEA-PIG; ANTAGONIST; PHOSPHOLIPIDS	Platelet-activating factor (PAF, 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) activates neutrophils (polymorphonuclear leukocytes, PMN) through a receptor that specifically recognizes short sn-2 residues. We oxidized synthetic [2-arachidonoyl]phosphatidylcholine to fragment and shorten the sn-2 residue, and then examined the phospholipid products for the ability to stimulate PMN. 1-Palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine was fragmented by ozonolysis to 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphocholine. This phospholipid activated human neutrophils at submicromolar concentrations, and its effects were inhibited by specific PAF receptor antagonists WEB2086, L659,989, and CV3988. 1-Palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine next was fragmented by an uncontrolled free radical-catalyzed reaction: it was treated with soybean lipoxygenase to form its sn-2 15-hydroperoxy derivative (which did not activate neutrophils) and then allowed to oxidize under air. The secondary oxidation resulted in the formation of numerous fragmented phospholipids (Stremler, K. E., Stafforini, D. M., Prescott, S. M., and McIntyre, T. M. (1991) J. Biol. Chem. 266, 11095-11103), some of which activated PMN. Hydrolysis of sn-2 residues with phospholipase A2 destroyed biologic activity, as did hydrolysis with PAF acetylhydrolase. PAF acetylhydrolase is specific for short or intermediate length sn-2 residues and does not hydrolyze the starting material (Stremler, K. E., Stafforini, D. M., Prescott, S. M., and McIntyre, T. M. (1991) J. Biol. Chem. 266, 11095-11103). Neutrophil activation was completely blocked by L659,989, a specific PAF receptor antagonist. We conclude that diacylphosphatidylcholines containing an sn-2 polyunsaturated fatty acyl residue can be oxidatively fragmented to species with sn-2 residues short enough to activate the PAF receptor of neutrophils. This suggests a new mechanism for the appearance of biologically active phospholipids, and shows that PAF receptor antagonists block the action of both PAF and these PAF-like lipids.	UNIV UTAH,NORA ECCLES HARRISON CARDIOVASC RES & TRAINING INST,BLDG 500,SALT LAKE CITY,UT 84112; UNIV UTAH,DEPT INTERNAL MED,SALT LAKE CITY,UT 84112; UNIV UTAH,DEPT PHARMACOL,SALT LAKE CITY,UT 84112; UNIV UTAH,DEPT BIOCHEM,SALT LAKE CITY,UT 84112	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah					NATIONAL CANCER INSTITUTE [T32CA009602] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044525, R37HL044525, R01HL035828] Funding Source: NIH RePORTER; NCI NIH HHS [5T32 CA09602] Funding Source: Medline; NHLBI NIH HHS [HL35828, HL44525] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMES BN, 1960, J BIOL CHEM, V235, P769; BANERJI B, 1989, J LIPID RES, V30, P1907; BENVENISTE J, 1988, FEBS LETT, V226, P371, DOI 10.1016/0014-5793(88)81456-X; BLANK ML, 1982, RES COMMUN CHEM PATH, V38, P3; BLANK ML, 1979, BIOCHEM BIOPH RES CO, V90, P1194, DOI 10.1016/0006-291X(79)91163-X; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRAQUET P, 1987, PLATELET ACTIVATING, P191; BRASH AR, 1987, BIOCHEMISTRY-US, V26, P5465, DOI 10.1021/bi00391a038; CASALSSTENZEL J, 1987, J PHARMACOL EXP THER, V241, P974; DEMOPOULOS CA, 1979, J BIOL CHEM, V254, P9355; DENT G, 1989, FEBS LETT, V244, P365, DOI 10.1016/0014-5793(89)80564-2; DIAGNE A, 1984, BIOCHIM BIOPHYS ACTA, V793, P221, DOI 10.1016/0005-2760(84)90324-2; ENGLER RL, 1989, AM J CARDIOL, V63, pE19; ESTREBAUER H, 1982, BIOCHEM J, V208, P129; FLORAS JS, 1989, CIRCULATION S2, V80, P395; GOETZL EJ, 1980, BIOCHEM BIOPH RES CO, V94, P881, DOI 10.1016/0006-291X(80)91317-0; GUPTA CM, 1977, P NATL ACAD SCI USA, V74, P4315, DOI 10.1073/pnas.74.10.4315; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; HWANG SB, 1985, J BIOL CHEM, V260, P5639; HWANG SB, 1989, MOL PHARMACOL, V35, P48; HWANG SB, 1988, J PHARMACOL EXP THER, V246, P534; INOUE K, 1988, OXYGEN RADICALS BIOL, P291; ITABE H, 1988, BIOCHIM BIOPHYS ACTA, V961, P13; ITABE H, 1988, BIOCHIM BIOPHYS ACTA, V962, P8; KUBES P, 1990, AM J PHYSIOL, V259, pG300, DOI 10.1152/ajpgi.1990.259.2.G300; LEE TC, 1987, PLATELET ACTIVATING, P115; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; METCALF JA, 1986, LABORATORY MANUAL NE, P52; MUELLER HW, 1984, J BIOL CHEM, V259, P4554; OFLAHERTY JT, 1983, RES COMMUN CHEM PATH, V39, P291; OFLAHERTY JT, 1983, BIOCHEM BIOPH RES CO, V111, P1, DOI 10.1016/S0006-291X(83)80108-9; OFLAHERTY JT, 1984, RES COMMUN CHEM PATH, V43, P3; SATOUCHI K, 1985, BIOCHEM BIOPH RES CO, V128, P1409, DOI 10.1016/0006-291X(85)91097-6; SHEN TY, 1987, PLATELET ACTIVATING, P153; SNYDER F, 1985, MED RES REV, V5, P107, DOI 10.1002/med.2610050105; SPINNEWYN B, 1988, GINKGOLIDES CHEM BIO, P665; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4223; STAHL GL, 1988, J PHARMACOL EXP THER, V244, P898; STEWART AG, 1988, BRIT J PHARMACOL, V94, P1225, DOI 10.1111/j.1476-5381.1988.tb11642.x; STREMLER KE, 1989, J BIOL CHEM, V264, P5331; STREMLER KE, 1991, J BIOL CHEM, V266, P11095; TAGESSON C, 1988, GINKGOLIDES CHEM BIO, P553; TAM BK, 1970, J BIOL CHEM, V245, P2295; TERASHITA Z, 1983, LIFE SCI, V32, P1975, DOI 10.1016/0024-3205(83)90049-8; TOKUMURA A, 1989, J LIPID RES, V30, P219; TOKUMURA A, 1988, BIOCHEM BIOPH RES CO, V155, P863, DOI 10.1016/S0006-291X(88)80575-8; VALONE FH, 1987, PLATELET ACTIVATING, P137; VOELKEL NF, 1986, PROSTAGLANDINS, V32, P359, DOI 10.1016/0090-6980(86)90005-5; WU MS, 1986, J PHARMACOL EXP THER, V239, P841; WYKLE RL, 1981, BIOCHEM BIOPH RES CO, V100, P1651, DOI 10.1016/0006-291X(81)90708-7; YOSHIDA JI, 1986, J PHARM PHARMACOL, V38, P878, DOI 10.1111/j.2042-7158.1986.tb03375.x; ZIMMERMAN GA, 1990, J CELL BIOL, V110, P529, DOI 10.1083/jcb.110.2.529; ZIMMERMAN GA, 1988, J CLIN INVEST, V81, P531, DOI 10.1172/JCI113351; ZIMMERMAN GA, 1985, J CLIN INVEST, V76, P2235, DOI 10.1172/JCI112232; 1973, CD853 AM CHEM SOC	56	200	207	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					11104	11110						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	1645725				2022-12-25	WOS:A1991FQ77400062
J	WILEY, HS; HERBST, JJ; WALSH, BJ; LAUFFENBURGER, DA; ROSENFELD, MG; GILL, GN				WILEY, HS; HERBST, JJ; WALSH, BJ; LAUFFENBURGER, DA; ROSENFELD, MG; GILL, GN			THE ROLE OF TYROSINE KINASE-ACTIVITY IN ENDOCYTOSIS, COMPARTMENTATION, AND DOWN-REGULATION OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; LIGAND-INDUCED INTERNALIZATION; CELL-SURFACE RECEPTORS; MEDIATED ENDOCYTOSIS; EGF RECEPTOR; TRANSFERRIN RECEPTOR; RAPID ENDOCYTOSIS; HUMAN-FIBROBLASTS; RATE CONSTANTS; COATED PITS	Occupancy-induced down-regulation of cell surface epidermal growth factor (EGF) receptors attenuates signal transduction. To define mechanisms through which down-regulation of this class of growth factor receptors occurs, we have investigated the relative roles of ligand-induced internalization and recycling in this process. Occupied, kinase-active EGF receptors were internalized through a high affinity, saturable endocytic system at rates up to 10-fold faster than empty receptors. In contrast, full length EGF receptors lacking tyrosine kinase activity underwent internalization at a rate independent of occupancy. This "kinase-independent" internalization rate appeared to reflect constitutive receptor internalization since it was similar to the internalization rate of both receptors lacking a cytoplasmic domain and of antibodies bound to empty receptors. EGF internalized by either kinase-active or kinase-inactive receptors was efficiently recycled and was found within endosomes containing recycling transferrin receptors. However, targeting of internalized receptors to lysosomes did not require receptor kinase activity. All receptors that displayed ligand-induced internalization also underwent down-regulation, indicating that the proximal cause of down-regulation is occupancy-induced endocytosis. Tyrosine kinase activity greatly enhances this process by stabilizing receptor association with the endocytic apparatus.	UNIV ILLINOIS, DEPT CHEM ENGN, URBANA, IL 61801 USA; HOWARD HUGHES MED INST, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, SCH MED, LA JOLLA, CA 92093 USA	University of Illinois System; University of Illinois Urbana-Champaign; Howard Hughes Medical Institute; University of California System; University of California San Diego	WILEY, HS (corresponding author), UNIV UTAH, MED CTR, DEPT PATHOL, DIV CELL BIOL & IMMUNOL, 50 N MED DR, SALT LAKE CITY, UT 84132 USA.			Wiley, Steven/0000-0003-0232-6867	NIADDK NIH HHS [AM 13149] Funding Source: Medline; NIDDK NIH HHS [DK 33602] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM013149] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033602] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AJIOKA RS, 1987, J CELL BIOL, V104, P77, DOI 10.1083/jcb.104.1.77; AJIOKA RS, 1986, P NATL ACAD SCI USA, V83, P6445, DOI 10.1073/pnas.83.17.6445; ANDERSON RGW, 1977, CELL, V10, P351, DOI 10.1016/0092-8674(77)90022-8; BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; BARAK LS, 1982, J CELL BIOL, V95, P846, DOI 10.1083/jcb.95.3.846; BASU SK, 1981, CELL, V24, P493, DOI 10.1016/0092-8674(81)90340-8; BEISIEGEL U, 1981, J BIOL CHEM, V256, P1923; BENVENISTE M, 1988, J CELL BIOL, V106, P1903, DOI 10.1083/jcb.106.6.1903; BESTERMAN JM, 1981, J CELL BIOL, V91, P716, DOI 10.1083/jcb.91.3.716; BOMSEL M, 1989, J CELL BIOL, V109, P3243, DOI 10.1083/jcb.109.6.3243; BROWN MS, 1983, CELL, V32, P663, DOI 10.1016/0092-8674(83)90052-1; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; COURTOY PJ, 1984, J CELL BIOL, V98, P870, DOI 10.1083/jcb.98.3.870; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DUNN WA, 1984, J CELL BIOL, V98, P2148, DOI 10.1083/jcb.98.6.2148; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; GEXFABRY M, 1986, AM J PHYSIOL, V250, P1123; GILL GN, 1988, COLD SPRING HARB SYM, V53, P467, DOI 10.1101/SQB.1988.053.01.054; GILL GN, 1984, J BIOL CHEM, V259, P7755; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; GOLDSTEIN B, 1984, BIOPHYS J, V46, P573, DOI 10.1016/S0006-3495(84)84056-4; HAIGLER HT, 1979, J CELL BIOL, V81, P382, DOI 10.1083/jcb.81.2.382; HEISERMANN GJ, 1990, J BIOL CHEM, V265, P12820; HONEGGER AM, 1987, MOL CELL BIOL, V7, P4568, DOI 10.1128/MCB.7.12.4568; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HONEGGER AM, 1990, J CELL BIOL, V110, P1541, DOI 10.1083/jcb.110.5.1541; HOPKINS CR, 1990, NATURE, V346, P335, DOI 10.1038/346335a0; HORVAT G, 1969, J CELL BIOL, V42, P469, DOI 10.1083/jcb.42.2.469; HUECKSTEADT T, 1986, J BIOL CHEM, V261, P8655; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; KAPLAN J, 1981, SCIENCE, V212, P14, DOI 10.1126/science.6259730; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; KING AC, 1984, BIOCHEM BIOPH RES CO, V124, P585, DOI 10.1016/0006-291X(84)91594-8; KLAUSNER RD, 1983, P NATL ACAD SCI-BIOL, V80, P2263, DOI 10.1073/pnas.80.8.2263; KORC M, 1985, P NATL ACAD SCI USA, V82, P6172, DOI 10.1073/pnas.82.18.6172; KOVAL M, 1989, J CELL BIOL, V108, P2169, DOI 10.1083/jcb.108.6.2169; LLOYD CE, 1983, J CELL BIOL, V96, P521, DOI 10.1083/jcb.96.2.521; LUND KA, 1990, J BIOL CHEM, V265, P15713; LUND KA, 1990, J BIOL CHEM, V265, P20517; MAGNUSSON S, 1989, BIOCHEM J, V257, P651, DOI 10.1042/bj2570651; MCGRAW TE, 1990, CELL REGUL, V1, P369, DOI 10.1091/mbc.1.4.369; MCKINLEY DN, 1988, J CELL PHYSIOL, V136, P389, DOI 10.1002/jcp.1041360302; MURTHY U, 1986, J CELL BIOL, V103, P333, DOI 10.1083/jcb.103.2.333; MYERS AC, 1987, J BIOL CHEM, V262, P6494; NAKANE PK, 1974, J HISTOCHEM CYTOCHEM, V22, P1084, DOI 10.1177/22.12.1084; OPRESKO L, 1980, CELL, V22, P47, DOI 10.1016/0092-8674(80)90153-1; OPRESKO LK, 1987, J BIOL CHEM, V262, P4116; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; RITGER PD, 1968, DIFF EQUAT, P40; RUSSELL DS, 1987, J BIOL CHEM, V262, P11833; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; SHANNON LM, 1966, J BIOL CHEM, V241, P2166; SORKIN A, 1989, BIOCHIM BIOPHYS ACTA, V1011, P88, DOI 10.1016/0167-4889(89)90083-9; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; SORKIN A, 1991, J CELL BIOL, V112, P55, DOI 10.1083/jcb.112.1.55; SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415; STEIN BS, 1986, J BIOL CHEM, V261, P319; STOSCHECK CM, 1984, J CELL BIOL, V98, P1048, DOI 10.1083/jcb.98.3.1048; VERREY F, 1990, CELL REGUL, V1, P471, DOI 10.1091/mbc.1.6.471; WARD DM, 1990, BIOCHEM J, V270, P369, DOI 10.1042/bj2700369; WATERS CM, 1990, BIOCHEMISTRY-US, V29, P3563, DOI 10.1021/bi00466a020; WATTS C, 1985, J CELL BIOL, V100, P633, DOI 10.1083/jcb.100.2.633; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WILEY HS, 1988, J CELL BIOL, V107, P801, DOI 10.1083/jcb.107.2.801; WILEY HS, 1982, J BIOL CHEM, V257, P4222; WILEY HS, 1981, CELL, V25, P433, DOI 10.1016/0092-8674(81)90061-1; WILEY HS, 1985, CURR TOP MEMBR TRANS, V24, P369; WILEY HS, 1985, J BIOL CHEM, V260, P5290; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955; WILLINGHAM MC, 1983, EXP CELL RES, V146, P163, DOI 10.1016/0014-4827(83)90334-8	71	248	253	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					11083	11094						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	1645724				2022-12-25	WOS:A1991FQ77400060
J	MUI, ALF; KAY, RJ; HUMPHRIES, RK; KRYSTAL, G				MUI, ALF; KAY, RJ; HUMPHRIES, RK; KRYSTAL, G			PURIFICATION OF THE MURINE INTERLEUKIN-3 RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; GM-CSF; ALPHA-CHAIN; CELL-LINES; CLONING; PHOSPHORYLATION; ELECTROPHORESIS; EXPRESSION; PROTEIN; BINDING	In this report we describe the purification of the murine interleukin 3 receptor (mIL-3R) to apparent homogeneity using a two-step procedure involving biotinylated mIL-3 (B-mIL-3) and affinity binding to immobilized antiphosphotyrosine and streptavidin agarose (SA). Purification was monitored using an assay for detergent solubilized mIL-3Rs that utilized unglycosylated I-125-mIL-3 and concanavalin A (ConA)-Sepharose beads. The final material consisted of a 140-kDa tyrosine and serine phosphorylated protein that was >98% pure as assessed by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis of either [S-35]methionine-labeled, silver-stained, or radioiodinated preparations. Characterization of the purified receptor revealed that it migrated identically under reducing and nonreducing conditions in SDS gels, possessed 10 kDa of N-linked carbohydrate, and was cleaved upon storage at 4-degrees-C to a 70-kDa form. These properties suggested that the purified mIL-3R was identical to that identified by cross-linking studies. The K(D) of the purified receptor was 1-5 nM, similar to estimates obtained using intact normal mouse bone marrow cells and mIL-3-dependent cell lines. The two-step purification procedure also isolated a 120-kDa serine phosphorylated but nontyrosine phosphorylated mIL-3R species. Apart from phosphorylation differences, the 140- and 120-kDa species were apparently identical, yielding, after alkaline phosphatase treatment, the same molecular mass on SDS gels and similar chymotryptic peptide maps. Amino acid sequence and composition data obtained from the more abundant and more stable serine phosphorylated 120-kDa mIL-3R, further purified by SDS-polyacrylamide gel electrophoresis, suggested that the purified mIL-3R may be identical to the predicted sequence of the recently isolated cDNA clone AIC2A. This was further suggested by comparing chymotryptic maps of the 120-kDa mIL-3R with the Aic2A protein and using antibodies corresponding to the amino and carboxyl termini of the AIC2A cDNA product. However, the Aic2A protein, when expressed on the surface of COS or 3T3 cells or following detergent solubilization and partial purification with biotinylated mIL-3 and SA, displayed a substantially lower affinity for mIL-3.	BRITISH COLUMBIA CANC RES CTR, TERRY FOX LAB, 601 W 10TH AVE, VANCOUVER V5Z 1L3, BC, CANADA; UNIV BRITISH COLUMBIA, DEPT PATHOL, VANCOUVER V5Z 1L3, BC, CANADA; UNIV BRITISH COLUMBIA, DEPT MED GENET, VANCOUVER V5Z 1L3, BC, CANADA; UNIV BRITISH COLUMBIA, DEPT MED, VANCOUVER V5Z 1L3, BC, CANADA	British Columbia Cancer Agency; University of British Columbia; University of British Columbia; University of British Columbia				Krystal, Gerald/0000-0002-1961-6281; Humphries, Richard/0000-0003-0540-7005				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIBA S, 1990, J BIOL CHEM, V265, P19777; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; FEIGE JJ, 1988, J BIOL CHEM, V263, P14023; FUKUNAGA R, 1990, J BIOL CHEM, V265, P14008; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; GOUGH NM, 1985, EMBO J, V4, P645, DOI 10.1002/j.1460-2075.1985.tb03678.x; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HARA T, 1992, FASEB J, V6, pA1606; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; ISFORT RJ, 1988, P NATL ACAD SCI USA, V85, P7982, DOI 10.1073/pnas.85.21.7982; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KAY R, 1991, Methods in Molecular and Cellular Biology, V2, P254; KINDLER V, 1986, P NATL ACAD SCI USA, V83, P1001, DOI 10.1073/pnas.83.4.1001; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KRYSTAL G, 1987, ANAL BIOCHEM, V167, P86, DOI 10.1016/0003-2697(87)90136-9; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MURTHY SC, 1990, EXP HEMATOL, V18, P11; MURTHY SC, 1989, BLOOD, V73, P1180; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PALASZYNSKI EW, 1984, J IMMUNOL, V132, P1872; PODSKALNY JM, 1986, J BIOL CHEM, V261, P14076; SCHRADER JW, 1986, ANNU REV IMMUNOL, V4, P205, DOI 10.1146/annurev.iy.04.040186.001225; SCHREURS J, 1988, FASEB J, V2, pA1652; Schreurs J, 1990, GROWTH FACTORS, V2, P221, DOI 10.3109/08977199009071508; SORENSEN P, 1989, J BIOL CHEM, V264, P19253; SORENSEN PHB, 1989, BLOOD, V73, P406; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0	29	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1992	267	23					16523	16530						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JJ458	1644833				2022-12-25	WOS:A1992JJ45800083
J	DUMONT, DJ; YAMAGUCHI, TP; CONLON, RA; ROSSANT, J; BREITMAN, ML				DUMONT, DJ; YAMAGUCHI, TP; CONLON, RA; ROSSANT, J; BREITMAN, ML			TEK, A NOVEL TYROSINE KINASE GENE LOCATED ON MOUSE CHROMOSOME-4, IS EXPRESSED IN ENDOTHELIAL-CELLS AND THEIR PRESUMPTIVE PRECURSORS	ONCOGENE			English	Article							FIBROBLAST GROWTH-FACTOR; PROTO-ONCOGENE; MESSENGER-RNAS; EMBRYONIC-DEVELOPMENT; INSITU HYBRIDIZATION; TRANSFORMING GENE; 2 ISOFORMS; W-LOCUS; RECEPTOR; LOCALIZATION	A search for protein tyrosine kinases expressed during murine cardiogenesis resulted in the isolation of a novel tyrosine kinase, designated tek, which maps to mouse chromosome 4 between the brown and pmv-23 loci. The deduced amino acid sequence of tek predicts that it encodes a putative receptor tyrosine kinase that contains a 21 amino acid kinase insert and which is most closely related in its catalytic domains to FGFR1 and the product of the ret proto-oncogene. In situ hybridization analysis of adult tissues, as well as sectioned and whole-mount embryos, showed that tek is specifically expressed in the endocardium, the leptomeninges and the endothelial lining of the vasculature from the earliest stages of their development. Moreover, examination of the morphology of tek-expressing cells, and staging of tek expression relative to that of the endothelial cell marker von Willebrand factor, revealed that tek is expressed prior to von Willebrand factor and appears to mark the embryonic progenitors of mature endothelial cells. tek encodes a novel putative receptor tyrosine kinase that may be critically involved in the determination and/or maintenance of cells of the endothelial lineage.	MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, 600 UNIV AVE, TORONTO M5G 1X5, ONTARIO, CANADA; UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO M5S 1A1, ONTARIO, CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto								BEDDINGTON RSP, 1989, MOL BIOL MED, V6, P263; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BERNARD O, 1991, P NATL ACAD SCI USA, V88, P7625, DOI 10.1073/pnas.88.17.7625; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; COFFIN JD, 1988, DEVELOPMENT, V102, P735; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; DAVIS CA, 1991, DEVELOPMENT, V111, P287; DUBREUIL P, 1990, ANN NY ACAD SCI, V599, P58, DOI 10.1111/j.1749-6632.1990.tb42364.x; EISEMANN A, 1991, ONCOGENE, V6, P1195; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; FUJITA H, 1991, BIOCHEM BIOPH RES CO, V174, P946, DOI 10.1016/0006-291X(91)91510-J; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEMMATIBRIVANLOU A, 1990, DEVELOPMENT, V110, P325; HOLTZMAN DA, 1987, P NATL ACAD SCI USA, V84, P8325, DOI 10.1073/pnas.84.23.8325; HORMIA M, 1984, EUR J CELL BIOL, V33, P217; JAFFE EA, 1973, J CLIN INVEST, V52, P2757, DOI 10.1172/JCI107471; JOYNER AL, 1987, GENE DEV, V1, P29, DOI 10.1101/gad.1.1.29; KAUFMAN MH, 1981, J ANAT, V133, P235; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; Lyon M., 1989, GENETIC VARIANTS STR; MAHER PA, 1991, J CELL BIOL, V112, P955, DOI 10.1083/jcb.112.5.955; MANASEK FJ, 1976, CELL SURFACE ANIMAL, P545; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MUSLIN AJ, 1991, DEVELOPMENT, V112, P1095; NODEN DM, 1989, AM REV RESPIR DIS, V140, P1097, DOI 10.1164/ajrccm/140.4.1097; NODEN DM, 1988, DEVELOPMENT, V103, P121; NODEN DM, 1990, ANN NY ACAD SCI, V588, P236, DOI 10.1111/j.1749-6632.1990.tb13214.x; OBRIEN SJ, 1990, GENETIC MAPS; PARDANAUD L, 1987, DEVELOPMENT, V100, P339; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; RENSHAW MW, 1988, MOL CELL BIOL, V8, P4547, DOI 10.1128/MCB.8.10.4547; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; RUNYAN RB, 1990, CELL REGUL, V1, P301, DOI 10.1091/mbc.1.3.301; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SAFRAN A, 1990, ONCOGENE, V5, P635; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; STEPHENSON DA, 1991, P NATL ACAD SCI USA, V88, P6, DOI 10.1073/pnas.88.1.6; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TOMASI V, 1990, Biofactors, V2, P213; VU TH, 1989, MOL CELL BIOL, V9, P4563, DOI 10.1128/MCB.9.10.4563; WAGNER RC, 1980, ADV MICROCIRCULAT, V9, P45; WANG JYJ, 1983, MOL CELL BIOL, V3, P773, DOI 10.1128/MCB.3.5.773; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R	54	341	351	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1992	7	8					1471	1480						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1630810				2022-12-25	WOS:A1992JE81300002
J	AGUILARBRYAN, L; NICHOLS, CG; RAJAN, AS; PARKER, C; BRYAN, J				AGUILARBRYAN, L; NICHOLS, CG; RAJAN, AS; PARKER, C; BRYAN, J			COEXPRESSION OF SULFONYLUREA RECEPTORS AND KATP CHANNELS IN HAMSTER INSULINOMA TUMOR (HIT) CELLS - EVIDENCE FOR DIRECT ASSOCIATION OF THE RECEPTOR WITH THE CHANNEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; LIGAND-BINDING SYSTEMS; DEPENDENT K+-CHANNELS; GLIBENCLAMIDE-BINDING; H-3 GLIBENCLAMIDE; POTASSIUM CHANNEL; B-CELLS; TOLBUTAMIDE; DIAZOXIDE; PURIFICATION	Cell membranes isolated from hamster insulinoma (HIT T15) cells at passages 65-74 contain high and low affinity receptors for a sulfonylurea derivative, 5-[I-125]iodo,2-hydroxyglyburide (K(D) values of approximately 7 nM and 16-mu-M). Between passages 75 and 85, the estimated B(max) for the high affinity receptor decreases approximately 10-fold from approximately 1.6 to 0.16 pmol/mg membrane protein. By contrast, the density of low affinity binding sites, 800-1000 pmol/mg, is unaltered. The drop in high affinity receptors is paralleled by a decrease in the density of K(ATP) channels assessed using patch-clamp and Rb-86(+) efflux techniques. These results strongly support the idea that the high affinity sulfonylurea receptor is an integral part of the K(ATP) channel.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110	Baylor College of Medicine; Washington University (WUSTL)	AGUILARBRYAN, L (corresponding author), BAYLOR COLL MED,DEPT MED,1 BAYLOR PL,HOUSTON,TX 77030, USA.		Nichols, Colin/D-6336-2012		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045742] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041898, R01DK027635] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45742] Funding Source: Medline; NIDDK NIH HHS [DK27635, DK41898] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGUILARBRYAN L, 1990, J BIOL CHEM, V265, P8218; ASHCROFT FM, 1989, J PHYSIOL-LONDON, V408, P413, DOI 10.1113/jphysiol.1989.sp017467; ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; BERNARDI H, 1988, P NATL ACAD SCI USA, V85, P9816, DOI 10.1073/pnas.85.24.9816; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; FELDMAN HA, 1972, ANAL BIOCHEM, V48, P317, DOI 10.1016/0003-2697(72)90084-X; FOSSET M, 1988, J BIOL CHEM, V263, P7933; FRENCH JF, 1990, BIOCHEM BIOPH RES CO, V167, P1400, DOI 10.1016/0006-291X(90)90678-G; KOVACS RJ, 1991, AM J PHYSIOL, V261, pH604, DOI 10.1152/ajpheart.1991.261.2.H604; KRAMER W, 1988, FEBS LETT, V229, P355, DOI 10.1016/0014-5793(88)81155-4; LEDERER WJ, 1989, J PHYSIOL-LONDON, V419, P193, DOI 10.1113/jphysiol.1989.sp017869; MISLER S, 1986, P NATL ACAD SCI USA, V83, P7119, DOI 10.1073/pnas.83.18.7119; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NELSON DA, 1992, J BIOL CHEM, V267, P14928; NIKI I, 1989, PFLUG ARCH EUR J PHY, V415, P47, DOI 10.1007/BF00373140; PANTEN U, 1989, BIOCHEM PHARMACOL, V38, P1217, DOI 10.1016/0006-2952(89)90327-4; QIN D, 1988, AM J PHYSIOL, V255, pH980, DOI 10.1152/ajpheart.1988.255.4.H980; ROBERTSON DW, 1990, J MED CHEM, V33, P1529, DOI 10.1021/jm00168a001; SANTERRE RF, 1981, P NATL ACAD SCI-BIOL, V78, P4339, DOI 10.1073/pnas.78.7.4339; SCHMIDANTOMARCHI H, 1987, J BIOL CHEM, V262, P15840; STURGESS NC, 1985, LANCET, V2, P474; TRUBE G, 1986, PFLUG ARCH EUR J PHY, V407, P493, DOI 10.1007/BF00657506; TRUBE G, 1984, PFLUG ARCH EUR J PHY, V401, P178, DOI 10.1007/BF00583879; ZHANG HJ, 1989, DIABETES, V38, P44, DOI 10.2337/diabetes.38.1.44; ZUNKLER BJ, 1988, N-S ARCH PHARMACOL, V337, P225; ZUNKLER BJ, 1988, FEBS LETT, V239, P241, DOI 10.1016/0014-5793(88)80925-6	27	56	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14934	14940						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634534				2022-12-25	WOS:A1992JF08800066
J	FLORINCHRISTENSEN, J; FLORINCHRISTENSEN, M; DELFINO, JM; STEGMANN, T; RASMUSSEN, H				FLORINCHRISTENSEN, J; FLORINCHRISTENSEN, M; DELFINO, JM; STEGMANN, T; RASMUSSEN, H			METABOLIC-FATE OF PLASMA-MEMBRANE DIACYLGLYCEROLS IN NIH-3T3 FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED FIBROBLASTS; INTRACELLULAR TRANSLOCATION; PHOSPHATIDIC-ACID; LIPID TRANSFER; PHOSPHATIDYLCHOLINE; VESICLES; FUSION; KINASE; HYDROLYSIS; MESSENGER	We have examined the metabolism of three radiolabeled 1,2-diacylglycerols (DGs) in NIH 3T3 fibroblasts. Since the lipids used are not appreciably taken up by the cells, we used a phosphatidylserine (PS)-based liposome fusion system to rapidly associate the lipid species with the plasma membrane. When 1,2[1-C-14]dioleoyl-sn-3-glycerol ([C-14]DOG) is delivered in this way, it is rapidly converted predominantly to phosphatidylcholine (PC) and triacylglycerol (TG) and to a lesser extent, to monoacylglycerol (MG) and fatty acids (FA), as well as phosphatidic acid (PA) and phosphatidylinositol (PI). We present evidence that [C-14] DOG is largely utilized as an intact molecule rather than being broken down to FA and then incorporated to cell lipids. Examination of the metabolism of 1-stearoyl-2-[1-C-14]myristoyl-sn-3-glycerol ([C-14]SMG) and I-stearoyl-2-arachidonoyl-sn-3-glycerol ([C-14] SAG) reveal important differences. Both produce substantial labeling of PC but [C-14]SMG gives rise to the highest proportion of TG and the lowest of PA and PI, whereas [C-14]SAG yields the opposite pattern. When phosphatidic acid labeled on its glycerol backbone (1,2-dioleoyl-sn-[U-C-14]glycero-3-phosphate) was supplied to the cells via the liposomes, rapid appearance of labeled DG was found which then decreased with concomitant labeling of cellular PC and TG. Only small amounts of the glycerol backbone were recovered in Pl. Our experiments identify three types of processes involved in the metabolism of plasma membrane DGs: (i) transferase-catalyzed conversions to PC and TG, (ii) lipolytic breakdown to MG and FA, and (iii) phosphorylation to PA and then conversion to Pl. The relative proportions of each DG species converted to these different products are strongly dependent on the fatty acyl composition of the particular DG molecular species, even though formation of PC is the major event in all cases. Since DGs are important second messengers, our study supports the view that conversion to PC and TG can play a key role in DG signal attenuation.	YALE UNIV,DEPT INTERNAL MED,NEW HAVEN,CT 06510; YALE UNIV,DEPT CELL BIOL,NEW HAVEN,CT 06510; YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510	Yale University; Yale University; Yale University				Florin-Christensen, Monica/0000-0003-0456-3970	NIAID NIH HHS [AI 18599] Funding Source: Medline; NIDDK NIH HHS [DK-19813] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018599, R37AI018599] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK019813, R01DK019813] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BESTERMAN JM, 1986, P NATL ACAD SCI USA, V83, P6785, DOI 10.1073/pnas.83.18.6785; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BISHOP WR, 1988, ONCOGENE RES, V2, P205; BISHOP WR, 1986, J BIOL CHEM, V261, P2513; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOLLAG WB, 1991, ENDOCRINOLOGY, V128, P231, DOI 10.1210/endo-128-1-231; DANIEL LW, 1986, J BIOL CHEM, V261, P9128; DECOURCELLES DD, 1985, J BIOL CHEM, V260, P5762; DUNN WA, 1980, J BIOL CHEM, V255, P5971; EXTON JH, 1990, J BIOL CHEM, V265, P1; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GUPTA CM, 1977, P NATL ACAD SCI USA, V74, P4315, DOI 10.1073/pnas.74.10.4315; Kates M., 1986, TECHNIQUES LIPIDOLOG; MACDONALD ML, 1988, J BIOL CHEM, V263, P1584; MAJERUS PW, 1986, SCIENCE, V234, P1519, DOI 10.1126/science.3024320; MUIR JG, 1987, J CELL PHYSIOL, V130, P382, DOI 10.1002/jcp.1041300311; NICHOLS JW, 1983, J BIOL CHEM, V258, P5368; PAGANO RE, 1983, TRENDS BIOCHEM SCI, V8, P157, DOI 10.1016/0968-0004(83)90161-5; PAGANO RE, 1981, J CELL BIOL, V91, P872, DOI 10.1083/jcb.91.3.872; PAGANO RE, 1985, J BIOL CHEM, V260, P1909; PAGANO RE, 1983, J BIOL CHEM, V258, P2034; PELECH SL, 1989, TRENDS BIOCHEM SCI, V14, P24; SALINGER Z, 1966, J LIPID RES, V7, P174; SIMPSON CMF, 1991, J BIOL CHEM, V266, P15902; STEGMANN T, 1989, ANNU REV BIOPHYS BIO, V18, P187, DOI 10.1146/annurev.bb.18.060189.001155; STEGMANN T, 1986, J BIOL CHEM, V261, P966; SUTHERLAND CA, 1982, J BIOL CHEM, V257, P4006; TAKUWA N, 1987, BIOCHEM J, V243, P647, DOI 10.1042/bj2430647; VANCE DE, 1990, BIOCHEM CELL BIOL, V68, P1151, DOI 10.1139/o90-172; WEINSTEIN JN, 1977, SCIENCE, V195, P489, DOI 10.1126/science.835007; WIRTZ KWA, 1982, LIPID PROTEIN INTERA, V1, P151; ZILVERSMIT DB, 1984, J LIPID RES, V25, P1563	32	47	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14783	14789						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634522				2022-12-25	WOS:A1992JF08800044
J	GOTO, Y; DESILVA, MG; TOSCANI, A; PRABHAKAR, BS; NOTKINS, AL; LAN, MS				GOTO, Y; DESILVA, MG; TOSCANI, A; PRABHAKAR, BS; NOTKINS, AL; LAN, MS			A NOVEL HUMAN INSULINOMA-ASSOCIATED CDNA, IA-1, ENCODES A PROTEIN WITH ZINC-FINGER DNA-BINDING MOTIFS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-IIIA; MOLECULAR-CLONING; NUCLEOTIDE-SEQUENCE; G0/G1 TRANSITION; C-FOS; GENE; POLYPEPTIDE; CELLS; CLONES; REGION	A subtraction library was constructed from human insulinoma (beta-cell tumor) and glucagonoma (alpha-cell tumor) cDNA phagemid libraries. Differential screening of 153 clones with end-labeled mRNAs from insulinoma, glucagonoma, and HeLa cells resulted in the isolation of a novel cDNA clone designated IA-1. This cDNA clone has a 2838-base pair sequence consisting of an open reading frame of 1530 nucleotides, which translates into a protein of 510 amino acids with a pI value of 9.1 and a molecular mass of 52,923 daltons. At the 3'-untranslated region there are seven ATTTA sequences between two polyadenylation signals (AATAAA). The IA-1 protein can be divided into two domains based upon the features of its amino acid sequence. The NH2-terminal domain of the deduced protein sequence (amino acids 1-250) has four classical pro-hormone dibasic conversion sites and an amidation signal sequence, Pro-Gly-Lys-Arg. The COOH-terminal domain (amino acids 251-510) contains five putative "zinc-finger" DNA-binding motifs of the form X3-Cys-X2-4-Cys-X12-His-X3-4-His-X4 which has been described as a consensus sequence for members of the Cys2-His2 DNA-binding protein class. Northern blot analysis revealed IA-1 mRNA in five of five human insulinoma and three of three murine insulinoma cell lines. Expression of this gene was undetectable in normal tissues. Additional tissue studies revealed that the message is expressed in several tumor cell lines of neuroendocrine origin including pheochromocytoma, medullary thyroid carcinoma, insulinoma, pituitary tumor, and small cell lung carcinoma. The restricted tissue distribution and unique sequence motifs suggest that this novel cDNA clone may encode a protein associated with the transformation of neuroendocrine cells.	NIDR,ORAL MED LAB,BLDG 30,RM 121,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)			Lan, Michael/CAF-1839-2022					BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BRAY P, 1986, P NATL ACAD SCI USA, V83, P8893, DOI 10.1073/pnas.83.23.8893; BROWN RS, 1986, NATURE, V324, P215, DOI 10.1038/324215a0; Brunstedt J, 1984, METHODS DIABETES R C, P245; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EMI M, 1986, GENE, V41, P305; HELMAN LJ, 1988, J BIOL CHEM, V263, P11559; JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KINZLER KW, 1988, NATURE, V332, P371, DOI 10.1038/332371a0; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kreil G, 1986, PROTEIN COMPARTMENTA, P61; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; ROSENBERG UB, 1986, NATURE, V319, P336, DOI 10.1038/319336a0; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SCHWARTZ TW, 1983, GASTROENTEROLOGY, V85, P1411; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHIRASU Y, 1988, J BIOCHEM-TOKYO, V104, P259, DOI 10.1093/oxfordjournals.jbchem.a122454; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TATEMOTO K, 1978, P NATL ACAD SCI USA, V75, P4115, DOI 10.1073/pnas.75.9.4115; TERAZONO K, 1988, J BIOL CHEM, V263, P2111; TOMITA N, 1989, BIOCHEM BIOPH RES CO, V158, P569, DOI 10.1016/S0006-291X(89)80087-7; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557	33	142	151	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15252	15257						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634555				2022-12-25	WOS:A1992JF08800109
J	KURAZONO, H; MOCHIDA, S; BINZ, T; EISEL, U; QUANZ, M; GREBENSTEIN, O; WERNARS, K; POULAIN, B; TAUC, L; NIEMANN, H				KURAZONO, H; MOCHIDA, S; BINZ, T; EISEL, U; QUANZ, M; GREBENSTEIN, O; WERNARS, K; POULAIN, B; TAUC, L; NIEMANN, H			MINIMAL ESSENTIAL DOMAINS SPECIFYING TOXICITY OF THE LIGHT-CHAINS OF TETANUS TOXIN AND BOTULINUM NEUROTOXIN TYPE-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOTOR-NERVE TERMINALS; MESSENGER-RNA; CLOSTRIDIAL NEUROTOXINS; TRANSMITTER RELEASE; CHROMAFFIN CELLS; NEUROTRANSMITTER RELEASE; INHIBITS EXOCYTOSIS; NUCLEOTIDE-SEQUENCE; APLYSIA NEURONS; FORMS CHANNELS	To define conserved domains within the light (L) chains of clostridial neurotoxins, we determined the sequence of botulinum neurotoxin type B (BoNT/B) and aligned it with those of tetanus toxin (TeTx) and BoNT/A, BoNT/Cl, BoNT/D, and BoNT/E. The L chains of BoNT/B and TeTx share 51.6% identical amino acid residues whereas the degree of identity to other clostridial neurotoxins does not exceed 36.5%. Each of the L chains contains a conserved motif, HExxHxxH, characteristic for metalloproteases. We then generated specific 5'- and 3'-deletion mutants of the L chain genes of TeTx and BoNT/A and tested the biological properties of the gene products by microinjection of the corresponding mRNAs into identified presynaptic cholinergic neurons of the buccal ganglia of Aplysia californica. Toxicity was determined by measurement of neurotransmitter release, as detected by depression of postsynaptic responses to presynaptic stimuli (Mochida, S., Poulain, B., Eisel, U., Binz, T., Kurazono, H., Niemann, H., and Tauc, L. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 7844-7848). Our studies allow the following conclusions. 1) Residues Cys439 of TeTx and Cys430 of BoNT/A, both of which participate in the interchain disulfide bond, play no role in the toxification reaction. 2) Derivatives of TeTx that lacked either 8 amino- or 65 carboxyl-terminal residues are still toxic, whereas those lacking 10 amino- or 68 carboxyl-terminal residues are nontoxic. 3) For BoNT/A, toxicity could be demonstrated only in the presence of added nontoxic heavy (H) chain. A deletion of 8 amino-terminal or 32 carboxyl-terminal residues from the L chain had no effect on toxicity, whereas a removal of 10 amino-terminal or 57 carboxyl-terminal amino acids abolished toxicity. 4) The synergistic effect mediated by the H chain is linked to the carboxyl-terminal portion of the H chain, as demonstrated by injection of H(C)-specific mRNA into neurons containing the L chain. This finding suggests that the H(C) domain of the H chain becomes exposed to the cytosol during or after the putative translocation step of the L chain.	FED RES CTR VIRUS DIS ANIM,INST MICROBIOL,PAUL EHRLICH STR 28,POB 1149,W-7400 TUBINGEN,GERMANY; RIJKSINST VOLKSGEZONDHEID MILIEUHYG,3720 BA BILTHOVEN,NETHERLANDS; CNRS,NEUROBIOL CELLULAIRE & MOLEC LAB,F-91198 GIF SUR YVETTE,FRANCE; TOKYO MED COLL,DEPT PHYSIOL,SHINJUKU KU,TOKYO 160,JAPAN	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Tokyo Medical University				Eisel, Ulrich/0000-0003-4178-0384				AGUILERA J, 1992, FEMS MICROBIOL LETT, V90, P99; AHNERTHILGER G, 1989, FEBS LETT, V242, P245, DOI 10.1016/0014-5793(89)80478-8; BHATTACHARYYA SD, 1989, INFECT IMMUN, V57, P3053, DOI 10.1128/IAI.57.10.3053-3057.1989; BINZ T, 1990, NUCLEIC ACIDS RES, V18, P5556, DOI 10.1093/nar/18.18.5556; BINZ T, 1990, J BIOL CHEM, V265, P9153; BITTNER MA, 1989, J BIOL CHEM, V264, P10354; BLACK JD, 1986, J CELL BIOL, V103, P535, DOI 10.1083/jcb.103.2.535; BOQUET P, 1984, EUR J BIOCHEM, V144, P339, DOI 10.1111/j.1432-1033.1984.tb08469.x; BOQUET P, 1982, P NATL ACAD SCI-BIOL, V79, P7614, DOI 10.1073/pnas.79.24.7614; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; DEKLEVA ML, 1990, J BACTERIOL, V172, P2498, DOI 10.1128/jb.172.5.2498-2503.1990; DEPAIVA A, 1990, FEBS LETT, V277, P171, DOI 10.1016/0014-5793(90)80836-8; DONOVAN JJ, 1986, BIOCHEMISTRY-US, V25, P2872, DOI 10.1021/bi00358a020; DREYER F, 1987, N-S ARCH PHARMACOL, V335, P1, DOI 10.1007/BF00165027; DRUMMOND DR, 1985, NUCLEIC ACIDS RES, V13, P7375, DOI 10.1093/nar/13.20.7375; EISEL U, 1986, EMBO J, V5, P2495, DOI 10.1002/j.1460-2075.1986.tb04527.x; ENDO T, 1987, PHARMACOL THERAPEUT, V34, P403, DOI 10.1016/0163-7258(87)90002-7; GANSEL M, 1987, PFLUG ARCH EUR J PHY, V409, P533, DOI 10.1007/BF00583812; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HAUSER D, 1990, NUCLEIC ACIDS RES, V18, P4924, DOI 10.1093/nar/18.16.4924; HOCH DH, 1985, P NATL ACAD SCI USA, V82, P1692, DOI 10.1073/pnas.82.6.1692; JONGENEEL CV, 1989, FEBS LETT, V242, P211, DOI 10.1016/0014-5793(89)80471-5; JOU WM, 1980, CELL, V19, P683, DOI 10.1016/S0092-8674(80)80045-6; KOZAK MJ, 1987, J MOL BIOL, V196, P631; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; KRIEGLSTEIN K, 1990, EUR J BIOCHEM, V188, P39; KROHNE G, 1989, J CELL BIOL, V109, P2003, DOI 10.1083/jcb.109.5.2003; MAISEY EA, 1988, EUR J BIOCHEM, V177, P683, DOI 10.1111/j.1432-1033.1988.tb14423.x; MAYER T, 1988, J BIOL CHEM, V263, P14956; MCINNES C, 1990, FEBS LETT, V261, P323, DOI 10.1016/0014-5793(90)80582-4; MOCHIDA S, 1990, P NATL ACAD SCI USA, V87, P7844, DOI 10.1073/pnas.87.20.7844; MOCHIDA S, 1989, FEBS LETT, V253, P47, DOI 10.1016/0014-5793(89)80926-3; MORRIS RE, 1989, BOTULINUM NEUROTOXIN, P121; POULAIN B, 1991, J BIOL CHEM, V266, P9580; POULAIN B, 1990, J PHYSIOL-PARIS, V84, P247; POULAIN B, 1989, EUR J BIOCHEM, V185, P197, DOI 10.1111/j.1432-1033.1989.tb15102.x; POULAIN B, 1988, P NATL ACAD SCI USA, V85, P4090, DOI 10.1073/pnas.85.11.4090; POULAIN B, 1989, J BIOL CHEM, V264, P21928; POULET S, 1992, BIOCHEM BIOPH RES CO, V183, P107, DOI 10.1016/0006-291X(92)91615-W; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIAVO G, 1990, INFECT IMMUN, V58, P4136, DOI 10.1128/IAI.58.12.4136-4141.1990; SCHMIDT JJ, 1984, BIOCHEM BIOPH RES CO, V119, P900, DOI 10.1016/0006-291X(84)90858-1; SCHMITT A, 1981, N-S ARCH PHARMACOL, V317, P326, DOI 10.1007/BF00501314; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHONE CC, 1987, EUR J BIOCHEM, V167, P175, DOI 10.1111/j.1432-1033.1987.tb13320.x; SHONE CC, 1985, EUR J BIOCHEM, V151, P75, DOI 10.1111/j.1432-1033.1985.tb09070.x; SIMPSON LL, 1988, J PHARMACOL EXP THER, V245, P867; SIMPSON LL, 1986, ANNU REV PHARMACOL, V26, P427, DOI 10.1146/annurev.pa.26.040186.002235; SIMPSON LL, 1980, J PHARMACOL EXP THER, V212, P16; STECHER B, 1989, FEBS LETT, V255, P391, DOI 10.1016/0014-5793(89)81129-9; STECHER B, 1989, FEBS LETT, V248, P23, DOI 10.1016/0014-5793(89)80424-7; STOEVA S, 1990, BIOCHEMISTRY-US, V29, P527, DOI 10.1021/bi00454a029; TAUC L, 1974, NATURE, V250, P496, DOI 10.1038/250496a0; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; WELLER U, 1988, N-S ARCH PHARMACOL, V338, P99; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	57	74	94	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14721	14729						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634516				2022-12-25	WOS:A1992JF08800036
J	RUBIN, DC; SWIETLICKI, E; ROTH, KA; GORDON, JI				RUBIN, DC; SWIETLICKI, E; ROTH, KA; GORDON, JI			USE OF FETAL INTESTINAL ISOGRAFTS FROM NORMAL AND TRANSGENIC MICE TO STUDY THE PROGRAMMING OF POSITIONAL INFORMATION ALONG THE DUODENAL-TO-COLONIC AXIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE SMALL-INTESTINE; ACID-BINDING-PROTEIN; HOMEOBOX-CONTAINING GENE; HORMONE FUSION GENES; AGGREGATION CHIMERAS; MESSENGER-RNA; PANETH CELLS; STEM-CELLS; IMMUNOCYTOCHEMICAL LOCALIZATION; SUBEPITHELIAL FIBROBLASTS	The four principal cellular constituents of the mouse intestinal epithelium are all derived from a multipotent stem cell functionally anchored near the base of its crypts. Differentiation of enterocytes, enteroendocrine, and goblet cells occurs during an orderly upward migration from monoclonal crypts supplied by a single active stem cell to adjacent polyclonal small intestinal villi or to their colonic homologs, the surface epithelial cuffs. Paneth cells differentiate as they descend to the base of crypts. This epithelium undergoes rapid and perpetual renewal yet is able to maintain cephalocaudal (duodenal-to-colonic) differences in the differentiation programs of its four cell types from the time of its initial cytodifferentiation in late fetal life (embryonic (E) days 16-17). Rat liver fatty acid-binding protein/human growth hormone transgenes (Fabpl/hGH) have been used as novel phenotypic markers to describe the biological properties of gut stem cells and the differentiation programs of their enterocytic and enteroendocrine lineages. To determine whether the multipotent stem cell is able to retain a "positional" address in the absence of luminal signals, we prepared isografts from the proximal small intestine or distal small intestine and colon of E15-E16 Fabpl/hGH transgenic mice and their normal littermates and implanted them into the subcutaneous tissues of young, adult male CBY/B6 nude mice. Immunocytochemical and histochemical studies indicate that appropriate position-specific differences in the differentiation programs of each of the four principal cell lineages are present along the cephalocaudal and crypt-to-villus (or crypt-to-epithelial cuff) axes of isografts harvested 4-6 weeks after implantation. This suggests that the gut stem cell can be characterized not only by its multipotency and enormous capacity for self-renewal but also by its ability to be programmed (? imprinted) with positional information. Transgene expression is reduced in a number of enteroendocrine subpopulations in small intestinal and colonic isografts compared to the intact gut. Moreover, the decision to express the Fabpl/hGH transgene appears to be coordinated between adjacent crypts as evidenced by (i) the presence of multicrypt patches of wholly reporter (hGH)-positive or reporter-negative cells in the intact colon and in colonic isografts and (ii) by the presence of coherent bands of reporter-positive or -negative cells that emanate from adjacent monophenotypic crypts and extend to the apical extrusion zone of distal small intestinal villi. The apparent coordination of transgene expression between adjacent crypts raises questions about whether cephalocaudal differences in the differentiation programs of gut epithelial cell populations may be determined by a smaller population of stem cells than one would have anticipated based on the number of anatomically definable crypts.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,BOX 8103,660 S EUCLID AVE,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)				Rubin, Deborah/0000-0002-4192-909X; Roth, Kevin/0000-0002-0643-995X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K08HD000946] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037960] Funding Source: NIH RePORTER; NICHD NIH HHS [HD00946] Funding Source: Medline; NIDDK NIH HHS [DK37960] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAMSON S, 1977, J EXP MED, V145, P1567, DOI 10.1084/jem.145.6.1567; ALNAFUSSI AI, 1982, VIRCHOWS ARCH B, V40, P51, DOI 10.1007/BF02932850; CAIRNIE AB, 1975, CELL TISSUE KINET, V8, P189, DOI 10.1111/j.1365-2184.1975.tb01219.x; CHENG H, 1974, AM J ANAT, V141, P537, DOI 10.1002/aja.1001410407; CHENG H, 1985, ANAT REC, V211, P420, DOI 10.1002/ar.1092110408; COHN SM, 1991, P NATL ACAD SCI USA, V88, P1034, DOI 10.1073/pnas.88.3.1034; DEXTER TM, 1987, ANNU REV CELL BIOL, V3, P423; DONY C, 1987, EMBO J, V6, P2965, DOI 10.1002/j.1460-2075.1987.tb02602.x; DRESSLER GR, 1989, DIFFERENTIATION, V41, P193, DOI 10.1111/j.1432-0436.1989.tb00747.x; DUPREY P, 1988, GENE DEV, V2, P1647, DOI 10.1101/gad.2.12a.1647; ERLANDSEN SL, 1974, J HISTOCHEM CYTOCHEM, V22, P401, DOI 10.1177/22.6.401; ERSELIUS JR, 1990, DEVELOPMENT, V110, P629; GALLIOT B, 1989, DEVELOPMENT, V107, P343; GAUNT SJ, 1987, DEVELOPMENT, V101, P51; GAUNT SJ, 1988, DEVELOPMENT, V103, P135; GAUNT SJ, 1991, BIOESSAYS, V13, P505, DOI 10.1002/bies.950131004; GAUNT SJ, 1986, NATURE, V324, P662, DOI 10.1038/324662a0; GREEN RP, 1992, DNA CELL BIOL, V11, P31, DOI 10.1089/dna.1992.11.31; GRIFFITHS DFR, 1988, NATURE, V333, P461, DOI 10.1038/333461a0; HAFFEN K, 1983, DIFFERENTIATION, V23, P226; HANSBROUGH JR, 1991, AM J PHYSIOL, V260, pG929, DOI 10.1152/ajpgi.1991.260.6.G929; HART MH, 1988, GASTROENTEROLOGY, V94, P682, DOI 10.1016/0016-5085(88)90239-9; HAUFT SM, 1989, J BIOL CHEM, V264, P8419; HOLLAND PWH, 1988, DEVELOPMENT, V102, P159; INOUE M, 1988, AM J PATHOL, V132, P49; JAMES R, 1991, J BIOL CHEM, V266, P3246; JORDAN CT, 1990, GENE DEV, V4, P220, DOI 10.1101/gad.4.2.220; KEDINGER M, 1987, CELL DIFFER DEV, V20, P171, DOI 10.1016/0045-6039(87)90431-3; KEDINGER M, 1986, DEV BIOL, V113, P474, DOI 10.1016/0012-1606(86)90183-1; LOWE JB, 1987, J BIOL CHEM, V262, P5931; MARSH MN, 1974, GASTROENTEROLOGY, V67, P636; MARSH MN, 1974, GASTROENTEROLOGY, V67, P622; MASKENS AP, 1979, GUT, V20, P775, DOI 10.1136/gut.20.9.775; MCKEEL DW, 1978, ARCH PATHOL LAB MED, V102, P122; MEAD R, 1987, DEV BIOL, V121, P273, DOI 10.1016/0012-1606(87)90159-X; MOSER AR, 1992, J CELL BIOL, V116, P1517, DOI 10.1083/jcb.116.6.1517; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; MURPHY P, 1989, NATURE, V341, P156, DOI 10.1038/341156a0; MURPHY P, 1991, DEVELOPMENT, V111, P61; OBUOFORIBO AA, 1977, J ANAT, V24, P779; OUELLETTE AJ, 1989, J CELL BIOL, V108, P1687, DOI 10.1083/jcb.108.5.1687; PEETERS T, 1975, GUT, V16, P553, DOI 10.1136/gut.16.7.553; PONDER BAJ, 1985, NATURE, V313, P689, DOI 10.1038/313689a0; PONDER BAJ, 1985, J EMBRYOL EXP MORPH, V87, P229; PONDER BAJ, 1986, HISTOCHEM J, V18, P217, DOI 10.1007/BF01676230; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; ROTH KA, 1990, P NATL ACAD SCI USA, V87, P6408, DOI 10.1073/pnas.87.16.6408; ROTH KA, 1991, J BIOL CHEM, V266, P5949; ROTH KA, 1990, J CELL BIOL, V110, P1791, DOI 10.1083/jcb.110.5.1791; ROTH KA, 1991, P NATL ACAD SCI USA, V88, P9407, DOI 10.1073/pnas.88.21.9407; ROTH KA, 1992, IN PRESS AM J PHYSL; RUBIN DC, 1991, J CELL BIOL, V113, P1183, DOI 10.1083/jcb.113.5.1183; SANDGREN EP, 1991, CELL, V66, P245, DOI 10.1016/0092-8674(91)90615-6; SATOH Y, 1986, DIGESTION, V34, P115, DOI 10.1159/000199319; SATOH Y, 1986, ANAT EMBRYOL, V173, P317, DOI 10.1007/BF00318915; SCHMIDT GH, 1990, MUTAT RES, V228, P149, DOI 10.1016/0027-5107(90)90071-B; SCHMIDT GH, 1988, DEVELOPMENT, V103, P785; SCHMIDT GH, 1985, CELL, V40, P425, DOI 10.1016/0092-8674(85)90156-4; SCHMIDT GH, 1985, J EMBRYOL EXP MORPH, V85, P121; SCHMIDT GH, 1985, J EMBRYOL EXP MORPH, V88, P219; SCHMIDT GH, 1984, ANAT REC, V210, P407, DOI 10.1002/ar.1092100216; SEEBURG PH, 1982, DNA-J MOLEC CELL BIO, V1, P239, DOI 10.1089/dna.1.1982.1.239; SENIOR PV, 1988, DEVELOPMENT, V104, P431; SIMO P, 1991, DEVELOPMENT, V112, P477; SIMONASSMANN P, 1989, J CELL BIOL, V109, P1837, DOI 10.1083/jcb.109.4.1837; SIMONASSMANN P, 1986, DIFFERENTIATION, V32, P59, DOI 10.1111/j.1432-0436.1986.tb00556.x; SIMONASSMANN P, 1990, J CELL BIOL, V110, P849, DOI 10.1083/jcb.110.3.849; SIMONASSMANN P, 1988, DEVELOPMENT, V102, P339; STCLAIR WH, 1985, CELL TISSUE KINET, V18, P255; SWEETSER DA, 1986, J BIOL CHEM, V261, P5553; SWEETSER DA, 1988, GENE DEV, V2, P1318, DOI 10.1101/gad.2.10.1318; SWEETSER DA, 1988, P NATL ACAD SCI USA, V85, P9611, DOI 10.1073/pnas.85.24.9611; TAVASSOLI M, 1990, BLOOD, V76, P1059; THOMPSON EM, 1990, DEVELOPMENT, V110, P477; UITDERDYK HG, 1986, GENET RES, V47, P125; VOGELS R, 1990, DEVELOPMENT, V110, P1159; WESER E, 1977, GASTROENTEROLOGY, V73, P524; WINTON DJ, 1990, P ROY SOC B-BIOL SCI, V241, P13, DOI 10.1098/rspb.1990.0059; WINTON DJ, 1989, MUTAGENESIS, V4, P404, DOI 10.1093/mutage/4.5.404; WINTON DJ, 1988, NATURE, V333, P463, DOI 10.1038/333463a0; WOLGEMUTH DJ, 1989, NATURE, V337, P464, DOI 10.1038/337464a0; WRIGHT NA, 1982, CELL TISSUE KINET, V15, P595, DOI 10.1111/j.1365-2184.1982.tb01066.x	82	87	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15122	15133						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634547				2022-12-25	WOS:A1992JF08800091
J	SORRENTINO, S; GLITZ, DG; HAMANN, KJ; LOEGERING, DA; CHECKEL, JL; GLEICH, GJ				SORRENTINO, S; GLITZ, DG; HAMANN, KJ; LOEGERING, DA; CHECKEL, JL; GLEICH, GJ			EOSINOPHIL-DERIVED NEUROTOXIN AND HUMAN LIVER RIBONUCLEASE - IDENTITY OF STRUCTURE AND LINKAGE OF NEUROTOXICITY TO NUCLEASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; L-TRYPTOPHAN INGESTION; CATIONIC PROTEIN; MYALGIA-SYNDROME; MOLECULAR-CLONING; HUMAN ANGIOGENIN; HUMAN-PLACENTA; INHIBITOR; PURIFICATION; BINDING	Eosinophil-derived neurotoxin (EDN) and human liver RNase were found to be indistinguishable from each other but distinct from the pancreatic ribonucleases in their nucleolytic activity on polynucleotides or small defined substrates. Antibodies to EDN and liver RNase showed identical cross-reactivities in assays of nuclease inhibition and in a radioimmunoassay. In each instance, EDN and liver RNase were easily distinguished from bovine or human pancreatic RNase. When injected intrathecally into rabbits, 5-10-mu-g of EDN or liver RNase each was neurotoxic as judged by induction of the Gordon phenomenon. Human pancreatic RNase was less neurotoxic, and up to 20-fold higher levels of bovine pancreatic RNase showed no effect. Treatment of EDN, liver RNase, and eosinophil cationic protein with iodoacetic acid at pH 5.5 resulted in inactivation of their RNase activity and also destroyed their neurotoxicity. EDN conformation was not greatly affected by iodoacetate treatment since interaction of the modified protein with antibodies was only slightly altered. We conclude that RNase activity is necessary but not sufficient to induce neurotoxic action.	UNIV CALIF LOS ANGELES, SCH MED, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA; MAYO CLIN & MAYO FDN, ALLERG DIS RES LAB, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DEPT IMMUNOL, ROCHESTER, MN 55905 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Mayo Clinic; Mayo Clinic					NCRR NIH HHS [RR 585] Funding Source: Medline; NIAID NIH HHS [AI 07047, AI 09728] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI009728, R37AI009728] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALDHOUS P, 1991, NATURE, V353, P490; BARKER RL, 1989, J IMMUNOL, V143, P952; BEINTEMA JJ, 1988, BIOCHEMISTRY-US, V27, P4530, DOI 10.1021/bi00412a046; BEINTEMA JJ, 1988, PROG BIOPHYS MOL BIO, V51, P165, DOI 10.1016/0079-6107(88)90001-6; BEINTEMA JJ, 1984, ANAL BIOCHEM, V136, P48, DOI 10.1016/0003-2697(84)90306-3; BLACKBURN P, 1982, J BIOL CHEM, V257, P316; BLACKBURN P, 1977, J BIOL CHEM, V252, P5904; Blackburn P, 1982, ENZYMES, VXV, P317; BULPITT KJ, 1990, ARTHRITIS RHEUM, V33, P918, DOI 10.1002/art.1780330702; CHARBONNEAU H, 1989, PRACTICAL GUIDE PROT, P20; CHUSID MJ, 1975, MEDICINE, V54, P1, DOI 10.1097/00005792-197501000-00001; CRESTFIELD AM, 1963, J BIOL CHEM, V238, P2413; DURACK DT, 1981, P NATL ACAD SCI-BIOL, V78, P5165, DOI 10.1073/pnas.78.8.5165; DURACK DT, 1979, P NATL ACAD SCI USA, V76, P1443, DOI 10.1073/pnas.76.3.1443; FREDENS K, 1982, J ALLERGY CLIN IMMUN, V70, P361, DOI 10.1016/0091-6749(82)90025-2; GLEICH GJ, 1986, P NATL ACAD SCI USA, V83, P3146, DOI 10.1073/pnas.83.10.3146; Gordon MH, 1933, BRIT MED J, V1933, P641, DOI 10.1136/bmj.1.3771.641; HALLAHAN TW, 1991, P NATL ACAD SCI USA, V88, P2222, DOI 10.1073/pnas.88.6.2222; HAMANN KJ, 1989, GENE, V83, P161, DOI 10.1016/0378-1119(89)90414-9; HARPER JW, 1988, P NATL ACAD SCI USA, V85, P7139, DOI 10.1073/pnas.85.19.7139; HERTZMAN PA, 1990, NEW ENGL J MED, V322, P869, DOI 10.1056/NEJM199003293221301; KAUFMAN LD, 1991, LANCET, V337, P1071, DOI 10.1016/0140-6736(91)91717-9; KUNITZ M, 1946, J BIOL CHEM, V164, P563; LEE FS, 1989, BIOCHEMISTRY-US, V28, P225, DOI 10.1021/bi00427a031; LIBONATI M, 1969, EUR J BIOCHEM, V8, P81, DOI 10.1111/j.1432-1033.1969.tb00498.x; MADDOX DE, 1983, J EXP MED, V158, P1211, DOI 10.1084/jem.158.4.1211; MARTIN RW, 1990, ANN INTERN MED, V113, P124, DOI 10.7326/0003-4819-113-2-124; MOLINA HA, 1988, AM J TROP MED HYG, V38, P327, DOI 10.4269/ajtmh.1988.38.327; NG SC, 1989, POSTGRAD MED J, V65, P843, DOI 10.1136/pgmj.65.769.843; PALACIOS R, 1972, J BIOL CHEM, V247, P2316; PALMER KA, 1986, P NATL ACAD SCI USA, V83, P1965, DOI 10.1073/pnas.83.7.1965; PLAPP BV, 1973, J BIOL CHEM, V248, P4896; ROSENBERG HF, 1989, P NATL ACAD SCI USA, V86, P4460, DOI 10.1073/pnas.86.12.4460; ROSENBERG HF, 1989, J EXP MED, V170, P163, DOI 10.1084/jem.170.1.163; ROUBENOFF R, 1990, ARTHRITIS RHEUM, V33, P930, DOI 10.1002/art.1780330703; SCHARSCHMIDT BF, 1988, CECIL TXB MED, P852; SHAPIRO R, 1991, BIOCHEMISTRY-US, V30, P2246, DOI 10.1021/bi00222a030; SHAPIRO R, 1988, BIOCHEM BIOPH RES CO, V156, P530, DOI 10.1016/S0006-291X(88)80874-X; SHAPIRO R, 1986, BIOCHEMISTRY-US, V25, P3527, DOI 10.1021/bi00360a008; SHAPIRO R, 1987, P NATL ACAD SCI USA, V84, P8783, DOI 10.1073/pnas.84.24.8783; SHAPIRO R, 1987, P NATL ACAD SCI USA, V84, P2238, DOI 10.1073/pnas.84.8.2238; Sierakowska H, 1977, Prog Nucleic Acid Res Mol Biol, V20, P59; SILVER RM, 1990, NEW ENGL J MED, V322, P874, DOI 10.1056/NEJM199003293221302; SLIFMAN NR, 1986, J IMMUNOL, V137, P2913; SORRENTINO S, 1988, J BIOL CHEM, V263, P16125; SORRENTINO S, 1991, FEBS LETT, V288, P23, DOI 10.1016/0014-5793(91)80994-E; SORRENTINO S, 1985, BIOCHIM BIOPHYS ACTA, V827, P135, DOI 10.1016/0167-4838(85)90081-0; STRYDOM DJ, 1985, BIOCHEMISTRY-US, V24, P5486, DOI 10.1021/bi00341a031; TOLANDER LM, 1991, ARCH NEUROL-CHICAGO, V48, P436, DOI 10.1001/archneur.1991.00530160106024; WEICKMANN JL, 1981, BIOCHEMISTRY-US, V20, P1272, DOI 10.1021/bi00508a035; YAMASHITA K, 1986, ARCH BIOCHEM BIOPHYS, V250, P263, DOI 10.1016/0003-9861(86)90725-3	51	130	131	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14859	14865						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634526				2022-12-25	WOS:A1992JF08800055
J	HUANG, RS; SORISKY, A; CHURCH, WR; SIMONS, ER; RITTENHOUSE, SE				HUANG, RS; SORISKY, A; CHURCH, WR; SIMONS, ER; RITTENHOUSE, SE			THROMBIN RECEPTOR-DIRECTED LIGAND ACCOUNTS FOR ACTIVATION BY THROMBIN OF PLATELET PHOSPHOLIPASE-C AND ACCUMULATION OF 3-PHOSPHORYLATED PHOSPHOINOSITIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							FLOW CYTOMETRIC MEASUREMENTS; ALPHA-THROMBIN; PHOSPHATIDYLINOSITOL; CA-2+	Using three experimental approaches, we have addressed the questions of whether the presence of saturably bound thrombin plays a role in potentiating the activation of platelet phospholipase C (PLC) and/or accumulation of the 3-phosphorylated phosphoinositides (3-PPI), i.e. phosphatidylinositol 3,4-bisphosphate and phosphatidylinositol 3,4,5-trisphosphate, and whether the generation of tethered ligand (Vu, T-K. H., Hung, D. T., Wheaton, V. I., and Coughlin, S. R. (1991) Cell 64, 1057-1068) by thrombin can account fully for thrombin's proteolytic effects in activating platelets, as gauged by the above parameters. We have 1) measured PLC activation or 3-PPI after we have exposed platelets to thrombin for various periods and either blocked thrombin's proteolytic activity without interrupting its binding or blocked both binding and proteolytic activity of thrombin; 2) attempted to potentiate 3-PPI accumulation, using combinations of protein kinase C stimulation, Ca2+ elevation, and saturating but proteolytically inactive thrombins; and 3) compared the activation of platelets by thrombin with activation by the "thrombin" receptor-directed peptide, SFLLRNPNDKYEPF (SFLL; a portion of the tethered ligand created by thrombin's proteolytic activity), and examined the effect of thrombin on this latter activation. We conclude that the initial and sustained effects of thrombin in stimulating PLC and the accumulation of 3-PPI are completely attributable to thrombin's proteolytic activity. Further, thrombin's effects in promoting these responses can be accounted for by the actions of SFLL peptide, and by implication, formation of tethered ligand.	UNIV VERMONT,COLL MED,DEPT BIOCHEM,BURLINGTON,VT 05405; BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118	University of Vermont; Boston University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038622, R01HL015335, R29HL040467] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-40467, HL-15335, HL-38622] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERNDT MC, 1981, PLATELETS BIOL PATHO, V2, P43; DAVIES TA, 1988, CYTOMETRY, V9, P138, DOI 10.1002/cyto.990090207; DAVIES TA, 1990, J BIOL CHEM, V265, P11522; DAVIES TA, 1989, J BIOL CHEM, V264, P19600; HARMON JT, 1986, J BIOL CHEM, V261, P5928; HENRIKSEN RA, 1989, BIOCHEMISTRY-US, V28, P2078, DOI 10.1021/bi00431a017; HUANG EM, 1987, BIOCHEM J, V242, P11, DOI 10.1042/bj2420011; HUANG R, 1991, J BIOL CHEM, V266, P1652; KING WG, 1991, BIOCHEM J, V278, P475, DOI 10.1042/bj2780475; KNUPP CL, 1988, THROMB RES, V49, P23, DOI 10.1016/0049-3848(88)90356-8; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; LUNDBLAD RL, 1975, BIOCHEM BIOPH RES CO, V66, P482, DOI 10.1016/0006-291X(75)90536-7; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; NESHEIM ME, 1979, BIOCHEMISTRY-US, V18, P996, DOI 10.1021/bi00573a010; NOLAN RD, 1990, J BIOL CHEM, V265, P2441; RITTENHOUSE SE, 1983, P NATL ACAD SCI-BIOL, V80, P5417, DOI 10.1073/pnas.80.17.5417; RITTENHOUSESIMMONS S, 1979, J CLIN INVEST, V63, P580, DOI 10.1172/JCI109339; TAM SW, 1979, J BIOL CHEM, V254, P8723; TOLLEFSEN DM, 1974, J BIOL CHEM, V249, P2646; TRAVER AP, 1987, J BIOL CHEM, V262, P17268; VADNAL RE, 1989, BIOCHEM BIOPH RES CO, V163, P995, DOI 10.1016/0006-291X(89)92320-6; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922	23	129	131	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18435	18438						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1655750				2022-12-25	WOS:A1991GJ47200007
J	TOMEO, AC; EGAN, RW; DURAN, WN				TOMEO, AC; EGAN, RW; DURAN, WN			PRIMING INTERACTIONS BETWEEN PLATELET-ACTIVATING-FACTOR AND HISTAMINE IN THE INVIVO MICROCIRCULATION	FASEB JOURNAL			English	Note						MICROCIRCULATION; PRIMING; PAF; HISTAMINE; LEUKOCYTE	HUMAN POLYMORPHONUCLEAR LEUKOCYTES; HUMAN-ENDOTHELIAL CELLS; RESPONSES; RECEPTOR; LEUKOTRIENE-B4; PERMEABILITY; BINDING; POTENT	To elucidate whether priming exists between platelet-activating factor (PAF) and histamine in the microcirculation, we measured the clearance of FITC-dextran 150 in response to the topical applications of substimulatory concentrations of PAF and histamine. Maximal priming by PAF was observed when a 5-min interval separated the applications of 10(-9)M PAF and 10(-6)M histamine. The mean (+/- SEM) clearance resulting from this sequence of agonist administration was 7529 +/- 659 nl.2 h-1.g-1, representing a 4.5-fold enhancement in FITC-dextran 150 clearance compared with that evoked by 10(-6)M histamine alone (1664 +/- 397 nl.2 h-1.g-1). Lowering the PAF priming dose to 10(-11)M, or reversing the order of agonist addition to the microcirculation, resulted in diminished but significant responses of 3545 +/- 1143 and 4467 +/- 1170 nl.2 hr-1.g-1, respectively. Coapplication of PAF and histamine or increasing the time interval between the agonists to 15 min greatly reduced the responses to 1906 +/- 678 and 2770 +/- 837, respectively. The PAF receptor antagonist WEB 2086 (2 mg/kg i.v.), the H-1 blocker pyrilamine (10 mg/kg i.v.), and leukocyte depletion with cyclophosphamide (150 mg/kg i.p.) completely abolished the PAF priming effect. In addition, the 5-lipoxygenase inhibitor RG 5901 (1 or 10 mg/kg i.v.) produced a two-thirds attenuation in PAF priming. We conclude that 1) PAF has the ability to prime the in vivo microvascular actions of histamine in both a concentration and time-dependent fashion; 2) this primed response is receptor mediated; and 3) histamine can prime the microcirculation for enhanced responses to PAF. Our data also demonstrate that leukocytes and the release of leukotrienes participate in PAF priming.	UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT SURG,NEWARK,NJ 07103; SCHERING PLOUGH CORP,BLOOMFIELD,NJ 07003	Rutgers State University New Brunswick; Rutgers State University Medical Center; Merck & Company; Schering Plough Corporation	TOMEO, AC (corresponding author), UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT PHYSIOL,DIV MICROCIRCULATORY RES,NEWARK,NJ 07103, USA.				NHLBI NIH HHS [HL 43146] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043146] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEAVEN MA, 1976, NEW ENGL J MED, V294, P30, DOI 10.1056/NEJM197601012940108; BUSSOLINO F, 1987, J IMMUNOL, V139, P2439; CHILTON FH, 1982, J BIOL CHEM, V257, P5402; DAHLEN SE, 1981, P NATL ACAD SCI-BIOL, V78, P3887, DOI 10.1073/pnas.78.6.3887; DELMAESTRO RF, 1981, MICROVASC RES, V22, P255, DOI 10.1016/0026-2862(81)90096-0; DILLON PK, 1988, CIRC RES, V62, P732, DOI 10.1161/01.RES.62.4.732; DILLON PK, 1988, INFLAMMATION, V12, P563, DOI 10.1007/BF00914318; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; GARCIA JGN, 1988, THROMB RES, V51, P83, DOI 10.1016/0049-3848(88)90285-X; GAY JC, 1986, BLOOD, V67, P931; HONDA C, 1991, NATURE, V349, P342; HUMPHREY DM, 1982, LAB INVEST, V47, P227; HWANG SB, 1988, J BIOL CHEM, V263, P3225; HWANG SB, 1986, J BIOL CHEM, V261, P532; INGRAHAM LM, 1982, BLOOD, V59, P1259; KORTH R, 1987, FASEB J, V46, P444; KUBES P, 1990, AM J PHYSIOL, V258, pG158, DOI 10.1152/ajpgi.1990.258.1.G158; LAMBRECHT G, 1986, BRIT J PHARMACOL, V87, P287, DOI 10.1111/j.1476-5381.1986.tb10816.x; LEWIS RE, 1988, MICROVASC RES, V35, P27, DOI 10.1016/0026-2862(88)90048-9; MAJNO G, 1961, J BIOPHYS BIOCHEM CY, V11, P571, DOI 10.1083/jcb.11.3.571; MALMSTEN CL, 1980, ACTA PHYSIOL SCAND, V110, P449, DOI 10.1111/j.1748-1716.1980.tb06696.x; MCINTYRE TM, 1985, J CLIN INVEST, V76, P271, DOI 10.1172/JCI111957; NORTHOVER AM, 1989, AGENTS ACTIONS, V26, P367, DOI 10.1007/BF01967303; PALMBLAD J, 1984, J IMMUNOL, V132, P3041; PINCKARD RN, 1979, J IMMUNOL, V123, P1847; PIPER PJ, 1987, BRIT J PHARMACOL, V90, P771, DOI 10.1111/j.1476-5381.1987.tb11231.x; VERCELLOTTI GM, 1988, BLOOD, V71, P1100; WARREN JS, 1989, J CLIN INVEST, V83, P669, DOI 10.1172/JCI113931; YOUNG JM, 1985, PROSTAGLANDINS, V30, P545, DOI 10.1016/0090-6980(85)90018-8	29	16	16	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1991	5	13					2850	2855		10.1096/fasebj.5.13.1655549	http://dx.doi.org/10.1096/fasebj.5.13.1655549			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GJ471	1655549				2022-12-25	WOS:A1991GJ47100014
J	LOETSCHER, H; GENTZ, R; ZULAUF, M; LUSTIG, A; TABUCHI, H; SCHLAEGER, EJ; BROCKHAUS, M; GALLATI, H; MANNEBERG, M; LESSLAUER, W				LOETSCHER, H; GENTZ, R; ZULAUF, M; LUSTIG, A; TABUCHI, H; SCHLAEGER, EJ; BROCKHAUS, M; GALLATI, H; MANNEBERG, M; LESSLAUER, W			RECOMBINANT 55-KDA TUMOR-NECROSIS-FACTOR (TNF) RECEPTOR - STOICHIOMETRY OF BINDING TO TNF-ALPHA AND TNF-BETA AND INHIBITION OF TNF ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE; MOLECULAR-CLONING; SOLUBLE FORM; HUMAN-URINE; EXPRESSION; LYMPHOTOXIN; PROTEINS; PURIFICATION; ENDOTOXIN; CACHECTIN	The extracellular domain of the 55-kDa TNF receptor (rsTNFR-beta) has been expressed as a secreted protein in baculovirus-infected insect cells and Chinese hamster ovary (CHO)/dhfr- cells. A chimeric fusion protein (rsTNFR-beta-h-gamma-3) constructed by inserting the extracellular part of the receptor in front of the hinge region of the human IgG C-gamma-3 chain has been expressed in mouse myeloma cells. The recombinant receptor proteins were purified from transfected cell culture supernatants by TNF-alpha- or protein G affinity chromatography and gel filtration. In a solid phase binding assay rsTNFR-beta was found to bind TNF-alpha with high affinity comparable with the membrane-bound full-length receptor. The affinity for TNF-beta was slightly impaired. However, the bivalent rsTNFR-beta-h-gamma-3 fusion protein bound both ligands with a significantly higher affinity than monovalent rsTNFR-beta reflecting most likely an increased avidity of the bivalent construct. A molecular mass of about 140 kDa for both rsTNFR-beta. TNF-alpha and rsTNFR-beta.TNF-beta complexes was determined in analytical ultracentrifugation studies strongly suggesting a stoichiometry of three rsTNFR-beta molecules bound to one TNF-alpha or TNF-beta trimer. Sedimentation velocity and quasielastic light scattering measurements indicated an extended structure for rsTNFR-beta and its TNF-alpha and TNF-beta complexes. Multiple receptor binding sites on TNF-alpha trimers could also be demonstrated by a TNF-alpha-induced agglutination of Latex beads coated with the rsTNFR-beta-h-gamma-3 fusion protein. Both rsTNFR-beta and rsTNFR-beta-h-gamma-3 were found to inhibit binding of TNF-alpha and TNF-beta to native 55- and 75-kDa TNF receptors and to prevent TNF-alpha and TNF-beta bioactivity in a cellular cytotoxicity assay. Concentrations of rsTNFR-beta-h-gamma-3 equimolar to TNF-alpha were sufficient to neutralize TNF activity almost completely, whereas a 10-100-fold excess of rsTNFR-beta was needed for similar inhibitory effects. In view of their potent TNF antagonizing activity, recombinant soluble TNF receptor fragments might be useful as therapeutic agents in TNF-mediated disorders.	UNIV BASEL,BIOCTR,CH-4056 BASEL,SWITZERLAND; NIPPON ROCHE RES CTR,DEPT MOLEC GENET,KAMAKURA,KANAGAWA 247,JAPAN	University of Basel; Roche Holding	LOETSCHER, H (corresponding author), F HOFFMANN LA ROCHE & CO LTD,PHARMA RES NEW TECHNOL,PRTB,BLDG 15-40,CH-4002 BASEL,SWITZERLAND.							AGGARWAL BB, 1985, J BIOL CHEM, V260, P2345; ANTONI G, 1989, ANAL BIOCHEM, V179, P158, DOI 10.1016/0003-2697(89)90217-0; BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437; BEUTLER B, 1987, NEW ENGL J MED, V316, P379; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; CHERNYAK VY, 1982, ANAL BIOCHEM, V123, P110, DOI 10.1016/0003-2697(82)90630-3; COLLINS T, 1986, P NATL ACAD SCI USA, V83, P446, DOI 10.1073/pnas.83.2.446; DEMBIC Z, 1990, Cytokine, V2, P231, DOI 10.1016/1043-4666(90)90022-L; DEVLIN JJ, 1984, LYMPHOKINES, V9, P313; DURCHSCHLAG H, 1989, COLLOID POLYM SCI, V267, P1139, DOI 10.1007/BF01496937; ECK MJ, 1989, J BIOL CHEM, V264, P17595; ENGELMANN H, 1989, J BIOL CHEM, V264, P11974; ENGELMANN H, 1990, J BIOL CHEM, V265, P1531; GAMBLE JR, 1985, P NATL ACAD SCI USA, V82, P8667, DOI 10.1073/pnas.82.24.8667; GATANAGA T, 1990, P NATL ACAD SCI USA, V87, P8781, DOI 10.1073/pnas.87.22.8781; GRAY PW, 1990, P NATL ACAD SCI USA, V87, P7380, DOI 10.1073/pnas.87.19.7380; GRAY PW, 1984, NATURE, V312, P721, DOI 10.1038/312721a0; HELLER RA, 1990, P NATL ACAD SCI USA, V87, P6151, DOI 10.1073/pnas.87.16.6151; HOHMANN HP, 1990, J BIOL CHEM, V265, P15183; HOHMANN HP, 1989, J BIOL CHEM, V264, P14927; JOHNSON DR, 1990, P NATL ACAD SCI USA, V87, P5183, DOI 10.1073/pnas.87.13.5183; JONES EY, 1989, NATURE, V338, P225, DOI 10.1038/338225a0; KOHNO T, 1990, P NATL ACAD SCI USA, V87, P8331, DOI 10.1073/pnas.87.21.8331; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANTZ M, 1990, J CLIN INVEST, V86, P1396, DOI 10.1172/JCI114853; LOETSCHER H, 1990, J BIOL CHEM, V265, P20131; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; LOETSCHER H, 1991, IN PRESS OXFORD SURV; MICHIE HR, 1988, NEW ENGL J MED, V318, P1481, DOI 10.1056/NEJM198806093182301; NEDOSPASOV SA, 1986, NUCLEIC ACIDS RES, V14, P7713, DOI 10.1093/nar/14.19.7713; NOPHAR Y, 1990, EMBO J, V9, P3269, DOI 10.1002/j.1460-2075.1990.tb07526.x; OLD LJ, 1985, SCIENCE, V230, P630, DOI 10.1126/science.2413547; OLSSON I, 1989, EUR J HAEMATOL, V42, P270, DOI 10.1111/j.1600-0609.1989.tb00111.x; PECK R, 1989, CELL IMMUNOL, V122, P1, DOI 10.1016/0008-8749(89)90143-3; PEETRE C, 1988, EUR J HAEMATOL, V41, P414; PENNICA D, 1984, NATURE, V312, P724, DOI 10.1038/312724a0; PORTEU F, 1990, J EXP MED, V172, P599, DOI 10.1084/jem.172.2.599; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P229, DOI 10.1016/0010-4655(82)90174-6; ROTHSTEIN JL, 1988, P NATL ACAD SCI USA, V85, P607, DOI 10.1073/pnas.85.2.607; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHLAEGER EJ, 1989, ADV ANIMAL CELL BIOL, P386; SCHOENFELD HJ, 1991, J BIOL CHEM, V266, P3863; SECKINGER P, 1989, J BIOL CHEM, V264, P11966; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; TAKEDA K, 1986, NATURE, V323, P338, DOI 10.1038/323338a0; TALMADGE JE, 1988, CANCER RES, V48, P544; TAVERNIER J, 1989, FEBS LETT, V257, P315, DOI 10.1016/0014-5793(89)81560-1; TRACEY KJ, 1989, LANCET, V1, P1122; TRAUNECKER A, 1989, NATURE, V339, P68, DOI 10.1038/339068a0; VILCEK J, 1986, J EXP MED, V163, P632, DOI 10.1084/jem.163.3.632; Ware C. F., 1987, LYMPHOKINES, V14, P307	54	175	207	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					18324	18329						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1655744				2022-12-25	WOS:A1991GG55300092
J	SURETTE, MG; CHACONAS, G				SURETTE, MG; CHACONAS, G			STIMULATION OF THE MU-DNA STRAND CLEAVAGE AND INTRAMOLECULAR STRAND TRANSFER-REACTIONS BY THE MU-B-PROTEIN IS INDEPENDENT OF STABLE BINDING OF THE MU-B-PROTEIN TO DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRATION HOST FACTOR; BACTERIOPHAGE-MU; INVITRO TRANSPOSITION; MICROSCOPIC ANALYSIS; TARGET IMMUNITY; SITE; ENDS; TRANSPOSOSOMES; REPLICATION; MECHANISM	Interactions between the Mu A and Mu B proteins are important in the early steps of the in vitro transposition of a mini-Mu plasmid. We have examined these interactions by assaying Mu B stimulation of Mu A-mediated strand cleavage and strand transfer reactions. We have previously shown that in the presence of ATP the Mu B protein can stimulate the Mu A-directed cleavage reaction of mini-Mu plasmids carrying a terminal base pair mutation (Surette, M. G., Harkness, T., and Chaconas, G. (1991) J. Biol. Chem. 266, 3118-3124). Here we demonstrate that in the absence of a non-Mu DNA target molecule the Mu B protein stimulates intramolecular integration of a mini-Mu in an ATP-dependent fashion. Furthermore, modification of the Mu B protein with N-ethylmaleimide severely compromises the ability of B to form a stable complex with DNA; however, the modified protein stimulates the strand cleavage and intramolecular strand transfer reactions as efficiently as the untreated protein. These results indicate that the Mu B protein is capable of stimulating the Mu A protein through direct interaction in the absence of stable Mu B-DNA complex formation. Our results increase the spectrum of Mu B protein activities and uncouple the stimulatory properties of the Mu B protein from stable DNA binding but not the ATP cofactor requirement.			SURETTE, MG (corresponding author), UNIV WESTERN ONTARIO,DEPT BIOCHEM,LONDON N6A 5C1,ONTARIO,CANADA.							ADZUMA K, 1989, CELL, V57, P41, DOI 10.1016/0092-8674(89)90170-0; ADZUMA K, 1988, CELL, V53, P257, DOI 10.1016/0092-8674(88)90387-X; ADZUMA K, 1991, J BIOL CHEM, V266, P6159; ARTHUR A, 1979, MOL GEN GENET, V175, P267, DOI 10.1007/BF00397226; BAKER TA, 1991, CELL, V65, P1003, DOI 10.1016/0092-8674(91)90552-A; BETERMIER M, 1989, MOL MICROBIOL, V3, P1159, DOI 10.1111/j.1365-2958.1989.tb00266.x; BETERMIER M, 1987, MOL GEN GENET, V210, P77, DOI 10.1007/BF00337761; CHACONAS G, 1988, BIOESSAYS, V9, P205, DOI 10.1002/bies.950090606; CHACONAS G, 1985, J BIOL CHEM, V260, P2662; CHACONAS G, 1987, PHAGE MU, P137; CRAGIE R, 1985, CELL, V41, P867; CRAIGIE R, 1984, CELL, V39, P387, DOI 10.1016/0092-8674(84)90017-5; CRAIGIE R, 1987, CELL, V51, P493, DOI 10.1016/0092-8674(87)90645-3; FAELEN M, 1978, NATURE, V271, P580, DOI 10.1038/271580a0; HARSHEY RM, 1986, J GENET, V65, P159, DOI 10.1007/BF02931149; LAVOIE BD, 1990, J BIOL CHEM, V265, P1623; LEUNG PC, 1989, NATURE, V338, P656, DOI 10.1038/338656a0; MAXWELL A, 1987, P NATL ACAD SCI USA, V84, P699, DOI 10.1073/pnas.84.3.699; MILLER JL, 1986, GENE, V48, P101, DOI 10.1016/0378-1119(86)90356-2; MILLER JL, 1984, NUCLEIC ACIDS RES, V12, P8627, DOI 10.1093/nar/12.22.8627; MIZUUCHI K, 1986, ANNU REV GENET, V20, P385; MIZUUCHI K, 1983, CELL, V35, P785, DOI 10.1016/0092-8674(83)90111-3; MIZUUCHI M, 1989, CELL, V58, P399, DOI 10.1016/0092-8674(89)90854-4; NASH HA, 1987, J BACTERIOL, V169, P4124, DOI 10.1128/jb.169.9.4124-4127.1987; Pato ML, 1989, MOBILE DNA, P23; Riordan J.F., 1967, METHOD ENZYMOL, V11, P541; SHAPIRO JA, 1979, P NATL ACAD SCI USA, V76, P1933, DOI 10.1073/pnas.76.4.1933; SURETTE MG, 1989, J BIOL CHEM, V264, P3028; SURETTE MG, 1989, EMBO J, V8, P3483, DOI 10.1002/j.1460-2075.1989.tb08513.x; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; SURETTE MG, 1991, J BIOL CHEM, V266, P3118; SURETTE MG, 1990, THESIS U W ONTARIO L; SYMONDS N, 1987, PHAGE MU, P1; TOUSSAINT A, 1987, J BACTERIOL, V169, P5700, DOI 10.1128/jb.169.12.5700-5707.1987; TOUSSAINT A, 1983, MOBILE GENETIC ELEME, P105; WIJFFELMAN C, 1977, MOL GEN GENET, V151, P169, DOI 10.1007/BF00338691	36	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17306	17313						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1654329				2022-12-25	WOS:A1991GF44500052
J	ITOH, H; GILMAN, AG				ITOH, H; GILMAN, AG			EXPRESSION AND ANALYSIS OF GS-ALPHA MUTANTS WITH DECREASED ABILITY TO ACTIVATE ADENYLYLCYCLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING REGULATORY PROTEINS; ADENYLATE-CYCLASE; SIGNAL TRANSDUCTION; ESCHERICHIA-COLI; GTPASE ACTIVITY; CYCLIC-AMP; 2 FORMS; SUBUNIT; SITE; IDENTIFICATION	We have constructed mutants of the alpha-subunit of G(s). in an attempt to identify sites in the protein that are important for its interaction with adenylylcyclase. Some residues specific for those G proteins that activate adenylylcyclase were replaced with residues characteristic of G(i-alpha). Mutant proteins were expressed in Escherichia coli, and two of these were purified to homogeneity and characterized in detail. Mutation of trp263, leu268, or arg269 caused a significant loss of the capacity of G(s-alpha) to stimulate adenylylcyclase, and the triple mutant had less than 1% of the ability of wild type G(s-alpha) to activate the enzyme. Guanine nucleotide binding and GTP hydrolysis by the mutant proteins were unaltered, as was guanosine 5'-3-O-(thio)triphosphate-induced enhancement of intrinsic tryptophan fluorescence. Mutant proteins also appeared to have a reduced affinity for the G protein beta-gamma subunit complex. Secondary structure analysis and comparison with the structure of p21ras suggests that the region of G(s-alpha) that we have identified is part of a loop that may be involved in interaction of the protein with adenylylcyclase. Although these residues are essential for activation of adenylylcyclase, they are not sufficient to do this when placed in the context of another G protein a subunit.			ITOH, H (corresponding author), UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA.				NIGMS NIH HHS [GM34497] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034497, R01GM034497] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAY P, 1986, P NATL ACAD SCI USA, V83, P8893, DOI 10.1073/pnas.83.23.8893; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; CHEE WW, 1989, J BIOL CHEM, V264, P5687; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; DERETIC D, 1987, J BIOL CHEM, V262, P10839; FREISSMUTH M, 1989, J BIOL CHEM, V264, P21907; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P752; HINGORANI VN, 1987, FEBS LETT, V220, P15, DOI 10.1016/0014-5793(87)80867-0; HOLBROOK SR, 1989, P NATL ACAD SCI USA, V86, P7415; HOLBROOK SR, 1989, P NATL ACAD SCI USA, V86, P1751, DOI 10.1073/pnas.86.6.1751; JONES DT, 1989, SCIENCE, V244, P790, DOI 10.1126/science.2499043; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAGUIRE ME, 1980, J BIOL CHEM, V255, P1030; MASTERS SB, 1986, PROTEIN ENG, V1, P47, DOI 10.1093/protein/1.1.47; MASTERS SB, 1988, SCIENCE, V241, P448, DOI 10.1126/science.2899356; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MAY DC, 1985, J BIOL CHEM, V260, P5829; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; NAVON SE, 1987, J BIOL CHEM, V262, P15746; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; OSAWA S, 1990, CELL, V63, P697, DOI 10.1016/0092-8674(90)90136-3; PARKER EM, 1991, J BIOL CHEM, V266, P519; QUAN F, 1989, P NATL ACAD SCI USA, V86, P4321, DOI 10.1073/pnas.86.11.4321; RALL T, 1987, FEBS LETT, V224, P365, DOI 10.1016/0014-5793(87)80486-6; ROBISHAW JD, 1986, P NATL ACAD SCI USA, V83, P1251, DOI 10.1073/pnas.83.5.1251; ROBISHAW JD, 1986, J BIOL CHEM, V261, P9587; SCHUBERT B, 1989, SCIENCE, V245, P516, DOI 10.1126/science.2547248; STERNWEIS PC, 1981, ADV CYCLIC NUCL PROT, V14, P23; SULLIVAN KA, 1987, NATURE, V330, P758, DOI 10.1038/330758a0; WOON CW, 1989, BIOCHEMISTRY-US, V28, P4547, DOI 10.1021/bi00437a006; YATANI A, 1987, SCIENCE, V238, P1288, DOI 10.1126/science.2446390	39	72	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					16226	16231						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1651937				2022-12-25	WOS:A1991GB97700104
J	MEI, L; HUGANIR, RL				MEI, L; HUGANIR, RL			PURIFICATION AND CHARACTERIZATION OF A PROTEIN TYROSINE PHOSPHATASE WHICH DEPHOSPHORYLATES THE NICOTINIC ACETYLCHOLINE-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WEIGHT ACID-PHOSPHATASE; SRC GENE-PRODUCT; HUMAN-PLACENTA; TORPEDO-CALIFORNICA; BOVINE HEART; PHOSPHORYLATION; FAMILY; PHOSPHOTYROSINE; IDENTIFICATION; DESENSITIZATION	The nicotinic acetylcholine receptor (nAChR) is phosphorylated to a high stoichiometry on tyrosine residues both in vitro and in vivo. Moreover, tyrosine phosphorylation has been shown to regulate the functional properties of the receptor. We report here the purification and characterization of a protein tyrosine phosphatase that dephosphorylates tyrosine-phosphorylated nAChR from Torpedo electroplax, a tissue highly enriched in the nAChR. The P-32-labeled tyrosine phosphorylated nAChR was used as a substrate to monitor the enzyme activity during purification. The protein tyrosine phosphatase activity was purified using three consecutive cation-exchange columns (phosphocellulose, S Sepharose Fast Flow, Bio-Rex 70), followed by two affinity matrices (p-aminobenzylphosphonic acid-agarose and thiophosphotyrosyl nAChR-Sepharose 4B). The enzyme activity was purified to homogeneity, with an overall purification of 25,000-fold and a yield of 20%. The purified enzyme had an apparent molecular mass of 43 kDa on sodium dodecyl sulfate-polyacrylamide gels and migrated as a monomer during Superose 12 chromatography. It had a neutral pH optimum and a specific activity of 18-mu-mol/mg of protein/min, with a K(m) of 4.7-mu-M for tyrosine-phosphorylated nAChR. The phosphatase was specific for tyrosine phosphorylated nAChR; it showed no activity towards the nAChR phosphorylated on serine residues by cAMP-dependent protein kinase. The enzyme also dephosphorylated P-32-labeled poly(Glu-Tyr) (4:1). However, it did not dephosphorylate p-nitrophenylphosphate. The tyrosine phosphatase was inhibited by ammonium molybdate (IC50 of 2-mu-M), sodium vanadate (IC50 of 150-mu-M) and the divalent cations Mg2+, Mn2+, and Ca2+ at millimolar concentrations, but not by 100-mu-M ZnCl or 10 mM NaF. Poly (Glu, Tyr) (4:1) and heparin inhibited the enzyme activity at micromolar concentrations. These unique properties of the purified enzyme suggest that it may be a novel protein tyrosine phosphatase that specifically dephosphorylates the nAChR.	JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,PCTB 905,725 N WOLFE ST,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University			Mei, Lin/G-8755-2012		NINDS NIH HHS [NS24418] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024418] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; CHERNOFF J, 1985, ARCH BIOCHEM BIOPHYS, V240, P135, DOI 10.1016/0003-9861(85)90016-5; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; COTTON PC, 1983, MOL CELL BIOL, V3, P1157, DOI 10.1128/MCB.3.6.1157; DISSING J, 1979, BIOCHIM BIOPHYS ACTA, V569, P159, DOI 10.1016/0005-2744(79)90051-2; FOULKES JG, 1981, FEBS LETT, V130, P197, DOI 10.1016/0014-5793(81)81118-0; GUAN KL, 1990, P NATL ACAD SCI USA, V87, P1501, DOI 10.1073/pnas.87.4.1501; HIRANO AA, 1988, J NEUROCHEM, V50, P1147; HOPFIELD JF, 1988, NATURE, V336, P677, DOI 10.1038/336677a0; HUGANIR RL, 1986, NATURE, V321, P774, DOI 10.1038/321774a0; HUGANIR RL, 1982, J BIOL CHEM, V257, P9372; HUGANIR RL, 1983, P NATL ACAD SCI-BIOL, V80, P1130, DOI 10.1073/pnas.80.4.1130; HUGANIR RL, 1990, NEURON, V5, P555, DOI 10.1016/0896-6273(90)90211-W; HUGANIR RL, 1984, P NATL ACAD SCI USA, V81, P6963; HUGANIR RL, 1983, SOC NEUR ABSTR, V9, P578; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; JONES SW, 1989, J BIOL CHEM, V264, P7747; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LAU KHW, 1989, BIOCHEM J, V257, P23, DOI 10.1042/bj2570023; LI HC, 1982, CURR TOP CELL REGUL, V21, P129; LI HC, 1988, METHOD ENZYMOL, V159, P346; MANESS PF, 1988, P NATL ACAD SCI USA, V85, P5001, DOI 10.1073/pnas.85.14.5001; MATTHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P4444, DOI 10.1073/pnas.87.12.4444; MILES K, 1988, MOL NEUROBIOL, V2, P91, DOI 10.1007/BF02935341; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; PANG DT, 1988, P NATL ACAD SCI USA, V85, P762, DOI 10.1073/pnas.85.3.762; QU Z, 1990, NEURON, V2, P267; SAFRAN A, 1987, J BIOL CHEM, V262, P10506; SHRINER CL, 1984, J BIOL CHEM, V259, P1383; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; STROUD RM, 1990, BIOCHEMISTRY-US, V29, P11009, DOI 10.1021/bi00502a001; SUDOL M, 1986, MOL CELL BIOL, V6, P2839, DOI 10.1128/MCB.6.8.2839; TONKS N K, 1988, Biochemistry, V27, P8695, DOI 10.1021/bi00424a001; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1988, J BIOL CHEM, V263, P6722; TONKS NK, 1989, TRENDS BIOCHEM SCI, V14, P497, DOI 10.1016/0968-0004(89)90184-9; TUNG HYL, 1987, ANAL BIOCHEM, V161, P412; WALLACE BG, 1991, NEURON, V6, P869, DOI 10.1016/0896-6273(91)90227-Q; ZAVOICO GB, 1984, BIOCHIM BIOPHYS ACTA, V770, P225, DOI 10.1016/0005-2736(84)90134-2; ZHANG ZY, 1990, ARCH BIOCHEM BIOPHYS, V282, P39, DOI 10.1016/0003-9861(90)90084-C	43	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					16063	16072						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1651933				2022-12-25	WOS:A1991GB97700081
J	NORCUM, MT				NORCUM, MT			STRUCTURAL-ANALYSIS OF THE HIGH MOLECULAR MASS AMINOACYL-TRANSFER RNA-SYNTHETASE COMPLEX - EFFECTS OF NEUTRAL SALTS AND DETERGENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARGINYL-TRANSFER RNA; RAT-LIVER; MACROMOLECULAR COMPLEXES; MULTIENZYME COMPLEX; SHEEP LIVER; WEIGHT; RABBIT; ORGANIZATION; PURIFICATION; PROTEINS	The effects of a variety of detergents and neutral salts on the structure of the eukaryotic high molecular mass aminoacyl-tRNA synthetase complex have been directly determined by observing alterations in the composition, sedimentation behavior, and electron microscopic appearance of the rabbit reticulocyte complex. The intact complex is shown to exhibit the enzymatic activities, polypeptide composition, relative stoichiometry, and morphological features that are characteristic of this eukaryotic multienzyme particle. The structure of the high molecular mass aminoacyl-tRNA synthetase complex is seen to be resistant to both ionic and nonionic detergents. However, both 3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonate and deoxycholate induce formation of large protein aggregates. In contrast, the chaotropic salts LiCl and NaSCN both selectively remove individual polypeptides from the high molecular mass aminoacyl-tRNA synthetase complex and promote formation of specific particulate subcomplexes which have distinct sizes, polypeptide compositions, and structural features. These data support the view that many of the protein interactions within the high molecular mass aminoacyl-tRNA synthetase complex are hydrophobic in nature. This study also provides direct evidence that the complex contains a core of tightly interacting synthetases onto which the remaining polypeptides are arrayed. The structural alterations observed here may account for the ability of these reagents to markedly inhibit several enzymatic activities within the complex.			NORCUM, MT (corresponding author), UNIV MISSISSIPPI,MED CTR,DEPT BIOCHEM,JACKSON,MS 39216, USA.				NIGMS NIH HHS [GM40521] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM040521] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERBEC H, 1989, MOL CELL BIOCHEM, V86, P125, DOI 10.1007/BF00222612; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CIRAKOGLU B, 1985, BIOCHIM BIOPHYS ACTA, V829, P173, DOI 10.1016/0167-4838(85)90186-4; CIRAKOGLU B, 1985, EUR J BIOCHEM, V151, P101, DOI 10.1111/j.1432-1033.1985.tb09074.x; CIRAKOGLU B, 1985, FEBS LETT, V183, P185; DANG CV, 1982, FEBS LETT, V142, P1, DOI 10.1016/0014-5793(82)80206-8; DANG CV, 1986, BIOCHEM J, V239, P249, DOI 10.1042/bj2390249; DANG CV, 1979, J BIOL CHEM, V254, P5350; DEUTSCHER MP, 1984, J CELL BIOL, V99, P373, DOI 10.1083/jcb.99.2.373; DEUTSCHER MP, 1981, RNA PROTEIN SYNTHESI, P249; DURRUM EL, 1952, SCIENCE, V116, P428, DOI 10.1126/science.116.3016.428; GODAR DE, 1988, BIOCHEMISTRY-US, V27, P6921, DOI 10.1021/bi00418a038; HAMPEL A, 1984, FED PROC, V43, P2991; JACOBOMOLINA A, 1989, J BIOL CHEM, V264, P16608; JOHNSON DL, 1981, P NATL ACAD SCI-BIOL, V78, P4059, DOI 10.1073/pnas.78.7.4059; JOHNSON DL, 1980, J BIOL CHEM, V255, P4362; KELLERMANN O, 1982, J BIOL CHEM, V257, P1041; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZARD M, 1985, BIOCHEMISTRY-US, V24, P5099, DOI 10.1021/bi00340a021; MIRANDE M, 1989, J BIOL CHEM, V264, P842; MIRANDE M, 1982, J BIOL CHEM, V257, P1049; NORCUM MT, 1989, J BIOL CHEM, V264, P15043; SCHIMMEL P, 1987, ANNU REV BIOCHEM, V56, P125, DOI 10.1146/annurev.bi.56.070187.001013; SIHAG RK, 1983, J BIOL CHEM, V258, P1846; SIVARAM P, 1988, J BIOL CHEM, V263, P18891; SIVARAM P, 1990, J BIOL CHEM, V265, P5774; VELLEKAMP G, 1987, J BIOL CHEM, V262, P9927; YANG DCH, 1985, CURR TOP CELL REGUL, V26, P325	28	31	31	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15398	15405						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1651330				2022-12-25	WOS:A1991GB09700085
J	PALCZEWSKI, K; BUCZYLKO, J; IMAMI, NR; MCDOWELL, JH; HARGRAVE, PA				PALCZEWSKI, K; BUCZYLKO, J; IMAMI, NR; MCDOWELL, JH; HARGRAVE, PA			ROLE OF THE CARBOXYL-TERMINAL REGION OF ARRESTIN IN BINDING TO PHOSPHORYLATED RHODOPSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; 48-KDA PROTEIN; S-ANTIGEN; PHOSPHODIESTERASE; ACTIVATION; SEQUENCE	The structural and functional properties of arrestin were studied by subjecting the protein to limited proteolysis. Limited proteolysis by trypsin cleaves arrestin (48 kDa), producing 20-25-kDa fragments. Prior to this stage of proteolysis, trypsin produced 46.6-, 45.4-, and 42-kDa fragments. Structural analysis of the proteolytic fragments demonstrated major cleavage at the carboxyl terminus, indicating that the carboxyl terminus is highly exposed. We found that forms of arrestin truncated at their carboxyl terminus maintained their functional properties and bound to phosphorylated rhodopsin. Native arrestin binds only to photoexcited phosphorylated rhodopsin, whereas the truncated arrestin binds to phosphorylated rhodopsin independent of its exposure to light. The truncated forms of arrestin were separated from native arrestin by a chromatographic procedure and subsequently characterized in functional studies. The binding of the truncated forms of arrestin to phosphorylated photoexcited rhodopsin is more tight than the binding of native arrestin as determined by a direct binding assay and the phosphodiesterase assay. We suggest that the acidic carboxyl-terminal region of arrestin may act as a regulator for light-dependent binding to phosphorylated rhodopsin.	UNIV FLORIDA,DEPT OPHTHALMOL,GAINESVILLE,FL 32610; UNIV FLORIDA,DEPT BIOCHEM & MOLEC BIOL,GAINESVILLE,FL 32610	State University System of Florida; University of Florida; State University System of Florida; University of Florida	PALCZEWSKI, K (corresponding author), GOOD SAMARITAN HOSP,RS DOW NEUROL SCI INST,1120 NW 20TH AVE,PORTLAND,OR 97209, USA.				NATIONAL EYE INSTITUTE [R37EY006226, U10EY008067, R01EY006226] Funding Source: NIH RePORTER; NEI NIH HHS [EY 08067, EY 06226, EY 06225] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCZYLKO J, 1991, P NATL ACAD SCI USA, V88, P2568, DOI 10.1073/pnas.88.6.2568; DAYHOFF MO, 1969, ATLAS PROTEIN SEQUEN, V4, P75; Kuhn H., 1980, Neurochemistry International, V1, P269, DOI 10.1016/0197-0186(80)90066-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEBMAN PA, 1982, METHOD ENZYMOL, V81, P532; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P4201; PALCZEWSKI K, 1990, Investigative Ophthalmology and Visual Science, V31, P217; PALCZEWSKI K, 1991, IN PRESS J BIOL CHEM, V266; POGOZHEVA ID, 1989, BIOL MEMBRANY, V6, P1248; SCHLEICHER A, 1989, BIOCHEMISTRY-US, V28, P1770, DOI 10.1021/bi00430a052; SHICHI H, 1990, CURR EYE RES, V9, P103, DOI 10.3109/02713689008999428; SHINOHARA T, 1987, P NATL ACAD SCI USA, V84, P6975, DOI 10.1073/pnas.84.20.6975; SHINOHARA T, 1988, PROGR RETINAL RES, V8, P51; SMITH DP, 1990, P NATL ACAD SCI USA, V87, P1003, DOI 10.1073/pnas.87.3.1003; TSUNASAWA S, 1989, BIOCHIM BIOPHYS ACTA, V994, P191, DOI 10.1016/0167-4838(89)90160-X; Walsh K. A., 1970, METHODS ENZYMOL, V19, P41; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; YAMAKI K, 1988, FEBS LETT, V234, P39, DOI 10.1016/0014-5793(88)81298-5; 1968, EUR J BIOCHEM, V5, P151	23	84	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15334	15339						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1651326				2022-12-25	WOS:A1991GB09700076
J	YAMAGATA, Y; CZERNIK, AJ; GREENGARD, P				YAMAGATA, Y; CZERNIK, AJ; GREENGARD, P			ACTIVE CATALYTIC FRAGMENT OF CA2+ CALMODULIN-DEPENDENT PROTEIN KINASE-II - PURIFICATION, CHARACTERIZATION, AND STRUCTURAL-ANALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT CHAIN KINASE; SQUID GIANT SYNAPSE; MOLECULAR-CLONING; REGULATORY DOMAIN; BINDING DOMAIN; RAT-BRAIN; CA-2+-INDEPENDENT ACTIVITY; NEUROTRANSMITTER RELEASE; PHOSPHORYLATION SITES; AUTO-REGULATION	We report the purification and characterization of an active catalytic fragment of Ca2+/Calmodulin-dependent protein kinase II, derived from autophosphorylation and subsequent limited chymotryptic digestion of the purified rat forebrain soluble kinase. The purified fragment was completely Ca2+/calmodulin-independent, existed as a monomer, and phosphorylated synapsin I at the same sites as does the native form of Ca 2+/calmodulin-dependent protein kinase II. Kinetic studies with the purified fragment revealed a more than 10-fold increase in V(max) and a 50% decrease in K(m) for synthetic peptide substrates, compared with native Ca2+/calmodulin-dependent protein kinase II. No P-32-labeled autophosphorylated residues were detected in the purified active fragment, indicating that the autophosphorylation sites were not contained within this fragment. Comparative studies of this active fragment (30 kDa) and its inactive counterpart (32-kDa fragment) revealed certain structural details of both fragments. Calmodulin-overlay study, immunoblot analysis, and direct amino acid sequencing suggest that both fragments contain the entire NH2-terminal catalytic domain and were generated by distinct cleavage within the regulatory domain. The putative cleavage sites for both fragments are discussed.			YAMAGATA, Y (corresponding author), ROCKEFELLER UNIV, MOLEC & CELLULAR NEUROSCI LAB, 1230 YORK AVE, NEW YORK, NY 10021 USA.		Yamagata, Yoshiki/T-6489-2019		NIMH NIH HHS [MH-39327] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH039327, R01MH039327] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BAHLER M, 1987, NATURE, V326, P704, DOI 10.1038/326704a0; BENNETT MK, 1983, J BIOL CHEM, V258, P2735; BENNETT MK, 1987, P NATL ACAD SCI USA, V84, P1794, DOI 10.1073/pnas.84.7.1794; BULLEIT RF, 1988, NEURON, V1, P63, DOI 10.1016/0896-6273(88)90210-3; BURGESS WH, 1984, J CELL BIOL, V99, P550, DOI 10.1083/jcb.99.2.550; COLBRAN RJ, 1989, BIOCHEM J, V258, P313, DOI 10.1042/bj2580313; COLBRAN RJ, 1988, J BIOL CHEM, V263, P18145; COLBRAN RJ, 1989, J BIOL CHEM, V264, P4800; CZERNIK AJ, 1987, P NATL ACAD SCI USA, V84, P7518, DOI 10.1073/pnas.84.21.7518; ERONDU NE, 1985, J NEUROSCI, V5, P3270; FONG YL, 1989, J BIOL CHEM, V264, P16759; FONG YL, 1990, J BIOL CHEM, V265, P11091; GOLDENRING JR, 1983, J BIOL CHEM, V258, P2632; HANLEY RM, 1988, BIOCHEM BIOPH RES CO, V152, P122, DOI 10.1016/S0006-291X(88)80688-0; HANLEY RM, 1987, SCIENCE, V237, P293, DOI 10.1126/science.3037704; HANSON PI, 1989, NEURON, V3, P59, DOI 10.1016/0896-6273(89)90115-3; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HUTTNER WB, 1979, P NATL ACAD SCI USA, V76, P5402, DOI 10.1073/pnas.76.10.5402; KELLY PT, 1988, P NATL ACAD SCI USA, V85, P4991, DOI 10.1073/pnas.85.14.4991; KEMP BE, 1987, J BIOL CHEM, V262, P2542; KENNEDY MB, 1981, P NATL ACAD SCI-BIOL, V78, P1293, DOI 10.1073/pnas.78.2.1293; KENNELLY PJ, 1987, J BIOL CHEM, V262, P11958; KWIATKOWSKI AP, 1990, BIOCHEMISTRY-US, V29, P153, DOI 10.1021/bi00453a019; KWIATKOWSKI AP, 1989, BIOCHEMISTRY-US, V28, P5380, DOI 10.1021/bi00439a010; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI Y, 1986, P NATL ACAD SCI USA, V83, P4253, DOI 10.1073/pnas.83.12.4253; LEVINE H, 1987, BIOCHEM BIOPH RES CO, V148, P1104, DOI 10.1016/S0006-291X(87)80246-2; LEVINE H, 1987, EUR J BIOCHEM, V168, P481, DOI 10.1111/j.1432-1033.1987.tb13442.x; LIN CR, 1987, P NATL ACAD SCI USA, V84, P5962, DOI 10.1073/pnas.84.16.5962; LIN JW, 1990, P NATL ACAD SCI USA, V87, P8257, DOI 10.1073/pnas.87.21.8257; LLINAS R, 1985, P NATL ACAD SCI USA, V82, P3035, DOI 10.1073/pnas.82.9.3035; LOU LL, 1986, P NATL ACAD SCI USA, V83, P9497, DOI 10.1073/pnas.83.24.9497; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCGUINNESS TL, 1985, J BIOL CHEM, V260, P1696; MILLER SG, 1988, NEURON, V1, P593, DOI 10.1016/0896-6273(88)90109-2; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; MILLER SG, 1985, J BIOL CHEM, V260, P9039; NAIRN AC, 1985, ANNU REV BIOCHEM, V54, P931, DOI 10.1146/annurev.bi.54.070185.004435; NICHOLS RA, 1990, NATURE, V343, P647, DOI 10.1038/343647a0; PAYNE ME, 1988, J BIOL CHEM, V263, P7190; PEARSON RB, 1988, SCIENCE, V241, P970, DOI 10.1126/science.3406746; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; SCHULMAN H, 1988, ADV SEC MESS PHOSPH, V22, P39; SCHWORER CM, 1988, J BIOL CHEM, V263, P13486; SCHWORER CM, 1986, J BIOL CHEM, V261, P8581; SIMPSON RJ, 1984, BIOCHEM INT, V8, P787; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; SUDHOF TC, 1989, SCIENCE, V245, P1474, DOI 10.1126/science.2506642; THIEL G, 1988, P NATL ACAD SCI USA, V85, P6337, DOI 10.1073/pnas.85.17.6337; TOBIMATSU T, 1989, J BIOL CHEM, V264, P17907; TOBIMATSU T, 1988, J BIOL CHEM, V263, P16082; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALDMANN R, 1990, BIOCHEMISTRY-US, V29, P1679, DOI 10.1021/bi00459a002; WAXHAM MN, 1990, P NATL ACAD SCI USA, V87, P1273, DOI 10.1073/pnas.87.4.1273; [No title captured]	58	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15391	15397						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1651329				2022-12-25	WOS:A1991GB09700084
J	CARROLL, MA; SALA, A; DUNN, CE; MCGIFF, JC; MURPHY, RC				CARROLL, MA; SALA, A; DUNN, CE; MCGIFF, JC; MURPHY, RC			STRUCTURAL IDENTIFICATION OF CYTOCHROME-P450-DEPENDENT ARACHIDONATE METABOLITES FORMED BY RABBIT MEDULLARY THICK ASCENDING LIMB CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID METABOLISM; CORTEX	The medullary thick ascending limb of Henle's loop (mTALH) contributes importantly to the regulation of extracellular fluid volume and composition and metabolizes arachidonic acid (AA) chiefly by a cytochrome P450 monooxygenase pathway. Rabbit mTALH cells, when incubated with radiolabeled [C-14]AA, form products that segregate into two peaks designated P1 and P2 based on their reverse-phase high pressure liquid chromatography retention times. We have now definitively identified their chemical structures. mTALH cells, isolated from the rabbit outer medulla, were homogenized and incubated with [C-14]AA in the presence of NADPH. The AA metabolites in P1 and P2 were identified by gas chromatographic-mass spectrometric methods, including fast atom bombardment, negative ion electron capture, and electron ionization. All mass spectrometric data, the lack of UV chromophores, and comparisons with authentic standards were consistent with P1 containing two principal components: 19-hydroxy-5,8,11,14 eicosatetraenoic acid (19-HETE) and 20 - hydroxy - 5,8,11,14 - eicosatetraenoic acid (20-HETE), P2 contained primarily 1,20-eicosa-5,8,11,14-tetraenedioic acid (20-COOH-AA). The biological properties of P1 and P2 were compared with those of the authentic standards of 19- and 20-HETE and 20-COOH-AA. P1 dose dependently relaxed precontracted mesenteric arterial rings, as did authentic (19S)- and (19R)-HETE, whereas 20-HETE relaxed at lower and contracted at higher concentrations. As P1 contained a mixture of 19- and 20-HETE, each of these AA metabolites presumably contributed to the vascular relaxation produced by P1. Neither P2 nor 20-COOH-AA exhibited vasoactivity, but each demonstrated a similar potency in inhibiting rabbit medullary Na+-K+-ATPase activity. As previously reported, P2 was a more potent inhibitor of Na+-K+-ATPase than P1. The lesser inhibitory activity of P1 presumably reflects the presence of similar amounts of 19-HETE, the least active metabolite, and 20-HETE, which resembles 20-COOH-AA in its capacity to inhibit Na+-K+-ATPase. Thus, the biological activity of the less polar peak, P1, can be accounted for by 19- and 20-HETE, and that of P2, by 20-COOH-AA.	NATL JEWISH CTR IMMUNOL & RESP MED,DEPT PEDIAT,DENVER,CO 80206	National Jewish Health	CARROLL, MA (corresponding author), NEW YORK MED COLL,DEPT PHARMACOL,VALHALLA,NY 10595, USA.		Sala, Angelo/H-5478-2019; Murphy, Robert/AAO-5349-2020	Murphy, Robert/0000-0002-9430-6515; Sala, Angelo/0000-0001-9290-0257	NCRR NIH HHS [RR01152] Funding Source: Medline; NHLBI NIH HHS [HL34300] Funding Source: Medline; NIGMS NIH HHS [GM41026] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001152] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034300] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041026] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALAZY M, 1986, ANAL CHEM, V58, P1098, DOI 10.1021/ac00297a026; BAUMERT T, 1989, EUR J BIOCHEM, V182, P223, DOI 10.1111/j.1432-1033.1989.tb14821.x; Bjorkhem I, 1970, Eur J Biochem, V17, P450, DOI 10.1111/j.1432-1033.1970.tb01186.x; CARROLL MA, 1988, AM J PHYSIOL, V255, pF151, DOI 10.1152/ajprenal.1988.255.1.F151; CARROLL MA, 1990, AM J PHYSIOL, V258, pF1084; DOUGLAS JG, 1990, KIDNEY INT, V38, pS43; ESCALANTE B, 1988, BIOCHEM BIOPH RES CO, V152, P1269, DOI 10.1016/S0006-291X(88)80422-4; ESCALANTE B, 1989, J PHARMACOL EXP THER, V248, P229; ESCALANTE B, 1991, SCIENCE, V251, P799, DOI 10.1126/science.1846705; ESCALANTE B, 1990, PROSTAGLANDIN THROMB, V21, P209; FERRERI NR, 1984, J PHARMACOL EXP THER, V231, P441; HIRT DL, 1989, J CLIN INVEST, V84, P1805, DOI 10.1172/JCI114365; Jorgensen P L, 1974, Methods Enzymol, V32, P277; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; NAVARRO J, 1978, ARCH BIOCHEM BIOPHYS, V191, P125, DOI 10.1016/0003-9861(78)90074-7; OLIW EH, 1981, J BIOL CHEM, V256, P9924; RYHAGE R, 1959, ARK KEMI, V14, P497; SACERDOTI D, 1988, BIOCHEM PHARMACOL, V37, P521, DOI 10.1016/0006-2952(88)90223-7; SCHWARTZMAN M, 1985, NATURE, V314, P620, DOI 10.1038/314620a0; SOBERMAN RJ, 1988, J BIOL CHEM, V263, P7996; TAKAHASHI K, 1990, AM J PHYSIOL, V258, pF781, DOI 10.1152/ajprenal.1990.258.4.F781; VANROLLINS M, 1984, J LIPID RES, V25, P507; ZIRROLLI JA, 1991, J AM SOC MASS SPECTR, V1, P325	23	128	129	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1991	266	19					12306	12312						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FV180	1648091				2022-12-25	WOS:A1991FV18000034
J	RABON, E; SACHS, G; BASSILIAN, S; LEACH, C; KEELING, D				RABON, E; SACHS, G; BASSILIAN, S; LEACH, C; KEELING, D			A K+-COMPETITIVE FLUORESCENT INHIBITOR OF THE H,K-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							(K+ + H+)-ATPASE; CONFORMATIONALLY RESTRAINED ANALOGS; GASTRIC MEMBRANE-VESICLES; REVERSIBLE INHIBITORS; CATION-TRANSPORT; BINDING; (H+; 1-ARYL-4-METHYLPYRROLO<3,2-C>QUINOLINES; 4-(ARYLAMINO)QUINOLINES; (H+/K+)-ATPASE	The interactions of a novel fluorescent compound, 1-(2-methylphenyl)-4-methylamino-6-methyl-2, 3-dihydropyrrolo[3,2-c]quinoline (MDPQ) with the gastric H,K-ATPase were determined. MDPQ was shown to inhibit the H,K-ATPase and its associated K+-phosphatase competitively with K+, with K(i) values of 0.22 and 0.65-mu-M, respectively. It also inhibited H+ transport with an IC50 of 0.29-mu-M, but at a concentration of 3.5-mu-M, reduced the steady-state level of phosphoenzyme by only 28%. The fluorescence of the inhibitor increased upon binding to the enzyme. 70% of this increment was quenched by K+, independently of Mg2+. The binding of MgATP to a high affinity site (K0.5(ATP) < 1-mu-M) markedly increased the fluorescence due to the formation of an inhibitor-phosphoenzyme complex saturating with a K0.5(MDPQ) of 0.94-mu-M. The K+-dependent fluorescent quench (K0.5(K+) = 1.8 mM) required the ionophore, nigericin, indicating that K+ and MDPQ were competing at an extracytosolic site on the enzyme. Formation also of an enzyme-vanadyl-inhibitor complex was shown by the fact that Mg2+ plus vanadate enhanced MDPQ fluorescence in the absence of MgATP and decreased fluorescence in the presence of MgATP. The minimal stoichiometry of bound MDPQ determined by fluorescence titrations in the presence of MgATP was 1.4 mol/mol phosphoenzyme. The data suggest that this compound can serve as a probe of conformation at an extracytosolic site of the H,K-ATPase.	UNIV CALIF LOS ANGELES,SCH MED,DEPT PHYSIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,LOS ANGELES,CA 90024; SMITHKLINE BEECHAM,WELWYN GARDEN CIT AL6 9AR,HERTS,ENGLAND	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; GlaxoSmithKline	RABON, E (corresponding author), VET ADM WADSWORTH MED CTR,CTR ULCER RES & EDUC,LOS ANGELES,CA 90073, USA.			Leach, Colin/0000-0003-3608-1546	NIADDK NIH HHS [AM34286] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM034286] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BROWN TH, 1990, J MED CHEM, V33, P527, DOI 10.1021/jm00164a010; CHANG H, 1977, BIOCHIM BIOPHYS ACTA, V464, P313, DOI 10.1016/0005-2736(77)90006-2; FALLER LD, 1983, BIOCHEMISTRY-US, V22, P4676, DOI 10.1021/bi00289a011; GUNTHER RD, 1987, J BIOL CHEM, V262, P13966; HELMICHDEJONG ML, 1987, BIOCHIM BIOPHYS ACTA, V905, P358, DOI 10.1016/0005-2736(87)90464-0; KEELING DJ, 1989, J BIOL CHEM, V264, P5545; KEELING DJ, 1988, BIOCHEM PHARMACOL, V37, P2231, DOI 10.1016/0006-2952(88)90586-2; MENDLEIN J, 1990, J BIOL CHEM, V265, P5030; RABON E, 1978, BIOCHEMISTRY-US, V17, P3345, DOI 10.1021/bi00609a027; RABON EC, 1982, J BIOL CHEM, V257, P6296; RABON EC, 1990, J BIOL CHEM, V265, P19594; SACCOMANI G, 1975, J BIOL CHEM, V250, P4802; SACCOMANI G, 1980, HYDROGEN ION TRANSPO, P175; SACHS G, 1976, J BIOL CHEM, V251, P7690; SCHACKMANN R, 1977, J MEMBRANE BIOL, V32, P361, DOI 10.1007/BF01905228; SCHRIJEN JJ, 1980, BIOCHIM BIOPHYS ACTA, V597, P331, DOI 10.1016/0005-2736(80)90110-8; SCHRIJEN JJ, 1981, BIOCHIM BIOPHYS ACTA, V640, P473, DOI 10.1016/0005-2736(81)90472-7; SKRABANJA ATP, 1987, BIOCHIM BIOPHYS ACTA, V903, P434, DOI 10.1016/0005-2736(87)90050-2; SKRABANJA ATP, 1984, BIOCHIM BIOPHYS ACTA, V774, P91, DOI 10.1016/0005-2736(84)90278-5; SMOLKA A, 1990, FASEB J, V4, pA1994; WALLMARK B, 1980, J BIOL CHEM, V255, P5313; WALLMARK B, 1987, J BIOL CHEM, V262, P2077	22	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1991	266	19					12395	12401						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FV180	1648097				2022-12-25	WOS:A1991FV18000047
J	EISEMANN, A; AHN, JA; GRAZIANI, G; TRONICK, SR; RON, D				EISEMANN, A; AHN, JA; GRAZIANI, G; TRONICK, SR; RON, D			ALTERNATIVE SPLICING GENERATES AT LEAST 5 DIFFERENT ISOFORMS OF THE HUMAN BASIC-FGF RECEPTOR	ONCOGENE			English	Article							FIBROBLAST GROWTH-FACTOR; PROTEIN-TYROSINE KINASE; MESSENGER-RNA; ENZYMATIC AMPLIFICATION; MOUSE-BRAIN; GENE; DNA; EXPRESSION; CDNA; CELLS	Fibroblast growth factors (FGFs) are polypeptide mitogens that induce the proliferation of a wide variety of cell types. Of the seven family members, the best characterized are basic and acidic FGF. In addition to their mitogenic effects, they participate in angiogenesis, differentiation and maintenance of survival of neurons, cell migration and embryonal development. Of all family members, keratinocyte growth factor (KGF) is unique in that it is a specific mitogen for epithelial cells and does not interact with the FGF receptor of fibroblasts. To study the interactions between KGF and its receptor, we isolated KGF and FGF receptors from keratinocytes and fibroblasts, respectively. In the course of this study, we isolated five different variants of the FGF receptor from human fibroblasts and showed that all were derived from a single genetic locus. Four of these variants encode transmembrane receptors and can be divided into two subgroups that differ from one another with respect to the number (two or three) of immunoglobulin (Ig)-like domains. Within each subgroup, one receptor differed from the other by the presence of a two-codon insertion. Thus, all the variations among the four isoforms are localized to their ligand binding domains. The fifth isoform encodes a molecule truncated just 3' to the first Ig-like domain and thus could be secreted from the cell. The transcripts encoding the long and short isoforms were found to be expressed in many cell types, but their reltive levels of expression varied greatly depending on the cell type. These findings indicate that alternative splicing generates diverse FGF receptor isoforms in human cells.	NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892; TECHNION ISRAEL INST TECHNOL,DEPT BIOL,IL-32000 HAIFA,ISRAEL; GEORGETOWN UNIV HOSP,DIV MED ONCOL,WASHINGTON,DC 20007	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Technion Israel Institute of Technology; Georgetown University	RON, D (corresponding author), NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892, USA.		Graziani, Grazia/G-5747-2012	Graziani, Grazia/0000-0002-0221-768X				ANDERSON KJ, 1988, NATURE, V332, P360, DOI 10.1038/332360a0; BOTTARO DP, 1990, J BIOL CHEM, V265, P12767; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHANG JH, 1988, J BIOL CHEM, V263, P12824; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GOSPADAROWICZ D, 1990, J CLIN ORTHOPED RELA, V58, P231; GOSPODAROWICZ D, 1975, J BIOL CHEM, V250, P2515; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; LATHROP B, 1985, J CELL BIOL, V100, P1540, DOI 10.1083/jcb.100.5.1540; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LINKHART TA, 1981, DEV BIOL, V86, P19, DOI 10.1016/0012-1606(81)90311-0; Maniatis T., 1982, MOL CLONING; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MARICS I, 1989, ONCOGENE, V4, P335; MOORE R, 1986, EMBO J, V5, P919, DOI 10.1002/j.1460-2075.1986.tb04304.x; MORRISON RS, 1986, P NATL ACAD SCI USA, V83, P7537, DOI 10.1073/pnas.83.19.7537; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; OLWIN BB, 1989, J CELL BIOCHEM, V39, P443, DOI 10.1002/jcb.240390410; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P5449, DOI 10.1073/pnas.86.14.5449; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; RUTA M, 1989, P NATL ACAD SCI USA, V86, P8722, DOI 10.1073/pnas.86.22.8722; RUTA M, 1988, ONCOGENE, V3, P9; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTONI MJ, 1989, EMBO J, V8, P385, DOI 10.1002/j.1460-2075.1989.tb03389.x; SHAPIRO MB, 1986, NUCLEIC ACIDS RES, V14, P65, DOI 10.1093/nar/14.1.65; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; THOMAS KA, 1987, FASEB J, V1, P434, DOI 10.1096/fasebj.1.6.3315806; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TOGARI A, 1985, J NEUROSCI, V5, P307; WALICKE P, 1986, P NATL ACAD SCI USA, V83, P3012, DOI 10.1073/pnas.83.9.3012; ZHAN X, 1988, MOL CELL BIOL, V8, P4387	45	117	127	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1991	6	7					1195	1202						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1650441				2022-12-25	WOS:A1991GV26000015
J	TAGLICHT, D; PADAN, E; SCHULDINER, S				TAGLICHT, D; PADAN, E; SCHULDINER, S			OVERPRODUCTION AND PURIFICATION OF A FUNCTIONAL NA+/H+ ANTIPORTER CODED BY NHAA (ANT) FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-VESICLES; PROTON ANTIPORT; INTRACELLULAR PH; H+ ANTIPORT; SODIUM; PROTEINS; GENE; TRANSPORT; GRADIENT; BACTERIA	A Na+/H+ antiporter coded by the nhaA (ant) gene of Escherichia coli has been overproduced and purified. The amino-terminal sequence of the protein has been determined and shown to correlate with initiation at a GUG codon, 75 bases upstream from the previously suggested AUG initiation codon. The purified protein, when reconstituted into proteoliposomes, has Na+/H+ antiport activity. It can mediate sodium uptake when a transmembrane pH gradient is applied. Downhill sodium efflux is shown to be highly dependent on pH and is accelerated by a transmembrane pH gradient. An imposed membrane potential negative inside accelerates Na+ efflux at all pH values tested. These findings suggest that the antiporter is electrogenic both at acid and alkaline pH. The activation at alkaline pH values (2000-fold increase) is consistent with the proposed role of the antiporter in regulation of internal pH at the alkaline pH range.			TAGLICHT, D (corresponding author), HEBREW UNIV JERUSALEM,INST LIFE SCI,IL-91904 JERUSALEM,ISRAEL.		Schuldiner, Shimon/F-7628-2012	Schuldiner, Shimon/0000-0002-4874-6237				BASSILANA M, 1984, BIOCHEMISTRY-US, V23, P1015, DOI 10.1021/bi00300a033; BASSILANA M, 1984, BIOCHEMISTRY-US, V23, P5288, DOI 10.1021/bi00317a029; BECK JC, 1979, ARCH BIOCHEM BIOPHYS, V194, P208, DOI 10.1016/0003-9861(79)90611-8; BINGHAM RJ, 1989, J BACTERIOL, V172, P2184; BOOTH IR, 1985, MICROBIOL REV, V49, P359, DOI 10.1128/MMBR.49.4.359-378.1985; BORON WF, 1983, J MEMBRANE BIOL, V72, P1, DOI 10.1007/BF01870311; BREY RN, 1980, J BIOL CHEM, V255, P39; CABANTCHIK ZI, 1990, BLOOD CELL BIOCH, V1, P359; CASTLE AM, 1986, J BIOL CHEM, V261, P7797; EHRING R, 1980, NATURE, V283, P537, DOI 10.1038/283537a0; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; GOLD L, 1987, ESCHERICHIA COLI SAL, P1302; GOLDBERG EB, 1987, P NATL ACAD SCI USA, V84, P2615, DOI 10.1073/pnas.84.9.2615; HAUSSINGER D, 1988, PH HOMEOSTASIS MECHA; KARPEL R, 1988, J BIOL CHEM, V263, P10408; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LeBlanc G, 1988, NA PLUS H PLUS EXCHA, p[103, Na+/H+exchange]; MAIDEN MCJ, 1987, NATURE, V325, P641, DOI 10.1038/325641a0; MOCHIZUKIODA N, 1985, J BACTERIOL, V163, P395, DOI 10.1128/JB.163.1.395-397.1985; NEWMAN MJ, 1981, J BIOL CHEM, V256, P1804; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; PADAN E, 1987, J MEMBRANE BIOL, V95, P189, DOI 10.1007/BF01869481; PADAN E, 1989, J BIOL CHEM, V264, P20297; PADAN E, 1981, BIOCHIM BIOPHYS ACTA, V650, P151, DOI 10.1016/0304-4157(81)90004-6; PAN JW, 1990, J BIOL CHEM, V265, P9247; RIZZOLO LJ, 1976, BIOCHEMISTRY-US, V15, P3433, DOI 10.1021/bi00661a006; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHULDINER S, 1986, J BACTERIOL, V168, P936, DOI 10.1128/jb.168.2.936-939.1986; SCHULDINER S, 1978, BIOCHEMISTRY-US, V17, P706, DOI 10.1021/bi00597a023; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; VIITANEN PV, 1985, METHOD ENZYMOL, V125, P429; WEST IC, 1974, BIOCHEM J, V144, P87, DOI 10.1042/bj1440087	32	241	245	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					11289	11294						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	1645730				2022-12-25	WOS:A1991FQ77400090
J	HOWARD, P; DAY, KH; KIM, KE; RICHARDSON, J; THOMAS, J; ABRAHAM, I; FLEISCHMANN, RD; GOTTESMAN, MM; MAURER, RA				HOWARD, P; DAY, KH; KIM, KE; RICHARDSON, J; THOMAS, J; ABRAHAM, I; FLEISCHMANN, RD; GOTTESMAN, MM; MAURER, RA			DECREASED CATALYTIC SUBUNIT MESSENGER-RNA LEVELS AND ALTERED CATALYTIC SUBUNIT MESSENGER-RNA STRUCTURE IN A CAMP-RESISTANT CHINESE-HAMSTER OVARY CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; MOUSE LYMPHOMA-CELLS; CYCLIC-AMP; REGULATORY SUBUNIT; INHIBITOR PROTEIN; MAMMALIAN-CELLS; PROLACTIN GENE; C-ALPHA; HYBRIDIZATION; PURIFICATION	The mechanisms responsible for decreased levels of cAMP-dependent protein kinase activity in a mutant Chinese hamster ovary cell line have been examined. The cAMP-resistant Chinese hamster ovary 10260 cell line was found to possess only 20% of the cAMP-dependent protein kinase activity found in wild-type cells. The presence of decreased concentrations of the catalytic subunit in these cells was confirmed through binding studies using a radiolabeled, heat-stable inhibitor of the kinase. Cloned Chinese hamster ovary catalytic subunit cDNAs were isolated, characterized, and used as hybridization probes to examine the relative concentrations of catalytic subunit mRNAs in the wild-type and 10260 cell lines. A 40-50% decrease in the concentration of the mRNA for the C-alpha-isozyme of the catalytic subunit was observed in 10260 cells, as compared with wild-type. This decrease in catalytic subunit mRNA concentration probably accounts for a portion of the decreased kinase activity in the mutant cells. Further analysis of C-alpha mRNA by polymerase chain reaction confirmed the decreased expression of C-alpha mRNA in 10260 cells and further demonstrated the presence of two different species of C-alpha mRNA in the 10260 cells. One species of C-alpha cDNAs was indistinguishable from the wild-type cDNA, but the other species was shorter. Nucleotide sequence analysis of the amplified cDNAs led to the identification of a 191-base pair deletion in the shorter cDNA. Gene transfer studies using wild-type and 10260 C-alpha cDNAs demonstrated that the longer cDNA from the 10260 cells produced wild-type activity, but the shorter cDNA was inactive. These studies suggest that at least two alterations in gene expression are responsible for decreased cAMP-dependent protein kinase activity in the 10260 cell line. One alteration results in an approximately 2-fold decrease in the concentrations of C-alpha mRNA in the cells. The other change produces two species of C-alpha mRNA; one of the C-alpha mRNAs does not encode an active kinase.	UNIV IOWA,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; UPJOHN CO,DEPT CELL BIOL,KALAMAZOO,MI 49001; NCI,DIV CANC BIOL & DIAG,MOLEC BIOL LAB,BETHESDA,MD 20892	University of Iowa; Pfizer; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				safi, awaisbashir/0000-0003-0128-7122; Kim, Kyoon/0000-0001-5133-1692	NHLBI NIH HHS [HL 14388] Funding Source: Medline; NIDDK NIH HHS [DK25295] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAVANI SR, 1987, EUR J BIOCHEM, V167, P221, DOI 10.1111/j.1432-1033.1987.tb13326.x; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; CHENG HC, 1986, J BIOL CHEM, V261, P989; CHRIVIA JC, 1988, J BIOL CHEM, V263, P5739; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EVAIN D, 1979, J BIOL CHEM, V254, P6931; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIDDES J C, 1981, Journal of Molecular and Applied Genetics, V1, P3; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GOTTESMAN MM, 1980, SOMAT CELL GENET, V6, P45, DOI 10.1007/BF01538695; GOTTESMAN MM, 1980, CELL, V22, P329, DOI 10.1016/0092-8674(80)90342-6; HENIKOFF S, 1984, GENE AMST, V28, P350; INSEL PA, 1975, SCIENCE, V190, P896, DOI 10.1126/science.171770; KAFATOS FC, 1979, NUCLEIC ACIDS RES, V7, P1541, DOI 10.1093/nar/7.6.1541; KIM KE, 1988, MOL ENDOCRINOL, V2, P1374, DOI 10.1210/mend-2-12-1374; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MAURER RA, 1985, J BIOL CHEM, V260, P4684; MAURER RA, 1989, J BIOL CHEM, V264, P6870; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MURPHY CS, 1985, SOMAT CELL MOLEC GEN, V11, P605, DOI 10.1007/BF01534725; MURTAUGH MP, 1982, J CELL BIOL, V95, P64, DOI 10.1083/jcb.95.1.64; OLSEN SR, 1989, J BIOL CHEM, V264, P18662; ORELLANA SA, 1990, J BIOL CHEM, V265, P3048; RICHARDSON JM, 1990, J BIOL CHEM, V265, P13635; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT JD, 1986, P NATL ACAD SCI USA, V83, P1613, DOI 10.1073/pnas.83.6.1613; SHOWERS MO, 1986, J BIOL CHEM, V261, P6288; SINGH TJ, 1985, J BIOL CHEM, V260, P3927; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEINBERG RA, 1978, CELL, V15, P1351, DOI 10.1016/0092-8674(78)90060-0; STEINBERG RA, 1983, J CELL BIOL, V97, P1072, DOI 10.1083/jcb.97.4.1072; STEINBERG RA, 1977, CELL, V10, P361; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; UHLER MD, 1986, J BIOL CHEM, V261, P5360; UHLER MD, 1986, P NATL ACAD SCI USA, V83, P1300, DOI 10.1073/pnas.83.5.1300; VANPATTEN SM, 1986, J BIOL CHEM, V261, P5514; WALSH DA, 1971, J BIOL CHEM, V246, P1977; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3682	44	34	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10189	10195						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	1645343				2022-12-25	WOS:A1991FP08600032
